,CID,name,smiles,7.1-Drug Indication,8.1-Pharmacodynamics,8.2-MeSH Pharmacological Classification,"8.5-Absorption, Distribution and Excretion",8.6-Metabolism/Metabolites,8.7-Biological Half-Life
0,10001,"3,3,3-Trifluoropropylamine",C(CN)C(F)(F)F,,,,,,
1,10002,"3,3-Dichloro-1,1,1-trifluoropropane",C(C(Cl)Cl)C(F)(F)F,,,,,,
2,10003,"2,2,2-Trifluoroethyl ethyl ether",CCOCC(F)(F)F,,,,,,
3,10004,3-Fluoropropionic acid,C(CF)C(=O)O,,,,,,
4,10005,Cyanoguanidine,C(#N)N=C(N)N,,,,,,
5,10006,Hydantoin,C1C(=O)NC(=O)N1,,,,,,
6,10007,Chlorphentermine,CC(C)(CC1=CC=C(C=C1)Cl)N,['Used as an appetite suppressant.'],"['Chlorphentermine is a relatively weak stimulant with little abuse potential. It presents a prominent serotonergic profile leading to pulmonary hypertension and cardiac fibrosis after prolonged use. Thus, this drug is no longer used.']",['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)'],"['Well absorbed following oral administration.', 'CHLORPHENTERMINE HAS GREATER TISSUE:BLOOD RATIO IN RATS THAN PHENTERMINE, & TISSUE ACCUMULATION OF CHLORO-DERIV INCR RELATIVE TO PLASMA LEVELS AFTER CHRONIC DOSING.', 'IN MICE, UNIDENTIFIED CONJUGATE (60% OF DOSE), WHICH IS NEITHER GLUCURONIDE NOR N-ACETYL DERIV, WAS NOT FORMED BY LIVER MICROSOMES, BUT IN RATS, CHLORPHENTERMINE IS EXCRETED UNCHANGED IN URINE.', 'FOLLOWING ORAL ADMIN TO MAN, N-OXIDATION TAKES PLACE & UNDER NORMAL CONDITIONS OF URINARY PH, URINE IS MAIN ELIMINATION ROUTE FOR CHLORPHENTERMINE; ACIDIFYING THE URINE INCR URINARY EXCRETION OF UNCHANGED DRUG @ EXPENSE OF N-OXIDIZED PRODUCTS.']","['... CHLORPHENTERMINE IS METABOLIZED VIA UNRECOGNIZED ROUTE TO AFFORD UNUSUAL CONJUGATE, WHICH IS NEITHER GLUCURONIDE NOR N-ACETYL DERIV, IN URINE OF MOUSE, WHEREAS IN RAT CHLORPHENTERMINE IS EXCRETED UNCHANGED.']",['40 hours']
7,10008,Fluorobenzene,C1=CC=C(C=C1)F,,,,,,
8,10009,3-Aminopyridine,C1=CC(=CN=C1)N,,,,,,
9,10010,DL-Homocystine,C(CSSCCC(C(=O)O)N)C(C(=O)O)N,,,,,,
10,10011,8-Fluoro-3-methyloctanoic acid,CC(CCCCCF)CC(=O)O,,,,,,
11,10012,CID 10012,CC(CCCCCCCCC(=O)[O-])CCCCCCCCF.[Na+],,,,,,
12,10013,18-Fluoro-10-methyloctadecanoic acid,CC(CCCCCCCCC(=O)O)CCCCCCCCF,,,,,,
13,10014,"1,19-Difluorononadecan-10-one",C(CCCCC(=O)CCCCCCCCCF)CCCCF,,,,,,
14,10015,7-Tridecanone,CCCCCCC(=O)CCCCCC,,,,,,
15,10016,2-Fluoroethyl acetate,CC(=O)OCCF,,,,,,
16,10017,2-Fluoroethyl chloroformate,C(CF)OC(=O)Cl,,,,,,
17,10018,2-Fluoroethyl thiolacetate,CC(=O)SCCF,,,,,,
18,10019,3-Fluoropropan-1-amine,C(CN)CF,,,,,,
19,10020,Hydantoic acid,C(C(=O)O)NC(=O)N,,,,,,
20,10021,Ethyl 9-fluorononanoate,CCOC(=O)CCCCCCCCF,,,,,,
21,10022,1-Bromo-4-fluorobutane,C(CCBr)CF,,,,,,
22,10023,1-Chloro-4-fluorobutane,C(CCCl)CF,,,,,,
23,10024,Diethoxymethane,CCOCOCC,,,,,,
24,10025,6-Fluorohexylamine,C(CCCF)CCN,,,,,,
25,10026,Amyl nitrite,CCCCCON=O,['For the rapid relief of angina pectoris.'],"['Amyl nitrite, in common with other alkyl nitrites, is a potent vasodilator. It expands blood vessels, resulting in lowering of the blood pressure. Alkyl nitrite functions as a source of nitric oxide, which signals for relaxation of the involuntary muscles. Adverse effects are related to this pharmacological activity and include hypotension, headache, flushing of the face, tachycardia, dizziness, and relaxation of involuntary muscles, especially the blood vessel walls and the anal sphincter.']",['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],"['Amyl nitrite vapors are absorbed rapidly through the pulmonary alveoli, manifesting therapeutic effects within one minute after inhalation.']","['Hepatic. The drug is metabolized rapidly, probably by hydrolytic denitration; approximately one-third of the inhaled amyl nitrite is excreted in the urine.']",
26,10027,1-Fluorooctane,CCCCCCCCF,,,,,,
27,10028,"7-Cyano-2-heptene-4,6-diynoic acid",C(=CC(=O)O)C#CC#CC#N,,,,,,
28,10029,1-Fluorononane,CCCCCCCCCF,,,,,,
29,10030,9-Fluoro-1-nonyne,C#CCCCCCCCF,,,,,,
30,10031,1-Chloro-9-fluorononane,C(CCCCF)CCCCCl,,,,,,
31,10032,"Nonanol, 9-fluoro-",C(CCCCO)CCCCF,,,,,,
32,10033,9-Fluorononanal,C(CCCCF)CCCC=O,,,,,,
33,10034,Methyl 18-fluorooctadecanoate,COC(=O)CCCCCCCCCCCCCCCCCF,,,,,,
34,10035,"Ether, 4-cyanobutyl 4'-fluorobutyl",C(CCOCCCCF)CC#N,,,,,,
35,10036,"Methane, bis(2-(2-fluoroethoxy)ethoxy)-",C(COCOCCOCCF)OCCF,,,,,,
36,10037,Allene,C=C=C,,,,,,
37,10038,Ketene,C=C=O,,,,,,
38,10039,Carbonyl sulfide,C(=O)=S,,,,"['Carbonyl sulfide is absorbed via the respiratory tract based on the finding of histological damage in the brains of rats exposed to carbonyl sulfide gas.', 'Carbonyl sulfide, a new hydrophobic and volatile metabolite of disulfiram was found in blood samples from alcoholics treated with single or repeated doses of disulfiram. The dosage schedule included 400 mg of disulfiram every second or third day. After an interval of 3 days with no treatment, all were given a dose of 400 mg and blood samples taken before ingestion and 4 hr after ingestion. Of the samples take before this last dose, five had detectable concentrations of carbonyl sulfide (10 to 54 nmol/L) and the sixth was negative. In the samples taken after 4 hr, the carbony sulfide concentrations were higher in all subjects. Four subjects had carbonyl sulfide concentrations in the range 20 to 60 nmol/L. Two subjects showed 30-fold increases: from 10 to 28 nmol/L and from 16 to 540 nmol/L.']","['In vitro studies suggest that carbonyl sulfide is metabolized to hydrogen sulfide and thiosulfate ... and in vivo evidence suggests that it is metabolized by carbonic anhydrase ... and the mixed function oxidase enzyme system to carbon dioxide.', 'Pre-exposure to acetazolamide (a carbonic anhydrase inhibitor) resulted in a decrease in mortality in rats exposed via intraperitoneal injection to a lethal dose of carbonyl sulfide ... There is also in vitro evidence that carbonyl sulfide is metabolized by the mixed-function oxidase enzyme system to carbon dioxide ... However, the metabolism was not inhibited by the cytochrome P-450 monooxygenase inhibitors (SKF 525-A, 4-methylpyrazole, metyrapone) or substrate (carbon disulfide).', '... Studies on carbon disulfide metabolism using rat-liver microsomes ... demonstrated that carbonyl sulfide is an intermediate in formation of carbon dioxide ... The first step is microsomal cytochrome P450-mediated, NADPH-dependent ... & common by-product, atomic sulfur, seems ... Implicated in inhibition of P450 by carbon disulfide and by carbonyl sulfide.', 'Carbonyl sulfide is evidently metabolized to hydrogen sulfide by carbonic anhydrase. It is the hydrogen sulfide produced that is responsible for carbonyl sulfide toxicity.', '... In microsomes, (CS2) metabolism was increased by phenobarbital pretreatment of the rats and decreased with pretreatment of the rats with cobaltous chloride. In both microsomes and hepatocytes, CS2 metabolism was inhibited by SKF-525A. Carbon dioxide (CO2) was the major volatile metabolite of CS2 in hepatocytes, and carbonyl sulfide (COS) was the major volatile metabolite in microsomal incubations. Addition of cytosol to microsomal incubations shifted the predominant volatile metabolite from COS to CO2 but did not change total volatile metabolite formation. Acetazolamide, a carbonic anhydrase inhibitor, significantly decreased COS metabolism but not CS2 metabolism in isolated hepatocytes or microsomes fortified with dialyzed cytosol. When [(18)O]H2O was included in incubations of microsomes and CS2, a substantial portion of the resulting COS was [(18)O] enriched.']",
39,10040,Thiophosgene,C(=S)(Cl)Cl,,,,,,
40,10041,Neopentane,CC(C)(C)C,,,,"['Routes of Entry: Inhalation, ingestion; skin and/or eye contact.', 'Studies were done on the pulmonary absorption of inhaled vapors of 20 gasoline-related hydrocarbon vapors, including neopentane. Male F344 rats were exposed to 1000 to 5000 ppm vapors of neopentane for 80 to 100 min. The uptake for neopentane was 5.4%. Highly volatile and branched hydrocarbons were less well absorbed than less volatile and unbranched hydrocarbons; unsaturated compounds were better absorbed than saturated ones. Less absorption could be the reason for the reduced toxicity seen with increased branching.']","['2,2-Dimethylpropane was hydroxylated by rat liver microsomes to its parent alcohol 2,2-dimethylpropanol.']",
41,10042,Neurine,C[N+](C)(C)C=C.[OH-],,,,,,
42,10043,"n,n,n-Trimethylethenaminium",C[N+](C)(C)C=C,,,,,,
43,10044,"2,2,3-Trimethylbutane",CC(C)C(C)(C)C,,,,,,
44,10045,"3,3-Dimethyl-2-butanol",CC(C(C)(C)C)O,,,,,,
45,10046,Bromopicrin,C([N+](=O)[O-])(Br)(Br)Br,,,,,,
46,10047,Bornylene,CC1(C2CCC1(C=C2)C)C,,,,,,
47,10048,endo-2-Chlorobornane,CC1(C2CCC1(C(C2)Cl)C)C,,,,,,
48,10049,Borneol,C[C@]12CC[C@@H](C1(C)C)C[C@H]2O,,,,"[""To develop a GC-FID method to determine borneol's concentration in mouse tissues, and to investigate the tissue distribution after intravenous and intranasal administrations of borneol, mouse brains, hearts, livers, spleens, lungs and kidneys were collected at 1, 3, 5, 10, 20, 30, 60, 90, 120 min after administration of borneol with the dose of 30.0 mg/kg. The drug in tissues was extracted with ethyl acetate, and borneol's concentration detected by GC, with octadecane as the internal standard. The calibration curve showed a good linear relationship. Extraction recoveries, inter-day and intra-day precisions and stability were in conformity with the analytical requirements of biological samples. Borneol was mainly distributed in most tissues, more in heart, brain and kidney, and less in liver, spleen and lung. The established GC-FID method is applicable for content determination of borneol in tissues. After intravenous and intranasal administrations in mice, borneol is mainly distributed in abundant blood-supply tissues. After intranasal administration, brain tissues showed the highest target coefficient and target effectiveness."", '... In order to understand the blood and brain pharmacokinetics after intravenous, intranasal, or oral administration and to investigate the superiority and feasibility of intranasal administration, a simple gas chromatographic (GC) method with flame ionization detection (FID) was developed for the quantification of borneol. Blood samples and brain were collected from mice at 1, 3, 5, 10, 20, 30, 60, 90, and 120 min after intravenous, intranasal, or oral administration of borneol at a dosage of 30.0 mg/kg. Sample preparations were carried out by liquid-liquid extraction with an internal standard solution of octadecane. The pharmacokinetic parameters were calculated /using computer software/. The calibration curves were linear in the range of 0.11-84.24 ug/mL and 0.16-63.18 ug/g for borneol in plasma and brain, respectively. The methodological and extraction recoveries were both in the range of 85%-115%. The intra-day and inter-day variabilities for plasma and brain samples were </= 5.00% relative standard deviation (RSD). The absolute bioavailabilities F of intranasal and oral administrations were 90.68% and 42.99%. The relative brain targeted coefficients Re of intranasal and oral administrations were 68.37% and 38.40%. The GC-FID method developed could be applied to determination and pharmacokinetic study. The borneol from injection was distributed and metabolized fast without absorption process. The borneol from oral administration was distributed more slowly and had the lowest absolute bioavailability. Nasal administration of borneol was quickly absorbed into the blood and brain, was easy to use and had a greater safety than infection, which makes it worthy of further development as an administration route for encephalopathy treatment.', 'The aim of this work was to study the in situ and in vivo nasal absorption of borneol. A novel single pass in situ nasal perfusion technique was applied to examine the rate and extent of nasal absorption of borneol by rats. Experimental conditions, such as perfusion rate, pH and drug concentration, were investigated. The in situ experiments showed that the nasal absorption of borneol was not dependent on drug concentration, and fitted a first order process. The absorption rate constant, Ka, influenced with an increase in perfusion speed. The borneol was well absorbed in the conditions of the nasal cavity within the pH range and pH value of physiological conditions. In vivo studies of borneol absorption were carried out in rats and the pharmacokinetics parameters of intranasal (in) was compared with intravenous (iv) administration. The bioavailabilities of borneol was 90.82% for i.n. while Tmax values were 10 min. MRT (Mean Residence Time) were 262.55 +/- 67.35 min and 204.22 +/- 14.50 min for in and iv methods, respectively. The results demonstrate that borneol could be absorbed promptly and thoroughly by in administration in rats.', ""Previous studies have indicated that borneol has double side effects on the central nervous system (CNS), but the mechanism is unknown. The aim of this study was to clarify the relationship between excitation ratio [contents of excitatory amino acids (AAs) versus that of inhibitory] and the content of natural borneol after a single oral dose. Mice were administered a 1.2 g/kg dose of natural borneol (containing 98% D: -borneol) by oral ingestion. Brain samples were collected before administration and at 0.083, 0.167, 0.25, 0.333, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hr after administration. The brain concentration of natural borneol and contents of AA neurotransmitters in mice brain were determined by GC-MS and HPLC-FLU, respectively. After per oral application, natural borneol was absorbed rapidly into the brain and could be determined 5 min after dosing. The maximal brain concentration (86.52 ug/g) was reached after 1 hr post-dosing. Natural borneol could affect the contents of AA neurotransmitters in mice brain: L: -aspartic acid increased significantly from 0.083 to 1 hr after administration, L: -glutamic acid increased significantly at 0.333 hr and decreased from 1.5 to 5 hr, gamma-amino-N-butyric acid increased significantly from 0.167 to 5 hr, whereas glycine was not affected. The excitation ratio is the contents of excitatory AAs versus that of inhibitory AAs, which reflects the excitatory or inhibitory state of the body. The excitation ratio elevated transitorily and then declined 0.5 hr post-dosing; there were significant differences between 1.5-5 hr post-dose compared with pre-dose. The present study indicated that natural borneol could affect the contents of AA neurotransmitters, and the change in excitatory ratio led to borneol's double side effects on the CNS."", 'The percutaneous absorptions of camphene, isoborneol-acetate, limonene, menthol and alpha-pinene as constituents of a foam bath (Pinimenthol) were measured on animals using radioactively labeled ingredients. Pharmacokinetic measurements showed maximum blood levels for all tested ingredients 10 min after the onset of percutaneous absorption. None of the ingredients was preferentially absorbed. Blood levels of all ingredients after 10 min of percutaneous absorption were a direct function of the size of the skin area involved.']",,
49,10050,"Camphor, (1S,4S)-(-)-",C[C@]12CCC(C1(C)C)CC2=O,,,,,,
50,10051,"5-[(3S,5R,10S,11S,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-12-oxo-2,3,4,5,6,7,8,9,11,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CC[C@@H](C[C@H]1CCC3C2[C@@H](C(=O)[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O)O,,,,,,
51,10052,N~2~-(8-{[16-(Acetyloxy)-14-hydroxy-17-(2-oxo-2H-pyran-4-yl)androstan-3-yl]oxy}-1-hydroxy-8-oxooctylidene)arginine,CC(=O)O[C@H]1C[C@@]2(C3CC[C@@H]4C[C@H](CC[C@@]4(C3CC[C@@]2([C@H]1C5=CC(=O)OC=C5)C)C)OC(=O)CCCCCCC(=O)NC(CCCN=C(N)N)C(=O)O)O,,,,,,
52,10053,"5-[(3S,5R,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CC[C@@H](C[C@H]1CCC3C2[C@@H](C[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O)O,,,,,,
53,10054,"3-[(3R,5R,10S,11R,13R,14S,17R)-3,11,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CC[C@H](C[C@H]1CCC3C2[C@@H](C[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O)O,,,,,,
54,10055,"[(3S,5R,10S,13R,14S,16S)-3-[(2R,5S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(C[C@@H](C5C6=CC(=O)OC6)OC(=O)C)O)C)C)O)OC)O,,,,,,
55,10056,"(3beta,5beta,8xi,9xi,16beta)-16-(Acetyloxy)-3,14-dihydroxycard-20(22)-enolide",CC(=O)O[C@H]1C[C@@]2(C3CC[C@@H]4C[C@H](CC[C@@]4(C3CC[C@@]2([C@H]1C5=CC(=O)OC5)C)C)O)O,,,,,,
56,10057,"[(3S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3(C(C2)CCC4C3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O,,,,,,
57,10058,"[(3S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4R,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@H]2CC[C@]3(C(C2)CCC4C3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O,,,,,,
58,10059,"5-[(3S,5R,10S,13R,14S,16S,17R)-3,14,16-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=COC(=O)C=C5)O)O)C)O,,,,,,
59,10060,"5-[(3R,5R,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CC[C@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O,,,,,,
60,10061,"5-[(3S,5R,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O,,,,,,
61,10062,"3beta,14-Dihydroxy-14beta-bufa-4,20,22-trienolide",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CCC5=C[C@H](CC[C@]35C)O,,,,,,
62,10063,Bufogenin,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@]35[C@H](O5)C[C@@H]4C6=COC(=O)C=C6)C)O,,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
63,10064,"(4S,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,,,,,,
64,10065,9-Fluoro-17-methyl-11-oxotestosterone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2(C(=O)C[C@]4([C@H]3CC[C@]4(C)O)C)F,,,,,,
65,10066,CID 10066,C1[C@H]2C=C[C@H]1[C@H]3[C@@H]2[C@@]4(C(=C([C@@]3(C4(Cl)Cl)Cl)Cl)Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['... From mammalian studies that the inversion of the unchlorinated norbornene nucleus in isodrin and endrin (as compared with aldrin and dieldrin) exposes this ring to enzymatic hydroxylation in vivo and greatly incr the rate of elimination of these cmpd from mammalian tissues, in contrast to their behavior in insect tissues.']","['When isodrin was incubated with homogenates from excised roots of bean seedlings (phaseolus vulgaris) ... cmpd corresponding chromatographically to endrin ketone (delta-keto endrin) was observed. A second metabolite, present in very small amt, observed, but not identified. No endrin was found.', '... Isodrin ... is converted to endrin by rabbit liver microsomes. Apparently no further metabolism of the product endrin occurs with this enzyme system.', 'Conversion of isodrin to endrin ... has been demonstrated in both susceptible & resistant strains of houseflies. ... Susceptible & resistant flies topically treated with isodrin & endrin contained small ... amt (3-4% of applied dose) of water sol substance that appeared to be identical to the semi-caged keto derivative ... /which is/ known rearrangement product of endrin.', 'After application of (14)C labeled isodrin (1 mg/plant) to leaves of young white cabbage, 44% of the applied radioactivity was recovered in the plants & soil after 4 wk, & 37% after 10 wk. After 10 wk only conversion products of isodrin were detectable as residues. After application of (14)C isodrin to soil (0.19 ppm), carrots contained only 3.1% of the applied radioactivity after 4 wk & 4.0% after 12 wk. In both experiments, endrin and delta ketoendrin were identified as conversion products of isodrin.', 'For more Metabolism/Metabolites (Complete) data for ISODRIN (11 total), please visit the HSDB record page.']",
66,10067,"3-(Acetyloxy)-4,7,14,16,20-pentahydroxy-4,9-epoxycevan-15-yl 2-methylbutanoate",CCC(C)C(=O)O[C@H]1[C@@H](C2C(CN3C[C@H](CC[C@H]3[C@@]2(C)O)C)C4[C@@]1(C5[C@@H](CC6[C@]7([C@]5(C4)O[C@@]6([C@H](CC7)OC(=O)C)O)C)O)O)O,,,,,,
67,10068,"(3S,5S,10S,13R,14S,17R)-3,5,14-trihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)C=O)O,,,,,,
68,10069,"5-[(3S,10R,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",CC1C(C(C(C(O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,,,,,,
69,10070,"3-[(3S,5R,10S,13R,14S,17R)-3-[(2R,5R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)OC)O,,,,,,
70,10071,3-Epiuzarigenin,C[C@]12CC[C@H](C[C@@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O,,,,,,
71,10072,Isomethadone,CCC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C,,,,,,
72,10073,"1-[(9R,12R,19R)-12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5-trien-8-yl]ethanone",CC[C@]12CCCN3[C@H]1C4(CC3)[C@@H](CC2)N(C5=C4C=CC=C5OC)C(=O)C,,,,,,
73,10074,beta-ERYTHROIDINE,CO[C@@H]1C[C@]23C4=C(CCN2CC=C3C=C1)COC(=O)C4,,,,,,
74,10075,Thebacon,CC(=O)OC1=CCC2C3CC4=C5C2(C1OC5=C(C=C4)OC)CCN3C,,,,,,
75,10076,CID 10076,C1CN[C@H]2CC3=C4[C@@]15C2C=C[C@@H]([C@@H]5OC4=C(C=C3)O)O,,,,,,
76,10077,"(4S,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4,,,,,,
77,10078,CID 10078,COC1=C2C3=C(C[C@H]4C5[C@]3(CCN4)C(O2)C(C=C5)O)C=C1,,,,,,
78,10079,Carbiphene hydrochloride,CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CCN(C)CCC3=CC=CC=C3.Cl,,,,,,
79,10080,Carbifene,CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CCN(C)CCC3=CC=CC=C3,,,,,,
80,10081,CID 10081,C=CCC1(C(=O)NC(=NC1=O)S)C2CCCC=C2,,,,,,
81,10082,CID 10082,CCCC(C)C1(C(=O)NC(=NC1=O)S)CCSC,,,,,,
82,10083,Pipradrol,C1CCNC(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,"['Used to manage fatigue and depression,,,. Used as an adjunct therapy in the management of obesity.']","['Pipradrol (Meratran) is a psychoactive agent and a central nervous system stimulant that has proven useful in the field of psychiatry.  Pipradrol was initially used as an adjunct in the dietary management of obesity as well as for the management of dementia symptoms. Numerous reports have been made on the properties of pipradrol, demonstrating its favorable effects in the treatment of depression and fatigue in addition to a variety of other conditions including narcolepsy, spasmodic torticollis, schizophrenia and in geriatric practice.']",,"['Rapidly absorbed.', 'Quickly excreted in the urine  (3.5%) and stool (5%).', 'Distributed in the liver, kidney and brain tissue.', 'Rapidly cleared.']","['Rapidly metabolized, and not found in plasma approximately 4 hours post administration.']",
83,10084,Tris(P-aminophenyl)methanol,C1=CC(=CC=C1C(C2=CC=C(C=C2)N)(C3=CC=C(C=C3)N)O)N,,,,,,
84,10085,N-Ethyl-3-piperidyl phenylcyclopentylglycolate hydrochloride,CCN1CCCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.Cl,,,,,,
85,10086,N-Ethyl-3-piperidyl phenylcyclopentylglycolate,CCN1CCCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
86,10087,Flurenol,C1=CC=C2C(=C1)C3=CC=CC=C3C2(C(=O)O)O,,,,,,
87,10088,CID 10088,CC=C(C)C(=O)O[C@@H]1CC(CC2C1(CCC3(C2=CCC4C3(CCC5C4(CCC(=O)C5(C)C)C)C)C)C(=O)O)(C)C,,,,,,
88,10089,Phenadoxone,CCC(=O)C(CC(C)N1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
89,10090,Normethadone,CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,['For use in the treatment of cough when other less potent treatments have failed.'],['Normethadone is an opioid which suppresses coughing by central and peripheral mechanisms.'],"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
90,10091,Bovosidol A,CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=COC(=O)C=C6)O)C)CO)O)OC)O,,,,,,
91,10092,"(3S,5R,10R,13R,14S,16S,17R)-13-methyl-3,14,16-tris(oxidanyl)-17-(5-oxidanylidene-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",C[C@]12CCC3C([C@]1(C[C@@H]([C@@H]2C4=CC(=O)OC4)O)O)CC[C@H]5[C@@]3(CC[C@@H](C5)O)C=O,,,,,,
92,10093,"3,14-Dihydroxy-19-oxobufa-20,22-dienolide",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC[C@@H]5[C@@]3(CC[C@@H](C5)O)C=O,,,,,,
93,10094,"3-[(3S,5S,10R,13R,14S,17R)-3,14-dihydroxy-10-(hydroxymethyl)-13-methyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@@H]5[C@@]3(CC[C@@H](C5)O)CO,,,,,,
94,10095,"(3S,5S,10R,13R,14S,17R)-3,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@@H]5[C@@]3(CC[C@@H](C5)O)C=O,,,,,,
95,10096,CID 10096,C[C@@H]1C2C(CCC1=CC(=O)OCCN(C)C)[C@]3(CC[C@@H](C(C3CC2=O)(C)C)O)C,,,,,,
96,10097,"7-Chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,6'-cyclohex-2-ene]-1',3-dione",CC1CC(=CC(=O)C12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,,,,,,
97,10098,Jervine,C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5C(=O)C4=C3C)C)O)C)NC1,,,,,"['Malformations in hatched chicks were produced by direct application of 1-2 mg of cyclopamine to the embryonic shield of windowed chicken eggs. This showed that maternal metabolic alteration of cyclopamine was not necessary. /PRC: Cyclopamine is a member of the jerveratum group as is jervine/. /CYCLOPAMINE/', 'INCORPORATION OF ACETATE-1-(14)C, CHOLESTEROL-4-(14)C, & OF CHOLESTEROL-26-(14)C INTO JERVINE & VERATRAMINE GAVE A LABELING PATTERN CONSISTENT WITH THE HYPOTHESIS THAT A KEY INTERMEDIATE DERIVED FROM EPIRUBIJERVINE WAS CONVERTED INTO THE C-NOR-D-HOMOSTEROIDAL ALKALOIDS (JERVINE & VERATRAMINE) BY SEPARATE PATHWAYS IN VERATRUM GRANDIFLORUM.']",
98,10099,"1H-3a,7-Methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-, (3R,3aS,7S,8aS)-",C[C@@H]1CC[C@@H]2C13CC=C(C(C3)C2(C)C)C,,,,,,
99,10100,Propoxyphene,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C,['For the relief of mild to moderate pain.'],"['Propoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. The analgesic effect of propoxyphene is due to the d-isomer, dextropropoxyphene. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action.']","['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']","['The major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys.  In 48 hours, approximately 20% to 25% of the administered dose of propoxyphene is excreted via the urine, most of which is free or conjugated norpropoxyphene.', '16 L/kg', '2.6 L/min', 'Following oral administration, propoxyphene hydrochloride and napsylate are absorbed principally in the upper small intestine. The napsylate salt appears to be absorbed more gradually than the hydrochloride salt. Equimolar doses of propoxyphene hydrochloride or napsylate provide similar plasma concentrations. The bioavailability of oral propoxyphene hydrochloride doses of 65, 130, or 195 mg is equivalent to that of oral propoxyphene napsylate doses of 100, 200, or 300 mg, respectively.', 'Peak plasma propoxyphene concentrations are usually achieved within 2-2.5 hours following oral administration of propoxyphene hydrochloride capsules or propoxyphene napsylate suspension (no longer commercially available in the US) and within 3 hours following oral administration of propoxyphene napsylate tablets. The analgesic effect occurs within 15 minutes to 1 hour and persists for 4-6 hours. Therapeutic plasma propoxyphene concentrations are 50 ng/mL or greater. Peak plasma concentrations achieved with the recommended 65-mg dose of propoxyphene hydrochloride may range from 50-120 ng/mL, while concentrations of the norpropoxyphene metabolite range from 100-200 ng/mL.', 'Only a small fraction of the absorbed dose (30%-70%) enters the general circulation in unmetabolized form. The rest is metabolized by intestinal and hepatic enzymes during absorption. Single dose kinetics indicate complete oral absorption. Peak plasma levels of propoxyphene after an oral 65 mg dose are 84-94 ng/ml (0.084-0.094 ug/ml) and are reached in 1.1-1.5 hr.', 'The delay in absorption has been attributed to slower gastric emptying and/or the physical barrier produced by the food mass. The effect of meal composition on the absorption of propoxyphene /Darvon/ has been studied in 6 healthy volunteers. On an empty stomach, peak plasma levels occurred at about 2 hr, while ... high carbohydrate & high fat meals delayed peak times to about 3 hr & high protein to about 4 hr. Although the absorption rate was decreased by food, high carbohydrate & high protein meals slightly increased the overall bioavailability of propoxyphene.', 'For more Absorption, Distribution and Excretion (Complete) data for (d)-PROPOXYPHENE (11 total), please visit the HSDB record page.']","['Hepatic', 'Propoxyphene undergoes extensive first-pass metabolism by intestinal and hepatic enzymes. Propoxyphene is metabolized mainly via N-demethylation (mediated by cytochrome P-450 (CYP) isoenzyme 3A4) to form norpropoxyphene. Ring hydroxylation and glucuronide formation appear to be minor metabolic pathways for the drug. Norpropoxyphene has an elimination half-life of 30-36 hours. Norpropoxyphene and unchanged propoxyphene are excreted mainly in urine. Approximately 20-25% of an orally administered 65-mg dose of propoxyphene hydrochloride may be recovered in urine as unchanged drug (trace amount) and free or conjugated norpropoxyphene within 48 hours.It appears that the unchanged drug is excreted mainly within 6 hours and the metabolite is excreted in the 6- to 48-hour period following administration. Renal clearance of propoxyphene is about 2.6 L/minute.', 'Formation of cytochrome p450 metabolic intermediate complexes in vivo occurred with propoxyphene in native & phenobarbital-induced rats. In vivo formation correlated with relative ability for it to form metabolic intermediate complexes & inhibit mixed function oxidation reactions in vitro.', 'Yields 3-dimethylamino-1,2-diphenyl-2-butyl propionate-n-oxide iN pig & 3-methylamino-1,2-diphenyl-2-butyl propionate iN rat. From table/', 'Presystemic metabolism is believed to occur mainly in the liver with some minor intestinal participation. The aim of this study was to investigate the respective part of each of these two organs in the metabolism of the analgesic d-propoxyphene. Pharmacological doses of d-propoxyphene were given in the duodenum (ID), the portal vein (IP), and the femoral vein (IV) of male Wistar rats. A tracer dose of (14)C-d-propoxyphene was also administered either in IV, IP, or ID as well as in hepatectomized rats or rats with bile duct diversion. In vitro demethylation occurring in liver and intestinal microsomes was also studied. Absolute DP bioavailability obtained after oral administration was two times higher than that observed after portal administration (48.9% vs. 23.2%, respectively), an result opposite (i.e. a lower bioavailability) of that expected on the basis of the existence of a liver enzyme saturation phenomenon. The (14)C-d-propoxyphene cumulative excretion after (14)C-d-propoxyphene administration was significantly lower after IV or ID administration than after injection in the portal vein as a bolus or within 20 min. The biliary excretion of the labeled compound varied in the opposite direction, being greater after IV or ID than after IP administration, suggesting that the metabolism of d-propoxyphene in the liver is influenced by an extrahepatic transformation. This most likely occurs in the gut since the production of (14)C-d-propoxyphene after IV administration was similar to that after ID administration. This transformation did not prohibit d-propoxyphene detection in the systemic blood but was sufficient to increase the part eliminated with bile and to decrease the part demethylated NP. Demethylation mainly occurs in the liver since the production of (14)C-d-propoxyphene was nearly abolished in hepatectomized rats. Furthermore, microsomes of hepatic but not of intestinal origin were able to demethylate d-propoxyphene. Our data suggest that the transformation of d-propoxyphene occurring in gut after oral administration is responsible for changes in the hepatic metabolism of the drug.', 'Dextropropoxyphene has known human metabolites that include Nordextropropoxyphene.']","['6-12 hours', 'Propoxyphene has an elimination half-life of 6-12 hours.', 'The half life of elimination of the parent compound is 6 to 12 hours. The half life of elimination of norpropoxyphene is 30 to 36 hours.', '... Norpropoxyphene has a longer plasma half-life in the dog than propoxyphene. /Propoxyphene hydrochloride/', 'In geriatric patients 70-78 years of age, elimination half-lives of propoxyphene and norpropoxyphene reportedly were 13-35 and 22-41 hours, respectively.']"
100,10101,Ketobemidone,CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O,"['For the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.']",,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']","['34% (oral), 44% (rectal)']","['Ketobemidone is mainly metabolised by conjugation of the phenolic hydroxyl group, and by N-desmethylation. Only about 13-24% is excreted unchanged after iv. administration.', 'Ketobemidone has known human metabolites that include Ketobemidone O-glucuronide, Ketobemidone sulfate, and Norketobemidone.']",['Plasma half-life: 2.42 +/- 0.41 h (m +/- SD). Elimination half-life: 3.27 +/- 0.32 h']
101,10102,CID 10102,C[C@@]12CCC[C@]3(C1)C=CC([C@@H]3CC2)(C)C,,,,,,
102,10103,CID 10103,CC(=O)O[C@@H]1[C@@H](C2(CCC3C([C@@]24[C@@H]1O4)CC[C@H]5C3(CC[C@@H](C5)O)C)C)C6=CC(=O)OC=C6,,,,,,
103,10104,"5-[(2S,4R,6R,7R,11R,14S,16S)-14,16-dihydroxy-7,11-dimethyl-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadecan-6-yl]pyran-2-one",C[C@]12CCC3C([C@@]14[C@H](O4)C[C@@H]2C5=COC(=O)C=C5)CC[C@]6([C@@]3(CC[C@@H](C6)O)C)O,,,,,,
104,10105,Promoxolane,CC(C)C1(OCC(O1)CO)C(C)C,,,,,,
105,10106,"1,4-Cineole",CC(C)C12CCC(O1)(CC2)C,,,,,"['1_4_cineole has known human metabolites that include 7-Oxabicyclo[2.2.1]heptan-2-ol, 1-methyl-4-(1-methylethyl)-.']",
106,10107,Chlorfenvinphos,CCOP(=O)(OCC)OC(=CCl)C1=C(C=C(C=C1)Cl)Cl,,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'A pesticide or chemical agent that kills mites and ticks. This is a large class that includes carbamates, formamides, organochlorines, organophosphates, etc, that act as antibiotics or growth regulators. (See all compounds classified as Acaricides.)']","['PEAK CONCN OF RADIOACTIVE MATERIAL IN URINE OF STEERS, AFTER SPRAY APPLICATION OF (32)P-LABELED CHLORFENVINPHOS, OCCURRED IN SAMPLES AT 3 HR POST-TREATMENT. ... RESIDUES OF CHLORFENVINPHOS ... WERE BELOW LIMITS OF DETECTION IN ORGANS OF EXPOSED SHEEP. RESIDUE LEVELS NEVER REACHED 0.1 PPM. AFTER ORAL ADMIN TO RATS & DOGS, (14)C CHLORFENVINPHOS WAS RAPIDLY METABOLIZED AND EXCRETED. ABOUT 90% WAS ELIMINATED IN URINE; REMAINDER, VIA FECES AND, TO A LESSER EXTENT, VIA EXPIRED GASES. ... STUDIES HAVE SHOWN THAT THIS COMPD REACTED WITH AND WAS BOUND BY PROTEINS IN BLOOD PLASMA OF MAMMALS AND IN HOMOGENATES OF HOUSE FLY HEADS.', 'Dosage levels of 112 mg/hr/man /applied to left forearm/ ... produced blood levels of 0.012 ppm or more measured 24 hr after exposure. ... 70.8 mg/hr/man caused ... a blood level of 0.006 ppm 24 hr after exposure.', 'Oral dosages as high as 1 mg/kg did not affect cholinesterase or the awake-sleep cycle of rats. At dosages over 2 mg/kg, the cholinesterase activities of both brain & red cells were significantly decr, & the spontaneous EEG showed a prominent arousal pattern with suppression of curves characteristic of sleep. Maximal inhibition of brain cholinesterase occurred 3 hr after dosing & lasted for more than 72 hr.']","['... CHLORFENVINPHOS ... /IS/ DETOXIFIED IN MAMMALS EXTENSIVELY BY O-DEALKYLATION.', 'MICROSOMES FROM RABBIT LIVERS WERE INCUBATED WITH CHLORFENVINPHOS. OXIDATIVE CLEAVAGE OF ESTER BOND ... /OCCURRED/ VIA HYDROXYLATION ... TO GIVE 1-HYDROXYETHYL PHOSPHATE TRIESTER. THIS ... INTERMEDIATE BROKE DOWN ... TO 2-CHLORO-1-(2,4-DICHLOROPHENYL) VINYL ETHYL HYDROGEN PHOSPHATE. OXIDATIVE CLEAVAGE OF THE C-O BOND, RATHER THAN HYDROLYSIS OF THE P-O BOND, YIELDED ACETALDEHYDE ... .', ""AFTER ORAL ADMIN TO RATS AND DOGS...IN RATS, 32.3% OF DOSE WAS ACCOUNTED FOR BY 2-CHLORO-1-(2,4-DICHLOROPHENYL) VINYL MONOETHYL PHOSPHATE; 41% BY 1-(2',4'-DICHLOROPHENYL) ETHYL BETA-D-GLUCOPYRANOSIDURONIC ACID; 7% BY 2,4-DICHLOROMANDELIC ACID; 2.6% BY 2,4-DICHLOROPHENYLETHANEDIOL GLUCURONIDE; AND 4.3% BY 2,4-DICHLOROHIPPURIC ACID. IN DOGS THIS WAS 69.6% 2-CHLORO-1-(2,4-DICHLOROPHENYL) VINYL MONOETHYL PHOSPHATE; 3.6% 1-(2',4'-DICHLOROPHENYL) ETHYL BETA-D-GLUCOPYRANOSIDURONIC ACID; 13.4% /UNIDENTIFIED COMPD/; 2.7% 2,4-DICHLOROPHENYLETHANEDIOL GLUCURONIDE. AFTER IV ADMINISTRATION, CHLORFENVINPHOS WAS RAPIDLY METABOLIZED TO O-DESETHYL ANALOG (2-CHLORO-1-(2,4-DICHLOROPHENYL) VINYL MONOETHYL PHOSPHATE) (83%), 2,4-DICHLOROMANDELIC ACID (9%), AND 1-(2',4'-DICHLOROPHENYL) ETHYL BETA-D-GLUCOPYRANOSIDURONIC ACID (8%) IN DOGS."", 'One metabolite of chlorfenvinphos in humans is desethyl chlorvinphos.', 'For more Metabolism/Metabolites (Complete) data for CHLOROFENVINPHOS (6 total), please visit the HSDB record page.']",
107,10108,"3,5,5-Trimethylcyclohex-3-en-1-one",CC1=CC(CC(=O)C1)(C)C,,,,,,
108,10109,Bis(2-chloroethyl) sulfone,C(CCl)S(=O)(=O)CCCl,,,,,,
109,10110,Propiolic acid,C#CC(=O)O,,,,,,
110,10111,Methylguanidine,CN=C(N)N,,,,,,
111,10112,Calcium Carbonate,C(=O)([O-])[O-].[Ca+2],['For relief of heartburn and acid indigestion. May also be used as a nutritional supplement or to treat hypocalcemia.'],"['Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and <i>Helicobacter pylori</i> (<i>H. pylori</i>). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion. The acid-neutralizing capacity of calcium carbonate is 58 mEq/15 ml.  When used as a nutritional supplement, calcium carbonate acts by directly increasing calcium stores within the body.']",['Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)'],"['Maximal absorption occurs at doses of 500 mg or less taken with food. Oral bioavailability depends on intestinal pH, the presence of food and dosage.', 'Excreted mainly in the feces. The majority of renally filtered calcium is reabsorbed in the ascending limb of the loop of Henle and the proximal and distal convoluted tubules. Also secreted by sweat glands.', ""Calcium is rapidly distributed taken up by skeletal tissues following absorption and distribution into extracellular fluids. Bone contains 99% of the body's calcium and the remaining 1% is approximately equally distributed between intracellular and extracellular fluids."", 'Calcium absorption is best when a person consumes no more than 500 mg at one time. So a person who takes 1,000 mg/day of calcium from supplements, for example, should split the dose rather than take it all at once.', 'Amount of calcium absorbed from calcium carbonate is usually stated to be 10%, but ... depends upon amount of gastric acid; in 1 study, 0-2% of single 2 g dose was ... absorbed in achlorhydric persons, 9-16% in normal subjects, and 11-37% in patients with peptic ulcer ...', 'Fraction absorbed seems to be nearly the same when CaCO3 is given chronically in daily doses of 20 g /as when it is given in single 2 g dose/. ... Amount absorbed probably reaches a plateau at a dose of about 20 g.', '... Increased calcium excretion almost always follows admin of antacid doses of calcium carbonate ...', 'For more Absorption, Distribution and Excretion (Complete) data for CALCIUM CARBONATE (15 total), please visit the HSDB record page.']","['None.', 'After ingestion /of CaCO3 tablets/, it is converted to sol calcium salts in stomach, and calcium is thereby made available for absorption.']",
112,10113,Oxamide,C(=O)(C(=O)N)N,,,,,,
113,10114,Enoxolone,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,,,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
114,10115,Hopane,CC(C)[C@H]1CC[C@]2([C@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCCC5(C)C)C)C)C)C,,,,,,
115,10116,delta8(14)-Pimaric acid,CC1(CCC2C(=C1)CCC3C2(CCCC3(C)C(=O)O)C)C=C,,,,,,
116,10117,"Abieta-8(14),13(15)-dien-18-oic acid",CC(=C1CCC2C(=C1)CCC3C2(CCCC3(C)C(=O)O)C)C,,,,,,
117,10118,"(1S,5R,9R,13R)-13-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid",C[C@]12CCC[C@@](C1CC[C@@]34C2CC[C@@](C3)(C(=C)C4)O)(C)C(=O)O,,,,,,
118,10119,"[(3S,5R,10S,13R,14S,16S,17R)-3,14-dihydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",CC(=O)O[C@H]1C[C@@]2(C3CC[C@@H]4C[C@H](CC[C@@]4(C3CC[C@@]2([C@H]1C5=COC(=O)C=C5)C)C)O)O,,,,,,
119,10120,"5-[(3S,5S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)C)O,,,,,,
120,10121,CID 10121,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C,,,,,,
121,10122,"(2R,8aS)-1-[6-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-4-methylhex-3-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol",CC(=CCCC1[C@]2(CCCC(C2CC[C@@]1(C)O)(C)C)C)CC[C@@H]3C(=C)CCCC3(C)C,,,,,,
122,10123,7-epi-alpha-Selinene,CC1=CCCC2(C1CC(CC2)C(=C)C)C,,,,,,
123,10124,Thiazosulfone,C1=CC(=CC=C1N)S(=O)(=O)C2=CN=C(S2)N,,,,,,
124,10125,"AMMONIUM, ETHYL(m-HYDROXYPHENYL)DIMETHYL-, HYDROXIDE",CC[N+](C)(C)C1=CC(=CC=C1)O.[OH-],,,,,,
125,10126,CID 10126,CCCCN=C(NS(=O)(=O)C1=CC=C(C=C1)C)[O-].[Na+],,,,,,
126,10127,Nitrosulfathiazole,C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)NC2=NC=CS2,,,,,,
127,10128,2-Pinanol,CC1(C2CCC(C1C2)(C)O)C,,,,,"['A NUMBER OF TERPENOIDS WERE ORALLY ADMIN TO RABBITS, & THE METABOLITES WERE ISOLATED FROM URINE BY VARIOUS CHROMATOGRAPHIC METHODS. THE MAJOR METABOLITE OF PINANE WAS ALPHA-TERPINEOL & MINOR METABOLITES WERE PINAN-2-OL & PINAN-3-OL.']",
128,10129,Pinane,CC1CCC2CC1C2(C)C,,,,,"['The major metabolite of pinane was alpha-terpineol and minor metabolites were pinan-2-ol and pinan-3-ol.', 'The biotransformation of (+)-, (-)-, and (+-)-alpha-pinenes, (-)-beta-pinene (nopinene), (-)-cis-pinane, (+)-3-carene, (-)-cis-carane, myrcene, and p-cymene in rabbits was investigated. The major metabolites were as follows: (-)-trans-verbenol from (+)-, (-)-, and (+/-)-alpha-pinenes; (-)-10-pinanol and (-)-1-p-menthene-7,8-diol from (-)-beta-pinene; (-)-alpha-terpineol and (-)-trans-sobrerol from (-)-cis-pinane; (-)-m-mentha-4,6-dien-8-ol, 3-caren-9-ol, (-)-3-carene-9-carboxylic acid, and 3-carene-9,10-dicarboxylic acid from (+)-3-carene; carane-9,10-dicarboxylic acid from (-)-cis-carane; and myrcene-3(10)-glycol, myrcene-1,2-glycol, uroterpenol, and p-cymene-9-carboxylic acid from p-cymene. These metabolisms include allylic oxidation, epoxidation, stereoselective gem-dimethyl hydroxylation and its oxidation, cleavage of a conjugated double bond by epoxidation, and regioselective oxidation, some of which are not found usually in chemical reactions, and due to which various new compounds were determined. This biotransformation of the monoterpene hydrocarbons gave some insect pheromones in high yield.']",
129,10130,Pinonic acid,CC(=O)C1CC(C1(C)C)CC(=O)O,,,,,,
130,10131,Pinic acid,CC1(C(CC1C(=O)O)CC(=O)O)C,,,,,,
131,10132,Mesoxalic acid,C(=O)(C(=O)O)C(=O)O,,,,,,
132,10133,Chenodeoxycholic acid,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,"['Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.']","['It acts by reducing levels of cholesterol in the bile, helping gallstones that are made predominantly of cholesterol to dissolve. Chenodeoxycholic acid is ineffective with stones of a high calcium or bile acid content.']","['Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']","['Chenodiol is well absorbed from the small intestine.', 'About 80% of its bacterial metabolite lithocholate is excreted in the feces.']","['Chenodiol is well absorbed from the small intestine and taken up by the liver where it is converted to its taurine and glycine conjugates and secreted in bile. At steady-state, an amount of chenodiol near the daily dose escapes to the colon and is converted by bacterial action to lithocholic acid. About 80% of the lithocholate is excreted in the feces; the remainder is absorbed and converted in the liver to its poorly absorbed sulfolithocholyl conjugates. During chenodiol therapy there is only a minor increase in biliary lithocholate, while fecal bile acids are increased three- to fourfold.']",
133,10134,"17-[(5R)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",C[C@H](CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C,,,,,,
134,10135,CID 10135,CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CC[C@@H](C4)O)C)C,,,,,,
135,10136,CID 10136,CC1CC([C@@H](NC1)[C@@H](C)C2=C(C3=C(C=C2)[C@@H]4CC=C5CC(CCC5([C@H]4C3)C)OC6C(C(C(C(O6)CO)O)O)O)C)O,,,,,,
136,10137,"(1S,7S)-3,3,7-trimethyl-8-methylidenetricyclo[5.4.0.02,9]undecane",C[C@]12CCCC(C3[C@@H]1CCC3C2=C)(C)C,,,,,,
137,10138,CID 10138,C1C2=CC(=O)C(=CC2=C3C1(COC4=C3C=CC(=C4O)O)O)O,,,,,,
138,10139,Fluorogesarol,C1=CC(=CC=C1C(C2=CC=C(C=C2)F)C(Cl)(Cl)Cl)F,,,,,,
139,10140,Glycocholic acid,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)']",,,
140,10141,"5,8-Dihydroxy-1,4-naphthoquinone",C1=CC(=C2C(=O)C=CC(=O)C2=C1O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
141,10142,CID 10142,CC1=C(C(=O)C(=C2C(=O)C(=C(C(=O)C2=O)C)O)C(=C1O)O)O,,,,,,
142,10143,Isocorydine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC)OC,,,,,,
143,10144,Liriodenine,C1OC2=C(O1)C3=C4C(=C2)C=CN=C4C(=O)C5=CC=CC=C53,,,,,,
144,10145,"1,2,9,10-Tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline",CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC)OC)OC,,,,,,
145,10146,Nuciferine,CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=CC=C43)OC)OC,,,,,,
146,10147,Chelidonine (+),CN1CC2=C(C=CC3=C2OCO3)C4C1C5=CC6=C(C=C5CC4O)OCO6,,,,,,
147,10148,Cynodontin,CC1=CC(=C2C(=C1O)C(=O)C3=C(C=CC(=C3C2=O)O)O)O,,,,,,
148,10149,Javanicin,CC1=C(C(=C2C(=C1O)C(=O)C=C(C2=O)OC)O)CC(=O)C,,,,,,
149,10150,Catenarin,CC1=CC(=C2C(=C1O)C(=O)C3=C(C2=O)C(=CC(=C3)O)O)O,,,,,,
150,10151,Islandicin,CC1=CC(=C2C(=C1O)C(=O)C3=C(C2=O)C(=CC=C3)O)O,,,,,,
151,10152,Erythroglaucin,CC1=CC(=C2C(=C1O)C(=O)C3=C(C2=O)C(=CC(=C3)OC)O)O,,,,,,
152,10153,Corydine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)OC)OC)O)OC,,,,,,
153,10154,Boldine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
154,10155,"Benzene-1,2,3,4-tetracarboxylic acid",C1=CC(=C(C(=C1C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
155,10156,"7-Acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a]heptalen-9(5H)-one",CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)O)OC)OC)OC,,,,,['Colchiceine is a known human metabolite of (R)-colchicine.'],
156,10157,"(10-Acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl) 2-methylbutanoate",CCC(C)C(=O)OC1C(C2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C)OC(=O)C,,,,,,
157,10158,(+)-Samidin,CC(=CC(=O)OC1C(C2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C)OC(=O)C)C,,,,,,
158,10159,"1,8-Dimethyl-5-phenylphenazin-5-ium-2,7-diamine;chloride",CC1=CC2=NC3=C(C=CC(=C3C)N)[N+](=C2C=C1N)C4=CC=CC=C4.[Cl-],,,,,,
159,10160,"1,8-Dimethyl-5-phenylphenazin-5-ium-2,7-diamine",CC1=CC2=NC3=C(C=CC(=C3C)N)[N+](=C2C=C1N)C4=CC=CC=C4,,,,,,
160,10161,Benzoflavine,CC1=CC2=C(C=C1N)N=C3C=C(C(=CC3=C2C4=CC=CC=C4)C)N,,,,,,
161,10162,"ACRIDINE, 3-AMINO-9-(p-AMINOPHENYL)-",C1=CC=C2C(=C1)C(=C3C=CC(=CC3=N2)N)C4=CC=C(C=C4)N,,,,,,
162,10163,Lucidin,C1=CC=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)CO)O,,,,,,
163,10164,"13-Berbinol, 9,10-dimethoxy-2,3-(methylenedioxy)-",COC1=C(C2=C(C=C1)C(C3C4=CC5=C(C=C4CCN3C2)OCO5)O)OC,,,,,,
164,10165,Capauridin,COC1=C(C2=C(CC3C4=C(C(=C(C=C4CCN3C2)OC)OC)O)C=C1)OC,,,,,,
165,10166,Eleutherin,C[C@H]1CC2=C([C@H](O1)C)C(=O)C3=C(C2=O)C=CC=C3OC,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
166,10167,Khellinol,CC1=CC(=O)C2=C(O1)C(=C3C(=C2O)C=CO3)OC,,,,,,
167,10168,Rhein,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)C(=O)O,['No approved indication.'],"['**Liver: **Reverses animal models of non-alcoholic fatty liver disease by lowering liver lipids and reducing inflammation. Also reverses and prevents fibrosis in liver injury.  **Kidney: **Protects against fibrosis in nephropathy models and improves epithelial tight junction function.  **Bone and joint:** Decreases inflammation and cartilage destruction and also corrects altered osteoblast acitivity.  **Lipid lowering and anti-obesity:** Reduces body weight and fat content, and lowers high density lipoprotein and low density lipoprotein. May prevent adipocyte differentiation.  **Anti-oxidant/Pro-oxidant**: Reduces levels of reactive oxygen species (ROS) at concentrations of about 2-16 microM but induces the generation of ROS at concentrations of 50 microM and above.  **Anti-cancer:** Rhein has been observed to produce DNA damage and suppress DNA repair in cancer cells. It induces apoptosis via ER stress, calcium, and mitochondria mediated pathways. Rhein also prevents cancer cell invasion into systemic circulation by preventing angiogenesis and breakdown of the extracellular matrix. Finally, rhein suppresses the activation of several tumor promoting signalling pathways.  **Anti-inflammatory: ** Suppresses the production of pro-inflammatory cytokines such as interleukin-1beta and interleukin-6.  **Anti-diabetic: **Lowers plasma glucose and increases survival of islet beta cells in type 2 diabetes mellitus models.  **Anti-microbial:** Inhibits arylamine N-acteyltransferase and cell growth in Helicobacter pylori. Rhien also appears to be effective against many genotypes of Staphylococcus aureus.  **Anti-allergenic:** Inhibits production of leukotrienes and the release of histamine from mast cells.']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],"['Tmax of 1.6-2.6 hours.', '37% is excreted in urine and 53% in feces as estimated in rats.', '15-60L.', 'Total CL is 1.5 L/h and renal CL is 0.1 L/h.']",['Metabolized primarily to rhein glucuronide and rhien sulfate.'],['4-10h.']
168,10169,"4,5,7-Trihydroxy-9,10-dioxo-9,10-dihydroanthracene-1-carboxylic acid",C1=CC(=C2C(=C1C(=O)O)C(=O)C3=C(C2=O)C(=CC(=C3)O)O)O,,,,,,
169,10170,CID 10170,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
170,10171,2-Bromolysergic acid diethylamide,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C,,,,,,
171,10172,APO-beta-ERYTHROIDINE,C1CN2CCC3=C2C(=CC=C3)C4=C1COC(=O)C4,,,,,,
172,10173,"6-Methyl-9,10-didehydroergoline-8-carboxamide",CN1CC(C=C2C1CC3=CNC4=CC=CC2=C34)C(=O)N,,,,,,
173,10174,CID 10174,C1=CC2=C(C=C1O)OC3=C4C=CC(=O)C=C4OC(=C23)O,,,,,,
174,10175,Cotoin,COC1=CC(=C(C(=C1)O)C(=O)C2=CC=CC=C2)O,,,,,,
175,10176,Cholanthrene,C1CC2=C3C1=CC=CC3=CC4=C2C=CC5=CC=CC=C54,,,,,,
176,10177,Indirubin,C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)']",,,
177,10178,Tetryl,CN(C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,"['Seven rabbits orally administered 36 mg/kg/day (range of 32.3-40.0 mg/kg/day) for up to 30 days excreted picramic acid in their urine. Picramic acid was not detected in the urine of two control rabbits (the detection limit was 0.05 mg/L). In addition, the ratio of sulfoconjugates to total sulfates increased with duration of treatment in the treated rabbits, but not in the controls. These data support the hypothesis that tetryl is metabolized to picric acid by removal of the methylnitramine complex, and further metabolized to picramic acid by reduction of a nitro group. The increased sulfoconjugates may be caused by conjugation of picramic acid to sulfates.', 'Studies in rabbits have shown that after oral administration, tetryl was metabolized to picric acid, which was further metabolized to picramic acid by nitro reduction.']",
178,10179,"1,2,3,5-Benzene-tetracarboxylic acid",C1=C(C=C(C(=C1C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
179,10180,Lucanthone,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O,['Intended for use as a radiation sensitizer in the treatment of brain cancer.'],"['Although lucanthone has structural and biochemical similarities to Actinomycin D, it has no hematological or gastro-intestinal toxicity at clinically tolerated doses. In trials, Lucanthone was found to be safe, practical and effective and was proposed for use in clinical protocols for the treatment of cancer. The specificity of lucanthone in combination with radiation for the treatment of brain tumors arises from the fact that lucanthone acts preferentially on cycling cells (most of the normal brain cells are non-cycling) and the fact that lucanthone crosses the blood brain barrier efficiently.']",['Agents that act systemically to kill adult schistosomes. (See all compounds classified as Schistosomicides.)'],['Orally available'],,
180,10181,CID 10181,CCC1=C(C2=NC1=CC3=C(C4=C([N-]3)C(=C5[C@H]([C@@H](C(=N5)C=C6C(=C(C(=C2)[N-]6)C=C)C)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)[C@H](C4=O)C(=O)OC)C)C.[Mg+2],,,,,,
181,10182,CID 10182,CCC1=C(C2=NC1=CC3=C(C4=C([C@@H](C(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C4=N3)C(=O)OC)O)C)C,,,,,,
182,10183,CID 10183,CC1(CC2=C(CO1)C(=C3C(=CC(=O)C(=C3C(=O)O)O)O2)O)O,,,,,,
183,10184,11H-Benzo[a]fluoren-11-one,C1=CC=C2C(=C1)C=CC3=C2C(=O)C4=CC=CC=C34,,,,,,
184,10185,"(2r)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4h-chromen-4-one",C1=CC(=C(C=C1[C@@H]2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,,,,,,
185,10186,CID 10186,COC1=C(C=CC(=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O)O,,,,,,
186,10187,"1,8,9-Trihydroxyanthracene",C1=CC2=CC3=C(C(=CC=C3)O)C(=C2C(=C1)O)O,,,['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)'],,,
187,10188,Dichloralphenazone,CC1=CC(=O)N(N1C)C2=CC=CC=C2.C(C(Cl)(Cl)Cl)(O)O.C(C(Cl)(Cl)Cl)(O)O,,,,,,
188,10189,Eugenin,CC1=CC(=O)C2=C(C=C(C=C2O1)OC)O,,,,,,
189,10190,CID 10190,CCCCC[C@H]([C@@H]1[C@H](C[C@H](C[C@H](C[C@H](C[C@H](C[C@H](C[C@@H](C(=CC=CC=CC=CC=C[C@@H]([C@H](OC1=O)C)O)C)O)O)O)O)O)O)O)O,,,,,,
190,10191,"(1R,6R,7S,17R)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione",CC=C1C[C@H]([C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(CO)O)C,,,,,,
191,10192,CID 10192,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=CC=C3)Cl.Cl,,,,,,
192,10193,CID 10193,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=CC=C3)Cl,,,,,,
193,10194,"2,4,6-Trimethylbenzoic acid",CC1=CC(=C(C(=C1)C)C(=O)O)C,,,,,,
194,10195,5-Nitrobarbituric acid,C1(C(=O)NC(=O)NC1=O)[N+](=O)[O-],,,,,,
195,10196,"(1R,7R,17R)-4-ethylidene-7-hydroxy-7-methyl-6-methylidene-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione",CC=C1CC(=C)[C@@](C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC1=O)(C)O,,,,,,
196,10197,CID 10197,C[C@@H](C(C(C)C)(C(=O)OCC1=CCN2[C@@H]1[C@H](CC2)O)O)O,,,,,,
197,10198,Retronecine,C1CN2CC=C([C@@H]2[C@@H]1O)CO,,,,"['Lactating rats dosed with (3)H-retronecine excreted within 3 hr approx 0.08% of the applied radioactivity in the milk mainly as yet not identified water soluble retronecine-derived metabolites and approx 0.02% as unchanged pyrrolizidine alkaloids (pas). Highest tissue levels of pas and metabolites, 6 hr after admin were found in liver and lungs.']","['Steric hindrance around the ester groups was the major factor inhibiting hydrolysis of pyrrolizidine alkaloids. Enzymic hydrolysis of retronecine di-isovalerate occurred primarily at the allylic 9-ester group. The results supported the view that a factor contributing to the lower hepatotoxicity of semisynthetic retronecine diesters compared with some natural pyrrolizidine alkaloids, is their greater susceptibility to detoxication by hydrolysis.', 'Levels of pyrrolic metabolites were measured in the livers of rats given some pyrrolizidine alkaloids and semisynthetic derivatives. Structural and chemical features favoring the formation of such metabolites were defined. The most important of these were steric hindrance or chemical properties giving resistance to ester hydrolysis; lipophilic character, allowing access to hepatic microsomal enzymes; a conformation favoring microsomal oxidation of the pyrroline ring in preference to n-oxidation.', 'Levels of pyrrolic metabolites were measured in the livers of rats given some pyrrolizidine alkaloids and semisynthetic derivatives. ... Heliotridine-based alkaloids gave more pyrrole than similar retronecine esters, heliotridine ditiglate gave less pyrrole than retronecine ditiglate because the former was more open to hydrolytic attack.']",
198,10199,Isoindolin-1-one,C1C2=CC=CC=C2C(=O)N1,,,,,,
199,10200,1H-Indole-3-thiol,C1=CC=C2C(=C1)C(=CN2)S,,,,,,
200,10201,"(3aS,5aS,9bS)-3,5a,9-trimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione",CC1[C@@H]2CC[C@]3(C=CC(=O)C(=C3[C@H]2OC1=O)C)C,,,,,,
201,10202,"Cholestane, (5alpha)-",CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C,,,,,,
202,10203,"(3S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one",CC12CC[C@@H](CC1CCC3C2CCC4(C3CCC4=O)C)O,,,,,,
203,10204,Epitestosterone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@H]2O)CCC4=CC(=O)CC[C@]34C,,,,,['Epitestosterone has known human metabolites that include Epitestosterone O-glucuronide.'],
204,10205,Plumbagin,CC1=CC(=O)C2=C(C1=O)C=CC=C2O,,,"['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Chemical substances that prevent or reduce the probability of CONCEPTION. (See all compounds classified as Contraceptive Agents.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
205,10206,Cepharanthine,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
206,10207,Aloe-emodin,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CO,,,,,,
207,10208,Chrysophanol,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],"['A comparative oral pharmacokinetic study of five anthraquinones (aloe-emodin, emodin, rhein, chrysophanol and physcion) from the extract of Rheum palmatum L. was performed in normal and thrombotic focal cerebral ischemia (TFCI)-induced rats. The plasma samples were clarified through solid phase extraction prior to simultaneous determination of the anthraquinones with a validated high-performance liquid chromatography-fluorescence system. The results indicated that the Cmax, t(1/2) and AUC(0-t), of aloe-emodin, rhein, emodin and chrysophanol in TFCI-induced rats were nearly double, whereas the CL values were remarkably decreased (p < 0.05) over those of the normal rats. The plasma drug concentration-time data of five anthraquinones to rats fitted a two-compartment open model. The five anthraquinones in rat plasma were absorbed quickly and eliminated slowly in both groups. The obtained results could be helpful for evaluating the impact of the efficacy and safety of the drug in clinical applications.', 'ETHNOPHARMACOLOGICAL RELEVANCE: Quyu Qingre granules (QYQRGs) are useful traditional Chinese composite prescription in the treatment of blood stasis syndrome. Comparing differences of pharmacokinetic properties of compounds in QYQRG between normal and blood stasis syndrome rabbits can provide much helpful information. The primary objective of this study was to compare the pharmacokinetics of rhein and chrysophanol after orally administering 2.0 g/kg b.w. QYQRG in normal and acute blood stasis model rabbits.  MATERIALS AND METHODS: The blood samples were collected subsequently at 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 240, 360 and 480 min after orally administrating QYQRG. The concentrations of rhein and chrysophanol in rabbit plasma were determined by HPLC and main pharmacokinetic parameters were obtained.  RESULTS: The pharmacokinetic parameters AUC(0-infinity), T(lag), Cmax and K21 of both rhein and chrysophanol were markedly different in the acute blood stasis model rabbits. It was also found that parameters A, beta, MRT and T(1/2beta) of rhein and the parameters a and T1/2a of chrysophanol all exhibited significant difference between the normal and acute blood stasis model rabbits.  CONCLUSIONS: The absorption time of rhein and chrysophanol was accelerated and the absorption amount of these two compounds was increased in rabbits with acute blood stasis, suggesting that rhein and chrysophanol would possibly be the two effective compounds in QYQRG.', 'AIM OF THE STUDY: The present study comparatively investigated the tissue distributions of rhubarb anthraquinone derivatives (AQs) to examine whether they undergo different uptakes in normal or CCl(4)-induced liver-damaged rats, to explore possible reasons for the different toxicities of AQs in pathological model rats and normal rats at the tissue distribution level.  MATERIALS AND METHODS: The total rhubarb extract (14.49 g/kg of body weight per day based on the quantity of crude material) was administrated orally to normal and model rats for 12 weeks. The concentrations of free AQs in tissues were quantitated by liquid chromatography-tandem mass spectrometry (LC-MS). After drug withdrawal for 4 weeks, tissue distributions were again determined.  RESULTS: The five free AQs-aloe-emodin, rhein, emodin, chrysophanol and physcion-were detected in the liver, kidney and spleen, while only rhein, aloe-emodin and emodin reached the quantitative limit. The tissue distributions of rhein (p < 0.001), aloe-emodin (p < 0.001) and emodin (p < 0.05) in normal rats were higher than those in model rats with rhein>aloe-emodin>emodin in kidney and spleen tissues and aloe-emodin > rhein > emodin in liver tissues. Free AQs were not detected in the tissues after drug withdrawal for 4 weeks.  CONCLUSIONS: These results suggest that the tissue toxicity of AQs in normal animals is higher than that in pathological model animals with little accumulative toxicity of rhubarb. The results are concordant with the traditional Chinese theory of You Gu Wu Yun recorded first in Su Wen, a classical Chinese medical treatise.']","['The studies presented here were designed to elucidate the enzymes involved in the biotransformation of naturally occurring 1, 8-dihydroxyanthraquinones and to investigate whether biotransformation of 1,8-dihydroxyanthraquinones may represent a bioactivation pathway. We first studied the metabolism of emodin (1, 3,8-trihydroxy-6-methylanthraquinone), a compound present in pharmaceutical preparations. With rat liver microsomes, the formation of two emodin metabolites, omega-hydroxyemodin and 2-hydroxyemodin, was observed. The rates of formation of omega-hydroxyemodin were not different with microsomes from rats that had been pretreated with inducers for different cytochrome P450 enzymes. Thus, the formation of omega-hydroxyemodin seems to be catalyzed by several cytochrome P450 enzymes at low rates. The formation of 2-hydroxyemodin was increased in liver microsomes from 3-methylcholanthrene-pretreated rats and was inhibited by alpha-naphthoflavone, by an anti-rat cytochrome P450 1A1/2 antibody, and, to a lesser degree, by an anti-rat cytochrome P450 1A1 antibody. These data suggest the involvement of cytochrome P450 1A2 in the formation of this metabolite. However, other cytochrome P450 enzymes also seem to catalyze this reaction. The anthraquinone chrysophanol (1,8-dihydroxy-3-methylanthraquinone) is transformed, in a cytochrome P450-dependent oxidation, to aloe-emodin (1, 8-dihydroxy-3-hydroxymethylanthraquinone) as the major product formed. The mutagenicity of the parent dihydroxyanthraquinones and their metabolites was compared in the in vitro micronucleus test in mouse lymphoma L5178Y cells. 2-Hydroxyemodin induced much higher micronucleus frequencies, compared with emodin. omega-Hydroxyemodin induced lower micronucleus frequencies, compared with emodin. Aloe-emodin induced significantly higher micronucleus frequencies than did chrysophanol. These data indicate that the cytochrome P450-dependent biotransformation of emodin and chrysophanol may represent bioactivation pathways for these compounds.', 'Chrysophanol, a major anthraquinone component occurring in many traditional Chinese herbs, is accepted as important active component with various pharmacological actions such as antibacterial and anticancer activity. Previous studies demonstrated that exposure to chrysophanol induced cytotoxicity, but the mechanisms of the toxic effects remain unknown. In the present metabolism study, three oxidative metabolites (M1-M3, aloe-emodine, 7-hydroxychrysophanol, and 2-hydroxychrysophanol) and five GSH conjugates (M4-M8) were detected in rat and human liver microsomal incubations of chrysophanol supplemented with GSH, and the formation of the metabolites was NADPH dependent except M4 and M5. M4 and M5 were directly derived from parent compound chrysophanol, M6 arose from M2, and M7 and M8 resulted from the oxidation of M4 and M5. Metabolites M5 and M6 were also observed in bile of rats after exposure to chrysophanol, M1-M3 and one NAC conjugate (M9) were detected in urine of rats administrated chrysophanol, and urinary metabolite M9 originated from the degradation of biliary GSH conjugation M6. Recombinant P450 enzyme incubation and microsome inhibition studies demonstrated that P450 1A2 was the primary enzyme responsible for the metabolic activation of chrysophanol and that P450 2B6 and P450 3A4 also participated in the generation of the oxidative metabolites. ...']",
208,10209,Menadiol,CC1=C(C2=CC=CC=C2C(=C1)O)O,,,,,,
209,10210,Diphenic acid,C1=CC=C(C(=C1)C2=CC=CC=C2C(=O)O)C(=O)O,,,,,,
210,10211,Byakangelicin,CC(C)([C@@H](COC1=C2C(=C(C3=C1OC(=O)C=C3)OC)C=CO2)O)O,,,,,,
211,10212,Imperatorin,CC(=CCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)C,,,,"['A rapid and sensitive assay for the quantification of imperatorin in plasma and tissues has been developed. An analysis was performed by gas chromatography/mass spectrometry in the selected ion-monitoring mode. The main pharmacokinetic parameters obtained were T(max) = 1.23 +/- 0.26 hr, C(max) = 0.95 +/- 0.38 ug/mL, AUC = 3.42 +/- 0.52 hr ug/mL and K(a) = 1.34 +/- 0.18 hr. The experimental results showed that imperatorin was easily absorbed, but its elimination was slow, from 3 to 12 hr after oral administration. The concentrations of imperatorin in rat liver, kidney, lung, and heart were higher than those in other organs. To determine the free fraction in serum, samples were filtered using ultrafiltration membranes with a molecular weight cut-off of 10 kDa, and extracted using liquid-liquid extraction. The protein binding values in rat plasma, spontaneous hypertensive rat plasma, human plasma and human serum albumin were 84 +/- 3, 69 +/- 7, 81 +/- 7 and 75 +/- 3%, respectively.', 'In this study, a simple and sensitive gas chromatography-mass spectrometry method was developed for the study of bioavailability and protein binding and the metabolism of imperatorin in rat. The results showed that the pharmacokinetics of imperatorin after intravenous and oral administration in rats exhibited linear characteristics. The absolute bioavailability of imperatorin was calculated as approximately 3.85, approximately 33.51 and approximately 34.76% for 6.25, 12.5 and 25 mg/kg, respectively. The low bioavailability of imperatorin may be attributed to the poor absorption or extensive metabolism. The phase I metabolites of imperatorin formed in vitro by rat liver microsomes were studied, and two metabolites were isolated and identified as xanthotoxol and heraclenin. Following oral administration of imperatorin, one metabolite (heraclenin) was detected in rat plasma, and two potential metabolites (xanthotoxol and heraclenin) were detected in rat urine. However, none of potential metabolites was detected in rat feces and bile. The results showed that the metabolites of imperatorin were excreted by kidney, and heraclenin was associated with an active component. Demethylation and oxygenization were the main metabolic pathways. In vitro plasma protein binding of imperatorin was 90.1 and 92.6% for the spiked rat plasma concentrations of 1.0 and 50.0 ug/mL, respectively, indicating that imperatorin showed slow distribution into the intra- and extracellular space.']","['Imperatorin (IMP) is a major constituent of many herbal medicines and possesses anti-osteoporosis activity. The present research work aimed to study the biotransformation processes of IMP and evaluated the anti-osteoporosis activity of the transformed metabolites. Among 18 strains of filamentous fungi screened, Penicillium janthinellum AS 3.510 exhibited good capability to metabolize IMP to the new derivatives. Ten transformed products were isolated and purified, and their structures were identified accurately based on spectroscopic data. Eight metabolites (2-8 and 10) were novel and previously unreported. The major biotransformation reactions involved hydroxylation of the prenyloxy side-chain and the lactone ring-opening reaction of furocoumarin skeleton. In addition, anti-osteoporosis activities of all products (1-10) were evaluated using MC3T3-E1 cells. The results showed that products 5 and 8 had the best bioactivities in increasing MC3T3-E1 cell growth. These products could be used in future therapeutic regimens for treating osteoporosis.', 'In this study, a simple and sensitive gas chromatography-mass spectrometry method was developed for the study of bioavailability and protein binding and the metabolism of imperatorin in rat. The results showed that the pharmacokinetics of imperatorin after intravenous and oral administration in rats exhibited linear characteristics. The absolute bioavailability of imperatorin was calculated as approximately 3.85, approximately 33.51 and approximately 34.76% for 6.25, 12.5 and 25 mg/kg, respectively. The low bioavailability of imperatorin may be attributed to the poor absorption or extensive metabolism. The phase I metabolites of imperatorin formed in vitro by rat liver microsomes were studied, and two metabolites were isolated and identified as xanthotoxol and heraclenin. Following oral administration of imperatorin, one metabolite (heraclenin) was detected in rat plasma, and two potential metabolites (xanthotoxol and heraclenin) were detected in rat urine. However, none of potential metabolites was detected in rat feces and bile. The results showed that the metabolites of imperatorin were excreted by kidney, and heraclenin was associated with an active component. Demethylation and oxygenization were the main metabolic pathways. In vitro plasma protein binding of imperatorin was 90.1 and 92.6% for the spiked rat plasma concentrations of 1.0 and 50.0 ug/mL, respectively, indicating that imperatorin showed slow distribution into the intra- and extracellular space.']",
212,10213,"Glycine, N,N'-1,2-cyclohexanediylbis[N-(carboxymethyl)-",C1CCC(C(C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
213,10214,Phosphoadenosine phosphosulfate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OS(=O)(=O)O)OP(=O)(O)O)O)N,,,,,,
214,10215,Indigo,C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],['WAS OBSERVED IN 24-HR URINE SAMPLES COLLECTED AT 14-DAY INTERVALS FROM 6 SHEEP GRAZING PASTURE OF OESTROGENIC CLOVER FROM JULY TO LATE OCTOBER. GENERALLY IT OCCURRED IN ONLY 1 URINE SAMPLE AT EACH COLLECTION BUT FROM MID-AUGUST TO MID-SEPTEMBER IT WAS PRESENT IN 3 OR 4 SAMPLES.'],"['TWO MOLECULES OF INDOLE WERE OXIDIZED TO FORM ONE MOLECULE OF INDIGOTIN (INDIGO) IN PSEUDOMONAS INDOLOXIDANS, WITH INDOXYL BEING DETECTED AS INTERMEDIATE.']",
215,10216,"Methyl 16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-4,6,8,18-tetraene-19-carboxylate",CC1C2CN3CCC4C(C3CC2C(=CO1)C(=O)OC)NC5=CC=CC=C45,,,,,,
216,10217,Dihydroberberine,COC1=C(C2=C(C=C1)C=C3C4=CC5=C(C=C4CCN3C2)OCO5)OC,,,,,,
217,10218,"(1R)-1-[[(3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol",CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2CC1C[C@@H]4C5=CC(=C(C=C5CCN4)O)OC)OC)OC,,,,,,
218,10219,Emetine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,,,"['Agents which are destructive to amebae, especially the parasitic species causing AMEBIASIS in man and animal. (See all compounds classified as Amebicides.)', 'Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)', 'Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)', 'Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla. (See all compounds classified as Emetics.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']","['EMETINE IS ABSORBED FROM PARENTERAL SITES OF ADMINISTRATION & IS EXCRETED ... SLOWLY.', 'ALTHOUGH DRUG APPEARS IN URINE 20-40 MIN AFTER INJECTION, EMETINE CAN STILL BE FOUND THERE 40-60 DAYS AFTER TREATMENT HAS BEEN DISCONTINUED. ... HIGHEST CONCN OF ALKALOID IS FOUND IN LIVER ... APPRECIABLE AMT ARE ALSO FOUND IN LUNG, KIDNEY, & SPLEEN.', '... EMETINE SHOWS A PREDILECTION FOR ACCUMULATING IN MUSCULAR ORGANS ... .']","['AMINOACYLATION OF EMETINE', 'Emetine undergoes slow hepatic metabolism, with urine metabolites detectable for 40-60 days ... .']",
219,10220,(+/-)-Isocorypalmine,COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)OC,,,,,,
220,10221,"2-Hydroxy-3-methyl-1,4-naphthoquinone",CC1=C(C2=CC=CC=C2C(=O)C1=O)O,,,,,,
221,10222,Retene,CC1=C2C=CC3=C(C2=CC=C1)C=CC(=C3)C(C)C,,,,,,
222,10223,"Cadina-1(10),4-diene",CC1=CC2C(CCC(=C2CC1)C)C(C)C,,,,,,
223,10224,"1,6-Dimethyl-4-isopropyltetralin",CC1CCC(C2=C1C=CC(=C2)C)C(C)C,,,,,,
224,10225,Cadalene,CC1=CC2=C(C=CC(=C2C=C1)C)C(C)C,,,,,,
225,10226,Flavianic acid,C1=CC2=C(C=C1S(=O)(=O)O)C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
226,10227,Kokusaginine,COC1=C(C=C2C(=C1)C(=C3C=COC3=N2)OC)OC,,,,,,
227,10228,Osthole,CC(=CCC1=C(C=CC2=C1OC(=O)C=C2)OC)C,,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']","['ETHNOPHARMACOLOGICAL RELEVANCE: Libanotis buchtormensis is the source of an important traditional medicine from Shaanxi province of China used in the treatment of many illnesses. Libanotis buchtormensis supercritical extract (LBSE) has analgesic, sedative and anti-inflammatory qualities. Osthole is one of the major bioactive components of LBSE; it is known for its significant anti-tumor, analgesic, and anti-inflammatory properties, it also alleviates hyperglycemia.  AIM OF THE STUDY: The purpose of the present study was to compare the pharmacokinetics and tissue distribution of osthole in Sprague-Dawley (SD) rats after oral administration of pure osthole and LBSE. The two preparations were administered at the same osthole dose (approximately 130 mg/kg). The results should provide some guidance for the clinical applications of Libanotis buchtormensis.  MATERIALS AND METHODS: Comparative pharmacokinetics and tissue distribution of osthole in SD rats after oral administration of pure osthole and LBSE were analyzed using reversed-phase high-performance liquid chromatography (RP-HPLC). All pharmacokinetic data were analyzed using 3P97 software. Samples of blood and internal organs (heart, liver, spleen, lungs and kidney) were collected and pretreated according to the experimental schedule. After pretreatment, plasma and tissue samples were extracted using ether-ethyl acetate mixture (3:1, v/v). The concentration of osthole in the plasma and tissues were determined using the RP-HPLC method.  RESULTS: The procedure described in this paper shows good precision and stability and is suitable for the osthole assays in biological samples. We found that the average plasma concentration-time profile of osthole after oral administration of osthole and LBSE showed a single peak. There were also clear differences between plasma concentrations of osthole after oral administration of pure osthole and LBSE. Non-osthole ingredients in LBSE showed some pharmacokinetic interactions with osthole and hence decreased its absorption levels (p<0.05). Our results show different tissue distribution of osthole in the single and composite administration regimens.  CONCLUSIONS: This study compares the pharmacokinetic characteristics and tissue distribution of osthole in rats after oral administration of pure osthole and LBSE; the results might be useful in clinical application of this traditional Chinese herbal medicine.', ""ETHNOPHARMACOLOGICAL RELEVANCE: Bushen Yizhi prescription (BSYZ) is a traditional Chinese compound prescription, which is commonly used in China for treating ShenXu and hypophrenia based on traditional Chinese medicine and Alzheimer's Disease according to modern Chinese medicine. Cnidium monnieri (L.) Cusson fruits (CM) is treated as the main herb of BSYZ, and its main active ingredient Osthole (OST) is considered as one of the major active ingredients of BSYZ. Even though OST plays an important role in the BSYZ its bioavailability is poor. In order to investigate whether the bioavailability of OST was influenced by BSYZ and CM extract, the comparative evaluations on pharmacokinetics of OST after oral administration of pure OST at different doses, CM and BSYZ extract were studied.  MATERIALS AND METHODS: 30 rats were randomly assigned to five groups and orally administered with pure OST at different doses (15, 75 and 150 mg/kg), CM (15 mg/kg OST) and BSYZ (15 mg/kg OST) extract. At different predetermined time points after administration, the concentrations of OST in rat plasma were determined by using the HPLC-UV method, and main pharmacokinetic parameters were investigated.  RESULTS: The results showed that the pharmacokinetic parameters of OST were significantly different (p<0.05) among the groups. The AUC(0 to t), AUC(0 to infinity) and Cmax of OST were significantly increased after oral administration of BSYZ extract, followed by CM extract, in comparison to pure osthole at different doses.  CONCLUSIONS: This present study indicated that the bioavailability of pure OST after oral administration was extremely low and it was dramatically enhanced because of the synergistic effect of the traditional Chinese Bushen Yizhi prescription."", 'A simple high-performance liquid chromatographic method was developed to study the pharmacokinetics of osthole in rat plasma. After addition of an internal standard (paeonol), plasma was deproteinized by acetonitrile for sample clean-up. The drugs were separated on a reversed-phase column and detected by UV absorption at 323 nm. Acetonitrile-water-diethylamine (50:50:0.1, v/v/v) (pH 3.0, adjusted with orthophosphoric acid) was used as the mobile phase. It was applied to the pharmacokinetic study of osthole in rats after a dose of 10 mg/kg by intravenous administration. A biphasic phenomenon with a rapid distribution followed by a slower elimination phase was observed from the plasma concentration-time curve.']","['Osthole is an active ingredient and one of the major coumarin compounds that were identified in the genus Cnidium moonnieri (L.) Cussion, the fruit of which was used as traditional Chinese medicine to treat male impotence, ringworm infection and blood stasis conventionally. Recent studies revealed that osthole has diverse pharmacological effects, such as improving male sexual dysfunction, anti-diabetes, and anti-hypertentions. The inhibition of thrombosis and platelet aggregation and protection of central nerve were also observed. On the other hand, the metabolism of osthole has not yet been investigated thoroughly. Herein the biotransformation of osthole in rat was investigated after oral administration of osthole by using efficient and sensitive ultra-performance liquid chromatography-tandem quadrupole-time of flight mass spectrometry (UPLC-QTOF/MS). Eighteen osthole metabolites and the parent drug were detected and identified in rat urine. Fourteen metabolites of osthole were identified and characterized for the first time. Structures of metabolites of osthole were elucidated by comparing fragment pattern under MS/MS scan and change of molecular weight with those of osthole. The main phase I metabolic pathways were summed as 7-demethylation, 8-dehydrogenation, hydroxylation on coumarin and 3,4-epoxide. Sulfate conjugates were detected as phase II metabolites of osthole.', ""The biotransformation of osthole (1) by Alternaria longipes was carried out, and five transformed products were obtained in the present research work. Based on their extensive spectral data, the structures of these metabolites were characterized as 4'-hydroxyl-osthole (2), 4'-hydroxyl-2',3'-dihydroosthole (3), 2',3'-dihydroxylosthole (4), osthole-4'-oic acid methyl ester (5), and osthole-4'-oic acid glucuron-1-yl ester (6), respectively. Among them, products 5 and 6 were new compounds.""]",
228,10229,9-Phenanthrol,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)O,,,['Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)'],,,
229,10230,Dihydralazine,C1=CC=C2C(=C1)C(=NN=C2NN)NN,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
230,10231,Dillapiol,COC1=C(C2=C(C=C1CC=C)OCO2)OC,,,,,,
231,10232,"2,4,5-Triphenylimidazole",C1=CC=C(C=C1)C2=C(N=C(N2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
232,10233,Reticulin,CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)O)O)OC,,,,,,
233,10234,Binapacryl,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)C=C(C)C,,,,"['BINAPACRYL WAS ABSORBED POORLY, IF AT ALL, THROUGH SKIN OF MICE AND RABBITS.', 'After a single administration of binapacryl, both rats and rabbits excreted 7-17% in the urine within 48 hr. As late as the tenth day, 0.12% of the dose was detected in the urine of rats ... .']","['WHEN ADMINISTERED ORALLY TO GUINEA PIGS, THIS COMPOUND GIVES RISE TO ... /2-SEC-BUTYL-4,6-DINITROPHENOL/ IN BLOOD.', 'Following oral doses of binapacryl, the urine of both rabbits and rats contained oxidation products of the butyl side chain of dinoseb, including the acid. In addition, rat urine contained traces of free 6-aminophenol and the urine of rabbits contained a substantial amount of this compound and its glucuronide.']",
234,10235,Cytisine,C1[C@H]2CNC[C@@H]1C3=CC=CC(=O)N3C2,['Indicated for use in smoking cessation.'],"['Various models have been run where the affinity of nAChR agonists to the receptor subtype are tested to help identify the molecules, groups and steric conformation that are vital to greater affinity. By using a nAChR muscle receptor subtype (1)21 model the following results were obtained: anatoxin > epibatidine > acetylcholine > DMPP >> CYTISINE > pyrantel > nicotine > coniine > tubocurare > lobeline, where anatoxin had the highest activity efficacy and tubocurare the lowest. Acetylcholine on the other hand induced a much longer opening time of the receptor though anatoxin is more potent. The results suggest that anatoxin derivatives would be helpful in understanding structure-activity relationships (SAR) for muscle nAChRs (Cooper et al., 1996).']",,"['Oral: 6.2 l/kg Oral (5 mg/kg; tested in rabbits).', 'Renal: 43 mL/min.', 'The pharmacokinetic behavior of cytisine was studied in mice by means of tritiated cytisine after intravenous and oral administration of a sublethal dose of 2 mg/kg. After oral administration the maximum blood level is reached after 2 hr. The absorption rate is approximately 42%. From the blood level after intravenous administration a half-life of 200 min was calculated. Within 24 hr after intravenous administration 32% and after oral administration 18% of the administered radioactivity was excreted into urine. Following intravenous administration 3% of the dose was found in the feces within 6 hr. Among the examined organs and tissues the highest concentrations were reached in the liver, adrenals and kidneys. In the bile the highest concentration after intravenous administration was 200 times that in the blood.', 'Experimental study of pharmacokinetics of transdermal system with cytisine in rabbits showed a possibility of controlled intake of the drug over a 4-day period. The two stages of attaining the stationary levels of cytisin concentrations are revealed. The first stage lasted during first 24 hr and the second stage during succeeding 3 days. Using the data on intravenous cytisine injection we found that the stationary concentrations and the rate of cytisine intake in the first stage is twice as large as in the second stage. Thus cytisine can be classed as a short-living drug.']",,"['4.8 hours.', '... The absorption rate is approximately 42%. From the blood level after intravenous administration a half-life of 200 min was calculated.']"
235,10236,Ninhydrin,C1=CC=C2C(=C1)C(=O)C(C2=O)(O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)']",,,
236,10237,Bicuculline,CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,,,"['Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. (See all compounds classified as Convulsants.)', 'Drugs that bind to but do not activate GABA-A RECEPTORS thereby blocking the actions of endogenous or exogenous GABA-A RECEPTOR AGONISTS. (See all compounds classified as GABA-A Receptor Antagonists.)']",,,
237,10238,Adenosine-5'-phosphosulfate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OS(=O)(=O)O)O)O)N,,,,,,
238,10239,Oxycinchophen,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2O)C(=O)O,,,,,,
239,10240,Captodiame,CCCCSC1=CC=C(C=C1)C(C2=CC=CC=C2)SCCN(C)C,['Captodiame is indicated for the treatment of anxiety.'],,,['Renal.'],,
240,10241,9-Fluorenone,C1=CC=C2C(=C1)C3=CC=CC=C3C2=O,,,,,"['FLUORENONE IS FORMED FROM 9-HYDROXYFLUORENE.', 'FLUORENONE WAS FORMED AS A METABOLITE OF FLUORENE IN MOSQUITO FISH (GAMBUSIA) OF THE MODEL ECOSYSTEM STUDY.', 'The metabolism of fluorene, a tricyclic aromatic hydrocarbon, by Cunninghamella elegans ATCC 36112 was investigated. Approximately 69% of the 9-(14)C-fluorene added to cultures was metabolized within 120 hours. The major ethyl acetate-soluble metabolites were 9-fluorenone (62%), 9-fluorenol, and 2-hydroxy-9-fluorenone (together, 7.0%). Similarly to bacteria, Cunninghamella elegans oxidized fluorene at the C-9 position of the five-member ring to form as alcohol and the corresponding ketone. In addition, Cunninghamella elegans produced the novel metabolite 2-hydroxy-9-fluorenone.']",
241,10242,"1H-Pyrrolo[2,1-b]quinazolin-9-one, 3-hydroxy-2,3-dihydro-",C1CN2C(=NC3=CC=CC=C3C2=O)C1O,,,,,,
242,10243,Quinoline-4-carboxylic acid,C1=CC=C2C(=C1)C(=CC=N2)C(=O)O,,,,,,
243,10244,CID 10244,CC1=C2C(=C3C=CC=CC3=N2)C=CN1,,,,,,
244,10245,"13-Methyl-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one",CC1C2CNCC1C3=CC=CC(=O)N3C2,,,,,,
245,10246,CID 10246,C1CCN2CC3CC([C@H]2C1)CN4C3=CC=CC4=O,,,,,,
246,10247,"1,1'-Azonaphthalene",C1=CC=C2C(=C1)C=CC=C2N=NC3=CC=CC4=CC=CC=C43,,,,,,
247,10248,Elemicin,COC1=CC(=CC(=C1OC)OC)CC=C,,,,,,
248,10249,Nicotyrine,CN1C=CC=C1C2=CN=CC=C2,,,,,,
249,10250,Lumazine,C1=CN=C2C(=N1)C(=O)NC(=O)N2,,,,,,
250,10251,Flavanone,C1C(OC2=CC=CC=C2C1=O)C3=CC=CC=C3,,,,,,
251,10252,Salacetamide,CC(=O)NC(=O)C1=CC=CC=C1O,,,,,,
252,10253,Salicyluric acid,C1=CC=C(C(=C1)C(=O)NCC(=O)O)O,,,,,,
253,10254,"2,4,6-Trimethylbenzaldehyde",CC1=CC(=C(C(=C1)C)C=O)C,,,,,,
254,10255,Kainic acid,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O,,,"['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)', 'Drugs that bind to and activate excitatory amino acid receptors. (See all compounds classified as Excitatory Amino Acid Agonists.)']",,,
255,10256,Indole-3-carboxaldehyde,C1=CC=C2C(=C1)C(=CN2)C=O,,,,,,
256,10257,Bufotenine,CN(C)CCC1=CNC2=C1C=C(C=C2)O,,['Bufotenin is a tryptamine related to the neurotransmitter serotonin.'],"['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",['Rapidly absorbed following intravenous administration.'],"['Upon oral administration, bufotenine is extensively metabolized by monoamine oxidase enzymes.', 'Bufotenine is a known human metabolite of n,n-dimethyl-5-methoxytryptamine.']",
257,10258,Indoxyl sulfate,C1=CC=C2C(=C1)C(=CN2)OS(=O)(=O)O,,,,,,
258,10259,"(2R)-2-Hydroxy-2-[(R)-1-methoxyethyl]-3-methylbutanoic acid [(7aS)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl]methyl ester",CC(C)C(C(C)OC)(C(=O)OCC1=CCN2C1CCC2)O,,,,,,
259,10260,"N-(4-oxo-5,6-dihydrodithiolo[3,4-b]pyrrol-3-ylidene)acetamide",CC(=O)N=C1C2=C(NCC2=O)SS1,,,,,,
260,10261,"2-Cyclopenten-1-one, 3-methyl-2-(2Z)-2-pentenyl-",CCC=CCC1=C(CCC1=O)C,,,,,,
261,10262,"2,3-Dimethylbut-2-enedioic acid",CC(=C(C)C(=O)O)C(=O)O,,,,,,
262,10263,"1,2,3,4-Tetramethylbenzene",CC1=C(C(=C(C=C1)C)C)C,,,,,,
263,10264,"2,3,4,5-Tetrahydroxypentanoic acid",C(C(C(C(C(=O)O)O)O)O)O,,,,,,
264,10265,Stearyltrimethylammonium pentachlorophenate,CCCCCCCCCCCCCCCCCC[N+](C)(C)C.C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)[O-],,,,,,
265,10266,"6-Aminohexane-1,2,3,4,5-pentol",C(C(C(C(C(CO)O)O)O)O)N,,,,,,
266,10267,"1,6-di-O-phosphono-beta-D-fructofuranose",C([C@@H]1[C@H]([C@@H]([C@](O1)(COP(=O)(O)O)O)O)O)OP(=O)(O)O,,,"['Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)']",,,
267,10268,3-Furoic acid,C1=COC=C1C(=O)O,,,,,,
268,10269,"2,6-DI-Tert-butyl-4-methoxyphenol",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)OC,,,,,,
269,10270,"(1aR,7aR,7bS)-1,1,7-trimethyl-4-methylidene-2,3,4a,5,6,7,7a,7b-octahydro-1aH-cyclopropa[e]azulene",CC1CCC2[C@@H]1[C@H]3[C@H](C3(C)C)CCC2=C,,,,,,
270,10271,"2,4,6-Trinitroaniline",C1=C(C=C(C(=C1[N+](=O)[O-])N)[N+](=O)[O-])[N+](=O)[O-],,,,,,
271,10272,Aspergillic acid,CCC(C)C1=CN=C(C(=O)N1O)CC(C)C,,,,,,
272,10273,"Pyridine-3,4-dicarboxylic acid",C1=CN=CC(=C1C(=O)O)C(=O)O,,,,,,
273,10274,CID 10274,C1=CC2=C(C(=C(OC2=CC1=O)C3=CC(=C(C(=C3)O)O)O)O)O,,,,,,
274,10275,Amiphenazole,C1=CC=C(C=C1)C2=C(N=C(S2)N)N,,,['Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)'],,,
275,10276,"2,4,5-Trimethoxybenzoic acid",COC1=CC(=C(C=C1C(=O)O)OC)OC,,,,,,
276,10277,1-Methyl-7-isopropylnaphthalene,CC1=C2C=C(C=CC2=CC=C1)C(C)C,,,,,,
277,10278,Methyl 2-[(6-o-pentopyranosylhexopyranosyl)oxy]benzoate,COC(=O)C1=CC=CC=C1OC2C(C(C(C(O2)COC3C(C(C(CO3)O)O)O)O)O)O,,,,,,
278,10279,"2',5'-Dihydroxyacetophenone",CC(=O)C1=C(C=CC(=C1)O)O,,,,,,
279,10280,"L-threo-2,3-Hexodiulosonic acid, gamma-lactone",C(C([C@@H]1C(=O)C(=O)C(=O)O1)O)O,,,,,,
280,10281,Thymoquinone,CC1=CC(=O)C(=CC1=O)C(C)C,,,,,,
281,10282,p-Menth-1-en-3-ol,CC1=CC(C(CC1)C(C)C)O,,,,,,
282,10283,3-Chloro-4-nitrophenol,C1=CC(=C(C=C1O)Cl)[N+](=O)[O-],,,,,,
283,10284,1-Hydroxyisoquinoline,C1=CC=C2C(=C1)C=CNC2=O,,,,,,
284,10285,4-Methylquinoline,CC1=CC=NC2=CC=CC=C12,,,,,"['Some 4-methylquinoline metabolites have been identified from in vitro studies. 4-methylquinoline subjected to metabolism for 60 minute by S-9 microsomal fraction prepared from 3-methylchloanthrene-induced rat liver... /identified/ the primary metabolites ... as 4-hydroxymethylquinoline (38.7%), 3-hydroxy-4-hydroxy-methylquinoline (8.0%), 4methylquinoline -N-oxide (3.6%), and 3-hydroxy-4-methylquinoline (1.6%).', 'The major metabolite of 4-MeQ was 4-hydroxymethylquinoline, which was not mutagenic under the assay condition employed.']",
285,10286,Chromone,C1=CC=C2C(=C1)C(=O)C=CO2,,,,,,
286,10287,CID 10287,COC1=CC=C(C=C1)C2=C(OC3=C(C2=O)C=C(C=C3O)O)O,,,,,,
287,10288,"3-Methyl-1,8,9-anthracenetriol",CC1=CC2=C(C(=C1)O)C(=C3C(=C2)C=CC=C3O)O,,,,,,
288,10289,CID 10289,COC1=C(C=CC(=C1)C2=CC(=C3C(=CC(=O)C=C3O2)O)O)O,,,,,,
289,10290,Pamaquine,CCN(CC)CCCC(C)NC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
290,10291,CID 10291,C12=C(NC(=O)C(=O)N1)NC(=NC2=O)N,,,,,,
291,10292,"2,4'-Biphenyldiamine",C1=CC=C(C(=C1)C2=CC=C(C=C2)N)N,,,,,,
292,10293,CID 10293,COC(CNC(=O)C1=CC=CC=C1OCC(=O)[O-])C[Hg].O.[Na+],,,,,,
293,10294,[3-[[2-(Carboxymethoxy)benzoyl]amino]-2-methoxypropyl]mercury,COC(CNC(=O)C1=CC=CC=C1OCC(=O)O)C[Hg],,,,,,
294,10295,Thioxanthen-9-one,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3S2,,,,,,
295,10296,2-Phenylpropionic acid,CC(C1=CC=CC=C1)C(=O)O,,,,,,
296,10297,(-)-Norephedrine,C[C@@H]([C@@H](C1=CC=CC=C1)O)N,"['For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.']","['Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.']","['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Agents that are used to suppress appetite. (See all compounds classified as Appetite Depressants.)', 'Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)', 'Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)']","['Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.', 'Phenylpropanolamine is well absorbed orally, and the peak blood concentration is attained within one to two hours. ... The drug is principally excreted unchanged; the major route of excretion is renal. Since phenylpropanolamine is a weak base, elimination is enhanced in acid urine.', 'Phenylpropanolamine is readily absorbed from the GI tract. Nasal decongestion reportedly occurs within 15-30 minutes after oral administration of 25 mg of phenylpropanolamine hydrochloride and appears to persist for 3 hours. Plasma concentrations of the drug required for a therapeutic effect are not known. In one study, peak plasma concentrations of 100 ng/mL were reached in 1-2 hours and concentrations remained greater than 60 ng/ml for 6 hours following oral administration of 50 mg of phenylpropanolamine hydrochloride to fasting adults. Following administration of 150 mg of an extended-release preparation of the drug, peak plasma concentrations of 300 ng/mL occurred after 3.5 hours and phenylpropanolamine concentrations remained greater than 180 ng/mL for 12 hours. /Phenylpropanolamine hydrochloride/', 'Animal studies indicate that phenylpropanolamine is distributed into various tissues and fluids, including /cerebrospinal fluid/ and brain. /Phenylpropanolamine hydrochloride/', 'The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride from a controlled release caplet and solution were studied in 12 male subjects, aged 18 to 36 yr, who received either a 75 mg caplet once daily or a 25 mg solution 3 times daily for 4 days. Maximum plasma concentrations, time to maximum concentration, and areas under the concentration-time curves are reported for both caplet and solution. The mean first order absorption rate constant, elimination half-life and lag time for the drug from the caplet were 0.488 ngxhr/mL, 5.84 hr, and 0.394 hr, respectively, and 2.87 ngxhr/mL, 3.73 hr, and 0.325 hr, respectively, from the solution. The smaller apparent mean first order absorption rate constant and longer elimination half-life from the caplet is due to the slow release of drug, thereby slowing its absorption and producing sustained plasma drug concentrations.', 'For more Absorption, Distribution and Excretion (Complete) data for PHENYLPROPANOLAMINE (6 total), please visit the HSDB record page.']","['Hepatic', 'Like other phenylisopropanolamines, small amounts of the drug are slowly metabolized in the liver to an active hydroxylated metabolite. About 80-90% of a dose of phenylpropanolamine is excreted unchanged in the urine within 24 hours. /Phenylpropanolamine hydrochloride/']","['2.1 to 3.4 hours.', 'The half-life ranges from 2.7 to 3.4 hrs. /Phenylpropanolamine hydrochloride/', 'Phenylpropanolamine reportedly has a half-life of 3-4 hours. /Phenylpropanolamine hydrochloride/', 'The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HCl) from a controlled-release (CR) caplet and solution was studied in 12 male subjects, who  received either a 75 mg PPA HCl CR caplet once daily or a 25 mg PPA HCl solution given three times a day. All subjects received the medication for 4 consecutive days. ... The mean elimination half-life  for PPA HCl from the CR caplet was  5.84 hr and 3.73 hr, for the solution. ...']"
297,10298,Auramine,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)']",,,
298,10299,4-Chloromandelic acid,C1=CC(=CC=C1C(C(=O)O)O)Cl,,,,,,
299,10300,CID 10300,C1CCC(=C(C1)NO)N=O,,,,,,
300,10301,"1,4-Benzodioxane",C1COC2=CC=CC=C2O1,,,,,,
301,10302,"6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline",CC1C2=CC(=C(C=C2CCN1)OC)OC,,,['Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. (See all compounds classified as Catechol O-Methyltransferase Inhibitors.)'],,,
302,10303,Methyl red,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2C(=O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],['METHYL RED IS BOUND TO BOVINE SERUM ALBUMIN...'],"['METHYL RED IN MICRO-ORGANISM /WAS METABOLIZED TO/ ANTHRANILIC ACID & N,N-DIMETHYL-P-PHENYLENEDIAMINE. SCHELINE RR, ACTA PHARMAC TOX, 26, 332 (1968). GINGELL R, XENOBIOTICA, 3, 165 (1973).']",
303,10304,Bialamicol,CCN(CC)CC1=CC(=CC(=C1O)CC=C)C2=CC(=C(C(=C2)CN(CC)CC)O)CC=C,,,,,,
304,10305,"2,4,6-Triphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
305,10306,Methaphenilene,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=C2,,,,,,
306,10307,Chlornaphazine,C1=CC=C2C=C(C=CC2=C1)N(CCCl)CCCl,,,,,"['RATS INJECTED WITH N,N-BIS(2-CHLOROETHYL)-2-NAPHTHYLAMINE EXCRETED 2-AMINO-1-NAPHTHYL HYDROGEN SULFATE & 2-ACETAMIDO-6-NAPHTHYL HYDROGEN SULFATE.']",
307,10308,Iminodibenzyl,C1CC2=CC=CC=C2NC3=CC=CC=C31,,,,,,
308,10309,"1-(2-Furanyl)-n,n'-bis(2-furanylmethylene)-methanediamin",C1=COC(=C1)C=NC(C2=CC=CO2)N=CC3=CC=CO3,,,,,,
309,10310,Diphenoquinone,C1=CC(=O)C=CC1=C2C=CC(=O)C=C2,,,,,,
310,10311,Melarsoprol,C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO,,,['Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)'],,,
311,10312,Atropaldehyde,C=C(C=O)C1=CC=CC=C1,,,,,,
312,10313,N-Hydroxybenzamide,C1=CC=C(C=C1)C(=O)NO,,,,,,
313,10314,Conhydrine,CCC(C1CCCCN1)O,,,,,,
314,10315,Butyrophenone,CCCC(=O)C1=CC=CC=C1,,,,,,
315,10316,Azoxybenzene,C1=CC=C(C=C1)N=[N+](C2=CC=CC=C2)[O-],,,,,,
316,10317,"2,4-Diaminoazobenzene",C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)N)N,,,,"['WHEN CHRYSOIDINE WAS FED TO MICE, ONLY VERY SMALL AMOUNTS (23.8 MICROMOLES/KG PROTEIN AFTER 7 DAYS) WERE FOUND BOUND TO LIVER PROTEINS.']",,
317,10318,Dibutylaminoethyl p-fluorobenzoate hydrochloride,CCCCN(CCCC)CCOC(=O)C1=CC=C(C=C1)F.Cl,,,,,,
318,10319,2-(Dibutylamino)ethyl 4-fluorobenzoate,CCCCN(CCCC)CCOC(=O)C1=CC=C(C=C1)F,,,,,,
319,10320,Benquinox,C1=CC=C(C=C1)C(=O)NNC2=CC=C(C=C2)N=O,,,,,,
320,10321,Capillin,CC#CC#CC(=O)C1=CC=CC=C1,,,,,,
321,10322,Piperonyl alcohol,C1OC2=C(O1)C=C(C=C2)CO,,,,"['... Male Swiss-Webster-mice, Sprague-Dawley-rats, or hamsters were administered 13 carbon-14 labeled MDP compounds such as tropital, piperonal, piperonyl-alcohol, piperonylic-acid, safrole, dihydrosafrole, or piperonyl-butoxide. Urine, feces, and expired air were collected for 48 hours for carbon-14 assay. Carbon-14 activity in the intestine, liver, and carcass was determined. ... Carbon-dioxide was not an important route of elimination in the metabolism of piperonyl-alcohol, piperonal, piperonylic-acid, and tropital. Their metabolites were excreted primarily in the urine. ...']","['The metabolism of methylenedioxyphenyl (MDP) compounds was studied in mammals. The purpose of the study was to investigate the mechanism and significance of demethylation of MDP and similar compounds in relation to the metabolism and mode of action of commercial synergist chemicals such as piperonyl-butoxide and tropital. Male Swiss-Webster-mice, Sprague-Dawley-rats, or hamsters were administered 13 carbon-14 labeled MDP compounds such as tropital, piperonal, piperonyl-alcohol, piperonylic-acid, safrole, dihydrosafrole, or piperonyl-butoxide. Urine, feces, and expired air were collected for 48 hours for carbon-14 assay. Carbon-14 activity in the intestine, liver, and carcass was determined. Urine samples were analyzed for metabolites. Compounds such as dihydrosafrole, safrole, myristicin, and piperonyl-butoxide were largely metabolized by oxidation of the methylene group of the MDP moiety to yield radiolabeled carbon-dioxide. The radiolabel ultimately appearing as carbon-dioxide was first liberated as radioactive formate. Carbon-dioxide was not an important route of elimination in the metabolism of piperonyl-alcohol, piperonal, piperonylic-acid, and tropital. Their metabolites were excreted primarily in the urine. No marked species difference was noted in carbon-14 tissue distribution after dosing with tropital and piperonyl-butoxide. Oxidation or conjugation of the side chain was the major metabolic pathway for tropital, piperonal, piperonyl-alcohol, and piperonylic-acid. Urinary metabolites of piperonyl-butoxide included many compounds lacking the MDP moiety and small amounts of 6-propyl-piperonylic-acid and its glycine conjugate. Urinary metabolites of tropital included glycine and glucuronic-acid conjugates of piperonylic-acid. In an in-vitro experiment, radiolabeled piperonyl-butoxide, tropital, safrole, and other MDP compounds were incubated with mouse liver microsomes and were assayed for metabolites. Metabolites such as formate and catechols were detected. The authors conclude that demethylation of the MDP moiety is the major metabolic pathway in mammals given piperonyl-butoxide, safrole, dihydrosafrole and myristicin.', 'After oral administration of piperine (170 mg/kg) to rats, the metabolites in bile and urine were examined by thin-layer chromatography, high-performance liquid chromatography and combined gas chromatography-mass spectrometry. Four metabolites of piperine, viz. piperonylic acid, piperonyl alcohol, piperonal and vanillic acid were identified in the free form in 0-96 hr urine whereas only piperic acid was detected in 0-6 hr bile. ...', ""The neolignan, burchellin, a natural compound that reduces urine excretion in larvae of the bloodsucking bug, Rhodnius prolixus, a vector of Chagas' disease, is rapidly degraded in the hemolymph of the insect. The main product that accumulates in this tissue has been shown to be piperonyl alcohol. Other catabolites have been identified by GC-MS analysis.""]",
322,10323,Salicylaldehyde isonicotinoyl hydrazone,C1=CC=C(C(=C1)C=NNC(=O)C2=CC=NC=C2)O,,,,,,
323,10324,2-Ethyl-3-hydroxyhexanal,CCCC(C(CC)C=O)O,,,,,,
324,10325,Hexahydroindan,C1CCC2CCCC2C1,,,,,,
325,10326,Indan,C1CC2=CC=CC=C2C1,,,,,,
326,10327,Phthalan,C1C2=CC=CC=C2CO1,,,,,,
327,10328,Indoline,C1CNC2=CC=CC=C21,,,,,,
328,10329,"2,3-Dihydrobenzofuran",C1COC2=CC=CC=C21,,,,,,
329,10330,CID 10330,C1C2=CC=CC=C2N=C1S,,,,,,
330,10331,Benzofuran-2-carboxylic acid,C1=CC=C2C(=C1)C=C(O2)C(=O)O,,,,,,
331,10332,"3,4-Diaminotoluene",CC1=CC(=C(C=C1)N)N,,,,,,
332,10333,4-Methylresorcinol,CC1=C(C=C(C=C1)O)O,,,,,,
333,10334,"Toluene-3,4-dithiol",CC1=CC(=C(C=C1)S)S,,,,,,
334,10335,"2,4,5-Trimethylphenol",CC1=CC(=C(C=C1C)O)C,,,,,,
335,10336,2-Methyl-2-butenal,CC=C(C)C=O,,,,,,
336,10337,"2-Chloro-1,3-propanediol",C(C(CO)Cl)O,,,,,,
337,10338,"3-Butene-1,2-diol",C=CC(CO)O,,,,,,
338,10339,Mesoxalaldehyde,C(=O)C(=O)C=O,,,,,,
339,10340,Sodium Carbonate,C(=O)([O-])[O-].[Na+].[Na+],"['Used topically for dermatitides, mouthwash, vaginal douche; veterinary use as emergency emetic.Occasionally, for dermatitides topically as a lotion. Medication (Vet): In solution to cleanse skin, in eczema, to soften scabs of ringworm.']","['Alkalizing buffering action: Sodium bicarbonate is an alkalinizing agent that dissociates to provide bicarbonate ion. Bicarbonate in excess of that needed to buffer hydrogen ions causes systemic alkalinization and, when excreted, urine alkalinization as well.  Oral antacid action: Taken orally, sodium bicarbonate neutralizes stomach acid by the above mechanism.']",,"['The uptake of sodium, via exposure to sodium carbonate, is much less than the uptake of sodium via food. Therefore, sodium carbonate is not expected to be systemically available in the body. Furthermore,  an oral uptake of sodium carbonate will result in a neutralization in the stomach due to the gastric acid.', 'Filtered and reabsorbed by the kidney; less than 1% of filtered bicarbonate is excreted.', 'Distribution occurs naturally and is confined to the systemic circulation.', 'The major extracellular buffer in the blood and the interstitial fluid of vertebrates is the bicarbonate buffer system ... . Carbon dioxide from the tissues diffuses rapidly into red blood cells, where it is hydrated with water to form carbonic acid. This reaction is accelerated by carbonic anhydrase, an enzyme present in high concentrations in red blood cells. The carbonic acid formed dissociates into bicarbonate and hydrogen ions. Most of the bicarbonate ions diffuse into the plasma. Since the ratio of H2CO3 to dissolved CO2 is constant at equilibrium, pH may be expressed in terms of bicarbonate ion concentration and partial pressure of CO2 by means of the Henderson-Hasselbach equation: pH = pk + log [HCO3-]/aPCO2. The blood plasma of /humans/ normally has a pH of 7.40. Should the pH fall below 7.0 or rise above 7.8, irreversible damage may occur. Compensatory mechanisms for acid-base disturbances function to alter the ratio of HCO3 - to PCO2 , returning the pH of the blood to normal. ... The uptake of sodium, via exposure to sodium carbonate, is much less than the uptake of sodium via food. Therefore, sodium carbonate is not expected to be systemically available in the body. Furthermore ... an oral uptake of sodium carbonate will result in a neutralization in the stomach due to the gastric acid.']",['None.'],
340,10341,2(5H)-Furanone,C1C=CC(=O)O1,,,"['Agents that are used to suppress appetite. (See all compounds classified as Appetite Depressants.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
341,10342,"2-Methyl-1,3-dioxolane",CC1OCCO1,,,"['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)']",,,
342,10343,CID 10343,C[N+](C)(C)C(CC1=CN=C(N1)S)C(=O)[O-],,,,,,
343,10344,CID 10344,C[N+](C)(C)C(CC1=CN=C(N1)S)C(=O)O,,,,,,
344,10345,Norcamphor,C1CC2CC1CC2=O,,,,,,
345,10346,"4,6-Di-tert-butyl-m-cresol",CC1=CC(=C(C=C1C(C)(C)C)C(C)(C)C)O,,,,,,
346,10347,Meconic acid,C1=C(OC(=C(C1=O)O)C(=O)O)C(=O)O,,,,,,
347,10348,"(3S,6S)-2-(hydroxymethyl)-6-(4-hydroxyphenoxy)oxane-3,4,5-triol",C1=CC(=CC=C1O)O[C@H]2C(C([C@@H](C(O2)CO)O)O)O,,,,,,
348,10349,Methylsuccinic acid,CC(CC(=O)O)C(=O)O,,,,,,
349,10350,3-Deoxyhexonic acid,C(C(C(CO)O)O)C(C(=O)O)O,,,,,,
350,10351,3-Furaldehyde,C1=COC=C1C=O,,,,,,
351,10352,Bicyclo[2.2.1]hept-2-ene,C1CC2CC1C=C2,,,,,,
352,10353,p-MENTHAN-8-OL,CC1CCC(CC1)C(C)(C)O,,,,,,
353,10354,"Cyclohexene, 1-methyl-3-(1-methylethenyl)-",CC1=CC(CCC1)C(=C)C,,,,,,
354,10355,Arecaidine,CN1CCC=C(C1)C(=O)O,,,,,,
355,10356,"3,5-Dimethylbenzoic acid",CC1=CC(=CC(=C1)C(=O)O)C,,,,,,
356,10357,6-O-alpha-D-glucopyranosyl-beta-D-glucopyranose,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O,,,,,,
357,10358,"[(2S,3S)-3-hydroxy-1-methoxybutan-2-yl]imino-oct-1-enyl-oxidoazanium",CCCCCCC=C[N+](=N[C@@H](COC)[C@H](C)O)[O-],,,,,,
358,10359,"2-Amino-1-(3,4-dihydroxyphenyl)ethanone",C1=CC(=C(C=C1C(=O)CN)O)O,,,,,,
359,10360,CID 10360,C1=CC(=C(C=C1C(=O)[O-])I)F.[Na+],,,,,,
360,10361,4-Fluoro-3-iodobenzoic acid,C1=CC(=C(C=C1C(=O)O)I)F,,,,,,
361,10362,"Cyclohexanone, 2-methyl-5-(1-methylethyl)-",CC1CCC(CC1=O)C(C)C,,,,,,
362,10363,"2-Cyclohexen-1-one, 6-methyl-3-(1-methylethyl)-",CC1CCC(=CC1=O)C(C)C,,,,,,
363,10364,Carvacrol,CC1=C(C=C(C=C1)C(C)C)O,,,,"['CARVACROL APPEARS TO BE SLOWLY ABSORBED FROM INTESTINE IN RABBIT, SINCE 22 HR AFTER ADMIN OF 1.5 G, SOME 30% WAS STILL IN GASTRO-INTESTINAL TRACT, ABOUT 25% OF DOSE HAVING BEEN EXCRETED IN URINE.', 'CARVACROL APPLIED TO INTACT SHAVED ABDOMINAL SKIN OF MOUSE WAS NOT ABSORBED WITHIN 2 HR.']","['/WHEN FED TO RABBITS,/ THE SUBSTITUTED MONOPHENOLS, THYMOL & CARVACROL, WHICH OCCUR IN ESSENTIAL OILS OF PLANTS...ARE...CONJUGATED WITH GLUCURONIC ACID & SULFATE.', 'CARVACROL IS METABOLIZED BY CONJUGATION WITH GLUCURONIC ACID & SULFATE.', 'Carvacrol has known human metabolites that include (2-methyl-5-propan-2-ylphenyl) hydrogen sulfate and (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(2-methyl-5-propan-2-ylphenoxy)oxane-2-carboxylic acid.']",
364,10365,"2,4-Pyridinedicarboxylic acid",C1=CN=C(C=C1C(=O)O)C(=O)O,,,,,,
365,10366,"Pyridine-3,5-dicarboxylic acid",C1=C(C=NC=C1C(=O)O)C(=O)O,,,,,,
366,10367,"2,6-Pyridinedicarboxylic acid",C1=CC(=NC(=C1)C(=O)O)C(=O)O,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)']",,,
367,10368,CID 10368,C1=CC(=CC=C1C(=O)[O-])F.[Na+],,,,,,
368,10369,"Cyclohexene, 4-methyl-1-(1-methylethyl)-",CC1CCC(=CC1)C(C)C,,,,,,
369,10370,CID 10370,C=C[C@@H]1CN=C(O1)S,,,,,,
370,10371,3-Pyridinecarboxaldehyde,C1=CC(=CN=C1)C=O,,,,,,
371,10372,Chlorthion,COP(=S)(OC)OC1=CC(=C(C=C1)[N+](=O)[O-])Cl,,,,['...absorbed by intact skin.'],"['/It is/ rapidly hydrolyzed to dimethyl thiophosphate & 3-chloro-4-nitrophenol. To a limited extent, there is oxidation to the phosphate & hydrolysis to phosphoric acid & 3-chloronitrophenol.', '3-CHLORO-4-NITROPHENYL DIMETHYL PHOSPHOROTHIOATE YIELDS 3-CHLORO-4-NITROPHENOL IN RAT, RABBIT, & IN FLY; IT YIELDS 3-CHLORO-4-NITROPHENYL DIMETHYL PHOSPHATE IN RAT, RABBIT, & FLY: NAKATSUGAWA T, TOLMAN NM, & DAHM PA; BIOCHEM PHARMAC 17: 1517 (1968). /FROM TABLE/', '...INVESTIGATORS EXAMINED METABOLISM OF...CHLORTHION...IN RAT & COCKROACH. BY MEANS OF ION EXCHANGE CHROMATOGRAPHY, SUBSTANTIAL AMT OF DEALKYLATED ORGANOPHOSPHORUS COMPD WERE FOUND IN URINE OF RATS AFTER ORAL ADMIN.']",
372,10373,beta-Eucaine,CC1CC(CC(N1)(C)C)OC(=O)C2=CC=CC=C2,,,,,,
373,10374,Chlorazanil,C1=CC(=CC=C1NC2=NC=NC(=N2)N)Cl,,,,,,
374,10375,"Demethoxyyangonin;5,6-Dehydrokavain",COC1=CC=C(C=C1)C=CC2=CC(=CC(=O)O2)OC,,,,,,
375,10376,"4-Methoxy-2-(2-phenylethenyl)-2,3-dihydropyran-6-one",COC1=CC(=O)OC(C1)C=CC2=CC=CC=C2,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
376,10377,Olivetol,CCCCCC1=CC(=CC(=C1)O)O,,,,,,
377,10378,Oxanilic acid,C1=CC=C(C=C1)NC(=O)C(=O)O,,,,,,
378,10379,Indophenol,C1=CC(=O)C=CC1=NC2=CC=C(C=C2)O,,,,,,
379,10380,CID 10380,CCCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)N(C)C)S,,,,,,
380,10381,Aurothioglycanide,C1=CC=C(C=C1)NC(=O)C[S-].[Au+],,,,,,
381,10382,2-Mercaptoacetanilide,C1=CC=C(C=C1)NC(=O)CS,,,,,,
382,10383,"3,5-Dimethoxyphenol",COC1=CC(=CC(=C1)O)OC,,,,,,
383,10384,N-(4-aminobutyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide,COC1=C(C=CC(=C1)C=CC(=O)NCCCCN)O,,,,,,
384,10385,(m-Hydroxyphenethyl)trimethylammonium hydroxide,C[N+](C)(C)CCC1=CC(=CC=C1)O.[OH-],,,,,,
385,10386,Leptodactyline,C[N+](C)(C)CCC1=CC(=CC=C1)O,,,,,,
386,10387,Benzyl chloroformate,C1=CC=C(C=C1)COC(=O)Cl,,,,,,
387,10388,"4,4'-Azodianisole",COC1=CC=C(C=C1)N=NC2=CC=C(C=C2)OC,,,,,,
388,10389,"4,4'-Dimethylazobenzene",CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)C,,,,,,
389,10390,Diphenylacetylene,C1=CC=C(C=C1)C#CC2=CC=CC=C2,,,,,,
390,10391,Beclamide,C1=CC=C(C=C1)CNC(=O)CCCl,"['Has been used in the management of epilepsy and epilepsy related behavioural disorders.  It was used for generalised tonic-clonic seizures, and was not effective for absence seizures.  More recently focus has shifted to the use of beclamide in behavioural disorders. In mentally handicapped epileptic patients it has been found to decrease anxiety, antisocial and demanding behaviours, and impulsivity. Mood stabilizing effects were also noted. [2]  Additionally, due to its effects on monoamines, beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes. [2]']",,,['Metabolites appear in urine only. 4- hydroxybeclamide is present in the urine to a greater extent than 3 hydroxybeclamide. Approximately 20% of the radiolabel was excreted in urine.'],"['Rapidly metabolized. Major pathway of metabolism is oxidation of the benzene ring to yield 3-hydroxyphenyl and 4-hydroxyphenyl metabolites, and oxidation of the benyl methylene to yield benzoic acid. 3 and 4 hydroxyphenyl metabolites are excreted extensively as gluconuride and sulphate conjugates, and benzoic acid is excreted as a glycine conjugate (hippuric acid).']",
391,10392,Phenylcarbamic acid,C1=CC=C(C=C1)NC(=O)O,,,,,,
392,10393,2-(4-Hydroxyphenyl)ethanol,C1=CC(=CC=C1CCO)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
393,10394,3-(4-Hydroxyphenyl)propionic acid,C1=CC(=CC=C1CCC(=O)O)O,,,,,"['4-hydroxy- 4-Hydroxyphenylpropionic acid is a known human metabolite of 3,4-dihydroxyphenylpropionic acid.']",
394,10395,"5-(1,2-Heptadiene-4,6-diynyl)dihydro-2(3H)-furanone",C#CC#CC=C=CC1CCC(=O)O1,,,,,,
395,10396,gamma-Stearolactone,CCCCCCCCCCCCCCC1CCC(=O)O1,,,,,,
396,10397,Ethyl 9-fluoro-3-oxononanoate,CCOC(=O)CC(=O)CCCCCCF,,,,,,
397,10398,(N'-cyanocarbamimidoyl)azanide;methylmercury(1+),C[Hg+].C(#N)N=C(N)[NH-],,,,,,
398,10399,Cycloheptanol,C1CCCC(CC1)O,,,,,,
399,10400,Cycloheptanone,C1CCCC(=O)CC1,,,,['THEY DO NOT TEND TO ACCUMULATE IN BODY TISSUES... /ALICYCLIC HYDROCARBONS/'],"[""NOVEL MINOR (1-2%) METABOLITES...HAVE BEEN DETECTED IN RAT & RABBIT URINE. 2-HYDROXYCYCLOALKYLMERCAPTURIC ACIDS...WHICH WERE PRESENT AS...SULFATES ('DOUBLE CONJUGATES') ARE PRESUMABLY FORMED BY WAY OF DEHYDRATION OF THE CYCLOALKANOLS (MAJOR METABOLITE) TO CYCLOALKENES WITH SUBSEQUENT EPOXIDATION & MERCAPTURATION.""]",
400,10401,Caprolactone,C1CCC(=O)OCC1,,,,,,
401,10402,Citronellic acid,CC(CCC=C(C)C)CC(=O)O,,,,,,
402,10403,Cyclooctanone,C1CCCC(=O)CCC1,,,,,,
403,10404,Dixanthogen,CCOC(=S)SSC(=S)OCC,,,,,,
404,10405,5-Nonanone,CCCCC(=O)CCCC,,,,['5-Nonanone is absorbed from the gastrointestinal tract of the rat. ... Radioactivity excreted in the urine accounted for approx 50% of the dose after 72 hr.'],"['Metabolic studies confirmed the in vivo conversion of 5-nonanone to 2,5-nonanedione, methyl-n-butyl ketone, and 2,5-hexanedione, the latter of which is the most active neurotoxic metabolite of n-hexane and methyl-n-butyl ketone. The neurotoxicities of n-hexane, methyl-n-butyl ketone, and 5-nonanone are linked by virtue of their metabolism to a gamma -diketone, 2,5-hexanedione.', 'Metabolic transformations incl omega-1 oxidation to 2,5-nonoanedione with subsequent oxidative and decarboxylative steps to produce methyl n-butyl ketone and 2,5-hexanedione. In addition, 5-nonanone is oxidized to carbon dioxide (38% of the dose). ... No unchanged 5-nonanone was detected in the urine, but both methyl n-butyl ketone and 2,5-hexanedione were present.']",
405,10406,Octamylamine,CC(C)CCCC(C)NCCC(C)C,,,,,,
406,10407,(E)-beta-farnesene,CC(=CCCC(=CCCC(=C)C=C)C)C,,,,,,
407,10408,"6,10,14-Trimethylpentadecan-2-one",CC(C)CCCC(C)CCCC(C)CCCC(=O)C,,,,,,
408,10409,Cyclopentadecanone,C1CCCCCCCC(=O)CCCCCC1,,,,,,
409,10410,CID 10410,C(CC(=O)[O-])CF.[Na+],,,,,,
410,10411,4-fluorobutanoic Acid,C(CC(=O)O)CF,,,,,,
411,10412,CID 10412,C(CC(=O)[O-])CO.[Na+],,,,,,
412,10413,4-Hydroxybutanoic acid,C(CC(=O)O)CO,"['Used as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance.']","['GHB predominantly works at two distinct binding sites in the central nervous system: it works as an agonist at the newly-characterized excitatory GHB receptor, while acting as a weak agonist at the inhibitory GABAB receptor. Since it is a naturally occurring substance, its physiological action is similar to that of some endogenous neurotransmitters in mammalian brain. GHB is probably synthesized from GABA in GABAergic neurons, and released when the neurons fire.']",,"['Animal studies indicate that metabolism is the major elimination pathway for sodium oxybate, producing carbon dioxide and water via the tricarboxylic acid (Krebs) cycle and secondarily by beta-oxidation. Succinic acid enters the Krebs cycle where it is metabolized to carbon dioxide and water. Fecal and renal excretion is negligible. 5% renal elimination.', '190 to 384 mL/kg', 'apparent oral cl=9.1 mL/min/kg [healthy adults receiving a single oral dose of 25 mg/kg]', 'Gamma-hydroxybutyric acid (GHB) ... absorption and disposition kinetics have been studied in 8 healthy male volunteers following oral administration of single doses of 12.5, 25 and 50 mg/kg The AUC increased disproportionately with the dose and so the apparent oral clearance decreased significantly as the dose was increased, whereas the terminal half-life and mean residence time increased. The peak plasma concentrations normalized to the lowest dose fell significantly with increasing doses, whilst the corresponding peak times increased. These findings suggest that both the oral absorption and the elimination of GHB are capacity-limited processes. GHB did not bind to significant extent to plasma proteins over the therapeutic concentration range. The pharmacokinetic parameters in healthy volunteers were not significantly different from those previously observed in alcohol-dependent patients with compensated alcoholic liver disease.', 'After ingestion, GHB is rapidly absorbed and quickly crosses the blood-brain barrier. It is not protein bound and is rapidly metabolized and excreted through the lungs. It has specific binding sites and selective brain distribution with the highest concentration in the basal ganglia.', 'Sodium oxybate is a hydrophilic compound that is rapidly but incompletely absorbed after oral administration with bioavailability approximately 25%. Administration of sodium oxybate immediately after a high fat meal results in delayed and decreased absorption. /Sodium oxybate/', 'Monocarboxylate transporter 1 (MCT1) is an important determinant of the renal transport of the drug of abuse, gamma-hydroxybutyric acid (GHB). The objective of this study was to investigate the role of MCT2 and MCT4, present in tissues including intestine, kidney, skeletal muscle, and brain, in the membrane transport of GHB and the MCT substrate l-lactate. mRNA and protein of MCT2 and MCT4 were expressed in MDA-MB231 cells, as detected by reverse transcription-polymerase chain reaction and Western blot analysis; MCT1 and MCT3 were not detected. The uptake of GHB or l-lactate by MDA-MB231 cells was pH-dependent but not sodium-dependent. The concentration-dependent uptake of GHB was best fitted to a single-transporter model with a diffusional clearance component (K(m) of 17.6 +/- 1.5 mM, V(max) of 50.6 +/- 9.0 nmol x mg(-1) min(-1) and diffusional clearance of 0.20 +/- 0.07 microl x mg(-1) min(-1)). On the other hand, the concentration-dependent uptake of l-lactate was best fitted to a two-transporter model (K(m) of 21 +/- 2.5 and 3.0 +/- 1.5 mM, and V(max) of 268 +/- 72 and 62.9 +/- 42.2 nmol x mg(-1)min(-1), respectively). The uptake of GHB and l-lactate was inhibited by MCT inhibitors alpha-cyano-4-hydroxycinnamate (CHC), phloretin, and p-chloromercuribenzoic acid; CHC inhibited GHB and l-lactate uptake with IC(50) values of 1.71 +/- 0.39 and 0.71 +/- 0.11 mM, respectively. Small interfering RNA treatment to silence MCT2 or MCT4 significantly decreased their protein expression and the uptake of l-lactate and GHB; however, the decrease in GHB uptake with MCT2 inhibition was smaller than that for MCT4. This investigation demonstrated that GHB is a substrate for both MCT2 and MCT4; these transporters may be important in the nonlinear disposition of GHB, as well as influencing its tissue distribution.', 'For more Absorption, Distribution and Excretion (Complete) data for 4-HYDROXYBUTANOIC ACID (7 total), please visit the HSDB record page.']","['gamma-Hydroxybutyrate (chemical formula HOOC-CH2-CH2- CH2OH) is a four-carbon molecule that is found naturally in the central nervous system and, in higher concentrations, in peripheral tissues. It has a structure much like gamma-aminobutyric acid (GABA), which is better understood than GHB and acts as an inhibitory neurotransmitter in vivo. gamma-Aminobutyric acid is catabolized by transamination to succinate semialdehyde, which is then oxidized to succinate. Brain tissue is capable of reducing succinate semialdehyde to GHB. Concentrations of both GHB and GHB-oxidizing enzymes are 15 to 20 times higher in kidney, heart, skeletal muscle, and brown fat than in the central nervous system.', 'Animal studies indicate that metabolism is the major elimination pathway for sodium oxybate, producing carbon dioxide and water via the tricarboxylic acid (Krebs) cycle and secondarily by beta-oxidation. The primary pathway involves a cytosolic NADP+-linked enzyme, GHB dehydrogenase, that catalyses the conversion of sodium oxybate to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase. Succinic acid enters the Krebs cycle where it is metabolized to carbon dioxide and water. A second mitochondrial oxidoreductase enzyme, a transhydrogenase, also catalyzes the conversion to succinic semialdehyde in the presence of alpha-ketoglutarate. An alternate pathway of biotransformation involves beta-oxidation via 3,4-dihydroxybutyrate to carbon dioxide and water. No active metabolites have been identified. /Sodium oxybate/']","['30 to 60 minutes', 'Elimination: 0.5 to 1 hour. In a clinical study performed in 16 cirrhotic patients, the elimination half life was significantly longer (mean of 59 and 32 versus 22 minutes in healthy patients. /Sodium oxybate/']"
413,10414,Chloroazodin,C(=NCl)(N)N=NC(=NCl)N,,,,,,
414,10415,"N,1,5-Trimethylhexylamine",CC(C)CCCC(C)NC,,,,,,
415,10416,Malvalic acid,CCCCCCCCC1=C(C1)CCCCCCC(=O)O,,,,,,
416,10417,Phytomonic acid,CCCCCCC1CC1CCCCCCCCCC(=O)O,,,,,,
417,10418,Epifluorohydrin,C1C(O1)CF,,,,,,
418,10419,2-Butyne,CC#CC,,,,,,
419,10420,Fluoroacetonitrile,C(C#N)F,,,,,,
420,10421,Azomethane,CN=NC,,,,,,
421,10422,Azetidine,C1CNC1,,,,,,
422,10423,Oxetane,C1COC1,,,,,,
423,10424,Trimethylallylammonium hydroxide,C[N+](C)(C)CC=C.[OH-],,,,,,
424,10425,Allyltrimethylaminium,C[N+](C)(C)CC=C,,,,,,
425,10426,Trichloromethyl chloroformate,C(=O)(OC(Cl)(Cl)Cl)Cl,,,,,,
426,10427,Methanedisulfonic acid,C(S(=O)(=O)O)S(=O)(=O)O,,,,,,
427,10428,4-Hydroxy-4-methyltetrahydro-2H-pyran-2-one,CC1(CCOC(=O)C1)O,,,,,,
428,10429,1-Chloro-3-methyl-2-butene,CC(=CCCl)C,,,,,,
429,10430,Isovaleric acid,CC(C)CC(=O)O,,,,['It is readily absorbed from the gastrointestinal tract in man.'],"['In contrast to valeric acid, isovaleric acid is ketogenic. ...Is metabolized by the liver to give two- and three-carbon fragments. The isopropyl fragment of isovaleric acid is readily converted to acetoacetate and is an efficient source of carbon atoms for fatty acid and cholesterol synthesis. Isovaleric acid ... has been identified in the fermentative organs of ruminant animals.', 'Isovaleric acid is an intermediate in leucine metabolism. High blood concentrations of isovaleric acid occur in patients with the clinical disorder ""isovaleric acidemia."" This is a genetic defect of leucine metabolism in which the enzyme isovaleryl-coenzyme A dehydrogenase is inhibited or absent. The disease is characterized by episodic acidosis, slight mental retardation, and an unpleasant body odor.', 'RATS RECEIVING LABELED ISOVALERIC ACID EXCRETED NONRADIOACTIVE ISOVALTHINE.', 'Isovalerate given iv to normal rats was rapidly metabolized, with a 50% decr in plasma concn after 11 min, and this time was shortened to 5 min by the simultaneous admin of glycine. The hypoglycin metabolite methylenecyclopropylacetate-CoA inhibited butyryl-CoA dehydrogenase and isovaleryl-CoA dehydrogenase in liver.', 'Gas chromatographic and mass spectrometric parameters of isovaleryl-beta-D-glucuronide, a new metabolite in the urine of patients with isovaleric acidemia, were presented. The significance of this metabolite for the detoxication of isovalerate in isovaleric acid media is discussed.']",
430,10431,Cacodyl oxide,C[As](C)O[As](C)C,,,,,,
431,10432,CID 10432,C1C(=O)NC(=N1)S,,,,,,
432,10433,"1,3-Cyclohexanediol",C1CC(CC(C1)O)O,,,,,,
433,10434,"1,3-Cyclohexanedione",C1CC(=O)CC(=O)C1,,,,,,
434,10435,"1,3,5-Triazine-2,4-diamine",C1=NC(=NC(=N1)N)N,,,,,,
435,10436,Orcinol,CC1=CC(=CC(=C1)O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
436,10437,CID 10437,C1C(=O)NC(=NC1=O)S,,,,,,
437,10438,Phorone,CC(=CC(=O)C=C(C)C)C,,,,,,
438,10439,2-Aminopyridine,C1=CC=NC(=C1)N,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']","['It may enter the body through the skin.', 'PYRIDINE & ITS ALKYL DERIVATIVES ARE ABSORBED FROM GI TRACT, INTRAPERITONEAL CAVITY & LUNGS. PERITONEAL ABSORPTION IS APPARENTLY ONLY SLIGHTLY MORE RAPID & COMPLETE THAN GI ABSORPTION... IN GENERAL THE BASES ARE RAPIDLY ABSORBED THROUGH INTACT SKIN. /ALKYL DERIVATIVES OF PYRIDINE/', 'MAJORITY OF /PYRIDINE/ DERIVATIVES TESTED ... PENETRATE INTACT GUINEA PIG SKIN READILY. AMINOPYRIDINES, VINYLPYRIDINES & 4-PICOLINE PENETRATE SKIN MOST RAPIDLY & AMYL DERIV & 5-ETHYL-2-METHYLPYRIDINE ARE LEAST READILY ABSORBED. /AMINOPYRIDINES/']","['Rats were fed 100 or 1000 ppm methapyrilene in their diet for 1, 2, 4, 8 or 16 weeks. Liver microsomes were prepared from both control and treated rats. After incubation with 1 mM methapyrilene, eight metabolites were detected and six were quantitated. /One/ ... metabolites /was/ identified as ... 2-aminopyridine. ...']",
439,10440,18-Pentatriacontanone,CCCCCCCCCCCCCCCCCC(=O)CCCCCCCCCCCCCCCCC,,,,,,
440,10441,10-Nonadecanone,CCCCCCCCCC(=O)CCCCCCCCC,,,,,,
441,10442,"1,3-Propanediol",C(CO)CO,,,,,,
442,10443,Dicyanamide,C(#N)NC#N,,,,,,
443,10444,Thiazolidine,C1CSCN1,,,,,,
444,10445,CID 10445,C(=N)(S)SSC(=N)S,,,,,,
445,10446,Neophytadiene,CC(C)CCCC(C)CCCC(C)CCCC(=C)C=C,,,,,,
446,10447,6-Methyloctanoic acid,CCC(C)CCCCC(=O)O,,,,,,
447,10448,Methionol,CSCCCO,,,,,,
448,10449,2-Fluoroethyl isocyanate,C(CF)N=C=O,,,,,,
449,10450,"1,3-Dioxane",C1COCOC1,,,,,"['beta-Hydroxyethoxyacetic acid, rather than oxalic acid or diglycolic acid, was the major urinary metabolite of dioxane in rats. Uniformly labeled (14)C dioxane was administered to two rats by oral intubation. Composite 24 hr urine samples were collected and analyzed for metabolites using thin layer ion exchange column chromatography and gas chromatography-mass spectrometry, and by nuclear magnetic resonance spectroscopy. One major and two minor (14)C containing compounds were confirmed by thin layer chromatography. The two minor compounds were identical to (14)C dioxane and (14)C diethylene glycol. The major compound was identified as beta-hydroxyethoxyacetic acid using the other four analytical methods. beta-Hydroxyethoxyacetic acid accounted for approximately 85% of the radioactivity in the urine, with dioxane and diethylene glycol accounting for the remaining 15%. /Dioxane/']",
450,10451,"1,3-Dithiane",C1CSCSC1,,,,,,
451,10452,"1,4-Dithiane",C1CSCCS1,,,,,,
452,10453,Isophytol,CC(C)CCCC(C)CCCC(C)CCCC(C)(C=C)O,,,,,,
453,10454,Cheirolin,CS(=O)(=O)CCCN=C=S,,,,,,
454,10455,Iberin,CS(=O)CCCN=C=S,,,,,,
455,10456,"3,3'-Iminodipropionic acid",C(CNCCC(=O)O)C(=O)O,,,,,,
456,10457,Suberic acid,C(CCCC(=O)O)CCC(=O)O,,,,,,
457,10458,Tridecanedioic acid,C(CCCCCC(=O)O)CCCCCC(=O)O,,,,,,
458,10459,Hexadecanedioic acid,C(CCCCCCCC(=O)O)CCCCCCC(=O)O,,,,,,
459,10460,Hexenal,CCCC=CC=O,,,"['Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)']",,,
460,10461,Mustard gas,C(CCl)SCCCl,,,"['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE. (See all compounds classified as Chemical Warfare Agents.)']","['It has been demonstrated that 80% of sulfur mustard applied to the skin evaporates, 10% remains in the skin and 10% gets absorbed systemically. It can penetrate the skin by contact with either the liquid or vapor. The rate of penetration is proportional to dose, temperature and humidity.', 'Levels of mustard in the tissues of an Iranian patient who died 7 days after exposure to mustard gas were qualitatively analysed. The concentrations of sulfur mustard determined by GC/MS and atomic absorption spectrophotometer in the tissues were as follows:  fat (from thigh) 15.1 mg/kg; brain 10.7 mg/kg; abdominal skin 8.4 mg/kg; kidney 5.6 mg/kg; muscle 3.9 mg/kg; liver 2.4 mg/kg; cerebrospinal fluid         1.9 mg/L; spleen 1.5 mg/kg; blood 1.1 mg/L.', '(35)S-labeled sulfur mustard diffused rapidly throughout the body after intravenous (IV) injection in experiments employing rabbits. Activity was retained chiefly in the liver, lungs, and kidneys, with approximately 20 percent of the (35)S activity being excreted in 12 hours.', '...  /The toxicokinetics of/ sulfur mustard (SM) ... as well as its major DNA-adduct were studied in male hairless guinea pigs for the intravenous, respiratory and percutaneous routes. The study comprised measurement of the concentration-time course of SM in blood and measurement of the concentrations of intact SM and its adduct to guanine in various tissues at several time points after administration of, or exposure to SM. ...  In contrast with nerve agents of the phosphofluoridate type, SM partitions strongly to various organs, especially the lung, spleen, liver and bone marrow. The respiratory toxicity of SM appears to be local, rather than systemic. ...', 'For more Absorption, Distribution and Excretion (Complete) data for BIS(2-CHLOROETHYL)SULFIDE (11 total), please visit the HSDB record page.']","[""The metabolism of sulfur mustard has not been studied extensively. Sulfur mustard tends to undergo intramolecular cyclization to create a hyperactive compound. Conversion to this derivative is facilitated in aqueous solution, which accounts for the sensitivity of mucosal tissues, such as the eye, to its action. Sulfur mustard cyclic intermediates react with and alkylate electron-rich molecular structures, such as the sulfhydryl (-SH) and amino (-NH2) groups of proteins and nucleic acids. Metabolic pathways, including direct alkylation reactions, glutathione reactions, hydrolysis, and oxidation, are presumed based on the finding of sulfur mustard DNA adducts in tissues and the identification of urinary products. ... Thiodiglycol was also found in the urine of people exposed to airborne sulfur mustard during the Iran-Iraq. A sulfur mustard adduct in DNA, the 2'-deoxyguanosine derivative of N7-HETE-guanine, N7-(2-hydroxyethylthioethyl)-2'deoxyguanosine, as well as albumin- and hemoglobin-sulfur mustard adducts, have been detected in the blood of two sulfur mustard poisoning victims of the Iran-Iraq War. ...."", ""Studies of casualties of the Iran-Iraq War with obvious signs of sulfur mustard-induced cutaneous injuries have identified significant amounts of the sulfur mustard metabolite, thiodiglycol, in human urine for up to 2 weeks after sulfur mustard exposure. ...  DNA-, hemoglobin- and albumin-sulfur mustard adducts have been detected in the blood of sulfur mustard poisoning victims. In two subjects following an accidental predominantly cutaneous exposure to sulfur mustard, thiodiglycol, thiodiglycol sulfoxide, and closely related metabolites, 1,1'-sulfonylbis[2-(methylsulfinyl)ethane] and 1-methylsulfinyl-2-[2-methylthio) ethylsulfonyl]ethane, derived from the action of beta-lyase on cysteine conjugates, were detected in the urine. Thiodiglycol sulfoxide concentrations were 20 to 35 times thiodiglycol concentrations. The beta-lyase metabolites were detected at concentrations comparable with those of thiodiglycol sulphoxide"", ""... the excretion of thiodiglycol in human urine /was measured/ following an accidental exposure to sulfur mustard vapor and aerosol. Detectable levels of thiodiglycol in urine were measured for 13 days after exposure to an undetermined level. The patient's urine was randomly sampled for 6 months after exposure and no further thiodiglycol elimination was detected. Maximum thiodiglycol excretion was seen on postexposure day 4. First-order elimination kinetics was observed, and the half-life of thiodiglycol elimination was estimated to be 1.2 days."", 'After absorption, sulfur mustard undergoes intermolecular cyclization to form an ethylene episulfonium ion intermediate, liberating a free chloride anion.', 'For more Metabolism/Metabolites (Complete) data for BIS(2-CHLOROETHYL)SULFIDE (11 total), please visit the HSDB record page.']","['...in the rat, following a 6-hour cutaneous exposure to radiolabeled sulfur mustard with occlusion, the urinary excretion of radiolabel had a half-life of 1.4 days; the half-life of excretion in feces, which varied slightly with dose, was approximately 1.6 days. Most of the radioactivity was found in the urine. Most of the dose was eliminated by 3 days; however, measurable urinary excretion of radiolabel continued for >3 months.']"
461,10462,"N,N'-Dinitroethylenediamine",C(CN[N+](=O)[O-])N[N+](=O)[O-],,,,,,
462,10463,"Heptadeca-8,10,12-trien-4,6-diyne-1,14-diol",CCCC(C=CC=CC=CC#CC#CCCCO)O,,,,['Absorption of cicutoxin is rapid and occurs through the skin as well as through the gut.'],,
463,10464,1-Fluoroundecane,CCCCCCCCCCCF,,,,,,
464,10465,Heptadecanoic acid,CCCCCCCCCCCCCCCCC(=O)O,,,,,,
465,10466,16-Hydroxyhexadecanoic acid,C(CCCCCCCC(=O)O)CCCCCCCO,,,,,,
466,10467,Arachidic acid,CCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
467,10468,Pentacosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
468,10469,Hexacosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
469,10470,Octacosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
470,10471,Triacontanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
471,10472,1-Tetracosanol,CCCCCCCCCCCCCCCCCCCCCCCCO,,,,,,
472,10473,Dimethylamine hydrochloride,CNC.Cl,,,,,,
473,10474,Potassium silver cyanide,[C-]#N.[C-]#N.[K+].[Ag+],,,,"['IN 30 DAYS, 72% OF (14)C FROM IP DOSE OF (14)C-CYANIDE TO MICE WAS EXCRETED IN URINE & FECES, 25% IN EXPIRED AIR, & 3% WAS RETAINED ... PEAK EXCRETION OCCURRED WITHIN 10 MIN IN EXPIRED AIR & WITHIN 6-24 HR IN URINE & FECES. /CYANIDE/', 'CYANIDE ION IS READILY ABSORBED AFTER ORAL OR PARENTERAL ADMIN. ... PART OF ABSORBED CYANIDE IS EXCRETED UNCHANGED BY THE LUNG. LARGER PORTIONS ... CONVERTED BY ... SULFURTRANSFERASE TO RELATIVELY NONTOXIC THIOCYANATE ION. /CYANIDE/', 'CYANIDES ARE RAPIDLY ABSORBED FROM SKIN & ALL MUCOSAL SURFACES & ARE MOST DANGEROUS WHEN INHALED, BECAUSE TOXIC AMT ARE RAPIDLY ABSORBED THROUGH BRONCHIAL MUCOSA & ALVEOLI. /CYANIDES/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. /Cyanide/', 'For more Absorption, Distribution and Excretion (Complete) data for POTASSIUM SILVER CYANIDE (9 total), please visit the HSDB record page.']","['... CYANIDE ION IS CONJUGATED WITH SULFUR TO FORM THIOCYANATE. ... CONJUGATION IS CATALYZED BY ... RHODANESE WHICH IS WIDELY DISTRIBUTED IN MOST ANIMAL TISSUES ... /LIVER/ PARTICULARLY ACTIVE. ... RHODANESE MECHANISM IS CAPABLE OF DETOXICATING ONLY LIMITED AMT OF CYANIDE, SUCH AS ARE FORMED DURING NORMAL METAB. /SRP: ANOTHER SULFUR DONOR IS 3-MERCAPTOPYRUVATE. THE ENZYME, MERCAPTOSULFUR TRANSFERASE IS LOCALIZED IN CYTOSOL./ THIOCYANATE CONJUGATION IS TRUE DETOXIFICATION REACTION WHICH IS ACCOMPANIED BY 200 FOLD REDUCTION OF TOXICITY. /CYANIDE/', '/ONE OF/ THE MAJOR MECHANISM/S/ FOR REMOVING CYANIDE FROM THE BODY IS ITS ENZYMATIC CONVERSION, BY THE MITOCHONDRIAL ENZYME RHODANESE (TRANSSULFURASE), TO THIOCYANATE, WHICH IS RELATIVELY ... /LESS TOXIC/. /CYANIDE/']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
474,10475,Silver cyanide,[C-]#N.[Ag+],,,,"['THE CYANIDE ION IS READILY ABSORBED AFTER ORAL OR PARENTERAL ADMIN. PROLONGED LOCAL CONTACT WITH CYANIDE SOLN ... MAY RESULT IN ABSORPTION OF TOXIC AMT THROUGH SKIN. PART OF ABSORBED CYANIDE IS EXCRETED UNCHANGED BY LUNG. LARGER PORTION ... IS CONVERTED BY ... SULFURTRANSFERASE TO ... RELATIVELY NONTOXIC THIOCYANATE ION. /CYANIDE ION/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. Presumably, the accumulation of cyanide in erythrocytes is a reflection of its binding to methemoglobin. /Cyanide/', 'All forms of silver are extremely cumulative once they enter body tissues, and very little is excreted. /Silver & cmpd/', 'CYANIDES ARE RAPIDLY ABSORBED FROM SKIN & ALL MUCOSAL SURFACES & ARE MOST DANGEROUS WHEN INHALED, BECAUSE TOXIC AMT ARE ABSORBED THROUGH BRONCHIAL MUCOSA & ALVEOLI. /CYANIDES/', 'For more Absorption, Distribution and Excretion (Complete) data for SILVER CYANIDE (8 total), please visit the HSDB record page.']","['... CYANIDE ION IS CONJUGATED WITH SULFUR TO FORM THIOCYANATE. ... CONJUGATION IS CATALYZED BY ... RHODANESE WHICH IS WIDELY DISTRIBUTED IN MOST ANIMAL TISSUES ... /LIVER/ PARTICULARLY ACTIVE. ... RHODANESE MECHANISM IS CAPABLE OF DETOXICATING ONLY LIMITED AMT OF CYANIDE, SUCH AS ARE FORMED DURING NORMAL METAB. /ANOTHER SULFUR DONOR IS 3-MERCAPTOPYRUVATE. THE ENZYME, MERCAPTOSULFUR TRANSFERASE IS LOCALIZED IN CYTOSOL./ THIOCYANATE CONJUGATION IS TRUE DETOXICATION REACTION WHICH IS ACCOMPANIED BY 200 FOLD REDUCTION OF TOXICITY. /CYANIDE/', '/ONE OF/ THE MAJOR MECHANISM/S/ FOR REMOVING CYANIDE FROM THE BODY IS ITS ENZYMATIC CONVERSION, BY THE MITOCHONDRIAL ENZYME RHODANESE (TRANSSULFURASE), TO THIOCYANATE, WHICH IS RELATIVELY ... /LESS TOXIC/. /CYANIDE/', 'Aliphatic nitriles have been postulated to manifest their toxicity through cyanide (CN) liberation. The signs of toxicity and effect of equitoxic LD50 doses of saturated and unsaturated aliphatic mono- and dinitriles on tissue and blood CN levels, tissue glutathione levels and cytochrome c oxidase activities were studied in rats. Signs of toxicity were classified into cholinomimetic effects observed with unsaturated nitriles and CNS effects observed with saturated potassium cyanide. Hepatic and blood CN levels 1 hr after treatment were highest following malononitrile and decreased in the order of propionitrile > potassium cyanide > butyronitrile > acrylonitrile > allylcyanide > fumaronitrile > acetonitrile. The order differed in brain where potassium cyanide preceded malononitrile and PCN. Hepatic and cytochrome c oxidase were significantly inhibited and corresponded to their CN levels. No significant inhibition of cytochrome c oxidase was observed in vitro. Acrylonitrile was the only nitrile which significantly reduced tissue GSH levels. Toxic expression of aliphatic nitriles depended on CN release and their degree of unsaturation. With unsaturated aliphatic nitriles CN release played a minimal role in their toxicity. /Cyanides/', 'Acute toxicity and metabolism of 7 dinitriles in mice was studied in relation to the chemical structures. The oral LD50 for each nitrile was detected under different conditions for mice pretreated with either carbon tetrachloride (CCl4) or olive oil. All test nitriles were metabolized into cyanide in vivo and in vitro. The cyanide level was variable among the compounds (0.35-0.74 ug cyanide/g brain) at death in the brains of mice, the level from malononitrile and adiponitrile being comparable to that found in mice killed by dosing with potassium cyanide. After receiving each nitrile, the mean survival time of mice pretreated with CCl4 was prolonged and their brain cyanide level decreased when compared with the corresponding control. With malononitrile, the former did not significantly change and the latter decreased slightly. Brain cyanide levels of control mice at death showed a peak at the lower log P region, whereas those of CCl4 pretreated animals remained lower independently of log P, with the exception of malononitrile. Microsomal metabolism of nitriles to cyanide was greatly inhibited when microsomes were prepared from livers of mice pretreated with CCl4. The relationship between log (1/LD50-CCl4), LD50 in mice pretreated with CCl4, and log P fits a parabolic plot. /Cyanides/']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
475,10476,Cyanogen bromide,C(#N)Br,,,,"['Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. Presumably, the accumulation of cyanide in erythrocytes is a reflection of its binding to methemoglobin. /Cyanide/', 'The cyanide ion is readily absorbed after oral or parenteral admin. Prolonged local contact with cyanide soln ... may result in absorption of toxic amt through skin. Part of absorbed cyanide is excreted unchanged by the lung. Larger portion ... is converted by sulfurtransferase to relatively nontoxic thiocyanate ion. /Cyanide/', 'Once absorbed into the body, cyanide can form complexes with heavy metal ions. /Cyanide/', 'Presumably, the accumulation of cyanide in erythrocytes is a reflection of its binding to methemoglobin. /Cyanide/']","['The small quantity of cyanide always present in human tissues is metabolized at the approximate rate of 17 ug/kg x min, primarily by the hepatic enzyme rhodanese, which catalyzes the irreversible reaction of cyanide and a sulfane to produce thiocyanate, a relatively nontoxic compound excreted in the urine. ... The limiting factor under normal conditions is the availability of a sulfane as a substrate for rhodanese, and sulfur is administered therapeutically as sodium thiosulfate to accelerate this reaction. The lethal dose of cyanide is time dependent because of the ability of the body to detoxify small amounts of cyanide via the rhodanese-catalyzed reaction with sulfane. A given amount of cyanide absorbed slowly may cause no biological effects even though the same amount administered over a very short period of time may be lethal. /Hydrogen cyanide and cyanogen chloride/', '... Cyanide ion is conjugated with sulfur to form thiocyanate. ... conjugation is catalyzed by the enzyme rhodanese which is widely distributed in most animal tissues except blood, liver being particularly active. ... the rhodanese mechanism is capable of detoxicating only limited amt of cyanide, such as are formed during normal metab. /another sulfur donor is 3-mercaptopyruvate. The enzyme, mercaptosulfur transferase is localized in cytosol./ /Cyanide/', '/One of/ the major mechanism/s/ for removing cyanide from the body is its enzymatic conversion, by the mitochondrial enzyme rhodanese (transsulfurase), to thiocyanate, which is relatively ... /less toxic/. /Cyanide/']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
476,10477,Cyanogen chloride,C(#N)Cl,,,,"['Much of total body burden appears to reside in the erythrocyte, bound to endogenous methemoglobin and, to a lesser extent, normal hemoglobin. However, cyanide is detectable in virtually every organafter significant exposures, particularly those organs with high blood flow.']","['Cyanogen chloride is apparently converted to cyanide ion in vivo by a reaction with hemoglobin and glutathione, which eventually liberates the CN ion.', 'Forms cyanide in the body', 'The small quantity of cyanide always present in human tissues is metabolized at the approximate rate of 17 ug/kg x min, primarily by the hepatic enzyme rhodanese, which catalyzes the irreversible reaction of cyanide and a sulfane to produce thiocyanate, a relatively nontoxic compound excreted in the urine. ... The limiting factor under normal conditions is the availability of a sulfane as a substrate for rhodanese, and sulfur is administered therapeutically as sodium thiosulfate to accelerate this reaction. The lethal dose of cyanide is time dependent because of the ability of the body to detoxify small amounts of cyanide via the rhodanese-catalyzed reaction with sulfane. A given amount of cyanide absorbed slowly may cause no biological effects even though the same amount administered over a very short period of time may be lethal. /Hydrogen cyanide and cyanogen chloride/', 'Cyanogen chloride is apparently converted to cyanide ion in vivo by a reaction with hemoglobin and glutathione, which eventually liberates the CN ion.', 'Cyanogen chloride reacts rapidly with both serum and red cells, but cyanide is produced only from ther reaction with red cells. As would be expected...., higher percentage conversions of cyanogen chloride to cyanide are obtained with washed red cells than with whole blood. ... Cyanogen chloride reacts rapidly with rat hemoglobin, no more than 1% of the original cyanogen chloride added being left after 5 sec from a mixture of cyanogen chloride (17.3 ug/mL) and of hemoglobin (5-7 vol O2%). ... It would appear that the essential reactions in the production of of cyanide from cyanogen chloride and blood are an initial reaction with hemoglobin followed by liberation of cyanide by reaction with glutathione. However, cyanogen chloride reacts directly with glutathione. The rate of reaction is of the same order as with hemoglobin. ... Since the rate of reaction of cyanogen chloride with hemoglobin and with glutathione is of the same order, it is possible that both reactions contribute to the conversion of cyanogen chloride to cyanide in vivo.']","['The blood elimination half-life of cyanide varies widely, from a few minutes to up to 66 hours, depending on many factors...']"
477,10478,Cyanogen iodide,C(#N)I,,,,,"['The small quantity of cyanide always present in human tissues is metabolized at the approximate rate of 17 ug/kg x min, primarily by the hepatic enzyme rhodanese, which catalyzes the irreversible reaction of cyanide and a sulfane to produce thiocyanate, a relatively nontoxic compound excreted in the urine. ... The limiting factor under normal conditions is the availability of a sulfane as a substrate for rhodanese, and sulfur is administered therapeutically as sodium thiosulfate to accelerate this reaction. The lethal dose of cyanide is time dependent because of the ability of the body to detoxify small amounts of cyanide via the rhodanese-catalyzed reaction with sulfane. A given amount of cyanide absorbed slowly may cause no biological effects even though the same amount administered over a very short period of time may be lethal. /Hydrogen cyanide and cyanogen chloride/']",
478,10479,Dimethylcadmium,[CH3-].[CH3-].[Cd+2],,,,,,
479,10480,Hartshorn salt,C(=O)(O)O.N.N,,,,,,
480,10481,Guanidine nitrate,C(=N)(N)N.[N+](=O)(O)[O-],,,,,,
481,10482,Acetyl bromide,CC(=O)Br,,,,,,
482,10483,Acetyl iodide,CC(=O)I,,,,,,
483,10484,Thioacetic acid,CC(=O)S,,,,,,
484,10485,2-Bromo-2-methylpropane,CC(C)(C)Br,,,,['Tert-butyl bromide absorbed through skin of mice.'],,
485,10486,2-Chloro-2-methylpropane,CC(C)(C)Cl,,,,,,
486,10487,Carbon tetraiodide,C(I)(I)(I)I,,,,,,
487,10488,"2-Hydroxy-N,N,N-trimethylethan-1-aminium hexonate",C[N+](C)(C)CCO.C(C(C(C(C(C(=O)[O-])O)O)O)O)O,,,,,,
488,10489,Amylene dichloride,CC(C(C)(C)Cl)Cl,,,,,,
489,10490,"[(3S,8R,10S,13R,14R,17R)-3,8,14-trihydroxy-13-methyl-17-(6-oxopyran-3-yl)-2,3,6,7,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-10-yl]methyl acetate",CC(=O)OC[C@]12CC[C@@H](C=C1CC[C@]3(C2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O)O,,,,,,
490,10491,Perfluorooctyl iodide,C(C(C(C(C(F)(F)I)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,"['Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)', 'Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)', 'Agents that increase energy expenditure and weight loss by neural and metabolic regulation. (See all compounds classified as Anti-Obesity Agents.)']",,,
491,10492,"(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol",C[C@@]12CC[C@H](C1(C)C)C[C@@H]2O,,,,"[""To develop a GC-FID method to determine borneol's concentration in mouse tissues, and to investigate the tissue distribution after intravenous and intranasal administrations of borneol, mouse brains, hearts, livers, spleens, lungs and kidneys were collected at 1, 3, 5, 10, 20, 30, 60, 90, 120 min after administration of borneol with the dose of 30.0 mg/kg. The drug in tissues was extracted with ethyl acetate, and borneol's concentration detected by GC, with octadecane as the internal standard. The calibration curve showed a good linear relationship. Extraction recoveries, inter-day and intra-day precisions and stability were in conformity with the analytical requirements of biological samples. Borneol was mainly distributed in most tissues, more in heart, brain and kidney, and less in liver, spleen and lung. The established GC-FID method is applicable for content determination of borneol in tissues. After intravenous and intranasal administrations in mice, borneol is mainly distributed in abundant blood-supply tissues. After intranasal administration, brain tissues showed the highest target coefficient and target effectiveness."", '... In order to understand the blood and brain pharmacokinetics after intravenous, intranasal, or oral administration and to investigate the superiority and feasibility of intranasal administration, a simple gas chromatographic (GC) method with flame ionization detection (FID) was developed for the quantification of borneol. Blood samples and brain were collected from mice at 1, 3, 5, 10, 20, 30, 60, 90, and 120 min after intravenous, intranasal, or oral administration of borneol at a dosage of 30.0 mg/kg. Sample preparations were carried out by liquid-liquid extraction with an internal standard solution of octadecane. The pharmacokinetic parameters were calculated /using computer software/. The calibration curves were linear in the range of 0.11-84.24 ug/mL and 0.16-63.18 ug/g for borneol in plasma and brain, respectively. The methodological and extraction recoveries were both in the range of 85%-115%. The intra-day and inter-day variabilities for plasma and brain samples were </= 5.00% relative standard deviation (RSD). The absolute bioavailabilities F of intranasal and oral administrations were 90.68% and 42.99%. The relative brain targeted coefficients Re of intranasal and oral administrations were 68.37% and 38.40%. The GC-FID method developed could be applied to determination and pharmacokinetic study. The borneol from injection was distributed and metabolized fast without absorption process. The borneol from oral administration was distributed more slowly and had the lowest absolute bioavailability. Nasal administration of borneol was quickly absorbed into the blood and brain, was easy to use and had a greater safety than infection, which makes it worthy of further development as an administration route for encephalopathy treatment.', 'The aim of this work was to study the in situ and in vivo nasal absorption of borneol. A novel single pass in situ nasal perfusion technique was applied to examine the rate and extent of nasal absorption of borneol by rats. Experimental conditions, such as perfusion rate, pH and drug concentration, were investigated. The in situ experiments showed that the nasal absorption of borneol was not dependent on drug concentration, and fitted a first order process. The absorption rate constant, Ka, influenced with an increase in perfusion speed. The borneol was well absorbed in the conditions of the nasal cavity within the pH range and pH value of physiological conditions. In vivo studies of borneol absorption were carried out in rats and the pharmacokinetics parameters of intranasal (in) was compared with intravenous (iv) administration. The bioavailabilities of borneol was 90.82% for i.n. while Tmax values were 10 min. MRT (Mean Residence Time) were 262.55 +/- 67.35 min and 204.22 +/- 14.50 min for in and iv methods, respectively. The results demonstrate that borneol could be absorbed promptly and thoroughly by in administration in rats.', ""Previous studies have indicated that borneol has double side effects on the central nervous system (CNS), but the mechanism is unknown. The aim of this study was to clarify the relationship between excitation ratio [contents of excitatory amino acids (AAs) versus that of inhibitory] and the content of natural borneol after a single oral dose. Mice were administered a 1.2 g/kg dose of natural borneol (containing 98% D: -borneol) by oral ingestion. Brain samples were collected before administration and at 0.083, 0.167, 0.25, 0.333, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, and 5 hr after administration. The brain concentration of natural borneol and contents of AA neurotransmitters in mice brain were determined by GC-MS and HPLC-FLU, respectively. After per oral application, natural borneol was absorbed rapidly into the brain and could be determined 5 min after dosing. The maximal brain concentration (86.52 ug/g) was reached after 1 hr post-dosing. Natural borneol could affect the contents of AA neurotransmitters in mice brain: L: -aspartic acid increased significantly from 0.083 to 1 hr after administration, L: -glutamic acid increased significantly at 0.333 hr and decreased from 1.5 to 5 hr, gamma-amino-N-butyric acid increased significantly from 0.167 to 5 hr, whereas glycine was not affected. The excitation ratio is the contents of excitatory AAs versus that of inhibitory AAs, which reflects the excitatory or inhibitory state of the body. The excitation ratio elevated transitorily and then declined 0.5 hr post-dosing; there were significant differences between 1.5-5 hr post-dose compared with pre-dose. The present study indicated that natural borneol could affect the contents of AA neurotransmitters, and the change in excitatory ratio led to borneol's double side effects on the CNS.""]",,
492,10493,Sinoside,CC1[C@H](C(C[C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C=O)OC)O,,,,,,
493,10494,Oleanolic acid,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O,,,,,,
494,10495,"5-beta-CARD-20(22)-ENOLIDE, 3-alpha,14,16-beta-TRIHYDROXY-, 16-ACETATE",CC(=O)O[C@H]1C[C@@]2(C3CC[C@@H]4C[C@@H](CC[C@@]4(C3CC[C@@]2([C@H]1C5=CC(=O)OC5)C)C)O)O,,,,,,
495,10496,Anemonin,C1CC2(C13C=CC(=O)O3)C=CC(=O)O2,,,,,,
496,10497,"3-[(1R,3S,5S,10R,11R,13R,14S,17R)-1,3,5,11,14-pentahydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12C[C@H](C3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3([C@@H](C[C@@H](C5)O)O)CO)O)O,,,,,,
497,10498,CID 10498,CN1CC[C@]23C4C(=O)C=C[C@]2([C@@H]1CC5=C3C(=C(C=C5)OC)O4)O,,,,,,
498,10499,Hymenin,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@@]1(C=CC3=O)O)C)OC(=O)C2=C,,,,,,
499,10500,"(10S,13S,14S,16R)-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosane-10,12,13,14,16,22,23-heptol",CC1CCC2[C@@](C3C(CN2C1)C4CC56C([C@@]4([C@H](C3O)O)O)[C@@H](CC7C5(CCC(C7(O6)O)O)C)O)(C)O,,,,,,
500,10501,Sarmentoside C,CC1[C@@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O,,,,,,
501,10502,"(3S,5S,8R,9S,10S,13R,14S)-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",C[C@H]1[C@@H]([C@H]([C@H](C(O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5(C(CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O)O,,,,,,
502,10503,"(3S,5S,10S,13R,14S,17R)-3-[(2R,5S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O,,,,,,
503,10504,"(3S,5S)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CCC3(C4CCC5(C(CCC5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)OC)O,,,,,,
504,10505,"3,14-Dihydroxycarda-5,20(22)-dienolide",C[C@]12CC[C@@H](CC1=CCC3C2CC[C@]4([C@@]3(CCC4C5=CC(=O)OC5)O)C)O,,,,,,
505,10506,"3-[(3S,5R,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2S,5S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)O)O,,,,,,
506,10507,"11,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl 3,3-dimethylbutanoate",CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)COC(=O)CC(C)(C)C)O)C)O,,,,,,
507,10508,"[2-[(17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 3-cyclopentylpropanoate",CC12CCC(=O)C=C1CCC3C2C(CC4(C3CC[C@@]4(C(=O)COC(=O)CCC5CCCC5)O)C)O,,,,,,
508,10509,Tetranitromethane,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE. (See all compounds classified as Chemical Warfare Agents.)', 'Substances that are energetically unstable and can produce a sudden expansion of the material, called an explosion, which is accompanied by heat, pressure and noise. Other things which have been described as explosive that are not included here are explosive action of laser heating, human performance, sudden epidemiological outbreaks, or fast cell growth. (See all compounds classified as Explosive Agents.)', 'Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION). (See all compounds classified as Oxidants.)']",['The substance can be absorbed into the body by inhalation of its vapor and by ingestion.'],['Rat hepatic microsomes catalyzed denitrification of TNM to nitrite and formaldehyde.'],
509,10510,"(2'S,3S)-2'-ethenyl-4'-methylspiro[1H-indole-3,7'-9-oxa-4-azatetracyclo[6.3.1.02,6.05,11]dodecane]-2-one",CN1C[C@]2(C3CC4[C@]5(C2C1C3CO4)C6=CC=CC=C6NC5=O)C=C,,,,,,
510,10511,"(2R,3R,5R,8R,10R,17S)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-4,5,7,8,14-pentol",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@]6(C([C@@H]5[C@@]4(C(C6OC)O)O)O)O)C(CC2O)OC)OC)COC,,,,,,
511,10512,"10-methoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one",COC1=CC2=C(C=C1)N3C4C25CCN6C5CC7C4C(CC3=O)OCC=C7C6,,,,,,
512,10513,"1-[(4S)-14-hydroxy-15-oxa-1,11-diazahexacyclo[16.3.1.04,12.04,21.05,10.013,19]docosa-5,7,9,17-tetraen-11-yl]ethanone",CC(=O)N1C2C3C4CC5[C@]2(CCN5CC4=CCOC3O)C6=CC=CC=C61,,,,,,
513,10514,"11-methoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one",COC1=CC2=C(C=C1)C34CCN5C3CC6C7C4N2C(=O)CC7OCC=C6C5,,,,,,
514,10515,CID 10515,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](CC4)O,,,,,,
515,10516,CID 10516,CN1CC[C@]23[C@@H]4[C@H](C=CC2[C@@H]1CC5=C3C(=C(C=C5)OCCN6CCOCC6)O4)O,,,,,,
516,10517,Methadyl acetate,CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,['Used mainly in the treatment of narcotic dependence.'],['Methadyl Acetate is a narcotic analgesic with a long onset and duration of action. The drug decreases a patients opioid use by preventing opioid withdrawal and in how it can mimic some of the effects of opioids.'],"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
517,10518,Heptabarbital,CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2,['Used mainly for sedation and hypnosis.'],,,,['Hepatic.'],
518,10519,Benzomethamine chloride,CC[N+](C)(CC)CCN(C)C(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
519,10520,Benzomethamine,CC[N+](C)(CC)CCN(C)C(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
520,10521,Malachite Green Carbinol base,CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)N(C)C)O,,,,,,
521,10522,Chlorobenzilate,CCOC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,,,,"['When daily doses of 12.8 mg/kg bw chlorobenzilate were given orally to male mongrel dogs on five days a week for 35 weeks, approximately 40% of the total dose was excreted unchanged or as metabolites in the urine. No significant storage of chlorobenzilate was reported in the depot fat of rats or dogs.', 'Adult male rats fed labeled chlorobenzilate excreted 42.78% of the total recovered radioactivity in the feces and 25.63% in the urine, and 15.47% was found in the GI tract and 3.31% in the liver.', ""Residues of the acaricide chlorobenzilate were determined in 35 urinary collections obtained from 5 male citrus grove field workers over a period of 23 days. During spray operations, the workers rode in tractors covered only by a canopy, and wore no protective gear (respirators, or face masks). Chlorobenzilate was analyzed as p,p'-dichlorobenzophenone (DPB) by a gas chromatographic method (limit of detection 2 ppb; avg recovery 97%). Urinary values obtained from workers ranged from 0.07 to 6.2 ppm, with an overall avg value of 1.3 ppm. By comparison, non-exposed humans averaged <0.01 ppm urinary p,p'-dichlorobenzophenone."", 'Although structurally similar to DDT, chlorobenzilate is much more rapidly excreted following absorption, chiefly in the urine as the benzophenone and benzoic acid derivatives.']","[""Chlorobenzilate is metabolized by rat liver homogenates to para,para'-dichlorobenzilic acid, para,para'-dichlorobenzyhydrol, para-chlorobenzoic acid and para,para-dichlorobenzophenone"", 'Chlorobenzilate was actively metabolized by /rat/ liver fractions. Major metabolites were dichlorobenzophenone and chlorobenzoic acid. Dichlorobenzilic acid, dichlorobenzhydrol, and three unidentified compounds were also found.', ""Yeast Rhodotorula gracilis metabolized chlorobenzilate ... arising ... were 4,4'-dichlorobenzilic acid and 4,4'-dichlorobenzophenone. Using (14)C-chlorobenzilate ... labeled at carboxyl group, (14)CO2 was obtained. The major steps appear to be hydrolysis followed by decarboxylation.""]",
522,10523,Trachelanthine,CC(C)[C@@](C(C)O)(C(=O)OC[C@H]1CC[N+]2([C@H]1CCC2)[O-])O,,,,,,
523,10524,"(1R,9S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene",CN1CC[C@]23CCCCC2[C@@H]1CC4=C3C=C(C=C4)OC,,,,,,
524,10525,"5-(Hexopyranosyloxy)-14-hydroxy-19-oxobufa-3,20,22-trienolide",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC[C@]5([C@@]3(CCC=C5)C=O)O[C@H]6C(C([C@@H](C(O6)CO)O)O)O,,,,,,
525,10526,CID 10526,C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CCC5=C[C@H](CC[C@]35C=O)O,,,,,,
526,10527,"Butyric acid, 2-(dimethylaminomethyl)-2-phenyl-, benzyl ester, hydrochloride",CCC(CN(C)C)(C1=CC=CC=C1)C(=O)OCC2=CC=CC=C2.Cl,,,,,,
527,10528,Benzyl 2-[(dimethylamino)methyl]-2-phenylbutanoate,CCC(CN(C)C)(C1=CC=CC=C1)C(=O)OCC2=CC=CC=C2,,,,,,
528,10529,CID 10529,CC(C)CC1(C(=NC(=NC1=O)S)[O-])CC=C.[Na+],,,,,,
529,10530,CID 10530,CC(C)CC1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
530,10531,Dihydroergotamine,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,"['Dihydroergotamine (DHE) in all formulations is indicated for the acute treatment of migraine with or without aura in adults. As an injection, DHE is also indicated for the acute treatment of cluster headache episodes.  DHE is not indicated for migraine prevention or the management of hemiplegic or basilar migraine.']","['DHE is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. It is thought to exert its therapeutic effect through both neurological and vascular mechanisms. Its serotonin agonist activity may contribute to decreasing glutamatergic activity of the trigeminal system and subsequent cortical depolarization which is thought to participate in the neurological pathophysiology of migraine. The same serotonin agonist activity also contributes to vasoconstriction, producing both the characteristic side effect of chest tightness and potentially contributing to a therapeutic effect by counteracting the vasodilation due to calcitonin gene-related peptide (CGRP) release in migraine attacks.']","['A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)']","['When delivered intranasally, DHE has a bioavailability of approximately 40% with a tmax of 30-60 min.. Oral formulations have largely been unsuccessful due to a 1% bioavailability owing to a high degree of first-pass metabolism. Both intramuscular and intravenous administration produces 100% bioavailability with a tmax of 1-2 min and 24-34 min respectively.', 'DHE is primarily eliminated through hepatic metabolism followed by biliary excretion. 6-7% of a single intramuscular dose is excreted in the urine.', 'DHE has a steady-state volume of distribution of 800 L.', 'The total clearance of DHE is 1.5 L/h with renal clearance contributing 0.1 L/h.']","[""DHE is metabolized in the liver to four identified metabolites. 8'--hydroxy dihydroergotamine is the primary metabolite and an active one with equipotency for adrenergic and 5-HT receptors. 8'--hydroxy dihydroergotamine is present at plasma concentrations 5-7 times that of DHE. The remaining metabolites are Dihydrolysergic acid, dihydrolysergic amide, and a fourth metabolite formed through oxidative opening of the proline ring are considered minor metabolites. After intranasal administration, it has been found that metabolites represent 20-30% of plasma AUC.""]",['DHE exhibits a biphasic elimination with half lives of 0.7-1 h and 10-13 h.']
531,10532,Xenytropium bromide,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC=C5.[Br-],,,,,,
532,10533,"8-[([1,1'-Biphenyl]-4-yl)methyl]-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octan-8-ium",C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CC4=CC=C(C=C4)C5=CC=CC=C5,,,,,,
533,10534,"Norbornane, 2-methyl-3-methylene-2-(4-methyl-3-pentenyl)-",CC(=CCCC1(C2CCC(C2)C1=C)C)C,,,,,,
534,10535,2-Bromo-2-ethylbutyramide,CCC(CC)(C(=O)N)Br,,,,,,
535,10536,"(5'R,6R,7S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol",C[C@@H]1CC[C@@]2([C@H](C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1,,,,,,
536,10537,"Cerium(3+);1-(hydroxymethyl)ethane-1,1,2-tricarboxylate",C(C(=O)[O-])C(CO)(C(=O)[O-])C(=O)[O-].[Ce+3],,,,,,
537,10538,"1-(Hydroxymethyl)ethane-1,1,2-tricarboxylic acid",C(C(=O)O)C(CO)(C(=O)O)C(=O)O,,,,,,
538,10539,"2-(1-Aziridinyl)-dodecahydronaphtho(1,8-de)-1,3,2-diazaphosphorine 2-oxide",C1CC2CCCC3C2C(C1)NP(=O)(N3)N4CC4,,,,,,
539,10540,CID 10540,COS(=O)(=O)[O-].[Na+],,,,,,
540,10541,Trimethyl phosphate,COP(=O)(OC)OC,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/']","['Rats treated orally at 100 mg/kg and mice treated ip at 1000 mg/kg with (32)P-labeled trimethyl phosphate excreted primarily dimethyl phosphate in the urine. Only traces of the parent compound were detected, and only in the rats at less than 6 hr after treatment. S-Methyl cysteine and S-methyl cysteine N-acetate were also isolated. Small amounts of S-methyl glutathione were detected, presumably the initial methylation product in this series of metabolites ... . Metabolism of trimethyl phosphate was faster in the mouse than in the rat, but there was no evidence of further conversion to monomethyl phosphate in either species ... .']",
541,10542,"(3R,4S,5R,6R)-2-[[(2R,3S,4S,5R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol",C([C@@H]1[C@@H]([C@@H]([C@H](C(O1)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)O[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO)O)O)O)O)O)O)O,,,,,,
542,10543,"Phosphonium, tetrakis(hydroxymethyl)-, hydroxide",C(O)[P+](CO)(CO)CO.[OH-],,,,,,
543,10544,Tetrakis(hydroxymethyl)phosphonium,C(O)[P+](CO)(CO)CO,,,,,,
544,10545,Ascaridole,CC(C)C12CCC(C=C1)(OO2)C,,,,,,
545,10546,Tripropyl phosphate,CCCOP(=O)(OCCC)OCCC,,,,,,
546,10547,Echothiophate iodide,CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-],,,"['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)', 'Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. (See all compounds classified as Miotics.)']",,,
547,10548,Echothiophate,CCOP(=O)(OCC)SCC[N+](C)(C)C,['For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.'],"['Echothiophate Iodide is a potent, long-acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma. Echothiophate iodide will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy.']","['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)', 'Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. (See all compounds classified as Miotics.)']",['This ophthalmic medication may be systemically absorbed.'],,
548,10549,2-(Ethylsulfonyl)ethanol,CCS(=O)(=O)CCO,,,,,,
549,10550,Thujyl alcohol,CC1C2CC2(CC1O)C(C)C,,,,,,
550,10551,"Glycine, sulfate (3:1)",C(C(=O)O)N.C(C(=O)O)N.C(C(=O)O)N.OS(=O)(=O)O,,,,,,
551,10552,"2,3-Dibromopropene",C=C(CBr)Br,,,,,,
552,10553,2-Methyl-2-butene,CC=C(C)C,,,,,,
553,10554,1-Chloro-2-methylpropane,CC(C)CCl,,,,,,
554,10555,1-Chloro-2-methylpropene,CC(=CCl)C,,,,"['(2-(14)C)1-Chloro-2-methylpropene (3.5 mCi/mmol; radiochemical purity, 96%) was administered by gavage to male Fischer 344 rats in single or up to four daily doses of 150 mg/kg bw in corn oil. The compound was extensively absorbed and rapidly excreted: 92% of the single dose was eliminated within 24 hr after treatment. It was rapidly distributed to the tissues; liver and kidney contained higher concentrations of radiolabel than forestomach and glandular stomach, which had similar levels. The tissue concentrations increased monotonically after repeated doses but had declined significantly after four days of recovery following treatment. After a single dose, about 35% of the administered radiolabel was found in urine, 52% was exhaled and 5% was detected in the feces. In the expired air, about 25% of the dose was (14)C-carbon dioxide; 30% was volatile compounds, of which 96% was unchanged compound. ...', '(2-(14)C)1-Chloro-2-methylpropene (3.5 mCi/mmol; radiochemical purity, 96%) was administered by gavage to male B6C3F1 mice as a single dose of 150 mg/kg bw in corn oil. The compound was extensively absorbed and rapidly excreted; urine contained about 46% of the dose after 24 hr, 25% was expired as carbon dioxide and 5% as the unchanged compound, whereas 9% of the dose was found in the feces. The highest levels of radiolabel in tissues were detected in kidney, liver, forestomach and thymus 24 hr after administration. ...', 'A recent 2 yr carcinogenicity study found that gavage admin of 3-chloro-2-methylpropene containing 5% 1-chloro-2-methylpropene (dimethylvinyl chloride), caused forestomach neoplasms in rats and mice. Similar chronic studies revealed that dimethylvinyl chloride caused forestomach neoplasms in both rats and mice; neoplasms of the nasal and oral cavities were observed in rats but not in mice. In the current studies, /the metabolic basis/ of these differences /has been investigated/. Daily doses of 150 mg/kg of 2-(14)C-dimethylvinyl chloride or 2-(14)C-3-chloro-2-methylpropene were admin to rats for 1, 2, or 4 consecutive days. One daily dose of 150 mg/kg of dimethylvinyl chloride was admin to mice. Both /cmpds/ were rapidly metabolized; however, 3-chloro-2-methylpropene was cleared at a slightly lower rate. Rats exhaled approx 25 and 10% of the dimethylvinyl chloride and 3-chloro-2-methylpropene as C02, respectively. Mice exhaled 25% of the dimethylvinyl chloride as C02. Rats expired 30% of the administered dimethylvinyl chloride unchanged in the 24 hr after dosing compared to only 7% of the administered 3-chloro-2-methylpropene. Mice expired 5% of the administered dimethylvinyl chloride in the same time period. This observation may explain the occurrence of tumors in the nasal and oral cavities of rats treated with dimethylvinyl chloride but not in rats treated with 3-chloro-2-methylpropene or in mice treated with dimethylvinyl chloride in 2 yr carcinogenicity studies. The 24 hr urinary excretion in rats was 35% of the administered dimethylvinyl chloride compared to 58% of 3-chloro-methylpropene. Mice excreted 47% of the administered dimethylvinyl chloride in 24 hr in the urine. An unusual urinary metabolite of dimethylvinyl chloride, 2-amino-6-methyl-4-thia-5-heptene-1,7-dioic acid, was identified.']","['... The main urinary metabolite of 1-chloro-2-methylpropene was trans-2-amino-6-methyl-4-thia-5- heptene-1,7-dioic acid, indicating oxidation before glutathione conjugation. This metabolite constituted 23% of the total urinary radiolabel, and its corresponding N-acetyl derivative accounted for 9%. The profile of the urinary metabolites was quantitatively and qualitatively similar after one, two and four treatments.', '... As in rats, trans-2-amino-6-methyl-4-thia-5-heptene-1,7-dioic acid was the major urinary metabolite /in mice, constituting 35% of the total urinary radiolabel. Its N-acetyl derivative accounted for 12%.', 'Recent metabolism and disposition studies of 1-chloro-2-methylpropene (dimethylvinyl chloride) revealed cysteine and N-acetylcysteine conjugates of 3-chloro-2-methylpropenoic acid as the major metabolites. In the present studies /the authors/ have investigated various steps in the metabolic pathway to determine which step was responsible for the observed trans (E)-stereochemistry of these metabolites. In vitro incubation studies of dimethylvinyl chloride with rat liver microsomes indicated cytochrome P-450-catalyzed aliphatic hydroxylation to be only stereoselective. Both (E)- and (Z)-3-chloro-2-methylpropenols formed in an identical ratio of 2:1 in incubations with microsomes from untreated male and female rats and phenobarbital-treated male rats. No alcohol formation was observed in incubations using microsomes from beta-naphthoflavone-treated male rats. Investigation of the subsequent conjugation reactions of sulfur nucleophiles with haloenoic carbonyl compounds showed that both (E)- and (Z)-3-chloro-2-methylpropenals reacted rapidly with N-acetylcysteine, the E-adduct being the sole product in either case. In contrast, the Michael reaction of the corresponding acids with N-acetylcysteine was very sluggish. Also, whereas the E-acid yielded exclusively the corresponding E-adduct, the Z-isomer afforded both Z- and E-conjugates in the ratio of 3:4. Glutathione S-transferases had poor activity towards conjugation of glutathione with these acids. Formation of only an E-glutathione conjugate could be observed from either the E- or Z-acid in these enzymatic reactions. Direct Michael reaction of glutathione with (E)-3-bromo-2-methylpropenoic acid, used in chemical synthesis of the conjugates, yielded both the E- and Z-adducts in the ratio of 95:5.']",
555,10556,1-Iodo-2-methylpropane,CC(C)CI,,,,,,
556,10557,Methallyl alcohol,CC(=C)CO,,,,,,
557,10558,2-Methyl-1-propanethiol,CC(C)CS,,,,,,
558,10559,2-Iodobutane,CCC(C)I,,,,,,
559,10560,2-Butanethiol,CCC(C)S,,,,,"['Simple aliphatic and aromatic thiols undergo S-methylation in mammals to produce the corresponding methyl thioether or sulfide. Methylation is catalysed by thiopurine methyltransferase in the cytoplasm and thiol methyltransferase in microsomes, and both reactions require S-adenosyl-l-methionine as a methyl group donor. Thiopurine methyltransferase is present in human liver, kidney, and erythrocytes; preferential substrates for this enzyme include aromatic and heterocyclic thiols. S-Methylation of aliphatic thiols is catalysed by microsomal thiol methyltransferase, and the resulting methyl thioether (sulfide) metabolite would undergo S-oxidation to give the methyl sulfoxide and methyl sulfone analogues as urinary products. Thiols may react with glutathione and other endogenous thiol substances to form mixed disulfides. Both microsomal and cytoplasmic thioltransferasess have been reported to catalyse the formation of mixed disulfides. The resulting mixed disulfides can undergo reduction back to thiols, oxidative desulfuration, or oxidation to a sulfonic acid via the intermediate thiosulfinate and sulfinic acids. The principal form in the circulation would probably be a mixed disulfide formed with albumin. /Simple thiols/']",
560,10561,CID 10561,C(=N)(S)S.N,,,,,,
561,10562,CID 10562,C(=N)(S)S,,,,,,
562,10563,Barium carbonate,C(=O)([O-])[O-].[Ba+2],,,,"['0.06 mg barium/animal (as barium carbonate) was given im to rats (strain not given). Most of the dose was resorbed from the injection site within 3 days. 20% of the initial dose remained in the body (mostly in the skeleton) after 280 days. Average barium carbonate concentration at 1 hr was 50% that of barium chloride.', '... The absorption of specific barium salt anions /was examined/ in male Sprague-Dawley rats administered radiolabelled barium chloride, sulfate, or carbonate to fasted (24 hr) and non-fasted rats /strain not given/ by gastric intubation. Animals were sacrificed from 2 to 480 min after administration and blood concentrations were measured. In general, barium blood concentrations were higher in fasted animals and reached a peak 15 min after dosing, whereas non-fasted animals had lower barium blood concentrations and peaked 60 min after dosing. The peak blood concentration of the carbonate and sulfate salts were 45% and 85%, respectively, of that of the chloride.', 'A study ... in which rats /strain not given/ were exposed to barium chloride and barium carbonate in drinking water found the following non-skeletal distribution (skeletal tissue was not examined in the study) 24 hours after ingestion: heart > eye > skeletal muscle > kidney > blood > liver.']","['The in vivo solubility in rats of barium chloride, barium carbonate, barium sulfate, and barium fused in clay /was studied/. The chloride and the carbonate disappeared rapidly from the injection site. The sulfate dissolved more slowly; a half-life of 26 days was calculated. The fused clay was largely retained, the half-life being calculated as 1390 days.']",
563,10564,Cadmium carbonate,C(=O)([O-])[O-].[Cd+2],,,,"['The cereal crops (barley - Hordeum vulgare L., maize - Zea mays L., wheat - Triticum vulgare L.) were grown in a greenhouse using a sandy soil type treated with various doses of cadmium carbonate (salt), copper carbonate (malachite), lead carbonate (cerussite), and zinc carbonate (smithsonite), added jointly. The following levels of these metals were used: Cd - 5, 10, 50 ug g-1 soil; Cu and Ph-50, 100, 500 ug g-1 soil; Zn-150, 300, 1500 ug g-1 soil. Sequential extraction was adopted to partition the metals into five operationally-defined fractions: exchangeable, carbonate, Fe-Mn oxides, organic, and residual. The residual was the most abundant fraction in the untreated (control) soil for all the metals studied (50 to 60% of the total metal content). The concentrations of exchangeable Cd, Cu, Pb, and Zn were relatively low in untreated soil but increased (over the three year period) in treated soils for Cd, Zn, and Cu, whereas only small changes were observed for Pb. This experiment showed a significant increase in Cd, Zn, and Cu in tissue of plants grown on the treated soil, but a non-significant change in plant tissue with respect to Pb concentration.']",,
564,10565,Cobalt carbonate,C(=O)([O-])[O-].[Co+2],,,,,,
565,10566,"2,3-Dimethyl-1,3-butadiene",CC(=C)C(=C)C,,,,,,
566,10567,"1,1-Dichloroacetone",CC(=O)C(Cl)Cl,,,,"['... Dermal absorption of two haloketones (1,1-dichloropropanone and 1,1,1-trichloropropanone) and chloroform while bathing, /were examined/ by collecting and analyzing time profiles of expired breath samples of six human subjects during and following a 30-min bath. The disinfection byproduct concentrations in breath increased towards a maximum concentration during bathing. The maximum haloketone breath concentration during dermal exposure ranged from 0.1 to 0.9 ug /cu m, which was approximately two orders of magnitude lower than the maximum chloroform breath concentration during exposure. Based on a one-compartment model, the in vivo permeability of chloroform, 1,1-dichloropropanone, and 1,1,1-trichloropropanone were approximated to be 0.015, 7.5 x 10- 4, and 4.5 x 10- 4 cm /hr, respectively. Thus, haloketones are much less permeable across human skin under normal bathing conditions than is chloroform...']",,
567,10568,Tetraiodoethylene,C(=C(I)I)(I)I,,,,,,
568,10569,Abietic acid,CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C,,,"['Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
569,10570,"(3S)-3,11-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one",CC12CC[C@@H](CC1CCC3C2C(CC4(C3CCC4=O)C)O)O,,,,,,
570,10571,16-Formyl-gitoxigenin,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=CC(=O)OC5)OC=O)O)C)O,,,,,,
571,10572,"[2-[(9R)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",CC(=O)OCC(=O)C1(CCC2C1(CC([C@]3(C2CCC4=CC(=O)CCC43C)F)O)C)O,,,,,,
572,10573,11-epi-Sarnovid [German],CC1[C@@H](C(C([C@@H](O1)O[C@@H]2CC[C@]3([C@@H](C2)CCC4C3C(C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)OC)O,,,,,,
573,10574,Periplogenin,C[C@]12CC[C@@H](C[C@]1(CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O)O,,,,,,
574,10575,Emicymarin,CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C)O)OC)O,,,,,,
575,10576,"(17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O,,,,,,
576,10577,Estriol succinate,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2OC(=O)CCC(=O)O)OC(=O)CCC(=O)O)CCC4=C3C=CC(=C4)O,,,,,,
577,10578,Dithiazanine iodide,CCN1C2=CC=CC=C2SC1=CC=CC=CC3=[N+](C4=CC=CC=C4S3)CC.[I-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)']","['Absorption of this blue violet compound from the intestinal tract is minimal but is sufficient to cause a faint blue coloration of tissues. Since most of the drug remains unabsorbed in ingesta, feces and vomitus of dogs are blue green to purple in color.']",,
578,10579,"3,3'-Diethylthiadicarbocyanine",CCN1C2=CC=CC=C2SC1=CC=CC=CC3=[N+](C4=CC=CC=C4S3)CC,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)']",,,
579,10580,E 161g;all-trans-Canthaxanthin,CC1=C(C(CCC1=O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)CCC2(C)C)C)C)C,,,,,,
580,10581,"1,5,5,6-Tetramethyl-1,3-cyclohexadiene",CC1C(=CC=CC1(C)C)C,,,,,,
581,10582,Myrtenol,CC1(C2CC=C(C1C2)CO)C,,,,,,
582,10583,"Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1R,2R,4S)-rel-",CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C,,,,,,
583,10584,CID 10584,C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
584,10585,Ethyl benzenesulfonate,CCOS(=O)(=O)C1=CC=CC=C1,,,,,,
585,10586,alpha-Bisabolol,CC1=CCC(CC1)C(C)(CCC=C(C)C)O,,,,,,
586,10587,"2,2,2-Trichloro-1-ethoxyethanol",CCOC(C(Cl)(Cl)Cl)O,,,,,,
587,10588,Ethyl trichloroacetate,CCOC(=O)C(Cl)(Cl)Cl,,,,,,
588,10589,Ferrous oxalate,C(=O)(C(=O)[O-])[O-].[Fe+2],,,,"['...Bioavailability of Ferosol-1 /(a ferrous oxalate antianemic powder including copper, zinc, and cobalt) was determined/ by giving it to rabbits with experimental posthemorrhagic anemia. ...Iron from Ferosol-1 was found to be well assimilated and to take place in hemopoetic processes of rabbit. /Ferosol-1/', 'In hemochromatosis and other disorders associated with iron overload, a significant fraction of the total iron in plasma circulates in the form of low molecular weight complexes not bound to transferrin. Efficient and unregulated clearance of this form of iron by the liver may account for the hepatic iron loading and toxicity that characterize these diseases. ...This possibility /was tested/ by examining the hepatic removal process for representative iron complexes in the single-pass perfused rat liver. Hepatic uptake of both ferrous and ferric 55Fe from ultrafiltered human serum was found to be highly efficient and effectively irreversible (single-pass extraction of 1 microM iron, 58-75%). Similar high efficiencies were seen for iron complexed to specific physiologic and nonphysiologic coordinators, including histidine, citrate, fructose, oxalate and glutamate, and tricine. Because of lower plasma flow rates, single-pass extraction of these iron complexes in vivo should be even greater. Autoradiography confirmed that most iron had been removed by parenchymal cells. Hepatic removal from Krebs-tricine buffer was saturable with similar kinetic parameters for ferrous and ferric iron (apparent Km, 14-22 microM; V max, 24-38 nmol/min/g liver). These findings suggest that high levels of non-transferrin-bound iron in plasma may be an important cause of hepatic iron loading in iron overload states.']",,
589,10590,"1-(3,11-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-hydroxyethanone",CC12CCC(CC1CCC3C2C(CC4(C3CCC4C(=O)CO)C)O)O,,,,,,
590,10591,"2-[4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid",CC(CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,,,,
591,10592,"(17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one",CC12CCC(=O)CC1CCC3C2C(CC4(C3CC[C@@]4(C(=O)CO)O)C)O,,,,,,
592,10593,"1-[(17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone",CC12CCC(CC1CCC3C2CCC4(C3CC[C@@]4(C(=O)CO)O)C)O,,,,,,
593,10594,"Ethanesulfonic acid, 2-(((3alpha,5beta,12alpha)-3,12-dihydroxy-24-oxocholan-24-yl)amino)-",CC(CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)']",,,
594,10595,Lithocholyltaurine,CC(CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,,,"['Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)', 'Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
595,10596,"Estra-1(10),2,4-triene-3,17-diol",CC12CCC3[C@@H](C1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,,,,,,
596,10597,Isoequilenin,CC12CCC3=C(C1CCC2=O)C=CC4=C3C=CC(=C4)O,,,,,,
597,10598,N-(Ethylmercuri)-p-toluenesulfonanilide,CC[Hg]N(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)C,,,,,,
598,10599,Methallenestril,CCC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(C)(C)C(=O)O,,,,"['ESTROGENS USED IN THERAPY ARE...READILY ABSORBED THROUGH SKIN & MUCOUS MEMBRANES. WHEN THEY ARE APPLIED FOR LOCAL ACTION, ABSORPTION IS OFTEN SUFFICIENT TO CAUSE SYSTEMIC EFFECTS, & IN FACTORY WORKERS GYNECOMASTIA HAS FOLLOWED HANDLING OF DIETHYLSTILBESTROL WITHOUT GLOVES. /ESTROGENS/', 'URINARY EXCRETION RATE OF ESTROGENS IS QUITE SIMILAR WHETHER AGENTS ARE GIVEN ORALLY OR INTRAVENOUSLY, WHICH SUGGESTS THAT ABSORPTION OF MOST ESTROGENS FROM GI TRACT IS PROMPT & QUITE COMPLETE. /ESTROGENS/', 'NATURAL ESTROGENS ARE SOL IN WATER, &, WHEN INJECTED DISSOLVED IN OIL, ARE RAPIDLY ABSORBED & QUICKLY METABOLIZED. ... INACTIVATION OF ESTROGEN IN BODY IS CARRIED OUT MAINLY IN THE LIVER. /ESTROGENS/', 'CERTAIN PROPORTION OF ESTROGEN REACHING.../THE LIVER/ IS EXCRETED INTO THE BILE, ONLY TO BE REABSORBED FROM THE INTESTINE & CARRIED BACK AGAIN TO THE LIVER BY THE PORTAL VEIN. /ESTROGENS/']",,
599,10600,"3-Ethyl-2,4-dimethyl-1H-pyrrole",CCC1=C(NC=C1C)C,,,,,,
600,10601,2-Acetylbutyrolactone,CC(=O)C1CCOC1=O,,,,,,
601,10602,Trinitromethane,C([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
602,10603,"7,11b-Dihydroindeno[2,1-c]chromene-3,4,6a,9,10(6H)-pentol",C1C2=CC(=C(C=C2C3C1(COC4=C3C=CC(=C4O)O)O)O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
603,10604,Forbisen,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C3=C(N(N(C3=O)C4=CC=CC=C4)C)C,,,,,,
604,10605,"Colchiceine, N-deacetyl-N-methyl-",CNC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)O)OC)OC)OC,,,,,,
605,10606,Cyclocumarol,CC1(CC(C2=C(O1)C3=CC=CC=C3OC2=O)C4=CC=CC=C4)OC,,,,,,
606,10607,Podofilox,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,['For treatment of external genital warts (<i>Condyloma acuminatum</i>).'],"['Podofilox, also called podophyllotoxin, is a purer and more stable form of podophyllin in which only the biologically active portion of the compound is present. Podofilox is used to remove certain types of warts on the outside skin of the genital areas.']","['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. (See all compounds classified as Keratolytic Agents.)', 'Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)']","['Topical application of 0.05 mL of 0.5% podofilox solution to external genitalia did not result in detectable serum levels. Applications of 0.1 to 1.5 mL resulted in peak serum levels of 1 to 17 ng/mL one to two hours after application.', 'Small amounts of podofilox may be absorbed systemically following topical application. In a study in adults with anogenital warts caused by human papillomavirus, topical application of 0.05 mL of podofilox 0.5% solution to external genitalia did not result in detectable serum concentrations of the drug; however, topical application of 0.1-1.5mL of the solution resulted in peak serum concentrations of 1-17 ng/mL at 1-2 hours after application.']",,"['1.0 to 4.5 hours.', 'The serum elimination half-life of podofilox is estimated to range from 1-4.5 hours.']"
607,10608,Fluorescein sodium,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)[O-])C(=O)[O-].[Na+].[Na+],,,"['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']","['Uranine is rapidly absorbed in the lungs and in the respiratory tract, and is affected by the presence of surfactants. It is not metabolized in the lung. Inhaled uranine is excreted in the urine.', 'Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).', 'Fluorescein sodium has been demonstrated to be excreted in human milk.', 'Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.', 'For more Absorption, Distribution and Excretion (Complete) data for D&C Yellow No. 8 (7 total), please visit the HSDB record page.']","['Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.']","['... The pharmacokinetics of fluorescein and fluorescein glucuronide /were studied/ for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. ... The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, ... .']"
608,10609,Dimethoxanate hydrochloride,CN(C)CCOCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31.Cl,,,,,,
609,10610,Dimethoxanate,CN(C)CCOCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
610,10611,CID 10611,C[C@H]1[C@@H](OC=C2C1=C(C(=O)C(=C(O)O)C2=O)C)C,,,,,,
611,10612,Dimethazan,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCN(C)C,,,,,,
612,10613,"2,4-Dinitroresorcinol",C1=CC(=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])O,,,,,,
613,10614,Triphenylmethane,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
614,10615,"N,N-Diphenylacetamide",CC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
615,10616,Ambucetamide,CCCCN(CCCC)C(C1=CC=C(C=C1)OC)C(=O)N,,,,,,
616,10617,Florantyrone,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C=C(C=C4)C(=O)CCC(=O)O,,,,,,
617,10618,Noramidopyrine,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC,,,,,,
618,10619,Mepiperphenidol bromide,CC(C)C(C1=CC=CC=C1)C(CC[N+]2(CCCCC2)C)O.[Br-],,,,,,
619,10620,Mepiperphenidol,CC(C)C(C1=CC=CC=C1)C(CC[N+]2(CCCCC2)C)O,,,,,,
620,10621,Hesperidin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,,,,,,
621,10622,CID 10622,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=O)C4=C(C=C(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,,,,,,
622,10623,CID 10623,CC1=CC(=O)C(=C(O1)O)C(=O)C,,,,,,
623,10624,Psilocybine,CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,,,"['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)']","['In a clinical study eight volunteers received psilocybin in psychoactive oral doses of 212+ or -25 ug/kg body weight. To investigate the elimination kinetics of psilocin, the first metabolite of psilocybin, urine was collected for 24 hr and psilocin concentrations were determined by high-performance liquid chromatography with column switching and electrochemical detection (HPLC-ECD). Sample workup included protection of the unstable psilocin with ascorbic acid, freeze-drying, and extraction with methanol. Peak psilocin concentrations up to 870 ug/l were measured in urine samples from the 2-4 hr collection interval. The psilocin excretion rate in this period was 55.5+ or -33.8 microg/h. The limit of quantitation (10 ug/L) was usually reached 24 hr after drug administration. Within 24 hr, 3.4+ or -0.9% of the applied dose of psilocybin was excreted as free psilocin. Addition of beta-glucuronidase to urine samples and incubation for 5 hr at 40 degrees C led to twofold higher psilocin concentrations, although 18+ or -7% of the amount of unconjugated PI was decomposed during incubation. /In conclusion/ that in humans psilocin is partially excreted as psilocin-O-glucuronide and that enzymatic hydrolysis extends the time of detectability for psilocin in urine samples.']",['Psilocybin is rapidly and completely hydrolyzed to psilocin in vivo.'],
624,10625,6-Amino-7-(3-dimethylallyl)purine,CC(=CCN1C=NC2=NC=NC(=C21)N)C,,,,,,
625,10626,"1H-Pyrrolizine-7-methanol, 2,3,5,7a-tetrahydro-1-hydroxy-, (1S-cis)-",C1CN2CC=C(C2C1O)CO,,,,,,
626,10627,"[7-(2-methylbut-2-enoyloxy)-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl 2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate",CC=C(C)C(=O)OC1CCN2C1C(=CC2)COC(=O)C(C(C)O)(C(C)(C)O)O,,,,,,
627,10628,"3-Ethyl-2,4,5-trimethyl-1H-pyrrole",CCC1=C(NC(=C1C)C)C,,,,,,
628,10629,3-Hydroxybenzothiophene,C1=CC=C2C(=C1)C(=CS2)O,,,,,,
629,10630,Ethadione,CCN1C(=O)C(OC1=O)(C)C,,,,,,
630,10631,Medroxyprogesterone,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C,,,"['Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)', 'Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)']","['No specific investigation on the absolute bioavailability of medroxyprogesterone (MPA) in humans has been conducted. MPA is rapidly absorbed from the gastrointestinal tract, and maximum MPA concentrations are obtained between 2 to 4 hours after oral administration.', 'Administration of medroxyprogesterone acetate with food increases the bioavailability of MPA. A 10 mg dose of medroxyprogesterone acetate, taken immediately before or after a meal, increased MPA Cmax (50 to 70%) and AUC (18 to 33%). The half-life of MPA was not changed with food.', 'Medroxyprogesterone is approximately 90% protein bound, primarily to albumin; no MPA binding occurs with sex hormone binding globulin.', 'Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.', 'For more Absorption, Distribution and Excretion (Complete) data for MEDROXYPROGESTERONE (10 total), please visit the HSDB record page.']","['Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. ...MPA is almost exclusively eliminated via hepatic metabolism. In 14 patients with advanced liver disease, MPA disposition was significantly altered (reduced elimination). In patients with fatty liver, the mean percent dose excreted in the 24-hour urine as intact MPA after a 10 mg or 100 mg dose was 7.3% and 6.4%, respectively.']",['Elimination half-life of oral preparation is 32 to 44 hr. /Acetate/']
631,10632,"(17beta)-17-Methylandrost-5-ene-3,17-diol",C[C@@]1(CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O,,,,,,
632,10633,Mestanolone,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,,,,,,
633,10634,Androstenediol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC=C4[C@@]3(CC[C@@H](C4)O)C,,,"['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",,,
634,10635,Androstanolone,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,,,"['Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)']",['Bioavailability is very low (0-2%) following oral administration.'],,
635,10636,CID 10636,C1=CC=C2C(=C1)C(=CC(=O)C2=O)S(=O)(=O)[O-].[Na+],,,,,,
636,10637,"1-Naphthalenesulfonic acid, 3,4-dihydro-3,4-dioxo-",C1=CC=C2C(=C1)C(=CC(=O)C2=O)S(=O)(=O)O,,,,,,
637,10638,Luminol,C1=CC2=C(C(=C1)N)C(=O)NNC2=O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Compound such as LUMINESCENT PROTEINS that cause or emit light (PHYSICAL LUMINESCENCE). (See all compounds classified as Luminescent Agents.)']",,,
638,10639,Physcion,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)OC,,,,,,
639,10640,"isoquinoline-1,3,4(2H)-trione",C1=CC=C2C(=C1)C(=O)C(=O)NC2=O,,,,,,
640,10641,N-Methylprotriptyline,CN(C)CCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,,,,,,
641,10642,CID 10642,C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC(=C(C=C4)O)O)O)O)O,,,,,,
642,10643,Auranetin,COC1=CC=C(C=C1)C2=C(C(=O)C3=CC(=C(C(=C3O2)OC)OC)OC)OC,,,,,,
643,10644,CID 10644,COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
644,10645,Pyrathiazine hydrochloride,C1CCN(C1)CCN2C3=CC=CC=C3SC4=CC=CC=C42.Cl,,,,,,
645,10646,Pyrathiazine,C1CCN(C1)CCN2C3=CC=CC=C3SC4=CC=CC=C42,,,,,,
646,10647,CID 10647,C1=COC(=C1)C(=C(C2=CC=CO2)N=O)NO,,,,,,
647,10648,Tetrahydrozoline hydrochloride,C1CC(C2=CC=CC=C2C1)C3=NCCN3.Cl,,,"['Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (See all compounds classified as Ophthalmic Solutions.)', 'Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
648,10649,Dequalinium chloride,CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.[Cl-].[Cl-],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
649,10650,alpha-Collatolic acid,CCCCCC(=O)CC1=C2C(=CC(=C1)OC)OC3=C(C=C(C(=C3CC(=O)CCCCC)C(=O)O)O)OC2=O,,,,,,
650,10651,Hydroquinine,CCC1CN2CCC1CC2[C@@H](C3=C4C=C(C=CC4=NC=C3)OC)O,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
651,10652,Blastomycin,CCCC[C@@H]1[C@@H]([C@@H](OC(=O)C(C(OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,,,,,,
652,10653,beta-Norcoralydine,COC1=C(C=C2C3CC4=CC(=C(C=C4CN3CCC2=C1)OC)OC)OC,,,,,,
653,10654,"Dibenzyl benzene-1,3-dicarboxylate",C1=CC=C(C=C1)COC(=O)C2=CC(=CC=C2)C(=O)OCC3=CC=CC=C3,,,,,,
654,10655,CID 10655,C1=CC=C2C(=C1)C(=CC=C2O)N=NC3=CC=C(C=C3)S(=O)(=O)[O-].[Na+],,,,,,
655,10656,"Benzenesulfonic acid, 4-[(4-hydroxy-1-naphthalenyl)azo]-",C1=CC=C2C(=C1)C(=CC=C2O)N=NC3=CC=C(C=C3)S(=O)(=O)O,,,,,,
656,10657,beta-Cadinene,CC1=CC[C@@H]2[C@@H](C1)[C@@H](CC=C2C)C(C)C,,,,,,
657,10658,Angelicin,C1=CC2=C(C=CO2)C3=C1C=CC(=O)O3,,,"['A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes. (See all compounds classified as Tranquilizing Agents.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']","['OBJECTIVE: To investigate the nasal absorption regularities of psoralen and isopsoralen of different concentrations.  METHOD: Building an experimental model of rat in situ nasal recirculation and determining the contents of psoralen and isopsoralen by HPLC.  RESULT: The nasal absorption of psoralen and isopsoralen fitted in with zero order kinetics, getting saturated with the increase of concentration.  CONCLUSION: A suitable concentration is necessary for the preparation of nasal remedies psoralen and isopsoralen.', 'Coumarin components from Psoralea corylifolia L. are novel drugs in which psoralen and isopsoralen are the active components. The pharmacokinetics, tissue distribution and excretion of the two compounds were studied by liquid chromatography-tandem mass spectrometry after intravenous administration to Wistar rats. The elimination half-lives of psoralen and isopsoralen were 4.88 and 5.35 hr. After dosing, the area under the curves of the tissues decreased in the following order: liver > lung > heart > kidney > spleen > brain for psoralen; and kidney > lung > liver > heart > spleen > brain for isopsoralen. After dosing, 51.27% of psoralen and 56.25% of isopsoralen were excreted as prototype, and urine was the major excretion route. In addition, the pharmacokinetics of psoralen and isopsoralen after oral administration to Wistar rats were also studied. The elimination half-lives of psoralen and isopsoralen were 4.13 and 5.56 hr, and their relative bioavailabilities were 61.45% and 70.35%. Overall, the results show that coumarin components from P. corylifolia L. have high oral bioavailability, they are rapidly and widely distributed into tissues after intravenous administration, but they are slowly cleared and excreted']",,['...The elimination half-lives of psoralen and isopsoralen /after iv administration to Wistar rats/ were 4.88 and 5.35 hr. ...The elimination half-lives of psoralen and isopsoralen /after oral administration to Wistar rats/ were 4.13 and 5.56 hr...']
658,10659,Apiole,COC1=C2C(=C(C(=C1)CC=C)OC)OCO2,,,,,,
659,10660,Dimenhydrinate,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,"['Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.']","['Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. It has a short duration of action of 4-8 hours. Patients should be counselled regarding pronounced drowsiness, avoiding alcohol and other sedatives, and exercising caution when operating a motor vehicle or heavy machinery.']","['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']","['A 50 mg oral film coated tablet reaches a C<sub>max</sub> of 72.6 ng/mL with a T<sub>max</sub> of 2.7 hours. A 100 mg suppository reaches a C<sub>max</sub> of 112.2 ng/mL with a T<sub>max</sub> of 5.3 hours.', 'Dimenhydrinate is predominantly eliminated in the urine. 1-3% of the dissociated diphenhydramine is eliminated in the urine unchanged, while 64% of diphenhydramine is eliminated in the urine as metabolites. The elimination of dimenhydrinate has not been fully studied.', 'The volume of distribution of dimenhydrinate is 3-4 L/kg.', 'DIMENHYDRINATE (ETHANOLAMINES): DURATION OF ACTION (HR) 4-6. /FROM TABLE/', 'H1 ANTAGONISTS ARE READILY ABSORBED FROM GI TRACT & PARENTERAL SITES OF ADMIN. FOLLOWING ORAL ADMIN, EFFECTS START WITHIN 15 TO 30 MIN, ARE FULLY DEVELOPED WITHIN 1 HR, & LAST ABOUT 3 TO 6 HR, ALTHOUGH SOME...ACT LONGER. /ANTIHISTAMINES/']","['Dimenhydrinate is a theoclate salt that separates into [diphenhydramine] and [8-chlorotheophylline]. diphenhydramine can either be N-glucuronidated by UGTs to diphenhydramine N-glucuronide or N-demethylated by CYP2D6, CYP1A2, CYP2C9, and CYP2C19 to N-desmethyldiphenhydramine. N-desmethyldiphenhydramine can be N-demethylated again by the same enzymes to N,N-didesmethyldiphenhydramine, which undergoes oxidative deamination to form diphenylmethoxyacetic acid.', 'EXTENSIVE STUDIES OF METABOLIC FATE OF ANTIHISTAMINES HAVE BEEN LIMITED TO A FEW COMPD. ... MAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/']",['The plasma elimination half life of dimenhydrinate is 5-8 hours.']
660,10661,8-Chlorotheophylline,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl,"['When used in combination with [DB01075] as the antiemetic [DB00985], 8-chlorotheophylline  is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.']",,,,,
661,10662,Dibromsalicil,C1=CC(=C(C=C1Br)C(=O)C(=O)C2=C(C=CC(=C2)Br)O)O,,,,,,
662,10663,Malonyl coenzyme A lithium salt,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(=O)O)O,,,,,,
663,10664,Pyridoxamine dihydrochloride,CC1=NC=C(C(=C1O)CN)CO.Cl.Cl,,,,,,
664,10665,N-Hydroxyphthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)O,,,,,,
665,10666,Ricinine,CN1C=CC(=C(C1=O)C#N)OC,,,,,,
666,10667,"1,2-Naphthoquinone",C1=CC=C2C(=C1)C=CC(=O)C2=O,,,,,"['1,2-Naphthoquinone is metabolized to 1,2-dihydroxynaphthalene in pigs. /From Table/', '1-Naphthol was metabolized by tyrosinase, polyphenol oxidase, primarily to 1,2-naphthoquinone and to small amounts of 1,4-naphthoquinone as well as to covalently bound products. The inhibition of covalent binding by ethylenediamine, which reacts specifically with 1,2-naphthoquinone but not 1,4-naphthoquinone, suggested that most of the covalent binding was due to 1,2-naphthoquinone or a metabolite of similar structure.', 'In rat liver microsomal preparations, 1-naphthol is metabolized by the cytochrome p450 mixed function oxidase to 1,4-naphthoquinone and covalently bound species. The major binding species are derived from 1,4-naphthoquinone but not 1,2-naphthoquinone. 1-Naphthol is also metabolized by tyrosinase (monophenol monooxygenase; polyphenol oxidase) primarily to 1,2-naphthoquinone and covalently bound products; most of the covalent binding was derived from a 1,2-naphthoquinone derivative.', 'The hepatic microsomal metabolism of 1-naphthol, 1,2- and 1,4-naphthoquinone has been shown to generate active oxygen species by using electron spin resonance spin-trapping techniques. 1-Naphthol, in the presence of NADPH, and 1,2- and 1,4-naphthoquinone, with either NADH or NADPH, caused a stimulation in both the rate of microsomal oxygen consumption and the formation of superoxide spin adduct, 5,5-dimethyl-2-hydroxyperoxypyrrolidino-1-oxyl (DMPO-OOH). Superoxide dismutase, but not catalase, prevented the formation of this spin adduct, further supporting the suggestion that the superoxide free radical was the major oxy-radical formed during the microsomal metabolism of 1-naphthol and the naphthoquinones. These results are compatible with the suggestion that 1-naphthol may exert its toxicity to isolated hepatocytes and other cellular systems by metabolism to naphthoquinones followed by their redox cycling with concomittant generation of active oxygen species, in particular superoxide free radicals.', '...The toxicity of 1-naphthol may be mediated by the formation of 1,2-naphthoquinone and/or 1,4-naphthoquinone, which may then be metabolized by 1-electron reduction to naphthoquinone radicals. These, in turn, may covalently bind to important cellular macromolecules or enter a redox cycle with molecular oxygen thereby generating active oxygen species. Both of these processes appear to play a role in producing the cytotoxic effects of 1-naphthol.']",
667,10668,Dimethylthiambutene,CC(C=C(C1=CC=CS1)C2=CC=CS2)N(C)C,['Dimethylthiambutene is an opioid analgesic previously used in moderate pain relief.'],,,,,
668,10669,Medrylamine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)OC,,,,,,
669,10670,Benanserin hydrochloride,CC1=C(C2=C(N1CC3=CC=CC=C3)C=CC(=C2)OC)CCN.Cl,,,,,,
670,10671,9-Aminofluorene,C1=CC=C2C(=C1)C(C3=CC=CC=C32)N,,,,,,
671,10672,"2,7-Naphthalenedisulfonic acid, 3-hydroxy-4-nitroso-, disodium salt",C1=CC2=C(C(=C(C=C2C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])O)N=O.[Na+].[Na+],,,,,,
672,10673,"2,7-Naphthalenedisulfonic acid, 3-hydroxy-4-nitroso-",C1=CC2=C(C(=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)O)N=O,,,,,,
673,10674,Cloperidone hydrochloride,C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC(=CC=C4)Cl.Cl,,,,,,
674,10675,Cloperidone,C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC(=CC=C4)Cl,,,,,,
675,10676,"Naphthalene-1,6-disulfonic acid",C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C(=C1)S(=O)(=O)O,,,,,,
676,10677,5-Nitroquinoline-2-carboxylic acid,C1=CC2=C(C=CC(=N2)C(=O)O)C(=C1)[N+](=O)[O-],,,,,,
677,10678,Pyrogallol triacetate,CC(=O)OC1=C(C(=CC=C1)OC(=O)C)OC(=O)C,,,,,,
678,10679,"2,7-Diaminofluorene",C1C2=C(C=CC(=C2)N)C3=C1C=C(C=C3)N,,,,,,
679,10680,Flavone,C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2,,,,,,
680,10681,CID 10681,C1=CC=C(C(=C1)C(=O)O)O.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
681,10682,CID 10682,C1=CC=C(C(=C1)C(=O)[O-])O.C1=CC=C(C(=C1)C(=O)[O-])O.[Sr+2],,,,,,
682,10683,Allomethadione,CC1C(=O)N(C(=O)O1)CC=C,,,,,,
683,10684,beta-Amino-1H-indole-3-propanol,C1=CC=C2C(=C1)C(=CN2)CC(CO)N,,,,,,
684,10685,Tryptophol,C1=CC=C2C(=C1)C(=CN2)CCO,,,,,,
685,10686,"1,2,3-Trimethylbenzene",CC1=C(C(=CC=C1)C)C,,,,"['... Ten healthy male volunteers were exposed to trimethylbenzene (TMB) vapor in an exposure chamber for 2 hr at a work load of 50 W. The subjects were exposed on four occasions, to 25 ppm of 1,2,4-TMB, 1,2,3-TMB, and 1,3,5-TMB, respectively, and 2 ppm of 1,2,4-TMB. Urine was collected from the onset of exposure until the following morning. All six possible dimethylhippuric acid (DMHA) isomers were analyzed by high-performance liquid chromatography. About 22% of the inhaled amount of 1,2,4-TMB was excreted as DMHAs within 24 hr, mainly as 3,4-DMHA. The 24-hr recovery of 1,2,3-TMB as DMHAs was 11%. Only 3% of the absorbed amount of 1,3,5-TMB was excreted as 3,5,-DMHA. ...  In addition to analysis of DMHAs, the excretion of unconjugated dimethylbenzoic acids in urine was estimated to account for approximately 3% of the dose of all TMBs. In conclusion, the urinary excretion of DMHA isomers may serve as a good indicator of TMB exposure. In this controlled short-term-exposure study the sum of excretion rate of several DMHA isomers reflected exposure more closely than did the excretion rate of any single DMHA.']","['The structure was investigated of the mercapturic acid excreted in urine of rats after the i.p. administration of 1,2,3-trimethylbenzene. Of the two regioisomeric mercapturic acids, i.e. N-acetyl-S-(2,3-dimethylbenzyl)-L-cysteine and N-acetyl-S-(2,6-dimethyl-benzyl)-L-cysteine, only the former was isolated by preparative HPLC and identified, by comparison with an authentic specimen. The excretion rate of the mercapturate was estimated to be approximately 5% of dose, not a substantial metabolic route.', 'Toxicity of Tri- and Tetramethylbenzenes: Material: 1,2,3-trimethylbenzene; Route of entry: oral (subacute); Species: rat; Dose or concentration: 1.2 g/kg; Results or Effects: Metabolites: 2,3-dimethylhippuric acid 17.3%, 2,3-dimethylbenzoic glucuronide 19.4%, and 2,3-dimethylbenzoic sulfate 19.9%. /From table/']","['... Ten healthy male volunteers were exposed to trimethylbenzene (TMB) vapor in an exposure chamber for 2 hr at a work load of 50 W. The subjects were exposed on four occasions, to 25 ppm of 1,2,4-TMB, 1,2,3-TMB, and 1,3,5-TMB, respectively, and 2 ppm of 1,2,4-TMB. Urine was collected from the onset of exposure until the following morning. All six possible dimethylhippuric acid (DMHA) isomers were analyzed by high-performance liquid chromatography. ...  The half-times of the different DMHA isomers ranged from 4 to 16 hr.']"
686,10687,"2,3-Dimethylphenol",CC1=C(C(=CC=C1)O)C,,,,,"['2,3-DIMETHYLPHENOL YIELDS 3,4-DIMETHYLCATECHOL, 2,3-DIMETHYLPHENYL-BETA-D-GLUCURONIDE, AND 2,3-DIMETHYLPHENYL SULFATE AS METABOLITES IN THE RABBIT. /FROM TABLE/', 'HYDROXYLATION OF AROMATIC HYDROCARBONS WAS STUDIED FOLLOWING THEIR ORAL ADMINISTRATION TO RATS THAT ALSO RECEIVED A PURIFIED DIET CONTAINING NEOMYCIN TO REDUCE THE LEVELS OF NORMALLY OCCURRING SIMPLE URINARY PHENOLS. PHENOLIC METABOLITES WERE QUANTITATIVELY ESTIMATED IN HYDROLYZED URINE SAMPLES BY GAS CHROMATOGRAPHY. O-XYLENE ADMINISTERED AT A DOSE OF 100 MG/KG WAS METABOLIZED TO 3,4-DIMETHYLPHENOL TO THE EXTENT OF 0.1% OF THE DOSE GIVEN AND VERY SMALL AMOUNTS OF 2,3-DIMETHYLPHENOL.', 'FOUR PERSONS WERE EXPOSED TO XYLENES. 2,3- AND 3,4-XYLENOL WERE OBSERVED IN THE URINE OF THOSE EXPOSED TO O-XYLENE; 2,4-XYLENOL WAS OBSERVED AFTER M-XYLENE AND 2,5-XYLENOL AFTER P-XYLENE.', '3,4-Dimethylphenol is a known human metabolite of o-xylene.']",
687,10688,"2,3-Dimethyl-p-benzoquinone",CC1=C(C(=O)C=CC1=O)C,,,,,,
688,10689,CID 10689,C(C(C(=O)[O-])O)(C(=O)O)O.[Na+],,,,,,
689,10690,Gluconic acid,C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,['For use as part of electrolyte supplementation in total parenteral nutrition.'],['Used as part of electrolyte salts to maintain cation-anion balance in solutions.'],,"['(99)TCM-LABELED GLUCONATE WAS ACCUMULATED RELATIVELY EARLY IN THE KIDNEY, AND ESP IN THE URINARY TRACT.']",,
690,10691,CID 10691,C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Na+],,,,,,
691,10692,Copper gluconate,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Cu+2],,,,,,
692,10693,Pentachloroaniline,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)N,,,,,"['PENTACHLOROANILINE IS A METABOLITE OF THE PESTICIDE PENTACHLORONITROBENZENE (QUINTOZENE) IN ANIMALS, PLANTS, SOIL, ETC.', 'PENTACHLOROANILINE LEVELS IN URINE WERE MEASURED & CORRELATED TO THE TYPE OF PCNB FORMULATION USED.', 'PURE PENTACHLORONITROBENZENE WAS ADMIN TO RHESUS MONKEYS AS SINGLE ORAL DOSES OF 0.5, 2, OR 91 MG/KG & IN A 70-DAY FEEDING STUDY @ LEVEL OF 2 PPM IN DAILY DIET. PENTACHLOROANILINE WAS A MAJOR METABOLITE.', 'PENTACHLORONITROBENZENE WAS ADMIN TO RATS AND BEAGLE DOGS, IN THE DIET, AND TO COWS. PENTACHLOROANILINE WAS FOUND IN TISSUE OF TREATED ANIMALS OF ALL 3 SPECIES.', 'For more Metabolism/Metabolites (Complete) data for PENTACHLOROANILINE (8 total), please visit the HSDB record page.']",
693,10694,"2,3,5,6-Tetramethylphenol",CC1=CC(=C(C(=C1C)O)C)C,,,,,,
694,10695,"1,2,3,5-Tetramethylbenzene",CC1=CC(=C(C(=C1)C)C)C,,,,,,
695,10696,"3,4,5-Trimethylphenol",CC1=CC(=CC(=C1C)C)O,,,,,,
696,10697,"4,5-Dimethylresorcinol",CC1=CC(=CC(=C1C)O)O,,,,,,
697,10698,"2,4,6-Trimethylphenol",CC1=CC(=C(C(=C1)C)O)C,,,,,"['HYDROXYLATION OF AROMATIC HYDROCARBONS WAS STUDIED FOLLOWING THEIR ORAL ADMINISTRATION TO RATS WHICH ALSO RECEIVED A PURIFIED DIET CONTAINING NEOMYCIN TO REDUCE THE LEVELS OF NORMALLY OCCURRING SIMPLE URINARY PHENOLS. PHENOLIC METABOLITES WERE QUANTITATIVELY ESTIMATED IN HYDROLYZED URINE SAMPLES BY GAS CHROMATOGRAPHY. /1,3,5-TRIMETHYLBENZENE/ ADMINISTERED AT A DOSE OF 100 MG/KG WAS METABOLIZED TO 2,4,6-TRIMETHYLPHENOL TO THE EXTENT OF 0.4% OF THE DOSE GIVEN.']",
698,10699,"2-Amino-4,6-dichlorophenol",C1=C(C=C(C(=C1N)O)Cl)Cl,,,,,,
699,10700,2-Thiophenecarboxylic acid,C1=CSC(=C1)C(=O)O,,,,,,
700,10701,2-Nitroimidazole,C1=CN=C(N1)[N+](=O)[O-],,,,,,
701,10702,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",CC[C@@H]1[C@@H]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)C,,,,,,
702,10703,O-Cymene,CC1=CC=CC=C1C(C)C,,,,,,
703,10704,2-Methylbenzamide,CC1=CC=CC=C1C(=O)N,,,,,,
704,10705,Uridine diphosphate-N-acetylglucosamine,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)O,,,,,,
705,10706,Gallacetophenone,CC(=O)C1=C(C(=C(C=C1)O)O)O,,,,,,
706,10707,"1,2-Dinitrobenzene",C1=CC=C(C(=C1)[N+](=O)[O-])[N+](=O)[O-],,,,"['Readily absorbed through the skin, either as solid, liquid, or vapor. /Dinitrobenzene/']","['Nitroreductase activity was previously known to occur under nitrogen atmosphere in the cytosolic and microsomal fractions of liver homogenates. This study describes a subcellular nitroreductase activity which occurs in liver mitochondria under aerobic conditions. Mitochondria were isolated from rat liver and assayed for their capacity to reduce certain nitro compounds by measuring spectrophotometrically both the appearance of amino compounds and the consumption of nicotinamide adenine dinucleotide. Intact mitochondria were found to possess a p-dinitrobenzene reductase activity. The activity was destroyed by heat, and was present at only 20% in the microsomal fraction. It was strictly nicotinamide adenine dinucleotide-dependent, while only little or no activity occurred with reduced nicotinamide adenine dinucleotide or other oxidative substrates. Nitro reduction was inhibited by thiol reagents. Rat liver mitochondria showed about 15% activity with o-dinitrobenzene and m-dinitrobenzene, while there was less than 5% activity with a series of p-nitro compounds including chloramphenicol.', 'The metabolism of radiolabeled dinitrobenzene isomers was compared in hepatocytes and hepatic subcellular fractions isolated from male Fischer-344 rats. Under aerobic conditions, reduction was the major metabolic pathway for m- and p-dinitrobenzene in hepatocytes with m- and p-nitroaniline accounting for 74.0 + or - 1.2 and 81.0 + or - 0.6% (mean + or - SE, n= 4), respectively, of the radioactivity present after a 30 min incubation. The major metabolite of o-dinitrobenzene in similar incubations was S-(2-nitrophenyl)glutathione which represented 48.1 + or - 5.5% of the total radioactivity; o-nitroaniline accounted for 29.5 + or - 2.1% of the radioactivity. Incubation of dinitrobenzene with microsomes produced nitroanilines as well as nitrosonitrobenzenes and nitrophenylhydroxylamines. Reduction of o- and m-dinitrobenzene by microsomes was reduced nicotinamide adenine dinucleotide-dependent. Reduction of p-dinitrobenzene could be supported by nicotinamide adenine dinucleotide as well as reduced nicotinamide adenine dinucleotide, although the rate of reduction was slower with NADH. Conjugation of o- and p-dinitrobenzene, but not m-dinitrobenzene, with glutathione occurred in cytosol incubations although only o-dinitrobenzene formed the glutathione conjugate in intact hepatocytes.']",
707,10708,"1,2,4-Benzenetricarboxylic acid",C1=CC(=C(C=C1C(=O)O)C(=O)O)C(=O)O,,,,,,
708,10709,"3,4-Dinitrobenzoic acid",C1=CC(=C(C=C1C(=O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
709,10710,2-(Carboxycarbonyl)benzoic acid,C1=CC=C(C(=C1)C(=O)C(=O)O)C(=O)O,,,,,,
710,10711,CID 10711,C1=CC(=C(C=C1C2=C(C(=C3C=CC(=O)C=C3O2)O)O)O)O,,,,,,
711,10712,D-Cellobiose,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O,,,,,,
712,10713,Dichloromethotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=C(C=C(C=C3Cl)C(=O)N[C@@H](CCC(=O)O)C(=O)O)Cl,,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
713,10714,"2,4,5-Trimethylbenzoic acid",CC1=CC(=C(C=C1C)C(=O)O)C,,,,,,
714,10715,Apronalide,CC(C)C(CC=C)C(=O)NC(=O)N,,,,,,
715,10716,Ammonium salicylate,C1=CC=C(C(=C1)C(=O)O)O.N,,,,,,
716,10717,CID 10717,C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2)C(=O)[O-])O.C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2)C(=O)[O-])O.[Ca+2],,,,,,
717,10718,Benzoylpas,C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2)C(=O)O)O,,,,,,
718,10719,Chamazulene,CCC1=CC2=C(C=CC2=C(C=C1)C)C,,,,,,
719,10720,Santene,CC1=C(C2CCC1C2)C,,,,,,
720,10721,o-Tolunitrile,CC1=CC=CC=C1C#N,,,,,,
721,10722,2-Methylbenzaldehyde,CC1=CC=CC=C1C=O,,,,,"['p-Tolualdehyde was oxidized to p-toluic acid by resting cells of pseudomonas aeruginosa. Perillaldehyde dehydrogenase, isolated from soil pseudomonad, catalyzed the oxidn of m- & p-tolualdehyde but not o-tolualdehyde.', 'Aldehydes are readily oxidized to organic acids. Oxidation of aldehydes is catalyzed by aldehyde dehydrogenase, which has been found in the brain, erythrocytes, liver, kidney, heart, and placenta. /Aldehydes/']",
722,10723,"1,2,3,4-Tetrahydro-1-naphthol",C1CC(C2=CC=CC=C2C1)O,,,,,,
723,10724,1-Tetralone,C1CC2=CC=CC=C2C(=O)C1,,,,,,
724,10725,CID 10725,COC1=C(C=C(C=C1)C2=C(C(=C3C(=CC(=CC3=O)OC)O2)O)O)O,,,,,,
725,10726,Tropic acid,C1=CC=C(C=C1)C(CO)C(=O)O,,,,,,
726,10727,N-Ethylacetanilide,CCN(C1=CC=CC=C1)C(=O)C,,,,,,
727,10728,Ethyl acetylsalicylate,CCOC(=O)C1=CC=CC=C1OC(=O)C,,,,,,
728,10729,CID 10729,C1=NC2=C(NC1=O)NC(=NC2=O)N,,,,,,
729,10730,CID 10730,CC1=C2C=C(C(=O)C=C2OC(=C1)O)O,,,,,,
730,10731,Anthranol,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2O,,,['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)'],,,
731,10732,Ammonium mandelate,C1=CC=C(C=C1)C(C(=O)O)O.N,,,,,,
732,10733,2-Methylethylamino-1-phenyl-1-propanol hydrochloride,CC[NH+](C)C(C)C(C1=CC=CC=C1)O.[Cl-],,,,,,
733,10734,Etafedrine hydrochloride,CCN(C)C(C)C(C1=CC=CC=C1)O,,,,,,
734,10735,"N,N-Diethylisonicotinamide",CCN(CC)C(=O)C1=CC=NC=C1,,,,,,
735,10736,2-[(Dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl palmitate,CCCCCCCCCCCCCCCC(=O)OCC(C(C1=CC=C(C=C1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,,,,,,
736,10737,4-(Dimethylamino)benzophenone,CN(C)C1=CC=C(C=C1)C(=O)C2=CC=CC=C2,,,,,,
737,10738,"1,1-Diphenylhydrazine hydrochloride",C1=CC=C(C=C1)N(C2=CC=CC=C2)N.Cl,,,,,,
738,10739,"1,1-Diphenylhydrazine",C1=CC=C(C=C1)N(C2=CC=CC=C2)N,,,,,"['The present study provides the first evidence for in vitro metabolic conversion of a 1,1-disubstituted hydrazine to the corresponding nitrosamine. The study shows that superoxide radical which is generated by NADPH-cytochrome reductase is involved in the oxidation of 1,1-diphenylhydrazine to N-nitrosodiphenylamine catalyzed by rat liver microsomes.', 'The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome P450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome P450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intermediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/', 'By microsomes obtained from bovine ciliary body, 1,1-diphenylhydrazine was oxidized to N-nitrosodiphenylamine in the presence of NADPH. This reaction was stimulated by riboflavin which was recognized to be an electron carrier. The oxidizing activity by microsomes was markedly inhibited by superoxide dismutase, but not by SKF 525-A or carbon monoxide. Similarly, the oxidation of 1,1-diphenylhydrazine to its corresponding nitrosamine occurred in varying degrees when the hydrazine derivative was exposed to visible light in the presence of photosensitizers such as riboflavin, flavin adenine dinucleotide, flavin mononucleotide, lumiflavin, lumichrome, NAD+, NADH, NADP+, or NADPH. The photochemical oxidation was inhibited by active oxygen-scavengers such as superoxide dismutase, L-ascorbic acid or alpha-tocopherol. The superoxide radical involved in the photochemical reaction was determined by measuring the oxidation of epinephrine to adrenochrome. The oxidation of epinephrine was well correlated to that of 1,1-diphenylhydrazine. Thus, the present study provided evidence that the superoxide radical is responsible for the oxidation of a hydrazine derivative to a corresponding nitrosamine by ocular tissue microsomes and by photosensitizers.', 'The first evidence for the reductive metabolism of a noncyclic nitrosamine to the corresponding hydrazine derivative in vivo and in vitro is provided. Under anaerobic conditions, N-nitrosodiphenylamine was reduced by guinea pig liver 9000 g supernatant to 1,1-diphenylhydrazine in the presence of 2-hydroxypyrimidine or to acetaldehyde diphenylhydrazone in the presence of acetaldehyde. These metabolites were identified unequivocally by comparative study with authentic samples. In addition, the study shows that such reductive reactions of the nitrosamine can be catalyzed by guinea pig and rabbit liver aldehyde oxidase in the presence of its electron donors. When the nitrosamine was given orally to acetaldehyde-treated guinea pigs, a metabolite was detected from plasma and identified as acetaldehyde diphenylhydrazone by comparison with the authentic sample.']",
739,10740,"1,1-Diphenylethylene",C=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
740,10741,"4-Hydroxy-3,5-dimethoxybenzyl alcohol",COC1=CC(=CC(=C1O)OC)CO,,,,,,
741,10742,Syringic acid,COC1=CC(=CC(=C1O)OC)C(=O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
742,10743,"4-Hydroxy-3,5-dimethoxycinnamic acid",COC1=CC(=CC(=C1O)OC)C=CC(=O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
743,10744,Quinoline sulfate,C1=CC=C2C(=C1)C=CC=N2.OS(=O)(=O)O,,,,,,
744,10745,Acetylsalicylsalicylic acid,CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C(=O)O,,,,,,
745,10746,"2-(3,5-Diiodo-4-hydroxybenzyl)cyclohexanecarboxylic acid",C1CCC(C(C1)CC2=CC(=C(C(=C2)I)O)I)C(=O)O,,,,,,
746,10747,"1,2,3,4-Tetrahydro-2-naphthol",C1CC2=CC=CC=C2CC1O,,,,,"['BETA-TETRALOL IS A METABOLITE OF TETRALIN IN RABBITS.', 'THE MAJOR METABOLITE OF BETA-TETRALOL IN RABBITS IS BETA-TETRALOL GLUCURONIDE.']",
747,10748,7-Methoxycoumarin,COC1=CC2=C(C=C1)C=CC(=O)O2,,,,,['7-methoxycoumarin has known human metabolites that include 4-Hydroxy-7-methoxycoumarin and 7-Hydroxycoumarin.'],
748,10749,Thiacetarsamide,C1=CC(=CC=C1C(=O)N)[As](SCC(=O)O)SCC(=O)O,,,['Pharmacological agents destructive to nematodes in the superfamily Filarioidea. (See all compounds classified as Filaricides.)'],,,
749,10750,Proflavine dihydrochloride,C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.Cl.Cl,,,,,,
750,10751,CID 10751,C1=C2C=C(C(=O)C=C2OC(=C1)O)O[C@H]3C(C([C@@H](C(O3)CO)O)O)O,,,,,,
751,10752,Coumarin-3-carboxylic acid,C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)O,,,,,,
752,10753,Furothiazole,CC(=O)NC1=NC(=CS1)C2=CC=C(O2)[N+](=O)[O-],,,,,,
753,10754,Benzidine dihydrochloride,C1=CC(=CC=C1C2=CC=C(C=C2)N)N.Cl.Cl,,,,,,
754,10755,Benzidine sulphate,C1=CC(=CC=C1C2=CC=C(C=C2)[NH3+])[NH3+].[O-]S(=O)(=O)[O-],,,,,,
755,10756,N-(2-Butoxyphenyl)acetamide,CCCCOC1=CC=CC=C1NC(=O)C,,,,,,
756,10757,2-Chloroacetophenone,C1=CC=C(C=C1)C(=O)CCl,,,"['Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. (See all compounds classified as Irritants.)', 'Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes. (See all compounds classified as Tear Gases.)']",,,
757,10758,Mandelonitrile,C1=CC=C(C=C1)C(C#N)O,,,,,,
758,10759,CID 10759,C1=CC=C(C=C1)C(=O)[O-].[Na+],,,,,,
759,10760,Butopyronoxyl,CCCCOC(=O)C1=CC(=O)CC(O1)(C)C,,,,,,
760,10761,Monophosphothiamine,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCOP(=O)(O)O.[Cl-],,,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
761,10762,Thiamine nitrate,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[N+](=O)([O-])[O-],,,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
762,10763,Dibutoline sulfate,CCCCN(CCCC)C(=O)OCC[N+](C)(C)CC.CCCCN(CCCC)C(=O)OCC[N+](C)(C)CC.[O-]S(=O)(=O)[O-],,,,,,
763,10764,Dibutoline,CCCCN(CCCC)C(=O)OCC[N+](C)(C)CC,,,,,,
764,10765,CID 10765,C1=CC=C(C=C1)C(=CN=O)O,,,,,,
765,10766,Amylocaine hydrochloride,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1.Cl,,,,,,
766,10767,Amylocaine,CCC(C)(CN(C)C)OC(=O)C1=CC=CC=C1,['The most common indication for the usage of amylocaine was spinal anesthesia.'],"['Like all other local anesthetics, amylocaine acts as a membrane stabilizing drug that reversibly decreases the rate of depolarization and depolarization of excitable membranes. In this way, the conduction of neuronal signals for certain bodily movements can be blocked. In particular, when administered for spinal anesthesia, the resultant anesthesia can typically extend from the chest to the legs.']",,"['A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.', 'A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.', 'A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.', 'A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.']",['A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.'],['A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.']
767,10768,Tutocaine hydrochloride,CC(CN(C)C)C(C)OC(=O)C1=CC=C(C=C1)N.Cl,,,,,,
768,10769,Tutocaine,CC(CN(C)C)C(C)OC(=O)C1=CC=C(C=C1)N,,,,,,
769,10770,Hexylcaine,CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2,"['Used as a local anesthetic for surface application, infiltration or nerve block']",['Hexylcaine is a local ester-class anesthetic. Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve.'],,,['Hydrolyzed by plasma esterases to benzoic acid and other derivatives'],['<10 minutes']
770,10771,Chrysoidine,C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)N)N.Cl,,,,"['WHEN CHRYSOIDINE WAS FED TO MICE, ONLY VERY SMALL AMOUNTS (23.8 MICROMOLES/KG PROTEIN AFTER 7 DAYS) WERE FOUND BOUND TO LIVER PROTEINS.']",,
771,10772,Coixol,COC1=CC2=C(C=C1)NC(=O)O2,,,,,,
772,10773,CID 10773,C1=CC=C(C=C1)C(=O)NCC(=O)[O-].[Na+],,,,,,
773,10774,N'-Phenylbenzohydrazide,C1=CC=C(C=C1)C(=O)NNC2=CC=CC=C2,,,,,,
774,10775,Mephenesin carbamate,CC1=CC=CC=C1OCC(COC(=O)N)O,,,,,,
775,10776,Homarylamine,CNCCC1=CC2=C(C=C1)OCO2,,,,,,
776,10777,2'-Chloroacetanilide,CC(=O)NC1=CC=CC=C1Cl,,,,,['YIELDS O-CHLOROANILINE IN THE RAT. BRAY HG ET AL; BIOCHEM J 47: 483 (1950). /FROM TABLE/'],
777,10778,o-Tolyl acetate,CC1=CC=CC=C1OC(=O)C,,,,,,
778,10779,Hydroxystilbamide,C1=CC(=CC=C1C=CC2=C(C=C(C=C2)C(=N)N)O)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,,,,,,
779,10780,"Ethyl 2,4-dichlorophenoxyacetate",CCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
780,10781,Piperocaine hydrochloride,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2.Cl,,,,,,
781,10782,Piperocaine,CC1CCCCN1CCCOC(=O)C2=CC=CC=C2,,,,,,
782,10783,Clomethiazole,CC1=C(SC=N1)CCCl,['Investigated for use/treatment in strokes.'],,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,['Clomethiazole has known human metabolites that include NLA-715.'],
783,10784,2-Iodophenol,C1=CC=C(C(=C1)O)I,,,,,,
784,10785,2-Hydroxycyclohexan-1-one,C1CCC(=O)C(C1)O,,,,,,
785,10786,"3,4,5-Trihydroxypentanal",C(C=O)C(C(CO)O)O,,,,,,
786,10787,"1,2,4-Benzenetriol",C1=CC(=C(C=C1O)O)O,,,,,,
787,10788,Dazomet,CN1CN(C(=S)SC1)C,,,,"['One hr after oral administration to rats, unhydrolyzed mylone was found in stomach. Carbon disulfide equiv to 1-3% of dose was found in stomach and 1.5% of dose was found in exhaled air. After either intravenous or oral administration of mylone to dogs, carbon disulfide was found in exhaled air...', 'Not readily absorbed by the skin.', 'In a rat metabolism study, dazomet, metam sodium, and MITC were tested at two dose levels. All three were excreted mainly in urine with small amounts excreted in feces. Three different compounds (MITC, carbon dioxide [CO2], carbon oxide sulfide [COS]/carbon disulfide [CS2]) were found to be excreted in the lungs over a 73 hour collection period. There were no differences between males and females in amounts excreted via the three excretion routes; however, tissue and plasma levels, and plasma area under the curves (AUCs) were consistently higher in females than in males. It should be noted that these differences were approximately 2-fold or less. All three compounds were rapidly absorbed from the GI tract. High uptake was seen in the liver, kidneys, and lung, with the lowest level in testes, brain and eyes. Metabolic profiles detected in urine, liver, and kidneys were basically similar for the three compounds but there were some differences, mainly quantitative in nature.']","['One hr after oral administration to rats, unhydrolyzed mylone was found in stomach. Carbon disulfide equiv to 1-3% of dose was found in stomach and 1.5% of dose was found in exhaled air.', 'Isotopic labeling of metham, methyl isothiocyanate and dazomet with (13)CH3 and (14)CH3 and of metham and methyl isothiocyanate with (13)C S provided the materials for metabolite identification by (13)C NMR and quantitation by HPLC analysis and radiocarbon counting. Rats and mice were treated ip and the metabolites studied at 48 hr. Most of the (14)CH3 label for each cmpd in mice appears in urine (58-80%) or is retained in the body (8-12%), particularly the liver or kidney. The major metabolites in each case from rats are S-(N-methylthiocarbamoyl)glutathione in the bile and S-(N-methylthiocarbamoyl)mercapturic acid in the urine, whereas from mice the mercapturate is a minor metabolite. Methylamine is a major urinary component following treatment with methylamine or dazomet. (rats and mice) or metham (mice) but not with methyl isothiocyanate. Detoxification by conjugation with glutathione appears to involve direct reaction with methyl isothiocyanate, glutathione S-transferase catalyzed reaction for metham, and the intermediate of either methyl isothiocyanate or metham for dazomet.', 'In a rat metabolism study, dazomet, metam sodium, and MITC were tested at two dose levels. All three were excreted mainly in urine with small amounts excreted in feces. Three different compounds (MITC, carbon dioxide [CO,], carbon oxide sulfide [COSIlcarbon disulfide [CS,]) were found to be excreted in the lungs over a 73 hour collection period. There were no differences between males and females in amounts excreted via the three excretion routes; however, tissue and plasma levels, and plasma area under the curves (AUCs) were consistently higher in females than in males.']",
788,10789,Tropolone,C1=CC=C(C(=O)C=C1)O,,,,,,
789,10790,"9,10,16-Trihydroxyhexadecanoic acid",C(CCCC(C(CCCCCCO)O)O)CCCC(=O)O,,,,,,
790,10791,Sodium sesquicarbonate,C(=O)(O)[O-].C(=O)([O-])[O-].[Na+].[Na+].[Na+],,,,,,
791,10792,"1,2-Dibromobutane",CCC(CBr)Br,,,,,,
792,10793,"1,3-Dichloroacetone",C(C(=O)CCl)Cl,,,,['... Readily absorbed through the intact skin of rats and humans.'],,
793,10794,CID 10794,CNC(=NC)S,,,,,,
794,10795,"1,1-Dimethoxyethane",CC(OC)OC,,,,,,
795,10796,Cesium carbonate,C(=O)([O-])[O-].[Cs+].[Cs+],,,,,,
796,10797,2-Methylfuran,CC1=CC=CO1,,,,,,
797,10798,Lysidine,CC1=NCCN1,,,,,,
798,10799,Acetarsone diethylamine salt,CCNCC.CC(=O)NC1=C(C=CC(=C1)[As](=O)(O)O)O,,,,,,
799,10800,"4,6-Dinitro-O-cresol",CC1=CC(=CC(=C1O)[N+](=O)[O-])[N+](=O)[O-],,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Chemicals used to destroy pests of any sort. The concept includes fungicides (FUNGICIDES, INDUSTRIAL); INSECTICIDES; RODENTICIDES; etc. (See all compounds classified as Pesticides.)', 'Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that ATP synthesis does not occur. Included here are those IONOPHORES that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Uncoupling Agents.)']","['DNOC is rapidly absorbed following inhalation, ingestion and via skin contact. Skin absorption is more rapid when DNOC is applied in an oily formulation rather than in aqueous solution, peak plasma concentration is higher and occurs earlier, indicative of a solvent effect on skin penetration.', 'It was shown that the amount of DNOC absorbed from the gastrointestinal tract of the rat, and the resulting blood level, depend on the type of fat administered shortly after dosing with DNOC (olive oil or castor oil). Gastrointestinal uptake of DNOC increases when 0.2 mL of olive oil is given, whereas 1.0 mL has no influence. Castor oil in a non- purgative dose (0.2 mL) inhibits resorption, and then slows down the decrease of DNOC blood level over a period of 48 h. Rapeseed oil, which is more slowly absorbed than olive oil, shows only a slight inhibitory effect on DNOC digestive absorption.', 'Blood plasma analysis after dinitro-o-cresol dosing of cows showed at least 95% of the absorbed DNOC bound to plasma proteins; the fact that identical doses of DNOC in ruminants give far lower blood concentrations than in rats and rabbits may be explained by the extensive reduction of the compounds in the rumen.', 'When Hedolit (0.1 g) was applied dermally to guinea pigs, it could be detected in the blood serum and to a lesser extent in the testes and semen.', 'For more Absorption, Distribution and Excretion (Complete) data for 4,6-Dinitro-o-cresol (10 total), please visit the HSDB record page.']","['DNOC appears to be metabolized to less toxic metabolites readily eliminated via the urine. Although small quantities of DNOC may be conjugated, most of the dose appears to be reduced to mono amino derivatives and then subsequently conjugated prior to excretion. These relatively harmless metabolites have been found in the urine and kidney of humans and animals exposed to DNOC.', 'The major metabolic route in the rat and the rabbit following oral administration is by reduction to 6-amino-4-nitro-o-cresol (6-ANOC, 10 - 12% of administered dose) and, to a lesser extent, to 4-amino-6-nitro-o-cresol (4-ANOC), 4-ANOC conjugates and other minor metabolites.', 'In the rabbit, 5% of DNOC single oral doses of 20 or 30 mg/kg is excreted unchanged and 1% as conjugated DNOC in 2-day urine collection. The main metabolic pathway is the reduction of DNOC to 6-amino-4-nitro-o-cresol (6-ANOC), and to a lesser extent to 4-amino-6-nitro-o-cresol (4-ANOC). Urinary content of 6-ANOC accounted for 11-12% of the administered dose. Small amounts of other metabolites, such as 4-ANOC conjugates and 3-amino-5-nitrosalicylic acid (3-ANSA), which is produced via an oxidative pathway, are also excreted in the urine.', 'The metabolism of 4,6-dinitro-o-cresol (DNOC) was studied in rats and in the rabbit. Inbred Wistar-rats received labeled and unlabeled DNOC by gavage in doses of 0.4 to 10 mg/kg bw, with urine and feces being collected separately. When labeled DNOC was administered, blood, a number of organs, and the residual carcasses were collected at sacrifice 1 or 3 days after treatment for use in radioactivity measurements. A female albino white-New-Zealand-rabbit received 76 mg of unlabeled DNOC by gavage, with urine being collected via a catheter at regular intervals over the ensuing 24 hr. ...In rats receiving labeled DNOC in a dose of 0.4 mg/kg, radioactivity was eliminated with a half time of 1-1.5 days. Approximately 25% of the introduced dose was still contained in the body at sacrifice 3 days after treatment, with the major portion being concentrated in the residual carcass. Here, the introduced dose had little effect on the overall pattern of DNOC distribution. The metabolites detected in rat urine were identified as 4,6-diacetamido-o-cresol (DAAOC), 3,5-dinitro-2-hydroxybenzylalcohol, 4-acetamido-6-nitro-o-cresol, 6-acetamido-4-nitro-o-cresol, DNOC, and 6-amino-4-nitro-o-cresol, with 4-acetamido-6-nitro-o-cresol, 6-acetamido-4-nitro-o-cresol, 6-amino-4-nitro-o-cresol, and DAAOC also being present as conjugates. The metabolites detected in rabbit urine were identified as DAAOC, amino-nitro-o-cresol, acetamido-nitro-o-cresol, and 6-amino-4-nitro-o-cresol. The authors conclude that nitro group reduction, followed by acetylation or conjugation, constitutes the major pathway of DNOC biotransformation. When DNOC is administered with a methanol extract of wheat leaves, the major biotransformation reaction is methyl group oxidation.', 'DNOC was rapidly metabolized by rat cecal microorganisms and could /no/ longer be detected after 1 hr. Simultaneously, 6-ANOC (the monoamine derivative of DNOC) was detected in increasing amounts, reaching maximum levels after 1 hr, indicating an 80% DNOC conversion. Thereafter, the 6-ANOC concentration decreased until it represented only 3% of the initial DNOC concentration at 12 hr. DAOC (the diamine derivative) concentrations increased over the entire incubation period and reached maximum levels at 12 hr, when it represented 90% of the DNOC conversion. When incubated alone 6-ANOC concentrations decreased and DAOC concentrations increased in the same time-dependent manner observed in the DNOC experiments. Analogous experiments using DNBP (dinoseb) and 6-ANBP (the monamine derivative of dinoseb) gave similar results. However, the metabolic turnovers were slower. Rat cecal microorganisms metabolize DNOC and DNBP to the corresponding 6-amino compounds, which are in turn reduced to the diamino derivatives. Hematologic effects reported in rats exposed to DNBP may have been induced by amino metabolites formed in the intestine from DNBP metabolism.']","['No reports found; [TDR, p. 567]', 'Formulated DNOC was applied to the shaved skin of male and female rats in a single dose of 18.1 mg DNOC/kg b.w. and was kept in contact with the skin for 8 hr. Two formulations were used: water-based (621 g a.i./L) and oil-based (130 g a.i./L). ... The average half life absorption time (time from exposure required to reach 50% of DNOC blood peak concentration) was 15 hr for males and 13 hr for females. The average half life elimination time (time required for DNOC blood concentration to decrease to 50% of its peak value after reaching a peak) was 24 hr. ... When applied under the same conditions as an oily formulation, the peak plasma concentrations represent 5.0% of the applied dose in males and 5.8% in females (38-45 ug/mL of blood). The peak plasma level occurred after 8 hr in males and 24 hr in females. The average absorption half-liife was 2.8 hr and the average elimination half-life was 34 hr.', 'The major route of elimination is in the urine, with a half life in the rat of between 24 and 36 hours following oral administration of 0.4 mg/kg body weight (bw). A shorter half life of 6.5 hours has been reported in the rabbit. Excretion is reported to be slower in humans, and half lives ranging from 4 days to over 6 days have been reported in heavily exposed workers.', 'The half-life in man is 5.78 days.']"
800,10801,Butylmalonic acid,CCCCC(C(=O)O)C(=O)O,,,,,,
801,10802,Pyrithiamine,CC1=C(C=CC=[N+]1CC2=CN=C(N=C2N)C)CCO.Br.[Br-],,,"['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']",,,
802,10803,1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-(2-hydroxyethyl)-2-methylpyridinium,CC1=C(C=CC=[N+]1CC2=CN=C(N=C2N)C)CCO,,,,,,
803,10804,Eulicin,C(CCCCN=C(N)N)CCCC(C(CCCN)NC(=O)CCCCCCCCN=C(N)N)O,,,,,,
804,10805,Vanylglycol,COC1=C(C=CC(=C1)C(CO)O)O,,,,,"['3-Methoxy-4-hydroxyphenylethyleneglycol has known human metabolites that include 1,2-Ethanediol, 1-(3-methoxy-4-(sulfooxy)phenyl)- and 3-Methoxy-4-hydroxyphenylglycol glucuronide.']",
805,10806,"2-Hydroxy-5-(phenylazo)-2,4,6-cycloheptatrien-1-one methacrylate",CC(=C)C(=O)OC1=CC(=CC=CC1=O)N=NC2=CC=CC=C2,,,,,,
806,10807,Ethyl 2-chloropropionate,CCOC(=O)C(C)Cl,,,,,,
807,10808,Ethyl dichloroacetate,CCOC(=O)C(Cl)Cl,,,,,,
808,10809,Phenarsone sulfoxylate,C1=CC(=C(C=C1[As](=O)(O)[O-])NCS(=O)[O-])O.[Na+].[Na+],,,,,,
809,10810,(5-Arsono-2-hydroxyanilino)methanesulfinic acid,C1=CC(=C(C=C1[As](=O)(O)O)NCS(=O)O)O,,,,,,
810,10811,Glybuthiazol,CC(C)(C)C1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
811,10812,M-Cymene,CC1=CC(=CC=C1)C(C)C,,,,,,
812,10813,Crimidine,CC1=CC(=NC(=N1)Cl)N(C)C,,,,"['The drug acts within 20 to 40 minutes of ingestion, but is rapidly excreted ... it is said that 20 times the lethal dose of Castrix can be eliminated by the dog in 13 hours ... .']",,
813,10814,"3,4-Dihydroxy-5-(3,4,5-trihydroxyphenoxy)carbonylbenzoic acid",C1=C(C=C(C(=C1C(=O)OC2=CC(=C(C(=C2)O)O)O)O)O)C(=O)O,,,,,,
814,10815,Methyl 3-amino-4-hydroxybenzoate,COC(=O)C1=CC(=C(C=C1)O)N,,,,,,
815,10816,4-Chlorobenzohydrazide,C1=CC(=CC=C1C(=O)NN)Cl,,,,,,
816,10817,1-(4-Methylphenyl)ethanol,CC1=CC=C(C=C1)C(C)O,,,,,,
817,10818,P-Toluenesulfinic acid,CC1=CC=C(C=C1)S(=O)O,,,,,,
818,10819,Perillyl alcohol,CC(=C)C1CCC(=CC1)CO,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,"['Limonen-10-ol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[(4-prop-1-en-2-ylcyclohexen-1-yl)methoxy]oxane-2-carboxylic acid.']",
819,10820,4-Isopropylbenzoic acid,CC(C)C1=CC=C(C=C1)C(=O)O,,,,,,
820,10821,Phenylacetylene,C#CC1=CC=CC=C1,,,,,,
821,10822,4-Ethylpyridine,CCC1=CC=NC=C1,,,,,,
822,10823,3-Ethylpyridine,CCC1=CN=CC=C1,,,,,,
823,10824,m-Anisidine,COC1=CC=CC(=C1)N,,,,"['The substance can be absorbed into the body by inhalation of its vapour, through the skin and by ingestion.']",,
824,10825,Carinamide,C1=CC=C(C=C1)CS(=O)(=O)NC2=CC=C(C=C2)C(=O)O,,,,,,
825,10826,Cerium triacetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Ce+3],,,,,,
826,10827,Acoin,CCOC1=CC=C(C=C1)N=C(NC2=CC=C(C=C2)OC)NC3=CC=C(C=C3)OC.Cl,,,,,,
827,10828,"2-(4-Ethoxyphenyl)-1,3-bis(4-methoxyphenyl)guanidine",CCOC1=CC=C(C=C1)N=C(NC2=CC=C(C=C2)OC)NC3=CC=C(C=C3)OC,,,,,,
828,10829,Evernic acid,CC1=CC(=CC(=C1C(=O)OC2=CC(=C(C(=C2)C)C(=O)O)O)O)OC,,,,,,
829,10830,Diperodon hydrochloride,C1CCN(CC1)CC(COC(=O)NC2=CC=CC=C2)OC(=O)NC3=CC=CC=C3.Cl,,,,,,
830,10831,Diperodon,C1CCN(CC1)CC(COC(=O)NC2=CC=CC=C2)OC(=O)NC3=CC=CC=C3,,,,,,
831,10832,Amanozine,C1=CC=C(C=C1)NC2=NC=NC(=N2)N,,,,,,
832,10833,"3,5-Dibromotyrosine",C1=C(C=C(C(=C1Br)O)Br)CC(C(=O)O)N,,,,,,
833,10834,Benzoyltropein,CN1C2CCC1CC(C2)OC(=O)C3=CC=CC=C3,,,,,,
834,10835,"2,6-Dibromo-4-(chloroimino)cyclohexa-2,5-dienone",C1=C(C(=O)C(=CC1=NCl)Br)Br,,,,,,
835,10836,Methamphetamine,C[C@@H](CC1=CC=CC=C1)NC,['For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.'],"['Methamphetamine is a potent central nervous system stimulant which affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. The acute effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite.']","['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)', 'Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)', 'Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)', 'Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)']","['Methamphetamine is rapidly absorbed from the gastrointestinal tract with peak methamphetamine concentrations occurring in 3.13 to 6.3 hours post ingestion. Moreover, when administered intranasally or as an inhalation, methamphetamine also demonstrates a high degree of absorption. It is distributed to most parts of the body. Because methamphetamine has a high lipophilicity it is distributed across the blood brain barrier and crosses the placenta.', 'Excretion occurs primarily in the urine, the rate of which is dependent on urine pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.', 'Methamphetamine is readily absorbed from the GI tract and effects persist for 6-12 hours but may continue up to 24 hr after large doses. /Methamphetamine hydrochloride/', 'Single pharmacological doses of amphetamines (ie, 10-25 mg) given to human volunteers produce peak plasma levels within 1-2 hr & are rapidly absorbed from the GI tract. Amphetamine absorption usually is complete by 4-6 hr. The illicit use of amphetamines ... by insertion into the vagina (termed ""balling"") before intercourse suggests that these compounds are also absorbed through mucosal surfaces. ... Methamphetamine ... /has/ absorption characteristics similar to those of amphetamines. ... Sustained release prepn are avail as resin-bound rather than soluble salts. These compounds display reduced peak blood levels compared with std amphetamine prepn, but total bioavailability & time to peak levels remain similar. Pharmacokinetics in overdose are not well described.', 'Methamphetamine is eliminated principally in urine. Urinary excretion of the drug is pH dependent, and excretion is enhanced in acidic urine. Following oral administration of methamphetamine hydrochloride, approximately 62% of the administered dose is excreted in urine within the first 24 hours, with metabolites and unchanged drug accounting for about two-thirds and one-third, respectively, of the recovered drug.', 'Methamphetamine hydrochloride has been measured in human sweat at a median range of 63.0 (low dose 16.8-175) and 307 (high dose 199-607) ng per patch(1). /Methamphetamine hydrochloride/', '/MILK/ Amphetamines are distributed into milk. Therefore, nursing should be avoided during therapy with amphetamines.']","['Hepatic. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine, with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine. Other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine.', 'Methamphetamine is metabolized in the liver by aromatic hydroxylation, N-dealkylation, and deamination; at least 7 metabolites have been identified in urine.', 'A species difference was found in a study of the metabolism of methamphetamine, (+/-)-2-methylamino-1-phenylpropane. In man, 22% of an oral dose was excreted into urine unchanged, & 15% of the dose was excreted as 4-hydroxymethamphetamine. After ip admin to rat, 4-hydroxymethamphetamine was principal urinary metabolite (31% of dose), together with 4-hydroxynorephedrine (16%) & unchanged drug (11% of dose). In the guinea pig an ip dose was extensively metabolized to benzoic acid & its glycine & glucuronic acid conjugates.', 'In vivo metab of N-alkylated amphetamines in rat produced 4-hydroxy- & 4-hydroxy-3-methoxy-metabolites. Relative quantities of phenolic metabolites formed were dependent upon the length of the N-alkyl substituent.', 'Metamphetamine has known human metabolites that include 4-Hydroxymethamphetamine and Amphetamine.']","['The biological half-life has been reported in the range of 4 to 5 hours.', 'The biologic half-life of methamphetamine reportedly is 4-5 hours.']"
836,10837,4-Phenylsemicarbazide,C1=CC=C(C=C1)NC(=O)NN,,,,,,
837,10838,Cyclomethycaine hydrochloride,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OC3CCCCC3.Cl,,,,,,
838,10839,Cyclomethycaine,CC1CCCCN1CCCOC(=O)C2=CC=C(C=C2)OC3CCCCC3,,,,,,
839,10840,"Mercury, bis(4-methylphenyl)-",CC1=CC=C(C=C1)[Hg]C2=CC=C(C=C2)C,,,,,,
840,10841,"1,4-Benzenediamine, N-(4-aminophenyl)-",C1=CC(=CC=C1N)NC2=CC=C(C=C2)N,,,,,,
841,10842,Bis(3-nitrophenyl) disulfide,C1=CC(=CC(=C1)SSC2=CC=CC(=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
842,10843,3'-Methylacetanilide,CC1=CC(=CC=C1)NC(=O)C,,,,,,
843,10844,Oxophenarsine hydrochloride,C1=CC(=C(C=C1[As]=O)N)O.Cl,,,,,,
844,10845,Oxophenarsine,C1=CC(=C(C=C1[As]=O)N)O,,,,,,
845,10846,"Mercury, (3-chloro-4-hydroxyphenyl)hydroxy-",C1=CC(=C(C=C1[Hg])Cl)O.O,,,,,,
846,10847,(3-Chloro-4-hydroxyphenyl)mercury,C1=CC(=C(C=C1[Hg])Cl)O,,,,,,
847,10848,Bis(2-chloroethyl)ethylamine,CCN(CCCl)CCCl,,,,"['Nitrogen mustards are absorbed through the skin, respiratory and GI tract ... /Chloroethylamines/', 'Absorption may occur after skin or eye exposure to liquid or vapor nitrogen mustard and may cause systemic toxicity. .../Nitrogen mustards/ ...are highly reactive and combine rapidly with proteins, DNA, or other molecules. Therefore, within minutes following exposure intact mustard or its reactive metabolites are not found in tissue or biological fluids. /Nitrogen mustards/']",,
848,10849,Diallylcyanamide,C=CCN(CC=C)C#N,,,,,,
849,10850,Tricaprylin,CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,,,"['Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)']","['In the small intestine, most triglycerides are split into monoglycerides, free fatty acids, and glycerol, which are absorbed by the intestinal mucosa. Within the epithelial cells, resynthesized triglycerides collect into globules along with cholesterol and phospholipids and are encased in a protein coat as chylomicrons. Chylomicrons are transported in the lymph to the thoracic duct and eventually to the venous system. The chylomicrons are removed from the blood as they pass through the capillaries of adipose tissue. Fat is stored in adipose cells until it is transported to other tissues as free fatty acids which are used for cellular energy or incorporated into cell membranes. When 14C-labeled long-chain triglycerides are administered intravenously, 25% to 30% of the radiolabel is found in the liver within 30 to 60 minutes, with less than 5% remaining after 24 hours. Lesser amounts of radiolabel are found in the spleen and lungs. After 24 hours, nearly 50% of the radiolabel has been expired in carbon dioxide, with 1% of the carbon label remaining in the brown fat. The concentration of radioactivity in the epididymal fat is less than half that of the brown fat.', 'After absorption, long- chain saturated fatty acids are transported mainly via the intestinal lymph as triglycerides. Fatty acids with 10 or less carbon atoms are transported mainly from the intestine via the portal blood vessels. There are also data indicating that unsaturated long-chain fatty acids are absorbed mainly via the lymph vessels.', 'The skin penetration enhancement of drugs by tricaprylin has been demonstrated in vivo using Wistar rats and in vitro using hairless female mice. ... The drug permeation ratio in the presence of triglycerides increased in the following order: Tricaprylin (C8) > Triolein (CI8) > Tributyrin (C4) > Triacetin (C2).']",,
850,10851,Trilaurin,CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC,,,,,,
851,10852,S-Benzylisothiourea hydrochloride,C1=CC=C(C=C1)CSC(=N)N.Cl,,,,,,
852,10853,Benzylurea,C1=CC=C(C=C1)CNC(=O)N,,,,,,
853,10854,"1,2-Di-p-tolylethane",CC1=CC=C(C=C1)CCC2=CC=C(C=C2)C,,,,,,
854,10855,"4,4'-Azodianiline",C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)N,,,,,,
855,10856,CID 10856,C1=CC=C(C=C1)C=CC(=O)[O-].[Na+],,,,,,
856,10857,"3-Phenoxy-1,2-propanediol",C1=CC=C(C=C1)OCC(CO)O,,,,,,
857,10858,N-Benzylideneaniline,C1=CC=C(C=C1)C=NC2=CC=CC=C2,,,,,,
858,10859,Cyverine,CN(CCC1CCCCC1)CCC2CCCCC2,,,,,,
859,10860,"1,5-Diphenylcarbazone",C1=CC=C(C=C1)NNC(=O)N=NC2=CC=CC=C2,,,,,,
860,10861,Butyl 3-phenylprop-2-enoate,CCCCOC(=O)C=CC1=CC=CC=C1,,,,,,
861,10862,"2-Propenoic acid, 3-phenyl-, 3-(diethylamino)propyl ester, hydrochloride",CCN(CC)CCCOC(=O)C=CC1=CC=CC=C1.Cl,,,,,,
862,10863,3-(Diethylamino)propyl 3-phenylprop-2-enoate,CCN(CC)CCCOC(=O)C=CC1=CC=CC=C1,,,,,,
863,10864,Pentylbenzene,CCCCCC1=CC=CC=C1,,,,,,
864,10865,Phenylethylguanidine,C1=CC=C(C=C1)CCNN=C(N)N,,,,,,
865,10866,Domiphen bromide,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1.[Br-],,,,,,
866,10867,Benzyl sulfide,C1=CC=C(C=C1)CSCC2=CC=CC=C2,,,,,,
867,10868,Dicyclohexylcarbodiimide,C1CCC(CC1)N=C=NC2CCCCC2,,,,,,
868,10869,Benzyl methyl ether,COCC1=CC=CC=C1,,,,,,
869,10870,Isobutylbenzene,CC(C)CC1=CC=CC=C1,,,,,,
870,10871,4'-Chloroacetanilide,CC(=O)NC1=CC=C(C=C1)Cl,,,,"['IN MICE, BUCCAL ABSORPTION WAS RELATED PARABOLICALLY TO ANALGESIC ACTIVITY: CMPD INCL P-CHLOROACETANILIDE.']","['YIELDS 2-ACETAMIDO-5-CHLOROPHENOL; 4-ACETAMIDO-2-CHLOROPHENOL; 5-ACETAMIDO-2-CHLOROPHENOL; & P-ACETAMIDOPHENOL IN RATS. /FROM TABLE/', 'P-CHLOROACETANILIDE GIVES P-CHLOROANILINE IN CHICK & RAT. /FROM TABLE/', 'OXIDATION OF 4-CHLOROACETANILIDE TO N-HYDROXY-4-CHLOROACETANILIDE IS CATALYZED BY HAMSTER-LIVER MICROSOMES. THE ENZYME, A TYPICAL MONO-OXYGENASE, IS INDUCED BY 3-METHYLCHOLANTHRENE, BUT NOT BY PHENOBARBITAL. PRESENCE OF 0.1 MOLAR SODIUM FLUORIDE ENHANCES RATE OF REACTION.', '4-CHLOROACETANILIDE WAS OXIDIZED TO 4-CHLOROGLYCOLANILIDE & 4-CHLOROOXANILIC ACID IN RABBIT (18% & 20% OF THE DOSE, RESPECTIVELY, IN 24 HR URINE), BUT ONLY TO 4-CHLOROGLYCOLANILIDE (11%) IN PIG.', 'For more Metabolism/Metabolites (Complete) data for P-CHLOROACETANILIDE (17 total), please visit the HSDB record page.']",
871,10872,"Benzenamine, 4-[(4-aminophenyl)azo]-N,N-dimethyl-",CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,,,,,,
872,10873,Benzyl ethyl ether,CCOCC1=CC=CC=C1,,,,,,
873,10874,3-Butylpyridine,CCCCC1=CN=CC=C1,,,,,,
874,10875,4-Methylphenylhydrazine,CC1=CC=C(C=C1)NN,,,,,,
875,10876,beta-(2-Furyl)acrylic acid,C1=COC(=C1)C=CC(=O)O,,,,,,
876,10877,CID 10877,CC(C)CC(=O)[O-].[Na+],,,,,,
877,10878,CID 10878,C(=O)(O)O.O.O.[Na+].[AlH4-],,,,,,
878,10879,Alumanuide,[AlH4-],,,,,,
879,10880,Diethyl ethylenedicarbamate,CCOC(=O)NCCNC(=O)OCC,,,,,,
880,10881,Tropone,C1=CC=CC(=O)C=C1,,,,,,
881,10882,Ethyl valerate,CCCCC(=O)OCC,,,,,,
882,10883,Ethyl levulinate,CCOC(=O)CCC(=O)C,,,,,,
883,10884,Isobutyl urethane,CCOC(=O)NCC(C)C,,,,,,
884,10885,Isobutyl butyrate,CCCC(=O)OCC(C)C,,,,,,
885,10886,Pentyl hexanoate,CCCCCC(=O)OCCCCC,,,,,,
886,10887,9-Heptadecanone,CCCCCCCCC(=O)CCCCCCCC,,,,,,
887,10888,12-Tricosanone,CCCCCCCCCCCC(=O)CCCCCCCCCCC,,,,,,
888,10889,Cetyl palmitate,CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC,,,,,,
889,10890,Pentyl butyrate,CCCCCOC(=O)CCC,,,,,,
890,10891,p-Toluidine hydrochloride,CC1=CC=C(C=C1)N.Cl,,,,,,
891,10892,"1,4-Difluorobenzene",C1=CC(=CC=C1F)F,,,,,,
892,10893,4-Iodoaniline,C1=CC(=CC=C1N)I,,,,,,
893,10894,4-Iodophenol,C1=CC(=CC=C1O)I,,,,,"['4-Iodophenol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(4-iodophenoxy)oxane-2-carboxylic acid.']",
894,10895,Isobutyl propionate,CCC(=O)OCC(C)C,,,,,,
895,10896,Methylaminoheptane,CCCCCC(C)NC,,,,,,
896,10897,"1,2-Dibromoethene",C(=CBr)Br,,,,,,
897,10898,2-Bromoethanol,C(CBr)O,,,,,,
898,10899,1-Chloropropane,CCCCl,,,,,"['... Hydroxypropylmercapturic acid /was found/ in the urine of rats injected subcutaneously with a 40% wt/vol solution of 1-chloropropane in arachis oil. ... Hepatic microsomes from phenobarbital induced rats produced a variety of metabolites: propene, 1,2-epoxypropane, 1,2-propandiol, propienic acid, and an unidentified species bound to protein.']",
899,10900,"1,2-Dichloroethylene",C(=CCl)Cl,,,,"['1,2-Dichloroethene appears to be absorbed quickly by the lungs. One study reported that approximately 75% of the inhaled chemical was absorbed through the lungs in humans.', '1,2-DCE is largely excreted through the lungs.']","['Numerous xenobiotics are known to be bioactivated and to covalently bind to proteins, but the resulting amino acid adducts are unknown. In this study, the amino acid adducts of 12 (14)C-labeled aliphatic halides were examined after formation in an in vitro rat hepatic microsomal system. After exhaustive solvent extraction of the polypeptide microsomal protein, the amino acid adducts were isolated by Pronase digestion, followed by filtration through a 500 mol-wt exclusion membrane. 1,2-Dichloroethylene had a single major amino acid adduct. ...', '1,2-Dichloroethene is metabolized in the liver, by hepatic microsomal cytochrome P-450, to form dichloroethanol and dichloroacetic acid.', 'Incubation of rat liver microsomes with 1,2-dichloroethylene caused a fall in microsomal cytochrome p450 content (as determined by measuring the oxidation of reduced nicotinamide adenine dinucleotide at 340 nm), without affecting other microsomal enzymes. The decrease in cytochrome p450 occurred only in the presence of reduced nicotinamide adenine dinucleotide, suggesting that the dichloroethylene must be metabolized to exert its destructive action. The loss of cytochrome p450 was probably due to destruction of heme, since the fall in cytochrome p450 was always accompanied by a parallel decrease in microsomal heme content.', 'Metabolism of 1,2-DCE is initially catalyzed by hepatic CYP450 ... . Studies suggest that the metabolism of 1,2-DCE involves epoxidation of the ethylene double-bond, forming dichlorinated epoxides, which can undergo a nonenzymatic rearrangement and produce several metabolites. Following rearrangement of the intermediate epoxide, reduction of the resulting dichloroacetaldehyde to dichloroethanol may be catalyzed by alcohol dehydrogenase (ADH). Studies ... provide evidence that dichloroacetaldehyde is the predominant metabolite of CYP450, which is extensively converted to dichloroethanol and dichloroacetate by dehydrogenases present in hepatocytes. Oxidative dechlorination of the minor metabolite, dichloroacetic acid (DCA), to glyoxylate is catalyzed by glutathione S-transferase zeta (GSTZ).']",
900,10901,Aminoacetonitrile,C(C#N)N,,,,,,
901,10902,"1,2-Ethanedithiol",C(CS)S,,,,,"['Urinary metabolites could result from methylation, S-oxidation of one S atom to yield a polar sulfonate, and the formation of mixed disulfides of low relative molecular mass such as cysteine, an endogenous thiol. /Dithiols/', 'Simple aliphatic and aromatic thiols undergo S-methylation in mammals to produce the corresponding methyl thioether or sulfide. Methylation is catalysed by thiopurine methyltransferase in the cytoplasm and thiol methyltransferase in microsomes, and both reactions require S-adenosyl-l-methionine as a methyl group donor. Thiopurine methyltransferase is present in human liver, kidney, and erythrocytes; preferential substrates for this enzyme include aromatic and heterocyclic thiols. S-Methylation of aliphatic thiols is catalysed by microsomal thiol methyltransferase, and the resulting methyl thioether (sulfide) metabolite would undergo S-oxidation to give the methyl sulfoxide and methyl sulfone analogues as urinary products. Thiols may react with glutathione and other endogenous thiol substances to form mixed disulfides. Both microsomal and cytoplasmic thioltransferasess have been reported to catalyse the formation of mixed disulfides. The resulting mixed disulfides can undergo reduction back to thiols, oxidative desulfuration, or oxidation to a sulfonic acid via the intermediate thiosulfinate and sulfinic acids. The principal form in the circulation would probably be a mixed disulfide formed with albumin. /Simple thiols/']",
902,10903,Methoxyethane,CCOC,,,,,,
903,10904,Formic acid (ammonium salt),C(=O)O.N,,,,,,
904,10905,CID 10905,C(#N)[S-].[Na+],,,,,,
905,10906,tert-Butyl nitrite,CC(C)(C)ON=O,,,,,,
906,10907,"2,2,4-Trimethylpentane",CC(C)CC(C)(C)C,,,,"['Respiration is the most likely route by which 2,2,4-trimethylpentane is absorbed. Although it has not been determined, the respiratory uptake of 2,2,4-trimethylpentane is probably similar to that seen for n-octane. Oral absorption of (14)C-2,2,4-trimethylpentane has been reported ... to occur to the extent of 86% in male rats based on recovery of radioactivity in urine, expired organics, and expired (14)C-carbon dioxide. Dermal bioavailability has not been reported, but absorption of 2,2,4-trimethylpentane through the skin would be expected to be minor based on percutaneous results reported for n-heptane and n-octane. Oral gavage studies ... in male rats with (14)C-2,2,4-trimethylpentane (0.5 mg/kg, single dose) revealed that the radioactivity is selectively distributed in the kidneys 72 hr after administration. It has been suggested that the renal retention of 2,2,4-trimethylpentane is related to the hydrocarbon-induced nephropathy observed specifically in male rats.', 'Metabolic disposition of 2,2,4-trimethylpentane was studied in male and female Fischer 334 rats. Rats were treated with a single oral dose of (14)C 2,2,4-trimethylpentane (4.4 mmol/kg; 2 microCi/mmol). Radiolabeled material in kidney, liver, and plasma was determined at 4, 8, 12, 24, and 48 hr after dosing. Maximum concentration of 2,2,4-trimethylpentane derived radioactivity in kidney, liver, and and plasma of male rats was found after 12 hr (1252, 1000, and 403 nmol eg/g, respectively), whereas those measured in females were found after 8 hr (557, 1163, and 317 nmol eq/g, respectively). A selective retention of the 2,2,4-trimethylpentane derived radiolabel in the kidneys of male rats was noted when peak tissue concentration was expressed as a percentage of administered dose. Kidney concentrations of 2,2,4-trimethylpentane derived radiolabel increased in a nonlinear, but dose dependent radiolabel increased in a nonlinear, but dose-dependent, manner; the kidney to plasma ratio was greater at low doses than at higher doses. Increased retention of radiolabel material in the kidney was associated with a significant increase in renal concentration of the male rat specific protein, alpha 2u-globulin, 24 and 48 hr after 2,2,4-trimethylpentane administration. Total radioactivity collected in urine 48 hr after 2,2,4-trimethylpentane administration was similar in males and females (32 and 31% of dose). Identification and quantitation of the urinary metabolites of 2,2,4-trimethylpentane showed that both male and female rats metabolize 2,2,4-trimethylpentane via the same pathway and at a similar rate. Female rats, however, excreted more conjugates of 2,4,4-trimethyl-2-pentanol in urine than males. 2,2,4-Trimethyl-2-pentanol was the major metabolite present in the male rat kidney, but was absent in the female rat kidney. The renal retention of 2,4,4-trimethyl-2-pentanol appears to account for the delayed clearance observed in the disposition of (14)C 2,2,4-trimethylpentane derived radiolabel. Based on the concomitant accumulations in renal alpha 2u-globulin concentration and renal 2,4,4-trimethyl-2-pentanol concentration, an association is speculated between these two components. The male rat specific accumulation of 2,4,4-trimethyl-2-pentanol may therefore reflect the accumulation of a metabolite-alpha 2u-globulin complex. This may be relevant to the male-rat-specific nephrotoxicity produced by 2,2,4-trimethyl-pentane.', 'A study was conducted to determine if the rate of uptake and route of excretion of inhaled hydrocarbons and their metabolites might be different for branched alkanes relative to straight chain isomers. Male F344/N rats were exposed by nose only inhalation to nominal concentrations of 1 or 350 ppm (14)C labeled octane and isooctane for a period of 2 hours. Urine and feces were collected as were exhalants at 3, 6, 9, 18, 24, 30, 42, 54, and 66 hr post exposure. Exhalants were also collected at 1 and 2 hr post exposure. Elimination was most exclusively via the kidneys for isooctane while octane was eliminated about equally in urine and as exhaled carbon dioxide. Isooctane was excreted through the kidneys over the entire 70 hr, whereas octane excretion was essentially completed after 10 to 20 hr. At 70 hr after exposure about 5% of the octane equivalents inhaled at 1 ppm remained in the carcass. The author suggests that the different patterns of metabolites excretion of isooctane compared to octane may be a factor affecting the differences in nephrotoxicity between these two compounds.']","['Metabolism of 2,2,4-trimethylpentane probably occurs by omega and omega-l oxidation to yield the corresponding alcohol and acid metabolites. While the exact structure of these remains to be elucidated, there is evidence that the cytochrome p450 system, lauric acid hydroxylases, and palmitoyl CoA oxidase in the liver and kidneys play a role in the biotransformation of 2,2,4-trimethylpentane. Studies indicate that 2,2,4-trimethylpentane (radiolabeled with (14)C) is metabolized by the cytochrome p450 system and that modulation of this enzyme system (with phenobarbital and metyrapone) will alter the disposition and renal retention of 2,2,4-trimethylpentane. Pretreatment of male rats with phenobarbital decreased the expired organics (from 40 to 10% of dose) and increased the urine radioactivity (from 46 to 80%), but did not alter the retention of radioactivity in the kidneys. Metyrapone (an inhibitor of cytochrome p450) increased the elimination half-life of expired 2,2,4-trimethylpentane (2.8 to 3.8 hr), did not alter urinary radioactivity, and decreased radioactivity retention in the kidney by 37%. From these studies, elimination of 2,2,4-trimethylpentane (isooctane) occurs mainly by metabolism to water-soluble products which are excreted in the urine and by exhalation of parent material.', 'Metabolic disposition of 2,2,4-trimethylpentane was studied in male and female rats. Rats were treated with a single oral dose of (14)C 2,2,4-trimethylpentane (4.4 mmol/kg; 2 uCi/mmol). Identification and quantitation of the urinary metabolites of 2,2,4-trimethylpentane showed that both male and female rats metabolize 2,2,4-tremethylpentane via the same pathway and at a similar rate. Female rats, however, excreted more conjugates of 2,4,4-trimethyl-2-pentanol in urine than males. 2,4,4-Trimethyl-2-pentanol was the major metabolite present in the male rat kidney, but was absent in the female rat kidney.', 'When (14)C 2,2,4-trimethylpentane was administered to an adult male Fischer-344 rat (300 mg/kg, ig) 22, 16, and 10 hr before sacrifice, 16% of the administered radioactivity was eliminated in the urine as 2,2,4-trimethylpentane metabolites.']",
907,10908,Tert-butyl acetate,CC(=O)OC(C)(C)C,,,,,"['Butyl acetates are readily hydrolyzed to acid and alcohol in blood, liver, small intestines and respiratory passages, and this has been demonstrated in vitro in homogenates. ... /butyl acetates/', 'A continuous 5 hr-exposure to approximately 440 ppm tert-butyl acetate in air (via a tracheal canule) resulted in continuously increasing concentrations of tert-butyl acetate and tert-butyl alcohol (metabolite of tert-butyl acetate) in the blood of rats. This accumulation of tert-butyl acetate and tert-butyl alcohol was reproduced during a continuous exposure to about 900 ppm tert-butyl acetate in air over a period of 4 hr and 15 min. After the inhalation approximately 50% of the blood level of tert-butyl acetate decreased within 45 min, but that of tert-butyl alcohol remained unchanged at a high level.']",['... When tert-butyl acetate was added to human blood samples the... /half-life/ was 300 minutes.']
908,10909,CID 10909,CC(C)(O)S(=O)(=O)[O-].[Na+],,,,,,
909,10910,"2-Propanesulfonic acid, 2-hydroxy-",CC(C)(O)S(=O)(=O)O,,,,,,
910,10911,Dodecamethylcyclohexasiloxane,C[Si]1(O[Si](O[Si](O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)(C)C)(C)C)C,,,,"['/Researchers/ evaluated the percutaneous absorption of neat D6 radiolabeled with (14)C following application to human skin in vitro. The test substance was applied under semiocclusive conditions in a Teflon flowthrough diffusion cell system. Human epidermis was prepared from abdominal skin (6 donors). The epidermis with the top layer of dermis was separated from the rest of the skin by dermatoming, and the skin samples were mounted in replicate. Skin samples from 3 donors passed the barrier integrity test. A physiological receptor fluid was pumped beneath the skin samples. Skin samples from each of the 6 donors were dosed with neat (14)C-cylohexasiloxane (14C-D6) at a target dose of 6 mg/sq cm during the 24-hour-exposure period. At the conclusion of the assay, the majority of the applied dose was located on the skin surface (46.407% of applied dose) or volatilized from the dosing site and collected in charcoal traps (40.057% of applied dose). Practically no (14)C-D6 penetrated through the skin and into the receptor fluid. The percentage of applied neat (14)C-D6 recovered from all samples that were analyzed was 89.542% +/- 4.154%, which included 3.075% of the applied neat (14)C-D6 (SE of the mean = 0.852% of the applied dose) that was found in the skin. The results of an additional experiment indicated that, after the skin was washed at 24 hours, the portion of (14)C-D6 observed in the skin did not penetrate through the skin, but continued to evaporate. Thus, it was concluded that, under the conditions of this assay, D6 was not percutaneously absorbed.', '/Researchers/ evaluated the disposition of (14)C-D6 using 10 groups of Fischer 344 rats (CDF(F-344)/ CrlBR strain). The animals were 8 to 10 weeks old and body weight ranges were 163 to 219 g (males) and 133 to 155 g (females). A single oral dose of (14)C-D6 (in corn oil, 1000 mg/kg body weight) was administered to a group of 4 males and 4 females; metabolism cages were used for the collection of urine, feces, and expired air. The animals were killed at 168 hours postdosing, and selected tissues and remaining carcasses collected and analyzed for radioactivity. Expired volatiles and feces were also analyzed for parent D6 concentration. A separate group of rats (6 males and 6 females), cannulated via jugular vein, was used to determine radioactivity and parent D6 concentration in the blood at 15 minutes and at 1, 6, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdosing. Wholebody autoradiography (WBA) was used for qualitative in vivo assessment of tissue distribution of radioactivity in male and female rats after single oral administration of D6 (in corn oil). Animals in the WBA groups were killed at 1, 4, 24, 48, 96, and 168 hours postdosing. In males and females, the majority of the administered dose was excreted in the feces. Based on the recovered radioactivity (urine, expired volatiles, expired CO2, tissues, and carcass), the absorption of D6 was 11.88% (males) and 11.83% (females) of the administered dose. For most of the recovered radioactivity, a similar pattern of distribution of the radioactivity was noted in males and females. However, considerable variability in the levels of radioactivity in expired volatiles was reported, which may have been due to off gassing from the fecal pellets that were not collected, as intended, but remained on the inside of the cage. The authors noted that this phenomenon could potentially produce some false high values for expired volatiles and absorption due to partitioning from the fecal matter into the air. All of the radioactivity in the expired volatiles was attributed to parent D6. Metabolic profile evaluation of the urine and feces indicated that all of the radioactivity in the urine consisted of polar metabolites, whereas, in the feces, the majority was parent D6, with a trace nonpolar metabolite. Whole body autoradiography data supported mass balance data showing that the majority of administered D6 in corn oil stayed in the gastrointestinal (GI) tract and was excreted in the feces within 48 hours. Low levels of radioactivity were detected in organs and tissues, such as the liver, fat tissue, and bone marrow, indicating some absorption of D6. Statistical analysis of blood curves indicated the presence of small amounts of metabolites in the blood, based on the difference between radioactivity and parent AUCs (AUCmetabolites = AUCradioactivity  AUCparent).', 'Silicone [poly(dimethylsiloxane)] gel used in breast implants has been known to migrate through intact silicone elastomer shells, resulting in the clinically observable ""gel bleed"" on the implant surface. Although silicon concentrations in capsular tissues of women with silicone prostheses have been measured with element-specific silicon analyses, no silicone-specific investigation of these tissues has been performed as yet. A combination of element-specific inductively coupled plasma high-resolution isotope dilution mass spectrometry (ICP-HR-IDMS) and species-specific gas chromatography coupled mass spectrometry (GC-MS) was used to analyze silicon, platinum, and siloxanes in prosthesis capsule, muscle, and fat tissues of women (n=3) who had silicone gel-filled breast implants and in breast tissue of non-augmented women (n=3) as controls. In all tissues of augmented women, siloxanes, in particular octamethylcyclotetrasiloxane (D4), decamethylcyclopentasiloxane (D5), and dodecamethylcyclohexasiloxane (D6) were identified. Depending on the siloxane species and type of tissue analyzed, siloxane levels in the range of about 10-1,400 ng/g were detected; total silicon was found in all tissue samples in the range of about 8,900-85,000 ng/g. Higher platinum levels ranging from 25-90 ng/g were detected in fibrin layer and fat tissue of two patients with prostheses. No siloxanes were detected in control breast tissue samples. This investigation of human tissues by a combination of element-specific and species-specific analytical techniques clearly demonstrates for the first time that platinum and siloxanes leak from prostheses and accumulate in their surrounding tissues.', 'To examine the distribution of low molecular weight silicones in body organs, separate groups of female CD-1 mice were injected with either breast implant distillate composed primarily of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, and tetradecamethylcycloheptasiloxane or a polydimethylsiloxane oil containing low molecular weight linear siloxanes. Mice were injected subcutaneously in the suprascapular area and killed at different times. Levels of individual low molecular weight silicones were measured in 10 different organs (brain, heart, kidney, liver, lung, mesenteric lymph nodes, ovaries, spleen, skeletal muscle, and uterus). In mice treated with the cyclosiloxane mixture and killed at 3, 6, or 9 weeks, highest levels of cyclosiloxanes were found in the mesenteric lymph nodes, ovaries, and uterus, but all organs examined contained cyclosiloxanes. In a cohort killed at 1 year, most organs contained measurable cyclosiloxanes with highest levels in mesenteric lymph nodes, abdominal fat, and ovaries. Of the individual cyclosiloxanes measured, selective retention of decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane relative to octamethylcyclotetrasiloxane was seen in all organs at all time points studied. Organs from animals receiving the linear siloxane mixture were harvested at 9, 12, and 15 weeks. ... Maximum levels in the brain, lungs, and mesenteric lymph nodes /were found/, but all other organs contained measurable levels. These data are, to the best of our knowledge, the first demonstration that after a single subcutaneous injection silicones are widely distributed throughout the body and can persist over an extended period.', 'The disposition of (14)C-dodecamethylcyclohexasiloxane (D6) was evaluated in male and female F344 rats following a single oral administration of 1000 mg of (14)C-D6 in corn oil/kg of body weight. Animals (N=4/sex) were housed in glass metabolism cages for collection of excreta and expired volatiles. At 168 hr post-dose, animals were sacrificed and selected tissues and remaining carcasses were collected. All samples were analyzed for radioactivity content. Feces and expired volatiles were also analyzed for parent D6 concentration. A separate group of animals, cannulated via the jugular vein, (N=6/sex) was used to determine radioactivity and parent D6 concentration in blood at predetermined time points. Whole-body autoradiography (WBA) was used for qualitative in vivo assessment of tissue distribution of radioactivity. The majority of administered radioactivity (>80%), regardless of sex, was eliminated in the feces. Total absorption (radioactivity recovered in urine, expired volatiles, expired CO2, tissues and carcass) in males and females was 11.88% and 11.83%, respectively. Both sexes showed similar patterns of disposition (Urine: 0.38% and 0.32%; Expired volatiles: 11.20% and 11.21%; Expired CO2: 0.13% and 0.09%; Tissues: 0.03% and 0.04%; Carcass: 0.14% and 0.17% for males and females, respectively). The entire radioactivity in the expired volatiles was attributed to parent D6. Metabolic profile evaluation showed that the entire radioactivity in the urine consisted of polar metabolites, whereas in the feces the majority was parent D6 with a trace of nonpolar metabolite. The WBA data also showed that the majority of D6 remained in the GI tract and was excreted in feces within 48 hr. Low levels of radioactivity were systemically available and distributed to organs and tissues such as liver, brown fat and bone marrow. Statistical analysis of the blood curves indicated the presence of small levels of metabolites in the blood (approximately 117 ug equivalent D6*hr/g of blood). In summary, approximately 12% of (14)C-D6 delivered in corn oil appeared to be absorbed after a single oral administration to F344 rats.']",,
911,10912,Hexadecamethylheptasiloxane,C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,,,,,,
912,10913,Decamethylcyclopentasiloxane,C[Si]1(O[Si](O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)(C)C)C,,,,"['To assess the fate of D5 absorbed from the skin in intact animals, (14)C-D5 was applied to the dorsal surface of male and female rats. Hair at the application site was clipped prior to application and the application site was covered with a non-occlusive elastic wrap. The study was designed to permit differentiation between D5 exhaled after absorption and D5 evaporating from the application site. After application of D5, the animals were transferred to metabolic cages for the collection of urine and feces. The majority (about 85%) of the applied (14)C-D5 volatilized from the skin. After 96 hr, 0.35% of the administered D5 remained at the application site and less than 1% of the applied (14)C-activity was recovered in urine and carcass with trace levels of (14)C-activity recovered in feces, CO2 traps, and tissues. The total amount of D5 absorbed was <1%.', 'Octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) are cyclic siloxanes used as chemical intermediates with some applications in consumer products. The in vitro percutaneous absorption of (14)C-D4 and (14)C-D5 was studied in flow-through diffusion cells. Single doses were applied neat and in antiperspirant formulations to dermatomed human skin for 24 hr. The majority of applied D4 and D5 (approximately 90%) volatilized before being absorbed. Only 0.5% of applied D4 was absorbed while the absorption of D5 (0.04%) was one order of magnitude lower. The largest percentage (>90%) of the absorbed D4 and D5 was found in the skin. The fate of D4 and D5 absorbed in the skin was studied in rat in vivo. A single dose of (14)C-D4 (10, 4.8 and 2 mg/sq cm) and (14)C-D5 (10 mg/sq cm) was topically applied inside a dosing chamber attached to the dorsal area. Rats were housed in metabolism cages up to 24 hr to enable collection of urine, feces, expired/escaped volatiles. The majority of applied D4 or D5 had volatilized from the skin surface. Less than 1.0% of the applied D4 and only 0.2% of applied D5 was absorbed with approximately 60% of absorbed D4 and 30% of absorbed D5 reaching systemic compartments. The amount absorbed into the skin decreased with time showing that residual D4 and D5 diffused back to the skin surface and continued to evaporate. Overall, a low tendency to pass through the skin into systemic compartments was demonstrated for both D4 (< or = 0.5% of applied dose) and D5 (<0.1% of applied dose).', 'Toxicokinetic studies were performed in rats after dosing by gavage with (14)C-D5 (single dose of 1000 mg/kg bw) dissolved in different vehicles (corn oil and simethicone fluid) and as a neat material. The carrier had a significant influence on the extent of absorption of (14)C-D5. After administration of neat D5, approximately 10% of the dose was absorbed from the gastrointestinal tract. Based on blood area under the curve (AUC), absorption increased after administration of D5 in corn oil and decreased after administration in simethicone fluid. Elimination half-lives for D5-associated radioactivity in blood ranged from 45 (simethicone) to 240 hr (corn oil), and were between 117 (neat) and 242 hr (simethicone) for parent D5. The radioactivity eliminated in the urine consisted entirely of polar metabolites of D5. Mass balance analysis indicated that approximately 60-80 % of the administered D5 was excreted unchanged in the feces, and up to 20% of administered D5 as water soluble metabolites in urine. Half of the systemically available D5 was eliminated as unchanged D5 in exhaled air. However, the kinetics and tissue distribution observed after oral dosing were qualitatively different from the distributions after inhalation or dermal exposures. Higher relative concentrations of D5 were noted in liver and spleen as compared to exposure to D5 by inhalation and dermal application.', 'Separate 77-d fish feeding studies were conducted on the cyclic volatile methylsiloxane (cVMS) chemicals octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane with the rainbow trout, Oncorhynchus mykiss, with the determination of biomagnification factor (BMF) and lipid-adjusted BMF (BMF(L)) values as the final experimental metrics. The studies used fish food concentrations of about 500 ug/g for exposure periods of 35 d, followed by a depuration period of 42 d with clean food. The fish tissue concentrations of D4 and D5 achieved empirical steady-state by day 21 in each study. By day 7 of exposure, total (14)C activity of both compounds had moved from the fish gastrointestinal (GI) tract into surrounding tissue. An absence of significant fish growth during the initial depuration phase allowed for measurement of empirical depuration rate constants (k2) independent of growth dilution for D4 and D5 of 0.035 and 0.040/d, respectively, corresponding to elimination half-lives of approximately 20d. These rate constants indicated that about 70-75% of steady-state was achieved during exposure in both studies, resulting in empirical steady-state BMF and BMF(L) values of 0.28 and 0.66 for D4, respectively, and 0.32 and 0.85 for D5, respectively. Kinetic modeling using simple first-order uptake and depuration dynamics produced good agreement with experimental data, with D4 and D5 assimilation efficiencies of 40% and 44%, respectively. Growth-corrected depuration rate constants modeled over the entire study data set indicated slower elimination kinetics for D4 (k2 of 0.007/d or half-life of 100 d) compared to D5 (k2 of 0.010/d or elimination half-life of 69 d). Kinetic BMFk values (i.e., k1/k2) for D4 and D5 were 1.7 and 1.3, respectively, with lipid-adjusted BMFk(L) values of 4.0 and 3.4, respectively.', 'For more Absorption, Distribution and Excretion (Complete) data for DECAMETHYLCYCLOPENTASILOXANE (13 total), please visit the HSDB record page.']","['Major metabolites of D5 were identified in urine collected from Fischer (F-344) rats administered ... (14)C-D5 orally and via intravenous injection ... The metabolites of D5 are as follows: Me(2)Si(OH)(2), MeSi(OH)(3), MeSi(OH)(2)OSi(OH)(3), MeSi(OH)(2)OSi(OH)(2)Me, MeSi(OH)(2)OSi(OH)Me(2), Me(2)Si(OH)OSi(OH)Me(2), Me(2)Si(OH)OSiMe(2)OSi(OH)Me(2), nonamethylcyclopentasiloxanol, and hydroxymethylnonamethylcyclopentasiloxane. No parent ... D5 was present in urine. The presence of certain metabolites such as ... Me(2)Si(OH)(2) ... clearly established the occurrence of demethylation at the silicon-methyl bonds. Metabolites of the linear siloxane are structurally different from that obtained for cyclic siloxane except for the commonly present Me(2)Si(OH)(2). Mechanistic pathways for the formation of the metabolites were proposed.']","['Toxicokinetic studies were performed in rats after dosing by gavage with (14)C-D5 (single dose of 1000 mg/kg bw) dissolved in different vehicles (corn oil and simethicone fluid) and as a neat material. The carrier had a significant influence on the extent of absorption of (14)C-D5.  ... Half of the systemically available D5 was eliminated as unchanged D5 in exhaled air. ...', 'Separate 77-d fish feeding studies were conducted on the cyclic volatile methylsiloxane (cVMS) chemicals octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane with the rainbow trout, Oncorhynchus mykiss, with the determination of biomagnification factor (BMF) and lipid-adjusted BMF (BMF(L)) values as the final experimental metrics. The studies used fish food concentrations of about 500 ug/g for exposure periods of 35 d, followed by a depuration period of 42 d with clean food. ... An absence of significant fish growth during the initial depuration phase allowed for measurement of empirical depuration rate constants (k2) independent of growth dilution for D4 and D5 of 0.035 and 0.040/d, respectively, corresponding to elimination half-lives of approximately 20d.']"
913,10914,Hexamethylcyclotrisiloxane,C[Si]1(O[Si](O[Si](O1)(C)C)(C)C)C,,,,,,
914,10915,Uranyl acetate,CC(=O)O.CC(=O)O.O=[U]=O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['Sol compounds are highly transportable from lung to other parts of the body; these include uranium hexafluoride, uranyl nitrate, uranyl chloride, uranyl fluoride, & uranyl acetates, sulfates & carbonates. Moderately transportable compounds include uranium tetrafluoride, uranium dioxide /&/ tetraoxide ... Insoluble, slightly transportable compounds include high-fired uranium dioxide, triuranium octoxide, & uranium hydrides & carbides. /Uranium compounds/', 'For rabbits fed an oat diet, the urinary pH dropped to 4.2 from 7.6 and the urinary excretion of intravenously injected uranyl acetate (3 mg/kg) dropped to 7% in 3 hr from 21% for rabbits infused with saline. For rabbits infused with 0.87% sodium bicarbonate, 81% was excreted in the same time period. The kidney content resulting from these three regimes was 65, 25, and 4 ug uranium/g wet tissue, and prompt bicarbonate infusion resulted in a roughly six-fold reduction in the uranium content of the kidney. Thus, the amount of uranium deposited in the kidney depends most importantly on the amount of uranium introduced to the blood, the amount of complexing agents circulating, the acidity of the urine, and the glomerular filtration rate.', 'GI absorption of small doses of soluble uranyl salts in mammals is about 10%; insoluble salts are poorly absorbed. Absorption of uranium salts from sites of im injection and from peritoneal cavity is poor. ... Soluble uranyl salts are also absorbed through skin. Following inhalation the absorption of uranium salts from the lung tissues into blood depends upon ... solubility and particle size. /Soluble uranyl salts/', 'In acute human exposure situations, uranium deposits in the kidney are eliminated with a half-time of 2 to 6 days. Inhaled soluble uranium salts that reach the alveoli are almost completely absorbed and then cleared rapidly to the urine, kidneys, and bone, with none left in the lungs by 30 days. /Soluble uranium compounds/', '... Studies /had been done on/ the retention of uranium in bone tissue of beagle dogs after iv injection of 0.3 mg U(VI)/kg body weight. Of the injected dose, 7.7% was retained in the bone tissue, from where it was eliminated with an average half-life of two-and-a-half yr. Elimination varied for different parts of the skeleton from less than a year to no detectable elimination. The longest half-time was seen in cortical bone tissue. /Hexavalent uranium/']",,"['The biologic half times of soluble uranium compounds (e.g., uranium hexafluoride, uranyl fluoride, uranium tetrachloride, uranyl nitrate hexahydrate) are estimated in days or weeks. Those of the less soluble compounds (e.g., uranium tetrafluoride, uranium dioxide, triuranium octaoxide) are estimated in years. /Soluble uranium compounds/']"
915,10916,Uranium dioxide,O=[U]=O,,,,,,
916,10917,Levocarnitine,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,"['For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.']","['Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 &micro;mol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The ""vitamin BT"" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.']",,"['Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours.', 'Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval.  Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days.', 'The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss.', 'Total body clearance was found to be a mean of 4L/h.', 'L-Carnitine is a naturally occurring compound that facilitates the transport of fatty acids into mitochondria for beta-oxidation. ... In humans, the endogenous carnitine pool, which comprises free L-carnitine and a range of short-, medium- and long-chain esters, is maintained by absorption of L-carnitine from dietary sources, biosynthesis within the body and extensive renal tubular reabsorption from glomerular filtrate. In addition, carrier-mediated transport ensures high tissue-to-plasma concentration ratios in tissues that depend critically on fatty acid oxidation. The absorption of L-carnitine after oral administration occurs partly via carrier-mediated transport and partly by passive diffusion. After oral doses of 1-6 g, the absolute bioavailability is 5-18%. In contrast, the bioavailability of dietary L-carnitine may be as high as 75%. Therefore, pharmacological or supplemental doses of L-carnitine are absorbed less efficiently than the relatively smaller amounts present within a normal diet. L-Carnitine and its short-chain esters do not bind to plasma proteins and, although blood cells contain L-carnitine, the rate of distribution between erythrocytes and plasma is extremely slow in whole blood. After iv administration, the initial distribution volume of L-carnitine is typically about 0.2-0.3 L/kg, which corresponds to extracellular fluid volume. There are at least three distinct pharmacokinetic compartments for L-carnitine, with the slowest equilibrating pool comprising skeletal and cardiac muscle. L-Carnitine is eliminated from the body mainly via urinary excretion. Under baseline conditions, the renal clearance of L-carnitine (1-3 mL/min) is substantially less than glomerular filtration rate (GFR), indicating extensive (98-99%) tubular reabsorption. The threshold concentration for tubular reabsorption (above which the fractional reabsorption begins to decline) is about 40-60 umol/L, which is similar to the endogenous plasma L-carnitine level. Therefore, the renal clearance of L-carnitine increases after exogenous administration, approaching GFR after high iv doses. ...', 'In mammals, the carnitine pool consists of nonesterified L-carnitine and many acylcarnitine esters. Of these esters, acetyl-L-carnitine is quantitatively and functionally the most significant. Carnitine homeostasis is maintained by absorption from diet, a modest rate of synthesis, and efficient renal reabsorption. Dietary L-carnitine is absorbed by active and passive transfer across enterocyte membranes. Bioavailability of dietary L-carnitine is 54-87% and is dependent on the amount of L-carnitine in the meal. Absorption of L-carnitine dietary supplements (0.5-6 g) is primarily passive; bioavailability is 14-18% of dose. Unabsorbed L-carnitine is mostly degraded by microorganisms in the large intestine. Circulating L-carnitine is distributed to two kinetically defined compartments: one large and slow-turnover (presumably muscle), and another relatively small and rapid-turnover (presumably liver, kidney, and other tissues). At normal dietary L-carnitine intake, whole-body turnover time in humans is 38-119 hr. In vitro experiments suggest that acetyl-L-carnitine is partially hydrolyzed in enterocytes during absorption. In vivo, circulating acetyl-L-carnitine concentration was increased 43% after oral acetyl-L-carnitine supplements of 2 g/day, indicating that acetyl-L-carnitine is absorbed at least partially without hydrolysis. After single-dose intravenous administration (0.5 g), acetyl-L-carnitine is rapidly, but not completely hydrolyzed, and acetyl-L-carnitine and L-carnitine concentrations return to baseline within 12 h. At normal circulating l-carnitine concentrations, renal l-carnitine reabsorption is highly efficient (90-99% of filtered load; clearance, 1-3 mL/min), but displays saturation kinetics. Thus, as circulating L-carnitine concentration increases (as after high-dose intravenous or oral administration of L-carnitine), efficiency of reabsorption decreases and clearance increases, resulting in rapid decline of circulating L-carnitine concentration to baseline. Elimination kinetics for acetyl-L-carnitine are similar to those for L-carnitine. There is evidence for renal tubular secretion of both L-carnitine and acetyl-L-carnitine. ...', 'The pharmacokinetics of L-carnitine and its metabolites were investigated in 7 healthy subjects following the oral administration of 0, 0.5, 1, and 2 g 3 times a day for 7 days. Mean plasma concentrations of L-carnitine across an 8-hour dose interval increased significantly (P < 0.05) from a baseline of 54.2 +/- 9.3 uM to 80.5 +/- 12.5 uM following the 0.5-g dose; there was no further increase at higher doses. There was a significant increase (P <0.001) in the renal clearance of L-carnitine indicating saturation of tubular reabsorption. Trimethylamine plasma levels increased proportionately with L-carnitine dose, but there was no change in renal clearance. A significant increase in the plasma concentrations of trimethylamine-N-oxide from baseline was evident only for the 2-g dose of L-carnitine (from 34.5 +/- 2.0 to 149 +/- 145 uM), and its renal clearance decreased with increasing dose (P <0.05). There was no evidence for nonlinearity in the metabolism of trimethylamine to trimethylamine-N-oxide. In conclusion, the pharmacokinetics of oral L-carnitine display nonlinearity above a dose of 0.5 g 3 times a day.', 'Evidence indicates L-carnitine is absorbed in the intestine by a combination of active transport and passive diffusion. Reports of bioavailability following an oral dose have varied substantially, with estimates as low as 16 to 18% and as high as 54 to 87% ... The mucosal absorption of carnitine appears to be saturated at about a 2-g dose. Max blood concn is reached approx 3.5 hr after an oral dose and slowly decr, with a half-life of about 15 hr. Elimination of carnitine occurs primarily through the kidneys. The heart, skeletal muscle, liver, kidneys, and epididymis have specific transport systems for carnitine that concentrate carnitine within these tissues. Despite evidence indicating incr levels of free carnitine and carnitine metabolites in the blood and urine following an oral dose, no significant change in RBC carnitine levels was noted in healthy subjects, suggesting either a slow repletion of tissue stores of carnitine following an oral dose or a low capability to transport carnitine into tissues under normal conditions.', 'For more Absorption, Distribution and Excretion (Complete) data for L-CARNITINE (11 total), please visit the HSDB record page.']","['After oral administration L-carnitine which is unabsorbed is metabolized in the gastrointestinal tract by bacterial microflora. Major metabolites include trimethylamine N-oxide and [3H]-gamma-butyrobetaine.', 'In mammals, L-carnitine is synthesized from epsilon-N-trimethyllysine, which is derived from post-translationally methylated lysine residues in proteins, and protein turnover. In normal humans, the rate of synth is est to be ca 1.2 umol/kg/day. The rate of L-carnitine biosynth is regulated by the avail of epsilon-N-trimethyllysine. Thus, conditions that incr protein methylation and/or protein turnover may incr the rate of L-carnitine biosynth.', 'Synthesis of carnitine begins with methylation of the amino acid L-lysine by S-adenosylmethionine (SAMe). Magnesium, vitamin C, iron, vitamins B3 and B6, and alpha-ketoglutarate - along with the cofactors responsible for creating SAMe (methionine, folic acid, vitamin B12, and betaine) - are all required for endogenous carnitine synthesis.', 'Unabsorbed L-carnitine is degraded by micro-organisms in the large intestine. Major metabolites identified are trimethylamine oxide in urine and gamma-butyrobetaine in feces.', 'Carnitine plays an indispensable role in fatty acid oxidation. Previous studies revealed that fetal carnitine is derived from the mother via transplacental transfer. Recent studies demonstrated the presence and importance of an active fatty acid oxidation system in the human placenta and in the human fetus. In view of these findings ... carnitine metabolism /was studied/ in the fetal-placental unit by measuring carnitine metabolites, intermediary metabolites of carnitine biosynthesis, as well as the activity of carnitine biosynthesis enzymes in human term placenta, cord blood and selected embryonic and fetal tissues (5-20 weeks of development). Placenta contained low but detectable activity of gamma-butyrobetaine dioxygenase. This enzyme, which was considered to be expressed only in kidney, liver and brain, catalyzes the last step in the carnitine biosynthesis pathway. In addition, ...  human fetal kidney, liver and spinal cord already have the capacity to synthesize carnitine. The ability of the placenta and fetus to synthesize carnitine suggests that in circumstances when maternal carnitine supply is limited, carnitine biosynthesis by the fetal-placental unit may supply sufficient carnitine for placental and fetal metabolism. /Carnitine/', 'For more Metabolism/Metabolites (Complete) data for L-CARNITINE (7 total), please visit the HSDB record page.']","['17.4 hours (elimination) following a single intravenous dose.', 'Distribution: 0.585 hours; Elimination: 17.4 hours', '... Half-life /in blood/ ca 15 hr ...']"
917,10918,(3-Carboxy-2-(R)-hydroxy-propyl)-trimethyl-ammonium,C[N+](C)(C)C[C@@H](CC(=O)O)O,,,,,,
918,10919,Pentamethonium bromide,C[N+](C)(C)CCCCC[N+](C)(C)C.[Br-].[Br-],,,,,,
919,10920,Pentamethonium,C[N+](C)(C)CCCCC[N+](C)(C)C,,,,,,
920,10921,Decamethonium bromide,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[Br-].[Br-],,,['Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)'],,,
921,10922,Isopentylamine hydrochloride,CC(C)CCN.Cl,,,,,,
922,10923,Chlorvinyldichlorarsin,C(=C[As](Cl)Cl)Cl,,,,,,
923,10924,1-Iodo-3-methylbutane,CC(C)CCI,,,,,,
924,10925,3-Methylbutane-1-thiol,CC(C)CCS,,,,,,
925,10926,"1,1-Dichlorobutane",CCCC(Cl)Cl,,,,,,
926,10927,Butyramide,CCCC(=O)N,,,,"['Lung endothelial permeabilities were determined by injecting butyramide & other test substances into the jugular vein of anesthetized dogs, followed by analysis of sequential blood samples from the carotid artery. The mathematically derived permeability surface product for butyramide was 42.']",,
927,10928,Ethyl chloroformate,CCOC(=O)Cl,,,,,,
928,10929,Isopropyl nitrite,CC(C)ON=O,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
929,10930,Isovaleramide,CC(C)CC(=O)N,,,,,,
930,10931,"3,3-Dimethylacrylic acid",CC(=CC(=O)O)C,,,,,,
931,10932,3-Aminobutanoic acid,CC(CC(=O)O)N,,,,,,
932,10933,CID 10933,C(=NC(=N)S)(N)S,,,,,,
933,10934,"2,4-Dimethylthiazole",CC1=CSC(=N1)C,,,,,,
934,10935,Maleimide,C1=CC(=O)NC1=O,,,,,,
935,10936,"1-(tert-Pentyloxy)-2,2,2-trichloroethanol",CCC(C)(C)OC(C(Cl)(Cl)Cl)O,,,,,,
936,10937,Furtrethonium iodide,C[N+](C)(C)CC1=CC=CO1.[I-],,,['Drugs that bind to and activate cholinergic receptors. (See all compounds classified as Cholinergic Agonists.)'],,,
937,10938,Furtrethonium,C[N+](C)(C)CC1=CC=CO1,,,['Drugs that bind to and activate cholinergic receptors. (See all compounds classified as Cholinergic Agonists.)'],,,
938,10939,Oxapropanium iodide,C[N+](C)(C)CC1COCO1.[I-],,,,,,
939,10940,Oxapropanium,C[N+](C)(C)CC1COCO1,,,,,,
940,10941,M-phenylenediamine dihydrochloride,C1=CC(=CC(=C1)N)N.Cl.Cl,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
941,10942,"1,3-Phenylenediamine sulfate",C1=CC(=CC(=C1)N)N.OS(=O)(=O)O,,,,,,
942,10943,"1,3-Dichlorobenzene",C1=CC(=CC(=C1)Cl)Cl,,,,"['The dichlorobenzenes may be absorbed through the lung, gastrointestinal tract, and intact skin. Relatively low water solubility and high lipid solubility favor their penetration of most membranes by diffusion, including pulmonary and GI epithelia, the brain, hepatic parenchyma, renal tubules, and the placenta. /Dichlorobenzenes/', 'Information on the quantitative absorption of 1,3-DCB in humans and animals is not available for any route of exposure; however, absorption of the compound can be inferred from studies that have detected 1,3-DCB or metabolites in the breast milk, blood, and fat of humans and in the bile and urine of exposed animals. Distribution is believed to be similar to the other DCB isomers, but data demonstrating this are not presently available. Similar to the other DCB isomers, 1,3-DCB is initially metabolized by cytochrome P-450 enzymes, followed by extensive conjugation, primarily to glutathione, has been reported. 1,3-DCB is eliminated mainly in the urine, similar to the other DCB isomers.', 'Children can be exposed to DCBs prenatally, as indicated by the detection of all three isomers in placenta samples, as well as through breast feeding. 1,2-DCB concentrations measured in whole human milk range from 3 to 29 ppb. 1,3- and 1,4-DCB were detected together in whole human milk with mean and maximum concentrations of 6 and 75 ppb, respectively. These isomers were detected in milkfat samples at a mean concentration of 161 ppb and a maximum concentration of 4,180 ppb. 1,2-, 1,3-, and 1,4-DCB measured separately in whole human milk samples had concentrations of 9, <5, and 25 ppb, respectively, while the milk fat of these samples contained 230 ppb of 1,2-DCB and 640 ppb of 1,4-DCB.']","['M-Dichlorobenzene yields N-acetyl-S-(2,4-dichlorophenyl)-L-cysteine, 2,4-dichlorophenol, and 3,5-dichlorophenol in rabbit. /from table/', 'When fed to rabbits, m-dichlorobenzene yielded glucuronides (31%, sulfates (11%), mercapturic acid (9%) and catechols (4%). ...2,4-Dichlorophenylmercapturic acid and 3,5-dichlorocatechol were also observed...', '1,3-Dichlorobenzene was reported to be among several metabolites of gamma-pentachloro-1-cyclohexane in corn and pea seedlings.', 'The S-containing metabolites of m-dichlorobenzene (m-DCB) were identified by using gas chromatography-mass spectrometry and disposition of m-DCB metabolites studied. In the blood, urine and feces of rats dosed with m-DCB, 2,4- and 3,5-dichlorophenyl methylsulfoxide and 3,5- and 2,4-dichlorophenyl methanesulfonate emerged, while their possible precursors, 3,5- and 2,4-dichlorophenyl methyl sulfide were not detected in the blood, urine, and feces. However, after heating the alkalinized urine and feces, the methyl sulfides appeared. ...', 'For more Metabolism/Metabolites (Complete) data for 1,3-DICHLOROBENZENE (8 total), please visit the HSDB record page.']","['Half-life in blood was 4.4 hr (oral administration, 200 mg/kg, male Wistar rats)']"
943,10944,Carbocloral,CCOC(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
944,10945,Methyl beta-chloro-gamma-fluorobutyrate,COC(=O)CC(CF)Cl,,,,,,
945,10946,Chloroacetic anhydride,C(C(=O)OC(=O)CCl)Cl,,,,,,
946,10947,3-Methylcyclopentadecanone,CC1CCCCCCCCCCCCC(=O)C1,,,,,,
947,10948,"Carbamic acid, 1-methylbutyl ester",CCCC(C)OC(=O)N,,,,,,
948,10949,"6-Methyl-1,3,5-triazine-2,4-diamine",CC1=NC(=NC(=N1)N)N,,,,,,
949,10950,"2-Pentanone, 4-(acetyloxy)-",CC(CC(=O)C)OC(=O)C,,,,,,
950,10951,Aniline sulfate,C1=CC=C(C=C1)N.C1=CC=C(C=C1)N.OS(=O)(=O)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
951,10952,Chlorocyclohexane,C1CCC(CC1)Cl,,,,['THEY DO NOT TEND TO ACCUMULATE IN BODY TISSUES... /ALICYCLIC HYDROCARBONS/'],,
952,10953,delta-Valerolactone,C1CCOC(=O)C1,,,,,,
953,10954,Cycloheptadec-9-en-1-one,C1CCCC=CCCCCCCCC(=O)CCC1,,,,,,
954,10955,14-Heptacosanone,CCCCCCCCCCCCCC(=O)CCCCCCCCCCCCC,,,,,,
955,10956,4-Methylpentanenitrile,CC(C)CCC#N,,,,,,
956,10957,Isobutyl formate,CC(C)COC=O,,,,,,
957,10958,Isobutyl nitrite,CC(C)CON=O,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
958,10959,2-Chloroethyl acetate,CC(=O)OCCCl,,,,,,
959,10960,2-Hydroxyethyl acetate,CC(=O)OCCO,,,,,,
960,10961,Barium cyanide,[C-]#N.[C-]#N.[Ba+2],,,,"['The cyanide ion is readily absorbed after oral or parenteral admin. prolonged local contact with cyanide solution ... May result in absorption of toxic amount through skin. Part of absorbed cyanide is excreted unchanged by lung. Larger portion ... is converted by sulfurtransferase ... to relative nontoxic thiocyanate ion. /Cyanide/', 'In 30 days, 72% of (14)C from IP dose of (14)C-Cyanide to mice was excreted in urine and feces, 25% in expired air, and 3% was retained ... Peak excretion occurred within 10 min in expired air and within 6-24 hr in urine and feces. /Cyanide/', 'Cyanides are rapidly absorbed from skin and mucosal surfaces and are most dangerious when inhaled because toxic amounts are rapidly absorbed through bronchial mucosa and alveoli. /Cyanide/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. /Cyanides/', 'Inhalation of cyanide salt dusts is dangerous because the cyanide will dissolve on contact with moist mucous membranes and be absorbed into the bloodstream. /Cyanide salts/']","['Conjugation of cyanide ion and sulfur donor is catalyzed by various sulfur transferases distributed in many animal tissues, liver particularly active. Source of sulfur donor for conjugation is probably thiosulfate.', '/One of/ the major mechanisms for removing cyanide from the body is its enzymatic conversion, by the mitochondrial enzyme rhodanese (transsulfurase), to thiocyanate, which is relatively ... /less toxic/. /Cyanide/', '/Cyanide/ ... Reacts ... With trivalent iron of cytochrome oxidase in mitochondria to form the cytochrome oxidase-CN complex ... The cytochrome-oxidase-CN complex is dissociable; the mitochondrial enzyme sulfurtransferase ... Mediates transfer of sulfur from thiosulfate to cyanide ion. Thus, thiocyanate is formed ... Kinetic studies indicate that the cleavage of the thiosulfate sulfur-sulfur bond is the rate-limiting step in this reaction. Relatively minor pathways incl combination with cystine to form 2-imino-thiazolidine-4-carboxylic acid, oxidation to carbon dioxide & formate, & formation of cyanocobalamin. /cyanide/', 'Thiocyanate conjugation is true detoxification reaction which is accompanied by 200-fold reduction of toxicity. /Cyanide/', '... Cyanide ion is conjugated with sulfur to form thiocyanate. ... Conjugation is catalyzed by ... Rhodanese which is widely distributed in most animal tissues ... /liver/ particularly active. ... Rhodanese mechanism is capable of detoxicating only limited amt of cyanide, such as are formed during normal metab. /another sulfur donor is 3-mercaptopyruvate. The enzyme, mercaptosulfur transferase is localized in cytosol/.  /Cyanide//']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
961,10962,1-Iodobutane,CCCCI,,,,,['1-iodobutane has known human metabolites that include butyl-glutathione.'],
962,10963,3-Chloropropionitrile,C(CCl)C#N,,,,['IT IS PROBABLY ABSORBED THROUGH THE INTACT SKIN.'],,
963,10964,Malonaldehyde,C(C=O)C=O,,,,"['IN PRIMARY RAT SKIN FIBROBLAST CULTURES GROWN IN A MEDIUM CONTAINING 1X10(-5), 1X10(-4), OR 1X10(-3) MOLAR OF 1,3-(14)C MALONALDEHYDE, THERE WAS A LIMITED, CONCENTRATION-DEPENDENT UPTAKE OF MALONALDEHYDE BY 24 HR (APPROXIMATELY 4% AT ALL CONCENTRATIONS). 83-89% OF THE (14)C WAS OXIDIZED TO (14)CO2 BY 24 HR AND APPROXIMATELY 5% WAS RECOVERED IN THE MAJOR LIPIDS. LIMITED CELLULAR UPTAKE OF MALONALDEHYDE MAY EXPLAIN THE TOLERANCE OF CELLS GROWN IN CULTURE TO RELATIVELY HIGH CONCENTRATIONS.', 'TWELVE HOURS AFTER INTUBATION WITH 1,3-(14)C MALONALDEHYDE, MALE WISTAR RATS SHOWED 60-70%, 5-15% AND 9-17% OF ADMINISTERED RADIOACTIVITY IN EXPIRED CARBON DIOXIDE, FECES AND URINE, RESPECTIVELY. IN VITRO EXPERIMENTS SHOWED METABOLISM TO BE PRIMARILY IN MITOCHONDRIA VIA REACTIONS INVOLVING OXYGEN UTILIZATION AND (14)CO2 PRODUCTION. THE APPARENT KM AND VMAX WERE 0.5 MMOL AND 9.3 NMOL/MIN/MG PROTEIN FOR OXYGEN UPTAKE, RESPECTIVELY, AND 2.0 MMOL AND 2.4 NMOL/MIN/MG PROTEIN FOR (14)CO2 PRODUCTION.']","['THIOBARBITURIC ACID-REACTING MATERIAL PRODUCED DURING ENZYMIC MICROSOMAL LIPID PEROXIDATION WAS IDENTIFIED AS MALONALDEHYDE. PHOSPHOLIPID ARACHIDONATE WAS ESTABLISHED AS THE MAJOR SOURCE OF THE MALONALDEHYDE PRODUCED IN THE REACTION.', '(14)C-ACETATE APPEARED TO BE THE MAJOR ACCUMULATING METABOLITE IN RAT LIVER MITOCHONDRIAL PREPARATIONS FOLLOWING A 120-MINUTE INCUBATION WITH (14)C-MALONALDEHYDE. A PROBABLE BIOCHEMICAL ROUTE FOR MALONALDEHYDE METABOLISM INVOLVES OXIDATION OF MALONALDEHYDE BY MITOCHONDRIAL ALDEHYDE DEHYDROGENASE FOLLOWED BY DECARBOXYLATION TO PRODUCE CARBON DIOXIDE AND ACETATE.', 'Two aldehyde dehydrogenases in the rat-liver cytosol fraction account for virtually all of the metabolizing activity for malonaldehyde.', 'After oral administration of malonaldehyde (158 mg/kg body weight) to rats, increased quantities of formaldehyde, acetaldehyde, acetone and malonaldehyde itself were found in the urine. Additionally, methyl ethyl ketone, not found in control rats, was present in the urine of the animals that had received malonaldehyde.']",
964,10965,2-Chloroethyl methyl sulfide,CSCCCl,,,,,,
965,10966,Ethyl isothiocyanate,CCN=C=S,,,,,,
966,10967,Bis(chloromethyl) ether,C(OCCl)Cl,,,,,['The hydrolysis products of BCME are formaldehyde and hydrochloric acid (HCl).'],"['No reports found; [TDR, p. 191]']"
967,10968,Ethyl thiocyanate,CCSC#N,,,,,,
968,10969,Heptaminol hydrochloride,CC(CCCC(C)(C)O)N.Cl,,,,,,
969,10970,Succinyl chloride,C(CC(=O)Cl)C(=O)Cl,,,,,,
970,10971,Cellocidin,C(#CC(=O)N)C(=O)N,,,,,,
971,10972,N-Acetylglycine,CC(=O)NCC(=O)O,,,,,,
972,10973,Isobutyl carbamate,CC(C)COC(=O)N,,,,,,
973,10974,Isobutyl nitrate,CC(C)CO[N+](=O)[O-],,,,,,
974,10975,Myrcenol,CC(C)(CCCC(=C)C=C)O,,,,,,
975,10976,2-Heptanol,CCCCCC(C)O,,,,,,
976,10977,1-Chloropentane,CCCCCCl,,,,,,
977,10978,n-Butylmercuric chloride,CCCC[Hg]Cl,,,,,,
978,10979,Propyl nitrite,CCCON=O,,,,,,
979,10980,Barium acetate,CC(=O)[O-].CC(=O)[O-].[Ba+2],,,,,,
980,10981,Beryllium acetate,[Be+2].CC(=O)[O-].CC(=O)[O-],,,,,,
981,10982,Octodrine,CC(C)CCCC(C)N,,,,,,
982,10983,Galegine,CC(=CCN=C(N)N)C,,,,,,
983,10984,Isoamyl carbamate,CC(C)CCOC(=O)N,,,,,,
984,10985,Isoamyl nitrate,CC(C)CCO[N+](=O)[O-],,,,,,
985,10986,Cadmium acetate,CC(=O)[O-].CC(=O)[O-].[Cd+2],,,,"['MONGOLIAN GERBILS WERE INJECTED IP WITH TRACE QUANTITIES OF (115)CD-CADMIUM ACETATE OVER 12 WK PERIOD. AFTER 3 WK EQUILIBRATION PERIOD GERBILS WERE SACRIFICED. AS IN OTHER SPECIES, CADMIUM LEVELS WERE HIGHER IN LIVER & KIDNEYS THAN IN OTHER TISSUES.', 'FORTY-EIGHT & 96 HR AFTER ORAL ADMIN OF 2 MG CADMIUM AS CADMIUM ACETATE, THE TISSUES OF SOFTSHELL TURTLE RETAINED 9.43 & 4.02% OF ADMIN DOSE AS CADMIUM. LIVER RETAINED GREATEST AMT. CADMIUM CONCN PER G WET WT WAS HIGHEST IN INTESTINES AT 48 HR, & IN LIVER AT 96 HR.', 'Male rats treated ip with cadmium acetate (1 mg Cd/kg, daily) for 8 days, then the liver was isolated, homogenized, the supernatant fractionated on Sephadex G-75, and the fractions analyzed by atomic absorption spectroscopy for cadmium and zinc. A small amount of cadmium was bound to a high molecular weight protein fraction (fraction A) and the majority of cadmium was bound to metallothionein fraction (fraction B). In addition, to a binding to high molecular weight protein fraction and metallothionein fraction, zinc also bound to a third fraction located between high molecular weight protein fraction and metallothionein fraction. Concentrations of cadmium and zinc in all fractions remained almost unchanged when determined 3 and 8 days after termination of treatment with cadmium acetate. The zinc content in fraction B was approximately two fold that in other fractions, and the content of cadmium + zinc decreased with time (ie 3 days vs 8 days). The molar ratio of zinc/cadmium in metallothionein fraction slightly decreased (ie the ratio on day 8 was slightly lower than that on day 3 after cessation of treatment).']",,
986,10987,Strontium acetate,CC(=O)[O-].CC(=O)[O-].[Sr+2],,,,,,
987,10988,Diisoamylamine,CC(C)CCNCCC(C)C,,,,,,
988,10989,Diisopentyl ether,CC(C)CCOCCC(C)C,,,,,,
989,10990,Diisopentyl sulfide,CC(C)CCSCCC(C)C,,,,,,
990,10991,"8-Amino-8-oxo-2-octene-4,6-diynoic acid",C(=CC(=O)O)C#CC#CC(=O)N,,,,,,
991,10992,1-Chlorohexane,CCCCCCCl,,,,,,
992,10993,3-Hexen-1-ol,CCC=CCCO,,,,,,
993,10994,Glutaronitrile,C(CC#N)CC#N,,,,,,
994,10995,"Mercury, chloropentyl-",CCCCC[Hg]Cl,,,,,,
995,10996,Butyl nitrite,CCCCON=O,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
996,10997,Calcium formate,C(=O)[O-].C(=O)[O-].[Ca+2],,,,,,
997,10998,Cobaltous formate,C(=O)[O-].C(=O)[O-].[Co+2],,,,,,
998,10999,Cupric formate,C(=O)[O-].C(=O)[O-].[Cu+2],,,,,,
999,11000,Cycloheptatriene,C1C=CC=CC=C1,,,,,,
1000,11001,"(9Z,12Z)-Ethyl octadeca-9,12-dienoate",CCCCCC=CCC=CCCCCCCCC(=O)OCC,,,,,,
1001,11002,Dibutyl sulfide,CCCCSCCCC,,,,,,
1002,11003,"2-Nonanone, 9-fluoro-",CC(=O)CCCCCCCF,,,,,,
1003,11004,Agrocybin,C(C#CC#CC#CC(=O)N)O,,,,,,
1004,11005,Myristic acid,CCCCCCCCCCCCCC(=O)O,,,,"['IN NORMAL RATS, HIGHER RADIOACTIVITY WAS FOUND IN HEART, LIVER, SPLEEN & ADRENALS 2 HR AFTER ADMIN OF PALMITIC ACID THAN AFTER ADMIN OF MYRISTIC ACID. IN GRANULOMA POUCH-BEARING RATS, RADIOACTIVITY SHOWED HIGHER DISTRIBUTION IN ADRENALS & POUCH EXUDATE 2 HR AFTER PALMITIC ACID ADMIN, COMPARED TO THOSE GIVEN MYRISTIC ACID. RADIOACTIVITY IN THE POUCH WALL WAS GREATER IN RATS GIVEN MYRISTIC ACID.', 'Fatty acids originating from adipose tissue stores are either bound to serum albumin or remain unesterified in the blood.', 'Oleic, Palmitic, Myristic, and Stearic Acids are primarily transported via the lymphatic system, and Lauric Acid is transported by the lymphatic and (as a free fatty acid) portal systems.']","['IN RATS FED COCONUT OIL, MYRISTIC ACID WAS ONE OF THE PRINCIPAL FATTY ACIDS PRESENT IN HEPATIC AND ADIPOSE TISSUE TRIGLYCERIDES. ETHANOL INCR THE PROPORTIONS OF MYRISTIC ACID.', 'IN ADDITION TO METABOLISM BY BETA-OXIDATION, MYRISTIC ACID HAS BEEN SHOWN TO UNDERGO CHAIN ELONGATION TO PALMITIC & STEARIC ACIDS, DESATURATION TO MYRISTOLEIC ACID & INCORPORATION INTO HEPATIC NEUTRAL LIPIDS (& TO A LESSER EXTENT, PHOSPHOLIPIDS).', 'THE CONVERSION OF SATURATED FATTY ACIDS TO MONOUNSATURATED FATTY ACIDS BY THE 9000 X G SUPERNATANT RAT LIVER HOMOGENATE WAS LESS FOR MYRISTIC ACID THAN FOR PALMITIC ACID. THESE FATTY ACIDS PRODUCED ONLY DELTA9-MONOENOIC ACIDS OF THE SAME CHAIN LENGTH.', 'MYRISTATE INCORPORATED FROM (14)C-LABELED ACETATE WAS PREFERENTIALLY ESTERIFIED INTO TRIGLYCERIDE, WHEREAS THE LABELED STEARATE WAS CONVERTED INTO PHOSPHOLIPIDS IN THE ISOLATED RAT ADIPOSE CELLS.', 'For more Metabolism/Metabolites (Complete) data for MYRISTIC ACID (6 total), please visit the HSDB record page.', 'Tetradecanoic acid has known human metabolites that include 13-Hydroxytetradecanoic acid.']",
1005,11006,Hexadecane,CCCCCCCCCCCCCCCC,,,,"['JP-8 jet fuel has been reported to cause systemic and dermal toxicities in animal models and humans. There is a great potential for human exposure to JP-8. In this study, we determined percutaneous absorption and dermal toxicity of three components of JP-8 (i.e., xylene, heptane, and hexadecane) in vivo in weanling pigs. In vivo percutaneous absorption results suggest a greater absorption of hexadecane (0.43%) than xylene (0.17%) or heptane (0.14%) of the applied dose after 30 min exposure.', 'Hexadecane has been identified in two human atherosclerotic aortas at concentrations of 40 and 60 ng/g.', '... Pigs were exposed to JP-8 jet fuel-soaked cotton fabrics for 1 and 4 d with repeated daily exposures. Preexposed and unexposed skin was then dermatomed and placed in flow-through in vitro diffusion cells. Five cells with exposed skin and four cells with unexposed skin were dosed with a mixture of 14 different hydrocarbons (HC) consisting of nonane, decane, undecane, dodecane, tridecane, tetradecane, pentadecane, hexadecane, ethyl benzene, o-xylene, trimethyl benzene (TMB), cyclohexyl benzene (CHB), naphthalene, and dimethyl naphthalene (DMN) in water + ethanol (50:50) as diluent. Another five cells containing only JP-8-exposed skin were dosed solely with diluent in order to determine the skin retention of jet fuel HC. The absorption parameters of flux, diffusivity, and permeability were calculated for the studied HC. The data indicated that there was a two-fold and four-fold increase in absorption of specific aromatic HC like ethyl benzene, o-xylene, and TMB through 1- and 4-d JP-8 preexposed skin, respectively. Similarly, dodecane and tridecane were absorbed more in 4-d than 1-d JP-8 preexposed skin experiments. The absorption of naphthalene and DMN was 1.5 times greater than the controls in both 1- and 4-d preexposures. CHB, naphthalene, and DMN had significant persistent skin retention in 4-d preexposures as compared to 1-d exposures that might leave skin capable of further absorption several days postexposure. The possible mechanism of an increase in HC absorption in fuel preexposed skin may be via lipid extraction from the stratum corneum as indicated by Fourier transform infrared (FTIR) spectroscopy. This study suggests that the preexposure of skin to jet fuel enhances the subsequent in vitro percutaneous absorption of HC, so single-dose absorption data for jet fuel HC from naive skin may not be optimal to predict the toxic potential for repeated exposures. For certain compounds, persistent absorption may occur days after the initial exposure.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', '1-(14)C n-hexadecane, a model compound for the non-volatile aliphatic hydrocarbon components of crude oil, was administered by intrapericardial injection to the spiny lobster, panulirus argus, and the clawed or American lobster, homarus americanus. Experiments were conducted in Florida (spiny lobster) and Maine (American lobster). The animals were sacrificed at various times from 0.5 hr to 8 weeks after administration of the dose. The tissues and fluids were analyzed for (14)C content by digestion or catalytic oxidation and liquid scintillation counting. Selected tissues(hepatopancreas, tail muscle and hemolymph) were extracted with ethyl acetate to allow quantitation of the unmetabolized n-hexadecane by thin layer chromatography. n-Hexadecane-derived radioactivity was very persistent in both the spiny lobster (half-life = 4.6 wk) and the American lobster (half-life = 11.2 wk). In both lobsters, the hepatopancreas acquired the highest specific activity and the tail muscle had the longest half life for elimination from an individual tissue. Although hexadecane was metabolized more rapidly in the hepatopancreas of the spiny lobster than in the hepatopancreas of the American lobster, unmetabolized hexadecane persisted in the hepatopancreases of both species for at least 8 weeks after the dose (the longest time studied).']",,
1006,11007,1-Iodohexadecane,CCCCCCCCCCCCCCCCI,,,,,,
1007,11008,Dotriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Samples of the pork, veal and chicken imported into Italy from other countries were analyzed to ascertain saturated and unsaturated hydrocarbon levels. Gas chromatography-mass spectrometry analysis showed overall n-alkane levels to be in the range of 0.3-10.5 ppm. n-Alkanes ranged from C12-C33. Phytenes were found only in bovine tissue. No alkenes were present in any of the samples analyzed. /n-Alkanes/', 'Nose only inhalation exposure and intratracheal inoculation were described as methods which allow lung only exposures to hazardous materials. For nose only inhalation studies, animals were restrained in stocklike holders or whole body tubes and the nose of each animal protruded into either a chamber or channel where the aerosols were delivered. Over 70% of the material was deposited in the lung of the exposed animals, compared to 13% obtained by traditional exposure methods. There was little external body exposure and therefore little ingestion through preening. Particulate deposition and distribution were quite reproducible, with animal to animal variation of less than 20%. The major disadvantage to the nose only exposure system was that the animals were restrained and not allowed access to food or water during exposure. Results obtained using dotriacontane and catechol were described. For intratracheal inoculation, the material being studied was placed in the lung to allow direct interaction with lung cells. A blunt needle was carefully inserted down the throat of the animal, past the tracheal rings to the bifurcation of the lung where the material was injected. The technique was similar for rats, mice, and hamsters. The procedure was fairly simple and rapid, allowing injection of many animals per day. A wide range of treatment doses could be given and repeated over long periods of time; the chemicals bypassed the upper respiratory tract. The disadvantages to the method included the fact that this was not a normal route of exposure, anesthesia was required, the particle size delivered to the lung may not be uniform, and special care was needed to insure that animals survived the procedure.']",,
1008,11009,Copper(I) cyanide,[C-]#N.[Cu+],,,,"['IN 30 DAYS, 72% OF (14)C FROM IP DOSE OF (14)C-CYANIDE TO MICE WAS EXCRETED IN URINE & FECES, 25% IN EXPIRED AIR, & 3% WAS RETAINED ... PEAK EXCRETION OCCURRED WITHIN 10 MIN IN EXPIRED AIR & WITHIN 6-24 HR IN URINE & FECES. /CYANIDE/', 'CYANIDE ION IS READILY ABSORBED AFTER ORAL OR PARENTERAL ADMIN. PROLONGED LOCAL CONTACT WITH CYANIDE SOLN OR WITH HYDROGEN CYANIDE MAY RESULT IN ABSORPTION OF TOXIC AMT THROUGH SKIN. PART OF ABSORBED CYANIDE IS EXCRETED UNCHANGED BY THE LUNG. ... LARGER PORTION ... CONVERTED BY ... SULFURTRANSFERASE TO RELATIVELY NONTOXIC THIOCYANATE ION. /CYANIDE ION/', 'CYANIDES ARE RAPIDLY ABSORBED FROM SKIN & ALL MUCOSAL SURFACES & ARE MOST DANGEROUS WHEN INHALED, BECAUSE TOXIC AMT ARE RAPIDLY ABSORBED THROUGH BRONCHIAL MUCOSA & ALVEOLI. /CYANIDES/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. /Cyanide/', 'For more Absorption, Distribution and Excretion (Complete) data for COPPER(I) CYANIDE (7 total), please visit the HSDB record page.']","['INORGANIC CYANIDE ION IS CONJUGATED WITH SULFUR TO FORM THIOCYANATE. ... THE CONJUGATION IS CATALYZED BY ... RHODANESE WHICH IS WIDELY DISTRIBUTED IN MOST ANIMAL TISSUES EXCEPT BLOOD, LIVER BEING PARTICULARLY ACTIVE. ... RHODANESE MECHANISM IS CAPABLE OF DETOXICATING ONLY LIMITED AMT OF CYANIDE, SUCH AS ARE FORMED DURING NORMAL METAB. /ANOTHER SULFUR DONOR IS 3-MERCAPTOPYRUVATE. THE ENZYME, MERCAPTOSULFUR TRANSFERASE IS LOCALIZED IN CYTOSOL./ /CYANIDE/', '/ONE OF/ THE MAJOR MECHANISMS FOR REMOVING CYANIDE FROM THE BODY IS ITS ENZYMATIC CONVERSION, BY THE MITOCHONDRIAL ENZYME RHODANASE (TRANSSULFURASE), TO THIOCYANATE, WHICH IS RELATIVELY ... /LESS TOXIC/. /CYANIDE/', 'Pseudomonas putida utilizes cyanide as the sole source of carbon and nitrogen. Agar, alginate, and carrageenan were screened as the encapsulating matrices for P. putida. Alginate-immobilized cells of P. putida degraded sodium cyanide (NaCN) more efficiently than non-immobilized cells or cells immobilized in agar or carrageenan. The end products of biodegradation of cyanide were identified as ammonia (NH3) and carbon dioxide (CO2). These products changed the medium pH. In bioreactors, the rate of cyanide degradation increased with an increase in the rate of aeration. Maximum utilization of cyanide was observed at 200 ml min-1 of aeration. Immobilized cells of P. putida degraded cyanides, cyanates and thiocyanates to NH3 and CO2. Use of Na(14C)-CN showed that 70% of carbon of Na(14C)-CN was converted into 14CO2 and only 10% was associated with the cell biomass. The substrate-dependent kinetics indicated that the Km and Vmax values of P. putida for the substrate, NaCN were 14 mM and 29 nmol of oxygen consumed mg protein-1 min-1 respectively.']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
1009,11010,Dimethylzinc,[CH3-].[CH3-].[Zn+2],,,,,,
1010,11011,Trichloroacetonitrile,C(#N)C(Cl)(Cl)Cl,,,,"['About 2% of a single oral dose of 108 mg/kg bw trichloroacetonitrile to rats was excreted in urine within 24 hr as thiocyanate, the product of released cyanide metabolized by rhodanese']","['When administered orally to rats, the haloacetonitriles (HAN) were metabolized to cyanide and excreted in the urine as thiocyanate. The extent of thiocyanate excretion was chloroacetonitrile (CAN) greater than bromochloroacetonitrile (BCAN) greater than dichloroacetonitrile (DCAN)  greater than dibromoacetonitrile (DBAN) much greater than trichloroacetonitrile (TCAN).']",
1011,11012,"3-[(3S,5R,10S,13R,14S,16S,17R)-3,14,16-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=CC(=O)OC5)O)O)C)O,,,,,,
1012,11013,"3-[(3S,5R,10S,11R,13R,14S,17R)-11,14-dihydroxy-10,13-dimethyl-3-[(2S,5S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3[C@@H](C[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O)O,,,,,,
1013,11014,Scillaridin A,C[C@]12CCC3C([C@]1(CC[C@@H]2C4=COC(=O)C=C4)O)CC=C5[C@@]3(CCC=C5)C,,,,,,
1014,11015,"3-[(3R,5R,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CC[C@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O,,,,,,
1015,11016,Triethylenephosphoramide,C1CN1P(=O)(N2CC2)N3CC3,,,"['A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']","['AFTER IP ADMIN OF (32)P-TEPA TO MICE, RADIOACTIVITY WAS NOT LOCALIZED SELECTIVELY IN ANY OF TISSUES EXAMINED. DURING FIRST 24 HR AFTER TREATMENT SOME 60-75% OF DOSE WAS EXCRETED VIA URINE, COMPARED WITH ONLY 2-5% IN FECES. IN URINE, 80% OF RADIOACTIVITY WAS IDENTIFIED AS INORGANIC PHOSPHATE, REMAINDER AS AN UNIDENTIFIED METABOLITE WHICH COULD BE HYDROLYZED TO GIVE ORGANIC PHOSPHATE. IN RATS, 80% OF RADIOACTIVITY IN BLOOD WAS ASSOC WITH HEMOGLOBIN. DURING FIRST 24 HR 89-90% OF RADIOACTIVITY WAS EXCRETED IN URINE; HOWEVER, IN CONTRAST WITH MOUSE, 50-70% OF URINARY RADIOACTIVITY WAS PRESENT AS UNCHANGED TEPA. PATTERN OF METAB IN DOGS IS ESSENTIALLY SIMILAR TO THAT...FOR RATS. RECOVERY OF UNCHANGED TEPA IN URINE WAS ABOUT 25-30% OF DOSE OVER SAME PERIOD. TISSUE DISTRIBUTION STUDIES SHOWED...RETENTION WAS UNIFORMLY LOW, WITH EXCEPTION OF BONE MARROW IN WHICH SELECTIVE UPTAKE RESULTED IN CONCN 6-10 TIMES THAT...IN OTHER TISSUES.', 'THE SPERM-RICH FRACTION OF BOAR SEMEN WAS TREATED IN VITRO FOR 10 MIN WITH AN EQUAL VOL OF 1% SOLN OF (14)C-LABELED TEPA. ON AVERAGE, 0.8% WAS TAKEN UP IN THE SPERMATOZOA; 69% WAS ASSOCIATED WITH THE HEADS & 31% WITH THE TAILS & ACROSOMES.']",,
1016,11017,Poldine methylsulfate,C[N+]1(CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.COS(=O)(=O)[O-],,,,,,
1017,11018,Poldine,C[N+]1(CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,,,,,,
1018,11019,Phenadoxone hydrochloride,CCC(=O)C(CC(C)N1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
1019,11020,Propallylonal,CC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
1020,11021,Pachygenol,C[C@]12CCC3C([C@]1(CCC2C4=CC(=O)OC4)O)CC=C5[C@@]3(CC[C@@H](C5)O)CO,,,,,,
1021,11022,"3,14-Dihydroxy-19-oxocarda-5,20(22)-dienolide",C[C@]12CCC3C([C@]1(CCC2C4=CC(=O)OC4)O)CC=C5[C@@]3(CC[C@@H](C5)O)C=O,,,,,,
1022,11023,Zinc citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Zn+2].[Zn+2].[Zn+2],,,,,,
1023,11024,Tricholine citrate,C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O,,,"['Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues. (See all compounds classified as Lipotropic Agents.)', 'Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
1024,11025,Lead tetraacetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Pb+2],,,,,,
1025,11026,Titanium tetraisopropanolate,CC(C)[O-].CC(C)[O-].CC(C)[O-].CC(C)[O-].[Ti+4],,,,,,
1026,11027,3-Thujanone,CC1C2CC2(CC1=O)C(C)C,,,,,,
1027,11028,CID 11028,[Li+].CC(=O)[O-],,,,,,
1028,11029,Magnesium Carbonate,C(=O)([O-])[O-].[Mg+2],['Used as an over the counter antacid.'],['Neutralizes acid in the stomach.'],"['Chemicals that are used to oxidize pigments and thus effect whitening. (See all compounds classified as Bleaching Agents.)', 'Materials that readily absorb moisture from their surroundings. (See all compounds classified as Hygroscopic Agents.)']","['About 40-60% of magnesium is absorbed following oral administration. Percent absorption decreases as dose increases.', 'Primarily eliminated in urine.', 'Vd for magnesium is 0.2-0.4L/kg. About 50% distributes to bone.', 'Maximum magnesium clearance is directly proportional to creatinine clearance.', 'IN SHEEP TRIAL REAGENT GRADE MATERIAL DEMONSTRATED 72% TRUE ABSORPTION VALUES, WHILE COMMERCIAL MAGNESITE HAD ONLY 14% VALUE DRAMATIZING NEED FOR MORE BIOLOGIC AVAILABILITY STUDIES ON MANY FEED INGREDIENTS.']",['Magnesium does not appear to be metabolized in any way.'],['Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult.']
1029,11030,CID 11030,C1=CC(=CC=C1N)S(=O)(=O)[N-]C2=NC=CN=C2.[Na+],,,,,,
1030,11031,CID 11031,C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Na+],,,,,,
1031,11032,Antidipsin,CCCCN(CCCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
1032,11033,Sulfacarbamide,C1=CC(=CC=C1N)S(=O)(=O)NC(=O)N,,,,,,
1033,11034,CID 11034,C1=CC(=CC=C1N=NC2=C(C=C(C=C2)O)O)S(=O)(=O)[O-].[Na+],,,,,,
1034,11035,"4-((2,4-Dihydroxyphenyl)azo)benzenesulphonic acid",C1=CC(=CC=C1N=NC2=C(C=C(C=C2)O)O)S(=O)(=O)O,,,,,,
1035,11036,CID 11036,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
1036,11037,"Benzenesulfonic acid, 4-[[4-(dimethylamino)phenyl]azo]-",CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
1037,11038,3-Pinanone,CC1C2CC(C2(C)C)CC1=O,,,,,,
1038,11039,Methyl isobutyrate,CC(C)C(=O)OC,,,,,,
1039,11040,Methyl lactate,CC(C(=O)OC)O,,,,"['Since hydrolysis of lactate esters is fairly rapid, elimination pathways are probably the same as those for lactic acid and alcohol. /Lactic esters/']","['Hydrolysis of lactate esters to lactic acid and alcohol has been reported to occur after both skin application and oral administration. Lactic acid is a naturally occurring metabolite, and its toxicity is mostly a result of its acidity. /Lactate esters/']",
1040,11041,ZINC oxalate,C(=O)(C(=O)[O-])[O-].[Zn+2],,,,,,
1041,11042,CID 11042,C1=CC2=C(C(=C(C=C2S(=O)(=O)O)I)O)N=C1.C(=O)(O)[O-].[Na+],,,,,,
1042,11043,Chiniofon,C1=CC2=C(C(=C(C=C2S(=O)(=O)O)I)O)N=C1,,,,,,
1043,11044,Chlorimine picryl sulfonate,C1C[NH+]1CCCCl.C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1044,11045,"2,4,6-Trinitrobenzenesulfonic acid",C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1045,11046,1-(3-Chloropropyl)aziridine,C1CN1CCCCl,,,,,,
1046,11047,CID 11047,CCOC(=O)C(C1=C(OC2=CC=CC=C2C1=O)O)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
1047,11048,Eosin,C1=CC=C(C(=C1)C2=C3C=C(C(=O)C(=C3OC4=C(C(=C(C=C24)Br)[O-])Br)Br)Br)C(=O)[O-].[Na+].[Na+],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1048,11049,"2-(2,4,5,7-Tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid",C1=CC=C(C(=C1)C2=C3C=C(C(=O)C(=C3OC4=C(C(=C(C=C24)Br)O)Br)Br)Br)C(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
1049,11050,Phenalen-1-one,C1=CC2=C3C(=C1)C=CC(=O)C3=CC=C2,,,,,,
1050,11051,Elymoclavin,CN1CC(=CC2C1CC3=CNC4=CC=CC2=C34)CO,,,,,,
1051,11052,o-Thymotic acid,CC1=C(C(=C(C=C1)C(C)C)O)C(=O)O,,,,,,
1052,11053,Violacein,C1=CC2=C(C(=O)N=C2C=C1)C3=C(NC(=C3)C4=CNC5=C4C=C(C=C5)O)O,,,,,,
1053,11054,Lucanthone hydrochloride,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O.Cl,,,['Agents that act systemically to kill adult schistosomes. (See all compounds classified as Schistosomicides.)'],"[""...The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. ...The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. ...Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p=0.0536.""]",,"['A sublethal dose of 100 mg lucanthone hydrochloride/kg (Miracil D, Nilodin; NSC-14574) administered ip into Chinese hamsters (median lethal dose for 30-day survival (LD50/30) of 315 mg/kg)  ... Serum concentration of lucanthone hydrochloride in the Chinese hamster, determined spectrophotometrically, reached a peak of 8 microgram/ml by 1.5 hours post inoculation and then decreased exponentially with a half-life of approximately 6 hours, so that by 30 hours post inoculation it was unmeasurable.']"
1054,11055,Primetin,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=CC(=C3O2)O)O,,,,,,
1055,11056,Polyporic acid,C1=CC=C(C=C1)C2=C(C(=O)C(=C(C2=O)O)C3=CC=CC=C3)O,,,,,,
1056,11057,Gentian violet,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']","['Nine male and 9 female Hubbard adult broiler breeders were used to study tissue residues of gentian violet, each bird was given (14)C-gentian violet orally. T/2 of radioactivity from (14)C-gentian violet in blood differed between sexes (1.43 hr and 1.68 hr for males and females, respectively). At 8 hr after administration only 1 bird had detectable amt of radioactivity in muscle. Detectable levels of radioactivity were found in liver at 120 hr after dosing and in kidney at 432 hr after dosing. All eggs collected during 1St 144 hr contained very low but detectable levels of radioactivity.']",['Gentian violet is shown to undergo a one-electron reduction by the cytochrome P450 monooxygenase system to produce a carbon-centered free radical as demonstrated by direct electron spin resonance techniques.'],
1057,11058,Pavatrine hydrochloride,CCN(CC)CCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13.Cl,,,,,,
1058,11059,Pavatrin,CCN(CC)CCOC(=O)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
1059,11060,Thiphenamil hydrochloride,CCN(CC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.Cl,,,,,,
1060,11061,Thiphenamil,CCN(CC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1061,11062,CID 11062,COC1=C(C2=C(C(=COC2=CC1=O)C3=CC=C(C=C3)O)O)O,,,,,,
1062,11063,CID 11063,C1=CC=C(C=C1)C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O,,,,,,
1063,11064,"10-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione",CC12CCC3C(C1CCC2=O)CCC4=CC(=O)C=CC34O,,,,,,
1064,11065,Amitriptyline hydrochloride,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,,,"['A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']",,,
1065,11066,Oxyberberine,COC1=C(C2=C(C=C1)C=C3C4=CC5=C(C=C4CCN3C2=O)OCO5)OC,,,,,,
1066,11067,Sulfur Yellow S,C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])[O-].[K+].[K+],,,,,,
1067,11068,Quinine (Hydrobromide),COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.Br,,,,,,
1068,11069,Quinidine sulfate,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.OS(=O)(=O)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6. (See all compounds classified as Cytochrome P-450 CYP2D6 Inhibitors.)']","['ABOUT 90% OF QUINIDINE IN PLASMA IS BOUND TO PLASMA PROTEINS (ALPHA/ACID GLYCOPROTEIN AND ALBUMIN) THE DRUG ENTERS ERYTHROCYTES & ... BINDS TO HEMOGLOBIN; AT STEADY STATE, CONCN OF QUINIDINE IN PLASMA & ERYTHROCYTES ARE APPROXIMATELY EQUAL. QUINIDINE ACCUMULATES RAPIDLY IN MOST TISSUES EXCEPT BRAIN, & ... VOL OF DISTRIBUTION IS 2-3 L/KG. /QUINIDINE/', 'METABOLITES AND SOME OF THE PARENT DRUG (20%) ARE EXCRETED IN URINE; ELIMINATION HALF-TIME IS ABOUT 6 HR. /QUINIDINE/', 'LIVER METABOLISM & RENAL EXCRETION ARE THE MAIN ROUTES OF ELIMINATION. ENTEROHEPATIC CIRCULATION WOULD NOT SIGNIFICANTLY ALTER ABSORPTION KINETICS AS REFLECTED BY BLOOD CONCENTRATION.', 'PEAK PLASMA CONCN OF 0.29 UG/ML OF QUINIDINE WERE MEASURED @ 4 HR AFTER ADMIN OF SUSTAINED RELEASE CAPSULE (250 MG QUINIDINE BISULFATE) AND DECLINED STEADILY DURING THE NEXT 8 HR, WHILE AFTER ADMIN OF SUSTAINED RELEASE TABLET (300 MG QUINIDINE SULFATE) THEY WERE FAIRLY EVEN DURING 2-10 HR AFTER DOSING. PLASMA CONCENTRATIONS WERE HIGHER AT LATER TIMES FOR THE CAPSULE THAN FOR THE TABLET. THE BIOAVAILABILITY OF QUINIDINE FROM THE CAPSULES DURING 12 HR WAS 184% COMPARED TO THE TABLET. MEAN QUINIDINE PLASMA CONCN WERE SIGNIFICANTLY GREATER @ 3, 4, 6, 8, & 10 HR AFTER ADMIN OF THE CAPSULE THAN AFTER THE TABLET.', 'For more Absorption, Distribution and Excretion (Complete) data for QUINIDINE SULFATE (24 total), please visit the HSDB record page.']","[""QUINIDINE YIELDS 2'-HYDROXYQUINIDINE AS METABOLITE IN MAN. /QUINIDINE; FROM TABLE/"", 'MOST URINARY METABOLITES ARE HYDROXYLATED AT ONLY ONE SITE, EITHER ON THE QUINOLINE RING OR ON THE QUINUCLIDINE RING; SMALL AMOUNTS OF DIHYDROXY COMPOUNDS ARE ALSO FOUND. THE FRACTION OF A DOSE OF QUINIDINE THAT IS METABOLIZED & THE METABOLIC PATHWAY APPEAR TO VARY CONSIDERABLY FROM PATIENT TO PATIENT.', 'Quinidine is metabolized in the liver, principally via hydroxylation to 3-hydroxyquinidine and 2-quinidinone. The metabolites may be pharmacologically active. Approximately 10-50% of a dose is excreted in urine (probably by glomerular filtration) as unchanged drug within 24 hr. /Quinidine/']","['THE ELIMINATION HALF-LIFE OF QUINIDINE RANGES FROM 4 TO 10 HR IN HEALTHY PERSONS, WITH USUAL MEAN VALUE OF 6 TO 7 HR. HALF-LIFE IS SIGNIFICANTLY PROLONGED IN ELDERLY PERSONS, EVEN WHEN THEY ARE APPARENTLY HEALTHY. /QUINIDINE/', '... EXCRETED IN URINE; ELIMINATION HALF-TIME IS ABOUT 6 HR. /QUINIDINE/', 'Quinidine generally has a plasma half-life of 6-8 hr in healthy individuals, but half-life may range from 3-16 hr or longer. In one study in patients with Plasmodium falciparum malaria, the elimination half-life of the drug averaged 12.8 hr (range: 6.6-24.8 hr). /Quinidine/']"
1069,11070,Hydrocotarnine hydrochloride hydrate,CN1CCC2=CC3=C(C(=C2C1)OC)OCO3.O.Cl,,,,,,
1070,11071,Amisometradine,CC(=C)CN1C(=CC(=O)N(C1=O)C)N,,,,,,
1071,11072,Naphthocaine hydrochloride,CCN(CC)CCOC(=O)C1=CC=C(C2=CC=CC=C21)N.Cl,,,,,,
1072,11073,Naphthocaine,CCN(CC)CCOC(=O)C1=CC=C(C2=CC=CC=C21)N,,,,,,
1073,11074,N-Methylphthalimide,CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
1074,11075,1-Nitro-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2[N+](=O)[O-])O,,,,,,
1075,11076,Syntaverin,CC1=CC2=CC3=C(C=C2C(=N1)CC4=CC5=C(C=C4)OCO5)OCO3,,,,,,
1076,11077,Resazurin,C1=CC2=C(C=C1O)OC3=CC(=O)C=CC3=[N+]2[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
1077,11078,Propoxycaine hydrochloride,CCCOC1=C(C=CC(=C1)N)C(=O)OCCN(CC)CC.Cl,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
1078,11079,Naphazoline hydrochloride,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32.Cl,,,"['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)']","['Following topical application of naphazoline hydrochloride solutions to the conjunctiva, local vasoconstriction usually occurs within 10 minutes and may persist for 2-6 hours. Occasionally, enough naphazoline may be absorbed to produce systemic effects. Information on the distribution and elimination of the drug in humans is not available']",,
1079,11080,1-Naphthyl isothiocyanate,C1=CC=C2C(=C1)C=CC=C2N=C=S,,,,,,
1080,11081,"7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O,,,,,,
1081,11082,6-Aminopenicillanic acid,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N)C(=O)O)C,,,,,,
1082,11083,Allethrolone,CC1=C(C(=O)CC1O)CC=C,,,,,,
1083,11084,"1,2,3,4-Tetrafluorobenzene",C1=CC(=C(C(=C1F)F)F)F,,,,,,
1084,11085,"2,4,6-Trichloro-m-cresol",CC1=C(C(=C(C=C1Cl)Cl)O)Cl,,,,,,
1085,11086,2'-Aminoacetophenone,CC(=O)C1=CC=CC=C1N,,,,,"['YIELDS 2-CARBOXAMIDO-4-METHYLQUINAZOLINE, 2-HYDROXYMETHYL-4-METHYLQUINAZOLINE, & 4-METHYLQUINAZOLINE IN PSEUDOMONAS. /FROM TABLE/', '2-AMINO-3-HYDROXYACETOPHENONE WAS ISOLATED FROM URINE OF RATS GIVEN 15 MG 2-AMINOACETOPHENONE/KG/DAY FOR 4 DAYS & FROM THE SUPERNATANT OF CULTURES OF RAT LIVER MICROSOMES INCUBATED WITH 2-AMINOACETOPHENONE FOR 2 HR AT 37 C.', ""IN CELL-FREE EXTRACTS OF BACILLUS SUBTILIS, 2'-AMINOACETOPHENONE WAS UTILIZED AS RAPIDLY AS AMINOACETONE.""]",
1086,11087,2-Nitrobenzoic acid,C1=CC=C(C(=C1)C(=O)O)[N+](=O)[O-],,,,,,
1087,11088,Thymol iodide,CC1=CC(=C(C=C1C2=CC(=C(C=C2C)OI)C(C)C)C(C)C)OI,,,,,,
1088,11089,Trimellitic anhydride,C1=CC2=C(C=C1C(=O)O)C(=O)OC2=O,,,,"['Tissue concentration time-course data were collected for rats exposed to 0.95 mg/cu m trimellitic anhydride (TMA) for 45 min ... Animals were sacrificed 3 hr, 1, 2, 4, 8, 16, and 32 days following exposure. In general, the highest tissue concentrations were obtained at the first time point (T-max<3 hr). A second T-max of eight days was reported for lung lymph nodes in male rats, suggesting a possible role in the gender differences observed for lung toxicity ...']",,"['... Biological half-lives /in rats/ ranging from 3 to 46 days were estimated ... Specific half-lives for trimellitic anhydride in the lungs were estimated to be 21 days in male rats and 16 days in female rats ... In lung associated lymph nodes, half-lives of 13 and 33 days were estimated for male and female rats, respectively ...']"
1089,11090,2'-Nitroacetanilide,CC(=O)NC1=CC=CC=C1[N+](=O)[O-],,,,,,
1090,11091,CID 11091,[Li+].C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
1091,11092,Paeonol,CC(=O)C1=C(C=C(C=C1)OC)O,,,,,['Paeonol has known human metabolites that include (2-Acetyl-5-methoxyphenyl) hydrogen sulfate.'],
1092,11093,2-Methylbenzyl chloride,CC1=CC=CC=C1CCl,,,,,,
1093,11094,1-Naphthylamine hydrochloride,C1=CC=C2C(=C1)C=CC=C2N.Cl,,,,,,
1094,11095,(+/-)-Eriodictyol,C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O,,,,,,
1095,11096,9-Methyl-9-azabicyclo[3.3.1]nonan-3-one,CN1C2CCCC1CC(=O)C2,,,,,,
1096,11097,Dihydroxydimethylstilbene,CC(=C(C)C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,,,,,,
1097,11098,N-Methyldiphenylamine,CN(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1098,11099,p-HYDROXYNOREPHEDRINE,CC(C(C1=CC=C(C=C1)O)O)N,,,,,,
1099,11100,Furoin,C1=COC(=C1)C(C(=O)C2=CC=CO2)O,,,,,,
1100,11101,2-Nitrobenzaldehyde,C1=CC=C(C(=C1)C=O)[N+](=O)[O-],,,,,,
1101,11102,Thonzonium bromide,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CC=N2.[Br-],,,,,,
1102,11103,Hematoporphyrin,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O,,,['Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)'],,,
1103,11104,Guaiacol carbonate,COC1=CC=CC=C1OC(=O)OC2=CC=CC=C2OC,,,,,,
1104,11105,Neutral red,CC1=CC2=NC3=C(C=C(C=C3)N(C)C)N=C2C=C1N.Cl,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
1105,11106,Neutral Red Base,CC1=CC2=NC3=C(C=C(C=C3)N(C)C)N=C2C=C1N,,,,,,
1106,11107,"4,4'-Bipyridine",C1=CN=CC=C1C2=CC=NC=C2,,,,,,
1107,11108,"N,N-Bis(2-chloroethyl)aniline",C1=CC=C(C=C1)N(CCCl)CCCl,,,"['A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']",,,
1108,11109,Lodal,C[N+]1=CC2=CC(=C(C=C2CC1)OC)OC.[Cl-],,,,,,
1109,11110,"6,7-Dimethoxy-2-methyl-3,4-dihydroisoquinolinium",C[N+]1=CC2=CC(=C(C=C2CC1)OC)OC,,,,,,
1110,11111,Proflavine hemisulfate,C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.OS(=O)(=O)O,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1111,11112,Nicotinic acid hydrazide,C1=CC(=CN=C1)C(=O)NN,,,,,,
1112,11113,CID 11113,[Li+].C1=CC=C(C=C1)C(=O)[O-],,,,,,
1113,11114,Metabutethamine hydrochloride,CC(C)CNCCOC(=O)C1=CC(=CC=C1)N.Cl,,,,,,
1114,11115,Metabutethamine,CC(C)CNCCOC(=O)C1=CC(=CC=C1)N,,,,,,
1115,11116,Butethamine hydrochloride,CC(C)CNCCOC(=O)C1=CC=C(C=C1)N.Cl,,,,,,
1116,11117,Butethamine,CC(C)CNCCOC(=O)C1=CC=C(C=C1)N,,,,,,
1117,11118,5-Nitro-2-propoxyaniline,CCCOC1=C(C=C(C=C1)[N+](=O)[O-])N,,,,,,
1118,11119,"2,4-Dichloroanisole",COC1=C(C=C(C=C1)Cl)Cl,,,,,,
1119,11120,Dimethyl oxalate,COC(=O)C(=O)OC,,,,,,
1120,11121,2-Bromo-p-xylene,CC1=CC(=C(C=C1)C)Br,,,,,,
1121,11122,p-Toluquinone,CC1=CC(=O)C=CC1=O,,,,"['QUINONE IS READILY ABSORBED FROM GASTROENTERIC TRACT & SC TISSUES. IT IS PARTIALLY EXCRETED UNCHANGED; BUT BULK IS ELIMINATED IN CONJUGATION WITH HEXURONIC, SULFURIC, & OTHER ACIDS. /1,4-BENZOQUINONE/']","['YIELDS METHYLBENZOSEMIQUINONE IN ESCHERICHIA. YIELDS METHYLQUINOL IN PIG; IN PEA; AND IN DESULFOVIBRIO. /FROM TABLE/', 'Quinones (ie, 6,12-dione) have been shown to undergo oxidation-reduction cycles involving quinone, hydroquinone, and molecular oxygen, resulting in the formation of oxygen radicals and semiquinone radicals. /Quinones/']",
1122,11123,"2,4-Dichloroaniline",C1=CC(=C(C=C1Cl)Cl)N,,,,,"['The metabolism of four (14)C-labeled thiobis(formamidine) insecticides was studied in Sprague Dawley rats & ICR mice. The insecticides were derived from a series of 2,4-disubstituted anilines. The compounds studied included 2,4-dichloroaniline. Each compound was orally admin in corn oil solution to 2 female rats & 4 female mice in doses of 10-13 mg/kg. In every case, the corresponding anilines were detected as free aniline, in minor amounts except for the dichloro series. There were no significant differences observed between the compounds studied. The general metabolism schemes for all 4 compounds were similar. Metabolism of these compounds involves rapid hydrolysis of the parent compound in the stomach to simple formamidine, which is then converted to an N-formylaniline that has various metabolic fates, particularly through oxidation of methyl groups.', 'In order to reveal the urinary metabolites of p-chloronitrobenzene (CNB), an investigation was conducted to separate and identify urinary metabolites by gas chromatography/mass spectrometry following the administration of the compound to rats. Six male Sprague-Dawley-rats were given a single dose of 100 mg/kg CNB diluted in olive-oil and injected intraperitoneally. Urine was collected from the six rats at from 8 to 24 hours after exposure. Trace amounts of unchanged CNB were detected in the urine of the rats, but most of the CNB appeared to have been metabolized prior to excretion. Nine substances were identified: p-chloroaniline, 2,4-dichloroaniline, p-nitrothiophenol, 2-chloro-5-nitrophenol, 2-amino-5-chlorophenol, p-chloroformanilide, 4-chloro-2-hydroxyacetanilide, a small amount of p-chloroacetanilide and traces of unchanged CNB.', 'The urinary metabolites of p-chloronitrobenzene (p-CNB) in humans were determined using urine samples from acutely poisoned subjects. The six subjects were longshoremen hospitalized after being exposed to p-CNB while loading torn bags of the substance. Moment analysis and compartment model analysis of the urinary excretion rate of metabolites of p-CNB versus time curves were used for the pharmacokinetic evaluation. The findings suggest that the average values of the ratio of excreted amount of each metabolite to the total amount of the five metabolites and mean residence time in the six subjects were, respectively, 12.2% and 6.7 days for 2-chloro-5-nitrophenol (619103), 48.0% and 7.0 days for N-acetyl-S-(4-nitrophenyl)-L-cysteine, 1.2% and 3.7 days for 2,4-dichloroaniline, 29.9% and 10.0 days for p-chloroaniline, and 8.7% and 6.0 days for 2-amino-5-chlorophenol. The rates of transformation of p-CNB to 2-chloro-5-nitrophenol and p-chloroaniline appeared to be slow, but the resulting p-chloroaniline was metabolized relatively rapidly in the human body. The authors note that the ratio of the excretion amounts of the five metabolites was nearly constant among the subjects, whereas the rate of metabolism of the parent compound and the mean residence time varied widely among the individuals.']",
1123,11124,Methyl propionate,CCC(=O)OC,,,,,,
1124,11125,Lithium carbonate,[Li+].[Li+].C(=O)([O-])[O-],"['Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder.']","[""Lithium's mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.""]","['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)']","['Lithium absorption is rapid and oral bioavailability is close to 100%.', 'Lithium is primarily eliminated through the kidneys and elimination in the feces is insignificant.', 'Apparent volume of distribution is 0.7 to 1.0L/kg.', 'Clearance is generally between 10 and 40mL/min but may be as low as 15mL/min in elderly patients and those with renal impairment.', '... Lithium /carbonate/ crosses placenta and is present in mother and fetus in same concentration.', 'Lithium /carbonate/ is completely absorbed six to eight hours after oral administration. Since the onset of action is slow (five to ten days), parenteral administration is of no advantage. The plasma half-life is 17 to 36 hours, and this drug is eliminated almost entirely by the kidneys. Lithium clearance averages approximately 20% of creatinine clearance, but significant variability exists among patients.', 'The population pharmacokinetics of lithium were determined using the nonlinear mixed effects model (NONMEM) program in 79 psychiatric inpatients who were at least 18 yr old, had normal renal function, and were receiving lithium carbonate 2 or 3 times daily. With the initial model, the mean lithium volume of distribution was 32.8 L and the mean lithium clearance was 1.36 L/hr. With an intermediate model, lithium clearance estimates improved on the basis of patient size (weight and body surface area), daily lithium dosage, age, gender, and race. When only the most significant variables, lean body weight and creatinine clearance, were retained, a final model was obtained that yielded a coefficient of variation for lithium clearance of about 24% and gave fairly accurate predictions of steady-state lithium concentrations (coefficient of variation, about 16%). It was concluded that analysis of lithium pharmacokinetics with the nonlinear mixed-effects model program suggested that lean body weight and creatinine clearance are important predictors of lithium clearance.', 'Lithium disposition in plasma, red blood cells and urine was studied in acute self-poisoned patient upon chronic lithium therapy (n=4) and in chronic intoxicated patients receiving oral lithium (n=10). Following acute intoxication upon chronic lithium therapy, lithium pharmacokinetics did not differ from previous reports. Terminal plasma half life ranged from 19.0-29.0 hr and RBC/plasma ratio was 0.32 +/- 0.11. the distribution volume of the terminal phase, Vz, was estimated at 0.84 +/- 0.32 L/kg and renal clearance was 0.38 +/- 0.11 ml/mn/kg. After chronic intoxication lithium pharmacokinetics differed from those of the acute patients. Terminal plasma half-life ranged from 36.5-79.4 hr and zero-order decline appeared in 8 of the 10 patients. The RBC/plasma ratio was 0.87 +/- 0.22 on admission. Vz was estimated at 0.71 +/- 0.27 L/kg and renal clearance was 0.16 +/- 0.07 ml/mn/kg. These modifications in lithium elimination kinetics could be related to the decrease in the glomerular filtration rate with age or renal dysfunction in this group of patients.', 'For more Absorption, Distribution and Excretion (Complete) data for LITHIUM CARBONATE (22 total), please visit the HSDB record page.']",['Lithium carbonate is not metabolized before excretion.'],"['The half life of lithium carbonate is 18 to 36 hours. Other sources say it may be 7 to 20 hours.', 'The plasma half-life is 17 to 36 hours.', 'The plasma half-life (in healthy volunteers) shows a considerable variability: from 5 to 40 hr, with most values between 15 and 30 hr, it depends on the duration of treatment as well as on kidney function and age. /Li+/', 'The usual elimination half-life is 12 to 27 hr, but it may rise to nearly 60 hr if renal excretion is compromised. /Li+/', '...  The elimination half-life averages 20 to 24 hr. /Li+/', 'For more Biological Half-Life (Complete) data for LITHIUM CARBONATE (9 total), please visit the HSDB record page.']"
1125,11126,2-Methylthiophene,CC1=CC=CS1,,,,,,
1126,11127,Phenobutiodil,CCC(C(=O)O)OC1=C(C=C(C=C1I)I)I,,,,,,
1127,11128,Linamarin,CC(C)(C#N)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,"['WISTAR RATS, ABOUT 100 G IN WEIGHT, WERE DOSED BY STOMACH TUBE WITH 30 MG OF PURE LINAMARIN (A MAJOR CYANOGENIC GLUCOSIDE IN CASSAVA). NO INTACT LINAMARIN WAS IDENTIFIED IN THE FECES OR BLOOD BUT 5.65 MG WAS EXCRETED IN THE URINE ALONG WITH 0.823 MG OF THIOCYANATE ION.', 'THE AMNIOTIC FLUIDS AND BLOOD SAMPLES OF 40 PREGNANT WOMEN WERE ANALYZED FOR THIOCYANATE. THE CONCENTRATION IN THE AMNIOTIC FLUIDS VARIED FROM 0.66-3.88 MMOL/L WHILE THOSE OF THE BLOOD SAMPLES VARIED FROM 0.70-2.80 MMOL/L. THE HIGHEST CONCENTRATIONS OCCURRED IN THE LOWER CLASS WHO EAT A LOT OF GARI (CASSAVA PUDDING), WHICH IS THE STAPLE DIET THAT CONTAINS THE CYANOGENIC GLYCOSIDE LINAMARIN. THE DETOXIFICATION PRODUCT, THIOCYANATE, SEEMS TO PENETRATE THE PLACENTAL BARRIER. THE IMPLICATION OF THIS IN THE ETIOLOGY OF GOITER AND CRETINISM WAS DISCUSSED.']","['THE BIOSYNTHESIS OF LINAMARIN FROM RADIOACTIVE VALINE OR ACETONE CYANOHYDRIN BY UDP-GLUCOSE-DEPENDENT KETONE CYANOHYDRIN GLUCOSYLTRANSFERASE IN FLAX SEEDLINGS WAS INHIBITED BY PREINCUBATION OF FLAX SEEDLINGS WITH ISOLEUCINE, THE PRECURSOR OF LOTAUSTRALIN.']",
1128,11129,"Norcarane, 7,7-dimethyl-3-methylene-",CC1(C2C1CC(=C)CC2)C,,,,,,
1129,11130,Triethylamine hydrochloride,CCN(CC)CC.Cl,,,,,,
1130,11131,CID 11131,C1=CC(=CC=C1C[As](=O)(O)[O-])NCC(=O)N.[Na+],,,,,,
1131,11132,CID 11132,C1=CC(=CC=C1C[As](=O)(O)O)NCC(=O)N,,,,,,
1132,11133,CID 11133,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=NC3=CC=C(C=C3)S(=O)(=O)[O-].[Na+],,,,,,
1133,11134,4-((4-(Anilino)phenyl)azo)benzenesulphonic acid,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=NC3=CC=C(C=C3)S(=O)(=O)O,,,,,,
1134,11135,Neostibosan,C1=CC(=CC=C1N)[Sb](=O)(O)O,,,,,,
1135,11136,Pcmbs,C1=CC(=CC=C1S(=O)(=O)O)[Hg]Cl,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Chemical agents that react with SH groups. This is a chemically diverse group that is used for a variety of purposes. Among these are enzyme inhibition, enzyme reactivation or protection, and labelling. (See all compounds classified as Sulfhydryl Reagents.)']",,,
1136,11137,3-Nitrophenol,C1=CC(=CC(=C1)O)[N+](=O)[O-],,,,"['The retention of radiolabeled 3-nitrophenol by various tissues of frog and crayfish following admin of 5 mg/kg via the lymph sac in frog and 3 mg/kg via pericardial injection in crayfish gradually decr in each organ except the gall bladder of the frog and the gut contents. In frogs, biliary excretion was minor compared with renal elimination, whereas in crayfish the gills represented the major route of excretion.', 'The permeation of nitrophenols through epidermal cells from newborn rat skin cultured on type IV collagen-coated Millipore filters was studied under various conditions. The order of permeation through the cultured skin cells was found to be p-> m- > o-nitrophenol at both 10 and approx 37 C. This order was the same as that of their affinities to isolated skin cells. The permeation of nitrophenols was not inhibited by the inhibitors of energy transduction 2-deoxyglucose and NaN3. These results suggest that the permeation of nitrophenols across a cultured cell layer occurs by simple diffusion. The order of permeation of nitrophenols across newborn abdominal epidermis was exactly the opposite of that of their permeation across a cultured cell layer.']","['Yields m-aminophenol, 4-nitrocatechol, m-nitrophenyl-beta-d-glucuronide, m-nitrophenyl sulfate, & nitroquinol in rabbit.', 'M-nitrophenyl-beta-d-glucoside in fly. Yields m-nitroanisole in guinea pig. /From table/', 'The metabolism of nitrobenzene in male Fischer-344 rats, CD rats, and B6C3F1 mice was examined. m-Nitrophenol was one of the metabolites which was excreted as the sulfate ester by Fischer-344 rats and sulfate ester and glucuronide by CD rats. B6C3F1 mice excreted the same metabolites (except the glucuronide of m-nitrophenol) in the urine as did CD rats and also excreted p-aminophenol sulfate. In all 3 animal strains, urinary excretion of nitrobenzene metabolites peaked 12-24 hr after oral admin of nitrobenzene.', 'In vivo studies with nitrophenols ... meta-& para-nitrophenol are reduced more readily than the ortho isomer ...', 'For more Metabolism/Metabolites (Complete) data for 3-NITROPHENOL (10 total), please visit the HSDB record page.']",
1137,11138,"1,3,5-Benzenetricarboxylic acid",C1=C(C=C(C=C1C(=O)O)C(=O)O)C(=O)O,,,,,,
1138,11139,N-Methylepinephrine,CN(C)CC(C1=CC(=C(C=C1)O)O)O,,,,,,
1139,11140,3-Nitroanisole,COC1=CC=CC(=C1)[N+](=O)[O-],,,,,,
1140,11141,CID 11141,C1=CC(=CC=C1C(=O)[O-])N.[Na+],,,,,,
1141,11142,beta-Phellandrene,CC(C)C1CCC(=C)C=C1,,,,,,
1142,11143,Aluminium isopropoxide,CC(C)[O-].CC(C)[O-].CC(C)[O-].[Al+3],,,,,,
1143,11144,Aluminum palmitate,CCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCC(=O)[O-].[Al+3],,,,,,
1144,11145,Neburon,CCCCN(C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
1145,11146,Tristearin,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC,,,,"['In the small intestine, most triglycerides are split into monoglycerides, free fatty acids, and glycerol, which are absorbed by the intestinal mucosa. Within the epithelial cells, resynthesized triglycerides collect into globules along with cholesterol and phospholipids and are encased in a protein coat as chylomicrons . Chylomicrons are transported in the lymph to the thoracic duct and eventually to the venous system. The chylomicrons are removed from the blood as they pass through the capillaries of adipose tissue. Fat is stored in adipose cells until it is transported to other tissues as free fatty acids which are used for cellular energy or incorporated into cell membranes.', 'When 14C-labeled long-chain triglycerides are administered intravenously, 25% to 30% of the radiolabel is found in the liver within 30 to 60 minutes, with less than 5% remaining after 24 hours. Lesser amounts of radiolabel are found in the spleen and lungs. After 24 hours, nearly 50% of the radiolabel has been expired in carbon dioxide, with 1% of the carbon label remaining in the brown fat. The concentration of radioactivity in the epididymal fat is less than half that of the brown fat.', 'The absorption of [1- 14C]tristearin was evaluated using groups consisting of six to seven male Wistar rats (weights =200 to 250 g). The rats were prepared either with an external bile fistula or a sham operation (control group), and then allowed to recover for 6 to 12 hours. Weighed doses of [1- 14C]tristearin were fed in a pellet of bran. Doses of 25, 50, 100, and 200 mg were administered to four groups, respectively. The rats were killed after 16 hours and lipid from the stomach, small gut, and colon (with feces) was extracted. Absorption was expressed as the percentage of the dose that had left the stomach. Only rats in which 80% or more of the dose had left the stomach were used. Tristearin absorption was classified as poor at all administered doses. Significantly lower absorption of tristearin was noted only in the 200 mg dose group ( p <.02, n=6)', 'Feeding expt with (14)C-labelled tristearin indicated that ruminal bacteria actively hydrogenated, degraded, and synthesized fatty acids. Stearic acid seemed to be absorbed from small intestine at slower rate than other fatty acids.']",['Hydrolysis of /Tristearin/ by hepatic triacylglycerol lipase in plasma from ICR mice has been demonstrated in vitro.'],
1146,11147,Tripalmitin,CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC,,,,,,
1147,11148,Trimyristin,CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC,,,,,,
1148,11149,N-(2-Aminophenyl)acetamide,CC(=O)NC1=CC=CC=C1N,,,,,,
1149,11150,Diphenylmagnesium,C1=CC=[C-]C=C1.C1=CC=[C-]C=C1.[Mg+2],,,,,,
1150,11151,Brocresine,C1=CC(=C(C=C1CON)O)Br,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
1151,11152,[6]-Shogaol;6-Shogaol,CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC,,,,,,
1152,11153,"Ethanol, aluminum salt",CC[O-].CC[O-].CC[O-].[Al+3],,,,,,
1153,11154,1-[(5-Nitrofuran-2-yl)methylideneamino]imidazolidin-2-one,C1CN(C(=O)N1)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1154,11155,Bis(p-chlorophenoxy)methane,C1=CC(=CC=C1OCOC2=CC=C(C=C2)Cl)Cl,,,,,,
1155,11156,2-Propylpiperidine hydrochloride,CCCC1CCCCN1.Cl,,,,,,
1156,11157,Benzylhydrazine,C1=CC=C(C=C1)CNN,,,,,,
1157,11158,4-Aminobenzaldehyde,C1=CC(=CC=C1C=O)N,,,,,,
1158,11159,Glyodin,CCCCCCCCCCCCCCCCCC1=NCCN1.CC(=O)O,,,,,,
1159,11160,Methyl isovalerate,CC(C)CC(=O)OC,,,,,,
1160,11161,Glycylglycylglycine,C(C(=O)NCC(=O)NCC(=O)O)N,,,,,,
1161,11162,"1,4-Cyclohexanediol",C1CC(CCC1O)O,,,,,,
1162,11163,Glycylglycine,C(C(=O)NCC(=O)O)N,,,,,,
1163,11164,Glycidol,C1C(O1)CO,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['The comparative disposition of glycidol was investigated in rats following oral (po) or intravenous (iv) administration at doses of 37.5 and 75 mg/kg. These were the doses used in the National Toxicology Program (NTP) oncogenicity study with glycidol. Approximately 87-92% of the dose was absorbed from the gastrointestinal tract of the rat. (14)C-Glycidol equivalents were eliminated in urine (40-48% of dose in 72 hr), feces (5-12%), and exhaled as CO2 (26-32%). At both doses, 9-12% and 7-8% (estimated) of the dose remained in tissues at 24 and 72 hr following dosing, respectively. In general, the concentrations of glycidol equivalents in tissues were proportional to the dose.  The highest concentrations of radioactivity were observed in blood cells, thyroid, liver, kidney, and spleen, and the lowest in adipose tissue, skeletal muscle, and plasma. The pattern of distribution of radioactivity in tissues was similar for both the iv and po routes. The total recovery of radioactivity ranged from 87 to 91% of dose. Urinary radioactivity was resolved by high-performance liquid chromatography (HPLC) analysis into 15 metabolites. There were one major (14-21% of the dose) and four lesser metabolites (each representing 2-8%); the others were minor, each representing 1% or less of the dose. In general, the urinary metabolic profile was similar following either iv or po administration at the two doses studied. Previous studies by other investigators suggested that alpha-chlorohydrin, which was presumably formed from glycidol by the HCl in the stomach, was metabolized and excreted in urine as beta-chlorolactic acid. The results of the present study show that very little, if any, urinary radioactivity coeluted with authentic beta-chlorolactic acid following either iv or po administration. Therefore, it is concluded that the conversion of glycidol to alpha-chlorohydrin is quantitatively insignificant. However, it may be significant with regard to glycidol reproductive toxicity. Also, the NTP oncogenicity study with glycidol was carried out within the dose range in which its disposition characteristics were linear.', 'Absorbed through skin.', 'Approximately 87-92% of 37.5 or 75 mg/kg body weight (bw) orally administered glycidol is absorbed from the gastrointestinal tract of male Fischer 344 rats. Seven to eight per cent of the dose remained in tissues 72 hr following administration. The highest concentrations of radioactivity were observed in blood cells, thyroid, liver, kidney and spleen.']","['Glycidol is rapidly hydrolyzed to glycerol (97.2%) and  alpha-chlorohydrin (3-chloro-1,2-propanediol, 2.8%) in 0.1 M hydrochloric acid, with a half-life of 10 min. At pH 7 or 8, glycidol readily reacts with glutathione to form S-(2,3-dihydroxypropyl)glutathione.', 'S-(2,3-Dihydroxypropyl)glutathione, S-(2,3-dihydroxypropyl)cysteine and beta-chlorolactic acid are the major metabolites isolated from rat urine after intraperitoneal administration of glycidol. The generation of beta-chlorolactic acid is presumably a result of initial formation of alpha-chlorohydrin, with subsequent oxidation by alcohol and aldehyde dehydrogenases. Glycidol is hydrolyzed to glycerol by rat liver microsomal preparations.', 'Liver epoxide hydrase converted glycidol to glycerol. Glycidol was a substrate for lung and liver cytosolic glutathione S-transferases.', '... The DNA damaging effects of 3-MCPD and its metabolites, glycidol and beta-chlorolactic acid, /were also studied/  in the in vitro comet assay on CHO cells. /The/ results show the absence of genotoxic potential of 3-MCPD in vivo in the target as well as in the non-target organs. Glycidol, the epoxide metabolite, induced DNA damages in CHO cells. beta-Chlorolactic acid, the main metabolite of 3-MCPD in rats, was shown to be devoid of DNA-damaging effects in vitro in mammalian cells.']",
1164,11165,Propylamine hydrochloride,CCCN.Cl,,,,,,
1165,11166,Allyl iodide,C=CCI,,,,,,
1166,11167,Methyl isothiocyanate,CN=C=S,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)']","['A study from the open literature determined the fate of radiolabeled metam and MITC following intraperitoneal injection of mice (Swiss-Webster, male). ... A mean value of 58% of the metam and 80% of the MITC was excreted in mouse urine by 48 hours. Feces, expired CO2 and carcass accounted for 6, 5 and 7.5% of the total metam dose, respectively, and 5, 4 and 6% of the total MITC dose in mice. Radioactive label was widely distributed among tissues. Liver, kidney and, interestingly, hair, accounted for the largest proportions of the tissue fraction for both metam and MITC....', 'Tissue content following MITC administration was highest in the thyroid at 168 hours, with liver, kidneys, whole blood and adrenals comprising relatively high secondary sites of accumulation. Female lungs at the high dose were also important sites. Total tissue levels at 168 hours did not exceed 2.3% of the administered dose of ... MITC at either the low or high doses.', 'The oral-exposure metabolism study compared the absorption, tissue distribution, and excretion of metam sodium and MITC. Rats were given radiolabeled metam sodium at 10 or 100 mg/kg, or MITC at 4.4 or 33 mg/kg by gastric gavage. Feces were collected at 24-hr intervals for up to 7 days. Expired air was collected at 24-hr intervals for up to 3 days, passing through a series of 3 traps capable of selectively capturing MITC, CO2 and carbonyl sulfide - CS2, respectively. ... MITC appeared to be even more readily taken up; by 24 hr 88-96% of the dose was absorbed, increasing to 94-100% by 168 hours.', 'The metabolism of methyl, ethyl, butyl and allyl isothiocyanate, which occur as glucosinolates in a number of plants, was studied. Oral administration of the substances to the rat was followed by their renal excretion as mercapturic acids, which were isolated as dicyclohexylamine salts. ... The mercapturic acids were very labile dithiocarbamidic acid esters, formed by the addition of the isothiocyanate group to the SH group of the cysteine component.']","['The metabolism of /several compounds, including/ ... methyl isocyanate ... in rats and mice using various carbon-14 (C-14) and carbon-13 (C-13)  labeled preparations was studied ... . Male  albino-Swiss-Webster-mice were treated intraperitoneally with C-14 labeled compounds at 0.05  millimolar/kilogram body weight. Urine, feces, and carbon-dioxide were collected and the mice  were sacrificed at 6, 24, or 48 hours for tissue analysis. Male Sprague-Dawley-rats were  treated intraperitoneally with C-14 labeled compounds as for mice, and with C-13 labeled  compounds orally, intraperitoneally, and intraperitoneally with cannulation with ...  33mg/kg MITC...  in mice, most of the C-14 labeled  compounds were in the urine, with a small portion in the body.  S-(N-methyl-thiocarbonyl)glutathione was a major metabolite in the urine. In rats, the major  metabolites were S-(N-methyl-thiocarbonyl)glutathione in bile and  S-(N-methyl-thiocarbonyl)mercapturic-acid in the urine ... . Glutathione detoxification involved direct reaction for MITC,  glutathione-S-transferase catalyzed reaction for metham... .']",
1167,11168,Methyl thiocyanate,CSC#N,,,,,"['ENZYMES IN THE LIVER AND PERHAPS OTHER ORGANS ARE KNOWN TO LIBERATE CYANIDE ION FROM METHYL...THIOCYANATE... GLUTATHIONE S-TRANSFERASE CATALYZES THE ATTACK OF REDUCED GLUTATHIONE @ THIOCYANATE SULFUR, RESULTING IN LIBERATION OF HYDROGEN CYANIDE, OXIDIZED GLUTATHIONE & THE MERCAPTAN MOIETY OF THE ORGANOTHIOCYANATE.', 'METHYL THIOCYANATE UP TO 5 MMOL REDUCED THE HYDROGEN ION SECRETION OF BULLFROG, RANA CATESBEIANA, GASTRIC MUCOSA WITHOUT EXHIBITING ANY APPRECIABLE INHIBITORY EFFECT ON MICROSOMAL ATPASE ACTIVITY. NO CONVERSION OF METHYL THIOCYANATE TO THIOCYANATE ION, A POTENT INHIBITOR OF GASTRIC ACID SECRETION, WAS DEMONSTRATED IN THE GASTRIC MUCOSA.']",
1168,11169,Octamethylcyclotetrasiloxane,C[Si]1(O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)C,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']","['Inhalation of octamethylcyclotetrasiloxane (D4) induces CYP2B1/2 protein and causes liver enlargement. We have developed a pharmacodynamic (PD) extension to a physiologically based pharmacokinetic (PBPK) model to characterize these dose-response behaviors. The PD model simulates interactions of D4 with a putative receptor, leading to increased production of cytochrome P450 2B1/2. Induction was modeled with a Hill equation with dissociation constant, Kd, and Hill coefficient, N. Both a 1- and a 5-compartment liver model were evaluated. The PBPK model provided excellent simulations of tissue D4 and hepatic CYP2B1/2 protein concentrations following 6 hr/day, 5-day inhalation exposures to 0, 1, 7, 30, 70, 150, 300, 500, 700, or 900 ppm D4. Either the 1- or 5-compartment liver model could accurately simulate increases in CYP2B1/2 protein in the liver. With a 1-compartment liver, Kd and N were 0.67 uM (free liver concentration) and 1.9, respectively. The 5-compartment model used higher N-values (approximately 4.0) and varied Kd between compartments. The fitted 5-compartment model parameters were Kd = 0.67 uM in the midzonal compartment with geometric differences in Kd between compartments of 2.9. On the basis of unbound (free) plasma concentrations, D4 appeared to be a higher potency inducer than phenobarbital (PB). Dose-response curves for increased liver weights had N/mS 1.0 and Kd/mS 3.4 uM, very different values from those for enzyme induction. Exposure concentration leading to a 0.1% increase in CYP2B1/2 protein predicted by the 1- and 5-compartment models were 2.1 ppm and 5.1 ppm, respectively. The 1- and 5-compartment liver models provided very similar fits to the whole liver induction data, excluding the lowest dose, but the 5-compartment liver model had the additional advantage of simultaneously describing the regional induction of CYP2B1/2.', '... The aim of this study was to quantify cyclic volatile methylsiloxanes (cVMS) in blood plasma of pregnant and postmenopausal women, and to investigate possible links to self-reported use of PCPs for the latter group. Participants were recruited from two studies, namely the Norwegian Women and Cancer Study (NOWAC) and the North Norwegian Mother-and-child Study (MISA). For the NOWAC cohort, 94 plasma samples from postmenopausal women were analyzed (blood drawn in 2005) and information about PCP use and breast implants was derived from a self-administered questionnaire. In the MISA study, the collection of the plasma samples (blood drawn in 2009) constituted a re-sampling because the original serum vacutainers used were contaminated with cVMS. D4 (octamethylcyclotetrasiloxane) was the dominant compound in plasma for both cohorts. For the NOWAC samples, more than 85% of the women had D4 concentrations above the LOQ (2.74 ng/mL), while the detection frequency was only 18% for the MISA participants. The highest cVMS plasma concentrations were observed for D4: 12.7 ng/mL (NOWAC) and 2.69 ng/mL (MISA). For the other cVMS, decamethylcyclopentasiloxane (D5) and dodecamethylcyclohexasiloxane (D6) concentrations were below the detection limit in most samples. There was no significant correlation between the concentrations of D4 and the reported total body cream use. Sampling time (2005 versus 2009) and age of the donors could explain the differences between the two cohorts.', 'Octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) are cyclic siloxanes used as chemical intermediates with some applications in consumer products. The in vitro percutaneous absorption of (14)C-D4 and (14)C-D5 was studied in flow-through diffusion cells. Single doses were applied neat and in antiperspirant formulations to dermatomed human skin for 24 hr. The majority of applied D4 and D5 (approximately 90%) volatilized before being absorbed. Only 0.5% of applied D4 was absorbed while the absorption of D5 (0.04%) was one order of magnitude lower. The largest percentage (>90%) of the absorbed D4 and D5 was found in the skin. The fate of D4 and D5 absorbed in the skin was studied in rat in vivo. A single dose of (14)C-D4 (10, 4.8 and 2 mg/sq cm) and (14)C-D5 (10 mg/sq cm) was topically applied inside a dosing chamber attached to the dorsal area. Rats were housed in metabolism cages up to 24 hr to enable collection of urine, feces, expired/escaped volatiles. The majority of applied D4 or D5 had volatilized from the skin surface. Less than 1.0% of the applied D4 and only 0.2% of applied D5 was absorbed with approximately 60% of absorbed D4 and 30% of absorbed D5 reaching systemic compartments. The amount absorbed into the skin decreased with time showing that residual D4 and D5 diffused back to the skin surface and continued to evaporate. Overall, a low tendency to pass through the skin into systemic compartments was demonstrated for both D4 (< or = 0.5% of applied dose) and D5 (<0.1% of applied dose).', 'There is potential for human exposure to cyclic siloxanes by the respiratory route. To determine the pharmacokinetics of octamethylcyclotetrasiloxane (D4), a material commonly found in personal care products, the respiratory intake and uptake of D4 were measured in 12 healthy volunteers (25-49 years) on two occasions. Subjects inhaled 10 ppm D4 (122 micrograms/liter) or air (control) during a 1-hr exposure via a mouthpiece in a double-blind, randomized fashion. Inspiratory and expiratory D4 concentrations were continuously measured. Exhaled air and plasma D4 levels were measured before, during, and after exposures. Individual D4 uptakes were measured under steady-state conditions during three rest periods (10, 20, and 10 min, respectively) alternating with two 10-min exercise periods. Mean D4 intake was 137 +/- 25 mg (SD) and the mean deposition efficiency was equivalent to 0.74/(1 + 0.45 VE), where VE is the minute ventilation. No changes in lung function were induced by the D4 vapor. Plasma measurements of D4 gave a mean peak value of 79 +/- 5 ng/g (SEM) and indicated a rapid nonlinear blood clearance. Using lung volume and respiratory surface area estimates based on functional residual capacity measurements, we developed a model and determined that the effective mass transfer coefficient for D4 was 5.7 x 10(-5) cm/s from lung air to blood. In an additional eight subjects, we compared D4 deposition with mouthpiece and nasal breathing at resting ventilations. For these individuals, mean deposition was similar for the two exposure protocols, averaging 12% after correction for exposure system losses. These are the first data describing the intake and absorption of D4 and they should contribute to a meaningful safety assessment of the compound.', 'For more Absorption, Distribution and Excretion (Complete) data for OCTAMETHYLCYCLOTETRASILOXANE (20 total), please visit the HSDB record page.']","['In a recent pharmacokinetic study, six human volunteers were exposed by inhalation to 10 ppm (14)C-D4 for 1 hr during alternating periods of rest and exercise. Octamethylcyclotetrasiloxane (D4) concentrations were determined in exhaled breath and blood. Total metabolite concentrations were estimated in blood, while the amounts of individual metabolites were measured in urine. Here, we use these data to develop a physiologically based pharmacokinetic (PBPK) model for D4 in humans. Consistent with PBPK modeling efforts for D4 in the rat, a conventional inhalation PBPK model assuming flow-limited tissue uptake failed to adequately describe these data. A refined model with sequestered D4 in blood, diffusion-limited tissue uptake, and an explicit pathway for D4 metabolism to short-chain linear siloxanes successfully described all data. Hepatic extraction in these volunteers, calculated from model parameters, was 0.65 to 0.8, i.e., hepatic clearance was nearly flow-limited. The decreased retention of inhaled D4 seen in humans during periods of exercise was explained by altered ventilation/perfusion characteristics during exercise and a rapid approach to steady-state conditions. The urinary time course excretion of metabolites was consistent with a metabolic scheme in which sequential hydrolysis of linear siloxanes followed oxidative demethylation and ring opening. The unusual properties of D4 (high lipophilicity coupled with high hepatic and exhalation clearance) lead to rapid decreases in free D4 in blood. The success of D4 PBPK models with a similar physiological structure in both humans and rats increases confidence in the utility of the model for predicting human tissue concentrations of D4 and metabolites during inhalation exposures.', 'Octamethylcyclotetrasiloxane (D4) is an industrial chemical of significant commercial importance. In this study, its major urinary metabolites were identified. The urine samples described here were collected from male and female Fischer rats (F-344) administered [(14)C]D4 i.v. The metabolite profile was obtained using an HPLC system equipped with a radioisotope detector. HPLC analysis was performed on a C18 column, using an acetonitrile/water mobile phase. The HPLC radiochromatogram revealed two major and at least five minor metabolites. The two major metabolites, constituting 75 to 85% of the total radioactivity, were identified as dimethylsilanediol [Me(2)Si(OH)(2)] and methylsilanetriol [MeSi(OH)(3)]. Formation of MeSi(OH)(3) clearly established demethylation at the silicon-methyl bonds of D4. No parent D4 was present in urine. The minor metabolites identified were tetramethyldisiloxane-1,3-diol [Me(2)Si(OH)-O-Si(OH)Me(2)], hexamethyltrisiloxane-1,5-diol [Me(2)Si(OH)-OSiMe(2)-OSi(OH)Me(2)], trimethyldisiloxane-1,3,3-triol [MeSi(OH)(2)-O-Si(OH)Me(2)], dimethyldisiloxane-1,1,3,3-tetrol [MeSi(OH)(2)-O-Si(OH)(2)Me], and dimethyldisiloxane-1,1,1,3,3-pentol [Si(OH)(3)-O-Si(OH)(2)Me]. The structural assignments were based on gas chromatography-mass spectrometry analysis of the tetrahydrofuran metabolite extracts, which were derivatized using bis(trimethylsiloxy)triflouroacetamide, a trimethylsilylating agent. The structures were confirmed by synthesizing (14)C-labeled standards and comparing their HPLC radiochromatograms with the corresponding components in the rat urine. GC-MS spectral comparisons of the trimethylsilylated derivatized standards and urinary components also were made to further confirm their identities. Finally, several of the urinary metabolites were fractionated using HPLC, and GC-MS comparisons were again made for positive structural identification. The pathways for metabolite formation are not yet understood, but a mechanistic hypothesis has been proposed to account for the various metabolites observed thus far.', 'The retention, distribution, metabolism, and excretion of (14)C-octamethylcyclotetrasiloxane (D4) were studied in Fischer 344 rats after single and multiple exposures to 7, 70, or 700 ppm (14)C-D(4). ... Urinary metabolites included dimethylsilanediol and methylsilanetriol plus five minor metabolites. Relative abundance of these metabolites was the same from every test group.', 'Cytochrome P450 has been shown to catalyze the demethylation of octamethylcyclotetrasiloxane, which is an example of Si-demethylation ...']",
1169,11170,Hexadecamethylcyclooctasiloxane,C[Si]1(O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)C,,,,,,
1170,11171,Octadecamethyloctasiloxane,C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,,,,,,
1171,11172,Octadecamethylcyclononasiloxane,C[Si]1(O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O[Si](O1)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)(C)C)C,,,,,,
1172,11173,3-Methyl-2-buten-1-OL,CC(=CCO)C,,,,,,
1173,11174,2-Nitroguanidine,C(=N[N+](=O)[O-])(N)N,,,,,,
1174,11175,"4(5H)-Thiazolone, 2-amino-",C1C(=O)N=C(S1)N,,,,,,
1175,11176,Propyl isovalerate,CCCOC(=O)CC(C)C,,,,,,
1176,11177,Magnesium stearate,CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Mg+2],,,,,,
1177,11178,ZINC stearate,CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Zn+2],,,,"['In humans with no excessive intake of zinc, the body burden half-time of absorbed radio-labelled zinc has been observed to range from 162 to 500 days. After parenteral administration of 65Zn2+, half-times ranged from 100 to 500 days. /Zinc ions/', 'Within certain limits, mammals can maintain the total body zinc and the physiologically required levels of zinc in the various tissues constant, both at low and high dietary zinc intakes. The sites of regulation of zinc metabolism are: absorption of Zn2+ from the gastrointestinal tract, excretion of zinc in urine, exchange of zinc with erythrocytes, release of zinc from tissue, and secretion of zinc into the gastrointestinal tract. Regulation of gastrointestinal absorption and gastrointestinal secretion probably contributes the most to zinc homeostasis. /Zinc ions/']",['Zinc is mostly bound to organic ligands rather than free in solution as a cation. Zinc is found in diffusible and non-diffusible forms in the blood and about 66% of the diffusible form of zinc in the plasma is freely exchangeable and loosely bound to albumin. A small amount of the non-diffusible form of zinc is tightly bound to 2-macroglobulin in the plasma and is not freely exchangeable with other zinc ligands. Zinc is incorporated into and dissociated from alpha2-macroglobulin only in the liver. /Zinc ions/'],"['For zinc, whole body: 162-500 days; [TDR, p. 1245]', 'In humans with no excessive intake of zinc, the body burden half-time of absorbed radio-labelled zinc has been observed to range from 162 to 500 days. After parenteral administration of 65Zn2+, half-times ranged from 100 to 500 days. /Zinc ions/']"
1178,11179,ZINC undecylenate,C=CCCCCCCCCC(=O)[O-].C=CCCCCCCCCC(=O)[O-].[Zn+2],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
1179,11180,Zinc caprylate,CCCCCCCC(=O)[O-].CCCCCCCC(=O)[O-].[Zn+2],,,,,,
1180,11181,Allylurea,C=CCNC(=O)N,,,,,,
1181,11182,Methyl propyl ether,CCCOC,,,,,,
1182,11183,"Magnesium, diethyl-",C[CH2-].C[CH2-].[Mg+2],,,,,,
1183,11184,Dicyanonickel,[C-]#N.[C-]#N.[Ni+2],,,,,,
1184,11185,Diethylzinc,C[CH2-].C[CH2-].[Zn+2],,,,,,
1185,11186,ZINC cyanide,[C-]#N.[C-]#N.[Zn+2],,,,"['IN 30 DAYS, 72% OF (14)C FROM IP DOSE OF (14)C-CYANIDE TO MICE WAS EXCRETED IN URINE & FECES, 25% IN EXPIRED AIR, & 3% WAS RETAINED ... PEAK EXCRETION OCCURRED WITHIN 10 MIN IN EXPIRED AIR & WITHIN 6-24 HR IN URINE & FECES. /CYANIDE/', 'THE CYANIDE ION IS READILY ABSORBED AFTER ORAL OR PARENTERAL ADMIN. PROLONGED LOCAL CONTACT WITH CYANIDE SOLN OR WITH HYDROGEN CYANIDE MAY RESULT IN ABSORPTION OF TOXIC AMT THROUGH SKIN. PART OF ABSORBED CYANIDE IS EXCRETED UNCHANGED BY THE LUNG. LARGER PORTION ... CONVERTED BY THE ENZYME SULFURTRANSFERASE TO RELATIVE NONTOXIC THIOCYANATE ION. /CYANIDE/', 'CYANIDES ARE RAPIDLY ABSORBED FROM SKIN AND ALL MUCOSAL SURFACES & ARE MOST DANGEROUS WHEN INHALED, BECAUSE TOXIC AMT ARE ABSORBED THROUGH BRONCHIAL MUCOSA & ALVEOLI. /CYANIDES/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. Presumably, the accumulation of cyanide in erythrocytes is a reflection of its binding to methemoglobin. /Cyanide/', 'For more Absorption, Distribution and Excretion (Complete) data for ZINC CYANIDE (8 total), please visit the HSDB record page.']","['... CYANIDE ION IS CONJUGATED WITH SULFUR TO FORM THIOCYANATE. ... CONJUGATION IS CATALYZED BY ... RHODANESE WHICH IS WIDELY DISTRIBUTED IN MOST ANIMAL TISSUES ... /LIVER/ PARTICULARLY ACTIVE. ... RHODANESE MECHANISM IS CAPABLE OF DETOXICATING ONLY LIMITED AMT OF CYANIDE, SUCH AS ARE FORMED DURING NORMAL METAB. /ANOTHER SULFUR DONOR IS 3-MERCAPTOPYRUVATE. THE ENZYME, MERCAPTOSULFUR TRANSFERASE IS LOCALIZED IN CYTOSOL./ /CYANIDE/', '/ONE OF/ THE MAJOR MECHANISM/S/ FOR REMOVING CYANIDE FROM THE BODY IS ITS ENZYMATIC CONVERSION, BY THE MITOCHONDRIAL ENZYME RHODANESE (TRANSSULFURASE), TO THIOCYANATE, WHICH IS RELATIVELY ... /LESS TOXIC/. /CYANIDE/']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
1186,11187,Maleic acid monoamide,C(=CC(=O)O)C(=O)N,,,,,,
1187,11188,"Butanoic acid, 2,3-dihydroxypropyl ester",CCCC(=O)OCC(CO)O,,,,,,
1188,11189,ZINC propionate,CCC(=O)[O-].CCC(=O)[O-].[Zn+2],,,,"['Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/']",,
1189,11190,CID 11190,C(=CN=O)NO,,,,,,
1190,11191,Allyl ethyl ether,CCOCC=C,,,,,,
1191,11192,ZINC acetate,CC(=O)[O-].CC(=O)[O-].[Zn+2],"['Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections.']","['Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations.  Studies on oral zinc for specific conditions shows the following evidence in various conditions:  **Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently.  **Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements.   **Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition.']",,"['Zinc is absorbed in the small intestine by a carrier-mediated mechanism. Under regular physiologic conditions, transport processes of uptake do not saturate. The exact amount of zinc absorbed is difficult to determine because zinc is secreted into the gut. Zinc administered in aqueous solutions to fasting subjects is absorbed quite efficiently (at a rate of 60-70%), however, absorption from solid diets is less efficient and varies greatly, dependent on zinc content and diet composition.    Generally, 33% is considered to be the average zinc absorption in humans. More recent studies have determined different absorption rates for various populations based on their type of diet and phytate to zinc molar ratio. Zinc absorption is concentration dependent and increases  linearly with  dietary zinc up to a maximum rate.  Additionally zinc status may influence zinc absorption. Zinc-deprived humans absorb this element with increased efficiency, whereas humans on a high-zinc diet show a reduced efficiency of absorption.', 'The excretion of zinc through gastrointestinal tract accounts for approximately one-half of all zinc eliminated from the body.   Considerable amounts of zinc are secreted through both biliary and intestinal secretions, however most is reabsorbed. This is an important process in the regulation of zinc balance. Other routes of zinc excretion include both urine and surface losses (sloughed skin, hair, sweat).   Zinc has been shown to induce intestinal metallothionein, which combines zinc and copper in the intestine and prevents their serosal surface transfer. Intestinal cells are sloughed with approximately a 6-day turnover, and the metallothionein-bound copper and zinc are lost in the stool and are thus not absorbed.  Measurements in humans of endogenous intestinal zinc have primarily been made as fecal excretion; this suggests that the amounts excreted are responsive to zinc intake, absorbed zinc and physiologic need.  In one study, elimination kinetics in rats showed that a small amount of ZnO nanoparticles was excreted via the urine, however, most of the nanoparticles were excreted via the feces.', 'A pharmacokinetic study was done in rats to determine the distribution and other metabolic indexes of zinc in two particle sizes.  It was found that zinc particles were mainly distributed to organs including the liver, lung, and kidney within 72 hours without any significant difference being found according to particle size or rat gender.', 'In one study of healthy patients, the clearance of zinc was found to be 0.63  0.39 g/min.', 'Zinc salts are not equal in solubility, which is important in zinc absorption. The solubility of zinc salts is affected by gastric pH. Healthy subjects were given a single oral dose of 50 mg elemental zinc as the acetate ... under either high (pH > 5) or low (pH < 3) intragastric pH conditions. The mean plasma zinc area under the curve for zinc acetate at low pH (AL) /and/ ... at high pH (AH) ... were 524 /and/ 378 ... ug/hr/dL ...', 'Absorption /of zinc acetate/  by the GI tract is variable in animals and poor in humans. Accumulation occurred in the liver and pancreas. Some regulation of intake and output of zinc probably takes place in the intestines. In rats and mice, metallothionein, a low-molecular-mass cytoplasmic metalloprotein, takes considerable part in this process. Excreted predominantly with feces. Urinary excretion is negligible.', 'In a study with human volunteers, most of the zinc in a zinc acetate solution (0.1 mmol/L) administered by intestinal perfusion was absorbed from the jejunum, followed by the duodenum and the ileum (357, 230 or 84 nmol/ liter per min per 40 cm respectively). The absorption showed a linear increase at concentrations of 0.1- 1.8 mmol/ L.', 'The absorption of zinc from soluble zinc acetate, zinc sulfate ... and insoluble zinc oxide was compared in ten human volunteers who were dosed orally with 50 mg Zn in various forms separated by two weeks intervals. Bioavailability of zinc from the various forms was compared on the basis of plasma zinc levels and area under the plasma curve (AUC) analysis. Plasma peak levels were observed after about 2.5 hours for all forms, but maximal plasma Zn concentration amounted to 221 and 225 ug/dL for the acetate and the sulphate form while the peak plasma level for Zn from the oxide was only 159 ug/dL. When AUC values for the different zinc forms were compared, it appeared that the bioavailability of zinc oxide was about 60% of the bioavailability of the soluble forms. /Zinc salts/']","['Zinc is released from food as free ions during its digestion. These freed ions may then combine with endogenously secreted ligands before their transport into the enterocytes in the duodenum and jejunum.. Selected transport proteins may facilitate the passage of zinc across the cell membrane into the hepatic circulation. With high intake, zinc may also be absorbed through a passive paracellular route.   The portal system carries absorbed zinc directly into the hepatic circulation, and then it is released into systemic circulation for delivery to various tissues. Although, serum zinc represents only 0.1% of the whole body zinc, the circulating zinc turns over rapidly to meet tissue needs.']",['The half-life of zinc in humans is approximately 280 days.']
1192,11193,2-Iodooctane,CCCCCCC(C)I,,,,,,
1193,11194,Allyl ether,C=CCOCC=C,,,,,,
1194,11195,ZINC formate,C(=O)[O-].C(=O)[O-].[Zn+2],,,,"['Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/']",,
1195,11196,"2,6-Nonadienal",CCC=CCCC=CC=O,,,,,,
1196,11197,Tetracosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
1197,11198,Ethylamine hydrochloride,CCN.Cl,,,,,,
1198,11199,Polyvinyl alcohol,C=CO,['For use as a lubricant to prevent further irritation or to relieve dryness of the eye(s).'],['Temporarily relieves burning and irritation due to dryness of the eye or from exposure to wind or sun. Lubricates the eyes and helps protect against further eye irritation/dryness.'],,"['Polyvinyl alcohol is poorly absorbed from gastrointestinal tract, and readily eliminated from the body.', 'This drug does not accumulate in the body when administered orally.', 'The fate of poly(vinyl alcohol) (PVA, 195,000 g/mol) was studied in rabbits and nude mice after intraperitoneal (i.p.) administration. In-vivo fluorescence imaging using nude mice allowed for studies of tetramethylrhodamine labeled PVA distribution in the body and tracking the urinary excretion. The excreted PVA was studied in detail after collecting the urine of rabbits over a time period of 28 days. The PVA was separated from the urine by dialysis and analyzed by FTIR spectroscopy, (1)H-NMR spectroscopy, and size exclusion chromatography (SEC). Even after extensive dialysis, it was found that the excreted PVA showed a characteristic brownish color. The spectroscopic techniques revealed that this color was caused by the urine pigment (a metabolite of bilirubin) that could not be separated completely from the PVA. SEC showed unambiguously that the PVA with the very high molar mass had a glomerular permeability in the kidneys. Simultaneously, histological studies of the kidneys and the liver demonstrated that the tissues did not show any obvious damage.', 'Polyvinyl alcohol (PVA) is a polymer with a wide range of molecular weights and uses. Recently, low molecular weight formulations of PVA have been used as components of contraceptive products designed for intravaginal administration in human females. Previous studies in animals have determined that little or no absorption of PVA occurs from the gastrointestinal (GI) tract. However, there is some concern that PVA of lower molecular weights might be absorbed across membranes of the reproductive tract. Consequently, this work has investigated the absorption of low molecular weight PVA across biological membranes of the reproductive and GI tracts of Fischer 344 rats. Oral administration of ten consecutive daily doses of (14)C PVA resulted in little apparent absorption of the dose from the GI tract. In contrast, intravaginal administration of (14)C PVA resulted in increasing concentrations of PVA-derived radioactivity in major tissues following one, three or ten daily doses of the estimated human dose of 3 mg/kg. PVA-derived radioactivity was concentrated mainly in the liver, reaching a peak greater than 1750 ng equivalents/g tissue 24 hours following ten daily doses. Over 300 ng equivalents/g tissue were still present in the liver 30 days following the last dose.', '/Researchers/ report on the distribution of PVA of low (mol. wt 37,000), medium (mol. wt 133,000) and high (mol. wt 195,000) grades following 4 weeks of daily subcutaneous injection of 1 mL of 5% solutions to female Holtzman rats. Polymers of medium and high molecular weights were found in the tissues of the adrenal medulla, spleen, myocardium, liver and kidney. Low molecular weight polymers were not found in any tissues.', 'PVA sponges (Ivalon) implanted into guinea pigs or rats appeared to disintegrate or deform, suggestive of phagocytosis by macrophages and giant cells or resorption, but there was no indication of the ultimate fate of the sponges or the cellular PVA. Therefore it would seem that while subcutaneously injected PVA may undergo bioaccumulation and implanted PVA undergo partial resorption, intravenous or orally administered PVA is quickly eliminated.', 'For more Absorption, Distribution and Excretion (Complete) data for POLYVINYL ALCOHOL (7 total), please visit the HSDB record page.']",,"['When injected intravenously, polyvinyl alcohol has a half-life of 90 min.  Intraocularly, in eye drop form, the half-life is 7.2 minutes.']"
1199,11200,Chlorodimethylarsine,C[As](C)Cl,,,,,,
1200,11201,"1,1-Dibromoethane",CC(Br)Br,,,,,,
1201,11202,2-Bromopropene,CC(=C)Br,,,,,,
1202,11203,2-Chloropropene,CC(=C)Cl,,,,,,
1203,11204,Acetyl fluoride,CC(=O)F,,,,,,
1204,11205,Carbon tetrabromide,C(Br)(Br)(Br)Br,,,,,"['UNDER ANAEROBIC REDUCING CONDITIONS POLYHALOGENATED METHANES, CBR4, FORM COMPLEXES WITH FERROUS CYTOCHROME P450. CARBON MONOXIDE DETECTED AS A METABOLIC PRODUCT OF THE INTERACTION.', 'Carbon tetrabromide is metabolized in vitro to produce carbon monoxide but the in vivo significance has not been established.']","['For bromide (depends on compound and route of administration) whole body: 1 hour to 12 days; [TDR, p. 214]']"
1205,11206,tert-Butyl iodide,CC(C)(C)I,,,,,,
1206,11207,Methanesulfonyl fluoride,CS(=O)(=O)F,,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)']",,,
1207,11208,"2,2-Dimethyloxirane",CC1(CO1)C,,,,,,
1208,11209,Tetramethylammonium hexafluorophosphate,C[N+](C)(C)C.F[P-](F)(F)(F)(F)F,,,,,,
1209,11210,"3,3-Dimethyl-1-butene",CC(C)(C)C=C,,,,,,
1210,11211,"1,1-Dihydroperfluoroheptyl acrylate",C=CC(=O)OCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
1211,11212,Octafluorocyclopentene,C1(=C(C(C(C1(F)F)(F)F)(F)F)F)F,,,,,,
1212,11213,CID 11213,CC1C[C@@]23[C@]14[C@@H]5C[C@H]([C@H]2CCCN3C[C@@H]6[C@H]4O6)OC5=O,,,,,,
1213,11214,psi-Caudoside,CC1[C@H](C(C[C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3C(=O)[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)OC)O,,,,,,
1214,11215,"2,3,3-Trimethylpentane",CCC(C)(C)C(C)C,,,,,,
1215,11216,"2,3,3-Trimethyl-1-pentene",CCC(C)(C)C(=C)C,,,,,,
1216,11217,"7-(Acetyloxy)-4,14,16,20-tetrahydroxy-3-[(2-methylbutanoyl)oxy]-4,9-epoxycevan-15-yl 2-hydroxy-2-methylbutanoate",CCC(C)C(=O)O[C@H]1CC[C@]2(C3[C@@]1(O[C@@]24CC5C6CN7C[C@H](CC[C@H]7[C@@](C6[C@H]([C@@H]([C@]5(C4[C@@H](C3)OC(=O)C)O)OC(=O)C(C)(CC)O)O)(C)O)C)O)C,,,,,,
1217,11218,"(3S,5S,10S,13R,14S,17R)-3-[(2R,5R)-6-[[(3R,6S)-4,6-dihydroxy-2-methyloxan-3-yl]oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@@H](C(C[C@H](O1)O)O)OCC2[C@H](C(C([C@@H](O2)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)O)OC)O,,,,,,
1218,11219,"3-[(3S,5S,10R,13R,14S,17R)-3,5,14-trihydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)CO)O,,,,,,
1219,11220,Bromotrinitromethane,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])Br,,,,,,
1220,11221,CID 11221,CC(=O)O[C@H]1CC[C@H]2[C@@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C,,,,,,
1221,11222,18-Hydroxycorticosterone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)CO)O,,,,,,
1222,11223,Chlorphenoxamine hydrochloride,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C.Cl,,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']",,,
1223,11224,Doxylamine succinate,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C.C(CC(=O)O)C(=O)O,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
1224,11225,Bufotalinin,C[C@]12CCC3C([C@@]14[C@H](O4)C[C@@H]2C5=COC(=O)C=C5)CC[C@]6([C@@]3(CC[C@@H](C6)O)C=O)O,,,,,,
1225,11226,Phenoperidine,CCOC(=O)C1(CCN(CC1)CCC(C2=CC=CC=C2)O)C3=CC=CC=C3,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
1226,11227,"P'-Amidodiphosphoric(III,V) acid, diethyl-, P,P-diethyl P'-methyl ester",CC[N+](CC)(P(OCC)OCC)P(=O)([O-])OC,,,,,,
1227,11228,Diethoxyphosphanyl-diethyl-[hydroxy(methoxy)phosphoryl]azanium,CC[N+](CC)(P(OCC)OCC)P(=O)(O)OC,,,,,,
1228,11229,"3,3-Dimethylpentane",CCC(C)(C)CC,,,,,,
1229,11230,4-Carvomenthenol,CC1=CCC(CC1)(C(C)C)O,,,,"['The terpenes disturb lipid arrangement in the intercellular region of the stratum corneum (SC) that leads to the increased permeability of the skin. This effect is used in technology of transdermal drug forms and depends on physicochemical properties of terpenes and their amounts penetrated to the stratum corneum; however terpenes do not need penetrate into viable skin tissue and this event is not even desired.  To correlate skin absorption and elimination kinetics of four cyclic terpenes, namely alpha-pinene, beta-pinene, eucalyptol and terpinen-4-ol, applied as neat substance with their physicochemical properties.  The terpenes were applied onto the human skin in vitro, and after 1-4 h their content in the separated by a tape-stripping method stratum corneum layers and in the epidermis/dermis was determined using GC. Similarly, the amounts of terpenes in the skin were analysed during 4 h following 1 h absorption.  The fastest and progressive penetration into all skin layers was observed for terpinen-4-ol. All studied terpenes are absorbed in the viable epidermis/dermis, however penetration into this layers is time-dependent process, constantly increasing during 4 h. Like for stratum corneum, the largest cumulation in epidermis/dermis was observed for terpinen-4-ol. The elimination of terpenes from the stratum corneum was fast, especially in deeper layers, and much faster if the initial cumulation was small.  Investigated cyclic terpenes represent different penetration and elimination characteristics and do not permeate across the skin to the acceptor medium due to large cumulation in the skin tissue. The penetration of terpenes into stratum corneum is greater if their log P-value is close to 3.', ""The purpose of this study was to evaluate the in vitro cutaneous penetration of five terpenes--linalool, linalyl acetate, terpinen-4-ol, citronellol and alpha-pinene--applied in pure essential oils or in dermatological formulations (o/w emulsion, oily solution or hydrogel) containing 0.75 % w/w of the essential oils. Different skin absorption was observed depending on the type of the vehicle and terpenes' log P values. Cutaneous accumulation of terpenes is several times higher when they are applied in pure essential oils than in topical vehicles. Penetration of terpinen-4-ol to the skin was better from an oily solution (approximately 90 ug/cm (2)) than from an emulsion (60 ug/cm (2)). No penetration of linalyl acetate from topical vehicles into viable skin was observed, but also for this terpene penetration to the upper layers of the stratum corneum was 2-times higher when an oily solution was used. In contrast, the cutaneous absorption of linalool was the same from both vehicles (50-60 ug/cm (2)). The skin penetration of alpha-pinene was not traceable when it was applied in an oily solution. Only a small amount (approximately 5 ug/cm (2)) of this terpene was determined in viable skin after application as a hydrogel. Citronellol applied in a hydrogel penetrated into all skin layers in a total amount of 25 ug/cm (2), while no penetration into viable skin layers after application of an oily solution was noted. Only citronellol permeated into the acceptor medium."", 'This work aimed to evaluate the effect induced by excipients conventionally used for topical dosage forms, namely isopropyl myristate (IPM) or oleic acid (OA) or polyethylene glycol 400 (PEG400) or Transcutol (TR), on the human skin permeability of terpinen-4-ol (T4OL) contained in the pure Tea tree oil. The effect of such excipients was determined by evaluating the absorption of T4OL using human epidermis and the perturbation of the organization of stratum corneum by ATR-FTIR. Among the tested excipients OA enhanced the absorption of T4OL by perturbing the stratum corneum lipid barrier. Other excipients caused a weak enhancement effect and their use should be carefully monitored.', 'The purpose of this study was to investigate dermal pharmacokinetics of terpinen-4-ol in rats following topical administration of plai oil derived from the rhizomes of Zingiber cassumunar Roxb. Unbound terpinen-4-ol concentrations in dermal tissue were measured by microdialysis. The dermal pharmacokinetic study of terpinen-4-ol was performed under non-occlusive conditions. The oil was topically applied at a dose of 2, 4, and 8 mg/square cm plai oil corresponding to the amount of 1.0, 1.9, and 3.8 mg/square cm terpinen-4-ol, respectively. Following topical application of the oil, terpinen-4-ol rapidly distributed into the dermis and demonstrated linear pharmacokinetics with no changes in the dose-normalized area under the concentration-time curves across the investigated dosage range. The mean percentages of free terpinen-4-ol distributed in the dermis per amount of administered were 0.39 +/- 0.06 %, 0.41 +/- 0.08 %, and 0.30 +/- 0.03 % for 2, 4, and 8 mg/square cm doses, respectively. The dermal pharmacokinetics of terpinen-4-ol could provide information for its further formulation development and therapy schedules.']","['(R)-Terpinen-4-ol was mixed in an artificial diet at a concentration of 1 mg/g of diet, and the diet was fed to the last instar larvae of common cutworm (Spodoptera litura). Metabolites were recovered from frass and analyzed spectroscopically. (R)-Terpinen-4-ol was transformed mainly to (R)-p-menth-1-en-4,7-diol. Similarly, (S)-terpinen-4-ol was transformed mainly to (S)-p-menth-1-en-4,7-diol. The C-7 position (allylic methyl group) of (R)- and (S)-terpinen-4-ol was preferentially oxidized.', 'We examined the in vitro metabolism of (+)-terpinen-4-ol by human liver microsomes and recombinant enzymes. The biotransformation of (+)-terpinen-4-ol was investigated by gas chromatography-mass spectrometry (GC-MS). (+)-Terpinen-4-ol was found to be oxidized to (+)-(1R,2S,4S)-1,2-epoxy-p-menthan-4-ol, (+)-(1S,2R,4S)-1,2-epoxy-p-menthan-4-ol, and (4S)-p-menth-1-en-4,8-diol by human liver microsomal P450 enzymes. The identities of (+)-terpinen-4-ol metabolites were determined through the relative abundance of mass fragments and retention times on GC-MS. Of 11 recombinant human P450 enzymes tested, CYP1A2, CYP2A6, and CYP3A4 were found to catalyze the oxidation of (+)-terpinen-4-ol. Based on several lines of evidence, CYP2A6 and CYP3A4 were determined to be major enzymes involved in the oxidation of (+)-terpinen-4-ol by human liver microsomes. First, of the 11 recombinant human P450 enzymes tested, CYP1A2, CYP2A6 and CYP3A4 catalyzed oxidation of (+)-terpinen-4-ol. Second, oxidation of (+)-terpinen-4-ol was inhibited by (+)-menthofuran and ketoconazole, inhibitors known to be specific for these enzymes. Finally, there was a good correlation between CYP2A6 and CYP3A4 activities and (+)-terpinen-4-ol oxidation activities in the 10 human liver microsomes.']",
1230,11231,"Allophanic acid, 1-ethynylcyclohexyl ester",C#CC1(CCCCC1)OC(=O)NC(=O)N,,,,,,
1231,11232,Tri-M-cresyl phosphate,CC1=CC(=CC=C1)OP(=O)(OC2=CC=CC(=C2)C)OC3=CC=CC(=C3)C,,,,"['The distribution and excretion of (14)C-labeled isomerically pure tri-o-, tri-m- and tri-p-cresyl phosphates has been examined in F344/N rats... Groups of male rats were administered 2, 20, or 200 mg/kg of the respective (14)C-labeled isomerically pure tricresyl phosphate in corn oil by gavage, or 20 mg/kg was administered intravenously. All three compounds were well absorbed after oral administration; however, the pattern of excretion of each of the three triesters was different. Tri-o-cresyl phosphate was excreted primarily in the urine with approximately 70% of the label appearing in urine and 20% in feces within 24 hours for all three dose levels administered. Tri-m-cresyl phosphate was excreted primarily in the feces at all four dose levels administered (0.5, 2, 20, or 200 mg/kg); however, as the dose increased the percentage excreted in the feces also increased and that excreted in urine decreased. Tri-p-cresyl phosphate exhibited yet a different excretion pattern; at low doses (0.5 or 2 mg/kg) the primary route of excretion was the urine, whereas at higher doses (20 or 200 mg/kg) the primary route of excretion was the feces. Evaluation of biliary excretion following intravenous administration indicated that after administration of 2 or 20 mg/kg tri-o-cresyl phosphate or tri-m-cresyl phosphate approximately 40% to 60% of the label was excreted in the bile within the first 6 hours. However, tri-p-cresyl phosphate exhibited a dose dependent increase which represented an approximate doubling of biliary excretion between the 2 mg/kg and 20 mg/kg doses. The percentage of administered label appearing in feces was less than that excreted in bile for all three triesters, suggesting that substantial enterohepatic recycling occurs. Within 3 days after administration essentially 100% of the label of all three isomers had been excreted. All three isomers were rapidly distributed to muscle and liver and then redistributed to adipose tissue and skin; however, the parent compounds were rapidly cleared with no tendency to bioaccumulate in specific organs or tissues. Within 12 hours of dermal administration of a 50 mg/kg dose of (14)C-tri-o-cresyl phosphate to the intrascapular region of cats, 73% of the radioactivity had disappeared from the site of application, and within 24 hours it reached its maximum concentration in all organs and tissues examined... Within 10 days after administration, 28% of the applied radio activity had been excreted in the urine and 20% in the feces. Although studies of skin absorption have not been conducted with other isomeric tricresyl phosphate esters, the similarity of structure and physical properties (solubility, etc.) make it likely that these compounds are also absorbed through the skin.', 'After a single oral dose (500 mg/kg) of tri- m-cresyl phosphate (TMCP) or TPCP to rabbits, 92% of TMCP  and  95% of  TPCP was eliminated in the feces within 4 days...', '... TRI-METATOLYL ... PHOSPHATES ... ABSORBED WITH DIFFICULTY BY HUMAN BODY (DIGESTIVE ROUTE & VIA SKIN).', '... /TRITOLYL PHOSPHATE/ CAN NORMALLY PENETRATE INTO BODY BY INGESTION OF LIQ OR SPRAY IN ATMOSPHERE & BY CUTANEOUS ABSORPTION. ... IT SEEMS THAT ONLY PHOSPHATES CONTAINING ORTHO-SUBSTITUTED PHENOL ARE ABSORBED THROUGH SKIN. /ISOMERIC MIXT/']",,
1232,11233,"3,3-Dimethylhexane",CCCC(C)(C)CC,,,,,,
1233,11234,Glycerylphosphorylcholine,C[N+](C)(C)CCOP(=O)([O-])OCC(CO)O,,,,,,
1234,11235,Dibutyldifluorostannane,CCCC[Sn](CCCC)(F)F,,,,,,
1235,11236,Semicarbazide hydrochloride,C(=O)(N)NN.Cl,,,,"['... Binds to cytosine residues in RNA, to deoxycytosine residues in DNA in vitro and to cytosine and deoxycytosine nucleosides']",,
1236,11237,Ethylaluminum dichloride,CC[Al](Cl)Cl,,,,,,
1237,11238,Dichloroalumane,[AlH](Cl)Cl,,,,,,
1238,11239,3-Methyl-1-butene,CC(C)C=C,,,,,,
1239,11240,2-Methyl-1-butene,CCC(=C)C,,,,,,
1240,11241,3-Chloro-2-methylpropene,CC(=C)CCl,,,,"['2-(14)C 3-Chloro-2-methylpropene (specific activity, 2.5 mCi/umol; radiochemical purity, 93%; 5% 1-chloro-2-methylpropene) was administered by gavage to male Fischer 344 rats as single or up to four daily doses of 150 mg/kg body weight in corn oil. The compound was extensively absorbed and rapidly excreted: 82% of the single dose was eliminated within 24 hours after treatment. It was rapidly distributed to tissues, and the highest concentrations were found in forestomach, liver and kidney; the concentration of radiolabel was considerably lower in glandular stomach than in forestomach. The tissue concentrations were approximately doubled after two doses, but little additional increase was observed after four doses. The concentrations decreased after cessation of treatment. After a single dose, about 58% of the administered radiolabel was found in the urine, 22% was exhaled and 2% was detected in the feces. In the expired air, about 12% of the dose was (14)C-carbon dioxide and 7% was volatile compounds.']","['The main urinary metabolite was N-acetyl-S-(2-methylpropenyl)cysteine, which constituted 45% of the total urinary radiolabel. This metabolite is presumed to arise from direct conjugation of glutathione with 3-chloro-2-methylpropene.', '... Daily doses of 150 mg/kg 2-(14)C-1-chloro-2-methylpropene (DMVC) or 2-(14)C-3-chloro-2-methylpropene (CMP) were admin to male Fischer 344 rats for 1, 2, or 4 consecutive days. One daily dose of 150 mg/kg DMVC was admin to male B6C3F1 mice. Both DMVC and CMP were rapidly metabolized; however, CMP was cleared at a slightly slower rate. Rats exhaled approx 25 and 10% of the DMVC and CMP as carbon dioxide, respectively. Mice exhaled 25% of the DMVC as carbon dioxide. Rats expired 30% of the admin DMVC unchanged in the 24 hr after dosing compared to only 7% of the admin CMP. Mice expired 5% of the admin DMVC in the same time period. ... The 24 hr urinary excretion in rats was 35% of the admin DMVC compared to 58% of CMP. Mice excreted 47% of the admin DMVC in 24 hr in the urine. An unusual metabolite of DMVC, 2-amino-6-methyl-4-thia-5-heptene-1,7-dioic acid was identified.']",
1241,11242,3-Chloro-1-butene,CC(C=C)Cl,,,,,,
1242,11243,"1-Propene, 1,2-dichloro-",CC(=CCl)Cl,,,,,"['Metabolism of 1,2-D in the rat results in the formation of a mercapturic acid conjugate excreted largely in the urine. Proposed reactive intermediates include 1,2-epoxypropane; this intermediate is suspected of being responsible for mutagenic effects of 1,2-D. Glutathione pathways are seen as a detoxification mechanisms, & liver & kidney toxicity at high concns may be due to saturation of these pathways.']",
1243,11244,"1-Propene, 3,3-dichloro-",C=CC(Cl)Cl,,,,,,
1244,11245,"1,1-Dichloropropene",CC=C(Cl)Cl,,,,,,
1245,11246,Silver acetate,CC(=O)[O-].[Ag+],,,,,,
1246,11247,Thallium acetate,CC(=O)[O-].[Tl+],,,,"['The distribution of thallium among body organs and brain regions was investigated in male and female Wistar rats. Rats were injected intraperitoneally with a thallium acetate solution. The dose used was 16 mg/kg as thallium, half the median lethal dose for adult rodents. Rats were sacrificed from 0.125 to 3 days after dosing. Tissue thallium concentrations peaked at about 1 day and then began to decrease. Higher levels of thallium were found in testes, kidney and heart than were noted in brain and liver. The testes lost thallium more rapidly than the kidney and heart. Brain contained significantly lower levels of thallium than all other organs examined. No significant differences were noted in thallium concentration between the various brain regions. Peak concentration of thallium in the cortex was attained at 1 to 2 days after injection. All other organs reached their maximum concentration between 0.75 and 1 day. Thallium began to decrease at different rates, depending on the region. Rats ranging in age from newborn to 20 days old were injected with thallium; regional brain content in the cortex, hypothalamus and cerebellum was analyzed 1 day later. Rats did not show differences in the thallium contents in brain regions until 5 days after birth, when cortical concentration was less than that of the newborn.', 'In acute thallium poisoning, human brain areas densely populated with neurons were found to accumulate thallium more than other areas, and the gray matter contained higher thallium levels than nonneural tissues. /Soluble thallium cmpd/']",,['BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']
1247,11248,Ferrous carbonate,C(=O)([O-])[O-].[Fe+2],,,,"['Gastrointestinal absorption of iron is adequate.../yet/...lower from...ferrous carbonate.../than ferrous sulfate, fumarate, gluconate, succinate, glutamate, and lactate/.', 'No differences were found in iron absorption by normal human males given oral test doses of 10 or 100 mg ferrous sulfate or ferrous carbonate, respectively.', 'Twenty-four lambs, averaging 29 kg, were used to determine the effect of supplemental dietary Fe on performance and Cu, P, Zn and Mn utilization. Treatments consisted of supplemental Fe at 0, 300, 600 or 1,200 mg/kg diet as ferrous carbonate. The basal diet contained 154 mg Fe/kg diet and consisted of 90% Coastal bermudagrass pellets, 9.45% group corn, .5% sodium chloride and .05% vitamin mix. Lambs were slaughtered after having ad libitum access to diets for 98 to 121 days. Dietary Fe did not affect lamb /weight/ gain or feed intake. Supplemental Fe increased Fe concentrations in liver (P<0.01), spleen (P<0.01) and bone (P<0.10), but not in kidney and muscle. Serum Fe concentrations and percentage transferrin saturation in serum were increased (P<0.01) by supplemental Fe at 28 and 84 days, but not at the termination of the study. Plasma Cu was decreased (P<0.01) at 56 days, whereas serum ceruloplasmin activity was reduced (P<0.01) at 28 days in lambs fed 1,200 mg Fe/kg diet compared with lambs fed 600 mg Fe/kg diet. Lower levels of Fe (300 and 600) reduced (P<0.01) ceruloplasmin by 56 days and plasma Cu by 84 days compared with controls. Liver Cu also was decreased (P<0.05) by supplemental Fe. Plasma P was decreased slightly (P<0.10) by 28 days and significantly (P<0.01) at the other sampling dates by supplemental Fe.']",,
1248,11249,"2,3-Dimethyl-1-butene",CC(C)C(=C)C,,,,,,
1249,11250,"2,3-Dimethyl-2-butene",CC(=C(C)C)C,,,,,,
1250,11251,3-Methyl-2-butanone,CC(C)C(=O)C,,,,"['When a dose of 1000 mg/kg methyl isopropyl ketone was administered to rats, 38-54% was eliminated unchanged in 25-35 hours, predominantly in the expired air.']","['Ketones are not readily metabolized in the body. With most of the lower ketones as much as 50% of the dose may be eliminated unchanged from the body, mainly in the exhaled air and to a small extent in the urine. The major metabolic pathway of ketones is reduction to the corresponding secondary alcohols, which are usually eliminated as glucuronic acids. In rats, 38-54% of a dose of 1000 mg/kg bw methyl isopropyl ketone was eliminated unchanged in about 25-35 hours, mainly in the expired air. Administration of this ketone to rabbits increased the glucuronic acid output. It has been suggested that MIPK is a normal constituent of human urine.']",
1251,11252,3-Chloro-2-butanol,CC(C(C)Cl)O,,,,,,
1252,11253,1-Bromo-1-nitroethane,CC([N+](=O)[O-])Br,,,,,,
1253,11254,"2,2'-Bioxirane",C1C(O1)C2CO2,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']","['Experiments were carried out to study the uptake, retention, routes of elimination, and identification of butadiene metabolites in rats and mice. Male Sprague-Dawley rats and male B6C3F1 mice were administered (14)C labeled butadiene by inhalation at 0.14 to 13000 microg/l air. The percentage of (14)C absorbed and retained at 6 hours after exposure was 1.5 to 17 in rats and 4 to 20 in mice. Major routes of elimination were exhalation and urine discharge, accounting for 75 to 85% of the total (14)C. About 12% of (14)C remained in the carcass 65 hours after the exposure. At the 13 microg/l dose, all (14)C was accounted for as metabolites. At the lowest butadiene concentrations (14)C in urine and exhaled air represented 40 and 20% of the total (14)C eliminated. At the highest butadiene concentration (14)C in urine decreased to 8 % of total (14)C eliminated or retained in carcass. More than 90% of (14)C in blood samples consisted of butadiene metabolites, of which 60 to 80 % was nonvolatile material. The amount of metabolites increased with the concentration of inhaled butadiene, but the increase was not proportional to the uptake. At 130 and 1800 microg/l butadiene mice had about twofold higher amount of 1,2-epoxy-3-butene than rats. The quantities of butadiene-diepoxide in rats subjected to the same exposure levels of butadiene were 0.1 and 1 nmol/ml blood after 6 hours. /Butadiene/']","['Experiments were carried out to study the uptake, retention, routes of elimination, and identification of butadiene metabolites in rats and mice. Male Sprague-Dawley rats and male B6C3F1 mice were administered (14)C labeled butadiene by inhalation at 0.14 to 13000 microg/l air. The percentage of (14)C absorbed and retained at 6 hours after exposure was 1.5 to 17 in rats and 4 to 20 in mice. Major routes of elimination were exhalation and urine discharge, accounting for 75 to 85% of the total (14)C. About 12% of (14)C remained in the carcass 65 hours after the exposure. At the 13 microg/l dose, all (14)C was accounted for as metabolites. At the lowest butadiene concentrations (14)C in urine and exhaled air represented 40 and 20% of the total (14)C eliminated. At the highest butadiene concentration (14)C in urine decreased to 8 % of total (14)C eliminated or retained in carcass. More than 90% of (14)C in blood samples consisted of butadiene metabolites, of which 60 to 80 % was nonvolatile material. The amount of metabolites increased with the concentration of inhaled butadiene, but the increase was not proportional to the uptake. At 130 and 1800 microg/l butadiene mice had about twofold higher amount of 1,2-epoxy-3-butene than rats. The quantities of butadiene-diepoxide in rats subjected to the same exposure levels of butadiene were 0.1 and 1 nmol/ml blood after 6 hours. /Butadiene/', 'Diepoxybutane (DEB) is a known human metabolite of butadiene_monoxide.']",
1254,11255,"2,2,3-Trimethylpentane",CCC(C)C(C)(C)C,,,,,,
1255,11256,CID 11256,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O,,,,,,
1256,11257,Monoacetyldapsone,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)N,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,['Monoacetyldapsone is a known human metabolite of dapsone.'],
1257,11258,"1,3-DITHIOLANE, 2-(p-FLUOROPHENYL)-2-METHYL-",CC1(SCCS1)C2=CC=C(C=C2)F,,,,,,
1258,11259,Metahexamide,CC1=C(C=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2)N,,,,,,
1259,11260,"2,3-Dimethylpentane",CCC(C)C(C)C,,,,,,
1260,11261,3-Methyl-2-pentanol,CCC(C)C(C)O,,,,,,
1261,11262,3-Methyl-2-pentanone,CCC(C)C(=O)C,,,,,,
1262,11263,"2,3-Dichloropropionic acid",C(C(C(=O)O)Cl)Cl,,,,,,
1263,11264,2-Methyl-3-pentanol,CCC(C(C)C)O,,,,,,
1264,11265,2-Methyl-3-pentanone,CCC(=O)C(C)C,,,,,,
1265,11266,2-Hydroxybutyric acid,CCC(C(=O)O)O,,,,,,
1266,11267,dl-Isoserine,C(C(C(=O)O)O)N,,,,,,
1267,11268,2-Bromo-3-methylbutyric acid,CC(C)C(C(=O)O)Br,,,,,,
1268,11269,"2,3,4-Trimethylpentane",CC(C)C(C)C(C)C,,,,,,
1269,11270,"2,3,4-Trimethyl-2-pentene",CC(C)C(=C(C)C)C,,,,,,
1270,11271,"2,4-Dimethyl-3-pentanone",CC(C)C(=O)C(C)C,,,,,,
1271,11272,"3,21-Dihydroxypregnane-11,20-dione",CC12CCC(CC1CCC3C2C(=O)CC4(C3CCC4C(=O)CO)C)O,,,,,,
1272,11273,Formestane,C[C@]12CCC(=O)C(=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,['For the treatment of estrogen-receptor positive breast cancer in post-menopausal women.'],"['By significantly reducing estrogen levels in the bloodstream, formestane may exhibit antitumor activity.    In one trial involving 147 postmenopausal females with advanced breast cancers resistant to standard therapies, 22% of patients achieved a partial response, while another 20% achieved disease stabilization. [3]  In comparative trials comparing a non-steroidal aromatase inhibitor, anastrozole, with formestane, it was found that anastrozole was more effective and consistent at suppressing estrogen levels in the body. However, these results were of unverified clinical significance. [5]']","['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (See all compounds classified as Aromatase Inhibitors.)']","['Formestane has poor oral bioavailability, but is fully bioavailable when administered via the established intramuscular route. The AUC after an intravenous pulse dose does not vary considerably from that of an intramuscular dose.   Within 24-48 h of the first dose of intramuscular formestane, a C(max) of 48.0 +/- 20.9 nmol/l was achieved in one study. [2]', 'Renal elimination. >95% in urine, <5% in feces.', 'Vd = 1.8 L/kg; widely distributed to organs and tissues when delivered intravenously. [2]', 'Plasma clearance is approximately 4.2 L/(h kg), when delivered intravenously.   In women, following a 500mg dose of formestane, 20% was excreted as glucuronide within the first 24 hours. [1]  One long term metabolite (3beta,4alpha-dihydroxy-5alpha-androstan-17-one) can be detected for 90 hours. A longer detection time is possible with more sensitive technology, which may be of utility in sports drug testing. [1]']","[""Hepatic metabolism. Phase I of metabolism is mainly reductive in nature. The reduction products 3 beta-hydroxy-5alpha-androstane-4,17-dione and 3alpha-hydroxy-5beta-androstane-4,17-dione are produced, and further reduced.  A notable step in the process of metabolism is a keto reduction on carbon number three of the molecule. The main metabolite which is produced from formestane is 4-hydroyxyandrost-4-ene-3,17-dione-4-glucuronide.  The oxidation products identified were 4-hydroxyandrosta-4,6-diene-3,17-dione and 4-hydroxyandrosta-1,4-diene-3,17-dione.  In phase II, conjugation was diverse and included sulfatation and glucuronidation. 4-hydroxytestosterone, the 17-hydroxylated analog to formestane, was identified as one particular metabolite found in women's urine. This finding was the result of an oral administration of 500mg of formestane in women.""]","['Terminal plasma elimination half life of 18 minutes, when delivered intravenously. [2]']"
1273,11274,17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C[C@H](C(=O)C4)CO)C,,,,,,
1274,11275,17-beta-Hydroxy-5-alpha-androst-2-ene-2-methanol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(CC(=CC4)CO)C,,,,,,
1275,11276,21-Acetoxypregnenolone,CC(=O)OCC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,,,,,,
1276,11277,"2-Naphthalenesulfonic acid, 1-hydroxy-",C1=CC=C2C(=C1)C=CC(=C2O)S(=O)(=O)O,,,,,,
1277,11278,"1-Naphthalenesulfonic acid, 2-hydroxy-",C1=CC=C2C(=C1)C=CC(=C2S(=O)(=O)O)O,,,,,,
1278,11279,2-Hydroxy-6-methylbenzoic acid,CC1=C(C(=CC=C1)O)C(=O)O,,,,,,
1279,11280,"17-(Dimethyl-hexyl)-10,13-dimethyl-dodecahydro-cyclopenta(A)phenanthren-7-one",CC(C)CCCC(C)C1CCC2C1(CCC3C2C(=O)C=C4C3(CCC=C4)C)C,,,,,,
1280,11281,Isothebaine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=CC=C4)OC)O)OC,,,,,,
1281,11282,Amotriphene hydrochloride,CN(C)CC(=C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC.Cl,,,,,,
1282,11283,Amotriphene,CN(C)CC(=C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC,,,,,,
1283,11284,12-Hydroxymethyl-7-methylbenz(a)anthracene,CC1=C2C=CC3=CC=CC=C3C2=C(C4=CC=CC=C14)CO,,,,,"['12-Hydroxymethyl-7-methylbenz(a)anthracene is a known human metabolite of 7,12 Dimethylbenzanthracene.']",
1284,11285,7-Hydroxymethyl-12-methylbenz[a]anthracene,CC1=C2C(=C(C3=CC=CC=C13)CO)C=CC4=CC=CC=C42,,,,,"['7-Hydroxymethyl-12-methylbenz[a]anthracene is a known human metabolite of 7,12 Dimethylbenzanthracene.']",
1285,11286,8-Methoxycaffeine,CN1C2=C(N=C1OC)N(C(=O)N(C2=O)C)C,,,,,,
1286,11287,"1,8-Dimethylnaphthalene",CC1=C2C(=CC=CC2=CC=C1)C,,,,,,
1287,11288,"Benzene-1,2,3-tricarboxylic acid",C1=CC(=C(C(=C1)C(=O)O)C(=O)O)C(=O)O,,,,,,
1288,11289,Chlorotrianisene,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC,"['Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.']","['Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential&nbsp;increased risk of puerperal thromboembolism&nbsp;associated with the use of large doses of estrogens.']","['Non-steroidal compounds with estrogenic activity. (See all compounds classified as Estrogens, Non-Steroidal.)', 'Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)']","['Absorption following oral administration is rapid.', '...LONG-ACTING...BECAUSE OF SEQUESTRATION IN ADIPOSE TISSUE &, THEREFORE, IS NOT WIDELY USED.', '...SUGGESTS THAT DRUG IS CONVERTED IN LIVER TO MORE ACTIVE FORM. ... IT IS STORED IN FAT, FROM WHICH IT IS SLOWLY RELEASED TO GIVE SUSTAINED ACTION.', 'ESTROGENIC ACTIVITY HAS BEEN FOUND IN ADIPOSE TISSUE UP TO MONTH AFTER CESSATION OF THERAPY.']","['Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated.', 'RATE OF O-DEMETHYLATION WAS MAXIMAL AT 0.4 MMOLAR NADPH. ALTHOUGH NADH DID NOT CATALYZE REACTION ALONE, IT HAD SYNERGISTIC EFFECT IN PRESENCE OF EQUIMOLAR AMT OF NADPH. EXTRACTS FROM INCUBATION MIXT CONTAINED 1 MAJOR (MONO-O-DEMETHYLATED) & A MINOR (BIS-O-DEMETHYLATED) METAB.']",
1289,11290,Phenindamine tartrate,CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
1290,11291,Phenindamine,CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4,"['Used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold.']","['Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms.']","['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
1291,11292,Pararosaniline hydrochloride,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N.Cl,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. (See all compounds classified as Fixatives.)']",,,
1292,11293,C.I. Basic Red 9,C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. (See all compounds classified as Fixatives.)']",,,
1293,11294,Malachite green,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3.[Cl-],,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)', 'Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['The disposition of malachite green was determined in channel catfish (Ictalurus punctatus) after intravascular dosing (0.8 mg/kg) or waterborne exposure (0.8 mg/L for 1 hr). After intravascular dosing, mean plasma concentrations of the parent compound exhibited a triphasic decline with a terminal elimination half-life of 6.2 hr. Malachite green was rapidly absorbed and concentrated in the tissues during waterborne exposure. The rate of accumulation was directly related to pH of the exposure water. After waterborne exposure, elimination of the parent compound from plasma also was triphasic with a terminal half-life of 4.7 hr. In muscle, the half-life of the parent compound was approximately 67 hr. Malachite green and its metabolites were widely distributed in all tissues. In fish exposed to 14C-labeled malachite green, total drug equivalent concentrations were highest in abdominal fat and lowest in plasma. Malachite green was rapidly and extensively metabolized to its reduced form, leucomalachite green, which was slowly eliminated from the tissues. Leucomalachite green is an appropriate target analyte for monitoring exposure of channel catfish to this drug.', '... A 6-day-lasting therapeutic bath of rainbow trout was performed in malachite green of 0.2 mg/L concentration. Its residues were then observed in muscle, liver and skin of treated fish. Immediately after the bath, malachite green was detected in muscle, liver and skin at the levels of 0.383, 0.834 and 0.649 mg/kg, respectively, as a sum of both coloured form and leukoform. Eight weeks after the bath, an expressive decrease of the coloured form of malachite green was found while its leukoform was detected in fish as late as after 10 months. Results of analyses were found negative twelve months after the bath.']",,
1294,11295,Malachite green cation,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3,,,,,,
1295,11296,"4,5,6,7-Tetrahydroxybenzo[7]annulen-8-one",C1=CC2=CC(=O)C(=C(C(=C2C(=C1)O)O)O)O,,,,,,
1296,11297,4-Hydroxytryptamine,C1=CC2=C(C(=C1)O)C(=CN2)CCN,,,,,,
1297,11298,2-Methyl-6-nitroaniline,CC1=C(C(=CC=C1)[N+](=O)[O-])N,,,,,,
1298,11299,CID 11299,CCC(=O)[C@]1(CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C)O,,,,,,
1299,11300,delta5-Cholestene,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCCC4)C)C,,,,,,
1300,11301,"3alpha,17beta-Dihydroxy-5alpha-androstane",CC12CCC(CC1CCC3C2CCC4(C3CCC4O)C)O,,,,,,
1301,11302,5beta-Dihydrotestosterone,C[C@]12CCC(=O)C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,,,,,,
1302,11303,"Androstan-17-one, 3-hydroxy-, (3beta,5alpha)-",CC12CC[C@@H](C[C@@H]1CCC3C2CCC4(C3CCC4=O)C)O,,,,,,
1303,11304,"1,4-Dimethylnaphthalene",CC1=CC=C(C2=CC=CC=C12)C,,,,,,
1304,11305,"1,4-Dihydroxynaphthalene",C1=CC=C2C(=C1)C(=CC=C2O)O,,,,,,
1305,11306,"1,5-Dimethylnaphthalene",CC1=C2C=CC=C(C2=CC=C1)C,,,,,,
1306,11307,Coumithoate,CCOP(=S)(OCC)OC1=CC2=C(C=C1)C3=C(CCCC3)C(=O)O2,,,,,,
1307,11308,"2,3,4-Trimethoxybenzoic acid",COC1=C(C(=C(C=C1)C(=O)O)OC)OC,,,,,,
1308,11309,9-Bromophenanthrene,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)Br,,,,,,
1309,11310,Acetomenaphthone,CC1=C(C2=CC=CC=C2C(=C1)OC(=O)C)OC(=O)C,,,,,,
1310,11311,Theophylline olamine,CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CO)N,,,,,,
1311,11312,"2,6-Dinitrophenol",C1=CC(=C(C(=C1)[N+](=O)[O-])O)[N+](=O)[O-],,,,"['/The investigators/ ... studied the pharmacokinetics of ... dinitrophenol isomers /incl 2,6-dinitrophenol/ and showed that elimination from the blood of mice, rabbits, guinea pigs, rats, and monkeys was complete within 30 hr.', 'Dinitrophenol isomers are readily absorbed from the gastrointestinal tract and through the skin and lungs. The dinitrophenol isomers are not stored to any significant extent in the tissues of humans or lab animals following absorption, but are readily excreted, primarily via the urine. /Dinitrophenol/', 'Absorption of dinitro compounds can take place with ease through the lungs, the gut, or the intact skin. The rate of absorption through skin is likely to be greater when the substances are applied in oily rather than aq soln. /Dinitro cmpd/', '... Dinitro compounds are persistent yellow dye-stuffs, staining exposed skin, hair, wool, fur, and feathers a distinct yellow or orange color which remains obvious for weeks or even months afterwards, despite the action of water and weather. Such staining provides evidence of at least external contact with the chemicals. /Dinitro cmpd/']","['Metabolites of 2,6-Dinitrophenol: 2-amino-6-nitrophenol, 6-amino-2-nitrophenol, 2,6-diaminophenol /From table/']","['The half-lives for elimination of 2,6-dinitrophenol from the blood of mice and rats following a single large dose given intraperitoneally are 238 min and 210 min, respectively. /From table/']"
1312,11313,Congo red,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N)S(=O)(=O)[O-].[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,"['Congo red, an azo dye derived from benzidine, and 2-azoxyfluorene, a derivative of 2-aminofluorene, were reduced during overnight incubation with a suspension of rat intestinal bacteria. HPLC and uv spectral analysis verified the presence of benzidine in the extracts of the Congo red incubations. ... Extracts of the Congo red incubations were mutagenic toward Salmonella typhimurium TA1538 in the presence of post-mitochondrial activating system, but Congo red was not mutagenic without this reductive pretreatment. ... The utility of the Ames test in screening for potential mutagens may be expanded by a reductive pretreatment utilizing cecal bacteria.']",
1313,11314,"3,3'-(Biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonic acid)",C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)N)S(=O)(=O)O,,,,,,
1314,11315,4-((2-Hydroxy-1-naphthyl)azo)benzenesulphonic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)S(=O)(=O)O)O,,,,,,
1315,11316,1-Bromo-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2Br)O,,,,,,
1316,11317,"1,2-Dimethylnaphthalene",CC1=C(C2=CC=CC=C2C=C1)C,,,,,,
1317,11318,"Naphthalene-1,2-diol",C1=CC=C2C(=C1)C=CC(=C2O)O,,,,,['Dihydrodiol is a known human metabolite of naphthalene.'],
1318,11319,(R)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol;2-hydroxybenzoic acid,C=CC1CN2CCC1CC2[C@@H](C3=CC=NC4=CC=CC=C34)O.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
1319,11320,(R)-alpha-(5-Vinylquinuclidine-2-yl)quinoline-4-methanol,C=CC1CN2CCC1CC2[C@@H](C3=CC=NC4=CC=CC=C34)O,,,,,,
1320,11321,1-Acetylisatin,CC(=O)N1C2=CC=CC=C2C(=O)C1=O,,,,,,
1321,11322,CID 11322,C1=NC2=C(C(=N1)S)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
1322,11323,Bis(diphenylmethyl) ether,C1=CC=C(C=C1)C(C2=CC=CC=C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1323,11324,Benzophenone oxime,C1=CC=C(C=C1)C(=NO)C2=CC=CC=C2,,,,,,
1324,11325,N-(2-Bromoethyl)phthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)CCBr,,,,,,
1325,11326,"1,7-Dimethylnaphthalene",CC1=CC2=C(C=CC=C2C=C1)C,,,,,,
1326,11327,"1,3-Dimethylnaphthalene",CC1=CC2=CC=CC=C2C(=C1)C,,,,,,
1327,11328,"1,6-Dimethylnaphthalene",CC1=CC2=CC=CC(=C2C=C1)C,,,,"['The distribution, excretion and metabolism of 1,6-dimethylnaphthalene following i.p. administration of a single dose of 20 mg/kg to rats, was investigated using radiotracer (3H) and a gas chromatography-mass spectrometry technique (GC-MS). After 72 hr, about 94% of the given dose was excreted in urine and feces. In organs and tissues, the highest concentration during the first hours after administration was detected in fat, liver, spleen and kidneys. Then gradual decline of tritium was noticed in all examined tissues.']","['Yields 5-methyl-2-naphthoic acid in Nocardia... /from table/', 'In /rat/ urine, the following substances were identified and quantified by GC peak areas: unchanged 1,6-dimethylnaphthalene, 1-methyl-hydroxynaphthalenes, 1-hydroxymethyl-6-methylnaphthalene, 1,6-dimethyl-thionaphthalene, 6-methyl-1-naphthoic aldehyde, 6-methyl-1-naphthoic acid, 1,6-dimethyl-thionaphthalene and 1,6-dimethyl-methylthionaphthalene.']",
1328,11329,"2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate;3,3-dimethyl-7-oxo-6-[(2-prop-2-enylsulfanylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.CC1(C(N2C(S1)C(C2=O)NC(=O)CSCC=C)C(=O)O)C,,,,,,
1329,11330,"3,3-Dimethyl-7-oxo-6-{2-[(prop-2-en-1-yl)sulfanyl]acetamido}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)CSCC=C)C(=O)O)C,,,,,,
1330,11331,"2,4,6-Trichlorophenoxyacetic acid",C1=C(C=C(C(=C1Cl)OCC(=O)O)Cl)Cl,,,,,,
1331,11332,"(2,6-Dichlorophenoxy)acetic acid",C1=CC(=C(C(=C1)Cl)OCC(=O)O)Cl,,,,,,
1332,11333,Lactulose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@]([C@H]2O)(CO)O)CO)O)O)O)O,"['Lactulose is indicated for use as a laxative in the treatment of chronic constipation in adults and geriatric patients.  Additionally, lactulose is also employed as an adjunct to protein restriction and supportive therapy for the prevention and treatment of portal-systemic encephalopathy (PSE), including both the hepatic pre-coma and coma variations. In particular, lactulose solution has been effective at managing PSE resulting from surgical portacaval shunts or from chronic hepatic diseases like cirrhosis.  Moreover, there have also been studies demonstrating the capacity for lactulose to minimize the formation of gallstones and even some investigations regarding the experimental use of the agent in developing novel anticancer agents owing to its ability to bind galactin carbohydrates involved in various tumor progressions.']","['Lactulose formulations are most commonly administered via the oral route or the rectal route. Consequently, because the substance experiences minimal absorption by the gut it typically remains localized in the gastrointestinal tract environment and ultimately demonstrates almost all of its pharmacologic effects within the gut. In particular, as lactulose elicits its laxative effects in enhancing stool amounts and softening stool, such biochemical and physiologic activities can cause increased bowel sounds (borborygmi), a feeling of bloatedness, belching, frequent flatus, and diarrhea.']","['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']","['After administration by the oral route, less than 3% of the given dose of lactulose solution is absorbed by the small intestine. The remaining unabsorbed lactulose reaches the large intestine where it is metabolized - but even then, negligible quantities of unchanged lactulose or its metabolites are absorbed across the colon.', 'The renal excretion of any lactulose that manages to be absorbed into the circulation has been determined to be 3% or less and is generally complete within 24 hours. Any unabsorbed lactulose is largely excreted with stool.', 'Negligible amounts of lactulose - metabolized or non-metabolized - are absorbed into the body.. Most lactulose that is administered subsequently remains predominantly around the gastrointestinal tract area.', 'Negligible amounts of lactulose - metabolized or non-metabolized - are absorbed into the body.. Regardless, data regarding the clearance of lactulose is not readily available or accessible.']","['Lactulose is essentially only metabolized in the colon by saccharolytic bacteria that are present there. In particular, the substance is broken down into lactic acid and small amounts of acetic and formic acid. Specific examples of bacteria that normally inhabit the large intestine that are capable of lactulose metabolism include Lactobacilli, Bacteroides, Escherichia coli, and Clostridia.']",['The data regarding the half-life of lactulose is not readily available or accessible.']
1333,11334,"2,3-Dichlorophenol",C1=CC(=C(C(=C1)Cl)Cl)O,,,,"['Because of their high lipid solubility and low ionization at physiological pH, dichlorophenols would be expected to be readily absorbed following ingestion. /Dichlorophenols/', 'Dichlorophenol isomers are absorbed through the skin and from the gut. /Dichlorophenol isomers/', '... Readily absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/']","['Metabolites of ortho-dichlorobenzene (o-DCB) were identified by gas chromatography (GC) and mass spectrometry (MS) in urine samples of exposed chemical factory workers. The three workers were exposed to 1 to 4 parts per million o-DCB used as a solvent. ... The GC total ion chromatograms of the urine samples contained peaks corresponding to the retention times of a standard containing 2,3-dichlorophenol, 3,4-dichlorophenol, 3,4-dichlorocatechol, and 4,5-dichlorocatechol...', 'Microsomes were prepared from livers obtained from male Wistar-rats pretreated with phenobarbital, 3-methylcholanthrene, isosafrole, or dexamethasone. Reversed phase high performance liquid chromatography analysis was performed to identify the metabolites of 1,2-dichlorobenzene (1,2-DICB) and 1,4-dichlorobenzene (1,4-DICB). Covalent binding of 1,2-DICB and 1,4-DICB to microsomal protein and DNA was determined, and molecular orbit computer calculations were conducted. The major metabolites of both dichlorobenzene isomers were dichlorophenols and dichlorohydroquinones. The metabolite 2,5-dichlorophenol was associated with 1,2-DICB, and the metabolites 2,3-dichlorophenol and 3,4-dichlorophenol were associated with 1,4-DICB. ...  Covalent binding of 1,2-DICB and 1,4-DICB metabolites with protein was observed, while DNA binding occurred only to a very small extent. ....', '1,2-Dichlorobenzene gave 3,4-dichlorophenol with smaller amounts of 2,3-dichlorophenol, 3,4- and 4,5-dichlorocatechol and 3,4-dichlorophenylmercapturic acid also observed; 1,3-dichlorobenzene gave 2,4-dichlorophenol as the major product with 3,5-dichlorophenol, 3,4-dichlorocatechol, and 2,4-dichlorophenylmercapturic acid also identified; 1,4-dichlorobenzene gave 2,5-dichlorophenol as the major metabolite with 2,5-dichlorquinol identified as a minor product.', '... To investigate the relation between metabolism and toxicity of 1,2-dichlorobenzene (1,2-DCB), the biotransformation, tissue distribution, blood kinetics, and excretion at three different oral dose levels (5, 50 and 250 mg/kg) of the radiolabelled compound were investigated in the male Wistar rat. A toxic dose level (250 mg/kg...) was included. ... The concentration of parent chemical was essentially constant during 3 and 6 hr for the mid- and high-dose level respectively, and then declined. 1,2-DCB could only be detected in blood in the first 2 hr after administration of the 5-mg/kg dose. The major route of biotransformation was via the glutathione pathway and 60% of the urinary metabolites were mercapturic acids. In addition, the major metabolites in bile were conjugates of glutathione. Other major metabolites in urine were the sulfate conjugates of 2,3- and 3,4-dichlorophenol (DCP). No significant differences in metabolic profiles were observed between the different doses. Induction with phenobarbital resulted in the increased excretion of sulfate conjugates (30% in the induced rat, 20% in the control rat), mainly the conjugate of 3,4-DCP...', '2,3-dichlorophenol is a known human metabolite of 1,2-dichlorobenzene.']",
1334,11335,"2,6-Dimethylphenol",CC1=C(C(=CC=C1)C)O,,,,,,
1335,11336,"3,4,5,6-Tetrabromo-o-cresol",CC1=C(C(=C(C(=C1Br)Br)Br)Br)O,,,,,,
1336,11337,"1,6-Bis[(2-chloroethyl)amino]-1,6-dideoxyhexitol",C(CCl)NCC(C(C(C(CNCCCl)O)O)O)O,,,,,,
1337,11338,CID 11338,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)[O-].[Na+],,,,,,
1338,11339,Docusate,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,"['Indicated for the treatment of constipation associated with dry, hard stools or opioid induced constipation. Though recently, pressure has been building to end the use of docusate over concerns of efficacy.']","[""Docusate sodium is a laxative and an anionic detergent that supposedly promotes incorporation of water and fats into stool through a reduction in surface tension, resulting in softer fecal mass. Docusate's onset of action is 6-72 hours orally and 2-15 minutes rectally. The effects of docusate are thought to be exerted locally in the jejunum.""]","['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']","['Docusate is not absorbed systemically. As the actions of docusate are local and it is not absorbed, the pharmacokinetic parameters are not available.', 'If docusate is systemically absorbed, it undergoes biliary excretion.']",,
1339,11340,2'-Methylacetophenone,CC1=CC=CC=C1C(=O)C,,,,,,
1340,11341,1-Bromo-2-nitrobenzene,C1=CC=C(C(=C1)[N+](=O)[O-])Br,,,,,,
1341,11342,Anthrarobin,C1=CC=C2C(=C1)C=C3C(=C2O)C=CC(=C3O)O,,,,,,
1342,11343,CID 11343,C1C(=O)N=C(N1C(=O)C2=CC=CC=C2)S,,,,,,
1343,11344,CID 11344,CCCCOC(=O)C1=CC=C(C=C1)N.C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1344,11345,"1,2-Diisopropylbenzene",CC(C)C1=CC=CC=C1C(C)C,,,,,,
1345,11346,2'-Nitroacetophenone,CC(=O)C1=CC=CC=C1[N+](=O)[O-],,,,,,
1346,11347,8-Ethoxycaffeine,CCOC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C,,,,,,
1347,11348,"3,4-Dinitrophenol",C1=CC(=C(C=C1O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1348,11349,3-Hydroxyflavone,C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)O,,,,,"[""It has been reported that flavonoids efficiently protect against peroxynitrite toxicity. Two pharmacophores have been identified in flavonoids, namely the catechol group in ring B and the hydroxyl (OH) group at the 3-position. In this study, this structure-activity relationship was further examined. It was found that catechol (1,2-dihydroxybenzene) is a potent peroxynitrite scavenger, whereas phenol (hydroxybenzene) is not. Of the flavonols tested without a catechol group in ring B, kaempferol (OH groups at positions 3,5,7,4') and galangin (OH groups at positions 3,5,7) are also potent scavengers, whereas apigenin (OH groups at positions 5,7,4') and chrysin (OH groups at positions 5,7) are not. This confirms the importance of the OH group at the 3-position. However, the synthetic flavonol TUM 9761 and 3-hydroxyflavone (OH group only at position 3) are poor scavengers. Based on these results, the structure-activity relationship on the peroxynitrite scavenging activity of flavonols was refined. The catechol in ring B remains important. Also the 3-OH group remains important, but the activity of this pharmacophore is influenced by the substituents at position 5 and at position 7."", '3-Hydroxyflavone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-Trihydroxy-6-(4-oxo-2-phenylchromen-3-yl)oxyoxane-2-carboxylic acid.']",
1349,11350,Iodoalphionic acid,C1=CC=C(C=C1)C(CC2=CC(=C(C(=C2)I)O)I)C(=O)O,,,,,,
1350,11351,4-tert-Butyl-2-phenylphenol,CC(C)(C)C1=CC(=C(C=C1)O)C2=CC=CC=C2,,,,,,
1351,11352,1-Aminoacridine,C1=CC=C2C(=C1)C=C3C(=N2)C=CC=C3N,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
1352,11353,4-Aminoacridine,C1=CC=C2C(=C1)C=C3C=CC=C(C3=N2)N,,,,,,
1353,11354,"N,N-Dimethyl-2,5-difluoro-p-(2,5-difluorophenylazo)aniline",CN(C)C1=C(C=C(C(=C1)F)N=NC2=C(C=CC(=C2)F)F)F,,,,,,
1354,11355,CID 11355,C1=CC=C(C(=C1)C(=O)[O-])O.[K+],,,,,,
1355,11356,5-Methyl-2-nitroaniline,CC1=CC(=C(C=C1)[N+](=O)[O-])N,,,,,,
1356,11357,2-Ethylaniline,CCC1=CC=CC=C1N,,,,,['2-ethylaniline has known human metabolites that include 2-Ethylacetanilide.'],
1357,11358,2-Bromoanisole,COC1=CC=CC=C1Br,,,,,,
1358,11359,8-Aminoquinoline,C1=CC2=C(C(=C1)N)N=CC=C2,,,,,,
1359,11360,CID 11360,C1=CC(=O)C2=CC=CNC2=C1,,,,,,
1360,11361,CID 11361,CN1C=NC2=C1C(=O)N=C(N2)N,,,,,,
1361,11362,"10-Chloro-5,10-dihydrophenarsazine",C1=CC=C2C(=C1)NC3=CC=CC=C3[As]2Cl,,,,,,
1362,11363,"1-Phenyl-1,2-propanedione",CC(=O)C(=O)C1=CC=CC=C1,,,,,,
1363,11364,N-Methylacetanilide,CC(=O)N(C)C1=CC=CC=C1,,,,,,
1364,11365,N-Chloroacetanilide,CC(=O)N(C1=CC=CC=C1)Cl,,,,,,
1365,11366,Cyclovalone,COC1=C(C=CC(=C1)C=C2CCCC(=CC3=CC(=C(C=C3)O)OC)C2=O)O,,,,,,
1366,11367,Diloxanide,CN(C1=CC=C(C=C1)O)C(=O)C(Cl)Cl,"['Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis.']","['Diloxanide is a luminal amebicide, however the mechanism of action of diloxanide is unknown. Diloxanide destroys the trophozoites of E. histolytica that eventually form into cysts. The cysts are then excreted by persons infected with asymptomatic amebiasis. Diloxanide furoate is a prodrug, and is hydrolyzed in the gastrointestinal tract to produce diloxanide, the active ingredient.']","['Agents which are destructive to amebae, especially the parasitic species causing AMEBIASIS in man and animal. (See all compounds classified as Amebicides.)']","['Bioavailability is 90% (in diloxanide parental form), however diloxanide furoate is slowly absorbed from the gastrointestinal tract.', 'Renal (90%, rapidly excreted as glucuronide metabolite). 10% is excreted in the feces as diloxanide.']","['Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation (99% of diloxanide occurs as glucuronide and 1% as free diloxanide in the systemic circulation).']",['3 hours']
1367,11368,Isoxsuprine hydrochloride,CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O.Cl,,,"['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)', 'Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']","['Isoxsuprine hydrochloride is almost completely absorbed from the gastrointestinal tract. After oral admin of the drug, peak plasma concns occur within 1 hr and persist for about 3 hr. ...Isoxsurprine crosses the placenta. The drug is partially conjugated in the body and is excreted in the urine. Fecal excretion of the drug is negligible.']",,['Mean plasma half-life of the drug is 1.25 hr.']
1368,11369,"2,6-Diethylaniline",CCC1=C(C(=CC=C1)CC)N,,,,,"['2,6-DIETHYLANILINE IS A MINOR METABOLITE OF BUTACHLOR IN SOIL.', 'MUCOR SUFUI CONVERTED BUTACHLOR INTO 12 METABOLITES, INCLUDING 2,6-DIETHYLANILINE, IN SOIL.', 'Incubation of 2,6-diethylaniline with NADPH-fortified microsomes produced 4-amino-3,5-diethylphenol as the major oxidation product. 4-Amino-3,5-diethylphenol underwent further oxidation to 3,5-diethyl-benzoquinone-4-imine which is isolated as a minor metabolite during 2,6-diethylaniline metabolism.']",
1369,11370,2-Methoxybenzoic acid,COC1=CC=CC=C1C(=O)O,,,,,,
1370,11371,"2,2'-Iminodibenzoic acid",C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC=C2C(=O)O,,,,,,
1371,11372,2-Bromonaphthalene,C1=CC=C2C=C(C=CC2=C1)Br,,,,,,
1372,11373,6-Aminoquinoline,C1=CC2=C(C=CC(=C2)N)N=C1,,,,,,
1373,11374,6-Hydroxyquinoline,C1=CC2=C(C=CC(=C2)O)N=C1,,,,,,
1374,11375,3-Aminoquinoline,C1=CC=C2C(=C1)C=C(C=N2)N,,,,,,
1375,11376,3-Hydroxyquinoline,C1=CC=C2C(=C1)C=C(C=N2)O,,,,,['3OHQ is a known human metabolite of quinoline.'],
1376,11377,7-Aminoquinoline,C1=CC2=C(C=C(C=C2)N)N=C1,,,,,,
1377,11378,CID 11378,C1=CNC2=CC(=O)C=CC2=C1,,,,,,
1378,11379,2-Aminoquinoline,C1=CC=C2C(=C1)C=CC(=N2)N,,,,,,
1379,11380,Chlorazine,CCN(CC)C1=NC(=NC(=N1)Cl)N(CC)CC,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,"['In the metabolism of atrazine ... & other triazines, N-dealkylation of their cysteine & glutathione conjugation is usually observed, including oxidation of N-alkyl groups. /s-Triazines/']",
1380,11381,3-Phenylphenol,C1=CC=C(C=C1)C2=CC(=CC=C2)O,,,,,,
1381,11382,"4-[4-(4-Hydroxyphenyl)-2,3-diisocyanobuta-1,3-dienyl]phenol",[C-]#[N+]C(=CC1=CC=C(C=C1)O)C(=CC2=CC=C(C=C2)O)[N+]#[C-],,,,,,
1382,11383,N-(2-Ethoxyphenyl)acetamide,CCOC1=CC=CC=C1NC(=O)C,,,,,,
1383,11384,2-Aminoacridine,C1=CC=C2C(=C1)C=C3C=C(C=CC3=N2)N,,,,,,
1384,11385,3-Aminoacridine,C1=CC=C2C(=C1)C=C3C=CC(=CC3=N2)N,,,,,,
1385,11386,"2,3-Dimethylnaphthalene",CC1=CC2=CC=CC=C2C=C1C,,,,,,
1386,11387,"2,6-Dimethylnaphthalene",CC1=CC2=C(C=C1)C=C(C=C2)C,,,,,,
1387,11388,Anatabine,C1C=CCN[C@@H]1C2=CN=CC=C2,,,,,,
1388,11389,"2,3'-Bipyridine",C1=CC=NC(=C1)C2=CN=CC=C2,,,,,,
1389,11390,"Naphthalene-2,6-disulfonic acid",C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C=C1S(=O)(=O)O,,,,,,
1390,11391,Debrisoquin sulfate,C1CN(CC2=CC=CC=C21)C(=N)N.C1CN(CC2=CC=CC=C21)C(=N)N.OS(=O)(=O)O,,,,,,
1391,11392,2-Nitronaphthalene,C1=CC=C2C=C(C=CC2=C1)[N+](=O)[O-],,,,,,
1392,11393,2-Naphthylacetic acid,C1=CC=C2C=C(C=CC2=C1)CC(=O)O,,,,,,
1393,11394,2-Acetamidonaphthalene,CC(=O)NC1=CC2=CC=CC=C2C=C1,,,,,,
1394,11395,"2,2'-Azonaphthalene",C1=CC=C2C=C(C=CC2=C1)N=NC3=CC4=CC=CC=C4C=C3,,,,,,
1395,11396,"2,7-Dimethylnaphthalene",CC1=CC2=C(C=C1)C=CC(=C2)C,,,,,,
1396,11397,"2,7-Dihydroxynaphthalene",C1=CC(=CC2=C1C=CC(=C2)O)O,,,,,,
1397,11398,2-Phenylpropylamine,CC(CN)C1=CC=CC=C1,,,,,,
1398,11399,CID 11399,C1=CC=C(C=C1)C(=O)[O-].[K+],,,,,,
1399,11400,Ethyl 3-aminobenzoate,CCOC(=O)C1=CC(=CC=C1)N,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)']",,,
1400,11401,2-tert-Butylamino-1-(3-fluorophenyl)ethanol hydrobromide,CC(C)(C)NCC(C1=CC(=CC=C1)F)O.Br,,,,,,
1401,11402,2-(Tert-butylamino)-1-(3-fluorophenyl)ethanol,CC(C)(C)NCC(C1=CC(=CC=C1)F)O,,,,,,
1402,11403,alpha-Butylaminomethyl-3-fluorobenzyl alcohol hydrobromide,CCCCNCC(C1=CC(=CC=C1)F)O.Br,,,,,,
1403,11404,2-Butylamino-1-(3-fluorophenyl)ethanol,CCCCNCC(C1=CC(=CC=C1)F)O,,,,,,
1404,11405,O-Desmethylmethoxyphenamine,CC(CC1=CC=CC=C1O)NC,,,,,['O-Desmethylmethoxyphenamine is a known human metabolite of ac1ocg1j.'],
1405,11406,Allyl benzoate,C=CCOC(=O)C1=CC=CC=C1,,,,,,
1406,11407,Mercuric benzoate,C1=CC=C(C=C1)C(=O)[O-].C1=CC=C(C=C1)C(=O)[O-].[Hg+2],,,,,,
1407,11408,"Benzoic acid, 5-fluoropentyl ester",C1=CC=C(C=C1)C(=O)OCCCCCF,,,,,,
1408,11409,Butyl 2-furoate,CCCCOC(=O)C1=CC=CO1,,,,,,
1409,11410,CID 11410,C1=CC=C2C(=C1)NC(=N2)S,,,,,,
1410,11411,CID 11411,C1=CC=C(C=C1)C=C2C(=O)N=C(N2)S,,,,,,
1411,11412,"3,4-Dimethylhexane",CCC(C)C(C)CC,,,,,,
1412,11413,Potassium oxalate,C(=O)(C(=O)[O-])[O-].[K+].[K+],,,"['Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) (See all compounds classified as Reducing Agents.)']",,,
1413,11414,"1,2-Dibromobenzene",C1=CC=C(C(=C1)Br)Br,,,,,,
1414,11415,1-Bromo-2-iodobenzene,C1=CC=C(C(=C1)Br)I,,,,,,
1415,11416,"1,2-Dimethylcyclohexane",CC1CCCCC1C,,,,,,
1416,11417,"3,4-Dimethylpyridine",CC1=C(C=NC=C1)C,,,,,,
1417,11418,2-Methylcyclohexanol,CC1CCCCC1O,,,,,,
1418,11419,2-Methylcyclohexanone,CC1CCCCC1=O,,,,,"['WHEN A KETONE /METHYLCYCLOHEXANONE/ CAN BE REDUCED TO YIELD 2 PRODUCTS (IE, CIS- & TRANS-ALCOHOL), THE THERMODYNAMICALLY MORE STABLE ALC (ONE HAVING 2 EQUATORIAL SUBSTITUENTS) WAS ALWAYS FOUND TO PREDOMINATE. ...IN VIVO, MORE STABLE ALC REPRESENTED ABOUT 70% OF 2 PRODUCTS.']",
1419,11420,"2,3-Dimethylpyridine",CC1=C(N=CC=C1)C,,,,,,
1420,11421,"1,2-Benzoquinone",C1=CC(=O)C(=O)C=C1,,,,,,
1421,11422,2-Bromo-4-methylaniline,CC1=CC(=C(C=C1)N)Br,,,,,,
1422,11423,4-Bromo-2-methylaniline,CC1=C(C=CC(=C1)Br)N,,,,,,
1423,11424,"2-Hydroxy-4-methyl-2,4,6-cycloheptatrien-1-one",CC1=CC(=O)C(=CC=C1)O,,,,,,
1424,11425,CID 11425,CCCCCCCCC(=C(CCCCCCCCCCCC(=O)OCC)I)I,,,,,,
1425,11426,Dicysteine diethylester,CCOC(=O)C(CSSCC(C(=O)OCC)N)N,,,,,,
1426,11427,2-Hydroxy-4-(methylthio)butyric acid,CSCCC(C(=O)O)O,,,,,"['CHICK LIVER HOMOGENATES CATALYZED THE OXIDATION OF 2-HYDROXY-4-(METHYLTHIO)BUTANOIC ACID TO KETOMETHIONINE & BOTH CHICK LIVER SUPERNATANTS & RAT LIVER SUPERNATANTS CONVERTED KETOMETHIONINE TO THE HYDROXY DERIVATIVE OR TO METHIONINE.', 'IN RAT TISSUE, BOTH FLAVINE COENZYME & GLUTAMINE ARE REQUIRED FOR THE CONVERSION OF 2-HYDROXY-4-METHYLTHIOBUTYRIC ACID INTO METHIONINE. PER GRAM OF TISSUE, THE KIDNEY POSSESSES GREATER CONVERSION ACTIVITY THAN THE LIVER, BRAIN, SMALL INTESTINE, & MUSCLE, ALTHOUGH ON A TOTAL ORGAN BASIS THE LIVER IS THE MOST IMPORTANT. MOST OF THE CONVERSION ACTIVITY IS LOCATED IN THE SUPERNATANT FRACTION OF THE LIVER.']",
1427,11428,3-Pentanol,CCC(CC)O,,,,,,
1428,11429,"1,2-Butanediol",CCC(CO)O,,,,['... EVEN WHEN EXPOSURES WERE PROLONGED AND REPEATED ... IT WAS NOT ABSORBED THROUGH THE SKIN /OF RABBITS/ IN TOXIC AMT.'],"['... 1.0 g/kg of 1,2 butanediol /given/ intravenously during a 2-min period to rabbits ... was metabolized slowly, as shown by the fact that the blood level fell slowly and that there was only slow excretion via the urine. That which was excreted in the urine was found either as the glucuronide or unchanged. Tissue analysis showed no accumulation of 1,2-butanediol.', '... Glucuronides or other metabolites /were not found/ in the urine of rabbits given 1,2-butanediol orally.']",
1429,11430,Potassium Carbonate,C(=O)([O-])[O-].[K+].[K+],,,,,,
1430,11431,Rubidium carbonate,C(=O)([O-])[O-].[Rb+].[Rb+],,,,,,
1431,11432,"4-Amino-1,2,4-triazole",C1=NN=CN1N,,,,,,
1432,11433,"Acetic acid;[2-hydroxy-5-(2,4,4-trimethylpentan-2-yl)phenyl]mercury",CC(=O)O.CC(C)(C)CC(C)(C)C1=CC(=C(C=C1)O)[Hg],,,,,,
1433,11434,"[2-Hydroxy-5-(2,4,4-trimethylpentan-2-yl)phenyl]mercury",CC(C)(C)CC(C)(C)C1=CC(=C(C=C1)O)[Hg],,,,,,
1434,11435,CID 11435,CC(=O)N1CC(=O)N=C1S,,,,,,
1435,11436,CID 11436,C1=CC(=CC(=C1)[N+](=O)[O-])N=NC2=CC(=C(C=C2)O)C(=O)[O-].[Na+],,,,,,
1436,11437,2-Hydroxy-5-((3-(hydroxy(oxido)amino)phenyl)diazenyl)benzoic acid,C1=CC(=CC(=C1)[N+](=O)[O-])N=NC2=CC(=C(C=C2)O)C(=O)O,,,,,,
1437,11438,Mercuric imidosuccinate,C1CC(=O)N=C1[O-].C1CC(=O)N=C1[O-].[Hg+2],,,,,,
1438,11439,Succinimide,C1CC(=O)NC1=O,,,,,,
1439,11440,4-Hydroxy-2-methyl-5-(propan-2-yl)benzoic acid,CC1=CC(=C(C=C1C(=O)O)C(C)C)O,,,,,,
1440,11441,"1-Bromo-2,4-dinitrobenzene",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Br,,,,,,
1441,11442,Allethrin,CC1=C(C(=O)CC1OC(=O)C2C(C2(C)C)C=C(C)C)CC=C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['WHEN RADIOACTIVE PYRETHROID IS ADMIN ORALLY TO MAMMALS, IT IS ABSORBED FROM INTESTINAL TRACT OF THE ANIMALS & DISTRIBUTED IN EVERY TISSUE EXAMINED. EXCRETION OF RADIOACTIVITY IN RATS ADMIN TRANS-ISOMER: DOSAGE: 500 MG/KG; INTERVAL 20 DAYS; URINE 36%; FECES 64%; TOTAL 100%. /PYRETHROIDS/', 'Pyrethrins are absorbed through intact skin when applied topically. When animals were exposed to aerosols of pyrethrins with piperonyl butoxide being released into the air, little or none of the combination was systemically absorbed. /Pyrethrins/', 'Although limited absorption may account for the low toxicity of some pyrethroids, rapid biodegradation by mammalian liver enzymes (ester hydrolysis and oxidation) is probably the major factor responsible. Most pyrethroid metabolites are promptly excreted, at least in part, by the kidney. /Pyrethroids/', 'There were no major /metabolic/ differences between sexes, between low and high dose groups, nor between single-dose groups and repeated dose groups. The majority of radioactivity was eliminated within 3 days. Urinary elimination ranged from approximately 25 - 50% and fecal elimination ranged from 50 - 70%. There was no bioaccumulation of residue in tissues. ... /d-trans-Allethrin/', 'When allethrin labelled with (14)C in the acid moiety or with (3)H in the alcohol moiety was administered orally to male Sprague Dawley rats at levels ranging from 1 to 5 mg/kg body weight, the radiocarbon and tritium from the acid- and alcohol-labellings were eliminated in the urine (30% and 20.7%, respectively) and feces (29% and 27%, respectively) in 48 hr. ... Most of the metabolites excreted in the urine were ester-form metabolites together with two hydrolyzed products, chrysanthemum dicarboxylic acid (CDCA) and allethrolone. ...']","['AFTER ADMINISTRATION OF LABELED ALLETHRIN TO MALE RATS, THE MAJOR METABOLITES FOUND WERE ALCOHOL-ACIDS. FROM NMR AND MASS SPECTRA A THIRD METABOLITE WAS IDENTIFIED AS ALLETHRIN WITH ONE CYCLOPROPANE METHYL HYDROXYLATED AND OXIDATION OF THE TRANSMETHYL TO A CARBOXYL GROUP. ...', '/IN STUDYING THE METABOLISM OF ALLETHRIN IN HOUSEFLIES, IT WAS FOUND THAT IN/ ALLETHRIN LABELED IN THE KETOCYCLOPENTENYL PORTION OF THE MOLECULE, A METABOLITE THAT BEHAVED AS KETOCYCLOPENTENOL WAS ISOLATED BY PAPER CHROMATOGRAPHY. ... INVESTIGATORS USING ALLETHRIN LABELED IN CHRYSANTHEMUMIC ACID PORTION OF MOLECULE WERE ABLE TO DETECT ONLY TRACES OF ACID IN HOUSEFLY HOMOGENATES OR EXCRETA. ... ONLY TRACES OF UNCHANGED ALLETHRIN WERE RECOVERABLE AND THE BULK OF THE RECOVERED MATERIAL MUST BE A DERIVATIVE OF THE INTACT ESTER OR OF THE ACID.', ""Allethrin is oxidized not only at the chrysanthemate isobutenyl moiety to the corresponding primary alcohol but also at the allyl group to 1'-hydroxyprop-2'-enyl and 2',3'-dihydroxy-propyl derivatives, or at a methyl group on the cyclopropyl moiety to a hydroxy derivative. Allethrin is also converted to chrysanthemum dicarboxylic acid and allethrolone."", 'When allethrin was applied topically to houseflies, chromatography indicated the presence of allethrone and chrysanthemic acid in addition to allethrin and three unidentified compounds.', 'For more Metabolism/Metabolites (Complete) data for ALLETHRINS (10 total), please visit the HSDB record page.']",
1442,11443,"2,4-Diisocyanato-1-methylbenzene",CC1=C(C=C(C=C1)N=C=O)N=C=O,,,,"['... The route dependent metabolism of (14)C toluene 2,4-diisocyanate and (14)C toluene 2,4 diamine in Fischer 344 rats /was investigatd/. Forty-eight hours after an oral dose of 60 mg (14)C toluene 2,4 diisocyanate/kg bw, 81%, 8% and 4% of the radioactivity was found in the feces, urine and tissue/carcass/gastrointestinal tract contents, respectively. Markedly different results were obtained following inhalation exposure of rats to 2 ppm (14.2 mg/cu m) (14)C toluene 2,4 diisocyanate for 2 hr. Forty eight hours after exposure, 47%, 15% and 34% of the recovered radioactivity was in the feces, urine and tissue/carcass/gastrointestinal tract contents, respectively.', 'In comparative studies, (14)C toluene 2,4-diamine, the hydrolysis product of (14)C toluene 2,4-diisocyanate, was administered to rats at doses of 3 mg/kg bw (orally or intravenously) and 60 mg/kg bw orally. After 48 hr, the distribution of radioactivity was similar in all cases (urine, 64-72%; feces, 20-31%; and tissue/carcass/gastrointestinal tract, 2-5%). Comparison of the toluene 2,4-diisocyanate inhalation group with the oral toluene 2,4-diisocyanate and toluene 2,4-diamine treatment groups indicated that a larger percentage of the inhaled radioactivity was in the tissues/carcass and that excretion of radioactivity into the urine was slower following toluene 2,4-diisocyanate inhalation.', 'Following inhalation or oral exposure to (14)C toluene 2,4-diisocyanate, about 90% and 65% of the quantitated urinary metabolites were acid labile conjugates. In contrast, only 16 39% of the urinary metabolites were conjugated following oral administration of (14)C toluene 2,4-diamine.', 'Inhalation exposure to toluene 2,4-diisocyanate results primarily in the formation of acid labile conjugates, with little or no toluene 2,4-diamine being formed. This suggests that the disposition of inhaled toluene 2,4-diisocyanate is quite different from that of orally administered toluene 2,4-diisocyanate or of intravenously or orally administered toluene 2,4-diamine.', 'For more Absorption, Distribution and Excretion (Complete) data for 2,4-TOLUENE DIISOCYANATE (6 total), please visit the HSDB record page.']","['65 % of quantitated urinary metabolites were acid-labile conjugates. Free /toluene diamine (TDA)/ and its mono - and diaceyl derivatives /were/ present in urine. 94 % of (14)C-dose /was present/ in urine, feces, tissues and carcass 48 hrs after dosing.  81 % in feces, 8 % in urine, 4 % tissues (highest in GI tract). ... /In/expired air (14)C, /was/  negligible. ... /Toluene diamine/', 'In man, tolylene-2,4-diisocyanate is metab into 2,4-diaminotoluene. ...', 'Inhalation exposure to toluene 2,4-diisocyanate results primarily in the formation of acid labile conjugates, with little or no toluene 2,4-diamine being formed.', 'Subjects exposed to 2,4-TDI and 2,6-TDI in a test chamber (5.5 ppb for 7.5 hours) had the corresponding amines in plasma and urine - identified by gas chromatography-mass spectrometry (GC-MS) after hydrolysis. Elimination from plasma was slow. Elimination in urine had a slow and a fast phase, the latter with a biological half time of one to two hours. Two persons were exposed to three concentrations in the range 3.4-9.7 ppb for 4 hours, and there was a correlation between TDI levels in air and TDA levels in plasma. Elimination from plasma had two phases. The biological half time was two to five hours for the fast phase and more than six days for the slow phase.']","['Whole body: a few hours; [TDR, p. 1156]', 'The toxicokinetics of 2,4- and 2,6-toluenediisocyanates in 11 chronically exposed workers at two flexible foam polyurethane production plants have been reported. ... The half life in urine ranged from 5.8 to 11 days for 2,4 and 2.6 toluene diamines. The differences in exposure were reflected by the plasma toluene diamine concentrations. The mean half life in plasma was 21 (range, 14-34) days for 2,4-toluene diamine and 21 (16-26) days for 2,6-toluene diamine. The study showed that the half life in plasma of chronically exposed workers for 2,4- and 2,6-toluene diamine was twice as long as for volunteers with short term exposure.', 'Two men were exposed to toluene diisocyanate atmospheres at three different air concn (ca 25, 50 & 70 ug/cu m). The toluene diisocyanate atmospheres were generated by a gas-phase permeation method, & the exposures were performed in an 8-cu m stainless-steel test chamber. ... The isomeric composition of the air in the test chamber was 30% 2,4-toluene diisocyanate and 70% 2,6-toluene diisocyanate. ... In plasma, 2,4- & 2,6-toluenediamine showed a rapid-phase elimination half-time of ca 2-5 hr, & that for the slow phase was greater than 6 days. ... The cumulated amount of 2,4-toluenediamine excreted in the urine over 24 hr was ca 15%-19% of the estimated inhaled dose of 2,4-toluene diisocyanate, & that of 2,6-toluenediamine was ca 17%-23% of the inhaled dose of 2,6-toluene diisocyanate.']"
1443,11444,beta-alanyl-3-methyl-L-histidine,CN1C=NC=C1CC(C(=O)O)NC(=O)CCN,,,,,,
1444,11445,"2,2'-Dimethylazobenzene",CC1=CC=CC=C1N=NC2=CC=CC=C2C,,,,,,
1445,11446,2-Bromovaleric acid,CCCC(C(=O)O)Br,,,,,,
1446,11447,"2,3-Dimethylhexane",CCCC(C)C(C)C,,,,,,
1447,11448,tert-Butyl methacrylate,CC(=C)C(=O)OC(C)(C)C,,,,,,
1448,11449,"2,3-Octanedione",CCCCCC(=O)C(=O)C,,,,,,
1449,11450,3-tert-Butylphenol,CC(C)(C)C1=CC(=CC=C1)O,,,,,,
1450,11451,m-Phenolsulfonic acid,C1=CC(=CC(=C1)S(=O)(=O)O)O,,,,,,
1451,11452,CID 11452,CC(=O)NC1=CC(=CC=C1)[As](=O)(O)[O-].[Na+],,,,,,
1452,11453,(3-Acetamidophenyl)arsonic acid,CC(=O)NC1=CC(=CC=C1)[As](=O)(O)O,,,,,,
1453,11454,(1-Bromoethyl)benzene,CC(C1=CC=CC=C1)Br,,,,,,
1454,11455,3'-Methylacetophenone,CC1=CC(=CC=C1)C(=O)C,,,,,,
1455,11456,3-Bromobenzoic acid,C1=CC(=CC(=C1)Br)C(=O)O,,,,,,
1456,11457,1-Bromo-3-nitrobenzene,C1=CC(=CC(=C1)Br)[N+](=O)[O-],,,,,,
1457,11458,6-O-beta-D-Galactopyranosyl-D-galactose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)O)O)O)O)O,,,,,,
1458,11459,"3,5-Dinitrophenol",C1=C(C=C(C=C1[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
1459,11460,3'-Methoxyacetophenone,CC(=O)C1=CC(=CC=C1)OC,,,,,,
1460,11461,3-Methoxybenzoic acid,COC1=CC=CC(=C1)C(=O)O,,,,,,
1461,11462,1-Bromo-4-isopropylbenzene,CC(C)C1=CC=C(C=C1)Br,,,,,,
1462,11463,Terpinolene,CC1=CCC(=C(C)C)CC1,,,,,"['In plants, monoterpene hydrocarbons are produced by the isoprene pathway. /Monoterpene hydrocarbons/']",
1463,11464,4-Bromobenzoic acid,C1=CC(=CC=C1C(=O)O)Br,,,,,,
1464,11465,"4-Bromo-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)Br,,,,,,
1465,11466,1-Bromo-4-nitrobenzene,C1=CC(=CC=C1[N+](=O)[O-])Br,,,,,,
1466,11467,gamma-Terpineol,CC(=C1CCC(CC1)(C)O)C,,,,,,
1467,11468,p-Menth-3-en-1-ol,CC(C)C1=CCC(CC1)(C)O,,,,,,
1468,11469,2-(Methoxymethyl)-5-nitrofuran,COCC1=CC=C(O1)[N+](=O)[O-],,,,,,
1469,11470,4-Acetylbenzoic acid,CC(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
1470,11471,"4,4'-Azobisbenzoic acid",C1=CC(=CC=C1C(=O)O)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
1471,11472,4-Pyridinemethanol,C1=CN=CC=C1CO,,,,,,
1472,11473,Nitrosobenzene,C1=CC=C(C=C1)N=O,,,,,,
1473,11474,Piconol,C1=CC=NC(=C1)CO,,,,,,
1474,11475,3-Ethylaniline,CCC1=CC(=CC=C1)N,,,,,,
1475,11476,3-Methylbenzyl alcohol,CC1=CC(=CC=C1)CO,,,,,['3-Methylbenzylalcohol is a known human metabolite of m-xylene.'],
1476,11477,3-Chlorobenzaldehyde,C1=CC(=CC(=C1)Cl)C=O,,,,,,
1477,11478,Methenamine mandelate,C1N2CN3CN1CN(C2)C3.C1=CC=C(C=C1)C(C(=O)O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1478,11479,(3R)-2-amino-3-hydroxy-3-phenylpropanoic acid,C1=CC=C(C=C1)[C@H](C(C(=O)O)N)O,,,,,,
1479,11480,"N'-(3-Chlorophenyl)-N,N-dimethylurea",CN(C)C(=O)NC1=CC(=CC=C1)Cl,,,,,,
1480,11481,Benzpyrinium bromide,CN(C)C(=O)OC1=C[N+](=CC=C1)CC2=CC=CC=C2.[Br-],,,,,,
1481,11482,Benzpyrinium,CN(C)C(=O)OC1=C[N+](=CC=C1)CC2=CC=CC=C2,,,,,,
1482,11483,2-chloroethyl N-(3-chlorophenyl)carbamate,C1=CC(=CC(=C1)Cl)NC(=O)OCCCl,,,,,,
1483,11484,"2-(3,5-Dichlorophenoxy)acetic acid",C1=C(C=C(C=C1Cl)Cl)OCC(=O)O,,,,,,
1484,11485,2-Chloroacetanilide,C1=CC=C(C=C1)NC(=O)CCl,,,,,,
1485,11486,Diphenylamine sulfate,C1=CC=C(C=C1)NC2=CC=CC=C2.OS(=O)(=O)O,,,,['IT IS SIMILAR TO ANILINE...BUT...LESS READILY ABSORBED THROUGH THE SKIN & RESPIRATORY TRACT. /DIPHENYLAMINE/'],,
1486,11487,Diphenylamine,C1=CC=C(C=C1)NC2=CC=CC=C2,,,,"['...Stated to be less readily absorbed through the skin and respiratory tract /than aniline/.', 'After administration of diphenylamine (5 ppm) in feed to holstein cow for 4 days, 1.4% of dose detected in feces but none in urine or milk.', 'A Holstein cow was fed diphenylamine at 5 ppm in the diet for 4 days. Residues of diphenylamine were not detected in the milk or urine, and only in small amounts (1.4%) of the total dose were detected in the feces.', 'Diphenylamine is readily absorbed through inhalation and skin contact.']","['.../Diphenylamine/ has been converted to 4-hydroxydiphenylamine in rat and man. An antioxidant DPA actually promotes lipid hydroperoxide formation and oxygen consumption while markedly inhibiting generation of thiobarbituric acid reactive substances. /Diphenylamine/ abolishes formation of cyclooxygenase-dependent conversion products of arachidonate.', ""The urinary metabolites include 4-hydroxy-DPA, 4,4'-dihydroxy-DPA, and their conjugates. There is no evidence of N-hydroxylation."", '...Fate of diphenylamine in dairy cow has been studied. None of the parent compound was detected in the milk or in urine, but small amount (1.4%) were identified in feces. The major metabolites were mono- and di-hydroxylated derivatives. Diphenylamine was rapidly metabolized by beef-liver microsomes.', 'Fifty percent of 5 ppm diphenylamine disappeared during a 30-minute incubation with liver extract. It was /suggested/ that microsomal hydroxylation of diphenylamine occurs, followed by conjugation and elimination.', 'Diphenylamine has known human metabolites that include Diphenylamine N-glucuronide.']",
1487,11488,Diphenylmercury,C1=CC=C(C=C1)[Hg]C2=CC=CC=C2,,,,,,
1488,11489,CID 11489,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=NC3=CC(=CC=C3)S(=O)(=O)[O-].[Na+],,,,,,
1489,11490,4-(Phenylamino)-3'-sulfoazobenzene,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=NC3=CC(=CC=C3)S(=O)(=O)O,,,,,,
1490,11491,"3,3'-Dimethylazobenzene",CC1=CC(=CC=C1)N=NC2=CC=CC(=C2)C,,,,,,
1491,11492,m-Tyramine,C1=CC(=CC(=C1)O)CCN,,,,,,
1492,11493,3'-Chloroacetanilide,CC(=O)NC1=CC(=CC=C1)Cl,,,,,"['YIELDS 4-ACETAMIDO-2-CHLOROPHENOL IN RABBIT: DALY ET AL, BIOCHEM PHARMAC, 17, 31 (1968); M-CHLOROANILINE IN RAT: BRAY ET AL, BIOCHEM J, 47, 483 (1950); 3-CHLOROGLYCOLLANILIDE IN RABBIT: KIESE, M & LENK, W, BIOCHEM PHARMAC, 20, 379 (1971). /FROM TABLE/', 'WHEN INCUBATED WITH RABBIT LIVER MICROSOMES, 3-CHLOROACETANILIDE WAS HYDROXYLATED IN THE 4-POSITION TO 3-CHLORO-4-HYDROXYACETANILIDE.']",
1493,11494,3'-Methoxyacetanilide,CC(=O)NC1=CC(=CC=C1)OC,,,,,,
1494,11495,"3,4-Dichlorophenoxyacetic acid",C1=CC(=C(C=C1OCC(=O)O)Cl)Cl,,,,,,
1495,11496,3-(3-Hydroxyphenyl)-2-propenoic acid,C1=CC(=CC(=C1)O)C=CC(=O)O,,,,,,
1496,11497,3-Chlorophenoxyacetic acid,C1=CC(=CC(=C1)Cl)OCC(=O)O,,,,,['YIELDS 5-CHLORO-2-HYDROXYPHENOXYACETIC ACID PROBABLY IN ASPERGILLUS. /FROM TABLE/'],
1497,11498,Trolnitrate phosphate,C(CO[N+](=O)[O-])N(CCO[N+](=O)[O-])CCO[N+](=O)[O-].OP(=O)(O)O.OP(=O)(O)O,,,,,,
1498,11499,Trolnitrate,C(CO[N+](=O)[O-])N(CCO[N+](=O)[O-])CCO[N+](=O)[O-],,,,,,
1499,11500,N-Benzylacetamide,CC(=O)NCC1=CC=CC=C1,,,,,,
1500,11501,4-Benzylideneaminophenol,C1=CC=C(C=C1)C=NC2=CC=C(C=C2)O,,,,,,
1501,11502,Stilbene,C1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
1502,11503,N-Methylphenethylamine,CNCCC1=CC=CC=C1,,,,,,
1503,11504,4-Ethylaniline,CCC1=CC=C(C=C1)N,,,,,,
1504,11505,4-Methylbenzyl alcohol,CC1=CC=C(C=C1)CO,,,,,"['/OTHER TOXICITY INFORMATION/ Pulmonary metabolites of p-xylene, p-methylbenzyl alcohol (PMBA) and 2,5-dimethylphenol (DMP), were employed to investigate the divergent effects of p-xylene on pulmonary and hepatic metabolism. Rats were given PMBA, DMP, or 10% cremophore (control) ip daily for 3 days, and effects on hepatic and pulmonary microsomal metabolism were determined 12 hours later. Both PMBA and DMP mimic the decrease in pulmonary benzyloxyresorufin-O-debenzylase activity previously reported for p-xylene, but neither could account for the potent induction of cytochrome P450 in the liver. Only PMBA had a consistent effect on P450IIB apoprotein levels, decreasing them in both the liver and lung. These data suggest that PMBA may have a significant role in the inhibition of pulmonary P450 caused by p-xylene.', '4-Methylbenzylalcohol is a known human metabolite of p-xylene.']",
1505,11506,"1,4-Benzenedimethanol",C1=CC(=CC=C1CO)CO,,,,,,
1506,11507,3-Methylhexane,CCCC(C)CC,,,,,,
1507,11508,3-Methyl-1-pentanol,CCC(C)CCO,,,,,,
1508,11509,3-Hexanone,CCCC(=O)CC,,,,,,
1509,11510,N-Hydroxyurethane,CCOC(=O)NO,,,,,,
1510,11511,"2,4-Dimethylhexane",CCC(C)CC(C)C,,,,,,
1511,11512,4-Methylheptane,CCCC(C)CCC,,,,,,
1512,11513,4-Heptanol,CCCC(CCC)O,,,,,,
1513,11514,Isobutyl isovalerate,CC(C)CC(=O)OCC(C)C,,,,,,
1514,11515,4-Octanol,CCCCC(CCC)O,,,,,,
1515,11516,4-Octanone,CCCCC(=O)CCC,,,,,,
1516,11517,Butyl octanoate,CCCCCCCC(=O)OCCCC,,,,,,
1517,11518,Ethyl 6-fluorohexanoate,CCOC(=O)CCCCCF,,,,,,
1518,11519,3-Methylheptane,CCCCC(C)CC,,,,,,
1519,11520,3-Heptanol,CCCCC(CC)O,,,,,,
1520,11521,Propyl hydroxycarbamate,CCCOC(=O)NO,,,,,,
1521,11522,1-Bromo-4-iodobenzene,C1=CC(=CC=C1Br)I,,,,,,
1522,11523,"1,4-Dimethylcyclohexane",CC1CCC(CC1)C,,,,,,
1523,11524,4-Methylcyclohexanol,CC1CCC(CC1)O,,,,,,
1524,11525,4-Methylcyclohexanone,CC1CCC(=O)CC1,,,,,,
1525,11526,"2,5-Dimethylpyridine",CC1=CN=C(C=C1)C,,,,,,
1526,11527,3-Octanol,CCCCCC(CC)O,,,,,,
1527,11528,CID 11528,CC=CC=CC(=O)[O-].[K+],,,,,,
1528,11529,Butyl propionate,CCCCOC(=O)CC,,,,,,
1529,11530,Butyl chloroacetate,CCCCOC(=O)CCl,,,,,,
1530,11531,"2-Octanone, 1-fluoro-",CCCCCCC(=O)CF,,,,,,
1531,11532,Pentyl hydroxycarbamate,CCCCCOC(=O)NO,,,,,,
1532,11533,1-Bromo-1-propene,CC=CBr,,,,,,
1533,11534,Bromoacetonitrile,C(C#N)Br,,,,,,
1534,11535,"1,2-Butadiene",CC=C=C,,,,,,
1535,11536,1-Chloropropene,CC=CCl,,,,,,
1536,11537,"1,2-Diiodoethene",C(=CI)I,,,,,,
1537,11538,CID 11538,C(#N)[O-].[K+],,,,,,
1538,11539,CID 11539,C(=O)[O-].[K+],,,,,,
1539,11540,3-Methoxyprop-2-enyl(trimethyl)azanium;bromide,C[N+](C)(C)CC=COC.[Br-],,,,,,
1540,11541,3-Methoxyprop-2-enyl(trimethyl)azanium,C[N+](C)(C)CC=COC,,,,,,
1541,11542,"2,2-Dimethylpentane",CCCC(C)(C)C,,,,,,
1542,11543,2-Methylpentan-2-ol,CCCC(C)(C)O,,,,,,
1543,11544,tert-Butyl isothiocyanate,CC(C)(C)N=C=S,,,,,,
1544,11545,Betaine hydrochloride,C[N+](C)(C)CC(=O)O.[Cl-],,,"['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues. (See all compounds classified as Lipotropic Agents.)']",,,
1545,11546,"4,4-Dimethyl-2-pentanone",CC(=O)CC(C)(C)C,,,,,,
1546,11547,[Dimethylamino(methoxy)phosphoryl] diethyl phosphite,CCOP(OCC)OP(=O)(N(C)C)OC,,,,,,
1547,11548,Bethanechol chloride,CC(C[N+](C)(C)C)OC(=O)N.[Cl-],,,"['Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)', 'Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)']",,,
1548,11549,"1,1-Dimethylcyclohexane",CC1(CCCCC1)C,,,,,,
1549,11550,1-Methylcyclohexanol,CC1(CCCCC1)O,,,,,,
1550,11551,"2,2-Dimethylhexane",CCCCC(C)(C)C,,,,,,
1551,11552,3-Methylbutanal,CC(C)CC=O,,,,,"['Aldehydes are readily oxidized to organic acids, which, in turn, can serve as substrates for fatty acid oxidation pathways and the Krebs cycle. ... Oxidation of aldehydes is catalyzed by aldehyde dehydrogenase, which has been found in the brain, erythrocytes, liver, kidney, heart, and placenta. /Aldehydes/', '... The detoxification of aldehydes can be seen to proceed basically via two routes: (1) an oxidation to yield readily metabolized acids; (2) inactivation by reaction with sulfhydryl groups, particularly glutathione. Under conditions that either deplete glutathione levels, or that result in an inhibition of aldehyde dehydrogenase (for example, Antabuse treatment), the acute and chronic effects of aldehyde toxicity might be more fully expressed. /Aldehydes/', '3-Methylbutanal is a volatile aldehyde which in the rat is derived, at least in part, from colonic bacterial breakdown of leucine. It has been proposed as a toxin in the pathogenesis of hepatic encephalopathy in man. The mean plasma 3-methylbutanal concentration in non-fasting patients with hepatic encephalopathy, 0.244 umol/liter (range 0-1.30) was not significantly different from the mean value in controls, 0.116 umol/liter (0-0.349). Oral leucine feeding resulted in significant increases in plasma 3-methylbutanal concentrations in both control subjects and patients with cirrhosis. Peak leucine and 3-methylbutanal values occurred at approximately the same time and usually within 120 min of leucine ingestion. Pre-treatment with neomycin had no effect on the results of leucine feeding. No changes occurred in the clinical condition or psychometric performance of patients with cirrhosis fed leucine despite increases in plasma 3-methylbutanal of up to 700% over basal values. In man plasma 3-methylbutanal, at least in part, derives from ingested leucine independently of the action of colonic bacteria.', 'The cytochrome P450-catalyzed formation of olefinic products from a series of xenobiotic aldehydes has been demonstrated. Isobutyraldehyde and trimethylacetaldehyde, but not propionaldehyde, are converted to the predicted olefinic products, suggesting a requirement for branching at the alpha carbon. In addition, the four C5 aldehydes of similar hydrophobicity were compared for their ability to undergo the reaction. The straight-chain valeraldehyde gave no olefinic products with five different rabbit liver microsomal P450 isozymes. However, increasing activity was seen with the other isomers in the order of isovaleraldehyde, 2-methylbutyraldehyde, and trimethylacetaldehyde, with all of the P450 cytochromes.']",
1552,11553,3-Bromopropionic acid,C(CBr)C(=O)O,,,,,['3-BROMOPROPIONIC ACID WAS ISOLATED FROM THE URINE OF RATS TREATED WITH 1-BROMOPROPANE.'],
1553,11554,Hydroxymethylimino-methyl-oxidoazanium,C[N+](=NCO)[O-],,,"['An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']","['.../CROSSES/ THE PLACENTA IN RATS & HAMSTERS.', '...EXCRETED IN MILK DURING LACTATION.']","['METHYLAZOXYMETHANOL IS A SUBSTRATE FOR THE ENZYME HORSE LIVER ALCOHOL DEHYDROGENASE. THE ALDEHYDIC FORM OF METHYLAZOXYMETHANOL IS A VERY UNSTABLE CMPD WHICH RAPIDLY RELEASES CARBONIUM IONS.', '1,2-DIMETHYLHYDRAZINE (DMH) IS HIGHLY METABOLIZED BY ISOLATED PERFUSED RAT LIVER. AFTER 1 HR OF PERFUSION, THE MEDIAN AMT OF DMH AND ITS METABOLITES IN THE MEDIUM WERE: DMH 16, AZOMETHAN 3, AZOXYMETHANE 42, AND METHYLAZOXYMETHANOL 30% OF THE GIVEN DOSE.', 'THE NDDO SEMIEMPIRICAL MOLECULAR ORBITAL STUDY METHOD WAS USED TO MODEL PROPOSED NONENZYME METABOLIC PATHWAYS FOR THE DECOMP OF METHYLAZOXYMETHANOL TO METHYLDIAZONIUM.', 'THE NDDO SEMIEMPIRICAL MOLECULAR ORBITAL STUDY METHOD WAS USED TO CHARACTERIZE THE REACTIVITIES OF METHYLAZOXYMETHANOL (MAM) AND ITS METABOLITES WITH DNA NUCLEOPHILIC BASE SITES.', 'FOLLOWING...ORAL ADMIN TO RATS, CYCASIN IS SPLIT BY BETA-GLUCOSIDASE OF BACTERIAL FLORA TO FORM METHYLAZOXYMETHANOL. ENZYMATIC HYDROLYSIS TO METHYLAZOXYMETHANOL ALSO OCCURS IN SUBCUTANEOUS TISSUES OF NEWBORN MICE & RATS, WHICH IN EARLY POSTNATAL PERIOD CONTAIN GLUCOSIDASE THAT DISAPPEARS AFTER 14TH-25TH DAY OF LIFE.']",
1554,11555,Dicyanodiamidine sulfate,C(=NC(=O)N)(N)N.C(=NC(=O)N)(N)N.OS(=O)(=O)O,,,,,,
1555,11556,CID 11556,CC(=O)N=C(N)S,,,,,,
1556,11557,Acetyl nitrate,CC(=O)O[N+](=O)[O-],,,,,,
1557,11558,5-Methyl-2(5H)-furanone,CC1C=CC(=O)O1,,,,,,
1558,11559,alpha-Angelica lactone,CC1=CCC(=O)O1,,,,,,
1559,11560,3-Bromotoluene,CC1=CC(=CC=C1)Br,,,,,,
1560,11561,1-Bromo-3-iodobenzene,C1=CC(=CC(=C1)I)Br,,,,,,
1561,11562,3-Bromoaniline,C1=CC(=CC(=C1)Br)N,,,,,,
1562,11563,3-Bromophenol,C1=CC(=CC(=C1)Br)O,,,,,"['p-Bromophenol and o-bromophenol were the major urinary phenolic bromobenzene metabolites although m-bromophenol and 4-bromocatechol were also excreted in detectable quantities. With the exception of o-bromophenol, urinary metabolites were excreted primarily as conjugates.', '2-bromophenol (2-(BP)), 3-BP, and 4-BP can all be formed during the metabolism of bromobenzene in both rats and guinea-pigs. 2-BP is formed predominantly by spontaneous isomerization of the 2,3-oxide. 3-BP is formed via the sulfur-series pathway to phenols, which involves the enterohepatic circulation, with the key intermediate being S-(2-hydroxy-4-bromocyclohexa-3,5-dienyl)-L-cysteine, derived from the 4-S-glutathione conjugate of the 3,4-oxide. 4-BP is formed by the sulfur-series route from the S-(2-hydroxy-5-bromocyclohexa-3,5-dienyl)-L-cysteine. Additional suggested in vivo routes to 3- and 4-BP involve dehydration/aromatization of the 3,4-dihydro-3,4-diol, possibly by way of conjugates.']",
1563,11564,"1,3-Dimethylcyclohexane",CC1CCCC(C1)C,,,,,,
1564,11565,"3,5-Dimethylpyridine",CC1=CC(=CN=C1)C,,,,,,
1565,11566,3-Methylcyclohexanol,CC1CCCC(C1)O,,,,,,
1566,11567,3-Methylcyclohexanone,CC1CCCC(=O)C1,,,,,,
1567,11568,3-Aminophenol,C1=CC(=CC(=C1)O)N,,,,,"['Yields m-acetamidophenol in Cordyceps. Yields 4-aminocatechol in rabbit. /From table/', 'Yields m-aminophenyl-beta-d-glucoside in housefly & in locust. Yields m-aminophenyl-beta-d-glucuronide in rabbit. /From table/', 'Yields m-aminophenyl sulfate in rat, in hen, in tick, in housefly. /From table/']",
1568,11569,3-Methoxybenzaldehyde,COC1=CC=CC(=C1)C=O,,,,,,
1569,11570,3'-Ethoxyacetanilide,CCOC1=CC=CC(=C1)NC(=O)C,,,,,,
1570,11571,"3,5-Dichlorophenol",C1=C(C=C(C=C1Cl)Cl)O,,,,"['Because of their high lipid solubility and low ionization at physiological pH, dichlorophenols would be expected to be readily absorbed following ingestion. /Dichlorophenols/', 'Dichlorophenol isomers are absorbed through the skin and from the gut. /Dichlorophenol isomers/', '... Readily absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/']","['3,5-Dichlorophenol is a metabolite of the pesticides polychlorinated phenols and benzene hexachloride.']",
1571,11572,4-Methylcyclohexene,CC1CCC=CC1,,,,,,
1572,11573,3-Methylcyclohexene,CC1CCCC=C1,,,,,,
1573,11574,1-Methylcyclohexene,CC1=CCCCC1,,,,,,
1574,11575,Iodobenzene,C1=CC=C(C=C1)I,,,,,"['The monohydroxylation of halobenzenes by phenobarbital-induced rat liver microsomes was studied. p-Halophenol was the major metabolite from all 4 halobenzenes; o-halophenol formation decreased as the halogen atom size increased. Vmax for total hydroxylation (ortho and para products) correlated well with the sigma + Hammett constant with a negative rho value. This implied a positively charged intermediate in the rate-determining step. Vmax for either ortho or para hydroxylation alone did not correlate with a Hammett constant, implying that the product-determining step occurred after the rate-determining step. Rate-determining formation of a radical cation intermediate probably explained this data. /Halobenzenes/', 'Detoxification of halogenobenzenes by sulfate, glucuronic-acid, and mercapturic-acid conjugation was studied. Chinchilla-rabbits received oral doses of chlorobenzene, bromobenzene, and iodobenzene equivalent to 150, 210, and 272 mg/kg, respectively ... Ethereal sulfates (E), glucuronides (G), and mercapturic-acids (M) were quantitated in rabbit urine. For chlorobenzene, the percentages of the dose excreted as conjugates were: G, 25.2; E, 26.6; and M, 20.4. For bromobenzene percentages were: G, 40.2; E, 36.8; M, 20.9. For iodobenzene, percentages were: G, 31.3; E, 29.6; M, 22.6 ...']",
1575,11576,Butyl acetoacetate,CCCCOC(=O)CC(=O)C,,,,,,
1576,11577,Ethyl butylcarbamate,CCCCNC(=O)OCC,,,,,,
1577,11578,Calcium levulinate,CC(=O)CCC(=O)[O-].CC(=O)CCC(=O)[O-].[Ca+2],"['This new application of calcium is intended for use as a food fortifier, to fortify foods like sauces, condiments, beer, beverages, soft drinks, milk and milk products, soy milk and soy products with calcium nutrition. Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation. In essence, calcium levulinate is ultimately a relatively new calcium supplementation option.']","['The relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide. The resultant calcium levulinate formulation, when used as a calcium supplement, possesses a high calcium content that is observed to be 14.8% higher than the content typically found in calcium lactate. Moreover, this formulation also demonstrates a high solubility of more than 30% at 25. Furthermore, the calcium levulinate is believed to be non-toxic and non-allergic, making it especially suitable for injection or infusion administrations. Additionally, this levulinate formulation is reported as having a good taste, little irritation with a pH value of 7, and good stability such that no precipitation or deterioration occurs during use. Finally, this calcium levulinate formulation is also believed to have good compatibility with calcium lactate, calcium chloride, and other material complexes which allows the formulation to also complex effectively with a diverse variety of foodstuffs and pharmaceutical dosage forms.']",['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],"['General calcium absorption occurs primarily in the duodenum by an active transcellular and saturable system, which is stimulated and regulated by 1,25(OH)2D,25 and through a passive and vitamin D-independent paracellular transport in the jejunum and ileum, and even in the colon - where absorption is only about 4% even when the intake is high. Ultimately, calcium absorption depends mainly on the amount of intake - in general, absorption increases at lower intakes and decreases at high intakes.  Readily accessible data regarding the specific absorption of calcium levulinate is not available although the formulation is considered a low molecular weight organic calcium ion type that is easily absorbed through the intestinal wall.', 'Calcium leaves the body mainly in urine and feces, but also in other body tissues and fluids, like sweat. Overall, a typical daily calcium loss for a healthy adult man or woman via renal excretion is approximately 5 mmol/day while endogenous fecal calcium losses are about 2.1 mg/kg per day in adults and about 1.4 mg/kg per day in children.', ""99% of the body's calcium supply is stored in the bones and teeth where it supports their structure and function. Elsewhere, 1% or less of this calcium supply is used for essential metabolic functions like vascular contraction and vasodilation, muscle function, nerve transmission, intracellular signaling, and hormonal secretion, among other activities."", ""Despite inter-individual differences, general clinical lab tests list some reference calcium clearance values as being considered a 'normal range', like urine calcium as approximately < 250 mg/24 h.""]","[""Although calcium levulinate dissociates into absorbable calcium ion once it is administered into the body, there have been studies to suggest that the levulinate component is metabolized to 4-hydroxypentanoate - a compound that has similar pharmacologic effects as but at a lower level of potency than the 'date rape' drug gamma-hydroxybutyrate.""]",['Readily accessible data regarding the half-life of calcium levulinate is not available.']
1578,11579,Levulinic acid,CC(=O)CCC(=O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
1579,11580,2-Fluoroethyl 6-fluorohexanoate,C(CCC(=O)OCCF)CCF,,,,,,
1580,11581,"Decanoic acid, 10-fluoro-, 2-fluoroethyl ester",C(CCCCC(=O)OCCF)CCCCF,,,,,,
1581,11582,2-Methylhexane,CCCCC(C)C,,,,,,
1582,11583,2-Hexanone,CCCCC(=O)C,,,,"['Inhalation is the primary route of exposure; however, dermatologic exposure can lead to skin irritation and this absorption may contribute to chronic exposure and polyneuropathy. Ingestion has rarely been reported.', 'Methyl n-butyl ketone (MNBK) is readily absorbed by lung, gi tract and through skin. It is not eliminated extensively unchanged in breath or urine. Radioactivity derived from (1-14)C-MNBK was excreted slowly by man, suggesting that exposure may lead to prolonged toxic metabolite exposure.', 'Humans exposed for 7.5 hr to 10 or 50 ppm or for 4 hr to 100 ppm of methyl n-butyl ketone (MNBK) absorbed between 75 and 92% of inhaled vapor. Two volunteers exposed by skin contact to (1-14)C-MNBK absorbed 4.8 ug/min/sq cm and 8.0 ug/min/sq cm, respectively.', 'Oral gavage administration of radiolabeled MnBK to rats indicated that 98% of the dose was absorbed. Beagle dogs that inhaled 50 or 100 ppm MnBK for 6 hr absorbed 65-68% of the vapor. absorption of radiolabeled MnBK through dog skin was observed to be slow at first but increased dramatically after 20 min of exposure ... It was concluded that approximately twice as much MnBK would be absorbed during a 1-hr dermal exposure as would be absorbed by inhalation of 25 ppm of MnBK vapor for 1 hr. Therefore, repeated dermal exposure to MnBK may contribute to its toxicity. Concomitant exposure to methyl ethyl ketone (MEK) may increase absorption of MnBK', 'For more Absorption, Distribution and Excretion (Complete) data for 2-HEXANONE (8 total), please visit the HSDB record page.']","['/Investigators/ studied the biotransformation of MnBK by the guinea pig and concluded that the primary metabolite was hexanedione.', '/2-Hexanone/ is metabolized by the liver to a common toxic metabolite, 2,5-hexanedione. This compound is a direct neurotoxin.', 'In guinea pigs and rats, methyl butyl ketone was oxidatively and reductively metabolized. 2,5-Dimethyl-2,3-dihydrofuran; 5-hydroxy-2-hexanone; 2-hexanol; and 2,5-hexanedione were compounds identified in serum of guinea pigs dosed with MBK.', 'Urinary metabolites from Charles river rats: 2-hexanol; 5-hydroxy-2-hexanone; 2,5-hexanedione; 2,5-dimethylfuran; gamma-valerolactone; norleucine; and urea. Apparently, alpha-oxidation to carbon dioxide is detoxification mechanism and omega-1 oxidation leads to activation.', 'For more Metabolism/Metabolites (Complete) data for 2-HEXANONE (8 total), please visit the HSDB record page.']","['No reports found; [TDR, p. 776]']"
1583,11584,Allyl acetate,CC(=O)OCC=C,,,,['IT IS...ABSORBED THROUGH INTACT SKIN.'],"['A MERCAPTURIC ACID WAS ISOLATED FROM URINE OF RATS TREATED SC WITH ALLYL ACETATE & IDENTIFIED AS 3-HYDROXYPROPYLMERCAPTURIC ACID N-ACETYL-S-3-HYDROXYPROPYL-L-CYSTEINE.', 'MERCAPTURIC ACIDS WERE DETECTED IN URINE OF RATS FOLLOWING ADMIN OF VARIOUS ALLYL ESTERS WHICH COULD BE METAB BY ACYL-OXYGEN FISSION OR ALKYL-OXYGEN FISSION TO YIELD 3-HYDROXYMERCAPTURIC ACID OR ALLYLMERCAPTURIC ACID. LATTER OCCURRED ONLY WHEN THE ESTER WAS FORMED FROM A STRONG ACID.']",
1584,11585,Mercuric potassium cyanide,C(#N)[Hg-2](C#N)(C#N)C#N.[K+].[K+],,,,,,
1585,11586,Tetracyanomercury(2-),C(#N)[Hg-2](C#N)(C#N)C#N,,,,,,
1586,11587,"1,4-Pentadiene",C=CCC=C,,,,,,
1587,11588,"1,2-Pentadiene",CCC=C=C,,,,,,
1588,11589,"2-Butene, 1-chloro-",CC=CCCl,,,,,,
1589,11590,Calcid,[C-]#N.[C-]#N.[Ca+2],,,,,,
1590,11591,Mercuric cyanide,C(#N)[Hg]C#N,,,,"['CYANIDE ION IS READILY ABSORBED AFTER ORAL OR PARENTERAL ADMIN. PROLONGED LOCAL CONTACT WITH CYANIDE SOLN OR WITH HYDROGEN CYANIDE MAY RESULT IN ABSORPTION OF TOXIC AMT THROUGH SKIN. ... PART OF ABSORBED CYANIDE IS EXCRETED UNCHANGED BY THE LUNG. LARGER PORTION ... CONVERTED BY ... SULFURTRANSFERASE TO RELATIVELY NONTOXIC THIOCYANATE ION. /CYANIDE/', 'IN 30 DAYS, 72% OF (14)C FROM IP DOSE OF (14)C-CYANIDE TO MICE WAS EXCRETED IN URINE & FECES, 25% IN EXPIRED AIR, & 3% WAS RETAINED ... PEAK EXCRETION OCCURRED WITHIN 10 MIN IN EXPIRED AIR & WITHIN 6-24 HR IN URINE & FECES. /CYANIDE/', 'CYANIDES ARE RAPIDLY ABSORBED FROM SKIN & ALL MUCOSAL SURFACES & ARE MOST DANGEROUS WHEN INHALED, BECAUSE TOXIC AMT ARE ABSORBED THROUGH BRONCHIAL MUCOSA & ALVEOLI. /CYANIDES/', 'Cyanide is distributed to all organs and tissues via the blood, where its concn in red cells is greater than that in plasma by a factor of two or three. Presumably, the accumulation of cyanide in erythrocytes is a reflection of its binding to methemoglobin. /Cyanides/', 'For more Absorption, Distribution and Excretion (Complete) data for MERCURIC CYANIDE (7 total), please visit the HSDB record page.']","['... CYANIDE ION IS CONJUGATED WITH SULFUR TO FORM THIOCYANATE. ... CONJUGATION IS CATALYZED BY ... RHODANESE WHICH IS WIDELY DISTRIBUTED IN MOST ANIMAL TISSUES ... /LIVER/ PARTICULARLY ACTIVE. ... RHODANESE MECHANISM IS CAPABLE OF DETOXICATING ONLY LIMITED AMT OF CYANIDE, SUCH AS ARE FORMED DURING NORMAL METAB. /SRP: ANOTHER SULFUR DONOR IS 3-MERCAPTOPYRUVATE. THE ENZYME, MERCAPTOSULFUR TRANSFERASE IS LOCALIZED IN CYTOSOL./ /CYANIDE/', '/ONE OF/ THE MAJOR MECHANISM/S/ FOR REMOVING CYANIDE FROM THE BODY IS ITS ENZYMATIC CONVERSION, BY THE MITOCHONDRIAL ENZYME RHODANESE (TRANSSULFURASE), TO THIOCYANATE, WHICH IS RELATIVELY ... /LESS TOXIC/. /CYANIDE/']",['Half-life for the conversion of cyanide to thiocyanate from a non-lethal dose in man is between 20 min and 1 hr. /Cyanide/']
1591,11592,"2,5-Dimethylhexane",CC(C)CCC(C)C,,,,,,
1592,11593,Acetoxyacetone,CC(=O)COC(=O)C,,,,,,
1593,11594,2-Methylheptane,CCCCCC(C)C,,,,,,
1594,11595,N-Butylurea,CCCCNC(=O)N,,,,,,
1595,11596,Butyl carbamate,CCCCOC(=O)N,,,,,,
1596,11597,1-Hexene,CCCCC=C,,,,,"['The epoxidation of 1-hexene (1a) and 2-methyl-1-hexene (1b), two hydrocarbons present in the ambient air as pollutants, is catalyzed by some human and rat P450 enzymes. The enantioselectivities of these processes, when the reactions were carried out using rat and human liver microsomal preparations, were modest and dependent on both P450 composition and substrate concentrations. Various p450 isoforms (rat p450 2B1 and human P450 2C10 and 2A6) catalyzed the double bond oxidation of 1a and 1b with different product enantioselectivities. In the case of 1a, a moderately enantioselective hydroxylation at the allelic C(3) with the formation of 1-hexen-3-ol (4a) by microsomes from control or preinduced rats was also observed. The oxidation of this metabolite was, in turn, catalyzed by rat liver microsomes and mainly by rat p450 2C11, leading exclusively to the formation of 1-hexen-3-one, with no double bond epoxidation being observed. The stereochemical course of the microsomal epoxide hydrolase-catalyzed hydrolysis of the epoxy alcohols, threo-(:)- and erythro-(:)-1,2-epoxyhexan-3-ol, theoretically expected to be formed from 4a, has been investigated.']",
1597,11598,"1,5-Hexadiene",C=CCCC=C,,,,,,
1598,11599,"Hexa-1,4-diene",CC=CCC=C,,,,,,
1599,11600,Dipropenyl,CC=CC=CC,,,,,,
1600,11601,3-Hexene,CCC=CCC,,,,,,
1601,11602,"Hexa-1,3-diene",CCC=CC=C,,,,,,
1602,11603,1-Fluoropentane,CCCCCF,,,,,,
1603,11604,4-Pentenenitrile,C=CCCC#N,,,,,,
1604,11605,"1,3-Cyclohexadiene",C1CC=CC=C1,,,,,,
1605,11606,"Methanol, (methyl-ONN-azoxy)-, acetate (ester)",CC(=O)OCN=[N+](C)[O-],,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)']","['IN RATS INJECTED WITH (3)H-METHYLAZOXYMETHANOL ACETATE ON DAY 14 OF PREGNANCY, 4% OF INJECTED RADIOACTIVITY WAS FOUND IN FETUSES; RADIOACTIVITY WAS ALSO FOUND IN LIVER & KIDNEY OF TREATED MOTHERS. DNA & RNA FROM FETAL BRAIN CONTAINED GUANINE METHYLATED IN 7-POSITION.']",,
1606,11607,2-Methyl-1-(2-methylpropylsulfanyl)propane;hydrate,CC(C)CSCC(C)C.O,,,,,,
1607,11608,Isobutyl sulfide,CC(C)CSCC(C)C,,,,,,
1608,11609,Hydroxycarbamic acid hexyl ester,CCCCCCOC(=O)NO,,,,,,
1609,11610,1-Heptene,CCCCCC=C,,,,,['BINDING WAS INVESTIGATED OF DIFFERENT 1-ALKENES TO CYTOCHROME P450 IN MICROSOMES FROM F344 RATS.'],
1610,11611,2-Heptene,CCCCC=CC,,,,,,
1611,11612,3-Heptene,CCCC=CCC,,,,,,
1612,11613,Butyl isothiocyanate,CCCCN=C=S,,,,,,
1613,11614,Butyl formate,CCCCOC=O,,,,,,
1614,11615,Mercuric thiocyanate,C(#N)[S-].C(#N)[S-].[Hg+2],,,,,,
1615,11616,Lead thiocyanate,C(#N)[S-].C(#N)[S-].[Pb+2],,,,,,
1616,11617,Diallyl sulfide,C=CCSCC=C,,,"['Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. (See all compounds classified as Cytochrome P-450 Enzyme Inhibitors.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)']",,['Diallyl sulfide (DAS) ... is sequentially converted to diallyl sulfoxide (DASO) and diallyl sulfone (DASO2) by cytochrome P450 2E1 (CYP2E1).'],
1617,11618,Oxepane,C1CCCOCC1,,,,,,
1618,11619,"2-Octanone, 8-fluoro-",CC(=O)CCCCCCF,,,,,,
1619,11620,4-Methylsulfinyl-3-butenyl isothiocyanate,CS(=O)C=CCCN=C=S,,,,,,
1620,11621,Oct-4-ene,CCCC=CCCC,,,,,,
1621,11622,2-Tridecanone,CCCCCCCCCCCC(=O)C,,,,,,
1622,11623,"2-Dodecanone, 12-fluoro-",CC(=O)CCCCCCCCCCF,,,,,,
1623,11624,12-Fluorododecanoic acid,C(CCCCCC(=O)O)CCCCCF,,,,,,
1624,11625,"Octane, 1-bromo-8-fluoro-",C(CCCCBr)CCCF,,,,,,
1625,11626,"Octane, 1-chloro-8-fluoro-",C(CCCCCl)CCCF,,,,,,
1626,11627,"1,8-Difluorooctane",C(CCCCF)CCCF,,,,,,
1627,11628,8-Fluorooctylamine,C(CCCCF)CCCN,,,,,,
1628,11629,8-Fluorooctanal,C(CCCC=O)CCCF,,,,,,
1629,11630,"ETHER, BUTYL 2-(beta-FLUOROETHOXY)ETHYL",CCCCOCCOCCF,,,,,,
1630,11631,"Ether, 4-chlorobutyl 4-fluorobutyl",C(CCF)COCCCCCl,,,,,,
1631,11632,"Ether, bis(4-fluorobutyl)",C(CCF)COCCCCF,,,,,,
1632,11633,CID 11633,CCCCCCCCCCCCCCCCCC(=O)[O-].[K+],,,,,,
1633,11634,Octadec-6-enoic acid,CCCCCCCCCCCC=CCCCCC(=O)O,,,,,,
1634,11635,Octadecane,CCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/', 'The trans-membrane transport of hydrocarbons is an important and complex aspect of the process of biodegradation of hydrocarbons by microorganisms. The mechanism of transport of (14)C n-octadecane by Pseudomonas sp. DG17, an alkane-degrading bacterium, was studied by the addition of ATP inhibitors and different substrate concentrations. When the concentration of n-octadecane was higher than 4.54 umol/L, the transport of (14)C n-octadecane was driven by a facilitated passive mechanism following the intra/extra substrate concentration gradient. However, when the cells were grown with a low concentration of the substrate, the cellular accumulation of n-octadecane, an energy-dependent process, was dramatically decreased by the presence of ATP inhibitors, and n-octadecane accumulation continually increased against its concentration gradient. Furthermore, the presence of non-labeled alkanes blocked (14)C n-octadecane transport only in the induced cells, and the trans-membrane transport of n-octadecane was specific with an apparent dissociation constant K t of 11.27 umol/L and V max of 0.96 umol/min/mg protein. The results indicated that the trans-membrane transport of n-octadecane by Pseudomonas sp. DG17 was related to the substrate concentration and ATP.']",,
1635,11636,Heptacosane,CCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
1636,11637,Monomethylammonium chloride,C[NH3+].[Cl-],,,,,,
1637,11638,Fluoromethane,CF,,,,,,
1638,11639,Methoxyammonium chloride,CO[NH3+].[Cl-],,,,,,
1639,11640,CID 11640,CC[AsH2],,,,,,
1640,11641,Vinyl bromide,C=CBr,,,,"['IN SUBACUTE INHALATION STUDIES, RATS WERE EXPOSED TO 44 G/CU M (10,000 PPM) VINYL BROMIDE IN AIR 7 HR/DAY ON 5 DAYS A WK FOR 4 WK; OR RATS, RABBITS & MONKEYS WERE EXPOSED TO 1.1 OR 2.2 G/CU M (250 OR 500 PPM) VINYL BROMIDE FOR 6 HR A DAY ON 5 DAYS A WK FOR 6 MO. ... NON-VOLATILE BROMIDE LEVELS IN BLOOD INCR WITH DURATION OF EXPOSURE IN ALL THREE SPECIES & WERE PROPORTIONAL TO CONCN OF VINYL BROMIDE INHALED.', 'INHALATION PHARMACOKINETICS OF THE HALOGENATED ETHYLENES VINYL FLUORIDE, VINYL BROMIDE, PERCHLORETHYLENE (PER) AND TRICHLOROETHYLENE (TRI) WERE COMPARATIVELY STUDIED IN RATS. CMPD WITH LOW BOILING POINTS ARE ENRICHED IN TISSUES LESS THAN THOSE WITH HIGHER BOILING POINTS & VICE-VERSA.', 'Comparative pharamacokinetics of vinyl fluoride, vinylidene fluoride, vinyl chloride ... & vinyl bromide were studied by inhalation in rats. Metabolic elimination of halogenated ethylenes was a saturable dose-dependent process. If animals were exposed to atmospheric concn of halogenated ethylene, which exceeded saturation, elimination was determined by a zero-order law. In contrast, below saturation, first-order kinetics was obtained.', 'Vinyl bromide is readily absorbed upon inhalation by rats and showed an 11-fold accumulation within the rats compared with the concentration in gaseous phase. Metabolism is saturable at exposure concentrations greater than 250 mg/cu m. Following inhalation in vinyl bromide by rats, rabbits, and monkeys, plasma levels of nonvolatile bromide increased with exposure duration, and more rapidly in phenobarbital-pretreated rats.', 'The US EPA calculated a permeability coefficient of 5.5X10(-3) cm/hr for vinyl bromide through human skin. Comparable calculations for vinyl chloride gave a value of 7.3X10(-3) cm/hr.']","['WHEN MIXTURE OF VINYL BROMIDE IN AIR WAS PASSED THROUGH MOUSE-LIVER MICROSOMAL SYSTEM, A VOLATILE ALKYLATING METABOLITE WAS FORMED, AS DEMONSTRATED BY TRAPPING WITH 4-(4-NITROBENZYL)PYRIDINE.', 'Results of experiments in vitro indicate that the primary metabolite formed by mixed-function oxidases from vinyl bromide is 2-bromoethylene oxide, while the rearrangement product of the latter, 2-bromoacetaldehyde, might be the major alkylating agent bound to protein. Irreversible protein binding of metabolites of 1,2-(14)C-vinyl bromide has been established both with rat-liver microsomes in vitro & in rats in vivo.', 'Vinyl bromide is metabolized, since bromide ion is found in the blood of exposed animals. ... Metabolism is expected to be similar to that of vinyl chloride, probably proceeding through epoxidation, with subsequent conjugation to macromolecules and other biologic compounds.', 'The first step in biotransformation of ... vinyl bromide ... has been proposed to involve microsomal oxidation leading to epoxide formation across the double bond. ... /It has been/ suggested that the resulting oxiranes are highly reactive and therefore can covalently bind to nucleic acids with the eventual end result of mutations and cancer.', 'For more Metabolism/Metabolites (Complete) data for VINYL BROMIDE (14 total), please visit the HSDB record page.']",
1641,11642,Vinylamine,C=CN,,,,,,
1642,11643,Chlorofluoromethane,C(F)Cl,,,,,,
1643,11644,Chloroiodomethane,C(Cl)I,,,,,,
1644,11645,Dimethylmercury,C[Hg]C,,,,,,
1645,11646,Methyl isocyanide,C[N+]#[C-],,,,,,
1646,11647,N-Methylhydroxylamine,CNO,,,,,,
1647,11648,Dimethyl selenide,C[Se]C,,,,"['Inorganic selenium /converted/ to less toxic methylated compounds such as dimethylselenide (DMSe) and trimethylselenonium (TMSe). This study investigated the role of vitamin B12, a cofactor of methionine synthetase, in selenium methylation in the rat. Vitamin B12-depleted rats expired 16% of dosed 75Se-selenite as DMSe compared to 45% for control rats and excreted less TMSe in the urine (6.1% of dose) than control (9% of dose) rats. At the same time, higher (p < 0.05) tissue (liver, kidney, muscle) selenium levels and lower (p < 0.05) blood selenium levels were found in vitamin B12-deficient rats. Primary hepatocytes from vitamin B12-deficient rats volatilized 15% of selenite in incubation medium in 5 hr as compared to 49% in hepatocytes from control rats. Hepatocytes from vitamin B12-deficient rats were less resistant to selenite toxicity. In vitro methylation of selenium with liver extract from vitamin B12-deficient rats showed one-third to one-half the rate of volatilization of selenium as compared to control rats. S-adenosylmethionine was required for this reaction. These results show that vitamin B12 deficiency significantly decreases the ability of rats to methylate selenium.']","['The anticarcinogenic activity of selenium in animal models is well established. The active forms of selenium involved have not been identified to date, but conversion of selenium via hydrogen selenide (H2Se) to methylated forms such as dimethylselenide and trimethylselenonium ion is an important metabolic fate. By controlling the entry of selenium into various points within this pathway through selection of appropriate starting compounds, it is possible to pinpoint more closely the form(s) of selenium responsible for its anticarcinogenic activity. Selenobetaine in the chloride form [(CH3)2Se+CH2COOH] and its methyl ester are extensively metabolized in the rat to mono-, di-, and trimethylated selenides, largely bypassing the inorganic H2Se intermediary pool. The chemopreventive efficacy of these selenobetaines was determined at 1 and 2 ppm selenium supplemented in the diet throughout the duration of the experiment using the dimethylbenz(a)anthracene induced mammary tumor model in rats. There was a dose-dependent inhibitory response to both compounds, and they appeared to be slightly more active than selenite. These doses were without any adverse effects on the animals. Coadministration of selenobetaine with arsenite (5 ppm arsenic) enhanced the tumor-suppressive effect of selenobetaine, although arsenic by itself was totally inactive. Arsenite is known to inhibit certain steps in selenium methylation. The substantial prophylactic efficacy of methylated selenides and the enhancement by arsenite suggest that partially methylated forms of selenium may be directly involved in the anticarcinogenic action of selenium.']",
1648,11649,"Methanamine, N,N-dimethyl-, hydrochloride (1:1)",C[NH+](C)C.[Cl-],,,,,,
1649,11650,"Guanidine, carbonate",C(=N)(N)N.C(=N)(N)N.C(=O)(O)O,,,,,,
1650,11651,Trimethylbismuth,C[Bi](C)C,,,,,,
1651,11652,"1,1-Dibromoethylene",C=C(Br)Br,,,,,,
1652,11653,Dibromoiodomethane,C(Br)(Br)I,,,,,,
1653,11654,1-Bromo-1-chloroethane,CC(Cl)Br,,,,,,
1654,11655,Dichloroiodomethane,C(Cl)(Cl)I,,,,,,
1655,11656,Trimethylantimony,C[Sb](C)C,,,,,,
1656,11657,Methylcyclopropane,CC1CC1,,,,,,
1657,11658,"2,2-Dibromopropane",CC(C)(Br)Br,,,,,,
1658,11659,Dibromodichloromethane,C(Cl)(Cl)(Br)Br,,,,,,
1659,11660,"2,2-Dichloropropane",CC(C)(Cl)Cl,,,,,,
1660,11661,Tetramethyltin,C[Sn](C)(C)C,,,,,,
1661,11662,Triphenylantimony dichloride,C1=CC=C(C=C1)[Sb](C2=CC=CC=C2)(C3=CC=CC=C3)(Cl)Cl,,,,,,
1662,11663,Einecs 209-835-7,CC(C)C(Br)Br,,,,,,
1663,11664,"1,1-Dichloroisobutane",CC(C)C(Cl)Cl,,,,,,
1664,11665,2-Iodo-2-methylbutane,CCC(C)(C)I,,,,,,
1665,11666,Perchloromethyl mercaptan,C(SCl)(Cl)(Cl)Cl,,,,,,
1666,11667,Ethanesulfonyl chloride,CCS(=O)(=O)Cl,,,,,,
1667,11668,Ethanesulfonic acid,CCS(=O)(=O)O,,,,,,
1668,11669,"2,3,3-Trimethyl-1-butene",CC(=C)C(C)(C)C,,,,,,
1669,11670,"2,3-Dimethyl-2-butanol",CC(C)C(C)(C)O,,,,,,
1670,11671,2-Hydroxyisobutyric acid,CC(C)(C(=O)O)O,,,,,,
1671,11672,2-Methyl-2-nitropropane,CC(C)(C)[N+](=O)[O-],,,,,,
1672,11673,2-Chloro-2-nitropropane,CC(C)([N+](=O)[O-])Cl,,,,,,
1673,11674,"1,1-Dichloro-1-nitroethane",CC([N+](=O)[O-])(Cl)Cl,,,,['GC/MS ANALYSES OF PROFILES OF VOLATILE CONSTITUENTS OBTAINED FROM CORD BLOOD & MATERNAL BLOOD SAMPLES REFLECT TRANSPLACENTALLY ACQUIRED HALOGENATED HYDROCARBONS & ACCUM IN FETAL CORD BLOOD.'],,
1674,11675,"2,2,3,3-Tetramethylbutane",CC(C)(C)C(C)(C)C,,,,,,
1675,11676,"2,3,3-Trimethyl-2-butanol",CC(C)(C)C(C)(C)O,,,,,,
1676,11677,"1,1,1,2,2,3,3-Heptachloropropane",C(C(C(Cl)(Cl)Cl)(Cl)Cl)(Cl)Cl,,,,,,
1677,11678,"Propane, octachloro-",C(C(Cl)(Cl)Cl)(C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
1678,11679,Perflisopent,C(C(C(F)(F)F)(F)F)(C(F)(F)F)(C(F)(F)F)F,,,,,,
1679,11680,"3-[(3S,5R,10S,13R,14S,17R)-3-[(2R,5S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14,16-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@@H](C(C([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC([C@@H]5C6=CC(=O)OC6)O)O)C)C)O)OC)O,,,,,,
1680,11681,"4'-Oxo-1,1',1',3',6'-pentamethyl-1,3'-bipiperidinium diiodide",CC1CC(=O)C(C[N+]1(C)C)(C)[N+]2(CCCCC2)C.[I-].[I-],,,,,,
1681,11682,"1,1,2,5-Tetramethyl-5-(1-methylpiperidin-1-ium-1-yl)piperidin-1-ium-4-one",CC1CC(=O)C(C[N+]1(C)C)(C)[N+]2(CCCCC2)C,,,,,,
1682,11683,Megestrol acetate,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,"['For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.']","['Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. These effects include induction of secretory changes in the endometrium, increase in basal body temperature, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. Mestrogel has slight glucocorticoid activity and very slight mineralocorticoid activity. This drug has no estrogenic, androgenic, or anabolic activity. The precise mechanism of megestrol&rsquo;s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.']","['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS. (See all compounds classified as Appetite Stimulants.)']","['Variable, but well absorbed orally.', 'The major route of drug elimination in humans is urine.  Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.']",['Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.'],['34 hours']
1683,11684,"2,2-Dimethylbutyric acid",CCC(C)(C)C(=O)O,,,,,,
1684,11685,"2,3-Dimethyl-3-pentanol",CCC(C)(C(C)C)O,,,,,,
1685,11686,Dimethylmalonic acid,CC(C)(C(=O)O)C(=O)O,,,,,,
1686,11687,Algestone,CC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O)O,,,"['Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)', 'Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. (See all compounds classified as Progestins.)', 'Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)']",,,
1687,11688,"1,1,1-Trinitroethane",CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
1688,11689,"4',5'-Dibromofluorescein",C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)Br)OC5=C3C=CC(=C5Br)O,,,,,,
1689,11690,beta-Erythroidine hydrochloride,CO[C@@H]1C[C@]23C4=C(CC[NH+]2CC=C3C=C1)COC(=O)C4.[Cl-],,,,,,
1690,11691,CID 11691,CC(=O)[O-].C[NH+]1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,,,,,,
1691,11692,Bromotriphenylmethane,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)Br,,,,,,
1692,11693,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],['Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).'],,"['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']",,,
1693,11694,"1,3'-Bipiperidin-4'-one, 1',3',6'-trimethyl-, dihydrochloride",CC1CC(=O)C(C[NH+]1C)(C)[NH+]2CCCCC2.[Cl-].[Cl-],,,,,,
1694,11695,"1,2,5-Trimethyl-5-piperidin-1-ylpiperidin-4-one",CC1CC(=O)C(CN1C)(C)N2CCCCC2,,,,,,
1695,11696,"2-Ethyl-2-nitro-1,3-propanediol",CCC(CO)(CO)[N+](=O)[O-],,,,,,
1696,11697,"Amidopyrophosphoric acid, diethyl-, trimethyl ester",CCN(CC)P(=O)(OC)OP(=O)(OC)OC,,,,,,
1697,11698,Dimethyl morpholinophosphoramidate,COP(=O)(N1CCOCC1)OC,,,,"['DIMETHYLMORPHOLINOPHOSPHORAMIDATE INJECTED INTO RATS WAS NOT ACCUMULATED IN ANY TISSUES & LEVELS APPROACHING 0 WERE OBSERVED AT 40 HR AFTER INJECTION. URINE LEVELS WERE REDUCED TO 0 BY 4 DAYS AFTER INJECTION.', 'URINARY EXCRETION RATE WAS DETERMINED FOR 4, 8, 12 & 24 HR PERIODS FOLLOWING ITS IM INJECTION INTO HUMANS. WHEN DMMPA WAS INJECTED INTO DELTOID MUSCLE, IT COULD BE DETECTED IN URINE FOR 6 DAYS BUT NOT ON THE 7TH DAY.']",,
1698,11699,"3-Hydroxy-2,2-dimethylpropanal",CC(C)(CO)C=O,,,,,,
1699,11700,"Amidopyrophosphoric acid, dimethyl-, trimethyl ester",CN(C)P(=O)(OC)OP(=O)(OC)OC,,,,,,
1700,11701,"2,2-Dimethylsuccinic acid",CC(C)(CC(=O)O)C(=O)O,,,,,,
1701,11702,3-Ethyl-3-pentanol,CCC(CC)(CC)O,,,,,,
1702,11703,Tetraethylgermane,CC[Ge](CC)(CC)CC,,,,,,
1703,11704,Tetraethyltin,CC[Sn](CC)(CC)CC,,,,,"['The dealkylation of tetraethyltin to triethyltin ... is fast. ...', 'The metabolism of tetraethyltin to triethyltin assures that the relative distribution and chemical forms of tin are similar after treatment with tetraethyl- or triethyltin.', 'Tetraethyltin was rapidly metabolized by isolated rat liver microsome preparations, and in rats after iv injection, to form triethyltin derivatives. Also, the triethyltin products were shown to be metabolized further to diethyltin derivatives in an in vitro system.', 'The reduced form of nicotinamide-adenine dinucleotide phosphate and oxygen dependent microsomal metabolism of the di-, tri- and tetra-ethyl-substituted derivatives of germanium, tin, and lead gave rise to ethylene as a major product and ethane as a minor product in rats. These reactions were catalyzed by liver microsomal cytochrome p450-dependent monooxygenase. Since formation of ethane and ethylene was differentially inhibited by anaerobiosis, results suggested that a large portion of the ethane produced was derived by a reductive mechanism. Triethyltin bromide in the absence and presence of the reduced form of nicotinamide-adenine dinucleotide phosphate converted cytochrome p450 into cytochrome p420 and affected the function of monooxygenase in vitro. Tetraethyltin caused the reduced form of nicotinamide-adenine dinucleotide phosphate and the time-dependent formation of cytochrome p420, suggesting that tetraethyltin was converted into triethyltin salts in significant concentrations. The order of potency in formation of cytochrome p420 was closely paralleled by the ability of tin derivatives to induce microsomal lipid peroxidation in vitro.', 'The metabolism and toxicity of some ethyl-substituted organotin compounds in isolated rat hepatocytes were studied. Tetra- and triethyltin derivatives were metabolized by isolated rat hepatocytes to yield ethane and ethylene. Hydrocarbon formation from tetraethyltin was larger than that obtained with triethyltin bromide and ethylene was the major product (95%) of tetraethyltin metabolism. At a triethyltin salt concentration of 100 uM, the major product formed by cells from untreated rats was ethane. Pretreatment in vivo by phenobarbital resulted in a marked increase in the overall rate of hydrocarbon production and a change in ethylene ratio; ethylene was the predominant metabolite produced. 5,6-Benzoflavone pretreatment in vivo resulted in a small depression in overall hydrocarbon production. No metabolites of diethyltin dichloride (100 uM) by isolated rat heptocytes was detected. Triethyltin bromide (100 uM) was a potent inhibitor of phase 1 (oxidation) and phase 2 (conjugation) metabolism of biphenyl in isolated hepatocytes from phenobarbital-pretreated rats: diethyltin dichloride affected particularly the phase 1 metabolism of the aromatic hydrocarbon. Triethyl- and diethyltin salts reduced O2 consumption and ATP levels in these cells. The triethyl derivative was more effective. Tetraethyltin was not apparently toxic to hepatocytes. Trypan blue dye exclusion and lactate dehydrogenase loss by the cell isolated from phenobarbital-pretreated rats indicated that triethyltin bromide was more toxic than diethyltin dichloride. The diethyl derivative was more potent in stimulating lipid peroxidation as indicated by the formation of thiobarbituric acid-reactive products than triethyltin.']",
1704,11705,"O,S-Diethyl O-(p-nitrophenyl) phosphorothioate",CCOP(=O)(OC1=CC=C(C=C1)[N+](=O)[O-])SCC,,,,,,
1705,11706,"1,10-Decanediaminium, N,N,N',N'-tetraethyl-N,N'-dimethyl-, diiodide",CC[N+](C)(CC)CCCCCCCCCC[N+](C)(CC)CC.[I-].[I-],,,,,,
1706,11707,10-[Diethyl(methyl)azaniumyl]decyl-diethyl-methylazanium,CC[N+](C)(CC)CCCCCCCCCC[N+](C)(CC)CC,,,,,,
1707,11708,3-Methyl-3-hexanol,CCCC(C)(CC)O,,,,,,
1708,11709,Dipropyl sulfone,CCCS(=O)(=O)CCC,,,,"['Following oral administration of (35S)-dipropyl sulfone to male Wistar rats (4.24 mmol/kg body wt), the only radioactive component subsequently found in the blood and bile was the sulfone. Biliary excretion played an important role in the elimination of this compound, with 16% of the dose excreted during the first twenty-four hours and 33% passing through the bile duct over a two day period. Bile/plasma concentration ratios remained constant during the first day (c. 46-fold), suggesting that a concentration process was taking place and that active transport of this low molecular weight compound into the bile was occurring.']",,
1709,11710,3-Methyl-3-heptanol,CCCCC(C)(CC)O,,,,,,
1710,11711,Ethyldichloroarsine,CC[As](Cl)Cl,,,,"['Skin absorption - 100,000 mg/min/cu m /from table/']",,
1711,11712,Tribromoethylene,C(=C(Br)Br)Br,,,,,,
1712,11713,2-Bromopropan-1-ol,CC(CO)Br,,,,,,
1713,11714,"3-Methyl-1,2-butadiene",CC(=C=C)C,,,,,,
1714,11715,Bromoacetone,CC(=O)CBr,,,,,"['... In this study, the factors influencing the disposition and biotransformation of 1-bromopropane (1-BrP) were examined in male F344 rats and B6C3F1 mice following inhalation exposure (800 ppm) or intravenous administration (5, 20, and 100 mg/kg). (1,2,3-13C)1-BrP and (1-14C)1-BrP were administered to enable characterization of urinary metabolites using NMR spectroscopy, LC-MS/MS, and HPLC coupled radiochromatography. ... The molar ratio of exhaled 14CO2 to total released bromide, which decreased as dose increased, demonstrated that the proportion of 1-BrP metabolized via oxidation relative to pathways dependent on glutathione conjugation is inversely proportional to dose in the rat. (14C)1-BrP equivalents were recovered in urine (13-17%, rats; 14-23% mice), feces (< 2%), or retained in the tissues and carcass (< 6%) of rats and mice administered iv 5 to 100 mg/kg (14C)1-BrP. Metabolites characterized in urine of rats and mice include N-acetyl-S-propylcysteine, N-acetyl-3-(propylsulfinyl)alanine, N-acetyl-S-(2-hydroxypropyl)cysteine, 1-bromo-2-hydroxypropane-O-glucuronide, N-acetyl-S-(2-oxopropyl)cysteine, and N-acetyl-3-[(2-oxopropyl)sulfinyl]alanine. These metabolites may be formed following oxidation of 1-bromopropane to 1-bromo-2-propanol and bromoacetone and following subsequent glutathione conjugation with either of these compounds ...']",
1715,11716,3-Buten-2-OL,CC(C=C)O,,,,,,
1716,11717,1-Aminopropane-2-thiol,CC(CN)S,,,,,,
1717,11718,"2,2-Dichloroethanol",C(C(Cl)Cl)O,,,,,,
1718,11719,Methylurea,CNC(=O)N,,,,,,
1719,11720,CID 11720,CN=C(N)S,,,,,,
1720,11721,2-Methoxypropane,CC(C)OC,,,,,,
1721,11722,Methyl carbamate,COC(=O)N,,,,"['RATS INJECTED IP WITH METHYL CARBAMATE...EXCRETED...CARBAMATE...IN URINE...', 'DNA BINDING OF...(14)C-METHYL CARBAMATE LABELED IN METHYL GROUP HAS BEEN INVESTIGATED IN MOUSE LIVER & KIDNEY. ... INCORP OF (3)H-METHYL CARBAMATE INTO LIVER-CELL RNA HAS BEEN EXAMINED IN MICE...']",,
1722,11723,"N,N-Dimethylethylamine",CCN(C)C,,,,"['... The aims of the study were three-fold: to assess the skin uptake of the industrial catalyst N,N-dimethylethylamine (a) in vitro from water solutions by fresh guinea-pig and human skin specimens, (b) in gaseous form in vivo in human volunteers, and (c) to estimate the relevance of the uptake as an occupational hazard. ... N,N-dimethylethylamine, diluted with water or isotonic saline solution was applied to fresh human or guinea-pig skin, mounted in Teflon flow-through cells with a perfusion fluid flow rate of 1.5 mL/hr, samples being collected at 2-hr intervals for 48 hr. Three healthy male volunteers each had their right forearm exposed (in a Plexiglass chamber) for 4 hr to N,N-dimethylethylamine at each of three different levels (250, 500 and 1000 mg/cu m air). Urine was collected up to 24 hr after the start of each experiment. ... N,N-dimethylethylamine penetrated both guinea-pig and human skin. The median steady-state flux and permeability coefficient (Kp) values, were 0.009 mg/sq cm x hr and 0.001 cm/hr, respectively, for guinea-pig skin, and 0.017 mg/sq cm x hr and 0.003 cm/hr, respectively, for human skin. The median uptake in the three volunteers at the different N,N-dimethylethylamine exposure levels (250, 500 or 1000 mg/cu m) was 44, 64 and 88 ug, respectively. The median Kp for all experiments was 0.037 cm/hr. /The authors concluded that/ uptake of DMEA through the skin is of far less importance than simultaneous uptake via the airways. Thus, the amount of N,N-dimethylethylamine excreted in urine is a variable of limited use for the purposes of biological monitoring...']","['... During 8 hr, four healthy volunteers were exposed to four different N,N-dimethylethylamine air concentrations (10, 20, 40 and 50 mg/cu m; 20 mg/cu m, two subjects only). N,N-dimethylethylamine was biotransformed into dimethylethylamine N-oxide (DMEAO). On average, DMEAO, accounted for 90% of the combined amount of N,N-dimethylethylamine and DMEAO excreted into the urine. The half-lives of N,N-dimethylethylamine and DMEAO in plasma were 1.3 and 3.0 hr, respectively. The urinary excretion of N,N-dimethylethylamine and DMEAO followed a two-phase pattern. The half-lives in the first phase were 1.5 hr for N,N-dimethylethylamine and 2.5 hr for DMEAO. In the second phase, which started about 9 hr after the end of exposure, half-lives of 7 hr for N,N-dimethylethylamine and 8 hr for DMEAO were recorded. The combined concentration of N,N-dimethylethylamine and DMEAO, in both plasma and urine, showed an excellent correlation with the air concentration of N,N-dimethylethylamine. Thus, both urinary excretion and plasma concentration can be used for biological monitoring of exposure to N,N-dimethylethylamine. An 8-hr exposure to 10 mg N,N-dimethylethylamine/cu m corresponds to a postexposure plasma concentration and 2-hr postexposure urinary excretion of 4.9 umol/L and 75 mmol/mol creatinine, respectively.', 'In /mould core manufacturing/ workers exposed to 0.003 - 0.007 mg/L, inhaled dimethylethylamine was excreted in urine as the original amine and as its metabolite dimethylethylamine-N-oxide.', 'In an inhalation study with human volunteers exposed to 10 to 50 mg/cu m (3.3 to 16.7 ppm) of dimethylethylamine over 8 hr, alveolar uptake was 80% to 90%. Most of the substance was eliminated in the urine either as unchanged dimethylethylamine (10%) or as an oxidized metabolite dimethylethylamine-N-oxide (90%).']","['... In 12 mould core makers in four different foundries using the Ashland cold box technique ... half lives after the end of exposure for N,N-dimethylethylamine in urine of 1.5 hours and dimethylethylamine-N-oxide (DMEAO) of three hours....', '... / In four healthy volunteers/ the half-lives of dimethylethylamine (DMEA) and /the metabolite/ dimethylethylamine N-oxide (DMEAO) in plasma were 1.3 and 3.0 hr, respectively. The urinary excretion of DMEA and DMEAO followed a two-phase pattern. The half-lives in the first phase were 1.5 hr for DMEA and 2.5 hr for DMEAO. In the second phase, which started about 9 hr after the end of exposure, half-lives of 7 hr for DMEA and 8 hr for DMEAO were recorded. ...']"
1723,11724,Methyl nitrate,CO[N+](=O)[O-],,,,,,
1724,11725,Methylcyclobutane,CC1CCC1,,,,,,
1725,11726,Manganese carbonate,C(=O)([O-])[O-].[Mn+2],,,,"['The subcellular distribution of manganese (Mn) in brains of mice chronically admin Mn in different chemical forms with food was examined using gel chromatography. Male ddY-mice were divided into five groups of six animals each, & Groups 1 to 4 were given 2 grams/kilogram Mn of standard laboratory mouse chow) in the form of manganese chloride (MnCl2), manganese acetate (MnAc), manganese carbonate (MnCO3), or manganese oxide (MnO2), in the diets for 12 months, while Group 5 served as control. 24 hr after the last feed, animals were decapitated & brains were rapidly removed for study of the different regions (corpus striatum (CS), hypothalamus, midbrain, cerebral cortex (CC), hippocampus, cerebellum, & medulla oblongata). Subcellular fractions (mitochondrial, microsomal & cytosolic) & gel chromatography fractions were analyzed for Mn contents using flame atomizer absorption spectrophotometry. Results showed that CC levels of Mn in mice exposed to the nearly insoluble MnCO3 & MnO2 were higher than in controls, while Mn concns in the CS were similar to those in controls. Microsomal Mn in treated mice was also higher than in controls. The gel chromatographic profile of CS showed that 20% Mn was in the high molecular weight (MW) fractions, 45% was in the middle MW fractions, while 32% was in the low MW fractions. The % Mn in high MW fractions was higher (29% to 49%) in the Mn treated groups, than in controls. The % of Mn in low MW fractions of the MnO2 exposed group (9%) was lower than in the MnCl2, MnAc, & MnCO3 exposed groups (42%, 36%, & 38%, respectively). The authors conclude that the brain regional distribution of Mn from the virtually insoluble cmpds is different from that of soluble Mn cmpds, & that striatal subcellular & gel chromatographic profiles are similar for the divalent Mn cmpds. They add that there is more Mn associated with fast migrating ligands in the striatal cytosol of the Mn treated groups than in the controls, & that these binding characteristics are different from those of other organs.']",,
1726,11727,Lead(II) carbonate,C(=O)([O-])[O-].[Pb+2],,,,"['IVE: This study was designed to evaluate the source of Pb in blood of ... 49 children (48 < 5 years of age) along with 18 adults (> 20 years of age) ... .  Mean PbB level of the children was 7.5 ug/dL (range, 1.5-25.7 ug/dL; n = 49; geometric mean, 6.6 ug/dL), with four children whose PbB was > 12 ug/dL. The isotopic data for blood samples lay around two distinct arrays. The blood of all children analyzed for Pb isotopes contained a contribution of Pb from the Magellan mine, which for young children ranged from 27% up to 93% (mean, 64%; median, 71%). Subtraction of the ore component gave a mean background PbB of 2.3 ug/dL. Several children whose PbB was > 9 ug/dL and most of the older subjects have complex sources of Pb. ...  The death of the birds acted as a sentinel event; otherwise, the exposure of the community, arising from such a toxic form of Pb, could have been tragic ...', 'Adult male dogs were given daily doses of 34.1 mg and 68.2 mg basic lead carbonate for 60 days. Ratio of urinary lead excretion to total lead admin was very small, 0.24 & 0.09% respectively. 98.7 & 98.9% respectively of total lead admin was fecally excreted. Urinary and fecal excretions totalled 98.4 & 97.9% respectively. The highest concn was found in teeth and bones, followed by bone marrow, hair, and trachea. /Basic lead carbonate/']",,
1727,11728,"Carbamodithioic acid, dimethyl-, compd. with N-methylmethanamine (1:1)",C[NH2+]C.CN(C)C(=S)[S-],,,,,,
1728,11729,2-Bromopropionic acid,CC(C(=O)O)Br,,,,,,
1729,11730,Bromotrifluoroethylene,C(=C(F)Br)(F)F,,,,,,
1730,11731,"1,2-Dimethylpropylamine",CC(C)C(C)N,,,,,,
1731,11732,3-Methyl-2-butanol,CC(C)C(C)O,,,,,,
1732,11733,"1,1,2-Trichloropropane",CC(C(Cl)Cl)Cl,,,,,,
1733,11734,2-Chloropropionic acid,CC(C(=O)O)Cl,,,,,,
1734,11735,2-Chloroacrylic acid,C=C(C(=O)O)Cl,,,,,,
1735,11736,"1,2-Dichloro-1,2-difluoroethene",C(=C(F)Cl)(F)Cl,,,,,,
1736,11737,"1,1-Dimethylurea",CN(C)C(=O)N,,,,,,
1737,11738,"3,4,4-Trimethylpent-2-en",CC=C(C)C(C)(C)C,,,,,,
1738,11739,Methyl trichloroacetate,COC(=O)C(Cl)(Cl)Cl,,,,,,
1739,11740,"11,17,21-Trihydroxy-16-methylidenepregna-1,4-diene-3,20-dione",CC12CC(C3C(C1CC(=C)C2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,,,,,,
1740,11741,"3,3'-Sulfonyldianiline",C1=CC(=CC(=C1)S(=O)(=O)C2=CC=CC(=C2)N)N,,,,,,
1741,11742,4-Cumylphenol,CC(C)(C1=CC=CC=C1)C2=CC=C(C=C2)O,,,,,,
1742,11743,"Benzenesulfonamide, N,N,4-trimethyl-",CC1=CC=C(C=C1)S(=O)(=O)N(C)C,,,,,,
1743,11744,Tribromoethyl acetate,CC(=O)OCC(Br)(Br)Br,,,,,,
1744,11745,Ethyl 2-bromoisobutyrate,CCOC(=O)C(C)(C)Br,,,,,,
1745,11746,"2,3-Dibromopropionic acid",C(C(C(=O)O)Br)Br,,,,,,
1746,11747,"2,3-Pentanedione",CCC(=O)C(=O)C,,,,,"['We developed a system to expose cultured human bronchial/tracheal epithelial cells (NHBEs) to flavoring vapors. NHBEs were exposed for 6 hr to diacetyl or 2,3-pentanedione vapors (25 or >/= 60 ppm)... Analysis of the basolateral medium indicated that NHBEs metabolize diacetyl and 2,3-pentanedione to acetoin and 2-hydroxy-3-pentanone, respectively.']",
1747,11748,Methyl pyruvate,CC(=O)C(=O)OC,,,,,,
1748,11749,2-Nitrobutane,CCC(C)[N+](=O)[O-],,,,,,
1749,11750,1-Chloro-1-nitropropane,CCC([N+](=O)[O-])Cl,,,,,,
1750,11751,Chloromalonic acid,C(C(=O)O)(C(=O)O)Cl,,,,,,
1751,11752,"2,4-Dimethyl-3-pentanol",CC(C)C(C(C)C)O,,,,,,
1752,11753,17beta-Hydroxy-5alpha-androst-2-ene-2-carboxaldehyde,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(CC(=CC4)C=O)C,,,,,,
1753,11754,delta(sup5)-Cholestenone,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(=O)C4)C)C,,,,,,
1754,11755,19-Nortestosterone cyclopenytlpropionate,CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35,,,,,,
1755,11756,Ethylmalonic acid,CCC(C(=O)O)C(=O)O,,,,,,
1756,11757,"1,1-Dinitropropane",CCC([N+](=O)[O-])[N+](=O)[O-],,,,,,
1757,11758,N-Nitrosodiisopropylamine,CC(C)N(C(C)C)N=O,,,,,,
1758,11759,"1,3-Dichloro-2-nitrobenzene",C1=CC(=C(C(=C1)Cl)[N+](=O)[O-])Cl,,,,,,
1759,11760,2-Nitroresorcinol,C1=CC(=C(C(=C1)O)[N+](=O)[O-])O,,,,,,
1760,11761,"2,3-Dinitrotoluene",CC1=C(C(=CC=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,"['The metabolites produced from 5 dinitrotoluene isomers (2,3-, 2,4-, 2,5-, 2,6- and 3,4-DNT) by Escherichia coli strain W3110, isolated from human intestine, were identified. Data obtained from thin-layerand gas chromatography or liquid scintilation counting indicated that the metabolites produced by the Escherichia coli were 2 monoaminonitrotoluenes and hydroxylaminonitrotoluenes in all cases. This finding indicates that dinitrotoluene is reduced via hydroxylaminonitrotoluenes to monoaminonitrotoluenes in Escherichia coli. In addition , the reduction reactivities of Dinitrotoluene isomers were 3- > 2- for 2,3-DNT, 4- > 2- for 2,4-DNT, 5- > 2- for 2,5-DNT and 3- > 4- for 3,4-DNT.', 'Bioactivation of dinitrotoluene in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.']",
1761,11762,"1,1'-Bi-2-naphthol",C1=CC=C2C(=C1)C=CC(=C2C3=C(C=CC4=CC=CC=C43)O)O,,,,,,
1762,11763,"2,3,4-Trinitrotoluene",CC1=C(C(=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1763,11764,"1,8-Dinitronaphthalene",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=CC=C2)[N+](=O)[O-],,,,,,
1764,11765,"3,8-Diamino-5-ethyl-6-phenylphenanthridinium chloride",CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N.[Cl-],,,['Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)'],,,
1765,11766,9-Phenylanthracene,C1=CC=C(C=C1)C2=C3C=CC=CC3=CC4=CC=CC=C42,,,,,,
1766,11767,9-Nitroanthracene,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2[N+](=O)[O-],,,,,,
1767,11768,Anthragallol,C1=CC=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)O)O,,,,,,
1768,11769,5-Nitroacenaphthene,C1CC2=CC=C(C3=CC=CC1=C23)[N+](=O)[O-],,,,,"['The metabolism of ... 5-nitroacenaphthene, by the 9000 x g supernatant from the livers of Aroclor-pretreated rats was studied. The major primary metabolites were 1-hydroxy-5-nitroacenaphthene and 2-hydroxy-5-nitroacenaphthene. These metabolites were oxidized to 1-oxo-5-nitroacenaphthene and 2-oxo-5-nitroacenaphthene, hydroxylated to cis-1,2-dihydroxy-5-nitroacenaphthene and trans-1,2-dihydroxy-5-nitroacenaphthene, and reduced to 1-hydroxy-5-aminoacenaphthene and 2-hydroxy-5-aminoacenaphthene. Reduction of 1- and 2-oxo-5-nitroacenaphthene to 1-oxo- and 2-oxo-5-aminoacenaphthene was also observed. When incubations were carried out in a N2-enriched atmosphere (10% O2 in N2), the major metabolites were 1-hydroxy- and 2-hydroxy-5-nitroacenaphthene and 2-oxo-5-aminoacenaphthene. Selected metabolites were tested for mutagenicity toward Salmonella typhimurium TA 98. The most mutagenic of the metabolites tested, in the presence or absence of rat liver 9000 x g supernatant, were 1-hydroxy-5-nitroacenaphthene and 1-oxo-5-nitroacenaphthene. These results indicate that the 9000 x g supernatant from the livers of Aroclor-pretreated rats is capable of catalyzing both the oxidation and reduction of 5-nitroacenaphthene and that the reduced derivatives of 1-hydroxy- or 2-hydroxy- or 1-oxo- or 2-oxo-5-nitroacenaphthene are proximate mutagens.']",
1769,11770,Pentafluorobenzoic acid,C1(=C(C(=C(C(=C1F)F)F)F)F)C(=O)O,,,,,,
1770,11771,"2,4,6-Trinitromesitylene",CC1=C(C(=C(C(=C1[N+](=O)[O-])C)[N+](=O)[O-])C)[N+](=O)[O-],,,,,,
1771,11772,"2,4,6-Trinitro-m-cresol",CC1=C(C(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
1772,11773,Triphenylarsine,C1=CC=C(C=C1)[As](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1773,11774,Triphenylbismuth,C1=CC=C(C=C1)[Bi](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1774,11775,Triphenylamine,C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1775,11776,Triphenylphosphine,C1=CC=C(C=C1)P(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1776,11777,Triphenylantimony,C1=CC=C(C=C1)[Sb](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1777,11778,Triphenyl guanidine,C1=CC=C(C=C1)N=C(N)N(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1778,11779,3-Nitrophthalimide,C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)NC2=O,,,,,,
1779,11780,Bromopyrine,CC1=CC(=O)N(N1C)C2=CC=C(C=C2)Br,,,,,,
1780,11781,1-Methylindole,CN1C=CC2=CC=CC=C21,,,,,,
1781,11782,"2,3-Dimethylbenzoic acid",CC1=C(C(=CC=C1)C(=O)O)C,,,,,,
1782,11783,2-Methyl-3-nitroaniline,CC1=C(C=CC=C1[N+](=O)[O-])N,,,,,,
1783,11784,2-Chloro-6-nitrophenol,C1=CC(=C(C(=C1)Cl)O)[N+](=O)[O-],,,,,,
1784,11785,Cholest-5-en-3-yl benzoate,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C5=CC=CC=C5)C)C,,,,,,
1785,11786,"[(3S,9S,14S,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CC(C)CCCC(C)[C@H]1CC[C@@H]2C1(CC[C@H]3C2CC=C4C3(CC[C@@H](C4)OC(=O)C)C)C,,,,,,
1786,11787,4-Chloro-1-naphthol,C1=CC=C2C(=C1)C(=CC=C2Cl)O,,,,,,
1787,11788,Glycosmicine,CN1C2=CC=CC=C2C(=O)NC1=O,,,,,,
1788,11789,"1,1'-Binaphthalene",C1=CC=C2C(=C1)C=CC=C2C3=CC=CC4=CC=CC=C43,,,,,,
1789,11790,alpha-Naphthoflavone,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,,,,,,
1790,11791,Hexaethylbenzene,CCC1=C(C(=C(C(=C1CC)CC)CC)CC)CC,,,,,,
1791,11792,Paramyon,CCC(C1=CC=C(C=C1)[N+](C)(C)C)C(CC)C2=CC=C(C=C2)[N+](C)(C)C.[I-].[I-],,,,,,
1792,11793,Trimethyl-[4-[4-[4-(trimethylazaniumyl)phenyl]hexan-3-yl]phenyl]azanium,CCC(C1=CC=C(C=C1)[N+](C)(C)C)C(CC)C2=CC=C(C=C2)[N+](C)(C)C,,,,,,
1793,11794,Pentaethylbenzene,CCC1=CC(=C(C(=C1CC)CC)CC)CC,,,,,,
1794,11795,1-Phenylnaphthalene,C1=CC=C(C=C1)C2=CC=CC3=CC=CC=C32,,,,,,
1795,11796,2-Hydroxyanthraquinone,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)O,,,,,,
1796,11797,"2,2'-Dimethylbiphenyl",CC1=CC=CC=C1C2=CC=CC=C2C,,,,,,
1797,11798,"2,7-Diaminoanthraquinone",C1=CC2=C(C=C1N)C(=O)C3=C(C2=O)C=CC(=C3)N,,,,,,
1798,11799,Diisopropyl phthalate,CC(C)OC(=O)C1=CC=CC=C1C(=O)OC(C)C,,,,,,
1799,11800,"9,10-Dichloroanthracene",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2Cl)Cl,,,,,,
1800,11801,Dansyl chloride,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)Cl,,,,,,
1801,11802,"2,4-Dinitro-1-naphthol",C1=CC=C2C(=C1)C(=CC(=C2O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1802,11803,"1,5-Dinitronaphthalene",C1=CC2=C(C=CC=C2[N+](=O)[O-])C(=C1)[N+](=O)[O-],,,,,,
1803,11804,3-Methyluric acid,CN1C2=C(C(=O)NC1=O)NC(=O)N2,,,,,,
1804,11805,Tribenzyl isocyanurate,C1=CC=C(C=C1)CN2C(=O)N(C(=O)N(C2=O)CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
1805,11806,Pamabrom,CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br,,,,,,
1806,11807,2-Amino-2-methyl-1-propanol,CC(C)(CO)N,,,,['METABOLISM AND DISTRIBUTION OF (3)H-LABELED 2-AMINO-2-METHYLPROPANOL WAS STUDIED IN RATS RECEIVING NORMAL OR CHOLINE-DEFICIENT DIETS. TRITIUM APPEARED IN THE SERUM OF BOTH GROUPS 30 MIN AFTER THE IP INJECTION BUT THE LEVEL WAS GENERALLY LOWER IN THE CHOLINE-DEFICIENT GROUP. RATS ON THE NORMAL DIET EXCRETED MORE OF THE AMINO ACID IN THE URINE THAN DID THE CHOLINE-DEFICIENT RATS IN BOTH GROUPS ONLY THE UNCHANGED AMINO ACID WAS EXCRETED. LIVERS FROM THE CHOLINE-DEFICIENT GROUP HAD A GREATER UPTAKE AND RETENTION OF THE LABEL THAN THOSE FROM NORMAL RATS. MOST OF THE LABEL WAS FOUND IN THE CYTOSOL OF BOTH LIVER AND KIDNEY.'],,
1807,11808,8-Bromotheophylline,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br,"['Bromotheophylline is used as a diuretic and also, in combination with [DB00316], it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.']","['Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain. This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion.']",,"['When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.', 'This pharmacokinetic property has not been determined.', 'This pharmacokinetic property has not been determined.', 'This pharmacokinetic property has not been determined.']",['This pharmacokinetic property has not been determined.'],['The apparent elimination half-life is registered to be 21.35 hours.']
1808,11809,Pyrabrom,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br.CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,,,,,,
1809,11810,Pentachloroethylbenzene,CCC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
1810,11811,3-hydroxy-L-kynurenine,C1=CC(=C(C(=C1)O)N)C(=O)C[C@@H](C(=O)O)N,,,,,,
1811,11812,2-Hydroxyisophthalic acid,C1=CC(=C(C(=C1)C(=O)O)O)C(=O)O,,,,,,
1812,11813,"2,6-Dinitrotoluene",CC1=C(C=CC=C1[N+](=O)[O-])[N+](=O)[O-],,,,"['After ip and oral administration of 2,6-DNT, the distribution and elimination were determined in strain A mice. In a 30 wk bioassay and at total ip doses of 600, 1500, or 3000 mg/kg, or total oral doses of 1200, 3000, or 6000 mg/kg, the urine was the major route of elimination of both ip and orally administered (3)H-labeled 2,6-DNT, with 87.6, 55.2 and 49.1% of ip doses of 1, 10 and 100 mg/kg, respectively, excreted within 4 hr. The corresponding amounts excreted after oral administration were 33.6, 25.2 and 24.3%, which increased to 53.7, 53.5 and 48.6% after 8 hr. The distribution of 2,6-DNT in various tissues (blood, liver, kidneys, lungs, small and large intestine) showed no evidence for preferential uptake or retention at any of the ip or po doses. Terminal half-lives of radioactive material in the liver were 1.11, 0.95 and 1.16 hr after ip doses of 1, 10 and 100 mg/kg, respectively.']","['Hydrolyzed urine from workers exposed to dinitrotoluene contained 2,4- and 2,6-DNT, 2,4- and 2,6-dinitrobenzoic acid, 2,4- and 2,6-dinitrobenzyl alcohol, 2-amino-4-nitrobenzoic acid, and 2-(N-acetyl)amino-4-nitrobenzoic acid. ... The percentages of 2,4- and 2,6-DNT metabolites in the urine of individual subjects ranged from 79% to 93%.', 'Bioactivation of dinitrotoluene in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.', 'Urine specimens were collected over 72 hr from workers at a dinitrotoluene manufacturing plant. Samples were analyzed for 2,4- and 2,6-DNT and putative metabolites by GC/MS. Urine from workers exposed to dinitrotoluene contained 2,4- and 2,6-DNT, 2,4- and 2,6-dinitrobenzoic acid, 2,4-and 2,6-dinitrobenzyl glucuronide, 2-amino-4-nitrobenzoic acid and N-(acetyl)amino-4-nitrobenzoic acid. Excretion of these metabolites peaked near the end of the workshift, but declined to low or undetectable concentrations by the start of work the following day. The calculated half-times for elimination of total dinitrotoluene-related material detected in urine ranged from 1.0-2.7 hr, and those of individual metabolites from 0.8-4.5 hr. The most abundant metabolites were 2,4-dinitrobenzoic acid and 2-amino-4-nitrobenzoic acid, collectively accounting for 74-86% of the dinitrotoluene metabolites detected.', 'The metabolism and excretion of the hepatocarcinogen 2,6-DNT was investigated in Fischer 344 rats in vivo and in isolated perfused livers. Urinary excretion accounted for half of the dose (10 mg/kg) 72 hr after administration of (14)C-2,6-DNT. 2,6-Dinitrobenzoic acid, 2,6-dinitrobenzyl alcohol glucuronide, and 2-amino-6-nitrobenzoic acid accounted for 95% of the urinary (14)C. Fecal excretion accounted for 1/5 of the dose in 72 hr. 2,6-Dinitrobenzyl alcohol glucoronide was the major metabolite found in the perfusate and bile of isolated perfused rat livers. Biliary excretion of 2,6-dinitrobenzyl alcohol glucoronide by livers from male rats was 3.3 and 8.6-fold that of female rats on perfusion with 20 and 70 uM (14)C 2,6-DNT, respectively. No sex-dependent differences in biliary flow rates were observed. Twice as much (14)C was found to be covalently bound to hepatic macromolecules in male than female rat livers in vivo. Decreased biliary excretion of 2,6-dinitrobenzyl alcohol glucoronide may account for the lesser amount of (14)C found to be covalently bound in female rat livers. Observations with 2,6-DNT parallel those made with 2,4-DNT, suggesting that both isomers are metabolized by the liver, excreted in the bile, deconjugated and further metabolized by the intestinal microflora, and transported back to the liver for, perhaps, additional metabolism and covalent binding to an endogenous component of the liver.', 'For more Metabolism/Metabolites (Complete) data for 2,6-DINITROTOLUENE (11 total), please visit the HSDB record page.']",
1813,11814,"2-Chloro-1,3-dinitrobenzene",C1=CC(=C(C(=C1)[N+](=O)[O-])Cl)[N+](=O)[O-],,,,,,
1814,11815,"1,3-Indandione",C1C(=O)C2=CC=CC=C2C1=O,,,,,,
1815,11816,Methyl 2-benzoylbenzoate,COC(=O)C1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
1816,11817,"2,4,6-Trinitroanisole",COC1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,"['Reduced metabolites, possibly hydroxylamines, may be the proximal mutagenic intermediates.']",
1817,11818,"1,3-Dinitronaphthalene",C1=CC=C2C(=C1)C=C(C=C2[N+](=O)[O-])[N+](=O)[O-],,,,,,
1818,11819,2-Chloronaphthalen-1-ol,C1=CC=C2C(=C1)C=CC(=C2O)Cl,,,,,,
1819,11820,1-Methyl-2-quinolone,CN1C(=O)C=CC2=CC=CC=C21,,,,,,
1820,11821,"Isoquinolinium, 1,1'-(p-phenylenebis(oxymethylene))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2,2-dimethyl-, diiodide",C[N+]1(CCC2=CC(=C(C=C2C1COC3=CC=C(C=C3)OCC4C5=CC(=C(C=C5CC[N+]4(C)C)OC)OC)OC)OC)C.[I-].[I-],,,,,,
1821,11822,"1-[[4-[(6,7-dimethoxy-2,2-dimethyl-3,4-dihydro-1H-isoquinolin-2-ium-1-yl)methoxy]phenoxy]methyl]-6,7-dimethoxy-2,2-dimethyl-3,4-dihydro-1H-isoquinolin-2-ium",C[N+]1(CCC2=CC(=C(C=C2C1COC3=CC=C(C=C3)OCC4C5=CC(=C(C=C5CC[N+]4(C)C)OC)OC)OC)OC)C,,,,,,
1822,11823,1-Nitronaphthalen-2-amine,C1=CC=C2C(=C1)C=CC(=C2[N+](=O)[O-])N,,,,,,
1823,11824,Toyocamycin,C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C#N,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
1824,11825,"2,4'-Dinitrobiphenyl",C1=CC=C(C(=C1)C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1825,11826,"3,3-Diphenylacrylic acid",C1=CC=C(C=C1)C(=CC(=O)O)C2=CC=CC=C2,,,,,,
1826,11827,4-Chloro-2-phenylphenol,C1=CC=C(C=C1)C2=C(C=CC(=C2)Cl)O,,,,,,
1827,11828,1-Naphthylhydroxylamine,C1=CC=C2C(=C1)C=CC=C2NO,,,,,,
1828,11829,5-Nitroquinoline,C1=CC2=C(C=CC=N2)C(=C1)[N+](=O)[O-],,,,,,
1829,11830,8-Nitroquinoline,C1=CC2=C(C(=C1)[N+](=O)[O-])N=CC=C2,,,,,,
1830,11831,2-Nitrofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)[N+](=O)[O-],,,"['Any substance in the air which could, if present in high enough concentration, harm humans, animals, vegetation or materials. Substances include GASES; PARTICULATE MATTER; and volatile ORGANIC CHEMICALS. (See all compounds classified as Air Pollutants.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,['Bacteroides vulgatus readily reduces 2-nitrofluorene to 2-aminofluorene...'],
1831,11832,"ANILINE, N,N-DIMETHYL-p-(1-NAPHTHYLAZO)-",CN(C)C1=CC=C(C=C1)N=NC2=CC=CC3=CC=CC=C32,,,,,,
1832,11833,4-Methylcoumarin,CC1=CC(=O)OC2=CC=CC=C12,,,,,,
1833,11834,7-(3-(Dimethylamino)-2-methylpropoxy)flavone,CC(CN(C)C)COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
1834,11835,N-(3-(Dimethylamino)propyl)-2-((4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy)acetamide,CN(C)CCCNC(=O)COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
1835,11836,"alpha-(1-Aminoethyl)-2,4-dihydroxybenzyl alcohol hydrochloride",CC(C(C1=C(C=C(C=C1)O)O)O)[NH3+].[Cl-],,,,,,
1836,11837,"4-(2-Amino-1-hydroxypropyl)benzene-1,3-diol",CC(C(C1=C(C=C(C=C1)O)O)O)N,,,,,,
1837,11838,Isopropyl salicylate,CC(C)OC(=O)C1=CC=CC=C1O,,,,,,
1838,11839,"2,4,6-Tribromoanisole",COC1=C(C=C(C=C1Br)Br)Br,,,,,"[""Zebrafish (Danio rerio) were fed a diet containing a mixture of 11 structurally diverse brominated flame retardants (BFRs) at nominal concentrations of either 1 or 100 nmol/g for up to 42 days, followed by an elimination period of 14 days. Uptake rates and elimination constants for five of the BFRs were calculated from measurements of their concentrations in the male fish during the exposure and elimination phases. Observed uptake efficiencies were highest for 2,4,4'-tribromodiphenyl ether (BDE 28) and 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) and were lowest for decabromodiphenyl ether (BDE 209). Estimated half-lives for TBECH and 2,4,6-tribromophenol were short (<2 d). Four BFR metabolites were identified in the fish: 2,2',3,4',5',6-Hexabromodiphenyl ether (BDE 149), 2,2',4,4',5,6'-hexabromodiphenyl ether (BDE 154), 2,4,6-tribromoanisole, and 1,2,4,5-hexabromobenzene. These metabolites were still present in the zebrafish after the 14 day elimination period.""]",
1839,11840,5-Methylisatin,CC1=CC2=C(C=C1)NC(=O)C2=O,,,,,,
1840,11841,3-Acetoxyindole,CC(=O)OC1=CNC2=CC=CC=C21,,,,,,
1841,11842,"1,2,3-Tribromobenzene",C1=CC(=C(C(=C1)Br)Br)Br,,,,,,
1842,11843,2-Methylresorcinol,CC1=C(C=CC=C1O)O,,,,,,
1843,11844,"2,3-Dichloroaniline",C1=CC(=C(C(=C1)Cl)Cl)N,,,,,"[""The metabolic fate of propanil in plants was studied. The conversion of this compound in soil to 3,3',4,4'-tetrachloroazobenzene is catalyzed by soil peroxidases. This reaction also occurs in the presence of crystalline horseradish peroxidase. In some plants propanil is rapidly hydrolyzed to give 3,4-dichloroaniline. Crude extracts of barnyard grass, fresh horseradish root, rice, & commercially purified crystalline horseradish enzyme were prepared. It was inferred that the differences in substrate specificity among peroxidases may account for the failure of some plants to convert the aniline to azo compounds such as in the conversion to dichloroaniline to tetrachloroazobenzene. ... Enzymatically catalyzed products of mono- & dichloroanilines were prepared by mixing barnyard grass supernatants or horseradish peroxidase with an acetic buffer, hydrogen peroxide & various aniline substrates & allowed to react for 30 min. Preparations made from fresh horseradish & from horseradish peroxidase gave products with all anilines except 2,5- & 2,6-dichloroanilines. Barnyard grass & rice plants gave products only with 2,3-dichloroaniline of the dichloroaniline substrates studied.""]",
1844,11845,"1,2,3-Triiodobenzene",C1=CC(=C(C(=C1)I)I)I,,,,,,
1845,11846,"2,6-Dichloroaniline",C1=CC(=C(C(=C1)Cl)N)Cl,,,,,,
1846,11847,"2,6-Dibromophenol",C1=CC(=C(C(=C1)Br)O)Br,,,,,,
1847,11848,"2,3-Dimethylsuccinic acid",CC(C(C)C(=O)O)C(=O)O,,,,,,
1848,11849,"2,4-Dinitromesitylene",CC1=CC(=C(C(=C1[N+](=O)[O-])C)[N+](=O)[O-])C,,,,,,
1849,11850,Galactitol,C([C@H]([C@@H]([C@@H]([C@H](CO)O)O)O)O)O,,,,,,
1850,11851,Dimethyl L-tartrate,COC(=O)[C@@H]([C@H](C(=O)OC)O)O,,,,,,
1851,11852,Pentabromophenol,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)O,,,,['... Rapidly absorbed from gastroenteric tract.'],,
1852,11853,"Benzene, hexaiodo-",C1(=C(C(=C(C(=C1I)I)I)I)I)I,,,,,,
1853,11854,Pentabromobenzene,C1=C(C(=C(C(=C1Br)Br)Br)Br)Br,,,,,,
1854,11855,Pentachlorobenzene,C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['... Pentachlorobenzene ... accumulated to appreciable extent in both maternal & fetal tissues /after daily oral administration of 50, 100 & 200 mg/kg to rats on days 6-15 of gestation or 22-day-old fetuses/.', 'The mean levels of chlorobenzenes (including pentachlorobenzene) in human milk and adipose tissue were determined and ranged from traces to 25 ug/kg for human milk and from not detected to 146 ug/kg for adipose tissue. The distribution of different chlorobenzene isomers in adipose tissue and milk was different.', 'Single oral doses of 0.5 mg/kg of (14)c-pentachlorobenzene were given to male and female rhesus monkeys. The chemical was readily absorbed and evidence indicates that the lymphatic system was involved in the absorption process. The major excretory pathway was via the feces. It is suggested that the metabolic system involved some mechanism other than the hepatic cytochrome p450. It is suggested that two different hydroxylation pathways could be involved. The first calls for oxidation of the pentachlorobenzene to pentachlorophenol, aND the 2ND calls for nucleophilic displacement reactions of pentachlorobenzene to tetrachlorophenols in sites which are metabolically active, other than the liver.', 'The reported data are part of a continuing monitoring program of chlorinated hydrocarbons in adipose tissue of canadians in order to monitor disappearance of restricted organochlorine pesticides as well as the appearance of new environmental contaminants. Human adipose tissues were obtained during autopsies on accident victims. Pentachlorobenzene was found in all tissues sampled, regardless of geographic region, age, or sex of the subject. Amounts recovered were erratic, however, making quantitative determinations invalid.', 'For more Absorption, Distribution and Excretion (Complete) data for PENTACHLOROBENZENE (8 total), please visit the HSDB record page.']","['The biliary excretion of metabolites of hexachlorobenzene was studied in rats dosed intragastrically with (14)c-hexachlorobenzene. By GLC-mass spectrometry, 1.8% of the (14)C excreted in the 24 hour bile was shown to be due to pentachlorobenzene.', 'Pentachlorobenzene is a metabolite of hexachlorobenzene in chick embryo liver cell primary culture.', 'Pentachlorobenzene yields chlorobenzene in rabbit. From table/', 'When pentachlorobenzene was added to culture of mold, degradation produced following metabolites: pentachlorophenol, 2,3,4,5- & 2,3,4,6-tetrachlorophenol; 1,2,3,4-tetrachlorobenzene; 1,2,4,5- &/or 1,2,3,5-tetrachlorobenzene; 2,3,4-, 2,4,6- & 3,4,5-trichlorophenol; & 1,3,5-trichlorobenzene.', 'For more Metabolism/Metabolites (Complete) data for PENTACHLOROBENZENE (8 total), please visit the HSDB record page.', 'Pentachlorobenzene has known human metabolites that include Pentachlorophenol.']",
1855,11856,Pentaiodobenzene,C1=C(C(=C(C(=C1I)I)I)I)I,,,,,,
1856,11857,Diethyl methylmalonate,CCOC(=O)C(C)C(=O)OCC,,,,,,
1857,11858,Ethyl 2-chloroacetoacetate,CCOC(=O)C(C(=O)C)Cl,,,,,,
1858,11859,"3,4,5-Trichlorophenol",C1=C(C=C(C(=C1Cl)Cl)Cl)O,,,,['The compounds are absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/'],,
1859,11860,"2,6-Dichloro-1,4-phenylenediamine",C1=C(C=C(C(=C1Cl)N)Cl)N,,,,,"['2,6-DICHLORO-4-NITROANILINE DCNA WAS ABSORBED BY ROOTS OF LETTUCE & TOMATOES GROWN IN TREATED SOIL & WAS TRANSLOCATED TO LEAVES, WHERE IT UNDERWENT RAPID DEGRADATION TO POLAR METABOLITES. TRANSIENT METABOLITES 2,6-DICHLORO-P-PHENYLENEDIAMINE WAS NOT DETECTED.']",
1860,11861,"2,4-Dibromo-6-methylphenol",CC1=CC(=CC(=C1O)Br)Br,,,,,,
1861,11862,"2,4,6-Triiodophenol",C1=C(C=C(C(=C1I)O)I)I,,,,,,
1862,11863,3-Ethyl-2-methylpentane,CCC(CC)C(C)C,,,,,,
1863,11864,2-Nitro-1-butanol,CCC(CO)[N+](=O)[O-],,,,,,
1864,11865,2-Nitrofuran,C1=COC(=C1)[N+](=O)[O-],,,,,,
1865,11866,2-Nitrothiophene,C1=CSC(=C1)[N+](=O)[O-],,,,,,
1866,11867,O-Phenolsulfonic acid,C1=CC=C(C(=C1)O)S(=O)(=O)O,,,,,,
1867,11868,"2,5-Dimethylbenzenesulfonic acid",CC1=CC(=C(C=C1)C)S(=O)(=O)O,,,,,,
1868,11869,"N,N-Dimethyl-o-toluidine",CC1=CC=CC=C1N(C)C,,,,,,
1869,11870,CI-501 Pamoate,CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
1870,11871,"2,4-Dichloro-6-nitrophenol",C1=C(C=C(C(=C1[N+](=O)[O-])O)Cl)Cl,,,,,,
1871,11872,"2,6-Dinitro-p-cresol",CC1=CC(=C(C(=C1)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
1872,11873,"3,5-Dinitrosalicylic acid",C1=C(C=C(C(=C1C(=O)O)O)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1873,11874,"2,3,4-Trihydroxybenzoic acid",C1=CC(=C(C(=C1C(=O)O)O)O)O,,,,,,
1874,11875,2-Nitrobenzoyl chloride,C1=CC=C(C(=C1)C(=O)Cl)[N+](=O)[O-],,,,,,
1875,11876,2-Nitrobenzamide,C1=CC=C(C(=C1)C(=O)N)[N+](=O)[O-],,,,,,
1876,11877,"N,N-Dimethyl-2-nitroaniline",CN(C)C1=CC=CC=C1[N+](=O)[O-],,,,,,
1877,11878,"2,4,5-Trinitrotoluene",CC1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1878,11879,"2,5-Dinitrobenzoic acid",C1=CC(=C(C=C1[N+](=O)[O-])C(=O)O)[N+](=O)[O-],,,,,,
1879,11880,"2,4-Dinitrobenzoic acid",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)O,,,,,,
1880,11881,4-Hydroxyphthalic acid,C1=CC(=C(C=C1O)C(=O)O)C(=O)O,,,,,,
1881,11882,5-Hydroxy-2-nitrobenzoic acid,C1=CC(=C(C=C1O)C(=O)O)[N+](=O)[O-],,,,,,
1882,11883,"3,4-Dinitrotoluene",CC1=CC(=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,"['Bioactivation of dinitrotoluene in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.', 'The metabolites produced from 5 DNT isomers (2,3-, 2,4-, 2,5-, 2,6- and 3,4-DNT) by Escherichia coli strain W3110, isolated from human intestine, were identified. Data obtained from metabolites produced by the Escherichia coli were 2 monoaminonitrotoluenes and hydroxylaminonitrotoluenes in all cases. This finding indicates that DNT is reduced via hydroxylaminonitrotoluenes to monoaminonitrotoluenes in Escherichia coli. In addn, the redn reactivities of DNT isomers were 3- > 2- for 2,3-DNT, 4- > 2- for 2,4-DNT, 5- > 2- for 2,5-DNT and 3- > 4- for 3,4-DNT.']",
1883,11884,1-Methylanthracene,CC1=CC=CC2=CC3=CC=CC=C3C=C12,,,,,,
1884,11885,1-Aminoanthracene,C1=CC=C2C=C3C(=CC2=C1)C=CC=C3N,,,,,,
1885,11886,4-Methylacridine,CC1=CC=CC2=CC3=CC=CC=C3N=C12,,,,,,
1886,11887,"2,4-Dinitrophenetole",CCOC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1887,11888,2-Nitrophenylacetonitrile,C1=CC=C(C(=C1)CC#N)[N+](=O)[O-],,,,,,
1888,11889,2-Nitrophenetole,CCOC1=CC=CC=C1[N+](=O)[O-],,,,,,
1889,11890,2-Nitrophenyl acetate,CC(=O)OC1=CC=CC=C1[N+](=O)[O-],,,,,,
1890,11891,"2,5-Dibromobenzoic acid",C1=CC(=C(C=C1Br)C(=O)O)Br,,,,,,
1891,11892,"2,5-Dimethylbenzoic acid",CC1=CC(=C(C=C1)C)C(=O)O,,,,,,
1892,11893,CID 11893,CCC(C)C1C(=O)C(=C(N1)O)C(=O)C,,,,,,
1893,11894,Methyl 2-bromobenzoate,COC(=O)C1=CC=CC=C1Br,,,,,,
1894,11895,Methyl 2-chlorobenzoate,COC(=O)C1=CC=CC=C1Cl,,,,,,
1895,11896,"2,4-Dibromobenzoic acid",C1=CC(=C(C=C1Br)Br)C(=O)O,,,,,,
1896,11897,"2,4-Dimethylbenzoic acid",CC1=CC(=C(C=C1)C(=O)O)C,,,,,,
1897,11898,3-Methyl-4-nitroaniline,CC1=C(C=CC(=C1)N)[N+](=O)[O-],,,,,,
1898,11899,"2,4-Dichloronitrobenzene",C1=CC(=C(C=C1Cl)Cl)[N+](=O)[O-],,,,,"['The metabolism of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-dichloro-1-nitrobenzene by Mucor javanicus was investigated, together with 2,4-dichloro-1-nitrobenzene metabolism by other fungi. The main metabolites were the corresponding dichloroanilines, accompanied by a lesser amt of 2,5-dichloro-1-nitrobenzene and 2,6-dichloro-1-nitrobenzene (3-or4-substituted) from 2,3-dichloro-1-nitrobenzene or 2,4-dichloro-1-nitrobenzene, respectively. Similar metabolic patterns were observed with M griseocyanus, M praini, M hiemalis, or Aspergillus flavus.']",
1899,11900,5-Chloro-2-nitrophenol,C1=CC(=C(C=C1Cl)O)[N+](=O)[O-],,,,,,
1900,11901,CID 11901,C1=CC2=NC(=O)C(=O)C2=CC1=[N+](O)[O-],,,,,,
1901,11902,Methyl 2-furoate,COC(=O)C1=CC=CO1,,,,,,
1902,11903,1-Ethyl-2-methylbenzene,CCC1=CC=CC=C1C,,,,,,
1903,11904,2-Methylstyrene,CC1=CC=CC=C1C=C,,,,,"['o-Vinyltoluene, m-vinyltoluene and p-vinyltoluene were given i.p. to rats and urine was analyzed for acidic metabolites by gas chromatography mass spectrometry. Different derivatives were prepared and used to identify the structure of the metabolites. Different types (11) of metabolites were found, although all metabolites were not produced from each vinyltoluene isomer. The metabolites identified were: methylphenylethylene glycol, methylmandelic acid, methylphenylglyoxylic acid, hydroxymethylphenylethylene glycol, carboxyphenylethylene glycol, hydroxymethylphenylglyoxylic acid, methylbenzoylglycine, methylphenylacetylglycine, vinylbenzoylglycine, N-acetylcysteine conjugate of methylphenylethanol and glucuronide of methylphenylethylene glycol. Metabolites (> 90%) recovered were excreted during the 1st 24 hr. For the sum of all metabolites, there was an approximately linear relation between given dose and recovered amount of metabolites. Repeated daily administration was not followed by any appreciable increase in metabolite excretion and no enzyme induction phenomenon was apparent.']",
1904,11905,2-Chlorobenzyl bromide,C1=CC=C(C(=C1)CBr)Cl,,,,,,
1905,11906,2-Chlorobenzyl chloride,C1=CC=C(C(=C1)CCl)Cl,,,,,,
1906,11907,2-Hydroxybenzonitrile,C1=CC=C(C(=C1)C#N)O,,,,,,
1907,11908,N-Hydroxy-2-toluidine,CC1=CC=CC=C1NO,,,,,,
1908,11909,2-Nitrosotoluene,CC1=CC=CC=C1N=O,,,,,,
1909,11910,8-Methylquinoline,CC1=C2C(=CC=C1)C=CC=N2,,,,,,
1910,11911,5-Aminoquinoline,C1=CC(=C2C=CC=NC2=C1)N,,,,,,
1911,11912,7-(3-(Dimethylamino)propoxy)flavone,CN(C)CCCOC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3,,,,,,
1912,11913,9-Methylacridine,CC1=C2C=CC=CC2=NC3=CC=CC=C13,,,,,,
1913,11914,(r)-Mandelic acid,C1=CC=C(C=C1)[C@H](C(=O)O)O,,,,,,
1914,11915,Benzoylformic acid,C1=CC=C(C=C1)C(=O)C(=O)O,,,,,,
1915,11916,"N,N-Dimethylbenzamide",CN(C)C(=O)C1=CC=CC=C1,,,,,,
1916,11917,"1,3-Dimethyl-1,3-diphenylurea",CN(C1=CC=CC=C1)C(=O)N(C)C2=CC=CC=C2,,,,,,
1917,11918,"1,1-Diphenylethane",CC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1918,11919,"1,2-Bis(chloromethyl)benzene",C1=CC=C(C(=C1)CCl)CCl,,,,,,
1919,11920,2-(Hydroxymethyl)benzoic acid,C1=CC=C(C(=C1)CO)C(=O)O,,,,,,
1920,11921,2-Nitrobenzyl chloride,C1=CC=C(C(=C1)CCl)[N+](=O)[O-],,,,,,
1921,11922,2-Nitrobenzonitrile,C1=CC=C(C(=C1)C#N)[N+](=O)[O-],,,,,,
1922,11923,2-Nitrobenzyl alcohol,C1=CC=C(C(=C1)CO)[N+](=O)[O-],,,,,,
1923,11924,2-Benzylbenzoic acid,C1=CC=C(C=C1)CC2=CC=CC=C2C(=O)O,,,,,,
1924,11925,2-Naphthylammonium chloride,C1=CC=C2C=C(C=CC2=C1)[NH3+].[Cl-],,,,,,
1925,11926,3-Methylquinoline,CC1=CC2=CC=CC=C2N=C1,,,,,,
1926,11927,7-Methylquinoline,CC1=CC2=C(C=CC=N2)C=C1,,,,,,
1927,11928,2-Chloroquinoline,C1=CC=C2C(=C1)C=CC(=N2)Cl,,,,,,
1928,11929,N-Nitroso-N-ethylaniline,CCN(C1=CC=CC=C1)N=O,,,,,,
1929,11930,"1,3,5-Triphenylbenzene",C1=CC=C(C=C1)C2=CC(=CC(=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1930,11931,"3,3'-Dimethylbiphenyl",CC1=CC(=CC=C1)C2=CC=CC(=C2)C,,,,,,
1931,11932,"(1,1'-Biphenyl)-4,4'-diamine, 3,3'-dimethyl-, dihydrochloride",CC1=C(C=CC(=C1)C2=CC(=C(C=C2)[NH3+])C)[NH3+].[Cl-].[Cl-],,,,,,
1932,11933,"3,3'-Dichlorobenzidine dihydrochloride",C1=CC(=C(C=C1C2=CC(=C(C=C2)N)Cl)Cl)N.Cl.Cl,,,,['... In 1954 /results from laboratory tests indicated/ that skin is principal portal of entry of benzidines. ... It was considered likely that the hydrochloride salt could be absorbed percutaneously. /Benzidines/'],"[""A metabolism study ... in rats and dogs showed that fecal excretion was the major route of excretion of intravenously injected 3,3'-dichlorobenzidine.""]",
1933,11934,2-Phenylnaphthalene,C1=CC=C(C=C1)C2=CC3=CC=CC=C3C=C2,,,,,,
1934,11935,"Benzenemethanamine, N-nitroso-N-phenyl-",C1=CC=C(C=C1)CN(C2=CC=CC=C2)N=O,,,,,,
1935,11936,2-Methylanthracene,CC1=CC2=CC3=CC=CC=C3C=C2C=C1,,,,,,
1936,11937,2-Aminoanthracene,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)N,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
1937,11938,2-Methylacridine,CC1=CC2=CC3=CC=CC=C3N=C2C=C1,,,,,,
1938,11939,"2,6-Dimethylanthracene",CC1=CC2=CC3=C(C=C(C=C3)C)C=C2C=C1,,,,,,
1939,11940,"9,10-Dihydroanthracene",C1C2=CC=CC=C2CC3=CC=CC=C31,,,,,,
1940,11941,"4,4'-Dimethylbiphenyl",CC1=CC=C(C=C1)C2=CC=C(C=C2)C,,,,,,
1941,11942,"N,N'-Diacetylbenzidine",CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C,,,,"[""N,N'-DIACETYLBENZIDINE WAS A METABOLITE PRESENT IN THE URINE OF MALE SPRAGUE-DAWLEY RATS FOLLOWING 4 IP INJECTIONS OF 50 MG 4,4'-DINITROBIPHENYL & OF MALE GUINEA-PIGS FOLLOWING 4 IP INJECTIONS OF 35 MG."", 'The average environmental exposure levels of four of the workers /in a dye manufacturing facility/ were 4.3, 5.2, 11.7, and 17.4 mg total particulate/cu m. The corresponding urinary concentrations of benzidine average 52, 11, 10, and 112 ppb, respectively /SRP: from the precursor during manufacturing/. /Benzidine-based dyes/', ""The major route of excretion in rats after a single oral admin of 0.5-50 mg/kg radiolabeled benzidine appeared to be via the feces ... . At the lowest dose studied, 74% of the radiolabel was excreted in the feces during the first 3 days after exposure, as opposed to only 17% in the urine. With incr dose the percentage of radiolabel excreted in the feces decr, while that in the urine incr. At the low and mid-level doses (0.5 and 5.0 mg/kg), the major radiolabeled cmpd were identified as 3-hydroxy-N,N'-diacetylbenzidine glucuronide (39 and 37%), N,N'-diacetylbenzidine (13 and 17%), N-hydroxy-N,N'-diacetylbenzidine glucuronide (4 and 5%), N-acetylbenzidine (3 and 4%), and free benzidine (2%). As the dose was incr (50 mg/kg), the percentage of N-hydroxy-N,N'-diacetylglucuronide incr substantially (to 24%), largely at the expense of N,N'-diacetylbenzidine (reduced to 4%). No radioactivity was detected in expired air."", ""Urinary excretion of benzidine and its metabolites was found to occur in humans during workshift exposure, which was determined to be primarily dermal, although inhalation may also have been a contributory route ... . Mean concn of urinary cmpd detected after exposure in the spring were: benzidine (0.28 mg/l), N-acetylbenzidine (0.27 mg/l), N,N'-diacetylbenzidine (0.52 mg/l), and conjugated 3-hydroxybenzidine (3.9 mg/l) ... . When determined during hot, humid weather, these values incr 1.5- to 5-fold, presumably due to enhanced dermal contact and subsequent absorption. Fecal excretion was not determined.""]","[""N,N'-DIACETYLBENZIDINE YIELDS N-HYDROXY-N,N'-DIACETYLBENZIDINE WHICH WAS HYDROXYLATED BY FORTIFIED LIVER MICROSOMES."", 'The metabolic N-oxidation, N-acetylation and N-deacetylation of the carcinogen benzidine and its N-acetylated metabolites were examined in vitro with rat and mouse liver subcellular fractions. N-acetylbenzidine and N,N-diacetylbenzidine was found to occur with NADPH-, NADH-fortified microsomes, although total oxidation at both nitrogens of N-acetylbenzidine was substantially faster than the N-oxidation of N,N\'-diacetylbenzidine (four times for the mouse and 48 times for the rat). In both species, N-oxidation of N-acetylbenzidine to the arylhydroxylamine, N\'-hydroxy-N-acetylbenzidine (N\'-OH-ABZ), was somewhat faster than the formation of the arylhydroxamic acid, N-hydroxy-N-acetylbenzidine (N-OH-ABZ). N-Acetylation of benzidine and N-acetylbenzidine by liver cytosol was ... efficient for both species (0.7-2.9 nmol/min/mg cytosolic protein), and these rates were found to be 3-10 times faster than their corresponding rates of N-oxidation. N-Deacetylation of N-acetylbenzidine and N,N\'-diacetylbenzidine by mouse liver microsomes occurred at a rate that was comparable with N-acetylation; while N-deacetylation by rat liver microsomes was relatively slow, only 1-2% of the rate of N-acetylation. In the case of N-hydroxylated derivatives, N-OH-N-acetylbenzidine and N\'-OH-N""-acetylbenzidine hepatic cytosolic N-acetylation by both rats and mice to form N-OH-N,N\'-diacetylbenzidine was quite rapid (0.5-1.9 nmol/min/mg cytosol protein). Hepatic microsomal deacetylation of N-OH-N,N\'-diacetylbenzidine also occurred with both species and was 2-4 times the rate of N-acetylation. These studies indicate that a significant concentration of potentially electrophilic monoacetylated N-oxidized metabolites may accumulate within the liver cell, and that they may serve as intermediates in the synthesis of the highly toxic metabolite, N-OH-N,N\'-diacetylbenzidine. A major metabolic pathway for the formation of N-OH-N,N\'-diacetylbenzidine is proposed as: Benzidine-N-acetylbenzidine-N\'OH-N-acetylbenzidine-N-OH-N,N\'diacetylbenzidine. The activation of N-OH-N,N\'diacetylbenzidine by cytosolic N,O-acyltransferase and N\'-OH-N-acetylbenzidine by cytosolic sulfotransferase and O-acetyltransferase (acetyl CoA-dependent binding to DNA) were also examined. N-OH-N,N\'-diacetylbenzidine N,O-acyltransferase and N\'-OH-N-acetylbenzidine O-acetyltransferase were found to be significant pathways for rat and mouse liver, respectively. In addition, the DNA adduct formed from N-OH-N,N\'-diacetylbenzidine in the presence of partially-purified rat hepatic N,O-acyltransferase was shown to be N\'-(deoxyguanosin-8-yl) N-acetylbenzidine, which is identical to that formed in rat liver in vivo and in the direct', ""(14)C-labeled benzidine was incubated with Salmonella typhimurium strains TA-98 or TA-98/1,8-DNP6 for up to 24 hours. ... Metabolites were studied by thin layer chromatography and high pressure liquid chromatography. Benzidine metabolized by TA-98 to two major products: N-acetylbenzidine and N,N'-diacetylbenzidine. Unidentified polar metabolites amounting to 8% of the total (14)C activity were also found. Incubation with TA-98/1,8-DNP6 did not produce N-acetylbenzidine or N,N'-diacetyl benzidine; however, the same polar metabolites as produced by TA-98 were observed. The sensitivity of TA-98/1,8-DNP6 to mutagenesis by benzidine, N-acetylbenzidine and N,N'-diacetylbenzidine was investigated with metabolic activation by hamster liver S9 mix. All three compounds showed mutagenic activity; however, ... TA-98/1,8-DNP6 was less sensitive than TA-98. Salmonella strain TA-98/1,8-DNP6 is deficient in this acetylation activity and resistant to benzidine mutagenesis. Endogenous bacterial metabolism may play a role in benzidine mutagenesis."", 'The azo reduction and acetylation in vitro and the mutagenic activation in vivo of three azo dyes were studied. In the presence of rat-liver 9000 g supernatant, benzidine was released from direct black 38 and direct brown 95, whereas hardly any benzidine was produced during incubation of direct blue 6. Incubation of benzidine with isolated rat hepatocytes resulted in the appearance of diacetylbenzidine. No diacetylbenzidine was formed during incubation of benzidine with rat-liver 9000 g supernatant unless ... acetyl coenzyme A was added to the incubation medium. Isolated rat hepatocytes were capable to produce diacetylbenzidine from direct black 38, direct blue 6 or direct brown 95 without supplementation with acetyl coenzyme A. ... Rat liver has a considerable capacity to reduce azo compounds. nevertheless, for some compounds, like direct black 38, extrahepatic enzymes, most likely present in the intestinal flora, may also play a substantial role in the azo cleavage.', ""For more Metabolism/Metabolites (Complete) data for 4,4'-DIACETYLBENZIDINE (18 total), please visit the HSDB record page.""]",
1942,11943,4-Methoxybiphenyl,COC1=CC=C(C=C1)C2=CC=CC=C2,,,,,"['SPECIES VARIATION IN IN VITRO O-DEMETHYLATION TO 4-HYDROXYBIPHENYL (RECORDED AS NMOL/MG LIVER-HR) RANGED FROM 0.4 RAINBOW TROUT, 0.9 FROG, 1.7 CHICKEN, 8.0 RABBIT, 3.0 RAT, 3.2 MOUSE, 2.3 HAMSTER, TO 2.3 GUINEA PIG. /FROM TABLE/', 'THE CONVERSION OF BIPHENYL & 4-METHOXYBIPHENYL TO 4-HYDROXYBIPHENYL BY RAT LIVER MICROSOMES WAS MEDIATED BY THE MICROSOMAL MONOOXYGENASE SYSTEM & BOTH SUBSTRATES BOUND TO CYTOCHROME P450 TO GIVE A TYPE I BINDING SPECTRUM, ALTHOUGH THE MAXIMUM & MINIMUM WAVELENGTHS DIFFERED BETWEEN THE 2 SUBSTRATES. THE DIFFERENTIAL EFFECT OF ENZYME INDUCERS, METYRAPONE INHIBITION, & ETHANOL INHIBITION ON BIPHENYL 4-HYDROXYLATION & METHOXYBIPHENYL O-DEMETHYLATION SUGGESTS THAT THESE 2 REACTIONS ARE MEDIATED BY DIFFERENT CYTOCHROME P450 HEMOPROTEINS.', 'THE MICROSOMAL & SOLUBLE FRACTIONS FROM A TROUT LIVER HOMOGENATE DEALKYLATED 4-METHOXYBIPHENYL. LIVER PREPN FROM THE FROG RANA TEMPORARIA DEALKYLATED 4-METHOXYBIPHENYL ... 2-DEALKYLATION OCCURRED MORE RAPIDLY THAN 4-DEALKYLATION IN THE TROUT PREPN, WHEREAS THE REVERSE WAS TRUE FOR THE FROG PREPN.', 'The effects of beta-naphthoflavone on 4-methoxybiphenyl and biphenyl metabolism were studied in rats. Male Wistar rats were pretreated with 0 to 80 mg/kg beta-naphthoflavone. Forty hours later, the animals were /sacrificed/ and hepatocytes and liver microsomes were isolated. After incubation with 4-methoxybiphenyl or biphenyl, the rate of production of 4-hydroxybiphenyl was measured. Hepatic microsomes from rats pretreated with 0 or 40 mg/kg beta-naphthoflavone and incubated with biphenyl or 4-methoxybiphenyl were treated with metyrapone, alpha-naphthoflavone or ethanol and the effects on 4-methoxybiphenyl-O-demethylase (MBPD) and biphenyl-4-hydroxylase (BPOH) activity were investigated. The rate of formation of 4-hydroxybiphenyl from 4-methoxybiphenyl hepatocytes and microsomes from non-pretreated rats was essentially the same as that from biphenyl in hepatocytes and microsomes from rats pretreated with beta-naphthoflavone. MBPD and BPOH activities in microsomes from rats not pretreated with beta-naphthoflavone were essentially the same. MBPD activity was inhibited by metyrapone to a significantly greater extent than BPOH activity. BPOH activity, however, was inhibited to a greater extent by ethanol and alpha-naphthoflavone than MBPD activity. Hepatocytes were incubated with biphenyl with or without beta-naphthoflavone pretreatment and the pattern of conjugation of 4-hydroxybiphenyl was determined. In non-pretreated rats, sulfate and glucuronic acid conjugates of 4-hydroxybiphenyl were formed in approximately equal amounts, each presenting 41 to 44% of the total 4-hydroxybiphenyl formed. In the pretreated rats, the sulfate conjugate represented only 22% of the total 4-hydroxybiphenyl formed while the qlucuronic acid conjugate represented 60% of the total. The /results suggest/ that the difference in cellular metabolism between biphenyl and 4-methoxybiphenyl is due to competition between beta-naphthoflavone and biphenyl or their metabolites for common metabolic pathways. The type of cytochrome P450 involved in forming 4-hydroxybiphenyl does not effect the pattern of conjugation.', 'The response of hepatocytes to 4-hydroxybiphenyl (HP) in the presence of ascorbic acid was investigated in vitro. Livers from male Wistar rats were excised and hepatocyte suspensions were prepared. For assay of 0-demethylation of 4-methoxybiphenyl (MBP) the acidified incubation mixture was incubated with crude beta-glucuronidase. Total HP was extracted and fluorescence was measured. For assay of conjugated metabolites of HP and sequential metabolism of MBP the incubation mixture was extracted to remove unconjugated metabolites of HP and the mixture was treated with crude beta-glucuronidase. Ascorbic acid was added to the cell incubations with preincubated at 37 C for 5 min before adding the appropriate substrate. During a 60 min incubation of hepatocytes with HP about 55 nanomoles of conjugates were produced; 84% was in the form of glucuronide conjugates. Preincubation with ascorbic acid at 130 to 600 micromoles significantly incr glucuronylation in a dose related manner between 130 and 400 micromoles. Higher ascorbic acid concentrations resulted in sulfation inhibition. Sulfate was the major conjugate produced during the conjugation of HP from MBP in the presence of ascorbic acid. The normal serum concentrations of ascorbic acid did not effect the glucuronylation pathway but high concentrations inhibited sulfation and enhanced glucuronylation to a similar degree. Ascorbic acid did not effect 0-demethylation of MBP nor did it influence cellular lipid peroxidation. The /results suggest/ that high concentrations of ascorbic acid inhibit sulfation of MBP in isolated rat hepatocytes. Inhibition occurs when HP is added directly to the cells or by in situ generation from HP.']",
1943,11944,2-Naphthonitrile,C1=CC=C2C=C(C=CC2=C1)C#N,,,,,,
1944,11945,6-Nitroquinoline,C1=CC2=C(C=CC(=C2)[N+](=O)[O-])N=C1,,,,,,
1945,11946,7-Nitroquinoline,C1=CC2=C(C=C(C=C2)[N+](=O)[O-])N=C1,,,,,,
1946,11947,Bis(2-methoxyphenyl)diazene,COC1=CC=CC=C1N=NC2=CC=CC=C2OC,,,,,,
1947,11948,2-Benzylnaphthalene,C1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2,,,,,,
1948,11949,"ANILINE, N,N-DIMETHYL-p-(2-NAPHTHYLAZO)-",CN(C)C1=CC=C(C=C1)N=NC2=CC3=CC=CC=C3C=C2,,,,,,
1949,11950,2-Ethoxybenzaldehyde,CCOC1=CC=CC=C1C=O,,,,,,
1950,11951,"Naphthalene-2,7-diamine",C1=CC(=CC2=C1C=CC(=C2)N)N,,,,,,
1951,11952,2-Aminoacetophenone,C1=CC=C(C=C1)C(=O)CN,,,,,,
1952,11953,Benzoyl cyanide,C1=CC=C(C=C1)C(=O)C#N,,,,,,
1953,11954,N-Methylbenzamide,CNC(=O)C1=CC=CC=C1,,,,,,
1954,11955,Benzohydrazide,C1=CC=C(C=C1)C(=O)NN,,,,,"['Benzohydrazide yields benzoic acid in rabbit: El Masri, AM, Smith, JN, & Williams, RT, Biochem J, 68, 587 (1958). /from table/', '... Benzohydrazide ... /is/ metabolized by rabbits to yield hippuric acid & hydrazine.']",
1955,11956,N-Ethyl-N-methylaniline,CCN(C)C1=CC=CC=C1,,,,,,
1956,11957,N-Methyl-N-nitrosoaniline,CN(C1=CC=CC=C1)N=O,,,,,"['SODIUM PHENOBARBITAL 80 MG/KG IP INCR ACTIVITIES OF N-DEMETHYLASE OF NMA IN FEMALE & MALE RATS. FEMALES HAD HIGHER INCR THAN MALES. INCR BY METHYLCHOLANTHRENE WAS OBSERVED ONLY IN FEMALES.', 'HIPPURIC ACID ACCOUNTED FOR 80% OF RADIOACTIVITY FROM LABELED NMA RECOVERED IN RAT URINE.', 'RESULTS OF STEADY STATE KINETICS & ISOTOPE EFFECTS EXAM FOR DEMETHYLATION OF DIMETHYLNITROSAMINE & ITS DEUTERATED ANALOG USING RAT LIVER PREPARATIONS INDICATED THAT BREAKAGE OF C-H BOND IS RATE DETERMINING STEP OF THE ENZYMATIC OXIDATION.', '... Reduction of nitrate to nitrite /in the gastrointestinal tract/ permits the formation of highly carcinogenic nitrosamines by reaction with secondary amines from the diet. /Nitrosamines/', 'For more Metabolism/Metabolites (Complete) data for N-METHYL-N-NITROSOBENZENAMINE (10 total), please visit the HSDB record page.', 'N-nitroso-n-methylaniline (NMPhA) has known human metabolites that include N-(hydroxymethyl)-N-phenylnitrous amide.']","['(4.7 MG/KG, IP TO RATS) DISTRIBUTED THROUGHOUT EXTRACELLULAR WATER & CLEARED FROM WHOLE BLOOD BY METAB WITH HALF-LIFE OF 66 MIN. LESS THAN 1% OF DOSE WAS EXCRETED & EXPIRED AS PARENT CMPD. 24 HR AFTER INJECTION 46% OF 1-METHYL-(14)C WAS EXPIRED WITH HALF-LIFE OF 2.1 HR.']"
1957,11958,"2-Methoxy-5-methyl-1,4-benzoquinone",CC1=CC(=O)C(=CC1=O)OC,,,,,,
1958,11959,N-Ethylbenzamide,CCNC(=O)C1=CC=CC=C1,,,,,,
1959,11960,"4,4'-Dichloroazoxybenzene",C1=CC(=CC=C1N=[N+](C2=CC=C(C=C2)Cl)[O-])Cl,,,,,"[""MICROBIAL OXIDATION OF 4-CHLOROANILINE BY SOIL FUNGUS FUSARIUM OXYSPORUM WAS STUDIED...METABOLITES INCLUDED 4,4'-DICHLOROAZOXYBENZENE."", ""(14)C-LABELED P-CHLOROANILINE IS METABOLIZED COMPLETELY BY CHLORELLA FUSCA RUBRA TO WATER-SOLUBLE PRODUCTS INCL 4,4'-DICHLOROAZOXYBENZENE.""]",
1960,11961,Methyl benzoyl acetate,CCC(=O)OC(=O)C1=CC=CC=C1,,,,,,
1961,11962,p-Tolyl benzoate,CC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2,,,,,,
1962,11963,Naepaine hydrochloride,CCCCC[NH2+]CCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
1963,11964,Naepaine,CCCCCNCCOC(=O)C1=CC=C(C=C1)N,,,,,,
1964,11965,2-Fluoroethyl benzoate,C1=CC=C(C=C1)C(=O)OCCF,,,,,,
1965,11966,tert-Butyl peroxybenzoate,CC(C)(C)OOC(=O)C1=CC=CC=C1,,,,,"['...This study was designed to determine whether the organic hydroperoxides, tert-butyl hydroperoxide, cumene hydroperoxide and tert-butyl peroxybenzoate are metabolized by human carcinoma skin keratinocytes to free radicals. Incubation of keratinocytes prepared from cutaneous squamous cell carcinoma in phosphate-buffered saline (pH 7.4) containing desferrioxamine with tert-butyl hydroperoxide, cumene hydroperoxide and tert-butyl peroxybenzoate in the presence of spin trap (3,5-dibromonitrosobenzene sulfonic acid) resulted in the generation of corresponding methyl radical adducts. Prior heating of the cells to 100 degrees C abolished the generation of radical adducts. The addition of ethanol to the reaction mixture also inhibited formation of radical adducts. These data provide the first direct evidence that human carcinoma skin cells can generate free radicals from organic hydroperoxides. Since free radicals are suggested to be involved in the cascade of events occurring during tumor promotion this metabolic capacity may be an important determinant of human cancer risk for hydroperoxides.']",
1966,11967,3-Fluoropropyl benzoate,C1=CC=C(C=C1)C(=O)OCCCF,,,,,,
1967,11968,ortho-Hydroxycinnamic acid,C1=CC=C(C(=C1)C=CC(=O)O)O,,,,,,
1968,11969,2-Chlorophenoxyacetic acid,C1=CC=C(C(=C1)OCC(=O)O)Cl,,,,,"['YIELDS 2-CHLORO-4-HYDROXYPHENOXYACETIC ACID IN AVENA. ; YIELDS O-CHLOROPHENOL IN ARTHROBACTER.. /FROM TABLE/', 'FOLLOWING ADMIN OF N-CYCLOPROPYL-2-(2-CHLOROPHENOXY ETHYLAMINE-HCL (200 MG, ORALLY) TO HUMANS, 2-CHLOROPHENOXYACETIC ACID WAS IDENTIFIED IN THE URINE.']",
1969,11970,2-Hydroxyphenylacetic acid,C1=CC=C(C(=C1)CC(=O)O)O,,,,,,
1970,11971,CID 11971,CC1=CC=CC=C1N=C(N)S,,,,,,
1971,11972,2-Acetamidophenol,CC(=O)NC1=CC=CC=C1O,,,,,,
1972,11973,Brolene,C1=CC(=C(C=C1C(=N)N)Br)OCCCOC2=C(C=C(C=C2)C(=N)N)Br.C(CS(=O)(=O)O)O,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1973,11974,Dibrompropamidine,C1=CC(=C(C=C1C(=N)N)Br)OCCCOC2=C(C=C(C=C2)C(=N)N)Br,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1974,11975,"2,4-Diaminoanisole dihydrochloride",COC1=C(C=C(C=C1)N)N.Cl.Cl,,,,"['The percutaneous absorption of 2,4-diaminoanisole dihydrochloride by hairless rats was approx 2 times higher than that of 2-(2,4-diaminophenoxy)ethanol dihydrochloride because of its high lipid affinity. The penetration of both compounds through the skin was concentration-dependent and studied by (14)C-labelling.']","['2,4-Diamino(ring-U-14C)anisole 2HCl administered i.p. to rats was excreted chiefly via the urine (79 and 85% of the dose in 24 and 48 h, respectively). The isotope in the feces was 2.1 and 8.9% of the dose at 24 and 48 h. The major metabolic pathway was acetylation of the amine group(s), resulting in 4-acetylamino-2-aminoanisole and 2,4-diacetylaminoanisole. Oxidative pathways yielded 2,4-diacetylaminophenol (O-demethylation), 5-hydroxy-2,4-diacetylaminoanisole (ring hydroxylation) and 2-methoxy-5-(glycolamido)acetanilide or its isomer (omega-oxidation). These major metabolites were excreted in the urine as free and glucuronic acid conjugates.']",
1975,11976,"2,4-Diaminoanisole",COC1=C(C=C(C=C1)N)N,,,,"['Following ip administration of 50 mg/kg bw (14)C-labelled 2,4-diaminoanisole to rats, 85% of radioactivity was excreted in urine and 9% in feces after 48 hr.', 'Injection of (3)H-2,4-diaminoanisole (10-200 mg/kg) into rats led to irreversible binding of liver and kidney proteins. Irreversibly bound material was preferentially localized in the microsomal fraction. Non-bound (3)H-2,4-diaminoanisole was rapidly cleared from plasma, liver and kidneys, whereas considerable amounts irreversibly bound could still be demonstrated 24 hr after a dose of 100 mg/kg ip.', 'Scalp penetration of 2,4-diaminoanisole (DAA) that occurs under conditions of hair dye usage was evaluated for both rhesus monkey and man using (14)C-labeled material. Average dose excretion of DAA in rhesus monkey was 0.02% and in man 0.015%.', 'No fixation of 2,4-diaminoanisole which passes through the cutaneous barrier is found in either liver or thyroid of hairless rats, 4 days after topical application.', 'For more Absorption, Distribution and Excretion (Complete) data for 2,4-DIAMINOANISOLE (7 total), please visit the HSDB record page.']","['Following ip administration of 50 mg/kg bw (14)C-labelled 2,4-diaminoanisole to rats... . Major metabolites were 4-acetylamino-2-aminoanisole, 2,4-diacetylaminoanisole, 2,4-diacetylaminophenol, 5-hydroxy-2,4-diacetylaminoanisole and 2-methoxy-5-(glycolamido)acetanilide or its isomer. These metabolites were excreted in urine both free and as glucuronides and sulfates.']",
1976,11977,Nitrosoethylurethane,CCN(C(=O)OCC)N=O,,,,,,
1977,11978,5-Methylindole,CC1=CC2=C(C=C1)NC=C2,,,,,,
1978,11979,5-Methylbenzimidazole,CC1=CC2=C(C=C1)N=CN2,,,,,,
1979,11980,Ethyl 2-furoate,CCOC(=O)C1=CC=CO1,,,,,,
1980,11981,3-Methyl-4-nitrosophenol,CC1=C(C=CC(=C1)O)N=O,,,,,,
1981,11982,Propyl 2-furoate,CCCOC(=O)C1=CC=CO1,,,,,,
1982,11983,2-Indanone,C1C(=O)CC2=CC=CC=C21,,,,,,
1983,11984,2-Methylbenzimidazole,CC1=NC2=CC=CC=C2N1,,,,,,
1984,11985,2-Hydroxybenzimidazole,C1=CC=C2C(=C1)NC(=O)N2,,,,,,
1985,11986,2-Chlorobenzoxazole,C1=CC=C2C(=C1)N=C(O2)Cl,,,,,,
1986,11987,2-Chlorobenzothiazole,C1=CC=C2C(=C1)N=C(S2)Cl,,,,,,
1987,11988,2-Hydrazinobenzothiazole,C1=CC=C2C(=C1)N=C(S2)NN,,,,,,
1988,11989,2-(Methylthio)benzothiazole,CSC1=NC2=CC=CC=C2S1,,,,,,
1989,11990,"1,2-Phenylenediamine dihydrochloride",C1=CC=C(C(=C1)N)N.Cl.Cl,,,,,,
1990,11991,4-Methylhexan-3-ol,CCC(C)C(CC)O,,,,,,
1991,11992,2-Bromoaniline,C1=CC=C(C(=C1)N)Br,,,,,,
1992,11993,1-Chloro-2-iodobenzene,C1=CC=C(C(=C1)Cl)I,,,,,,
1993,11994,"1,2-Diiodobenzene",C1=CC=C(C(=C1)I)I,,,,,,
1994,11995,2-Iodoaniline,C1=CC=C(C(=C1)N)I,,,,,,
1995,11996,"2,5-Diaminotoluene dihydrochloride",CC1=C(C=CC(=C1)N)N.Cl.Cl,,,,"['A 1-mL subcutaneous administration of 0.4% aqueous (14)C-toluene-2,5-diamine hydrochloride (specific activity: 12.8 mCi/g toluene-2,5-diamine) was given to 18 Sprague-Dawley rats. More than 65% of the radioactivity was excreted in the urine within 24 hours. After 5 days, approximately 15% of the radioactivity was found in the feces, and 6.9% was detected in the total-body homogenate.', 'Eighteen Sprague-Dawley rats were given 1-mL oral doses of a 1.6% aqueous solution of radioactive toluene-2,5-diamine hydrochloride (specific activity, 15.8 mCi/g toluene-2,5-diamine) by stomach tube. Within 24 hours, more than 70% of the radioactivity was excreted in the urine. After 5 days, a total of 10% was detected in the feces, 1.2% was detected in the body homogenate, and 1.4% remained in the gastrointestinal tract.']",,
1996,11997,2-Chloro-p-phenylenediamine dihydrochloride,C1=CC(=C(C=C1N)Cl)N.Cl.Cl,,,,,,
1997,11998,"2-Chloro-1,4-diaminobenzene",C1=CC(=C(C=C1N)Cl)N,,,,,,
1998,11999,2-Mercapto-5-chloroanilinium chloride,C1=CC(=C(C=C1Cl)[NH3+])S.[Cl-],,,,,,
1999,12000,2-Amino-4-chlorobenzenethiol,C1=CC(=C(C=C1Cl)N)S,,,,,,
2000,12001,N-Nitroso-N-methylurethane,CCOC(=O)N(C)N=O,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']",,"['Methylation of nucleic acids in vivo and in vitro has been demonstrated; the main reaction product is 7-methylguanine, and 3-methyladenine has been found to be another. Methylation also occurs in /SRP: non-target/ organs.']",
2001,12002,"1,2,4-Tribromobenzene",C1=CC(=C(C=C1Br)Br)Br,,,,,,
2002,12003,"3,4-Dibromophenol",C1=CC(=C(C=C1O)Br)Br,,,,,,
2003,12004,"2,4-Dibromoaniline",C1=CC(=C(C=C1Br)Br)N,,,,,,
2004,12005,"2,4-Dibromophenol",C1=CC(=C(C=C1Br)Br)O,,,,,"[""The metabolism and disposition of (14)C-labelled 2,2',4,4'-tetrabromodiphenyl ether (BDE47) were investigated in F344 rats and B6C3F1 mice. Approximately 75-85% of 1 umol BDE47 per kg was absorbed following oral administration to either rats or mice. Sex and species differences were observed in tissue distribution and excretion of BDE47-derived radioactivity. Absorption and distribution of (14)C to major tissues were dose-proportional in male rats from 0.1 to 1,000 umol per kg. BDE47-derived radioactivity increased in all rat and mouse tissues examined following repeated daily doses of 1 umol per kg. Accumulation of (14)C in tissues of mice was less than in corresponding rat tissues. Glutathione conjugates of BDE47 were excreted in rat bile. A glucuronide and a sulfate conjugate of 2,4-dibromophenol were detected in the urine of BDE47-treated rats. BDE47 appears to induce its own metabolism. Increased formation of reactive metabolites over time may correlate with toxicological effects in BDE47-treated rodents.""]",
2005,12006,"2,5-Dibromotoluene",CC1=C(C=CC(=C1)Br)Br,,,,,,
2006,12007,2-Chloro-4-methylaniline,CC1=CC(=C(C=C1)N)Cl,,,,,"[""FORMS 2,2'-DICHLORO-4,4'-DIMETHYLAZOBENZENE IN HORSERADISH. KNOWLES ET AL, J ECOL ENT 62: 411 (1969). /FROM TABLE/""]",
2007,12008,2-Chloro-5-methylphenol,CC1=CC(=C(C=C1)Cl)O,,,,,,
2008,12009,1-Methyluracil,CN1C=CC(=O)NC1=O,,,,,,
2009,12010,"Oxalic acid, dithio-, S,S-diethyl ester",CCOC(=S)C(=S)OCC,,,,,,
2010,12011,"2,5-Dichloro-1,4-benzoquinone",C1=C(C(=O)C=C(C1=O)Cl)Cl,,,,,,
2011,12012,Citraconic anhydride,CC1=CC(=O)OC1=O,,,,,,
2012,12013,2-Bromohexanoic acid,CCCCC(C(=O)O)Br,,,,,,
2013,12014,"2-Pentene, 3-methyl-",CCC(=CC)C,,,,,,
2014,12015,1-Chloro-2-methylbutane,CCC(C)CCl,,,,,,
2015,12016,3-Chloropentane,CCC(CC)Cl,,,,,,
2016,12017,"1,2-Dichlorobutane",CCC(CCl)Cl,,,,,,
2017,12018,"2,3-Dichloro-1-propanol",C(C(CCl)Cl)O,,,,,,
2018,12019,3-Aminopentane,CCC(CC)N,,,,,,
2019,12020,1-Penten-3-OL,CCC(C=C)O,,,,,,
2020,12021,Dimethyl carbonate,COC(=O)OC,,,,,,
2021,12022,"N,N-Diethylmethylamine",CCN(C)CC,,,,,,
2022,12023,3-Methyl-1H-pyrrole,CC1=CNC=C1,,,,,,
2023,12024,3-Methylthiophene,CC1=CSC=C1,,,,,,
2024,12025,2-Pyrrolidinone,C1CC(=O)NC1,,,,"['The percutaneous absorption has been investigated in rats of a mixture (3:2, w/w) of N-methyl-2-pyrrolidinone and 2-pyrrolidinone, a combination intended for use as a vehicle in the formulation of an antimycotic drug to enhance skin penetration on dermal application, following co-administration of the two (14)C-radiolabelled compounds by the dermal and oral routes. Radioactivity was excreted predominantly in the urine after either route of administration, and comparison of the respective excretion profiles indicated that about three-quarters of the applied dose was absorbed through the skin. Plasma concentrations of each parent compound, as determined by radio-HPLC, reached peak values at 2 hr after oral dosing, and remained relatively uniform during 1-6 hr after application to the skin, suggesting constant percutaneous absorption during this period. N-Methyl-2-pyrrolidinone appeared to be absorbed through the skin more extensively and at a slightly faster rate than 2-pyrrolidinone; total percutaneous absorption tended to be more extensive in female than in male rats. Together, these two 14C-compounds accounted for most of the plasma radioactivity up to 6-8 hr post-administration. However, by 12 hr (when plasma levels were relatively low), most of the radioactivity was associated with unknown polar metabolites. In view of the extensive percutaneous absorption and little first-pass metabolism of the two pyrrolidinones, the oral route was considered to represent a valid alternative to the dermal route for the assessment of the systemic toxicity of the two compounds.']","['THE URINARY EXCRETION OF RADIOACTIVE METABOLITES FOLLOWING THE IP ADMIN OF A RANGE OF DOSES OF 2,5-(14)C-2-LABELED N-NITROSOPYRROLIDINE TO RATS WAS EXAMINED. PYRROLIN-2-ONE WAS ONE OF SEVERAL METABOLITES IDENTIFIED.', 'PYRROLIDONE WAS IDENTIFIED AS A URINARY METABOLITE OF METHADONE.', 'AN ENZYME SYSTEM RESIDING IN THE SOL FRACTION OF RABBIT LIVER CATALYZES THE CONVERSION OF DELTA 1-PYRROLINE TO GAMMA-AMINOBUTYRIC ACID & ITS LACTAM, 2-PYRROLIDONE.', '2-PYRROLIDONE WAS IDENTIFIED AS A METABOLITE OF (14)C-PUTRESCINE IN SLICED RAT LIVER IN VITRO. IT IS ALSO SYNTHESIZED FROM PUTRESCINE BY THE SPLEEN & LUNG, BUT NOT BY KIDNEY, BRAIN, HEART OR MUSCLE.', 'For more Metabolism/Metabolites (Complete) data for 2-PYRROLIDONE (6 total), please visit the HSDB record page.']",
2025,12026,Pinacolyl methylphosphonic acid,CC(C(C)(C)C)OP(=O)(C)O,,,,,,
2026,12027,2-Propylmalonic acid,CCCC(C(=O)O)C(=O)O,,,,,,
2027,12028,Trimecaine,CCN(CC)CC(=O)NC1=C(C=C(C=C1C)C)C,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
2028,12029,"1,5-Dimethyl-2,4-dinitrobenzene",CC1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C,,,,,,
2029,12030,"2,4-Dinitro-5-methylphenol",CC1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
2030,12031,Benzylmalonic acid,C1=CC=C(C=C1)CC(C(=O)O)C(=O)O,,,,,,
2031,12032,2-Amino-5-nitrobenzoic acid,C1=CC(=C(C=C1[N+](=O)[O-])C(=O)O)N,,,,,,
2032,12033,4-Hydroxy-3-nitrobenzoic acid,C1=CC(=C(C=C1C(=O)O)[N+](=O)[O-])O,,,,,,
2033,12034,n-Pentylmalonic acid,CCCCCC(C(=O)O)C(=O)O,,,,,,
2034,12035,Acetylcysteine,CC(=O)N[C@@H](CS)C(=O)O,['Acetylcysteine is indicated for mucolytic therapy and in the management of [acetaminophen] overdose.'],"['Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose. It has a short duration of action as it is given every 1-8 hours depending on route of administration, and has a wide therapeutic window. Patients should be counselled regarding diluting oral solutions in cola for taste masking, the risk of hypersensitivity, and the risk of upper gastrointestinal hemorrhage.']","['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)', 'Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']","['An 11 g dose in the form of an effervescent tablet for solution reaches a mean C<sub>max</sub> of 26.5 g/mL, with a T<sub>max</sub> of 2 hours, and an AUC of 186 g\\*h/mL.', 'An oral dose of radiolabelled acetylcysteine is 13-38% recovered in the urine in the first 24 hours, while 3% is recovered in the feces.', 'The volume of distribution of acetylcysteine is 0.47 L/kg.', 'Acetylcysteine has a mean clearance of 0.11 L/hr/kg.', 'Following oral administration (e.g., when used as an antidote for acetaminophen overdosage), acetylcysteine is absorbed from the GI tract.', 'Oral acetylcysteine is rapidly absorbed, but the bioavailability is low (10-30%) due to significant first-pass metabolism. Intact acetylcysteine has a relatively small volume of distribution (0.5 L/kg). Serum concentrations after intravenous administration of an initial loading dose of 150 mg/kg over 15 minutes are about 500 mg/L. A steady state plasma concentration of 35 mg/L (10-90 mg/L) was reached in about 12 hours following the loading dose with a continuous infusion of 50 mg/kg over 4 hours and 100 mg/kg over the next 16 hours.']","['Acetylcysteine can be deacetylated by aminoacylase 1 or other undefined deacetylases before undergoing the normal metabolism of cysteine.', 'Following oral inhalation or intratracheal instillation, most of the administered drug appears to participate in the sulfhydryl-disulfide reaction; the remainder is absorbed from the pulmonary epithelium, deacetylated by the liver to cysteine, and subsequently metabolized.', 'Acetylcysteine undergoes rapid deacetylation in vivo to yield cysteine or oxidation to yield diacetylcystine.']","['The mean terminal half life of acetylcysteine in adults is 5.6 hours and in pre-term neonates is 11 hours.', 'Following IV administration of acetylcysteine, mean elimination half lives of 5.6 and 11 hours have been reported in adults and in neonates, respectively. The mean elimination half life was increased by 80% in patients with severe liver damage (i.e., alcoholic cirrhosis (Child-Pugh score of 7-13) or primary and/or secondary biliary cirrhosis (Child-Pugh score of 5-11)).']"
2035,12036,Ethyl [2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]sulfanylformate;hydrochloride,CCOC(=O)SC(=C(C)N(CC1=CN=C(N=C1N)C)C=O)CCO.Cl,,,,,,
2036,12037,Ethyl [2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]sulfanylformate,CCOC(=O)SC(=C(C)N(CC1=CN=C(N=C1N)C)C=O)CCO,,,,,,
2037,12038,Ethyl vanillate,CCOC(=O)C1=CC(=C(C=C1)O)OC,,,,,,
2038,12039,Chorismic acid,C=C(C(=O)O)O[C@@H]1C=C(C=C[C@H]1O)C(=O)O,,,,,,
2039,12040,2-Methyl-3-hexanol,CCCC(C(C)C)O,,,,,,
2040,12041,Ethyl pyruvate,CCOC(=O)C(=O)C,"['Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.']",,,,,
2041,12042,"Carbamic acid, dimethyldithio-, ethyl ester",CCSC(=S)N(C)C,,,,,,
2042,12043,2-Chloro-2-butenedioic acid,C(=C(C(=O)O)Cl)C(=O)O,,,,,,
2043,12044,Isopropyl isobutyrate,CC(C)C(=O)OC(C)C,,,,,,
2044,12045,Citraconic acid dimethyl ester,CC(=CC(=O)OC)C(=O)OC,,,,,,
2045,12046,2-Methylglutaric acid,CC(CCC(=O)O)C(=O)O,,,,,,
2046,12047,DL-Lysine monohydrochloride,C(CCN)CC(C(=O)O)N.Cl,,,,,,
2047,12048,3-Ethylpentane,CCC(CC)CC,,,,,,
2048,12049,2-Ethylbutylamine,CCC(CC)CN,,,,,,
2049,12050,Diethylcyanamide,CCN(CC)C#N,,,,,,
2050,12051,"N,N-Diethylformamide",CCN(CC)C=O,,,,,"['N,n-diethylformamide has known human metabolites that include N-Ethyl-N-(1-hydroxyethyl)formamide.']",
2051,12052,Triethyl silane,CC[SiH](CC)CC,,,,,,
2052,12053,2-Phenyl-2-propanol,CC(C)(C1=CC=CC=C1)O,,,,,"['DIMETHYLPHENYLCARBINOL IS A METABOLITE OF ISOPROPYLBENZENE.', 'The enantioselective metabolism of cumene was studied in rabbits. The major metabolites identified /in urine/ were 2-phenyl-2-propanol, (R)-(+)-2-phenyl-1-propanol, (S)-(+)-2-phenylpropanoic acid and (R)-(-)-2-hydroxy-2-phenylpropanoic acid. Based on these metabolites, two routes of cumene metabolism were /noted/.']",
2053,12054,4-Phosphonobenzoic acid,C1=CC(=CC=C1C(=O)O)P(=O)(O)O,,,,,,
2054,12055,4-Arsonophenylglycinamide,C1=CC(=CC=C1NCC(=O)N)[As](=O)(O)O,,,,,,
2055,12056,Benzoyl bromide,C1=CC=C(C=C1)C(=O)Br,,,,,,
2056,12057,Benzenesulfinic acid,C1=CC=C(C=C1)S(=O)O,,,,,,
2057,12058,1-Acetylpiperidine,CC(=O)N1CCCCC1,,,,,,
2058,12059,3-Isopropylphenol,CC(C)C1=CC(=CC=C1)O,,,,,,
2059,12060,3-Iodobenzoic acid,C1=CC(=CC(=C1)I)C(=O)O,,,,,['3-Iodobenzoic acid has known human metabolites that include 3-Iodobenzoyl glyucuronide.'],
2060,12061,"Benzoic acid, 3,5-diamino-, hydrochloride (1:2)",C1=C(C=C(C=C1[NH3+])[NH3+])C(=O)O.[Cl-].[Cl-],,,,,,
2061,12062,"3,5-Diaminobenzoic acid",C1=C(C=C(C=C1N)N)C(=O)O,,,,,,
2062,12063,"3,5-Dibromobenzoic acid",C1=C(C=C(C=C1Br)Br)C(=O)O,,,,,,
2063,12064,"3,5-Dichloronitrobenzene",C1=C(C=C(C=C1Cl)Cl)[N+](=O)[O-],,,,,,
2064,12065,"3,5-Diiodo-4-hydroxybenzoic acid",C1=C(C=C(C(=C1I)O)I)C(=O)O,,,,,,
2065,12066,"2,6-Dichloro-4-nitrophenol",C1=C(C=C(C(=C1Cl)O)Cl)[N+](=O)[O-],,,,,,
2066,12067,"3,5-Dinitrotoluene",CC1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-],,,,['Excretion of dinitrotoluene in excess of 25 mg/L indicates significant absorption /in industrial exposed populations/. /Dinitrotoluene/'],"['Bioactivation of DNT in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.']",
2067,12068,"3,5-Dinitroaniline",C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])N,,,,,,
2068,12069,5-Nitroisophthalic acid,C1=C(C=C(C=C1C(=O)O)[N+](=O)[O-])C(=O)O,,,,,,
2069,12070,Methyl 3-bromobenzoate,COC(=O)C1=CC(=CC=C1)Br,,,,,,
2070,12071,"Benzoic acid, 4-fluoro-3-iodo-, ethyl ester",CCOC(=O)C1=CC(=C(C=C1)F)I,,,,,,
2071,12072,Dihydrocarveol,CC1CCC(CC1O)C(=C)C,,,,,,
2072,12073,"3,4-Dimethylbenzoic acid",CC1=C(C=C(C=C1)C(=O)O)C,,,,,,
2073,12074,2-Chloro-4-nitrophenol,C1=CC(=C(C=C1[N+](=O)[O-])Cl)O,,,,,,
2074,12075,"2,5-Dinitrotoluene",CC1=C(C=CC(=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,"['The metabolites produced from 5 DNT isomers (2,3-, 2,4-, 2,5-, 2,6- and 3,4-DNT) by Escherichia coli strain W3110, isolated from human intestine, were identified. Data obtained from metabolites produced by the Escherichia coli were 2 monoaminonitrotoluenes and hydroxylaminonitrotoluenes in all cases. This finding indicates that DNT is reduced via hydroxylaminonitrotoluenes to monoaminonitrotoluenes in Escherichia coli. In addn, the redn reactivities of DNT isomers were 3- > 2- for 2,3-DNT, 4- > 2- for 2,4-DNT, 5- > 2- for 2,5-DNT and 3- > 4- for 3,4-DNT.', 'Bioactivation of dinitrotoluene in the rat is thought to occur by the following processes: The methyl group is oxidized to an alcohol by a cytochrome p450 dependent pathway; the benzyl alcohol is conjugated with glucoronic acid and excreted in the bile. Intestinal microflora hydrolyze the glucuronide and reduce one nitro group, forming an aminonitrobenzyl alcohol which can be readsorbed from the intestine. The amino group oxidized to an hydroxylamine by hepatic enzymes and conjugated with sulfate. Decomposition of the sulfate ester yields a highly electrophilic nitrenium (or carbonium) ion which can react with DNA and other biological nucleophiles.']",
2075,12076,2-Amino-4-nitrobenzoic acid,C1=CC(=C(C=C1[N+](=O)[O-])N)C(=O)O,,,,,,
2076,12077,3-Formylbenzoic acid,C1=CC(=CC(=C1)C(=O)O)C=O,,,,,,
2077,12078,3-Nitrobenzyl chloride,C1=CC(=CC(=C1)[N+](=O)[O-])CCl,,,,,,
2078,12079,3-Nitrobenzonitrile,C1=CC(=CC(=C1)[N+](=O)[O-])C#N,,,,,,
2079,12080,"1,1-Dichloro-2,2-diethoxyethane",CCOC(C(Cl)Cl)OCC,,,,,,
2080,12081,Methyl 4-bromobenzoate,COC(=O)C1=CC=C(C=C1)Br,,,,,,
2081,12082,Methyl 4-aminobenzoate,COC(=O)C1=CC=C(C=C1)N,,,,,,
2082,12083,Methyl 4-nitrobenzoate,COC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
2083,12084,4-Chlorobenzamide,C1=CC(=CC=C1C(=O)N)Cl,,,,,,
2084,12085,4-Iodobenzoic acid,C1=CC(=CC=C1C(=O)O)I,,,,,['4-Iodobenzoic acid has known human metabolites that include 4-Iodobenzoyl glyucuronide.'],
2085,12086,4-Ethylbenzoic acid,CCC1=CC=C(C=C1)C(=O)O,,,,,,
2086,12087,4-Cyanobenzoic acid,C1=CC(=CC=C1C#N)C(=O)O,,,,,,
2087,12088,4-Formylbenzoic acid,C1=CC(=CC=C1C=O)C(=O)O,,,,,,
2088,12089,4-Hydrazinobenzoic acid,C1=CC(=CC=C1C(=O)O)NN,,,,,,
2089,12090,4-Nitrobenzonitrile,C1=CC(=CC=C1C#N)[N+](=O)[O-],,,,,,
2090,12091,4-Nitrobenzamide,C1=CC(=CC=C1C(=O)N)[N+](=O)[O-],,,,,,
2091,12092,4-(Dimethylamino)benzoic acid,CN(C)C1=CC=C(C=C1)C(=O)O,,,,,,
2092,12093,4-Ethoxybenzoic acid,CCOC1=CC=C(C=C1)C(=O)O,,,,,,
2093,12094,4-Nitrobenzyl acetate,CC(=O)OCC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
2094,12095,"Glycine, N-(4-nitrophenyl)-",C1=CC(=CC=C1NCC(=O)O)[N+](=O)[O-],,,,,,
2095,12096,3-Ethylhexane,CCCC(CC)CC,,,,,,
2096,12097,5-Methylfurfural,CC1=CC=C(O1)C=O,,,,,,
2097,12098,Benzyl iodide,C1=CC=C(C=C1)CI,,,,,,
2098,12099,3-Methylbenzyl bromide,CC1=CC(=CC=C1)CBr,,,,,,
2099,12100,3-Ethyltoluene,CCC1=CC=CC(=C1)C,,,,,,
2100,12101,3-Ethylphenol,CCC1=CC(=CC=C1)O,,,,,['3-ethylphenol has known human metabolites that include 3-Ethylphenyl sulfate.'],
2101,12102,3-Methylbenzyl chloride,CC1=CC(=CC=C1)CCl,,,,,,
2102,12103,3-Chlorobenzyl chloride,C1=CC(=CC(=C1)Cl)CCl,,,,,,
2103,12104,3-Methylbenzonitrile,CC1=CC(=CC=C1)C#N,,,,,,
2104,12105,3-Methylbenzaldehyde,CC1=CC(=CC=C1)C=O,,,,,"['... m-Xylene (m-XYL) has been shown to alter cytochrome P-450 (CYP) activity in an organ- and isozyme-specific manner. The purpose of this work was to determine if the metabolism of m-XYL to the inhibitory metabolite m-tolualdehyde (m-ALD) is the cause of inhibition of CYP isozymes following in vivo inhalation exposure to m-XYL (100, 300 ppm), 3-methylbenzyl alcohol (3-MBA) (50, 100 ppm), or m-ALD (50, 100 ppm). A single 6-hr inhalation exposure of rats to m-XYL inhibited pulmonary CYPs 2B1, 2E1, and 4B1 in a dose-dependent manner. Inhalation of 3-MBA inhibited pulmonary CYPs 2B1 and 4B1 in a dose-dependent manner. m-ALD inhibited pulmonary CYPs 2B1 and 2E1 in a dose-dependent manner, while 4B1 activity was increased dose dependently. Nasal mucosa CYP 2B1 and 2E1 activity was inhibited following exposure to m-XYL dose dependently, 3-MBA inhibited nasal mucosa CYPs 2E1 and 4B1 dose dependently. CYPs 2B1, 2E1, and 4B1 were inhibited in a dose-dependent fashion following inhalation of m-ALD. Following high-performance liquid chromatography (HPLC) analysis, m-ALD was detected after in vivo exposure to m-XYL, m-ALD, and 3-MBA in a dose-dependent manner, with highest m-ALD levels in the nasal mucosa and lung. Alteration of cytochrome P-450 activity by m-XYL could result in increased or decreased toxicity, changing the metabolic profiles of xenobiotics in coexposure scenarios in an organ-specific manner.', 'p-Tolualdehyde was oxidized to p-toluic acid by resting cells of pseudomonas aeruginosa. Perillaldehyde dehydrogenase, isolated from soil pseudomonad, catalyzed the oxidn of m- & p-tolualdehyde but not o-tolualdehyde.', 'Aldehydes are readily oxidized to organic acids. Oxidation of aldehydes is catalyzed by aldehyde dehydrogenase, which has been found in the brain, erythrocytes, liver, kidney, heart, and placenta. /Aldehydes/']",
2105,12106,Tri-p-tolyl phosphite,CC1=CC=C(C=C1)OP(OC2=CC=C(C=C2)C)OC3=CC=C(C=C3)C,,,,,,
2106,12107,N-Phenylpropanamide,CCC(=O)NC1=CC=CC=C1,,,,,['N-phenylpropionamide is a known human metabolite of alfentanil.'],
2107,12108,Phenyl chloroacetate,C1=CC=C(C=C1)OC(=O)CCl,,,,,,
2108,12109,"Benzenamine, 4-methyl-N-phenyl-",CC1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
2109,12110,4-Nitrophenyl phenyl ether,C1=CC=C(C=C1)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2110,12111,"4,4'-Methylenediphenol",C1=CC(=CC=C1CC2=CC=C(C=C2)O)O,,,,"['Bisphenol F (BPF) as an endocrine disrupting compounds (EDCs) pollutant in the environment poses a great threat to human health. To evaluate the toxicity of BPF at the protein level, the effects of BPF on human serum albumin (HSA) were investigated at three temperatures 283, 298, and 308 K by multiple spectroscopic techniques. The experimental results showed that BPF effectively quenched the intrinsic fluorescence of HSA via static quenching. The number of binding sites, the binding constant, the thermodynamic parameters and the binding subdomain were measured, and indicated that BPF could spontaneously bind with HSA on subdomain IIA through H-bond and van der Waals interactions. Furthermore, the conformation of HSA was demonstrably changed in the presence of BPF. The work provides accurate and full basic data for clarifying the binding mechanisms of BPF with HSA in vivo and is helpful for understanding its effect on protein function during its transportation and distribution in blood.', ""The distribution of bisphenol F (4,4'-dihydroxydiphenyl-methane, BPF) was studied in female Sprague-Dawley rats. Pregnant and nonpregnant animals were gavaged with a single dose of 7 or 100 mg/kg [(3)H]BPF and were kept for 96 hr  in metabolic cages. The excretion of BPF residues occurred mainly in urine (43-54% of the administered dose), which was found to contain at least six different metabolites, and to a lesser extent in feces (15-20% of the administered dose). Sulfatase treatment and subsequent high-performance liquid chromatography analyses suggest that the major urinary metabolite (more than 50% of the radioactivity present in urine) is a sulfate conjugate of BPF. At 96 hr, BPF residues were detectable in all tissues examined with the largest amounts in the liver (0.5% of the dose). In pregnant rats dosed at day 17 of gestation, BPF residues were detected in the uterus, placenta, amniotic fluid, and fetuses (0.9-1.3% of the administered dose). Large amounts of radioactivity (8-10% of the dose) were still located in the digestive tract lumen at the end of the study. After administration of a single oral dose of [(3)H]BPF, 46% of the distributed radioactivity was excreted in bile over a 6 hr period. In rats, BPF and/or its metabolites very likely undergo enterohepatic cycling, which could be responsible for the relatively high amounts of residues still excreted 4 days after BPF administration. This bisphenol is efficiently absorbed and distributed to the reproductive tract in female rats, and its residues pass the placental barrier at a late stage of gestation in rats.""]","[""Bisphenol F [4,4'-dihydroxydiphenyl-methane] (BPF) has a broad range of applications in industry (liners lacquers, adhesives, plastics, coating of drinks and food cans). Free monomers of this bisphenol can be released into the environment and enter the food chain, very likely resulting in the exposure of humans to low doses of BPF. This synthetic compound has been reported to be estrogenic. A study of BPF distribution and metabolism in rats has demonstrated the formation of many metabolites, with multiple biotransformation pathways. In the present work we investigated the in vitro biotransformation of radio-labeled BPF using rat and human liver subcellular fractions. BPF metabolites were separated, isolated by high-performance liquid chromatography (HPLC), and analysed by mass spectrometry (MS), MS(n), and nuclear magnetic resonance (NMR). Many of these metabolites were characterized for the first time in mammals and in humans. BPF is metabolized into the corresponding glucuronide and sulfate (liver S9 fractions). In addition to these phase II biotransformation products, various hydroxylated metabolites are formed, as well as structurally related apolar metabolites. These phase I metabolic pathways are dominant for incubations carried out with liver microsomes and also present for incubations carried out with liver S9 fractions. The formation of the main metabolites, namely meta-hydroxylated BPF and ortho-hydroxylated BPF (catechol BPF) is P450 dependent, as is the formation of the less polar metabolites characterized as BPF dimers. Both the formation of a catechol and of dimeric metabolites correspond to biotransformation pathways shared by BPF, other bisphenols and estradiol."", 'Bisphenol A (BPA) and bisphenol F (BPF) are widely used to manufacture plastics and epoxy resins. Both compounds have been shown to be present in the environment and are food contaminants, with, as a result, a low but chronic exposure of humans. However, the fate and possible bioactivation of these compounds at the level of human cell lines was not completely elucidated yet. In this study, /the researchers/ investigated the ability of human cells (intestinal cell line: LS174T, hepatoma cell line: HepG2, and renal cell line: ACHN) to biotransform BPA and BPF, and focused on the cytotoxicity and genotoxicity of these two bisphenols, through the use of a novel and efficient genotoxic assay based on the detection of histone H2AX phosphorylation. BPA and BPF were extensively metabolized in HepG2 and LS174T cell lines, with stronger biotransformation capabilities in intestinal cells than observed in liver cells. Both cell lines produced the glucuronide as well as the sulfate conjugates of BPA. Conversely, the ACHN cell line was found to be devoid of any metabolic capabilities for the two examined bisphenols. Cytotoxicity was tested for BPA, BPF, as well as one metabolite of BPF produced in vivo in rat, namely dihydroxybenzophenone (DHB). In the three cell lines used, /the researchers/ observed similar ranges of toxicity, with DHB being weakly cytotoxic, BPF exhibiting an intermediary cytotoxicity, and BPA being the most cytotoxic compound tested. BPA and DHB were not found to be genotoxic, whatever the cell line examined. BPF was clearly genotoxic in HepG2 cells. These results demonstrate that some human cell lines extensively metabolize bisphenols and establish the genotoxic potential of bisphenol F.', 'Bisphenol F (BPF) is present in the environment and as a contaminant of food. Humans may, therefore, be exposed to BPF, and an assessment of this risk is required. BPF has been shown to have genotoxic and endocrine-disruptor properties in a human hepatoma cell line (HepG2), which is a model system for studies of xenobiotic toxicity. In this study, we investigated the ability of HepG2 cells to biotransform BPF, because metabolism may affect the observed effects of BPF, and we compared this metabolic capacity with that of human hepatocytes. Cells were incubated for 24 hours with (3)H-BPF. The culture medium was then concentrated and its metabolites were isolated by high-performance liquid chromatography and identified by mass spectrometry. BPF was largely metabolized into the corresponding sulfate by the HepG2 cell line. BPF was metabolized into both sulfate and glucuronide by human hepatocytes, but with differences between individuals. The metabolism of BPF in both HepG2 cells and human hepatocytes suggests the existence of a detoxification pathway. Thus, these two cell models differ in metabolic capacity. It is, therefore, very important, when assessing the toxic effects of substances in vitro, to determine, in parallel, the biotransformation capacities of the model used to extrapolate in vivo.']",
2111,12112,3-Benzylpyridine,C1=CC=C(C=C1)CC2=CN=CC=C2,,,,,,
2112,12113,Phenacaine hydrochloride,CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCC)C.Cl,,,,,,
2113,12114,CID 12114,CC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C)S,,,,,,
2114,12115,1-Ethyl-3-phenylurea,CCNC(=O)NC1=CC=CC=C1,,,,,,
2115,12116,Dibenzyl sulfoxide,C1=CC=C(C=C1)CS(=O)CC2=CC=CC=C2,,,,,,
2116,12117,"N,N'-Diphenylacetamidine",CC(=NC1=CC=CC=C1)NC2=CC=CC=C2,,,,,,
2117,12118,Hexanilide,CCCCCC(=O)NC1=CC=CC=C1,,,,,,
2118,12119,4-(Ethylamino)phenol,CCNC1=CC=C(C=C1)O,,,,,,
2119,12120,3-Ethoxyaniline,CCOC1=CC=CC(=C1)N,,,,,,
2120,12121,3-Methylphenylacetic acid,CC1=CC(=CC=C1)CC(=O)O,,,,,,
2121,12122,3-Hydroxyphenylacetic acid,C1=CC(=CC(=C1)O)CC(=O)O,,,,,['3-hydroxyphenylacetic acid has known human metabolites that include 2-Phenylacetic acid.'],
2122,12123,3-Bromoacetanilide,CC(=O)NC1=CC(=CC=C1)Br,,,,,,
2123,12124,Metacetamol,CC(=O)NC1=CC(=CC=C1)O,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
2124,12125,3-Nitrophenylacetonitrile,C1=CC(=CC(=C1)[N+](=O)[O-])CC#N,,,,,,
2125,12126,3-Ethoxybenzoic acid,CCOC1=CC=CC(=C1)C(=O)O,,,,,,
2126,12127,Isovanillin,COC1=C(C=C(C=C1)C=O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2127,12128,"2-Chloro-1,1-diethoxyethane",CCOC(CCl)OCC,,,,,,
2128,12129,"2,2-Diethoxyethanol",CCOC(CO)OCC,,,,,,
2129,12130,N-Nitrosodipropylamine,CCCN(CCC)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['Transplacental transport of N-nitrosodi-n-propylamine was shown in  pregnant hamster. After  a single 100 mg/kg subcutaneous injection, N-nitrosodi-n-propylamine was  detected in the maternal blood, placenta, fetus, and amniotic fluid. The  concentration of the chemical in maternal blood reached a maximum at 45 and  90 minutes after the injection, whereas a single peak at 90 minutes was  observed in the fetus. Analysis for metabolites was not conducted, but 1.6%  of the unchanged compound was found in the placenta and 1.3% in the fetus at  day 14 of gestation.', 'Diffusion of N-nitroso-di-n-propylamine through rat skin in vitro has  been demonstrated.', '/MILK/ In goats, one hour after oral administration of 30 mg/kg bw NDPA, 4.9 mg/kg NDPA were found in milk ... . Only traces were found in the milk after 24 hours.']","['The ability of human liver cytochrome P450s to metabolize the environmental carcinogen N-nitrosodi-n-propylamine (NDPA) was investigated. The maximum rate of NDPA depropylation in seven human liver microsomal samples was 1.15 nmol/min/mg (range 0.53-2.60). Troleandomycin, a P450 3A4/5 inhibitor, inhibited depropylation modestly (10-60%) in three of seven samples. Diethyldithiocarbamic acid, a potent 2E1 inhibitor, and a 2E1 inhibitory monoclonal antibody (mAb) inhibited the reaction in all samples (23 to almost 100%). No significant inhibition was observed with the 2C9 inhibitor sulfaphenazole or with mAbs to 3A4, 2A6 and 2D6. The 2C8/9/18/19 mAb inhibited depropylation in one sample by approximately 25% and approximately 25% of the activity in another sample could not be accounted for by the inhibitors. Denitrosation of NDPA by three of the microsomal samples exhibited low K(m) values (51-86 microM) while two of these also had high K(m) values (2.6 and 4.6 mM). Purified human P450 2B6 and 3A4 and human P450 2A6, 2C8, 2C9 and 2D6 membranes had high K(m) values relative to their maximum turnover rates and are unlikely to participate in NDPA metabolism at micromolar concentrations. Conversely, purified rabbit 2E1 exhibited K(m) and V(max) values for depropylation of 52 microM and 13.4 nmol propionaldehyde/min/nmol P450, respectively. Values for denitrosation were 66 microM and 1.44 nmol nitrite/min/nmol P450, respectively. The toxicity of NDPA in transfected human liver epithelial cells expressing 2E1 was dose dependent down to 50 microM. No toxicity was observed in control cells or those expressing 2A6. These results indicate that 2E1 is the major human liver microsomal isoform responsible for NDPA metabolism at low micromolar concentrations. We also show that purified P450s catalyze the denitrosation of NDPA at approximately 10-20% of the rate of depropylation and K(m) values for both reactions are the same for each isozyme. This is consistent with the formation of an initial intermediate common to both pathways, presumably an alpha-nitrosamino radical.', 'Urine collected during 48 hours after administration of an oral LD50 dose to rats contained the following compounds: N-nitroso-3-hydroxy-n-propyl-n-propylamine, N-nitroso-2-carboxyethyl-n-propylamine and, to a lesser extent, N-nitroso-2-hydroxy-n-propyl-n-propylamine and N-nitroso-carboxymethyl-n-propylamine.', 'We have identified propionaldehyde, n-propranolo, isopropanol and N-nitroso-2-hydroxy-propylpropylamine following incubation of N-nitrosodi-n-propylamine with a microsomal fraction from rat liver. Based on the yields of the various products, we have shown that beta-oxidation occurs at about 15% of the level of alpha-oxidation, beta- as well as alpha-oxidation was shown to be carried out by the microsomal mixed function oxidase system. N-nitroso-2-hydroxy-propylpropylamine is further oxidized by the microsomal preparation to yield N-nitroso-2-oxopropylpropylamine.', 'Analysis of 24 hr urine samples of rats admin N-nitrosodipropylamine, N-nitroso-2-hydroxypropylpropylamine or N-nitroso-2-oxopropylpropylamine showed that the major excretion product in each case was the beta-glucuronide of N-nitroso-2-hydroxypropylpropylamine. This conjugate was present at levels of about 5% of the admin dose for N-nitrosodipropylamine based on exhaustive hydrolysis of the urine sample with beta-glucuronidase. Only low levels (less than 2%) of the unchanged nitrosamine or their unconjugated metabolite (N-nitroso-2-hydroxypropylpropylamine for admin of N-nitrosodi-n-propylamine) were detected.', 'For more Metabolism/Metabolites (Complete) data for N-Nitrosodi-n-propylamine (12 total), please visit the HSDB record page.', 'NDPA has known human metabolites that include Alpha-OH NDPA and Dipropylimine.']",
2130,12131,Glycerol trihexanoate,CCCCCC(=O)OCC(COC(=O)CCCCC)OC(=O)CCCCC,,,,,,
2131,12132,Bendazol,C1=CC=C(C=C1)CC2=NC3=CC=CC=C3N2,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)', 'A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,,
2132,12133,Triamylamine,CCCCCN(CCCCC)CCCCC,,,,,,
2133,12134,Tripentyl borate,B(OCCCCC)(OCCCCC)OCCCCC,,,,,,
2134,12135,"2-Propenamide, 3-phenyl-",C1=CC=C(C=C1)C=CC(=O)N,,,,,,
2135,12136,Benzyl carbamate,C1=CC=C(C=C1)COC(=O)N,,,,,,
2136,12137,4-(Methylamino)azobenzene,CNC1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
2137,12138,"4,4'-Ethylenedianiline",C1=CC(=CC=C1CCC2=CC=C(C=C2)N)N,,,,,,
2138,12139,CID 12139,C1=CC=C(C=C1)NNC(=NNC2=CC=CC=C2)S,,,,,,
2139,12140,"1,3-Diphenoxy-2-propanol",C1=CC=C(C=C1)OCC(COC2=CC=CC=C2)O,,,,,,
2140,12141,2-(Benzyloxy)ethanol,C1=CC=C(C=C1)COCCO,,,,,,
2141,12142,"Benzene, (2-chloroethenyl)-",C1=CC=C(C=C1)C=CCl,,,,,,
2142,12143,(E)-Benzaldehyde oxime,C1=CC=C(C=C1)C=NO,,,,,,
2143,12144,Ethyl phenyl sulfide,CCSC1=CC=CC=C1,,,,,,
2144,12145,Phenylcarbylamine chloride,C1=CC=C(C=C1)N=C(Cl)Cl,,,,,,
2145,12146,Cyclohexyl acetate,CC(=O)OC1CCCCC1,,,,['THEY DO NOT TEND TO ACCUMULATE IN BODY TISSUES... /ALICYCLIC HYDROCARBONS/'],,
2146,12147,N-(4-Iodophenyl)acetamide,CC(=O)NC1=CC=C(C=C1)I,,,,,,
2147,12148,P-Tolylurea,CC1=CC=C(C=C1)NC(=O)N,,,,,,
2148,12149,p-Tolyl isothiocyanate,CC1=CC=C(C=C1)N=C=S,,,,,,
2149,12150,4-Ethoxyphenol,CCOC1=CC=C(C=C1)O,,,,,"['4-Ethoxyphenol has known human metabolites that include (2S,3S,4S,5R)-6-(4-ethoxyphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
2150,12151,CID 12151,C1=CC(=CC=C1N=NC(=O)N=NC2=CC=C(C=C2)N(O)O)N(O)O,,,,,,
2151,12152,Benzyl azide,C1=CC=C(C=C1)CN=[N+]=[N-],,,,,,
2152,12153,N-Propylaniline,CCCNC1=CC=CC=C1,,,,,,
2153,12154,1-Formyl-2-phenylhydrazine,C1=CC=C(C=C1)NNC=O,,,,,,
2154,12155,Propoxybenzene,CCCOC1=CC=CC=C1,,,,,,
2155,12156,(2-Chloroethoxy)benzene,C1=CC=C(C=C1)OCCCl,,,,,,
2156,12157,4-Bromophenylhydrazine hydrochloride,C1=CC(=CC=C1NN)Br.Cl,,,,,,
2157,12158,(4-Bromophenyl)hydrazine,C1=CC(=CC=C1NN)Br,,,,,,
2158,12159,"1-Propanol, 3-(diethylamino)-",CCN(CC)CCCO,,,,,,
2159,12160,4-Ethyltoluene,CCC1=CC=C(C=C1)C,,,,,,
2160,12161,4-Methylstyrene,CC1=CC=C(C=C1)C=C,,,,,"['o-Vinyltoluene, m-vinyltoluene and p-vinyltoluene were given i.p. to rats and urine was analyzed for acidic metabolites by gas chromatography mass spectrometry. Different derivatives were prepared and used to identify the structure of the metabolites. Different types (11) of metabolites were found, although all metabolites were not produced from each vinyltoluene isomer. The metabolites identified were: methylphenylethylene glycol, methylmandelic acid, methylphenylglyoxylic acid, hydroxymethylphenylethylene glycol, carboxyphenylethylene glycol, hydroxymethylphenylglyoxylic acid, methylbenzoylglycine, methylphenylacetylglycine, vinylbenzoylglycine, N-acetylcysteine conjugate of methylphenylethanol and glucuronide of methylphenylethylene glycol. Metabolites (> 90%) recovered were excreted during the 1st 24 hr. For the sum of all metabolites, there was an approximately linear relation between given dose and recovered amount of metabolites. Repeated daily administration was not followed by any appreciable increase in metabolite excretion and no enzyme induction phenomenon was apparent.', 'The role of cytochrome-P-450 in initiating the metabolism of styrene derivatives was investigated in Holtzman-rat liver homogenates. Six parasubstituted styrenes were prepared from the corresponding acetophenones by borohydride reduction to p-bromostyrene, p-chlorostyrene, p-cyanostyrene, p-methylstyrene, p-phenylstyrene, and p-methoxystyrene. Styrene derivatives were incubated with liver homogenates with the addition of reduced nicotinamide-adenine-dinucleotide-phosphate (NADPH) or carbon-monoxide (CO). The conversion of tritiated beta-4-phenylstyrene to alpha-beta-diolstyrene depended on an oxygen source and the presence of NADPH in the microsomal system in order to catalyze the substrate. With p-methylstyrene, p-methoxystyrene, and p-phenylstyrene, metabolic attack was confined to the vinyl group. All six styrenes gave a type 1 difference binding spectrum in the microsomal substrate. The metabolism of p-phenylstyrene was confirmed by its inhibition by the addition of CO and by its stimulation and phenobarbital. The substituents did not affect the spectral dissociation constants or the values for enzymatic epoxidation. The authors conclude that the lack of significant polar substituent effects on enzymatic epoxidation of styrenes is not consistent with earlier studies in which it was determined that the reagent is electrophilic. The discrepancy may be due to the involvement of different species of cytochrome-P-450 enzymes or different modes of substrate action.']",
2161,12162,4-Bromobenzonitrile,C1=CC(=CC=C1C#N)Br,,,,,,
2162,12163,4-Chlorobenzonitrile,C1=CC(=CC=C1C#N)Cl,,,,,,
2163,12164,p-Chloromercuriphenol,C1=CC(=CC=C1O)[Hg]Cl,,,,,,
2164,12165,N-Methyl-p-toluidine,CC1=CC=C(C=C1)NC,,,,,,
2165,12166,p-Nitrosotoluene,CC1=CC=C(C=C1)N=O,,,,,,
2166,12167,4-Chloroanisole,COC1=CC=C(C=C1)Cl,,,,,,
2167,12168,"1-(2-Furyl)-1,3-butanedione",CC(=O)CC(=O)C1=CC=CO1,,,,,,
2168,12169,(2e)-3-(2-Furyl)acrylamide,C1=COC(=C1)C=CC(=O)N,,,,,,
2169,12170,Furfuryl acetate,CC(=O)OCC1=CC=CO1,,,,,,
2170,12171,"1,4-Bis(chloromethyl)benzene",C1=CC(=CC=C1CCl)CCl,,,,,,
2171,12172,Terephthalonitrile,C1=CC(=CC=C1C#N)C#N,,,,,,
2172,12173,Terephthalaldehyde,C1=CC(=CC=C1C=O)C=O,,,,,,
2173,12174,3-(2-Furyl)acrylaldehyde,C1=COC(=C1)C=CC=O,,,,,,
2174,12175,Ethyl aminoacetate hydrochloride,CCOC(=O)C[NH3+].[Cl-],,,,,,
2175,12176,Ethyl glycinate,CCOC(=O)CN,,,,,,
2176,12177,2-Methylpent-2-enal,CCC=C(C)C=O,,,,,,
2177,12178,3-Hexanol,CCCC(CC)O,,,,,,
2178,12179,"Pentanal, 3-oxo-",CCC(=O)CC=O,,,,,,
2179,12180,Methyl butyrate,CCCC(=O)OC,,,,,"['A radiochemical assay for carboxylesterase based on the substrate methyl[1-(14)C]butyrate is described. The blank value corresponds to 1.04 ug (liver)-1.44 mg (plasma) of tissues with the highest and lowest activity respectively, which constitute the sensitivity of the method. The hydrolysis of methyl butyrate and 4-nitrophenyl butyrate by plasma, liver, lung, heart, diaphragm, cerebrum, kidney and duodenum of rat have been compared. The results showed that the two substrates were hydrolysed preferentially by two different groups of the enzyme. The effect of selective esterase inhibitors showed that both groups can be characterized as carboxylesterase, because bis-4-nitrophenyl phosphate inhibits the hydrolysis of both substrates, physostigmine has only a slight effect and EDTA is no inhibitor. The exception is the enzyme in the duodenum which is inhibited by all three inhibitors. The effect of phenobarbital induction and soman treatment on enzyme activity towards the two substrates were similar. Sex difference in the plasma activity towards methyl butyrate, but not 4-nitrophenyl butyrate, indicates that the group of carboxylesterase preferentially hydrolyzing 4-nitrophenyl butyrate may be the most important for the detoxification of soman.']",
2180,12181,Methyl but-2-enoate,CC=CC(=O)OC,,,,,,
2181,12182,Ethyl propiolate,CCOC(=O)C#C,,,,,,
2182,12183,Ethyl iodoacetate,CCOC(=O)CI,,,,,,
2183,12184,Ethyl glycolate,CCOC(=O)CO,,,,,,
2184,12185,Ethyl thioglycolate,CCOC(=O)CS,,,,,,
2185,12186,5-Methyl-3-hexanol,CCC(CC(C)C)O,,,,,,
2186,12187,5-Methylhexan-3-one,CCC(=O)CC(C)C,,,,,,
2187,12188,CID 12188,CC(=O)CC(=O)[O-].[Na+],,,,,,
2188,12189,But-2-enoic anhydride,CC=CC(=O)OC(=O)C=CC,,,,,,
2189,12190,"1,3-Dimethoxy-2-propanol",COCC(COC)O,,,,,,
2190,12191,"2-Butenoic acid, ethyl ester",CCOC(=O)C=CC,,,,,,
2191,12192,Ethyl diazoacetate,CCOC(=O)C=[N+]=[N-],,,,,,
2192,12193,2-Ethoxy-2-hydroxyethenediazonium,CCOC(=C[N+]#N)O,,,,,,
2193,12194,"1,3-Diethylurea",CCNC(=O)NCC,,,,,,
2194,12195,Ethyl ethylcarbamate,CCNC(=O)OCC,,,,,,
2195,12196,"S,S-Diethyl carbamodithioate",CCSC(=O)SCC,,,,,,
2196,12197,Diethyl sulfite,CCOS(=O)OCC,,,,,,
2197,12198,Propylene glycol diacetate,CC(COC(=O)C)OC(=O)C,,,,,,
2198,12199,Ethyl propylcarbamate,CCCNC(=O)OCC,,,,,,
2199,12200,"1,3-Dinitroglycerin",C(C(CO[N+](=O)[O-])O)O[N+](=O)[O-],,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
2200,12201,Diethyl but-2-enedioate,CCOC(=O)C=CC(=O)OCC,,,,,,
2201,12202,5-Nonanol,CCCCC(CCCC)O,,,,,,
2202,12203,4-Decanone,CCCCCCC(=O)CCC,,,,,,
2203,12204,Diethyl azelate,CCOC(=O)CCCCCCCC(=O)OCC,,,,,,
2204,12205,"1,4-Diaminobenzene dihydrochloride",C1=CC(=CC=C1N)N.Cl.Cl,,,,"['...APPLIED TO SKIN OF DOGS IN GELS & FLUIDS...16 MG WERE ABSORBED WHEN 50 ML OF LAURYL SULFATE-BASED GEL CONTAINING 1.5 G P-PHENYLENEDIAMINE WAS APPLIED FOR 3 HR & FREE ACCESS TO AIR WAS ALLOWED... AMT ROSE TO 110 MG /WHEN AREA WAS COVERED WITH ALUMINUM FOIL. HYDROGEN PEROXIDE APPLIED BEFORE TREATMENT, 2 MG ABSORBED/.']",,
2205,12206,Methyl valerate,CCCCC(=O)OC,,,,,,
2206,12207,4-Iodotoluene,CC1=CC=C(C=C1)I,,,,,,
2207,12208,"1,4-Diiodobenzene",C1=CC(=CC=C1I)I,,,,,,
2208,12209,2-Methylbutyl acetate,CCC(C)COC(=O)C,,,,,,
2209,12210,6-Methylheptan-3-one,CCC(=O)CCC(C)C,,,,,,
2210,12211,1-Mononitroglycerin,C(C(CO[N+](=O)[O-])O)O,,,,,,
2211,12212,N-(5-methylhexan-2-ylidene)hydroxylamine,CC(C)CCC(=NO)C,,,,,,
2212,12213,Butan-2-one semicarbazone,CCC(=NNC(=O)N)C,,,,,,
2213,12214,"1,2,3-Trihydroxypropyl propanoate",CCC(=O)OC(C(CO)O)O,,,,,,
2214,12215,Dimethyl but-2-enedioate,COC(=O)C=CC(=O)OC,,,,,,
2215,12216,3-Nonanol,CCCCCCC(CC)O,,,,,,
2216,12217,Pentyl propionate,CCCCCOC(=O)CC,,,,,,
2217,12218,Ethylmethylamine hydrochloride,CC[NH2+]C.[Cl-],,,,,,
2218,12219,"Ethanamine, N-methyl-",CCNC,,,,,,
2219,12220,beta-Butene,CC=CC,,,,,,
2220,12221,Propargyl chloride,C#CCCl,,,,,,
2221,12222,2-Propynal,C#CC=O,,,,,,
2222,12223,"1,2-Difluoroethane",C(CF)F,,,,"['... Main factor affecting fate of fluorocarbons is body fat, where they are concentrated and slowly released into blood at concn that should not cause any risk of cardiac sensitization. /Fluorocarbons/', 'There is a significant accumulation of fluorocarbons in brain, liver, and lung compared to blood levels, signifying a tissue distribution of fluorocarbons similar to that of chloroform. /Fluorocarbons/', 'Abosrption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'Although fluorocarbons cause cardiac sensitization in certain animal species, rapid elimination prevents the development of cardiotoxic concentrations from aerosol bronchodilator use except at exceedingly high doses (12 to 24 doses in 2 minutes). /Fluorocarbons/', 'Fluorocarbon compounds are lipid-soluble and thus are generally well absorbed through lung. Absorption after ingestion is 35 to 48 times lower than after inhalation ... Fluorocarbons are eliminated by way of lung. /Fluorocarbon compounds/']",,
2223,12224,"1,2-Diiodoethane",C(CI)I,,,,,,
2224,12225,2-Iodoethanol,C(CI)O,,,,,,
2225,12226,Ethyl isocyanide,CC[N+]#[C-],,,,,,
2226,12227,N'-hydroxymethanimidamide,C(=NO)N,,,,,,
2227,12228,Methyl isocyanate,CN=C=O,,,['Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. (See all compounds classified as Antisickling Agents.)'],"['...  Female  Wistar rats were given (14)C labeled /methyl isocyanate/ by ip injection or  inhalation exposure, and free and  protein bound radioactivity was determined in blood, brain,  liver, kidney and lung samples. ...  Free and protein bound radioactivity were  present in all tissues within 30  minutes of the injection of methyl isocyanate at doses of 15  and 30 mg/kg. The relative order  of activity in the tissues for both forms of radioactivity  from highest to lowest was kidneys,  liver, lung, brain, blood hemolysate. Brain radioactivity  remained constant over a 10 day  period during which the activity of the other tissues  decreased. Radioactivity was present in  the globin fractions of blood proteins and the  hydantoin fractions of blood and tissue  proteins. Methyl isocyanate exposure by inhalation  produced comparable results.', 'The uptake and distribution of methyl isocyanate were studied in guinea pigs and mice. Male  English guinea pigs ... were exposed to 0.5 to 15 ppm of (14)C labeled methyl isocyanate vapor for 1 to 6 hours.  ... . Male and pregnant female Swiss Webster mice were exposed to 2.10 ppm of  (14)C labeled methyl isocyanate for 6 hours. ... Methyl isocyanate derived  (14)C activity was detected in venous and arterial blood within minutes of exposure; however,  blood methyl isocyanate concentrations in animals exposed by way of the tracheal cannula were  much lower than in those which breathed normally. Methyl isocyanate was cleared slowly from  the blood; most of it was cleared within 3 days. Methyl isocyanate was cleared more rapidly  from the urine than from bile. The highest concentrations of methyl isocyanate in male mice 2 hours after exposure were found in the lung, sternum, gastrointestinal tract, spleen, and  kidney. Twenty four hours after exposure, highest methyl isocyanate concentrations were in the  blood and lung. In female mice the highest concentrations at 2 hours after exposure were found  in the lung, fetus, spleen, uterus, and kidney. After 24 hours the highest concentrations were  in the lung, spleen, and fetus. /It was/ concluded that inhaled methyl isocyanate is taken up  rapidly in the blood. This uptake is much higher in normal animals than in those breathing  through a tracheal tube.', 'The substance can be absorbed into the body by inhalation, through the skin and by ingestion.', 'Through the use of radioactively labeled methyl isocyanate (MIC), the deposition, penetration, and clearance of this highly reactive compound in the airway at the tissue and cellular levels have been directly examined. Guinea pigs were exposed to 14C-MIC vapors at concentrations ranging from 0.38 to 15.2 ppm for periods of 1-6 hr. Solubilization of tissues from these animals showed the airway tissues to have the highest level of radioactivity. In the nasal region, 14C deposition, as monitored by histoautoradiography, was limited to the epithelial layer, was related to dose, and was dependent on the specific epithelial cell type. The squamous epithelium was minimally labeled on the surface and the label did not penetrate the cell layer. However, radioactivity was detected throughout the entire nasal respiratory epithelial layer. The lack of nasal deposition in tracheotomized animals demonstrated that the 14C accumulation at this site was due to the scrubbing action of the nasal region with no contribution from blood recirculation. Cellular localization in the tracheobronchial region showed epithelial and subepithelial deposition in a dose-dependent manner with accumulation of the label at the subepithelial region. Radioactivity penetrated to the level of the terminal bronchiole but was not detected in the alveolar region. The persistence of airway radioactivity over the 48-hr postexposure period monitored suggests the covalent modification of airway macromolecules. Despite its broad specificity and high reactivity, MIC undergoes selective reactions in the airways which are dependent on respiratory region and cell type.']","['S-(N-methylcarbamoyl)glutathione, a chemically-reactive glutathione conjugate, has been  isolated from the bile of rats administered methyl isocyanate ... . The ability of this  glutathione adduct to donate an N-methylcarbamoyl moiety to the free sulfhydryl group of  cysteine was evaluated in vitro... . The glutathione adduct reacted readily with cysteine in buffered aqueous media (pH  7.4, 37 degrees C) and after 2 hr, 42.5% of the substrate existed in the form of  S-(N-methylcarbamoyl)cysteine. The reverse reaction, ie between the cysteine adduct and free  glutathione, also took place readily under these conditions. It is concluded that conjugation  of methyl isocyanate with glutathione in vivo affords a reactive S-linked product which  displays the potential to carbamoylate nucleophilic amino acids.', 'S-(N-Methylcarbamoyl)-N-acetylcysteine, a chemically labile mercapturic acid conjugate, was  identified ...  in the urine of rats dosed ip with  methyl isocyanate (45.2 umol). The corresponding cysteine conjugate, however, was not detected  in urine. ... The fraction of the injected dose of methyl isocyanate which appeared in 24 hr urine as S-(N-Methylcarbamoyl)-N-acetylcysteine ...  was 24.8 +/- 1.9% (mean +/- SD, N=4).  Thus, conjugation of methyl isocyanate with glutathione, followed by metabolism of the  resulting S-(N-Methylcarbamoyl)-N-acetylcysteine adduct ... appears to represent a quantitatively important pathway of biotransformation of methyl isocyanate in the rat. However, in view of the known carbamoylating properties and in vitro cytotoxicity of S-linked  conjugates of methyl isocyanate, it seems unlikely that the glutathione pathway of metabolism  fulfills a conventional detoxification role in the case of methyl isocyanate. In contrast, it  is proposed that carbamate thioester conjugates of methyl isocyanate, which can revert  spontaneously to free methyl isocyanate under physiological conditions may actually contribute  to the multisystem adverse effects of this highly toxic isocyanate in vivo.', '... Methylisocyanate readily forms a glutathione conjugate in the lung after inhalation. From there, the conjugate is distributed to other tissues, where the reactive electrophilic parent cmpd may be regenerated. Such conjugates are considered transport forms of toxicants.', 'Monomethylamine, dimethylamine, and trimethylamine are endogenous substances as well as  metabolites of methyl isocyanate, the /cmpd/ involved in the 1984 accident at Bhopal, India.', 'For more Metabolism/Metabolites (Complete) data for METHYL ISOCYANATE (6 total), please visit the HSDB record page.', 'Methyl Isocyanate is a known human metabolite of n-methylformamide.']",
2228,12229,Formylhydrazine,C(=O)NN,,,,,,
2229,12230,Ethyl methyl sulfide,CCSC,,,,,,
2230,12231,Methyl nitrite,CON=O,,,,,,
2231,12232,Dimethyl disulfide,CSSC,,,,,"['The metabolism of methanethiol was studied in rats. The levels of volatile sulfur compounds methanethiol, dimethylsulfide and dimethyldisulfide in the air expired by rats exposed to a noncomatogenic dose of methanethiol through the colon were elevated.', 'Hydrogen sulfide is formed by the subgingival microbiotas of periodontal pockets. The capacity of these microbiotas to form various volatile sulfur compounds in human serum was studied. Hydrogen sulfide was the predominant volatile sulfur compound. Only traces of dimethyl sulfide and dimethyl disulfide were detected. There was an extensive degradation of the serum proteins. In most of the reaction mixtures hydrogen sulfide reached highly toxic levels.']",
2232,12233,"3,3-Dimethyl-1-butanol",CC(C)(C)CCO,,,,,,
2233,12234,"Ethanaminium, 2-mercapto-N,N,N-trimethyl-",CC([N+](C)(C)C)S,,,,,,
2234,12235,"2,4-Dimethyl-2-pentanol",CC(C)CC(C)(C)O,,,,,,
2235,12236,"Amidodiphosphoric acid, diethyl-, P',P'-diethyl P-methyl ester",CCN(CC)P(=O)(OC)OP(=O)(OCC)OCC,,,,,,
2236,12237,"Amidodiphosphoric acid, dimethyl-, P',P'-diethyl P-methyl ester",CCOP(=O)(OCC)OP(=O)(N(C)C)OC,,,,,,
2237,12238,tert-Amyl acetate,CCC(C)(C)OC(=O)C,,,,,,
2238,12239,Dibutyl sulfate,CCCCOS(=O)(=O)OCCCC,,,,,,
2239,12240,2-Methyl-2-hexanol,CCCCC(C)(C)O,,,,,,
2240,12241,"2,2,2-Trichloroethyl acetate",CC(=O)OCC(Cl)(Cl)Cl,,,,,,
2241,12242,2-Methyl-2-heptanol,CCCCCC(C)(C)O,,,,,,
2242,12243,2-Methyl-2-pentene,CCC=C(C)C,,,,,,
2243,12244,Isovaleronitrile,CC(C)CC#N,,,,,,
2244,12245,2-Chloropentane,CCCC(C)Cl,,,,,,
2245,12246,2-Aminopentane,CCCC(C)N,,,,,,
2246,12247,4-Penten-2-OL,CC(CC=C)O,,,,,,
2247,12248,Pent-3-en-2-one,CC=CC(=O)C,,,,,,
2248,12249,N-Methylisobutylamine,CC(C)CNC,,,,,,
2249,12250,1-Methoxy-2-methylpropane,CC(C)COC,,,,,,
2250,12251,Methoxyacetic acid,COCC(=O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
2251,12252,2-Nitroethanol,C(CO)[N+](=O)[O-],,,,,,
2252,12253,N-Ethylacetamide,CCNC(=O)C,,,,,,
2253,12254,Ethylurea,CCNC(=O)N,,,,,,
2254,12255,CID 12255,CCN=C(N)S,,,,,,
2255,12256,Ethyl isopropyl ether,CCOC(C)C,,,,,,
2256,12257,Isopropyl formate,CC(C)OC=O,,,,,,
2257,12258,CID 12258,CCOC(=N)S,,,,,,
2258,12259,Ethyl nitrate,CCO[N+](=O)[O-],,,,,,
2259,12260,"2,4-Dimethyl-2-pentene",CC(C)C=C(C)C,,,,,,
2260,12261,"2,4-Dichloropentane",CC(CC(C)Cl)Cl,,,,,,
2261,12262,"2,4-Pentanediol",CC(CC(C)O)O,,,,,,
2262,12263,Diacetamide,CC(=O)NC(=O)C,,,,,,
2263,12264,Diisopropyl sulfide,CC(C)SC(C)C,,,,,,
2264,12265,"2,5-Dimethyl-1H-pyrrole",CC1=CC=C(N1)C,,,,,,
2265,12266,"2,5-Dimethylfuran",CC1=CC=C(O1)C,,,,,,
2266,12267,"N-Nitrosobis(2,2,2-trifluoroethyl)amine",C(C(F)(F)F)N(CC(F)(F)F)N=O,,,,,,
2267,12268,3-Iodotoluene,CC1=CC(=CC=C1)I,,,,,,
2268,12269,1-Chloro-3-iodobenzene,C1=CC(=CC(=C1)I)Cl,,,,,,
2269,12270,"1,3-Diiodobenzene",C1=CC(=CC(=C1)I)I,,,,,,
2270,12271,3-Iodoaniline,C1=CC(=CC(=C1)I)N,,,,,,
2271,12272,3-Iodophenol,C1=CC(=CC(=C1)I)O,,,,,,
2272,12273,CID 12273,C1=CNC(=CC1=O)O,,,,,,
2273,12274,"2,6-Dibromopyridine",C1=CC(=NC(=C1)Br)Br,,,,,,
2274,12275,"1,3-Bis(chloromethyl)benzene",C1=CC(=CC(=C1)CCl)CCl,,,,,,
2275,12276,"1,3-Dicyanobenzene",C1=CC(=CC(=C1)C#N)C#N,,,,,,
2276,12277,DI-Sec-butylamine,CCC(C)NC(C)CC,,,,,,
2277,12278,1-Methylbutyl acetate,CCCC(C)OC(=O)C,,,,,,"['No reports found; [TDR, p. 95]']"
2278,12279,"1,3,5-Tribromobenzene",C1=C(C=C(C=C1Br)Br)Br,,,,,,
2279,12280,"3,5-Dibromophenol",C1=C(C=C(C=C1Br)Br)O,,,,,,
2280,12281,"3,5-Dichloroaniline",C1=C(C=C(C=C1Cl)Cl)N,,,,"['Using hairless rat skin maintained in a Franz diffusion cell, the percutaneous penetration of four aromatic amines: para-chloroaniline, meta-trifluoromethylaniline, dichloro-3,4-aniline and dichloro-3,5-aniline were studied. The purpose of the studies was to determine the permeation parameters (rate of permeation, permeability rat constant) in order to compare the rate of absorption of the four amines. The results show that the four amines penetrate significantly across the skin, but with different rates. 10 h after in vitro application (2 mg/cm sq), the extent of permeation was para-chloroaniline meta-trifluoromethylaniline > dichloro-3,4-aniline > dichloro-3,5-aniline.']","['Three bacterial strains were isolated from soils adapted to iprodione and identified as Pseudomonas fluorescens, Pseudomonas sp. and Pseudomonas paucimobilis. The first two strains transformed iprodione to N-(3,5-dichlorophenyl)-2,4-dioxoimidazolidine and under restrictive conditions to 3,5-dichlorophenylurea acetic acid; the latter subsequently degraded N-(3,5-dichlorophenyl)-2,4-dioxoimidazolidine to 3,5-dichlorophenylurea acetic acid and 3,5-dichlorophenylurea acetic acid to 3,5-dichloroaniline. We constructed bacterial combinations consisting of Pseudomonas paucimobilis plus one of the iprodione degraders and showed that these combinations transformed iprodione into 3,5-dichloroaniline. It is known that 3,5-dichloroaniline was the major metabolite found in adapted soils, suggesting that such a bacterial combination might be responsible for degrading iprodione into 3,5-dichloroaniline in adapted soils.']",
2281,12282,"1,3,5-Triiodobenzene",C1=C(C=C(C=C1I)I)I,,,,,,
2282,12283,6-Methyluracil,CC1=CC(=O)NC(=O)N1,,,"['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,"['UNCHANGED 6-METHYL-2-THIOURACIL (46% OF DOSE), 6-METHYLURACIL (9%), 6-METHYL-2-METHYLTHIOURACIL (2%), 6-METHYL-4-OXOPYRIMIDINE (2%), 2-AMINO-6-METHYL-4-OXOPYRIMIDINE (0.2%), & UREA (1%) WERE EXCRETED IN URINE OF RATS THAT HAD BEEN TREATED ORALLY WITH 6-METHYL-2-THIOURACIL.', '...STUDIES INDICATED THE FORMATION OF FOUR VOLATILE SUBSTANCES AFTER IRRADIATION OF A 10 PPM AQ BROMACIL SOLN FOR 6 DAYS. THE MAJOR PRODUCT (37%) WAS 6-METHYLURACIL.', 'A MIXED CULTURE OF PSEUDOMONAS SPECIES & PROACTINOMYCES RUBER UTILIZED 6-METHYLURACIL AS THE SOLE SOURCE OF CARBON & NITROGEN. 6-METHYLURACIL WAS OXIDATIVELY CONVERTED TO URACIL WHICH WAS SUBSEQUENTLY METABOLIZED TO BARBITURIC ACID & UREA.']",
2283,12284,3-Methylglutaric acid,CC(CC(=O)O)CC(=O)O,,,,,,
2284,12285,"2,4,6-Heptanetrione",CC(=O)CC(=O)CC(=O)C,,,,,,
2285,12286,3-Bromopyridine,C1=CC(=CN=C1)Br,,,,,,
2286,12287,3-Chloropyridine,C1=CC(=CN=C1)Cl,,,,,,
2287,12288,4-Chloropyridine,C1=CN=CC=C1Cl,,,,,,
2288,12289,Iodocyclohexane,C1CCC(CC1)I,,,,,,
2289,12290,4-Hydroxypyridine,C1=CNC=CC1=O,,,,,,
2290,12291,N-Methylpiperidine,CN1CCCCC1,,,,,,
2291,12292,3-Methyladipic acid,CC(CCC(=O)O)CC(=O)O,,,,,,
2292,12293,Propyl hexanoate,CCCCCC(=O)OCCC,,,,,,
2293,12294,Butyl hexanoate,CCCCCC(=O)OCCCC,,,,,,
2294,12295,Adipic acid monoethyl ester,CCOC(=O)CCCCC(=O)O,,,,,,
2295,12296,4-Methyl-1-pentanol,CC(C)CCCO,,,,,,
2296,12297,2-Hexanol,CCCCC(C)O,,,,,['Hexanol is a known human metabolite of hexane.'],
2297,12298,Pentanamide,CCCCC(=O)N,,,,,,
2298,12299,Pent-2-enoic acid,CCC=CC(=O)O,,,,,,
2299,12300,4-Chlorobutyric acid,C(CC(=O)O)CCl,,,,,,
2300,12301,Ethoxyacetic acid,CCOCC(=O)O,,,,,,
2301,12302,1-Nitrobutane,CCCC[N+](=O)[O-],,,,,,
2302,12303,N-Propylurea,CCCNC(=O)N,,,,,,
2303,12304,"Propane, 1-(1-methylethoxy)-",CCCOC(C)C,,,,,,
2304,12305,2-Chloroethyl chloroformate,C(CCl)OC(=O)Cl,,,,,,
2305,12306,Propyl carbamate,CCCOC(=O)N,,,,['RATS INJECTED IP WITH N-PROPYL CARBAMATE OR CORRESPONDING N-HYDROXYCARBAMATE EXCRETE BOTH CARBAMATE & N-HYDROXYCARBAMATE IN URINE... BINDING OF ((14)C-PROPYL)-N-PROPYL CARBAMATE TO DNA OF MOUSE LIVER WAS VERY LOW COMPARED WITH THAT OF ((14)C-ETHYL)-ETHYL CARBAMATE...'],,
2306,12307,N-Propyl nitrate,CCCO[N+](=O)[O-],,,,,,
2307,12308,3-Bromo-1-propanol,C(CO)CBr,,,,,,
2308,12309,1-Pentyne,CCCC#C,,,,,,
2309,12310,2-Pentyne,CCC#CC,,,,,,
2310,12311,Vinyl vinyl chloride,C=CC=CCl,,,,,,
2311,12312,"1-Chloro-1,2-butadiene",CC=C=CCl,,,,,,
2312,12313,3-Chloro-1-propanol,C(CO)CCl,,,,,,
2313,12314,"1,3-Diiodopropane",C(CI)CI,,,,,,
2314,12315,N-Methylpropylamine,CCCNC,,,,,,
2315,12316,2-Chloroethyl methyl ether,COCCCl,,,,,,
2316,12317,"Ether, 2-fluoroethyl methyl",COCCF,,,,,,
2317,12318,Diethylmercury,CC[Hg]CC,,,,,,
2318,12319,N-Ethylformamide,CCNC=O,,,,,,
2319,12320,Ethyl vinyl sulfide,CCSC=C,,,,,,
2320,12321,Divinyl sulfide,C=CSC=C,,,,,,
2321,12322,"2,5-Dimethyl-1,5-hexadiene",CC(=C)CCC(=C)C,,,,,,
2322,12323,5-Methyl-2-hexanol,CC(C)CCC(C)O,,,,,,
2323,12324,But-2-enedioyl dichloride,C(=CC(=O)Cl)C(=O)Cl,,,,,,
2324,12325,CID 12325,C([C@@H](C(=O)O)N)SC(=CCl)Cl,,,,,,
2325,12326,D-Arginine hydrochloride,C(C[C@H](C(=O)O)N)CN=C(N)N.Cl,,,,,,
2326,12327,Ethyl undecanoate,CCCCCCCCCCC(=O)OCC,,,,,,
2327,12328,Monomethyl adipate,COC(=O)CCCCC(=O)O,,,,,,
2328,12329,Dimethyl adipate,COC(=O)CCCCC(=O)OC,,,,,"['The metabolism of dibasic esters by rat nasal mucosal tissues was studied in-vitro. Homogenates of olfactory tissue from the ethmoturbinates and respiratory tissue from the nasoturbinates and maxilloturbinates of Crl:CDBR-rats were incubated with dimethyl succinate, dimethyl glutarate, or dimethyl adipate. Values of the reaction velocity at saturating substrate concentration (Vmax), the second order rate constant for binding and catalysis (V/K), the Michaelis constant (Km), and the dibasic ester concentration required to produce half maximal inhibition of the reaction rate (Ksi) were computed. The dibasic esters were hydrolyzed to their monomethyl esters by both the olfactory and respiratory mucosal homogenates. No diacid metabolites were detected. The rates of hydrolysis were always greater in the olfactory than in the respiratory homogenates. Vmaxs in olfactory tissue from male rats were 5 to 9 times higher than in respiratory tissue. In female rats, Vmaxs in the olfactory homogenates were 6 to 13 times those of the respiratory mucosa. V/Ks in male and female olfactory tissue were 4 to 11 and 6 to 10 times those in the corresponding respiratory tissue, respectively. When dimethyl glutarate was used as the substrate, V/Ks were similar for male and female olfactory tissue. In the case of dimethyl succinate and dimethyl adipate, V/K values for female olfactory tissue were 0.5 and 2 times those of the male tissues, respectively. The largest Km values in the olfactory tissues occurred when dimethyl adipate was used as the substrate, followed by dimethyl adipate and dimethyl glutarate in that order. The Ki values ranged from 24 to 46.5 millimolar. Female rats were pretreated with 1% bis-p-nitrophenyl phosphate, a carboxylesterase specific inhibitor. Bis-p-nitrophenyl phosphate decreased the rates of hydrolysis of dimethyl adipate, dimethyl glutarate, and dimethyl succinate in olfactory tissue by 79.8, 81, and 72%, respectively. The corresponding rates of hydrolysis in respiratory tissue were reduced by 87, 73, and 95%. The authors conclude that lesions induced in the nasal cavity of rodents by inhaled esters may be due to toxic acid metabolites.']",
2329,12330,2-Methyl-2-heptene,CCCCC=C(C)C,,,,,,
2330,12331,5-Methyl-1-hexanol,CC(C)CCCCO,,,,,,
2331,12332,Hexanamide,CCCCCC(=O)N,,,,,,
2332,12333,3-Nitropentane,CCC(CC)[N+](=O)[O-],,,,,,
2333,12334,3-Chloropropyl acetate,CC(=O)OCCCCl,,,,,,
2334,12335,1-Iodopentane,CCCCCI,,,,,['1-iodopentane has known human metabolites that include pentyl-glutathione.'],
2335,12336,4-Chlorobutyronitrile,C(CC#N)CCl,,,,,,
2336,12337,"1,4-Diiodobutane",C(CCI)CI,,,,,,
2337,12338,Butyl methyl ether,CCCCOC,,,,,,
2338,12339,Butyl methyl sulfide,CCCCSC,,,,,,
2339,12340,Ethyl propyl ether,CCCOCC,,,,,,
2340,12341,2-Chloroethyl ethyl ether,CCOCCCl,,,,,,
2341,12342,"1,2-Diformylhydrazine",C(=O)NNC=O,,,,,,
2342,12343,"1,4-Cyclohexadiene",C1C=CCC=C1,,,,,,
2343,12344,5-Methylhexanoic acid,CC(C)CCCC(=O)O,,,,,,
2344,12345,Methylene diacetate,CC(=O)OCOC(=O)C,,,,,,
2345,12346,Diisobutyl ether,CC(C)COCC(C)C,,,,,,
2346,12347,2-Chlorooctane,CCCCCCC(C)Cl,,,,,,
2347,12348,Pentyl acetate,CCCCCOC(=O)C,,,,,,"['No reports found; [TDR, p. 95]']"
2348,12349,2-Ethoxyethanol carbamate,CCOCCOC(=O)N,,,,,,
2349,12350,1-Heptyne,CCCCCC#C,,,,,,
2350,12351,CID 12351,C.CCCCCC#N,,,,,,
2351,12352,Hexanenitrile,CCCCCC#N,,,,,,
2352,12353,"1,5-Dichloropentane",C(CCCl)CCCl,,,,,,
2353,12354,"1,5-Diiodopentane",C(CCI)CCI,,,,,,
2354,12355,Butyl ethyl ether,CCCCOCC,,,,,,
2355,12356,2-Methoxy ethyl formate,COCCOC=O,,,,,,
2356,12357,Butyl thiocyanate,CCCCSC#N,,,,,,
2357,12358,"Mercury, dipropyl-",CCC[Hg]CCC,,,,,,
2358,12359,"Mercury, bis(fulminato)-",[C-]#[N+][O-].[C-]#[N+][O-].[Hg+2],,,,,,
2359,12360,Fulminate,[C-]#[N+][O-],,,,,,
2360,12361,2-(2-Chloroethoxy)ethanol,C(COCCCl)O,,,,,,
2361,12362,Methoxy(methoxymethoxy)methane,COCOCOC,,,,,,
2362,12363,Cycloheptene,C1CCC=CCC1,,,,,,
2363,12364,Adipamide,C(CCC(=O)N)CC(=O)N,,,,,,
2364,12365,Nitrooxymethyl nitrate,C(O[N+](=O)[O-])O[N+](=O)[O-],,,,,,
2365,12366,Ethyl palmitate,CCCCCCCCCCCCCCCC(=O)OCC,,,,,,
2366,12367,2-Nonanol,CCCCCCCC(C)O,,,,,,
2367,12368,"1,6-Dibromohexane",C(CCCBr)CCBr,,,,,,
2368,12369,1-Bromoheptane,CCCCCCCBr,,,,,,
2369,12370,1-Octyne,CCCCCCC#C,,,,,,
2370,12371,1-Chloroheptane,CCCCCCCCl,,,,,,
2371,12372,Heptanenitrile,CCCCCCC#N,,,,,,
2372,12373,"1,6-Diiodohexane",C(CCCI)CCI,,,,,,
2373,12374,"Hexane-1,6-diol",C(CCCO)CCO,,,,,"['There are no detailed studies with respect to toxicokinetics or metabolism. However, based on the structure and shown after oral application to rabbits, oxidation of both alcohol-groups resulting in the formation of adipic acid was observed.']",
2374,12375,"1,2-Diethoxyethane",CCOCCOCC,,,,,,
2375,12376,Ethylene formate,C(COC=O)OC=O,,,,,,
2376,12377,Dipropyl disulfide,CCCSSCCC,,,,,,
2377,12378,"(1Z,3Z,5Z,7Z)-cycloocta-1,3,5,7-tetraene",C1=CC=CC=CC=C1,,,,,,
2378,12379,CID 12379,CCCCCCCCCCCC(=O)[O-].[Na+],,,,,,
2379,12380,1-Iodooctane,CCCCCCCCI,,,,,['1-iodooctane has known human metabolites that include octyl-glutathione.'],
2380,12381,"1,7-Heptanediol",C(CCCO)CCCO,,,,,,
2381,12382,"Mercury, dibutyl-",CCCC[Hg]CCCC,,,,,,
2382,12383,1-Chloro-3-(3-chloropropoxy)propane,C(COCCCCl)CCl,,,,,,
2383,12384,2-(2-Methoxyethoxy)ethyl acetate,CC(=O)OCCOCCOC,,,,,,
2384,12385,Octanedinitrile,C(CCCC#N)CCC#N,,,,,,
2385,12386,Dibutyl disulfide,CCCCSSCCCC,,,,,,
2386,12387,Octyl nitrite,CCCCCCCCON=O,,,,,,
2387,12388,Tridecane,CCCCCCCCCCCCC,,,,"['... The purpose of the present study was to investigate the percutaneous absorption of JP-8 across pig ear skin and human skin in vitro and to study the effect of JP-8 exposure on the skin barrier function and irritation in Yucatan minipigs. JP-8 spiked with 5.0 microCi of radiolabeled (14)C tridecane, nonane, naphthalene or toluene (selected components of JP-8) was used for the in vitro percutaneous absorption studies with excised pig ear skin and human skin. For in vivo studies, 250 microl of JP-8 or two of its components (toluene or nonane) was placed in a Hill top chamber(R) and affixed over the marked treatment area for 24 hr. Transepidermal water loss (TEWL), skin capacitance (moisture content) and skin irritation (erythema and edema) were evaluated before treatment and at 1,2 and 24 hr after removal of the patches. The components of JP-8 such as tridecane, nonane, naphthalene and toluene permeated significantly through pig ear skin and human skin and the permeation rates were found to be proportional to their composition in JP-8. The steady state flux values of tridecane across pig ear skin and human skin did not differ significantly (P>0.05). Though the steady state flux values of nonane, naphthalene and toluene were statistically different between porcine and human skin (P<0.01), the values were close considering the large variations usually observed in the percutaneous absorption studies. Application of toluene, nonane or JP-8 increased the TEWL, JP-8 being the highest (3.5 times at 24 hr compared to baseline level). The skin moisture content decreased after the application of JP-8, though it was not significantly different (P>0.05) from the baseline level. JP-8 caused a moderate erythema and a moderate to severe edema. Though the edema decreased after 24 hr, the degree of erythema remained about the same until 24 hr. The skin irritation caused by JP-8 was greater than neat toluene or nonane. The TEWL data of toluene, nonane and JP-8 correlated well with the skin irritation data (erythema and edema). Exposure of JP-8, which contains hundreds of aliphatic and aromatic hydrocarbons, caused significant changes in the barrier function of the skin as indicated by an increase in TEWL and produced a significant erythema and edema in minipigs. Furthermore, the disruption of barrier function of skin, as indicated by increased TEWL after exposure to JP-8 might result in increased permeation of its own components and/or other chemicals exposed to skin. The present study provides further evidence that pig ear skin may be used as a model for predicting the rates of permeation of chemicals through human skin.', 'Dermal penetration and absorption of jet fuels in general, and JP-8 in particular, is not well understood, even though government and industry, worldwide, use over 4.5 billion gallons of JP-8 per year. Exposures to JP-8 can occur from vapor, liquid, or aerosol. Inhalation and dermal exposure are the most prevalent routes. JP-8 may cause irritation during repeated or prolonged exposures, but it is unknown whether systemic toxicity can occur from dermal penetration of fuels. The purpose of this investigation was to measure the penetration and absorption of JP-8 and its major constituents with rat skin, so that the potential for effects with human exposures can be assessed. We used static diffusion cells to measure both the flux of JP-8 and components across the skin and the kinetics of absorption into the skin. Total flux of the hydrocarbon components was 20.3 micrograms/sq cm/hr. Thirteen individual components of JP-8 penetrated into the receptor solution. The fluxes ranged from a high of 51.5 micrograms/sq cm/hr (an additive, diethylene glycol monomethyl ether) to a low of 0.334 micrograms/sq cm/hr (tridecane). Aromatic components penetrated most rapidly. Six components (all aliphatic) were identified in the skin. Concentrations absorbed into the skin at 3.5 hr ranged from 0.055 micrograms per gram skin (tetradecane) to 0.266 micrograms per gram skin (undecane). These results suggest: (1) that JP-8 penetration will not cause systemic toxicity because of low fluxes of all the components; and (2) the absorption of aliphatic components into the skin may be a cause of skin irritation.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', '... The present study is an ongoing approach to assess the dose-related percutaneous absorption of a number of aliphatic and aromatic hydrocarbons. The first treatment (1X) was comprised of mixtures containing undecane (4.1%), dodecane (4.7%), tridecane (4.4%), tetradecane (3%), pentadecane (1.6%), naphthalene (1.1%), and dimethyl naphthalene (1.3% of jet fuels) in hexadecane solvent using porcine skin flow through diffusion cell. Other treatments (n = 4 cells) were 2X and 5X concentrations. Perfusate samples were analyzed with gas chromatography-flame ionization detector (GC-FID) using head space solid phase micro-extraction fiber technique. We have standardized the assay to have a good linear correlation for all the tested components in media standards. Absorption parameters including diffusivity, permeability, steady state flux, and percent dose absorbed were estimated for all the tested hydrocarbons. This approach provides a baseline to access component interactions among themselves and with the diluent (solvents). A quantitative structure permeability relationship (QSPR) model was derived to predict the permeability of unknown jet fuel hydrocarbons in this solvent system by using their physicochemical parameters. Our findings suggested a dose related increase in absorption for naphthalene and dimethyl naphthalene (DMN).', 'For more Absorption, Distribution and Excretion (Complete) data for n-Tridecane (10 total), please visit the HSDB record page.']","['Alternative fuels are being considered for civilian and military uses. One of these is S-8, a replacement jet fuel synthesized using the Fischer-Tropsch process, which contains no aromatic compounds and is mainly composed of straight and branched alkanes. Metabolites of S-8 fuel in laboratory animals have not been identified. The goal of this study was to identify metabolic products from exposure to aerosolized S-8 and a designed straight-chain alkane/polyaromatic mixture (decane, undecane, dodecane, tridecane, tetradecane, pentadecane, naphthalene, and 2-methylnaphthalene) in male Fischer 344 rats. Collected blood and tissue samples were analyzed for 70 straight and branched alcohols and ketones ranging from 7 to 15 carbons. No fuel metabolites were observed in the blood, lungs, brain, and fat following S-8 exposure. Metabolites were detected in the liver, urine, and feces. Most of the metabolites were 2- and 3-position alcohols and ketones of prominent hydrocarbons with very few 1- or 4-position metabolites. Following exposure to the alkane mixture, metabolites were observed in the blood, liver, and lungs. Interestingly, heavy metabolites (3-tridecanone, 2-tridecanol, and 2-tetradecanol) were observed only in the lung tissues possibly indicating that metabolism occurred in the lungs. With the exception of these heavy metabolites, the metabolic profiles observed in this study are consistent with previous studies reporting on the metabolism of individual alkanes. Further work is needed to determine the potential metabolic interactions of parent, primary, and secondary metabolites and identify more polar metabolites. Some metabolites may have potential use as biomarkers of exposure to fuels.', 'The effect of cultural conditions on inosine production were investigated in the adenine auxotroph of Corynebacterium petrophilum SB 4082. The inosine production was dependent upon the amount of adenine in the medium. The addition of 10 mg adenine and 0.5 g of yeast extract to 100 mL of medium was optimal for inosine formation. Ammonium chloride or ammonium sulfate were effective as nitrogen sources. Tridecane was utilized as a carbon source.']",
2388,12389,Tetradecane,CCCCCCCCCCCCCC,,,,"['Dermal penetration and absorption of jet fuels in general, and JP-8 in particular, is not well understood, even though government and industry, worldwide, use over 4.5 billion gallons of JP-8 per year. Exposures to JP-8 can occur from vapor, liquid, or aerosol. Inhalation and dermal exposure are the most prevalent routes. JP-8 may cause irritation during repeated or prolonged exposures, but it is unknown whether systemic toxicity can occur from dermal penetration of fuels. The purpose of this investigation was to measure the penetration and absorption of JP-8 and its major constituents with rat skin, so that the potential for effects with human exposures can be assessed. We used static diffusion cells to measure both the flux of JP-8 and components across the skin and the kinetics of absorption into the skin. Total flux of the hydrocarbon components was 20.3 micrograms/sq cm/hr. Thirteen individual components of JP-8 penetrated into the receptor solution. The fluxes ranged from a high of 51.5 micrograms/sq cm/hr (an additive, diethylene glycol monomethyl ether) to a low of 0.334 micrograms/sq cm/hr (tridecane). Aromatic components penetrated most rapidly. Six components (all aliphatic) were identified in the skin. Concentrations absorbed into the skin at 3.5 hr ranged from 0.055 micrograms per gram skin (tetradecane) to 0.266 micrograms per gram skin (undecane). These results suggest: (1) that JP-8 penetration will not cause systemic toxicity because of low fluxes of all the components; and (2) the absorption of aliphatic components into the skin may be a cause of skin irritation.', 'JP-8 has been associated with toxicity in animal models and humans. There is a great potential for human exposure to JP-8. Quantitation of percutaneous absorption of JP-8 is necessary for assessment of health hazards involved in its occupational exposure. In this study, we selected three aliphatic (dodecane, tridecane, and tetradecane) and two aromatic (naphthalene and 2-methylnaphthalene) chemicals, which are major components of JP-8. We investigated the changes in skin lipid and protein biophysics, and macroscopic barrier perturbation from dermal exposure of the above five chemicals. Fourier transform infrared (FTIR) spectroscopy was employed to investigate the biophysical changes in stratum corneum (SC) lipid and protein. FTIR results showed that all of the above five components of JP-8 significantly (P<0.05) extracted SC lipid and protein. Macroscopic barrier perturbation was determined by measuring the rate of transepidermal water loss (TEWL). All of the five JP-8 components studied, caused significant (P<0.05) increase in TEWL in comparison to control. We quantified the amount of chemicals absorbed assuming 0.25 sq m body surface area exposed for 8 hr. Our findings suggest that tridecane exhibits greater permeability through skin among aliphatic and naphthalene among aromatic JP-8 components. Amount of chemicals absorbed suggests that tridecane, naphthalene and its methyl derivatives should be monitored for their possible systemic toxicity.', '... JP-8 is a complex mixture containing >200, mostly toxic, aliphatic and aromatic hydrocarbon compounds of which tetradecane and naphthalene were chosen as two representative chemical markers for computer simulations. Thus, transport and deposition of naphthalene and tetradecane vapors have been simulated in models of the human respiratory system. The inspiratory deposition data were analyzed in terms of regional deposition fractions (DFs) and deposition enhancement factors (DEF). The vapor depositions are affected by vapor properties (e.g. diffusivity), airway geometric features, breathing patterns, inspiratory flow rates, as well as airway-wall absorption parameter. Specifically, the respiratory uptake of vapors is greatly influenced by the degree of airway-wall absorption. For example, being an almost insoluble species in the mucus layer, the deposition of tetradecane vapor is nearly zero in the extrathoracic and tracheobronchial (TB) airways, that is, the DF is <1%. The remaining vapors may penetrate further and deposit in the alveolar airways. The DF of tetradecane vapors during inhalation in the alveolar region can range from 7% to 24%, depending on breathing waveform, inhalation rate, and thickness of the mucus layer. In contrast, naphthalene vapor almost completely deposits in the extrathoracic and TB airways and hardly moves downstream and deposits in the respiratory zone. The DFs of naphthalene vapor in the extrathoracic airways from nasal/oral to trachea under normal breathing conditions (Q = 15-60 L/min) are about 12-34%, although they are about 66-87% in the TB airways. In addition, the variation of breathing routes (say, from nasal breathing to oral breathing) may influence the vapor deposition in the regions of nasal and oral cavities, nasopharynx and oropharynx, but hardly affects the deposition at and beyond the larynx. The different deposition patterns of naphthalene and tetradecane vapors in the human respiratory system may indicate different toxic and hence health effects of these toxic jet-fuel components.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', 'For more Absorption, Distribution and Excretion (Complete) data for n-Tetradecane (7 total), please visit the HSDB record page.']","['Tetradecane can be metabolized by a cytochrome p450 mixed-function oxidase system.', 'Alternative fuels are being considered for civilian and military uses. One of these is S-8, a replacement jet fuel synthesized using the Fischer-Tropsch process, which contains no aromatic compounds and is mainly composed of straight and branched alkanes. Metabolites of S-8 fuel in laboratory animals have not been identified. The goal of this study was to identify metabolic products from exposure to aerosolized S-8 and a designed straight-chain alkane/polyaromatic mixture (decane, undecane, dodecane, tridecane, tetradecane, pentadecane, naphthalene, and 2-methylnaphthalene) in male Fischer 344 rats. Collected blood and tissue samples were analyzed for 70 straight and branched alcohols and ketones ranging from 7 to 15 carbons. No fuel metabolites were observed in the blood, lungs, brain, and fat following S-8 exposure. Metabolites were detected in the liver, urine, and feces. Most of the metabolites were 2- and 3-position alcohols and ketones of prominent hydrocarbons with very few 1- or 4-position metabolites. Following exposure to the alkane mixture, metabolites were observed in the blood, liver, and lungs. Interestingly, heavy metabolites (3-tridecanone, 2-tridecanol, and 2-tetradecanol) were observed only in the lung tissues possibly indicating that metabolism occurred in the lungs. With the exception of these heavy metabolites, the metabolic profiles observed in this study are consistent with previous studies reporting on the metabolism of individual alkanes. Further work is needed to determine the potential metabolic interactions of parent, primary, and secondary metabolites and identify more polar metabolites. Some metabolites may have potential use as biomarkers of exposure to fuels.', 'Jet propellant 8 (JP-8) jet fuel is a complex mixture of aromatic and aliphatic hydrocarbons. The aim of this study was to determine in vitro metabolic rate constants for semivolatile n-alkanes, nonane (C9), decane (C10), and tetradecane (C14), by rat liver microsomal oxidation. The metabolism was assessed by measuring the disappearance of parent compound by gas chromatography. Various concentrations of n-alkanes were incubated with liver microsomes from adult male F-344 rats. Nonlinear kinetic constants for nonane and decane were V(max) (nmol/mg protein/min) = 7.26 +/- 0.20 and 2.80 +/- 0.35, respectively, and K(M) (micro M) = 294.83 +/- 68.67 and 398.70 +/- 42.70, respectively. Metabolic capacity as assessed by intrinsic clearance (V(max)/K(M)) was approximately four-fold higher for nonane (0.03 +/- 0.005) than for decane (0.007 +/- 0.001). There was no appreciable metabolism of tetradecane even with higher microsomal protein concentration and longer incubation time. These results show a negative correlation between metabolic clearance and chain length of n-alkanes. These metabolic rate constants will be used to update existing physiologically based pharmacokinetic (PBPK) models for nonane and decane as part of developing a PBPK model for JP-8.', 'Candida lipolytica ATCC 8661 was grown in a mineral salts hydrocarbon medium. n-Tetradecane was one of the substrates used. ... Analyses of fluids from cultures grown on n-alkanes indicated a predominance of fatty acids and alcohols of the same chain length as the substrate. In addition, numerous other fatty acids and alcohols were present. Analyses of saponifiable and nonsaponifiable material obtained from the cells revealed essentially the same products. The presence of primary and secondary alcohols, as well as fatty acids, of the same chain length as the n-alkane substrate suggested that attack on both the methyl and alpha-methylene group was occurring.', 'For more Metabolism/Metabolites (Complete) data for n-Tetradecane (9 total), please visit the HSDB record page.']",
2389,12390,Tridecanenitrile,CCCCCCCCCCCCC#N,,,,,,
2390,12391,Pentadecane,CCCCCCCCCCCCCCC,,,,"['... Pigs were exposed to JP-8 jet fuel-soaked cotton fabrics for 1 and 4 d with repeated daily exposures. Preexposed and unexposed skin was then dermatomed and placed in flow-through in vitro diffusion cells. Five cells with exposed skin and four cells with unexposed skin were dosed with a mixture of 14 different hydrocarbons (HC) consisting of nonane, decane, undecane, dodecane, tridecane, tetradecane, pentadecane, hexadecane, ethyl benzene, o-xylene, trimethyl benzene (TMB), cyclohexyl benzene (CHB), naphthalene, and dimethyl naphthalene (DMN) in water + ethanol (50:50) as diluent. Another five cells containing only JP-8-exposed skin were dosed solely with diluent in order to determine the skin retention of jet fuel HC. The absorption parameters of flux, diffusivity, and permeability were calculated for the studied HC. The data indicated that there was a two-fold and four-fold increase in absorption of specific aromatic HC like ethyl benzene, o-xylene, and TMB through 1- and 4-d JP-8 preexposed skin, respectively. Similarly, dodecane and tridecane were absorbed more in 4-d than 1-d JP-8 preexposed skin experiments. The absorption of naphthalene and DMN was 1.5 times greater than the controls in both 1- and 4-d preexposures. CHB, naphthalene, and DMN had significant persistent skin retention in 4-d preexposures as compared to 1-d exposures that might leave skin capable of further absorption several days postexposure. The possible mechanism of an increase in HC absorption in fuel preexposed skin may be via lipid extraction from the stratum corneum as indicated by Fourier transform infrared (FTIR) spectroscopy. This study suggests that the preexposure of skin to jet fuel enhances the subsequent in vitro percutaneous absorption of HC, so single-dose absorption data for jet fuel HC from naive skin may not be optimal to predict the toxic potential for repeated exposures. For certain compounds, persistent absorption may occur days after the initial exposure.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', 'n-Hexadecane and n-pentadecane are similarly absorbed when given orally to rats.']","['Alternative fuels are being considered for civilian and military uses. One of these is S-8, a replacement jet fuel synthesized using the Fischer-Tropsch process, which contains no aromatic compounds and is mainly composed of straight and branched alkanes. Metabolites of S-8 fuel in laboratory animals have not been identified. The goal of this study was to identify metabolic products from exposure to aerosolized S-8 and a designed straight-chain alkane/polyaromatic mixture (decane, undecane, dodecane, tridecane, tetradecane, pentadecane, naphthalene, and 2-methylnaphthalene) in male Fischer 344 rats. Collected blood and tissue samples were analyzed for 70 straight and branched alcohols and ketones ranging from 7 to 15 carbons. No fuel metabolites were observed in the blood, lungs, brain, and fat following S-8 exposure. Metabolites were detected in the liver, urine, and feces. Most of the metabolites were 2- and 3-position alcohols and ketones of prominent hydrocarbons with very few 1- or 4-position metabolites. Following exposure to the alkane mixture, metabolites were observed in the blood, liver, and lungs. Interestingly, heavy metabolites (3-tridecanone, 2-tridecanol, and 2-tetradecanol) were observed only in the lung tissues possibly indicating that metabolism occurred in the lungs. With the exception of these heavy metabolites, the metabolic profiles observed in this study are consistent with previous studies reporting on the metabolism of individual alkanes. Further work is needed to determine the potential metabolic interactions of parent, primary, and secondary metabolites and identify more polar metabolites. Some metabolites may have potential use as biomarkers of exposure to fuels.']",
2391,12392,Heptyl ether,CCCCCCCOCCCCCCC,,,,,,
2392,12393,Hexadecyl acetate,CCCCCCCCCCCCCCCCOC(=O)C,,,,,,
2393,12394,1-Bromopentadecane,CCCCCCCCCCCCCCCBr,,,,,,
2394,12395,1-Hexadecene,CCCCCCCCCCCCCCC=C,,,,,"['1,2-EPOXYHEXADECANE HAS BEEN IDENTIFIED AS A METABOLITE OF HEXADEC-1-ENE IN RABBIT-LIVER MICROSOMES BY USING 1,2-EPOXYDECANE TO INHIBIT THE EPOXIDE HYDRATASE ACTIVITY; IN ITS ABSENCE ONLY 1,2-DIHYDROXYHEXADECANE WAS DETECTED.', 'HEXADEC-1-ENE IS OXYGENATED TO 1,2-EPOXYHEXADECANE BY RAT-LIVER MONO-OXYGENASE IN VITRO. THE COMPOUND CAUSES SKIN CARCINOMAS IN THE MOUSE. IT IS A VERY EFFECTIVE INHIBITOR OF, AND A VERY POOR SUBSTRATE FOR EPOXIDE HYDRATASE.']",
2395,12396,1-Hexadecyne,CCCCCCCCCCCCCCC#C,,,,,,
2396,12397,1-Pentadecanol,CCCCCCCCCCCCCCCO,,,,,,
2397,12398,Heptadecane,CCCCCCCCCCCCCCCCC,,,,"['In rats fed a diet of 25% Spirulina algae, heptadecane accumulated  in adipose tissue at 80.2 and 272 mg/g in males and females and in lung and muscle at approx. 10-20 mg/kg, respectively.', 'Following oral gavage of 1 g to rats, heptadecane was found in concentrations of 0.7, 1.4, 1.2, and 0.2% in the intestinal wall, liver, intestinal content, and feces, respectively.', '/MILK/ Dietary concentrations of 52 ppm fed to pigs for 12 months resulted in the excretion of some heptadecane in milk  during lactation.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', 'For more Absorption, Distribution and Excretion (Complete) data for n-Heptadecane (6 total), please visit the HSDB record page.']","['The in vitro metabolism of n-heptadecane was investigated using hepatic microsomes from Hubbard chickens, New Zealand rabbits, Wistar rats and rainbow trout. Incubations with the (14)C-labelled alkane for 1 hr showed that the rate of oxidation varied between species; the rate (per mg protein) in chickens was roughly 20-fold greater than the rate in trout, and roughly 10-fold greater than the rates in rats and rabbits. On the basis of cytochrome P-450 content, the rate of heptadecane metabolism was roughly 20-fold greater in the chicken than in the other species. Moreover, the lambda max Soret band of the reduced cytochrome P-450 CO-complex was observed at 452 nm in the chicken. Correlation between the rate of heptadecane metabolism and in vivo storage levels is discussed.']",
2398,12399,Dioctyl ether,CCCCCCCCOCCCCCCCC,,,,,,
2399,12400,Methyl triacontanoate,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
2400,12401,Nonadecane,CCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2401,12402,1-Iodooctadecane,CCCCCCCCCCCCCCCCCCI,,,,,,
2402,12403,Heneicosane,CCCCCCCCCCCCCCCCCCCCC,,,,"['Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.', 'Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2403,12404,1-Eicosanol,CCCCCCCCCCCCCCCCCCCCO,,,,,"['The lipids of the Gram-negative marine bacterium Marinobacter hydrocarbonoclasticus, cultivated in synthetic seawater on a single carbon source, acetate or n-icosane, were isolated, purified and their structures determined. Three different pools of lipids were isolated according to the sequential procedure used: ""unbound"" lipids extractable by solvents, lipids released under basic conditions (""ester bound"") and lipids released by acid hydrolysis (""amide bound""). Even-carbon-numbered, n-fatty acids were identified in the ""unbound"" lipids of both the acetate and n-icosane cultures. In addition to these compounds, n-icosane induced the formation of n-icosan-1-ol and n-icos-11-en-1-ol, and also of a series of -hydroxy acids ranging from C12 to C20. In the ""ester bound"" lipids of the two cultures, short and long chain fatty acids were identified together with the -hydroxy C12:0 acid. This hydroxy acid was, by far, the major compound identified in the ""amide bound"" lipids of the two cultures. Comparison of the analytical data for the two cultures, and the differences in composition thus observed for the ""unbound"" pool, suggest the following metabolic pathway for n-icosane: hydroxylation to the C20 primary alcohol, transformation into the C20 -hydroxy acid and subsequent degradation into lower homologues. In sharp contrast, lipids from the ""ester bound"" and ""amide bound"" pools were quite unaffected by the change of nutrient. Lipids from Escherichia coli were also examined in the same manner. The results are discussed in terms of geochemical implications, relative to the presence of ""unbound"" -hydroxy acids in particulate matter and sediments.']",
2404,12405,Docosane,CCCCCCCCCCCCCCCCCCCCCC,,,,"['Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.', 'Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']","['Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.']",
2405,12406,Pentacosane,CCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2406,12407,Hexacosane,CCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2407,12408,Octacosane,CCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/', 'Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.']",,
2408,12409,Nonacosane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['This report deals with a new human disorder characterized by the accumulation of plant long-chain n-alkanes in viscera of a human patient. Lipid analysis of tissues from an adult male after sudden death (affected with diffuse visceral granuloma containing lipophilic crystallized material) showed the presence of abnormal compounds identified as long-chain n-alkanes with 29 (n-nonacosane), 31 (n-hentriacontane) and 33 carbons (n-tritriacontane). Study of n-alkane distribution in patient tissues showed a major accumulation in lumbo-aortic lymph nodes, adrenal glands, lung (the highest levels were found in lung granulomas) and liver; significantly lower amounts were detected in myocardium and kidney, whereas no detectable level was found in brain. On the basis of the structural composition and of the tissue distribution of the accumulated n-alkanes, their dietary (plant) origin and the pathophysiological mechanism of the storage are discussed.', 'Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.']",,
2409,12410,Hentriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/', 'This report deals with a new human disorder characterized by the accumulation of plant long-chain n-alkanes in viscera of a human patient. Lipid analysis of tissues from an adult male after sudden death (affected with diffuse visceral granuloma containing lipophilic crystallized material) showed the presence of abnormal compounds identified as long-chain n-alkanes with 29 (n-nonacosane), 31 (n-hentriacontane) and 33 carbons (n-tritriacontane). Study of n-alkane distribution in patient tissues showed a major accumulation in lumbo-aortic lymph nodes, adrenal glands, lung (the highest levels were found in lung granulomas) and liver; significantly lower amounts were detected in myocardium and kidney, whereas no detectable level was found in brain. On the basis of the structural composition and of the tissue distribution of the accumulated n-alkanes, their dietary (plant) origin and the pathophysiological mechanism of the storage are discussed.']",,
2410,12411,Tritriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
2411,12412,Hexatriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
2412,12413,Pentatriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
2413,12414,CID 12414,C(=N)(N)[SeH],,,,,,
2414,12415,"1-Bromo-2,2-dimethylpropane",CC(C)(C)CBr,,,,,,
2415,12416,Trimethylacetonitrile,CC(C)(C)C#N,,,,,,
2416,12417,Trimethylacetaldehyde,CC(C)(C)C=O,,,,,,
2417,12418,"1,1,1,2-Tetrachloroethane",C(C(Cl)(Cl)Cl)Cl,,,,"['WHEN ADMIN SC TO MICE, HALF OF DOSE OF 1,1,1,2-TETRACHLOROETHANE WAS EXHALED UNCHANGED, & PART METABOLIZED WAS EXCRETED MAINLY AS TRICHLOROETHANOL & TO MINOR EXTENT AS TRICHLOROACETIC ACID.', 'INHALATION OR INGESTION OF 1,1,1,2-TETRACHLOROETHANE BY PREGNANT RATS & RABBITS RESULTED IN PRESENCE OF HIGH LEVELS OF CHEM IN FETUSES, INDICATING TRANS-PLACENTAL PASSAGE.', 'It can be absorbed through inhalation, ingestion, skin and/or eye contact.']","['... /1,1,1,2-TETRACHLOROETHANE WAS/ METAB ... TO GIVE FIRST DICHLOROACETIC ACID AND THEN GLYOXYLIC ACID. WITH PART OF TETRACHLOROETHANE, NONENZYMIC DEHYDROCHLORINATION OCCURS, WITH FORMATION OF TRICHLOROETHYLENE, WHICH IS ALSO FOUND IN BREATH.', '1,1,1,2-TETRACHLOROETHANE WAS SC INJECTED INTO MICE & EXCRETION WAS FOLLOWED FOR 3 DAYS. THE PART METABOLIZED WAS EXCRETED MAINLY AS 2,2,2-TRICHLOROETHANOL (17-49% OF DOSE) & TO LESSER EXTENT AS TRICHLOROACETIC ACID.', 'IN RATS, GUINEA PIGS & RABBITS, 1,1,1,2-TETRACHLOROETHANE UNDERWENT DEHALOGENATION BY PRODUCING TRICHLOROETHANOL WHICH IS ELIMINATED PRINCIPALLY IN URINE IN FORM OF CONJUGATED GLUCURONIC DERIVATIVE (UROCHLORALIC ACID). OXIDN TO TRICHLOROACETIC ACID IS CONSIDERABLE ONLY IN RATS.', '1,1,1,2-TETRACHLOROETHANE, WHEN ADMIN FOR 8 HR AS VAPOR @ 200 PPM TO RATS & MICE, PRODUCED THE FUJIWARA REACTION-POSITIVE URINARY METABOLITES TRICHLOROACETIC ACID, TRICHLOROETHANOL, & TOTAL TRICHLORO CMPD.', 'For more Metabolism/Metabolites (Complete) data for 1,1,1,2-TETRACHLOROETHANE (9 total), please visit the HSDB record page.']",
2418,12419,"[(9S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate",CCCCCC(=O)O[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CCC4=CC(=O)CCC34C)C)C(=O)C,,,,,,
2419,12420,Pharmakon1600-01500676,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)CO)O)O)O)O,,,,,,
2420,12421,CID 12421,CC12CC(C3C(C1CCC2(C(=O)COC(=O)C4=CC(=CC=C4)S(=O)(=O)[O-])O)CCC5=CC(=O)C=CC35C)O.[Na+],,,,,,
2421,12422,"3-[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy]carbonylbenzenesulfonic acid",CC12CC(C3C(C1CCC2(C(=O)COC(=O)C4=CC(=CC=C4)S(=O)(=O)O)O)CCC5=CC(=O)C=CC35C)O,,,,,,
2422,12423,Iodotrinitromethane,C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])I,,,,,,
2423,12424,Tetraphenylmethane,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2424,12425,CID 12425,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],,,,,,
2425,12426,Tetraethylsilane,CC[Si](CC)(CC)CC,,,,,,
2426,12427,"1,1-Bis((dimethylamino)methyl)propyl benzoate monohydrochloride",CCC(C[NH+](C)C)(CN(C)C)OC(=O)C1=CC=CC=C1.[Cl-],,,,,,
2427,12428,Amydricaine,CCC(CN(C)C)(CN(C)C)OC(=O)C1=CC=CC=C1,,,,,,
2428,12429,Tetrapropylammonium iodide,CCC[N+](CCC)(CCC)CCC.[I-],,,,,,
2429,12430,Tetraethanol ammonium hydroxide,C(CO)[N+](CCO)(CCO)CCO.[OH-],,,,,,
2430,12431,"2-Hydroxy-N,N,N-tris(2-hydroxyethyl)ethanaminium",C(CO)[N+](CCO)(CCO)CCO,,,,,,
2431,12432,Ammonia acetate,CC(=O)O.N,,,,,,
2432,12433,Dibromoacetic acid,C(C(=O)O)(Br)Br,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']","['Dibromoacetic acid (DBA) ... /was/ provided in drinking water in range-finding reproductive/developmental toxicity studies (rats) ...  Studies included absorption and biodisposition of DBA ...  including passage into placentas, amniotic fluid, fetuses ... or milk ... . The DBA ... range-finding reproductive/developmental toxicity studies each included 50 Sprague-Dawley rats/sex/group. DBA (0, 125, 250, 500, or 1000 ppm) ... was provided in drinking water 14 days premating through gestation and lactation (63 to 70 days). ... Satellite groups (6 male, 17 female rats/group/study ...  were used for bioanalytical sampling. Rats ...  had exposure-related reduced water consumption caused by apparent taste aversion to DBA ..., especially in the parental animals at the two highest exposure levels (500 and 1000 ppm DBA ... . Female rats consumed slightly higher mg/kg/day doses of DBA than male rats, especially during gestation and lactation; weanling rats consumed the highest mg/kg/day doses. DBA produced detectable and quantifiable concentrations in plasma, placentas, amniotic fluid, and milk. Plasma samples confirmed that rats drink predominately during the dark; this drinking pattern, not accumulation, produced detectable plasma concentrations for 18 to 24 hours/day...', 'Dibromoacetate was measured in the testicular interstitial fluid of male Sprague-Dawley rats given five daily gavage doses of 250 mg dibromoacetate/kg body weight ... . The level of dibromoacetate in testicular fluid peaked at 79 ug/mL (approximately 370 uM) 30 minutes after the last dose, and the half-life was approximately 1.5 hours.', 'Dibromoacetate was administered to Sprague-Dawley rats in drinking water at concentrations ranging from 125 to 1,000 ppm (mg/L) with exposures beginning 14 days before cohabitation and continuing through gestation and lactation ... Quantifiable levels of dibromoacetate were measured in parental and fetal plasma, placental tissue, amniotic fluid, and milk. Thus, dibromoacetate crosses the placenta and is taken up by fetal tissue.', 'The oral bioavailability of dibromoacetate was reported to be 30% in male F344/N rats ... . The lower bioavailability of dibromoacetate compared to dichloroacetate is due to greater first-pass metabolism of dibromoacetate in the liver.']",,['Dibromoacetate was measured in the testicular interstitial fluid of male Sprague-Dawley rats given five daily gavage doses of 250 mg dibromoacetate/kg body weight ... . The half-life was approximately 1.5 hours.']
2433,12434,"N,N-Dimethylthioacetamide",CC(=S)N(C)C,,,,,,
2434,12435,Trimethylurea,CNC(=O)N(C)C,,,,,,
2435,12436,"1,1,3,3-Tetrachloroacetone",C(C(=O)C(Cl)Cl)(Cl)Cl,,,,,,
2436,12437,Tetramethylurea,CN(C)C(=O)N(C)C,,,,,,
2437,12438,2-Sulfobenzoic acid,C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)O,,,,,,
2438,12439,"2,6-Dimethylbenzoic acid",CC1=C(C(=CC=C1)C)C(=O)O,,,,,,
2439,12440,Berberine acetonic,C[NH+]1CCC2=CC3=C(C4=C2[C@@H]1CC5=C4C(=C(C=C5)OC)O)OCO3.[Cl-],,,,,,
2440,12441,Bulbocapnine,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=C4C(=C(C=C5)OC)O)OCO3,,,,,,
2441,12442,Tetrachlorophthalic acid,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C(=O)O)C(=O)O,,,,,,
2442,12443,Tetrabromophthalic anhydride,C12=C(C(=C(C(=C1Br)Br)Br)Br)C(=O)OC2=O,,,,,,
2443,12444,1-Bromoanthraquinone,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)Br,,,,,,
2444,12445,CID 12445,COC1=C2C(=C(C=C(O2)C3=CC=CC=C3)O)C(=CC1=O)O,,,,,,
2445,12446,"3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,4,6-trimethyl-, diethyl ester",CCOC(=O)C1=C(NC(=C(C1C)C(=O)OCC)C)C,,,,,,
2446,12447,Basic violet 14,CC1=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=CC1=N.Cl,,,,"['...GAVE 12 MG MAGENTA IN ARACHIS OIL TO 60 STOCK MICE BY GASTRIC INSTILLATION FOR 52 WEEKS (TOTAL DOSE, 624 MG). DYE WAS FOUND TO HAVE STAINED THE TISSUES AT AUTOPSY.', 'CATIONIC DYES ARE WELL KNOWN TO BIND TO NUCLEIC ACIDS. /CATIONIC DYES/', 'CATIONIC DYES APPEAR TO HAVE SPECIAL ATTRIBUTE OF NITROGEN ATOM WHICH IS PART OF RESONANT SYSTEM RESPONSIBLE FOR COLOR, & WHICH APPEARS TO BE ASSOC WITH PROPENSITY TO VERY STRONG BINDING TO CARBOXYL GROUPS OF CORNEAL MUCOPROTEINS. /CATIONIC DYES/']",,
2447,12448,"4-[(4-Aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline",CC1=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=CC1=N,,,,"['CATIONIC DYES ARE WELL KNOWN TO BIND TO NUCLEIC ACIDS. /CATIONIC DYES/', 'CATIONIC DYES APPEAR TO HAVE SPECIAL ATTRIBUTE OF NITROGEN ATOM WHICH IS PART OF RESONANT SYSTEM RESPONSIBLE FOR COLOR, & WHICH APPEARS TO BE ASSOC WITH PROPENSITY TO VERY STRONG BINDING TO CARBOXYL GROUPS OF CORNEAL MUCOPROTEINS. /CATIONIC DYES/']",,
2448,12449,Brilliant green,CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=CC=CC=C3.OS(=O)(=O)[O-],,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
2449,12450,Brilliant Green cation,CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=CC=CC=C3,,,,,,
2450,12451,"Cholesterol, propionate",CCC(=O)O[C@H]1CCC2([C@H]3CCC4([C@H](C3CC=C2C1)CC[C@@H]4C(C)CCCC(C)C)C)C,,,,,,
2451,12452,"Androsta-4,6-diene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)C=CC4=CC(=O)CC[C@]34C,,,,,,
2452,12453,2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol dihydrochloride,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,,,,,,
2453,12454,Clopenthixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
2454,12455,CID 12455,CCC(=C(CC)C1=CC=C(C=C1)OC)C2=CC=C(C=C2)O,,,,,,
2455,12456,Berberine chloride,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],,,,,,
2456,12457,Berberine sulfate,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.OS(=O)(=O)[O-],,,,['...MAY BE ABSORBED THROUGH THE SKIN... /BERBERINE/'],,
2457,12458,CID 12458,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)S(=O)(=O)[O-])O.[Na+],,,,,,
2458,12459,1-Chloro-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2Cl)O,,,,,,
2459,12460,Phendimetrazine,CC1C(OCCN1C)C2=CC=CC=C2,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",['Phendimetrazine is readily absorbed from the GI tract and effects persist for about 4 hours after oral administration.'],"['Phendimetrazine is metabolized in the liver by N-demethylation to the active metabolite phenmetrazine. Phenmetrazine is hydroxylated, conjugated, and excreted in the urine.']",['The elimination half life of phendimetrazine is approximately 9 hours for the sustained release and 2 hours for the regular release preparation. The half life of phenmetrazine is approximately  8 hours.']
2460,12461,Phentydrone,C1CCC2=C(C1)C3=CC=CC=C3C2=O,,,,,,
2461,12462,"1,2,3-Trimethoxybenzene",COC1=C(C(=CC=C1)OC)OC,,,,,,
2462,12463,"1,2,3,4-Tetrachlorobenzene",C1=CC(=C(C(=C1Cl)Cl)Cl)Cl,,,,"['Three tetrachlorobenzene (TCB) congeners (1,2,3,4- 1,2,3,5- and 1,2,4,5-tetrachlorobenzene) were administered daily by gavage to pregnant Sprague-Dawley rats at levels of 50, 100, or 200 mg/kg from day 6-15 of gestation. Residues of all three congeners were found in maternal and fetal tissues but generally the amounts of the 1,2,4,5- isomer were about 100 times higher than the other two.']","['1,2,3,4-TETRACHLOROBENZENE WAS IDENTIFIED AS A PENTACHLOROBENZENE METABOLITE.', '3 STRAINS OF HOUSEFLIES WERE USED TO DETECT CORRELATIONS BETWEEN PESTICIDE RESISTANCE & METAB. 1,2,3,4-TETRACHLORO-BENZENE WAS FORMED AS METABOLITE OF LINDANE IN SUSCEPTIBLE & RESISTANT HOUSEFLIES.', 'ORAL ADMIN OF 100 MG HEXACHLOROBENZENE/KG 9 TIMES WITHIN 4 WK INCR WT OF LIVER BY 85% IN MALE & BY 30% IN FEMALE RATS. URINE OF RATS ADMIN TWICE A WK 100 MG HEXACHLOROBENZENE CONTAINED 1,2,3,4-TETRACHLOROBENZENE.', 'YIELDS 2,3,4,6-TETRACHLOROPHENOL IN RABBIT. /FROM TABLE/', 'For more Metabolism/Metabolites (Complete) data for 1,2,3,4-TETRACHLOROBENZENE (8 total), please visit the HSDB record page.']",
2463,12464,"2,3,4-Trichloroaniline",C1=CC(=C(C(=C1N)Cl)Cl)Cl,,,,,,
2464,12465,"1,2,3,4-Tetraiodobenzene",C1=CC(=C(C(=C1I)I)I)I,,,,,,
2465,12466,"2,3,4,5-Tetrachloroaniline",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)N,,,,,,
2466,12467,"1,2,3,5-Tetrabromobenzene",C1=C(C=C(C(=C1Br)Br)Br)Br,,,,,,
2467,12468,"1,2,3,5-Tetrachlorobenzene",C1=C(C=C(C(=C1Cl)Cl)Cl)Cl,,,,"['Three tetrachlorobenzene (TCB) congeners (1,2,3,4- 1,2,3,5- and 1,2,4,5-Tetrachlorobenzene were administered daily by gavage to pregnant Sprague-Dawley rats at levels of 50, 100, or 200 mg/kg from day 6-15 of gestation. Residues of all three congeners were found in maternal and fetal tissues but generally the amounts of the 1,2,4,5- isomer were about 100 times higher than the other two.']","['1,2,3,5-TETRACHLOROBENZENE WAS IDENTIFIED AS METABOLITE OF PENTACHLOROPHENOL.', 'CANTHATCH WHEAT SEEDS WERE TREATED WITH LINDANE-(14)C (480 PPM) & PLANTED, TOTAL (14)C RESIDUES WERE DETERMINED IN 19-DAY-OLD SEEDLINGS, 1,2,3,5-TETRACHLOROBENZENE WAS IDENTIFIED IN ROOT SAMPLES.', 'YIELDS 2,3,4,6-TETRACHLOROPHENOL IN RABBIT. /FROM TABLE/', 'Lindane administered to hen pheasants resulted in tetrachlorobenzene being identified ... as part of the array of metabolites found in eggs and chicks as well as in the body tissues of hens. /Tetrachlorobenzenes/', 'For more Metabolism/Metabolites (Complete) data for 1,2,3,5-TETRACHLOROBENZENE (7 total), please visit the HSDB record page.']",
2468,12469,"3,4,5-Trichloroaniline",C1=C(C=C(C(=C1Cl)Cl)Cl)N,,,,,,
2469,12470,"1,2,3,5-Tetraiodobenzene",C1=C(C=C(C(=C1I)I)I)I,,,,,,
2470,12471,"2,4,6-Trichloroaniline",C1=C(C=C(C(=C1Cl)N)Cl)Cl,,,,,"['YIELDS 3-AMINO-2,4,6-TRICHLOROPHENOL & 4-AMINO-3,5-DICHLOROPHENOL IN RABBITS. /FROM TABLE/', 'ACARICIDE BENZOYL CHLORIDE PENETRATED SPIDER MITE RAPIDLY & WAS METABOLIZED SLOWLY TO 2,4,6-TRICHLOROANILINE AS ONE OF ITS MINOR METABOLITES.']",
2471,12472,"1,1-Diethylurea",CCN(CC)C(=O)N,,,,,,
2472,12473,Pyrrole-2-carboxylic acid,C1=CNC(=C1)C(=O)O,,,,,,
2473,12474,Pamaquine naphthoate,CCN(CC)CCCC(C)NC1=C2C(=CC(=C1)OC)C=CC=N2.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
2474,12475,"3,4,5,6-Tetrahydrophthalic anhydride",C1CCC2=C(C1)C(=O)OC2=O,,,,,,
2475,12476,2-Amino-5-chlorobenzoic acid,C1=CC(=C(C=C1Cl)C(=O)O)N,,,,,,
2476,12477,4-Chloro-3-nitroaniline,C1=CC(=C(C=C1N)[N+](=O)[O-])Cl,,,,,,
2477,12478,Trimetozine,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCOCC2,,,,,,
2478,12479,Catechol diacetate,CC(=O)OC1=CC=CC=C1OC(=O)C,,,,,,
2479,12480,1-Phenylpyrrole,C1=CC=C(C=C1)N2C=CC=C2,,,,,,
2480,12481,5-Chlorosalicylaldehyde,C1=CC(=C(C=C1Cl)C=O)O,,,,,,
2481,12482,CID 12482,C1=CC=C(C=C1)C(=NC2=CC=CC=C2)S,,,,,,
2482,12483,Diethyl terephthalate,CCOC(=O)C1=CC=C(C=C1)C(=O)OCC,,,,,,
2483,12484,o-Toluidine hydrochloride,CC1=CC=CC=C1N.Cl,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']","['Following a single dose (400 mg/kg sc) of o-(methyl-(14)C-toluidine ... to male F344 rats, 56% of the (14)C was recovered in the 24 hr urine, 2.4% in the feces and 1% as exhaled (14)CO2. After 48 hr, 83.9% of the (14)C appeared in the urine, 3.3% in the feces and 1.4% was exhaled. /2-Aminotoluene/', 'Via the respiratory tract and skin. /2-Aminotoluene/']",['One of /the/ metabolites /is/ o-nitrosotoluene.'],
2484,12485,CID 12485,CC1=CN=C(NC1=O)S,,,,,,
2485,12486,"1,2,4,5-Tetrabromobenzene",C1=C(C(=CC(=C1Br)Br)Br)Br,,,,,,
2486,12487,"2,4,5-Trichloroaniline",C1=C(C(=CC(=C1Cl)Cl)Cl)N,,,,,,
2487,12488,"1,2,4,5-Tetraiodobenzene",C1=C(C(=CC(=C1I)I)I)I,,,,,,
2488,12489,2-Methyl-1H-pyrrole,CC1=CC=CN1,,,,,,
2489,12490,4-Hydroxyisophthalic acid,C1=CC(=C(C=C1C(=O)O)C(=O)O)O,,,,,,
2490,12491,Diethyl isophthalate,CCOC(=O)C1=CC(=CC=C1)C(=O)OCC,,,,,,
2491,12492,Brinaldix,C[C@@H]1CCC[C@@H](N1NC(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N)C,,,['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)'],,,
2492,12493,Triethylammonium bromide,CC[NH+](CC)CC.[Br-],,,,,,
2493,12494,CID 12494,C1=CC(=CC=C1C(=O)N=N)N(O)O,,,,,,
2494,12495,1-Iodo-4-nitrobenzene,C1=CC(=CC=C1[N+](=O)[O-])I,,,,,,
2495,12496,Aluminum stearate,CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Al+3],,,,,,
2496,12497,Phenyl propionate,CCC(=O)OC1=CC=CC=C1,,,,,,
2497,12498,Proguanil hydrochloride,CC(C)N=C(N)N=C(N)NC1=CC=C(C=C1)Cl.Cl,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']",,,
2498,12499,2-Propylpiperidin-1-ium;bromide,CCCC1CCCC[NH2+]1.[Br-],,,,,,
2499,12500,"Benzene, propenyl-",CC=CC1=CC=CC=C1,,,,,,
2500,12501,CID 12501,C1=CC=C(C=C1)N=CS,,,,,,
2501,12502,CID 12502,CC(=NC1=CC=CC=C1)S,,,,,,
2502,12503,(3-Bromopropyl)benzene,C1=CC=C(C=C1)CCCBr,,,,,,
2503,12504,p-Tolylhydrazine hydrochloride,CC1=CC=C(C=C1)NN.Cl,,,,,,
2504,12505,N-Chloro-p-benzoquinoneimine,C1=CC(=O)C=CC1=NCl,,,,,,
2505,12506,Tetrahydrofurfuryl acetate,CC(=O)OCC1CCCO1,,,,,,
2506,12507,4-Methoxystyrene,COC1=CC=C(C=C1)C=C,,,,,,
2507,12508,Isopropyl propionate,CCC(=O)OC(C)C,,,,,,
2508,12509,Ethyl hydrazinoacetate,CCOC(=O)CNN,,,,,,
2509,12510,1-Chloro-4-iodobenzene,C1=CC(=CC=C1Cl)I,,,,,,
2510,12511,"1,4-Cyclohexanedione",C1CC(=O)CCC1=O,,,,,,
2511,12512,tert-Butyl ethyl ether,CCOC(C)(C)C,,,,"['... Inhalation is the most likely mode of exposure, with about 30% of inhaled ethyl tert-butyl ether (ETBE) being retained by the lungs and distributed around the body. ...', 'After inhalation exposure methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE) and tert-amyl methyl ether (TAME) are rapidly taken up by both rats and humans; after termination of exposure, clearance by exhalation and biotransformation to urinary metabolites is rapid in rats. In humans, clearance by exhalation is slower in comparison to rats. Biotransformation of MTBE and ETBE is both qualitatively and quantitatively similar in humans and rats after inhalation exposure under identical conditions. The extent of biotransformation of TAME is also quantitatively similar in rats and humans; the metabolic pathways, however, are different. ...', 'To contribute to the characterization of potential adverse effects of ethyl tert-butyl ether (ETBE), its biotransformation was compared in humans and rats after inhalation exposure. Human volunteers (3 males and 3 females) and rats (5 males and 5 females) were exposed to 4 (4.5+/-0.6) and 40 (40.6+/-3.0) ppm ETBE for 4 hr in a dynamic exposure system. Urine samples from rats and humans were collected for 72 hr at 6-hr intervals, and blood samples were taken in regular intervals for 48 hr. In urine, ETBE and the ETBE-metabolites tert-butanol (t-butanol), 2-methyl-1,2-propane diol, and 2-hydroxyisobutyrate were quantified; ETBE and t-butanol were determined in blood samples. After the end of the exposure period to inhalation of 40-ppm ETBE, blood concentrations of ETBE were found at 5.3+/-1.2 uM in rats and 12.1+/-4.0 uM in humans. The ETBE blood concentrations, after inhalation of 4-ppm ETBE, were 1.0+/-0.7 uM in rats and 1.3+/-0.7 uM in humans. ETBE was rapidly cleared from blood. After the end of the 40-ppm ETBE exposure period, the blood concentrations of t-butanol were 13.9+/-2.2 uM in humans and 21.7+/-4.9 uM in rats. After 4-ppm ETBE exposure, blood concentrations of t-butanol were 1.8+/-0.2 uM in humans and 5.7+/-0.8 uM in rats. t-Butanol was cleared from human blood with a half-life of 9.8+/-1.4 hr in humans after 40-ppm ETBE exposure. In urine samples from controls and in samples collected from the volunteers and rats before the exposure, low concentrations of t-butanol, 2-methyl-1,2-propane diol, and 2-hydroxyisobutyrate were present. In the urine of both humans and rats exposed to ETBE, the concentrations of these compounds were significantly increased. 2-Hydroxy-isobutyrate was recovered in urine as the major excretory product formed from ETBE; t-butanol and 2-methyl-1,2-propane diol were minor metabolites. All metabolites of ETBE excreted with urine were rapidly eliminated in both species after the end of the ETBE exposure. Excretion half-lives for the different urinary metabolites of ETBE were between 10.2 and 28.3 hr in humans and 2.6 and 4.7 hr in rats. The obtained data indicate that ETBE biotransformation and excretion are similar for rats and humans, and that ETBE and its metabolites are rapidly excreted by both species. Between 41 and 53% of the ETBE retained after the end of the exposure was recovered as metabolites in the urine of both humans and rats.', '... Eight healthy male volunteers were exposed to ethyl tert-butyl ether (ETBE) vapor (0, 5, 25, and 50 ppm) during 2 hr of light physical exercise. ETBE and the proposed metabolites tert-butyl alcohol (TBA) and acetone were analyzed in exhaled air, blood, and urine. Compared to a previous MTBE study lower respiratory uptake of ETBE (32-34%) was seen as well as a slightly higher respiratory exhalation (45-50% of absorbed ETBE). The kinetic profile of ETBE could be described by four phases in blood (average half-times of 2 min, 18 min, 1.7 hr, and 28 hr) and two phases in urine (8 min and 8.6 hr). Postexposure half-times of TBA in blood and urine were on average 12 and 8 hr, respectively. The 48-hr pulmonary excretion of TBA accounted for 1.4-3.8% of the absorbed ETBE, on an equimolar basis. Urinary excretion of ETBE and TBA was low, below 1% of the ETBE uptake, indicating further metabolism of TBA or other routes of metabolism and elimination. The kinetics of ETBE and TBA were linear up to 50 ppm. ...', 'For more Absorption, Distribution and Excretion (Complete) data for Ethyl tert-butyl ether (7 total), please visit the HSDB record page.']","['Following cessation of exposure, the blood concentration of ethyl tert-butyl ether (ETBE) falls rapidly, largely as a result of its metabolism to tertiary-butyl alcohol (TBA) and acetaldehyde. TBA may be further metabolized, first to 2-methyl-1,2-propanediol and then to 2-hydroxyisobutyrate, the two dominant metabolites found in urine of volunteers and rats. ...', 'The biotransformation of methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE), and tert-amyl methyl ether (TAME) was studied in humans and in rats after inhalation of 4 and 40 ppm of MTBE, ETBE, and TAME, respectively, for 4 hours, and the biotransformation of MTBE and TAME was studied after ingestion exposure in humans to 5 and 15 mg in water. tert-Butyl alcohol (TBA), a TBA conjugate, 2-methyl-1,2-propanediol, and 2-hydroxyisobutyrate were found to be metabolites of MTBE and ETBE. tert-Amyl alcohol (TAA), free and glucuronidated 2-methyl-2,3-butanediol (a glucuronide of TAA), 2-hydroxy-2-methyl butyrate, and 3-hydroxy-3-methyl butyrate were found to be metabolites of TAME. After inhalation, MTBE, ETBE, and TAME were rapidly taken up by both rats and humans; after termination of exposure, clearance from blood of the ethers by exhalation and biotransformation to urinary metabolites occurred with half-times of less than 7 hours in rats and humans. Biotransformation of MTBE and ETBE was similar in humans and rats after inhalation exposure. 2-Hydroxyisobutyrate was recovered as a major product in urine. All metabolites of MTBE and ETBE excreted with urine were eliminated with half-times of less than 20 hours. Biotransformation of TAME was qualitatively similar in rats and humans, but the metabolic pathways were different. In humans, 2-methyl-2,3-butanediol, 2-hydroxy-2-methyl butyrate, and 3-hydroxy-3methyl butyrate were recovered as major urinary products. In rats, however, 2-methyl-2,3-butanediol and its glucuronide were major TAME metabolites recovered in urine. After ingestion of MTBE and TAME, both compounds were rapidly absorbed from the gastrointestinal tract. Hepatic first-pass metabolism of these ethers was not observed, and a significant part of the administered dose was transferred into blood and cleared by exhalation. Metabolic pathways for MTBE and TAME and kinetics of excretion were identical after ingestion and inhalation exposures. ...', 'Oxidative demethylation of methyl tert-butyl ether (MTBE) and tert-amyl methyl ether (TAME) and deethylation of ethyl tert-butyl ether (ETBE) by CYP enzymes results in the formation of tertiary alcohols and aldehydes, both potentially toxic. The metabolism of these three alkoxyethers was studied in a panel of 12 human liver microsomes. The relatively low apparent Km(1) was 0.25+/-0.17 (mean+/-SD), 0.11+/-0.08 and 0.10+/-0.07 mM and the high apparent Km(2) was 2.9+/-1.8, 5.0+/-2.7 and 1.7+/-1.0 mM for MTBE, ETBE and TAME, respectively. Kinetic data, correlation studies, chemical inhibition and metabolism by heterologously expressed human CYPs support the assertion that the major enzyme involved in MTBE, ETBE and TAME metabolisms is CYP2A6, with a minor contribution of CYP3A4 at low substrate concentration.', '/The/ human liver is active in metabolizing methyl tert-butyl ether (MTBE) to tert-butyl alcohol (TBA), a major circulating metabolite and an exposure marker of MTBE. The activity is localized in the microsomal fraction but not in the cytosol. Formation of TBA in human liver microsomes is NADPH-dependent and is significantly inhibited by carbon monoxide, which inhibits cytochrome P450 (CYP) enzymes. These results provide strong evidence that CYP enzymes play a critical role in the metabolism of MTBE in human livers. Human liver is also active in the oxidative metabolism of 2 other gasoline ethers, ethyl tert-butyl ether (ETBE) and tert-amyl methyl ether (TAME). ... A large interindividual variation in metabolizing these gasoline ethers /was observed/ in 15 microsomal samples prepared from normal human livers. The activity level (pmol metabolite/min/mg) ranged from 204 to 2,890 for MTBE; 179 to 3,134 for ETBE; and 271 to 8,532 for TAME. The microsomal activities in metabolizing MTBE, ETBE, and TAME correlated highly with each other (r = 0.91 to 0.96), suggesting that these ethers are metabolized by the same enzyme(s). Correlation analysis of the ether-metabolizing activities with individual CYP enzyme activities in the human liver microsomes showed that the highest degree of correlation was with CYP isoform 2A6 (CYP2A6)+ (r = 0.94 for MTBE, 0.95 for ETBE, and 0.90 for TAME), which is constitutively expressed in human livers and known to be polymorphic. CYP2A6 displayed the highest turnover number in metabolizing gasoline ethers among a battery of human CYP enzymes expressed in human B-lymphoblastoid cells. CYP2A6 coexpressed with human CYP reductase by a baculovirus expression system was also more active than CYP isoform 2E1 (CYP2E1) in the metabolism of MTBE, ETBE, and TAME. Kinetic studies on MTBE metabolism with human liver microsomes (n = 3) exhibited an apparent Michaelis constant (Km) of 28 to 89 uM and a maximum rate of metabolism (Vmax) of 215 to 783 pmol/min/mg. Metabolism of MTBE, ETBE, and TAME by human liver microsomes was inhibited by coumarin, a known substrate of human CYP2A6, in a concentration-dependent manner. Monoclonal antibody against human CYP2A6 caused a significant inhibition (75% to 95%) of the metabolism of MTBE, ETBE, and TAME in human liver microsomes. ...', 'For more Metabolism/Metabolites (Complete) data for Ethyl tert-butyl ether (9 total), please visit the HSDB record page.', 'Tert-butyl ethyl ether (ETBE) has known human metabolites that include tert-butanol.']",
2512,12513,2-Iodopentane,CCCC(C)I,,,,,,
2513,12514,"2,5-Dimethylthiophene",CC1=CC=C(S1)C,,,,,,
2514,12515,m-Toluidinium chloride,CC1=CC(=CC=C1)[NH3+].[Cl-],,,,,,
2515,12516,"Ethyl 3,3-dimethylacrylate",CCOC(=O)C=C(C)C,,,,,,
2516,12517,CID 12517,C1(=NC(=NC(=N1)S)S)S,,,,,,
2517,12518,Thialdine,CC1NC(SC(S1)C)C,,,,,,
2518,12519,Phenylphosphine,C1=CC=C(C=C1)P,,,,['The substance can be absorbed into the body by inhalation.'],,
2519,12520,(R)-10-hydroxystearic acid,CCCCCCCC[C@H](CCCCCCCCC(=O)O)O,,,,,,
2520,12521,2-Chlorohexane,CCCCC(C)Cl,,,,,,
2521,12522,Succinamic acid,C(CC(=O)O)C(=O)N,,,,,,
2522,12523,Phytane,CCC(C)CCCC(C)CCCC(C)CCCC(C)C,,,,"['Rats absorb 2,6,10,14-tetramethylhexadecane (phytane) from the intestinal tract intact into the lymph. Intestinal microbes appeared to be unable to metabolize phytane in vitro. Rats metabolized phytane to (a) a tertiary alcohol tentatively identified as 2,6,10,14-tetramethylhexadecan-2-ol, and (b) a variety of short-chain acids which were excreted in the urine. These included acetic, isobutyric, and 2-methylbutyric acids. CO2 was a very minor product, even following intravenous injection of phytane. Lipoidal intermediates in the degradation of phytane could not be detected, suggesting that the initial attack on the molecule was rate-limiting. Urinary excretion products were apparent following oral but not intravenous, intraperitoneal, or subcutaneous administration of phytane. However, the tertiary alcohol was produced following both oral and intraperitoneal administration. ...']","['Rats absorb 2,6,10,14-tetramethylhexadecane (phytane) from the intestinal tract intact into the lymph. Intestinal microbes appeared to be unable to metabolize phytane in vitro. Rats metabolized phytane to (a) a tertiary alcohol tentatively identified as 2,6,10,14-tetramethylhexadecan-2-ol, and (b) a variety of short-chain acids which were excreted in the urine. These included acetic, isobutyric, and 2-methylbutyric acids. CO2 was a very minor product, even following intravenous injection of phytane. Lipoidal intermediates in the degradation of phytane could not be detected, suggesting that the initial attack on the molecule was rate-limiting. Urinary excretion products were apparent following oral but not intravenous, intraperitoneal, or subcutaneous administration of phytane. However, the tertiary alcohol was produced following both oral and intraperitoneal administration. ...']",
2523,12524,Succinaldehyde,C(CC=O)C=O,,,,,,
2524,12525,Manganese(II) acetate,CC(=O)[O-].CC(=O)[O-].[Mn+2],,,,"['The subcellular distribution of The subcellular distribution of manganese in brains of mice chronically administered manganese in different chemical forms with food was examined using gel chromatography. Male ddY-mice were divided into five groups of six animals each, and Groups 1 to 4 were given 2 g/kg manganese of standard laboratory mouse chow) in the form of manganese chloride, manganese acetate, manganese carbonate, or manganese oxide, in the diets for 12 months, while Group 5 served as control. Twenty four hours after the last feed, animals were decapitated and brains were rapidly removed for study of the different regions (corpus striatum, hypothalamus, midbrain, cerebral cortex, hippocampus, cerebellum, and medulla oblongata). Subcellular fractions (mitochondrial, microsomal and cytosolic) and gel chromatography fractions were analyzed for manganese contents using flame atomizer absorption spectrophotometry. Results showed that cerebral cortex levels of manganese in mice exposed to the nearly insoluble manganese carbonate and manganese oxide were higher than in controls, while manganese concentrations in the corpus striatum were similar to those in controls. Microsomal manganese in treated mice was also higher than in controls. The gel chromatographic profile of corpus striatum showed that 20% manganese was in the high molecular weight fractions, 45% was in the middle molecular weight fractions, while 32% was in the low molecular weight fractions. The percent manganese in high molecular weight fractions was higher (29% to 49%) in the manganese treated groups, than in controls. The percentage of manganese in low molecular weight fractions of the manganese oxide exposed group (9%) was lower than in the manganese chloride, manganese acetate, and manganese carbonate exposed groups (42%, 36%, and 38%, respectively).']",,
2525,12526,2-Acetamidoethyl disulfide,CC(=O)NCCSSCCNC(=O)C,,,,,,
2526,12527,1-Iodohexane,CCCCCCI,,,,,,
2527,12528,Butyl ethyl sulfide,CCCCSCC,,,,,,
2528,12529,Pentyl formate,CCCCCOC=O,,,,,,
2529,12530,Tridecanoic acid,CCCCCCCCCCCCC(=O)O,,,,,,
2530,12531,Tetradecyl acetate,CCCCCCCCCCCCCCOC(=O)C,,,,,,
2531,12532,Stearonitrile,CCCCCCCCCCCCCCCCCC#N,,,,,,
2532,12533,Octadecanal,CCCCCCCCCCCCCCCCCC=O,,,,,,
2533,12534,Tricosane,CCCCCCCCCCCCCCCCCCCCCCC,,,,"['Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.', 'Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2534,12535,Triacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2535,12536,"(2S,4R,8S,12S)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)C=CC5([C@H]4C(CC3([C@@]2(O1)C(=O)CO)C)O)C)C,,,,,,
2536,12537,"[(3S,5R,10S,13R,14S,16S)-3-[(2S,5S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate",CC1[C@@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(C[C@@H](C5C6=CC(=O)OC6)OC(=O)C)O)C)C)O)OC)O,,,,,,
2537,12538,"3-[(6-Deoxyhexopyranosyl)oxy]-5,12,14-trihydroxy-19-oxocard-20(22)-enolide",CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O,,,,,,
2538,12539,Acovenosigenin,C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@H]5[C@@]3([C@@H](C[C@@H](C5)O)O)C,,,,,,
2539,12540,Triphenyltin chloride,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)(C3=CC=CC=C3)Cl,,,,"['Triphenyltin chloride when dosed to rats was excreted mainly in the feces (88%) as a mixture of the mono-, di- and triphenyltin salts, and some free stannic (Sn(4+)) salts.', '... Triphenyltin chloride ... /readily penetrates/ through the skin, as evidenced by total tin content of 3-9 times that of controls in the fascia, kidneys, liver, & heart of animals with intact skin, & from 4.6 to 10 times that of controls in these tissues of animals with abraded skin ... .']",,
2540,12541,Thiometon,CCSCCSP(=S)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'A pesticide or chemical agent that kills mites and ticks. This is a large class that includes carbamates, formamides, organochlorines, organophosphates, etc, that act as antibiotics or growth regulators. (See all compounds classified as Acaricides.)']","['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'Following their absorption, most organophosphorus cmpd are excreted almost entirely as hydrolysis products in the urine. /Anticholinesterase agents/', 'For more Absorption, Distribution and Excretion (Complete) data for THIOMETON (6 total), please visit the HSDB record page.']","['Plasma and tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric and phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase, and by the cytochrome p-450 systems. Considerable variability exists in the human population for organophosphate metabolism by these routes. The A-esterases are found in plasma and in the hepatic endoplasmic reticulum and can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond. /Anticholinesterase agents/', 'These chemicals are detoxified by cytochrome p450-mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/']",
2541,12542,Fluoroacetamide,C(C(=O)N)F,,,,['THE CMPD IS ABSORBED BY THE SKIN.'],"['INVESTIGATORS ARE AGREED THAT FLUOROACETAMIDE IS LESS TOXIC THAN FLUOROACETATE. THIS HAS BEEN ATTRIBUTED TO THE FACT THAT METABOLISM OF THE FORMER TO THE LATTER IS SLOW. ... RECOVERED, FROM THE URINE OF RATS RECEIVING FLUOROACETAMIDE AT A RATE OF 3 MG/KG/DAY, 62% OF THE TOTAL INTAKE UNMETABOLIZED ... .', '2,4-Dinitrofluorobenzene reacts with glutathione to form a stable product similar to that formed with the model glutathione-S-transferase substrate, 1-chloro-2,4-dinitrobenzene. ... Fluoroacetamide, like fluoroacetate, undergoes no discernable chemical defluorinantion. Its enzymatic defluorination is approx 10% of that observed for fluoroacetate and only 0.2% of the rate for 2,4-dinitrofluorobenzene. An antibody raised to the fluoroacetate specific dehalogenase precipitated both fluoroacetate ad fluoroacetamide defluorinating activity but had no effect on either 1-chloro-2,4-dinitrobenzene or 2,4-dinitrofluorobenzene activity. ... 2,4-Dinitrofluorobenzene is metabolized by the glutathione-S-transferase while fluoroacetamide is metabolized by the fluoroacetate specific dehalogenase.', 'Fluoroacetate administered ip to rats and mice is defluorinated to give fluoride ion evident in urine and kidney by (19)F NMR. The use of 2-(13)C-, 1,2-(13)C-, and 1,2-(14)C-fluoroacetate, ... reveals a complex mixture of urinary metabolites including an S-(carboxymethyl) conjugate complex in rats and mice and sulfoxidation products ... in rats. ... Bile, following treatment with 2-(13)C- fluoroacetate, shows the presence of S-(carboxymethyl)glutathione or a related conjugate and an O-conjugate of fluoracetate. Incubation of (13)C-fluoroacetate with rat and mouse liver cytosol involves formation of S-((13)C-carboxymethyl) glutathione and fluoride ion. Fluorocitrate is also /detected in/ fluoracetate incubations with mouse liver cytosol. Fluoroacetamide administered ip to rats and mice yields urinary fluoride ion formed via fluoroacetate which is liberated on hydrolysis by an organophosphate-sensitive amidase. (19)F NMR ... of other metabolites of fluoroacetamide are consistent with fluoroacetohydroxamic acid in the liver of mice and fluorocitrate in the urine of rats. Fluoroethanol gives rinary fluoroacetate and fluoride ion in rats and mice and is converted to fluoroacetaldehyde by mouse and rat liver microsomes. (-)- and (+)-erythro- fluorocitrates administered ip to rats yield mostly the parent compounds in urine at 6 hr with increasing amounts of fluoride ion thereafter. ... Rat and mouse liver cytosols defluorinate (-)-erythro-fluorocitrate. Metabolic defluorination and pig heart aconitase also defluorinates (-)-erythro- fluorocitrate. Metabolic defluorination of fluoracetate and its progenitors, fluoroacetamide and fluoroethanol, is therefore attributable to both conjucation of fluoracetate with glutathione and conversion to (-)-erythro-fluorocitrate, which is both an inhibitor of and a substrate for aconitase. ... Urine of rats and mice poisoned with fluoroacetate or (-)-erythro-fluorocitrate show elevated citrate and glucose and diminished urea consistent with disruptions in the tricarboxylic acid cycle and ammonia metabolism.']",
2542,12543,N-Methyl-p-toluenesulfonamide,CC1=CC=C(C=C1)S(=O)(=O)NC,,,,,,
2543,12544,Glycochenodeoxycholic acid,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
2544,12545,Apocodeine,CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)OC)O,,,,,,
2545,12546,CID 12546,CC1=CC(=CC2=C1C3=CC(=O)C=C(C3=C(O2)O)O)O,,,,,,
2546,12547,"17-ethyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene",CCC1CCC2C1(CCC3C2CCC4C3(CCCC4)C)C,,,,,,
2547,12548,7-Hydroxyemodin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)O)O)O,,,,,,
2548,12549,O-Quaterphenyl,C1=CC=C(C=C1)C2=CC=CC=C2C3=CC=CC=C3C4=CC=CC=C4,,,,,,
2549,12550,Antimycin A,CCCCCCC1C(C(OC(=O)C(C(OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
2550,12551,Aminometradine,CCN1C(=O)C=C(N(C1=O)CC=C)N,,,,,,
2551,12552,Ethylbenzhydramine,CCN(CC)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2552,12553,2-Diacetylaminofluorene,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)C,,,,,,
2553,12554,CID 12554,CC(=O)N=C1C=CC2=NC(=CC(=NC(=O)C)C2=C1)C=CC3=CC=C(O3)N(O)O,,,,,,
2554,12555,Benzydamine,CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,"['Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions.   When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures.   When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures.']","['Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration.   Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.']",['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],"['Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way.', 'The relatively high lipid solubility of the weak base benzydamine is thought to be associated with considerable passive resorption within the renal tubule, which suggests that only approximately 5% of benzydamine is excreted unchanged in the urine. At the same time however, other studies have suggested that considerably larger amounts (50-65%) of the drug is excreted unchanged in urine.  While several inactive oxidized metabolites of benzydamine are excreted in urine, the benzydamine N-oxide metabolite can remain in plasma and demonstrate a half-life that is longer than the parent benzydamine compound.  Nevertheless, it is generally believed that excretion occurs mainly through urine and is mostly in the form of inactive metabolites or conjugation products.', 'The volume of distribution of benzydamine is 10 L.', 'Benzydamine demonstrateas a systemic clearance of 170 ml/min.']","['Benzydamine is primarily metabolized by oxidation, dealkylation, and conjugation into hydroxy, dealkylated, and N-oxide metabolites.  In general, however, when used at the recommended doses the levels at which benzydamine is absorbed or exposed into the body are usually not sufficient to produce systemic pharmacological effects [L']","['Approximately 13 h after oral administration, with a terminal half life of about 7.7 h.']"
2555,12556,"Indole-3,5,6-triol, 1-methyl-",CN1CC(=O)C2=CC(=C(C=C21)O)O,,,,,,
2556,12557,CID 12557,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[Na+],,,,,,
2557,12558,Pyrrolizidine,C1CC2CCCN2C1,,,,,,
2558,12559,Erythromycin stearate,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,,,"['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']","['PEAK CONCN IN PLASMA...0.3-0.5 UG/ML 4 HR AFTER ORAL ADMIN OF 250 MG OF BASE & ARE 0.3-1.9 UG/ML AFTER...500-MG TABLET. VARIOUS ESTERS OF ERYTHROMYCIN HAVE BEEN PREPARED TO...IMPROVE STABILITY & FACILITATE ABSORPTION. ...CONCN OF ERYTHROMYCIN IN PLASMA ARE LITTLE DIFFERENT IF STEARATE IS GIVEN ORALLY.', '...DIFFUSES READILY INTO INTRACELLULAR FLUIDS, & ANTIBACTERIAL ACTIVITY... ACHIEVED AT...ALL SITES EXCEPT BRAIN & CSF. ...ONE OF FEW ANTIBIOTICS THAT PENETRATES INTO PROSTATIC FLUID, CONCN ARE APPROX 40% OF...PLASMA. EXTENT OF BINDING...TO PLASMA PROTEINS VARIES...PROBABLY EXCEEDS 70% IN ALL.../FORMS OF DRUG/. /ERYTHROMYCIN/', 'ERYTHROMYCIN BASE IS ADEQUATELY ABSORBED FROM UPPER PART OF SMALL INTESTINE; IT IS INACTIVATED BY GASTRIC JUICE... FOOD IN STOMACH DELAYS ITS ULTIMATE ABSORPTION. /ERYTHROMYCIN/', 'ERYTHROMYCIN TRAVERSES PLACENTAL BARRIER; & CONCN OF DRUG IN FETAL PLASMA ARE ABOUT 5-20% OF THOSE IN MATERNAL CIRCULATION. /ERYTHROMYCIN/', 'For more Absorption, Distribution and Excretion (Complete) data for ERYTHROMYCIN STEARATE (11 total), please visit the HSDB record page.']",['IT IS HYDROLYZED IN SMALL INTESTINE & IN TISSUES TO YIELD ERYTHROMYCIN.'],
2559,12560,Erythromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,"['Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria. The indications for erythromycin have been summarized by body system below:  **Respiratory infections**  Mild to moderate upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with erythromycin. Mild to moderate lower-respiratory tract infections due to susceptible strains of Streptococcus pneumoniae or Streptococcus pyogenes may also be treated. Erythromycin treats listeriosis caused by Listeria monocytogenes may also be treated with erythromycin. Erythromycin is indicated to treat pertussis (whooping cough) caused by Bordetella pertussis. It is effective in eliminating the causative organism from the nasopharynx of infected individuals, rendering them noninfectious. Clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacteria. Respiratory tract infections due to Mycoplasma pneumoniae may also be treated with erythromycin.  Despite the fact that no controlled clinical efficacy studies have been conducted to this date, in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in  Legionnaires Disease. Finally, erythromycin is indicated to treat diphtheria and other infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers. In addition to the prevention of diphtheria, erythromycin can be used to prevent rheumatic fever in penicillin intolerant patients.    **Skin infections**  Mild to moderate skin or skin structure infections caused by Streptococcus pyogenes or Staphylococcus aureus may be treated with erythromycin, however, resistant staphylococcal organisms may emerge. Erythromycin can also be used to treat erythrasma, an infectious condition caused by Corynebacterium minutissimum.   **Gastrointestinal infections**  Intestinal amebiasis caused by Entamoeba histolytica can be treated with oral erythromycin. Extraenteric amebiasis warrants treatment with other antimicrobial drugs.   **Genital infections/STIs**  Erythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by N. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin. Syphilis, caused by Treponema pallidum, can be treated with erythromycin.  It serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. Erythromycin can also be used in the primary stage of primary syphilis. Another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. It is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by Chlamydia trachomatis. Erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. Finally, erythromycin is indicated to treat nongonococcal urethritis due to Ureaplasma urealyticum.']","['Macrolides, such as erythromycin, stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections. Erythromycin does not exert effects on nucleic acid synthesis. This drug has been shown to be active against most strains of the following microorganisms, effectively treating both in vitro and clinical infections. Despite this, it is important to perform bacterial susceptibility testing before administering this antibiotic, as resistance is a common issue that may affect treatment.   **A note on antimicrobial resistance, pseudomembranous colitis, and hepatotoxicity**  Many strains of Haemophilus influenzae are resistant to erythromycin alone but are found to be susceptible to erythromycin and sulfonamides used in combination. It is important to note that Staphylococci that are resistant to erythromycin may emerge during erythromycin and/or sulfonamide therapy. Pseudomembranous colitis has been reported with most antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, the physician should consider this diagnosis in patients with diarrhea after the administration of antibacterial agents. Erythromycin can cause hepatic dysfunction, cholestatic jaundice, and abnormal liver transaminases, particularly when erythromycin estolate is administered.']","['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']","['Orally administered erythromycin is readily absorbed. Food intake does not appear to exert effects on serum concentrations of erythromycin.  Some interindividual variation exists in terms of erythromycin absorption, which may impact absorption to varying degrees. The Cmax of erythromycin is 1.8 mcg/L and the Tmax is 1.2 hours. The serum AUC of erythromycin after the administration of a 500mg oral dose was 7.33.9 mg.h/l in one pharmacokinetic study. Erythromycin is well known for a bioavailability that is variable (18-45%) after oral administration and its susceptibility to broken down under acidic conditions.', 'In patients with normal liver function, erythromycin concentrates in the liver and is then excreted in the bile.Under 5% of the orally administered dose of erythromycin is found excreted in the urine. A high percentage of absorbed erythromycin is not accounted for, but is likely metabolized.', 'Erythromycin is found in most body fluids and accumulates in leucocytes and inflammatory liquid. Spinal fluid concentrations of erythromycin are low, however, the diffusion of erythromycin through the blood-brain barrier increases in meningitis, likely due to the presence of inflamed tissues which are easily penetrated. Erythromycin crosses the placenta.', 'The clearance of erythromycin in healthy subjects was 0.53  0.13 l/h/kg after a 125mg intravenous dose. In a clinical study of healthy patients and patients with liver cirrhosis, clearance of erythromycin was significantly reduced in those with severe liver cirrhosis. The clearance in cirrhotic patients was 42.2  10.1 l h1 versus 113.2  44.2 l h-1 in healthy patients.', 'Absorption of orally administered erythromycins occurs mainly in the duodenum. The bioavailability of the drugs is variable and depends on several factors including the particular erythromycin derivative, the formulation of the dosage form administered, acid stability of the derivative, presence of food in the GI tract, and gastric emptying time.', 'Erythromycin is rather slowly absorbed after oral administration. peak serum concentrations ranged from 0.1 to 4.8 ug/mL according to the form and the coating of erythromycin administered. The oral absorption is less that 50% and erythromycin is degraded by gastric acid. It is absorbed in the small intestine (mainly in duodenum for humans) as erythromycin base.', 'Erythromycin diffuses readily into intracellular fluids, achieving antibacterial activity in essentially all sites except the brain and CSF. Erythromycin penetrates into prostatic fluid, achieving concentrations approximately 40% of those in plasma. Concentrations in middle ear exudate reach only 50% of serum concentrations and thus may be inadequate for the treatment of otitis media caused by H. influenzae. Protein binding is approximately 70% to 80% for erythromycin base and even higher, 96%, for the estolate. Erythromycin traverses the placenta, and drug concentrations in fetal plasma are about 5% to 20% of those in the maternal circulation. Concentrations in breast milk are 50% of those in serum.', 'In an in vitro model using human skin, erythromycin was absorbed into the stratum corneum following topical application of 10-20 mg of the drug in a vehicle containing dimethylacetamide and 95% alcohol. The drug does not appear to be absorbed systemically following twice daily application of a 2% solution of the drug in a vehicle containing 77% alcohol and polyethylene glycol and acetone.  It is not known if erythromycin is absorbed from intact or denuded skin, wounds, or mucous membranes following topical application of an ointment containing the drug.', 'For more Absorption, Distribution and Excretion (Complete) data for Erythromycin (13 total), please visit the HSDB record page.']","['Hepatic first-pass metabolism contributes significantly to erythromycin metabolism after an oral dose. Erythromycin is partially metabolized by CYP3A4 enzyme to N-desmethylerythromycin. Erythromycin is also hydrolyzed to _anhydro_ forms (anhydroerythromycin [AHE] and other metabolites), and this process is promoted by acidic conditions. AHE is inactive against microbes but inhibits hepatic drug oxidation and is therefore considered to be an important contributor to erythromycin drug-drug interactions.', 'Twenty hours after an oral administration of 10 mg erythromycin to rats, about 37-43% of the administered radioactivity was recovered in the intestinal tract plus feces, 27.2 to 36.1% in the urine, 21-29% in the expired air. It was rapidly metabolized in the liver, mainly through demethylation process, and excreted in the bile as des-N-methyl-erythromycin, the major metabolite present only in the bile and in the intestinal contents of rats. The isotropic methyl group was eliminated in the expired air as CO2.']","['The elimination half-life of oral erythromycin was 3.5 hours according to one study and ranged between 2.4-3.1 hours in another study. Repetitive dosing of erythromycin leads to increased elimination half-life.', '... The serum elimination half-life of erythromycin is approximately 1.6 hours.', 'The serum half-life in normal subjects is 2 hours and in anuric subjects, 4-6 hours.']"
2560,12561,2-Isopropylaniline,CC(C)C1=CC=CC=C1N,,,,,,
2561,12562,"Acetic acid, (2,4-dinitrophenyl)-",C1=CC=C(C=C1)C(=O)OC([N+](=O)[O-])[N+](=O)[O-],,,,,,
2562,12563,2-Methylbiphenyl,CC1=CC=CC=C1C2=CC=CC=C2,,,,,,
2563,12564,3-Methylbiphenyl,CC1=CC(=CC=C1)C2=CC=CC=C2,,,,,,
2564,12565,Precocene II,CC1(C=CC2=CC(=C(C=C2O1)OC)OC)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
2565,12566,4-Methylbiphenyl,CC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
2566,12567,1-Dimethylamino-2-methyl-2-butanolbenzoat,CCC(C)(C(N(C)C)OC(=O)C1=CC=CC=C1)O,,,,,,
2567,12568,Acetyl benzoyl peroxide,CC(=O)OOC(=O)C1=CC=CC=C1,,,,['Liquid peroxides can be absorbed through the skin. /Organic peroxides/'],,
2568,12569,Benzoyl disulfide,C1=CC=C(C=C1)C(=O)SSC(=O)C2=CC=CC=C2,,,,,,
2569,12570,2-Propylphenol,CCCC1=CC=CC=C1O,,,,,,
2570,12571,Propyl isobutyrate,CCCOC(=O)C(C)C,,,,,,
2571,12572,Dimetilan,CC1=CC(=NN1C(=O)N(C)C)OC(=O)N(C)C,,,,"['Labeled dimetilan was administered orally to rats. Within 4 hr after treatment the urine contained 10% of the administered radioactivity and an additional 3% within the next 18 hr. ... Some production of carbon dioxide was observed. ... /in houseflies, American cockroaches, and German cockroaches/...13% of the injected dose was liberated as (14)CO2 within 1 hr...', '...Carbamate insecticides...are rapidly...eliminated in rats. Within 49 hr after ip injection of carbonyl (14)C-labeled carbamate 89% of radioactivity was eliminated. Part appeared as CO2 (25-77%), products in urine (12-65%), and products in feces (1-6%), with 2-12%...remaining in body. /Carbamates/', 'Carbamates penetrate rapidly into insects, from 40-80% of topical dosage of 1 ug per housefly, penetrating within 4-8 hr. ... In mammals...carbamates are not accumulated in body or excreted in milk. /Carbamates/', '.../Carbamate insecticides/ are rapidly... excreted in urine. /Carbamates/']","['Labeled dimetilan was administered orally to rats. ... 2 metabolites were recovered but not identified. ...other studies have shown a microsomal system, requiring TPNH and oxygen, that acts on n,n-dialkyl carbamates. Dealkylation occurs with formation of formaldehyde from n,n-dimethylcarbamates but not from n-methylcarbamates. Dimetilan was degraded by this system; and 2-methylcarbamoyl-3-methyl-5-pyrazolyl dimethyl carbamate + 2 unidentified compounds were observed. /in houseflies, American and German cockroaches/...hydrolysis of the carbamate ester group accounted for some metabolism, since 13% of the injected dose was liberated as (14)CO2...the metabolite formed first and the major product was probably 2-dimethylcarbamoyl-3-methyl-5-pyrazolyl n-hydroxymethyl n-methylcarbamate. ... A third metabolite found in all 3 insects co-chromatographed with 2-n-methylcarbamoyl-3-methyl-5-pyrazolyl dimethylcarbamate and exhibited the same biological activity.', '... The metabolism of dimetilan in Aspergillus niger van Tieghem /was studied/.  Together with hydrolysis, oxidation of the alkyl side chain appeared the most important modification (detoxification) process.', 'N-methyl hydroxylation appears to be major factor in detoxication in insects.']",['Dimetilan had half-life in houseflies... American cockroach... and German cockroach... of <0.5 hr.']
2572,12573,Dichlorophenylphosphine,C1=CC=C(C=C1)P(Cl)Cl,,,,,,
2573,12574,1-Iodo-3-nitrobenzene,C1=CC(=CC(=C1)I)[N+](=O)[O-],,,,,,
2574,12575,3-Hydroxy-4-methoxybenzoic acid,COC1=C(C=C(C=C1)C(=O)O)O,,,,,,
2575,12576,3-Nitrobenzamide,C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)N,,,,,,
2576,12577,5-Nitro-2-furoic acid,C1=C(OC(=C1)[N+](=O)[O-])C(=O)O,,,,,,
2577,12578,4'-Isopropylacetophenone,CC(C)C1=CC=C(C=C1)C(=O)C,,,,,,
2578,12579,"N~2~-(4-Chlorophenyl)-6-methyl-1,3,5-triazine-2,4-diamine",CC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)N,,,,,,
2579,12580,4-Propylphenol,CCCC1=CC=C(C=C1)O,,,,,"['4-n-Propylphenol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(4-propylphenoxy)oxane-2-carboxylic acid.']",
2580,12581,Benzenepropanenitrile,C1=CC=C(C=C1)CCC#N,,,,,,
2581,12582,2-Ethylhex-2-enal,CCCC=C(CC)C=O,,,,,,
2582,12583,CID 12583,C1(=NC(=O)N=C(N1)N)N,,,,,,
2583,12584,Ammelide,C1(=NC(=O)NC(=O)N1)N,,,,,,
2584,12585,2-Pentene,CCC=CC,,,,,,
2585,12586,"1,3-Dioxolane",C1COCO1,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],"['The compound was able to penetrate human skin.', 'The site of uptake of inhaled vapors profoundly influences which respiratory tract tissues receive the highest doses. How the site of uptake depends on the physicochemical properties of inhaled vapors has been the subject of experiment and speculation for decades, but remains undefined. Using techniques that distinguish between vapor uptake in the nose and lung during cyclic breathing by Beagle dogs, uptake of the vapors of 2,4-dimethypentane, propyl ether, butanone, dioxolane, and ethanol was examined. These compounds have blood/air partition coefficients ranging from 1 to 2000. The effect of altering respiratory rates on vapor uptake was examined for 2,4-dimethypentane and dioxolane vapors. Deposition of vapors in the nasal cavity during inhalation was highly dependent on the partition coefficient. Vapor deposited in the nasal mucosa during inhalation was desorbed to a substantial extent during exhalation. Lung uptake of total inhaled vapor was limited by the amount available after passage through the nose, but in no case did it exceed 50% of the available amount. The data suggest that the diffusion of vapor molecules through the tissue barrier separating the air/tissue interface from the tissue/blood interface constitutes a significant resistance for both nasal uptake and lung uptake of many inhaled vapors. The data were used to validate a mathematical model describing nasal uptake of vapors.', '... Three beagle dogs were exposed to dioxolane at nominal vapor concentrations of 500 ppm; vapor sampling was triggered for the entire inspiratory and expiratory portions of the breathing cycle during 10-min exposures. After correcting data to account for vapor that desorbed from the nasal passages during exhalation (after initially being absorbed in the nose during inhalation), net nasal uptake of dioxolane was 66.6%. Lung uptake was 2.1% for dioxolane. It can be concluded from this study that upper respiratory tract uptake of dioxolane is an important absorption mechanism for dogs under these experimental conditions. Upper respiratory tract absorption is likely to also be an important uptake mechanism in humans.']",,
2586,12587,4-Methylpentanoic acid,CC(C)CCC(=O)O,,,,,,
2587,12588,Isobutyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCC(C)C,,,,"['/LOW DISSOCIATION CONSTANTS & /...LACK OF WATER SOLUBILITY & ABILITY TO PENETRATE SKIN OR MUCOUS MEMBRANES PROBABLY EXPLAINS THE LACK OF IRRITATION OF HIGHER FATTY ACIDS, THE LIMITED AMT IN SOLN BEING NEUTRALIZED PROMPTLY. /FATTY ACIDS/']",,
2588,12589,1-Nitrohexane,CCCCCC[N+](=O)[O-],,,,,,
2589,12590,Heptanedinitrile,C(CCC#N)CCC#N,,,,,,
2590,12591,Nonadecanoic acid,CCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
2591,12592,Tetracosane,CCCCCCCCCCCCCCCCCCCCCCCC,,,,"['Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments.', 'Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/']",,
2592,12593,CID 12593,C(=O)(C(Cl)(Cl)Cl)[O-].[Na+],,,,,,
2593,12594,Dehydroepiandrosterone sulfate,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,['Investigated for use/treatment in asthma and burns and burn infections.'],,,,,
2594,12595,"Estra-1,3,5(10),7-tetraene-3,17-diol, (17alpha)-",CC12CCC3C(=CCC4=C3C=CC(=C4)O)C1CCC2O,,,,,,
2595,12596,5-Methylbenzo[c]phenanthrene,CC1=CC2=C(C3=CC=CC=C3C=C2)C4=CC=CC=C14,,,,,,
2596,12597,Isosorbide,C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O)O,"['Isosorbide was previously indicated for temporary reduction of intraocular pressure and used to interrupt an acute glaucoma attack, however, this is not a currently approved indication. Refer to [isosorbide mononitrate] and [isosorbide dinitrate] drug entries for more isosorbide indications.']","['Isosorbide reduces intraocular pressure through its effects on ocular blood vessels. While in the blood, isosorbide promotes redistribution of water toward the circulation, promoting the excretion of urine.']","['Compounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma. (See all compounds classified as Diuretics, Osmotic.)']","['Isosorbide is rapidly absorbed after oral administration. Refer to [isosorbide mononitrate] for detailed absorption information.', 'IN DOGS, 5.5 MILLIMOLES/KG IV CAUSED LESS SOLUTE EXCRETION THAN AN EQUIMOLAR DOSE OF MANNITOL. THE DISTRIBUTION SPACE OF LABELED ISOSORBIDE WAS 54% OF BODY WT IN INTACT & NEPHRECTOMIZED DOGS. PROXIMAL TUBULAR REABSORPTION OF ISOSORBIDE WAS PROBABLY PASSIVE.']",,"['TEN NORMAL MALES RECEIVED 0.25-1.5 G/KG ISOSORBIDE. DOSE RESPONSE EFFECTS ON WATER & OSMOLAR EXCRETION STATISTICALLY SIGNIFICANT. IN 9 VOLUNTEERS, ORALLY ADMIN ISOSORBIDE APPEARED RAPIDLY IN PLASMA & EXCRETED IN URINE WITH MEAN DISAPPEARANCE HALF-LIFE OF 8 HR.', 'ISOSORBIDE WAS RAPIDLY ABSORBED BY HUMANS FOLLOWING ORAL ADMIN & WAS EXCRETED UNCHANGED VIA KIDNEY WITH A MEAN DISAPPEARANCE T/2 OF APPROX 7 HR. IT INCREASED URINE VOLUME, CREATININE CLEARANCE, & SODIUM & CHLORIDE EXCRETION.', 'RABBITS GIVEN ORAL DOSES OF 2 G/KG FOR 1-7 DAYS HAD EST EXCRETION T/2 OF LESS THAN 6 HR IN ALL EYE TISSUE. PEAK LEVEL & EXCRETION T/2 WAS SIMILAR IN DAMAGED & UNDAMAGED EYE TISSUE, EXCEPT IN LENS OF DAMAGED EYES IN WHICH EXCRETION T/2 WAS SHORTER THAN OF NORMAL EYES.']"
2597,12598,Butaperazine,CCCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C,,,,"['NEUROLEPTIC CONCN-THERAPEUTIC RESPONSE CURVES EXAMINED FOR BUTAPERAZINE IN 10 SCHIZOPHRENIC PT DURING FIRST 12 DAYS OF TREATMENT. RESULTS SHOWED BUTAPERAZINE BOUND TO RED BLOOD CELLS WAS MORE STRONGLY CORRELATED WITH THERAPEUTIC RESPONSE THAN WAS PLASMA CONCN.', 'IN A STUDY ON 2 GROUPS OF NONRESPONDING SCHIZOPHRENICS AND ONE GROUP OF CLINICALLY RESPONDING PT WITH AFFECTIVE DISORDERS, THE NONRESPONDERS HAD 2 TO 7 TIMES LOWER LEVELS OF BUTAPERAZINE, 40 MG TWICE DAILY, IN PLASMA AND RED BLOOD CELLS AFTER A SINGLE DOSE OR CHRONIC DOSING.', 'EIGHT OF 10 CHRONIC SCHIZOPHRENIC PT RECEIVED A 40 MG LOADING DOSE OF BUTAPERAZINE AND THEN WERE TITRATED UNTIL A THERAPEUTIC RESPONSE WAS OBTAINED. THRICE DAILY USE OF THE DRUG SHOWED A HIGHER WHOLE BLOOD STEADY STATE DRUG PLASMA LEVEL THAN THE ONCE A DAY USE OF THE SAME TOTAL DAILY DOSE.']","['AFTER CHRONIC ADMIN OF PIPERAZINE-SUBSTITUTED PHENOTHIAZINE DRUGS...TO RATS, TISSUES CONTAINED DRUG METABOLITES, IN WHICH PIPERAZINE RING FISSION BY MULTIPLE OXIDATIVE N-DEALKYLATION HAD OCCURRED TO GIVE SUBSTITUTED ETHYLENEDIAMINE. /PIPERAZINE PHENOTHIAZINES/', 'IN RATS & DOGS, PRINCIPAL FECAL METABOLITES OF BUTAPERAZINE DIMALEATE RESULT FROM HYDROXYLATION OF PHENOTHIAZINE RING-SYSTEM & OXIDATIVE N-DEMETHYLATION. BUTAPERAZINE SULFOXIDE, BUTAPERAZINE SULFONE, & REDN PRODUCT OF BUTYRYL SIDE-CHAIN CARBONYL GROUP MAKE UP MINOR METABOLITES. /DIMALEATE/']",['BUTAPERAZINE (10-60 MG ORALLY) HAD AVG PEAK SERUM LEVELS OF 215 NG/ML IN HUMANS AND AN INITIAL RAPID PHASE HALF-LIFE OF 4 HR AND A SLOWER PHASE HALF-LIFE OF 12 HR. SERUM BUTAPERAZINE LEVELS WERE PROPORTIONAL TO THE DOSE ADMINISTERED.']
2598,12599,2'-Deoxyadenosine-5'-monophosphate,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(O)O)O,,,,,,
2599,12600,D-Mannoheptulose,C([C@H]([C@H]([C@@H]([C@@H](C(=O)CO)O)O)O)O)O,,,,,,
2600,12601,3-Trifluoromethyl-4-nitrophenol sodium salt,C1=CC(=C(C=C1[O-])C(F)(F)F)[N+](=O)[O-].[Na+],,,,,,
2601,12602,Thozalinone,CN(C)C1=NC(=O)C(O1)C2=CC=CC=C2,,,,,,
2602,12603,2-[7-(2-Ethoxy-2-oxoethoxy)-4-methyl-2-oxochromen-3-yl]ethyl-diethylazanium;chloride,CC[NH+](CC)CCC1=C(C2=C(C=C(C=C2)OCC(=O)OCC)OC1=O)C.[Cl-],,,,,,
2603,12604,Carbocromen,CCN(CC)CCC1=C(C2=C(C=C(C=C2)OCC(=O)OCC)OC1=O)C,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
2604,12605,"Phenazine-1,2-diamine",C1=CC=C2C(=C1)N=C3C=CC(=C(C3=N2)N)N,,,,,,
2605,12606,(2-Fluorophenyl)urea,C1=CC=C(C(=C1)NC(=O)N)F,,,,,,
2606,12607,5-Chloro-2-(trifluoromethyl)benzimidazole,C1=CC2=C(C=C1Cl)NC(=N2)C(F)(F)F,,,,,,
2607,12608,Methylphenyl phosphinic fluoride,CP(=O)(C1=CC=CC=C1)F,,,,,,
2608,12609,3'-Trifluoromethylformanilide,C1=CC(=CC(=C1)NC=O)C(F)(F)F,,,,,,
2609,12610,CID 12610,CC1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
2610,12611,"2,4-Bis(ethylamino)-6-fluoro-1,3,5-triazine",CCNC1=NC(=NC(=N1)F)NCC,,,,,,
2611,12612,4-Fluorophenylurea,C1=CC(=CC=C1NC(=O)N)F,,,,,,
2612,12613,Isoamyl isovalerate,CC(C)CCOC(=O)CC(C)C,,,,,,
2613,12614,Bicyclo[5.1.0]oct-3-ene,C1CC2CC2CC=C1,,,,,,
2614,12615,n-Butanesulfonyl fluoride,CCCCS(=O)(=O)F,,,,,,
2615,12616,4-Fluorobutanesulphonyl fluoride,C(CCS(=O)(=O)F)CF,,,,,,
2616,12617,Diisopropylammonium dichloroacetate,CC(C)NC(C)C.C(C(=O)O)(Cl)Cl,,,,,,
2617,12618,Diethylammonium chloride,CC[NH2+]CC.[Cl-],,,,,,
2618,12619,1-Fluoroheptane,CCCCCCCF,,,,,,
2619,12620,Docosanol,CCCCCCCCCCCCCCCCCCCCCCO,['For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).'],"['Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing.']",['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],"['Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.', 'Absorption of docosanol has been shown to be minimal under conditions reflecting normal clinical use. Of 209 plasma samples taken from ten subjects 24 hours after a multi-day test, only one had a docosanol level above the quantitation limits (19 nanograms/mL).', 'Long chain alcohols were detected in developing rat brain at their highest level of 0.0109% of the total lipids at the age of 10 days and decreased to 0.0036% at the age of 40 days. They consited mainly of hexadecanol, octadecanol, octadecenol, eicosanol, docosanol, and tetracosanol.', 'A mixture of cis-9[1(-14)C] octadecenol and [1(-14)C] docosanol was injected into the brains of 19-day-old rats, and incorporation of radioactivity into brain lipids was determined after 3, 12, and 24 hr. Both alcohols were metabolized by the brain but at different rates; each was oxidized to the corresponding fatty acid, but oleic acid was more readily incorporated into polar lipids. Substantial amounts of radioactivity were incorporated into 18:1 alkyl and alk-1-enyl moieties of the ethanolamine phosphoglycerides and into 18:1 alkyl moieties of the choline phosphoglycerides. Even after the disappearance of the 18:1 alcohol from the substrate mixture (12 hr), the 22:0 alcohol was not used to any measurable extent for alkyl and alk-1-enylglycerol formation.']","['The 22-carbon fatty alcohol, n-docosanol, exhibits in vitro antiviral activity against several lipid-enveloped viruses including herpes simplex viruses 1 and 2 by a mechanism that interferes with normal viral entry into target cells. We previously reported that mammalian cells incorporate significant quantities of radiolabeled n-docosanol. Herein, we report that cells extensively metabolize the internalized fatty alcohol. This is evidenced by incorporation of up to 60% of cell-associated radiolabel into phospholipids that copurify with phosphatidylcholine and phosphatidylethanolamine. Analysis by chemical (Vitride) reduction suggests that a significant portion of n-docosanol is oxidized to n-docosanoic acid and then incorporated as an acyl group on polar lipids. A measurable amount of radiolabel, however, is resistant to Vitride reduction, consistent with incorporation of n-docosanol into ether lipids. The rate and extent of metabolic conversion of n-docosanol vary with the cell type and surfactant used to suspend the compound. Furthermore, the anti-HSV activity of n-docosanol is quantitatively proportional to the amount of metabolism observed. These findings suggest that the anti-HSV activity of n-docosanol involves cellular uptake and metabolism of the drug.', 'A mixture of cis-9[1(-14)C] octadecenol and [1(-14)C] docosanol was injected into the brains of 19-day-old rats. Both alcohols were metabolized by the brain but at different rates; each was oxidized to the corresponding fatty acid. Substantial amounts of radioactivity were incorporated into 18:1 alkyl and alk-1-enyl moieties of the ethanolamine phosphoglycerides and into 18:1 alkyl moieties of the choline phosphoglycerides.']",
2620,12621,Tetramethylammonium tetrafluoroborate,[B-](F)(F)(F)F.C[N+](C)(C)C,,,,,,
2621,12622,CID 12622,C[SnH](C)C.C[SnH](C)C,,,,,,
2622,12623,Trimethylstannane,C[SnH](C)C,,,,,,
2623,12624,"1,1-Difluoro-2,2,2-trichloroethyl methyl ether",COC(C(Cl)(Cl)Cl)(F)F,,,,,,
2624,12625,"3-Bromo-3-chloro-1,1,1,2,2-pentafluoropropane",C(C(C(F)(F)F)(F)F)(Cl)Br,,,,,,
2625,12626,Heptafluorobutyramide,C(=O)(C(C(C(F)(F)F)(F)F)(F)F)N,,,,,,
2626,12627,"3-[(1R,3R,5R,10S,13R,14S,17R)-3-[(2S,5S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-1,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@@H](C(C([C@H](O1)O[C@@H]2C[C@H]3CCC4C([C@]3([C@@H](C2)O)C)CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)OC)O,,,,,,
2627,12628,Glycyclamide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,,,,,,
2628,12629,Agaric acid,CCCCCCCCCCCCCCCCC(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
2629,12630,Diphenylcarbamic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
2630,12631,Dicarfen,CCN(CC)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2631,12632,7-Methylbenzofuran-3(2H)-one,CC1=C2C(=CC=C1)C(=O)CO2,,,,,,
2632,12633,"Choline 2,6-xylyl ether bromide",CC1=C(C(=CC=C1)C)OCC[N+](C)(C)C.[Br-],,,,,,
2633,12634,Xylocholine,CC1=C(C(=CC=C1)C)OCC[N+](C)(C)C,,,,,,
2634,12635,Tetracyanoethylene,C(#N)C(=C(C#N)C#N)C#N,,,,,,
2635,12636,"2-Chloro-3,4-xylyl methylcarbamate",CC1=C(C(=C(C=C1)OC(=O)NC)Cl)C,,,,,,
2636,12637,"1,2-Dimethylpiperidine",CC1CCCCN1C,,,,,,
2637,12638,"Aziridinecarboxylic acid, methyl ester",COC(=O)N1CC1,,,,,,
2638,12639,N-(Ethoxycarbonyl)aziridine,CCOC(=O)N1CC1,,,,,,
2639,12640,"Aziridinecarboxylic acid, isopropyl ester",CC(C)OC(=O)N1CC1,,,,,,
2640,12641,"Aziridinecarboxylic acid, butyl ester",CCCCOC(=O)N1CC1,,,,,,
2641,12642,1-Chloro-2-hydroxy-3-butene,C=CC(CCl)O,,,,,,
2642,12643,M-(1-Ethylpropyl)phenyl methylcarbamate,CCC(CC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
2643,12644,"CARBAMIC ACID, METHYL-, 2,4-DICHLORO-5-ETHYL-m-TOLYL ESTER",CCC1=CC(=C(C(=C1Cl)C)Cl)OC(=O)NC,,,,,,
2644,12645,"Acetamide, 2-(diethylamino)-N-(5-ethyl-2-methylphenyl)-",CCC1=CC(=C(C=C1)C)NC(=O)CN(CC)CC,,,,,,
2645,12646,4-(Diethylamino)-5'-ethyl-2'-methylbutyranilide,CCC1=CC(=C(C=C1)C)NC(=O)CCCN(CC)CC,,,,,,
2646,12647,L-homoserine,C(CO)[C@@H](C(=O)O)N,,,,,,
2647,12648,(1-Chloroethyl)benzene,CC(C1=CC=CC=C1)Cl,,,,,,
2648,12649,gamma-Thujaplicin,CC(C)C1=CC=C(C(=O)C=C1)O,,,,,,
2649,12650,(R)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid,C[C@@](CC1=CC=C(C=C1)O)(C(=O)O)N,,,,,,
2650,12651,4-Methoxy-6-methyl-2H-pyran-2-one,CC1=CC(=CC(=O)O1)OC,,,,,,
2651,12652,"2-(P-Chloroanilino)-4-ethyl-6-amino-1,3,5-triazine",CCC1=NC(=NC(=N1)NC2=CC=C(C=C2)Cl)N,,,,,,
2652,12653,"Carbamic acid, methyl-, 4-chloro-3,5-xylyl ester",CC1=CC(=CC(=C1Cl)C)OC(=O)NC,,,,,,
2653,12654,Simeton,CCNC1=NC(=NC(=N1)OC)NCC,,,,,,
2654,12655,m-sec-Butylphenyl N-methylcarbamate,CCC(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
2655,12656,"N,N-Dimethylhistamine",CN(C)CCC1=CN=CN1,,,,,,
2656,12657,2-Azacyclooctanone,C1CCCNC(=O)CC1,,,,,,
2657,12658,CID 12658,CC=C(C)C=CC=C(C)C,,,,,,
2658,12659,4-Methyl-2-pentene,CC=CC(C)C,,,,,,
2659,12660,Nitrosoguanidine,C(=NN=O)(N)N,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
2660,12661,Diketene,C=C1CC(=O)O1,,,,,,
2661,12662,"4,6-Dimethyl-2H-pyran-2-one",CC1=CC(=O)OC(=C1)C,,,,,,
2662,12663,CID 12663,CC1=CC(=O)C=C(O1)O,,,,,,
2663,12664,Cyanuric fluoride,C1(=NC(=NC(=N1)F)F)F,,,,,,
2664,12665,2-Piperidone,C1CCNC(=O)C1,,,,,,
2665,12666,"(3,3,3-Trifluoropropyl)methyldichlorosilane",C[Si](CCC(F)(F)F)(Cl)Cl,,,,,,
2666,12667,"Hexanamide, 6-fluoro-",C(CCC(=O)N)CCF,,,,,,
2667,12668,"Cyclododeca-1,5,9-triene",C1CC=CCCC=CCCC=C1,,,,,,
2668,12669,Deuteriomethane,[2H]C,,,,,,
2669,12670,Methylmagnesium chloride,[CH3-].[Mg+2].[Cl-],,,,,,
2670,12671,Methylphosphonic dichloride,CP(=O)(Cl)Cl,,,,,,
2671,12672,"3,3,3-Trifluoropropene",C=CC(F)(F)F,,,,,,
2672,12673,Dimethylphosphoramidic dichloride,CN(C)P(=O)(Cl)Cl,,,,,,
2673,12674,Dimethyl malate,COC(=O)CC(C(=O)OC)O,,,,,,
2674,12675,Dodecafluoropentane,C(C(C(F)(F)F)(F)F)(C(C(F)(F)F)(F)F)(F)F,"['EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.']",,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
2675,12676,Roflurane,COC(C(F)Br)(F)F,,,,,,
2676,12677,"Malonic acid, (1-hydroxy-2,2,2-trifluoro-1-trifluoromethyl)ethyl-, diethyl ester",CCOC(=O)C(C(=O)OCC)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2677,12678,"2-Acetyl-3-hydroxy-4,4,4-trifluoro-3-(trifluoromethyl)butyric acid ethyl ester",CCOC(=O)C(C(=O)C)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
2678,12679,Hexamethylphosphoramide,CN(C)P(=O)(N(C)C)N(C)C,,,['Compounds that cause reproductive sterility in organisms. They are sometimes used to control pest populations by sterilizing males within the population. (See all compounds classified as Chemosterilants.)'],['SEVENTY PERCENT OF (32)P-LABELED HEXAMETHYLPHOSPHORAMIDE GIVEN IP WAS EXCRETED WITHIN 20 HR BY RATS & MICE AS (32)P. HEXAMETHYLPHOSPHORAMIDE IS EXCRETED IN MILK OF COWS FOLLOWING ITS ORAL ADMIN.'],"[""IN RATS & MICE, HEXAMETHYLPHOSPHORAMIDE UNDERGOES A SEQUENCE OF N-DEMETHYLATION REACTIONS TO YIELD PENTAMETHYLPHOSPHORAMIDE, N',N',N'',N'''-TETRAMETHYLPHOSPHORAMIDE & N', N'',N''-TRIMETHYLPHOSPHORAMIDE. IN VITRO STUDIES WITH RAT LIVER SLICES INDICATED OXIDATIVE DEMETHYLATION, WITH SIMULTANEOUS FORMATION OF FORMALDEHYDE."", 'The metabolism of hexamethylphosphoramide (HMPA), aminopyrine, ethoxycoumarin, ethoxyrsorufin, and pentoxyresorufin, by the monooxygenase cytochrome p450 dependent system, was studied in microsomes from nasal epithelial membranes and liver tissue of Sprague-Dawley rats. Nasal metabolism rates for the different substrates ranged from 9% of liver values for aminopyrine to 83% for ethoxycoumarin. HMPA-demethylase activity followed Michaelis-Menten kinetics in nasal mucosa microsomes but was biphasic in those from liver. SKF 525A, metyrapone, dioxolane and alpha-naphthoflavone (ANF), inhibitors of various p450 monoxygenase, were examined with regard to inhibition of nasal and liver ethoxycoumarin deethylase. In addition, activity of epoxide hydrolase, glutathione S-transferase, DT-diaphorase and UDP-glucuronyltransferase (UDP-GT) in nasal tissue homogenates were investigated. These activities were lower than those present in the liver. Various attempts to increase the activity of oxidative enzymes in nasal tissue by PB, 3-MC and ethanol failed, 3-MC and PB doubled the microsomal UDP-GT and the epoxide hydrolase activities. The results together with data from the literature sugggest that the balance between p450 isozymes and detoxifying enzymes differs in the nose compared with the liver. The activities of these enzymes in nasal tissue of different strains of rats also varies substantially with implications regarding the metabolic fate and activation of inhaled xenobiotics.', 'Two unique forms of cytochrome p450 (p450), designated NMa and NMb, were recently isolated in this laboratory from nasal microsomes of rabbits. In the present study, polyclonal antibodies to the pruified nasal cytochrome were prepared. Immunochemical analysis with specific rabbit anti-NMa and sheep anti-NMb antibodies indicated that p450 isozymes identical to or having a high structural homology with NMa are present in both olfactory and respiratory mucosa, as well as in liver, but NMb was detected only in the olfactory mucosa. Neither form was detected in other tissues examined, including brain, esophageal mucosa, heart, intestinal mucosa, kidney, and lung. The specific occurrence of NMb in the olfactory mucosa was further substantiated by the detection and specific inhibition by anti-NMb of the formation of unique NMb-dependent metabolites of testosterone in olfactory microsomes but not in microsomes from liver or respiratory mucosa. Similar experiments with antibody to previously purified rabbit hepatic p450 isozymes indicated that not all of the hepatic cytochromes are expressed in the nasal tissues. Thus, p450 isozymes structurally homologous to hepatic forms 2, 3a, and 4, but not 3b and 6, were found in the olfactory mucosa. On the other hand, only form 2 was detected in the respiratory mucosa. Immunoquantitation experiments revealed that NMa nd NMb are the major p450 forms in olfactory microsomes, whereas NMa and P450 form 2 (or its homolog) constitute the major portion of the respiratory nasal microsomal p450. The level of NMa in the liver is relatively low, accounting for less than 3% of total microsomal p450 in this tissue. In addition, evidence is provided that NMa is the major catalyst in the dealkylation of two nasal carcinogens, hexamethylphosphoramide and phenacetin, in both olfactory and respiratory nasal microsomes.', 'Possible roles of chtochrome p450 monooxygenases in nasal tissues are discussed. Nasal cytochrome p450 is known to occur in dogs, rats, monkeys mice, guinea pigs, and Syrian hamsters, and possible other species. The concentrations of cytochrome p450 in the olfactory mucosa of monkeys, dogs, and rats is much higher than in the nasal rspiratory mucosa. The substrate specificity of nasal cytochrome p450 is different from that of the liver. For example, whereas liver cytochrome p450 oxidizes benoz(a)pyrene faster than nasal cytochrome, the reverse is true for hexamethylphosphoramide (HMPA). Nasal cytochrome p450 may be involved in producing toxic or carcinogenic metabolites from inhaled compounds. For exampe, HMPA may be demethylated to formaldehyde by nasal cytochrome p450. Nasal cytochrome p450 may have a role in protecting lungs, since nasal metabolism of inhaled organic vapors can reduce the concentration of the vapors reaching the lungs. Nasal cytochrome p450 may help maintain acuity of the sense of smell through removal of odorants by metabolizing them. Without this function, odorants remaining in the mucus covering of the sensory organs might produce an unacceptably high background odor, thereby decreasing acuity. In species that are highly dependent on the sense of smell, the lack of olfactory acuity could have serious debilitating effects.', 'Hexamethylphosphoramide has known human metabolites that include Pentamethylphosphoramide.']",
2679,12680,Pentachloro-3-butenoyl chloride,C(=C(Cl)Cl)(C(C(=O)Cl)(Cl)Cl)Cl,,,,,,
2680,12681,"2,2-Dimethylglutaric acid",CC(C)(CCC(=O)O)C(=O)O,,,,,,
2681,12682,Tetramethoxysilane,CO[Si](OC)(OC)OC,,,,,,
2682,12683,Trimethylolpropane monoallyl ether,CCC(CO)(CO)COCC=C,,,,,,
2683,12684,"Diphosphoric(III,V) acid, tetraethyl ester",CCOP(OCC)OP(=O)(OCC)OCC,,,,,,
2684,12685,Diethyl methylphosphonate,CCOP(=O)(C)OCC,,,,,,
2685,12686,"(Carboxymethyl)dodecyldimethylammonium chloride, sodium salt",CCCCCCCCCCCC[N+](C)(C)CC(=O)[O-].[Na+].[Cl-],,,,,,
2686,12687,Carboxymethyl-dodecyl-dimethylazanium,CCCCCCCCCCCC[N+](C)(C)CC(=O)O,,,,,,
2687,12688,Dibutyltin dichloride,CCCC[Sn](CCCC)(Cl)Cl,,,"['An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']","['WITHIN 1 HR AFTER IV INJECTION OF 20 UMOL DIBUTYLTIN DICHLORIDE, RATS EXCRETED IN THE BILE 2X10-5 MOL ORGANOTIN/L. THE BILE/PLASMA QUOTIENT WAS 151:1 WHICH INDICATES AN ACTIVE TRANSPORT OF DIBUTYLTIN CHLORIDE FROM LIVER TO THE BILE. BIOTRANSFORMATION WAS NOT INVOLVED IN THE EXCRETION.', 'AFTER INJECTION OF DIBUTYL- & DIETHYLTIN COMPOUNDS, HIGHEST CONCENTRATIONS WERE FOUND IN LIVER & KIDNEY OF MICE & RATS. /DIBUTYL- AND DIETHYLTIN COMPOUNDS/']",,
2688,12689,"Arsine, dibromoethyl-",CC[As](Br)Br,,,,,,
2689,12690,Cyanodimethylarsine,C[As](C)C#N,,,,,,
2690,12691,Methylchloroketene,CC(=C=O)Cl,,,,,,
2691,12692,"2-Bromo-1,1-dichloroethane",C(C(Cl)Cl)Br,,,,,,
2692,12693,3-Chloro-3-buten-2-one,CC(=O)C(=C)Cl,,,,,,
2693,12694,"2,2-Dichloroacetamide",C(C(=O)N)(Cl)Cl,,,,,,
2694,12695,Hexafluoroacetone,C(=O)(C(F)(F)F)C(F)(F)F,,,,"['Most of an injected dose of radiolabeled HFA was excreted by the rat rapidly and unmetabolized in the urine, and no unusual accumulation or retention of HFA occurred in the testes.']",,
2695,12696,Ditert-butylphosphine oxide,CC(C)(C)P(=O)C(C)(C)C,,,,,,
2696,12697,sec-Butyldichloroarsine,CCC(C)[As](Cl)Cl,,,,,,
2697,12698,"2-Methyl-1,3-butanediol",CC(CO)C(C)O,,,,,,
2698,12699,N-Nitroso-N-methylurea,CN(C(=O)N)N=O,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']","['The high chemical reactivity of NMU renders it unlikely that enzymic catalysis is involved in its decomposition. NMU is a direct alkylating agent and alkylates nucleic acids both in vitro and in vivo. Such alkylation has been detected in a number of tissues, including brain, lung, kidney, liver, intestine, thymus and spleen, in a number of species, including mice, rats, hamsters and mini-pigs. All three hydrogen atoms in the methyl group of NMU are retained in the methylated nucleosides formed in nucleic acids after alkylation by NMU in vivo.']","['The cyanate ion produced by decomposilion of NMU at physiological pH can react with proteins by carbanoylation.', 'In vivo formation of NMU was shown by methylation of guanine at N7 after feeding of the precursors methylurea and sodium nitrite. /Species not specified/']",['NMU was not detected in the blood of rats 15 minutes after an i.v. injection of 100 mg/kg bw.']
2699,12700,"3,4-Dimethyl-3-penten-2-one",CC(=C(C)C(=O)C)C,,,,,,
2700,12701,Methyl pentafluoromethacrylate,COC(=O)C(=C(F)F)C(F)(F)F,,,,,,
2701,12702,Diethyl fluoromalonate,CCOC(=O)C(C(=O)OCC)F,,,,,,
2702,12703,"N,N-Diethylacetamide",CCN(CC)C(=O)C,,,,,"['IN MICE, THE DISCREPANCY BETWEEN IN VITRO & IN VIVO LIVER ENZYME INHIBITION ACTIVITY MAY BE DUE TO OXIDATIVE N-DEALKYLATION OF N,N-DIETHYLACETAMIDE OCCURRING IN VIVO, FACILITATING THE INHIBITION.']",
2703,12704,Methyl diethyldithiocarbamate,CCN(CC)C(=S)SC,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,"['Methyl N,N-diethyldithiocarbamate has known human metabolites that include MeDDC sulfine.']",
2704,12705,"Arsine, chlorodiethyl-",CC[As](CC)Cl,,,,,,
2705,12706,Dihydroxyurea,C(=O)(NO)NO,,,,,,
2706,12707,"Glycine, N-(trifluoroacetyl)-, vinyl ester",C=COC(=O)CNC(=O)C(F)(F)F,,,,,,
2707,12708,Ethyl 2-chloroacrylate,CCOC(=O)C(=C)Cl,,,,,,
2708,12709,Ethyl dimethylcarbamate,CCOC(=O)N(C)C,,,,,,
2709,12710,Aluminum;octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].[Al+3],,,,,,
2710,12711,Tripropyl borate,B(OCCC)(OCCC)OCCC,,,,,,
2711,12712,Tributyl borate,B(OCCCC)(OCCCC)OCCCC,,,,,,
2712,12713,2-Ethylhexyl methacrylate,CCCCC(CC)COC(=O)C(=C)C,,,,,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme A derivative, which then enters the normal lipid metabolism. /methacrylates/', 'Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Methacrylates/']",
2713,12714,"Arsine, chloroethylpropyl-",CCC[As](CC)Cl,,,,,,
2714,12715,Sec-butylurea,CCC(C)NC(=O)N,,,,,,
2715,12716,Isopropyl acrylate,CC(C)OC(=O)C=C,,,,,,
2716,12717,Hadacidin,C(C(=O)O)N(C=O)O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)']",,,
2717,12718,Thiocyanatoacetic acid methyl ester,COC(=O)CSC#N,,,,,,
2718,12719,"2-Heptanone, 1-fluoro-",CCCCCC(=O)CF,,,,,,
2719,12720,1-Buten-3-yne,C=CC#C,,,,,,
2720,12721,"4,4-Dimethylpent-2-ene",CC=CC(C)(C)C,,,,,,
2721,12722,"1,1,1,3,3,3-Hexafluoropropane",C(C(F)(F)F)C(F)(F)F,,,,,,['...newborn piglets ...were ventilated with air containing 0.8% HFP (v/v) for 30 min. This was done to assess accumulation of HFP during measurement of functional residual lung capacity by wash-in and wash-out techniques. A saturation concentration in blood between 2.0 and 2.5 mg/L was attained after 3 min ventilation and decreased with a half-life below 1 min after termination of the HFP supply.']
2722,12723,"5-Hexen-3-YN-2-OL, 2-methyl-",CC(C)(C#CC=C)O,,,,,,
2723,12724,4-Methyl-1-pentene,CC(C)CC=C,,,,,,
2724,12725,Isopropylurea,CC(C)NC(=O)N,,,,,,
2725,12726,"MERCURY, DI-sec-BUTYL-",CCC(C)[Hg]C(C)CC,,,,,,
2726,12727,"Arsine, butyldichloro-",CCCC[As](Cl)Cl,,,,,,
2727,12728,CID 12728,CC[AsH]CC,,,,,,
2728,12729,Ethyl 10-undecenoate,CCOC(=O)CCCCCCCCC=C,,,,,,
2729,12730,"Arsine, amyldichloro-",CCCCC[As](Cl)Cl,,,,,,
2730,12731,Pentylarsane,CCCCC[AsH2],,,,,,
2731,12732,1-Hexyne,CCCCC#C,,,,,,
2732,12733,2-Chloroethyl ethyl sulfide,CCSCCCl,,,,,,
2733,12734,"N,N'-Diisopropylcarbodiimide",CC(C)N=C=NC(C)C,,,,,,
2734,12735,2-Aminooctane,CCCCCCC(C)N,,,,,,
2735,12736,Dodecanedioic acid,C(CCCCCC(=O)O)CCCCC(=O)O,,,,,,
2736,12737,2-((2-Chloroethyl)thio)ethanol,C(CSCCCl)O,,,,,,
2737,12738,Distearyl thiodipropionate,CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC,,,,"['...LAURYL THIODIPROPIONATE IS ABSORBED FROM INTESTINAL TRACT OF DOG, RABBITS, AND RAT, & A LARGE PART IS ELIMINATED FROM THE BODY BY KIDNEYS, AS THIODIPROPIONIC ACID. WITH THE SAME ANIMALS /DISTEARYL THIODIPROPIONATE/...APPEAR/S/ TO BE ABSORBED WITH GREAT DIFFICULTY...ALTHOUGH SOME APPEARS IN URINE GREATER PART...IN FECES.']","['Dilauryl thiodipropionate (DLTDP), dicetyl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate, and ditridecyl thiodipropionate are dialkyl esters of their respective alcohols and thiodipropionic acid (TDPA) used in cosmetics. Ingested DLTDP was excreted in the urine as TDPA. Single-dose acute oral and parenteral studies and subchronic and chronic repeated dose oral studies did not suggest significant toxicity. Neither DLTDP nor TDPA was irritating to animal skin or eyes and they were not sensitizers. TDPA was neither a teratogen nor a reproductive toxicant. Genotoxicity studies were negative for TDPA and DLTDP. Clinical testing demonstrated some evidence of irritation but no sensitization or photosensitization. The Cosmetic Ingredient Review Expert Panel considered that the data from DLTDP reasonably may be extrapolated to the other dialkyl esters and concluded that these ingredients were safe for use in cosmetic products that are formulated to be nonirritating.']",
2738,12739,"1,7-Difluoroheptane",C(CCCF)CCCF,,,,,,
2739,12740,7-Fluoroheptanal,C(CCCF)CCC=O,,,,,,
2740,12741,2-Decanone,CCCCCCCCC(=O)C,,,,,,
2741,12742,1-Bromononane,CCCCCCCCCBr,,,,,,
2742,12743,Dipentyl ether,CCCCCOCCCCC,,,,,,
2743,12744,1-Bromoundecane,CCCCCCCCCCCBr,,,,,,
2744,12745,Octadec-10-enoic acid,CCCCCCCC=CCCCCCCCCC(=O)O,,,,,,
2745,12746,1-Methylcyclopentene,CC1=CCCC1,,,,,,
2746,12747,3-Methylisothiazole,CC1=NSC=C1,,,,,,
2747,12748,4-Methylthiazole,CC1=CSC=N1,,,,,,
2748,12749,2-Methylimidazole,CC1=NC=CN1,,,,"['... The disposition of [2-(14)C]-2-methylimidazole (2-MI) has been investigated following po administration of either 5, 50, or 150 mg/kg to male F344 rats. Excretion data indicated that absorption of 2-MI was both rapid and proportional to dose in the range studied. Approximately 90% of the total dose was eliminated in urine within 24 hr. Most of the remaining 14C was excreted in feces and as expired 14CO2. Excretion data were similar following iv administration of 5 mg/kg. Little or no enterohepatic circulation of compound occurred, since biliary excretion of 2-MI-derived 14C was negligible. Approximately 70% of the 14C excreted in urine, following all dosing, consisted of parent compound. High-performance liquid chromatography (HPLC) chromatograms for all treatment groups were similar, indicating that metabolism of 2-MI in rats was not affected by dose or route of administration.', 'The toxicokinetics of 2-methylimidazole (2-MI) were studied in male and female Fischer 344 rats after a single iv dose of 10 mg/kg or gavage dose of 25, 50, or 100 mg/kg. The 2-MI was formulated in 0.05 M phosphate-buffered saline (pH 7.4). The iv profiles could be best described by a two-compartment model with first-order elimination. The terminal elimination half-life, volume of distribution at steady state, and clearance values were 0.78 and 0.85/hr, 1.5 and 1.9 L, and 4.97 and 12.0 L/hr/kg for males and females, respectively. After a gavage dose, the plasma concentration time profiles could be best described by a one-compartment model, no lag phase, and first-order absorption and elimination. The peak 2-MI plasma concentrations increased proportionately with dose and were reached within 35 to 50 min (T(max)) for all groups. The estimated half-life value for 2-MI was about 1 hr for the iv group and the male 25-, 50-, or 100-mg/kg groups and female 25-mg/kg groups. Clearance increased for the male 100- and female 50- and 100- mg/kg groups. For a given dose group, clearance was also two to three times greater for female rats when compared to male rats. Absolute bioavailability for 2-MI was estimated to approach 97%. The results of this study indicated that 2-MI was (1) rapidly and completely absorbed, (2) quickly eliminated, (3) cleared differently for females than for males, (4) affected somewhat by dose for females, and (5) unlikely to undergo tissue accumulation following repeated exposure.']",,"['The toxicokinetics of 2-methylimidazole (2-MI) were studied in male and female Fischer 344 rats after a single iv dose of 10 mg/kg or gavage dose of 25, 50, or 100 mg/kg. The 2-MI was formulated in 0.05 M phosphate-buffered saline (pH 7.4) ... The estimated half-life value for 2-MI was about 1 hr for the iv group and the male 25-, 50-, or 100-mg/kg groups and female 25-mg/kg groups ...']"
2749,12750,"1,2,3,6-Tetrahydropyridine",C1CNCC=C1,,,,,,
2750,12751,2-Chlorocyclopentanone,C1CC(C(=O)C1)Cl,,,,,,
2751,12752,Phenyl silane,C1=CC=C(C=C1)[SiH3],,,,,,
2752,12753,Pyridine-N-oxide,C1=CC=[N+](C=C1)[O-],,,,,,
2753,12754,1-Bromo-2-chlorobenzene,C1=CC=C(C(=C1)Cl)Br,,,,,,
2754,12755,1-Methyl-2-pyridone,CN1C=CC=CC1=O,,,,,,
2755,12756,gamma-Caprolactone,CCC1CCC(=O)O1,,,,,,
2756,12757,Vinylcyclohexane,C=CC1CCCCC1,,,,,,
2757,12758,Tetrachlorocyclopentadiene,C1C(=C(C(=C1Cl)Cl)Cl)Cl,,,,,,
2758,12759,"2,3,5-Trimethylpyridine",CC1=CC(=C(N=C1)C)C,,,,,,
2759,12760,2-Methyl-5-nitroimidazole,CC1=NC=C(N1)[N+](=O)[O-],,,,,,
2760,12761,Dibromophenylarsine,C1=CC=C(C=C1)[As](Br)Br,,,,,,
2761,12762,Dichlorophenylarsine,C1=CC=C(C=C1)[As](Cl)Cl,,,,"['The purpose of the study was to identify binding sites of organic arsenic in the erythrocyte and to explain species differences in binding. Washed erythrocytes were exposed to graded concentrations of (14)C-phenyldichloroarsine (PDA) in phosphate-buffered saline containing 0.1% glucose and 0.1% bovine serum albumin. At low phenyldichloroarsine concentrations, all cells bind the arsenical rapidly (within 10 min) and quantitatively. Human, pig, hamster, guinea pig, and mouse erythrocytes approached saturation at 0.02-0.3 mumol phenyldichloroarsine/10(9) cells, depending on the species. Saturation points correlated well with each respective species erythrocyte glutathione content. In contrast, rat erythrocytes showed no sign of saturation at phenyldichloroarsine loads as high as 3.0 mumol/10(9) cells. Hemolysates of phenyldichloroarsine-treated erythrocytes were subjected to Sephadex G-75 gel filtration chromatography. (14)C from rat hemolysate was distributed between the hemoglobin and small molecular weight (glutathione-containing) fractions. In all other species, the (14)C eluted almost exclusively with the glutathione-containing fractions. In equilibrium dialysis experiments, human hemoglobin did not bind phenyldichloroarsine, whereas rat hemoglobin bound 2 phenyldichloroarsine/mol with Kd approximately 5 m. In conclusion, glutathione is the principle binding site of phenyldichloroarsine in erythrocytes. In most species,the arsenical does not bind to hemoglobin, even though it has free (titratable) sulfhydryls considerably in excess of the glutathione concentration. In rat erythrocytes, phenyldichloroarsine binds both to glutathione and to hemoglobin.']",,
2762,12763,Isopropylcyclohexane,CC(C)C1CCCCC1,,,,,,
2763,12764,4-Pyridinealdoxime,C1=CN=CC=C1C=NO,,,,,,
2764,12765,4-Methoxybenzenethiol,COC1=CC=C(C=C1)S,,,,,,
2765,12766,Cyclooctanol,C1CCCC(CCC1)O,,,,,,
2766,12767,Hexafluorocyclobutene,C1(=C(C(C1(F)F)(F)F)F)F,,,,,,
2767,12768,1-Bromo-4-methylbicyclo(2.2.2)octane,CC12CCC(CC1)(CC2)Br,,,,,,
2768,12769,"2,3,5-Trimethylphenol",CC1=CC(=C(C(=C1)O)C)C,,,,,,
2769,12770,"2,6-Dichloro-4-iodoaniline",C1=C(C=C(C(=C1Cl)N)Cl)I,,,,,,
2770,12771,"2,6-Dichloro-1,4-benzoquinone",C1=C(C(=O)C(=CC1=O)Cl)Cl,,,,,,
2771,12772,"2-Chloro-N,N-dimethylaniline",CN(C)C1=CC=CC=C1Cl,,,,,,
2772,12773,"2,4,6-Cycloheptatrien-1-one, 4-amino-2-hydroxy-",C1=CC(=CC(=O)C(=C1)O)N,,,,,,
2773,12774,5-Nitro-2-furaldehyde,C1=C(OC(=C1)[N+](=O)[O-])C=O,,,,,,
2774,12775,3-Ethyl-5-methylphenol,CCC1=CC(=CC(=C1)C)O,,,,,,
2775,12776,"2,4-Dichloro-6-ethyl-1,3,5-triazine",CCC1=NC(=NC(=N1)Cl)Cl,,,,,,
2776,12777,delta-Octalactone,CCCC1CCCC(=O)O1,,,,,,
2777,12778,Isonicotinaldehyde oxime 1-oxide,C1=CN(C=CC1=CN=O)O,,,,,,
2778,12779,Benzyl methyl disulfide,CSSCC1=CC=CC=C1,,,,,,
2779,12780,4-(2-Furyl)butan-2-one,CC(=O)CCC1=CC=CO1,,,,,,
2780,12781,"Furan, 2-[(1E)-2-nitroethenyl]-",C1=COC(=C1)C=C[N+](=O)[O-],,,,,,
2781,12782,"2-Imidazoline, 2-pentyl-",CCCCCC1=NCCN1,,,,,,
2782,12783,1-Oxaspiro[4.5]decan-2-one,C1CCC2(CC1)CCC(=O)O2,,,,,,
2783,12784,Pentamethylbenzene,CC1=CC(=C(C(=C1C)C)C)C,,,,,,
2784,12785,Trimethylhydroquinone,CC1=CC(=C(C(=C1O)C)C)O,,,,,,
2785,12786,"2,3,5,6-Tetrafluoroaniline",C1=C(C(=C(C(=C1F)F)N)F)F,,,,,,
2786,12787,"Toluene-2,3,5,6-tetrol",CC1=C(C(=CC(=C1O)O)O)O,,,,,,
2787,12788,5-Methyl-2-nitrophenol,CC1=CC(=C(C=C1)[N+](=O)[O-])O,,,,,,
2788,12789,CID 12789,C1=CN=C2C(=NC=NC2=O)N1,,,,,,
2789,12790,2-Fluoroadenine,C1=NC2=NC(=NC(=C2N1)N)F,,,,,,
2790,12791,2-Amino-2-phenylacetamide,C1=CC=C(C=C1)C(C(=O)N)N,,,,,,
2791,12792,"2-Furamide, 5-nitro-",C1=C(OC(=C1)[N+](=O)[O-])C(=O)N,,,,,,
2792,12793,Phenyl dihydrogen phosphate,C1=CC=C(C=C1)OP(=O)(O)O,,,,,"['Anaerobic phenol degradation has been shown to proceed via carboxylation of phenol to 4-hydroxybenzoate. However, in vitro the carboxylating enzyme was inactive with phenol; only phenylphosphate (phosphoric acid monophenyl ester) was readily carboxylated. We demonstrate in a denitrifying Pseudomonas strain that phenylphosphate is the first detectable product formed from phenol in whole cells and that subsequent phenylphosphate consumption parallels 4-hydroxybenzoate formation. These kinetics are consistent with phosphorylation being the first step in anaerobic phenol degradation. Various cosubstrates failed so far to act as phosphoryl donor for net phosphorylation of phenol in cell extracts. Yet, cells anaerobically grown with phenol contained an enzyme that catalyzed an isotope exchange between [U-14C]phenol and phenylphosphate. This transphosphorylation activity was anaerobically induced by phenol but was stable under aerobic conditions and required Mn2+ and polyethylene glycol. Activity was optimal at pH 5.5 and half-maximal with 0.6 mM Mn2+, 0.2 mM phenylphosphate, and 1 mM phenol. It is proposed that the phenol exchange/transphosphorylation reaction is catalyzed as partial reaction by an inducible phenol phosphorylating enzyme. The isotope exchange demands that a phosphorylated enzyme was formed in the course of the reaction, which might be similar to the phosphotransferase system of sugar transport.', 'The anaerobic metabolism of phenol in the beta-proteobacterium Thauera aromatica proceeds via para-carboxylation of phenol (biological Kolbe-Schmitt carboxylation). In the first step, phenol is converted to phenylphosphate which is then carboxylated to 4-hydroxybenzoate in the second step. Phenylphosphate formation is catalyzed by the novel enzyme phenylphosphate synthase, which was studied. Phenylphosphate synthase consists of three proteins whose genes are located adjacent to each other on the phenol operon and were overproduced in Escherichia coli. The promoter region and operon structure of the phenol gene cluster were investigated. Protein 1 (70 kDa) resembles the central part of classical phosphoenolpyruvate synthase which contains a conserved histidine residue. It catalyzes the exchange of free [(14)C]phenol and the phenol moiety of phenylphosphate but not the phosphorylation of phenol. Phosphorylation of phenol requires protein 1, MgATP, and another protein, protein 2 (40 kDa), which resembles the N-terminal part of phosphoenol pyruvate synthase. Proteins 1 and 2 catalyze the following reaction: phenol + MgATP + H(2)O-->phenylphosphate + MgAMP + orthophosphate. The phosphoryl group in phenylphosphate is derived from the beta-phosphate group of ATP. The free energy of ATP hydrolysis obviously favors the trapping of phenol (K(m), 0.04 mM), even at a low ambient substrate concentration. The reaction is stimulated severalfold by another protein, protein 3 (24 kDa), which contains two cystathionine-beta-synthase domains of unknown function but does not show significant overall similarity to known proteins. The molecular and catalytic features of phenylphosphate synthase resemble those of phosphoenolpyruvate synthase, albeit with interesting modifications.']",
2793,12794,CID 12794,CSC(=NC1=CC=CC=C1)S,,,,,,
2794,12795,"2-Chloro-4,6-diethyl-1,3,5-triazine",CCC1=NC(=NC(=N1)Cl)CC,,,,,,
2795,12796,3-Hydroxyphenylurea,C1=CC(=CC(=C1)O)NC(=O)N,,,,,,
2796,12797,trans-2-Phenoxycyclopropylamine,C1[C@@H]([C@H]1OC2=CC=CC=C2)N,,,,,,
2797,12798,Diethadione,CCC1(COC(=O)NC1=O)CC,,,,['IN RAT & RABBIT SERUM DIOXONE WAS BOUND MAINLY BY GLOBULINS & A SMALL EXTENT ALSO BY ALBUMINS.'],,
2798,12799,"1,3-Diazaspiro[4.5]decane-2,4-dione",C1CCC2(CC1)C(=O)NC(=O)N2,,,,,,
2799,12800,"1,3-Dimethyladamantane",CC12CC3CC(C1)CC(C3)(C2)C,,,,,,
2800,12801,Homophthalic anhydride,C1C2=CC=CC=C2C(=O)OC1=O,,,,,,
2801,12802,3-Acetylindole,CC(=O)C1=CNC2=CC=CC=C21,,,,,,
2802,12803,"1,2-Benzenediamine, N,N,N',N'-tetramethyl-",CN(C)C1=CC=CC=C1N(C)C,,,,,,
2803,12804,"5-Pyridin-4-yl-1,3,4-oxadiazol-2-amine",C1=CN=CC=C1C2=NN=C(O2)N,,,,,,
2804,12805,"GUANIDINE, (o-FLUOROBENZYL)-",C1=CC=C(C(=C1)CN=C(N)N)F,,,,,,
2805,12806,"6-(Trifluoromethyl)-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)N)N)C(F)(F)F,,,,,,
2806,12807,2-Nitro-3-phenyl-2-propene,CC(=CC1=CC=CC=C1)[N+](=O)[O-],,,,,,
2807,12808,CID 12808,CSC(=NC1=CC=C(C=C1)Cl)S,,,,,,
2808,12809,"2-Ethyl-4,6-dimethoxy-1,3,5-triazine",CCC1=NC(=NC(=N1)OC)OC,,,,,,
2809,12810,delta-Decalactone,CCCCCC1CCCC(=O)O1,,,,,,
2810,12811,N-2-Thiazolylacetoacetamide,CC(=O)CC(=O)NC1=NC=CS1,,,,,,
2811,12812,"Guanidine, (benzyloxy)-",C1=CC=C(C=C1)CON=C(N)N,,,,,,
2812,12813,gamma-Decalactone,CCCCCCC1CCC(=O)O1,,,,,,
2813,12814,Octachlorocyclopentene,C1(=C(C(C(C1(Cl)Cl)(Cl)Cl)(Cl)Cl)Cl)Cl,,,,,,
2814,12815,"1,2-Dichlorohexafluorocyclopentene",C1(=C(C(C(C1(F)F)(F)F)(F)F)Cl)Cl,,,,,,
2815,12816,3'-Methylcyclohexanespiro-5'-hydantoin,CN1C(=O)C2(CCCCC2)NC1=O,,,,,,
2816,12817,"8-Methyl-1,3-diazaspiro[4.5]decane-2,4-dione",CC1CCC2(CC1)C(=O)NC(=O)N2,,,,,,
2817,12818,"4-Bromo-N,N-dimethylbenzenesulfonamide",CN(C)S(=O)(=O)C1=CC=C(C=C1)Br,,,,,,
2818,12819,2-Hydroxy-1-naphthaldehyde,C1=CC=C2C(=C1)C=CC(=C2C=O)O,,,,,,
2819,12820,"1-(2,3-Dihydroxy-4-methoxyphenyl)ethanone",CC(=O)C1=C(C(=C(C=C1)OC)O)O,,,,,,
2820,12821,3-Acetylbenzenesulfonyl fluoride,CC(=O)C1=CC(=CC=C1)S(=O)(=O)F,,,,,,
2821,12822,Ethyl 3-nortricyclylcarbamate,CCOC(=O)NC1C2CC3C1C3C2,,,,,,
2822,12823,2-Cyano-3-phenylprop-2-enamide,C1=CC=C(C=C1)C=C(C#N)C(=O)N,,,,,,
2823,12824,CID 12824,CCSC(=NC1=CC=C(C=C1)Cl)S,,,,,,
2824,12825,"CARBAMIC ACID, alpha-METHYLPHENETHYL ESTER",CC(CC1=CC=CC=C1)OC(=O)N,,,,,,
2825,12826,"Mono(phenylcarbamate)-1,2-ethanediol",C1=CC=C(C=C1)NC(=O)OCCO,,,,,,
2826,12827,Phenethylsulfamide,C1=CC=C(C=C1)CCNS(=O)(=O)N,,,,,,
2827,12828,3-(5-Nitrofuran-2-yl)prop-2-enamide,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=O)N,,,,,,
2828,12829,"p-DITHIANE, OCTAFLUORO-",C1(C(SC(C(S1)(F)F)(F)F)(F)F)(F)F,,,,,,
2829,12830,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-(hydroxymethyl)-",C1CCC2(CC1)C(=O)N(C(=O)N2)CO,,,,,,
2830,12831,"1,3-Diazaspiro(4.4)nonane-2,4-dione, 3-(2-hydroxyethyl)-",C1CCC2(C1)C(=O)N(C(=O)N2)CCO,,,,,,
2831,12832,4-Chloro-3-(alpha-methylaminoethyl) indole,CC(CC1=CNC2=C1C(=CC=C2)Cl)N,,,,,,
2832,12833,5-Chloro-3-(2-aminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)Cl)N,,,,,,
2833,12834,5-Fluoro-alpha-methyltryptamine,CC(CC1=CNC2=C1C=C(C=C2)F)N,,,,,,
2834,12835,5-Methoxytryptophol,COC1=CC2=C(C=C1)NC=C2CCO,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
2835,12836,Diphenylchloroarsine,C1=CC=C(C=C1)[As](C2=CC=CC=C2)Cl,,,,,,
2836,12837,Cyclohexyl phenyl ketone,C1CCC(CC1)C(=O)C2=CC=CC=C2,,,,,,
2837,12838,"1,2,4,5-Tetracyanobenzene",C1=C(C(=CC(=C1C#N)C#N)C#N)C#N,,,,,,
2838,12839,"CARBAMIC ACID, o-CHLORO-alpha-METHYLPHENETHYL ESTER",CC(CC1=CC=CC=C1Cl)OC(=O)N,,,,,,
2839,12840,6-Nitropiperonal,C1OC2=C(O1)C=C(C(=C2)C=O)[N+](=O)[O-],,,,,,
2840,12841,2-(4-tert-Butylphenoxy)ethanol,CC(C)(C)C1=CC=C(C=C1)OCCO,,,,,,
2841,12842,3-Phenoxyphenol,C1=CC=C(C=C1)OC2=CC=CC(=C2)O,,,,,,
2842,12843,"CARBAMIC ACID, p-CHLORO-alpha-METHYLPHENETHYL ESTER",CC(CC1=CC=C(C=C1)Cl)OC(=O)N,,,,,,
2843,12844,delta-Dodecalactone,CCCCCCCC1CCCC(=O)O1,,,,,,
2844,12845,"Guanidine, (2-phenoxyethoxy)-",C1=CC=C(C=C1)OCCON=C(N)N,,,,,,
2845,12846,CID 12846,C=CCSC(=NC1=CC=C(C=C1)Cl)S,,,,,,
2846,12847,"1,3-Dimethylbarbital",CCC1(C(=O)N(C(=O)N(C1=O)C)C)CC,,,,,,
2847,12848,"1,3-Diazaspiro(4.5)decane-2,4-dione, 1-allyl-",C=CCN1C(=O)NC(=O)C12CCCCC2,,,,,,
2848,12849,"1,3-Diazaspiro(4.5)decane-2,4-dione, 1-(2-hydroxyethyl)-",C1CCC2(CC1)C(=O)NC(=O)N2CCO,,,,,,
2849,12850,"1,3-Diazaspiro(4.6)undecane-2,4-dione, 3-(hydroxymethyl)-",C1CCCC2(CC1)C(=O)N(C(=O)N2)CO,,,,,,
2850,12851,3-(2-Aminobutyl)-4-chloroindole,CCC(CC1=CNC2=C1C(=CC=C2)Cl)N,,,,,,
2851,12852,9-Cyclopentyladenine,C1CCC(C1)N2C=NC3=C(N=CN=C32)N,,,,,,
2852,12853,"3,5-Dimethyl-4-nitroso-1-phenylpyrazole",CC1=C(C(=NN1C2=CC=CC=C2)C)N=O,,,,,,
2853,12854,Biphenyl-3-carboxylic acid,C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)O,,,,,,
2854,12855,2-Phenylbenzimidazole,C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2,,,,,,
2855,12856,"Benzothiazole, 2-(2-pyridyl)-",C1=CC=C2C(=C1)N=C(S2)C3=CC=CC=N3,,,,,,
2856,12857,Methyl (p-fluoro-alpha-methylbenzyl)carbazate,CC(C1=CC=C(C=C1)F)NNC(=O)OC,,,,,,
2857,12858,CID 12858,C1=CC=C(C=C1)C(=O)C=CC2=CC=CO2,,,,,,
2858,12859,"2-Fluoro-4,6-bis(trifluoromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)F)C(F)(F)F)C(F)(F)F,,,,,,
2859,12860,"1,3,5-Triisopropylbenzene",CC(C)C1=CC(=CC(=C1)C(C)C)C(C)C,,,,,,
2860,12861,"2-Anilino-4,6-difluoro-1,3,5-triazine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)F)F,,,,,,
2861,12862,"2,4-Difluoro-6-(phenylthio)-1,3,5-triazine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)F)F,,,,,,
2862,12863,"1,3-Diazaspiro(4.6)undecane-2,4-dione, 1-acetyl-",CC(=O)N1C(=O)NC(=O)C12CCCCCC2,,,,,,
2863,12864,"1,3-Diazaspiro(4.5)decane-2,4-dione, 1-acetyl-8-methyl-",CC1CCC2(CC1)C(=O)NC(=O)N2C(=O)C,,,,,,
2864,12865,"1,3-Diazaspiro(4.6)undecane-2,4-dione, 3-allyl-",C=CCN1C(=O)C2(CCCCCC2)NC1=O,,,,,,
2865,12866,"1,3-Diazaspiro(4.6)undecane-2,4-dione, 3-(2-hydroxyethyl)-",C1CCCC2(CC1)C(=O)N(C(=O)N2)CCO,,,,,,
2866,12867,"2,6-Di-tert-butyl-P-benzoquinone",CC(C)(C)C1=CC(=O)C=C(C1=O)C(C)(C)C,,,,,"['THE URINARY & FECAL EXCRETION OF 3 NEW METABOLITES OF BUTYLATED HYDROXYTOLUENE (BHT, 3,5-DI-TERT-BUTYL-4-HYDROXYTOLUENE) WERE REVEALED BY GAS CHROMATOGRAPHY AFTER IP ADMIN TO MALE WISTAR RATS. THE STRUCTURES OF THESE METABOLITES, 2,6-DI-TERT-BUTYL-P-BENZOQUINONE, 2,6-DI-TERT-BUTYLHYDROQUINONE, & 2,6-DI-TERT-BUTYL-4-((METHYLTHIO)METHYL)PHENOL WERE IDENTIFIED BY COMPARISON OF GAS CHROMATOGRAPHIC & MASS SPECTRAL DATA WITH THOSE OF AUTHENTIC SAMPLES.', 'Quinones (ie, 6,12-dione) have been shown to undergo oxidation-reduction cycles involving quinone, hydroquinone, and molecular oxygen, resulting in the formation of oxygen radicals and semiquinone radicals. /Quinones/']",
2867,12868,"2,3,5,6-Tetrachloroterephthaloyl dichloride",C1(=C(C(=C(C(=C1Cl)Cl)C(=O)Cl)Cl)Cl)C(=O)Cl,,,,,,
2868,12869,"Nicotinonitrile, 2-chloro-4-(methoxymethyl)-6-methyl-5-nitro-",CC1=C(C(=C(C(=N1)Cl)C#N)COC)[N+](=O)[O-],,,,,,
2869,12870,2-Amino-5-chlorobenzophenone,C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)Cl)N,,,,,,
2870,12871,"1,3,5-Triazine-2,4-diamine, N,N'-diethyl-6-(trifluoromethyl)-",CCNC1=NC(=NC(=N1)C(F)(F)F)NCC,,,,,,
2871,12872,3-(5-Nitrofuran-2-yl)prop-2-enal semicarbazone,C1=C(OC(=C1)[N+](=O)[O-])C=CC=NNC(=O)N,,,,,,
2872,12873,3'-Methyl-4-aminoazobenzene,CC1=CC(=CC=C1)N=NC2=CC=C(C=C2)N,,,,,,
2873,12874,4-(p-Tolylazo)aniline,CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,,,,,,
2874,12875,"4,4'-Dithiodianiline",C1=CC(=CC=C1N)SSC2=CC=C(C=C2)N,,,,,,
2875,12876,Diphenyliodonium nitrate,C1=CC=C(C=C1)[I+]C2=CC=CC=C2.[N+](=O)([O-])[O-],,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
2876,12877,Diphenyliodonium,C1=CC=C(C=C1)[I+]C2=CC=CC=C2,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
2877,12878,"GUANIDINE, ((p-METHYLBENZYL)OXY)-, NITRATE",CC1=CC=C(C=C1)CON=C(N)N.[N+](=O)(O)[O-],,,,,,
2878,12879,2-[(4-Methylphenyl)methoxy]guanidine,CC1=CC=C(C=C1)CON=C(N)N,,,,,,
2879,12880,Dimethylallobarbital,CN1C(=O)C(C(=O)N(C1=O)C)(CC=C)CC=C,,,,,,
2880,12881,"3'-(2,3-Epoxypropyl)-1'-methylcyclohexanespiro-5'-hydantoin",CN1C(=O)N(C(=O)C12CCCCC2)CC3CO3,,,,,,
2881,12882,CID 12882,CC[O-].C1CCC2(CC1)C(=O)N(C(=O)[NH2+]2)CO,,,,,,
2882,12883,CID 12883,CC=C(C)C(=O)O[C@H]1CCN2C1C(=CC2)CO,,,,,,
2883,12884,1-Phenylisatin,C1=CC=C(C=C1)N2C3=CC=CC=C3C(=O)C2=O,,,,,,
2884,12885,"Fluoren-2-amine, 1,3,7-tribromo-",C1C2=C(C=CC(=C2)Br)C3=CC(=C(C(=C31)Br)N)Br,,,,,,
2885,12886,3-Fluoro-4-acetylaminobiphenyl,CC(=O)NC1=C(C=C(C=C1)C2=CC=CC=C2)F,,,,,,
2886,12887,4'-(m-Fluorophenyl)acetanilide,CC(=O)NC1=CC=C(C=C1)C2=CC(=CC=C2)F,,,,,,
2887,12888,"2,5-Diphenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=NN=C(O2)C3=CC=CC=C3,,,,,,
2888,12889,"3,5-Bis(trifluoromethyl)benzoic acid",C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C(=O)O,,,,,,
2889,12890,"1,3-Propanedione, 2-bromo-1,3-diphenyl-",C1=CC=C(C=C1)C(=O)C(C(=O)C2=CC=CC=C2)Br,,,,,,
2890,12891,((p-Phenylbenzyl)oxy)guanidine,C1=CC=C(C=C1)C2=CC=C(C=C2)CON=C(N)N,,,,,,
2891,12892,Dimorpholinethiuram disulfide,C1COCCN1C(=S)SSC(=S)N2CCOCC2,,,,,,
2892,12893,"Acetic acid, diphenoxy-",C1=CC=C(C=C1)OC(C(=O)O)OC2=CC=CC=C2,,,,,,
2893,12894,Sulfamoxole,CC1=C(OC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,['For the treatment of bacterial infection.'],"['Sulfamoxole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.']",['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
2894,12895,CID 12895,C1=CC=C(C=C1)CSC(=NC2=CC=C(C=C2)Cl)S,,,,,,
2895,12896,Disperse orange 3,C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
2896,12897,Dimethylphenobarbital,CCC1(C(=O)N(C(=O)N(C1=O)C)C)C2=CC=CC=C2,,,,,,
2897,12898,Tolylfluanid,CC1=CC=C(C=C1)N(SC(F)(Cl)Cl)S(=O)(=O)N(C)C,,,,"['A lactating goat was given 14C-ring-labelled tolylfluanid at a dose of 10 mg/kg bw per day by gavage for 3 days. Blood was taken 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 24 hr after the first dose. Milk was sampled before dosing and 8 hr after dosing. Urine and feces were collected at 24-hr intervals. The goat was killed 50 hr after the first dose (2 hr after the last dose), and the liver, kidney, muscle and fat were removed, weighed and sampled for radioactivity. The plasma concentration peaked at 2.2 ug/mL 50 min after dosing. By 50 hr after the first dose, the highest concentrations were seen in kidney (37 mg/kg), followed by liver (20 mg/kg). Low concentrations were found in fat (1.5 mg/kg) and muscle (0.53 mg/kg). The main route of excretion was urine (49% of the administered dose). Fecal excretion accounted for 10% of the administered dose, and only 0.24% was found in milk. ... Approximately 62% of the administered dose was recovered', 'Six Wistar (Bor:WISW SPF Cpb) rats were dosed orally and one was dosed by intravenous injection with ring-labelled tolylfluanid at 4 mg per rat, corresponding to a dose of 20 mg/kg bw. The rat treated intravenously was killed 5 min after dosing, and those treated orally were killed 2, 4, 8, 24, 48 and 72 hr after dosing. After oral administration, the radioactivity was absorbed relatively rapidly, as radioactivity was detected in all body tissues except compact bone 2 hr after treatment. The kidney, liver and intestinal tract had markedly higher concentrations than other tissues. After intravenous injection, the pattern was quite different, with high concentrations in all tissues, including fat, probably due to the presence of unchanged parent compound, which is relatively lipophilic. After oral administration, the distribution pattern was that of a hydrophilic substance, with no evidence of storage in a particular organ or tissue. ...The presence of high concentrations in the renal medulla and renal papillary area 2 hr after oral dosing indicated rapid, extensive renal excretion. Rapid fecal excretion also appeared to occur. Over the 24 hr after dosing, the concentrations in tissues and organs decreased rapidly, while depletion was much slower during the subsequent 48 hr. A slightly increased concentration of radioactivity in the infraorbital gland may have indicated some elimination in lachrymal fluid.', 'Groups of BOR: WISW (SPF Cpb) Wistar rats were given phenyl ring-labelled tolylfluanid at 2 mg/kg bw or at 1 mg/kg bw in combination with unlabelled tolylfluanid at 99 mg/kg bw by gavage. Another group of rats received unlabelled tolylfluanid at 2 mg/kg bw per day for 14 days and then a dose of 2 mg/kg bw of radiolabelled tolylfluanid by gavage. The plasma concentration peaked after about 1 h. By 24 h, the plasma 14C concentration had decreased by about 10-fold after 100 mg/kg bw and by about 100-fold after 2 mg/kg bw. The distribution volume in steady state was more than 14 times the body volume, indicating that 14C had been distributed rapidly into peripheral compartments. The short mean residence time in the central compartment of 14 hr indicated rapid redistribution into plasma before excretion. The radioactivity was rapidly excreted, 87-100% of the administered dose being excreted within 48 hr. The main route of excretion was the urine, particularly in females, which excreted < 85% of the administered dose by this route. The tissue concentrations of 14C at 48 hr were low after 100 mg/kg bw. Sex differences were seen in some tissues, with higher concentrations in erythrocytes, kidney, brain and skin in females and higher concentrations in thyroid in males.', 'A dose of 2 or 20 mg/kg bw of 14C-ring-labelled tolylfluanid was given orally to male and female Wistar rats. A further group of rats of each sex was pretreated for 14 days with non-radioactive tolylfluanid at a dose of 2 mg/kg bw before receiving radioactive compound. Tolylfluanid was quickly and almost completely absorbed (> 95%); the peak plasma concentration was reached within 1.5 hr. Within 48 hr, 75-80% of the radioactivity was excreted in urine, 14-25% in feces and 0.06% in expired air. In animals with biliary fistula, biliary secretion accounted for about 14% of the total elimination. Total residual radioactivity represented 0.07-0.2% of the total administered dose. Higher concentrations of radioactivity were found in liver and kidney (three to seven times the mean body concentration), and lower concentrations were found in perirenal fat, brain, gonads and thyroid (three to nine times less than the mean body concentration). Renal clearance was 3.1-4 mL/min, which corresponds to normal renal plasma flow in rats. No effect of dose was observed on pharmacokinetics.', 'Single doses of tolylfluanid labelled with 14C at the fluoridichloromethylsulfenyl group were administered orally to rats. At doses of 0.1-20 mg/kg bw, 50-60% of the administered activity was eliminated in urine and 20-30% in feces within 48 hr. ... In rats with biliary fistula given 0.5 mg/kg bw by intraduodenal administration, about 6% of the total radioactivity was eliminated in bile. When tolylfluanid was administered orally at a dose of 5 mg/kg bw, however, 16% of the activity was exhaled within 48 hr, and the maximal plasma concentration (about 1.5 ppm) was attained after 2 hr. ... Of the administered activity, 6% was retained (excluding gastrointestinal tract) for 8 hr after administration, 2% for 48 hr, 1% for 6 days and 0.5% for 12 days. The highest concentrations were found in the thyroid gland, with 5 ppm 1 day after administration and 1 ppm after 10 days. Whole-body autoradiography after intravenous injection of 10 mg/kg bw confirmed this observation.']","['In a metabolism study in rats, tolylfluanid was administered in single doses of 2 or 100 mg/kg bw, was readily absorbed and rapidly hydrolyzed within 48 hours. Absorption and excretion were independent of dose, sex and pretreatment. About 86-100% of the dose was recovered in 48 hours, with 56-80% of the dose being excreted in urine, 12-36% in the feces, and /about/ 0.48% found in the carcass. Urinary metabolite common to both sexes were dimethylaminosulfonylamino-benzoic acid (RNH 0166; 46-78%), and 4-methylamino-benzoic acid (RNH 0416; 3-6%). Fecal compounds identified were unchanged tolylfluanid (1-19%), dimethylaminosulfotoluidid (DMST; 5-8%), RNH 0166 (3-12%) and RNH 0416 (<1%). The data indicate that tolylfluanid hydrolyzed to DMST, which is then transformed to the major metabolite RNH 0166, which can be further demethylated to the minor metabolite, RNH 0416.', 'Series of metabolism studies showed that metabolic profile /is/ dependent upon label position. With [dichlorofluoromethyl-14C]-tolylfluanid labeling major urinary metabolite was thiazolidine-2-thione-4carbonic acid resulting from cleavage of the side chain and accounted for 73-74% and 50-63%, respectively by iv and oral routes. Benzene ring label resulted in metabolite 4-(dimethylamino-sulfonylamino) benzoic acid which accounted for 90% of urinary metabolic activity and 70% of fecal radioactivity.', '[fluorodichloromethyl-14C]Tolylfluanid was administered orally or intravenously to rats at a single dose of 5 or 10 mg/kg bw. The main metabolite in the urine of treated rats was thiazolidine-2-thioxo-4-carbonic acid, which accounted for 74% of the radioactivity in urine 8 hr after intravenous administration and for 50-63% after oral administration. Tolylfluanid was not detected in urine.', 'After administration of a single oral dose of 20 mg/kg bw of [14C-benzene ring]tolylfluanid to male Wistar rats, 90% of the radioactivity in urine and 70% of that in feces was due to one metabolite, 4-dimethylaminosulfonylaminobenzoic acid. A minor metabolite (6% of total radioactivity) was not characterized.', 'For more Metabolism/Metabolites (Complete) data for TOLYLFLUANID (7 total), please visit the HSDB record page.']","['The plasma concentration fell in a biphasic manner /in goats after 14C-ring-labelled tolylfluanid at a dose of 10 mg/kg bw per day by gavage for 3 days/, with a half-life of 1.6 hr during the first 6 hr after dosing and a half-life of 9.1 hr in the terminal phase. The mean residence time was 7.3 hr.', '...Urinary elimination /of tolylfluanid/ took place with a half-life of 2-3 hr during the first 24 hr and then more slowly, with a half-life of about 40 hr from the third day.']"
2898,12899,"Indole-2-carboxylic acid, 7-(bis(2-chloroethyl)amino)-",C1=CC2=C(C(=C1)N(CCCl)CCCl)NC(=C2)C(=O)O,,,,,,
2899,12900,"2,4-Dinitro-6-phenylphenol",C1=CC=C(C=C1)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
2900,12901,Phosmet,COP(=S)(OC)SCN1C(=O)C2=CC=CC=C2C1=O,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['After dermal application, imidan was moderately absorbed by skin of steer. Approx 9.6% ... was recovered in excreta within 7 days and less than 2% from blood. Principal route of elimination was via urine in which almost 8% of ... dose was recovered within 7 days. ... in rats, 79% of admin dose was eliminated via urine and 19% via feces. About 2% remained in tissues.', 'Excretion of oral dose of (14C)-Imidan ... was nearly complete within 48 hr in rats. In 72 hr, 79% was excreted in urine, 16% in feces, and 3% was retained, maximally in blood and kidneys.']","['After dermal application, Imidan was moderately absorbed by skin of steer. ... Paper chromatography and electrophoresis indicated that primary metabolic products were phthalamic & phthalic acids. ... after oral admin of labeled', '... Imidan to rats, the aq fraction remaining after extraction of urine with benzene contained 98% of the labeled Imidan metabolites excreted in urine. Using paper chromatography, the following metabolites were found: phthalic acid and a derivative, phthalamic acid, and about 8 other unidentified cmpd. In benzene fraction, imidoxon, n-hydroxymethylphthalimide and phthalimide were observed. ... in rat feces, imidoxon and unchanged Imidan were found.', 'In plants & mammals the initial step in metabolism appears to proceed via cleavage of the sulfur-methylene or nitrogen-methylene bond. Cleavage at sulfur-methylene bond is supported by tentative identification of n-hydroxymethyl-phthalimide ... from cotton plants.', 'Excretion-retention studies of Imidan ... in rats ... in all cases major metabolite was phthalamic acid, prodn of which involved amidase cleavage & removal of phosphorus-containing n-substituent group of Imidan.', 'For more Metabolism/Metabolites (Complete) data for PHOSMET (6 total), please visit the HSDB record page.']",
2901,12902,"2,4,6-Tri-tert-butylphenol",CC(C)(C)C1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,,,,,,
2902,12903,"BENZOIC ACID, p-FLUORO-, BENZOYLHYDRAZIDE",C1=CC=C(C=C1)C(=O)NNC(=O)C2=CC=C(C=C2)F,,,,,,
2903,12904,"Indole-2-carboxylic acid, 5-(bis(2-chloroethyl)amino)-",C1=CC2=C(C=C1N(CCCl)CCCl)C=C(N2)C(=O)O,,,,,,
2904,12905,CID 12905,C1=CC(=CC=C1CSC(=NC2=CC=C(C=C2)Cl)S)Cl,,,,,,
2905,12906,"Guanidine, (diphenylmethoxy)-, nitrate",C1=CC=C(C=C1)C(C2=CC=CC=C2)ON=C(N)N.[N+](=O)(O)[O-],,,,,,
2906,12907,2-Benzhydryloxyguanidine,C1=CC=C(C=C1)C(C2=CC=CC=C2)ON=C(N)N,,,,,,
2907,12908,"N-[(1R)-1-(4-acetylphenyl)-1,3-dihydroxypropan-2-yl]-2,2-dichloroacetamide",CC(=O)C1=CC=C(C=C1)[C@H](C(CO)NC(=O)C(Cl)Cl)O,,,,,,
2908,12909,"2-Methylsulfanyl-4,6-diphenyl-1,3,5-triazine",CSC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2909,12910,"Butyranilide, 4-(diethylamino)-5'-ethyl-2'-fluoro-",CCC1=CC(=C(C=C1)F)NC(=O)CCCN(CC)CC,,,,,,
2910,12911,2'-Chloro-3-(diethylamino)-5'-ethylbutyranilide,CCC1=CC(=C(C=C1)Cl)NC(=O)CC(C)N(CC)CC,,,,,,
2911,12912,"Benzoic acid, 2-(4-nitroso-7-oxo-1,3,5-cycloheptatrien-1-YL)hydrazide",C1=CC=C(C=C1)C(=O)NNC2=CC=C(C=CC2=O)N=O,,,,,,
2912,12913,"Isonicotinic acid, 2-(4-nitroso-7-oxo-1,3,5-cycloheptatrien-1-YL)hydrazide",C1=CC(=O)C(=CC=C1N=O)NNC(=O)C2=CC=NC=C2,,,,,,
2913,12914,Ethyl 4-benzamidobenzoate,CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2,,,,,,
2914,12915,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-allyl-1-phenyl-",C=CCN1C(=O)C2(CCCCC2)N(C1=O)C3=CC=CC=C3,,,,,,
2915,12916,CID 12916,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)NC(=O)C)I.[Na+],,,,,,
2916,12917,"2,5-Cyclohexadiene-delta(sup1,alpha)-acetonitrile, 2-chloro-alpha-(p-methoxyphenyl)-3-methyl-4-oxo-, oxime",CC1=C(C(=C(C#N)C2=CC=C(C=C2)OC)C=CC1=NO)Cl,,,,,,
2917,12918,"4-(4-Hydroxy-3,5-xylyloxy)-3,5-diiodophenethyl alcohol",CC1=CC(=CC(=C1O)C)OC2=C(C=C(C=C2I)CCO)I,,,,,,
2918,12919,CID 12919,C1=CC(=O)C(=CC=C1N=O)N=NC(=C2C=CN(C=C2)O)O,,,,,,
2919,12920,"2-Methyl-4,6-diphenoxy-1,3,5-triazine",CC1=NC(=NC(=N1)OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
2920,12921,Sterculic acid,CCCCCCCCC1=C(C1)CCCCCCCC(=O)O,,,,"['STERCULIC ACID IS A NATURALLY OCCURRING CYCLOPROPENOID FATTY ACID. THE DISTRIBUTION OF RADIOACTIVITY FROM STERCULIC ACID, LABELED ON 9,10-METHYLENE C OF THE CYCLOPROPENE RING, WAS INVESTIGATED IN TROUT, S GAIRDNERI. OF THE ADMIN DOSE, 50% WAS EXCRETED IN FECES & URINE BY 168 HR, BUT LESS THAN 1% OF THE DOSE WAS EXPIRED AS CO2 DURING THE SAME TIME PERIOD. INCORPORATION OF RADIOACTIVITY INTO MOST ORGANS PEAKED AT 119 HR & THE MAJORITY OF THE LABEL IN THE LIVER WAS IN THE FATTY ACID PORTION OF THE LIPID FRACTION. RAINBOW TROUT READILY ABSORB, TRANSPORT & INCORPORATE STERCULIC ACID INTO TISSUE LIPID, INCL MEMBRANE LIPID, BUT CANNOT OXIDIZE THE METHYLENE C OF THE CYCLOPROPENOID TO CO2.']",,
2921,12922,"1,3-Dicyclohexyl-5-methylbarbituric acid",CC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2922,12923,"Benzoic acid, 3-acetamido-5-acetamidomethyl-2,4,6-triiodo-, methyl ester",CC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)OC)I,,,,,,
2923,12924,"3,4,5-trimethoxy-N-(2-methylphenyl)benzamide",CC1=CC=CC=C1NC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
2924,12925,"2-Ethyl-4,6-diphenoxy-1,3,5-triazine",CCC1=NC(=NC(=N1)OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
2925,12926,"1-AZIRIDINEPROPIONAMIDE, N,N'-HEXAMETHYLENEBIS-, (crude product)",C1CN1CCC(=O)NCCCCCCNC(=O)CCN2CC2,,,,,,
2926,12927,((alpha-Methylbenzyl)oxy)guanidine cyclohexanesulfamate,CC(C1=CC=CC=C1)ON=C(N)N.C1CCC(CC1)NS(=O)(=O)O,,,,,,
2927,12928,2-(1-Phenylethoxy)guanidine,CC(C1=CC=CC=C1)ON=C(N)N,,,,,,
2928,12929,((alpha-Methylphenethyl)oxy)guanidine cyclohexanesulfamate,CC(CC1=CC=CC=C1)ON=C(N)N.C1CCC(CC1)NS(=O)(=O)O,,,,,,
2929,12930,2-(1-Phenylpropan-2-yloxy)guanidine,CC(CC1=CC=CC=C1)ON=C(N)N,,,,,,
2930,12931,"1,3-DIAZASPIRO(4.5)DECANE-2,4-DIONE, 3-(2-HYDROXYETHYL)-1-(p-METHOXYPHENYL)-",COC1=CC=C(C=C1)N2C(=O)N(C(=O)C23CCCCC3)CCO,,,,,,
2931,12932,Bensulide,CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)C1=CC=CC=C1,,,,"['Selective herbicide, adsorbed on the root surfaces, and a small amount is absorbed by the roots. Translocation of bensulide to the leaves does not occur, but metabolites are translocated.', 'In a metabolism study, bensulide technical, labelled with C in the 14 phenyl ring (> 96.4% radiopurity; 925 MBq/mMole) was dissolved in corn oil (vehicle) and administered to Sprague-Dawley rats (5/sex/group; 7-8 weeks of age; 185-235 g body weight) following 3 treatment regimes. Animals in Group I received a single oral dose of radioactive bensulide at 1 mg/kg bw. Animals in Group II received 14 consecutive doses (1 mg/kg/day) of non-radioactive bensulide technical (99% a.i.) in corn oil, followed by a 1 mg/kg dose of radiolabelled bensulide technical in corn oil on day 15. Group III animals received a single oral dose of radiolabelled bensulide technical at 100 mg/kg bw. An additional group of animals (Group IV; 3/sex/group) were given a single oral dose of radiolabelled bensulide 18 technical at 1 mg/kg bw and were subseqently used for autoradiological radiolabelled carbon dioxide release determinations. ... In Group I, total urinary excretion of 7 days after admin of radioactive bensulide technical accounted for 70 and 75% of the administered dose in males and females, respectively. ... In Group III, total urinary excretion accounted for 75 and 87% of the administered dose in males and females, respectively. ... For Group II (prior 14-day admin of non-radioactive bensulide technical before radioactive bensulide admin, both at 1 mg/kg), total urinary excretion of radioactivity over 7 days past dosing with radioactive bensulide accounted for 79 and 88% of the administered dose in males and females, respectively. For Group IV, urinary excretion of 14-C radioactivity derived from bensulide technical over a 48-hr period accounted for 67% for one male and 86% in one male. For Group I, total fecal excretion of radioactivity derived from 14C-bensulide technical over 7 days post-dosing accounted for 22 and 20% of the administered dose in males and females, respectively. ... For Group III, total fecal elim over 7 days post-dosing of bensulide-derived radioactivity accounted for 22 and 11% of the administered dose for males and females, respectively. ... In Group II animals, total fecal excretion of radioactivity over 7 days post-dosing accounted for 14 and 8% of the administered dose for males and females, respectively. ... In Group IV, fecal excretion of radioactivity over 48 hrs post-dosing accounted for 12% of the administered dose in one male and 7% in one female. ... The radioactivity found in the carcasses and in other tissues accounted for 0.3% to 2.5% and <0.1% of the administered dose, respectively.']",['Unchanged ring-labelled (14)-C bensulide could be detected in roots of lettuce plants after root application ... . A large part of the radioactive material in the leaves was evolved as radioactive carbon dioxide and some was present as labelled amino acids.'],
2932,12933,"6-chloro-3-(cyclopentylmethyl)-7-(dihydroxyamino)sulfanyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine",C1CCC(C1)CC2NC3=CC(=C(C=C3S(=O)(=O)N2)SN(O)O)Cl,,,,,,
2933,12934,CID 12934,C1=CC(=CC=C1N=C(S)SC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
2934,12935,"Barbituric acid, 1,3-dicyclohexyl-5-propyl-",CCCC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2935,12936,"Barbituric acid, 5-allyl-1,3-dicyclohexyl-",C=CCC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2936,12937,"Barbituric acid, 5-allyl-1,3-diphenyl-",C=CCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2937,12938,Benzobarbital,CCC1(C(=O)NC(=O)N(C1=O)C(=O)C2=CC=CC=C2)C3=CC=CC=C3,,,"['Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
2938,12939,"5-sec-Butyl-1,3-dicyclohexylbarbituric acid",CCC(C)C1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2939,12940,"Barbituric acid, 1,3-dicyclohexyl-5-isobutyl-",CC(C)CC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2940,12941,"Barbituric acid, 5-butyl-1,3-dicyclohexyl-",CCCCC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2941,12942,"Barbituric acid, 5-butyl-1,3-diphenyl-",CCCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2942,12943,"7-[(1R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid",CCCCC[C@@H](C=CC1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O,,,,,,
2943,12944,"1,3-Dicyclohexyl-5-(1-methylbutyl)barbituric acid",CCCC(C)C1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
2944,12945,Oradon [WHO-DD],CN1C2=C(C(=O)N(C1=O)C)NC=N2.COC(CN1C(=O)CCC1=O)C[Hg].O,,,,,,
2945,12946,"[3-(2,5-Dioxopyrrolidin-1-yl)-2-methoxypropyl]mercury",COC(CN1C(=O)CCC1=O)C[Hg],,,,,,
2946,12947,Hydroxychloroquine sulfate,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)']",,,
2947,12948,"(S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid",COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3CC4CCN3C[C@@H]4C=C)O.OS(=O)(=O)O,,,,,,
2948,12949,"Barbituric acid, 1,3-dicyclohexyl-5-phenyl-",C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C4=CC=CC=C4,,,,,,
2949,12950,CID 12950,C[NH+](C)CCC=C1C2=CC=CC=C2CS(=O)C3=CC=CC=C31.C(CC(=O)[O-])C(=O)O,,,,,,
2950,12951,"N,N-dimethyl-3-(5-oxo-6H-benzo[c][1]benzothiepin-11-ylidene)propan-1-amine",CN(C)CCC=C1C2=CC=CC=C2CS(=O)C3=CC=CC=C31,,,,,,
2951,12952,(5-Ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol;2-hydroxypropanoic acid,CC(C(=O)O)O.COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,,,,,,
2952,12953,"3,5,12,14-Tetrahydroxy-19-oxocard-20(22)-enolide",C[C@@]12[C@H](CC[C@@]1(C3CC[C@@]4(C[C@H](CC[C@@]4(C3C[C@H]2O)C=O)O)O)O)C5=CC(=O)OC5,,,,,,
2953,12954,CID 12954,C[C@@]1(C2C[C@H]3[C@@H](C(=O)C(=C(NCN4CCCC4)O)C(=O)[C@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O,,,,,,
2954,12955,Dimethyltin dichloride,C[Sn](C)(Cl)Cl,,,,,,
2955,12956,"1-Chloro-2,2-dimethylpropane",CC(C)(C)CCl,,,,,,
2956,12957,Pivalamide,CC(C)(C)C(=O)N,,,,,,
2957,12958,Dimethyl methylphosphonate,COP(=O)(C)OC,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']","['Dimethyl methylphosphonate (DMMP) is a widely used chemical. Diethyl ethylphosphonate (DEEP) has been proposed as a replacement for DMMP in several applications. ... To further characterize the toxicology of DMMP and DEEP, ... the biotransformation of these compounds and their ability to induce alpha(2u)-globulin accumulation in kidney /were investigated/. Biotransformation of both DMMP and DEEP were studied in male and female rats after single oral doses of 50 and 100 mg/kg. 31P-NMR and GC/MS showed that unchanged DMMP was excreted with urine; methyl phosphonate was identified as the only metabolite in urine. Unchanged DEEP was also excreted with urine; in addition, ethyl ethylphosphonate and ethylphosphonate were urinary metabolites. The majority of the applied dose of both compounds was recovered in urine within 24 hr indicating rapid absorption and excretion. No sex-differences in rates of formation or excretion of metabolites were seen.']","['Dimethyl methylphosphonate (DMMP) is a widely used chemical. Diethyl ethylphosphonate (DEEP) has been proposed as a replacement for DMMP in several applications. ... To further characterize the toxicology of DMMP and DEEP, ... the biotransformation of these compounds and their ability to induce alpha(2u)-globulin accumulation in kidney /were investigated/. Biotransformation of both DMMP and DEEP were studied in male and female rats after single oral doses of 50 and 100 mg/kg. 31P-NMR and GC/MS showed that unchanged DMMP was excreted with urine; methyl phosphonate was identified as the only metabolite in urine. Unchanged DEEP was also excreted with urine; in addition, ethyl ethylphosphonate and ethylphosphonate were urinary metabolites. The majority of the applied dose of both compounds was recovered in urine within 24 hr indicating rapid absorption and excretion. No sex-differences in rates of formation or excretion of metabolites were seen.']",
2958,12959,"O,O-Dimethyl dithiophosphate",COP(=S)(OC)S,,,,['IN THE UNITED STATES ON A NATIONAL BASIS FOR FISCAL YEAR 1970-74 ANALYSIS OF 267 URINE SAMPLES FROM GENERAL POPULATION REVEALED THE PRESENCE OF DIALKYL PHOSPHATE.'],"['O,O-DIMETHYL DITHIOPHOSPHATE IS PRODUCED AS METABOLITE FROM MANY ORGANOPHOSPHATE INSECTICIDES IN...PLANTS /&/ ANIMALS... EXAMPLES OF SUCH ORGANOPHOSPHATES ARE PHENTHOATE, MALATHION, DIMETHOATE, & SUPRACIDE.']",
2959,12960,Hexaethyl tetraphosphate,CCOP(=O)(OCC)OP(=O)(OCC)OP(=O)(OCC)OP(=O)(OCC)OCC,,,,"['/They/ ... are rapidly absorbed through mucous membrane of digestive system, respiratory system & the skin, and conveyed by the blood to various body tissues. ...The main route of elimination ... /is/ the kidneys. /Organophosphorus pesticides/', 'It is absorbed rapidly through the skin of warm blooded animals. ...', 'Toxicants can be absorbed by inhalation, ingestion, and skin penetration. ... All undergo hydrolytic degradation in liver and other tissues, usually within hr of absorption. Degradation products are of low toxicity, and are excreted in urine and feces. /Organophosphate cholinesterase-inhibiting pesticides/']",,
2960,12961,2-Mercaptoacetamide,C(C(=O)N)S,,,,,,
2961,12962,N-Methyl-N-formylhydrazine,CN(C=O)N,,,,,"['N-METHYL-N-FORMYLHYDRAZINE (MFH) IS FORMED BY HYDROLYSIS FROM GYROMITRIN, THE MAIN TOXIN OF THE EDIBLE MUSHROOM GYROMITRA ESCULENTA. CYTOCHROME P-450 MEDIATES THE OXIDN OF MFH TO HYDROXYLAMINE DERIV & FURTHER TO NITROSAMIDE. THIS NITROSAMIDE FORMATION MAY BE THE REASON FOR THE KNOWN HEPATOCARCINOGENICITY OF METHYLFORMYLHYDRAZINE.', 'AFTER ORAL APPLICATION OF THE EDIBLE MUSHROOM POISON GYROMITRIN A TIME AND DOSE DEPENDENT DECR OF CYTOCHROME P-450 WAS FOUND IN RAT LIVER MICROSOMES. THE MAXIMAL DECR TO ABOUT 50-60% OF THE CONTROL (AFTER 200 MG/KG, 80% OF LD50) WAS OBSERVED 8-12 HR AFTER APPLICATION, A NORMALIZATION OCCURRED AFTER 48 HR. COMPARABLE RESULTS WERE OBTAINED AFTER APPLICATION OF N-METHYL-N-FORMYLHYDRAZINE WHICH IS FORMED FROM GYROMITRIN RAPIDLY BY HYDROLYSIS.', 'MONOMETHYLHYDRAZINE, BUT NOT N-METHYL-N-FORMYLHYDRAZINE (MFH), A MUSHROOM POISON, CAN BE OXIDIZED BY THE WEAK OXIDANT 2,6-DICHLOROPHENOLINDOPHENOL. MFH MUST BE ACTIVATED IN VIVO INTO TOXIC METABOLITES WHICH ARE ULTIMATELY RESPONSIBLE FOR THE KNOWN HIGH CARCINOGENICITY OF MFH.', 'GYROMITRIN IS RAPIDLY HYDROLYSED, NON-ENZYMATICALLY, BOTH IN VITRO AND IN VIVO, TO ACETALDEHYDE AND N-METHYL-N-FORMYLHYDRAZINE; THE LATTER IS HYDROLYSED UNDER PHYSIOLOGICAL CONDITIONS AT A MUCH SLOWER RATE TO FORM N-METHYLHYDRAZINE AND FORMIC ACID. AT 37 C, 1 MM GYROMITRIN WAS HYDROLYSED TO N-METHYLHYDRAZINE, WITH A HALF-LIFE OF 122 MIN AT PH 2; WHEREAS AT PH 3 ONLY 9% APPEARED AS N-METHYLHYDRAZINE AFTER 72 HR.', 'N-METHYLHYDRAZINE WAS...FOUND IN THE MOUSE STOMACH AFTER ORAL ADMIN OF 4 MG/ANIMAL GYROMITRIN. GYROMITRIN, N-METHYLHYDRAZINE AND N-METHYL-N-FORMYLHYDRAZINE WERE FOUND IN THE PERITONEAL FLUID OF MICE 3 HR AFTER ORAL ADMIN OF 9 MG GYROMITRIN.']",
2962,12963,"1-Bromo-1-chloro-2,2-difluoroethene",C(=C(Cl)Br)(F)F,,,,,,
2963,12964,3-Methyl-4-penten-2-one,CC(C=C)C(=O)C,,,,,,
2964,12965,"N,N-Dimethylpropionamide",CCC(=O)N(C)C,,,,,,
2965,12966,Diethyl isopropylmalonate,CCOC(=O)C(C(C)C)C(=O)OCC,,,,,,
2966,12967,1-Ethyl-1-nitrosourea,CCN(C(=O)N)N=O,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']","['NEU was rapidly lost from the blood after its i.v. injection, with a half-life of 5-6 minutes. The high chemical reactivity of NEU renders it unlikely that enzymic catalysis is involved in its decomposition.', 'The tissue-disposition and fate of N-[(14)C]ethyl-N-nitrosourea has been studied in mice. A large part of the injected N-[(14)C]ethyl-N-nitrosourea radioactivity was found to be exhaled as (14)CO2. Whole-body autoradiography showed evenly distributed radioactivity in most tissues shortly after the administration of N-[(14)C]ethyl-N-nitrosourea which probably is due to the homogeneously distributed substance and the non-enzymatically formed ethyl-carbonium ions which have reacted with the tissues. The blood-brain barrier seemed to have a capacity to partially prevent the uptake of the substance in the central nervous system. A high radioactivity was observed in the liver, which may imply that N-[(14)C]ethyl-N-nitrosourea is enzymatically decomposed in this tissue. An observed labelling of kidneys may be connected with urinary excretion of radioactivity. The radioactivity in the liver and kidney decreased at later survival intervals and a distribution pattern appeared, which was characterized by a labelling of tissues with a high protein or steroid synthesis and of fat containing tissues. The distribution pattern corresponded to the one seen after the administration of [(14)C]acetaldehyde and is probably due to normal biosynthetic incorporation of radioactivity in the 2-carbon pool. Pretreatments with pyrazole, nialamide and diethyldithiocarbamate caused a marked inhibition of the exhalation of (14)CO2 and of the incorporation of radioactivity in the liver. This effect may be directed towards the decomposition of N-[(14)C]ethyl-N-nitrosourea itself, but an effect on the metabolism of formed 2-carbon fragments is also possible. The incorporation of radioactivity in other tissues was not influenced by the pretreatments.']","['In the ethylation of tRNA from calf liver with (14)C-labeled ENU in vitro, 1,7-diethylguanine was obtained as the main product. ... After in vivo ethylation, the main reaction product isolated from rat liver tRNA was 7-ethylguanine and a pyrimidine nucleotide-like fraction containing a 1,7-diethylguanine derivative with an opened imidazole ring.', 'NEU is a direct alkylating agent and has been shown to ethylate nucleic acids both in vitro and in vivo. 7-Ethylguanine, 06-ethylguanine, 3-ethyladenine and 7-ethyladenine and ethylphosphate triesters have been detected in rat tissues after administration of NEU in vivo. 06-Ethylguanine was lost from DNA of brain (a target organ) much more slowly than from liver DNA, whereas no such difference was observed for the rate of loss of the other ethylated products.']","['NEU was rapidly lost from the blood after its i.v. injection, with a half-life of 5-6 minutes.']"
2967,12968,S-Ethyl dipropylthiocarbamate,CCCN(CCC)C(=O)SCC,,,,"['ROOT ABSORPTION OF EPTC WAS REPORTED ... IN OAT ... & IN ALFALFA. THE ABSORBED EPTC WAS READILY MOVED UPWARD TO THE FOLIAGE. THIS CHEMICAL IS ALSO ABSORBED BY THE COLEOPTILES & CAN BE TRANSLOCATED DOWNWARD TO THE ROOTS. ... THE RADIOSULFURFROM LABELED EPTC ACCUMULATES IN GROWING STEM & ROOT TIPS AFTER THE APPLICATION TO THE LEAVES. WHEN THE APPLICATION WAS MADE TO THE ROOTS, THE DISTRIBUTION WAS MORE UNIFORM.', '... SEEDS OF KIDNEY BEAN, PEA, CORN, & OAT /WERE COVERED/ WITH DRY SOILS CONTAINING VARIOUS LEVELS OF (35)S EPTC, RANGING FROM 10 TO 100 PPM ... . NO SIGNIFICANT AMT OF RADIOACTIVITY WAS FOUND IN THE SEEDS AFTER 6 DAYS ... . A SIGNIFICANT AMT OF RADIOACTIVITY WAS TAKEN UP WHEN THE GERMINATING SEEDS /KIDNEY BEAN, PEA, CORN, & OAT/ WERE COVERED WITH WET SOIL CONTAINING (35)S EPTC. EPTC WAS ALSO TAKEN UP BY SEEDS THAT WERE GERMINATED BETWEEN 2 SHEETS OF FILTER PAPER MOISTENED WITH AN EPTC SOLN.', '... VAPORS MAY BE ABSORBED BY FOLIAGE.', '... AFTER A 0.6 MG DOSE /EPTC, ORAL, TO RATS/ 8% WAS EXCRETED IN THE URINE, 4% IN THE FECES, & 85% IN THE EXPIRED AIR, WHEREAS AFTER A DOSE OF 100.6 MG, 36, 11, & 38% WERE EXCRETED BY THESE ROUTES RESPECTIVELY. THE LARGER DOSE WAS ALSO EXCRETED MORE SLOWLY.', 'INCR THE DOSE OF EPTC /IN RATS/ FROM 0.63 TO 103 MG PER RAT LED TO A ... CORRESPONDING INCR IN URINARY EXCRETION OF RADIOACTIVITY. ... THE TIME FOR COMPLETE URINARY ELIMINATION OF RADIOACTIVITY WAS LIKEWISE EXTENDED /TO APPROX 35 HR FOR HIGHER DOSE/.']","['... THE RATE OF (35)S EPTC DEGRADATION IN GERMINATING SEEDS /WAS REPORTED/. DATA ... SHOW A GREATER DEGRADATION ... IN SEEDS OF THOSE SPECIES WHICH ARE RESISTANT TO THIS HERBICIDE THAN IN SUSCEPTIBLE SPECIES. THE RADIOSULFUR ... WAS INCORPORATED INTO CYSTEIC ACID, CYSTINE, METHIONINE, METHIONINE SULFONE & 2 UNIDENTIFIED COMPD.', 'COMPLETE OXIDATION OF THE ETHYL MOIETY OF THE EPTC MOLECULE TO CO2 BY RATS WAS REPORTED ... . INCREASING THE DOSE OF EPTC ... LED TO A DECR IN (14)CO2 OUTPUT ... . SIX MAJOR LABELED METABOLITES WERE FOUND ... AND THE RELATIVE AMOUNT OF 3 METABOLITES CHANGED WITH DOSE. ONE OF THE MAJOR METABOLITES WAS ... UREA, & 3 OTHERS, WHICH ACCOUNTED FOR 50-70% OF THE TOTAL RADIOACTIVITY IN THE URINE, WERE CONJUGATES OF EPTC OR EPTC-LIKE CMPD.', 'THIOCARBAMATE HERBICIDES ALSO REACT WITH GLUTATHIONE AFTER OXIDATIVE ACTIVATION. EG, EPTAM & ITS S-OXIDE LOWER HEPATIC GLUTATHIONE WHEN GIVEN TO MICE AND ARE EXCRETED AS A MERCAPTURIC ACID FROM RATS.', 'THE MAIN SOL METABOLITE WAS CARBAMOYLATED GLUTATHIONE. EPTC-SULFONE REACTED WITH GSH. EPTC WAS PARTIALLY OXIDIZED TO EPTC-SULFOXIDE IN IN VITRO ASSAYS USING 5 DAY OLD SEEDLINGS.', 'For more Metabolism/Metabolites (Complete) data for EPTAM (9 total), please visit the HSDB record page.']",
2968,12969,3-Methyl-1-pentene,CCC(C)C=C,,,,,,
2969,12970,2-Ethyl-1-butene,CCC(=C)CC,,,,,,
2970,12971,"3,4-Dichloro-1-butene",C=CC(CCl)Cl,,,,,"['Chloroprene is a metabolite of 3,4-dichloro-1-butene.']",
2971,12972,n-Octylmalonic acid,CCCCCCCCC(C(=O)O)C(=O)O,,,,,,
2972,12973,"N,N-Dimethylbutyramide",CCCC(=O)N(C)C,,,,,,
2973,12974,Methacrylic anhydride,CC(=C)C(=O)OC(=O)C(=C)C,,,,,,
2974,12975,"N,N-Dibutylformamide",CCCCN(CCCC)C=O,,,,,,
2975,12976,methyl N-carbamoylcarbamate,COC(=O)NC(=O)N,,,,,,
2976,12977,"Ethyl phosphite, (C2H5O)2(OH)P",CCOP(O)OCC,,,,,,
2977,12978,"Peroxide, bis(1-oxononyl)",CCCCCCCCC(=O)OOC(=O)CCCCCCCC,,,,,,
2978,12979,Dioctanoyl peroxide,CCCCCCCC(=O)OOC(=O)CCCCCCC,,,,,,
2979,12980,Dimethyl acetylenedicarboxylate,COC(=O)C#CC(=O)OC,,,,,,
2980,12981,"Hydroperoxide, 1-methylhexyl",CCCCCC(C)OO,,,,,,
2981,12982,1-Bromo-2-fluoroethane,C(CBr)F,,,,"['... MAIN FACTOR AFFECTING FATE OF FLUOROCARBONS IS BODY FAT, WHERE THEY ARE CONCENTRATED & SLOWLY RELEASED INTO BLOOD @ CONCN THAT SHOULD NOT CAUSE ANY RISK OF CARDIAC SENSITIZATION. /FLUOROCARBONS/', 'THERE IS A SIGNIFICANT ACCUMULATION OF FLUOROCARBONS IN BRAIN, LIVER & LUNG COMPARED TO BLOOD LEVELS, SIGNIFYING A TISSUE DISTRIBUTION OF FLUOROCARBONS SIMILAR TO THAT OF CHLOROFORM. /FLUOROCARBONS/', 'Abosrption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'Although fluorocarbons cause cardiac sensitization in certain animal species, rapid elimination prevents the development of cardiotoxic concentrations from aerosol bronchodilator use except at exceedingly high doses (12 to 24 doses in 2 minutes). /Fluorocarbons/', 'FLUOROCARBON COMPOUNDS ARE LIPID-SOLUBLE AND THUS ARE GENERALLY WELL ABSORBED THROUGH LUNG. ABSORPTION AFTER INGESTION IS 35 TO 48 TIMES LOWER THAN AFTER INHALATION. ... FLUOROCARBONS ARE ELIMINATED BY WAY OF LUNG. /FLUOROCARBON COMPOUNDS/']",,
2982,12983,1-Chloro-2-fluoroethane,C(CCl)F,,,,"['... MAIN FACTOR AFFECTING FATE OF FLUOROCARBONS IS BODY FAT, WHERE THEY ARE CONCENTRATED & SLOWLY RELEASED INTO BLOOD @ CONCN THAT SHOULD NOT CAUSE ANY RISK OF CARDIAC SENSITIZATION. /FLUOROCARBONS/', 'THERE IS A SIGNIFICANT ACCUMULATION OF FLUOROCARBONS IN BRAIN, LIVER & LUNG COMPARED TO BLOOD LEVELS, SIGNIFYING A TISSUE DISTRIBUTION OF FLUOROCARBONS SIMILAR TO THAT OF CHLOROFORM. /FLUOROCARBONS/', 'Absorption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'Although fluorocarbons cause cardiac sensitization in certain animal species, rapid elimination prevents the development of cardiotoxic concentrations from aerosol bronchodilator use except at exceedingly high doses (12 to 24 doses in 2 minutes). /Fluorocarbons/', 'FLUOROCARBON COMPOUNDS ARE LIPID-SOLUBLE AND THUS ARE GENERALLY WELL ABSORBED THROUGH LUNG. ABSORPTION AFTER INGESTION IS 35 TO 48 TIMES LOWER THAN AFTER INHALATION. ... FLUOROCARBONS ARE ELIMINATED BY WAY OF LUNG. /FLUOROCARBON COMPOUNDS/']",,
2983,12984,"4,4-Dimethyl-1-pentene",CC(C)(C)CC=C,,,,,,
2984,12985,N-tert-Butylacetamide,CC(=O)NC(C)(C)C,,,,,,
2985,12986,2-Methyl-1-pentene,CCCC(=C)C,,,,,,
2986,12987,"2-Methyl-1,4-pentadiene",CC(=C)CC=C,,,,,,
2987,12988,3-Methyl-3-buten-1-OL,CC(=C)CCO,,,,,,
2988,12989,Ethyl 3-ethoxypropionate,CCOCCC(=O)OCC,,,,,,
2989,12990,Hexenone,CCC=CC(=O)C,,,,,,
2990,12991,2-Butyn-1-OL,CC#CCO,,,,,,
2991,12992,"2,5-Dimethyl-2,4-hexadiene",CC(=CC=C(C)C)C,,,,,,
2992,12993,Pent-2-enal,CCC=CC=O,,,,,,
2993,12994,But-2-enedinitrile,C(=CC#N)C#N,,,,,,
2994,12995,2-(Vinyloxy)ethanol,C=COCCO,,,,,['/2-(Vinyloxy)ethanol/ metab in the body occurs via hydrolysis to form acetaldehyde which is rapidly oxidized and is therefore not important in the pathogenesis of intoxication. The detached ethylene glycol selectively attacks the kidneys- either itself or through its separation products.'],
2995,12996,Potassium;octanoic acid,CCCCCCCC(=O)O.[K+],,,,,,
2996,12997,1-Decyne,CCCCCCCCC#C,,,,,,
2997,12998,Diethylene glycol divinyl ether,C=COCCOCCOC=C,,,,,,
2998,12999,"Decane, 1-(ethenyloxy)-",CCCCCCCCCCOC=C,,,,,,
2999,13000,1-Bromotridecane,CCCCCCCCCCCCCBr,,,,,,
3000,13001,1-Eicosyne,CCCCCCCCCCCCCCCCCCC#C,,,,,,
3001,13002,Glycidaldehyde,C1C(O1)C=O,,,,['Absorbed through skin.'],,
3002,13003,2-Methylpyrrolidine,CC1CCCN1,,,,,,
3003,13004,Cyclopropyl methyl ketone,CC(=O)C1CC1,,,,,,
3004,13005,"2-Methyl-1,3-cyclopentanedione",CC1C(=O)CCC1=O,,,,,,
3005,13006,"1,2-Cyclohexanedione",C1CCC(=O)C(=O)C1,,,,,,
3006,13007,1-Ethylpiperidine,CCN1CCCCC1,,,,,,
3007,13008,"4,4-Dimethyl-1,3-dioxane",CC1(CCOCO1)C,,,,,,
3008,13009,"2,4-Dimethyl-1,3-dioxane",CC1CCOC(O1)C,,,,,,
3009,13010,"2,3-Dimethylmaleic anhydride",CC1=C(C(=O)OC1=O)C,,,,,,
3010,13011,2-Chloroanisole,COC1=CC=CC=C1Cl,,,,,,
3011,13012,2-Chlorocycloheptanone,C1CCC(C(=O)CC1)Cl,,,,,,
3012,13013,"Aziridinecarboxylic acid, propyl ester",CCCOC(=O)N1CC1,,,,,,
3013,13014,Dimethyl-phenyl-silane,C[SiH](C)C1=CC=CC=C1,,,,,,
3014,13015,3-Chlorobenzonitrile,C1=CC(=CC(=C1)Cl)C#N,,,,,,
3015,13016,Benzyl methyl sulfide,CSCC1=CC=CC=C1,,,,,,
3016,13017,N-Cyclohexylformamide,C1CCC(CC1)NC=O,,,,,,
3017,13018,4-Ethynyltoluene,CC1=CC=C(C=C1)C#C,,,,,,
3018,13019,4-Hydroxybenzonitrile,C1=CC(=CC=C1C#N)O,,,,,,
3019,13020,"2-Furanpropanol, tetrahydro-",C1CC(OC1)CCCO,,,,,,
3020,13021,"2-Amino-4,6-dimethylpyrimidine",CC1=CC(=NC(=N1)N)C,,,,,,
3021,13022,CID 13022,C1(=NC(=NC(=N1)S)N)N,,,,,,
3022,13023,1-Methylindan,CC1CCC2=CC=CC=C12,,,,,,
3023,13024,1-Methyl-1H-indene,CC1C=CC2=CC=CC=C12,,,,,,
3024,13025,3-Methyl-1H-indene,CC1=CCC2=CC=CC=C12,,,,,,
3025,13026,"2,3,5-Trihydroxytoluene",CC1=CC(=CC(=C1O)O)O,,,,,,
3026,13027,Mallorepine,CN1C=CC(=O)C(=C1)C#N,,,,,,
3027,13028,Acrylophenone,C=CC(=O)C1=CC=CC=C1,,,,,,
3028,13029,Chlorodimethylphenylsilane,C[Si](C)(C1=CC=CC=C1)Cl,,,,,,
3029,13030,2-Methyl-1-phenylpropene,CC(=CC1=CC=CC=C1)C,,,,,,
3030,13031,"2-Propanone, 1-(1-cyclohexen-1-yl)-",CC(=O)CC1=CCCCC1,,,,,,
3031,13032,N-Isopropylaniline,CC(C)NC1=CC=CC=C1,,,,,"['THE N-ISOPROPYLANILINE METABOLITES AFTER IP INJECTION OF (14)C-LABELED N-ISOPROPYLANILINE-HCL WERE ANALYZED CHROMATOGRAPHICALLY IN COMBINED URINE SAMPLES FROM FOUR RATS EVERY 24 HR FOR A TOTAL OF 96 HR. 24 HR URINE SAMPLES CONTAINED NO METABOLITES. 4-HYDROXY-N-ISOPROPYLANILINE & P-AMINOPHENOL CONSTITUTING THE MAJOR & MINOR METABOLITE WITH 61 & 8, RESPECTIVELY. N-PHENYL-2-AMINOPROPIONIC ACID, A TRACE METABOLITE, REPRESENTED LESS THAN 1 OF THE TOTAL RADIOACTIVITY.']",
3032,13033,4-Phenyl-1-butene,C=CCCC1=CC=CC=C1,,,,,,
3033,13034,4-Ethylbenzyl alcohol,CCC1=CC=C(C=C1)CO,,,,,,
3034,13035,"2,2,6,6-Tetramethylpiperidine",CC1(CCCC(N1)(C)C)C,,,,,,
3035,13036,"2,4,6-Trimethylstyrene",CC1=CC(=C(C(=C1)C)C=C)C,,,,,,
3036,13037,Vinyl benzoate,C=COC(=O)C1=CC=CC=C1,,,,,,
3037,13038,Phenyl dichlorophosphate,C1=CC=C(C=C1)OP(=O)(Cl)Cl,,,,,,
3038,13039,3-Fluorophenylurea,C1=CC(=CC(=C1)F)NC(=O)N,,,,,,
3039,13040,"2,3,4,5,6-Pentafluoroaniline",C1(=C(C(=C(C(=C1F)F)F)F)F)N,,,,,,
3040,13041,Pentafluorophenol,C1(=C(C(=C(C(=C1F)F)F)F)F)O,,,,,,
3041,13042,Pentafluorothiophenol,C1(=C(C(=C(C(=C1F)F)S)F)F)F,,,,,,
3042,13043,1-Phenyl-1-cyclohexene,C1CCC(=CC1)C2=CC=CC=C2,,,,,,
3043,13044,2-Hydroxy-5-nitrobenzyl bromide,C1=CC(=C(C=C1[N+](=O)[O-])CBr)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3044,13045,"1-AZIRIDINEMETHANOL, alpha,alpha-BIS(TRIFLUOROMETHYL)-",C1CN1C(C(F)(F)F)(C(F)(F)F)O,,,,,,
3045,13046,2-Mesitylenesulfonyl chloride,CC1=CC(=C(C(=C1)C)S(=O)(=O)Cl)C,,,,,,
3046,13047,1-Naphthaleneethanol,C1=CC=C2C(=C1)C=CC=C2CCO,,,,,,
3047,13048,"BENZYL ALCOHOL, p-AMINO-alpha-(1-(METHYLAMINO)ETHYL)-, HYDROCHLORIDE",CC(C(C1=CC=C(C=C1)N)O)[NH2+]C.[Cl-],,,,,,
3048,13049,1-(4-Aminophenyl)-2-(methylamino)propan-1-ol,CC(C(C1=CC=C(C=C1)N)O)NC,,,,,,
3049,13050,Ethyl mandelate,CCOC(=O)C(C1=CC=CC=C1)O,,,,,,
3050,13051,"3,4-Dimethyl-5-pentylidenefuran-2(5H)-one",CCCCC=C1C(=C(C(=O)O1)C)C,,,,,,
3051,13052,DL-m-Tyrosine,C1=CC(=CC(=C1)O)CC(C(=O)O)N,,,,,,
3052,13053,1-Fluoro-4-[(1E)-2-nitro-1-propenyl]benzene,CC(=CC1=CC=C(C=C1)F)[N+](=O)[O-],,,,,,
3053,13054,"Cyclohexene, 3,3,4,4,5,5,6,6-octafluoro-",C1=CC(C(C(C1(F)F)(F)F)(F)F)(F)F,,,,,,
3054,13055,"3,3,9-Trimethyl-3-azoniaspiro(5.5)undecane iodide",CC1CCC2(CC1)CC[N+](CC2)(C)C.[I-],,,,,,
3055,13056,"3,3,9-Trimethyl-3-azoniaspiro[5.5]undecane",CC1CCC2(CC1)CC[N+](CC2)(C)C,,,,,,
3056,13057,4-Nitro-1-naphthylamine,C1=CC=C2C(=C1)C(=CC=C2[N+](=O)[O-])N,,,,,,
3057,13058,"9,10-Dihydrophenanthrene",C1CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
3058,13059,5-Fluoro-beta-methyltryptamine hydrochloride,CC(C[NH3+])C1=CNC2=C1C=C(C=C2)F.[Cl-],,,,,,
3059,13060,3-(2-Amino-1-methylethyl)-5-fluoro-1H-indole,CC(CN)C1=CNC2=C1C=C(C=C2)F,,,,,,
3060,13061,1-Benzyl-2-bromobenzene,C1=CC=C(C=C1)CC2=CC=CC=C2Br,,,,,,
3061,13062,N-[2-(aziridine-1-carbonylamino)ethenyl]aziridine-1-carboxamide,C1CN1C(=O)NC=CNC(=O)N2CC2,,,,,,
3062,13063,"2-(Ethylamino)-4-fluoro-6-(isopropylamino)-1,3,5-triazine",CCNC1=NC(=NC(=N1)F)NC(C)C,,,,,,
3063,13064,"1,6-Dioxacyclododecane-7,12-dione",C1CCC(=O)OCCCCOC(=O)C1,,,,,,
3064,13065,"2,2-Diphenylpropane",CC(C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3065,13066,Butyl 4-methylbenzenesulfonate,CCCCOS(=O)(=O)C1=CC=C(C=C1)C,,,,,,
3066,13067,Ethyl 3-indoleacetate,CCOC(=O)CC1=CNC2=CC=CC=C21,,,,,,
3067,13068,9-Methylanthracene,CC1=C2C=CC=CC2=CC3=CC=CC=C13,,,,,,
3068,13069,9-Aminoanthracene,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2N,,,,,,
3069,13070,"1,2-Diphenyl-1-propene",CC(=CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3070,13071,N-cyclohexyl-4-methoxyaniline,COC1=CC=C(C=C1)NC2CCCCC2,,,,,,
3071,13072,m-tert-Butylphenyl methylcarbamate,CC(C)(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
3072,13073,Dibenzylmercury,C1=CC=C(C=C1)C[Hg]CC2=CC=CC=C2,,,,,,
3073,13074,"Barbituric acid, 5,5-diallyl-1-methyl-",CN1C(=O)C(C(=O)NC1=O)(CC=C)CC=C,,,,,,
3074,13075,Phenyltriethoxysilane,CCO[Si](C1=CC=CC=C1)(OCC)OCC,,,,,,
3075,13076,"9,10-Dimethylanthracene",CC1=C2C=CC=CC2=C(C3=CC=CC=C13)C,,,,,"['The metabolism of two polycyclic aromatic hydrocarbons i.e. anthracene and 9,10-dimethylanthracene by Micrococcus sp., Pseudomonas sp. and Bacillus macerans was examined. The above compounds were used as a sole carbon source for their growth. Using the reversed-phase thin layer chromatography techniques a number of anthracene and 9,10-dimethylanthracene metabolites were isolated and their structures identified spectroscopically. These included anthracene and 9,10-dimethylanthracene cis-dihydrodiols, hydroxy-methyl-derivatives and various phenolic compounds. Bacteria metabolize hydrocarbons using the dioxygenase enzyme system, which differs from the mammalian cytochrome P-450 monoxygenase. ...', 'In-vitro stereoselective metabolism of methylated anthracenes by rat liver microsomes, and the configurations and optical purity of the trans-dihydrodiol metabolites were investigated. Liver microsomes from untreated immature male Sprague-Dawley-rats and from rats pretreated with either 3-methylcholanthrene (3-MC) or phenobarbital (PB) were incubated with 9-methylanthracene (779022) (9-MA), 9-hydroxymethylanthracene (9-OHMA), or 9,10-dimethylanthracene (781431) (9,10-DMA) for 60 minutes. Metabolites were separated by reverse phase high performance liquid chromatography (HPLC). Results indicated that 9-MA, 9-OHMA and 9,10-DMA were metabolized by 3-MC, PB and control microsomes in a stereoselective manner. With the exception of the formation of 9-OHMA-trans-3,4 dihydrodiol by PB microsomes, all of the trans-dihydrodiol metabolites formed from the three microsomal enzyme systems were predominantly the R,R enantiomers. The 3-MC microsomes exhibited much higher stereoselectivity than the Pb or control microsomes in the formation of trans-dihydrodiols from anthracene, 9-MA, 9-OHMA and 9,10-DMA. Optical purities of the trans-dihydrodiol metabolites, determined by analysis of the chiral stationary phase HPLC profiles of the dihydrodiols or their corresponding tetrahydrodiol derivatives, ranged from 76 to 98 percent, 4 to 76 percent and 4 to 60 percent for 3-MC, PB and control microsomes, respectively. Methyl and hydroxymethyl substituents slightly decreased the stereoselectivity of the trans-dihydrodiol formation. The authors conclude that the lower optical purities of the trans-dihydrodiols formed by either PB or control microsomes are clearly due to the lower stereoselectivity of the cytochrome-P-450 enzymes or epoxidation of the polycyclic aromatic hydrocarbon substrates, but not due to the change of the stereoselectivity of the epoxide hydrolase enzymes.', 'The metabolism of the weakly-carcinogenic hydrocarbon, 9,10-dimethylanthracene (DMA) by rat-liver microsomal preparations has been examined. 9-Hydroxymethyl-10-methylanthracene (9-OHMeMA) and 9,10-dihydroxymethyl-anthracene (9,10-DiOHMeA) were identified as metabolites by comparing their chromatographic and spectral properties with those of the authentic compounds. The trans-1,2-dihydro-1,2-dihydroxy derivative of DMA (DMA 1,2-diol) was the major metabolite formed which was identified by its chromatographic, u.v., n.m.r. and mass spectral properties. The dihydrodiol was also formed in the oxidation of DMA in an ascorbic acid-ferrous sulphate-EDTA system. Two other dihydrodiols that were formed from DMA by metabolism appeared to be the trans-1,2- and 3,4-dihydrodiols of 9-OHMeMA (9-OHMeMA 1,2-diol and 9-OHMeMA 3,4-diol) and the further metabolism of DMA 1,2-diol yielded both of these dihydrodiols. When 9-OHMeMA was further metabolized, two main metabolites were formed; one was identified as 9,10-DiOHMeA and the other appeared to be 9-OHMeMA 3,4-diol. No metabolites were detected when 9,10-DiOHMeA was incubated with rat-liver microsomal fractions.']",
3076,13077,1-Naphthalenebutyric acid,C1=CC=C2C(=C1)C=CC=C2CCCC(=O)O,,,,,,
3077,13078,Bis(p-chlorophenyl)chloromethane,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)Cl)Cl,,,,,,
3078,13079,1-(2-Chlorophenyl)-2-(3-chlorophenyl)hydrazine,C1=CC=C(C(=C1)NNC2=CC(=CC=C2)Cl)Cl,,,,,,
3079,13080,alpha-((2-(1-Pyrrolidinyl)ethoxy)methyl)benzyl alcohol,C1CCN(C1)CCOCC(C2=CC=CC=C2)O,,,,,,
3080,13081,Carbophenothion,CCOP(=S)(OCC)SCSC1=CC=C(C=C1)Cl,,,,"['Following intraperitoneal injection /of carbophenothion/, mice excreted over 75% of the dose within 24 hr.', 'Excretion of carbophenothion is rapid.']","['OXIDATIVE METAB OF TRITHION WAS STUDIED ON FIELD-GROWING LETTUCE. SAMPLES WERE REMOVED @ VARIOUS TIMES AFTER SPRAYING & ANALYZED. ... PRINCIPAL ROUTE OF OXIDN INVOLVED THIOETHER OXIDN TO FORM SULFOXIDE & THEN SULFONE. THIS WAS FOLLOWED BY PHOSPHOROTHIONATE OXIDN TO FORM THIOLPHOSPHATE SULFONE ... .', '(14)C-Carbophenothion ... was rapidly and extensively metabolized by the rat. Some of the urinary label was due to products derived from 4-chlorothiophenol either via direct conjugation (glucuronide, 2.9%; sulfate, 5.9%) or via sequential methylation and oxidation to yield 4-chlorophenyl methyl sulfone and its 3-hydroxylation product ... . The major metabolite of /trithion/ ... was p-chlorobenzenesulfinic acid, which probably derived from ... trithion-S-oxide &/or its oxon. The corresponding sulfonic acid ... was also formed ... . At dosages of 5.3 and 0.53 mg/kg trithion, the rat excreted 93 and 40%, respectively, of the dose as a mixture of diethyl phosphate and diethyl thiophosphate.', 'In the presence of NADPH and under aerobic conditions, thioether containing organophosphorus and carbamate pesticides were oxidized by the flavin-adenine dinucleotide-dependent monooxygenase purified from pig microsomes.', 'Carbophenothion is metabolized to the oxon, and both compounds are oxidized to the corresponding sulfoxide and sulfone.']",
3081,13082,5-Allyl-1-phenylbarbituric acid,C=CCC1C(=O)NC(=O)N(C1=O)C2=CC=CC=C2,,,,,,
3082,13083,"7-Chloro-3,4-dihydro-2-(3-pyridyl)-1(2H)-naphthalenone",C1CC2=C(C=C(C=C2)Cl)C(=O)C1C3=CN=CC=C3,,,,,,
3083,13084,"[1,1'-Biphenyl]-4,4'-dicarboxylic acid",C1=CC(=CC=C1C2=CC=C(C=C2)C(=O)O)C(=O)O,,,,,,
3084,13085,"N,N'-Dibenzoylhydrazine",C1=CC=C(C=C1)C(=O)NNC(=O)C2=CC=CC=C2,,,,,,
3085,13086,Ameltolide,CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)N,,,,,,
3086,13087,"Acetanilide, 2-(diethylamino)-5'-ethyl-2'-fluoro-",CCC1=CC(=C(C=C1)F)NC(=O)CN(CC)CC,,,,,,
3087,13088,ethyl N-methyl-N-[(4-nitrophenyl)methylideneamino]carbamate,CCOC(=O)N(C)N=CC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3088,13089,"O,P'-Ddt",C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl)Cl,,,"['Non-steroidal compounds with estrogenic activity. (See all compounds classified as Estrogens, Non-Steroidal.)']",,,
3089,13090,2-Nitropyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)[N+](=O)[O-])C=C2,,,,,['2-nitropyrene has known human metabolites that include 2-aminopyrene.'],
3090,13091,"9H-Fluorene, 9-phenyl-",C1=CC=C(C=C1)C2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
3091,13092,2-Aminochrysene,C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC(=C4)N,,,,,,
3092,13093,CID 13093,C1[C@@H](O[C@@H](C1O)CO)N2C=NC3=C2N=C(N=C3S)N,,,,,,
3093,13094,CID 13094,C1=CC=C2C=C3C(=CC2=C1)C=CC4=C3C=CC5=C4O5,,,,,,
3094,13095,[2-Hydroxy-3-[3-(trifluoromethyl)phenyl]propyl] carbamate,C1=CC(=CC(=C1)C(F)(F)F)CC(COC(=O)N)O,,,,,,
3095,13096,"4-Acetamidophenyl 2,2,2-trichloroethyl carbonate",CC(=O)NC1=CC=C(C=C1)OC(=O)OCC(Cl)(Cl)Cl,,,,,,
3096,13097,Triphenylphosphine oxide,C1=CC=C(C=C1)P(=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3097,13098,"2,2,4,4-Tetrakis(trifluoromethyl)-1,3-dithietane",C1(SC(S1)(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F,,,,,,
3098,13099,"Dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate",COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC,,,,,,
3099,13100,"Acetophenone, 4',4'''-ethylenedi-",CC(=O)C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(=O)C,,,,,,
3100,13101,"N-(1,3-Dimethylbutyl)-N'-phenyl-p-phenylenediamine",CC(C)CC(C)NC1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
3101,13102,CID 13102,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)OC3[C@@H](CC4)O,,,,,,
3102,13103,2-Dodecyl-2-azaspiro(4.5)decane hydrochloride,CCCCCCCCCCCC[NH+]1CCC2(C1)CCCCC2.[Cl-],,,,,,
3103,13104,2-Dodecyl-2-azaspiro[4.5]decane,CCCCCCCCCCCCN1CCC2(C1)CCCCC2,,,,,,
3104,13105,"(1,2'-Binaphthalene)-1,2'-diamine",C1=CC=C2C(=C1)C=CC(=C2C3=C(C4=CC=CC=C4C=C3)N)N,,,,,,
3105,13106,"ETHYLENE, 1-BROMO-2,2-DIPHENYL-1-(o-FLUOROPHENYL)-",C1=CC=C(C=C1)C(=C(C2=CC=CC=C2F)Br)C3=CC=CC=C3,,,,,,
3106,13107,"ETHYLENE, 1-BROMO-1-(p-CHLOROPHENYL)-2,2-DIPHENYL-",C1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)Cl)Br)C3=CC=CC=C3,,,,,,
3107,13108,"(9S,14S,17S)-13,17-diethyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CCC4=CC(=O)CCC34)CC)O,,,,,,
3108,13109,Levonorgestrel,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,"['**Emergency contraception**  Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age. This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse. It has shown a lower efficacy when it is used off label within 96 hours.  **Long-term contraception or nonemergency contraception**  In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol. It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years. Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child. A subdermal implant is also available for the prevention of pregnancy for up to 5 years.  **Hormone therapy and off-label uses**  Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.']","['Levonorgestrel prevents pregnancy by interfering with ovulation, fertilization, and implantation. The levonorgestrel-only containing emergency contraceptive tablet is 89% effective if it is used according to prescribing information within 72 hours after intercourse. The intrauterine and implantable devices releasing levonorgestrel are more than 99% in preventing pregnancy. Levonorgestrel utilized as a component of hormonal therapy helps to prevent endometrial carcinoma associated with unopposed estrogen administration.']","['Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)', 'Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. (See all compounds classified as Contraceptive Agents, Female.)', 'Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)']","['Orally administered levonorgestrel is absorbed in the gastrointestinal tract while levonorgestrel administered through an IUD device is absorbed in the endometrium. Levonorgestrel is absorbed immediately in the interstitial fluids when it is inserted as a subdermal implant. After insertion of the subdermal implant, the Cmax of levonorgestrel is attained within 2-3 days.The Cmax following one dose of 0.75 mg of oral levonorgestrel is reached within the hour after administration, according to one reference. In a pharmacokinetic study of 1.5 mg of levonorgestrel in women with a normal BMI and those considered to be obese (BMI>30), mean Cmax was found to be 16.2 ng/mL and 10.5 ng/mL respectively. Tmax was found to be 2 hours for those with normal BMI and 2.5 hours for patients with increased BMI. The bioavailability of levonorgestrel approaches 100%.    Mean AUC has been shown to be higher in patients with a normal BMI, measuring at 360.1 h  ng/mL versus a range of 197.28 to 208.1 h  ng/mL in an obese group of patients.  Obesity may contribute to decreased efficacy of levonorgestrel in contraception.', 'Approximately 45% of an oral levonorgestrel dose and its conjugated or sulfate metabolites are found to be excreted in the urine. Approximately 32% of an orally ingested dose is found excreted in feces, primarily in the form of glucuronide conjugates of levonorgestrel.', 'One pharmacokinetic study determined a mean steady-state volume of distribution of 1.5 mg of levonorgestrel to be 162.2 L in those with normal BMI and in the range of 404.7 L to 466.4 L in obese patients with a body mass index of at least 30. Mean volume of distribution in 16 patients receiving 0.75 mg of levonorgestrel in another pharmacokinetic study was 260 L. The Plan B one-step FDA label reports an apparent volume of distribution of 1.8 L/kg.', 'Clearance was found to 4.8 L/h in healthy female volunteers with a normal BMI, and 7.70-8.51 L/h in obese patients after a single 1.5 mg dose. After a 0.75 mg dose of levonorgestrel in 16 patients in another pharmacokinetic study, mean clearance was calculated at 7.06 L/h. Following levonorgestrel implant removal, the serum concentration falls below 100 pg/mL within the first 96 hours and further falls below the sensitivity of detection within the range of 5 days to 2 weeks.', 'Norgestrel is absorbed from the gastrointestinal tract, metabolised by the liver and excreted in the urine and faeces as glucuronide and sulphate conjugates.', '(14)C-Norgestrel was administered to seven human subjects and 43% of dose was excreted in the urine within 5 days; the biological half-life of the radioactivity was 24 hr. Enzymic hydrolysis released only 32% of the urinary radioactivity and a further 25% was excreted as sulphate conjugates. The metabolites excreted in the urine were much less polar than those following the administration of the related compounds, norethisterone or lynestrenol. The 3alphaOH,5beta and 3betaOH,5beta isomers of the tetrahydronorgestrel (13beta-ethyl-17alpha-ethynyl-5 beta-gonane-3alpha,17beta-diol) were isolated from urine and identified by mass spectrometry and thin-layer and gas-liquid chromatography. Plasma radioactivity decreased more rapidly than after the administration of norethisterone and lynestrenol. About 2% of the administered dose was converted to acidic compounds. There was no apparent difference in the rate of excretion of radioactivity or in the metabolites after either oral or intravenous administration of norgestrel.', 'The binding of different synthetic steroids, used in hormonal contraception, to Sex Hormone Binding Globulin (SHBG) was studied by measuring their ability to displace tritiated testosterone from SHBG in a competitive protein binding system. Only 19-nortestosterone derivates had any significant ability to displace testosterone from SHBG, d-norgestrel (d-Ng) being the strongest displacer. Increasing the SHBG levels in women with previous constant plasma d-Ng levels increased these levels two- to sixfold. It is concluded that SHBG is the main carrier protein for d-Ng. The strong testosterone displacing activity of d-Ng might also explain androgenic side effects observed with d-Ng containig oral contraceptives.', 'The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg. It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.', 'No specific investigation of the absolute bioavailability of Aviane (levonorgestrel and ethinyl estradiol tablets, USP) in humans has been conducted. However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first-pass metabolism.', 'After a single dose of levonorgestrel and ethinyl estradiol 0.10 mg/0.02 mg tablets to 22 women under fasting conditions, maximum serum concentrations of levonorgestrel are 2.8 +/- 0.9 ng/mL (mean +/- SD) at 1.6 +/- 0.9 hours. At steady-state, attained from day 19 onwards, maximum levonorgestrel concentrations of 6 +/- 2.7 ng/mL are reached at 1.5 +/- 0.5 hours after the daily dose. The minimum serum levels of levonorgestrel at steady-state are 1.9 +/- 1 ng/mL. Observed levonorgestrel concentrations increased from day 1 (single dose) to days 6 and 21 (multiple doses) by 34% and 96%, respectively. Unbound levonorgestrel concentrations increased from day 1 to days 6 and 21 by 25% and 83%, respectively. The kinetics of total levonorgestrel are nonlinear due to an increase in binding of levonorgestrel to sex hormone binding globulin (SHBG), which is attributed to increased SHBG levels that are induced by the daily administration of ethinyl estradiol.', 'The bioavailability of levonorgestrel is generally accepted to be 100%. This generalization is based on two studies that used only a small number of women. In one of the studies, absolute bioavailabilities were determined for doses of 0.25 and 0.15 mg levonorgestrel, each of which was administered to five women in combination with ethinylestradiol (0.05 mg). The results show that the bioavailability for the 0.15-mg dose of levonorgestrel ranged from 72 to 125% (mean, 99%); that for the 0.15-mg dose ranged from 63 to 108% (mean, 89%).', 'For more Absorption, Distribution and Excretion (Complete) data for LEVONORGESTREL (14 total), please visit the HSDB record page.']","['After absorption of the oral emergency contraceptive preparation,  levonorgestrel is conjugated and forms a large number of sulfate conjugates. In addition, glucuronide conjugates have been identified in the plasma. High levels of conjugated and unconjugated 3, 5-tetrahydrolevonorgestrel are found in the plasma. The entire metabolic pathway for levonorgestrel has not been studied, however, 16-hydroxylation is one pathway that has been identified. Small quantities of 3, 5\xad tetrahydrolevonorgestrel and 16hydroxylevonorgestrel are also formed. No active metabolites have been identified. The rate of metabolism may be considerably different according to the patient and may explain a wide variation in levonorgestrel clearance. Liver CYP3A4 and CYP3A5 hepatic enzymes are reported to be involved in the metabolism of levonorgestrel.', '(14)C-Norgestrel was administered to seven human subjects and 43% of dose was excreted in the urine within 5 days ... Enzymic hydrolysis released only 32% of the urinary radioactivity and a further 25% was excreted as sulphate conjugates. The metabolites excreted in the urine were much less polar than those following the administration of the related compounds, norethisterone or lynestrenol. The 3alphaOH,5beta and 3betaOH,5beta isomers of the tetrahydronorgestrel (13beta-ethyl-17alpha-ethynyl-5 beta-gonane-3alpha,17beta-diol) were isolated from urine and identified by mass spectrometry and thin-layer and gas-liquid chromatography. Plasma radioactivity decreased more rapidly than after the administration of norethisterone and lynestrenol. About 2% of the administered dose was converted to acidic compounds. There was no apparent difference in the rate of excretion of radioactivity or in the metabolites after either oral or intravenous administration of norgestrel.', 'The comparative metabolism of dl-, d-, and l-norgestrel was investigated in African Green Monkeys (Cercopithecus aethiops). Total (14)C excretion in urine after a single oral dose of (14)C-dl-norgestrel (1 mg/kg) was significantly higher (51.4 +/- 5.0%) than that observed after administration of the d-enantiomer (37.5 +/- 5.4%) but not the l-enantiomer (44.2 +/- 8.9%). In all cases, the major part of the urinary radioactivity was present in a free fraction (48-62%), while an additional 13-27% was released by beta-glucuronidase preparations. No sulfate conjugates were detected. At least one major (16beta-hydroxylation) and one minor (16alpha-hydroxylation) metabolic pathway were stereoselective, i.e., they are operative with the I-but not the d-enantiomer. Three metabolites, 16beta-hydroxynorgestrel, 16alpha-hydroxynorgestrel, and 16-hydroxytetrahydronorgestrel (believed to be 16beta) were only detected in urine samples obtained from (14)C-dland -l-norgestrel-dosed animals. Following (14)C-d-norgestrel administration, 3alpha, 5beta-tetrahydronorgestrel was found to be the major urinary metabolite. These observations are compared with those reported earlier on the urinary metabolites of dl-norgestrel in women.', 'The in vitro metabolism of stereo-isomers (d, l and the racemic mixture dl) of norgestrel by a microsomal fraction from rabbit liver was investigated. The metabolism of the biologically active l-norgestrel was more rapid than that of d-norgestrel (sic.) which is biologically inactive. This was mainly due to the more ready conversion of l-norgestrel to ring-A reduced metabolites. There was no difference between the two isomers in respect of the amount undergoing hydroxylation; about 40% of each isomer was converted to hydroxylated metabolites after 30 min incubation. However, there were differences between the isomers, l-norgestrel being converted mainly to the 16beta-hydroxysteroid and d-norgestrel to the 16alpha-hydroxysteroid. Similar amounts of both isomers were hydroxylated at C-6. The metabolism of the racemic mixture was intermediate between that of the d and l isomers.', 'The rates of metabolism of synthetic gestagens derived from 19-nortestosterone by rabbit liver tissue in vitro were compared. Over a period of 1 hr norethisterone was metabolized as rapidly as 19-nortestosterone whereas d-norgestrel and lynestrenol were metabolized at a slightly lower rate. Less than 5% of l-norgestrel was metabolized. In all cases the reaction product was the tetrahydrosteroid. Lynestrenol was metabolised through norethisterone. Skeletal muscle, lung and small intestine also metabolized norethisterone and d-norgestrel but at a slower rate than liver tissue. Small amounts of norethisterone were metabolized by adipose tissue but heart and spleen were inactive. Lynestrenol and l-norgestrel were not metabolized by any of the extra-hepatic tissues studied.', 'In vitro studies were conducted on the metabolism of 3 steroids used in OCs (oral contraceptives) by small pieces of human jejunal mucosa. This was done because the gastrointestinal mucosa of humans is known to metabolize a number of drugs. Almost 40% of the ethinyl estradiol, 9.8% of the levonorgestrel, and 7% of the mestranol were metabolized after incubation. All these metabolic responses were significantly different from those in the control groups. Results of the study show that the metabolism of the ethinyl estradiol was related to the weight of the tissue used. These results are consistent with the known marked 1st pass effect of ethinyl estradiol. Norgestrel, known to have little or no 1st pass effect, did not show a high rate of gut metabolism. Under the experimental conditions employed, no Phase 1 metabolism of either ethinyl estradiol or levonorgestrel was apparent.', 'Following absorption, levonorgestrel is conjugated at the 17beta-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3alpha, 5beta-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3alpha, 5alpha-tetrahydrolevonorgestrel and 16beta-hydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.', 'The most important metabolic pathway for levonorgestrel occurs in the reduction of the delta4- and the 3-oxo-group as well as hydroxylations at positions 2alpha , 1beta, and 16beta, followed by conjugation. Most of the metabolites that circulate in the blood are sulfates of 3beta , 5beta -tetrahydro-levonorgestrel, while excretion occurs predominantly in the form of glucuronides. ... In-vitro studies on the biotransformation of levonorgestrel in human skin did not indicate any significant metabolism of levonorgestrel during skin penetration.', '/Investigators/ reviewed the metabolism of levonorgestrel in women treated orally with the radioactively labelled compound. Levonorgestrel was found mostly untransformed in serum within 1-2 hr after administration, but the concentrations of conjugated metabolites increased progressively between 4 and 24 hr after ingestion. Most of the conjugates were sulfates and glucuronides. In addition to the remaining unconjugated levonorgestrel, considerable amounts of unconjugated and sulfate-conjugated forms of 3alpha,5beta- tetrahydrolevonorgestrel were found; smaller quantities of conjugated and unconjugated 3alpha,5beta-tetrahydrolevonorgestrel and 16beta-hydroxylevonorgestrel were also identified. ... The major urinary metabolites were glucuronides (the most abundant was 3alpha,5beta-tetrahydrolevonorgestrel glucuronide) and smaller quantities of sulfates were found.', 'In vitro studies were conducted on the metabolism of 3 steroids used in OCs (oral contraceptives) by small pieces of human jejunal mucosa. This was done because the gastrointestinal mucosa of humans is known to metabolize a number of drugs. Almost 40% of the ethinyl estradiol, 9.8% of the levonorgestrel, and 7% of the mestranol were metabolized after incubation. All these metabolic responses were significantly different from those in the control groups. Results of the study show that the metabolism of the ethinyl estradiol was related to the weight of the tissue used. These results are consistent with the known marked 1st pass effect of ethinyl estradiol. Norgestrel, known to have little or no 1st pass effect, did not show a high rate of gut metabolism. Under the experimental conditions employed, no Phase 1 metabolism of either ethinyl estradiol or levonorgestrel was apparent.', 'For more Metabolism/Metabolites (Complete) data for LEVONORGESTREL (6 total), please visit the HSDB record page.']","['The elimination half-life of a 0.75 mg dose of 1.5 mg of levonorgestrel ranges between 20-60 hours post-administration. A pharmacokinetic study of women with a normal BMI and BMI over revealed an elimination half-life of 29.7 h and 41.0-46.4 hours, respectively. Another pharmacokinetic study revealed a mean elimination half-life of 24.4 hours after a 0.75 mg dose of levonorgestrel was administered to 16 patients.', '(14)C-Norgestrel was administered to seven human subjects and 43% of dose was excreted in the urine within 5 days; the biological half-life of the radioactivity was 24 hr. ...', 'The elimination half-life for levonorgestrel is approximately 36 +/- 13 hours at steady-state.', 'Mean (+/- SD) terminal half-life for levonorgestrel was determined to be 28 +/- 6.4 hours.', '... The mean half-life of elimination was found to be 13.2 hr and 9.9 hr for the 0.15-mg and 0.25-mg doses of levonorgestrel, respectively, when administered intravenously. These values were similar after oral dosing.']"
3109,13110,2-Dodecyl-2-methyl-2-azoniaspiro(4.5)decane iodide,CCCCCCCCCCCC[N+]1(CCC2(C1)CCCCC2)C.[I-],,,,,,
3110,13111,2-Dodecyl-2-methyl-2-azoniaspiro[4.5]decane,CCCCCCCCCCCC[N+]1(CCC2(C1)CCCCC2)C,,,,,,
3111,13112,Bis(4-nitrophenyl)methyl phosphate,COP(=O)(OC1=CC=C(C=C1)[N+](=O)[O-])OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3112,13113,Chloracyzine,CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
3113,13114,CID 13114,COC1=CC=C(C=C1)C(=C(C2=CC=CC=C2F)Br)C3=CC=CC=C3,,,,,,
3114,13115,CID 13115,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)F)Br)C3=CC=CC=C3,,,,,,
3115,13116,Porfiromycin,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4C)N,['Investigated for use/treatment in head and neck cancer.'],,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
3116,13117,"ETHYLENE, 1-BROMO-2,2-DIPHENYL-1-(alpha,alpha,alpha-TRIFLUORO-m-TOLYL)-",C1=CC=C(C=C1)C(=C(C2=CC(=CC=C2)C(F)(F)F)Br)C3=CC=CC=C3,,,,,,
3117,13118,1-(3-(5-Nitro-2-furyl)-1-(2-(5-nitro-2-furyl)vinyl)allylideneamino)guanidine hydrochloride,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=NN=C(N)N)C=CC2=CC=C(O2)[N+](=O)[O-],,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
3118,13119,Coco-Quinine,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3CC4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3CC4CCN3C[C@@H]4C=C)O.OS(=O)(=O)O,,,,,,
3119,13120,[(2S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol,COC1=CC2=C(C=CN=C2C=C1)C([C@@H]3CC4CCN3CC4C=C)O,,,,,,
3120,13121,"Disiloxane, 1,3-dimethyl-1,1,3,3-tetraphenyl-",C[Si](C1=CC=CC=C1)(C2=CC=CC=C2)O[Si](C)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3121,13122,Aceperone,CC(=O)NCC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
3122,13123,"Ethylamine, N,N-dimethyl-2-(2-(alpha-(alpha,alpha,alpha-trifluoro-o-tolyl)benzyloxy)ethoxy)-, oxalate",C[NH+](C)CCOCCOC(C1=CC=CC=C1)C2=CC=CC=C2C(F)(F)F.C(=O)(C(=O)[O-])O,,,,,,
3123,13124,"N,N-dimethyl-2-[2-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]ethoxy]ethanamine",CN(C)CCOCCOC(C1=CC=CC=C1)C2=CC=CC=C2C(F)(F)F,,,,,,
3124,13125,3-(Acetyloxy)-14-hydroxycard-20(22)-enolide,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C,,,,,,
3125,13126,Neodin-depositum,CC12CCC3C(C1CCC2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CCC34C,,,,,,
3126,13127,Magnesium cacodylate,C[As](=O)(C)[O-].C[As](=O)(C)[O-].[Mg+2],,,,,,
3127,13128,"2-Methylpropane-1,2-diamine",CC(C)(CN)N,,,,,,
3128,13129,"1,1,1,2-Tetrafluoroethane",C(C(F)(F)F)F,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)', 'Compressed gases or vapors in a container which, upon release of pressure and expansion through a valve, carry another substance from the container. They are used for cosmetics, household cleaners, and so on. Examples are BUTANES; CARBON DIOXIDE; FLUOROCARBONS; NITROGEN; and PROPANE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Aerosol Propellants.)']","['The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 hr, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (C(max)) tended to be higher in males than females. ... In the HFC 134a study, the gender difference in C(max) was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t(1/2)alpha (alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t(1/2)beta (beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. ... Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function.', 'Six male and six female Sprague-Dawley rats were ventilated head-only for 1 hr on a 15% atmosphere of 1,1,1,2-tetrafluoroethane (HFA-134a) in air in a magnetic resonance imaging spectrometer. Results from these dynamic 19F NMR studies suggest that a steady-state in vivo concentration of HFA-134a was approached at approximately 25 min into the exposure. Quantitative integration analysis using an external standard estimated this plateau to be 58.3 +/- 11.9 mg of absorbed HFA-134a per rat. The HFA-134a 19F NMR signal disappeared rapidly following removal of the test atmosphere, with an elimination half-life of 4.6 +/- 0.6 min in the male rats and 4.9 +/- 1.5 min in the female rats. The data suggest that there was no statistical difference between the sexes in amount absorbed or in elimination half-lives.', 'HFA134a (1,1,1,2-tetrafluoroethane) is a nonozone-depleting candidate to replace the chlorofluorocarbons used as propellants in metered-dose inhalers (MDIs) for pharmaceuticals that are widely used in the treatment of respiratory tract disease. As a means for ensuring the safety of such a compound for human use, it is necessary to establish that there is no excessive or unexpected accumulation in the body and in selected regions. A sensitive whole-body gamma-counting technique has been used with 18F-labeled HFA134a to measure the whole-body and regional absorption, distribution, and retention of HFA134a after administration in humans by single-breath inhalation. In seven healthy subjects, labeled HFA134a was rapidly eliminated by ventilation during the first few minutes, with an average of 9.6% of the radioactivity retained in the body at 5 min. This radioactivity cleared with an apparent terminal half-life of 1.5-4.2 hr to leave, on average, < 1% of the administered dose (< 750 micrograms, approximately 0.2 microCi) retained in the body at 5.8 hr. Disposition of radioactivity was independent of the position of label. Thus, there was no evidence of any significant degradative metabolism. On average, only 0.0056% of the administered dose appeared in the urine within the first 2 hr. Later samples contained no significant radioactivity. Inhaled HFA134a first distributed to all regions of the body and then cleared without evident accumulation in any specific region.', 'The safety, tolerability and pharmacokinetics of the chlorine-free propellant HFA134a were assessed in healthy subjects after single and repeat doses. Absorption and disposition were investigated in healthy subjects and severe chronic obstructive pulmonary disease (COPD) patients using labelled HFA134a. There were no clinically significant changes in vital signs, ECG, pulmonary function tests and laboratory parameters measured. No serious adverse events were reported. In both subjects and patients HFA134a was mainly eliminated by exhalation within the first few minutes after administration and was distributed throughout the body with no obvious accumulation in any specific region. HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min). Metabolism was not a significant route of elimination of HFA134a. Studies were also performed with salmeterol and salbutamol MDIs reformulated with HFA134a. The results showed that these MDIs were safe and well tolerated in healthy subjects and gave a similar pharmacodynamic response to the current MDIs.', 'For more Absorption, Distribution and Excretion (Complete) data for 1,1,1,2-TETRAFLUOROETHANE (8 total), please visit the HSDB record page.']","['The metabolic fate and disposition of [U-(14)C]-1,1,1,2-tetrafluoroethane ([U-(14)C]-HFC134a) has been determined in the male and female rat following a 1 hr single exposure by inhalation to atmospheres of 10,000 ppm. Of the inhaled dose, approx. 1% was recovered in urine, feces and expired air postexposure indicating that absorption of this fluorocarbon across the lung is poor. Of this 1%, approx, two-thirds were exhaled within 1 hr of the cessation of exposure as unchanged HFC134a. The remaining radioactivity was exhaled as [(14)C]-carbon dioxide or excreted in urine and feces as trifluoroacetic acid. Carbon dioxide was the major metabolite of HFC134a accounting for 0.22 and 0.27% of the inhaled dose in the male and female rat, respectively. Urinary excretion accounted for 0.09% of the dose and fecal excretion 0.04% of the dose by both sexes. Total metabolism measured as the sum of the radioactivities in urine, feces and as carbon dioxide amounted to 0.34 and 0.40% of the inhaled dose in male and female, respectively. There were no major sex differences in the rates, routes or amounts of radiolabel excreted. Analysis of a range of tissues at 5 days postexposure showed a relatively uniform distribution of radioactivity. There was no evidence for a specific uptake of HFC134a or a metabolite into any organ or tissue analyzed, including fat.', 'The chlorofluorocarbon substitute 1,1,1,2-tetrafluoroethane is subject to metabolism by cytochrome p450 in hepatic microsomes from rat, rabbit, and human. In rat and rabbit, the p450 form 2E1 is a predominant low KM, high rate catalyst of 1,1,1,2-tetrafluoroethane biotranformation and is prominently involved in the metabolism of other tetrahaloalkanes of greater toxicity than 1,1,1,2-tetrafluoroethane (eg, 1,2-dichloro-1,1-difluoroethane). In this study, it was determined that the human ortholog of p450 2E1 plays a role of similar importance in the metabolism of 1,1,1,2-tetrafluoroethane. In human hepatic microsomes from 12 individuals, preparations from subjects with relatively high p450 2E1 levels were shown to metabolize 1,1,1,2-tetrafluoroethane at rates 5- to 10-fold greater than microsomes of individuals with lower levels of this enzyme; the increased rate of metabolism of 1,1,1,2-tetrafluoroethane was specifically linked to increased expression of p450 2E1. The primary evidence for the conclusion is drawn from studies using mechanism based inactivation of p450 2E1 by diethyldithiocarbamate, competitive inhibition of 1,1,1,2-tetrafluoroethane oxidation by p-nitrophenol (a high affinity substrate for p450 2E1), strong positive correlations of rates of 1,1,1,2-tetrafluoroethane defluorination with p-nitrophenol hydroxylation in the study population, and correlation of p450 2E1 levels with rates of halocarbon oxidation. Thus, our findings support the conclusion that human metabolism of 1,1,1,2-tetrafluoroethane is qualitatively similar to that of the species (rat and rabbit) used for toxicological assessment of this halocarbon. Although hazard from 1,1,1,2-tetrafluoroethane exposure is not anticipated in most humans (based on toxicological evaluation in laboratory animals), our results suggest that 1,1,1,2-tetrafluoroethane exposure should be minimized for individuals with chemical exposure histories commensurate with elevation of p450 2E1 (ie, frequent contact with agents such as ethanol, trichloroethylene, or pyridine). Furthermore, these findings suggest that toxicity assessment of certain other haloethanes currently under consideration as replacements for chlorofluorocarbons should be considered in animals with elevated p450 2E1.', '1,1,1,2-Tetrafluoroethane, which lacks ozone depleting potential, has been selected as a replacement refrigerant for dichlorodifluoromethane in air conditioning and chiller applications, and as a propellant for pharmaceutical aerosols. A variety of paradigms using rats and rabbits have shown that 1,1,1,2-tetrafluoroethane has very little toxic potential. To strengthen the prediction of human hazard associated with 1,1,1,2-tetrafluoroethane exposure, the rate of metabolism of this halocarbon by human hepatic microsomes was evaluated relative to similar tissue preparations derived from rats and rabbits. Human microsomes defluorinated 1,1,1,2-tetrafluoroethane in a cytochrome p450 catalyzed reaction, common also to rat and rabbit. In absolute terms, the maximal rate of 1,1,1,2-tetrafluoroethane metabolism by human microsomes was very low, showed little interindividual variation among the samples evaluated (1.3 : 0.3 nmol fluoride ions/mg protein/15 min, x : standard deviation, n = 10), and did not exceed that in rat or rabbit liver microsomes. These findings support the argument that for characterization of 1,1,1,2-tetrafluoroethane toxicity, especially that which may be mediated by products of halocarbon metabolism, laboratory animals are an adequate surrogate for humans.', '1,1,1,2-Tetrafluoroethane (R-134a), a nonozone-depleting alternative air-conditioning refrigerant and propellant for pharmaceutical preparations, is oxidatively defluorinated by rat hepatic microsomes. In this report we show that induction of cytochrome P-450IIE1 in rats, by pyridine administration, resulted in an 8-fold increase in the rate of R-134a metabolism by hepatic microsomes (Vmax 47 vs. 6 nmol F-/mg microsomal protein/15 min). Furthermore, when data were normalized for P-450 content, a 4-fold increase in R-134a metabolism was noted for IIE1-enriched microsome preparations. In contrast, phenobarbital and Aroclor 1254 decreased the specific activity of hepatic microsomes for this function. The microsomal content of P-450IIE1, as evaluated by Western blot, was elevated significantly only in microsomes from pyridine-treated rats. p-Nitrophenol and aniline, which are metabolized at high rates by rat P-450IIE1, decreased the rate of R-134a defluorination by hepatic microsomes; Dixon plot analysis indicated competitive inhibition with a Ki of 36 microM p-nitrophenol or 115 microM aniline. Pyridine also potently induced defluorination of R-134a catalyzed by rabbit liver microsomes. Studies with individual P-450 isozymes purified from rabbit liver showed that the phenobarbital- and polycyclic hydrocarbon-induced isozymes (IIB1 and IA2) defluorinated R-134a at negligible rates (1.9 and 0.4 nmol F-/nmol P-450/60 min, respectively). In contrast, P-450IIE1 catalyzed defluorination of R-134a at a relatively high rate (16.2 nmol F-/nmol P-450/60 min); isozyme IA1, which also is induced by nitrogen-containing heterocycles such as pyridine, was somewhat active (5.3 nmol F-/nmol P-450/60 min).', 'The metabolism of 1,1,1,2-tetrafluoroethane by hepatocytes was investigated. Liver cells were isolated from male Fischer 344 rats and exposed to atmospheres containing 1,1,1,2-tetrafluoroethane and/or halothane and analyzed for fluoride. Fluoride was detected after exposure of hepatocytes to 25% 1,1,1,2-tetrafluoroethane, and the amount increased with the number of cells and with increasing 1,1,1,2-tetrafluoroethane concn. A nonlinear relationship was seen between 1,1,1,2-tetrafluoroethane concn and fluoride, indicating probable substrate saturation.  When hepatocytes were incubated with 25% 1,1,1,2-tetrafluoroethane and halothane, there was a reduction in fluoride production that was related to the concn of halothane. Hepatocytes from phenobarbital treated animals produced as much fluoride as untreated animals in the presence of 12.5% or less 1,1,1,2-tetrafluoroethane, however at a concn of 25% or more 1,1,1,2-tetrafluoroethane, phenobarbital treated cells produced more fluoride than untreated cells. It was concluded that 1,1,1,2-tetrafluoroethane can be metabolized by liver cells, and may involve cytochrome p450.']","['... Ten male volunteers were exposed to 500 ppm HFC-134a (2 hr, 50 W exercise). ... The post-exposure urinary excretion was 0.002% of the inhaled amount, and the half-time was 58 min (pooled data). ... The late decay in blood was consistent with a wash-out of HFC-134a from fat tissues, with a half-time of 114+/-21 min. ...', '... HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min). ...', 'Six male and six female Sprague-Dawley rats were ventilated head-only for 1 hr on a 15% atmosphere of 1,1,1,2-tetrafluoroethane (HFA-134a) in air in a magnetic resonance imaging spectrometer. ... The HFA-134a 19F NMR signal disappeared rapidly following removal of the test atmosphere, with an elimination half-life of 4.6 +/- 0.6 min in the male rats and 4.9 +/- 1.5 min in the female rats. ...', 'The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 hr, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). ... For the HFC 134a study, the t(1/2)alpha (alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t(1/2)beta (beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. ...', 'For more Biological Half-Life (Complete) data for 1,1,1,2-TETRAFLUOROETHANE (8 total), please visit the HSDB record page.']"
3129,13130,Methyl dihydrogen phosphate,COP(=O)(O)O,,,,,,
3130,13131,"1,1,1,2-Tetrachloropropane",CC(C(Cl)(Cl)Cl)Cl,,,,,,
3131,13132,"1,1-Dichloro-1,2,2-trifluoroethane",C(C(F)(Cl)Cl)(F)F,,,,,,
3132,13133,"2,2,3-Trichloropropionitrile",C(C(C#N)(Cl)Cl)Cl,,,,,,
3133,13134,Dimethyl hydrogen phosphate,COP(=O)(O)OC,,,,,,
3134,13135,Bismuth citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3],,,"['Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
3135,13136,Calcium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2],['For use as an over the counter calcium supplement.'],['Increases plasma calcium levels leading to a decrease in calcium flux and increase in calcium deposition into bone'],['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)'],"['The percentage of calcium absorbed varies inversely with intake. Tmax of about 3.5-5h varying with formulation.', 'Cleared via the kidneys but largely reabsorbed (98-99%) under normal conditions.']",,
3136,13137,Strontium monocitrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)O)O.[Sr+2],,,,,,
3137,13138,Tributylphosphine oxide,CCCCP(=O)(CCCC)CCCC,,,"['Herbicides that remove leaves from trees and growing plants. They may be either organic or inorganic. Several of the more persistent types have been used in military operations and many are toxic. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Defoliants, Chemical.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Chemicals that, while not possessing inherent pesticidal activity, nonetheless promote or enhance the effectiveness of other pesticides when combined. (See all compounds classified as Pesticide Synergists.)']",,,
3138,13139,Diethyl chlorophosphate,CCOP(=O)(OCC)Cl,,,,['Skin absorption.'],,
3139,13140,Acryloyl chloride,C=CC(=O)Cl,,,,,,
3140,13141,"Acetic acid, mercapto-, calcium salt (2:1)",C(C(=O)[O-])S.C(C(=O)[O-])S.[Ca+2],,,,,,
3141,13142,3-Bromo-2-butanone,CC(C(=O)C)Br,,,,,,
3142,13143,3-Methyl-3-buten-2-one,CC(=C)C(=O)C,,,,,,
3143,13144,Calcium lactate,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Ca+2],['Indicated for use as the nutritional supplement.'],"['Both components of calcium lactate, calcium ion and lactic acid, play essential roles in the human body as a skeletal element an energy source, respectively.']",,"['In order to be absorbed, calcium must be in its freely soluble form (Ca2+) or bound to a soluble organic molecule. Calcium absorption mainly occurs at the duodenum and proximal jejunum due to more acidic pH and the abundance of the calcium binding proteins. The mean calcium absorption is about 25% of calcium intake (range is 10  40%) in the small intestine, and is mediated by both passive diffusion and active transport.', 'Following oral administration to a human volunteer, 20 to 30% of a dose of lactic acid of up to 3000 mg was excreted via the urine during a period of 14 hours.', 'The majority of calcium absorbed (99%) is stored in the skeleton and teeth for structural integrity.', 'No pharmacokinetic data available.']","['In hepatic gluconeogenesis, lactic acid is converted to glucose. Lactic acid may be further catabolyzed in the lactic acid cycle.', 'RUMINAL INGESTA FROM COWS FED 2.5 L GRAIN-ALFALFA HAY MIXT PROVIDING 545 G OF SODIUM LACTATE & CALCIUM LACTATE DAILY INCUBATED WITH SODIUM LACTATE OR 17 POLY LACTIC ACID. ACETATE WAS PRIMARY END PRODUCT BUT OXIDN OF LACTATE CAUSED SYNTH OF BUTYRATE FROM ACETATE.']",['No pharmacokinetic data available.']
3144,13145,Copper dilactate,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Cu+2],,,,,,
3145,13146,Mercury(2+) lactate,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Hg+2],,,,,,
3146,13147,Chromium(II) oxalate,C(=O)(C(=O)[O-])[O-].[Cr+2],,,,,,
3147,13148,Cupric oxalate,C(=O)(C(=O)[O-])[O-].[Cu+2],,,,,,
3148,13149,Stannous oxalate,C(=O)(C(=O)[O-])[O-].[Sn+2],,,,,,
3149,13150,"3,3-Dimethyl-2-oxobutyric acid",CC(C)(C)C(=O)C(=O)O,,,,,,
3150,13151,"2-Butanol, 3-amino-1,1,1-trichloro-",CC(C(C(Cl)(Cl)Cl)O)N,,,,,,
3151,13152,Hexamethylacetone,CC(C)(C)C(=O)C(C)(C)C,,,,,,
3152,13153,"2,3,3-Trichloroacryloyl chloride",C(=C(Cl)Cl)(C(=O)Cl)Cl,,,,,,
3153,13154,Aluminum tartrate,[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[Al+3].[Al+3],,,,,,
3154,13155,"Copper(II) (2R,3R)-2,3-dihydroxysuccinate",[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[Cu+2],,,,,,
3155,13156,1-Bromo-2-butanone,CCC(=O)CBr,,,,,,
3156,13157,N-Propyl-N-nitrosourea,CCCN(C(=O)N)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
3157,13158,Lead malate,C(C(C(=O)[O-])O)C(=O)[O-].[Pb+2],,,,,,
3158,13159,3-Ethyl-2-pentene,CCC(=CC)CC,,,,,,
3159,13160,Formiminoglutaminsaure,C=NNC(CCC(=O)O)C(=O)O,,,,,,
3160,13161,CID 13161,CCOC(=NCC=C)S,,,,,,
3161,13162,8-Pentadecanone,CCCCCCCC(=O)CCCCCCC,,,,,,
3162,13163,Diethyl glutarate,CCOC(=O)CCCC(=O)OCC,,,,,,
3163,13164,Vinyl octanoate,CCCCCCCC(=O)OC=C,,,,,,
3164,13165,2-Hydroxyethyl acrylate,C=CC(=O)OCCO,,,,"['2-hydroxyethyl acrylate (HEA) has been evaluated in a study that examined metabolism and excretion in male Fischer 344 rat using oral, intraperitoneal, dermal and inhalation routes of exposure ... For the oral and intraperitoneal routes of exposure the rats (four animals/dose level/route of exposure) received a single dose of (14)C-HEA at 2.5 or 50 mg/kg bw. For the inhalation exposure, six rats were exposed to a target concentration of 8 ppm (14)C-HEA for six hours in a head only inhalation chamber. For the dermal exposure, four rats were treated with (14)C-HEA at a dose of 50 mg/kg. No qualitative differences in urinary metabolites between routes were observed, indicating no marked route-dependent differences in the metabolic fate of HEA. The results of the study indicate that once the chemical becomes systemically available it is rapidly metabolized and eliminated from the body as either CO2 in the expired air or urinary metabolites with approximately equal percentage of administered/exposed dose eliminated by each route. The half-lives of elimination of radioactivity were approximately 14 hours for urine and 17 hours for CO2. The halflife of elimination of radioactivity from plasma was approximately 26 hours although the label was not associated with parent HEA. The available metabolic data on HEA is consistent with information on studies with other acrylates where hydrolysis of the ester functionality is the primary metabolic pathway. By analogy with ethyl acrylate and acrylic acid, it is expected that a minor metabolic pathway for HEA will be via conjugation with glutathione with the resulting mercapturic acid derivatives being excreted in the urine.', 'The metabolism and excretion of HEA has been examined in male Fischer 344 rat using oral, intraperitoneal, dermal and inhalation routes of exposure ... For the oral and intraperitoneal routes of exposure the rats (4 animals/dose level/route of exposure) received a single dose of 2.5 or 50 mg/kg bw (approx 15-20 uCi). For the inhalation exposure six rats were exposed to a target concentration of 8 ppm (14)C HEA for 6 hours in a head only inhalation chamber. For the dermal exposure 4 rats were treated with (14)C HEA at a dose of 12.5 mg/kg bw. No qualitative differences in urinary metabolites between routes were observed, indicating no marked route-dependent differences in the metabolic fate of HEA. The results of the study indicate that once the chemical becomes systemically available it is rapidly metabolized and eliminated from the body as either CO2 in the expired air or urinary metabolites. The available metabolic data on HEA is consistent with information on substances with other acrylates where hydrolysis of the ester functionality is the primary metabolic pathway. By analogy with ethyl acrylate and acrylic acid it is expected that a minor metabolic pathway for HEA will be via conjugation with glutathione with the resulting mercapturic acid derivatives being excreted in the urine. For the oral and intraperitoneal routes (2.5 mg/kg bw) 35-36% of the administered dose was expired as (14)CO2 and 43-47% of the dose excreted via the urine by 48 hours post-dosing. At 50 mg/kg bw 40-45% of the dose was expired as (14)CO2 and 33-36% of the dose was excreted in the urine. Following dermal administration 66% of the dose was absorbed within 48 hours of the application with remaining 33% being associated with the application site. Of the absorbed dose 27% was excreted in the urine as metabolites of HEA and 27% was excreted in the expired air as (14)CO2. For inhalation 39% of the absorbed dose was eliminated in the urine by 48 hr and 41% was expired as (14)CO2. For all routes, 9-16% was found in the tissues and carcass and less than 3% in the feces.', 'Following oral administration of (14)C-HEA to Fisher 344 male rats, between 91 and 95% of the administered radioactivity was recovered in the urine, CO2, feces, tissues and carcass, volatile organics and final cage wash. At the low dose of 2.5 mg (14)C-HEA/kg body weight, for the oral route of administration, approximately 43-47 % of the dose was eliminated in the urine, the primary elimination route, whereas 35-36% of the dose was expired as (14)CO2, and the tissues and carcass accounted for between 9-13 % of the dose. Less than 1.5% of the administered dose of radioactivity was recovered in the feces and less than 1% was found in the final cage wash. Less than 0.2% of the dose was recovered as volatile organics in the expired air. At the higher dose of 50 mg/kg (14)C-HEA/kg body weight, for the oral route of administration, 33-36% of the dose was eliminated in the urine, whereas 40-45% of the dose was expired as (14)CO2. At this higher dose there was a shift from the urinary pathway as the primary route of elimination to the exhalation of (14)CO2 as the primary route of elimination. As with the 2.5 mg/kg dose, the tissues and carcass accounted for 10-13% of the dose and less than 0.6% of the recovered radioactivity was in the final cage wash, less than 0.1% was recovered as volatile organics in the expired air and less than 2.5% of the dose was recovered in the feces. Following the oral route of administration, 0.3-1.5% of the dose was expired as (14)CO2 as early as 15 minutes post-dosing. The peak of CO2 excretion occurred during or before the 4-8 hr collection interval. By 12 hr post-dosing with 2.5 mg/kg for the oral route of administration, 31-32  of the dose was expired as (14)CO2. For this same collection interval following 50 mg/kg oral administration, 41  of the dose was expired as (14)CO2. The exhalation of (14)CO2 derived from (14)C-HEA appeared to follow first-order kinetics as a biphasic process, except following dermal administration. Following oral administration, greater than 92% of the total radioactivity excreted via the urine was excreted during the first 12 hr collection interval.']",,"['Following the 2.5 mg/kg and 50 mg/kg oral dose /in Fisher 344 male rats/, the half-lives for the terminal phase of elimination via (14)CO2 were determined to be approximately 15, and 14 hr, respectively. The half-lives for the initial phase of elimination were 1.9, and 1.8, respectively.  The half life of elimination of radioactivity in the urine following oral administration were 10, and 9 hr for the 2.5 mg/kg bw oral and 50 mg/kg bw oral treatment groups, respectively.']"
3165,13166,1-Octyn-3-OL,CCCCCC(C#C)O,,,,,,
3166,13167,Calcium methionate,C(S(=O)(=O)[O-])S(=O)(=O)[O-].[Ca+2],,,,,,
3167,13168,"Ethylamine, N-methyl-N-nitroso-2,2,2-trifluoro-",CN(CC(F)(F)F)N=O,,,,,,
3168,13169,"Diisopropylamine, hydrochloride",CC(C)[NH2+]C(C)C.[Cl-],,,,,,
3169,13170,Disodium beta-glycerophosphate pentahydrate,C(CO)C(CCO)OP(=O)([O-])[O-].C(C(COP(=O)([O-])[O-])O)O.[Na+].[Na+].[Na+].[Na+],,,,,,
3170,13171,"1,5-Dihydroxypentan-3-yl dihydrogen phosphate",C(CO)C(CCO)OP(=O)(O)O,,,,,,
3171,13172,"N-Diazoacetyl-D,L-alanine ethyl ester",CCOC(=O)C(C)NC(=O)C=[N+]=[N-],,,,,,
3172,13173,CID 13173,CCOC(=O)C(C)NC(=C[N+]#N)O,,,,,,
3173,13174,sec-Butyl butyrate,CCCC(=O)OC(C)CC,,,,,,
3174,13175,5-Decanone,CCCCCC(=O)CCCC,,,,,,
3175,13176,Methyl divinyl acetylene,CC(=C)C#CC=C,,,,,,
3176,13177,"1,2-Diacetylethylene",CC(=O)C=CC(=O)C,,,,,,
3177,13178,Diazoacetylglycine hydrazide,C(C(=O)NN)NC(=O)C=[N+]=[N-],,,,,,
3178,13179,2-[(2-Hydrazinyl-2-oxoethyl)amino]-2-hydroxyethenediazonium,C(C(=O)NN)NC(=C[N+]#N)O,,,,,,
3179,13180,"2-Butene, 1,4-dibromo-",C(C=CCBr)Br,,,,,,
3180,13181,4-Penten-1-OL,C=CCCCO,,,,,,
3181,13182,"1,4-Dichloro-2-butyne",C(C#CCCl)Cl,,,,,,
3182,13183,Azoethane,CCN=NCC,,,,,,
3183,13184,"1,1-Dichloroheptane",CCCCCCC(Cl)Cl,,,,,,
3184,13185,Tetradecanedioic acid,C(CCCCCCC(=O)O)CCCCCC(=O)O,,,,,,
3185,13186,Bis(2-chloroethyl)ammonium chloride,C(CCl)[NH2+]CCCl.[Cl-],,,,,,
3186,13187,2-Nonanone,CCCCCCCC(=O)C,,,,,,
3187,13188,"Heptanoic acid, 7-chloro-",C(CCCCl)CCC(=O)O,,,,,,
3188,13189,"1,1-Dichlorononane",CCCCCCCCC(Cl)Cl,,,,,,
3189,13190,1-Undecene,CCCCCCCCCC=C,,,,,,
3190,13191,"1,9-Dichlorononane",C(CCCCCl)CCCCCl,,,,,,
3191,13192,Hexamethylene diisocyanate,C(CCCN=C=O)CCN=C=O,,,"['Any substance in the air which could, if present in high enough concentration, harm humans, animals, vegetation or materials. Substances include GASES; PARTICULATE MATTER; and volatile ORGANIC CHEMICALS. (See all compounds classified as Air Pollutants.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Toxic air-borne matter related to work performed They are usually produced by the specific nature of the occupation. (See all compounds classified as Air Pollutants, Occupational.)']","['Absorption of significant amounts of HDI into the general circulation would not be expected. Any free HDI that may reach the blood may bind to serum proteins and not be available as a free form in the blood.', 'Six males were administered an oral dose of 0.1 mg/kg HDA on 2 occasions 3 months apart, and urine was collected for several hours after dosing. Peak amounts of free HDA in single urine samples ranged from 0.080 to 0.19 mg 2-5 hours after dosing. Four of the 6 men tested had no detectable levels of HDA in their urine 10 hours after dosing; however, 2 subjects had detectable levels of HDA in the urine 15 hours after dosing. ... 1-6% of the total HDA dose was recovered in the urine. /1,6-Hexamethylene diamine/', '5 men (age, 36-50 years; mean age, 42 years) inhaled 95-L 15 ug (0.01-0.02 ppm) of HDI in air (range, 25-29 ug/cu m or approximately 0.004 ppm) for 7.5 hours. Blood and urine samples were taken at 2-hour intervals. Beginning almost immediately after exposure, urinary levels of 1,6-hexamethylene diamine (HDA) began to accumulate in the urine. The urinary elimination rates for all men ranged from 1.1 to 1.7 ug/hr, with the average urinary level of HDA ranging from 0.01-0.03 mmol/mol creatinine for the 5-hour sample and 0.006 mmol/mol creatinine for the 10-hour sample. HDA levels were undetectable by 15 hours after exposure began (or 7.5 hours after exposure ended). The cumulative excretion of HDA over a 28hour period was 8.0-14 ug, which is about 1l-21% of the inhaled dose of HDI.', 'On the basis of the ability to acetylate an oral dose of HDA, /investigators/ determined the phenotypes of 6 individuals as either rapid or slow acetylators. The rapid acetylators excreted approximately twice as much acetylated HDA over the subsequent 15 hours as did the slow acetylators. The potential importance of this difference in excretory rates with respect to toxicity has not been investigated. However, the author suggests that after measurements of urinary metabolites have been made in conjunction with determinations of acetylation phenotypes, it would be worth considering the possibility of biological monitoring of occupation exposure to HDA and HDI.']","['Volunteers exposed to HDI in a test chamber (3.6 ppb for 7.5 hours) had the corresponding amine (1,6-hexamethylene diamine, HDA) in hydrolyzed urine. The biological half time was about 1 hour. In a similar study with lower exposures (1.7 to 3.1 ppb for 2 hours), HDA levels in urine were proportional to HDI levels in air, and the half time was 2.5 hours. HDA could not be found in unhydrolyzed urine, which suggests that this metabolite occurs as an adduct. HDA was not detected in plasma in either of these studies. HDA could be identified in hydrolyzed urine from car painters exposed to prepolymerized HDI and production workers making HDI monomers. Of 22 car painters who used HDI-based paint and wore face masks with air filters, 4 had HDA in hydrolyzed urine; none of seven controls had detectable amounts.', 'Authors noted two pathways by which HDA could be metabolized: (1) to N-acetyl-1,6-hexamethylene diamine, via N-acetyl transferase, and (2) 6-aminohexanoic acid, via diamine oxidase. Both HDA metabolites may appear in the urine. /1,6-Hexamethylene diamine/', 'The hydrolysis of hexamethylene diisocyanate in water was tested in a dynamic and stationary system. Without catalysts, the reaction was very slow (< 1% in 10 min at 30 C) while the addition of simple carboxylic acid containing neutral buffers markedly catalyses the formation of 1,6-diaminohexane as the known hydrolysis product. It is suggested that the hydrolysis of inhaled hexamethylene diisocyanate in the lungs may be catalysed by bicarbonate in the blood, giving rise to amines found as urinary metabolites following occupational exposure.']","['Six males were administered an oral dose of 0.1 mg/kg HDA on 2 occasions 3 months apart, and urine was collected for several hours after dosing. ... The elimination half-life was calculated to be approximately 1.5 hours... /1,6-Hexamethylene diamine/', 'The urinary elimination was rapid, and half-time, for the concentration of 1,6-hexamethylene diamine in urine, showed an average of 1.2 hr (range 1.1-1.4 hr).']"
3192,13193,1-Chlorotridecane,CCCCCCCCCCCCCCl,,,,,,
3193,13194,CID 13194,CCCCCCCCCCCCCCCCCC(=O)[O-].[Na+],,,,,,
3194,13195,4-Methylimidazole,CC1=CN=CN1,,,,"[""4-methylimidazole (4-MI) was given orally to a cow in increased dosages to determine if it could be detected in her milk and be present at a concn high enough to affect her nursing calf. 4-MI was found in the milk, but the calf remained clinically normal throughout the experiment. The cow died after the fourth dose of 20 g 4-MI. Four groups of 10 mice each were given oral doses of water, normal milk, cow's milk after low doses of 4-MI, or cow's milk after high doses of 4-MI. All mice remained healthy after a 2-wk feeding trial. Six 3-day-old calves were given 4-MI directly in their bottles of milk up to 2 times the highest level found in toxic feed with only mild depression noted in one calf. Two pregnant cows were given 4-MI pre-partum to determine if it would get into the colostrum at higher levels. Both cows received 4-MI 3 days before they calved and for 2 wk afterward. Cow A exhibited trembling, excessive salivation and incoordination after the initial dose. Cow B and the newborn calves were never affected throughout the experiment. Each time the dose of 4-MI reached 1.5 g or more, Cow A would exhibit the previously described signs. 4-MI was detected in the colostrum but not in higher concentrations than in the other milk samples."", 'The toxicokinetics and metabolism of 4-methylimidazole (4-MZ) have been studied in the male F344 rat using 14C radiolabelled compound. Radioactivity in plasma and urine was profiled by HPLC. After gavage administration of 50 mg/kg, about 85% of the administered radioactivity was recovered in urine within 48 hr. The majority of the radioactivity in urine or plasma was associated with the parent compound and only one minor hydrophilic metabolite was present in urine and in plasma. Elimination of radioactivity via fecal, biliary or respiration was negligible. Elimination of 4-MZ after an iv dose of 5 mg/kg can be described by a two-compartment process with an estimated half-life of 1.8 hr and an estimated apparent volume of distribution of 2.3 L/kg. After gavage at doses of 5, 50 and 150 mg/kg, 4-MZ was readily absorbed with a estimated bioavailability of 60-70%. Urinary excretion data indicated that renal clearance of 4-MZ accounted for about 80% of total body plasma clearance. Based on the estimated AUC of metabolite and the estimated renal clearance of 4-MZ, the formation of metabolite and the renal clearance of 4-MZ appeared to be a saturable process.']",,['The toxicokinetics and metabolism of 4-methylimidazole (4-MZ) have been studied in the male F344 rat using 14C radiolabelled compound ... Elimination of 4-MZ after an iv dose of 5 mg/kg can be described by a two-compartment process with an estimated half-life of 1.8 hr ...']
3195,13196,"1,3-Dithiolane-2-thione",C1CSC(=S)S1,,,,,,
3196,13197,"(2R)-1,2-dimethylcyclopentane",C[C@@H]1CCCC1C,,,,,,
3197,13198,2-Cyclohexen-1-OL,C1CC=CC(C1)O,,,,,,
3198,13199,Cyclohexylphosphine,C1CCC(CC1)P,,,,,,
3199,13200,"Bicyclo[2.2.1]hepta-2,5-dien-7-ol",C1=CC2C=CC1C2O,,,,,,
3200,13201,"2-Isopropyl-1,3-dioxolane",CC(C)C1OCCO1,,,,,,
3201,13202,"1,2-Dichlorocyclohexane",C1CCC(C(C1)Cl)Cl,,,,,,
3202,13203,2-Chlorocyclohexanone,C1CCC(=O)C(C1)Cl,,,,,,
3203,13204,delta-Hexalactone,CC1CCCC(=O)O1,,,,,,
3204,13205,"2,6-Diaminotoluene",CC1=C(C=CC=C1N)N,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']","['2,6-TDA is rapidly absorbed in the digestive tract. ...  Rats given 10-milligram oral doses of (14)C-2,6-TDA eliminated 85% of the radioactivity in urine within 24 hours. No unmetabolized 2,6-TDA was found in the urine. After 6 days, 1% of the radioactivity could still be detected in tissues.', '... 2,6-Diaminotoluene was rapidly and extensively absorbed following oral administration, indicating that its lack of carcinogenicity is not due to poor absorption from the gastrointestinal tract. 2,6-DAT was also rapidly excreted, with 85% of 2,6-DAT-associated radioactivity being recovered in the urine within 24 hr. ...']","['It undergoes hydroxylation and N-acetylation, and the primary metabolites found in urine /of rats/ are 2,6-diacetylaminotoluene and 6-acetylamino-2-amino-3-hydroxytoluene.', '... Resolution of the urine by reverse phase HPLC demonstrated the presence of four metabolites, but none of the parent 2,6-DAT. Therefore, the lack of carcinogenicity of 2,6-DAT /in rats/ is not due to lack of biotransformation in vivo. Following separation by HPLC, the metabolites were analyzed by electron impact and fast atom bombardment mass spectroscopy and by NMR spectroscopy. The metabolites were identified as a) 3-hydroxy-2,6-DAT, b) 4-hydroxy-2-acetylamino-6-aminotoluene, c) 2-acetylamino-6-aminotoluene, and d) 2,6-di(acetylamino)-toluene. ...', 'Male F344-rats were randomly assigned to treatment groups and given a single 10 milligram dose of carbon-14 tagged 2,6-diaminotoluene by gavage. ...Four unique metabolites of 2,6-diaminotoluene were identified in the 24 hour urine specimens by reverse phase HPLC. The metabolites, identified by spectroscopic data, were 3-hydroxy-2,6-diaminotoluene, 5-hydroxy-2-acetylamino-6-aminotoluene, 2-acetylamino-6-aminotoluene, and 2,6-di(acetylamino)-toluene; the latter two metabolites caused significant mutagenicity in the presence of S9 activation. ...']","['Both 2,4-TDA and 2,6-TDA have been identified in hydrolyzed urine of persons exposed to toluene diisocyanates (TDI), and there are some studies of excretion of 2,4-TDA and 2,6-TDA by persons exposed to TDI. In one study of TDI-exposed workers, the half time in urine was determined to be 18 days for 2,4-TDA and 19 days for 2,6-TDA, and the half time in plasma 7.8 days for 2,4-TDA and 9.6 days for 2,6-TDA. In another study, in which volunteers were exposed to TDI for 4 hours, the half time in plasma for 2,4-TDA and 2,6-TDA was 2 to 5 hours during the initial elimination phase and more than 6 days in the slower phase.']"
3205,13206,2-Methyl-5-nitrofuran,CC1=CC=C(O1)[N+](=O)[O-],,,,,,
3206,13207,Cyclohexyl methyl ketone,CC(=O)C1CCCCC1,,,,,,
3207,13208,"2,4,6-Trimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)C)C,,,,,,
3208,13209,"s-Triazine, 2,4-diamino-6-fluoro-",C1(=NC(=NC(=N1)F)N)N,,,,,,
3209,13210,Trimethylolpropane phosphite,CCC12COP(OC1)OC2,,,,,,
3210,13211,4-Methylindan,CC1=C2CCCC2=CC=C1,,,,,,
3211,13212,CID 13212,C1=CC=C(C(=C1)C(=O)[O-])O.C1=CC=C(C(=C1)C(=O)[O-])O.[Ca+2],,,,,,
3212,13213,"1H-Indene, 2,3-dihydro-2-methyl-",CC1CC2=CC=CC=C2C1,,,,,,
3213,13214,Sodium 4-nitrophenolate,C1=CC(=CC=C1[N+](=O)[O-])[O-].[Na+],,,,"['Based on the rapid urinary elimination of the mononitrophenols, the compounds may be restricted primarily to the blood and urine following absorption by humans. /Mononitrophenols/', '... Shown to permeate the skin and produce damage at threshold concentration of 0.9 percent (wt/vol). /4-Nitrophenol/', 'EXCRETION BY MICE, RATS, RABBITS, AND GUINEA PIGS IS ... RAPID. MOST DOSES WERE COMPLETELY ELIMINATED FROM BLOOD WITHIN 2 HR AFTER ADMIN. RATES @ WHICH 4-NITROPHENOL DISAPPEARED FROM BLOOD DECR IN FOLLOWING DESCENDING ORDER: MOUSE, RABBIT, GUINEA PIG, RAT, AND MONKEY. /4-Nitrophenol/', 'Mononitrophenols are readily absorbed by the gastrointestinal tract & rapidly excreted primarily in the urine. ... Elimination of 4-nitrophenol by monkey following oral and ip doses of 20 mg/kg ... complete within 5 hr. /4-Nitrophenol/', 'For more Absorption, Distribution and Excretion (Complete) data for P-NITROPHENOL SODIUM SALT (7 total), please visit the HSDB record page.']","['... EXCRETION OF 4-NITROPHENOL FROM 19 YR OLD FEMALE FOLLOWING SUICIDAL ORAL DOSE OF NITROBENZENE /REPORTED/. LARGE QUANTITIES ... DETECTED IN URINE. /4-NITROPHENOL/', 'P-NITROPHENOL YIELDS P-NITROPHENYL-BETA-D-GALACTOSIDE IN GUINEA PIGS. YIELDS P-NITROPHENYL-ALPHA-D-GLUCOSIDE IN ASPERGILLUS. /FROM TABLE/ /4-NITROPHENOL/', '(ROBINSON ET AL; BIOCHEM J 50: 221 (1951)) P-NITROPHENOL YIELDS P-AMINOPHENOL IN RAT, BASS, CARP, CATFISH, LAMPREY, PERCH, PIKE, SALMON, STURGEON. YIELDS P-AMINOPHENOL & P-NITROPHENYL SULFATE, 4-NITROCATECHOL IN RABBIT. /FROM TABLE/ /4-NITROPHENOL/', 'SULFATE CONJUGATION OF 4-NITROPHENOL ... IS DECR DURING PREGNANCY IN RABBITS ... AND INCR WITH AGE IN RAT, GUINEA PIG, AND HUMANS ... RELATIVE RATES OF GLUCURONIDE VERSUS SULFATE CONJUGATION OF 4-NITROPHENOL MAY DEPEND ON LEVELS OF PHENOL PRESENT. /4-NITROPHENOL/', 'For more Metabolism/Metabolites (Complete) data for P-NITROPHENOL SODIUM SALT (11 total), please visit the HSDB record page.']",
3214,13215,CID 13215,CC1=CC=C(C=C1)S(=O)[O-].[Na+],,,,,,
3215,13216,"2-Naphthalenol, decahydro-",C1CCC2CC(CCC2C1)O,,,,,,
3216,13217,"2-Phenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=NN=CO2,,,,,,
3217,13218,4-Iodobenzenesulfonamide,C1=CC(=CC=C1S(=O)(=O)N)I,,,,,,
3218,13219,"2,5-Dinitrofuran",C1=C(OC(=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3219,13220,"2,2,6,6-Tetramethyl-4-piperidone",CC1(CC(=O)CC(N1)(C)C)C,,,,,,
3220,13221,Mecamylamine hydrochloride,CC1(C2CCC(C2)C1(C)NC)C.Cl,,,,,,
3221,13222,2-Phenylisobutyric acid,CC(C)(C1=CC=CC=C1)C(=O)O,,,,,,
3222,13223,"5-Norbornene-2,3-dicarboxylic anhydride",C1C2C=CC1C3C2C(=O)OC3=O,,,,,,
3223,13224,8-Hydroxyquinaldine,CC1=NC2=C(C=CC=C2O)C=C1,,,,,,
3224,13225,Trimethyl isocyanurate,CN1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
3225,13226,CID 13226,CC1=CC(=C(C=C1)C)S(=O)(=O)[O-].[Na+],,,,,,
3226,13227,2-(Dimethylamino)-2-phenylacetonitrile,CN(C)C(C#N)C1=CC=CC=C1,,,,,,
3227,13228,N-(2-Bromoethyl)-N-ethylaniline,CCN(CCBr)C1=CC=CC=C1,,,,,,
3228,13229,Cyclohexylbenzene,C1CCC(CC1)C2=CC=CC=C2,,,,,,
3229,13230,2-Vinylnaphthalene,C=CC1=CC2=CC=CC=C2C=C1,,,,,,
3230,13231,"2,6-Dibromo-4-nitroaniline",C1=C(C=C(C(=C1Br)N)Br)[N+](=O)[O-],,,,,,
3231,13232,Dimethoxane,CC1CC(OC(O1)C)OC(=O)C,,,,,,
3232,13233,"2,2,4,4,6,6-Hexamethyl-1,3,5-trithiane",CC1(SC(SC(S1)(C)C)(C)C)C,,,,,,
3233,13234,2-Methyl-2-phenylbutanoic acid,CCC(C)(C1=CC=CC=C1)C(=O)O,,,,,,
3234,13235,1-Adamantanecarboxylic acid,C1C2CC3CC1CC(C2)(C3)C(=O)O,,,,,,
3235,13236,Pentafluorophenylhydrazine,C1(=C(C(=C(C(=C1F)F)F)F)F)NN,,,,,,
3236,13237,"2,3,6-Trimethylnaphthalene",CC1=CC2=C(C=C1)C=C(C(=C2)C)C,,,,,,
3237,13238,"1-AZIRIDINECARBOXAMIDE, N-(p-TOLYL)-",CC1=CC=C(C=C1)NC(=O)N2CC2,,,,,,
3238,13239,Dicyclohexylphosphine,C1CCC(CC1)PC2CCCCC2,,,,,,
3239,13240,"Guanidine, 1-(benzyloxy)-1-methyl-, hydrochloride",CN(C(=N)N)OCC1=CC=CC=C1.Cl,,,,,,
3240,13241,1-Methyl-1-phenylmethoxyguanidine,CN(C(=N)N)OCC1=CC=CC=C1,,,,,,
3241,13242,Hept-1-enylbenzene,CCCCCC=CC1=CC=CC=C1,,,,,,
3242,13243,4-Nitrophenyl acetate,CC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3243,13244,"Furan,2-nitro-5-(2-nitroethenyl)-",C1=C(OC(=C1)[N+](=O)[O-])C=C[N+](=O)[O-],,,,,,
3244,13245,3-(4-Methoxy-phenyl)-acrylic acid,COC1=CC=C(C=C1)C=CC(=O)O,,,,,,
3245,13246,Cyclododecanone,C1CCCCCC(=O)CCCCC1,,,,,,
3246,13247,1-Naphthyl acetate,CC(=O)OC1=CC=CC2=CC=CC=C21,,,,,,
3247,13248,CID 13248,CC(C)CC1C(=O)N(C(=N1)S)CC=C,,,,,,
3248,13249,"Indole, 5-bromo-3-(dimethylamino)methyl-",CN(C)CC1=CNC2=C1C=C(C=C2)Br,,,,,,
3249,13250,Ethyl gallate,CCOC(=O)C1=CC(=C(C(=C1)O)O)O,,,,,,
3250,13251,CID 13251,C1=C(OC(=C1)[N+](=O)[O-])C=NN=C(N)S,,,,,,
3251,13252,Aminozectran,CC1=CC(=CC(=C1N)C)OC(=O)NC,,,,,,
3252,13253,4-Chlorodiphenylmethane,C1=CC=C(C=C1)CC2=CC=C(C=C2)Cl,,,,,,
3253,13254,4-Phenoxyphenol,C1=CC=C(C=C1)OC2=CC=C(C=C2)O,,,,,,
3254,13255,Benzyl phenyl sulfide,C1=CC=C(C=C1)CSC2=CC=CC=C2,,,,,,
3255,13256,4-Methylphenanthrene,CC1=C2C(=CC=C1)C=CC3=CC=CC=C32,,,,,,
3256,13257,1-Methylphenanthrene,CC1=C2C=CC3=CC=CC=C3C2=CC=C1,,,,,,
3257,13258,3-Methylphenanthrene,CC1=CC2=C(C=C1)C=CC3=CC=CC=C32,,,,,,
3258,13259,"Indole, 3-(2-amino-2-methylpropyl)-5-bromo-",CC(C)(CC1=CNC2=C1C=C(C=C2)Br)N,,,,,,
3259,13260,1-(5-chloro-1H-indol-3-yl)-2-methylpropan-2-amine,CC(C)(CC1=CNC2=C1C=C(C=C2)Cl)N,,,,,,
3260,13261,o-Nitrophenethyl acetate,CC(=O)OCCC1=CC=CC=C1[N+](=O)[O-],,,,,,
3261,13262,6-Acetamidocoumarin,CC(=O)NC1=CC2=C(C=C1)OC(=O)C=C2,,,,,,
3262,13263,Ametryn,CCNC1=NC(=NC(=N1)SC)NC(C)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Absorption, biotransformation, and excretion of (14)C-ametryne was rapid after oral dose to rat. In 24 hr, 52% of (14)C from ring labelled ametryne was excreted in urine and 18% in feces, and within 72 hr elimination was almost complete when further 6% had been excreted in urine, 14% in feces, and <2% remained in carcass. After 6 hr, levels of (14)C-ametryne were maximal in organs of absorption, biotransformation, and excretion by the stomach, liver, and kidneys, and also in spleen and lung, but these levels decreased with time although blood levels remained constant for 72 hr.', 'The excretion of ametryn utilizing uniformly labeled compound with (14)C-ametryn in the ring or in the ethyl or isopropyl side chains. Forty eight hours after oral dosing of six male and six female Sprague Dawley rats, 57.6% of the ring labeled activity had been excreted in the urine and 32.1% in the feces (total 89.7% of dose). When the fed compound was labeled in the side chains, however, much of the (14)C was excreted in expired air as carbon dioxide. When the fed compound was labeled in the isopropyl side chain, rats excreted 41.9% of the label in expired air, 20% in the urine, 2% in the feces, and 7% remained in the carcass (total 70.9%) at 48 hours. When the ethyl side chain contained the label, 18.1% of the label was excreted as carbon dioxide, 45% in the urine, 5% in the feces and 9% remained in the carcass (total 77.1% of dose). After 72 hours, total recovery was approximately 88% for both of the side chain labeled compounds.', 'Ring labeled ametryn /was administered/ orally to male and female Sprague Dawley rats and measured distribution of label in tissues at 6, 48 and 72 hours after dosing. Tissue distribution at 6 hours was greatest in kidney, followed by liver, spleen, blood, lung, fat, carcass, brain, and muscle. Blood levels remained relatively constant for 72 hours after dosing, while all other tissue levels dropped rapidly to <0.1% of dose per gram of tissue.', '... Most of the radioactive dose was excreted rapidly by lactating goats in urine (70%) and feces (20%) or predominantly in excreta (90%) by hens.', 'They are efficiently absorbed from intestine, and presumably there is some absorption across the skin and lung. /Urea-, uracil- and triazine-based herbicides/']","['V79 Chinese hamster cell lines were genetically engineered for the stable expression of human NADPH-cytochrome P450 oxidoreductase (CYPOR) alone or for the combined expression of NADPH-cytochrome P450 oxidoreductase and human cytochrome P450 1A2 (CYP1A2). As determined by immunoblotting, the expression level of cytochrome P450 1A2 in the latter cell line was found to be the same as in a previously constructed V79 cell line expressing cytochrome P450 1A2 only. The heterologous expression of NADPH-cytochrome P450 oxidoreductase in V79 cells resulted in increased sensitivity to quinone-type cytotoxins, eg. duroquinone and menadione, that exert their toxicity primarily through the production of reactive oxygen species during redox cycling. The metabolic properties of the cell line expressing both NADPH-cytochrome P450 oxidoreductase and cytochrome P450 1A2 were characterized regarding dealkylation and deethylation of 7-alkoxyresorufins and sulfoxidation of the triazine derivatives ametryne and terbutryne, in comparison with the cell line expressing only cytochrome P450 1A2. Increased NADPH-cytochrome P450 oxidoreductase activity impaired the cytochrome P450 1A2-dependent fluorometric resorufin assay, presumably by conversion of the 8-alkoxyresorufins and resorufin to their one-electron-reduced semiquinoneimine forms. The cytochrome P450 1A2-dependent metabolism of the triazine derivatives ametryne and terbutryne was moderately enhanced by increased NADPH-cytochrome P450 oxidoreductase activity. Interestingly, with NADPH-cytochrome P450 oxidoreductase overexpression sulfoxidation was increased 2-3-fold, compared with N-deethylation, with a 1.3-1.9-fold increase. Thus, the level of NADPH-cytochrome P450 oxidoreductase not only had an influence on cytochrome P450 1A2 activity rates but also affected the relative proportions of metabolites in cytochrome P450 1A2-specific metabolite profiles.', 'Usually metabolized by tolerant plants, & to lesser extent by sensitive plants to nontoxic substances such as hydroxyl or dealkylated derivatives. It appears likely that hydroxy-atrazine is the first metabolite, & that degradation within plants is the major protective mechanism.', '(14)C-labeled ametryn was administered orally to groups of six male and six female Sprague Dawley rats. When the label was in the isopropyl side chain, 41.9% of the label appeared as CO2. When the label was in the ethyl side chain, 18.1% of the label appeared as CO2. This indicated that the side chains were extensively metabolized. When the ring was uniformly labeled with carbon-14 and the compound fed orally to rats, 58% was excreted in the urine but it was not determined whether excretion of the original compound or metabolites had occurred.', '... The participation of P450 and flavin-containing monooxygenase in the sulfoxidation of four sulfur containing pesticides, ametryne; terbutryne, prometryne and methiocarb was investigated using human liver microsomes. All four reactions were demonstrated to be catalyzed predominantly by cytochrome P450.', 'For more Metabolism/Metabolites (Complete) data for Ametryne (8 total), please visit the HSDB record page.', 'Ametryn has known human metabolites that include 1,3,5-Triazine-2,4-diamine, N-(1-methylethyl)-6-(methylthio)- and 1,3,5-Triazine-2,4-diamine, N-ethyl-6-(methylthio)-.']",
3263,13264,1-Benzyl-4-methoxybenzene,COC1=CC=C(C=C1)CC2=CC=CC=C2,,,,,,
3264,13265,4-Styrylphenylamine,C1=CC=C(C=C1)C=CC2=CC=C(C=C2)N,,,,,,
3265,13266,Phenformin hydrochloride,C1=CC=C(C=C1)CCN=C(N)N=C(N)N.Cl,,,,,,
3266,13267,1-Cyclohexyl-5-methylbarbituric acid,CC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3267,13268,Fluorodopan,CC1=C(C(=O)NC(=O)N1)N(CCF)CCCl,,,,,,
3268,13269,2-(2-Hydroxyphenyl)benzoxazole,C1=CC=C(C(=C1)C2=NC3=CC=CC=C3O2)O,,,,,,
3269,13270,"1,3,5-Triazine-2,4-diamine, N-ethyl-N'-(1-methylpropyl)-6-(methylthio)-",CCC(C)NC1=NC(=NC(=N1)NCC)SC,,,,,,
3270,13271,4-Nitrodiphenylamine,C1=CC=C(C=C1)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3271,13272,Methyl 2-cyano-3-(5-nitrofuran-2-yl)prop-2-enoate,COC(=O)C(=CC1=CC=C(O1)[N+](=O)[O-])C#N,,,,,,
3272,13273,"5-[2-(5-nitrofuran-2-yl)ethenyl]-3H-1,3,4-oxadiazol-2-one",C1=C(OC(=C1)[N+](=O)[O-])C=CC2=NNC(=O)O2,,,,,,
3273,13274,(3-Phenylpropoxy)guanidine nitrate,C1=CC=C(C=C1)CCCON=C(N)N.[N+](=O)(O)[O-],,,,,,
3274,13275,2-(3-Phenylpropoxy)guanidine,C1=CC=C(C=C1)CCCON=C(N)N,,,,,,
3275,13276,1-Cyclohexyl-5-ethylbarbituric acid,CCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3276,13277,"10-Methylacridin-10-ium-2,7-diamine",C[N+]1=C2C=CC(=CC2=CC3=C1C=CC(=C3)N)N,,,,,,
3277,13278,3-(3-Pyridyl)coumarin,C1=CC=C2C(=C1)C=C(C(=O)O2)C3=CN=CC=C3,,,,,,
3278,13279,"4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one",CC1=CN(C(=O)N=C1N)[C@H]2CC([C@H](O2)CO)O,,,,,,
3279,13280,"Acetanilide, 2-chloro-N-ethyl-4'-sulfamoyl-",CCN(C1=CC=C(C=C1)S(=O)(=O)N)C(=O)CCl,,,,,,
3280,13281,Ethyl 4-nitrobenzoylacetate,CCOC(=O)CC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3281,13282,Diphenyl phosphate,C1=CC=C(C=C1)OP(=O)(O)OC2=CC=CC=C2,,,,,,
3282,13283,"4,4'-Methylenebis(2-methylaniline)",CC1=C(C=CC(=C1)CC2=CC(=C(C=C2)N)C)N,,,,,,
3283,13284,"N,N-Dimethyl-p-styrylaniline",CN(C)C1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
3284,13285,1-Cyclohexyl-5-isopropylbarbituric acid,CC(C)C1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3285,13286,Tris(2-hydroxyethyl) isocyanurate,C(CO)N1C(=O)N(C(=O)N(C1=O)CCO)CCO,,,,,,
3286,13287,"Coumarin, 6-chloro-3-(4-pyridyl)-",C1=CC2=C(C=C1Cl)C=C(C(=O)O2)C3=CC=NC=C3,,,,,,
3287,13288,CID 13288,C1=CC(=CC(=C1)O)C=NNC(=O)C2=CC=NC=C2,,,,,,
3288,13289,Ethyl N-acetyl-L-tyrosinate,CCOC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)C,,,,,,
3289,13290,Methoprotryne,CC(C)NC1=NC(=NC(=N1)NCCCOC)SC,,,,"['After oral administration, 85-95% elimination occurs within 24 hr, in the metabolized form and mainly in the urine. /In plants it is/ absorbed via the leaves and roots.']","['All of ... /methoxy & methylthio-substituted triazine/ herbicides were rapidly absorbed and metabolized when ingested; amine dealkylation and side chain oxidation are the predominant detoxification reactions. The mercapto derivatives of triazine may also undergo sulfoxidation followed by reaction with hepatic glutathione to yield mercapturic acid derivatives. /Prometon/', 'In ... plants, cleavage of the thiomethyl group and replacement with hydroxyl /occurs presumably/ after oxidation of the sulfur to sulfoxide and sulfone. Demethylation of the amino groups at C4 and C6, cleavage of the amine moieties and their replacement by hydroxyl, presumably followed by ring opening.']",
3290,13291,"Guanidine, 1-(benzyloxy)-2,3-diisopropyl-, hydrochloride",CC(C)NC(=NC(C)C)NOCC1=CC=CC=C1.Cl,,,,,,
3291,13292,"1-Phenylmethoxy-2,3-di(propan-2-yl)guanidine",CC(C)NC(=NC(C)C)NOCC1=CC=CC=C1,,,,,,
3292,13293,N-[4-(2-phenylethenyl)phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
3293,13294,5-sec-Butyl-1-cyclohexylbarbituric acid,CCC(C)C1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3294,13295,"Coumarin, 7-methoxy-4-(4-pyridyl)-",COC1=CC2=C(C=C1)C(=CC(=O)O2)C3=CC=NC=C3,,,,,,
3295,13296,4-Ethylsulfonylnaphthalene-1-sulfonamide,CCS(=O)(=O)C1=CC=C(C2=CC=CC=C21)S(=O)(=O)N,,,,,,
3296,13297,Sudan I,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['ADMIN ORALLY TO RABBITS, THIS DYESTUFF ... UNDERGOES REDUCTIVE SCISSION, BUT IS ALSO METABOLIZED BY HYDROXYLATION OF BENZENE RING.', 'YIELDS 2,6-DIHYDROXY-1-PHENYLAZONAPHTHALENE, 2-HYDROXY -1-(PARA-HYDROXYPHENYLAZO)NAPHTHALENE, & 1-PHENYLHYDRAZO-2-NAPHTHOL IN RABBITS & RATS. /FROM TABLE/', '... ORAL ADMIN IN RABBITS, 1.2% ... UNCHANGED, 1.5% AS 1-PARA-HYDROXYPHENYLAZO-2-NAPHTHOL, 44% AS FREE & CONJUGATED PARA-AMINOPHENOL, 24% AS PARA-AMINOPHENYLGLUCURONIDE, 0.5% AS ORTHO-AMINOPHENOL & 1.1% AS ANILINE; PARA-ACETAMIDOPHENYL GLUCURONIDE, 1-PARA-HYDROXYPHENYLAZO-2-NAPHTHOL GLUCURONIDE & 1-AMINO-2-NAPHTHOL ... .', ""... GLUCURONIDES OF 4',6-DIHYDROXY-1-PHENYLAZO-2-NAPHTHOL & 4'- & 6-HYDROXY-1-PHENYLAZO-2-NAPHTHOL WERE PRESENT IN ... BILE & URINE OF RABBITS. URINE ALSO CONTAINED 1-AMINO-2-NAPHTHYL HYDROGEN SULFATE, 1-AMINO-2-NAPHTHYL GLUCURONIDE & N-GLUCURONIDES OF 1-PHENYLHYDRAZO-2-NAPHTHOL & OF 4'-HYDROXY-1-PHENYLHYDRAZO-2-NAPHTHOL ... ."", 'For more Metabolism/Metabolites (Complete) data for C.I. SOLVENT YELLOW 14 (6 total), please visit the HSDB record page.', 'Sudan I has known human metabolites that include 1-Amino-2-naphthol and aniline.']",
3297,13298,N-Hydroxy-4-acetylaminostilbene,CC(=O)N(C1=CC=C(C=C1)C=CC2=CC=CC=C2)O,,,,,,
3298,13299,4'-Hydroxy-N-acetyl-4-aminostilben,CC(=O)NC1=CC=C(C=C1)C=CC2=CC=C(C=C2)O,,,,,,
3299,13300,1-Cyclohexyl-5-(1-methylbutyl)barbituric acid,CCCC(C)C1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3300,13301,1-Cyclohexyl-5-pentylbarbituric acid,CCCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3301,13302,"ACETAMIDE, N-PHENYL-N-(alpha,alpha,alpha-TRIFLUORO-m-TOLYL)-",CC(=O)N(C1=CC=CC=C1)C2=CC=CC(=C2)C(F)(F)F,,,,,,
3302,13303,CID 13303,C[NH2+]CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31.[Cl-],,,,,,
3303,13304,"Dibenzo[b,e]thiepin, 1-propanamine deriv.; 11-(3-Methylaminopropylidene)-6,11-dihydrodibenz[b,e]thiepine; Nordosulepin; Nordothiepin; Northiadene",CNCCC=C1C2=CC=CC=C2CSC3=CC=CC=C31,,,,,,
3304,13305,Lambast,COCCCNC1=NC(=NC(=N1)SC)NCCCOC,,,,['All of these herbicides /methoxy or methylthio substituted triazine herbicides/ are rapidly absorbed ... when ingested ... Metabolites of most compounds are excreted in urine & feces within 72 hr. /s-Triazines/'],['All of these herbicides /methoxy & methylthio substituted triazine herbicides/ are rapidly absorbed and metabolized when ingested; amine dealkylation and side chain oxidation are the predominant detoxification reactions. The mercapto derivatives of triazine may also undergo sulfoxidation followed by reaction with hepatic glutathione to yield mercapturic acid derivatives. /s-Triazines/'],
3305,13306,"1,5-Dicyclohexylbarbituric acid",C1CCC(CC1)C2C(=O)NC(=O)N(C2=O)C3CCCCC3,,,,,,
3306,13307,1-Cyclohexyl-5-phenylbarbituric acid,C1CCC(CC1)N2C(=O)C(C(=O)NC2=O)C3=CC=CC=C3,,,,,,
3307,13308,Boldenone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)C=C[C@]34C,,"[""Boldenone has primarily anabolic activity with low androgenic potency.  The drug is commonly used in doping within bodybuilding, even though this use is illegal. If intended to assist in bodybuilding, the drug is taken as part of a steroid stack of other anabolic steroids, usually with a potent androgen like testosterone as the 'base' of the stack. Boldenone is an androgen that differs from 17b-testosterone (17b-T) by only one double bond at the 1-position, and the removal of the methyl group protecting the 17-OH group allows it to be orally active.""]","['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",,,['14 days']
3308,13309,"6,11-Dihydro-N,N-dimethyldibenzo(b,e)thiepin-11-propylamine hydrochloride hydrate (2:2:1)",C[NH+](C)CCCC1C2=CC=CC=C2CSC3=CC=CC=C13.[Cl-],,,,,,
3309,13310,"3-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2CSC3=CC=CC=C13,,,,,,
3310,13311,"Sodium;5,7-dinitro-8-oxidonaphthalene-2-sulfonate",C1=CC2=C(C=C1S(=O)(=O)[O-])C(=C(C=C2[N+](=O)[O-])[N+](=O)[O-])[O-].[Na+],,,,,,
3311,13312,"Dimethyl-(4-oxo-3,3-diphenylhexyl)azanium;chloride",CCC(=O)C(CC[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
3312,13313,Norgestrienone,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O,,,"['Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)']",,,
3313,13314,Lormetazepam,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3Cl,['For the treatment of short-term insomnia'],"['Lormetazepam is a benzodiazepine which reduces central nervous system (CNS) activity. It produces anxiolytic, muscle relaxant, sedative and hypnotic effects. Because it is a short-acting benzodiapine, it does not produce significant sedation after waking.']",['Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)'],,['Metabolised to an inactive metabolite via glucuronide conjugation'],['The terminal phase half life is 11 h.']
3314,13315,CID 13315,C[NH+](C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)Br.[Cl-],,,,,,
3315,13316,"3-(2-bromo-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)Br,,,,,,
3316,13317,"Dibenz(b,e)thiepin, 6,11-dihydro-11-(3-(dimethylamino)propyl)-2-fluoro-, hydrochloride",C[NH+](C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)F.[Cl-],,,,,,
3317,13318,"3-(2-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)F,,,,,,
3318,13319,2-(4-Chlorophenyl)-2-(4-hydroxyiminonaphthalen-1-ylidene)acetonitrile,C1=CC=C2C(=NO)C=CC(=C(C#N)C3=CC=C(C=C3)Cl)C2=C1,,,,,,
3319,13320,Arlidin,CC(CCC1=CC=CC=C1)[NH2+]C(C)C(C2=CC=C(C=C2)O)O.[Cl-],,,"['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
3320,13321,Dicyclohexyl adipate,C1CCC(CC1)OC(=O)CCCCC(=O)OC2CCCCC2,,,,,,
3321,13322,"(3,3-Diphenylpropoxy)guanidine nitrate",C1=CC=C(C=C1)C(CCON=C(N)N)C2=CC=CC=C2.[N+](=O)(O)[O-],,,,,,
3322,13323,"2-(3,3-Diphenylpropoxy)guanidine",C1=CC=C(C=C1)C(CCON=C(N)N)C2=CC=CC=C2,,,,,,
3323,13324,"(17R)-17-Hydroxy-13-methyl-17-prop-2-enyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",CC12C=CC3=C4CCC(=O)C=C4CCC3C1CCC2(CC=C)O,,,,,,
3324,13325,"Barbituric acid, 1,3-dicyclohexyl-5-ethyl-",CCC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
3325,13326,Sulfapyrazole,CC1=NN(C(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)C3=CC=CC=C3,,,,,,
3326,13327,Clostebol acetate,CC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C(C(=O)CC[C@]34C)Cl)C,,,,,,
3327,13328,Dihydrotestosterone propionate,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)C4)C)C,,,,,,
3328,13329,1-(3-Ethoxy-3-phenylpropyl)-4-(3-methylphenyl)piperazine,CCOC(CCN1CCN(CC1)C2=CC=CC(=C2)C)C3=CC=CC=C3,,,,,,
3329,13330,Dipipanone hydrochloride,CCC(=O)C(CC(C)N1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
3330,13331,Dipipanone,CCC(=O)C(CC(C)N1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3331,13332,"Barbituric acid, 1,3-dicyclohexyl-5-pentyl-",CCCCCC1C(=O)N(C(=O)N(C1=O)C2CCCCC2)C3CCCCC3,,,,,,
3332,13333,Anisopirol,COC1=CC=CC=C1N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)O,,,,,,
3333,13334,Phentyrin,C1=CC(=CC=C1CC(C(=O)O)N)OC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
3334,13335,Indigotin disulfonate sodium,C1=CC2=C(C=C1S(=O)(=O)O)C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)O)O.[Na+].[Na+],,,,,,
3335,13336,"Disulfide, bis[2-nitro-4-(trifluoromethyl)phenyl]",C1=CC(=C(C=C1C(F)(F)F)[N+](=O)[O-])SSC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-],,,,,,
3336,13337,CID 13337,C[NH+](C)CCOC1CC2=CC=CC=C2CCC3=CC=CC=C13.C(=CC(=O)[O-])C(=O)O,,,,,,
3337,13338,"N,N-dimethyl-2-(2-tricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaenyloxy)ethanamine",CN(C)CCOC1CC2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
3338,13339,CID 13339,C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=C(C3=CC=CC=C3F)Br)C4=CC=CC=C4,,,,,,
3339,13340,CID 13340,C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=C(C3=CC(=CC=C3)F)Br)C4=CC=CC=C4,,,,,,
3340,13341,CID 13341,CC(CCC(=O)NCC(=O)[O-])C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C.[Na+],,,,,,
3341,13342,Vinblastine,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,"[""For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.""]","['Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (<i>Catharanthus roseus</i>) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects <i>in vitro</i>. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.']","['Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']","['The major route of excretion may be through the biliary system.', 'Vinblastine sulfate is unpredictably absorbed from the GI tract. Following iv administration, the drug is rapidly cleared from the blood and distributed into body tissues. Vinblastine crosses the blood brain barrier poorly and does not appear in the CSF in therapeutic concentrations.', 'The volume of the central compartment is 70% of body weight, probably reflecting very rapid tissue binding to formed elements of the blood. Extensive reversible tissue binding occurs. Low body stores are present at 48 and 72 hours after injection.', 'Following injection of tritiated vinblastine in the human cancer patient, 10% of the radioactivity was found in the feces and 14% in the urine; the remaining activity was not accounted for. Similar studies in dogs demonstrated that, over 9 days, 30% to 36% of radioactivity was found in the bile and 12% to 17% in the urine. A similar study in the rat demonstrated that the highest concentrations of radioactivity were found in the lung, liver, spleen, and kidney 2 hours after injection.', 'It is not known whether this drug is excreted in human milk.', 'For more Absorption, Distribution and Excretion (Complete) data for VINBLASTINE (9 total), please visit the HSDB record page.']","['Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes.', 'Vinblastine is reported to be extensively metabolized, primarily in the liver, to desacetylvinblastine, which is more active than the parent compound on a weight basis.', 'Since the major route of excretion may be through the biliary system, toxicity from this drug may be increased when there is hepatic excretory insufficiency. The metabolism of vinca alkaloids has been shown to be mediated by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily. This metabolic pathway may be impaired in patients with hepatic dysfunction or who are taking concomitant potent inhibitors of these isoenzymes such as erythromycin.']","['Triphasic: 35 min, 53 min, and 19 hours', 'Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern following rapid intravenous injection. The initial, middle, and terminal half-lives are 3.7 minutes, 1.6 hours, and 24.8 hours, respectively.', 'The elimination of VLB from the plasma of patients who received it by 5-day iv infusion at 1 to 2 mg/sq m daily was biphasic. In four patients who achieved partial remission, the average plasma half-life of VLB during the terminal phase was 29.4 +/- 14.6 days ...  However, in three patients whose disease merely stabilized, the plasma half-life was 6.4 +/- 1.6 days ...  In contrast, in five patients with refractory disease, this parameters was 2.3 +/- 0.3 days...', 'The pharmacokinetics of vinblastine in humans was examined using a radioimmunoassay specific for both the Vinca alkaloids and aromatic ring [3H]vinblastine. The data were consistent with a three-compartment open model system with the following values, alpha phase: t1/2=3.90+/-1.46 min; Vc=16.8+/-7.1 liters. beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters. ...']"
3342,13343,Cobaltous citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Co+2].[Co+2].[Co+2],,,,"['Cobalt injected in rabbits as the citrate is more rapidly eliminated; 50 and 65% urinary elimination of the total  dose of 10 and 13 mg, respectively, was eliminated in 24 hr.']",,
3343,13344,Potassium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[K+].[K+].[K+],"['For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.']","['Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals.  Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.']","['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",['Urinary; less than 5% unchanged.'],['Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.'],
3344,13345,Triethyl phosphonoacetate,CCOC(=O)CP(=O)(OCC)OCC,,,,,,
3345,13346,Demeton-O-methyl,CCSCCOP(=S)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
3346,13347,S-Methylisothiourea hemisulfate,CSC(=N)N.CSC(=N)N.OS(=O)(=O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3347,13348,CID 13348,CC(C)(CC(C(=O)NCCC(=O)[O-])O)O.[Na+],,,,,,
3348,13349,"3-[(2,4-Dihydroxy-4-methylpentanoyl)amino]propanoic acid",CC(C)(CC(C(=O)NCCC(=O)O)O)O,,,,,,
3349,13350,Fluoro-beta-alanine hydrochloride,C(C(C(=O)O)F)[NH3+].[Cl-],,,,,,
3350,13351,alpha-Fluoro-beta-alanine,C(C(C(=O)O)F)N,,,,,,
3351,13352,CID 13352,[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[K+],,,,,,
3352,13353,CID 13353,[Li+].[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,,,,,,
3353,13354,Lithium tartrate,[Li+].[Li+].[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O,,,,,,
3354,13355,Sodium tartrate,C(C(C(=O)[O-])O)(C(=O)[O-])O.[Na+].[Na+],,,,,,
3355,13356,"2-Amino-1-propene-1,1,3-tricarbonitrile",C(C#N)C(=C(C#N)C#N)N,,,,,,
3356,13357,Methyl 2-methylbutyrate,CCC(C)C(=O)OC,,,,,,
3357,13358,Ethitanin,CCOC(=O)[C@H](CS)[NH3+].[Cl-],,,,,,
3358,13359,Ethyl L-cysteinate,CCOC(=O)[C@H](CS)N,,,,,,
3359,13360,2-Hydroxyethyl methacrylate,CC(=C)C(=O)OCCO,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
3360,13361,Dimethoxyphosphinylradical,COP(=O)OC,,,,,,
3361,13362,1-Butyl-1-nitrosourea,CCCCN(C(=O)N)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['After oral admin N-nitroso-N-butylurea to mice, 60% of radioactivity was excreted in expired air and 15% in urine within 24 hr.']","['N-nitroso-N-butylurea (I) gave urea, an acidic substance from the butyl group of (I), butylurea, and N-(3-hydroxybutyl)urea from urine within 24 hr as (I) metabolites. The (I) carbamoyl group bound to proteins but not nucleic acids.']",
3362,13363,"2-Chloro-N,N-diethylethanamine hydrochloride",CCN(CC)CCCl.Cl,,,,,,
3363,13364,(2-Chloroethyl)diethylamine,CCN(CC)CCCl,,,,,,
3364,13365,DI-Sec-butylurea,CCC(C)NC(=O)NC(C)CC,,,,,,
3365,13366,S-176 Mustard,C(CNC(=O)CSCCCl)NC(=O)CSCCCl,,,,,,
3366,13367,Allyl mercaptan,C=CCS,,,,,,
3367,13368,2-Chloroethylammonium chloride,C(CCl)[NH3+].[Cl-],,,,,,
3368,13369,2-Chloroethylamine,C(CCl)N,,,,,,
3369,13370,Dibutyl phosphoramidate,CCCCOP(=O)(N)OCCCC,,,,,,
3370,13371,CID 13371,C(O)S(=O)(=O)[O-].[Na+],,,,,,
3371,13372,"Allylamine, 2-bromo-N-ethyl-",CCNCC(=C)Br,,,,,,
3372,13373,CID 13373,CCCCOC(=S)[S-].[K+],,,,,,
3373,13374,CID 13374,C(CCCN=C(S)[S-])CCN=C(S)[S-].[Na+].[Na+],,,,,,
3374,13375,CID 13375,C(CCCN=C(S)S)CCN=C(S)S,,,,,,
3375,13376,N-Butylformamide,CCCCNC=O,,,,,,
3376,13377,"Ethanamine, N-(2-chloroethyl)-2-fluoro-, hydrochloride",C(CF)[NH2+]CCCl.[Cl-],,,,,,
3377,13378,N-(2-chloroethyl)-2-fluoroethanamine,C(CF)NCCCl,,,,,,
3378,13379,2-Methylnonane,CCCCCCCC(C)C,,,,,,
3379,13380,Dodecyldimethylphosphine oxide,CCCCCCCCCCCCP(=O)(C)C,,,,,,
3380,13381,1-Decene,CCCCCCCCC=C,,,,,,
3381,13382,Diamyl sulfide,CCCCCSCCCCC,,,,,,
3382,13383,3-Bromothiophene,C1=CSC=C1Br,,,,,,
3383,13384,CID 13384,C1=CN=C(N1)S,,,,,,
3384,13385,Vinylene carbonate,C1=COC(=O)O1,,,,,,
3385,13386,"Aziridine, 1-ethyl-2-methylene-",CCN1CC1=C,,,,,,
3386,13387,1-Methyl-2-pyrrolidinone,CN1CCCC1=O,,,['An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)'],"['Male Sprague-Dawley rats were given a single ip injection (45 mg/kg) of radiolabeled 1-methyl-2-pyrrolidone. Plasma levels of radioactivity and cmpd were monitored for six hr and the results suggested a rapid distribution phase which was followed by a slow elimination phase. The major amount of label was excreted in the urine within 12 hr and accounted for approximately 75% of the labelled dose. ...', 'This study evaluated the toxicokinetics of N-((14)C)methylpyrrolidone (((14)C)NMP) after intravenous administration (0.1, 1, 10, 100, and 500 mg/kg, in saline solution) or topical application (20 and 40 uL/sq cm; 10 sq  cm, neat) in haired male Sprague-Dawley rats. Whatever the dose, unchanged NMP was intensively distributed into the body with a volume of distribution of 69% of body weight. After this phase, unchanged NMP declined almost linearly with time for 3 to 4 hr after administration and then followed a mono-exponential function (t1/2 = 0.8 hr) for the three lowest doses. The maximal plasma level of 5-hydroxy-N-methylpyrrolidone (5-HNMP), the main metabolite, was reached 4 to 6 hr later for the three lowest doses and 8 to 24 hr later for the highest doses. These findings indicate that the elimination of NMP is governed by a saturable metabolism process. The Michaelis-Menten parameters estimated from plasma levels of unchanged NMP were 2 mM and 3.8 mg/hr, respectively. Between 4 and 10% of the administered doses were excreted in the urine as unchanged NMP. Urinary clearance of NMP (0.03 to 0.07 mL/min) indicates intensive tubular reabsorption. 5-HNMP was the main urinary metabolite and accounted for 42 to 55% of the administered doses. Its maximal urinary excretion occurred between 4 and 6 hr after administration of the three lowest doses and between 8 and 24 hr for the two highest doses. Urinary clearance (0.9 to 1.3 mL/min) was compatible with renal elimination by simple glomerular filtration.', 'Metabolism studies were performed using (14)C and tritium labeled N-methyl-2-pyrrolidinone in the rat. Male Sprague-Dawley rats were injected with labeled or unlabeled N-methyl-2-pyrrolidinone at 45 mg/kg body weight. Urine, feces, expired air, and bile were collected at various times between drug administration and sacrifice. For pharmacokinetic studies, serial blood samples were analyzed at times between 30 minutes and 6 hours post injection. HPLC of plasma N-methyl-2-pyrrlidinone indicated a rapid distribution phase followed by a slow elimination phase with a half life of approximately 7 hours for the (14)C and 10 hours for the tritium isotope. Urinary excretion accounted for approx 70% of the total dose within 12 hours, and a 2:1 ratio in the administered dose was maintained in the urine. The tissue distribution of the radiolabeled isomers showed similar patterns. The rank order of tissue accumulation from highest to lowest concentration was liver, intestine, testes, stomach, kidneys, lungs, brain, heart, pancreas, and spleen. The bladder, thyroid, and thymus showed minimal N-methyl-2-pyrrolidinone levels.', 'Six male volunteers were exposed for eight hours on four different days to 0, 10, 25, and 50 mg/cu m N-methyl-2-pyrrolidone. ... N-Methyl-2-pyrrolidone was absorbed through the respiratory tract and readily eliminated from the body, mainly by biotransformation to other compounds. ...', 'For more Absorption, Distribution and Excretion (Complete) data for 1-METHYL-2-PYRROLIDINONE (8 total), please visit the HSDB record page.']","['The aim was to study the metabolic pathway for N-methyl-2-pyrrolidone in humans. Three healthy male volunteers were administered 100 mg N-methyl-2-pyrrolidone orally. All urine was collected during nine consecutive days. The identification and quantification of the metabolites were performed by gas chromatography/mass spectrometry (GC/MS). N-Methyl-2-pyrrolidone, 5-hydroxy-N-methyl-2-pyrrolidone (5-hydroxy-N-methyl-2-pyrrolidone), N-methylsuccinimide, and 2-hydroxy-N-methylsuccinimide were found in urine. The mean excreted fractions for N-methyl-2-pyrrolidone, 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide, and 2-hydroxy-N-methylsuccinimide were 0.8%, 44%, 0.4%, and 20%, respectively. There was no conjugation with glucoronic acid or sulfate or either 5-hydroxy-N-methyl-2-pyrrolidone or 2-hydroxy-N-methylsuccinimide. One-third of the orally dosed N-methyl-2-pyrrolidone was not recovered in urine as either N-methyl-2-pyrrolidone, 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide, or 2-hydroxy-N-methylsuccinimide. The half-lives for 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide, and 2-hydroxy-N-methylsuccinimide in urine were approximately 4, 8, and 17 hr, respectively.', 'A method for determination of N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide in human urine and of N-methylsuccinimide in human plasma was developed. N-Methylsuccinimide and 2-hydroxy-N-methylsuccinimide are metabolites of the ... organic solvent N-methyl-2-pyrrolidone. ... The method is applicable for analysis of urine and plasma samples from workers exposed to N-methyl-2-pyrrolidone.', 'This study described the isolation and identification of the major urinary metabolite of N-methylpyrrolidinone in the male Sprague-Dawley-rat following intravenous administration. The rats were injected via the tail vein with either unlabeled N-methylpyrrolidinone or (14)C labeled N-methylpyrrolidinone at 45 mg/kg. Urine was collected during 0 to 12, 12 to 24, and 24 to 48 hours after dosing and analyzed by gas chromatography/mass spectrometry. Thermospray liquid chromatography/mass spectrometry was performed on samples purified using high performance liquid chromatography method. The major metabolite correlated with 5-hydroxy-N-methylpyrrolidinone based on thin layer chromatography and mass spectral comparisons with an authentic sample.']",
3387,13388,2-Ethylthiophene,CCC1=CC=CS1,,,,,,
3388,13389,4-Pyridinecarboxaldehyde,C1=CN=CC=C1C=O,,,,,,
3389,13390,"2,4,5-Trichloro-1-methyl-1H-imidazole",CN1C(=C(N=C1Cl)Cl)Cl,,,,,,
3390,13391,2-Chlorobenzonitrile,C1=CC=C(C(=C1)C#N)Cl,,,,,,
3391,13392,1-Carbamoyl-3-methylpyrazole,CC1=NN(C=C1)NC=O,,,,,,
3392,13393,CID 13393,C1=CC=C(C=C1)S(=O)[O-].[Na+],,,,,,
3393,13394,3-Cyanophenol,C1=CC(=CC(=C1)O)C#N,,,,,,
3394,13395,Picolinaldehyde oxime,C1=CC=NC(=C1)C=NO,,,,,,
3395,13396,4-Aminobenzonitrile,C1=CC(=CC=C1C#N)N,,,,,,
3396,13397,4-Chlorobenzyl alcohol,C1=CC(=CC=C1CO)Cl,,,,,,
3397,13398,"3,3,5-Trimethylcyclohexanone",CC1CC(=O)CC(C1)(C)C,,,,,,
3398,13399,1H-Indazol-3-amine,C1=CC=C2C(=C1)C(=NN2)N,,,,,,
3399,13400,2-Acetylcyclohexanone,CC(=O)C1CCCCC1=O,,,,,,
3400,13401,3-Hydroxypicolinic acid,C1=CC(=C(N=C1)C(=O)O)O,,,,,,
3401,13402,5-Methylindan,CC1=CC2=C(CCC2)C=C1,,,,,,
3402,13403,"1-Ethyl-2,4-dimethylbenzene",CCC1=C(C=C(C=C1)C)C,,,,,,
3403,13404,"2,4-Dichlorobenzaldehyde",C1=CC(=C(C=C1Cl)Cl)C=O,,,,,,
3404,13405,4-Methylbenzoyl chloride,CC1=CC=C(C=C1)C(=O)Cl,,,,,,
3405,13406,1-Cyclohexylidenepropan-2-one,CC(=O)C=C1CCCCC1,,,,,,
3406,13407,Phenyl propyl sulfide,CCCSC1=CC=CC=C1,,,,,,
3407,13408,"1,2-Dimethylindole",CC1=CC2=CC=CC=C2N1C,,,,,,
3408,13409,Pericyclocamphanone,CC1(C2C3C2C(=O)C1(C3)C)C,,,,,,
3409,13410,4-Chlorophenyl acetate,CC(=O)OC1=CC=C(C=C1)Cl,,,,,,
3410,13411,"1,2,4,5-Tetrachloro-3,6-dimethylbenzene",CC1=C(C(=C(C(=C1Cl)Cl)C)Cl)Cl,,,,,,
3411,13412,"2,3,4,5,6-Pentachlorotoluene",CC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
3412,13413,CID 13413,C1=CC=C(C(=C1)C(=O)O)C(=O)[O-].[K+],,,,,,
3413,13414,"2,6-Dimethylquinoline",CC1=CC2=C(C=C1)N=C(C=C2)C,,,,,,
3414,13415,"1,2,4-Triethylbenzene",CCC1=CC(=C(C=C1)CC)CC,,,,,,
3415,13416,4-Tert-butylbenzyl alcohol,CC(C)(C)C1=CC=C(C=C1)CO,,,,,,
3416,13417,CID 13417,CSC(=NC1=CC(=CC=C1)Cl)S,,,,,,
3417,13418,"1,1-dichloro-N-(4,6-dichloro-1,3,5-triazin-2-yl)methanimine",C1(=NC(=NC(=N1)Cl)Cl)N=C(Cl)Cl,,,,,,
3418,13419,"2,4,6-Trimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)OC)OC,,,,,,
3419,13420,Cycloundecanone,C1CCCCCC(=O)CCCC1,,,,,,
3420,13421,"3-Ethyl-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane hydrochloride",CC[NH+]1CC2CCC(C1)(C2(C)C)C.[Cl-],,,,,,
3421,13422,"3-Ethyl-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane",CCN1CC2CCC(C1)(C2(C)C)C,,,,,,
3422,13423,"1-Methyl-1,3-diazaspiro[4.5]decane-2,4-dione",CN1C(=O)NC(=O)C12CCCCC2,,,,,,
3423,13424,"1,3-Diazaspiro(4.4)nonane-2,4-dione, 3-(hydroxymethyl)-",C1CCC2(C1)C(=O)N(C(=O)N2)CO,,,,,,
3424,13425,((5-(Hydroxymethyl)-m-dioxan-5-yl)methyl)trimethylammonium bromide,C[N+](C)(C)CC1(COCOC1)CO.[Br-],,,,,,
3425,13426,"[5-(Hydroxymethyl)-1,3-dioxan-5-yl]methyl-trimethylazanium",C[N+](C)(C)CC1(COCOC1)CO,,,,,,
3426,13427,3-(2-Aminopropyl)indole hydrochloride,CC(CC1=CNC2=CC=CC=C21)[NH3+].[Cl-],,,,,,
3427,13428,"2,3,4,5-Tetrachloronitrobenzene",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)[N+](=O)[O-],,,,"['This isomer exhibited greater absorption in rabbits than the 2,3,5,6-isomer.', 'Tetrachloronitrobenzene is not readily absorbed by animals exposed to concn of 0.1 to 3.0 g/kg. ... The primary route of elimination appears to be in the feces. /Tetrachloronitrobenzene/']","['Unabsorbed 2,3,4,5-TCNB was reduced, in large measure, in the gut to an amine which diazotizes readily and couples. Absorbed TCNB was partly converted to glucuronide (27% of dose) and to ethereal sulfate (7% of dose). 2,3,4,5-Tetrachloroaniline was isolated from urine.', '2,3,4,5-Tetrachloronitrobenzene was reduced in the gastrointestinal contents of rabbits to 2,3,4,5-tetrachloroaniline.', 'There appear to be two major pathways for the metabolism of nitrobenzene and substituted nitrobenzenes. The first of these is reduction of the nitro group to yield aniline or substituted anilines. For nitrobenzene and perhaps for pentachloronitrobenzene, reduction of the nitro group to the amine is accomplished by bacteria of the gastrointestinal tract. Addition of a second nitro group results in easier reduction of one of the nitro groups on dinitrobenzenes, since they can be reduced under aerobic conditions by hepatic and erythrocyte enzymes. Bacterial reduction of the dinitrobenzenes is probably not quantitatively important in vivo. The second pathway is replacement of a nitro group by glutathione. The relative importance of this pathway compared to nitro group reduction depends upon the compound. It has not been demonstrated to occur for nitrobenzene. It is the major route of metabolism for 1,2-dinitrobenzene but is not an important route for 1,3- or 1,4-dinitrobenzene in hepatocytes. Tetrachloronitrobenzene isomers in which the nitro group is flanked by chlorines and pentachloronitrobenzene undergo nitro group replacement, but 2,3,4,5-tetrachloronitrobenzene does not. ...', 'The metabolism of pentachloronitrobenzene (PCNB) in rats was studied. Metabolites isolated from rat excreta and identified were: N-acetyl-S-(pentachlorophenyl)cysteine, pentachlorothiophenol, pentachlorothioanisole, 2,3,4,5-tetrachlorothiophenol, 2,3,4,5-tetrachlorothioanisole, 2,3,4,6- and/or 2,3,5,6-tetrachloro-thiophenol and -thioanisole, 1,4-bis(methylthio)tetrachlorobenzene, 1,4-dimercapto-tetrachlorobenzene and/or 4-methylthio-tetrachlorothiophenol, pentachlorophenol, pentachloroanisole, 2,3,4,5-tetrachlorophenol, 2,3,4,5-tetrachloroanisole, 2,3,4,6- and/or 2,3,5,6-tetrachloro-phenol and -anisole, pentachlorobenzene, 2,3,4,5-tetrachloronitrobenzene, pentachloroaniline and 2,3,4,5-tetrachloroaniline.']",
3428,13429,N-(o-Bromobenzyl)-N-methyl-2-propynylamine hydrochloride,C[NH+](CC#C)CC1=CC=CC=C1Br.[Cl-],,,,,,
3429,13430,N-[(2-bromophenyl)methyl]-N-methylprop-2-yn-1-amine,CN(CC#C)CC1=CC=CC=C1Br,,,,,,
3430,13431,3-Fluoroadamantane-1-carboxylic acid,C1C2CC3(CC1CC(C2)(C3)F)C(=O)O,,,,,,
3431,13432,2-Methyl-1-nitronaphthalene,CC1=C(C2=CC=CC=C2C=C1)[N+](=O)[O-],,,,,,
3432,13433,2-Methyl-8-nitroquinoline,CC1=NC2=C(C=CC=C2[N+](=O)[O-])C=C1,,,,,,
3433,13434,"1,3-Bis(trichloromethyl)benzene",C1=CC(=CC(=C1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
3434,13435,((p-Chlorophenyl)azo)malononitrile,C1=CC(=CC=C1N=NC(C#N)C#N)Cl,,,,,,
3435,13436,Diphenyl disulfide,C1=CC=C(C=C1)SSC2=CC=CC=C2,,,,,,
3436,13437,"1,3-Difluoro-2-propanol benzenesulfonate",C1=CC=C(C=C1)S(=O)(=O)OC(CF)CF,,,,,,
3437,13438,9-Methylphenanthrene,CC1=CC2=CC=CC=C2C3=CC=CC=C13,,,,,,
3438,13439,2-Phenylbenzothiazole,C1=CC=C(C=C1)C2=NC3=CC=CC=C3S2,,,,,,
3439,13440,"2,4,6-Triethoxy-1,3,5-triazine",CCOC1=NC(=NC(=N1)OCC)OCC,,,,,,
3440,13441,"Hydrazine, 1-phenyl-2-(tetrahydrothien-3-YL)-, dioxide",C1CS(=O)(=O)CC1NNC2=CC=CC=C2,,,,,,
3441,13442,1-Phenyl-2-(tetrahydrothien-3-yl)hydrazine dioxide hydrochloride,C1CS(=O)(=O)CC1[NH2+]NC2=CC=CC=C2.[Cl-],,,,,,
3442,13443,4-Nitrosoantipyrine,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=O,,,,,,
3443,13444,(Dimethylamino)(1-naphthyl)acetonitrile,CN(C)C(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
3444,13445,Desylamine hydrochloride,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)[NH3+].[Cl-],,,,,,
3445,13446,Desylamine,C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)N,,,,,,
3446,13447,4-Hydroxy-3-nitrobiphenyl,C1=CC=C(C=C1)C2=CC(=C(C=C2)O)[N+](=O)[O-],,,,,,
3447,13448,"Phenol, o-(p-bromophenylformimidoyl)-",C1=CC=C(C(=C1)C=NC2=CC=C(C=C2)Br)O,,,,,,
3448,13449,"2-(2-Chlorophenoxy)-4,6-difluoro-1,3,5-triazine",C1=CC=C(C(=C1)OC2=NC(=NC(=N2)F)F)Cl,,,,,,
3449,13450,Terbutryn,CCNC1=NC(=NC(=N1)SC)NC(C)(C)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['They are efficiently absorbed from intestine, and presumably there is some absorption across the skin and lung. /Urea-, uracil- and triazine-based herbicides/', 'Absorbed through both foliage and roots. It appears to penetrate foliage rapidly, minimizing removal from foliage by rain. /It is/ translocated acropetally through xylem from roots and foliage, accumulating in apical meristems.', 'In mammals, following oral admin, 73-85% is eliminated in metabolized form in feces within 24 hr.']","['Terbutryn ... was metabolized by both rats and goats after a single oral dose by one or more of the following pathways: S-demethylation, conversion of thiomethyl into hydroxyl, N-de-ethylation, oxidation of the terminal carbon of the ethyl group to a carboxylic acid, oxidation of a terminal carbon of the t-butyl group to an alcohol or a carboxylic acid, or conjugation with glucuronic acid.', 'Carbon-labeled terbutryn was admin as single oral doses to rats and goats. Urine was collected at intervals up to 72 hr and then analyzed ... after isolation of glucuronides by chromatographic procedures. Five conjugates isolated and identified were: 2-amino-4-(t-butylamino)-6-(S-glucuronyl)-s-triazine; 2-(t-butylamino)-4-ethylamino-6-(S-glucuronyl)-s-triazine; 2-ethyl-amino-(2-methyl)glucuronylpropyl)amino-6-(S-methylthio)-s-triazine; 2-amino-4-(2-(1-glucuronyl-2-methylpropyl)amino)-6-methylthio-s-triazine; 2-ethylamino-4-(2-(2-methyl propan-1-olyl)amino)-6-(S-glucuronyl)-s-triazine.', 'After administration of terbutryne to rats, urinary metabolites observed ... included: 2-hydroxy terbutryne; 2-amino-4-hydroxy-6-t-butylamino-s-triazine; 2-amino-4-t-butylamino-6-mercapto-s-triazine; two S-glucuronides and two t-butyl-O-glucuronides. Other metabolites were formed by one or a combination of the following reactions: N-alkyl oxidation to alcohols or acids: S-demethylation; N-deethylation; and disulfide formation.', 'Microsomes prepared from livers from 30 to 70 year old patients undergoing liver resection were incubated with 6.3 to 1,000 uM atrazine, terbuthylazine, terbutryne, or ametryne , and the incubation mixtures were analyzed for metabolites. The compounds produced a variety of metabolites indicative of S-oxidation, N-dealkylation, and side chain C-oxidation. The metabolites were formed by processes showing biphasic kinetics, Michaelis constants for the first and second phases varying from 1.4 to 20 uM and from 54 to 530 uM, respectively. Atrazine, terbuthylazine, ametryne, or terbutryne at 25 uM was incubated with human liver microsomes containing substrates for cytochrome-P4501A2 (CYP1A2), cytochrome-P4502A6, cytochrome-P4502D6, cytochrome-P4502C9, cytochrome-P4502C19, cytochrome-P4502E1, or cytochrome-P4503A4 (CYP3A4) isozymes. Other microsomal preparations were incubated with 25 or 600 uM of the S-triazines in the presence or absence of alpha-naphthoflavone (aNF), furafylline, quinidine, sulfaphenazole, diethyl-dithiocarbamate, gestodene, or ketoconazole, inhibitors of various specific cytochrome-P450 (P450) isozymes, at concentrations 5 to 10 times greater than their inhibition constants. Microsomal preparations containing substrates for CYP1A2 and CYP3A4 showed the best correlation with the rates of metabolism of the S-triazines. Only aNF and furafylline, inhibitors of CYP1A2, inhibited metabolism of the S-triazines. A human liver microsomal preparation with demonstrated high levels of flavin containing monooxygenase (FMO) activity and purified recombinant human FMO-3 were incubated with ametryne and terbutryne. The extent of sulfoxidation of the two compounds was determined. No significant formation of sulfoxide metabolites was detected, indicating that the FMO system was not involved in the metabolism of S- triazines by human liver microsomes. The authors conclude that these results clearly identify CYP1A2 as the major phase-I P450 isozyme that is involved in the metabolism of S-triazines by human liver microsomes.', 'For more Metabolism/Metabolites (Complete) data for TERBUTRYNE (7 total), please visit the HSDB record page.', 'Terbutryn has known human metabolites that include 1-[[4-(tert-butylamino)-6-methylsulfanyl-1,3,5-triazin-2-yl]amino]ethanol, 2-[[4-(Ethylamino)-6-methylsulfanyl-1,3,5-triazin-2-yl]amino]-2-methylpropan-1-ol, and Terbutrynsulfoxide.']",
3450,13451,N-Cyclohexyl-N'-phenylurea,C1CCC(CC1)NC(=O)NC2=CC=CC=C2,,,,,,
3451,13452,"Benzene, 1,1'-(1,3-butadiene-1,4-diyl)bis-",C1=CC=C(C=C1)C=CC=CC2=CC=CC=C2,,,,,,
3452,13453,"1,5-Bis(furan-2-yl)penta-1,4-dien-3-one",C1=COC(=C1)C=CC(=O)C=CC2=CC=CO2,,,,,,
3453,13454,Metacaine,CCOC(=O)C1=CC(=CC=C1)[NH3+].CS(=O)(=O)[O-],,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)']",,,
3454,13455,Chlorthal-monomethyl,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)O)Cl)Cl,,,,,,
3455,13456,CID 13456,CC=C(C)C(=O)OC1CC[NH+]2C1C(=CC2)CO.[Cl-],,,,,,
3456,13457,7-Angeloylretronecine,CC=C(C)C(=O)OC1CCN2C1C(=CC2)CO,,,,,,
3457,13458,1-Butan-2-yl-3-(4-fluorophenyl)sulfonylurea,CCC(C)NC(=O)NS(=O)(=O)C1=CC=C(C=C1)F,,,,,,
3458,13459,1-Cyclohexyl-5-propylbarbituric acid,CCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3459,13460,5-Allyl-1-cyclohexylbarbituric acid,C=CCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3460,13461,Benzyl mandelate,C1=CC=C(C=C1)COC(=O)C(C2=CC=CC=C2)O,,,,,,
3461,13462,3-Nitrofluoranthene,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)[N+](=O)[O-],,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
3462,13463,5-Chloro-5-deoxyadenosine,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CCl)O)O)N,,,,,,
3463,13464,"N,N-Dimethyl-4,4-diphenyl-3-butenylamine hydrochloride",C[NH+](C)CCC=C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
3464,13465,"N,N-dimethyl-4,4-diphenylbut-3-en-1-amine",CN(C)CCC=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3465,13466,"Guanidine, (2-(2,2,6,6-tetramethylpiperidino)ethyl)-, sulfate (2:1)",CC1(CCCC([NH+]1CCN=C(N)N)(C)C)C.CC1(CCCC([NH+]1CCN=C(N)N)(C)C)C.[O-]S(=O)(=O)[O-],,,,,,
3466,13467,"2-[2-(2,2,6,6-Tetramethylpiperidin-1-yl)ethyl]guanidine",CC1(CCCC(N1CCN=C(N)N)(C)C)C,,,,,,
3467,13468,"Methyl-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]azanium;chloride",C[NH2+]CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-],,,,,,
3468,13469,CID 13469,C[NH+](C)CCC=C(C1=CC=CC=C1)C2=CC(=CC=C2)Cl.[Cl-],,,,,,
3469,13470,"3-Buten-1-amine, 4-(3-chlorophenyl)-N,N-dimethyl-4-phenyl-",CN(C)CCC=C(C1=CC=CC=C1)C2=CC(=CC=C2)Cl,,,,,,
3470,13471,Tigestol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCCC4,,,,,,
3471,13472,"Androsta-1,4-diene-3,17-dione",C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)C=C[C@]34C,,,,,,
3472,13473,3-(6H-benzo[c][1]benzothiepin-11-ylidene)propyl-dimethylazanium;chloride,C[NH+](C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31.[Cl-],,,,,,
3473,13474,Dimethyl-[4-(3-methylsulfanylphenyl)-4-phenylbut-3-enyl]azanium;chloride,C[NH+](C)CCC=C(C1=CC=CC=C1)C2=CC(=CC=C2)SC.[Cl-],,,,,,
3474,13475,"N,N-dimethyl-4-(3-methylsulfanylphenyl)-4-phenylbut-3-en-1-amine",CN(C)CCC=C(C1=CC=CC=C1)C2=CC(=CC=C2)SC,,,,,,
3475,13476,"N,N-dimethyl-4-(2-quinolin-4-ylethenyl)aniline",CN(C)C1=CC=C(C=C1)C=CC2=CC=NC3=CC=CC=C23,,,,,,
3476,13477,7-Hydroxy-4-methylcoumarin diethylphosphate,CCOP(=O)(OCC)OC1=CC2=C(C=C1)C(=CC(=O)O2)C,,,,,,
3477,13478,"Triethyl 1,3,5-triazine-2,4,6-tricarboxylate",CCOC(=O)C1=NC(=NC(=N1)C(=O)OCC)C(=O)OCC,,,,,,
3478,13479,Drocarbil,CC(=O)NC1=C(C=CC(=C1)[As](=O)(O)O)O.CN1CCC=C(C1)C(=O)OC,,,,,,
3479,13480,CID 13480,CC(=O)O.C1=CC=C(C=C1)[SnH](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3480,13481,Methyl N~5~-[N-(4-methylbenzene-1-sulfonyl)carbamimidoyl]ornithinate,CC1=CC=C(C=C1)S(=O)(=O)NC(=NCCCC(C(=O)OC)N)N,,,,,,
3481,13482,Diaphen,CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)Cl.[Cl-],,,,,,
3482,13483,2-(Diethylamino)ethyl alpha-chlorodiphenylacetate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)Cl,,,,,,
3483,13484,p-Butylmercaptobenzhydryl beta-dimethylaminoethyl sulfide hydrochloride,CCCCSC1=CC=C(C=C1)C(C2=CC=CC=C2)SCC[NH+](C)C.[Cl-],,,,,,
3484,13485,"O-Ethyl O,O-bis(4-nitrophenyl) phosphorate",CCOP(=O)(OC1=CC=C(C=C1)[N+](=O)[O-])OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3485,13486,"3,3'-Diethyl-2,2'-thiacarbocyanine iodide",CCN1C2=CC=CC=C2SC1=CC=CC3=[N+](C4=CC=CC=C4S3)CC.[I-],,,,,,
3486,13487,"3,3'-Diethylthiacarbocyanine",CCN1C2=CC=CC=C2SC1=CC=CC3=[N+](C4=CC=CC=C4S3)CC,,,,,,
3487,13488,3-(2-(Dimethylamino)ethyl)-5-phenylisoxazole citrate,C[NH+](C)CCC1=NOC(=C1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3488,13489,"N,N-dimethyl-2-(5-phenyl-1,2-oxazol-3-yl)ethanamine",CN(C)CCC1=NOC(=C1)C2=CC=CC=C2,,,,,,
3489,13490,CID 13490,CC(C)CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCCC(C)C)S,,,,,,
3490,13491,"6,7-Diethoxy-1-(3,4-diethoxybenzyl)-3,4-dihydroisoquinoline hydrochloride",CCOC1=C(C=C(C=C1)CC2=[NH+]CCC3=CC(=C(C=C32)OCC)OCC)OCC.[Cl-],,,,,,
3491,13492,"1-(3,4-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline",CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OCC)OCC)OCC,,,,,,
3492,13493,Etonitazene,CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OCC,,,,,,
3493,13494,Benzoylarginine nitroanilide,C1=CC=C(C=C1)C(=O)NC(CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
3494,13495,3-(2-(Diethylamino)ethyl)-5-phenylisoxazole citrate,CC[NH+](CC)CCC1=NOC(=C1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3495,13496,"N,N-diethyl-2-(5-phenyl-1,2-oxazol-3-yl)ethanamine",CCN(CC)CCC1=NOC(=C1)C2=CC=CC=C2,,,,,,
3496,13497,"N,N-Dimethyl-2-(1-methylpyrrolidin-3-YL)-2,2-diphenyl-acetamide",CN1CCC(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N(C)C,,,,,,
3497,13498,3-Phenyl-5-(2-piperidinoethyl)isoxazole citrate,C1CC[NH+](CC1)CCC2=CC(=NO2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3498,13499,3-Phenyl-5-(2-piperidin-1-ylethyl)isoxazole,C1CCN(CC1)CCC2=CC(=NO2)C3=CC=CC=C3,,,,,,
3499,13500,"6,7-dimethoxy-3-[(5S)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-3H-2-benzofuran-1-one;chloride",C[NH+]1CCC2=CC3=C(C(=C2[C@H]1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3.[Cl-],,,,,,
3500,13501,"6,7-dimethoxy-3-[(5S)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one",CN1CCC2=CC3=C(C(=C2[C@H]1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,,,,,,
3501,13502,CID 13502,C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=C(C3=CC=C(C=C3)F)Br)C4=CC=CC=C4,,,,,,
3502,13503,CID 13503,CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O)O,,,,,,
3503,13504,Tetrabutylammonium picrate,CCCC[N+](CCCC)(CCCC)CCCC.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
3504,13505,Diphenoxylate,CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,['For as adjunctive therapy in the management of diarrhea'],"['Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.']","['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)']","['90%', 'Fecal/renal elimination; less than 1% eliminated unchanged in urine.', 'In one study in fasting individuals, diphenoxylate hydrochloride was well absorbed from the GI tract following oral administration of an alcoholic solution of the drug without atropine sulfate. Peak plasma diphenoxylate concentrations occurred about 2 hours following administration of the drug. In a crossover bioavailability study of Lomotil tablets and oral solution, the bioavailability of the tablets was approximately 90% that of the solution; following an oral dose of four 2.5 mg tablets, an average peak plasma concentraton of diphenoxylic acid (an active metabolite of diphenoxylate) of 163 ng/ml occurred within about 2 hours. Diphenoxylate had an onset of action within 45 minutes to 1 hour and a duration of action of 3-6 hours. /Diphenoxylate hydrochloride/', 'Diphenoxylate is distributed into milk.', 'Diphenoxylate is rapidly and extensively metabolized to diphenoxylic acid, an active metabolite. The drug is also metabolized to hydroxydiphenoxylic acid. Diphenoxylate metabolites and their conjugates are slowly excreted, principally in feces via bile; lesser amounts are excreted in urine. Less than 1% is exceted unchanged in urine.']","['Hepatic', 'DIPHENOXYLATE YIELDS 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYLISONIPECOTIC ACID IN RATS & DOGS. /FROM TABLE/', '... MAIN METABOLIC REACTION /OF DIPHENOXYLATE/ IN MAN & OTHER SPECIES IS HYDROLYSIS TO YIELD LARGE AMT OF DIFENOXINE ...', 'Hepatic biotransformation; the major metabolic difenoxin (diphenoxylic acid) has similar activity.', 'Diphenoxylate is rapidly and extensively metabolized to diphenoxylic acid, an active metabolite. The drug is also metabolized to hydroxydiphenoxylic acid. Diphenoxylate metabolites and their conjugates are slowly excreted, principally in feces via bile; lesser amounts are excreted in urine. Less than 1% is exceted unchanged in urine.']","['12-14 hours', 'The half-life of diphenoxylate is 2.5 hours; that of diphenoxylic acid is 12 to 24 hours.', 'Diphenoxylate has a plasma half-life of about 2.5 hours. Diphenoxylic acid, an active metabolite of diphenoxylate, reportedly has an elimination half-life of 3-14 hours.']"
3505,13506,Amaranth,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']","['Of FD&C Red No.2 administered orally 10% appear in the urine and 43% in the feces (accounting for 53%). Part of the absorbed reduction product is further metabolized to unknown products', 'A single oral dose of 50 mg per animal was administered to four rats. Only 2.8% was absorbed from the gastro-intestinal tract; the metabolites in the urine and bile were predominantly products resulting from the reductive fission of the azo-linkage, such as 1-amino-4-naphthalene sulfonic acid and 1-amino-2-hydroxy-3,6-naphthalene disulfonic acid. The former compound was found also in the feces.', 'The absorption and elimination of 1-amino-4-naphthalene-sulfonic acid, one of the azo-reduction products in rats were examined after dosing by gavage, in drinking-water and mixed into the diet. Little is metabolized by mammalian liver azo-reductase systems, almost all reduction occurring through gut microflora. 1-amino-2-hydroxy-3,6-naphthalene sulfonic acid was not studied as it is not well absorbed.', '1-Amino-4-naphthalene sulfonic acid, one of the metabolites of amaranth, is absorbed to the extent of 18% after its oral administration.', 'For more Absorption, Distribution and Excretion (Complete) data for AMARANTH (12 total), please visit the HSDB record page.']","['2-Hydroxy-1-(p-sulfophenylazo)naphthalene-3,6-disulfonic acid yields 1-amino-2-hydroxynaphthalene-3,6-disulfonic acid in Escherichia and Proteus; 1-naphthylamine-4-sulfonic acid in Escherichia and Proteus.', 'The mechanism of the azo reduction of sulfonazo III and amaranth by the rat hepatic monooxygenase system was studied. Air strongly inhibited (greater than 95%) the enzymatic reduction of both azo compounds; a 100% CO atmosphere inhibited amaranth reduction (greater than 90%) but only slightly inhibited sulfonazo III reduction (13%). The addition of 50 microM sulfonazo III to microsomal incubations stimulated oxygen consumption, NADPH oxidation, and adrenochrome formation, whereas 100 microM amaranth did not. The reduction potentials of these two azo compounds were also very different (amaranth, E = -0.620 V; sulfonazo III, E = -0.265 V versus normal hydrogen electrode). The organic mercurial mersalyl converted cytochrome P-450 to cytochrome P-420 (68%) and markedly decreased NADPH-cytochrome P-450(c) reductase activity (97%) in microsomal preparations, presumably by inactivating or destroying functional sulfhydryl groups important for the catalytic activity of these enzymes. GSH was used to restore, and NADP+ to protect, the activities of the monooxygenase components from the effects of mersalyl. The data indicate that inactivation of NADPH-cytochrome P-450(c) reductase inhibits sulfonazo III and amaranth reduction, whereas inactivation of cytochrome P-450 inhibits only amaranth reduction. Furthermore, the reduction of sulfonazo III by purified microsomal NADPH-cytochrome P-450(c) reductase was significantly faster than the rate of reduction of amaranth. These studies demonstrate that two distinct sites of azo reduction exist in the monooxygenase system and that not all azo compounds are reduced by cytochrome P-450.', 'The liver enzyme that reduces azo-linkages plays little part in the metabolism /of rats/, as was shown in experiments in which the amaranth was given by intrasplenic infusion. Reduction of the compound is therefore most probably affected by the intestinal bacteria.', 'Amaranth is rapidly reduced by a suspension of bacteria obtained from large intestine and cecum of rats. /Investigators/ found that it is reduced by rat liver homogenates as well as by rat intestinal contents. Products of reductive cleavage of amaranth, namely, 1-amino-4-naphthalene sulfonic acid and 1-amino-2-hydroxy-3,6-naphthalene disulfonic acid (R-amino salt), are found in urine of rats fed the color.', 'For more Metabolism/Metabolites (Complete) data for AMARANTH (6 total), please visit the HSDB record page.']",
3506,13507,"3-Hydroxy-4-[(4-sulphonaphthyl)azo]naphthalene-2,7-disulphonic acid",C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)O)S(=O)(=O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)']",,,
3507,13508,Triphenyl(10-(triphenylphosphoranyl)decyl)phosphorane,C1=CC=C(C=C1)[P+](CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6.[Br-].[Br-],,,,,,
3508,13509,Triphenyl(10-triphenylphosphaniumyldecyl)phosphonium,C1=CC=C(C=C1)[P+](CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
3509,13510,CID 13510,C(#N)[O-].[Na+],,,,,,
3510,13511,Lanthanum acetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[La+3],,,,,,
3511,13512,"3,3-Dimethyl-1-Butyne",CC(C)(C)C#C,,,,,,
3512,13513,"Propanal, 2-chloro-2-methyl-",CC(C)(C=O)Cl,,,,,,
3513,13514,"1,1,1-Trichloroacetone",CC(=O)C(Cl)(Cl)Cl,,,,"['... Dermal absorption of two haloketones (1,1-dichloropropanone and 1,1,1-trichloropropanone) and chloroform while bathing, /were examined/ by collecting and analyzing time profiles of expired breath samples of six human subjects during and following a 30-min bath. The disinfection byproduct concentrations in breath increased towards a maximum concentration during bathing. The maximum haloketone breath concentration during dermal exposure ranged from 0.1 to 0.9 ug /cu m, which was approximately two orders of magnitude lower than the maximum chloroform breath concentration during exposure. Based on a one-compartment model, the in vivo permeability of chloroform, 1,1-dichloropropanone, and 1,1,1-trichloropropanone were approximated to be 0.015, 7.5 x 10- 4, and 4.5 x 10- 4 cm /hr, respectively. Thus, haloketones are much less permeable across human skin under normal bathing conditions than is chloroform...']",,
3514,13515,CID 13515,CC(O)S(=O)(=O)[O-].[Na+],,,,,,
3515,13516,Acetaldehyde hydroxysulfonate,CC(O)S(=O)(=O)O,,,,,,
3516,13517,(2H9)-tert-Butyl chloride,[2H]C([2H])([2H])C(C([2H])([2H])[2H])(C([2H])([2H])[2H])Cl,,,,,,
3517,13518,Perfluoropinacol,C(C(C(F)(F)F)(C(F)(F)F)O)(C(F)(F)F)(C(F)(F)F)O,,,,,,
3518,13519,3-Methyl-1-penten-3-ol,CCC(C)(C=C)O,,,,,,
3519,13520,Lithium citrate,[Li+].[Li+].[Li+].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O,"['Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.']","[""Although lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.""]",,,,
3520,13521,3-Aminopropyltriethoxysilane,CCO[Si](CCCN)(OCC)OCC,,,,,,
3521,13522,3-(Triethoxysilyl)propionitrile,CCO[Si](CCC#N)(OCC)OCC,,,,,,
3522,13523,"O,O-Diethyl S-(carbomethoxymethyl) thiothionophosphate",CCOP(=S)(OCC)SCC(=O)OC,,,,,,
3523,13524,Acethion,CCOC(=O)CSP(=S)(OCC)OCC,,,,"['All undergo hydrolytic degradation in liver & other tissues, usually within hours of absorption. Degradation products are...excreted in urine & feces. /Organophosphate pesticides/', 'Many of /the organophosphorus insecticides/ are excreted in the milk ... /Organophosphorus insecticides/']",['Degradation of acethion was rapid & 77-88% of injected dose appeared as chloroform extractables within 0.5 hr after treatment. Chromatographic separation & anal showed principal metabolite to be acethion acid. Some mono- & diethyl phosphorodithionic acids were also found.'],
3524,13525,Amidithion,COCCNC(=O)CSP(=S)(OC)OC,,,,,,
3525,13526,Demeton-S-methyl,CCSCCSP(=O)(OC)OC,,,,"[""Male Sprague-Dawley rats given single oral doses of 0.1, 0.5, 5 or 10 mg/kg or intravenous doses of 0.5 or 1 mg/kg of (14)C- demeton-S-methyl. Additional female rats were given a single oral dose of 0.5 mg/kg. The test material was very rapidly and nearly completely absorbed following oral administration. More than 50 percent of the administered radioactivity was eliminated in about three hours and approximately 90 percent within about eight hours following an oral dose of 0.5 or 5 mg/kg. Within 48 hours, radio- activity excreted in the urine accounted for 98-99 percent of the administered dose. Feces accounted for 0.5 - 2 percent and exhaled air for about 0.2 percent. Radioactivity remaining in the body was about 61 percent of the administered dose at two hours (about 39 percent having been already excreted at that time), about 1.3 percent at 24 hours, 0.5 percent at 48 hours and 0.2 percent at ten days. Total recovered radioactivity in experiments averaged 90-100 percent. Recovery percentages in excreta were largely independent of dose level, route of administration and sex of the animal. Rates of elimination were dose-proportional. In a separate experiment in which 0.5 mg/kg of (14)C-demeton-S-methyl was intraduodenally administered to male rats with bile duct fistulas, about 3 percent of the administered radioactivity was excreted in the bile within 24 hours. Blood levels of radioactivity peaked at about one hour following oral administration of 5 mg/kg of the test material. From zero to six hours following administration, the blood half-life was calculated to be about two hours. From six to 24 hours post-dosing, the half life was about six hours and after 24 hours it was considerably longer. Nearly all the radioactivity in blood after 24 hours was accounted for by a high retention in erythrocytes which had considerably higher levels of radioactivity than other organs and tissues for up to ten days. Serum levels after 24 hours were low compared to erythrocytes and at ten days were negligible. Distribution of radioactivity in various body organs and tissues was relatively uniform at two hours. Radioactivity did not concentrate in fat tissue or in the reticuloendothelial system (liver, spleen, bone marrow). By two days post-administration, radioactivity in most organs and tissues, except blood and erythrocytes, had dropped 130 fold. At ten days, radioactivity was nearly undetectable in the majority of organs and tissues except for blood and erythrocytes.  In a separate experiment, whole-body autoradiography confirmed previous findings regarding distribution of radioactivity in body tissues, but also indicated some  localized accumulation or radioactivity in the pineal gland, thyroid and in some glands of the genital tract (Cowper's gland, seminal vescicle, accessory genital gland)."", 'Demeton-S-methyl may be absorbed from the gastrointestinal tract; through the intact skin; and by inhalation of spray mist and dusts.', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for DEMETON-S-METHYL (6 total), please visit the HSDB record page.']","['In plants, the thioethyl group is oxidized to give the sulfoxide (oxydemeton-methyl) and sulfone (demeton-S-methyl sulfone). Hydrolysis gives dimethyl phosphate.', 'In mammals, following oral admin, metab involves oxidation of the thioethyl group to give the sulfoxide (oxydemeton-methyl) & sulfone (demeton-S-methyl sulfone), & hydrolysis to dimethyl phosphate.', 'Male Sprague-Dawley rats given single oral doses of 0.1, 0.5, 5 or 10 mg/kg or intravenous doses of 0.5 or 1 mg/kg of (14)C- demeton-S-methyl. Additional female rats were given a single oral dose of 0.5 mg/kg. ... Rat urine samples ... were collected and subjected to thin layer chromatographic and radioactivity counting methods designed to identify and quantitate the parent compound and metabolites. Zero-to-eight hour and eight to 24-hour samples were collected from male rats given a single oral dose of 5 or 10 mg/kg of 14C-demeton-S-methyl. About 92 percent of the administered radioactivity was recovered in the urine within eight hours. The main route of metabolism of demeton-S-methyl was oxidation of the side chain to form the corresponding sulfoxide. Some further slight oxidation of the same side chain to form the corresponding sulfone was also observed. Three corresponding O-demethylated metabolites of the sulfide, sulfoxide and sulfone moieties were also identified in the urine, as were two additional metabolites presumably resulting from cleavage of the O-methylphosphoric ester group and subsequent methylation and sulfoxidation steps. The parent compound, demeton-S-methyl, was nearly completely metabolized and was not detected in the urine (<1 percent). Approximately 99 percent of the radioactivity in the urine samples, equivalent to about 95 percent of the administered oral doses, was identified and quantitated as follows: demeton-S-methyl (unchanged parent compound), < 1 percent, demeton-S-methyl sulfoxide, 58 percent; demeton-S-methyl sulfone, 6 percent; O-demethyl-demeton - S-methyl, 6 percent; O-demethyl-demeton-D-methyl sulfoxide, 6 percent; O-demethyl-demeton-S-methyl sulfone, 4 percent; methyl sulfinyl-2-ethyl sulfinyl ethane, 8.4 percent and methyl sulfinyl-2-ethyl sulfonyl ethane, 10.4 percent. Another metabolite accounting for less than 1 percent of the radioactivity in the urine was not further investigated. Treatment of urine with glucuronidase or sulfatase did not indicate the presence of any glucuronide or sulfate conjugates.', 'The main metabolic route of demeton-S-methyl is oxidation of the side chain leading to the formation of the corresponding sulfoxide, oxydemeton methyl, and to lesser extent, after further oxidation, the sulfone. O-demethylation also occurs. Neither glucuronide nor sulfate conjugates have been identified.', 'A study of urinary metabolites of organophosphorus pesticides in agricultural workers was conducted. The cohort consisted of 40 workers exposed to demeton-S-methyl. ...Urine samples were collected 1 day before beginning work and 12-18 hrs or 2 or 3 days after work. They were analyzed for dimethyl-phosphorothiolate-potassium-salt in the case of demeton-S-methyl. ...Median concentration of dimethyl-phosphorothiolate-potassium-salt in mixers using demeton-S-methyl was 83 ng/cc after 3 days work.']","['Male Sprague-Dawley rats given single oral doses of 0.1, 0.5, 5 or 10 mg/kg or intravenous doses of 0.5 or 1 mg/kg of (14)C- demeton-S-methyl. Additional female rats were given a single oral dose of 0.5 mg/kg. ... Blood levels of radioactivity peaked at about one hour following oral administration of 5 mg/kg of the test material. From zero to six hours following administration, the blood half-life was calculated to be about two hours. From six to 24 hours post-dosing, the half life was about six hours and after 24 hours it was considerably longer.', '/For/ male rats given a single oral dose of 0.1, 0.5, 5, or 10 mg/kg or a single intravenous dose of 0.5 or 1 mg/kg, and female rats received a single oral dose of 0.5 mg/kg. ...During the first 6 hours postexposure, blood concentration decreased with a half-life of about 2 hours, then during the next 48 hours, the half-life was approximately 6 hours. Following that, the half-life was further extended, the urinary elimination half-life was 2 to 3 hours during the first 24 hours and 1.5 days thereafter.', 'Absorption after oral administration /to rats/ was rapid (peak blood concentration was reached within one hr) and almost complete (98-99% of the administered radioactivity was, in fact, eliminated through the urine). The blood concentration decreased with a half-life of about 2 hr during the first 6 hr for the next 48 hr. The half-life thereafter was even longer. The radioactivity associated with erythrocytes accounted for almost all of the blood radioactivity found 24 hr or more after dosing. The half-life of urinary elimination was 2-3 hr during the first 24 hr and 1.5 days thereafter.']"
3526,13527,2-Ethoxy-2-methylbutane,CCC(C)(C)OCC,,,,,,
3527,13528,Methacryloyl chloride,CC(=C)C(=O)Cl,,,,,,
3528,13529,"1,1,1,3,3,3-Hexafluoro-2-propanol",C(C(F)(F)F)(C(F)(F)F)O,,,,,"['Hexafluoroisopropanol has known human metabolites that include (2S,3S,4S,5R)-6-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
3529,13530,"1,1,3-Trichloroacetone",C(C(=O)C(Cl)Cl)Cl,,,,,,
3530,13531,"1,1,2,3-Tetrachlorobuta-1,3-diene",C=C(C(=C(Cl)Cl)Cl)Cl,,,,,,
3531,13532,"Methane, chlorodinitro-",C([N+](=O)[O-])([N+](=O)[O-])Cl,,,,,,
3532,13533,"2,3,4-Trimethylhexane",CCC(C)C(C)C(C)C,,,,,,
3533,13534,"3,4-Dimethylheptane",CCCC(C)C(C)CC,,,,,,
3534,13535,Meso-lanthionine,C([C@H](C(=O)O)N)SC[C@@H](C(=O)O)N,,,,,,
3535,13536,Methyl propiolate,COC(=O)C#C,,,,,,
3536,13537,"Acetamide, N,N'-ethylenebis(N-nitro-",CC(=O)N(CCN(C(=O)C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3537,13538,3-Cyanoalanine,C(C#N)C(C(=O)O)N,,,,,,
3538,13539,2-Hydroxypropyl methacrylate,CC(COC(=O)C(=C)C)O,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME A DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
3539,13540,Baeta,C(COCCN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
3540,13541,2-[(1-Hexylheptyl)oxy]ethanol,CCCCCCC(CCCCCC)OCCO,,,,,,
3541,13542,N-Nitrosodibutylamine,CCCCN(CCCC)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['Pregnant golden Syrian hamsters were injected with 20 uCi (4.8 mg/kg bw) of (14)C-nitrosodibutylamine (14)C-NDBA. The animals were killed after 20 min or 1 hr, and were used for whole-body autoradiography. For in vitro experiments, tissue slices from fetal (day 12 and 15 of gestation), infant (4, 10, or 20 days old) or adult (non-pregnant females) hamsters were incubated in a solution containing (14)C-NDBA (34 umol/mL; 0.12 uCi/mL) for 1 hr at 37 C. The autoradiography showed uptake of radioactivity in the fetuses and a labeling of fetal nasal, tracheal, and bronchial mucosa exceeded the radioactivity that was present in most other fetal tissues. The metabolizing capacity of these tissues in the 15-day-old fetuses had a high capacity to form (14)C-carbon dioxide (14)CO2 and tissue-bound (14)C from the (14)C-labeled NDBA, while tissues in the 12-day-old fetuses, did not. In infant hamsters, the (14)CO2 and (14)C-tissue-binding in the respiratory tissues were in some instances higher than in the tissues of adult animals. The incubation of tissues of adult hamsters showed that the highest formation of (14)CO2 and tissue-bound (14)C was produced by the nasal olfactory mucosa.']","['... After oral administration of NDBA; in guinea pigs, glucuronide of N-nitroso-n-butyl-n-(3-hydroxybutyl)amine and traces of N-nitroso-n-butyl-n-(2-hydroxy-3-carboxypropyl)amine were ... excreted.', 'The present investigations showed that assumed and established metabolites of dipropylnitrosamine and dibutylnitrosamine reach the Syrian hamster fetus after subcutaneous (s.c.) treatment of their mothers (at day 14 of gestation). The compounds [2-hydroxypropylpropylnitrosamine, HPPN; 2-oxopropylpropylnitrosamine, OPPN; methylpropylnitrosamine, MPN; N-nitrosobis(2-hydroxypropyl)amine, BHP; and 4-hydroxybutylbutylnitrosamine, HBBN] were still present in the examined tissue (maternal blood, placenta, fetus, amniotic fluid) 4--6 hr after s.c. injection. The overall incidence of transplacentally induced tumors was lower in the F1- than in the P-generation and comparatively longer latencies were also observed in the F1- generation. However, in some groups low incidences were found of tumors which did not occur in the mothers (i.e., nasal cavities: BHP, HBBN; trachea: HBBN; lungs: HPPN, BHP, HBBN; liver: OPN, MPN, BHP, HBBN). Compared to exposure at early gestation, the transplacental carcinogenic effect increased at day 14 of gestation. Neoplasms originating in other organs were not associated with a transplacental effect of the examined nitrosamines.', 'The effect of butylated hydroxyanisole (BHA) on P-450-dependent omega-hydroxylation of N,N-dibutylnitrosamine (NDBA) to N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), and the further oxidation of BBN to N-butyl-N-(3-carboxypropyl)nitrosamine (BCPN) by the alcohol/aldehyde dehydrogenase system was investigated using the post-mitochondrial supernatant of liver homogenates (S9) from acutely and chronically BHA pretreated animals or S9 fractions from untreated rats with BHA added. Acute oral BHA (50 and 250 mg.kg-1) did not change NDBA omega-oxidation, which was reduced by 35% only when the compound was administered 0.5% in the diet for 3 weeks. BCPN formation from BBN was unaffected by acute and chronic BHA pretreatment. In order to verify whether BHA or its metabolite(s) had a direct effect on NDBA and BBN oxidation, the compound was added to S9 fractions from untreated rats at various concentrations. Only when BHA concentrations were equimolar or in a 10-fold molar excess to the substrate concentration, we observed 30-50% inhibition of BBN formation and a reduced BCPN formation (60-80% of control values), from BBN. Thus, only at very high BHA concentrations could we confirm the inhibition of P-450-dependent mixed function oxidase and alcohol dehydrogenase activities involved in the metabolism of NDBA and BBN.', 'N-Nitrosodi-((1-14)C)butylamine (NDBA) has been shown to undergo a high first-pass metabolism in isolated perfused rat small intestinal segments. Metabolites resulting from omega-hydroxylation of NDBA, the bladder carcinogens N-nitrosobutyl-(4-hydroxybutyl)amine (NB4HBA) and N-nitrosobutyl-(3-carboxypropyl)-amine (NB3CPA), accounted for greater than 90% of the total radioactivity absorbed. In the present study using vascularly perfused rat small intestinal segments, the high first-pass metabolism of NDBA could be confirmed under near in vivo conditions despite the much higher absorption rate. At the end of the 36 min experimental period 70-80% of the dose have been absorbed via the portal blood as opposed to 1-10% of the dose after 2 h in vitro perfusion. omega-Hydroxylation was again the most important metabolic pathway. However, the relationship of NB3CPA to NB4HBA was shifted in favor of NB4HBA, indicating a concentration and absorption rate dependency in the further metabolism of NB4HBA to NB3CPA.', 'For more Metabolism/Metabolites (Complete) data for N,N-Dibutylnitrosoamine (16 total), please visit the HSDB record page.', 'N-nitrosodibutylamine has known human metabolites that include N-Butyl-N-(1-hydroxybutyl)nitrous amide.']",
3542,13543,N-(Hydroxymethyl)acrylamide,C=CC(=O)NCO,,,,['N-HYDROXYMETHYLACRYLAMIDE IV INJECTED INTO RATS @ 140 MG/KG WAS DISTRIBUTED THROUGHOUT THE TOTAL BODY WATER WITHIN A FEW MIN. BREAKDOWN OF N-HYDROXYMETHYLACRYLAMIDE TO ACRYLAMIDE WAS NEGLIGIBLE IN VITRO & IN VIVO. IT CAUSED A RAPID DECR IN LIVER GLUTATHIONE IN VIVO & GLUTATHIONE CONJUGATES WERE EXCRETED IN THE BILE.'],['IN VITRO BIOTRANSFORMATION OF ACRYLAMIDE & 10 RELATED CMPDS IN THE HEPATIC ENZYME SYSTEM OF THE MOUSE WERE STUDIED. ALL ANALOGS STUDIED WERE METABOLIZED BY HEPATIC GLUTATHIONE S-TRANSFERASE.'],
3543,13544,sec-Butyl nitrite,CCC(C)ON=O,,,,,,
3544,13545,Methylpropylnitrosamine,CCCN(C)N=O,,,,,,
3545,13546,Methyl 3-methyl-2-butenoate,CC(=CC(=O)OC)C,,,,,,
3546,13547,"Biguanide, 1-isobutyl-, monohydrochloride",CC(C)CN=C(N)N=C(N)N.Cl,,,,,,
3547,13548,i-Butylbiguanide,CC(C)CN=C(N)N=C(N)N,,,,,,
3548,13549,Dipropyl succinate,CCCOC(=O)CCC(=O)OCCC,,,,,,
3549,13550,n-Propyl acrylate,CCCOC(=O)C=C,,,,,,
3550,13551,Isopropyl methanesulfonate,CC(C)OS(=O)(=O)C,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']",,"['... Low quantities of 75 mg/kg were promptly metabolized producing urinary metabolites, S-isopropylcysteine and S-isopropylcysteine N-acetate, accounting for 30% of the administered dose.', '... Isopropyl methanesulfonate ... in rat was found to yield isopropanol and methanesulfonic acid.']",
3551,13552,Neopentyl acetate,CC(=O)OCC(C)(C)C,,,,,,
3552,13553,"1-Propanol, 2,2-dimethyl-, nitrate",CC(C)(C)CO[N+](=O)[O-],,,,,,
3553,13554,"Arsine, dichloropropyl-",CCC[As](Cl)Cl,,,,,,
3554,13555,"4-Methyl-1,3-pentadiene",CC(=CC=C)C,,,,,,
3555,13556,"2-Butene, 1,3-dichloro-",CC(=CCCl)Cl,,,,,,
3556,13557,"Propane, 2-(ethenyloxy)-",CC(C)OC=C,,,,,,
3557,13558,"3,5-Dimethylheptane",CCC(C)CC(C)CC,,,,,,
3558,13559,CID 13559,CC(C=C)N=C(NNC(=NC)S)S,,,,,,
3559,13560,"Dimagnesium(2+) ion 3-(phosphonatooxy)pentane-1,5-diol 3-(phosphonatooxy)propane-1,2-diol",C(CO)C(CCO)OP(=O)([O-])[O-].C(C(COP(=O)([O-])[O-])O)O.[Mg+2].[Mg+2],,,,,,
3560,13561,6-Undecanone,CCCCCC(=O)CCCCC,,,,,,
3561,13562,"Butanamide, 4-hydroxy-",C(CC(=O)N)CO,,,,,,
3562,13563,"N,N-Dimethylbutylamine",CCCCN(C)C,,,,,,
3563,13564,2-Bromoethyl acetate,CC(=O)OCCBr,,,,,,
3564,13565,"1-Butene, 4-chloro-",C=CCCCl,,,,,,
3565,13566,3-Butyn-1-OL,C#CCCO,,,,,,
3566,13567,Butyl nitrate,CCCCO[N+](=O)[O-],,,,,,
3567,13568,Hex-3-yne,CCC#CCC,,,,,,
3568,13569,4-Chloro-1-butanol,C(CCCl)CO,,,,,,
3569,13570,"1-Propene, 1-ethoxy-",CCOC=CC,,,,,,
3570,13571,Hexyltrichlorosilane,CCCCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
3571,13572,6-Methylheptan-2-one,CC(C)CCCC(=O)C,,,,,,
3572,13573,CID 13573,CC(C)CCOC(=S)[S-].[K+],,,,,,
3573,13574,Isopentyl dithiocarbonate,CC(C)CCOC(=S)S,,,,,,
3574,13575,Disodium iminodiacetate,C(C(=O)[O-])NCC(=O)[O-].[Na+].[Na+],,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
3575,13576,3-Decanone,CCCCCCCC(=O)CC,,,,,,
3576,13577,(E);-Hex-2-en-1-ol,CCCC=CCO,,,,,,
3577,13578,2-(2-Aminoethoxy)ethanol,C(COCCO)N,,,,,,
3578,13579,2-Chloroethyl palmitate,CCCCCCCCCCCCCCCC(=O)OCCCl,,,,,,
3579,13580,7-Aminoheptanoic acid,C(CCCN)CCC(=O)O,,,,,,
3580,13581,Diethylene glycol monovinyl ether,C=COCCOCCO,,,,,,
3581,13582,Dodecylammonium chloride,CCCCCCCCCCCC[NH3+].[Cl-],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
3582,13583,Dodecylamine,CCCCCCCCCCCCN,,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",['AMINES ARE WELL ABSORBED FROM GUT & RESPIRATORY TRACT. /AMINES/'],"['MONOAMINE...& DIAMINE OXIDASE...OCCUR WIDELY...MOST CONCN IN LIVER, KIDNEY, & INTESTINAL MUCOSA. ...ASSUMED THAT THEY PLAY AN IMPORTANT ROLE IN ""DETOXICATION"" OF AMINES...AMMONIA FORMED IS CONVERTED TO UREA. HYDROGEN PEROXIDE IS ACTED ON BY CATALASE...ALDEHYDE FORMED /GIVES A/...CARBOXYLIC ACID. /AMINES/']",
3583,13584,Methyl behenate,CCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
3584,13585,Octadecyl vinyl ether,CCCCCCCCCCCCCCCCCCOC=C,,,,,,
3585,13586,Butadiene monoxide,C=CC1CO1,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,"['IN RAT LIVER MICROSOMES, 1,3-BUTADIENE WAS METABOLIZED TO BUTADIENE MONOXIDE WHICH WAS SUBSEQUENTLY TRANSFORMED INTO 3-BUTENE-1,2-DIOL BY MICROSOMAL EPOXIDE HYDROLASE. IN METABOLISM OF BUTADIENE OXIDE IN MICROSOMES, 4 METABOLITES WERE DETECTED; 2 STEREOISOMERS OF DL-DIEPOXYBUTANE & 2 STEREOISOMERS OF 3,4-EPOXY-1,2-BUTANEDIOL. NO MESODIEPOXYBUTANE WAS DETECTED.', 'Butadiene_monoxide has known human metabolites that include diepoxybutane (DEB).']",
3586,13587,3-Methylfuran,CC1=COC=C1,,,,,,
3587,13588,2-Cyclopenten-1-one,C1CC(=O)C=C1,,,"['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
3588,13589,Glycidyl methyl ether,COCC1CO1,,,,,,
3589,13590,2-Ethyl-2-imidazoline,CCC1=NCCN1,,,,,,
3590,13591,N-Nitrosopyrrolidine,C1CCN(C1)N=O,,,,"['After ip administration of 6 mg/kg bw (2,5-(14)c)- or (3,4-(14)c)-NPYR to rats, these compounds were converted to (14)CO2 to extent of 18-25% within 6 hr; 7% of radioactivity was excreted in urine and only 1-2% in feces. Oral dose of 4 mg/kg bw (2,5-(14)c)-NPYR was converted to (14)CO2 to extent of 77%, while only 14% of dose of 650 mg/kg bw appeared as (14)CO2 in 24 hr.', ""Whole-body autoradiography performed with hemisections of mice at -80 C and dry tape-sections, using pretreated and non-pretreated mice, indicated uniform distribution of non-metabolized N-nitrosopyrrolidine in tissues. At the shortest survival intervals (1 and 5 min) a high level of metabolites were found in liver, tracheo-bronchial and nasal mucosa and harder's gland which indicates local formation of metabolites in these tissues. At later survival intervals (0.5-24 hr) metabolites were in addition found in tissues with rapid cell turnover and high rate of protein synthesis and in brown fat."", '... Nitrosamines ... can presumably cross the placenta since they are capable of inducing neoplasma in the offspring if administered to rats in late pregnancy. /Nitrosamines/', 'Differential pulsed polarography in 0.05M sulfuric acid was used for the determination of urinary concentration of nonmetabolized N-nitrosamines in rats 24-72 hr after intragastric administration of 0.01-0.5 LD50 of ... N-nitrosopyrrolidine. ... Most of the nitrosamines were recovered in urine in less than or equal to 10% of the administered amounts. ...']","['An excellent correlation was found between the metabolism of nitrosopyrrolidine and nitrosohexamethylenimine (probably via oxidation at the alpha-C) in rat liver microsomes and mutagenic potency in 2 bacterial mutagenic systems.', 'The structures of the DNA adducts formed in the metabolism of cyclic (carcinogen) N-nitrosamines are not known. The reactions with deoxyguanosine, catalyzed by porcine liver esterase, of alpha-acetoxy-N-nitrosopyrrolidine and 4-(carbethoxynitrosamino) butanal which are stable precursors to the reactive intermediates, alpha- hydroxy-N-nitrosopyrrolidine and 3-formyl-1-propanediazohydroxide, formed in the alpha-hydroxylation of the cyclic nitrosamine, N-nitrosopyrrolidine were studied. The same 2 major deoxyguanosine adducts were produced in each reaction. They were isolated by high-performance liquid chromatography and characterized by their UV spectra, mass spectra and proton magnetic resonance spectra. On the basis of these spectral data, the structures of the 2 major adducts were assigned as 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-8R- hydroxy-6R-methylpyrimido (1,2-a)purine-10(3H)one and 3-(2-deoxy-beta-D-erythro- pentofuranosyl)-5,6,7,8-tetrahydro-8S-h-ydroxy-6S-methylpyrimido(1,2,-a)purine- 10(3H)one, in which a new saturated 6-membered ring is formed by reaction at the 1- and N2-positions of deoxyguanosine. The same 2 adducts were formed in the reaction of crotonaldehyde (2-butenal) with deoxyguanosine. Mild acid hydrolysis of each of the 2 diastereomeric deoxyguanosine adducts yielded a pair of enantiomeric tricyclic 1,N2-guanine derivatives which had spectral properties in accordance with the assigned structures. Treatment of these tricyclic 1,N-2-guanine derivatives with sodium hydroxide and sodium borohydrate yielded N2-(3-hydroxy-1- methylpropyl) guanine, confirming the structural assignments. Unlike saturated dialkylnitrosamines which are metabolized to intermediates that give mainly 7-alkylation of deoxyguanosine, the intermediates formed in the alpha-hydroxylation of a cyclic nitrosamine, N-nitrosopyrrolidine, modify deoxyguanosine by forming cyclic 1,N2-adducts.', 'It is interesting to note that apparently all N,N-dialkylnitrosamines containing a tert-butyl group are noncarcinogenic. The list includes N-nitroso-1-proline, found in cured meats, particularly bacon. Although noncarcinogenic itself, nitrosoproline gives rise to the carcinogenic N-nitrosopyrrolidine during cooking. Aromatic nitrosamines are capable of transnitrosation, ie, under suitable conditions, their nitroso group can be transferred to appropriate amine-type compounds. It is thus possible that noncarcinogenic transnitrosating agents could form new carcinogenic N-nitroso compounds in the stomach.', 'Less than 1% of ip dose of NPYR appeared as n-nitroso-3-hydroxy-pyrrolidine in urine of rats. Alkylated base, which was not identified ... was isolated from hydrolysates of liver DNA. (3)h-NPYR administration to rats reacted with DNA and RNA; however, no products were characterized.', 'For more Metabolism/Metabolites (Complete) data for N-NITROSOPYRROLIDINE (25 total), please visit the HSDB record page.', 'NPYR has known human metabolites that include 2-Pyrrolidinol, 1-nitroso-.']",
3591,13592,4-Chlorocyclohexene,C1CC(CC=C1)Cl,,,,,,
3592,13593,1-Chlorocyclohexene,C1CCC(=CC1)Cl,,,,,,
3593,13594,2-Cyclohexen-1-one,C1CC=CC(=O)C1,,,,,,
3594,13595,CID 13595,C1=CC=C(C=C1)[S-].[Na+],,,,,,
3595,13596,1-Methylpyridinium iodide,C[N+]1=CC=CC=C1.[I-],,,,,,
3596,13597,N-Methylpyridinium,C[N+]1=CC=CC=C1,,,,,,
3597,13598,"Cyclopentane, 1-ethyl-2-methyl-, (1R,2R)-rel-",CC[C@@H]1CCC[C@H]1C,,,,,,
3598,13599,4-Nitroisothiazole,C1=C(C=NS1)[N+](=O)[O-],,,,,,
3599,13600,2-Pyrazoline-1-carboxamide,C1CN(N=C1)C(=O)N,,,,,,
3600,13601,"1,2-Cyclohexanediol",C1CCC(C(C1)O)O,,,,,,
3601,13602,2-Methylpyridine 1-oxide,CC1=CC=CC=[N+]1[O-],,,,,,
3602,13603,1-Methyl-2-piperidone,CN1CCCCC1=O,,,,,,
3603,13604,"1H-Imidazole, 2-ethyl-4,5-dihydro-4-methyl-",CCC1=NCC(N1)C,,,,,,
3604,13605,Cyclohexylmagnesium chloride,C1CC[CH-]CC1.[Mg+2].[Cl-],,,,,,
3605,13606,Phenyl isocyanide,[C-]#[N+]C1=CC=CC=C1,,,,,,
3606,13607,Cyclohexyl methyl ether,COC1CCCCC1,,,,,,
3607,13608,Bicyclo[2.2.2]oct-2-ene,C1CC2CCC1C=C2,,,,,,
3608,13609,1-Cyclooctene,C1CCCC=CCC1,,,,,,
3609,13610,1-Hydroxycyclohexanecarbonitrile,C1CCC(CC1)(C#N)O,,,,,,
3610,13611,5-Aminouracil,C1=C(C(=O)NC(=O)N1)N,,,,,,
3611,13612,1-Acetyl-1-cyclohexene,CC(=O)C1=CCCCC1,,,,,,
3612,13613,N-Nitrosohexamethyleneimine,C1CCCN(CC1)N=O,,,,,,
3613,13614,4-Chloronitrosobenzene,C1=CC(=CC=C1N=O)Cl,,,,,,
3614,13615,"2-Amino-4,6-dichlorotriazine",C1(=NC(=NC(=N1)Cl)Cl)N,,,,,,
3615,13616,"1,1-Dimethoxycyclohexane",COC1(CCCCC1)OC,,,,,,
3616,13617,"Tetramethyl-1,3-cyclobutanedione",CC1(C(=O)C(C1=O)(C)C)C,,,,,,
3617,13618,"2,3,6-Trichlorophenol",C1=CC(=C(C(=C1Cl)O)Cl)Cl,,,,['The compounds are absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/'],"['2,3,6-trichlorophenol is a known human metabolite of 1,2,4-trichlorobenzene.']",
3618,13619,"2,3,5-Trichlorophenol",C1=C(C=C(C(=C1O)Cl)Cl)Cl,,,,,"['2,3,5-trichlorophenol is a known human metabolite of 1,2,4-trichlorobenzene.']",
3619,13620,5-Bromo-1-methyl-4-nitro-1H-imidazole,CN1C=NC(=C1Br)[N+](=O)[O-],,,,,,
3620,13621,"1-Ethyl-2,3-dimethylbenzene",CCC1=CC=CC(=C1C)C,,,,,,
3621,13622,3-Methoxycatechol,COC1=CC=CC(=C1O)O,,,,,,
3622,13623,5-Aminobenzimidazole,C1=CC2=C(C=C1N)NC=N2,,,,,,
3623,13624,2-Aminobenzimidazole,C1=CC=C2C(=C1)NC(=N2)N,,,,,,
3624,13625,2(3H)-Benzothiazolone,C1=CC=C2C(=C1)NC(=O)S2,,,,,,
3625,13626,p-Chlorophenyl methyl sulfoxide,CS(=O)C1=CC=C(C=C1)Cl,,,,,,
3626,13627,"1-Ethyl-3,5-dimethylbenzene",CCC1=CC(=CC(=C1)C)C,,,,,,
3627,13628,"6-Ethyl-1,3,5-triazine-2,4-diamine",CCC1=NC(=NC(=N1)N)N,,,,,,
3628,13629,"4-Ethyl-1,2-dimethylbenzene",CCC1=CC(=C(C=C1)C)C,,,,,,
3629,13630,S-Phenyl thioacetate,CC(=O)SC1=CC=CC=C1,,,,,,
3630,13631,N-(2-Chloroethyl)aniline,C1=CC=C(C=C1)NCCCl,,,,,,
3631,13632,2-Azacyclononanone,C1CCCC(=O)NCCC1,,,,,,
3632,13633,CID 13633,C1CCCCC=CCCC1,,,,,,
3633,13634,"2-Ethyl-2-isobutyl-1,3-dioxolane",CCC1(OCCO1)CC(C)C,,,,,,
3634,13635,"2,6,7-Trioxa-1-phosphabicyclo(2.2.2)octane, 4-ethyl-, 1-sulfide",CCC12COP(=S)(OC1)OC2,,,,,,
3635,13636,"2,3,5,6-Tetrachlorophenol",C1=C(C(=C(C(=C1Cl)Cl)O)Cl)Cl,,,,"['The compounds are readily absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/', 'Chlorophenols ... are readily absorbed from all routes including percutaneous and inhalation. /Chlorophenols/']","['The comparative formation of chlorophenol metabolites of hexachlorocyclohexane was investigated in rats and mice. Male Swiss mice and female Wistar rats were fed a diet containing 500 parts per million hexachlorocyclohexane. Animals were killed after 2 months and hepatic chlorophenol metabolites were determined using hig performance liquid chromatography. Circulating concentrations of chlorophenols were determined in Wistar rats and Swiss mice given a single 200 mg/kg intraperitoneal injection of hexachlorocyclohexane. After 24 hours blood was collected by heart puncture and chlorophenols assayed chromatographically. Species differences in the rate of chlorophenol metabolite formation in vitro were also measured in hepatic microsome fractions prepared from Aroclor 1254 pretreated animals. Chlorophenol metabolites identified were 2,6-dichlorophenol, 2,3,5-trichlorophenol, 2,3,6-trichlorophenol, 2,4,6-trichlorophenol, 2,3,4,5-tetrachlorophenol, 2,3,5,6-tetrachlorophenol, and pentachlorophenol. No qualitative species difference was detected in chromatographic profiles of chlorophenols extracted from mouse and rat liver after continuous 2 month administration of hexachlorocyclohexane. Only 2,6-dichlorophenol was significantly higher in mouse live than that observed in rat liver: 1292.5 ng/g in mouse and 140.0 ng/g in rat. No qualitative difference was observed in the chlorophenols of blood of mice and rats. However, the concentration of 2,6-dichlorophenol was 11.52 ug/ml compared to 1.65 ug/ml in mouse blood. In vitro, 647 pmol/mg/hour 2,4,6-trichlorophenol were formed by rat liver microsomes, compared to 219 pmol/mg/hour by mouse liver microsomes. The authors conclude that hexachlorocyclohexane may be a tumor promoting agent which acts by facilitating the development of latent initiated cells of unknown origin. Differential plasma clearance of 2,6-dichlorophenol may account for species differences in its concentration; however it is unlikely that it plays a major role in the induction of liver tumors in mice.', 'The metabolism of tetrachlorobenzenes was investigated in the squirrel monkey and a comparison made of the interspecies metabolism of such compounds. Three groups of four male monkeys were given orally single doses of one of three tetrachlorobenzene isomers in corn-oil twice per week for 3 weeks. The dose levels for 1,2,3,4-tetrachlorobenzene and 1,2,3,5-tetrachlorobenzene were 100 mg/kg, and the dose level for 1,2,4,5-tetrachlorobenzene was 50 mg/kg. Respective levels of fecal excretion at 48 hours were 38, 36, and 18% of the initial doses. No metabolism occurred for 1,2,4,5-tetrachlorobenzene in the squirrel monkey. Fecal metabolites of 1,2,3,5-tetrachlorobenzene included 2,3,4,5-tetrachlorophenol (2% of dose), 2,3,4,6-tetrachlorophenol (14%), 2,3,5,6-tetrachlorophenol (9%), and 2,3,5,6-tetrachlorophenyl sulfinic acid (15%). For animals dosed with either 1,2,3,4-tetrachlorobenzene or 1,2,3,5-tetrachlorobenzene, the fecal radioactivity demonstrated elimination of at least 50% unchanged compound. Fecal metabolites in monkeys dosed with 1,2,3,4-tetrachlorobenzene included 1,2,4,5-tetrachlorophenol (22%), N-acetyl-S-(2,3,4,5-tetrachlorophenyl)cysteine (18%), 2,3,4,5-tetrachlorophenyl sulfinic acid (3%), 2,3,4-trichlorophenyl-methyl sulfide (0.6%), and 2,3,4,5-tetrachlorophenyl-methyl sulfide (0.2%). Different metabolic pathways were briefly compared for the squirrel monkey, the rat, and the rabbit. The authors conclude that the tetrachlorobenzenes studied are metabolized differently in different species and that different isomers are metabolized by different pathways.', 'After lindane was administered to rats in a single oral dose, the time profile of the degree of conjugation of the main phenolic metabolites was evaluated. In all urine samples 2,3-dichlorophenol, 2,4,5- and 2,4,6-trichlorophenol, and 2,3,5,6-tetrachlorophenol were constantly present. 2,3,5,6-Tetrachlorophenol and then 2,4,6-trichlorophenol were the prevalent metabolites in all cases. The degree of conjugation did not correlate with the dissociation constant of individual chlorinated phenols. Phenol conjugation declined with time after administration.']",
3636,13637,2-Hydroxybenzohydrazide,C1=CC=C(C(=C1)C(=O)NN)O,,,,,,
3637,13638,"2,3-Dihydrobenzo[d]isothiazole 1,1-dioxide",C1C2=CC=CC=C2S(=O)(=O)N1,,,,,,
3638,13639,2-Phenyl-2-imidazoline,C1CN=C(N1)C2=CC=CC=C2,,,,,,
3639,13640,"ANILINE, p-BROMO-N-METHYL-N-NITROSO-",CN(C1=CC=C(C=C1)Br)N=O,,,,,,
3640,13641,N-Nitroso-N-methyl-4-fluoroaniline,CN(C1=CC=C(C=C1)F)N=O,,,,,,
3641,13642,4'-Ethylacetophenone,CCC1=CC=C(C=C1)C(=O)C,,,,,,
3642,13643,N-methyl-n-benzylnitrosamine,CN(CC1=CC=CC=C1)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
3643,13644,"1,3,8,8-Tetramethyl-3-azabicyclo(3.2.1)octane hydrochloride",CC1(C2CCC1(C[NH+](C2)C)C)C.[Cl-],,,,,,
3644,13645,"1,3,8,8-Tetramethyl-3-azabicyclo[3.2.1]octane",CC1(C2CCC1(CN(C2)C)C)C,,,,,,
3645,13646,2-Chloroethyl phenyl sulfone,C1=CC=C(C=C1)S(=O)(=O)CCCl,,,,,,
3646,13647,"2,3,4,6-Tetrachloroanisole",COC1=C(C(=C(C=C1Cl)Cl)Cl)Cl,,,,,,
3647,13648,"1,2-Diaminonaphthalene",C1=CC=C2C(=C1)C=CC(=C2N)N,,,,,,
3648,13649,"2,3,4,5-Tetrachloroanisole",COC1=CC(=C(C(=C1Cl)Cl)Cl)Cl,,,,,,
3649,13650,3-Hydroxycoumarin,C1=CC=C2C(=C1)C=C(C(=O)O2)O,,,,,['3-Hydroxycoumarin is a known human metabolite of coumarin.'],
3650,13651,4-Phenylpyridine,C1=CC=C(C=C1)C2=CC=NC=C2,,,,,,
3651,13652,2-Ethylnaphthalene,CCC1=CC2=CC=CC=C2C=C1,,,,,,
3652,13653,CID 13653,C[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
3653,13654,Isopropyl benzoate,CC(C)OC(=O)C1=CC=CC=C1,,,,,,
3654,13655,4-Chloro-3-nitrobenzonitrile,C1=CC(=C(C=C1C#N)[N+](=O)[O-])Cl,,,,,,
3655,13656,trans-2-Phenylcyclopropanecarbonyl chloride,C1[C@H]([C@@H]1C(=O)Cl)C2=CC=CC=C2,,,,,,
3656,13657,"p-ANISIDINE, N-METHYL-N-NITROSO-",CN(C1=CC=C(C=C1)OC)N=O,,,,,,
3657,13658,2-Phenoxypropionic acid,CC(C(=O)O)OC1=CC=CC=C1,,,,,,
3658,13659,"1,3,3,8,8-Pentamethyl-3-azoniabicyclo(3.2.1)octane iodide",CC1(C2CCC1(C[N+](C2)(C)C)C)C.[I-],,,,,,
3659,13660,"1,3,3,8,8-Pentamethyl-3-azoniabicyclo[3.2.1]octane",CC1(C2CCC1(C[N+](C2)(C)C)C)C,,,,,,
3660,13661,p-Toluenesulfonyl azide,CC1=CC=C(C=C1)S(=O)(=O)N=[N+]=[N-],,,,,,
3661,13662,N-Phenylmaleimide,C1=CC=C(C=C1)N2C(=O)C=CC2=O,,,,,,
3662,13663,1'-Acetonaphthone,CC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
3663,13664,"1,2,3,4-Tetrahydrocarbazole",C1CCC2=C(C1)C3=CC=CC=C3N2,,,,,,
3664,13665,N-Methyl-1H-indole-3-ethylamine monohydrochloride,C[NH2+]CCC1=CNC2=CC=CC=C21.[Cl-],,,,,,
3665,13666,(1-Hydroxy-1-phenylpropan-2-yl)-dimethylazanium chloride,CC(C(C1=CC=CC=C1)O)[NH+](C)C.[Cl-],,,,,,
3666,13667,Salicylonitrile methylcarbamate,CNC(=O)OC1=CC=CC=C1C#N,,,,,,
3667,13668,"Benzo[C][1,2,5]oxadiazole-5-boronicacid",CC[NH2+]CC(C1=CC(=CC=C1)O)O.[Cl-],,,,,,
3668,13669,4'-tert-Butylacetophenone,CC(=O)C1=CC=C(C=C1)C(C)(C)C,,,,,,
3669,13670,"Ethyl 3-azatricyclo(3.2.1.0(sup2,4))octane-3-carboxylate",CCOC(=O)N1C2C1C3CCC2C3,,,,,,
3670,13671,N-Nitroso-N-methyl-4-nitroaniline,CN(C1=CC=C(C=C1)[N+](=O)[O-])N=O,,,,,,
3671,13672,"Acetic acid, phenyl-, 2-chloroethyl ester",C1=CC=C(C=C1)CC(=O)OCCCl,,,,,,
3672,13673,3-(Piperidinomethyl)-5-methylisoxazole hydrochloride,CC1=CC(=NO1)C[NH+]2CCCCC2.[Cl-],,,,,,
3673,13674,"5-Methyl-3-(piperidin-1-ylmethyl)-1,2-oxazole",CC1=CC(=NO1)CN2CCCCC2,,,,,,
3674,13675,Fonofos oxon,CCOP(=O)(CC)SC1=CC=CC=C1,,,,,,
3675,13676,Fonofos,CCOP(=S)(CC)SC1=CC=CC=C1,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)']","['When (14)C ethoxy labeled dyfonate was administered /to rats/, 95% of label was found in urine; 5% in feces; and ...0.5% in exhaled air. With (35)S label, 63% of dose was recovered in urine; 32% in feces; 2% in tissues; and 0.1% in exhaled air.', '/After oral admin in oil to rats/ ...polar products ...excreted in urine and feces.', 'After a single oral or ip dose of fonofos labeled in the ring position, 98% of the radioactivity was excreted in the urine and feces within 96 hours. Conditioning with unlabeled fonofos did not change the excretion pattern. Excretion of radioactivity from the (14)C-ethoxy moiety was essentially complete in 4 days, with about 91% in the urine, 7.4% in the feces, and 0.35% in the expired air. Radioactivity in the bile was an important source of activity in the feces. Tissue residues were very small and had virtually disappeared by the 16th day.', 'Rapidly absorbed through the skin.', 'When plants were grown in nitrogen deficient nutrient solution, concentration of dyfoxon /metabolite/ in greens were reduced due to deficiencies of all elements (potassium, calcium, and magnesium) except nitrogen.']","['Metabolism of dyfonate in rats was studied .../with (35)S label/. ...Diethyl phosphate and thiophosphate, methylphenylthioether, and thiolate analog of dyfonate were observed.', 'Dyfonate in oil was admin orally to albino rats. Rapid metabolism ...produced ...dyfonate oxon, o-ethyl o-methyl ethylphosphonate, methylphenyl sulfoxide and sulfone, o-ethyl ethylphosphonothioic acid, o-ethyl ethylphosphonic acid and 3-hydroxy- and 4-hydroxy-phenyl sulfones /and/ other unidentified materials... .', 'When phenyl (35)S fonofos was administered to mice, the (S)p isomer was eliminated, primarily in urine, more rapidly than the (R)p isomer. In addition to unchanged fonofos, other identified (35)Slabeled metabolites included: fonofos oxon, diphenyl disulfide, diphenyl disulfide oxide, methyl phenyl sulfoxide and sulfone, and 3-OH- and 4-OH-phenyl methyl sulfones. When phenyl (35)S-fonofos oxon was used, (35)S-labeled metabolites included methyl phenyl sulfoxide, methyl phenyl sulfone, and 3-OH- and 4-OH-phenyl methyl sulfones.', 'Dyfonate was incubated with microsomes ...from rat livers. ...The oxon, eop /o-ethyl ethylphosphonic acid/, etp /o-ethyl ethylphosphonothioic acid/ and thiophenol /were identified/ as major microsome metabolites. Formation of etp and the oxon required presence of nadph2.', 'For more Metabolism/Metabolites (Complete) data for FONOFOS (11 total), please visit the HSDB record page.']",
3676,13677,Tetrachloroveratrole,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC,,,,,,
3677,13678,"1,2,4,5-Tetrachloro-3,6-dimethoxybenzene",COC1=C(C(=C(C(=C1Cl)Cl)OC)Cl)Cl,,,,,,
3678,13679,Diphenyl sulfoxide,C1=CC=C(C=C1)S(=O)C2=CC=CC=C2,,,,,,
3679,13680,2-Acetyl-1-methylbenzimidazole oxime,CC(=NO)C1=NC2=CC=CC=C2N1C,,,,,,
3680,13681,"2-Chloro-4,6-dinitrophenol",C1=C(C=C(C(=C1[N+](=O)[O-])O)Cl)[N+](=O)[O-],,,,,,
3681,13682,"Methyl(beta,3,4-trihydroxy-alpha-methylphenethyl)ammonium chloride",CC(C(C1=CC(=C(C=C1)O)O)O)[NH2+]C.[Cl-],,,,,,
3682,13683,Dioxifedrine,CC(C(C1=CC(=C(C=C1)O)O)O)NC,,,,,,
3683,13684,2-((5-Nitrofuran-2-yl)methylene)hydrazinecarboximidamide hydrochloride,C1=C(OC(=C1)[N+](=O)[O-])C=NN=C(N)N.Cl,,,,,,
3684,13685,5-Nitrofurfurylidenaminoguanidin,C1=C(OC(=C1)[N+](=O)[O-])C=NN=C(N)N,,,,,,
3685,13686,"Acetic acid, phenoxy-, 2-chloroethyl ester",C1=CC=C(C=C1)OCC(=O)OCCCl,,,,,,
3686,13687,3-(2-Piperidinoethyl)-5-methylisoxazole hydrochloride,CC1=CC(=NO1)CC[NH+]2CCCCC2.[Cl-],,,,,,
3687,13688,"5-Methyl-3-(2-piperidin-1-ylethyl)-1,2-oxazole",CC1=CC(=NO1)CCN2CCCCC2,,,,,,
3688,13689,Phosfolan,CCOP(=O)(N=C1SCCS1)OCC,,,,"['A SINGLE ORAL DOSE (2 MG/KG) TO THE RAT OF (14)C-(C=N)PHOSFOLAN (CYOLANE) WAS RAPIDLY METABOLIZED ... THIOCYANATE WAS PRESENT IN LIVER, KIDNEY, & FAT, & WAS ALSO EXCRETED IN THE URINE (24%).', 'CYOLANE IS ... ACTIVE ... IN PLANTS THROUGH ROOT & FOLIAR ABSORPTION.']","['... IN PLANTS & ANIMALS, /PHOSFOLAN/ IS METABOLIZED AT THE N-P BOND TO LESS TOXIC, WATER-SOLUBLE COMPOUNDS.', 'A SINGLE ORAL DOSE (2 MG/KG) TO RAT OF [(14)C-(C=N)]PHOSFOLAN WAS RAPIDLY METABOLIZED TO GIVE AS MAJOR METABOLITES THIOCYANATE AND CARBON DIOXIDE (20%). ... FOURTEEN MINOR URINARY METABOLITES WERE IDENTIFIED ... THE LIKELY INITIAL STEPS IN BIOTRANSFORMATION OF PHOSFOLAN ARE P-N CLEAVAGE &/OR S-OXIDATION.', 'Results are presented of studies on the metabolism of two (14)C-dithiolane insecticides (phosfolan and mephosfolan) labeled in the imido carbon position. Rats, cotton plants, and a simulated rice paddy environment were used in the studies. In rats, both insecticides showed their major degradation route to be hydrolysis to iminodithiolane, then to thiocyanate, then CO2. In cotton plants treated with mephosfolan, hydroxylation of the methyl moiety of the iminodithiolane ring and conjugation as glucoside was a significant pathway. When a rice paddy environment was treated with mephosfolan, mephosfolan was found in the rice plants, but did not accumulate in the rice grain. The rice plants assimilated mephosfolan rapidly, degraded it, and incorporated the (14)C-carbon into the natural plant products. Mephosfolan was readily metabolized by fish in the paddy environment into the thiocyanate and many polar metabolites.']",
3689,13690,Azacyclotridecan-2-one,C1CCCCCC(=O)NCCCCC1,,,,,,
3690,13691,CID 13691,CCC(C)C1(C(=NC(=NC1=O)S)[O-])CC.[Na+],,,,,,
3691,13692,CID 13692,CCC(C)C1(C(=O)NC(=NC1=O)S)CC,,,,,,
3692,13693,Diphenylsilanediol,C1=CC=C(C=C1)[Si](C2=CC=CC=C2)(O)O,,,,,,
3693,13694,9-Chlorophenanthrene,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)Cl,,,,,,
3694,13695,9-Aminophenanthrene,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)N,,,,,,
3695,13696,Diphenylacetaldehyde,C1=CC=C(C=C1)C(C=O)C2=CC=CC=C2,,,,,,
3696,13697,N-Nitrosodicyclohexylamine,C1CCC(CC1)N(C2CCCCC2)N=O,,,,,,
3697,13698,2-Phenylindole,C1=CC=C(C=C1)C2=CC3=CC=CC=C3N2,,,,,,
3698,13699,4-Methoxybenzamide O-acetyloxime,CC(=O)ON=C(C1=CC=C(C=C1)OC)N,,,,,,
3699,13700,"Phenol, 2-octyl-",CCCCCCCCC1=CC=CC=C1O,,,,,,
3700,13701,l-Isoprenaline hydrochloride,CC(C)[NH2+]CC(C1=CC(=C(C=C1)O)O)O.[Cl-],,,,,,
3701,13702,Benzyl 3-chlorophenyl ether,C1=CC=C(C=C1)COC2=CC(=CC=C2)Cl,,,,,,
3702,13703,"2-Methyl-4,6-bis(trichloromethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
3703,13704,"2-(Allyloxy)-4-methyl-6-(trichloromethyl)-1,3,5-triazine",CC1=NC(=NC(=N1)OCC=C)C(Cl)(Cl)Cl,,,,,,
3704,13705,4-Methylazobenzene,CC1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
3705,13706,4-Nitro-L-phenylalanine,C1=CC(=CC=C1C[C@@H](C(=O)O)N)[N+](=O)[O-],,,,,,
3706,13707,Mephosfolan,CCOP(=O)(N=C1SCC(S1)C)OCC,,,,['Absorbed by the roots and leaves.'],"['Undergoes oxidation at the methyl group to form primary alcohol in addition to the formation of the thiocyanate ion in plants.', 'In the urine of rats dosed with cytrolane, TLC and MS indicated that the methyl moiety was attacked to produce carboxylic ions. Hydrolysis of the P-N bond was followed by ring opening and release of thiocyanate. The latter was the main tissue metabolite.', '(14)C Cytrolane ..., labeled at the imino carbon, was applied to leaves of cotton plants. After 42 days, about 60% of the label was recovered as unchanged cytrolane. A minor metabolite ... and a major metabolite ... were isolated as glucosides. Identification of the aglycones was made after hydrolysis of the glucosidic moiety with beta-glucosidase. Another minor metabolite was identified as thiocyanate. Other observed metabolites were not identified. The hydroxymethyl and its glucoside were also observed in other studies with cotton.', 'When (14)C labeled cytrolane was applied to rice, about 91% of the residue was unchanged material. The remainder of the radioactivity was composed of about 17 metabolites. Unextractable radioactivity was believed to be in the form of (14)C-labeled cellulose, lignin and starch. Fish kept in the rice paddy metabolized cytrolane to thiocyanate and many other metabolites.']",
3707,13708,Methyl paraoxon,COP(=O)(OC)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3708,13709,Methidathion,COC1=NN(C(=O)S1)CSP(=S)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Male and female CFI mice were treated dermally with (14)C-radiolabelled methidathion in the carbonyl carbon of the thiadiazole ring in acetone solution or formulated in petroleum hydrocarbon with emulsifier (the ratio of active ingredient to petroleum hydrocarbon to emulsifier was 6:10:1). The actual dermal dose was stated to be 12 mg/kg bw. The test solutions for both sexes were well absorbed through the skin as measured over a 72-hr period, with residual radioactivity on the skin in the acetone group of 0.47-0.67% and in the formulated product of 0.35-1.27% of the dose. The highest concentrations of radioactivity were recovered in the expired CO2 (50.85-64.1%) and urine (14.48-23.47%). Radioactivity found in tissues (0.3-0.7%) and blood (0.03-0.21%) was minimal. Total recovery represented 83-94% of the administered dose. The half-lives for the testing solutions on the skin were calculated for the acetone group to be 9.1 and 10.5 hr for males and females, and for the formulated group to be 10.4 and 10.9 hr for males and females, respectively. Blood and tissue levels appeared to plateau approximately 4 hr post-dosing, with tissue levels rarely exceeding 4 ppm.', 'Oral doses /in rats/ of three differently labeled forms ...were rapidly excreted in urine (up to 45%) and expired air (up to 36%). 24 hr after daily dosing ...for 10 days, <2% remained in tissues examined, and none after 48 hr. The lactating goat excreted around 1% of dose ...into milk in 72 hr.', 'Rats were dosed orally .../studies/ indicated complete absorption .../labeled/gs-13005 was distributed rapidly but radioactive content of all organs was below limit of detection 48 hr after dosage except for traces in muscles. Most ...was excreted in urine as polar metabolites... .', '...Oral dose of (14)C-carbonyl supracide ...was ...degraded by cow. 16-51% of (14)C was thought to have been excreted in expired air, 43% in urine, 4% in feces and 1% in milk. Serum levels of (14)C peaked within 5 hr of dosing.', 'For more Absorption, Distribution and Excretion (Complete) data for METHIDATHION (12 total), please visit the HSDB record page.']","['/In rats the/ product of final oxidation and main metabolite (up to 36% of applied dose /2-methoxy and thiadazole ring labeled (14)C/) was ...CO2. 2 ...Metabolites in urine were 2-methoxy-4-methylsulfinylmethyl-delta2-1,3,4-thiadiazolin-5-one (25%) and corresponding sulfone (7%). The methylthiomethyl derivative did not appear in significant amount. ...When labeled supracide was admin to lactating cow, analysis of milk, urine, and feces indicated that extensive degradation ...had occurred. No supracide or its oxygen analog was found in milk. ...In rumen ...degradation /to water sol metabolites/ ...was ...due to microbial activity. ...The locus l migratoria degraded the thiadiazole ring. Some CO2 and unidentified water-soluble metabolites were formed.', 'The most important metabolites observed /in rats following oral dose/ were 4-methylsulfinylmethyl- and 4-methylsulfonylmethyl-2-methoxy-1,3,4-thiadiazole-5-one. These metabolites originate by methylation and oxidation of the mercaptomethyl deriv liberated after hydrolysis of the p-s bond. Dimethyl phosphate, dimethyl phosphorothioate, methyl phosphate, inorganic phosphate and desmethyl gs-13005 were ...found in urine and/or feces. ...Cotton plants of delta-pine smoothleaf variety were grown and treated with (32)P labelled gs-13005 ...revealed ...desmethyl gs-13005, the oxon ...analog of gs-13005, dimethyl phosphorothioate, mono- and di-methyl phosphate, inorganic phosphate, unidentified metabolite and some unextracted radioactivity. ...In 5th instar tobacco budworms, gs-13005 was completely metabolized during 1st 4 hr. Small amount of thiolate analog and desmethyl analog formed ...but was depleted after 4 hr. Dimethyl phosphorothioate and dimethyl phosphate were major hydrolytic products. ...Other polar metabolites were ...observed.', '5-Methoxy-1,3,4-thiadiazol-2-one is a metabolite of supracide ... . The first oxidative degradation reaction takes place with dithioate going to thiolate.', 'Details of the metabolism of the acidic group of methidathion have been explored using  insecticide in which every carbon atom in this group was marked with (14)C. Up to 36% of the  dose applied to rats was recovered as carbon dioxide. ... In another study in rats, it was  shown that averages of 22.4, 25.8, and 17.7% of the applied dose were recovered as carbon  dioxide when the 2-methoxy, carbonyl, and methylene carbons, respectively, of the acidic  groups were labeled with (14)C. Dimethyl phosphate (33.6%) and dimethyl phosphorothioate  (24.2%) were the main urinary metabolites of methidathion, but 11.1% was recovered during the  first 48 hours as desmethyl methidathion. Almost 80% of intraperitoneal doses of (32)P  methidathion was excreted in 48 hr, including 7.1% in the feces.', 'For more Metabolism/Metabolites (Complete) data for METHIDATHION (11 total), please visit the HSDB record page.']","['Male and female CFI mice were treated dermally with (14)C- radiolabelled methidathion ... in acetone solution or formulated in petroleum hydrocarbon with emulsifier (the ratio of active ingredient to petroleum hydrocarbon to emulsifier was 6:10:1). The actual dermal dose was stated to be 12 mg/kg bw. ... The half-lives for the testing solutions on the skin were calculated for the acetone group to be 9.1 and 10.5 hr for males and females, and for the formulated group to be 10.4 and 10.9 hr for males and females, respectively. ...', 'In a metabolism study conducted in CD rats, C-14 labeled methidathion was administered at single and preconditioned doses of 0.3 or 3.0 mg/kg. ...The half-life for elimination was approximately 8 hr.']"
3709,13710,3-Methoxy-2-dibenzofuranamine,COC1=C(C=C2C3=CC=CC=C3OC2=C1)N,,,,,,
3710,13711,2'-Deoxycytidine,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O,,,,,,
3711,13712,2'-Deoxyuridine,C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O,,,"['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']",,,
3712,13713,"3,9-Diaminoacridine",C1=CC=C2C(=C1)C(=C3C=CC(=CC3=N2)N)N,,,,,,
3713,13714,Dichlorodiphenylethylene,C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)Cl,,,,,,
3714,13715,CID 13715,C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)[NH3+].[Cl-],,,,,,
3715,13716,3-Phenyl-5-(2-(dimethylamino)ethyl)isoxazole hydrochloride,C[NH+](C)CCC1=CC(=NO1)C2=CC=CC=C2.[Cl-],,,,,,
3716,13717,"N,N-dimethyl-2-(3-phenyl-1,2-oxazol-5-yl)ethanamine",CN(C)CCC1=CC(=NO1)C2=CC=CC=C2,,,,,,
3717,13718,Prosympal,CCN(CC)CC1COC2=CC=CC=C2O1,,,,,,
3718,13719,2-Phenylazo-4-methylphenol,CC1=CC(=C(C=C1)O)N=NC2=CC=CC=C2,,,,,,
3719,13720,4-Nitrophenyl phenyl sulfide,C1=CC=C(C=C1)SC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3720,13721,Methyl trithion,COP(=S)(OC)SCSC1=CC=C(C=C1)Cl,,,,,['OXIDATIVE METAB OF TRITHION.../IN/ FIELD-GROWING LETTUCE. ...PRINCIPAL ROUTE OF OXIDN INVOLVED THIOETHER OXIDN TO FORM THE SULFOXIDE & THEN THE SULFONE. ... FOLLOWED BY PHOSPHOROTHIONATE OXIDN TO FORM THE THIOLPHOSPHATE SULFONE. /TRITHION/'],
3721,13722,Cyclohexyl p-toluenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)OC2CCCCC2,,,,,,
3722,13723,"ANILINE, N-(((p-CHLOROPHENYL)THIO)METHYL)-N-METHYL-",CN(CSC1=CC=C(C=C1)Cl)C2=CC=CC=C2,,,,,,
3723,13724,alpha-((2-(1-Pyrrolidinyl)ethoxy)methyl)benzyl alcohol hydrochloride,C1CC[NH+](C1)CCOCC(C2=CC=CC=C2)O.[Cl-],,,,,,
3724,13725,"2-(2-Bromoethyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C(CBr)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
3725,13726,"2,6-Dichloroindophenol",C1=CC(=O)C=CC1=NC2=CC(=C(C(=C2)Cl)O)Cl,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
3726,13727,Sernyl,C1CCC(CC1)(C2=CC=CC=C2)[NH+]3CCCCC3.[Cl-],,,"['Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)']",,,
3727,13728,Diphenamid,CN(C)C(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,"['DIPHENAMID ... IS WELL ABSORBED & READILY METABOLIZED IN MAMMALS.', 'STUDIES WITH POSTEMERGENCE TREATMENTS ON CROPS OR WEEDS INDICATE ONLY A LOW LEVEL OF FOLIAR ABSORPTION. ... /IT/ IS ABSORBED VIA THE ROOTS AND TRANSLOCATED THROUGH THE ROOTS, STEM, & LEAVES.', 'TOMATO PLANTS (LYCOPERSICON ESCULENTUM MILL, VARIETY SHEYENNE), 27-35 DAYS OLD ... FUMIGATED WITH OZONE PRIOR TO EXPOSING ... ROOTS TO (14)C DIPHENAMID ... DIFFERENCES ... OBSERVED: 1. FUMIGATED PLANTS ABSORBED 70-100% AS MUCH DIPHENAMID AS DID CONTROLS, 2. FUMIGATED PLANTS ... CONTAINED LESS RADIOACTIVITY IN CHCL3-SOL FRACTION ... .', 'URINARY EXCRETION /BY RATS DOSED WITH (14)C-DIPHENAMID/ OF (14)C WAS FAIRLY RAPID AFTER IP DOSE; 51% WAS PRESENT IN 22 HR URINE & 89% IN 46 HR. THESE RESULTS INDICATED THAT THIS LIPID-SOL UNIONIZED CMPD WAS READILY ABSORBED IN RATS.', 'For more Absorption, Distribution and Excretion (Complete) data for DIPHENAMID (6 total), please visit the HSDB record page.']","['The metabolism of diphenamid in cell suspensions of soybeans was studied. When (l4)C-carbonyl-labeled diphenamid was added to the suspensions, the major products were identified as N-hydroxymethyl N-methyl-2,2-diphenylacetamide, N-methyl-2,2-diphenylacetamide, 2,2-diphenylacetamide, an unidentified glucoside, and an acidic conjugate of glucose, malonate and diphenamid.', 'In cotton, okra, peanut shoots, and soybean shoots, dealkylated products and water-soluble compounds were present. Brightleaf and burley tobacco shoots also had dealkylated products. In cotton, okra, peanut and soybean shoots, the presence of the glucoside and gentiobioside were observed.', 'Aquatic plants and algae were exposed to diphenamid in trays and jars. The vascular plants and aquatic algae absorbed and removed diphenamid from the water. In algae, water hyacinth, and parrotfeather, N-methyl-2,2-diphenylamide and other unidentified materials were observed.', 'METABOLISM ... IN CORN ROOTS ... WITH CARBONYL (14)C LABELING. ONLY CMPD IDENTIFIED ... N-METHYL-2,2-DIPHENYLACETAMIDE.', 'For more Metabolism/Metabolites (Complete) data for DIPHENAMID (14 total), please visit the HSDB record page.']","['HALF-LIVES FOR (14)C IN BLOOD OF RATS DOSED WITH (14)C-DIPHENAMID ... BY ORAL, IP, & SC ROUTES WERE SIMILAR (ABOUT 4 HR). HOWEVER, BLOOD LEVELS OF (14)C ... GREATER @ PEAK ABOUT 50 MIN AFTER IP DOSING THAN @ PEAK ABOUT 200 MIN AFTER DOSING BY OTHER TWO ROUTES.']"
3728,13729,3-[(Acetyloxy)methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,CC(=O)OCC1=C(N2C(C(C2=O)N)SC1)C(=O)O,,,,,,
3729,13730,2'-Deoxyadenosine,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)O,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
3730,13731,"Coumarin, 3-(3-pyridyl)-, N-oxide",C1=CC=C2C(=C1)C=C(C(=O)O2)C3=C[N+](=CC=C3)[O-],,,,,,
3731,13732,6-Bromo-3-(2-pyridyl)coumarin,C1=CC=NC(=C1)C2=CC3=C(C=CC(=C3)Br)OC2=O,,,,,,
3732,13733,"2-Butanone 2,4-Dinitrophenylhydrazone",CCC(=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])C,,,,,,
3733,13734,"1,2-Ethanediamine, N,N-dimethyl-N'-2-pyridinyl-N'-(3-thienylmethyl)-, monohydrochloride",C[NH+](C)CCN(CC1=CSC=C1)C2=CC=CC=N2.[Cl-],,,,,,
3734,13735,Azure A,C[N+](=C1C=CC2=NC3=C(C=C(C=C3)N)SC2=C1)C.[Cl-],,,,,,
3735,13736,3-Amino-7-(dimethylamino)phenothiazin-5-ium,C[N+](=C1C=CC2=NC3=C(C=C(C=C3)N)SC2=C1)C,,,,,,
3736,13737,Xenbucin,CCC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O,,,,,,
3737,13738,Oxolamine,CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2,,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
3738,13739,Bis(2-hydroxyethyl) terephthalate,C1=CC(=CC=C1C(=O)OCCO)C(=O)OCCO,,,,,,
3739,13740,Benzyldimethyloctylammonium chloride,CCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
3740,13741,Benzyldimethyloctylammonium,CCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,,
3741,13742,"2,4,6-Tris(2-chloroethoxy)-1,3,5-triazine",C(CCl)OC1=NC(=NC(=N1)OCCCl)OCCCl,,,,,,
3742,13743,Carbubarb,CCCCC1(C(=O)NC(=O)NC1=O)CCOC(=O)N,,,,,,
3743,13744,CID 13744,C1[C@@H]([C@H](OC1N2C=NC3=C2NC(=NC3=O)N)CO)O,,,,,,
3744,13745,"Phosphoric acid, 2-chloro-1-(2,4,5-trichlorophenyl)ethenyl dimethyl ester",COP(=O)(OC)OC(=CCl)C1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
3745,13746,Azinphosmethyl oxon,COP(=O)(OC)SCN1C(=O)C2=CC=CC=C2N=N1,,,,,,
3746,13747,"CARBODIIMIDE, BIS(3-CHLORO-o-TOLYL)-",CC1=C(C=CC=C1Cl)N=C=NC2=C(C(=CC=C2)Cl)C,,,,,,
3747,13748,"2,4-Dinitro-N-phenylaniline",C1=CC=C(C=C1)NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3748,13749,CID 13749,CCOC(=O)C=C(C)NC(C1=CC=CC=C1)C(=O)[O-].[K+],,,,,,
3749,13750,2-[(4-Ethoxy-4-oxobut-2-en-2-yl)amino]-2-phenylacetic acid,CCOC(=O)C=C(C)NC(C1=CC=CC=C1)C(=O)O,,,,,,
3750,13751,Phenbenzamine,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=C2,,,"['Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
3751,13752,Nitrodan,CN1C(=O)C(SC1=S)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3752,13753,Amino-[bromo(phenyl)methylene]-(4-nitrophenyl)ammonium,C1=CC=C(C=C1)C(=NNC2=CC=C(C=C2)[N+](=O)[O-])Br,,,,,,
3753,13754,Diazoxon,CCOP(=O)(OCC)OC1=NC(=NC(=C1)C)C(C)C,,,,,['Diazoxon has known human metabolites that include Diethyl phosphorothioate and Pyrimidinol.'],
3754,13755,Sulfaethoxypyridazine,CCOC1=NN=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
3755,13756,Demoxepam,C1C(=O)N=C2C=CC(=CC2=C(N1O)C3=CC=CC=C3)Cl,,,,,,
3756,13757,"7,9-Dimethylbenz[c]acridine",CC1=CC2=C(C=C1)N=C3C(=C2C)C=CC4=CC=CC=C43,,,,,,
3757,13758,Arlitene,CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
3758,13759,"N-(2,4-Dinitrophenyl)-M-toluidine",CC1=CC(=CC=C1)NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3759,13760,"Benzothiazole, 2,2'-ethylenebis-",C1=CC=C2C(=C1)N=C(S2)CCC3=NC4=CC=CC=C4S3,,,,,,
3760,13761,3-(Diethylamino)-5'-ethyl-2'-fluorobutyranilide,CCC1=CC(=C(C=C1)F)NC(=O)CC(C)N(CC)CC,,,,,,
3761,13762,Benzyldimethyldecylammonium chloride,CCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
3762,13763,Decyldimethylbenzylammonium,CCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,,,,,,
3763,13764,"Benzoic acid, 4-hydroxy-, [(5-nitro-2-furanyl)methylene]hydrazide",C1=CC(=CC=C1C(=O)NN=CC2=CC=C(O2)[N+](=O)[O-])O,,,,,,
3764,13765,Ethylestrenol,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,,,"['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']","['The absorption, distribution, metabolism and excretion of [3H]ethylestrenol were studied in the rat. 2. Approximately one third of an intragastric dose was absorbed; 17% of the dose was excreted in urine and 83% in faeces within 10 days. 3. The dose is distributed throughout the rat, and kidney and liver were found to contain respectively 2.5-3 and 5-7 times the average specific activity of all other tissues. 4. Unchanged ethylestrenol was the only component detected in urine. Ethylestrenol was also found in faeces, along with two different dihydroxylated dihydro derivatives and one trihydroxylated dihydro derivative.', 'It is not known whether anabolic steroids are distributed into breast milk. /Anabolic Steroids/']","['Ethylestrenol incubated with a post-mitochondrial supernatant fraction of rat liver plus co-factors gives norethandrolone as the major metabolite. A second (minor) metabolite was tentatively identified as 17 alpha-ethyl-5 epsilon-estrane-3 epsilon,17 beta-diol. A pathway is suggested for the metabolism of ethylestrenol in the rat.', 'Orabolin was oxidized at C-3 to form nilevar which in turn was metabolized in man by a ring reduction and side chain hydroxylation to form a 19-norpregnatriol. Identification of this metabolite, detection in urine is test for athletes suspected of drug misuse.']",
3765,13766,"17-Hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CCC2C1(C=CC3=C4CCC(=O)C=C4CCC23)C)O,,,,,,
3766,13767,"5,6-Dihydro-5,6-dihydroxy-7-methylbenz(a)anthracene",CC1=C2C(C(C3=CC=CC=C3C2=CC4=CC=CC=C14)O)O,,,,,,
3767,13768,Benzacine,CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
3768,13769,Testolactone,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C,['For palliative treatment of advanced breast cancer in postmenopausal women.'],"['Testolactone is a synthetic anti-neoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Despite some similarity to testosterone, testolactone has no in vivo androgenic effect. No other hormonal effects have been reported in clinical studies in patients receiving testolactone.']","['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)']","['Testolactone is well absorbed from the gastrointestinal tract.', 'No clinical effects in humans of testolactone on adrenal function have been reported; however, one study noted an increase in urinary excretion of 17-ketosteroids in most of the patients treated with 150 mg/day orally. It is metabolized to several derivatives in the liver, all of which preserve the lactone D-ring. These metabolites, as well as some unmetabolized drug, are excreted in the urine.', 'Elimination: Renal.', 'It is not known whether testolactone is distributed into milk.', 'Well absorbed from the gastrointestinal tract.', 'Biotransformation: Hepatic.']","['Hepatic. Metabolized to several derivatives in the liver, all of which preserve the lactone D-ring.', 'Testolactone is metabolized primarily in the liver and excreted in urine. Compounds recovered in urine after testolactone administration have included 3a, 13alpha-dihydroxy-13,17-seco-5beta-androsta-1-ene-17-oic acid lactone and its glucuronide, and unchanged testolactone.']",
3769,13770,Cyproheptadine hydrochloride,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']",,,
3770,13771,"1,7-Diphenylnaphthalene",C1=CC=C(C=C1)C2=CC3=C(C=CC=C3C4=CC=CC=C4)C=C2,,,,,,
3771,13772,"4,4-Diphenyl-1-(1-pyrrolidinyl)-2-butanone hydrochloride",C1CC[NH+](C1)CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
3772,13773,"2-Butanone, 4,4-diphenyl-1-(1-pyrrolidinyl)-",C1CCN(C1)CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3773,13774,"2,4-Dinitro-N-(4-nitrophenyl)aniline",C1=CC(=CC=C1NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
3774,13775,"2,4-Dinitro-N-(3-nitrophenyl)aniline",C1=CC(=CC(=C1)[N+](=O)[O-])NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3775,13776,Benzohexonium,C[N+](C)(C)CCCCCC[N+](C)(C)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-],,,"['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)', 'Agents having as their major action the interruption of neural transmission at nicotinic receptors on postganglionic autonomic neurons. Because their actions are so broad, including blocking of sympathetic and parasympathetic systems, their therapeutic use has been largely supplanted by more specific drugs. They may still be used in the control of blood pressure in patients with acute dissecting aortic aneurysm and for the induction of hypotension in surgery. (See all compounds classified as Ganglionic Blockers.)']",,,
3776,13777,3-(Diethylaminomethyl)-5-methylisoxazole citrate,CC[NH+](CC)CC1=NOC(=C1)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3777,13778,N-Ethyl-N-((5-methylisoxazol-3-yl)methyl)ethanamine,CCN(CC)CC1=NOC(=C1)C,,,,,,
3778,13779,3-(2-(Diethylamino)ethyl)-5-methylisoxazole citrate,CC[NH+](CC)CCC1=NOC(=C1)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3779,13780,"N,N-diethyl-2-(5-methyl-1,2-oxazol-3-yl)ethanamine",CCN(CC)CCC1=NOC(=C1)C,,,,,,
3780,13781,Creatinine sulfate mixture with serotonin,C[NH+]1CC(=O)N=C1N.C1=CC2=C(C=C1O)C(=CN2)CC[NH3+].[O-]S(=O)(=O)[O-],,,,,,
3781,13782,"Hydantoin, 1,3-bis(morpholinomethyl)-5,5-dimethyl-",CC1(C(=O)N(C(=O)N1CN2CCOCC2)CN3CCOCC3)C,,,,,,
3782,13783,Dinobuton,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)OC(C)C,,,,"['[CARBONYL-(14)C]DINOBUTON...WAS RAPIDLY HYDROLYZED IN ORALLY TREATED MICE & RATS... RATS EXCRETED VIRTUALLY ALL OF DOSE OF [PHENYL-(14)C] DINOBUTON IN 72 HR, BUT MICE EXCRETED LESS (74%); MORE THAN ONE-HALF OF URINARY LABEL IN BOTH...WAS POLAR MATERIAL...BUT SMALL AMT OF TWO AMINO-PHENOLS & TWO CARBOXYLIC ACIDS...IDENTIFIED']","['TWENTY-EIGHT DAYS AFTER TOPICAL APPLICATION...TO APPLE FRUITS, ABOUT 75 /%/...LOST. ANALYSES OF PEEL INDICATED PRESENCE OF...2-AMINO-6-SEC-BUTYL-4-NITROPHENOL & 3-(3,5-DINITRO-2-HYDROXYPHENYL)BUTYRIC ACID.', '...STUDIES WITH [RING-(14)C]DINOBUTON. TREATMENT OF WATER-SOL MATERIALS WITH BETA-GLUCOSIDASE &/OR GLUSULASE LIBERATED SIGNIFICANT PERCENTAGE OF (14)C ACTIVITY AS ETHER-EXTRACTABLE METABOLITES. TLC OF...EXTRACTS REVEALED PRESENCE OF DINOSEB, 4-AMINO-6-NITRO-2-SEC-BUTYLPHENOL, 6-AMINO-4-NITRO-2-SEC-BUTYLPHENOL, & OTHER UNIDENTIFIED PRODUCTS.', 'AFTER INJECTION OF DINOBUTON INTO STEMS OF BEAN PLANTS, DNBP /DINITRO-ORTHO-SEC-BUTYLPHENOL/, 4-NH2-NBP /4-AMINO-6-NITRO-2-SEC-BUTYLPHENOL/, & 6-NH2-NBP /6-AMINO-4-NITRO-2-SEC-BUTYLPHENOL/...OBSERVED IN CONJUGATED FORM AS BETA-GLUCOSIDES. SOME CO2 RELEASED BY HYDROLYSIS...WAS ALSO INCORPORATED INTO PLANT MATERIALS.', 'IN FRESH SHEEP RUMEN FLUID, DINOBUTON WAS RAPIDLY DECOMPOSED. SIMULTANEOUSLY, AMT OF 6-ANBP INCR. DIAMINOPHENOL (DABP) WAS END PRODUCT OF RUMINAL METABOLISM.', 'For more Metabolism/Metabolites (Complete) data for DESSIN (6 total), please visit the HSDB record page.']",
3783,13784,"4,4-Diphenyl-1-piperidino-2-butanone hydrochloride",C1CC[NH+](CC1)CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
3784,13785,"2-Butanone, 4,4-diphenyl-1-piperidino-",C1CCN(CC1)CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3785,13786,"4,4-Diphenyl-1-morpholino-2-butanone hydrochloride",C1COCC[NH+]1CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
3786,13787,"4,4-Diphenyl-1-morpholino-2-butanone",C1COCCN1CC(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3787,13788,"Calcium;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.[Ca+2],,,,,,
3788,13789,Canrenone,C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]45CCC(=O)O5)C,,,['Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE. (See all compounds classified as Mineralocorticoid Receptor Antagonists.)'],,,
3789,13790,"(17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one",CC1=CC2C3CC[C@](C3(CCC2C4(C1=CC(=O)CC4)C)C)(C)C(=O)C,,,,,,
3790,13791,Estradiol valerate,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,"['Estradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).   Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.']","[""Estrogen mediates its effects across the body through potent agonism of the Estrogen Receptor (ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptor: Estrogen Receptor Alpha (ER) and Estrogen Receptor Beta (ER). Estradiol also acts as a potent agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a major mediator of estradiol's rapid cellular effects.""]","['Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. (See all compounds classified as Estrogens.)']","['IM Injection: When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks.  Natazia: After oral administration of estradiol valerate, cleavage to 17-estradiol and valeric acid takes place during absorption by the intestinal mucosa or in the course of the first liver passage. This gives rise to estradiol and its metabolites, estrone and other metabolites. Maximum serum estradiol concentrations of 73.3 pg/mL are reached at a median of approximately 6 hours (range: 1.512 hours) and the area under the estradiol concentration curve [AUC(024h)] was 1301 pgh/mL after single ingestion of a tablet containing 3 mg estradiol valerate under fasted condition on Day 1 of the 28-day sequential regimen.', 'Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.']",['Exogenous estrogens are metabolized using the same mechanism as endogenous estrogens. Estrogens are partially metabolized by cytochrome P450.'],
3791,13792,"2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCCC(C(=O)O)N)O)O)N,,,,,,
3792,13793,"Borazine, 2,4,6-trichloro-1,3,5-triphenyl-",B1(N(B(N(B(N1Cl)C2=CC=CC=C2)Cl)C3=CC=CC=C3)Cl)C4=CC=CC=C4,,,,,,
3793,13794,Sodium 4-[2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoate,C1=CC(=CC=C1C(C(COC(=O)CCC(=O)[O-])NC(=O)C(Cl)Cl)O)[N+](=O)[O-].[Na+],,,,,,
3794,13795,"(Acetyloxy)methyl 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC(=O)OCOC(=O)C1C(SC2N1C(=O)C2NC(=O)CC3=CC=CC=C3)(C)C,,,,,,
3795,13796,"1-[(3,4-Diethoxyphenyl)methyl]-6,7-diethoxyisoquinolin-2-ium;chloride",CCOC1=C(C=C(C=C1)CC2=[NH+]C=CC3=CC(=C(C=C32)OCC)OCC)OCC.[Cl-],,,,,,
3796,13797,3-Phenyl-5-(2-(diethylamino)ethyl)isoxazole citrate,CC[NH+](CC)CCC1=CC(=NO1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3797,13798,"N,N-Diethyl-3-phenyl-5-isoxazoleethanamine",CCN(CC)CCC1=CC(=NO1)C2=CC=CC=C2,,,,,,
3798,13799,"Isoxazole, 5-phenyl-3-(2-piperidinoethyl)-, citrate",C1CC[NH+](CC1)CCC2=NOC(=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3799,13800,"5-Phenyl-3-(2-piperidin-1-ylethyl)-1,2-oxazole",C1CCN(CC1)CCC2=NOC(=C2)C3=CC=CC=C3,,,,,,
3800,13801,"3,20-Dioxo-6-(trifluoromethyl)pregn-4-en-17-yl acetate",CC(=O)C1(CCC2C1(CCC3C2CC(C4=CC(=O)CCC34C)C(F)(F)F)C)OC(=O)C,,,,,,
3801,13802,"[2-[(9R,11S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",C[C@H]1C[C@H]2C3CCC4=CC(=O)C=CC4([C@]3([C@H](CC2([C@]1(C(=O)COC(=O)C)O)C)O)F)C,,,,,,
3802,13803,Adenosine triphosphate disodium,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],,,,,,
3803,13804,Citicoline,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
3804,13805,CDP-choline,C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
3805,13806,Rhodamine 6G,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=[NH+]CC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC.[Cl-],,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']","['RHODAMINE 6G EXHIBITS HIGH PLASMA PROTEIN BINDING.', 'Rhodamine 6G and rhodamine B were reported to be excreted in the pancreatic juice in situ after intravenous infusion of 1 mg dye per minute to dogs (strain, age, and sex not specified) followed by the administration of secretin or cholecystokinin-pancreozymin stimulation. The rate of excretion was not reported.']",,
3806,13807,Basic Red 1,CCNC1=CC2=C(C=C1C)C(=C3C=C(C(=NCC)C=C3O2)C)C4=CC=CC=C4C(=O)OCC,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']","['RHODAMINE 6G EXHIBITS HIGH PLASMA PROTEIN BINDING.', 'Rhodamine 6G and rhodamine B were reported to be excreted in the pancreatic juice in situ after intravenous infusion of 1 mg dye per minute to dogs (strain, age, and sex not specified) followed by the administration of secretin or cholecystokinin-pancreozymin stimulation. The rate of excretion was not reported.']",,
3807,13808,p-Aspidin,CCCC(=O)C1=C(C(=C(C(=C1O)C)OC)CC2=C(C(C(=O)C(=C2O)C(=O)CCC)(C)C)O)O,,,,,,
3808,13809,Triamcinolone acetonide 21-dihydrogen phosphate,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COP(=O)(O)O)CCC5=CC(=O)C=C[C@@]53C)F)O,,,,,,
3809,13810,Fentanyl citrate,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,['Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.'],,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)', 'Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
3810,13811,Isodesmosine,C1=C(C=[N+](C(=C1CCC(C(=O)O)N)CCCC(C(=O)O)N)CCCCC(C(=O)O)N)CCC(C(=O)O)N,,,,,,
3811,13812,"Benzoic acid, 3,4,5-trimethoxy-, 1-methyl-2-(4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl)ethyl ester, monohydrochloride",CC(C[NH+]1CCN(CC1)C(=O)C2=CC(=C(C(=C2)OC)OC)OC)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC.[Cl-],,,,,,
3812,13813,"1-[4-(3,4,5-Trimethoxybenzoyl)piperazin-1-yl]propan-2-yl 3,4,5-trimethoxybenzoate",CC(CN1CCN(CC1)C(=O)C2=CC(=C(C(=C2)OC)OC)OC)OC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
3813,13814,Norbormide,C1=CC=C(C=C1)C(=C2C3C=C(C2C4C3C(=O)NC4=O)C(C5=CC=CC=C5)(C6=CC=CC=N6)O)C7=CC=CC=N7,,,"['Substances used to destroy or inhibit the action of rats, mice, or other rodents. (See all compounds classified as Rodenticides.)']",,,
3814,13815,CID 13815,C[C@@]1(C2C[C@H]3C(C(=O)C(=C(NCNC(CCCCN)C(=O)O)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O,,,,,,
3815,13816,C.I. Direct Red 2,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])N)C)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N.[Na+].[Na+],,,,"['... Excretion profiles based on parallel HPLC and radioassays of feces from rats dosed with (14)C labeled Direct Blue 15 or Direct Red 2 are presented. Based on these radioassays, about 74% of each dose was excreted via the feces; however, HPLC assays showed that only about 11% of each dose was present as intact dye in the excretement.']","[""absorption, metabolism and tissue distribution studies were conducted in the rat with (14)C-biphenyl ring labeled Direct Blue 15, a 3,3'-dimethoxybenzidine (DiMxBzd) based azo dye; Direct Red 2, based on 3,3'-dimethylbenzidine (DiMeBzd) and the corresponding benzidine congener amines. Single oral doses of (14)C labeled dyes (12 mg/kg) and molar equivalent doses of respective amines were admin, and urine and fecal samples collected at intervals up to 192 hr. ... A comparison of the metabolism of Direct Blue 15 with its base DiMxBzd, indicated the base was more extensively metabolized and that most of the (14)C in various extracts was identified in known metabolites. The metabolism of Direct Red 2 compared with its base DiMeBzd, indicated that the base was more extensively metabolized , yet only a small percentage of the (14)C in extracts was identified as known metabolites. Most of the (14)C present in the urine could not be extracted with benzene or chloroform, indicating high polarity. Distribution studies conducted with both dyes showed that the liver, kidney and lung accumulated and retained higher levels of (14)C than other tissues (at 72 hr). Peak levels of (14)C, which occurred 8-12 hr after dosing, were significantly higher with Direct Red 2 than Direct Blue 15. Tissue distribution data (72 hr for rats dosed with free amines compared with the dyes showed a generally lower but similar distribution pattern."", ""The metabolism of a benzidine based dye, Direct Black 38, a 3,3'-dimethylbenzidine based dye, Direct Red 2, and a 3,3'-dimethoxybenzidine based dye, Direct Blue 15, was studied both in pure cultures of anaerobic bacteria and in bacterial suspensions derived from intestinal contents of the rat. All of the pure cultures and the rat intestinal bacteria were able to reduce the azo linkages of Direct Black 38, Direct Red 2 and Direct Blue 15 with the subsequent formation of benzidine, 3,3'-dimethylbenzidine and 3,3'-dimethoxybenzidine, respectively. ... In vitro anaerobic incubations of rat intestinal microorganisms were evidently able to reduce and cleave the azo bonds of dyes derived from benzidine, 3,3'-dimethylbenzidine and 3,3'-dimethoxybenzidine to form potentially carcinogenic aromatic amines."", ""Direct Red 2 was /admin/ as an aqueous soln to rats and hamsters to determine whether the dye is cleaved to potentially carcinogenic aromatic amines. ... Assays of the urine from treated animals by EC/GC (electron capture gas chromatography) revealed appreciable levels of 3,3'-dimethylbenzidine, mono- and di-acetyldimethylbenzidine, and alkaline hydrolyzable conjugates. Peak concn of the metabolites in the urine occurred 12-24 hr after admin to rats, and within 12 hr in hamsters. The levels of all metabolites and conjugates diminished rapidly in both species after peak concn were reached, with no residues detected after 96 hr. The results ... demonstrated in vivo cleavage of the dye in both species. ...""]",
3816,13817,Azamin 4B,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)O)N)C)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)N,,,,,,
3817,13818,Methylphosphonic acid,CP(=O)(O)O,,,,,"['For the verification of the use of chemical warfare agents (CWA), sarin, soman and VX, a simple rapid and accurate method which allows us to simultaneously determine their degradation products, isopropyl methylphosphonic acid (IPMPA), pinacolyl methylphosphonic acid (PMPA), ethyl methylphosphonic acid (EMPA) and methylphosphonic acid (MPA), in human serum, was explored by indirect photometric detection ion chromatography (IPD-IC) which employs an anion-exchange column. IC analysis was performed after sample preparation with an Ag+-form cation-exchange resin cartridge, and the four methylphosphonic acids could be separated well. The proposed conditions are as follows: eluent, 0.5 mM phthalic acid-0.1 mM Tris (hydroxymethyl) aminomethane-5% acetonitrile; flow-rate, 1.0 ml/min; temperature, 50 degrees C; UV detector, 266 nm. All four methylphosphonic acids were eluted within 30 min with hardly any disturbance by impurities in the serum. Linear calibration curves were obtained for methylphosphonic acid, ethyl methylphosphonic acid and isopropyl methylphosphonic acid in the concentration range from 50 ng/ml to 1 ug/ml and for pinacolyl methylphosphonic acid from 100 ng/ml to 1 ug/ml. The relative standard deviation for the methylphosphonic acids ranged from 3.8 to 6.9% at 500 ng/ml and the detection limits were 40 ng/ml for methylphosphonic acid, ethyl methylphosphonic acid and isopropyl methylphosphonic acid and 80 ng/ml for pinacolyl methylphosphonic acid. The method would be suitable for analysis of human serum samples.']",
3818,13819,Chlorotriethylsilane,CC[Si](CC)(CC)Cl,,,,,,
3819,13820,Triethyltin chloride,CC[Sn](CC)(CC)Cl,,,,,,
3820,13821,CID 13821,CC[SnH](CC)CC.O,,,,,,
3821,13822,(C2H5)3SnH,CC[SnH](CC)CC,,,,,,
3822,13823,CID 13823,CC[SnH](CC)CC.CC[Sn+](CC)CC.[SH-],,,,,,
3823,13824,Tetrapropylgermane,CCC[Ge](CCC)(CCC)CCC,,,,,,
3824,13825,Bromodinitromethane,C([N+](=O)[O-])([N+](=O)[O-])Br,,,,,,
3825,13826,Oxalyl dihydrazide,C(=O)(C(=O)NN)NN,,,,,,
3826,13827,4-Amino-2-mercaptobutyric acid,C(CN)C(C(=O)O)S,,,,,,
3827,13828,CID 13828,C(CC(=O)O)C(C(=O)[O-])N.[K+],,,,,,
3828,13829,N-Nitrosodiisobutylamine,CC(C)CN(CC(C)C)N=O,,,,,,
3829,13830,Hydridotriethoxysilane,CCO[SiH](OCC)OCC,,,,,,
3830,13831,Tributylphosphine,CCCCP(CCCC)CCCC,,,,,,
3831,13832,Diazoacetylglycine ethyl ester,CCOC(=O)CNC(=O)C=[N+]=[N-],,,,,,
3832,13833,2-[(2-Ethoxy-2-oxoethyl)amino]-2-hydroxyethenediazonium,CCOC(=O)CNC(=C[N+]#N)O,,,,,,
3833,13834,N-Butyl-N-chloro-1-butanamine,CCCCN(CCCC)Cl,,,,,,
3834,13835,Allyl acrylate,C=CCOC(=O)C=C,,,,,,
3835,13836,Chlormequat chloride,C[N+](C)(C)CCCl.[Cl-],,,"['Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']","['Chlormequat was determined in four /sow/ milk samples in the range of 0.4 ng/g to 1.2 ng/g...', 'The distribution of Chlorocholine chloride (CCC) in the eggs of laying hens was studied using 15N-CCC. Twelve layers (37 weeks old) were divided into four groups and used in this study consisting of three feeding phases. In phase one (7 days), all the hens received a CCC-free diet [165 g CP/kg dry matter (DM); 11.58 MJ ME/kg DM]. In phase two (11 days), four levels of 15N-CCC: 0, 5, 50 and 250 ppm were added to the respective diets, while in phase three (7 days), CCC-free feed was again offered. Egg samples were taken and the 15N content of egg yolk and albumin were determined. At the end of phase two, there was a significant (p < 0.05) increase in 15N content in egg yolk from hens fed the 50 and 250 ppm CCC diets and in albumin from hens fed the 250 ppm CCC diet. The estimated 15N-CCC residue was 1.71, 6.64, 28.80 ppm in egg yolk and 1.58, 1.08 and 4.50 ppm in albumin from hens fed 5, 50 and 250 ppm CCC, respectively. The CCC residue, from quantitative analysis ranged from 0.21 to 0.93 and 0.93 to 2.43 ppm in yolk of hens fed 50 and 250 ppm CCC, respectively, whereas a range of 0.40-1.46 ppm, was found in the albumin of hens fed 250 ppm. The difference in measured CCC in yolk and albumin and that estimated from 15N-CCC could have been due to breakdown products of 15N-CCC. Seven days after withdrawal of 15N-CCC, the estimated 15N-CCC residue in egg yolk decreased to 0.43, 2.45 and 15.59 ppm, on 5, 50 and 250 ppm CCC dietary treatments, respectively, and to 2.46 ppm in albumin from hens fed 250 ppm CCC. The higher increase in 15N content could have been due to a higher incorporation of 15N-CCC into yolk than albumin during the process of rapid yolk deposition. This experiment showed that consumed CCC is distributed both into yolk and albumin in a dose dependent manner and that CCC is metabolized in laying hens. However, the level of CCC in the diet which could lead to accumulation of detectable CCC levels in eggs as observed in this study, is much higher than the established maximum residual limits in grains.', 'In mammals, following oral administration, 97% is eliminated within 24 hr, principally as the unchanged substance.']","['An experiment was conducted to evaluate the metabolic products of chlorocholine chloride (CCC) in eggs and meat of laying hens fed a diet containing (15)N-CCC. Ten brown laying hens were randomly divided into two groups of five each. One group was offered (15)N-CCC free diet while the other group received a diet with 100 ppm (15)N-CCC for 11 days. Samples of eggs and meat from the laying hens were collected. Egg yolks and albumen were separated. Meat was collected from the breast and femur. The metabolic products of CCC were measured using ion trap electrospray ionization mass spectrometry (ion trap-ESI-MS/MS). Determination of CCC or its metabolites in eggs and meat showed that CCC was metabolized to choline. Corresponding MS/MS spectra were obtained for m/z 104 (choline) or 105 ((15)N-choline), whereas nothing was detected at m/z 122 (CCC) or 123 ((15)N-CCC). The results from this study indicate that CCC will be metabolized in tissues of laying hens.', 'When (14)C-labeled CCC was applied to kohlrabi, cauliflower, or tomatoes, degradation of CCC was very small. The first product was probably choline which entered the plant pool. Small amounts of labeled methyl groups from choline were found as S-methyl methionine. CCC was not degraded when applied to sugarcane. In alfalfa, CCC was slowly metabolized and was primarily incorporated into choline of phosphatidylcholine.', 'Almond seedlings were treated with labeled CCC. Translocation to leaves and to the roots was observed. (14)CO2 was formed within 2 h after application. Radioactivity was observed in 17 known amino acids, an unidentified ninhydrin positive compound, malic acid, citric acid, choline and 2-chloroethylamine.', 'When CCC was incubated in rumen contents or juice under anaerobic conditions, microbial degradation of CCC did not occur.', 'For more Metabolism/Metabolites (Complete) data for CHLORMEQUAT CHLORIDE (7 total), please visit the HSDB record page.']",
3836,13837,Chlormequat,C[N+](C)(C)CCCl,,,"['Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']",,,
3837,13838,Hexamethyldisilazane,C[Si](C)(C)N[Si](C)(C)C,,,['Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. (See all compounds classified as Fixatives.)'],,,
3838,13839,Dipentyl methylphosphonate,CCCCCOP(=O)(C)OCCCCC,,,,,,
3839,13840,"2,2'-Iminodiethanol dimethanesulfonate hydrochloride",CS(=O)(=O)OCC[NH2+]CCOS(=O)(=O)C.[Cl-],,,,,,
3840,13841,Bismethanesulfonic acid iminobisethylene ester,CS(=O)(=O)OCCNCCOS(=O)(=O)C,,,,,,
3841,13842,(Hydroxymethyl)urea,C(NC(=O)N)O,,,,,['THE TICKS (BOOPHILUS MICROPLUS) WERE INJECTED WITH A DIMETHYL SULFOXIDE SOLN CONTAINING 1-(14)C-CARBARYL (0.5 TO 0.7 MCG) OR CARBONYL-(14)C-CARBARYL (0.2 MCG) IN 1- TO 3-MCL DOSES. TLC AUTORADIOGRAMS OF THE ACETONE EXTRACT TREATED WITH AMMONIA REVEALED THE PRESENCE OF N-HYDROXYMETHYLUREA.'],
3842,13843,Cyanomethyl acetate,CC(=O)OCC#N,,,,,,
3843,13844,3-Chlorodecane,CCCCCCCC(CC)Cl,,,,,,
3844,13845,3-Methylundecane,CCCCCCCCC(C)CC,,,,,,
3845,13846,CID 13846,CCCCCCCCCC(=O)[O-].[Na+],,,,,,
3846,13847,1-Ethoxy-2-(2-methoxyethoxy)ethane,CCOCCOCCOC,,,,,,
3847,13848,1-Chlorodecane,CCCCCCCCCCCl,,,,,,
3848,13849,Pentadecanoic acid,CCCCCCCCCCCCCCC(=O)O,,,,,,
3849,13850,CID 13850,CCCC=CC=CCCCCCCCCCO,,,,,,
3850,13851,2-Bromothiophene,C1=CSC(=C1)Br,,,,,,
3851,13852,Dihydro-2(3H)-thiophenone,C1CC(=O)SC1,,,,,,
3852,13853,"1,2-Epoxypentane",CCCC1CO1,,,,,,
3853,13854,Pyrrole-2-carboxaldehyde,C1=CNC(=C1)C=O,,,,,,
3854,13855,"2,5-Dimethyltetrahydrofuran",CC1CCC(O1)C,,,,,,
3855,13856,Ethylidenecyclohexane,CC=C1CCCCC1,,,,,,
3856,13857,4-Methylpyridine N-oxide,CC1=CC=[N+](C=C1)[O-],,,,,,
3857,13858,3-Methylpyridine 1-oxide,CC1=C[N+](=CC=C1)[O-],,,,,,
3858,13859,"1,3,2-Dioxathiane, 4,4-dimethyl-, 2-oxide",CC1(CCOS(=O)O1)C,,,,,,
3859,13860,4-Methylenecyclohexylmethanol,C=C1CCC(CC1)CO,,,,,,
3860,13861,2-Butyltetrahydrofuran,CCCCC1CCCO1,,,,,,
3861,13862,"2,6-Dimethyl-4H-pyran-4-one",CC1=CC(=O)C=C(O1)C,,,,,,
3862,13863,"2,4,6-Triaminopyrimidine",C1=C(N=C(N=C1N)N)N,,,,,,
3863,13864,CID 13864,C1=CC(=CC=C1C(=O)[O-])I.[Na+],,,,,,
3864,13865,(p-Hydroxyphenyl)dimethylsulfonium chloride,C[S+](C)C1=CC=C(C=C1)O.[Cl-],,,,,,
3865,13866,(4-Hydroxyphenyl)dimethylsulfonium,C[S+](C)C1=CC=C(C=C1)O,,,,,,
3866,13867,N-(2-Bromoethyl)anilinium bromide,C1=CC=C(C=C1)[NH2+]CCBr.[Br-],,,,,,
3867,13868,N-(2-Bromoethyl)aniline,C1=CC=C(C=C1)NCCBr,,,,,,
3868,13869,Trimethylolpropane phosphate,CCC12COP(=O)(OC1)OC2,,,,,,
3869,13870,"2,3,5,6-Tetrachlorotoluene",CC1=C(C(=CC(=C1Cl)Cl)Cl)Cl,,,,,,
3870,13871,"2,3,4,5-Tetrachlorotoluene",CC1=CC(=C(C(=C1Cl)Cl)Cl)Cl,,,,,,
3871,13872,5-Methoxyindole,COC1=CC2=C(C=C1)NC=C2,,,,,,
3872,13873,5-Chloro-2-methylbenzothiazole,CC1=NC2=C(S1)C=CC(=C2)Cl,,,,,,
3873,13874,"ANILINE, p-CHLORO-N-METHYL-N-NITROSO-",CN(C1=CC=C(C=C1)Cl)N=O,,,,,,
3874,13875,Bis(dimethylamino)dithiazolium,CN(C)C1=NC(=[N+](C)C)SS1.[Cl-],,,,,,
3875,13876,"3,5-Bis(dimethylamino)-1,2,4-dithiazol-1-ium",CN(C)C1=NC(=[N+](C)C)SS1,,,,,,
3876,13877,Neopentylbenzene,CC(C)(C)CC1=CC=CC=C1,,,,,,
3877,13878,Deisopropylatrazine,CCNC1=NC(=NC(=N1)N)Cl,,,,,['N-Desethylsimazine is a known human metabolite of Simazine.'],
3878,13879,1-Phenyl-2-butanone,CCC(=O)CC1=CC=CC=C1,,,,,,
3879,13880,1-Methyl-3-phenylurea,CNC(=O)NC1=CC=CC=C1,,,,,,
3880,13881,2-Pyridylmethyl acetate,CC(=O)OCC1=CC=CC=N1,,,,,,
3881,13882,2-(2-Chloroacetyl)benzonitrile,C1=CC=C(C(=C1)C#N)C(=O)CCl,,,,,,
3882,13883,Fenadiazole,C1=CC=C(C(=C1)C2=NN=CO2)O,,,,,,
3883,13884,gamma-Phenyl-gamma-butyrolactone,C1CC(=O)OC1C2=CC=CC=C2,,,,,,
3884,13885,"Naphthalene, decahydro-2,3-dimethyl-",CC1CC2CCCCC2CC1C,,,,,,
3885,13886,3-Phenylpyridine,C1=CC=C(C=C1)C2=CN=CC=C2,,,,,,
3886,13887,2-Phenylpyridine,C1=CC=C(C=C1)C2=CC=CC=N2,,,,,,
3887,13888,"1,4-Diacetylbenzene",CC(=O)C1=CC=C(C=C1)C(=O)C,,,,,,
3888,13889,"2,4,6-Triethyltriazine",CCC1=NC(=NC(=N1)CC)CC,,,,,,
3889,13890,3-Methyl-3-phenylbutanoic acid,CC(C)(CC(=O)O)C1=CC=CC=C1,,,,,,
3890,13891,"2-Chloro-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C=C(C2=O)Cl,,,,,,
3891,13892,2-Cyclohexylidenecyclohexanone,C1CCC(=C2CCCCC2=O)CC1,,,,,,
3892,13893,4-Amino-4-phenylbutanoic acid,C1=CC=C(C=C1)C(CCC(=O)O)N,,,,,,
3893,13894,CID 13894,CCNC1=NC(=NC(=N1)S)NCC,,,,,,
3894,13895,"1,4-Di-tert-butylbenzene",CC(C)(C)C1=CC=C(C=C1)C(C)(C)C,,,,,,
3895,13896,Pentachlorobenzoic acid,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)C(=O)O,,,,,,
3896,13897,CID 13897,CC1=C(C(=C(C=C1)C(C)C)O)C(=O)[O-].[Na+],,,,,,
3897,13898,Dibenzothiophene 5-oxide,C1=CC=C2C(=C1)C3=CC=CC=C3S2=O,,,,,,
3898,13899,3-(2-Aminopropyl)-7-chloroindole hydrochloride,CC(CC1=CNC2=C1C=CC=C2Cl)[NH3+].[Cl-],,,,,,
3899,13900,1-(7-chloro-1H-indol-3-yl)propan-2-amine,CC(CC1=CNC2=C1C=CC=C2Cl)N,,,,,,
3900,13901,N-Ethyl-N-phenylurethane,CCN(C1=CC=CC=C1)C(=O)OCC,,,,,,
3901,13902,"1,4-DI(Sec-butyl)benzene",CCC(C)C1=CC=C(C=C1)C(C)CC,,,,,,
3902,13903,CID 13903,CC1=CC(=C(C=C1C(=O)[O-])C(C)C)O.[Na+],,,,,,
3903,13904,Desmetryn,CC(C)NC1=NC(=NC(=N1)NC)SC,,,,"['... /Desmetryne is/ absorbed by leaves & roots ... /& translocated/ acropetally through xylem, & ... /accumulated/ in apical meristems.', 'They are efficiently absorbed from intestine, and presumably there is some absorption across the skin and lung. /Urea-, uracil- and triazine-based herbicides/']",['All of these herbicides /methoxy or methylthio substituted triazine herbicides/ are rapidly absorbed and metabolized when ingested; amine dealkylation and side chain oxidation are the predominant detoxification reactions. The mercapto derivatives of triazine may also undergo sulfoxidation followed by reaction with hepatic glutathione to yield mercapturic acid derivatives. /s-Triazines/'],
3904,13905,Simetryn,CCNC1=NC(=NC(=N1)SC)NCC,,,,,,
3905,13906,"1,1-Diethyl-3-phenylurea",CCN(CC)C(=O)NC1=CC=CC=C1,,,,,,
3906,13907,"ISOCYANIC ACID, p-XYLYLENE ESTER",C1=CC(=CC=C1CN=C=O)CN=C=O,,,,,,
3907,13908,Dibenzothiophene sulfone,C1=CC=C2C(=C1)C3=CC=CC=C3S2(=O)=O,,,,,,
3908,13909,"Imidazole-1-acetic acid, 2-methyl-5-nitro-, ethyl ester",CCOC(=O)CN1C(=NC=C1[N+](=O)[O-])C,,,,,,
3909,13910,"CARBAMIC ACID, DIMETHYL-, BENZO(b)THIEN-4-YL ESTER",CN(C)C(=O)OC1=C2C=CSC2=CC=C1,,,,,,
3910,13911,"2,3-Dihydro-6-chloro-2-(2-chloroethyl)-4H-1,3-benzoxazin-4-one",C1=CC2=C(C=C1Cl)C(=O)NC(O2)CCCl,,,,,,
3911,13912,3-(Dimethylaminomethyl)-5-phenylisoxazole hydrochloride,C[NH+](C)CC1=NOC(=C1)C2=CC=CC=C2.[Cl-],,,,,,
3912,13913,"N,N-Dimethyl-5-phenylisoxazole-3-methanamine",CN(C)CC1=NOC(=C1)C2=CC=CC=C2,,,,,,
3913,13914,"2,4,6-Tripropyl-1,3,5-triazine",CCCC1=NC(=NC(=N1)CCC)CCC,,,,,,
3914,13915,"Bicyclo[2.2.2]oct-5-ene-2,2,3,3-tetracarbonitrile",C1CC2C=CC1C(C2(C#N)C#N)(C#N)C#N,,,,,,
3915,13916,Pyrrolnitrin,C1=CC(=C(C(=C1)Cl)[N+](=O)[O-])C2=CNC=C2Cl,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
3916,13917,5-sec-Butyl-4-tolyl methylcarbamate,CCC(C)C1=C(C=CC(=C1)OC(=O)NC)C,,,,,,
3917,13918,N-(2-Chlorophenyl)benzamide,C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2Cl,,,,,,
3918,13919,"6-(Methylsulfanyl)-N~2~,N~4~-di(prop-2-en-1-yl)-1,3,5-triazine-2,4-diamine",CSC1=NC(=NC(=N1)NCC=C)NCC=C,,,,,,
3919,13920,((p-Chlorobenzyl)oxy)guanidine nitrate,C1=CC(=CC=C1CO[NH+]=C(N)N)Cl.[N+](=O)([O-])[O-],,,,,,
3920,13921,2-[(4-Chlorophenyl)methoxy]guanidine,C1=CC(=CC=C1CON=C(N)N)Cl,,,,,,
3921,13922,Guanoxyfen sulfate,C1=CC=C(C=C1)OCCCN=C(N)N.C1=CC=C(C=C1)OCCCN=C(N)N.OS(=O)(=O)O,,,,,,
3922,13923,Guanoxyfen,C1=CC=C(C=C1)OCCCN=C(N)N,,,,,,
3923,13924,"5H-Dibenzo[a,d]cyclohepten-5-one oxime",C1=CC=C2C(=C1)C=CC3=CC=CC=C3C2=NO,,,,,,
3924,13925,5-Chloro-2-(methylamino)benzophenone,CNC1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
3925,13926,Bentranil,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=O)O2,,,,,,
3926,13927,"4-amino-5-bromo-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one",C1[C@@H](O[C@@H](C1O)CO)N2C=C(C(=NC2=O)N)Br,,,,,,
3927,13928,alpha-(((5-Bromo-2-pyridyl)amino)methyl)benzyl alcohol hydrochloride,C1=CC=C(C=C1)C(CNC2=[NH+]C=C(C=C2)Br)O.[Cl-],,,,,,
3928,13929,alpha-[[(5-Bromo-2-pyridinyl)amino]methyl]benzenemethanol,C1=CC=C(C=C1)C(CNC2=NC=C(C=C2)Br)O,,,,,,
3929,13930,Heptachlor epoxide,C12C(C(C3C1O3)Cl)C4(C(=C(C2(C4(Cl)Cl)Cl)Cl)Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['RATS FED 30 MG/KG HEPTACHLOR HAD MAXIMUM CONCN OF HEPTACHLOR EPOXIDE IN FAT WITHIN 2-4 WEEKS; 12 WEEKS AFTER EXPOSURE ... DISCONTINUED, HEPTACHLOR EPOXIDE HAD COMPLETELY DISAPPEARED FROM ADIPOSE TISSUE.', 'The chief route of excretion is biliary, although nearly all organochlorines yield measurable urinary metabolites. ... Many of the unmetabolized pesticides are efficiently reabsorbed by the intestine (enterohepatic ciruclation) substantially retarding fecal excretion. /Solid organochlorine insecticides/', 'HEPTACHLOR CAN BE ABSORBED THROUGH SKIN & VIA LUNG & GASTROENTERIC TRACT. IN RAT, HEPTACHLOR IS METABOLIZED TO HEPTACHLOR EPOXIDE. HEPTACHLOR EPOXIDE IS ALSO THE OXIDATION PRODUCT OF HEPTACHLOR IN OTHER ANIMALS, AS WELL AS IN PLANTS & MICROORGANISMS, BUT NOT ALL HEPTACHLOR IS CONVERTED TO THE EPOXIDE, WHICH IS MORE TOXIC & MORE STABLE THAN THE PARENT COMPOUND.', 'HEPTACHLOR EPOXIDE IS ... FOUND IN BLOOD & FAT OF STILLBORN INFANTS, INDICATING TRANSPLACENTAL TRANSFER TO THE FETUS. IT IS ALSO EXCRETED IN HUMAN MILK.', 'For more Absorption, Distribution and Excretion (Complete) data for HEPTACHLOR EPOXIDE (11 total), please visit the HSDB record page.']","['... FECAL METABOLITE (A DEHYDROGENATED DERIVATIVE OF 1-HYDROXY-2,3-EPOXYCHLORDENE) WAS ISOLATED FROM RATS FED 10 MG/KG DIET HEPTACHLOR EPOXIDE FOR 30 DAYS.', 'DEHYDROCHLORINATION OF HEPTACHLOR EPOXIDE, FOLLOWED BY HYDROXYLATION & DOUBLE-BOND REARRANGEMENT, LEADS TO FORMATION OF METABOLITE WHICH IS THE PRINCIPAL FORM ... EXCRETED IN FECES.', 'A 3-DAY AQUATIC SYSTEM WAS USED TO EVALUATE UPTAKE & BIOTRANSFORMATION OF HEPTACHLOR EPOXIDE. WATER SAMPLES INDICATED RAPID FORMATION (APPROX 24 HR) OF 1-HYDROXYCHLORDENE & ITS EPOXIDE PLUS A POLAR METABOLITE FROM SNAIL (PHYSA & OEDOGONIUM), MOSQUITO (CULEX) & FISH (GAMBUSIA).', 'GROWING BROTH CULTURES OF NOCARDIOSIS METABOLIZED PURE CIS- OR TRANS-CHLORDANE TO AT LEAST 8 SOLVENT-SOLUBLE SUBSTANCES INCLUDING HEPTACHLOR ENDO-EPOXIDE.', 'For more Metabolism/Metabolites (Complete) data for HEPTACHLOR EPOXIDE (9 total), please visit the HSDB record page.']",
3930,13931,Triallyl isocyanurate,C=CCN1C(=O)N(C(=O)N(C1=O)CC=C)CC=C,,,,,,
3931,13932,Mesocaine,CC[NH+](CC)CC(=O)NC1=C(C=C(C=C1C)C)C.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
3932,13933,((5-(Hydroxymethyl)-2-phenyl-m-dioxan-5-yl)methyl)trimethylammonium bromide,C[N+](C)(C)CC1(COC(OC1)C2=CC=CC=C2)CO.[Br-],,,,,,
3933,13934,"[5-(Hydroxymethyl)-2-phenyl-1,3-dioxan-5-yl]methyl-trimethylazanium",C[N+](C)(C)CC1(COC(OC1)C2=CC=CC=C2)CO,,,,,,
3934,13935,1-Cyclohexyl-5-isobutylbarbituric acid,CC(C)CC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
3935,13936,CID 13936,C1=CC(=CC=C1CCCC(=O)[O-])N(CCCl)CCCl.[Na+],,,,,,
3936,13937,"alpha-(((3-Methoxypropyl)amino)methyl)-1,4-benzodioxan-2-methanol",COCCCNCC(C1COC2=CC=CC=C2O1)O,,,,,,
3937,13938,"Propanamide, 3-((2-mercaptoethyl)amino)-, mono(4-methylbenzenesulfonate) (salt)",CC1=CC=C(C=C1)S(=O)(=O)O.C(CNCCS)C(=O)N,,,,,,
3938,13939,3-(2-Sulfanylethylamino)propanamide,C(CNCCS)C(=O)N,,,,,,
3939,13940,Endosulfan sulfate,C1C2C(COS(=O)(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,"['ENDOSULFAN WAS APPLIED TO FORAGE CROPS ON WHICH CATTLE WERE ALLOWED TO GRAZE BEGINNING SEVEN DAYS AFTER APPLICATION. ENDOSULFAN SULFATE WAS FOUND IN THE SILAGE & IN THE FAT OF ONLY ONE ANIMAL. ... NO DETECTABLE RESIDUES WERE FOUND IN THE MILK FROM DAIRY COWS FED THE TREATED SILAGE.', 'The principal route of excretion for endosulfan and endosulfan sulfate is in the feces.']","['ADMINISTRATION OF THE /ENDOSULFAN/ SULFATE /ORALLY OR IP TO RATS/ ... GAVE RISE TO THE HYDROXYETHER & LACTONE.', 'IN GREEN /TOBACCO/ LEAVES, ENDOSULFAN SULFATE WAS METABOLIZED INTO ENDOSULFAN I, WHILE DURING CURING THE SULFATE RESIDUE WAS CONVERTED TO ENDOSULFAN II. IT IS ASSUMED THAT THE CONVERSION OF THE SULFATE IN THE INTACT LEAF INTO ENDOSULFAN I IS GOVERNED BY AN ENZYME WHICH IS LOST DURING THE CURING PROCESS.', 'IN TEMP STRESSED RATS ORALLY DOSED WITH ENDOSULFAN I OR II, ENDOSULFAN SULFATE WAS THE METABOLITE MOST COMMONLY RECOVERED FROM TISSUES, ORGANS & FECES REGARDLESS OF TEMP STRESS. THE DIOL, ALPHA-HYDROXY ETHER & LACTONE ... WERE FOUND IN MOST URINE & FECES SAMPLES.', '... WHITE MICE (BALB/C STRAIN) WERE FED (14)C-LABELED ENDOSULFAN. THE TWO ISOMERS WERE NOT COMPLETELY ABSORBED FROM GI TRACT BUT, ALONG WITH ENDOSULFAN SULFATE & DIOL, WERE EXCRETED IN FECES. ONLY A TRACE OF OXIDIZED ENDOSULFAN WAS FOUND IN KIDNEY & MUSCLE EXTRACTS BUT NEITHER OF THE TWO KNOWN METABOLITES NOR ENDOSULFAN WAS FOUND IN BLOOD OR BRAIN EXTRACTS. ... LARGE AMOUNTS OF ENDOSULFAN SULFATE WERE DETECTED IN THE LIVER & TRACES IN THE KIDNEY 24 HR AFTER /MICE/ ... RECEIVED SINGLE DOSES OF ENDOSULFAN.', 'For more Metabolism/Metabolites (Complete) data for ENDOSULFAN SULFATE (11 total), please visit the HSDB record page.']",
3940,13941,((5-(Hydroxymethyl)-2-methyl-2-phenyl-m-dioxan-5-yl)methyl)trimethylammonium bromide,CC1(OCC(CO1)(C[N+](C)(C)C)CO)C2=CC=CC=C2.[Br-],,,,,,
3941,13942,"[5-(Hydroxymethyl)-2-methyl-2-phenyl-1,3-dioxan-5-yl]methyl-trimethylazanium",CC1(OCC(CO1)(C[N+](C)(C)C)CO)C2=CC=CC=C2,,,,,,
3942,13943,Triamiphos,CN(C)P(=O)(N1C(=NC(=N1)C2=CC=CC=C2)N)N(C)C,,,,,"['Presumably demethylation of the amido groups, formation of N-hydroxy cmpd and hydrolytic cleavage of the phosphate moiety.']",
3943,13944,5-Butyl-1-(4-hydroxycyclohexyl)barbituric acid,CCCCC1C(=O)NC(=O)N(C1=O)C2CCC(CC2)O,,,,,,
3944,13945,2'-Deoxycytidine-5'-monophosphate,C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O)O,,,,,,
3945,13946,Chlordecone alcohol,C1(C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)O,,,,,,
3946,13947,Heptolamide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCCC2,,,,,,
3947,13948,"(17S)-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol",CC12CCC3C(C1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC,,,,,,
3948,13949,CID 13949,COC1=NC(=NC(=N1)NN=CC2=CC=C(O2)[N+](=O)[O-])OC,,,,,,
3949,13950,CID 13950,CC(C)N(CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-])C(C)C,,,,,,
3950,13951,"A-NOR-5-alpha-ANDROSTANE-2-beta,17-beta-DIOL, 2-alpha-ETHYNYL-",CC12CCC3C(C1CC[C@@H]2O)CCC4C3(C[C@](C4)(C#C)O)C,,,,,,
3951,13952,2-Ethynyl-2-hydroxy-A-norandrostan-17-one,CC12CCC3C(C1CCC2=O)CCC4C3(C[C@](C4)(C#C)O)C,,,,,,
3952,13953,Glyoctamide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCCCC2,,,,,,
3953,13954,1-Cyclohexyl-5-methyl-3-phenylbarbituric acid,CC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3954,13955,"1-Bromo-2,2-diphenyl-1-(p-fluorophenyl)ethylene",C1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)F)Br)C3=CC=CC=C3,,,,,,
3955,13956,Tri-p-tolylphosphine,CC1=CC=C(C=C1)P(C2=CC=C(C=C2)C)C3=CC=C(C=C3)C,,,,,,
3956,13957,"17-hydroxy-10,13,17-trimethyl-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one",CC12CCC(=O)C=C1CCC3C2=CCC4(C3CCC4(C)O)C,,,,,,
3957,13958,CID 13958,CC1=C2C=C(C(=O)C(=C2OC(=C1)O)C[NH+](CCO)CCO)O.[Cl-],,,,,,
3958,13959,CID 13959,CC1=C2C=C(C(=O)C(=C2OC(=C1)O)CN(CCO)CCO)O,,,,,,
3959,13960,CID 13960,CCCCC(C(=O)[O-])OC1=C(C=C(C(=C1I)NC(=O)C)I)I.[Na+],,,,,,
3960,13961,"2-(3-Acetamido-2,4,6-triiodophenoxy)hexanoic acid",CCCCC(C(=O)O)OC1=C(C=C(C(=C1I)NC(=O)C)I)I,,,,,,
3961,13962,Sulmarin disodium,CC1=CC(=O)OC2=CC(=C(C=C12)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+],,,,,,
3962,13963,Sulmarin,CC1=CC(=O)OC2=CC(=C(C=C12)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
3963,13964,Heteronium bromide,C[N+]1(CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O)C.[Br-],,,,,,
3964,13965,Heteronium,C[N+]1(CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O)C,,,,,,
3965,13966,Carcainium chloride,C[N+](C)(CC(=O)NC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
3966,13967,Carcainium,C[N+](C)(CC(=O)NC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2,,,,,,
3967,13968,1-Cyclohexyl-5-ethyl-3-phenylbarbituric acid,CCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3968,13969,"[4-(5-Butyl-2,4,6-trioxo-1,3-diazinan-1-yl)cyclohexyl] acetate",CCCCC1C(=O)NC(=O)N(C1=O)C2CCC(CC2)OC(=O)C,,,,,,
3969,13970,"Testosterone, 11beta-hydroxy-17-methyl-",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O,,,,,,
3970,13971,"2,5-Bis(4-nitrophenyl)-1,3,4-oxadiazole",C1=CC(=CC=C1C2=NN=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3971,13972,1-Cyclohexyl-5-isopropyl-3-phenylbarbituric acid,CC(C)C1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3972,13973,1-Cyclohexyl-3-phenyl-5-propylbarbituric acid,CCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3973,13974,5-Allyl-1-cyclohexyl-3-phenylbarbituric acid,C=CCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3974,13975,CID 13975,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)Cl)Br)C3=CC=CC=C3,,,,,,
3975,13976,Quinacridone,C1=CC=C2C(=C1)C(=O)C3=CC4=C(C=C3N2)C(=O)C5=CC=CC=C5N4,,,,,,
3976,13977,"Benzanilide, 2'-benzoylthio-",C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2SC(=O)C3=CC=CC=C3,,,,,,
3977,13978,5-Butyl-1-cyclohexyl-3-phenylbarbituric acid,CCCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3978,13979,"Carbamothioic acid, methyl-1-naphthalenyl-, O-2-naphthalenyl ester",CN(C1=CC=CC2=CC=CC=C21)C(=S)OC3=CC4=CC=CC=C4C=C3,,,,,,
3979,13980,1-Cyclohexyl-5-pentyl-3-phenylbarbituric acid,CCCCCC1C(=O)N(C(=O)N(C1=O)C2=CC=CC=C2)C3CCCCC3,,,,,,
3980,13981,C.I. Basic Brown 1,C1=CC(=CC(=C1)N=NC2=C(C=C(C=C2)N)N)N=NC3=C(C=C(C=C3)N)N,,,,,,
3981,13982,"1,5-Dicyclohexyl-3-phenylbarbituric acid",C1CCC(CC1)C2C(=O)N(C(=O)N(C2=O)C3=CC=CC=C3)C4CCCCC4,,,,,,
3982,13983,"Ketone, methyl 10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-YL",CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C,,,,,,
3983,13984,CID 13984,CC(=O)O[C@H]1CCC2C1(CCC3C2CCC4C3(C[C@](C4)(C#C)OC(=O)C)C)C,,,,,,
3984,13985,Bunamidine hydrochloride,CCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC.Cl,,,['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)'],,,
3985,13986,Bunamidine,CCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)'],,,
3986,13987,Dihydrotestosterone benzoate,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4OC(=O)C5=CC=CC=C5)C,,,,,,
3987,13988,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-fluorophenyl)-1-(3-(1-piperazinyl)propyl)-, hydrochloride",C1CN(CCN1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F.Cl,,,,,,
3988,13989,"7-chloro-5-(2-fluorophenyl)-1-(3-piperazin-1-ylpropyl)-3H-1,4-benzodiazepin-2-one",C1CN(CCN1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F,,,,,,
3989,13990,"1-Methyl-3-pyrrolidyl N,N-diphenylcarbamate",CN1CCC(C1)OC(=O)N(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3990,13991,"Disodium 3-(5-chloro-2-hydroxyphenylazo)-4,5-dihydroxynaphthalene-2,7-disulphonate",C1=CC(=C(C=C1Cl)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)[O-])S(=O)(=O)[O-])O)O)O.[Na+].[Na+],,,,,,
3991,13992,C.I. Mordant Blue 13,C1=CC(=C(C=C1Cl)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)O)O)O,,,,,,
3992,13993,"[(3S,5R,10S,13R,14S,16S,17R)-14,16-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] acetate",CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=CC(=O)OC5)O)O)C)C,,,,,,
3993,13994,CID 13994,C1CCN(C1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O,,,,,,
3994,13995,"7-chloro-5-phenyl-1-(2-pyrrolidin-1-ylethyl)-3H-1,4-benzodiazepin-2-one",C1CCN(C1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4,,,,,,
3995,13996,CID 13996,C1CCN(CC1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O,,,,,,
3996,13997,"7-chloro-5-phenyl-1-(2-piperidin-1-ylethyl)-3H-1,4-benzodiazepin-2-one",C1CCN(CC1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4,,,,,,
3997,13998,"but-2-enedioic acid;7-chloro-1-(2-morpholin-4-ylethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one",C1COCCN1CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O,,,,,,
3998,13999,"7-chloro-1-(2-morpholin-4-ylethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one",C1COCCN1CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4,,,,,,
3999,14000,"Indole, 3-(N-ethyl-N-(4-hydroxybutyl)amino)ethyl-, 3,4,5-trimethoxybenzoate (ester)",CCN(CCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC)CCC2=CNC3=CC=CC=C32,,,,,,
4000,14001,"Butyronitrile, 2,2-diphenyl-4-(4-oxo-1-phenyl-1,3,8-triazaspiro(4.5)dec-8-YL)-",C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCC(C#N)(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4001,14002,"2'-Butyl-9-fluoro-11-hydroxy-2'-methoxy-10,13,16-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,4'-[1,3]dioxane]-3,5'(6H)-dione",CCCCC1(OCC(=O)C2(O1)C(CC3C2(CC(C4(C3CCC5=CC(=O)C=CC54C)F)O)C)C)OC,,,,,,
4002,14003,Adenosine tetraphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,,,,,,
4003,14004,CID 14004,CCCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4004,14005,Quercetin pentaacetate,CC(=O)OC1=C(C=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
4005,14006,CID 14006,C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)[N+](=O)[O-])C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
4006,14007,CID 14007,C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)[N+](=O)[O-])C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4007,14008,CID 14008,CCOCCN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4008,14009,"7-chloro-1-[3-[4-(2-ethoxyethyl)piperazin-1-yl]propyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one",CCOCCN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F,,,,,,
4009,14010,CID 14010,C=COCCN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4010,14011,"7-chloro-1-[3-[4-(2-ethenoxyethyl)piperazin-1-yl]propyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one",C=COCCN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F,,,,,,
4011,14012,Chromium(III) acetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Cr+3],,,,,,
4012,14013,Ammonium bicarbonate,C(=O)(O)[O-].[NH4+],,,,"['There appears to be a more rapid excretion of ammonia following ammonium bicarbonate infusions, which result in higher unionized ammonia levels in blood compared, with those following ammonium chloride infusions.']",['Ammonium bicarbonate dissociated into free ammonia at level of cell membrane.'],
4013,14014,Dimethylsilanediol,C[Si](C)(O)O,,,,,,
4014,14015,Trimethyltin bromide,C[Sn](C)(C)Br,,,,,,
4015,14016,Trimethyltin chloride,C[Sn](C)(C)Cl,,,,"['... After a single gastric dose of 4.0 mg/kg trimethyltin chloride (2.4 mg tin/kg) to rats, the blood and brain concn of trimethyltin (expressed as tin) were 39 ug/ml and 1.3 ug/g, respectively, while ... after the 4th weekly dose of 4.0 mg/kg the corresponding concn were 120 ug/ml and 3.5 ug/g. In the marmoset treated with 3.0 mg/kg trimethyltin chloride (1.8 mg tin/g), the brain concn of trimethyltin corresponded to 1.53 ug/g at 24 and 0.74 ug/g at 48 hr, but between 48 and 92 hr there was hardly any loss of tin. ... The brain concn of trimethyltin 48 hr after treatment was the same in the rat and the marmoset, but when concn is corrected for blood content of the brain, the marmoset brain had nearly three times as much trimethyltin as the rat brain.', 'Naive rats injected with lithium chloride at various times following consumption of a novel saccharin solution subsequently avoided the ingestion of saccharin with the degree of the aversion related to the interval between ingestion and lithium chloride administration. Although a similar relationship was also evident in animals which had received a single intragastric administration of trimethyltin chloride 21 days prior to the pairing of saccarin and lithium chloride, the trimethyltin-pretreated subjects receiving delayed injections of lithium chloride displayed weaker taste aversions than those not trimethyltin. This disruption in the acquisition of taste aversions over long delays is consistent with other work suggesting that trimethyltin disrupts tasks involving short-term memory. The utility of the conditioned taste aversion paradigm in detecting and characterizing drug toxicity was discussed.', 'In vitro exposure of PHA-stimulated human lymphocytes to organotin compounds resulted in statistically significant increases in the frequencies of hyperdiploid cells. When taken together with our previous study demonstrating spindle inhibiting effects of the same organotin compounds by an indirect method, the present study strongly indicates that organotin compounds are able to induce aneuploidy, probably by affecting spindle function.', 'This study was designed to extend and confirm previous work to assess the distribution of (14)C labeled trimethyltin to liver, kidney, adrenal and fat. A comparison was also made of the maternal and fetal disposition of (14)C derived from labeled trimethyltin when administered at two different periods of gestation, days 12 and 17, to pregnant Sprague-Dawley rats. The rats were injected with 7.0 mg/kg trimethyltin chloride. The neuropathology seen following an in utero exposure to trimethyltin was much less severe than that observed after either neonatal or adult exposure to trimethyltin. The fetuses of dams expose on either gestational day 12 or 17 received substantial amounts of radiolabel derived from and in the form of (14)C trimethyltin. Peak radiolabel concentrations in gestational day 12 maternal and fetal brain were only 11 to 30 percent of those levels seen in gestational day 17 animals. Trimethyltin apparently readily crossed the placenta and entered the fetal blood and tissue, including the brain. There was no selective distribution of trimethyltin within the brain such as brainstem versus cerebrum versus cerebellum of the fetus or pup exposed in-utero or within the brain of the maternal rat exposed during gestation.']",,"['The clearance of trimethyltin is slower /than triethyltin/. Brain and blood concn, estimated 1 and 8 days after the last of 4 weekly doses, indicated a very much slower /rate than triethyltin/, approx 16 day clearance half-time. The clearance of trimethyltin in the marmoset was also slow from the brain; but from blood, probably because of the absence of binding to hemoblobin, it cleared with a half-time of 4 days. /Trimethyltin compounds/']"
4016,14017,(Aminomethyl)phosphonic acid,C(N)P(=O)(O)O,,,,,,
4017,14018,3-Ethyl-3-methylpentane,CCC(C)(CC)CC,,,,,,
4018,14019,Triethyllead chloride,CC[Pb](CC)(CC)Cl,,,,,,
4019,14020,"3,3-Diethylpentane",CCC(CC)(CC)CC,,,,,,
4020,14021,CID 14021,CCC[SnH](CCC)CCC.CCC[SnH](CCC)CCC.O,,,,,,
4021,14022,Tripropylstannane,CCC[SnH](CCC)CCC,,,,,,
4022,14023,Acetic acid;dibutyltin,CCCC[Sn]CCCC.CC(=O)O.CC(=O)O,,,,,,
4023,14024,3-Cyanopropyltriethoxysilane,CCO[Si](CCCC#N)(OCC)OCC,,,,,,
4024,14025,Tris(2-methoxyethoxy)vinylsilane,COCCO[Si](C=C)(OCCOC)OCCOC,,,,,,
4025,14026,"Ammonium, tetramethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
4026,14027,"1,4-Bis(triethylaminio)butane",CC[N+](CC)(CC)CCCC[N+](CC)(CC)CC,,,,,,
4027,14028,Diethyl (2-oxopropyl)phosphonate,CCOP(=O)(CC(=O)C)OCC,,,,,,
4028,14029,"DIPHOSPHORIC(III,V) ACID, P(sup V),P(sup V)-DIETHYL DIMETHYL ESTER",CCOP(=O)(OCC)OP(OC)OC,,,,,,
4029,14030,"DIPHOSPHORIC(III,V) ACID, P(sup III),P(sup III),P(sup V)-TRIETHYL METHYL ESTER",CCOP(OCC)OP(=O)(OC)OCC,,,,,,
4030,14031,"Diphosphoric(III,V) acid, tetramethyl ester",COP(OC)OP(=O)(OC)OC,,,,,,
4031,14032,"DIPHOSPHORIC(III,V) ACID, P(sup III),P(sup III)-DIETHYL DIMETHYL ESTER",CCOP(OCC)OP(=O)(OC)OC,,,,,,
4032,14033,Diethyl (3-oxobutyl)phosphonate,CCOP(=O)(CCC(=O)C)OCC,,,,,,
4033,14034,Tris(3-chloropropyl)phosphate,C(COP(=O)(OCCCCl)OCCCCl)CCl,,,,,,
4034,14035,"Acetic acid, ((dimethoxyphosphinothioyl)thio)-, ethyl ester (9CI)",CCOC(=O)CSP(=S)(OC)OC,,,,,,
4035,14036,"Ammonium O,O-diethyl dithiophosphate",CCOP(=S)(OCC)[S-].[NH4+],,,,,,
4036,14037,"2,5-Di(tert-butylperoxy)-2,5-dimethyl-3-hexyne",CC(C)(C)OOC(C)(C)C#CC(C)(C)OOC(C)(C)C,,,,,,
4037,14038,CID 14038,C(C(=O)[O-])Br.[Na+],,,,,,
4038,14039,Acethydrazide,CC(=O)NN,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
4039,14040,"3-Ethyl-2,4-dimethylpentane",CCC(C(C)C)C(C)C,,,,,,
4040,14041,Diethyl acetamidomalonate,CCOC(=O)C(C(=O)OCC)NC(=O)C,,,,,,
4041,14042,"1,5-Hexadiene-3,4-diol",C=CC(C(C=C)O)O,,,,,,
4042,14043,Cystine dimethyl ester dihydrochloride,COC(=O)C(CSSCC(C(=O)OC)N)N,,,,,,
4043,14044,DL-Allylglycine,C=CCC(C(=O)O)N,,,"['Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. (See all compounds classified as GABA Antagonists.)', 'Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. (See all compounds classified as Convulsants.)']",,,
4044,14045,"2,3,5-Trimethylhexane",CC(C)CC(C)C(C)C,,,,,,
4045,14046,Bucrilate,CC(C)COC(=O)C(=C)C#N,,,"['Substances used to cause adherence of tissue to tissue or tissue to non-tissue surfaces, as for prostheses. (See all compounds classified as Tissue Adhesives.)']",,,
4046,14047,CID 14047,CCCC(CCC)C(=O)[O-].[Na+],,,,,,
4047,14048,Aluminum;octane,CCCCCCC[CH2-].CCCCCCC[CH2-].CCCCCCC[CH2-].[Al+3],,,,,,
4048,14049,"1-Decanamine, N,N-didecyl-",CCCCCCCCCCN(CCCCCCCCCC)CCCCCCCCCC,,,,,,
4049,14050,2-Ethylhexyl dihydrogen phosphate,CCCCC(CC)COP(=O)(O)O,,,,,,
4050,14051,Ethambutol Hydrochloride,CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl.Cl,,,"['Drugs used in the treatment of tuberculosis. They are divided into two main classes: &quot;first-line&quot; agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and &quot;second-line&quot; drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)']",,,
4051,14052,Ethambutol,CC[C@@H](CO)NCCN[C@@H](CC)CO,"['Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with [isoniazid], [rifampin], and [pyrazinamide].']","['Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. It has a long duration of action as it is administered daily, and a moderate therapeutic window. Patients should be counselled regarding the risk of optic neuritis and hepatic toxicity.']","['Drugs used in the treatment of tuberculosis. They are divided into two main classes: &quot;first-line&quot; agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and &quot;second-line&quot; drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)']","['Oral ethambutol is approximately 75-80% orally bioavailable. A 25 mg/kg oral dose of ethambutol reaches a C<sub>max</sub> of 2-5 g/mL, with a T<sub>max</sub> of 2-4 hours. In a separate study, the AUC<sub>0-8</sub> varied from 6.3  5.5 h\\*mg/L to 10.8  7.6 h\\*mg/L depending on CYP1A2 genetic polymorphisms.', 'Ethambutol is 50% eliminated in the urine as the unmetabolized parent compound and 8-15% as inactive metabolites. 20-22% of a dose is eliminated unchanged in the feces.', 'Patients coinfected with tuberculosis and HIV have an estimated ethambutol volume of distribution of 76.2 L.', 'Patients coinfected with tuberculosis and HIV have an estimated ethambutol oral clearance of 77.4 L/h.', 'Approximately 75-80% of an oral dose of ethambutol hydrochloride is rapidly absorbed from the GI tract. Absorption is not substantially affected when the drug is administered with food. Following a single oral ethambutol hydrochloride dose of 25 mg/kg, peak serum ethambutol concentrations of 2-5 mcg/mL are attained within 2-4 hours; serum concentrations of the drug are undetectable 24 hours after the dose.', 'There is no evidence that accumulation of the drug occurs when ethambutol doses of 25 mg/kg are given once daily in patients with normal renal function. Serum concentrations of the drug are higher and accumulation may occur when ethambutol is used in patients with impaired renal function.', 'Ethambutol is widely distributed into most body tissues and fluids. Highest concentrations of the drug are found in erythrocytes, kidneys, lungs, and saliva; lower drug concentrations are found in ascitic fluid, pleural fluid, brain, and CSF. Peak intracellular concentrations of ethambutol in erythrocytes are about twice peak plasma concentrations and maintain this ratio for at least 24 hours after a single oral dose. In patients with meningitis, administration of an oral ethambutol hydrochloride dose of 25 mg/kg has produced peak CSF concentrations of the drug ranging from 0.15-2.0 ug/mL.', '/Ethambutol/ does not penetrate intact meninges, but 10 to 50% may penetrate the meninges of patients with tuberculous meningitis. Volume of distribution is 1.6 liters per kg', 'For more Absorption, Distribution and Excretion (Complete) data for ETHAMBUTOL (9 total), please visit the HSDB record page.']","[""Ethambutol is mainly oxidized by an aldehyde dehydrogenase to an aldehyde metabolite, followed by conversion to the dicarboxylic acid 2,2'-(ethylinediimino)di-butyric acid."", '... Up to 15% is excreted in the form of two metabolites, an aldehyde and a dicarboxylic acid derivative.', 'Ethambutol is partially inactivated in the liver by oxidation to an aldehyde intermediate, 2,2?-(ethylenediimino)-di-butyraldehyde, which is converted to the decarboxylic acid derivative, 2,2?-(ethylenediimino)-di-butyric acid.']","['Ethambutol has a half life of 3.3 hours in patients with normal renal function. In patients with renal failure, the half life could be 7 hours or longer.', 'The plasma half-life of ethambutol is approximately 3.3 hours in patients with normal renal function. The half-life is prolonged in patients with impaired renal or hepatic function. In patients with renal failure, the half-life may be 7 hours or longer.', 'Six normal adult volunteers were administered 15 mg/kg of ethambutol (EMB) by a constant-rate 1-hr infusion. Plasma and urine samples were collected up to 24 and 72 hr, respectively. ...  Subsequent postinfusion EMB levels exhibited multiphasic decay. In the 12-hr period following infusion, EMB levels showed biexponential decay. However, 24-hr plasma levels in all subjects were observed to be higher than those predicted using a two-compartment body model. The alpha phase in these subjects had a mean half-life of 8.6 min while the half-life of the beta phase ranged from 2.5 to 3.6 hr (mean 3.1). The half-life of the gamma phase estimated from plasma data points between 12 and 24 hr averaged 1.2 +/- 3.6 hr. A terminal gamma t1/2 of 15.4 +/- 1.7 hr was calculated from 12-72 hr urine data. ... Plasma EMB clearance ranged from 7.47 to 8.87 mL/min/kg (mean 8.57). ...']"
4052,14053,"Ethyl 6,8-dichlorooctanoate",CCOC(=O)CCCCC(CCCl)Cl,,,,,,
4053,14054,8-Chloro-6-hydroxyoctanoic acid ethyl ester,CCOC(=O)CCCCC(CCCl)O,,,,,,
4054,14055,Cyanoacetylene,C#CC#N,,,,,,
4055,14056,"1,1,1,3-Tetrachloropropane",C(CCl)C(Cl)(Cl)Cl,,,,,,
4056,14057,"3,3-Dimethylbutyric acid",CC(C)(C)CC(=O)O,,,,,,
4057,14058,"2,2,4,4-Tetramethylpentane",CC(C)(C)CC(C)(C)C,,,,,,
4058,14059,Guanoctine hydrochloride,CC(C)(C)CC(C)(C)N=C(N)N.Cl,,,,,,
4059,14060,Guanoctine,CC(C)(C)CC(C)(C)N=C(N)N,,,,,,
4060,14061,2-Cyanoethyltrichlorosilane,C(C[Si](Cl)(Cl)Cl)C#N,,,,,,
4061,14062,"2,2-Dimethylheptane",CCCCCC(C)(C)C,,,,,,
4062,14063,3-Cyanopropyltrichlorosilane,C(CC#N)C[Si](Cl)(Cl)Cl,,,,,,
4063,14064,"Mercury, diisopropyl-",CC(C)[Hg]C(C)C,,,,,,
4064,14065,Ethyl 6-chloro-6-oxohexanoate,CCOC(=O)CCCCC(=O)Cl,,,,,,
4065,14066,3-Acetyl-1-propanol,CC(=O)CCCO,,,,,,
4066,14067,"2,2,5,5-Tetramethylhexane",CC(C)(C)CCC(C)(C)C,,,,,,
4067,14068,Dicyanoacetylene,C(#CC#N)C#N,,,,,,
4068,14069,"2,6-Dimethylheptane",CC(C)CCCC(C)C,,,,,,
4069,14070,"2,7-Dimethyloctane",CC(C)CCCCC(C)C,,,,,,
4070,14071,Tridecyl acetate,CCCCCCCCCCCCCOC(=O)C,,,,,,
4071,14072,Propylene sulfide,CC1CS1,,,,,,
4072,14073,1-Methylaziridine,CN1CC1,,,,,,
4073,14074,1-Aziridineethanol,C1CN1CCO,,,,,,
4074,14075,"1,3,2-Dioxathiolane 2,2-dioxide",C1COS(=O)(=O)O1,,,,,,
4075,14076,1-(3-Aminopropyl)aziridine,C1CN1CCCN,,,,,,
4076,14077,1-(2-Cyanoethyl)aziridine,C1CN1CCC#N,,,,,,
4077,14078,CID 14078,C1(=NN=C(S1)S)S,,,,,,
4078,14079,2-Acetylpyrrole,CC(=O)C1=CC=CN1,,,,,,
4079,14080,1H-Imidazole-4-carboxylic acid,C1=C(NC=N1)C(=O)O,,,,,,
4080,14081,"1,3,5-Trimethylpyrazole",CC1=CC(=NN1C)C,,,,,,
4081,14082,1-Bromo-3-fluorobenzene,C1=CC(=CC(=C1)Br)F,,,,,,
4082,14083,"2,6-Dimethylpyridine N-oxide",CC1=[N+](C(=CC=C1)C)[O-],,,,,,
4083,14084,Benzylhydrazine hydrochloride,C1=CC=C(C=C1)CNN.Cl,,,,,,
4084,14085,4-Chlorostyrene,C=CC1=CC=C(C=C1)Cl,,,,,,
4085,14086,4-(Methylthio)phenol,CSC1=CC=C(C=C1)O,,,,,,
4086,14087,Methyl 3-(1-aziridinyl)propionate,COC(=O)CCN1CC1,,,,,,
4087,14088,N-Isopropylmaleimide,CC(C)N1C(=O)C=CC1=O,,,,,,
4088,14089,"(1,2-Dichloroethyl)benzene",C1=CC=C(C=C1)C(CCl)Cl,,,,,,
4089,14090,Phenylglyoxal,C1=CC=C(C=C1)C(=O)C=O,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4090,14091,1-Methyl-2-propylbenzene,CCCC1=CC=CC=C1C,,,,,,
4091,14092,1-Methyl-3-propylbenzene,CCCC1=CC=CC(=C1)C,,,,,,
4092,14093,CID 14093,C1=CC=C(C=C1)N=C(S)[S-].[NH4+],,,,,,
4093,14094,CID 14094,C1=CC=C(C=C1)N=C(S)S,,,,,,
4094,14095,1-Methyl-4-propylbenzene,CCCC1=CC=C(C=C1)C,,,,,,
4095,14096,CID 14096,C1=CC=C2C(=C1)C(=NC2=O)[O-].[K+],,,,,,
4096,14097,"1-(7-Bicyclo[4.2.0]octa-1,3,5-trienyl)ethanone",CC(=O)C1CC2=CC=CC=C12,,,,,,
4097,14098,4-Vinylbenzoic acid,C=CC1=CC=C(C=C1)C(=O)O,,,,,,
4098,14099,"4,6-Dimethoxy-1,3,5-triazin-2(1H)-one",COC1=NC(=NC(=O)N1)OC,,,,,,
4099,14100,3-Anilinopropionitrile,C1=CC=C(C=C1)NCCC#N,,,,,,
4100,14101,CID 14101,C1=CC=C2C(=C1)C(=O)C=C(O2)O,,,,,,
4101,14102,Chloramben-ammonium,C1=C(C=C(C(=C1C(=O)[O-])Cl)N)Cl.[NH4+],,,,,,
4102,14103,"2,3,4-Trimethylbenzoic acid",CC1=C(C(=C(C=C1)C(=O)O)C)C,,,,,,
4103,14104,2-Isopropyl-5-methylanisole,CC1=CC(=C(C=C1)C(C)C)OC,,,,,,
4104,14105,"6,7-Dimethyltetralin",CC1=CC2=C(CCCC2)C=C1C,,,,,,
4105,14106,"1,4-Cyclohexanedicarboxylic acid",C1CC(CCC1C(=O)O)C(=O)O,,,,,,
4106,14107,"Ammonium, phenethyltrimethyl-, iodide",C[N+](C)(C)CCC1=CC=CC=C1.[I-],,,,,,
4107,14108,Trimethylphenethylaminium,C[N+](C)(C)CCC1=CC=CC=C1,,,,,,
4108,14109,Hexylbenzene,CCCCCCC1=CC=CC=C1,,,,,,
4109,14110,N-Ethyl-O-toluenesulfonamide,CCNS(=O)(=O)C1=CC=CC=C1C,,,,,,
4110,14111,"1H-Indole-5-thiol, 3-(2-aminoethyl)-",C1=CC2=C(C=C1S)C(=CN2)CCN,,,,,,
4111,14112,6-Methoxy-1-tetralone,COC1=CC2=C(C=C1)C(=O)CCC2,,,,,,
4112,14113,4-Amino-3-phenylbutanoic acid,C1=CC=C(C=C1)C(CC(=O)O)CN,,,"['Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. (See all compounds classified as Convulsants.)', 'Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA). (See all compounds classified as GABA Agonists.)', 'A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes. (See all compounds classified as Tranquilizing Agents.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
4113,14114,3-Phenylprop-2-enyloxycarbonylamine,C1=CC=C(C=C1)C=CCOC(=O)N,,,,,,
4114,14115,Heptylbenzene,CCCCCCCC1=CC=CC=C1,,,,,,
4115,14116,Phenylhydroquinone,C1=CC=C(C=C1)C2=C(C=CC(=C2)O)O,,,,,"['2,5-dihydroxybiphenyl is a known human metabolite of 2-phenylphenol.']",
4116,14117,"Carbazole, 5,6,7,8-tetrahydro-3-amino-, hydrochloride",C1CCC2=C(C1)C3=C(N2)C=CC(=C3)[NH3+].[Cl-],,,,,,
4117,14118,"2,3,4,9-tetrahydro-1H-carbazol-6-amine",C1CCC2=C(C1)C3=C(N2)C=CC(=C3)N,,,,,,
4118,14119,Mobam,CNC(=O)OC1=C2C=CSC2=CC=C1,,,,"['Within 24 hr after administration of (14)C-labeled MOBAM to a dairy cow ... 86% ... had been excreted in urine .... Approx 12% ... in the feces. In collected urines after administration of methyl and carbonyl labeled MOBAM, the sulfoxide, sulfoxide-4-sulfate, 4-sulfate and 4-glucuronide were identified.']","['MOBAM, (14)C-labeled in the ring, carbonyl or methyl position, was incubated with rumen bacterial cultures. Strains of genera Anaerovibrio, Bacteroides, Butyrivibrio, Eubacterium, Lachnospira & Ruminococcus were demonstrated to degrade MOBAM. MOBAM was metabolized to 4-hydro-benzothiophene /and CO2/.', '(14)C-MOBAM was administered to dairy goats and a lactating cow/. Of carbonyl-(14)C & 38% of methyl-(14)C were exhaled as (14)CO within 24 hr.', 'Groups of male rats were administered labeled MOBAM by stomach tube. Urine & feces were collected daily. Hydroxybenzothiophene was recovered as the glucuronide & as the sulfate. Other metabolites were found but not identified. After administration of (14)C-MOBAM to dairy goats and a lactating cow, 2 metabolites were found in urine: 4-benzothienyl sulfate & 4-benzothienyl sulfate-1-oxide. These accounted for about 90% of the (14)C excreted in the urine.', 'In rats dosed with (14)C-ring labeled MOBAM, 76-87% of the label was excreted in 24 hr in urine. Benzenethienyl sulfate & glucuronide accounted for 83-87% of excreted (14)C. Within 24 hr after administration of methyl & carbonyl labeled MOBAM /to a dairy cow and a goat/, the sulfoxide, sulfoxide-4-sulfate, 4-sulfate & 4-glucuronide were identified.', 'For more Metabolism/Metabolites (Complete) data for MOBAM (7 total), please visit the HSDB record page.']",
4119,14120,M-DI(Sec-butyl)benzene,CCC(C)C1=CC(=CC=C1)C(C)CC,,,,,,
4120,14121,"3-Buten-2-one, 4-(4-hydroxy-3-methoxyphenyl)-, (3E)-",CC(=O)C=CC1=CC(=C(C=C1)O)OC,,,,,,
4121,14122,Diethyl benzylphosphonate,CCOP(=O)(CC1=CC=CC=C1)OCC,,,,,,
4122,14123,Isoniazid pyruvate,CC(=NNC(=O)C1=CC=NC=C1)C(=O)O,,,,,,
4123,14124,Vanilpyruvic acid,COC1=C(C=CC(=C1)CC(=O)C(=O)O)O,,,,,,
4124,14125,"1,3-Diphenylpropane",C1=CC=C(C=C1)CCCC2=CC=CC=C2,,,,,,
4125,14126,Nonylbenzene,CCCCCCCCCC1=CC=CC=C1,,,,,,
4126,14127,Hexyl 4-hydroxybenzoate,CCCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
4127,14128,Butyl gallate,CCCCOC(=O)C1=CC(=C(C(=C1)O)O)O,,,,,,
4128,14129,4-(4-Nitrobenzyl)pyridine,C1=CC(=CC=C1CC2=CC=NC=C2)[N+](=O)[O-],,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4129,14130,Bucetin,CCOC1=CC=C(C=C1)NC(=O)CC(C)O,,,,,,
4130,14131,"2-[2-(2,6-Dimethylpiperidin-2-yl)ethyl]guanidine",CC1CCCC(N1)(C)CCN=C(N)N,,,,,,
4131,14132,"1,3-Diamino-5-methylphenazinium chloride",C[N+]1=C2C=C(C=C(C2=NC3=CC=CC=C31)N)N.[Cl-],,,,,,
4132,14133,"1,3-Diamino-5-methylphenazin-5-ium",C[N+]1=C2C=C(C=C(C2=NC3=CC=CC=C31)N)N,,,,,,
4133,14134,"Indole-3-glyoxylamide, N,N,2-trimethyl-",CC1=C(C2=CC=CC=C2N1)C(=O)C(=O)N(C)C,,,,,,
4134,14135,"N-(2,4-Dinitrophenyl)glycine",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCC(=O)O,,,,,,
4135,14136,N-2-Pyridylmandelamide hydrochloride,C1=CC=C(C=C1)C(C(=O)NC2=CC=CC=[NH+]2)O.[Cl-],,,,,,
4136,14137,2-hydroxy-2-phenyl-N-(pyridin-2-yl)acetamide,C1=CC=C(C=C1)C(C(=O)NC2=CC=CC=N2)O,,,,,,
4137,14138,Heptyl 4-hydroxybenzoate,CCCCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
4138,14139,alpha-((5-Methyl-2-pyridylamino)methyl)benzyl alcohol hydrochloride,CC1=C[NH+]=C(C=C1)NCC(C2=CC=CC=C2)O.[Cl-],,,,,,
4139,14140,2-[(5-Methylpyridin-2-yl)amino]-1-phenylethanol,CC1=CN=C(C=C1)NCC(C2=CC=CC=C2)O,,,,,,
4140,14141,"5-Isoxazolecarboxylic acid, 3-methyl-, 2-benzylhydrazide",CC1=NOC(=C1)C(=O)NNCC2=CC=CC=C2,,,,,,
4141,14142,CID 14142,CN(C)CC(=O)[NH2+]N=CC1=CC=C(O1)[N+](=O)[O-].[Cl-],,,,,,
4142,14143,CID 14143,CN(C)CC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
4143,14144,Nafcaproic acid,CCC(CC)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
4144,14145,Dichlofluanid,CN(C)S(=O)(=O)N(C1=CC=CC=C1)SC(F)(Cl)Cl,,,,"['When applied to strawberries, dichlofluanid disappearance followed first order kinetics in the first 21 days.']","[""FOLLOWING TREATMENT FRUIT CONTAINS RESIDUES OF BOTH UNCHANGED COMPD & ITS METABOLITE, N,N'-DIMETHYL-N-PHENYL DIAMINO SULFIDE."", 'STUDIES ON METABOLIC FATE OF DICHLOFLUANID IN STRAWBERRIES SHOW IN VITRO REACTIONS WITH CELL THIOLS. IN PLANTS TREATED WITH (14)C-DICHLOFLUANID, NO PARENT CMPD DETECTED IN FRUIT. 83% WERE UNIDENTIFIED, VERY POLAR METABOLITES; 3% WAS THIAZOLIDINE-2-THIONE-4-CARBOXYLIC ACID.']",
4145,14146,Pyridinitril,C1=CC=C(C=C1)C2=C(C(=NC(=C2C#N)Cl)Cl)C#N,,,,,,
4146,14147,N-(5-Methyl-2-pyridyl)mandelamide hydrochloride,CC1=C[NH+]=C(C=C1)NC(=O)C(C2=CC=CC=C2)O.[Cl-],,,,,,
4147,14148,2-hydroxy-N-(5-methylpyridin-2-yl)-2-phenylacetamide,CC1=CN=C(C=C1)NC(=O)C(C2=CC=CC=C2)O,,,,,,
4148,14149,"Isoxazole, 5-(2-pyrrolidinoethyl)-3-phenyl-, hydrochloride",C1CC[NH+](C1)CCC2=CC(=NO2)C3=CC=CC=C3.[Cl-],,,,,,
4149,14150,"3-Phenyl-5-(2-pyrrolidin-1-ylethyl)-1,2-oxazole",C1CCN(C1)CCC2=CC(=NO2)C3=CC=CC=C3,,,,,,
4150,14151,"Acetic acid, phenyl-, 2-benzylhydrazide",C1=CC=C(C=C1)CC(=O)NNCC2=CC=CC=C2,,,,,,
4151,14152,m-DL-Sarcolysin,C1=CC(=CC(=C1)N(CCCl)CCCl)CC(C(=O)O)N,,,,,,
4152,14153,3-Phenyl-5-(2-morpholinoethyl)isoxazole hydrochloride,C1COCC[NH+]1CCC2=CC(=NO2)C3=CC=CC=C3.[Cl-],,,,,,
4153,14154,"4-[2-(3-Phenyl-1,2-oxazol-5-yl)ethyl]morpholine",C1COCCN1CCC2=CC(=NO2)C3=CC=CC=C3,,,,,,
4154,14155,CID 14155,C1=CC=C(C=C1)C(=O)N=NC2=CC=C(C=C2)N(O)O,,,,,,
4155,14156,"N-(4,6-Dimethyl-2-pyridyl)mandelamide hydrochloride",CC1=CC(=[NH+]C(=C1)NC(=O)C(C2=CC=CC=C2)O)C.[Cl-],,,,,,
4156,14157,"N-(4,6-dimethylpyridin-2-yl)-2-hydroxy-2-phenylacetamide",CC1=CC(=NC(=C1)NC(=O)C(C2=CC=CC=C2)O)C,,,,,,
4157,14158,CID 14158,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CS3)C(=O)[O-].[Na+],,,,,,
4158,14159,2-Naphthalen-1-yl-3-thiophen-2-ylpropanoic acid,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CS3)C(=O)O,,,,,,
4159,14160,"5,12-Naphthacenequinone",C1=CC=C2C=C3C(=CC2=C1)C(=O)C4=CC=CC=C4C3=O,,,,,,
4160,14161,"2-Anilino-3-chloro-1,4-naphthoquinone",C1=CC=C(C=C1)NC2=C(C(=O)C3=CC=CC=C3C2=O)Cl,,,,,,
4161,14162,3-Phenyl-5-(3-piperidinopropyl)isoxazole hydrochloride,C1CC[NH+](CC1)CCCC2=CC(=NO2)C3=CC=CC=C3.[Cl-],,,,,,
4162,14163,3-Phenyl-5-(3-(piperidin-1-yl)propyl)isoxazole,C1CCN(CC1)CCCC2=CC(=NO2)C3=CC=CC=C3,,,,,,
4163,14164,CID 14164,C1COCC[NH+]1CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-].[Cl-],,,,,,
4164,14165,2-(4-morpholinyl)-N-[(5-nitro-2-furanyl)methylideneamino]acetamide,C1COCCN1CC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
4165,14166,CID 14166,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CC=N3)C(=O)[O-].[K+],,,,,,
4166,14167,2-Naphthalen-1-yl-3-pyridin-2-ylpropanoic acid,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CC=N3)C(=O)O,,,,,,
4167,14168,"Acridine, 9-((3-(dimethylamino)propyl)amino)-, dihydrochloride",C[NH+](C)CCC[NH2+]C1=C2C=CC=CC2=NC3=CC=CC=C31.[Cl-].[Cl-],,,,,,
4168,14169,9-((3-Dimethylaminopropyl)amino)acridine,CN(C)CCCNC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
4169,14170,"(2R)-17-hydroxy-2,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one",C[C@@H]1CC2C3CCC4(C(C3CCC2=CC1=O)CCC4O)C,,,,,,
4170,14171,alpha-(2-Piperidinoethyl)-1-naphthaleneacetonitrile,C1CCN(CC1)CCC(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
4171,14172,"4,4'-(Pentamethylenedioxy)dianiline dihydrochloride",C1=CC(=CC=C1[NH3+])OCCCCCOC2=CC=C(C=C2)[NH3+].[Cl-].[Cl-],,,,,,
4172,14173,"1,5-Bis(4-aminophenoxy)pentane",C1=CC(=CC=C1N)OCCCCCOC2=CC=C(C=C2)N,,,,,,
4173,14174,4-(1-Azaspiro(4.5)dec-1-yl)-4'-fluoro-butyrophenone,C1CCC2(CC1)CCCN2CCCC(=O)C3=CC=C(C=C3)F,,,,,,
4174,14175,((5-(Hydroxymethyl)-2-phenyl-m-dioxan-5-yl)methyl)trimethylammonium bromide acetate,CC(=O)OCC1C(COC(O1)C2=CC=CC=C2)C[N+](C)(C)C.[Br-],,,,,,
4175,14176,"[4-(Acetyloxymethyl)-2-phenyl-1,3-dioxan-5-yl]methyl-trimethylazanium",CC(=O)OCC1C(COC(O1)C2=CC=CC=C2)C[N+](C)(C)C,,,,,,
4176,14177,"Butyrophenone, 4-(2-azaspiro(4.5)dec-2-YL)-4'-fluoro-",C1CCC2(C1)CCCN(C2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
4177,14178,17beta-Hydroxy-5alpha-androst-2-ene-2-carbonitrile,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(CC(=CC4)C#N)C,,,,,,
4178,14179,"17-Hydroxy-2,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC1CC2C3CCC4(C(C3CCC2=CC1=O)CCC4(C)O)C,,,,,,
4179,14180,Nicotinamide mononucleotide,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)N,,,,,,
4180,14181,beta-Nicotinamide ribose monophosphate,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)C(=O)N,,,,,,
4181,14182,Triphenyl borate,B(OC1=CC=CC=C1)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
4182,14183,Diethylene imidoxide oleate,CCCCCCCCC=CCCCCCCCC(=O)O.C1COCCN1,,,,,,
4183,14184,Methadone hydrochloride,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
4184,14185,8-(3-(p-Fluorobenzoyl)propyl)-8-methyl-8-azoniaspiro(4.5)decane iodide,C[N+]1(CCC2(CCCC2)CC1)CCCC(=O)C3=CC=C(C=C3)F.[I-],,,,,,
4185,14186,8-[3-(4-Fluorobenzoyl)propyl]-8-methyl-8-azoniaspiro[4.5]decane,C[N+]1(CCC2(CCCC2)CC1)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
4186,14187,"1,1'-Methylenedi-2-naphthol",C1=CC=C2C(=C1)C=CC(=C2CC3=C(C=CC4=CC=CC=C43)O)O,,,,,,
4187,14188,"1-Imidazolidinecarboxylic acid, 2,5-dioxo-4,4-diphenyl-, ethyl ester",CCOC(=O)N1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4188,14189,CID 14189,COC1=CC=C(C=C1)C(=C(C2=CC(=CC=C2)F)Br)C3=CC=CC=C3,,,,,,
4189,14190,Pyritinol,CC1=NC=C(C(=C1O)CO)CSSCC2=CN=C(C(=C2CO)O)C,,,,,,
4190,14191,"(4-(2,5-Dimethoxyphenyl)-4-hydroxy-4-phenyl-2-butyl)trimethylammonium iodide",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)[N+](C)(C)C.[I-],,,,,,
4191,14192,"[4-(2,5-Dimethoxyphenyl)-4-hydroxy-4-phenylbutan-2-yl]-trimethylazanium",CC(CC(C1=CC=CC=C1)(C2=C(C=CC(=C2)OC)OC)O)[N+](C)(C)C,,,,,,
4192,14193,CID 14193,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C.[Na+],,,,,,
4193,14194,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(3-(dimethylamino)propyl)-5-phenyl-",CN(C)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
4194,14195,"1,1'-Dibenzyl-4,4'-bipyridinium dichloride",C1=CC=C(C=C1)C[N+]2=CC=C(C=C2)C3=CC=[N+](C=C3)CC4=CC=CC=C4.[Cl-].[Cl-],,,,,,
4195,14196,Benzyl Viologen,C1=CC=C(C=C1)C[N+]2=CC=C(C=C2)C3=CC=[N+](C=C3)CC4=CC=CC=C4,,,,,,
4196,14197,14-Hydroxy-3-oxocard-20(22)-enolide,C[C@]12CCC(=O)C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C,,,,,,
4197,14198,"(1-Acetyl-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4C(=O)C)N,,,,,,
4198,14199,Pigment Red 49:1,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.[Ba+2],,,,,,
4199,14200,"1-Naphthalenesulfonic acid, 2-[(2-hydroxy-1-naphthalenyl)azo]-",C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)O)O,,,,,,
4200,14201,Pigment Red 49:2,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.[Ca+2],,,,,,
4201,14202,"2-{1,10-Dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl}-2-oxoethyl 2,2-dimethylpropanoate",CC12CC(C3C(C1CCC2(C(=O)COC(=O)C(C)(C)C)O)CCC4=CC(=O)C=CC34C)O,,,,,,
4202,14203,CID 14203,CC(=O)O[C@@H]1[C@@H]([C@]2(CCC3C([C@@]24[C@@H]1O4)CC[C@]5([C@@]3(CC[C@@H](C5)O)C)O)C)C6=COC(=O)C=C6,,,,,,
4203,14204,CID 14204,C1CN(CCN1CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F)CCO.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
4204,14205,"7-chloro-5-(2-fluorophenyl)-1-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-3H-1,4-benzodiazepin-2-one",C1CN(CCN1CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F)CCO,,,,,,
4205,14206,Azanium;carbamate;hydrate,C(=O)(N)[O-].[NH4+].O,,,,,,
4206,14207,CID 14207,COP(=O)(OC)S,,,,,,
4207,14208,CID 14208,CC[SnH](CC)CC.CC[SnH](CC)CC.O,,,,,,
4208,14209,"Phosphorodithioic acid, O,O-dimethyl S-carboxymethyl ester",COP(=S)(OC)SCC(=O)O,,,,,,
4209,14210,Omethoate,CNC(=O)CSP(=O)(OC)OC,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... . /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for OMETHOATE (10 total), please visit the HSDB record page.']","['Plasma & tissue esterases are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paraoxonases. These enzymes are found in the plasma and liver & hydrolyze a large number of organophosphorus compounds ... by cleaving the phosphoester, anhydride, P-F, P-CN bonds. /Anticholinesterase agents/', 'These chemicals are detoxified by cytochrome p450 mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/', 'Urine was collected from two male rats 12, 24, and 48 hr after an oral dose of 50 mg/kg bw radiolabelled omethoate. The cumulative percentages of administered radiolabel excreted over the indicated times were 16, 19, and 30%. The metabolites found in a 24-hr composite urine sample by ion-exchange chromatography were:  O,O-dimethylphosphoric acid (34%), unknown A (52%),  O,O-dimethylphosphorothioic acid (9.5%), and unknown B (4.5%). ...In the /study on on pulmonary excretion/..., the predominant form of excreted radiolabel was unchanged parent compound (26-62%), with N-methyl-2-(methylsulfinyl)acetamide accounting for 16-36% and an O-demethylated omethoate for 4-9%. Pretreatment of animals for 14 days with unlabelled omethoate followed by a single labelled dose resulted in no significant difference from the results obtained after a single administration.', 'Dealkylation of omethoate was proposed to be a significant detoxification mechanism on the basis of information from assays in fly heads. Oxidative metabolism of omethoate results in the de-N-methyl derivative, which is as toxic as the parent compound although less active as a cholinesterase inhibitor. Kinetic studies indicated that the reaction between acetylcholinesterase and omethoate was irreversible and bimolecular. Omethoate was 75-100 times more potent than dimethoate in inhibiting rat brain acetylcholinesterase activity.', 'Omethoate is a known human metabolite of Dimethoate.']",
4210,14211,Guancydine,CCC(C)(C)N=C(N)NC#N,,,,,,
4211,14212,Di(propylsulfonyl)ethene,CCCS(=O)(=O)C=CS(=O)(=O)CCC,,,,,,
4212,14213,Ammonium oxalate,C(=O)(C(=O)[O-])[O-].[NH4+].[NH4+],,,"['Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) (See all compounds classified as Reducing Agents.)']","['OXALATES ARE WELL ABSORBED FROM THE INTESTINE. /THEY ARE/...NOT BURNED IN THE BODY, BUT UNITE WITH TISSUE & BLOOD CALCIUM & ARE EXCRETED BY THE KIDNEY. /OXALATES/']",,
4213,14214,N-Methyldiacetamide,CC(=O)N(C)C(=O)C,,,,,,
4214,14215,Pebulate,CCCCN(CC)C(=O)SCCC,,,,"['In the rat, pebulate was readily absorbed, distributed, metabolized and eliminated, primarily in urine, feces, and CO2. Less than 3% was detected in total tissues. Major metabolites were identified in the urine as pebulate mercapturate, hydroxylated pebulate, butylamine and ethylbutylamine, hydroxyethylbutylamine, and hydroxylated pebulate mercapturate.', '...About 50% of /SRP: labeled/ compound administered to rats was expired as carbon dioxide in three days, about 25% /SRP: of labeled compound/ was excreted in the urine and 5% in the feces.', 'In adult rats...tissue accumulation studies showed that pebulate was absorbed and distributed throughout whole body with highest concentrations in the liver and blood. The accumulation of radioactivity in most internal organs increased with increasing dosages... This relationship is approximately linear between the dosages used. The biological half life in these organs was between 2-3.6 days.', 'Pebulate, EPTC, cycloate, butylate and vernolate (each at 0.3 mg, replicated 4 times,) were administered one time only as emulsifiable concentrates (1/100 aqueous dilution of a (14)C-labelled) to non-occluded skin of CD Crl:CD(SD)BR rats (10/compound). Evaluation was 10 hours after treating. Recovery of radioactivity averaged 76.1%, 93.7%, 94.9%, 95.4% and 92.9% for EPTC, cycloate, butylate, pebulate and vernolate, respectively. The high proportion of the applied dose for all 5 thiocarbamates was from the non-occlusive cover, indicating that a large percentage of the applied dose volatilized from the skin surface (captured by active carbon filters). EPTC recovery was comparatively lower due to its greater volatility and the volatility occurred during dosing, rather than during the 10 hour exposure. Cycloate absorption (material found in systemic circulation) was 15.90%, compared with 9.9%, 7.35%, 5.76% and 4.0% for pebulate, vernolate, EPTC and butylate, respectively. For pebulate, radioactivity was recovered in the following percentages: skin wash, 4.26%; non-occlusive cover, 79.37%; application site, 1.72%; untreated skin, 0.09%; total not absorbed, 85.45%; urine, 3.11%; feces, 0.14%; cage wash, 0.40%; carbon dioxide, 1.32%; expired volatiles, 0.14%; carcass, 4.81%; total absorbed dose, 9.90%; total recovered, 95.35%.']","['In the rat, pebulate was readily absorbed, distributed, metabolized and eliminated, primarily in urine, feces, and CO2. Less than 3% was detected in total tissues. Major metabolites were identified in the urine as pebulate mercapturate, hydroxylated pebulate, butylamine and ethylbutylamine, hydroxyethylbutylamine, and hydroxylated pebulate mercapturate.', 'Analysis of /adult rat/ urine samples revealed an extensive labeling of urinary constituents, such as urea, and many amino acids. ... Identification of labeled volatile cmpd in the urine revealed the presence of 0.3-2.8% as unchanged pebulate, and also a small amount of (14)C propylmercaptan and (14)C propanol. These results indicated a hydrolytic cleavage of the thiocarbamate molecule to propylmercaptan which was further converted to propanol by transthiolation. The propanol was then oxidized to a C-3 acid and entered a metabolic pool. Hydrolysis of the urine sample with strong acid converted some nonvolatile labeled metabolites to steam-volatile, isooctane-extractable metabolites, indicating that the pebulate molecule had undergone conjugation.', 'Pebulate is metabolized to the sulfoxide by mouse liver microsome-NADPH system, living mice, and photolysis. It is metabolized to sulfoxone and carbon dioxide in living mice. After oxidation to the sulfoxide, cleavage by the GSH-S-transferase system occurred with...pebulate. Mercaptans were released. /From table/']",['In adult rats...tissue accumulation studies showed that pebulate was absorbed and distributed throughout whole body with highest concentrations in the liver and blood. The accumulation of radioactivity in most internal organs increased with increasing dosages... This relationship is approximately linear between the dosages used. The biological half life in these organs was between 2-3.6 days.']
4215,14216,2-Ethyl-N-methylhexanamide,CCCCC(CC)C(=O)NC,,,,,,
4216,14217,Divinyl sulfoxide,C=CS(=O)C=C,,,,,,
4217,14218,"3-Hydroxy-2,2-dimethylpropyl 3-hydroxy-2,2-dimethylpropanoate",CC(C)(CO)COC(=O)C(C)(C)CO,,,,,,
4218,14219,Metformin hydrochloride,CN(C)C(=N)N=C(N)N.Cl,['Treatment of polycystic ovary syndrome'],,['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)'],"['Metformin is slowly and incompletely absorbed from the GI tract, mainly from the small intestine; absorption is complete within 6 hours. The absolute oral bioavailability of the drug under fasting conditions is reported to be approximately 50-60% with metformin hydrochloride doses of 0.5-1.5 g; binding of the drug to the intestinal wall may explain the difference between the amount of drug absorbed (as determined by the urinary and fecal excretion of unchanged drug) and the amount bioavailable in some studies. In single-dose studies with metformin hydrochloride conventional tablets doses of 0.5-1.5 g or 0.85-2.55 g, plasma metformin concentrations did not increase in proportion to increasing doses, suggesting an active saturable absorption process. Similarly, in single-dose studies with an extended-release tablet preparation (Glumetza) at doses of 0.5-2.5 g, plasma metformin concentrations did not increase in proportion to increasing doses. At steady state after administration of a metformin hydrochloride extended-release tablet preparation (Glucophage XR), the AUC and peak plasma concentrations were not dose proportional within the range of 0.5-2 g. However, limited data from studies in animals and in human intestinal cell cultures suggest that transepithelial transfer of metformin in the intestine may occur through a passive, nonsaturable mechanism, possibly involving a paracellular route. In several studies with another metformin hydrochloride extended-release tablet preparation (Fortamet) using doses of 1-2.5 g, metformin exposure was dose-related.', 'Following oral administration of metformin hydrochloride (0.5-1.5 g) as conventional tablets in healthy individuals or in patients with type 2 diabetes mellitus, plasma concentrations decline in a triphasic manner. Following multiple-dose administration of metformin hydrochloride (500 mg twice daily for 7-14 days) as conventional tablets in a limited number of patients with type 2 diabetes mellitus, peak plasma concentrations remained unchanged, but trough drug concentrations were higher than with single-dose administration, suggesting some drug accumulation in a peripheral tissue compartment. No accumulation of metformin appears to occur following repeated oral doses of the drug as extended-release tablets. The principal plasma elimination half-life of metformin averages approximately 6.2 hours; 90% of the drug is cleared within 24 hours in patients with normal renal function. The decline in plasma metformin concentrations is slower after oral than after IV administration of the drug, indicating that elimination is absorption rate-limited. Urinary excretion data and data from whole blood indicate a slower terminal-elimination phase half-life of 8-20 hours (e.g., 17.6 hours)1 suggesting that the erythrocyte mass may be a compartment of distribution.', 'Metformin is distributed rapidly in animals and humans into peripheral body tissues and fluids, particularly the GI tract; the drug also appears to distribute slowly into erythrocytes and into a deep tissue compartment (probably GI tissues). The highest tissue concentrations of metformin (at least 10 times the plasma concentration) occur in the GI tract (e.g., esophagus, stomach, duodenum, jejunum, ileum), with lower concentrations (twice the plasma concentration) occurring in kidney, liver, and salivary gland tissue. The drug distributes into salivary glands with a half-life of about 9 hours. Metformin concentrations in saliva are tenfold lower than those in plasma and may be responsible for the metallic taste reported in some patients receiving the drug. Any local effect of metformin on glucose absorption in the GI tract may be associated with the relatively high GI concentrations of the drug compared with those in other tissues. It is not known whether metformin crosses the blood-brain barrier or the placenta in humans or if the drug is distributed into human milk; however, in lactating rats, metformin is distributed into breast milk at levels comparable to those in plasma.', 'Renal clearance is approximately 3.5 times greater than creatinine clearance, indicating that tubular secretion is the principal route of metformin elimination. Following a single 850-mg oral dose of metformin hydrochloride, renal clearance averaged 552, 491, or 412 mL/minute in nondiabetic adults, diabetic adults, or healthy geriatric individuals, respectively. Renal impairment results in increased peak plasma concentrations of metformin, a prolonged time to peak plasma concentration, and a decreased volume of distribution. Renal clearance is decreased in patients with renal impairment (as measured by decreases in creatinine clearance) and, apparently because of reduced renal function with age, in geriatric individuals. In geriatric individuals, decreased renal and plasma clearance of metformin also results in increased plasma concentrations of the drug; volume of distribution remains unaffected.', 'For more Absorption, Distribution and Excretion (Complete) data for METFORMIN (12 total), please visit the HSDB record page.']",['Metformin is not metabolized in the liver or GI tract and is not excreted in bile; no metabolites of the drug have been identified in humans.'],"['The principal plasma elimination half-life of metformin averages approximately 6.2 hours ... .', 'The drug distributes into salivary glands with a half-life of about 9 hours.']"
4219,14220,DL-Methionine methylsulfonium chloride,C[S+](C)CCC(C(=O)O)N.[Cl-],,,,,,
4220,14221,"N,N-Dimethylheptanamide",CCCCCCC(=O)N(C)C,,,,,,
4221,14222,Triisobutylamine,CC(C)CN(CC(C)C)CC(C)C,,,,,,
4222,14223,N-Nitrosodiethanolamine,C(CO)N(CCO)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","[""N-Nitrosodiethanolamine (NDELA) was administered to rats whose bile was drained into the duodenum of a second group of animals, in which the natural bile flow was ligated, thus simulating enterohepatic circulation. The presence of NDELA and its metabolite N-(2-hydroxyethyl)-N-(carboxymethyl)nitrosamine in the urine of the bile-recipient rats indicated that NDELA was first excreted into the bile and then reabsorbed from the duodenum into the bloodstream. The enterohepatic recycling of NDELA may be a factor in the compound's known hepatocarcinogenicity."", 'After ip injection of 400 mg/kg body weight 3- (14)C-NMOR to rats, 3.3% of the label was excreted as (14)CO2 and 81% in the urine over 24 hours; 24% of the radioactivity was recovered as unchanged NMOR and 15% as N-nitrosodiethanolamine.', 'Although N-nitrosamines are rapidly and fairly evenly distributed throughout the bodies of rats after injection, the acute toxic damage they produce is more severe in the liver than elsewhere, and tumors following chronic exposure are confined mainly to the liver and kidney. /N-nitrosamines/', 'Rats were admin N-nitrosodiethanolamine (NDELA) iv or cutaneously. Blood & liver were analyzed for NDELA various times after admin. The excretion of NDELA & its acidic metabolite N-(2-hydroxyethyl)-N-carboxymethylnitrosamine (ECMN) was determined in urine 24 hr after treatment. The semilogarithmic blood concn-time plot after iv admin showed a triphasic profile indicating that a 3-compartment model may adequately describe the kinetics. After cutaneous application NDELA was rapidly absorbed through the skin, & the absolute bioavailability was calculated to be 27% from blood data, & to be 32% (NDELA & ECMN) from urine data. Hepatic NDELA levels reflected blood levels after both treatments, indicating that this organ does not accumulate NDELA to a significant extent. Urinary excretion of unchanged NDELA after iv & cutaneous admin was 83 & 2.5% of the admin dose, respectively. ECMN excretion was 4.9 & 2.5% of the admin dose after iv & cutaneous admin, respectively.', 'For more Absorption, Distribution and Excretion (Complete) data for N-NITROSODIETHANOLAMINE (11 total), please visit the HSDB record page.']","['N-nitroso-2-hydroxymorpholine, a mutagenic metabolite of N-nitrosomorpholine and N-nitrosodiethanolamine, reacted with deoxyguanosine at pH 7, 37 C, to give 3-(2-deoxy-beta-D-erythropentofuranosyl)-6,7-dihydro-6,7-dihydrox-yimidazo- (1,2-a)pyurine-9(3H)one, which is also formed by reaction of deoxyguanosine with glyoxal. The results suggest that this adduct might be involved in DNA binding by N-nitrosomorpholine and N-nitrosodiethanolamine.', 'Nitrosodiethanolamine was not metabolized by rat liver microsomes, but was metabolized by hepatocytes from the rats. In this case, a mechanism other than oxidation at the alpha-position may be responsible for its carcinogenic action.', 'The metabolism of N-nitrosodiethanolamine (NDELA) was studied to assess whether the formation of the beta-oxidated metabolites N-(2-hydroxyethyl)-N-(formylmethyl)nitrosamine (EFMN) and N-(2-hydroxyethyl)-N-(carboxymethyl)nitrosamine (ECMN) is involved in the mechanism of tumor induction in various animal species with different susceptibility to NDELA carcinogenicity. In vitro studies using liver S9 fractions from rats, hamster, B6C3F1 and CD-1 mice and rabbits showed that all the animal species metabolize NDELA through the beta-oxidation pathway, although to different extents. Urinary excretion of NDELA and its metabolite ECMN in rats, hamsters and mice after 5 mg/L suggest there is no correlation between carcinogenesis by NDELA and its beta-oxidation. ...', 'N-nitrosodiethanolamine is converted to N-(2-hydroxyethyl)-N-(formylmethyl)nitrosamine (EFMN) and N-(2-hydroxyethyl)-N-carboxymethyl) nitrosamine (ECMN) by rat S9 liver preparation as a result of beta-oxidation. The beta-oxidized metabolites were isolated and identified by gas chromatography-mass spectrometry (GC-MS) by comparison with authentic standards. An original gas chromatographic method with thermal energy detection was set up to measure both metabolites quantitatively. Under the experimental conditions described, when NAD+ was used as cofactor, about 1% of N-nitrosodiethanolamine (NDELA) was converted to EFMN and about half of the latter product was in turn converted to ECMN. The beta-nitrosamino aldehyde seems to transfer the nitroso moiety to other amino-compounds, even at physiological pH. ...', 'For more Metabolism/Metabolites (Complete) data for N-NITROSODIETHANOLAMINE (14 total), please visit the HSDB record page.']",
4223,14224,Tripropylborane,B(CCC)(CCC)CCC,,,,,,
4224,14225,Aluminum;butane,CCC[CH2-].CCC[CH2-].CCC[CH2-].[Al+3],,,,,,
4225,14226,Aluminum;hexane,CCCCC[CH2-].CCCCC[CH2-].CCCCC[CH2-].[Al+3],,,,,,
4226,14227,Trioctylamine,CCCCCCCCN(CCCCCCCC)CCCCCCCC,,,,,,
4227,14228,Hexyl octanoate,CCCCCCCC(=O)OCCCCCC,,,,,,
4228,14229,"2-Butenoic acid, 4-bromo-, methyl ester",COC(=O)C=CCBr,,,,,,
4229,14230,N-Butyl-N-methylformamide,CCCCN(C)C=O,,,,,,
4230,14231,"1,2-Octanediol",CCCCCCC(CO)O,,,,,,
4231,14232,"N,O-Dimethylhydroxylamine",CNOC,,,,,"['N, O-dimethylhydroxylamine was identified as a degradation product of linuron formed in the presence of extracts of Bacillus sphaericus ATCC 12123 by characterization of its dinitrophenyl derivative.']",
4232,14233,tert-Butylurea,CC(C)(C)NC(=O)N,,,,,,
4233,14234,"Isovaleric acid (4,7-dimethyl-1,6-octadien-3-YL) ester",CC(C)CC(=O)OC(C=C)C(C)CC=C(C)C,,,,,,
4234,14235,Myrcenyl acetate,CC(=O)OC(C)(C)CCCC(=C)C=C,,,,,,
4235,14236,Butyltin trichloride,CCCC[Sn](Cl)(Cl)Cl,,,,,,
4236,14237,"4,4-Dimethylpentanoic acid",CC(C)(C)CCC(=O)O,,,,,,
4237,14238,"1,3-Pentadiene, 2-methyl-",CC=CC(=C)C,,,,,,
4238,14239,CID 14239,CCOC(=O)CC(=NN=C(N)S)C,,,,,,
4239,14240,"N,N-Dimethyloctanamide",CCCCCCCC(=O)N(C)C,,,,,,
4240,14241,gamma-Ethylglutamate,CCOC(=O)CCC(C(=O)O)N,,,,,,
4241,14242,Dimethyl glutarate,COC(=O)CCCC(=O)OC,,,,,,
4242,14243,Hept-3-en-2-one,CCCC=CC(=O)C,,,,,,
4243,14244,5-Chlorovaleric acid,C(CCCl)CC(=O)O,,,,,,
4244,14245,2-Heptyne,CCCCC#CC,,,,,,
4245,14246,n-Amylhydrazine hydrochloride,CCCCCN[NH3+].[Cl-],,,,,,
4246,14247,Pentylhydrazine,CCCCCNN,,,,,,
4247,14248,Hex-3-enedinitrile,C(C=CCC#N)C#N,,,,,,
4248,14249,Dodecyltrimethylammonium bromide,CCCCCCCCCCCC[N+](C)(C)C.[Br-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
4249,14250,Cetrimide,CCCCCCCCCCCCCC[N+](C)(C)C.[Br-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
4250,14251,Trimethyltetradecylammonium,CCCCCCCCCCCCCC[N+](C)(C)C,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)', 'Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
4251,14252,CID 14252,CCCCCCCCCCCCCCCCS(=O)(=O)[O-].[Na+],,,,,,
4252,14253,1-Hexadecanesulfonic acid,CCCCCCCCCCCCCCCCS(=O)(=O)O,,,,,,
4253,14254,2-Decanol,CCCCCCCCC(C)O,,,,,,
4254,14255,9-Chlorononanoic acid,C(CCCCCl)CCCC(=O)O,,,,,,
4255,14256,Dodecanamide,CCCCCCCCCCCC(=O)N,,,,,,
4256,14257,Undecane,CCCCCCCCCCC,,,,"['Absorption of undecane occurs mainly by inhalation.', '... Pigs were exposed to JP-8 jet fuel-soaked cotton fabrics for 1 and 4 d with repeated daily exposures. Preexposed and unexposed skin was then dermatomed and placed in flow-through in vitro diffusion cells. Five cells with exposed skin and four cells with unexposed skin were dosed with a mixture of 14 different hydrocarbons (HC) consisting of nonane, decane, undecane, dodecane, tridecane, tetradecane, pentadecane, hexadecane, ethyl benzene, o-xylene, trimethyl benzene (TMB), cyclohexyl benzene (CHB), naphthalene, and dimethyl naphthalene (DMN) in water + ethanol (50:50) as diluent. Another five cells containing only JP-8-exposed skin were dosed solely with diluent in order to determine the skin retention of jet fuel HC. The absorption parameters of flux, diffusivity, and permeability were calculated for the studied HC. The data indicated that there was a two-fold and four-fold increase in absorption of specific aromatic HC like ethyl benzene, o-xylene, and TMB through 1- and 4-d JP-8 preexposed skin, respectively. Similarly, dodecane and tridecane were absorbed more in 4-d than 1-d JP-8 preexposed skin experiments. The absorption of naphthalene and DMN was 1.5 times greater than the controls in both 1- and 4-d preexposures. CHB, naphthalene, and DMN had significant persistent skin retention in 4-d preexposures as compared to 1-d exposures that might leave skin capable of further absorption several days postexposure. The possible mechanism of an increase in HC absorption in fuel preexposed skin may be via lipid extraction from the stratum corneum as indicated by Fourier transform infrared (FTIR) spectroscopy. This study suggests that the preexposure of skin to jet fuel enhances the subsequent in vitro percutaneous absorption of HC, so single-dose absorption data for jet fuel HC from naive skin may not be optimal to predict the toxic potential for repeated exposures. For certain compounds, persistent absorption may occur days after the initial exposure.', 'Dermal penetration and absorption of jet fuels in general, and JP-8 in particular, is not well understood, even though government and industry, worldwide, use over 4.5 billion gallons of JP-8 per year. Exposures to JP-8 can occur from vapor, liquid, or aerosol. Inhalation and dermal exposure are the most prevalent routes. JP-8 may cause irritation during repeated or prolonged exposures, but it is unknown whether systemic toxicity can occur from dermal penetration of fuels. The purpose of this investigation was to measure the penetration and absorption of JP-8 and its major constituents with rat skin, so that the potential for effects with human exposures can be assessed. We used static diffusion cells to measure both the flux of JP-8 and components across the skin and the kinetics of absorption into the skin. Total flux of the hydrocarbon components was 20.3 micrograms/sq cm/hr. Thirteen individual components of JP-8 penetrated into the receptor solution. The fluxes ranged from a high of 51.5 micrograms/sq cm/hr (an additive, diethylene glycol monomethyl ether) to a low of 0.334 micrograms/sq cm/hr (tridecane). Aromatic components penetrated most rapidly. Six components (all aliphatic) were identified in the skin. Concentrations absorbed into the skin at 3.5 hr ranged from 0.055 micrograms per gram skin (tetradecane) to 0.266 micrograms per gram skin (undecane). These results suggest: (1) that JP-8 penetration will not cause systemic toxicity because of low fluxes of all the components; and (2) the absorption of aliphatic components into the skin may be a cause of skin irritation.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', 'For more Absorption, Distribution and Excretion (Complete) data for n-Undecane (6 total), please visit the HSDB record page.']","['Alternative fuels are being considered for civilian and military uses. One of these is S-8, a replacement jet fuel synthesized using the Fischer-Tropsch process, which contains no aromatic compounds and is mainly composed of straight and branched alkanes. Metabolites of S-8 fuel in laboratory animals have not been identified. The goal of this study was to identify metabolic products from exposure to aerosolized S-8 and a designed straight-chain alkane/polyaromatic mixture (decane, undecane, dodecane, tridecane, tetradecane, pentadecane, naphthalene, and 2-methylnaphthalene) in male Fischer 344 rats. Collected blood and tissue samples were analyzed for 70 straight and branched alcohols and ketones ranging from 7 to 15 carbons. No fuel metabolites were observed in the blood, lungs, brain, and fat following S-8 exposure. Metabolites were detected in the liver, urine, and feces. Most of the metabolites were 2- and 3-position alcohols and ketones of prominent hydrocarbons with very few 1- or 4-position metabolites. Following exposure to the alkane mixture, metabolites were observed in the blood, liver, and lungs. Interestingly, heavy metabolites (3-tridecanone, 2-tridecanol, and 2-tetradecanol) were observed only in the lung tissues possibly indicating that metabolism occurred in the lungs. With the exception of these heavy metabolites, the metabolic profiles observed in this study are consistent with previous studies reporting on the metabolism of individual alkanes. Further work is needed to determine the potential metabolic interactions of parent, primary, and secondary metabolites and identify more polar metabolites. Some metabolites may have potential use as biomarkers of exposure to fuels.', 'Metabolism of undecane is likely to occur by hydroxylation to yield the corresponding alcohol.']",
4257,14258,"9-hexadecenoic acid, methyl ester, (9Z)-",CCCCCCC=CCCCCCCCC(=O)OC,,,,,,
4258,14259,Methyl arachidate,CCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
4259,14260,1-Tetradecene,CCCCCCCCCCCCC=C,,,,,"['CANDIDA GROWN IN MINERAL-SALTS HYDROCARBON MEDIUM USING 1-TETRADECENE AS SUBSTRATE. 1,2-DIOLS & OMEGA-UNSATURATED FATTY ACIDS DETERMINED.']",
4260,14261,Didecylamine,CCCCCCCCCCNCCCCCCCCCC,,,,,,
4261,14262,Methylenecyclobutane,C=C1CCC1,,,,,,
4262,14263,3-Methylcyclopentene,CC1CCC=C1,,,,,,
4263,14264,"1,3-Propane sultone",C1COS(=O)(=O)C1,,,,,,['HALF-LIFE IS 110 MIN AT 37 C IN PHOSPHATE BUFFER.']
4264,14265,2-Methylcyclopentanone,CC1CCCC1=O,,,,,,
4265,14266,2-Methyl-2-cyclopenten-1-one,CC1=CCCC1=O,,,,,,
4266,14267,"Aziridine, 1-butyl-",CCCCN1CC1,,,,,,
4267,14268,4-Bromopyridine,C1=CN=CC=C1Br,,,,,,
4268,14269,"4-Methyl-1,3-dioxane",CC1CCOCO1,,,,,,
4269,14270,"2,3-Dimethyl-2-cyclopenten-1-one",CC1=C(C(=O)CC1)C,,,,,,
4270,14271,N-(furan-2-ylmethylidene)hydroxylamine,C1=COC(=C1)C=NO,,,,,,
4271,14272,3-Vinylpyridine,C=CC1=CN=CC=C1,,,,,['3-Vinylpyridine is a known thirdhand smoke metabolite of Nicotine.'],
4272,14273,2-Pyridinecarboxaldehyde,C1=CC=NC(=C1)C=O,,,,,,
4273,14274,CID 14274,CC1=CC=C(C=C1)[O-].[Na+],,,,,,
4274,14275,5-Hydroxy-2-methylpyridine,CC1=NC=C(C=C1)O,,,,,,
4275,14276,Azocane,C1CCCNCCC1,,,,,,
4276,14277,"1,2-Dithiolane-4,4-dimethanol",C1C(CSS1)(CO)CO,,,,,,
4277,14278,"5-Hydroxymethyl-5-methyl-1,3-dioxane",CC1(COCOC1)CO,,,,,,
4278,14279,"3,4-Dibromo-1h-pyrrole-2,5-dione",C1(=C(C(=O)NC1=O)Br)Br,,,,,,
4279,14280,"2,4,5-Trimethylpyridine",CC1=CC(=NC=C1C)C,,,,,,
4280,14281,5-Iodocytosine,C1=NC(=O)NC(=C1I)N,,,,,,
4281,14282,4-Acetylpyridine,CC(=O)C1=CC=NC=C1,,,,,,
4282,14283,Cyclohexanecarboxamide,C1CCC(CC1)C(=O)N,,,,,,
4283,14284,4-Dimethylaminopyridine,CN(C)C1=CC=NC=C1,,,,,,
4284,14285,Nitrocyclohexane,C1CCC(CC1)[N+](=O)[O-],,,,,,
4285,14286,2-Acetylpyridine,CC(=O)C1=CC=CC=N1,,,,,,
4286,14287,2-Ethyl-6-methylpyridine,CCC1=CC=CC(=N1)C,,,,,,
4287,14288,"4-Methoxy-1,3,5-triazin-2-amine",COC1=NC=NC(=N1)N,,,,,,
4288,14289,Cyclohexyl isothiocyanate,C1CCC(CC1)N=C=S,,,,,,
4289,14290,4-Aminophenylarsenoxide,C1=CC(=CC=C1N)[As]=O,,,,,,
4290,14291,"3,5-Dimethyl-2-cyclohexen-1-one",CC1CC(=CC(=O)C1)C,,,,,,
4291,14292,"3,3-Dimethylglutarimide",CC1(CC(=O)NC(=O)C1)C,,,,,,
4292,14293,"2,3-Dichloro-N-methylmaleimide",CN1C(=O)C(=C(C1=O)Cl)Cl,,,,,,
4293,14294,"2,5-Dichlorostyrene",C=CC1=C(C=CC(=C1)Cl)Cl,,,,,,
4294,14295,2-Phenylpropan-1-ol,CC(CO)C1=CC=CC=C1,,,,,,
4295,14296,"2,3,5,6-Tetramethylpyrazine",CC1=C(N=C(C(=N1)C)C)C,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
4296,14297,"Cyclobutane-1,2-dicarboxylic acid",C1CC(C1C(=O)O)C(=O)O,,,,,,
4297,14298,Phenyltin trichloride,C1=CC=C(C=C1)[Sn](Cl)(Cl)Cl,,,,,,
4298,14299,"Cyclohexane, 1-methyl-4-(1-methylethenyl)-, cis-",CC1CCC(CC1)C(=C)C,,,,,,
4299,14300,4-Nitropyridine N-oxide,C1=C[N+](=CC=C1[N+](=O)[O-])[O-],,,,,,
4300,14301,N-Cyclohexylacetamide,CC(=O)NC1CCCCC1,,,,,,
4301,14302,Cyclohexyl carbamate,C1CCC(CC1)OC(=O)N,,,,,,
4302,14303,"1,2-Dithiolan-4-one, semicarbazone",C1C(=NNC(=O)N)CSS1,,,,,,
4303,14304,Dichloroethylphenylsilane,CC[Si](C1=CC=CC=C1)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
4304,14305,"5,6,7,8-Tetrahydro-2-naphthol",C1CCC2=C(C1)C=CC(=C2)O,,,,,,
4305,14306,3-Methylisoquinoline,CC1=CC2=CC=CC=C2C=N1,,,,,,
4306,14307,Methyl 4-chlorobenzoate,COC(=O)C1=CC=C(C=C1)Cl,,,,,,
4307,14308,"1,2-Dithiolane-3,5-dicarboxylic acid",C1C(SSC1C(=O)O)C(=O)O,,,,,,
4308,14309,p-Hydroxymercuribenzoic acid,C1=CC(=CC=C1C(=O)O)[Hg].O,,,['Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)'],,,
4309,14310,N-Butylaniline,CCCCNC1=CC=CC=C1,,,,,,
4310,14311,Butyl phenyl ether,CCCCOC1=CC=CC=C1,,,,,,
4311,14312,8-Hydroxyquinoline 1-oxide,C1=CC2=C(C(=C1)O)[N+](=CC=C2)[O-],,,,,,
4312,14313,7-Methylisatin,CC1=C2C(=CC=C1)C(=O)C(=O)N2,,,,,,
4313,14314,9-Methyl-6-(methylthio)-9H-purine,CN1C=NC2=C1N=CN=C2SC,,,,,,
4314,14315,1-Ethylnaphthalene,CCC1=CC=CC2=CC=CC=C21,,,,,,
4315,14316,3-Acetylthianaphthene,CC(=O)C1=CSC2=CC=CC=C21,,,,,,
4316,14317,"3,5-Dichloro-2-(trichloromethyl)pyridine",C1=C(C=NC(=C1Cl)C(Cl)(Cl)Cl)Cl,,,,,,
4317,14318,6-Methylisatin,CC1=CC2=C(C=C1)C(=O)C(=O)N2,,,,,,
4318,14319,3-Methyl-2-benzothiazolone hydrazone,CN1C2=CC=CC=C2SC1=NN,,,,,,
4319,14320,CID 14320,C1=CC=C(C(=C1)CN=C([NH3+])N)Cl.[Cl-],,,,,,
4320,14321,1-(2-Chlorobenzyl)guanidine,C1=CC=C(C(=C1)CN=C(N)N)Cl,,,,,,
4321,14322,Metolcarb,CC1=CC(=CC=C1)OC(=O)NC,,,,,,
4322,14323,"Butanamide, N-phenyl-",CCCC(=O)NC1=CC=CC=C1,,,,,,
4323,14324,"3-Azaspiro[5.5]undecane-2,4-dione",C1CCC2(CC1)CC(=O)NC(=O)C2,,,,,,
4324,14325,Diethyl(m-hydroxyphenyl)methylammonium chloride,CC[N+](C)(CC)C1=CC(=CC=C1)O.[Cl-],,,,,,
4325,14326,3-Hydroxyphenyl diethylmethylammonium,CC[N+](C)(CC)C1=CC(=CC=C1)O,,,,,,
4326,14327,4-Cyclohexylphenol,C1CCC(CC1)C2=CC=C(C=C2)O,,,,,,
4327,14328,"3',4'-Dimethoxyacetophenone",CC(=O)C1=CC(=C(C=C1)OC)OC,,,,,,
4328,14329,Debrisoquin hydrobromide,C1C[NH+](CC2=CC=CC=C21)C(=N)N.[Br-],,,,,,
4329,14330,Quinolylnitrone,C1=CC=C2C(=C1)C=CC(=N2)C=NO,,,,,,
4330,14331,"3-Azabicyclo(3.2.2)nonane, 3-(chloroacetyl)-",C1CC2CCC1CN(C2)C(=O)CCl,,,,,,
4331,14332,"3,5-Dimethoxybenzoic acid",COC1=CC(=CC(=C1)C(=O)O)OC,,,,,,
4332,14333,Diphenyl selenide,C1=CC=C(C=C1)[Se]C2=CC=CC=C2,,,,,,
4333,14334,"6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydrobenzofuran-2(4H)-one",CC1(CC(CC2(C1=CC(=O)O2)C)O)C,,,,,,
4334,14335,N'-Nitrosoanabasine,C1CCN(C(C1)C2=CN=CC=C2)N=O,,,,,"[""N'-nitrosoanabasine has known human metabolites that include N'-nitrosoanabasine, N-glucuronide.""]",
4335,14336,2-Bromofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)Br,,,,,,
4336,14337,Cycloate,CCN(C1CCCCC1)C(=O)SCC,,,,"['Using (14)C-ring-labeled cycloate /it was/ reported that about 82% of the radioactivity was excreted in rat urine & remainder in feces. No significant amt of radioactivity were found in resp CO2, indicating that the cyclohexyl ring was not broken.', 'Cycloate is rapidly absorbed by leaves ... . when applied to soil, cycloate is rapidly taken up by the roots of sugarbeets & translocated upward to the stems & leaves. ... no unchanged cycloate could be detected 3 days after treatment showing that it does not persist at all in plants.', 'After intragastric admin of 1000 mg/kg cycloate in rats, cycloate blood concn were 3.16 ug/mL after 30 min, 10 ug/mL after 1-6 hr, & 1.56 ug/mL after 18 hr. Shows rapid GI tract resorption, & rapid elimination from organism. Highest concn were found in lungs, kidneys, liver, heart & spleen after 1 hr, & in brain after 2 hr. A second maximum was found in spleen & lungs after 3 hr. Cycloate was not found in organs & blood after 24 hr.', '... Not absorbed percutaneously.', 'For more Absorption, Distribution and Excretion (Complete) data for CYCLOATE (13 total), please visit the HSDB record page.']","['Ethylcyclohexylamine was found as a metabolite /of cycloate/ in rat urine, providing direct evidence for cleavage at the carbonyl carbon and nitrogen bond in the thiocarbamate molecule.', 'Mouse liver microsome NADPH system showed sulfoxide degradation product of cycloate.', 'Cycloate is rapidly metabolized in the roots and leaves of sugarbeets to ethyl-cyclohexylamine, carbon dioxide, amino acids, sugars ...', '... The urinary metabolites incl cyclohexylamine and dicyclohexylamine...', 'For more Metabolism/Metabolites (Complete) data for CYCLOATE (15 total), please visit the HSDB record page.']","['/Rats & mice/ were treated with single oral doses of 10, 40 or 160 mg/kg radiolabeled cycloate. ... Plasma half-life values were approximately 60 hours for the rat and 30 hours for the mouse. ...']"
4337,14338,"4,4'-Dimethyl-2,2'-bipyridine",CC1=CC(=NC=C1)C2=NC=CC(=C2)C,,,,,,
4338,14339,2-Butylnaphthalene,CCCCC1=CC2=CC=CC=C2C=C1,,,,,,
4339,14340,3-(4-Hydroxy-3-methoxyphenyl)propionic acid,COC1=C(C=CC(=C1)CCC(=O)O)O,,,,,['Dihydroferulic acid has known human metabolites that include 3-[3-Methoxy-4-(sulfooxy)phenyl]propanoic acid.'],
4340,14341,"2-Ethyl-2-phenyl-1,3-dioxolane-4-methanol",CCC1(OCC(O1)CO)C2=CC=CC=C2,,,,,,
4341,14342,Diphenyltin dichloride,C1=CC=C(C=C1)[Sn](C2=CC=CC=C2)(Cl)Cl,,,,,,
4342,14343,5-Methyl-3-phenylisoxazole-4-carboxylic acid,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)O,,,,,,
4343,14344,"5,6,7,8-Tetrahydro-1-naphthyl methylcarbamate",CNC(=O)OC1=CC=CC2=C1CCCC2,,,,,,
4344,14345,"3',4',5'-Trimethoxyacetophenone",CC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
4345,14346,4-Aminobenzophenone,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)N,,,,,,
4346,14347,4-Hydroxybenzophenone,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)O,,,,,"['4-Hydroxybenzophenone has known human metabolites that include (2S,3S,4S,5R)-6-(4-Benzoylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
4347,14348,4-(Dimethylamino)biphenyl,CN(C)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
4348,14349,N-Benzyloxycarbonylglycine,C1=CC=C(C=C1)COC(=O)NCC(=O)O,,,,,,
4349,14350,Caryophyllene epoxide,CC1(CC2C1CCC3(C(O3)CCC2=C)C)C,,,,,['14-HYDROXYCARYOPHYLLENE OXIDE WAS ISOLATED FROM THE URINE OF RABBITS TREATED WITH (-)-CARYOPHYLLENE THE X-RAY CRYSTAL STRUCTURE OF 14-HYDROXYCARYOPHYLLENE (AS ACETATE DERIVATIVE) WAS REPORTED. THE METABOLISM WAS SHOWN TO PROGRESS THROUGH (-)-CARYOPHYLLENE OXIDE SINCE THE LATTER COMPOUND ALSO AFFORDED 14-HYDROXYCARYOPHYLLENE AS A METABOLITE.'],
4350,14351,"6H-Dibenzo(a,c)cyclohepten-6-one, 5,7-dihydro-",C1C(=O)CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
4351,14352,"4-Biphenylamine, 2'-nitro-",C1=CC=C(C(=C1)C2=CC=C(C=C2)N)[N+](=O)[O-],,,,,,
4352,14353,9-(2-Chloroethyl)carbazole,C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCl,,,,,,
4353,14354,"4-Biphenylamine, 3'-nitro-",C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(C=C2)N,,,,,,
4354,14355,"2-(4-Chlorophenyl)-1,3-benzoxazole",C1=CC=C2C(=C1)N=C(O2)C3=CC=C(C=C3)Cl,,,,,,
4355,14356,Benzoic acid nitrogen mustard,C1=CC(=CC=C1C(=O)O)N(CCCl)CCCl,,,,,,
4356,14357,"2,6-Naphthalenedicarboxylic acid",C1=CC2=C(C=CC(=C2)C(=O)O)C=C1C(=O)O,,,,,,
4357,14358,"2,2'-Dithiodianiline",C1=CC=C(C(=C1)N)SSC2=CC=CC=C2N,,,,,,
4358,14359,CID 14359,COC1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
4359,14360,Bis(4-chlorophenyl) disulfide,C1=CC(=CC=C1SSC2=CC=C(C=C2)Cl)Cl,,,,,,
4360,14361,"2,3,4,5,6-Pentachlorophenol;phenylmercury",C1=CC=C(C=C1)[Hg].C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,,,,,,
4361,14362,Butallylonal,CCC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
4362,14363,"2-Cyclopentyl-2-methyl-1,3-propane-diol dicarbamate",CC(COC(=O)N)(COC(=O)N)C1CCCC1,,,,,,
4363,14364,4-Biphenylglyoxal hydrate,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C(O)O,,,,,,
4364,14365,"2-(2-Chloroethyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C(CCl)C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
4365,14366,Ethyl 2-(((benzyloxy)carbonyl)amino)acetate,CCOC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
4366,14367,CID 14367,CCC1(C(=O)NC(=O)NC1=O)CC#CC[NH+](C)C.[Cl-],,,,,,
4367,14368,"Barbituric acid, 5-(4-(dimethylamino)-2-butynyl)-5-ethyl-",CCC1(C(=O)NC(=O)NC1=O)CC#CCN(C)C,,,,,,
4368,14369,Bromindione,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)Br,,,,,,
4369,14370,"Benzoic acid, 2-benzoyl-5-chloro-",C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)Cl)C(=O)O,,,,,,
4370,14371,"Acetamide, N-(5-hydroxy-9H-fluoren-2-YL)-",CC(=O)NC1=CC2=C(C=C1)C3=C(C2)C=CC=C3O,,,,,['1-hydroxy-AFF is a known human metabolite of 2-Acetylaminofluorene.'],
4371,14372,Pyrovalerone hydrochloride,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2.Cl,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
4372,14373,Pyrovalerone,CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
4373,14374,"Indole, 3-((diethylamino)methyl)-5-nitro-",CCN(CC)CC1=CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
4374,14375,m-((2-Chloroethyl)(2-fluoroethyl)amino)hydrocinnamic acid,C1=CC(=CC(=C1)N(CCF)CCCl)CCC(=O)O,,,,,,
4375,14376,"HYDROCINNAMIC ACID, m-(BIS(2-FLUOROETHYL)AMINO)-",C1=CC(=CC(=C1)N(CCF)CCF)CCC(=O)O,,,,,,
4376,14377,N-(2-Bromoethyl)dibenzylamine hydrochloride,C1=CC=C(C=C1)C[NH+](CCBr)CC2=CC=CC=C2.[Cl-],,,,,,
4377,14378,"N,N-dibenzyl-2-bromoethanamine",C1=CC=C(C=C1)CN(CCBr)CC2=CC=CC=C2,,,,,,
4378,14379,CID 14379,C1=CC=C(C=C1)CN=C(S)SCC2=CC=CC=C2,,,,,,
4379,14380,Azabon,C1CC2CCC1CN(C2)S(=O)(=O)C3=CC=C(C=C3)N,,,,,,
4380,14381,Ipodate calcium,CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)[O-])I)I.CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)[O-])I)I.[Ca+2],,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
4381,14382,Triphenylarsine oxide,C1=CC=C(C=C1)[As](=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4382,14383,Hydroxy(triphenyl)arsanium,C1=CC=C(C=C1)[As+](C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
4383,14384,"Barbituric acid, 5-ethyl-5-(4-(1-pyrrolidinyl)-2-butynyl)-",CCC1(C(=O)NC(=O)NC1=O)CC#CCN2CCCC2,,,,,,
4384,14385,"3,3',4',5-Tetrachlorosalicylanilide",C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
4385,14386,Zolamine hydrochloride,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CS2.Cl,,,,,,
4386,14387,Zolamine,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=NC=CS2,,,,,,
4387,14388,"Benz(a)anthracene, 5,6-dihydro-5,6-epoxy-7-methyl-",CC1=C2C3C(O3)C4=CC=CC=C4C2=CC5=CC=CC=C15,,,,,,
4388,14389,"Butanamide, 4-(diethylamino)-N-(5-ethyl-2-methoxyphenyl)-",CCC1=CC(=C(C=C1)OC)NC(=O)CCCN(CC)CC,,,,,,
4389,14390,Amitriptynol,CN(C)CCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)O,,,,,,
4390,14391,"ETHYLENE, 1-BROMO-2,2-DIPHENYL-1-(m-FLUOROPHENYL)-",C1=CC=C(C=C1)C(=C(C2=CC(=CC=C2)F)Br)C3=CC=CC=C3,,,,,,
4391,14392,CID 14392,C[NH+](C)CCC=C1C2=CC=CC=C2SCC3=C1C(=CC=C3)Cl.[Cl-],,,,,,
4392,14393,CID 14393,CN(C)CCC=C1C2=CC=CC=C2SCC3=C1C(=CC=C3)Cl,,,,,,
4393,14394,"Dibenz(b,e)thiepin, 6,11-dihydro-2-chloro-11-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
4394,14395,"3-(2-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=CC=CC=C2CSC3=C1C=C(C=C3)Cl,,,,,,
4395,14396,Clobenzepam,CN(C)CCN1C2=C(C=C(C=C2)Cl)NC3=CC=CC=C3C1=O,,,,,,
4396,14397,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-2-chloro-10-(2-(dimethylamino)ethyl)-",CN(C)CCN1C2=CC=CC=C2NC3=C(C1=O)C=C(C=C3)Cl,,,,,,
4397,14398,"Benzoic acid, 4-(4-acetyl-3-iodophenoxy)-3,5-diiodo-",CC(=O)C1=C(C=C(C=C1)OC2=C(C=C(C=C2I)C(=O)O)I)I,,,,,,
4398,14399,N-Acetylmelphalan,CC(=O)NC(CC1=CC=C(C=C1)N(CCCl)CCCl)C(=O)O,,,,,,
4399,14400,Nialamide monohydrochloride,C1=CC=C(C=C1)C[NH2+]C(=O)CCNNC(=O)C2=CC=NC=C2.[Cl-],,,,,,
4400,14401,CID 14401,CC(=O)O.C1=CC=C(C=C1)[PbH](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4401,14402,Triphenylplumbane,C1=CC=C(C=C1)[PbH](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4402,14403,"4-(Methyloxy)-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene-1,11-dione",COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C5C=COC5OC4=C1,,,"['Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)']",,,
4403,14404,"2-(3,11-Dimethyl-6-oxobenzo[b][1,4]benzodiazepin-5-yl)ethyl-dimethylazanium chloride",CC1=CC2=C(C=C1)N(C3=CC=CC=C3C(=O)N2CC[NH+](C)C)C.[Cl-],,,,,,
4404,14405,"5-[2-(Dimethylamino)ethyl]-3,11-dimethylbenzo[b][1,4]benzodiazepin-6-one",CC1=CC2=C(C=C1)N(C3=CC=CC=C3C(=O)N2CCN(C)C)C,,,,,,
4405,14406,CID 14406,C[NH+](C)CCCC1C2=C(CSC3=C1C=C(C=C3)Cl)C=CC(=C2)Cl.[Cl-],,,,,,
4406,14407,"3-(2,9-dichloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCC1C2=C(CSC3=C1C=C(C=C3)Cl)C=CC(=C2)Cl,,,,,,
4407,14408,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-7-chloro-10-(2-(dimethylamino-2-methyl)ethyl)-",CC(CN1C2=C(C=C(C=C2)Cl)NC3=CC=CC=C3C1=O)N(C)C,,,,,,
4408,14409,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-7-chloro-10-(3-(dimethylamino)propyl)-",CN(C)CCCN1C2=C(C=C(C=C2)Cl)NC3=CC=CC=C3C1=O,,,,,,
4409,14410,Decabromodiphenyl oxide,C1(=C(C(=C(C(=C1Br)Br)Br)Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)Br,,,,"['After admin of (14)C-decabromodiphenyl oxide by intragastric intubation, all  (14)C activity was eliminated by way of feces within 2 days.', 'Several studies have demonstrated that decabromodiphenyl oxide (DBDPO) is very poorly absorbed in rats following oral exposure, generally <1% of the amount ingested.', 'Studies with (14)C labeled decabromodiphenyl oxide administered orally to Sprague Dawley rats indicate that more than 99% of the administered label was excreted in feces within 2 days following administration. An analysis of bromine in tissues following long term exposure in diets that provided 0.1 mg/kg per day to rats indicated a slight increase in bromine content in liver and adipose tissue at 90 days but no significant increase following 12 months of exposure. A significant increase in the bromine content of adipose, but no other tissues, was observed following a similiar dose of decabromodiphenyl oxide for 2 years but not at lower doses. There was no indication as to whether the failure of decabromodiphenyl oxide to accumulate in tissues was due to lack of absorption from the gastrointestinal tract or rapid metabolism and clearance.', 'Retention of decabromodiphenyl oxide in the brain of neonatal mice /had recently reported/. A single oral dose of 14(C)-labelled decabromodiphenyl oxide (purity >98%) was given on postnatal day 3, 10 or 19 to neonatal NMRI mice. Two litters in each age categories were given 1.5 14(C) MBq/kg body weight. The radioactivity in the brain was determined after 24 hours or 7 days after dosing in each of the two litters from the three different age categories. The results of the study showed that 14(C) was taken up into the brain, but there were differences in the amount of radioactivity found in the different age mice. The mice exposed on postnatal day 3 or 10 had around 4% of the total administered dose of 14(C) in the brain at 24-hours after dosing, whereas only 0.6 % of the total administered dose was found at 24-hours in the brains of mice dosed on postnatal day 19. At day-7 after administration the amount of radioactivity in the brain had increased by around a factor of 2 in the mice exposed on postnatal days 3 or 10, whereas no noticeable change in the amount of radioactivity present had occurred in brains of the mice dosed on postnatal day.', 'For more Absorption, Distribution and Excretion (Complete) data for DECABROMODIPHENYL ETHER (36 total), please visit the HSDB record page.']","['... The unconjugated phenolic fractions isolated from the feces were examined by gas chromatography/mass spectrometry (GC/MS). Methoxyhydroxylated penta- to heptabrominated diphenyl ethers were identified. ... The methoxy and hydroxy substituents were on the same phenyl ring when both were present. In addition, trace amounts of debrominated metabolites and nonaBDEs were also found in the feces and bile, indicating debromination may have been the first step in decaBDE metabolism. A small proportion of monohydroxylated metabolites was found in tissues and feces, indicating a role for reductive dehalogenation followed by an oxidation step or direct oxidative dehalogenation reactions.', 'About 20% of the decaBDE-derived radioactivity in urine from noncannulated rats was protein bound at 72 hours (compared to >73% not associated with protein). Eighteen percent of the bound material was bound to albumin, a serum protein with the ability to bind (nonspecific protein binding) short chain fatty acids. In cannulated rats, 18.2% of the decaBDE-derived radioactivity was unbound, and all the remaining 68.3% was associated with albumin. Two polar metabolites were noted but not identified. Under the assumption that the bound materials are less polar than the unbound materials, this observation supports the concept that a substantial portion, but not all, of the metabolites in the fecal matter originate from the bile. About 90% of the biliary radiolabel was associated with an unidentified 79-kDa protein, with the percent of bound label decreasing from 94 to 87% in bile samples pooled at 1-24 hours, 24-48 hours, and 48-72 hours. Approximately 17% of the protein-bound biliary radioactivity collected over the first 24 hours was parent compound (and the remainder was unidentified metabolites); no parent compound was detected at 48 and 72 hours. The percent of total bound label in the bile samples also declined over time. None of the label in the bile was found to be unbound.', 'The metabolism of unlabeled decaBDE /was evaluated/ in male rats after gavage or i.v. injection. Blood samples were collected at specific intervals for up to 6 days. Pooled plasma samples from all 6 days were extracted and decaBDE and its metabolites were quantified. Analysis of the pooled samples indicated that the major neutral compound in the plasma was unmodified decaBDE with trace amounts of three nonaBDEs. Thirteen phenolic metabolites were determined in the plasma of both the orally and i.v. dosed rats, but only three phenolic metabolites were present in sufficiently high concentration for further analysis. These metabolites were characterized as a hydroxy-octaBDE, an hydroxy-nonaBDE, and an hydroxy/methoxy hexaBDE. The relative amount of each metabolite recovered was not reported, but the concentration of phenolic radioactivity in the plasma collected 3 and 7 days after oral gavage was four times higher than that of the neutral compounds (i.e., the parent or debrominated decaBDE). The authors indicated that reductive debromination may be the first step in the metabolic pathway of decaBDE, followed by oxidation to form phenolic metabolites. It was also suggested that the hydroxy/methoxy metabolites were probably formed via an arene oxide hydrolyzed to a dihydrodiol and further rearomatized followed by a methylation reaction.', 'DecaBDE metabolism /was studied/ in rats given a single oral dose by gavage. Results indicated that in noncannulated rats about 90% of the dose was excreted in the feces within 3 days after a single oral dose of 14C-labeled decaBDE and the majority of this radioactivity (65%) represented decaBDE metabolites. Measurement of bile radioactivity indicated that close to 10% of the total dose was excreted in the bile during the same period, with almost all of the excreted dose in bile in the form of metabolites. Analysis of radiolabeled materials from tissues of these rats at day 3 after decaBDE administration revealed that 42% of the radioactivity in the liver represented solvent extractable lipid-bound metabolites and 30% was in the form of extractable unconjugated metabolites (4 and 26% of which were hydroxylated and neutral metabolites, respectively). Twenty-seven percent of the radiolabel could not be extracted and was tissue bound. Only 1% of the extractable material was water soluble. A larger percentage (61%) of the radioactivity in the small intestine wall was tissue bound. Lipid-bound metabolites accounted for 7% of the label, water-soluble compounds for 11%, and unbound parent or metabolites for 20%. The percentage of the radiolabel found as water-soluble compounds in the intestinal wall was 10 times greater than the water-soluble metabolites in the liver, providing some support for the hypothesis that oxidative metabolism can occur in the intestinal mucosa. Most of the radioactivity (71-80%) in the lung, adipose tissue, and kidney was unbound parent or metabolites; 15-21% represented lipid-bound metabolites, and 1.5-8% was tissue bound. Formation of adducts was indicative of covalent and/or noncovalent interactions with cellular macromolecules.', 'For more Metabolism/Metabolites (Complete) data for DECABROMODIPHENYL ETHER (19 total), please visit the HSDB record page.']","['A large percentage of absorbed decabromodiphenyl oxide (DBDPO) appears to be rapidly metabolized in the liver and excreted in the bile with a half-life of <24 hr.', 'Pulmonary clearance was evaluated in rats following a single intratracheal injection of 0 or 20 mg decabromodiphenyl oxide (DBDPO) dust (purity 77.4%) suspended in rat serum. Based on determinations of total bromine content in the lungs 3, 10, 30, 91, and 365 d following exposure, the half-life for elimination of DBDPO from the lungs was estimated to be 150 d.', '...The distribution and elimination half-lives of parent BDE-209 and several debrominated nonhydroxylated metabolites based on assays of plasma, excreta, liver, and carcass over a 21-day period that followed 21 days of dosing with 0.36 ug/day /were modeled/. The BDE-209 data showed the best fit to a biphasic depletion pattern. The distribution half-lives were 1.0 and 1.2 days for liver and plasma, respectively. The elimination half-lives for the same tissues were 20.2 and 75.9 days, respectively. A plasma first order half-life for octaBDE-207 (7.9 days) was twice that of BDE-209 (3.9 days). In the liver, the first order half-life estimates for congeners 208, 191, and 197 (approximately 6 days) were greater than those for 206 and 207 (approximately 1 day). First-order estimates for 207 and 196 were intermediate (4-5 days). These values reflect the behavior of the parent BDE-209 and the debrominated, nonhydroxylated metabolites after absorption, distribution, and excretion but do not reflect the distribution and elimination of the hydroxylated metabolites.', 'Half-lives were determined from the slope of the total concentration-time curve by linear regression. The disposition of decaBDE in male rats after oral dosing was described by a two-compartment model with t1/2 beta and t1/2 gamma values of 6.9 hours and 51 hours, respectively. The results from the i.v. study were consistent with a three-compartment model with half-lives (t1/2 alpha, t1/2 beta, and t1/2 gamma) of 1.6 hours, 12 hours, and 58 hours, respectively. This value is lower than the 15-day half-life for humans.', 'For more Biological Half-Life (Complete) data for DECABROMODIPHENYL ETHER (7 total), please visit the HSDB record page.']"
4410,14411,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-7-methylthio-",CN(C)CCN1C2=C(C=C(C=C2)SC)NC3=CC=CC=C3C1=O,,,,,,
4411,14412,1-[(4-Chlorophenyl)methyl]-2-(pyrrolidin-1-ium-1-ylmethyl)benzimidazole;chloride,C1CC[NH+](C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl.[Cl-],,,,,,
4412,14413,3-(2-(Diethylamino)ethyl)-5-ethyl-5-phenylbarbituric acid hydrochloride,CCC1(C(=O)NC(=O)N(C1=O)CCN(CC)CC)C2=CC=CC=C2.Cl,,,,,,
4413,14414,"1-[2-(Diethylamino)ethyl]-5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)N(C1=O)CCN(CC)CC)C2=CC=CC=C2,,,,,,
4414,14415,Lachesine chloride,CC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
4415,14416,Lachesine,CC[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
4416,14417,"Butyrophenone, 4'-fluoro-4-(9-methyl-3,9-diazaspiro(5.5)undec-3-yl)-, dihydrochloride",C[NH+]1CCC2(CC1)CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F.[Cl-].[Cl-],,,,,,
4417,14418,"1-(4-Fluorophenyl)-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)butan-1-one",CN1CCC2(CC1)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
4418,14419,"[(10S,13S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] acetate",CC(=O)O[C@H]1CCC2[C@@]1(CCC3C2CCC4[C@@]3(CCC(=O)C4)C)C,,,,,,
4419,14420,"Diethyl 2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2)C(=O)OCC)C)C,,,,,,
4420,14421,Aflatoxin G1,COC1=C2C3=C(C(=O)OCC3)C(=O)OC2=C4C5C=COC5OC4=C1,,,,"['Aflatoxins B1 & G1 & their metabolites exist in systemic blood as protein conjugates. This conjugation is specific to plasma albumin & proceeds enzymatically by liver & kidney cells. The albumin-aflatoxin conjugate is permanent & conjugation is an irreversible one.', 'Three groups of four Large White sows were fed diets containing  either 800 ppb purified aflatoxin B1 (group 1), 800 ppb purified aflatoxin G1 (group 2) or 400  ppb B1 and 400 ppb G1 (group 3) throughout gestation and lactation. A control group of four  sows was fed a diet free of aflatoxins. Aflatoxins B1 and M1 were found in milk samples taken  five and 25 days after parturition from the sows of group 1, aflatoxin G1 was present in the  milk of the sows of group 2 and all three aflatoxins were present in samples from the sows of  group 3. The concentration of aflatoxin in the milk was about 1000-fold lower than that in the  feed, but increased over the 25 days after parturition.']","['Yields aflatoxin B3 in rhizopus ... yields aflatoxin gm1 in rat. From table/', 'Aflatoxin B1, aflatoxin B2, & aflatoxin G1 admin iv to rats were rapidly metabolized to 7 groups of metabolites each, 6 of which were excreted in the bile. All 3 toxins were hydroxylated at the 2- & 4-positions. Bile from the rats that had received aflatoxin G1 contained glucuronide.', '...The incubation of human liver microsomes with aflatoxin B1 /or/ aflatoxin G1 ...yielded genotoxic metabolites that induced umuC gene expression in Salmonella typhimurium (TA-1535/psK1002). The rank order of genotoxic potency was ...aflatoxin B1>aflatoxin G1. Microsomal activation of the ...aflatoxins was completely inhibited upon incubation with polyclonal antibodies against p450NF, and immunochemical determinations of p450NF /(nifedipine oxidase)/ in the liver microsomal preparations were correlated with the microsomal activation of ...aflatoxin G1 and aflatoxin B1. P450NF converted the ...aflatoxins to genotoxic metabolites in a reconstituted monooxygenase system containing the purified enzyme and an NADPH generating system. ...']",
4421,14422,Quaterphenyl,C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC=CC(=C3)C4=CC=CC=C4,,,,,,
4422,14423,CID 14423,C[NH+](C)CCCOC1=CC=CC=C1NC(=O)C=CC2=CC=CC=C2.[Cl-],,,,,,
4423,14424,N-[2-[3-(dimethylamino)propoxy]phenyl]-3-phenylprop-2-enamide,CN(C)CCCOC1=CC=CC=C1NC(=O)C=CC2=CC=CC=C2,,,,,,
4424,14425,Dodecyl gallate,CCCCCCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O,,,,,,
4425,14426,Benzilyloxyethyldiethylmethylammonium chloride,CC[N+](C)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Cl-],,,,,,
4426,14427,"3-AZASPIRO(5.5)UNDECANE, 3-(3-((alpha,alpha,alpha-TRIFLUORO-m-TOLYL)OXY)PROPYL)-",C1CCC2(CC1)CCN(CC2)CCCOC3=CC=CC(=C3)C(F)(F)F,,,,,,
4427,14428,CID 14428,C[NH+](C)CCC=C1C2=C(C3=CC=CC=C3C=C2)SCC4=CC=CC=C41.[Cl-],,,,,,
4428,14429,CID 14429,CN(C)CCC=C1C2=C(C3=CC=CC=C3C=C2)SCC4=CC=CC=C41,,,,,,
4429,14430,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-8-trifluoromethyl-",CN(C)CCN1C2=C(C=CC(=C2)C(F)(F)F)NC3=CC=CC=C3C1=O,,,,,,
4430,14431,"(16R,17R)-3-cyclopentyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16,17-diol",CC12CCC3C(C1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)OC5CCCC5,,,,,,
4431,14432,Eddha,C1=CC=C(C(=C1)C(C(=O)O)NCCNC(C2=CC=CC=C2O)C(=O)O)O,,,"['Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)']",,,
4432,14433,"Acetamide, N,N-(bis(2-(diethylamino)ethyl))-2-(4-chlorophenoxy)-",CCN(CC)CCN(CCN(CC)CC)C(=O)COC1=CC=C(C=C1)Cl,,,,,,
4433,14434,Flurazepam hydrochloride,CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.Cl.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
4434,14435,"2-Methyl-4-oxo-3-(pent-2-en-1-yl)cyclopent-2-en-1-yl 3-(3-methoxy-2-methyl-3-oxoprop-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate",CCC=CCC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)C=C(C)C(=O)OC)C,,,,,,
4435,14436,"3-[(3S,5S,7S,10S,13R,14S,17R)-3,7,14-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)[C@H](C[C@H]5[C@@]3(CC[C@@H](C5)O)C)O,,,,,,
4436,14437,"Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-, (11beta)-",CC(=O)OCC(=O)C1CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C,,,,,,
4437,14438,CID 14438,C[NH+](C)CCC=C1C2=C(C=C(C=C2)Cl)SCC3=CC=CC=C31.C(CC(=O)[O-])C(=O)O,,,,,,
4438,14439,CID 14439,CN(C)CCC=C1C2=C(C=C(C=C2)Cl)SCC3=CC=CC=C31,,,,,,
4439,14440,"Ethanamine, N,N-dimethyl-2-(2-(phenylmethyl)phenoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)",C[NH+](C)CCOC1=CC=CC=C1CC2=CC=CC=C2.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
4440,14441,"A'-Neogammacerane, (17alpha)-",CC(C)C1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C,,,,,,
4441,14442,Dexamethasone 17-acetate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C)C)O)F)C,,,,,,
4442,14443,Diethylmalonimidatedihydrochloride,COC1CC2CN3CCC4=C(C3CC2C(C1OC)C(=O)OC)NC5=C4C=CC(=C5)OC,,,,,,
4443,14444,CID 14444,CC(CCC(=O)NCCOS(=O)(=O)[O-])C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C.[Na+],,,,,,
4444,14445,"2-[4-(3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethyl hydrogen sulfate",CC(CCC(=O)NCCOS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,,,,,,
4445,14446,"1,4-Bis[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-3,5-dihydroxycyclohexane-1-carboxylic acid",C1C(C(C(CC1(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O)O,,,,,,
4446,14447,3beta-Tosyloxycholest-5-ene,CC1C[C@@H](CC2=CCC3C(C12)CCC4(C3CC[C@@H]4C(C)CCCC(C)C)C)OS(=O)(=O)C5=CC=C(C=C5)C,,,,,,
4447,14448,"Cholest-5-en-3-ol (3beta)-, nonanoate",CCCCCCCCC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CCC4C(C)CCCC(C)C)C)C,,,,,,
4448,14449,"(3S,5R,10R,13R,14S,17R)-3-[(2S,5R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C=O)O)OC)O,,,,,,
4449,14450,Dihydroouabin,CC1[C@@H](C(C([C@H](O1)O[C@H]2C[C@H]([C@@]3(C4C(CC[C@@]3(C2)O)[C@]5(CCC([C@]5(CC4O)C)C6CC(=O)OC6)O)CO)O)O)O)O,,,,,,
4450,14451,Hydroxymethylmercury,C[Hg+].[OH-],,,,,,
4451,14452,Copper carbonate,C(=O)([O-])[O-].[Cu+2],,,,"['Rats were fed a diet contain basic cupric carbonate, at doses of 0, 70, 220, 670 and 2,000 ppm as cupric hydroxide and 12 months, the levels of copper in the blood and tissues were determined by atomic absorption analysis. At the same time, fluctuations in the levels of iron and zinc, which are essential elements, were determined in the tissues. Levels of copper, iron and zinc in blood were practically unchanged after feeding for 12 months at the highest dose, 2000 ppm. Copper in the liver increased markedly at doses of 670 and 2000 ppm from 1 month, and the level reached about 50 times that of the control group. The level of copper in the kidney significantly increased at larger doses than 670 ppm. Iron concentration in the kidney did not change at smaller doses than 220 ppm, but significantly decreased at higher doses than 670 ppm. The level of copper in the kidney increased only at the highest dose. /Basic cupric carbonate/']",,
4452,14453,"1,1,2,2-Tetrachloroethylsulfenyl chloride",C(C(SCl)(Cl)Cl)(Cl)Cl,,,,,,
4453,14454,"2,2-Dimethylbutan-1-ol",CCC(C)(C)CO,,,,,,
4454,14455,"2,2-Dimethylvaleric acid",CCCC(C)(C)C(=O)O,,,,,,
4455,14456,Methyltrimethoxysilane,CO[Si](C)(OC)OC,,,,,,
4456,14457,Ferric ammonium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.N.[Fe+3],,,,"[""The absorption and endogenous excretion of iron in man was studied by monitoring the fecal excretion of a stable iron isotope (58Fe). The study was carried out for 12 healthy volunteers who were divided into two groups. Group I received 58Fe-labeled ferric ammonium citrate (III) (58FeAC) equivalent to 6 mg of iron as a control, and group II received a combination of 500 mg of vitamin C and 58FeAC. A new formula was used to calculate the 58Fe absorption ratio reflecting the pool of iron in the intestinal cells, and the ratio was compared with that obtained from Janghorbani's formula, which has been used as one of the common methods. As a result, the 58Fe absorption ratio in group II was statistically significantly higher than that of group I (34.4 +/- 6.1% vs. 15.0 +/- 5.5%, M +/- SD) using Janghorbani's formula. The similar absorption ratio (34.1 +/- 6.0% vs. 14.8 +/- 5.5%) was also obtained by our new formula. Our results confirmed the previous findings that the availability of iron is stimulated by the supplementation of vitamin C. Both formulae agreed in the absorption of iron, indicating that the endogenous excretion of iron (caused by the desquamated cells) in the intestine does not disguise the iron absorption."", 'The absorption of a commercial brand of small-particle reduced iron was evaluated in 10 normal subjects. For each subject, the hemoglobin incorporation method was used to measure the true absorption of 60 mg of iron from either ferrous sulfate or ferric ammonium citrate. The iron tolerance test (ITT) was also studied for these two compounds and for reduced iron. This procedure consisted of measuring the area under the curve of plasma iron elevations at specified times for 6 hours, or the peak plasma iron, corrected by the plasma iron disappearance rate obtained from measuring plasma iron at specified times for 4 hours after the slow intravenous injection of 0.4 mg of iron as ferric citrate. Only the ITT was used to measure the absorption of 60 mg of reduced iron. Reference dose iron ascorbate absorption was measured in each subject. The absorption of ferric ammonium citrate and reduced iron was expressed as percent of dose and also as absorption percent of that of ferrous sulfate. Mean % geometric ""true absorptions"" were 39.0 for reference dose, 10.4 for FeSO4 and 2.4 for ferric ammonium citrate. The later was 23% that of FeSO4. By ITT the mean geometric % absorptions were 7.9, 3.7 and 3.2 for FeSO4, ferric ammonium citrate and reduced iron respectively, or 47 and 41% of that of FeSO4. We propose that the true absorption of the commercial brand of reduced iron tested was 20% that of FeSO4 based on the relation between the ITT results of reduced iron and the ITT and true absorption values of ferric ammonium citrate in relation to FeSO4.']",,
4457,14458,CID 14458,CCCCCCCCCCCC[S-].CCCCCCCCCCCC[S-].CCCC[Sn]CCCC,,,,,,
4458,14459,"O,O,S-Triethyl thiophosphate",CCOP(=O)(OCC)SCC,,,,,,
4459,14460,CID 14460,C[NH+](C)C(=N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
4460,14461,"1,1-Dimethylguanidine",CN(C)C(=N)N,,,,,,
4461,14462,"2,2,3,4-Tetramethylpentane",CC(C)C(C)C(C)(C)C,,,,,,
4462,14463,(3R)-3-hydroxy-L-aspartic acid,[C@H]([C@H](C(=O)O)O)(C(=O)O)N,,,,,,
4463,14464,Mannograno,CS(=O)(=O)OCC(C(C(C(COS(=O)(=O)C)O)O)O)O,,,,,,
4464,14465,Tetraethylurea,CCN(CC)C(=O)N(CC)CC,,,,,,
4465,14466,"N,N-Diethylguanidine nitrate",CC[NH+](CC)C(=N)N.[N+](=O)([O-])[O-],,,,,,
4466,14467,"1,1-Diethylguanidine",CCN(CC)C(=N)N,,,,,,
4467,14468,"2,3-Diaminobut-2-enedinitrile",C(#N)C(=C(C#N)N)N,,,,,,
4468,14469,Ethyl 2-bromo-2-cyanoacetate,CCOC(=O)C(C#N)Br,,,,,,
4469,14470,N-Methylpropionamide,CCC(=O)NC,,,,,,
4470,14471,N-Methylacrylamide,CNC(=O)C=C,,,,,,
4471,14472,Bromal fluoroacetamide,C(C(=O)NC(C(Br)(Br)Br)O)F,,,,,,
4472,14473,5-Methyl-3-methylene-2-hexanone,CC(C)CC(=C)C(=O)C,,,,,,
4473,14474,Trifluoromethyl trifluorovinyl ether,C(=C(F)F)(OC(F)(F)F)F,,,,,,
4474,14475,2-Methylheptanoic acid,CCCCCC(C)C(=O)O,,,,,,
4475,14476,3-tert-Butylamino-3-methyl-1-butene hydrochloride,CC(C)(C)[NH2+]C(C)(C)C=C.[Cl-],,,,,,
4476,14477,"N-tert-Butyl-1,1-dimethylallylamine",CC(C)(C)NC(C)(C)C=C,,,,,,
4477,14478,"2,5,5-Trimethylheptane",CCC(C)(C)CCC(C)C,,,,,,
4478,14479,"Butanenitrile, 4-(dichloromethylsilyl)-",C[Si](CCCC#N)(Cl)Cl,,,,,,
4479,14480,"1,3-Dichlorobutane",CC(CCCl)Cl,,,,,,
4480,14481,Malathion diacid,COP(=S)(OC)SC(CC(=O)O)C(=O)O,,,,,,
4481,14482,"N-(2,2-Dichloro-1-hydroxyethyl)-2-fluoroacetamide",C(C(=O)NC(C(Cl)Cl)O)F,,,,,,
4482,14483,CID 14483,CCCCN=C(N)N=C([NH3+])N.[Cl-],,,,,,
4483,14484,N-Acetylcysteamine,CC(=O)NCCS,,,,,,
4484,14485,"Acetic acid, (acetylthio)-",CC(=O)SCC(=O)O,,,,,,
4485,14486,Hex-2-enoic acid,CCCC=CC(=O)O,,,,,,
4486,14487,Diisobutylhydroaluminum,CC(C)C[AlH]CC(C)C,,,,,,
4487,14488,Aluminum hydride,[AlH3],,,,,,
4488,14489,Prenyl acetate,CC(=CCOC(=O)C)C,,,,,,
4489,14490,6-Hydroxyhexanoic acid,C(CCC(=O)O)CCO,,,,,,
4490,14491,"1,6-Hexanedithiol",C(CCCS)CCS,,,,,,
4491,14492,CID 14492,CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+],,,,,,
4492,14493,"1,8-Octanedithiol",C(CCCCS)CCCS,,,,,,
4493,14494,"1,10-Decanedithiol",C(CCCCCS)CCCCS,,,,,,
4494,14495,Mercury(2+);octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].[Hg+2],,,,,,
4495,14496,Cyclobutanone,C1CC(=O)C1,,,,,,
4496,14497,"2,3-Dihydrothiophene 1,1-dioxide",C1CS(=O)(=O)C=C1,,,,,,
4497,14498,"cis-1,2-Dimethylcyclopentane",C[C@@H]1CCC[C@@H]1C,,,,,,
4498,14499,"2,3-Epoxy-2-methylpentane",CCC1C(O1)(C)C,,,,,,
4499,14500,Cyclopentanone oxime,C1CCC(=NO)C1,,,,,,
4500,14501,Tetrahydrofurfuryl bromide,C1CC(OC1)CBr,,,,,,
4501,14502,Methylenecyclohexane,C=C1CCCCC1,,,,,,
4502,14503,"4,5-Dichloro-3H-1,2-dithiol-3-one",C1(=C(SSC1=O)Cl)Cl,,,,,,
4503,14504,1-Methylpyrrole-2-carboxaldehyde,CN1C=CC=C1C=O,,,,,,
4504,14505,2-Acetylfuran,CC(=O)C1=CC=CO1,,,,,,
4505,14506,Bis(1-aziridinyl) ketone,C1CN1C(=O)N2CC2,,,,,,
4506,14507,"1,1'-Sulfinylbis(aziridine)",C1CN1S(=O)N2CC2,,,,,,
4507,14508,5-Methyl-1H-pyrrole-2-carbaldehyde,CC1=CC=C(N1)C=O,,,,,,
4508,14509,"Mercury, bromophenyl-",C1=CC=C(C=C1)[Hg]Br,,,,,,
4509,14510,4-Aminothiophenol,C1=CC(=CC=C1N)S,,,,,,
4510,14511,3-Methyl-2-cyclohexen-1-one,CC1=CC(=O)CCC1,,,,,,
4511,14512,"4,6-Dihydroxypyrimidine",C1=C(N=CNC1=O)O,,,,,,
4512,14513,"3,4-Dichloro-1H-pyrrole-2,5-dione",C1(=C(C(=O)NC1=O)Cl)Cl,,,,,,
4513,14514,2-Acetyl-5-methylfuran,CC1=CC=C(O1)C(=O)C,,,,,,
4514,14515,"Cyclohexanemethanol, 2-methyl-",CC1CCCCC1CO,,,,,,
4515,14516,Methyl phenyl sulfoxide,CS(=O)C1=CC=CC=C1,,,,,,
4516,14517,4-Fluorobenzonitrile,C1=CC(=CC=C1C#N)F,,,,,,
4517,14518,"5-Methyl-5-nitro-1,3-dioxane",CC1(COCOC1)[N+](=O)[O-],,,,,,
4518,14519,2-Methoxy-5-methylphenol,CC1=CC(=C(C=C1)OC)O,,,,,,
4519,14520,Citiolone,CC(=O)NC1CCSC1=O,,,,,,
4520,14521,3-Methyl-3-azoniabicyclo(3.2.2)nonane iodide,C[NH+]1CC2CCC(C1)CC2.[I-],,,,,,
4521,14522,3-Methyl-3-azabicyclo[3.2.2]nonane,CN1CC2CCC(C1)CC2,,,,,,
4522,14523,N-(2-Fluoroethyl)-aniline hydrochloride,C1=CC=C(C=C1)[NH2+]CCF.[Cl-],,,,,,
4523,14524,N-(2-fluoroethyl)aniline,C1=CC=C(C=C1)NCCF,,,,,,
4524,14525,Fenchone,CC1(C2CCC(C2)(C1=O)C)C,,,,,,
4525,14526,2-Hydroxyquinoxaline,C1=CC=C2C(=C1)NC(=O)C=N2,,,,,,
4526,14527,(1-Ethylpropyl)benzene,CCC(CC)C1=CC=CC=C1,,,,,,
4527,14528,3-Phenyl-2-butenal,CC(=CC=O)C1=CC=CC=C1,,,,,,
4528,14529,2-(4-Methylphenyl)propan-2-ol,CC1=CC=C(C=C1)C(C)(C)O,,,,,,
4529,14530,"3',4'-Dihydroxyacetophenone",CC(=O)C1=CC(=C(C=C1)O)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
4530,14531,"Benzoic acid, 4-arsenoso-",C1=CC(=CC=C1C(=O)O)[As]=O,,,,,,
4531,14532,"4-Ethoxybenzene-1,2-diamine",CCOC1=CC(=C(C=C1)N)N,,,,,,
4532,14533,4-Aminophenylacetic acid,C1=CC(=CC=C1CC(=O)O)N,,,,,,
4533,14534,2-Hydroxy-1-naphthylammonium chloride,C1=CC=C2C(=C1)C=CC(=C2[NH3+])O.[Cl-],,,,,,
4534,14535,1-Amino-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2N)O,,,,,['1-Amino-2-naphthol is a known human metabolite of Sudan I.'],
4535,14536,"2,4-Dimethylquinoline",CC1=CC(=NC2=CC=CC=C12)C,,,,,,
4536,14537,Tetrachlorocatechol,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)O)O,,,,,,
4537,14538,"delta(sup 2)-1,3,4-OXADIAZOLIN-5-ONE, 2-PHENYL-",C1=CC=C(C=C1)C2N=NC(=O)O2,,,,,,
4538,14539,CID 14539,C1=CC=C2C(=C1)N=C(C(=N2)S)S,,,,,,
4539,14540,3-Azabicyclo(3.2.2)nonane-3-acetonitrile,C1CC2CCC1CN(C2)CC#N,,,,,,
4540,14541,"2-Propenoic acid, 2-methyl-3-phenyl-",CC(=CC1=CC=CC=C1)C(=O)O,,,,,,
4541,14542,CID 14542,C1=CN=CC=C1C=NN=C(N)S,,,,,,
4542,14543,"PHENOL, p-(3-METHYL-2-BUTENYL)-",CC(=CCC1=CC=C(C=C1)O)C,,,,,,
4543,14544,"N,N-Bis(2-fluoroethyl)aniline hydrochloride",C1=CC=C(C=C1)[NH+](CCF)CCF.[Cl-],,,,,,
4544,14545,"N,N-bis(2-fluoroethyl)aniline",C1=CC=C(C=C1)N(CCF)CCF,,,,,,
4545,14546,"2,4-Dichlorocinnamicacid",C1=CC(=C(C=C1Cl)Cl)C=CC(=O)O,,,,,,
4546,14547,"2,2'-Dipyridylamine",C1=CC=NC(=C1)NC2=CC=CC=N2,,,,,,
4547,14548,"3-(3,4-Dichlorophenyl)prop-2-enoic acid",C1=CC(=C(C=C1C=CC(=O)O)Cl)Cl,,,,,,
4548,14549,"1,1,2,3,3-Pentamethylindan",CC1C(C2=CC=CC=C2C1(C)C)(C)C,,,,,,
4549,14550,"1-(2-Chlorophenyl)-1H-pyrrole-2,5-dione",C1=CC=C(C(=C1)N2C(=O)C=CC2=O)Cl,,,,,,
4550,14551,3-(2-Aminopropyl)-4-chloroindole hydrochloride,CC(CC1=CNC2=C1C(=CC=C2)Cl)[NH3+].[Cl-],,,,,,
4551,14552,"Dipyrido(1,2-a:2',1'-c)pyrazinediium, dibromide, monohydrate",C1=CC2=C3C=CC=C[NH+]3C=C[NH+]2C=C1.[Br-].[Br-],,,,,,
4552,14553,"7,10-Diazatricyclo[8.4.0.02,7]tetradeca-1,3,5,8,11,13-hexaene",C1=CC2=C3C=CC=CN3C=CN2C=C1,,,,,,
4553,14554,"2,2,2',4',5'-Pentachloroacetophenone",C1=C(C(=CC(=C1Cl)Cl)Cl)C(=O)C(Cl)Cl,,,,,,
4554,14555,3-(2-Aminopropyl)-5-chloroindole hydrochloride,CC(CC1=CNC2=C1C=C(C=C2)Cl)[NH3+].[Cl-],,,,,,
4555,14556,3-(2-Aminopropyl)-6-chloroindole hydrochloride,CC(CC1=CNC2=C1C=CC(=C2)Cl)[NH3+].[Cl-],,,,,,
4556,14557,1-(6-chloro-1H-indol-3-yl)propan-2-amine,CC(CC1=CNC2=C1C=CC(=C2)Cl)N,,,,,,
4557,14558,"2-Propenoic acid, 3-(1H-indol-3-yl)-",C1=CC=C2C(=C1)C(=CN2)C=CC(=O)O,,,,,,
4558,14559,2-(2-Aminoethyldithio)benzoic acid inner salt,C1=CC=C(C(=C1)C(=O)[O-])SSCC[NH3+],,,,,,
4559,14560,2-((2-Aminoethyl)dithio)benzoic acid,C1=CC=C(C(=C1)C(=O)O)SSCCN,,,,,,
4560,14561,3-Amino-4-biphenylol hydrochloride,C1=CC=C(C=C1)C2=CC(=C(C=C2)O)[NH3+].[Cl-],,,,,,
4561,14562,2-Amino-4-phenylphenol,C1=CC=C(C=C1)C2=CC(=C(C=C2)O)N,,,,,,
4562,14563,2-Methyl-3-nitronaphthalene,CC1=CC2=CC=CC=C2C=C1[N+](=O)[O-],,,,,,
4563,14564,4-Amino-4'-methylbiphenyl,CC1=CC=C(C=C1)C2=CC=C(C=C2)N,,,,,,
4564,14565,4-Amino-4'-hydroxybiphenyl,C1=CC(=CC=C1C2=CC=C(C=C2)O)N,,,,,,
4565,14566,Methyl hippurate,COC(=O)CNC(=O)C1=CC=CC=C1,,,,,,
4566,14567,2-[[(1-Phenylethylidene)amino]oxy]acetic acid,CC(=NOCC(=O)O)C1=CC=CC=C1,,,,,,
4567,14568,4-Chloro-3-sulfamoylbenzoic acid,C1=CC(=C(C=C1C(=O)O)S(=O)(=O)N)Cl,,,,,,
4568,14569,3-Methyldiphenylamine,CC1=CC(=CC=C1)NC2=CC=CC=C2,,,,,,
4569,14570,4-chloro-N-phenylaniline,C1=CC=C(C=C1)NC2=CC=C(C=C2)Cl,,,,,,
4570,14571,CID 14571,CC1(C2CCC1(CN(C2)C(=NC)S)C)C,,,,,,
4571,14572,4-[(Dimethylamino)sulfonyl]benzoic acid,CN(C)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
4572,14573,"1,3-Dioxolan-4-methanol, 2-(p-chlorophenyl)-2-methyl-",CC1(OCC(O1)CO)C2=CC=C(C=C2)Cl,,,,,,
4573,14574,3-(2-Aminobutyl)-4-chloroindole hydrochloride,CCC(CC1=CNC2=C1C(=CC=C2)Cl)[NH3+].[Cl-],,,,,,
4574,14575,"Hydrocinnamic acid, 3-amino-2,4,6-triiodo-",C1=C(C(=C(C(=C1I)N)I)CCC(=O)O)I,,,,,,
4575,14576,"3-(3-Hydroxy-2,4,6-triiodophenyl)-2-propenoic acid",C1=C(C(=C(C(=C1I)O)I)C=CC(=O)O)I,,,,,,
4576,14577,"3-Phenyl-5-(trichloromethyl)-1,2,4-oxadiazole",C1=CC=C(C=C1)C2=NOC(=N2)C(Cl)(Cl)Cl,,,,,,
4577,14578,"N-(2,2-dichloro-1-hydroxyethyl)-4-fluorobenzamide",C1=CC(=CC=C1C(=O)NC(C(Cl)Cl)O)F,,,,,,
4578,14579,Guaiacylglycerol,COC1=C(C=CC(=C1)C(C(CO)O)O)O,,,,,,
4579,14580,"2,4'-Methylenedianiline",C1=CC=C(C(=C1)CC2=CC=C(C=C2)N)N,,,,,,
4580,14581,4-methoxy-N-phenylaniline,COC1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
4581,14582,CID 14582,CCN=C(N1CC2CCC(C1)(C2(C)C)C)S,,,,,,
4582,14583,Methyl 2-cyclobutyl-2-hydroxy-2-phenylacetate,COC(=O)C(C1CCC1)(C2=CC=CC=C2)O,,,,,,
4583,14584,Fencamfamin,CCNC1C2CCC(C2)C1C3=CC=CC=C3,"['For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.']","['Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.']","['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
4584,14585,Diphenaldehyde,C1=CC=C(C(=C1)C=O)C2=CC=CC=C2C=O,,,,,,
4585,14586,9-Anthracenecarbonitrile,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C#N,,,,,,
4586,14587,"5-Chloro-10,11-dihydro-5H-dibenzo[a,d]cycloheptene",C1CC2=CC=CC=C2C(C3=CC=CC=C31)Cl,,,,,,
4587,14588,Dibenzosuberol,C1CC2=CC=CC=C2C(C3=CC=CC=C31)O,,,,,,
4588,14589,Dibenzosuberone,C1CC2=CC=CC=C2C(=O)C3=CC=CC=C31,,,,,,
4589,14590,"Carbamic acid, 2,2-dichloro-3-hydroxy-3-phenylpropyl ester",C1=CC=C(C=C1)C(C(COC(=O)N)(Cl)Cl)O,,,,,,
4590,14591,Prolintane hydrochloride,CCCC(CC1=CC=CC=C1)N2CCCC2.Cl,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
4591,14592,Prolintane,CCCC(CC1=CC=CC=C1)N2CCCC2,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
4592,14593,4-Amino-4'-nitrobiphenyl,C1=CC(=CC=C1C2=CC=C(C=C2)[N+](=O)[O-])N,,,,,,
4593,14594,"N-(2,2-dichloro-1-hydroxyethyl)-2-(4-fluorophenyl)acetamide",C1=CC(=CC=C1CC(=O)NC(C(Cl)Cl)O)F,,,,,,
4594,14595,CID 14595,C1CCC(CC1)NC(=NC2CCCCC2)S,,,,,,
4595,14596,"Ammonium, (3-(dimethylcarbamoyloxy)phenyl)trimethyl-, iodide",CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[I-],,,,,,
4596,14597,"Hydrocinnamic acid, 3-(2-fluoroethylamino)-, methyl ester, hydrochloride",COC(=O)CCC1=CC(=CC=C1)NCCF.Cl,,,,,,
4597,14598,Methyl 3-[3-(2-fluoroethylamino)phenyl]propanoate,COC(=O)CCC1=CC(=CC=C1)NCCF,,,,,,
4598,14599,"3-(N,N-Dimethylglycyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane",CC1(C2CCC1(CN(C2)C(=O)CN(C)C)C)C,,,,,,
4599,14600,"N,N,1,8,8-Pentamethyl-3-azabicyclo(3.2.1)octane-3-acetamide hydrochloride",CC1(C2CCC1(C[NH+](C2)CC(=O)N(C)C)C)C.[Cl-],,,,,,
4600,14601,"N,N-dimethyl-2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-3-yl)acetamide",CC1(C2CCC1(CN(C2)CC(=O)N(C)C)C)C,,,,,,
4601,14602,"1,8,8-Trimethyl-3-azabicyclo(3.2.1)octane-3-acetic acid ethyl ester hydrochloride",CCOC(=O)C[NH+]1CC2CCC(C1)(C2(C)C)C.[Cl-],,,,,,
4602,14603,"Ethyl 2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-3-yl)acetate",CCOC(=O)CN1CC2CCC(C1)(C2(C)C)C,,,,,,
4603,14604,Etebenecid,CCN(CC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
4604,14605,CID 14605,C1=C(C(=C(C(=C1I)O)I)CCCC(=O)O)I,,,,,,
4605,14606,"1-Naphthalenemethylamine, N-(2-bromoethyl)-N-ethyl-, hydrobromide (1:1)",CC[NH+](CCBr)CC1=CC=CC2=CC=CC=C21.[Br-],,,,,,
4606,14607,N-(2-Bromoethyl)-N-ethylnaphthalene-1-methylamine,CCN(CCBr)CC1=CC=CC2=CC=CC=C21,,,,,,
4607,14608,"1-Naphthalenemethylamine, N-(2-chloroethyl)-N-ethyl-, hydrochloride",CC[NH+](CCCl)CC1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
4608,14609,"1-Naphthalenemethylamine, N-(2-chloroethyl)-N-ethyl-",CCN(CCCl)CC1=CC=CC2=CC=CC=C21,,,,,,
4609,14610,2-Amino-7-nitrofluorene,C1C2=C(C=CC(=C2)N)C3=C1C=C(C=C3)[N+](=O)[O-],,,,,,
4610,14611,1-(2-Hydroxyphenyl)-3-phenylprop-2-en-1-one,C1=CC=C(C=C1)C=CC(=O)C2=CC=CC=C2O,,,,,,
4611,14612,(2-Nitro-2-phenylethenyl)benzene,C1=CC=C(C=C1)C=C(C2=CC=CC=C2)[N+](=O)[O-],,,,,,
4612,14613,4'-(Bis(2-chloroethyl)amino)acetanilide,CC(=O)NC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
4613,14614,3-(Diethylaminomethyl)-5-phenylisoxazole hydrochloride,CC[NH+](CC)CC1=NOC(=C1)C2=CC=CC=C2.[Cl-],,,,,,
4614,14615,Diethyl(5-phenylisoxazole-3-ylmethyl)amine,CCN(CC)CC1=NOC(=C1)C2=CC=CC=C2,,,,,,
4615,14616,Phenyl-5-(pyrrolidinomethyl)isoxazole hydrochloride,C1CC[NH+](C1)CC2=CC(=NO2)C3=CC=CC=C3.[Cl-],,,,,,
4616,14617,"3-Phenyl-5-(pyrrolidin-1-ylmethyl)-1,2-oxazole",C1CCN(C1)CC2=CC(=NO2)C3=CC=CC=C3,,,,,,
4617,14618,"Isoxazole, 5-phenyl-3-(pyrrolidinomethyl)-, hydrochloride",C1CC[NH+](C1)CC2=NOC(=C2)C3=CC=CC=C3.[Cl-],,,,,,
4618,14619,"5-Phenyl-3-(pyrrolidin-1-ylmethyl)-1,2-oxazole",C1CCN(C1)CC2=NOC(=C2)C3=CC=CC=C3,,,,,,
4619,14620,"2-Naphthalenemethylamine, N-(2-chloroethyl)-N-ethyl-, hydrochloride",CC[NH+](CCCl)CC1=CC2=CC=CC=C2C=C1.[Cl-],,,,,,
4620,14621,2-chloro-N-ethyl-N-(naphthalen-2-ylmethyl)ethanamine,CCN(CCCl)CC1=CC2=CC=CC=C2C=C1,,,,,,
4621,14622,CID 14622,C1=CC=C2C=C(C=CC2=C1)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
4622,14623,N-2-naphthylimidodicarbonimidic diamide,C1=CC=C2C=C(C=CC2=C1)N=C(N)N=C(N)N,,,,,,
4623,14624,5-Benzyloxyindole,C1=CC=C(C=C1)COC2=CC3=C(C=C2)NC=C3,,,,,,
4624,14625,CID 14625,CCC(=CC1=C(C(=C(C=C1I)I)O)I)C(=O)O,,,,,,
4625,14626,"3-Azabicyclo(3.2.1)octane-3-acetamide, N,N,alpha,1,8,8-hexamethyl-, hydrochloride",CC(C(=O)[NH+](C)C)N1CC2CCC(C1)(C2(C)C)C.[Cl-],,,,,,
4626,14627,"N,N-dimethyl-2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]octan-3-yl)propanamide",CC(C(=O)N(C)C)N1CC2CCC(C1)(C2(C)C)C,,,,,,
4627,14628,"3-Benzyl-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane hydrochloride",CC1(C2CCC1(C[NH+](C2)CC3=CC=CC=C3)C)C.[Cl-],,,,,,
4628,14629,"3-Benzyl-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane",CC1(C2CCC1(CN(C2)CC3=CC=CC=C3)C)C,,,,,,
4629,14630,Sigmodal,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC(=C)Br,,,,,,
4630,14631,Damsin,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@H]1CCC3=O)C)OC(=O)C2=C,,,,,,
4631,14632,3-(2-Piperidinoethyl)-2-benzoxazolinone hydrochloride,C1CC[NH+](CC1)CCN2C3=CC=CC=C3OC2=O.[Cl-],,,,,,
4632,14633,"2(3H)-Benzoxazolone, 3-[2-(1-piperidinyl)ethyl]-",C1CCN(CC1)CCN2C3=CC=CC=C3OC2=O,,,,,,
4633,14634,"1H-Imidazole, 2-((4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methyl)-4,5-dihydro-, monohydrochloride",CC1=CC(=CC(=C1CC2=NCC[NH2+]2)C)C(C)(C)C.[Cl-],,,,,,
4634,14635,3-Phenyl-5-(piperidinomethyl)isoxazole hydrochloride,C1CC[NH+](CC1)CC2=CC(=NO2)C3=CC=CC=C3.[Cl-],,,,,,
4635,14636,"1-[(3-Phenyl-1,2-oxazol-5-yl)methyl]piperidine",C1CCN(CC1)CC2=CC(=NO2)C3=CC=CC=C3,,,,,,
4636,14637,Oxolamine hydrochloride,CC[NH+](CC)CCC1=NC(=NO1)C2=CC=CC=C2.[Cl-],,,,,,
4637,14638,"Isoxazole, 5-phenyl-3-(2-pyrrolidinoethyl)-, hydrochloride",C1CC[NH+](C1)CCC2=NOC(=C2)C3=CC=CC=C3.[Cl-],,,,,,
4638,14639,"5-Phenyl-3-(2-pyrrolidin-1-ylethyl)-1,2-oxazole",C1CCN(C1)CCC2=NOC(=C2)C3=CC=CC=C3,,,,,,
4639,14640,1-[3-(P-Fluorobenzoyl)propyl]piperidinium chloride,C1CC[NH+](CC1)CCCC(=O)C2=CC=C(C=C2)F.[Cl-],,,,,,
4640,14641,Primaperone,C1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,,,,,,
4641,14642,Octyl 4-hydroxybenzoate,CCCCCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
4642,14643,N-(4-(Diethylamino)-2-butynyl)benzamide monohydrochloride,CC[NH+](CC)CC#CCNC(=O)C1=CC=CC=C1.[Cl-],,,,,,
4643,14644,N-[4-(Diethylamino)-2-butynyl]benzamide,CCN(CC)CC#CCNC(=O)C1=CC=CC=C1,,,,,,
4644,14645,CID 14645,C1=CC(=CC=C1NC(=NC2=CC=C(C=C2)Cl)S)Cl,,,,,,
4645,14646,"3-(p-Chlorobenzyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane hydrochloride",CC1(C2CCC1(C[NH+](C2)CC3=CC=C(C=C3)Cl)C)C.[Cl-],,,,,,
4646,14647,"3-[(4-Chlorophenyl)methyl]-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane",CC1(C2CCC1(CN(C2)CC3=CC=C(C=C3)Cl)C)C,,,,,,
4647,14648,"3-(p-Aminobenzyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane dihydrochloride",CC1(C2CCC1(C[NH+](C2)CC3=CC=C(C=C3)[NH3+])C)C.[Cl-].[Cl-],,,,,,
4648,14649,"4-[(1,8,8-Trimethyl-3-azabicyclo[3.2.1]octan-3-yl)methyl]aniline",CC1(C2CCC1(CN(C2)CC3=CC=C(C=C3)N)C)C,,,,,,
4649,14650,"1-Amino-4-(methylamino)anthracene-9,10-dione",CNC1=C2C(=C(C=C1)N)C(=O)C3=CC=CC=C3C2=O,,,,,,
4650,14651,CID 14651,CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)[O-])I)I.[Na+],,,,,,
4651,14652,Zolimidine,CS(=O)(=O)C1=CC=C(C=C1)C2=CN3C=CC=CC3=N2,,,,,,
4652,14653,3-(p-((2-Chloroethyl)(2-fluoroethyl)amino)phenyl)alanine,C1=CC(=CC=C1CC(C(=O)O)N)N(CCF)CCCl,,,,,,
4653,14654,3-(4-Nitrophenyl)-1-phenylprop-2-en-1-one,C1=CC=C(C=C1)C(=O)C=CC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4654,14655,Bis(4-nitrophenyl)sulfide,C1=CC(=CC=C1[N+](=O)[O-])SC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4655,14656,"1,1-Diphenylguanidine nitrate",C1=CC=C(C=C1)[NH+](C2=CC=CC=C2)C(=N)N.[N+](=O)([O-])[O-],,,,,,
4656,14657,"n,n-Diphenylguanidine",C1=CC=C(C=C1)N(C2=CC=CC=C2)C(=N)N,,,,,,
4657,14658,CID 14658,CC1(CCCC(N1CC[NH2+]C(=N)[NH3+])(C)C)C.[O-]S(=O)(=O)[O-],,,,,,
4658,14659,N-Aminodiphenylhydantoin,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)N)C3=CC=CC=C3,,,,,,
4659,14660,3-Methyl-2-(2-morpholinoethyl)-2-phenylbutyronitrile,CC(C)C(CCN1CCOCC1)(C#N)C2=CC=CC=C2,,,,,,
4660,14661,alpha-(2-(Dimethylamino)ethyl)-alpha-ethyl-1-naphthaleneacetonitrile,CCC(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
4661,14662,"[2-Chloro-1-(2,4-dichlorophenyl)ethenoxy]-diethoxy-sulfanylidene-lambda5-phosphane",CCOP(=S)(OCC)OC(=CCl)C1=C(C=C(C=C1)Cl)Cl,,,,,,
4662,14663,CID 14663,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)C(=O)NC)I.[Na+],,,,,,
4663,14664,"Butanamide, 2-(dimethylamino)-N-(4-ethoxyphenyl)-3-hydroxy-N-methyl-, monohydrochloride",CCOC1=CC=C(C=C1)N(C)C(=O)C(C(C)O)[NH+](C)C.[Cl-],,,,,,
4664,14665,2-(dimethylamino)-N-(4-ethoxyphenyl)-3-hydroxy-N-methylbutanamide,CCOC1=CC=C(C=C1)N(C)C(=O)C(C(C)O)N(C)C,,,,,,
4665,14666,"(5R,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC12CCCC[C@@H]1CCC3C2CCC4(C3CC[C@@H]4O)C,,,,,,
4666,14667,Triptil,C[NH2+]CCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.[Cl-],,,,,,
4667,14668,Isothipendyl hydrochloride,CC(CN1C2=CC=CC=C2SC3=C1N=CC=C3)N(C)C.Cl,,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
4668,14669,Prothipendyl hydrochloride,CN(C)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3.Cl,,,,,,
4669,14670,Prothipendyl,CN(C)CCCN1C2=CC=CC=C2SC3=C1N=CC=C3,,,,,,
4670,14671,"Acetic acid, (3-butyramido-2,4,6-triiodophenoxy)-",CCCC(=O)NC1=C(C(=C(C=C1I)I)OCC(=O)O)I,,,,,,
4671,14672,"Butyrophenone, 4-(4,4-dimethylpiperidino)-4'-fluoro-",CC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C,,,,,,
4672,14673,"1-Butanone, 4-(3-azaspiro(5.5)undec-3-YL)-1-(2-thienyl)-",C1CCC2(CC1)CCN(CC2)CCCC(=O)C3=CC=CS3,,,,,,
4673,14674,"3-AZASPIRO(5.5)UNDECANE, 3-(2-(p-FLUOROPHENOXY)ETHYL)-",C1CCC2(CC1)CCN(CC2)CCOC3=CC=C(C=C3)F,,,,,,
4674,14675,Aponal,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.Cl,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)', 'Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)', 'Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
4675,14676,Methdilazine hydrochloride,CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42.Cl,,,,"['Well absorbed after oral administration. /Antihistamines, phenothiazine-derivative/', 'The H1 antagonists are well absorbed from the GI tract. Following oral administration, peak plasma concn are achieved in 2 to 3 hr and effects usually last 4 to 6 hr; however, some of the drugs are much longer acting ... . /Histamine Antagonists: H1 Antagonists/', '... H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /Histamine Antagonists: H1 Antagonists/']","['MAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/', 'H1 blockers are among the many drugs that induce hepatic microsomal enzymes, and they may facilitate their own metabolism. /Histamine Antagonists: H1 Antagonists/']",
4676,14677,Methdilazine,CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,['Used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders'],"['In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Methdilazine is a histamine H<sub>1</sub> antagonist. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.']",,['Well absorbed in the digestive tract.'],,
4677,14678,Solvent red 1,COC1=CC=CC=C1N=NC2=C(C=CC3=CC=CC=C32)O,,,,,,
4678,14679,CID 14679,C1CCC(CC1)C(=CC2=CC=CC=C2F)C3=CC=CC=C3,,,,,,
4679,14680,"ETHYLENE, 1,1-DIPHENYL-2-(o-FLUOROPHENYL)-",C1=CC=C(C=C1)C(=CC2=CC=CC=C2F)C3=CC=CC=C3,,,,,,
4680,14681,"ETHYLENE, 1-(p-CHLOROPHENYL)-2,2-DIPHENYL-",C1=CC=C(C=C1)C(=CC2=CC=C(C=C2)Cl)C3=CC=CC=C3,,,,,,
4681,14682,"ETHYLENE, 1,1-DIPHENYL-2-(p-FLUOROPHENYL)-",C1=CC=C(C=C1)C(=CC2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
4682,14683,"6-Pteridinecarboxamide, 4,7-diamino-2-phenyl-",C1=CC=C(C=C1)C2=NC(=C3C(=N2)N=C(C(=N3)C(=O)N)N)N,,,,,,
4683,14684,"5-(4H-imidazol-2-ylmethyl)-6,11-dihydrobenzo[c][1]benzazepine",C1C=NC(=N1)CN2CC3=CC=CC=C3CC4=CC=CC=C42,,,,,,
4684,14685,"4,6-Diphenoxy-1,3,5-triazin-2-amine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)N)OC3=CC=CC=C3,,,,,,
4685,14686,"3-AZASPIRO(5.5)UNDECANE, 3-(3-(p-FLUOROPHENOXY)PROPYL)-",C1CCC2(CC1)CCN(CC2)CCCOC3=CC=C(C=C3)F,,,,,,
4686,14687,Ethynodiol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C[C@H](CC[C@H]34)O,,,,"['Absorption, distribution, excretion and metabolism of SC-11800EE, a combined steroid preparation consisting of SC-11800(ethynodiol diacetate)as gestagen and ethinyl estradiol (EE)as estrogen in 20:1 (w:w), were studied with the use of 14C-SC-11800 and 3H-EE by radiometry in female rats and by the whole body autoradiography in female normal and pregnant mice. The gestagen orally given with EE was rapidly absorbed from digestive tracts and distributed in tissues in various levels. Gestagen levels in liver and kidney exceeded that in plasma. About 75% of dosed radioactivity was excreted in feces largely via bile and more than 20% in urine within 72 hr after administration. The gestagen was metabolized extensively to more polar products and their conjugates. The pharmacokinetic behavior of the gestagen given with EE did not alter after repeated administrations for 7 days, but was slightly different from that without EE, possibly due to the estrogen effect. The pharmacokinetic behavior of the estrogen was independent from the gestagen given simultaneously. The distribution of the gestagen given with EE revealed by the whole body autoradiography in normal mice were essentially consistent with the radiometric results in rats and that in the pregnant mice showed that the gestagen in fetus was virtually nil under the present conditions.', 'Bioavailability and pharmacokinetics of norethisterone (NE) were studied in 12 women, aged 21-37 years, after oral doses of ethynodiol diacetate (EDA). Plasma NE levels, measured by radioimmunoassay, were used to compare the bioavailability of EDA tablets (Ovulen 50; 1 mg EDA plus .05 mg ethinyl estradiol) with that of a standard oral solution of EDA. The 3 different batches of tablets studied showed different in vitro dissolution rates, 82.6%, 94.6%, and 99% at 3 hours. No marked differences were seen in the bioavailability of the tablet formulations, which were essentially bioequivalent to the solution. Peak plasma NE levels were reached within 4 hours of EDA administration in solution or tablets. Following the peak, NE plasma levels declined in 2 phases, with mean terminal elimination 1/2-lives of 4-6.9 hours. These results have shown that small variations in in vitro dissolution rates do not affect the bioavailability of NE from tablets containing EDA.', 'Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers ...']","['After oral administration, norethisterone acetate and ethynodiol diacetate are rapidly converted to norethisterone by esterases during hepatic first-pass metabolism.', 'On administration of a single oral dose of [4-(14)C]ethynodiol diacetate (0.15 mg/kg) to rhesus monkey, plasma concentration of total 14C peaked after about 4 hr. About 60% of the plasma radioactivity was present as glucuronide conjugates and no unchanged drug was detected. Some 67 +/- 6% (mean +/- S.D.) of the dose of 14C was excreted in 4 days, 50 +/- 6% in urine and 18 +/- 2% in feces. Most of the urinary excretion occurred within 24 hr of dosage. Glucuronide conjugates accounted for 60% of the urinary 14C, and 46% of the fecal 14C was free steroids. Norethisterone and its tetrahydro metabolites were identified in the free, glucuronide and sulphate fractions of plasma and urine. Keto-4,5-dihydronorethisterones and trihydroxy metabolites were identified in the conjugated fractions of urine, and a complex mixture of polar metabolites was detected in feces.', 'All of the 17beta-ethynyl progestins reviewed follow similar metabolic paths. For three of these, norethynodrel, ethynodiol diacetate and lynestrenol, a principal metabolite is norethindrone. Biotransformation to more polar metabolites and conjugation proceed rapidly for these three precursor drugs and norethindrone. ... The compounds appear to be readily absorbed, and they and their metabolites are excreted to a greater extent in the urine than in the feces.', '... The ethynodiol diacetate was metabolized extensively to more polar products and their conjugates. ...', 'There is limited information on the metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids. Both levonorgestrel and norethindrone undergo extensive reduction of the alpha, beta-unsaturated ketone in ring A. Levonorgestrel also undergoes hydroxylation at carbons 2 and 16. The metabolites of both compounds circulate predominantly as sulfates. In urine, levonorgestrel metabolites are found primarily in the glucuronide form, whereas norethindrone metabolites are present in approximately equal amounts as sulfates and glucuronides. Of the progestogens structurally related to norethindrone, norethindrone acetate, ethynodiol diacetate, norethindrone enanthate, and perhaps lynestrenol, undergo rapid hydrolysis and are converted to the parent compound and its metabolites. There is no convincing evidence that norethynodrel is converted to norethindrone. Of the progestogens structurally related to levonorgestrel, it appears that neither desogestrel nor gestodene are transformed to the parent compound. However, there is evidence that norgestimate can be, at least partly, converted to levonorgestrel. ...']",
4687,14688,"(16R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16,17-tetrol",CC12CCC3C(C1C[C@H](C2O)O)CCC4=CC(=C(C=C34)O)O,,,,,,
4688,14689,alpha-Methyl-alpha-(2-piperidinoethyl)-1-naphthaleneacetonitrile,CC(CCN1CCCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
4689,14690,"N,N-dimethyl-3-(5-methyl-6H-benzo[c][1]benzazepin-11-ylidene)propan-1-amine",CN1CC2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31,,,,,,
4690,14691,"1-(4-Methoxyphenyl)-1,2-diphenylethylene",COC1=CC=C(C=C1)C(=CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4691,14692,Indole-3-carboxaldehyde azine,C1=CC=C2C(=C1)C(=CN2)C=NN=CC3=CNC4=CC=CC=C43,,,,,,
4692,14693,CID 14693,CCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCC)S,,,,,,
4693,14694,2-(Dimethylamino)ethanol;2-methyl-4-(4-phenylphenyl)butanoic acid,CC(CCC1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O.CN(C)CCO,,,,,,
4694,14695,4-(4-Biphenylyl)-2-methylbutanoic acid,CC(CCC1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O,,,,,,
4695,14696,"Butyrophenone, 4-(2-azaspiro(4.6)undec-2-YL)-4'-fluoro-",C1CCCC2(CC1)CCN(C2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
4696,14697,Methyl dehydroabietate,CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@]([C@@H]3CC2)(C)C(=O)OC)C,,,,,,
4697,14698,10-beta Hydroxy Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34O,,,,,,
4698,14699,CID 14699,COC1=CC=C(C=C1)C(=CC2=CC=CC=C2F)C3CCCCC3,,,,,,
4699,14700,CID 14700,COC1=CC=C(C=C1)C(=CC2=CC=CC=C2F)C3=CC=CC=C3,,,,,,
4700,14701,1-Fluoro-4-[2-(4-methoxyphenyl)-2-phenylethenyl]benzene,COC1=CC=C(C=C1)C(=CC2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
4701,14702,N-(p-(Bis(2-fluoroethyl)amino)benzylidene)-p-anisidine,COC1=CC=C(C=C1)N=CC2=CC=C(C=C2)N(CCF)CCF,,,,,,
4702,14703,"17-ethynyl-10-hydroperoxy-17-hydroxy-13-methyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34OO,,,,,,
4703,14704,alpha-Isopropyl-alpha-(2-morpholinoethyl)-1-naphthaleneacetonitrile,CC(C)C(CCN1CCOCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
4704,14705,"4-(7,9-Dimethyl-8-oxa-2-azaspiro(4.5)dec-2-yl)-4'-fluoro-butyrophenone",CC1CC2(CCN(C2)CCCC(=O)C3=CC=C(C=C3)F)CC(O1)C,,,,,,
4705,14706,Phenazocine hydrobromide,CC1C2CC3=C(C1(CCN2CCC4=CC=CC=C4)C)C=C(C=C3)O.Br,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
4706,14707,Phenazocine,CC1C2CC3=C(C1(CCN2CCC4=CC=CC=C4)C)C=C(C=C3)O,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
4707,14708,Furazabol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=NON=C5C4)C,,,,,,
4708,14709,Dehydroepiandrosterone acetate,CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=O)C)C,,,,,,
4709,14710,Homidium bromide,CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N.[Br-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,"['The metabolism of ethidium bromide by isolated rat hepatocytes is significantly enhanced by pre-treatment of animals with phenobarbitone (PB) and 3-methylcholanthrene (3-MC). Pre-treatment with PB and 3-MC results in a 2.5- and 1.5-fold increase, respectively in the amount of the principal metabolite, ethidium 8-N-glucuronide, compared with that formed by hepatocytes from untreated rats. The formation of ethidium 3-N-glucuronide is not enhanced by pre-treatment with either PB or 3-MC. Two new metabolites, hydroxyethidium glucuronide and a transient unidentified species, have been detected by HPLC and are formed only by hepatocytes from animals pre-treated with 3-MC.']",
4710,14711,4-[Benzyl(methyl)amino]-2-naphthalen-1-ylbutanenitrile,CN(CCC(C#N)C1=CC=CC2=CC=CC=C21)CC3=CC=CC=C3,,,,,,
4711,14712,alpha-sec-Butyl-alpha-(2-piperidinoethyl)-1-naphthaleneacetonitrile,CCC(C)C(CCN1CCCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
4712,14713,3-Methyl-2-(2-morpholin-4-ylethyl)-2-naphthalen-1-ylpentanenitrile,CCC(C)C(CCN1CCOCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
4713,14714,"Butyronitrile, 2-phenyl-4-piperidino-2-(2-piperidinoethyl)-",C1CCN(CC1)CCC(CCN2CCCCC2)(C#N)C3=CC=CC=C3,,,,,,
4714,14715,"Butyronitrile, 4-morpholino-2-(2-morpholinoethyl)-2-phenyl-",C1COCCN1CCC(CCN2CCOCC2)(C#N)C3=CC=CC=C3,,,,,,
4715,14716,2-Ethylhexyl diphenyl phosphate,CCCCC(CC)COP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,"['2-ethylhexyldiphenyl phosphate was given in daily doses of ... to rabbits in daily doses of 0.625-2.50 mL/kg. ... The amount of phenol (in all forms) found was ... 94% in rabbits. ... The amounts in the feces and urine were respectively ... 74% and 19.5% in rabbits. ... The intestinal absorption of 2-ethylhexyldiphenyl phosphate is low.', '2-ethylhexyldiphenyl phosphate was given in daily doses of 5 mL/kg to humans. ... The amount of phenol (in all forms) found was 96% in humans. ... The amounts in the feces and urine were respectively 83% and 13% in human subjects. ... The intestinal absorption of 2-ethylhexyldiphenyl phosphate is low.', 'The metabolic fate of 2-ethylhexyl diphenyl phosphate (EHDPP) was studied in male rats. Orally administered (14)C-EHDPP was rapidly absorbed and about 80% of the radioactivity was excreted in the urine and feces in the first 24 hr. By 7 days, 48% and 52% of the radioactivity was recovered in urine and feces, respectively. Since biliary excretion was low (6% for 2 days), urine seems to be the major excretion route of EHDPP. Radioactivity was widely distributed in all tissues examined. At 2 hr, the concentration was relatively high in blood, liver kidney and adipose tissue. The elimination of radioactivity from adipose tissue and liver was somewhat delayed, but almost all the radioactivity was eliminated by 7 days. The major metabolites in the urine were diphenyl phosphate (DPP) and phenol. p-Hydroxyphenyl phenyl phosphate (OH-DPP) and monophenyl phosphate (MPP) were also identified as minor metabolites.']",['The metabolic fate of 2-ethylhexyl diphenyl phosphate (EHDPP) was studied in male rats. Orally administered (14)C-EHDPP was rapidly absorbed and about 80% of the radioactivity was excreted in the urine and feces in the first 24 hr. ... The major metabolites in the urine were diphenyl phosphate (DPP) and phenol. p-Hydroxyphenyl phenyl phosphate (OH-DPP) and monophenyl phosphate (MPP) were also identified as minor metabolites.'],
4716,14717,"[(5S,9S,14S,17S)-2,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate",CC1=CC2([C@@H](CCC3[C@@H]2CCC4([C@H]3CC[C@@H]4OC(=O)C)C)CC1=O)C,,,,,,
4717,14718,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(dimethylamino)-1-methylethyl)-5-phenyl-, dihydrochloride",CC(CN(C)C)N1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.Cl.Cl,,,,,,
4718,14719,"7-chloro-1-[1-(dimethylamino)propan-2-yl]-5-phenyl-3H-1,4-benzodiazepin-2-one",CC(CN(C)C)N1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
4719,14720,"Picene, 1,2,3,4-tetrahydro-2,2,9-trimethyl-",CC1=C2C=CC3=C(C2=CC=C1)C=CC4=C3C=CC5=C4CC(CC5)(C)C,,,,,,
4720,14721,CID 14721,CC(C)C[NH+](CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O)CC(C)C.[Cl-],,,,,,
4721,14722,CID 14722,CC(C)CN(CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O)CC(C)C,,,,,,
4722,14723,"14-Hydroxy-3-oxocarda-4,20(22)-dienolide",C[C@]12CCC(=O)C=C1CCC3C2CC[C@]4([C@@]3(CCC4C5=CC(=O)OC5)O)C,,,,,,
4723,14724,"(17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione",CC1CC2C3CCC4=CC(=O)C=CC4(C3C(=O)CC2([C@]1(C(=O)CO)O)C)C,,,,,,
4724,14725,"Barbituric acid, 5-cyclohexyl-1,3-diphenyl-",C1CCC(CC1)C2C(=O)N(C(=O)N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4725,14726,CID 14726,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C4=CC=CC=C4C=C3)S(=O)(=O)[O-])O.[Na+],,,,,,
4726,14727,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(3-(diethylamino)propyl)-5-phenyl-, dihydrochloride",CCN(CC)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.Cl.Cl,,,,,,
4727,14728,"7-chloro-1-[3-(diethylamino)propyl]-5-phenyl-3H-1,4-benzodiazepin-2-one",CCN(CC)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
4728,14729,"(3S,9S,14S,17S)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol;dihydrochloride",CC12CC[C@H]3C([C@@H]1CC[C@@H]2N(C)CCCN(C)C)CC=C4C3(CC[C@@H](C4)O)C.Cl.Cl,,,,,,
4729,14730,"(3S,9S,14S,17S)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CC12CC[C@H]3C([C@@H]1CC[C@@H]2N(C)CCCN(C)C)CC=C4C3(CC[C@@H](C4)O)C,,,,,,
4730,14731,"Acetanilide, 2'-(4-(3,4-dimethoxyphenethyl)-1-piperazinyl)-",CC(=O)NC1=CC=CC=C1N2CCN(CC2)CCC3=CC(=C(C=C3)OC)OC,,,,,,
4731,14732,"(5S)-2,16-dimethyl-15-(6-methylheptan-2-yl)-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecan-5-ol",CC(C)CCCC(C)C1CCC2C1(CCC3C2CC4C5(C3(CC[C@@H](C5)O)C)O4)C,,,,,,
4732,14733,3-Formyl-digitoxigenin,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)OC=O,,,,,,
4733,14734,"alpha,alpha-Bis(2-morpholinoethyl)-1-naphthaleneacetonitrile",C1COCCN1CCC(CCN2CCOCC2)(C#N)C3=CC=CC4=CC=CC=C43,,,,,,
4734,14735,CID 14735,C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=CC3=CC=CC=C3F)C4=CC=CC=C4,,,,,,
4735,14736,CID 14736,C[NH+](C)CCC=C1C2=C(C=C(C=C2)Br)SCC3=CC=CC=C31.C(CC(=O)[O-])C(=O)O,,,,,,
4736,14737,CID 14737,CN(C)CCC=C1C2=C(C=C(C=C2)Br)SCC3=CC=CC=C31,,,,,,
4737,14738,CID 14738,CC(=O)NC1=CC=C(C=C1)N2CC[NH+](CC2)CCC[NH+](C)C.C(=CC(=O)[O-])C(=O)O.C(=CC(=O)[O-])C(=O)O,,,,,,
4738,14739,Piperamide,CC(=O)NC1=CC=C(C=C1)N2CCN(CC2)CCCN(C)C,,,,,,
4739,14740,"[(16R)-17-acetyl-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] hexanoate",CCCCCC(=O)O[C@@H]1CC2C3CCC4=CC(=O)CCC4C3CCC2(C1C(=O)C)C,,,,,,
4740,14741,Didecyl phenyl phosphite,CCCCCCCCCCOP(OCCCCCCCCCC)OC1=CC=CC=C1,,,,,,
4741,14742,"[2-[(9R,17R)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-16-methylidene-3-oxo-7,8,11,12,14,15-hexahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",CC(=O)OCC(=O)[C@]1(C(=C)CC2C1(CC([C@]3(C2CCC4=CC(=O)C=CC43C)F)O)C)O,,,,,,
4742,14743,Testosterone phenylpropionate,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@]35C,,,,,,
4743,14744,"[2-(2-formyl-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl] acetate",CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C(=CC34C)C=O)O)C)O,,,,,,
4744,14745,Cholesteryl isopropyl ether,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(C)C)C)C,,,,,,
4745,14746,3-12-Formyl-digoxigenin,C[C@]12CC[C@@H](C[C@H]1CCC3C2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)OC=O)OC=O,,,,,,
4746,14747,3-Formyl-gitaloxigenin,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=CC(=O)OC5)OC=O)O)C)OC=O,,,,,,
4747,14748,6-Oxocholestan-3-yl acetate,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC(=O)[C@@H]4C3(CC[C@@H](C4)OC(=O)C)C)C,,,,,,
4748,14749,C.I. Natural red 4,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Natural or synthetic dyes used as coloring agents in processed foods. (See all compounds classified as Food Coloring Agents.)']",,,
4749,14750,"4-O-[(2R,3S,4R,6S)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-ethyl butanedioate",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@@H]3[C@H]([C@@H](C[C@@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,,,,,,
4750,14751,CID 14751,C1C[C][C]CC[C][C]1.C1C[C][C]CC[C][C]1.[Ni],,,,,,
4751,14752,"1,5-Cyclooctadiyne",C1CC#CCCC#C1,,,,,,
4752,14753,CID 14753,C1=C(C=C(C(=C1Br)O)Br)Br.C1=C(C=C(C(=C1Br)O)Br)Br.C1=C(C=C(C(=C1Br)O)Br)Br.[BiH3],,,,,,
4753,14754,Sodium glycerophosphate,C(C(COP(=O)([O-])[O-])O)O.[Na+].[Na+],"['Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.']",['Glycerophosphate acts as a source of inorganic phosphate through hydrolysis.'],,"['Peak serum phosphate concentration is reached in 4h.', 'Inorganic phosphate produced is eliminated in the urine. There may be a very small amount of glycerophosphate excreted in the urine unchanged.']",['Glycerophosphate is hydrolyzed to form inorganic phosphate. The extent of this reaction is dependent on serum alkaline phosphatase activity.'],['Inorganic phosphate has a half-life of elimination of 2.06h.']
4754,14755,CID 14755,CC1=C(C=C(C=C1)S(=O)(=O)[O-])C.[Na+],,,,,,
4755,14756,"3,4-dimethylbenzenesulfonic Acid",CC1=C(C=C(C=C1)S(=O)(=O)O)C,,,,,,
4756,14757,Acetic acid;(4-methylphenyl)mercury,CC1=CC=C(C=C1)[Hg].CC(=O)O,,,,,,
4757,14758,p-Tolylmercury,CC1=CC=C(C=C1)[Hg],,,,,,
4758,14759,Amylmetacresol,CCCCCC1=C(C=C(C=C1)C)O,"['Sore throat, minor mouth and throat infections,,.']","['The mixture of amylmetacresol throat lozenge medications markedly reduces the infectivity of certain infectious viruses in the throat and in cough droplets, thus reducing opportunities for person-to-person transmission.    In addition, it relieves symptoms of sore throat/irritation of the throat,.  Amylmetacresol is thought to inhibit the inflammatory and pain mediators that are involved in the inflammation of the mouth and throat mucous membranes, as well as the sore throat.']",,['Rapidly absorbed and eliminated.'],,
4759,14760,CID 14760,CC(C)(C)C1=CC2=C(C=C1)C=CC(=C2S(=O)(=O)[O-])C(C)(C)C.[Na+],,,,,,
4760,14761,"2,7-Ditert-butylnaphthalene-1-sulfonic acid",CC(C)(C)C1=CC2=C(C=C1)C=CC(=C2S(=O)(=O)O)C(C)(C)C,,,,,,
4761,14762,1-Tridecyl-2-methyl-2-hydroxyethylimidazolinium chloride,CCCCCCCCCCCCC[N+]1=CC=[NH+]C1(C)CCO.[Cl-],,,,,,
4762,14763,2-(2-Methyl-1-tridecylimidazol-1-ium-2-yl)ethanol,CCCCCCCCCCCCC[N+]1=CC=NC1(C)CCO,,,,,,
4763,14764,Eucupine; Eucupreine; Isoamylhydrocupreine,CCC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OCCC(C)C)O,,,,,,
4764,14765,Ferric glycerophosphate,C(CO)C(CCO)OP(=O)([O-])[O-].C(C(COP(=O)([O-])[O-])O)O.[Fe+2].[Fe+2],,,,,,
4765,14766,Sodium aluminate,O=[Al-]=O.[Na+],,,,"['It was calculated that a dialysate aluminum concn of 0.2-1.0 mg/l (a concn readily found in many water supplies) would result in the direct transfer of aluminum into the blood of 3-16 mg for each dialysis treatment or 42-211 mg/mo. /Aluminum/', 'A given oral dose of aluminum results in significantly higher serum and tissue levels of the metal in nephrectomized rats than in intact controls in spite of the fact that only minimal amounts of aluminum are normally excreted in the urine. /Aluminum/', 'It was found that 70-90% of total aluminum bound to plasma proteins (60-70% to a high molecular weight protein and 10-20% to albumin while only 10-30% was unbound). This high affinity of aluminum for plasma proteins strongly suggests high levels of binding of aluminum to a variety of tissue proteins. /Aluminum/', 'It was shown that the uptake of aluminum into the blood during renal dialysis was due to the extensive binding of aluminum to plasma proteins leaving very little aluminum in the non-bound state in plasma. Thus, the plasma proteins served as a trap for accumulating the metal. It was shown that the component of plasma protein that binds aluminum is saturable. Consistent with this ... is the fact that, during dialysis with aluminum containing dialysate, plasma aluminum levels reach a plateau. /Aluminum/', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM ALUMINATE (18 total), please visit the HSDB record page.']",,"['The mean plasma half-life of aluminum after iv admin in dogs is approx 4.5 hr. /Aluminum/', 'The shorter half-life for the urinary elimination of aluminum was about 8 hr. /Aluminum/']"
4766,14767,Beryl,[Be+2].[Be+2].[Be+2].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[O-][Si](=O)[O-].[Al+3].[Al+3],,,,,,
4767,14768,Metasilicic acid,O[Si](=O)O,,,,,,
4768,14769,Alumina,O=[Al]O[Al]=O,,,,,,
4769,14770,Gallium arsenide,[Ga]#[As],,,,"['After exposure to 75 mg/ml of GaAs, the analysis of tissues from pregnant rats showed that gallium levels in the maternal blood were 300 fold less than the arsenic concentrations. Thus the fetal changes were due to the arsenic, not the gallium. The gallium concentrations in the fetus were greater than in the mother. The increase in the material and fetal gallium tissue concentrations at 75 mg/cu m were not proportional to the increases at 37 mg/cu m.', 'After intratracheal instillation into hamsters of GaAs ..., the compound was absorbed from the lungs in 24 hr. The blood levels were lower in the GaAs treated group. The arsenic blood levels in the hamsters treated with GaAs peaked at 48 hr and remained constant for 48 hr. ... After 4 days 50 percent of the arsenate ... was excreted in the urine ... . The slower absorption of GaAs from the lungs may account for the lesser fecal excretion', 'Excretion of arsenic absorbed from GaAs is probably as rapid as that found after inorganic arsenic administration; about 35% of soluble sodium arsenite was excreted within 48 hours in humans. GaAs is absorbed slowly from the lung, so arsenic excretion is expected to continue for several weeks after GaAs exposure. GaAs remaining in the lung is eliminated slowly; a single intratracheal dose of 100 mg/kg was excreted in about 3 months and had a half life in the range of 2 weeks.', 'A dose of 30 mg/kg of GaAs introduced into the lung by intratracheal administration produced enzymatic changes in the body characteristic of soluble arsenic compounds; equivalent changes were observed only when 1000 mg/kg GaAs was given by oral administration. The cumulative absorption of GaAs from the lung as measured by the amount of arsenic found in blood and urine was approximately 10-20% of the administered dose, and this appeared over a period of several days ... . This absorption was fairly constant over the dose range of 10-100 mg/kg ... . After oral administration, the amount absorbed appeared to depend on dose in the range 10-1,000 mg/kg; at 1000 mg/kg, less than 1% was absorbed, but the percentage of the dose absorbed rose to almost 10% at the 10 mg/kg dose. These results are all based on arsenic data because no gallium was detected in either blood or urine. Lung and fecal analyses found more gallium than arsenic, suggesting that gallium was more poorly absorbed from the lung than was arsenic and greater amounts of gallium were cleared from the lung by mucociliary mechanisms and subsequently swallowed.', 'Gallium arsenide administered by oral gavage at single doses of 10, 100, or 1,000 mg/kg to male Fischer rats ... or male Syrian hamsters Yamauchi was only slightly soluble in the gastrointestinal tract and therefore absorption was minimal. Fourteen days after dosing with gallium arsenide, 90.7% + or - 35.4% of the arsenic and 99.4% + or - 38.7% of the gallium was eliminated in the feces in the 1,000 mg/kg group. Less than 0.02% of the arsenic was excreted in the urine, and 0.3% was detected in the blood. Gallium was not detected in the blood or urine. Five days after dosing in hamsters, more than 80% to 90% of the total arsenic dose from gallium arsenide was eliminated in the feces, and less than 0.15% was excreted in the urine.']",['A number of experiments have demonstrated that GaAs dissociates in the lung or gut of mammals to gallium & arsenic with the latter behaving metabolically as any other inorganic arsenic species.'],
4770,14771,Arsenic pentoxide,O=[As](=O)O[As](=O)=O,,,,"['Experiments with grazing cows and cows kept indoors were performed to study the transfer of toxic elements from their ration into milk and edible tissues. First experiment was carried out with dairy cows. The toxic elements were administered, via wafers of concentrates which contained a mixture of cadmium, lead and mercury acetate and arsenic pentoxide. The dosing period was three months in which the daily intake for each cow was 152, 200, 1.7, and 33 mg for cadmium, lead, mercury, and arsenic, respectively. The daily intake of these elements for the control cows was 2, 50, 0.2, and 3.4 mg, respectively. The second experiment was carried out with dairy cows which were kept indoors and fed on concentrates and roughage. One group received cadmium, lead and mercury acetate, and arsenic trioxide. The dosing period lasted 28 months or 3 consecutive complete lactations. Liver and in particular kidney were the primary sites of element accumulation. Only for cadmium the proposed tolerance levels in liver and kidney were exceeded. Increased dietary concentrations of elements did not result in significantly higher concentrations in milk, blood and muscle tissue. Only soluble arsenic resulted in higher levels of this element in muscle tissue. Regarding the character of the pathological changes, no essential differences were observed between the control and experimental groups.']",,
4771,14772,Arsenic triselenide,[As](=[Se])[Se][As]=[Se],,,,,,
4772,14773,Barium peroxide,[O-][O-].[Ba+2],,,,,,
4773,14774,CID 14774,[O-][O-],,,,,,
4774,14775,Beryllium oxide,[Be]=O,,,,"[""...2 Persons who had ... constant exposure to beryllium oxide for 5 years showed appreciable excretion after 6 years' removal from contact ... no evidence of pulmonary involvement."", '... Distribution of beryllium oxide ... varies with the method of its prepn: after intratracheal instillation of beryllium oxide prepd by calcining alpha-BE(OH)2 for 10 hr @ 500 C was found in high concn in liver, kidneys & bones of rats, whereas prepn by calcining alpha-BE(OH)2 for 10 hr @ 1600 C ... remained mainly in the lung.', '... Rabbits given beryllium oxide ... IV a year or more before being killed or dying from osteosarcoma. Relatively high amt of the metal were found in the reticulo endothelial cells of liver & spleen. The lung also contained high concn. The levels in bone, kidney & heart were much lower.', '... The skeletal deposition of beryllium from the ... low fired oxide, inhaled for 40 to 100 days by dogs, showed ... 0.6% ... of that retained in the lung ... 0.6% ... in the liver; and ... 397% ... in the pulmonary lymph nodes.', 'For more Absorption, Distribution and Excretion (Complete) data for BERYLLIUM OXIDE (9 total), please visit the HSDB record page.']",,['Alveolar retention half-life for beryllium oxide was approx 6 mo.']
4775,14776,Dibismuth trioxide,O=[Bi]O[Bi]=O,,,,,,
4776,14777,Calcium dihydroxide,[OH-].[OH-].[Ca+2],,,,,,
4777,14778,Calcium oxide,O=[Ca],,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,,
4778,14779,Calcium peroxide,[O-][O-].[Ca+2],,,,,,
4779,14780,Calcium phosphide (Ca3P2),[P-3].[P-3].[Ca+2].[Ca+2].[Ca+2],,,,['The substance can be absorbed into the body by inhalation and by ingestion.'],"['Metal phosphides are hydrolyzed to phosphine and the corresponding metal cation. In rats, phosphine that is not excreted in the expired air is oxidized and appears in the urine, chiefly as hypophosphite and phosphite. ...An unidentified metabolite, detectable by paper chromatography and distinct from pyrophosphate and metaphosphate /was also reported/. The fact that (a) phosphine is incompletely oxidized; and (b) the proportion of an administered dose that is eliminated as expired phosphine increases with the dose suggests that the oxidative pathway is slow. /Metal phosphides/']",
4780,14781,Hydroxyapatite,[OH-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2],,,"['Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. (See all compounds classified as Biocompatible Materials.)']",,,
4781,14782,Cadmium oxide,O=[Cd],,,,"['Cadmium is a metallic impurity in various minerals. The two main cadmium exposure sources in general population are food and tobacco smoking...Cadmium is a cumulative toxic substance whose half-time for elimination is about 20 to 40 years and it is mainly stored in the liver and kidneys. Inhalation of cadmium oxide fumes may cause inhalation fevers or chemical pneumonitis. Cadmium chronic poisoning causes mainly renal tubulopathy and could be the cause of osteomalacia and diffuse osteoporosis. Cadmium is classified as certain carcinogen agent for humans by International Agency for Research on Cancer (IARC). The most relevant biological index exposure is the urinary cadmium. According to literature, no chelating agent can be still used in human cadmium poisonings. In France, some diseases caused by occupational exposure to cadmium may be compensated.', '1 YR INHALATION OF CADMIUM OXIDE ... BY DOGS @ LEVELS OF 3-7 MG/CU M DAILY RESULTED IN ... BLOOD CADMIUM CONCN AVG 0.22 MG% & URINE ... WERE 0.36 MG/L. MOST ... CADMIUM ... RETAINED IN LUNGS, CONSIDERABLE AMT IN KIDNEY & LIVER ... LESSER AMT IN BONE & TEETH. LACK OF EFFECT ... ATTRIBUTED TO LOW RATE OF SOLUBILITY ...', '... ARC-PRODUCED CD FUME PARTICLE DEPOSITION IN LARGE NUMBER OF 5 ANIMAL SPECIES AT LD50 DOSES ... /WITH/ PARTICULATE DIAMETER ... FROM 0.3 TO 0.5 MU ... /SHOWED/ AVG FUME DEPOSITION IN LUNG ... ABOUT SAME FOR ALL SPECIES, 11%, WITH RANGE BETWEEN 4.3 & 21.7% ...', 'RATS WHICH DIED WITHIN 3 DAYS OF EXPOSURE TO AEROSOL OF CADMIUM OXIDE (60 M UG/L FOR 30 MIN) SHOWED LUNG LEVEL OF 26.9 UG.', 'For more Absorption, Distribution and Excretion (Complete) data for CADMIUM OXIDE (7 total), please visit the HSDB record page.']",,"['IN RATS, INTRATRACHEALLY ADMIN CADMIUM OXIDE TAGGED WITH (109)CD, HALF-LIFE IN LUNG WAS 4 HR ...']"
4782,14783,Cadmium sulfide,S=[Cd],,,,"['AFTER A YR OF FEEDING 1 PPM CADMIUM (AS CADMIUM SULFIDE (CDS) OR CD CONTAINED IN ROLL SHELL LIVER) IN CA DEFICIENT DIET OF FEMALE RATS, ACCUM RATE IN LIVER & KIDNEY WAS 0.33-0.48%, WHEREAS THAT OF WATER SOL CD CMPD & CD FED AS CD POLLUTED RICE WAS 0.43-0.57%.', 'Rats were exposed 6 hr/day over 10 days to 0.3 mg/cu m of water soluble cadmium chloride and 0.2, 1.0 and 8.0 mg/cu m of insoluble cadmium sulfide, then killed at intervals over a 3-month period for serial measurements of lung, renal and fecal cadmium. Cadmium chloride and high-dose cadmium sulfide animals showed a transient increase in lung weight. Clearance of both compounds was biphasic. Approximately 40% of deposited material was cleared during the 10-day exposure period. For cadmium chloride, only 9% of the lung burden was cleared rapidly after the last exposure (half-life 1.0 days) and 47%. slowly (half-life 87 days), leaving a residual lung burden of 44%. For cadmium sulfide, 41% of the lung burden was cleared rapidly (half-life 1.4 days) and 40% slowly (half-life 42 days), leaving a final residue 19%. In the cadmium sulfide high-dose group, the retention of cadmium sulfide in the lung was greater than that in the cadmium sulfide low-dose groups, indicating that clearance mechanisms may possibly have been impaired in the high-dose group by too great a lung burden. For both compounds, fecal cadmium was initially high. Renal accumulation of cadmium was substantial for cadmium chloride during the exposure period and continued over the following months until it represented approximately 35% of the total cadmium cleared from the lung. For cadmium sulfide, renal accumulation was only 1% of the amount cleared from the lung. The bioavailability of cadmium from cadmium sulfide is thus poor, the majority being cleared from the lungs and excreted in the feces. However, the bioavailability of inhaled cadmium sulfide measured as cadmium in the kidney is greater than the bioavailability of orally ingested cadmium sulfide.']",,
4783,14784,Cadmium selenide,[Se]=[Cd],,,,,,
4784,14785,Cobalt trihydroxide,O.O.O.[Co],,,,,,
4785,14786,Cobalt(II) oxide,O=[Co],,,,"['The aim of this study was to verify the relationship between the cobalt oxide concentration in air and the cobalt concentration in urine. In the first study, we measured the cobalt concentration in the urine of 16 workers exposed to cobalt oxide in a Digital Video Cassette manufacturing plant at the beginning and end of their workshift during 2 working cycles. In the second study, we measured the exposure level to cobalt oxide and the cobalt concentration in urine at the end of the workshift of other 16 workers on 3 out of 5 consecutive work days (Monday, Wednesday and Friday). Four workers among the 16 participated twice. In the first study, the cobalt concentration in the urine increased about 1.5-3 fold during each workshift and then tended to decrease rapidly to the control value before the next workshift. In the second study, we examined the relationship between air and urine concentration using 22 samples after excluding data from workers with dust respirators. Comparing the air and urine concentrations for samples under 30 ug/cu m (n = 20), a significant correlation was found (r = 0.76). These results indicate that most of the inhaled cobalt oxide was excreted rapidly, and a good relationship was found between air and urine concentrations at the end of the workshift when the exposure level was under 30 ug/cu m. Therefore, the cobalt concentration in urine at the end of a workshift can be used as an indicator of one-day exposure to cobalt oxide when the exposure is low level.', 'The 24-hr deposition and clearence in hamsters exposed by inhalation and gavage to CoO showed that 87% was distributed throughout the body form an inhaled dose of 784 ug and 11.3%, form a 5-mg dose by gavage. The greatest amounts from both routes (60 and 11% respectively) remained in the gastrointestinal tract. The carcass retained the next largest amounts, 23% from inhalation and 0.34% by gavage; the lung, 3.3% by inhalation and less than 0.06 by gavage. The liver and kidneys had small fractional percentages of the administered dose.', 'Three beagle dogs were exposed to 60Co3O4 /cobaltosic oxide/ and sacrificed singly at 8, 64 and 128 days. Three beagle dogs were exposed to 60CoO /cobaltous oxide/ and sacrificed at 8, 16 and 64 days after exposure. Whole-body retention patterns showed that 60CoO left the body with a shorter effective half life than 60Co3O4. The concentration of 60Co detected in the blood was at least an order of magnitude higher in the dogs exposed to 60CoO than in the dogs exposed to 60Co3O4. Cobalt-60 translocated from the lung accumulated predominantly in the kidney, liver, skeleton and cartilagenous structures such as the trachea. Higher concentrations were reached earlier in the dogs exposed to 60CoO. After early fecal excretion of material deposited in the upper respiratory tract, excretion was greatest via the urine. The higher solubility of the 60CoO formed at 1400 C relative to 60Co3O4 formed at 850 C is noteworthy considering that generally aerosols formed at higher temperatures are more insoluble than aerosols formed at lower temperatures /Cobaltosic and cobaltous oxides/.', 'Cobalt concentration from processing cobalt oxide in urine: mean: 0.34 mg/L; range: 0.1-0.9 mg/L /From table/', 'For more Absorption, Distribution and Excretion (Complete) data for Cobaltous oxide (6 total), please visit the HSDB record page.']",,"['Chest counting data have been collected for about 4 yr for a case which involved inhalation of (60)Co-oxide. The measured chest burden ... decreases with successively increasing half times (about 10 months at early times to about 30 months after 3 yr)... With the exception of the long-term fraction in the lymph nodes, only one rate of elimination seems to be present, 225 days, throughout the period of observation.', 'The behavior of (60)Co has been studied in 5 men for periods of up to 11 yr after accidental inhalation of the irradiated metal or its oxide. It is concluded from body radioactivity measurements that long term clearance from the chest may be extremely slow, with observed biological half lives of up to 17 yr, while for the clearance of systemic burdens of (60)Co, a value in the region of 7 yr is suggested.', 'Intratracheally instilled cobaltous oxide (1.5 ug) was retained in the lung for a relatively long period with a half-time of about 15 days.']"
4786,14787,Chromium trihydroxide,O.O.O.[Cr],,,,"['The excretion & whole-body retention of various (51)Cr chromium compounds differed greatly in the rat & mouse. Thus, 7 days after the iv dose to mice, retained (51)Cr was 2% of Cr-EDTA, 20% of Cr-alloxantin, 40% of chromium chloride, & nearly 100% of chromium trihydroxide. There was high uptake of chromium trihydroxide in the liver.']",,
4787,14788,Iron disulfide,S=[Fe]=S,,,,,,
4788,14789,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],,,,,,
4789,14790,CID 14790,O.O=[Fe],,,,,,
4790,14791,Magnesium dihydroxide,[OH-].[OH-].[Mg+2],,,,,,
4791,14792,Magnesium Oxide,O=[Mg],,,['Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)'],,,
4792,14793,Lead dioxide,O=[Pb]=O,,,,"['This solubility was studied in vitro for the six following metal oxides: Cd, Cr, Fe, Mn, Pb, Zn, by holding particle oxides in suspension into human plasma at 37 degrees C, during variable time. The experimentation was realized on particles which belong to two categories which sizes are 0.45-2 and 2-5 mu. The evolution of metal oxide dissolved level according to time have enabled exponential relation parameters to be calculated. These parameters translate the particle oxide dissolution into plasma and have permitted to classify metal oxide in decreasing solubility order: Cd, Zn, PbO, Fe2O3, Fe3O4, Mn, PbO2, Pb3O4 and Cr2O3.']",,
4793,14794,Diantimony trioxide,[O-2].[O-2].[O-2].[Sb+3].[Sb+3],,,,,,
4794,14795,Iron selenide,[Fe]=[Se],,,,,,
4795,14796,Germanium dioxide,O=[Ge]=O,,,['Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)'],"['Germanium in various forms is absorbed from the gastrointestinal tract and excreted in the urine (68%) and the feces (9.7%) within 24 hours of administration. It is fairly equally distributed between plasma and red blood cells but is not bound to plasma proteins. Germanium may be transported in the blood, unbound to protein, since it leaves the bloodstream in a few hours. It is widely distributed in body tissue and not selectively retained by any single tissue. Often, within a week it has even disappeared from the tissues in which it was detected. /Germanium/', '... EXCRETION OF ... (71)GERMANIUM DIOXIDE IN RABBIT & DOG SHOWED ELIMINATION CHIEFLY VIA THE URINE AS WAS FOUND IN RAT. ESSENTIALLY SAME TYPE OF METABOLIC ACTIVITY OCCURRED WITH NEUTRON-ACTIVATED ... (71)GERMANIUM DIOXIDE DUSTS BY INHALATION.', '(71)GERMANIUM DIOXIDE WAS CLEARED ... MORE RAPIDLY FROM LUNGS, KIDNEYS, & LIVER (79% IN 1 DAY), & ONLY TRACER AMT REMAINED IN THESE ORGANS @ 4 & 7 DAYS.', '... NEUTRALIZED GERMANIUM DIOXIDE IS READILY ABSORBED FOLLOWING SMALL ... ORAL, SC, IM, OR IP DOSES IN RAT. BLOOD LEVELS ATTAINED SOMEWHAT LESS THAN 10 UG/G WITHIN FEW HR AFTER ... SINGLE SMALL DOSE, GERMANIUM LEAVES BLOODSTREAM WITHIN FEW HR. ... GERMANIUM ... DISTRIBUTED THROUGHOUT BODY ... NOT SELECTIVELY RETAINED IN ANY TISSUE ... .', 'For more Absorption, Distribution and Excretion (Complete) data for GERMANIUM DIOXIDE (13 total), please visit the HSDB record page.']","['... AN AVG AMT OF 90% OF IV INJECTED GERMANIUM OXIDE WAS EXCRETED IN URINE OF DOGS WITHIN 72 HR, & 75% IN THAT OF RABBITS, AN AVG OF 9% BEING EXCRETED IN FECES DURING THAT TIME. FROM THESE RESULTS IT IS APPARENT THAT GERMANIUM ... IS NOT INCORPORATED IN BODY ... .']",
4796,14797,Potassium Hydroxide,[OH-].[K+],"['Medically, the microscopic examination of potassium hydroxide (KOH) preparations is utilized in the diagnosis of fungal hyphae or trichomonads.  Samples from hair, skin, or nail tissue are obtained by scraping with a scalpel, cotton-tipped applicator and are inoculated directly onto the KOH solution.  In addition to the above, potassium hydroxide is used as a softener for nail grooves.']","['The corrosiveness of potassium hydroxide renders it a very useful agent in the decomposition/removal soft tissue and hair removal. It is incorporated into some nail products, shaving creams, and soaps.']","['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']","['KOH in aqueous solutions completely dissociates into K+ and OH- ions. Because of the neutralization of OH- by gastric HCl and the rapid blood pH regulation action (buffer capacity of extracellular body fluids, respiratory and renal compensation mechanisms), an alkalosis due to the OH- ions after KOH oral dosage in non-irritating conditions is thus prevented.  The uptake of potassium, in potassium hydroxide form, is much less than the oral uptake with therapeutic doses of KCl for treating potassium deficiency, of up to 10 g/day. Furthermore, the oral uptake of potassium from food/natural sources or from food additives is likely to be also much higher.', 'Interesting observations are also that alkalosis promotes renal excretion of K+, and that, for preventing hyperkalemia, extra cellular potassium is taken up by cells in exchange for hydrogen ions (Saxena, 1989). In other words, these compensating effects of K+ and OH- would attenuate the systemic effect of KOH.', '...It can also be stated that the substance will neither reach the foetus nor reach male and female reproductive organs in effective toxic concentrations. Therefore, no risk for reproductive toxicity is expected.', 'Under normal handling and use conditions (non-irritating) neither the concentration of potassium in the blood nor the pH of the blood will be increased above normal limits and therefore KOH is not expected to cause systemically toxic levels in the blood. The renal excretion of K+ can be elevated and the OH- ion is neutralised by the bicarbonate buffer system in the blood...', 'Alkalies penetrate skin slowly. /Alkalies/', 'Ammonium hydroxide penetrates fastest, followed by sodium hydroxide, potassium hydroxide, and finally calcium hydroxide.']","['KOH in aqueous solution is entirely dissociated into K+ and OH- ions. Due to the neutralization of OH- by gastric HCl and the quick and efficient blood pH regulation mechanisms (buffer capacity of extra cellular body fluids, respiratory and renal compensation mechanisms), an alkalosis due to the OH- ions after KOH oral dosage in non-irritating conditions is prevented.', 'KOH in aqueous solutions is completely dissociated into K+ and OH- ions. Due to the neutralization of OH- by gastric HCl and the quick and efficient blood pH regulation mechanisms (buffer capacity of extra cellular body fluids, respiratory and renal compensation mechanisms), an alkalosis due to the OH- ions after KOH oral dosage in non-irritating conditions is prevented.', '...In every case, it should be realised that aerosols of KOH are not stable. They are rapidly transformed due to an uptake of carbon dioxide from the atmosphere resulting in the formation of potassium bicarbonate and potassium carbonate. Cooper et al. (1979) reported that the transformation of respirable NaOH aerosols into carbonate aerosols could occur in seconds...']",
4797,14798,Sodium Hydroxide,[OH-].[Na+],['Used to destroy or kill the nail matrix (matrixectomies).'],"['Sodium Hydroxide 10% forms a strongly alkaline and caustic solution. As a caustic agent, it is used to destroy organic tissue by chemical action.']","['Strong alkaline chemicals that destroy soft body tissues resulting in a deep, penetrating type of burn, in contrast to corrosives, that result in a more superficial type of damage via chemical means or inflammation. Caustics are usually hydroxides of light metals. SODIUM HYDROXIDE and potassium hydroxide are the most widely used caustic agents in industry. Medically, they have been used externally to remove diseased or dead tissues and destroy warts and small tumors. The accidental ingestion of products (household and industrial) containing caustic ingredients results in thousands of injuries per year. (See all compounds classified as Caustics.)']","['There are no quantitative data for the absorption of sodium hydroxide through the skin. Solutions which contain 50 % sodium hydroxide have been shown to be corrosive and lethal when applied dermally to mice.', 'ALKALIS PENETRATE SKIN SLOWLY.', 'Ammonium hydroxide penetrates fastest, followed by sodium hydroxide, potassium hydroxide, and finally calcium hydroxide.']",,
4798,14799,Mercury oxonium sulfate,[O-2].[O-2].[O-]S(=O)(=O)[O-].[Hg+2].[Hg+2].[Hg+2],,,,,,
4799,14800,Potassium monosulfide,[SH-].[K+].[K+],,,,,,
4800,14801,Manganese dioxide,O=[Mn]=O,,,,,,
4801,14802,Molybdenum trioxide,O=[Mo](=O)=O,,,,"['Following rapid absorption from the gastrointestinal tract /of/ guinea pigs, molybdenum trioxide was found to be deposited rather uniformly in the critical organs within 4 hr ... .', 'Rats stored relatively more molybdenum from ingested molybdenum trioxide than from Powellite (CaMoO4). ... Significant storage above normal of molybdenum in bone was noted in all cases.', 'RABBITS SHOWED ... RAPID ABSORPTION OF MOLYBDENUM /AS MOLYBDENUM TRIOXIDE/ FOLLOWING INGESTION, WITH RAPIDLY RISING BLOOD LEVELS. MOLYBDENUM IS RAPIDLY ELIMINATED BY KIDNEYS, RETURNING ... TO NORMAL VALUES IN 72 HR ... FECAL ELIMINATION, WHICH IS ABOUT 1/2 THAT OF URINARY, RETURNED TO NORMAL ... IN 72 HR.', 'IN BLOOD, LEVEL DEPENDS LARGELY ON CONTENT OF MOLYBDENUM AND INORGANIC SULFATE IN DIET. ... RABBITS GIVEN SINGLE DOSE OF TRIOXIDE HAVE SHOWN A RISE FROM 130 TO 200 UG PER 100 ML, EVEN AS HIGH AS 1,850-1,970 UG ... .', 'For more Absorption, Distribution and Excretion (Complete) data for MOLYBDENUM TRIOXIDE (21 total), please visit the HSDB record page.']",,"['Data ... concerning excretion and the rapid clearance from the liver, kidney, spleen, testis, and hard tissues in animal studies show that the biological half time, at least for the most part of the absorbed molybdenum, must be in the order of hours and extending to a max of about one day in lab animals and cows. ... After a single subcutaneous injection in rats, the concentration of molybdenum in blood decr rapidly. After 24 hr, only about 1% of the max concn remained. During the next 10 days, concn in blood diminished with a half time of about 7 days. After application of doses up to 3 ug/kg to rats the biological half time was 3 hr for subcutaneous, and 6 hr for intragastric application. After single subcutaneous application of 0.02 to 1 ug molybdenum/kg to rats the biological half time in the kidneys, liver, spleen, jejunoileum, and skin varied between 2.5 and 4.7 days. /Molybdenum/']"
4802,14803,Sodium peroxide,[O-][O-].[Na+].[Na+],,,,,,
4803,14804,Sodium sulphide,[Na+].[Na+].[S-2],,,,,,
4804,14805,Nickel oxide,O=[Ni],,,,"['Ten days after the inhalation of a nickel oxide aerosol, ... 80% of the deposited dose was still retained in the lung of hamsters.', 'Wistar male rats were exposed to green nickel oxide aerosols (mass media aerodynamic diameter, 0.6 um) for 7 hr/day, 5 days/wk for less than or equal to 12 mo. The avg exposure concn was controlled at 0.3 mg/cu m and 1.2 mg/cu m. Rats were sacrificed following a 3-6 or 12 mo exposure. There were no differences in body wt gain between exposure groups and controls. Lung wt in exposed rats were heavier than those in the control groups. Nickel concn in lung of exposure groups were much higher than those of controls. The nickel concn in liver, kidney, spleen, and blood increased slightly with increased exposure times. The nickel content in lung during the 12 mo exposure was estimated theoretically. The estimated values agreed with the experimental data.', 'SIGNIFICANT UPTAKE & ACCUM OCCURRED IN 20, 40, & 80 MG NI/L IN 96 HR EXPT. MUSSELS SECRETED BYSSAL THREADS IN CONCN OF 20 MG NI/L, BUT NOT IN HIGHER CONCN.', 'AFTER ACUTE OR CHRONIC EXPOSURE OF RATS ... BY INHALATION, INCR IN NI OCCUR PREDOMINANTLY IN MICROSOMAL & SUPERNATANT FRACTIONS OF LUNG & LIVER. AFTER CHRONIC EXPOSURE, INCR AMT OF NI ARE ALSO OBSERVED IN NUCLEAR & MITOCHONDRIAL FRACTION OF THE LUNG.', 'For more Absorption, Distribution and Excretion (Complete) data for NICKEL OXIDE (8 total), please visit the HSDB record page.']",,"['Male rats were exposed to nickel oxide (NiO) aerosols (mass median aerodynamic diameter, 1.2 and 4.0 um). The average exposure concn was controlled from a low level of 0.6 mg/cu m to a high level of 70 mg/cu m and total exposure time was 140 hr. Some rats were sacrificed just after the exposure, whereas others were exposed for 1 mo and kept for 12 and 20 mo clearance periods before sacrifice. There were no differences in body wt grain between NiO exposure groups and controls. Nickel concn in lung of exposure groups were much higher than those of controls and decreased with increased clearance time. No apparent deposition of nickel was observed in the liver, kidney, spleen, and blood immediately after the exposure, but in the high exposure groups, nickel concn in the liver, spleen, and blood increased slightly with increasing clearance time. The biological half-time of NiO deposited in the lung, assuming that the amt of the clearance is proportional to the amt of the NiO deposited, was 11.5 and 21 mo for 1.2 and 4.0 um, respectively.', '... Half-life for the clearance of nickel /oxide/ from the deep tract /of the lungs/ of 36 days. The half-life for clearance from the tracheobronchiolar compartment was less than 1 day.']"
4805,14806,Zinc Oxide,O=[Zn],"['For adjunctive treatment of diaper dermatitis. Also, it can be used to treat minor skin irritations (eg, cuts, burns, and scrapes, poison ivy). Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light.']","['Zinc oxide has astringent, soothing and protective properties and is used in topical preparations for eczema, slight excoriations, wounds and haemorrhoids. It also reflects ultraviolet radiation and can be used as a physical sunscreen.']","['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation. (See all compounds classified as Sunscreening Agents.)']","['No significant percutaneous absorption from topically applied zinc oxide.', 'Intended for local use only, no systemic absorption.', 'Intended for local use only, no systemic absorption.', 'Intended for local use only, no systemic absorption.']","['Intended for local use only, no systemic absorption.']","['Intended for local use only, no systemic absorption.']"
4806,14807,Strontium peroxide,[O-][O-].[Sr+2],,,,,,
4807,14808,Thorium dioxide,O=[Th]=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['Retention of thorium from inhalation of thorium dioxide dust for 1 yr ... left 98% of the body burden of thorium in the lung and pulmonary lymph nodes, 2% in bone, and less than 0.1% in the rest of the body. The relative immobility of tissue-deposited thorium is shown by the presence of 97.7% in the pulmonary lymph nodes, 2.1% in the lung, and 0.003% in the femur, and fractions of the latter amount in the kidney, spleen, and liver 6 to 7 yr after inhalation exposure had been terminated.', 'The fecal to urinary ratio was 1.6 compared with 45 at higher dose levels, and in two patients given iv injections of 12 to 14 g Thorotrast, one excreted 0.37% in the urine on the first day and only a total of 0.7% in the next 16 days, and the other, only 0.1% in 108 days.', 'Thorium dioxide is taken up by the cells of the reticuloendothelial system ... and none of the thorium dioxide from the reticuloendothelial system is transferred to the skeleton.', 'The absorption of ... /thorium dioxide/ in rats ... is almost negligible. ... Thorium dioxide remains at the site for a long time, and only small quantities are gradually removed by lymphocytes to the regional lymph nodes.', 'For more Absorption, Distribution and Excretion (Complete) data for THORIUM DIOXIDE (10 total), please visit the HSDB record page.']","['Two cytogenetic parameters of radiation exposure, the frequency of micronucleus in erythroblasts, lymphocytes and red cells (Howell-Jolly) as well as chromosome aberrations in bone marrow cells and in lymphocytes were studied in 24 Thorotrast patients and in 32 atomic bomb (A-bomb) survivors who were exposed within 1 km from the Hiroshima (Japan) hypocenter. The incidence of both micronucleus and chromosome aberrations in these two exposed groups were significantly higher than that in non-exposed controls. ... The characteristics of lymphocyte chromosome aberrations differed considerably between Thorotrast patients and A-bomb survivors the incidence of unstable type aberrations and intracellular complexity of chromosome aberrations were much higher in the former group. The incidence of micronucleus in erythroblasts and lymphocytes was also higher in Thorotast patients. Such differences are attributable to the differences in the radiation quality (alpha-ray or gamma-ray + neutron) and in the mode of exposure (persistent or single) of these two groups.']","['Biological half-life for the long term clearance from the body was at least 14-15 yr, presumably because of the amt deposited in the skeleton.', 'In a subject who had accidentally inhaled thorium-228 dioxide (alpha emitter, radioactive half-life of 1.9 years), the biological half-life for long-term clearance of thorium-228 from the body was at least 14 years as a result of skeletal deposition']"
4808,14809,ZINC peroxide,OO.[Zn],,,,,,
4809,14810,Phosphorus trioxide,O=POP=O,,,,,,
4810,14811,Tungsten trioxide,O=[W](=O)=O,,,,"['RATS WERE FED FOR A PERIOD OF 100 DAYS ON DIETS IN WHICH TUNGSTEN HAD BEEN INCORPORATED EITHER AS THE FINELY GROUND METAL, TUNGSTEN OXIDE, SODIUM TUNGSTATE OR AS AMMONIUM PARATUNGSTATE. THE PRINCIPAL SITES OF DEPOSITION WERE BONE & SPLEEN WITH TRACE QUANTITIES (LESS THAN 1.0 MG% AS SPECIFIED BY AUTHORS) IN KIDNEY & LIVER, & IN SOME ANIMALS IN BLOOD, LUNG, MUSCLE & TESTES. NO MARKED DIFFERENCE IN DISTRIBUTION OF TUNGSTEN WAS FOUND WITH THE DIFFERENT COMPD INGESTED.', '...IN ANIMAL EXPERIMENTS, MUCH OF THE ABSORBED TUNGSTEN IS RAPIDLY EXCRETED IN THE URINE. ... THE RATE OF DECR IN BLOOD ACTIVITY FOLLOWING INHALATION OF TUNGSTIC OXIDE AEROSOL WAS SLOWER THAN THAT FOR INJECTED SODIUM TUNGSTATE, BUT THIS COULD BE ACCOUNTED FOR BY ACTIVITY ENTERING THE BLOOD FROM THE LUNG & THE GUT OVER AN EXTENDED PERIOD AFTER EXPOSURE.', '...DIETARY METABOLIC STUDY IN RATS MADE ON TUNGSTIC OXIDE...EQUIVALENT TO 0.1% W...REVEALED AFTER 100 DAYS ON THE DIETS THAT BONE & SPLEEN RETAINED THE MOST W; CONCENTRATIONS AVERAGED 115 & 75 PPM... LESS THAN 10 PPM WAS PRESENT IN LIVER, KIDNEY, & SKIN. BLOOD, LUNG, TESTES, & MUSCLE SHOWED TRACES OF W IN OCCASIONAL INSTANCES. EXCEPT FOR A SINGLE INSTANCE IN EACH ORGAN, THE HEART, & UTERUS WERE FREE OF W...', 'RATS...FED...100 DAYS ON DIETS IN WHICH TUNGSTEN...AS FINELY GROUND METAL, /OR/ TUNGSTEN OXIDE... PRINCIPLE SITES OF DEPOSITION WERE BONE & SPLEEN WITH TRACE QUANTITIES (LESS THAN 1.0 MG %...) IN KIDNEY & LIVER & IN SOME ANIMALS IN BLOOD, LUNG, MUSCLE & TESTES.', 'IN RAT FOLLOWING INGESTION OF (185)W 40% OF DOSE...EXCRETED IN URINE AFTER 24 HR & ABOUT 58%...ELIMINATED IN FECES OR HAD REMAINED UNABSORBED IN GUT WITH ONLY 2% REMAINING IN TISSUES. ... FOLLOWING INHALATION OF A (181)W-LABELLED TUNGSTIC OXIDE AEROSOL BY BEAGLE DOGS, 60% OF INHALED ACTIVITY WAS DEPOSITED IN RESP TRACT.']",,"['THE METABOLISM OF TUNGSTIC OXIDE FOLLOWING INHALATION HAS BEEN DETERMINED IN DOGS BY THE USE OF RADIOLABELED (181)WO3. AFTER INHALATION OF (181)WO3 MIST OF 98 UCI/ML SPECIFIC ACTIVITY FOR 6 HR, 1.9 TO 8.0 UCI WAS DEPOSITED IN THE RESP TRACT, 60% OF WHICH WAS IN THE LOWER PART OF THE TRACT. ...ABOUT 69% OF THE ACTIVITY WAS LOST, WITH A BIOLOGIC T/2 OF 4 HR, NEXT 23% WITH T/2 OF 20 HR, 4.6% MORE WITH T/2 OF 6.3 DAYS, & 3% WITH T/2 OF 100 DAYS.', '/IN DOGS FOLLOWING INHALATION OF (181)WO3 98 UCI/ML SPECIFIC ACTIVITY FOR 6 HR/ MEASUREMENTS MADE ON THE LOWER HALF OF THE BODY SHOWED...94% HAD A T/2 OF 9 HR & 4.1% A T/2 OF 6.3 DAYS, WITH THE REMAINING 1.6% OF THE RADIOACTIVITY WITH A T/2 OF 139 DAYS. RADIOACTIVITY WAS LOST RAPIDLY FROM THE BLOOD. ...THE LUNGS & KIDNEYS RETAINED MAXIMAL RADIOACTIVITY; OTHER TISSUES CONTAINED ONLY ABOUT 10% AS MUCH AS THESE ORGANS. IN TERMS OF TOTAL BODY BURDEN OF RADIOACTIVITY, MOST WAS FOUND IN THE SKELETON (37%), LUNGS (31%), KIDNEYS (15%), LIVER (9.7%), & SKELETAL MUSCLE (5.7%).', 'INHALED TUNGSTIC OXIDE IN DOGS REMOVED WITH BIOL T/2 OF LITTLE LESS THAN 9 HR FOR 94% OF ACTIVITY IN VISCERAL AREA WITH LONGEST T/2 OF 139 DAYS FOR 1.6% ACTIVITY.']"
4811,14812,Phosphoric anhydride,O=P12OP3(=O)OP(=O)(O1)OP(=O)(O2)O3,,,,,,
4812,14813,Antimony pentoxide,O=[Sb](=O)O[Sb](=O)=O,,,,,,
4813,14814,Vanadium pentoxide,O=[V](=O)O[V](=O)=O,,,,"['Median serum vanadium concentrations in /vanadium pentoxide/-exposed factory workers were 5.38 ug/L (range 2.18-46.3 ug/L), compared to 2.54 ug/L (range 1.01-12.5 ug/L) in unexposed controls.', '/A study/ found that 40% of endotracheally instilled (48)V2O5 (40 ug V/animal of 0.3 mg V/kg) was eliminated from the lungs within 1 hr of dosing, 90% had been cleared from the lung by day 3, and 40% had been excreted, primarily in the urine.', 'Lung deposition and clearance of inhaled vanadium pentoxide was ... studied over a period of 18 months in rats and mice. Female F-344 rats and B6C3F1 mice were exposed six hours/day, five days/week for up to 18 months at concentrations of 0, 0.5, 1, or 2 mg vanadium pentoxide/cu m (rats) and 0, 1, 2, or 4 (mice). Lung weights, vanadium lung burdens, and blood vanadium concentrations were determined periodically. Modeling of the data produced the significant outcome that lung burden data for both species followed a time-dependent decline in the deposition rates in the middle and high exposure groups but not in the low exposure group. Total lung doses were not proportional to exposure concentrations and for each species, by the end of 18 months, the overall lung doses in the lower two exposure concentrations were almost identical.', 'Studies of (48)V2O5 on rats demonstrate that it is absorbed in the gastrointestinal tract and via intratracheal instillation. It is distributed to all major organs sampled (except the brain) including blood, lungs, bone, kidneys, spleen, liver, testes, heart, intestines, stomach, trachea, and muscle. Both urinary excretion and fecal elimination were observed, with urine accounting for about twice as much of the elimination as feces.', 'For more Absorption, Distribution and Excretion (Complete) data for VANADIUM PENTOXIDE (15 total), please visit the HSDB record page.']","['Within tissues in organisms, V3+ and V4+ predominate because of largely reducing conditions; in plasma, however, which is high in oxygen, V5+ is formed.']","['Animal studies: 40% of absorbed dose eliminated in urine within 3 days; [TDR, p. 1212]', 'Groups of 60 female rats were exposed to particulate aerosols of vanadium pentoxide at concentrations of 0, 1, or 2 mg/cu m and groups of 40 female rats were exposed to 4 mg/cu m by inhalation, 6 hr/day, 5 days/wk for 16 days. ...Lung clearance half-times ranged from 4.42 to 4.96 days.', 'Groups of 60 female mice were exposed to particulate aerosols of vanadium pentoxide at concentrations of 0, 2, or 4 mg/cu m and groups of 40 female mice were exposed to 8 mg/cu m by inhalation, 6 hr/day, 5 days/wk for 16 days. ...Lung clearance half-times ranged from 2.40 to 2.55 days.']"
4814,14815,Uranium oxide sulfate,[O-]S(=O)(=O)[O-].O=[U+2]=O,,,,"['Sol compounds are highly transportable from lung to other parts of the body; these include uranium hexafluoride, uranyl nitrate, uranyl chloride, uranyl fluoride, & uranyl acetates, sulfates & carbonates. /Soluble uranium compounds/', 'GI absorption of small doses of soluble uranyl salts in mammals is about 10%; insoluble salts are poorly absorbed. Absorption of uranium salts from sites of im injection and from peritoneal cavity is poor. ... Soluble uranyl salts are also absorbed through skin. Following inhalation the absorption of uranium salts from the lung tissues into blood depends upon ... solubility and particle size. /Soluble uranyl salts/', 'In acute human exposure situations, uranium deposits in the kidney are eliminated with a half-time of 2 to 6 days. Inhaled soluble uranium salts that reach the alveoli are almost completely absorbed and then cleared rapidly to the urine, kidneys, and bone, with none left in the lungs by 30 days.   /Soluble uranium compounds/']",,"['The biologic half times of soluble uranium compounds (e.g., uranium hexafluoride, uranyl fluoride, uranium tetrachloride, uranyl nitrate hexahydrate) are estimated in days or weeks. /Soluble uranium compounds/']"
4815,14816,Dioxouranium(2+),O=[U+2]=O,,,,,,
4816,14817,Phosphorus pentasulfide,P12(=S)SP3(=S)SP(=S)(S1)SP(=S)(S2)S3,,,,,,
4817,14818,Phosphorus sesquisulfide,P12P3P1SP(S2)S3,,,,,,
4818,14819,Lead(II) sulfide,S=[Pb],,,,"['Biosynthesis of nanoparticles using microorganisms has attracted a lot of attention in recent years as this route has the potential to lead to synthesis of monodisperse nanoparticles. Here, we report the intracellular synthesis of stable lead sulfide nanoparticles by a marine yeast, Rhodosporidium diobovatum. The PbS nanoparticles were characterized by UV-visible absorption spectroscopy, X-ray diffraction (XRD) and energy dispersive atomic spectroscopy (EDAX). UV-visible absorption scan revealed a peak at 320 nm, a characteristic of the nanosize range. XRD confirmed the presence of PbS nanoparticles of cubic structure. Crystallite size as determined from transmission electron microscopy was found to be in the range of 2-5 nm. Elemental analysis by EDAX revealed the presence of particles composed of lead and sulfur in a 1:2 ratio indicating that PbS nanoparticles were capped by a sulfur-rich peptide. A quantitative study of lead uptake through atomic absorption spectrometry revealed that 55% of lead in the medium was accumulated in the exponential phase, whereas a further 35% was accumulated in the stationary phase; thus, the overall recovery of PbS nanoparticles was 90%. The lead-exposed yeast displayed a marked increase (280% over the control) in nonprotein thiols in the stationary phase. /PbS nanoparticles/', 'Data obtained from a feeding study in rats /showed that/ lead uptake into rat femurs was highly dependent on the chemical form of lead administered. Bioavailability was highest for lead acetate, intermediate for lead oxide, and lowest for lead sulfide and Alaskan mixed ore concentrate. This uptake was linearly related to dose over the range studied.', '... Under fasting conditions /in humans/ absorption of lead nitrate, lead sulfide, and lead cysteine ranged from 16 to 53%.', '/In rats/, absorption of sulfide, chromate, naphenate, and octoate were absorbed at only 44-67% the rate of absorption for lead acetate. ... Update of lead into the femurs of rats was highest for lead acetate, intermediate for lead oxide, and lowest for lead sulfide and a mixture of Alaskan ore concentrate.', 'The lead sulfide (PbS) in galena is insoluble and absorption from the lung is limited; however, in the stomach, some lead sulfide may be converted to slightly soluble lead chloride which may then be absorbed in moderate quantities.']",,
4819,14820,Strontium sulphide,S=[Sr],,,,,['GASTRIC ACID DECOMPOSES IT TO HYDROGEN SULFIDE.'],
4820,14821,Sachtolith,S=[Zn],,,,,,
4821,14822,CID 14822,C(C(C(C(C(C(=O)O)O)O)O)O)O.O.[OH-].[AlH3].[K+],,,,,,
4822,14823,Molybdenum disulfide,S=[Mo]=S,,,,"['Determination of molybdenum in tissues (lung, liver, kidney, spleen, bone) of guinea pigs following 25 days of inhalation of subLD50 doses of the sulfide, the dust and fume of the trioxide, and calcium molybdate showed rather uniform distribution in the tissues, incl bone, for all substances at the end of the exposure. Values from 10 to 60 ug/10 g fresh tissue were common for all substances except molybdate trioxide and calcium molybdate dusts, which were higher by a two to four fold factor in the kidney, lung, spleen, and bone. Other exceptions were high lung retentions (40 and 18 times, respectively) for the sulfide and molybdate over that by other tissues according to the thiocyanate method of analysis.', '... LARGE AMT /OF MOLYBDENUM/ TEND TO ACCUMULATE IN LIVER. /MOLYBDENUM/']",,
4823,14824,Manganese(III) oxide,O=[Mn]O[Mn]=O,,,,,,
4824,14825,Manganese tetroxide,O[Mn]=O.O[Mn]=O.[Mn],,,,,,
4825,14826,CID 14826,O.O=[Mn],,,,,,
4826,14827,Lead monoxide,O=[Pb],,,,"['The aim of this study was to investigate the percutaneous penetration of lead oxide (PbO) powder and the effect of rapid skin decontamination with two different detergents. Franz cells were used to study in vitro PbO skin penetration through human skin during a 24-hour period. The tests were performed without or with decontamination using either Ivory Liquid soap or a new experimental cleanser 30 minutes after the start of exposure. We confirm that PbO can pass through the skin with a median penetration of 2.9 ng/cm (25-75th percentiles 0.35-6). The cleaning procedure using Ivory Liquid soap significantly increased skin penetration with a median value of 23.6 ng/cm (25-75th percentiles 12-47.1; Mann-Whitney U test, P = 0.0002), whereas the new experimental cleanser only marginally increased penetration (7.1 ng/cm). Our results indicate that it is necessary to prevent skin contamination from occurring because a short contact can increase skin content and penetration even if quickly followed by washing. This study demonstrated that PbO powder can pass through the skin and that skin decontamination done after 30 minutes of exposure did not decrease skin absorption occurring over 24 hours and stresses the need to prevent skin contamination when using toxic substances.', '14 male volunteers were exposed to a lead oxide aerosol for 23 hr per day at an average concentration of 10.9 ug/cu m for up to 17 weeks. ... The air contribution to the lead blood levels was approx 1.4 ug of lead per 100 mL blood per 1 ug of lead per cu m.', 'Data obtained from a feeding study in rats /showed that/ lead uptake into rat femurs was highly dependent on the chemical form of lead administered. Bioavailability was highest for lead acetate, intermediate for lead oxide, and lowest for lead sulfide and Alaskan mixed ore concentrate. This uptake was linearly related to dose over the range studied.', 'The objective of this study was to determine percutaneous absorption of lead compounds, including lead sulfate, lead oxide, lead powder, and lead stearate. The lead content on the skin surface of 10 lead-battery workers was measured by the method of skin stripping, and urinary lead content of rats was measured with epicutaneous application of four lead compounds: lead sulfate, lead oxide, lead powder, and lead stearate. There were significant amounts of lead on the 9th and 10th skin strippings of the dorsal hand and the back of lead workers. The amount of lead on the dorsal hand was significantly correlated with the amount in the blood (n = 10, r 2 = 0.66, p < 0.05, linear regression). In rats, after lead compounds were applied for 12 days, total lead amount in urine significantly increased to 146.0 + or - 6.4 ng (SD) for lead stearate, 123.1 + or - 7.2 ng for lead sulfate, 115.9 + or - 5.3 ng for lead oxide, 47.8 + or - 6.9 ng for lead powder, and 10.3 ng for the control, which indicated significant skin absorption. It was concluded that significant amounts of inorganic lead compounds can be absorbed through the skin, and skin protection in lead-working or any contaminated environment should be carefully considered.', 'For more Absorption, Distribution and Excretion (Complete) data for Lead(II) Oxide (7 total), please visit the HSDB record page.']",,
4827,14828,Ferrous sulfide,S=[Fe],,,,,,
4828,14829,Copper(II) oxide,O=[Cu],,,"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['The pulmonary uptake of copper oxide /occurred/ in rats exposed to aerosols containing 50-80 mg/cu m. Animals were exposed for 15, 30, 45, or 60 minutes and killed immediately. Another group was exposed for 180 minutes and killed at 0, 3, 6, 12, 18, or 24 hours after exposure. Electron microscopic histologic examination showed that absorption of copper had occurred in animals exposed for 180 minutes. Copper oxide particles penetrated the epithelial cells of alveoli and were found in plasma 6 hours after exposure began. Copper oxide was also observed in the proximal convoluted tubules of the kidney. /Copper oxide/', 'VET: COPPER SOURCE. 80% COPPER CONTENT. LOW ABSORPTION RATE & HIGH FECAL EXCRETION RATE IN CATTLE & SWINE FEEDING TRIALS. IN GENERAL MONOGASTRIC ANIMALS UTILIZE /CUPRIC OXIDE/ BETTER THAN RUMINANTS. POULTRY UTILIZATION IS SOMEWHERE BETWEEN THE TWO.', 'Cheviot ewes (mean live weight 50 kg) were given single doses of 0, 2.5, 5, 10, or 20 g cupric oxide particles in gelatin capsules while receiving a diet of marginal copper content based on pelleted oats. After 65 days, liver copper concentrations had increased curvilinearly in relation to dose and all ewes given 10 or 20 g cupric oxide particles showed increases of at least 13.4 mmol/kg dry matter (850 ppm). Liver copper concentrations had generally declined after 85 days but biochemical and histological evidence of copper toxicity was recorded in one ewe which had received 20 g cupric oxide particles. Despite marked variations between individual sheep, a dose of 0.1 g/kg liveweight (5 g) was considered to be safe and did not induce clinical copper toxicity in five sheep of the susceptible North Ronaldsay breed given the same basal diet.', 'Crossbred steers, mean initial live weight 220 kg, were given a diet of barley and hay ad libitum. Each animal received a single oral does of 0, 5, 10, 20, or 40 g cupric oxide particles. A dose of 5 g cupric oxide particles increased liver copper stores for about 240 days and higher doses increased liver stores for longer but 40 g was no more effective than 20 g (85 mg/kg live weight). Variation among individuals was marked but the highest liver copper concentration recorded (7.59 mmol/kg dry matter) produced no biochemical evidence of copper toxicity. Cupric oxide particles were separated into three fractions, clumps, short rods and long; and 5 mg/kg live weight of each fraction given to steers of 173 kg mean live weight. The form of the particles did not affect either their retention in the alimentary tract or the accumulation of copper in the liver.', 'For more Absorption, Distribution and Excretion (Complete) data for COPPER(II) OXIDE (6 total), please visit the HSDB record page.']",,
4829,14830,Cu-O-Cu Linkage,O.[Cu].[Cu],,,,,,
4830,14831,Copper(II) sulfide,S=[Cu],,,,"['... COPPER SULFIDES ... ARE POORLY ABSORBED. /COPPER SULFIDES/', 'Ionic copper is absorbed from the stomach, duodenum, & jejunum. The initial absorption is about 30%, but the effective net absorption is only about 5% due to excretion of copper into the bile; biliary copper is bound to protein, & this complex is not reabsorbed. Absorption is influenced by a number of factors including the chemical forms of copper: oxides, hydroxides, iodides, glutamates, citrates, & pyrophosphates of copper are readily absorbed, but copper sulfides & other water insoluble salts are poorly absorbed. Copper complexes of some amino acids are easily absorbed, whereas copper porphyrins present in meat are very poorly absorbed. /Soluble copper salts/']",,
4831,14832,Cobalt sulfide,S=[Co],,,,,,
4832,14833,Hematite,[O-2].[O-2].[O-2].[Fe+3].[Fe+3],,,,['... Proportion ... introduced into lungs of experimental animals remained within lungs of Tracheo-bronchial lymph nodes throughout their remaining life-span. Particles appear to penetrate walls of alveoli & respiratory bronchioles and remain in connective tissues of lung within macrophages which form clusters of various sizes.'],,
4833,14834,Basic lead carbonate,C(=O)([O-])[O-].C(=O)([O-])[O-].[OH-].[OH-].[Pb+2].[Pb+2].[Pb+2],,,,"['Adult male dogs were given daily doses of 34.1 mg and 68.2 mg basic lead carbonate (white lead) for 60 days. Ratio of urinary lead excretion to total lead admin was very small; 0.24% and 0.09% respectively. 98.7% and 98.9% respectively of total lead admin was fecally excreted. Urinary and fecal excretions totalled 98.4 and 97.9% respectively. The highest concn was found in teeth and bones, followed by bone marrow, hair, and trachea.']",,
4834,14835,Potassium glycerophosphate trihydrate,C(CO)C(CCO)OP(=O)([O-])[O-].C(C(COP(=O)([O-])[O-])O)O.[K+].[K+].[K+].[K+],,,,,,
4835,14836,Hercules 7175,CN(C)C(=O)NC1CC2CC1CC2Cl,,,,,,
4836,14837,CID 14837,CC1=CC(=C(C=C1)NN=C2C(=O)C=CC(=NNC3=CC=C(C=C3)S(=O)(=O)[O-])C2=O)C.[Na+],,,,,,
4837,14838,"4-[2-[5-[(2,4-Dimethylphenyl)hydrazinylidene]-4,6-dioxocyclohex-2-en-1-ylidene]hydrazinyl]benzenesulfonic acid",CC1=CC(=C(C=C1)NN=C2C(=O)C=CC(=NNC3=CC=C(C=C3)S(=O)(=O)O)C2=O)C,,,,,,
4838,14839,Dibromsalan,C1=CC(=CC=C1NC(=O)C2=C(C=CC(=C2)Br)O)Br,,,,,,
4839,14840,"Acetic acid, (2,4-dichlorophenoxy)-, 2-butoxypropyl ester",CCCCOC(C)COC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,"['Leaves absorb nonpolar (ester) forms most readily. ... The esters of 2,4-D tend to resist washing from plants and are rapidly converted to the acid by the plants. ... Following foliar absorption, 2,4-D translocates within the phloem, probably moving with food material. Following root absorption, it may move upward in the transpiration stream. Translocation is influenced by the growth status of the plant. Accumulation of the herbicide occurs principally at the meristematic regions of shoots and roots. /2,4-D and its esters/', 'Plasma 2,4-D concn did not exceed 0.2 mg/l in workers exposed to 2,4-D ester at an atmospheric concn of 0.1 to 0.2 mg/l; no accumulation was noted during the work week. ... Workers ... developed 2,4-D urine concentrations of 3 to 14 mg/l after a day of exposure. /2,4-Dichlorophenoxyacetic acid ester/']","['Plants hydrolyze 2,4-D esters to 2,4-D, which is the active herbicide. ... Further metabolism ... occurs through three mechanisms, namely, side chain degradation, hydroxylation of the aromatic ring, and conjugation with plant constituents. /2,4-D esters/', 'HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID. /2,4-D ESTERS/', '2,4-D ESTERS ARE HYDROLYZED IN ANIMALS. THE PHENOXY ACIDS ARE EXCRETED PREDOMINANTLY AS SUCH IN THE URINE OF RATS AFTER THEIR ORAL ADMIN, ALTHOUGH MINOR PORTION IS CONJUGATED WITH AMINO ACIDS GLYCINE & TAURINE & WITH GLUCURONIC ACID. /2,4-D AND ESTERS/', 'Metabolites of 2,4-D other than conjugates have not been detected in human urine.']",['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/']
4840,14841,"1,2-Difluoroethene",C(=CF)F,,,,,,
4841,14842,"Benzyldimethyl(2-(2-((4-(1,1,3,3-tetramethylbutyl)-M-tolyl)oxy)ethoxy)ethyl)ammonium chloride",CC1=C(C=CC(=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2)C(C)(C)CC(C)(C)C.[Cl-],,,,,,
4842,14843,"Benzyldimethyl(2-(2-((4-(1,1,3,3-tetramethylbutyl)-m-tolyl)oxy)ethoxy)ethyl)ammonium",CC1=C(C=CC(=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2)C(C)(C)CC(C)(C)C,,,,,,
4843,14844,Manganese(2+) glycerol dihydrogen phosphate (1:1),C(CO)C(CCO)OP(=O)([O-])[O-].C(C(COP(=O)([O-])[O-])O)O.[Mn+2].[Mn+2],,,,,,
4844,14845,1-Methoxypropan-2-ol;2-methoxypropan-1-ol,CC(CO)OC.CC(COC)O,,,,,,
4845,14846,2-Methoxy-1-propanol,CC(CO)OC,,,,,,
4846,14847,Niacinamide adenylate,C1=CC(=CN=C1)C(=O)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)OP(=O)(O)O)O,,,,,,
4847,14848,CID 14848,CN1C(=C2C(=NC=N2)N=C1N)S,,,,,,
4848,14849,2-Amino-3-[(2-amino-2-carboxyethyl)disulfanyl]propanoic acid;molecular iodine,C(C(C(=O)O)N)SSCC(C(=O)O)N.II,,,,,,
4849,14850,CID 14850,CC1=CC(=C(C=C1)O)Cl.CC1=C(C(=CC=C1)Cl)O.CC1=C(C(=CC=C1)O)Cl.CC1=C(C=C(C=C1)O)Cl.CC1=CC(=CC(=C1)Cl)O.CC1=C(C=CC(=C1)O)Cl.CC1=C(C=CC(=C1)Cl)O.CC1=C(C=CC=C1Cl)O,,,,,,
4850,14851,2-Chloro-4-methylphenol,CC1=CC(=C(C=C1)O)Cl,,,,,,
4851,14852,2-Chloro-m-cresol,CC1=C(C(=CC=C1)O)Cl,,,,,,
4852,14853,3-Chloro-4-methylphenol,CC1=C(C=C(C=C1)O)Cl,,,,,,
4853,14854,3-Chloro-5-methylphenol,CC1=CC(=CC(=C1)Cl)O,,,,,,
4854,14855,4-Chloro-2-methylphenol,CC1=C(C=CC(=C1)Cl)O,,,,['The compounds are absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/'],"['An enzyme preparation metabolizing phenoxyacetate herbicides was made from a soil arthrobacter species. Crude extracts degraded 2,4-D, 4-chloro-2-methylphenoxyacetic acid, and 2- and 4-chlorophenoxyacetates. The products formed from 2,4-D, 4-chloro-2-methylphenoxyacetic acid, and 2-, and 4-dichlorophenoxyacetates were identified as 2,4-dichlorophenol, 2-methyl-4-chlorophenol, and 2- and 4-chlorophenols. The bacterial extract was capable of metabolizing catechol and 3-methyl, 4-chloro-, and 3,5-dichlorocatechols.', 'A bacterium capable of degrading 4-chloro-2-methylphenoxyacetic acid (MCPA) was isolated from soil and identified as flavobacterium peregrinum. Extracts of cells of flavobacterium peregrinum and of a phenoxy-acetate-metabolizing arthrobacter species dehalogenated 4-chloro-2-methylphenoxyacetic acid and several catechols but not 4-chloro-2-methylanisole. An arthrobacter species cell extract was fractionated, and an enzyme preparation was obtained which catalyzed the conversion of 4-chloro-2-methylphenoxyacetic acid to 4-chloro-2-methylphenol. The latter compound was not metabolized unless NADH was added.', 'Samples (200 g) of a sandy clay soil were incubated with 4-chloro-2-methylphenoxyacetic acid (MCPA) for 0-32 wk at 23 C. 4-chloro-2-methylphenol was identified as a degradation product of 4-chloro-2-methylphenoxyacetic acid.', 'The Gram-negative strain S1, isolated from activated sludge, metabolized 4-chloro-2-methylphenol by an inducible pathway via a modified ortho-cleavage route as indicated by a transiently secreted intermediate, identified as 2-methyl-4-carboxymethylenebut-2-en-4-olide by gas chromatography/mass spectrometry. Beside 4-chloro-2-methylphenol only 2,4-dichlorophenol and 4-chlorophenol were totally degraded, without an accumulation of intermediates. The chlorinated phenols tested induced activities of 2,4-dichlorophenol hydroxylase and catechol 1,2-dioxygenase type II. Phenol itself appeared to be degraded more efficiently via a separate, inducible ortho-cleavage pathway. The strain was characterized with respect to its physiological and chemotaxonomic properties. The fatty acid profile, the presence of spermidine as main polyamine, and of ubiquinone Q-10 allowed the allocation of the strain into the alpha-2 subclass of the Proteobacteria. Ochrobactrum anthropi was indicated by fatty acid analysis as the most similar organism, however, differences in a number of physiological features (e.g. absence of nitrate reduction) and pattern of soluble proteins distinguished strain S1 from this species.']",
4855,14856,3-Chloro-2-methylphenol,CC1=C(C=CC=C1Cl)O,,,,,,
4856,14857,CID 14857,C1=CC=C(C=C1)C(O)P(=O)=O,,,,,,
4857,14858,alpha-Hydroxybenzylphosphinic acid,C1=CC=C(C=C1)C(O)[P+](=O)O,,,,,,
4858,14859,"2-Ethyl-1,6-hexanediol",CCC(CCCCO)CO,,,,,,
4859,14860,6-Methoxyquinoline,COC1=CC2=C(C=C1)N=CC=C2,,,,,,
4860,14861,"5,6-Dimethyloct-7-yne-2,3-diol",CC(CC(C(C)O)O)C(C)C#C,,,,,,
4861,14862,Isodecanal,CC(C)CCCCCCC=O,,,,,"['Aldehydes are readily oxidized to organic acids, which, in turn, can serve as substrates for fatty acid oxidation pathways and the Krebs cycle. ... Oxidation of aldehydes is catalyzed by aldehyde dehydrogenase, which has been found in the brain, erythrocytes, liver, kidney, heart, and placenta. /Aldehydes/', '... The detoxification of aldehydes can be seen to proceed basically via two routes: (1) an oxidation to yield readily metabolized acids; (2) inactivation by reaction with sulfhydryl groups, particularly glutathione. Under conditions that either deplete glutathione levels, or that result in an inhibition of aldehyde dehydrogenase (for example, Antabuse treatment), the acute and chronic effects of aldehyde toxicity might be more fully expressed. /Aldehydes/']",
4862,14863,4-(2-Methylphenyl)butan-1-ol,CC1=CC=CC=C1CCCCO,,,,,,
4863,14864,"Carbonic acid, ethyl octynyl ester",CCCCCCC#COC(=O)OCC,,,,,,
4864,14865,Calcium diundec-10-enoate,C=CCCCCCCCCC(=O)[O-].C=CCCCCCCCCC(=O)[O-].[Ca+2],,,,,,
4865,14866,Nicoboxil,CCCCOCCOC(=O)C1=CN=CC=C1,"['The primary therapeutic use for which nicoboxil is currently indicated for is as an active ingredient in combination with the capsaicinoid nonivamide compound as a topical analgesic for the temporary relief of the pain of rheumatism, arthritis, lumbago, muscular aches, sprains and strains, sporting injuries, and other conditions where local warmth is beneficial.  Nevertheless, most of the available studies regarding the use of nicoboxil and nonivamide topical analgesics focus specifically on their efficacy and safety in treating acute non-specific low back pain, typically finding the combination analgesic to be an effective, safe, and well-tolerated medication for such an indication.']","['Topical applications consisting of the individual active ingredients of nicoboxil and nonivamide at doses considered to be therapeutic are generally not considered readily available commercially. Subsequently, the pharmacodynamics of nicoboxil are considered useful in commercially available combination products largely because they combine with those of nonivamide to offer a synergistic effect from the unique complementary actions of these two agents.  Subsequently, nonivamide is a synthetic capsaicin analog with analgesic properties which are assumed to result from the depletion of Substance P in the peripheral nociceptive C-fibres and A-delta nerve fibers upon repetitive topical application. Resultant stimulation of afferent nerve endings in the skin evidently causes a dilatory effect on the surrounding blood vessels accompanied by an intense, long-lasting sensation of warmth associated with the nonivamide use.  Given the proposed effect of nonivamide, it is believed that nicoboxil is a vitamin of the B complex that possesses vasodilating properties facilitated by prostaglandin. The observed hyperaemic increased blood flow effect of nicoboxil occurs earlier and is described as being more intense than the nonivamide hyperaemic effect. Nicoboxil and nonivamide are consequently generally indicated as a combination product because the pharmacodynamics of nicoboxil are considered useful as a complement to those of nonivamide, and vice versa. In essence, both compounds induce vasodilation by different effects and therefore have complementary abilities inducing increased blood flow, thus hastening the hyperaemic skin reaction.']",,"['Specific investigations on absorption of dermally applied nicoboxil in laboratory animals or target species were not available. Published data for nicotinate esters related to nicoboxil indicated however, that members of this class of compounds are in principle able to penetrate skin [12].  Regardless, there is interest in the studies that demonstrate nicoboxil and nonivamide combination topical applications as effective and safe analgesic products precisely because such topical formulations are expected to have much lower systemic absorption - and thus less exposure to systemic side effects (ie. like gastrointestinal upset, drowsiness, etc.) - than the oral non-steroidal anti-inflammatory drugs, opioids, muscle relaxants, and steroids that may be more commonly prescribed over a rubefacient like nicoboxil.    Nevertheless, despite the fact that topical nicoboxil and nonivamide products been available to use in some parts of Europe since the 1950s to treat discomfort of the muscuoskeletal system, the effects of nicoboxil and nonivamide have not been investigated in detail and a lack of detailed studies on nicoboxil pharmacodynamics and pharmacokinetics remains ongoing.', ""Following ester cleavage, the nicotinic acid metabolite is expected to enter the endogenous metabolic pool as a part of the vitamin B complex. The 2-butoxyethanol metabolite is believed to be mainly excreted primarily in the urine and to a certain extent, in exhaled air. In humans, the urinary elimination of 2-butoxyethanol's metabolite, 2-butoxyacetic acid was also reported."", 'Despite the fact that topical nicoboxil and nonivamide products been available to use in some parts of Europe since the 1950s to treat discomfort of the muscuoskeletal system, the effects of nicoboxil and nonivamide have not been investigated in detail and a lack of detailed studies on nicoboxil pharmacodynamics and pharmacokinetics remains ongoing. Readily accessible data regarding the volume of distribution of nicoboxil is subsequently not available.', 'The elimination of nicoboxil is considered to be rapid.  Despite the fact that topical nicoboxil and nonivamide products been available to use in some parts of Europe since the 1950s to treat discomfort of the muscuoskeletal system, the effects of nicoboxil and nonivamide have not been investigated in detail and a lack of detailed studies on nicoboxil pharmacodynamics and pharmacokinetics remains ongoing. Readily accessible data regarding the clearance of nicoboxil is subsequently not available.']","[""Any systemically absorbed nicoboxil is expected to be hydrolyzed to nicotinic acid and 2-butoxyethanol in blood plasma. In vitro it is reported that such hydrolysis reactions are catalyzed by esterase-like activity of serum albumin and by plasma esterases. The nicotinic acid metabolite is also capable of vascular dilatation. In humans, the urinary elimination of 2-butoxyethanol's metabolite, 2-butoxyacetic acid was also reported.  The metabolism of nicoboxil is considered to be rapid.""]","['The half-life of ester hydrolysis was found to be very short in the presence of human serum albumin - less than 15 minutes, 50uM.']"
4866,14867,2-Methyl-3-(2-methylbutyl)phenol,CCC(C)CC1=C(C(=CC=C1)O)C,,,,,,
4867,14868,Tribromsalan,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,,,,,,
4868,14869,5-Chlorosalicylanilide,C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)Cl)O,,,,,,
4869,14870,2-Hydroxypropyl laurate,CCCCCCCCCCCC(=O)OCC(C)O,,,,,,
4870,14871,"2,3-Dihydroxypropyl dodecanoate",CCCCCCCCCCCC(=O)OCC(CO)O,,,"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
4871,14872,"Ethanone, 1-[3-(2-phenylethenyl)phenyl]-",CC(=O)C1=CC=CC(=C1)C=CC2=CC=CC=C2,,,,,,
4872,14873,CID 14873,CC(C)C1=CC2=CC(=CC(=C2C=C1)C(C)C)S(=O)(=O)[O-].[Na+],,,,,,
4873,14874,"4,7-Di(propan-2-yl)naphthalene-2-sulfonic acid",CC(C)C1=CC2=CC(=CC(=C2C=C1)C(C)C)S(=O)(=O)O,,,,,,
4874,14875,2-Phenoxydecan-1-ol,CCCCCCCCC(CO)OC1=CC=CC=C1,,,,,,
4875,14876,"6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol",CCCCCC1=CC(=C2C3CC(=CCC3C(OC2=C1)(C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,,,,,,
4876,14877,"2,3-dihydroxypropyl (12R)-12-hydroxyoctadec-9-enoate",CCCCCC[C@H](CC=CCCCCCCCC(=O)OCC(CO)O)O,,,,,,
4877,14878,Propylene glycol monostearate,CCCCCCCCCCCCCCCCCC(=O)OCC(C)O,,,,,,
4878,14879,"2,2-dimethylpropanoic acid;(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O.CC(C)(C)C(=O)O,,,,,,
4879,14880,"(8R,9S,13S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@H](C1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,,,,,['Estradiol isomer has known human metabolites that include 2-hydroxyestradiol and 4-Hydroxyestradiol.'],
4880,14881,"dipotassium;[2-[(2S,4R,8S,11S,12R)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] phosphate",CC1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)C=CC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)COP(=O)([O-])[O-])C)O)F)C)C.[K+].[K+],,,,,,
4881,14882,CID 14882,CC1(O[C@@H]2CC3C4CCC5=CC(=O)C=CC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)COP(=O)(O)O)C)O)F)C)C,,,,,,
4882,14883,CID 14883,CCCCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCCCC(=O)O.C(C(CO)O)O,,,,,,
4883,14884,C.I. Vat violet 1,C1=CC=C2C(=C1)C3=C(C=C4C5=C6C(=CC(=C7C6=C(C=C5)C(=O)C8=CC=CC=C87)Cl)C9=C4C3=C(C2=O)C=C9)Cl,,,,,,
4884,14885,"C.I. Basic Violet 1, molybdatetungstatephosphate",CN=C1C=CC(=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N)C=C1,,,,,,
4885,14886,CI Pigment blue 1,CCNC1=CC(=CC2=CC=CC=C21)C(=C3C=CC(=[N+](CC)CC)C=C3)C4=CC=C(C=C4)N(CC)CC,,,,,,
4886,14887,CID 14887,[N+](=O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-].[BiH3],,,,,,
4887,14888,Arsenic trioxide,[O-2].[O-2].[O-2].[As+3].[As+3],"['Trisenox is indicated for induction of remission, and consolidation in adult patients with:']",,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],"['BOTH HUMAN & ANIMAL DATA INDICATE THAT OVER 80% OF INGESTED DOSE OF DISSOLVED INORG TRIVALENT ARSENIC IS ABSORBED FROM GI TRACT. ... IN CASE OF ARSENIC TRIOXIDE, WHICH IS ONLY SLIGHTLY SOL IN WATER, GI ABSORPTION WILL BE DEPENDENT ON FACTORS SUCH AS PARTICLE SIZE & PH OF THE GASTRIC JUICES.', 'FOLLOWING DIETARY ADMIN OF 215 PPM ARSENIC IN FORM OF ... ARSENIC TRIOXIDE FOR UP TO 52 DAYS IN RATS, HIGHEST ... LEVELS ... WERE FOUND IN KIDNEYS & LIVER & RELATIVELY LOWER LEVELS IN HAIR, BRAIN, BONE, MUSCLE & SKIN. ... TRIVALENT ARSENIC ... IS CONVERTED TO ... /PENTAVALENT ARSENIC IN MAN/ WHICH IS RAPIDLY EXCRETED BY KIDNEYS.', 'ORAL ADMIN OF 1 MG/KG BODY WT ARSENIC AS ARSENIC TRIOXIDE TO MONKEYS RESULTED IN APPROXIMATELY 80% ABSORPTION FROM THE GUT; 75% OF THE ADMIN DOSE WAS EXCRETED WITHIN 14 DAYS, PRIMARILY IN URINE.', '... MALE & ... FEMALE RATS, 21 DAYS OF AGE WERE GIVEN DIET CONTAINING 26.8 OR 215 MG/KG OF DIET ARSENIC AS ARSENIC TRIOXIDE AD LIBITUM. ... LITTERS OF FOLLOWING 3 PREGNANCIES WERE EVALUATED, AS WELL AS FIRST LITTER OF SECOND GENERATION. AMT ... FOUND IN NEWBORNS WAS LOWER IN FIRST LITTER OF FIRST GENERATION ... THAN LATER LITTERS ...', 'For more Absorption, Distribution and Excretion (Complete) data for ARSENIC TRIOXIDE (15 total), please visit the HSDB record page.']","['CHEMICAL SPECIATION STUDIES HAVE SHOWN THAT DIMETHYLARSINIC ACID & METHANEARSONIC ACID ARE PRIMARY FORMS OF ARSENIC PRESENT IN URINE OF HUMANS EXPOSED TO ... ARSENIC TRIOXIDE BY INHALATION.', 'Urinary profiles of arsenic smelter workers showed that dimethylarsenic acid was the major species followed by methyl arsenic, trivalent arsenic, and pentavalent arsenic.', 'Urinary concentrations of the four arsenic species, pentavalent (As(V)) and trivalent (As(III)) inorganic arsenic, monomethylarsonic acid (MMAA) and dimethylarsinic acid (DMAA), were followed for several days subsequent to the acute intoxication of two human subjects by arsenic trioxide and sodium orthoarsenate, respectively, in unsuccessful suicide attempts. Total arsenic concentrations ranged from 1.6 to 18.7 mg/1. The increasing predominance of the less toxic methylated species, especially dimethylarsinic acid, after 3 or 4 days supports the concept of methylation as a natural detoxification mechanism as part of an overall reduction/methylation sequence involved in the biotransformation of inorganic arsenic by the human body. However, the additional possibility of oxidation of As(III) to As(V) in vivo under extreme immediate postingestion conditions is suggested by initial high urinary As(V), As(III), monomethylarsonic acid and dimethylarsinic acid in both cases probably reflect species dependent differences in rates of direct elimination and reactivity with tissues as well as the efficiency of methylation.', 'Rat liver cytosol inactivates inorganic arsenic through methylation; S-adenosylmethionine is the methyl group donor and reduced glutathione is required for full activity. ... Pathway involves the formation of a monomethylated metabolite which is either rapidly further methylated into a dimethylated derivative or is spontaneously oxidized into monomethylarsinic acid. The dimethylated metabolite gives rise to dimethylarsinic acid. The first methylation reaction is rate limiting, can be stimulated by glutathione and is catalyzed by an enzyme different from that which transfers the second methyl group. The latter is sensitive to inhibition by inorganic arsenic. ... A large excess of thiol groups may prevent the methylation reactions probably by decreasing the amount of free trivalent arsenic.']","['AFTER A SINGLE ORAL DOSE OF 29 MG/KG ARSENIC TRIOXIDE, BLOOD LEVELS OF ARSENIC IN RATS REACHED A MAXIMUM AFTER 3 DAYS AND THEN DECREASED, WITH A SLOW BIOLOGICAL HALF-LIFE OF 60 DAYS. ARSENIC IN TISSUES WAS 1% OF ADMINISTERED DOSE. EXCRETION IN FECES WAS 68.6% DURING THE FIRST 4 DAYS, AND A TRACE AMOUNT WAS DETECTED IN BILE. IN RABBITS WITH SAME DOSE, FECAL EXCRETION WAS 62.9% DURING 7 DAYS.']"
4888,14889,Einecs 215-518-4,C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)[NH2+]C4=C5C(=C(C=C4)N)C(=O)C6=CC=CC=C6C5=O)N.[O-]S(=O)[O-].[Na+],,,,,,
4889,14890,Bis(4-amino-1-anthraquinonyl)amine,C1=CC=C2C(=C1)C(=C3C(=CC=C(C3=C2O)N=C4C=CC(=N)C5=C4C(=O)C6=CC=CC=C6C5=O)N)O,,,,,,
4890,14891,Undec-10-enoate,C=CCCCCCCCCC(=O)[O-],,,,,,
4891,14892,"(1S,16R)-16-methoxy-5-oxa-10-azoniatetracyclo[8.7.0.01,13.02,7]heptadeca-2(7),14-dien-4-one;chloride",CO[C@@H]1C[C@@]23C(CC[NH+]2CCC4=C3CC(=O)OC4)C=C1.[Cl-],,,,,,
4892,14893,"(1S,16R)-16-methoxy-5-oxa-10-azatetracyclo[8.7.0.01,13.02,7]heptadeca-2(7),14-dien-4-one",CO[C@@H]1C[C@@]23C(CCN2CCC4=C3CC(=O)OC4)C=C1,,,,,,
4893,14894,CID 14894,CO[C@@H]1CC23[C@H]4CC(=O)OCC4CCN2CCC3C=C1,,,,,,
4894,14895,Dinsed,C1=CC(=CC(=C1)S(=O)(=O)NCCNS(=O)(=O)C2=CC=CC(=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4895,14896,beta-Pinene,CC1(C2CCC(=C)C1C2)C,,,,"['Pinene is easily absorbed through the pulmonary system, the skin, and the intestine. /Pinene/', 'Following immersion of young pigs & one human subject for 30 minutes in baths containing 150 mL of a pine-oil mixture (Fichtennadel-Latschenkieferol Kneipp) in 450 L of water, alpha- & beta-pinene & limonene (components of Latschenkieferol) were detected in exhaled air within 20 minutes reaching maximum levels 50-75 minutes after start of the bath & remaining detectable after 1 day.']","['The biotransformation of (+)-, (-)-, and (+-)-alpha-pinenes, (-)-beta-pinene (nopinene), (-)-cis-pinane, (+)-3-carene, (-)-cis-carane, myrcene, and p-cymene in rabbits was investigated. The major metabolites were as follows: (-)-trans-verbenol from (+)-, (-)-, and (+/-)-alpha-pinenes; (-)-10-pinanol and (-)-1-p-menthene-7,8-diol from (-)-beta-pinene; (-)-alpha-terpineol and (-)-trans-sobrerol from (-)-cis-pinane; (-)-m-mentha-4,6-dien-8-ol, 3-caren-9-ol, (-)-3-carene-9-carboxylic acid, and 3-carene-9,10-dicarboxylic acid from (+)-3-carene; carane-9,10-dicarboxylic acid from (-)-cis-carane; and myrcene-3(10)-glycol, myrcene-1,2-glycol, uroterpenol, and p-cymene-9-carboxylic acid from p-cymene. These metabolisms include allylic oxidation, epoxidation, stereoselective gem-dimethyl hydroxylation and its oxidation, cleavage of a conjugated double bond by epoxidation, and regioselective oxidation, some of which are not found usually in chemical reactions, and due to which various new compounds were determined. This biotransformation of the monoterpene hydrocarbons gave some insect pheromones in high yield.']",
4896,14897,"Copper;5,7,15,17,23,25,33,35-octachloro-2,11,20,29,37,39-hexaza-38,40-diazanidanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3,5,7,9,11,13(18),14,16,19(39),20,22(27),23,25,28,30(37),31(36),32,34-nonadecaene",C1=C(C=C(C2=C1C3=NC4=NC(=NC5=C6C(=CC(=CC6=C([N-]5)N=C7C8=C(C(=CC(=C8)Cl)Cl)C(=N7)N=C2[N-]3)Cl)Cl)C9=C4C=C(C=C9Cl)Cl)Cl)Cl.[Cu+2],,,,,,
4897,14898,CID 14898,C1=C(C=C(C2=C1C3=NC4=NC(=NC5=NC(=NC6=C7C=C(C=C(C7=C(N6)NC2=N3)Cl)Cl)C8=C5C(=CC(=C8)Cl)Cl)C9=C4C=C(C=C9Cl)Cl)Cl)Cl,,,,,,
4898,14899,Isodecyl acrylate,CC(C)CCCCCCCOC(=O)C=C,,,,,"['Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Acrylates/']",
4899,14900,Glyceryl palmitate,CCCCCCCCCCCCCCCC(=O)OCC(CO)O,,,,,,
4900,14901,2-Hydroxypropyl oleate,CCCCCCCCC=CCCCCCCCC(=O)OCC(C)O,,,,,,
4901,14902,Isodecyl octyl phthalate,CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC(C)C,,,,,,
4902,14903,"Propylene glycol, allyl ether",CC(CO)OCC=C,,,,,,
4903,14904,CID 14904,C=CC1=CC=C(C=C1)Cl.C=CC1=CC(=CC=C1)Cl.C=CC1=CC=CC=C1Cl,,,,,,
4904,14905,3-Chlorostyrene,C=CC1=CC(=CC=C1)Cl,,,,,,
4905,14906,2-Chlorostyrene,C=CC1=CC=CC=C1Cl,,,,,,
4906,14907,CID 14907,CCCCC(=CS(=O)(=O)[O-])CC.[Na+],,,,,,
4907,14908,2-Ethylhex-1-ene-1-sulfonic acid,CCCCC(=CS(=O)(=O)O)CC,,,,,,
4908,14909,2-(1-Phenyl-ethylamino)-ethanol,CC(C1=CC=CC=C1)NCCO,,,,,,
4909,14910,"1,4-Diethylcyclohexane",CCC1CCC(CC1)CC,,,,,,
4910,14911,Trimethyl nonanone,CCCCC(C)C(C)C(C)C(=O)C,,,,,,
4911,14912,P-T-Butyl-M-cresol,CC1=C(C=CC(=C1)O)C(C)(C)C,,,,,,
4912,14913,"3,7,8,9-Tetramethyldec-4-yne-2,6-diol",CC(C)C(C)C(C)C(C#CC(C)C(C)O)O,,,,,,
4913,14914,D-Glucitol monopalmitate,CCCCCCCCCCCCCCCC(=O)OCC(C(C(C(CO)O)O)O)O,,,,,,
4914,14915,Chromium trioxide,O=[Cr](=O)=O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4915,14916,CID 14916,F.[F-].[Na+],,,,,,
4916,14917,Hydrofluoric Acid,F,,,,"['Increases in plasma fluoride levels were observed in humans inhaling 0.8-2.8 or 2.9-6.0 ppm fluoride as hydrogen fluoride of 60 minutes; maximum plasma concentrations were observed 60-90 minutes after exposure initiation.', 'A study in rats suggests that hydrogen fluoride is absorbed primarily by the upper respiratory tract, and that removal of hydrogen fluoride from inhaled air by the upper respiratory tract approaches 100% for exposures that range from 30 to 176 mg fluoride/cu m. Furthermore, it is apparent that distribution to the blood is rapid. Immediately following 40 minutes of intermittent exposure, plasma fluoride concentrations correlated closely (correlation coefficient = 0.98; p<0.01) with the concentration of hydrogen fluoride in the air passed through the surgically isolated upper respiratory tract. Plasma levels were not measured at time points <40 minutes.', 'To define the relationship between ionic fluoride concentration in the serum of workers and the amount of hydrofluoric acid (HF) in the work environment, pre-and postshift serum and urine samples of 142 HF workers and 270 unexposed workers were examined. The maximum and minimum concentrations of HF in the air in each workshop varied from the mean by less than 30%. The preexposure levels of serum and urinary fluoride in HF workers were higher (P < 0.001) than the control values. This suggests that fluoride excretion from the body continues for at least 12 hr. The postshift serum and urinary fluoride concentrations of these workers were significantly higher (P < 0.001) than the preshift concentrations. A good correlation (r = 0.64) was obtained between postshift serum fluoride and postshift urine fluoride. There was a linear relationship between mean serum fluoride concentration and HF concentration in the workshop. A mean fluoride concentration of 82.3 ug/L with a lower fiducial limit (95%, P = 0.05) of 57.9 ug/L was estimated to correspond to an atmospheric HF concentration of 3 ppm. ...', 'A study /was conducted/ to determine the absorption of inhaled hydrofluoric acid. Two human subjects were exposed for an 8 hour period in an industrial environment to fluorides consisting primarily of hydrogen fluoride and silicon tetrafluoride at an average airborne concentration of 3.8 mg F/cu m. Urine specimens were collected at 2 hour intervals during exposure and or approximately 2 days afterwards. There was a rapid rise in urinary fluoride excretion during exposure, and a peak output was reached in 2-4 hours after cessation of exposure. Within 24 hours, the urinary fluoride levels returned practically to base levels, although a slight elevation persisted into the following day. The total amounts of fluoride excreted daily by the two subjects were as follows: day of exposure, 9.64 and 8.56 mg fluoride; first day after exposure, 1.67 and 2.49; second day, 0.99 and 1.31; and third day, 0.89 and 1.34. The baseline daily urinary fluoride excretions before exposure were 0.9 and 1.2 mg fluoride, respectively.', 'For more Absorption, Distribution and Excretion (Complete) data for Hydrogen fluoride (18 total), please visit the HSDB record page.']",,['About 12-24 hr']
4917,14918,Methyl furan-3-carboxylate,COC(=O)C1=COC=C1,,,,,,
4918,14919,6-Methylhept-3-en-1-ol,CC(C)CC=CCCO,,,,,,
4919,14920,CID 14920,C(C(COP(=O)(O)[O-])O)O.[K+],,,,,,
4920,14921,"1-(3,5-Dimethylphenyl)ethanone",CC1=CC(=CC(=C1)C(=O)C)C,,,,,,
4921,14922,"3,7,11-Trimethyldodeca-2,10-dien-1-ol",CC(CCCC(=CCO)C)CCC=C(C)C,,,,,,
4922,14923,Ammonium Hydroxide,[NH4+].[OH-],,,,"['... EXCRETION IS PRIMARILY BY WAY OF KIDNEYS, BUT A NOT INSIGNIFICANT AMT IS PASSED THROUGH SWEAT GLANDS.', '... Ammonium toxicity induced by ammonium acetate administration in frogs led to variable excretion of ammonia and urea into the medium. When 11.45 mM/kg body wt of ammonium acetate was administered, ammonia excretion increased while urea excretion decreased. When 4.17 mM/kg body wt of ammonium acetate was administered, the urea excretion increased while NH3 excretion decreased.', 'Ammonium hydroxide penetrates fastest, followed by sodium hydroxide, potassium hydroxide, and finally calcium hydroxide.']","['Male rats gavaged with 1000 umol (15)N-ammonium chloride each day for 5 days excreted low, but significant amounts of excess (15)N-NO3- in urine on the 5 days of treatment & on the 5 subsequent days. An in vitro chemical model system was used to demonstrate that oxidation of ammonia to NO3- by the hydroxyl radical at physiological pH is chemically feasible. These results are consistent with the hypothesis that ammonia is oxidized to NO3- in vivo by a nonenzymic process which involves active O species such as the hydroxyl radical.']",
4923,14924,"2-Hydroxyethyl(trimethyl)azanium;iron;propane-1,2,3-tricarboxylic acid;hydrate",C[N+](C)(C)CCO.C(C(CC(=O)O)C(=O)O)C(=O)O.O.[Fe],,,,,,
4924,14925,Tricarballylic acid,C(C(CC(=O)O)C(=O)O)C(=O)O,,,,,,
4925,14926,"[2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate",CCCCCCCCCCCC(=O)OCC([C@@H]1[C@H]([C@@H](CO1)O)O)O,,,,,,
4926,14927,"Sorbitan, monohexadecanoate",CCCCCCCCCCCCCCCC(=O)OCC([C@@H]1[C@H]([C@@H](CO1)O)O)O,,,,,,
4927,14928,"Sorbitan, monooctadecanoate",CCCCCCCCCCCCCCCCCC(=O)OCC([C@@H]1[C@H]([C@@H](CO1)O)O)O,,,,"['WHEN DIGESTED, BOTH THE FATTY ACID AND THE POLYHYDRIC ALCOHOL SORBITAN ARE ABSORBED, BUT THE LATTER IS COMPLETELY EXCRETED IN URINE.']",,
4928,14929,CID 14929,CCCCCCCCC=CCCCCCCCC(=O)OCC([C@@H]1[C@H]([C@@H](CO1)O)O)O,,,,,,
4929,14930,Virac,CCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1.[Cl-],,,,,,
4930,14931,2-[(2-Pyridin-1-ium-1-ylacetyl)amino]ethyl propanoate,CCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,,,,,,
4931,14932,Domine,CCCCCCCCCCCCN(C)CCN(C)C,,,,,,
4932,14933,3'-Chloroacetophenone,CC(=O)C1=CC(=CC=C1)Cl,,,"['Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. (See all compounds classified as Irritants.)', 'Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes. (See all compounds classified as Tear Gases.)']",,,
4933,14934,6-Methylheptyl palmitate,CCCCCCCCCCCCCCCC(=O)OCCCCCC(C)C,,,,,,
4934,14935,Ammonium bifluoride,[NH4+].F.[F-],,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],"['Fluorides are absorbed from GI tract, lung, & skin. GI tract is major site of absorption. The relatively sol cmpd, such as sodium fluoride, are almost completely absorbed ... Fluoride has been detected in all organs & tissues examined ... There is no evidence that it is concentrated in any tissues except bone, thyroid, aorta, & perhaps kidney. Fluoride is preponderantly deposited in the skeleton & teeth, & the degree of skeletal storage is related to intake and age. ... A function of the turnover rate of skeletal components, with growing bone showing greater fluoride deposition than bone in mature animals. ... Major route of ... excretion is by way of kidneys ... also excreted in small amt by sweat glands, lactating breast, & GI tract. ... About 90% of fluoride ion filtered by glomerulus is reabsorbed by renal tubules. /Fluoride salts/', 'In female rats, the skeletons of younger rats apparently are more efficient at removing fluoride from circulation than are those of older rats. /Sodium fluoride/', 'Following ingestion, soluble fluorides are rapidly absorbed from the gastrointestinal tract at least to the extent of 97%. Absorbed fluoride is distributed throughout the tissues of the body by the blood. Fluoride concentrations is soft tissues fall to pre-exposure levels within a few hours of exposure. Fluoride exchanges with hydroxyl radicals of hydroxyapatite (the inorganic constituent of bone) to form fluorohydroxyapatite. Fluoride that is not retained is excreted rapidly in urine. In adults under steady state intake conditions, the urinary concentration of fluoride tends to approximate the concentration of fluoride in the drinking water. This reflects the decreasing retention of fluoride (primarily in bone) with increasing age. Under certain conditions perspiraton may be an important route of fluoride excretion. The concentration of fluoride retained in bones and teeth is a function of both the concentration of fluoride intake and the duration of exposure. Periods of excessive fluoride exposure will result in increased retention in the bone. However, when the excessive exposure is eliminated, the bone fluoride concentration will decrease to a concentration that is again reflective of intake. /Fluoride salts/', 'The degree of absorption of a fluoride compound is best correlated with its solubility. /Fluoride salts/', 'For more Absorption, Distribution and Excretion (Complete) data for AMMONIUM BIFLUORIDE (7 total), please visit the HSDB record page.']",,['Half-life: 2-9 hours']
4935,14936,Magnesium silicate hydrate,O.[O-][Si]1(O[Si]2(O1)O[Si](O2)([O-])[O-])[O-].[Mg+2].[Mg+2],,,,,,
4936,14937,"2,2,6,6-Tetrahydroxy-1,3,5,7-tetraoxa-2,4,6-trisilaspiro[3.3]heptane",O[Si]1(O[Si]2(O1)O[Si](O2)(O)O)O,,,,,,
4937,14938,Aluminum;disodium;hydroxide;phosphate,[OH-].[O-]P(=O)([O-])[O-].[Na+].[Na+].[Al+3],,,,,,
4938,14939,"1,3,5-Trichloro-2-(chloromethyl)benzene",C1=C(C=C(C(=C1Cl)CCl)Cl)Cl,,,,,,
4939,14940,Manganese(II) oxide,O=[Mn],,,,"['COMPARISON OF PERCENTAGE OF MANGANESE RETAINED BY INFANT RATS INGESTING (54)MANGANESE OXIDE OR (54)MANGANESE CHLORIDE SHOWED INVERSE DOSE DEPENDENCE FOR OXIDE AND RELATIVE DOSE INDEPENDENCE FOR CHLORIDE OVER RANGE 25-500 UG. 12 TIMES MORE CHLORIDE WAS RETAINED THAN OXIDE IN RANGE 100-500 UG.', '... Male ddY-mice were divided into five groups of six animals each, and  Groups 1 to 4 were given 2 g Mn/kg ... chow in the form of  manganese chloride, manganese acetate, manganese carbonate, or manganese oxide, in the diets  for 12 months, while Group 5 served as control. Twenty four hours after the last feed, animals  were decapitated and brains were rapidly removed for study of the different regions (corpus  striatum, hypothalamus, midbrain, cerebral cortex, hippocampus, cerebellum, and medulla  oblongata). ...  Results showed that cerebral cortex levels of manganese in mice exposed to  the nearly insoluble manganese carbonate and manganese oxide were higher than in controls,  while manganese concentrations in the corpus striatum were similar to those in controls.  Microsomal manganese in treated mice was also higher than in controls. / A/ gel chromatographic  profile of corpus striatum showed that 20% manganese was in the high molecular weight  fractions, 45% was in the middle molecular weight fractions, while 32% was in the low  molecular weight fractions. The percent manganese in high molecular weight fractions was  higher (29% to 49%) in the manganese treated groups than in controls. The percentage of  manganese in low molecular weight fractions of the manganese oxide exposed group (9%) was  lower than in the manganese chloride, manganese acetate, and manganese carbonate exposed  groups (42%, 36%, and 38%, respectively).', '... Monkeys and rats /exposed/ to an aerosol of Mn3O4 produced by the combustion of gasoline  containing methylcyclopentadienyl manganese tricarbonyl (MMT) 24 hr/day for 9 months. The  concentration of manganese in the kidneys increased in a dose-dependent manner in both  species, but liver concentrations remained the same, regardless of exposure concentration. ...  The authors interpreted these findings as indicating that manganese metabolism and excretion  are homeostatically controlled, primarily in the liver  /Mn3O4/.', 'Twenty-four crossbred Florida native wether lambs, 28 kg initially, were /fed/ ... a basal  diet (31 ppm manganese dry matter basis) supplemented with either 0, 500, 1,000, 2,000  or  4,000 ppm manganese from feed grade manganese oxide or 2,000, 4,000 or 8,000 ppm manganese   from reagent grade manganese carbonate...  for 84 d ... .  Manganese  concentration in kidney, spleen, heart, skeletal muscle, bone,  serum (P less than .01) and  liver (P less than .05) increased as dietary manganese increased.  Kidney P was reduced (P  less than .05) as dietary manganese increased; however, no other  tissue minerals were  affected. At comparable levels of supplementation, sheep fed feed-grade  manganese oxide  exhibited numerically greater tissue manganese concentration than did those  fed reagent grade  manganese carbonate and regression analysis indicated higher rates of tissue  uptake in  manganese oxide-supplemented sheep. ...', '... The manganese content of the blood and brains of mice given single sc injections  of three different forms of manganese, MnCl2, Mn3O4, or MMT, /were measured./ Increased  manganese concentrations were observed in both the blood and brain after the administration of  each of these compounds. The highest concentrations in the brain were achieved after  administration of soluble MnCl2. /Mn3O4/']",,
4940,14941,"Silicic acid, calcium salt",[O-][Si]([O-])([O-])[O-].[Ca+2].[Ca+2],,,,['The substance can be absorbed into the body by inhalation.'],,"['The biodurability of various glass fibers, rockwool, and ceramic fibers was examined in rat lungs and compared with natural mineral fibers ... Sized fractions of fibers were instilled intratracheally into Wistar rats ... The half-time of fiber elimination from the lung ranges from about 10 days for wollastonite to more than 300 days for crocidolite. The biodurability of man-made vitreous fibers (MMVF) is between these values and is dependent on the chemical composition of the fibers and the diameter and length distribution ...']"
4941,14942,Orthosilicic acid,O[Si](O)(O)O,,,,,,
4942,14943,CID 14943,[SH-].S=[BiH].S=[Bi+],,,,,,
4943,14944,CID 14944,S=[BiH],,,,,,
4944,14945,Ferrous oxide,O=[Fe],,,,,,
4945,14946,"2-methyl-3-[(4R,5R)-4-(methylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-5-yl]prop-2-en-1-ol",CC(=C[C@H]1[C@@H](CC2=CNC3=CC=CC1=C23)NC)CO,,,,,,
4946,14947,Chondrocurine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)N(CCC6=CC(=C5O)OC)C)OC,,,,,,
4947,14948,"2-Phenyl-1,4-cyclohexadiene",C1C=CCC(=C1)C2=CC=CC=C2,,,,,,
4948,14949,(+/-)-Tylocrebrine,COC1=C(C2=C(C=C1)C3=C(CC4CCCN4C3)C5=CC(=C(C=C52)OC)OC)OC,,,,,,
4949,14950,Carmine,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Natural or synthetic dyes used as coloring agents in processed foods. (See all compounds classified as Food Coloring Agents.)']",,,
4950,14951,"(2R,3S,4R,5R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1S,2S,3R,5S,6R)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol",C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OC4[C@@H]([C@H]([C@@H]([C@H](O4)CN)O)O)N)O)O)N,,,,,,
4951,14952,CID 14952,C[C@H]1[C@@H]2CC[C@]3(C(C2(CC[C@H]1O)C)[C@@H](CC4C3(C[C@@H](C4=C(CCC=C(C)C)C(=O)[O-])OC(=O)C)C)O)C.[Na+],,,,,,
4952,14953,CID 14953,CC1[C@@H]2CC[C@]3(C(C2(CC[C@H]1O)C)[C@@H](CC4C3(C[C@@H](C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,,,,,,
4953,14954,"9,10,21,25-Tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;dichloride",C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[Cl-].[Cl-],,,,,,
4954,14955,"9,10,21,25-Tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene",C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C,,,,,,
4955,14956,"(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid",C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,,,,"['The pharmacokinetics of amphotericin B vary substantially depending on whether the drug is administered as conventional amphotericin B (formulated with sodium desoxycholate), amphotericin B cholesteryl sulfate complex, amphotericin B lipid complex, or amphotericin B liposomal, and pharmacokinetic parameters reported for one amphotericin B formulation should not be used to predict the pharmacokinetics of any other amphotericin B formulation.', 'Amphotericin B is poorly absorbed from the GI tract and must be given parenterally to treat systemic fungal infections. In one study, immediately after completion of iv infusion of 30 mg of amphotericin B (administered over a period of several hours), average peak serum concentrations were about 1 ug/ml; when the dose was 50 mg, average peak serum concentrations were approximately 2 ug/ml. Immediately after infusion, no more than 10% of the amphotericin B dose can be accounted for in serum. Average minimum serum concentrations (recorded just prior to the next drug infusion) of approximately 0.4 ug/ml have been reported when doses of 30 mg were given daily or when doses of 60 mg were given every other day.', 'Information on the distribution of amphotericin B is limited, although distribution is apparently multicompartmental. The volume of distribution of the drug following administration of conventional amphotericin B has been reported to be 4 L/kg; the volume of distribution at steady state after administration of amphotericin B cholesteryl sulfate is reported to be 3.8-4.1 L/kg. Amphotericin B concentrations attained in inflamed pleura, peritoneum, synovium, and aqueous humor following IV administration of conventional amphotericin B reportedly are about 60% of concurrent plasma concentrations; the drug also is distributed into vitreous humor, pleural, pericardial, peritoneal, and synovial fluid. Amphotericin B reportedly crosses the placenta and low concentrations are attained in amniotic fluid.', 'Following IV administration of conventional amphotericin B, CSF concentrations of the drug are approximately 3% of concurrent serum concentrations. To achieve fungistatic CSF concentrations, the drug must usually be administered intrathecally. In patients with meningitis, intrathecal administration of 0.2-0.3 mg of conventional amphotericin B via a subcutaneous reservoir has produced peak CSF concentrations of 0.5-0.8 ug/mL; 24 hours after the dose, CSF concentrations were 0.11-0.29 ug/mL. Amphotericin B is removed from the CSF by arachnoid villi and appears to be stored in the extracellular compartment of the brain, which may act as a reservoir for the drug.', 'For more Absorption, Distribution and Excretion (Complete) data for AMPHOTERICIN B (14 total), please visit the HSDB record page.']",,"['Amphotericin B cholesteryl sulfate complex has a distribution half-life of 3.5 minutes and an elimination half-life of 27.5-28.2 hours. /Amphotericin B cholesteryl sulfate complex/', 'Following IV administration of conventional amphotericin B in patients whose renal function is normal prior to therapy, the initial plasma half-life is approximately 24 hours. After the first 24 hours, the rate at which amphotericin B is eliminated decreases and an elimination half-life of approximately 15 days has been reported.', 'Elimination, half life: Neonates: Variable (range, 18 to 62.5 hours). Children: Variable (range, 5.5 to 40.3 hours). Adults: Approximately 24 hours. Terminal half life: Approximately 15 days. NOTE: There is large interindividual variation among neonates in the elimination of amphotericin B. Amphotericin B may persist in the circulation of neonates for up to 17 days after it has been discontinued.', '. The half life of elimination of amphotericin B from the lungs /of rats/ was 4.8 days according to serial sacrifices done after a single dose of 3.2 mg of aerosol doses of amphotericin B per kg.']"
4956,14957,antimycin A1,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
4957,14958,"2-[1-[2-[7-(Carboxymethyl)-3-methyl-2,6-dioxopurin-1-yl]ethyl]-3-methyl-2,6-dioxopurin-7-yl]acetic acid;piperazine",CN1C2=C(C(=O)N(C1=O)CCN3C(=O)C4=C(N=CN4CC(=O)O)N(C3=O)C)N(C=N2)CC(=O)O.C1CNCCN1,,,,,,
4958,14959,"2-[1-[2-[7-(Carboxymethyl)-3-methyl-2,6-dioxopurin-1-yl]ethyl]-3-methyl-2,6-dioxopurin-7-yl]acetic acid",CN1C2=C(C(=O)N(C1=O)CCN3C(=O)C4=C(N=CN4CC(=O)O)N(C3=O)C)N(C=N2)CC(=O)O,,,,,,
4959,14960,"(1S,15S,16R,17R,18S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid",C[C@H]1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Chemical agents that increase the permeability of biological or artificial lipid membranes to specific ions. Most ionophores are relatively small organic molecules that act as mobile carriers within membranes or coalesce to form ion permeable channels across membranes. Many are antibiotics, and many act as uncoupling agents by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Ionophores.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']","['Nystatin penetrates eye poorly.', 'Nystatin is poorly absorbed from the GI tract, and detectable blood concentrations are not obtained after usual doses. Following oral administration, nystatin is excreted almost entirely in feces as unchanged drug.', 'In healthy individuals, mean salivary nystatin concentrations in excess of those required in vitro for growth inhibition of clinically important Candida persist for approximately 2 hours after the beginning of oral dissolution of two nystatin lozenges (400,000 units) administered simultaneously.', 'Not absorbed following topical application to intact skin or mucous membranes.', 'For more Absorption, Distribution and Excretion (Complete) data for NYSTATIN (6 total), please visit the HSDB record page.']",,
4960,14961,CID 14961,CC[C@@H]1C(C=C(C=CC(=O)[C@@H](C[C@@H]([C@@H](C([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)C)COC4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC,,,,,,
4961,14962,"[(1S)-2-[[1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[(1-hydroxy-3-oxobut-1-en-2-yl)amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate",CC1=C2C=C(C=C(C2=CC=C1)C(=O)O[C@H](C(=O)NC(=C3[C@H]([C@@H]([C@H]4N3C4)O)OC(=O)C)C(=O)NC(=CO)C(=O)C)[C@@]5(CO5)C)OC,,,,,,
4962,14963,CID 14963,CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C4C(=O)OC(C(OC(C(N4)C(=O)OC(C(O3)(C(=O)O)O)C(C5CN5C)O)(C)CNC(=O)C6=CC(=CC7=C(C=CC=C67)C)OC)(C(=O)O)O)C(C8CN8C)O)C)OC,,,,,,
4963,14964,Fomecin A,C1=C(C(=C(C(=C1O)O)O)C=O)CO,,,,,,
4964,14965,"methyl (1R,10S,12S,13R,21R,22S,23R,24R)-23-(dimethylamino)-4,8,12,22,24-pentahydroxy-1,12-dimethyl-6,17-dioxo-10-(3,4,5-trimethoxy-4,6-dimethyloxan-2-yl)oxy-20,25-dioxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2,4,7(16),8,14,18-hexaene-13-carboxylate",CC1C(C(C(C(O1)O[C@H]2C[C@]([C@@H](C3=CC4=C(C(=C23)O)C(=O)C5=C(C=C6C(=C5C4=O)O[C@H]7[C@H]([C@@H]([C@H]([C@@]6(O7)C)O)N(C)C)O)O)C(=O)OC)(C)O)OC)(C)OC)OC,,,,,,
4965,14966,CID 14966,CC[C@H]1CC[C@@H]2[C@@H]([C@@H](C[C@@]3(O2)CC[C@H]([C@H](O3)C[C@H](C)O)C)OC(=O)C=C[C@H]([C@@H]([C@H](C(=O)[C@H]([C@@H]([C@H](C(=O)[C@@]([C@@H]([C@H](CC=CC=C1)C)O)(C)O)C)O)C)C)O)C)C,,,,,,
4966,14967,"N-[1-hydroxy-3-(methylsulfanylmethylsulfinyl)propan-2-yl]-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide",CC1=C(C(=O)NC(=O)N1)C=CC(=O)NC(CO)CS(=O)CSC,,,,,,
4967,14968,CID 14968,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C(C(=C4C3=C(C(=CC(C(C(C(C(C(C(C1O)C)O)C(=O)OC)O)C)O)(C)O)C)OCO4)C)O)C2=O)OC(=O)C)C)C,,,,,,
4968,14969,Vancomycin,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,"['A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci.  Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains.']","['Vancomycin is a branched tricyclic glycosylated nonribosomal peptide often reserved as the ""drug of last resort"", used only after treatment with other antibiotics has failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: <i>Listeria monocytogenes</i>, <i>Streptococcus pyogenes</i>, <i>Streptococcus pneumoniae</i> (including penicillin-resistant strains), <i>Streptococcus agalactiae</i>, <i>Actinomyces</i> species, and <i>Lactobacillus</i> species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Poorly absorbed from gastrointestinal tract, however systemic absorption (up to 60%) may occur following intraperitoneal administration.', 'In the first 24 hours, about 75-80% of an administered dose of vancomycin is excreted in urine by glomerular filtration.', 'The volume of distribution, as discussed in the literature, varies between 0.4-1 L/kg.', 'The mean plasma clearance of vancomycin is about 0.058 L/kg/h.', 'Vancomycin hydrochloride is not appreciably absorbed from the GI tract in most patients and must be given parenterally for the treatment of systemic infections. Oral bioavailability usually is less than 5%; however, limited data suggest that clinically important serum concentrations of the drug may result following enteral or oral administration of vancomycin in some patients with colitis and/or in those with renal impairment.', 'In adults with normal renal function who received multiple 1 g doses of vancomycin (15 mg/kg) given by IV infusion over 1 hour, mean plasma concentrations immediately after completion of the infusion are approximately 63 ug/mL and mean plasma concentrations 2 and 11 hours later are approximately 23 or 8 ug/mL, respectively. When multiple 500-mg doses are given by IV infusion over 30 minutes, mean plasma concentrations are about 49 ug/mL immediately following the infusion and about 10 ug/mL 6 hours after infusion.', 'Vancomycin is distributed into milk following IV administration. Systemic absorption of oral vancomycin is very low and it is not known whether the drug distributes into human milk following oral administration.', 'Vancomycin readily crosses the placenta and is distributed into cord blood.', 'Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After IV administration of vancomycin hydrochloride, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue. Vancomycin hydrochloride does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.']","['Since almost 75-80% of the drug is excreted unchanged in the urine after the first 24 hours following administration, there is seemingly no apparent metabolism of the drug. The concentration of vancomycin in the liver tissue and bile 24 hours after administration has also been reported at or below detection limits as well.']","['Half-life in normal renal patients is approximately 6 hours (range 4 to 11 hours). In anephric patients, the average half-life of elimination is 7.5 days.', 'The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function.', 'In anephric patients, the average half-life of elimination is 7.5 days.']"
4969,14970,Vancocin HCL,C[C@@H]1[C@@H]([C@](C[C@H](O1)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H](C(C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O.Cl,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
4970,14971,"(1S,2R,18R,22S,25R,28R,40R)-48-[(2R,3S,4R,5R,6S)-3-[(2R,4R,5R,6R)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid",C[C@@H]1[C@@H]([C@](C[C@H](O1)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H](C(C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,,,,,,
4971,14972,"methyl (13S)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-10-methoxycarbonyl-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-18-ethyl-17-oxa-1,11-diazapentacyclo[13.4.1.04,12.05,10.016,18]icosa-4(12),5,7,9-tetraene-13-carboxylate",CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(CC7CN(CCC8=C6NC9=CC=CC=C89)CC1(C7O1)CC)C(=O)OC)OC)C,,,,,,
4972,14973,Tuberactinomycin B; Vinacetin A; Vioactane,C1C(NC(=NC1O)N)C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC(=O)CC(CCCN)N,,,,,,
4973,14974,Mikamycin B,CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=C(C=C6)N(C)C)C,,,,,,
4974,14975,"3,6-diamino-N-[[15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;sulfuric acid",C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CNC(=O)CC(CCCN)N)CO)N)N.OS(=O)(=O)O,,,,,,
4975,14976,CID 14976,CC1CC(C(C(O1)OC2C(CC(C(=O)C=CC3C(O3)C(C(OC(=O)C=CC2C)C)COC4C(C(C(C(O4)C)O)OC)OC)(C)O)C)O)OC,,,,,,
4976,14977,"[5-(3-acetylanilino)-4-amino-3-(dimethylcarbamoylamino)-1,2-dihydroxy-3-[(1R)-1-hydroxyethyl]-2-methylcyclopentyl]methyl 2-hydroxy-6-methylbenzoate",CC1=C(C(=CC=C1)O)C(=O)OCC2(C(C(C(C2(C)O)([C@@H](C)O)NC(=O)N(C)C)N)NC3=CC=CC(=C3)C(=O)C)O,,,,,,
4977,14978,Sangivamycin,C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
4978,14979,CID 14979,CC[C@@H]1C(C=C(C=CC(=O)[C@@H](C[C@@H](C([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
4979,14980,CID 14980,CC[C@@H]1C(C=C(C=CC(=O)[C@@H](CC(C([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC,,,,,,
4980,14981,"methyl (1R,9R,10S,11R,12R)-11-acetyloxy-12-ethyl-4-[(14S,16S,17S)-17-ethyl-16-hydroxy-14-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-14-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate",CC[C@H]1CN2CCC3=C(C[C@](C(C2)[C@H]1O)(C4=C(C=C5C(=C4)[C@]67CCN8C6[C@@](C=CC8)([C@H]([C@@]([C@@H]7N5C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC9=CC=CC=C39,,,,,,
4981,14982,Glycyrrhizic acid,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,"['Glycyrrhizic acid is widely applied in foods as a natural sweetener. As a therapeutic agent, is has been used in a vast variety of formulations as it is reported to be anti-inflammatory, anti-ulcer, anti-allergic, antioxidant, anti-tumor, anti-diabetic and hepatoprotective. Due to this properties, its indications have been: treatment of premenstrual syndrome, treatment of viral infections, anti-lipidemic and antihyperglycemic. It is also known to be used as a remedy for peptic ulcer and other stomach diseases.']","['Glycyrrhizic acid was reported to present antiallergic, antiviral and anti-inflammatory activities as well as improvements in glucose tolerance.   The effect of glycyrrhizic acid in metabolic syndrome generates a significant decrease in blood glucose, fasting blood glucose and mean serum insulin concentration.']",['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],"['Glycyrrhizic acid is mainly absorbed after presystemic hydrolysis and formation of glycyrrhetinic acid. Therefore, after oral administration of a dose of 100 mg of glycyrrhizic acid, this major metabolite appears in plasma in a concentration of 200 ng/ml while glycyrrhizic acid cannot be found. The finding of a minimal amount of glycyrrhizic acid in urine suggests the existence of a partial absorption in the gastrointestinal tract.', 'Glycyrrhizic acid presents a biphasic elimination from the central compartment with a dose-dependent second elimination phase. The majority of the administered dose is eliminated by the bile in which glycyrrhizic acid can be eliminated unchanged and undergoes enterohepatic cycling. On the other hand, the major metabolite, glycyrrhetinic acid, forms glucuronide and sulfate conjugates. These conjugates are efficiently transported into the bile and duodenum where commensal bacteria hydrolizes the conjugate for the formation of glycyrrhetinic acid and further reabsorption.  This reabsorption behavior seems to be related to the activity of 3-alpha-hydroxysteroid dehydrogenase which transports very efficiently the metabolite from the plasma to the bile.  About 1.1-2.5% of the administered dose of glycyrrhizic acid can be found in urine which corresponds to the minimal cycling and reabsorption of this compound.', 'The apparent volume of distribution of glycyrrhizic acid either in the central compartment and in steady-state are in the range of 37-64 ml/kg and 59-98 ml/kg, respectively.', 'The constant reabsorption of glycyrrhetic acid in the duodenum causes a delay in the terminal plasma clearance. The reported total body clearance of glycyrrhizic acid is reported to be in the range of 16-25 ml.kg/h.', 'GLYCYRRHIZIN WAS ABSORBED IN RAT SMALL INTESTINE; THERE WAS NO DETECTABLE AMT OF GLYCYRRHETINIC ACID IN BLOOD AFTER BOLUS INJECTION OF GLYCYRRHIZIN INTO PORTAL VEIN; GLYCYRRHETINIC ACID WAS PRESENT IN DETECTABLE AMT IN BLOOD AFTER ORAL ADMIN.', 'Glycyrrhizic acid (GZA) and glycyrrhetinic acid (GRA) can be determined rapidly and precisely by high-performance liquid chromatography (HPLC) in biological fluids and tissues from experimental animals and humans. From plasma and tissues, glycyrrhizic acid and glycyrrhetinic acid are extracted by organic solvents and the extracts can directly be used for HPLC. From bile or urine, extraction and determination of glycyrrhizic acid and glycyrrhetinic acid are more difficult due to interfering endogenous compounds and conjugation of glycyrrhetinic acid with glucuronides or sulfates. Extraction of glycyrrhizic acid and glycyrrhetinic acid from urine or bile can be performed by ion-pairing followed by extraction with organic solvents or by solid phase extraction. Glycyrrhetinic acid conjugates can be determined by chromatographic separation or by pretreatment with beta-glucuronidase. The pharmacokinetics of glycyrrhetinic acid and glycyrrhizic acid can be described by a biphasic elimination from the central compartment with a dose-dependent second elimination phase. Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours for glycyrrhizic acid and between 10-30 hours for glycyrrhetinic acid. The major part of both glycyrrhetinic acid or glycyrrhizic acid is eliminated by the bile. While glycyrrhizic acid can be eliminated unmetabolized and undergoes enterohepatic cycling, Glycyrrhetinic acid is conjugated to glycyrrhetinic acid glucuronide or sulfate prior to biliary excretion. Orally administered glycyrrhizic acid is almost completely hydrolyzed by intestinal bacteria and reaches the systemic circulation as glycyrrhetinic acid.', 'Glycyrrhizic acid is currently of clinical interest for treatment of chronic hepatitis. It is also applied as a sweetener in food products and chewing tobacco. In some highly exposed subgroups of the population, serious side effects such as hypertension and electrolyte disturbances have been reported. In order to analyze the health risks of exposure to this compound, the kinetics of glycyrrhizic acid and its active metabolites were evaluated quantitatively. Glycyrrhizic acid and its metabolites are subject to complex kinetic processes, including enterohepatic cycling and presystemic metabolism. In humans, detailed information on these processes is often difficult to obtain. Therefore, a model was developed that describes the systemic and gastrointestinal tract kinetics of glycyrrhizic acid and its active metabolite glycyrrhetic acid in rats. Due to the physiologically based structure of the model, data from earlier in vitro and in vivo studies on absorption, enterohepatic cycling, and presystemic metabolism could be incorporated directly. The model demonstrates that glycyrrhizic acid and metabolites are transported efficiently from plasma to the bile, possibly by the hepatic transfer protein 3-alpha-hydroxysteroid dehydrogenase. Bacterial hydrolysis of the biliary excreted metabolites following reuptake of glycyrrhetic acid causes the observed delay in the terminal plasma clearance of glycyrrhetic acid. These mechanistic findings, derived from analysis of experimental data through physiologically based pharmacokinetic modeling, can eventually be used for a quantitative health risk assessment of human exposure to glycyrrhizic acid containing products. Copyright 2000 Academic Press.', 'To assess the multiplicity for the biliary excretion of xenobiotic conjugates, glycyrrhizic acid (glycyrrhizin) was studied in rats after intravenous (IV) injection of 10 mg/kg glycyrrhizic acid and IV infusion of inhibitors, dibromosulfophthalein and indocyanine green. Indocyanine green did not affect the biliary excretion of glycyrrhizic acid, whereas dibromosulfophthalein reduced it significantly. The plasma level of glycyrrhizic acid was increased by dibromosulfophthalein, but not by indocyanine green. In Eisai hyperbilirubinemic rats, the biliary excretion of glycyrrhizic acid was severely impaired, resulting in an increased plasma level. The findings suggested that the biliary excretion of glycyrrhizic acid is mediated by the system shared by liquiritigenin glucuronides and dibromosulfophthalein, but not by indocyanine green, and that the system is hereditarily defective in Eisai hyperbilirubinemic rats.']","['When orally administered, glycyrrhizic acid is almost completely hydrolyzed by intestinal bacteria for the formation of glycyrrhetinic acid, which is an active metabolite and can enter systemic circulation, and two molecules of glucuronic acid. This metabolite is transported and taken in the liver for its metabolization to form glucuronide and sulfate conjugates.', 'BOLUS INJECTION OF GLYCYRRHIZIN GIVEN RATS IN PORTAL VEIN, GAVE RISE IN BLOOD LEVEL OF SUBSTANCE WHICH APPEARS TO BE GLUCURONIC ACID CONJUGATE FORMED AS METABOLITE OF GLYCYRRHETINIC ACID.']","['Depending on the dose, the second elimination phase in humans has a half-life of 3.5 hours.']"
4982,14983,CID 14983,CC1C=CC=CC=CC=CC=CC=CC=CC(CC(C(C(CC(=O)CC(C(CCC(=O)CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)C(=O)O)O)O[C@H]2C(C([C@H](C(O2)C)O)N)O,,,,,,
4983,14984,"Sulfamoyl 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate",CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)OS(=O)(=O)N)C,,,,,,
4984,14985,Vitamin E,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,"['Vitamin E supplementation is indicated for treatment of vitamin E deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet.']","[""Vitamin E is a collective term used to describe 8 separate fat soluble antioxidants, most commonly alpha-tocopherol. Vitamin E acts to protect cells against the effects of free radicals, which are potentially damaging by-products of the body's metabolism. Vitamin E deficiency is seen in persons with abetalipoproteinemia, premature, very low birth weight infants (birth weights less than 1500 grams, or 3&frac12; pounds), cystic fibrosis, and cholestasis and severe liver disease. Preliminary research suggests vitamin E may help prevent or delay coronary heart disease and protect against the damaging effects of free radicals, which may contribute to the development of chronic diseases such as cancer. It also protects other fat-soluble vitamins (A and B group vitamins) from destruction by oxygen. Low levels of vitamin E have been linked to increased incidence of breast and colon cancer.""]","['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)']","['10-33% of deuterium labelled vitamin E is absorbed in the small intestine. Absorption of Vitamin E is dependant upon absorption of the fat in which it is dissolved. For patients with poor fat absorption, a water soluble form of vitamin E may need to be substituted such as tocopheryl polyethylene glycol-1000 succinate.  In other studies the oral bioavailability of alpha-tocopherol was 36%, gamma-tocotrienol was 9%. The time to maximum concentration was 9.7 hours for alpha-tocopherol and 2.4 hours for gamma-tocotrienol.', ""Alpha tocopherol is excreted in urine as well as bile in the feces mainly as a carboxyethyl-hydrochroman (CEHC) metabolite, but it can be excreted in it's natural form."", '0.41L/kg in premature neonates given a 20mg/kg intramuscular injection.', '6.5mL/hr/kg in premature neonates given a 20mg/kg intramuscular injection.', 'The absorption of tocopherol in the digestive tract requires the presence of fat. The approximate tmax of the four different isomers of tocopherol is attained in the range of 3-6 hours. When compared with tocotrienols, tocopherols showed a reduced bioavailability. The bioavailability of tocopherols is highly dependent on the type of isomer that is administered where the alpha-tocopherol can present a bioavailability of 36%. This isomer specificity also determines the intestinal permeability in which the gamma-tocopherol presents a very low permeability. After oral administration, the Cmax, AUC and mean residence time of tocopherols showed to be dependent on the isomer and ranged from 590-2915 ng/ml,  3740-10169 ng/ml and 4.85-5.74 h, respectively.', 'The pharmacokinetic profile of tocopherol indicates a longer time of excretion for tocopherols when compared to tocotrienols. The different conjugated metabolites are excreted in the urine or feces depending on the length of their side-chain. Due to their polarity, intermediate-chain metabolites and short-chain metabolites are excreted via urine as glucoside conjugates. A mixture of all the metabolites and precursors can be found in feces. The long-chain metabolites correspond to >60% of the total metabolites in feces. It is estimated that the fecal excretion accounts for even 80% of the administered dose.', 'The apparent volume of distribution of tocopherol is approximately 0.5 ml.', 'The clearance rate of tocopherol is approximately 0.15 l/h.', 'alpha-Tocopherol is absorbed via the lymphatic pathway and transported in association with chylomicrons. In plasma, alpha-tocopherol is found in all lipoprotein fractions but mostly is associated with apo B containing lipoproteins. alpha-Tocopherol is associated with very low density lipoprotein when it is secreted from the liver. In the rat, about 90% of total body mass of alpha-tocopherol is recovered in the liver, skeletal muscle and adipose tissue. Most alpha-tocopherol is located in the mitochondrial fractions and in the endoplasmic reticulum, whereas little is found in cytosol and peroxisomes.', 'The level of retinal alpha-tocopherol of newborn rats could be altered by dietary manipulation of the mothers. The mothers were fed diets containing either 1 g alpha-tocopherol acetate/kg food or none, starting 21-25 days before the birth of their litters and lasting throughout the exposure period. This treatment resulted in three to fourfold differences in the retinal alpha-tocopherol levels of the pups. The combination of dietary and oxygen treatments also resulted in significant differences in retinal glutathione peroxidase activity, with the vitamin E deprived, oxygen exposed group having highest levels. Newborn rats both supplemented with and deprived of alpha-tocopherol had less vasoobliteration than did those nursed by mothers fed rat chow.', 'Vitamin E is stored unmodified in tissues (principally the liver and adipose tissue) and excreted via the feces. Excess vitamin E is converted to a lactone, esterified to glucuronic acid, and subsequently excreted in the urine.', 'Vitamin E is 20% to 50% absorbed by intestinal epithelial cells in the small intestine. Bile and pancreatic juice are needed for tocopherol absorption. Absorption is increased when administered with medium-chain triglycerides. Distribution to tissues via the lymphatic system occurs as a lipoprotein complex. High concentrations of vitamin E are found in the adrenals, pituitary, testes, and trombocytes.', 'For more Absorption, Distribution and Excretion (Complete) data for VITAMIN E (11 total), please visit the HSDB record page.']","['Alpha and gamma tocopherol are undergo beta oxidation and a process mediated by cytochrome P450s such as CYP4F2, CYP3A4, and CYP3A5. These processes convert alpha and gamma tocopherol to alpha-CEHC (2,5,7,8-tetramethyl-2-(2-carboxyethyl)-6-hydroxychroman) and gamma-CEHC (2,7,8-trimethyl-2-(2-carboxyethyl)-6-hydroxychroman) respectively, however the full process is not known.', ""Excess tocopherol is converted into their corresponding carboxyethylhydroxychroman (CEHC), based on the isomer of tocopherol. More deeply, the metabolism of tocopherol begins with the hepatic metabolism which is led by a CYP4F2/CYP3A4-dependent -hydroxylation of the side chains which leads to the formation of 13'-carboxychromanol. The metabolic pathway is followed by five cycles of -oxidation. The -oxidation cycles function by shortening the side chains, the first cycle results in the formation of carboxydimethyldecylhydroxychromanol followed by carboxymethyloctylhydroxychromanol. These two metabolites are categorized as long-chain metabolites and they are not excreted in the urine. Some intermediate-chain metabolites that are products of two rounds of -oxidation are carboxymethylhexylhydroxychromanol and carboxymethylbutylhydroxychromanol. These intermediate-chain metabolites can be found in human feces and urine. The catabolic end-product of tocopherols, as stated before, is CEHC which can be largely found in urine and feces.  Two new metabolites have been detected in human and mice feces. These new metabolites are 12'-hydroxychromanol and 11'-hydroxychromanol. Because of their chemistry, it is thought that these metabolites can be the evidence for a -1 and -2 hydroxylation which leads to an impaired oxidation of 12'-OH followed side-chain truncation."", 'Vitamin E is stored unmodified in tissues (principally the liver and adipose tissue) and excreted via the feces. Excess vitamin E is converted to a lactone, esterified to glucuronic acid, and subsequently excreted in the urine.', 'Alpha-tocopherol (Vitamin E), formed from homogentisic acid yields, in rabbits 4-hydroxy-4-methyl-6-(2,4,5-trimethyl-3,6-quinonyl)caproic acid ...', 'Vitamin E is likely the most important antioxidant in the human diet and alpha-tocopherol is the most active isomer. Alpha-tocopherol exhibits anti-oxidative capacity in vitro, and inhibits oxidation of ldl. Beside this, alpha-tocopherol shows anti-inflammatory activity and modulates expression of proteins involved in uptake, transport and degradation of tocopherols, as well as the uptake, storage and export of lipids such as cholesterol. Despite promising anti-atherogenic features in vitro, vitamin E failed to be atheroprotective in clinical trials in humans. Recent studies highlight the importance of long-chain metabolites of alpha-tocopherol, which are formed as catabolic intermediate products in the liver and occur in human plasma. These metabolites modulate inflammatory processes and macrophage foam cell formation via mechanisms different than that of their metabolic precursor alpha-tocopherol and at lower concentrations. Here we summarize the controversial role of vitamin E as a preventive agent against atherosclerosis and point the attention to recent findings that highlight a role of these long-chain metabolites of vitamin E as a proposed new class of regulatory metabolites. We speculate that the metabolites contribute to physiological as well as pathophysiological processes.']","['44 hours in premature neonates given a 20mg/kg intramuscular injection. 12 minutes in intravenous injection of intestinal lymph.', 'The elimination half-life of tocopherol is approximately 2.6 hours.', ""Little is known about alpha-tocopherol's bioavailability as a constituent of food or its dependence on a subject's age. To evaluate the alpha-tocopherol bioavailability from food, we used collard greens grown in deuterated water ((2)H collard greens) as a source of deuterium-labeled ((2)H) alpha-tocopherol consumed by younger and older adults in a post hoc analysis of a vitamin K study. Younger (mean +/- SD age: 32 +/- 7 y; n = 12 women and 9 men) and older (aged 67 +/- 8 y; n = 8 women and 12 men) adults consumed a test breakfast that included 120 g (2)H collard greens (1.2 +/- 0.1 mg (2)H-alpha-tocopherol). Plasma unlabeled alpha-tocopherol and (2)H-alpha-tocopherol were measured by using liquid chromatography-mass spectrometry from fasting (>12 hr) blood samples drawn before breakfast (0 hr) and at 24, 48, and 72 hr and from postprandial samples collected at 4, 5, 6, 7, 9, 12, and 16 hr. Times (12.6 +/- 2.5 h) of maximum plasma (2)H-alpha-tocopherol concentrations (0.82% +/- 0.59% total alpha-tocopherol), fractional disappearance rates (0.63 +/- 0.26 pools/d), half-lives (30 +/- 11 hr), and the minimum estimated (2)H-alpha-tocopherolabsorbed (24% +/- 16%) did not vary between age groups or sexes (n = 41). Unlabeled alpha-tocopherol concentrations were higher in older adults (26.4 +/- 8.6 umol/L) than in younger adults (19.3 +/- 4.2 umol/L; P = 0.0019) and correlated with serum lipids (r = 0.4938, P = 0.0012). In addition, (2)H-alpha-tocopherol half-lives were correlated with lipids (r = 0.4361, P = 0.0044). Paradoxically, alpha-tocopherol remained in circulation longer in participants with higher serum lipids, but the (2)H-alpha-tocopherol absorbed was not dependent on the plasma lipid status. Neither variable was dependent on age. These data suggest that plasma alpha-tocopherol concentrations are more dependent on mechanisms that control circulating lipids rather than those related to its absorption and initial incorporation into plasma.""]"
4985,14986,Tocopherols,CC1=C(C=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)O,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)']",,,
4986,14987,Lysergol,CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)CO,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
4987,14988,Neotropine,CCN(CC)CCOC(=O)C(C1CCC=C1)C2=CC=CS2,,,,,,
4988,14989,Aloin,C1=CC2=C(C(=C1)O)C(=O)C3=C([C@@H]2[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C(C=C3O)CO,,,['Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)'],,,
4989,14990,Propenzolate hydrochloride,CN1CCCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O.Cl,,,,,,
4990,14991,Propenzolate,CN1CCCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O,,,,,,
4991,14992,Clonitralid,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O.C(CO)N,,,"['Agents used to treat tapeworm infestations in man or animals. (See all compounds classified as Anticestodal Agents.)', 'Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)', 'Agents destructive to snails and other mollusks. (See all compounds classified as Molluscacides.)']","['WHOLE BODY RESIDUES WERE LOW IN INVERTEBRATES EXPOSED TO (14)C-BAYLUSCIDE (1 UG/L). WITHIN 48 HR, INVERTEBRATES (DAPHNIDS, SOWBUGS, SCUDS, GLASS SHRIMP, CRAYFISH, DAMSELFLY LARVAE, AND MIDGE LARVAE) REACHED PLATEAUS WHICH WERE 4 TO 87 TIMES THAT OF THE CONCN TO WHICH THEY WERE EXPOSED. A 50% REDUCTION IN THESE RESIDUES OCCURRED WITHIN 24 HR AFTER THE ORGANISMS WERE TRANSFERRED TO FRESH WATER.', 'RESIDUES OF CLONITRALIDE WERE RAPIDLY ACCUMULATED BY FISH EXPOSED TO THE LAMPRICIDE. MUSCLE RESIDUE LEVELS INCREASED TO NEAR THE TREATMENT CONCN DURING EXPOSURE. AFTER 10 DAYS OF WITHDRAWAL, RESIDUES IN PLASMA, BILE, & MUSCLE OF RAINBOW TROUT & COHO SALMON DECREASED TO LESS THAN 1% OF THEIR RESPECTIVE PEAK CONCN. IN ALL SPECIES TESTED, RESIDUES IN MUSCLE DROPPED BELOW THE LIMIT OF DETECTION (0.01 UG/G) WITHIN 3-14 DAYS. AFTER AN INITIAL INCREASE DURING EARLY WITHDRAWAL, BILE RESIDUES DECLINED STEADILY BUT HAD NOT DROPPED BELOW INITIAL LEVELS IN CHANNEL CATFISH IN 14 DAYS, OR BELOW DETECTABLE LEVELS (0.01 UG/ML) IN COHO SALMON AFTER 28 DAYS OF WITHDRAWAL.', 'RAINBOW TROUT EXPOSED TO CLONITRALIDE IN THE WATER QUICKLY BEGAN TO EXCRETE CONJUGATED & FREE CLONITRALIDE IN THE URINE, WITH THE LARGEST AMOUNT BEING EXCRETED DURING THE 12 HR EXPOSURE. THE TROUT CONTINUED TO EXCRETE CLONITRALIDE 60 HR AFTER EXPOSURE. FIFTEEN TIMES AS MUCH CONJUGATED AS FREE CLONITRALIDE WAS EXCRETED. AMONG FISH GIVEN IP INJECTIONS, 25% OF THE INJECTED DOSE WAS EXTRACTED IN THE URINE, & 20% RECOVERY IN THE BILE. CLONITRALIDE EXPOSURE HAD NO EFFECT ON THE URINE OUTPUT OR RENAL EXCRETION OF SODIUM, POTASSIUM, CALCIUM, OR CHLORIDE IONS.']",['GLUCURONIDE CONJUGATION HAS BEEN EXHIBITED IN RAINBOW TROUT EXPOSED TO CLONITRALIDE.'],
4992,14993,Trifenmorph,C1COCCN1C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,"['In dogs, rats and mice /trifenmorph/ was rapidly metabolized by gastrointestinal enzymes to triphenylcarbinol, and morpholine. Triphenylcarbinol was absorbed slowly and it was oxidized by hepatic systems to para-hydroxyphenyldiphenylcarbinol and also, ortho- and meta-hydroxytriphenylcarbinols to a lesser extent. Morpholine was rapidly absorbed and excreted in the urine unchanged as a glucuronic acid conjugate. Triphenylcarbinol and its hydroxy derivatives were found in urine and feces as free compounds and in three glucuronide fractions; diglucuronides, carbinol-group glucuronide and phenolic-groups glucuronides. In (14)C-labelled tracer dose studies no (14)CO2 was respired and, after 96 hours only 3% of the radioactivity remained in the carcass.']","['Rats and dogs were given (14)C labeled frescon as single oral doses. Frescon rapidly hydrolyzed to triphenylcarbinol and morpholine in the stomach. Morpholine was rapidly absorbed and excreted largely unchanged though some was degraded. Triphenylcarbinol was absorbed slowly and oxidized to p-hydroxyphenyldiphenylcarbinol. Triphenylcarbinol and its p-hydroxy analog were found in urine, bile and feces, both free and conjugated with glucuronic acid. Traces of ortho- and meta-hydroxyphenyldiphenylcarbinol were detected both free and conjugated. There appeared to be three glucuronide fractions, possibly diglucuronides of hydroxytriphenylcarbinols, carbinol-group derived glucuronides and phenolic-group derived glucuronides.', 'Fish (S. mossambicus) were exposed to frescon for 22 hr. Analyses of fish indicated the presence of unchanged frescon and a small amount of morpholine. Similar results were observed when bile was analyzed.']",
4993,14994,Dinoterb,CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O,,,,"['In rats given (14)C-labelled dinoterb, 98% of the radioactivity is excreted via the feces and urine within 168 hr.']","['The metabolism of alkyldinitrophenols in mammals involves the reduction of nitro groups, hydrolysis of ester groups, oxidation of alkyl groups, and conjugation. Some of these transformations may be also induced by sunlight. /Alkyldinitrophenols/']",
4994,14995,Desacetamidocolchicine,COC1=CC=C2C(=CC1=O)CCCC3=CC(=C(C(=C32)OC)OC)OC,,,,,,
4995,14996,CID 14996,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O.CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O.OS(=O)(=O)O,,,,,,
4996,14997,"N,S-Diacetylcysteamine",CC(=O)NCCSC(=O)C,,,,,,
4997,14998,"2,2-Diphenyl-2-methoxyacetic acid 2-(diethylamino)propyl ester hydrochloride",CC[NH+](CC)C(C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
4998,14999,"2-(Diethylamino)propyl 2-methoxy-2,2-diphenylacetate",CCN(CC)C(C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
4999,15000,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(diethylamino)-1-methylethyl) ester, hydrochloride",CC[NH+](CC)CC(C)OC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
5000,15001,"1-(Diethylamino)propan-2-yl 2-methoxy-2,2-diphenylacetate",CCN(CC)CC(C)OC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
5001,15002,"2,2-Diphenyl-2-ethoxyacetic acid (1-ethyl-3-piperidyl) ester hydrochloride",CC[NH+]1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
5002,15003,"(1-Ethylpiperidin-3-yl) 2-ethoxy-2,2-diphenylacetate",CCN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
5003,15004,Propanidid,CCCOC(=O)CC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OC,,,"['Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)']",,,
5004,15005,CID 15005,C1=CC=C(C=C1)CN=C(N)N=C([NH3+])N.[Cl-],,,,,,
5005,15006,2-Benzyl-1-(diaminomethylidene)guanidine,C1=CC=C(C=C1)CN=C(N)N=C(N)N,,,,,,
5006,15007,"3,5-Di-tert-butyl-4-hydroxybenzoic acid",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)O,,,,,,
5007,15008,"2,4,5-Trihydroxybutyrophenone",CCCC(=O)C1=CC(=C(C=C1O)O)O,,,,,,
5008,15009,Amidephrine mesylate,CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O.CS(=O)(=O)O,,,,,,
5009,15010,Amidephrine,CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O,,,['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)'],,,
5010,15011,"5,6-Dihydro-5,6-dihydroxydibenz(a,h)anthracene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C(C(C5=CC=CC=C54)O)O,,,,,,
5011,15012,"5,6-Epoxy-5,6-dihydrodibenz(a,h)anthracene",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C5C(O5)C6=CC=CC=C64,,,,,,
5012,15013,2-(Dimethylamino)ethyl acetate,CC(=O)OCCN(C)C,,,,,,
5013,15014,"(4S,4aR,7S,12bS)-9-methoxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-ol;chloride",C[NH+]1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)OC3[C@H](C=C4)O.[Cl-],,,,,,
5014,15015,"(4S,4aR,7S,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol",CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)OC3[C@H](C=C4)O,,,,,,
5015,15016,9-Oxodecanoic acid,CC(=O)CCCCCCCC(=O)O,,,,,,
5016,15017,"Hexane, 1-(pentafluorothio)-tridecafluoro-",C(C(C(C(F)(F)S(F)(F)(F)(F)F)(F)F)(F)F)(C(C(F)(F)F)(F)F)(F)F,,,,,,
5017,15018,3-Butyn-2-one,CC(=O)C#C,,,,,,
5018,15019,"(17S)-13-methyl-11,12,14,15,16,17-hexahydrocyclopenta[a]phenanthrene-3,17-diol",CC12CCC3=C(C1CC[C@@H]2O)C=CC4=C3C=CC(=C4)O,,,,,,
5019,15020,Mesterolone,C[C@H]1CC(=O)C[C@H]2[C@]1([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C)C,,,"['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",,,
5020,15021,CID 15021,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],,,,,,
5021,15022,2-Methyl-4-morpholino-2-phenylbutyronitrile,CC(CCN1CCOCC1)(C#N)C2=CC=CC=C2,,,,,,
5022,15023,alpha-(2-(Dimethylamino)ethyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CC(C)C(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5023,15024,"1,3-Dihydro-7-nitro-5-(alpha,alpha,alpha-trifluoro-o-tolyl)2H-1,4-benzodiazepin-2-one",C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3C(F)(F)F,,,,,,
5024,15025,Edtmp,C(CN(CP(=O)(O)O)CP(=O)(O)O)N(CP(=O)(O)O)CP(=O)(O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
5025,15026,2-Methylfluorene,CC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
5026,15027,"[(5S)-2-cyano-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate",CC(=O)OC1CCC2C1(CCC3C2CC[C@@H]4C3(CC(=CC4)C#N)C)C,,,,,,
5027,15028,alpha-Nitromethyl-2-piperonylthio-ethylamine hydrochloride,C1OC2=C(O1)C=C(C=C2)C(C[N+](=O)[O-])SCC[NH3+].[Cl-],,,,,,
5028,15029,"2-[1-(1,3-Benzodioxol-5-yl)-2-nitroethyl]sulfanylethanamine",C1OC2=C(O1)C=C(C=C2)C(C[N+](=O)[O-])SCCN,,,,,,
5029,15030,2-(alpha-(Nitromethyl)-2-chlorobenzylthio)ethylamine hydrochloride,C1=CC=C(C(=C1)C(C[N+](=O)[O-])SCC[NH3+])Cl.[Cl-],,,,,,
5030,15031,Nitralamine,C1=CC=C(C(=C1)C(C[N+](=O)[O-])SCCN)Cl,,,,,,
5031,15032,Pregnenolone carbonitrile,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,,,,,,
5032,15033,"2-Bromo-1,4-dichlorobenzene",C1=CC(=C(C=C1Cl)Br)Cl,,,,,,
5033,15034,"2,4-Dibromo-1-fluorobenzene",C1=CC(=C(C=C1Br)Br)F,,,,,,
5034,15035,4-(4-Nitrophenylazo)phenol,C1=CC(=CC=C1N=NC2=CC=C(C=C2)O)[N+](=O)[O-],,,,,,
5035,15036,"1,2-Epoxyhexane",CCCCC1CO1,,,,,,
5036,15037,1-Furfurylpyrrole,C1=CN(C=C1)CC2=CC=CO2,,,,,,
5037,15038,(Acetylmethylene)triphenylphosphorane,CC(=O)C=P(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5038,15039,"Acetophenone, 4'-nitro-2-(triphenylphosphoranylidene)-",C1=CC=C(C=C1)P(=CC(=O)C2=CC=C(C=C2)[N+](=O)[O-])(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5039,15040,"Phosphorodiamidic acid, tetramethyl-, pentachlorophenyl ester",CN(C)P(=O)(N(C)C)OC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
5040,15041,Pentachlorophenyl acetate,CC(=O)OC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
5041,15042,[4-(5-Chloro-2-methylsulfanylphenyl)-4-phenylbut-3-enyl]-dimethylazanium;chloride,C[NH+](C)CCC=C(C1=CC=CC=C1)C2=C(C=CC(=C2)Cl)SC.[Cl-],,,,,,
5042,15043,"4-(5-chloro-2-methylsulfanylphenyl)-N,N-dimethyl-4-phenylbut-3-en-1-amine",CN(C)CCC=C(C1=CC=CC=C1)C2=C(C=CC(=C2)Cl)SC,,,,,,
5043,15044,"cyclohexylsulfamic acid;N,N-dimethyl-3-(5-methyl-6H-benzo[c][1]benzazepin-11-ylidene)propan-1-amine",CN1CC2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31.C1CCC(CC1)NS(=O)(=O)O,,,,,,
5044,15045,1-(Hexahydro-1H-azepin-1-yl)-3-(phenyl sulfonyl)urea,C1CCCN(CC1)NC(=O)NS(=O)(=O)C2=CC=CC=C2,,,,,,
5045,15046,2-Phenylcyclohexanol,C1CCC(C(C1)C2=CC=CC=C2)O,,,,,,
5046,15047,Pseudouridine,C1=C(C(=O)NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
5047,15048,2-Methyladenine,CC1=NC(=C2C(=N1)N=CN2)N,,,,,,
5048,15049,"Phosphoramidic acid, phenyl-, diethyl ester",CCOP(=O)(NC1=CC=CC=C1)OCC,,,,,,
5049,15050,"1,1,1-Trimethoxyethane",CC(OC)(OC)OC,,,,,,
5050,15051,Trimethylgallium,C[Ga](C)C,,,,,,
5051,15052,"2-(Aminomethyl)-1,4-benzodioxane hydrochloride",C1C(OC2=CC=CC=C2O1)C[NH3+].[Cl-],,,,,,
5052,15053,"(2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methanamine",C1C(OC2=CC=CC=C2O1)CN,,,,,,
5053,15054,"D-Mannitol, 1,6-dideoxy-1,6-bis((2-hydroxyethyl)amino)-, 1,6-dimethanesulfonate (ester), dihydrochloride",CS(=O)(=O)OCC[NH2+]CC(C(C(C(CNCCOS(=O)(=O)C)O)O)O)O.[Cl-],,,,,,
5054,15055,"2-[[2,3,4,5-Tetrahydroxy-6-(2-methylsulfonyloxyethylamino)hexyl]amino]ethyl methanesulfonate",CS(=O)(=O)OCCNCC(C(C(C(CNCCOS(=O)(=O)C)O)O)O)O,,,,,,
5055,15056,"[(1R,4aR,10aS)-1,4a-dimethyl-6-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine",CC(C)C1=CC2=C(CC[C@H]3[C@]2(CCC[C@@]3(C)CN)C)C=C1,,,,,,
5056,15057,3-(2-Aminobutyl)-6-chloroindole hydrochloride,CCC(CC1=CNC2=C1C=CC(=C2)Cl)[NH3+].[Cl-],,,,,,
5057,15058,1-(6-chloro-1H-indol-3-yl)butan-2-amine,CCC(CC1=CNC2=C1C=CC(=C2)Cl)N,,,,,,
5058,15059,"HYDRAZINE, 1-ISONICOTINOYL-2-(alpha-METHYLPHENETHYL)-, DIHYDROCHLORIDE",CC(CC1=CC=CC=C1)[NH2+]NC(=O)C2=CC=CC=[NH+]2.[Cl-].[Cl-],,,,,,
5059,15060,N'-(1-phenylpropan-2-yl)pyridine-2-carbohydrazide,CC(CC1=CC=CC=C1)NNC(=O)C2=CC=CC=N2,,,,,,
5060,15061,"1,4-Bis(diazoacetyl)butane",C(CCC(=O)C=[N+]=[N-])CC(=O)C=[N+]=[N-],,,,,,
5061,15062,"2,7-Dihydroxyocta-1,7-diene-1,8-didiazonium",C(CCC(=C[N+]#N)O)CC(=C[N+]#N)O,,,,,,
5062,15063,"[(4S,5R,6R,16S,17S,18S)-4,5,16,17-tetrahydroxy-6,14,18-trimethyl-9-oxo-3,10-dioxapentacyclo[9.8.0.01,7.04,19.013,18]nonadec-14-en-8-yl] 2-hydroxy-2-methylbutanoate",CCC(C)(C(=O)OC1C2[C@H]([C@H]([C@@]3(C4C2(CO3)C(CC5[C@@]4([C@@H]([C@H](C=C5C)O)O)C)OC1=O)O)O)C)O,,,,,,
5063,15064,"p-ANISIDINE, N,N-BIS(2-CHLOROETHYL)-",COC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
5064,15065,"2,2,3-Trimethylcyclobutanone",CC1CC(=O)C1(C)C,,,,,,
5065,15066,Methylbicyclophosphate,CC12COP(=O)(OC1)OC2,,,,,,
5066,15067,"4-Methyl-2,6,7-trioxa-1-phosphabicyclo[2.2.2]octane",CC12COP(OC1)OC2,,,,,,
5067,15068,2'-Hydroxy-5'-methylacetophenone,CC1=CC(=C(C=C1)O)C(=O)C,,,,,,
5068,15069,4-Cyanothiazole,C1=C(N=CS1)C#N,,,,,,
5069,15070,Picolinamide,C1=CC=NC(=C1)C(=O)N,,,,,,
5070,15071,"4-(2,5-Dimethylphenyl)butanoic acid",CC1=CC(=C(C=C1)C)CCCC(=O)O,,,,,,
5071,15072,"Cyclopropyl ketone, oxime",C1CC1C(=NO)C2CC2,,,,,,
5072,15073,3-Methylpyrazole,CC1=CC=NN1,,,,,,
5073,15074,Isonicotinamide,C1=CN=CC=C1C(=O)N,,,,,,
5074,15075,"2,2'-Biphenyldiamine",C1=CC=C(C(=C1)C2=CC=CC=C2N)N,,,,,,
5075,15076,1-Heptadecanol,CCCCCCCCCCCCCCCCCO,,,,,,
5076,15077,1-Nonanethiol,CCCCCCCCCS,,,,,,
5077,15078,Guanazole,C1(=NC(=NN1)N)N,,,,,,
5078,15079,"4-Benzofurazanamine, N,N-dimethyl-7-nitro-",CN(C)C1=CC=C(C2=NON=C12)[N+](=O)[O-],,,,,,
5079,15080,"2,5-Diphenyl-1,3,4-thiadiazole",C1=CC=C(C=C1)C2=NN=C(S2)C3=CC=CC=C3,,,,,,
5080,15081,"N-Nitroso-2,6-dimethylmorpholine",CC1CN(CC(O1)C)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
5081,15082,"Hydrocinnamic acid, 3-acetamido-2,4,6-triiodo-",C1=C(C(=C(C(=C1I)CC(=O)N)I)CCC(=O)O)I,,,,,,
5082,15083,"2-(1-Dimethylaminoethyl)-1,4-benzodioxane",CN(C)CCC1COC2=CC=CC=C2O1,,,,,,
5083,15084,"2-(1-Diethylaminoethyl)-1,4-benzodioxane",CCN(CC)CCC1COC2=CC=CC=C2O1,,,,,,
5084,15085,Hexadecylbenzene,CCCCCCCCCCCCCCCCC1=CC=CC=C1,,,,,,
5085,15086,Tetradecylbenzene,CCCCCCCCCCCCCCC1=CC=CC=C1,,,,,,
5086,15087,"1,2,4-Tri-tert-butylbenzene",CC(C)(C)C1=CC(=C(C=C1)C(C)(C)C)C(C)(C)C,,,,,,
5087,15088,Dimethyl isophthalate,COC(=O)C1=CC(=CC=C1)C(=O)OC,,,,,,
5088,15089,"1,3,5-Tri-tert-butylbenzene",CC(C)(C)C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C,,,,,,
5089,15090,"1-Chloro-1,2-diphenylethylene",C1=CC=C(C=C1)C=C(C2=CC=CC=C2)Cl,,,,,,
5090,15091,Cycloheptanecarboxylic acid,C1CCCC(CC1)C(=O)O,,,,,,
5091,15092,"Benzyl alcohol, 3-amino-2,4,6-triiodo-",C1=C(C(=C(C(=C1I)N)I)CO)I,,,,,,
5092,15093,alpha-Cyclopropylmandelic acid,C1CC1C(C2=CC=CC=C2)(C(=O)O)O,,,,,,
5093,15094,gamma-Cadinene,CC1=CC2C(CC1)C(=C)CCC2C(C)C,,,,,,
5094,15095,"3,5,5,9-tetramethyl-2,4a,5,6,7,8-hexahydro-1H-benzo[7]annulene",CC1=CC2C(=C(CCCC2(C)C)C)CC1,,,,,,
5095,15096,Tributyltin chloride,CCCC[Sn](CCCC)(CCCC)Cl,,,,,,
5096,15097,"Tin, tri-n-butyl-, bromide",CCCC[Sn+](CCCC)CCCC.[Br-],,,,,,
5097,15098,Tetrabutyltin,CCCC[Sn](CCCC)(CCCC)CCCC,,,,,,
5098,15099,"beta-Alanine, N-dodecyl-",CCCCCCCCCCCCNCCC(=O)O,,,,,,
5099,15100,"2,3,6-Trimethylpyridine",CC1=C(N=C(C=C1)C)C,,,,,,
5100,15101,"2,8-Dimethylquinoline",CC1=C2C(=CC=C1)C=CC(=N2)C,,,,,,
5101,15102,Guanacline,CC1=CCN(CC1)CCN=C(N)N,,,,,,
5102,15103,Selenomethionine,C[Se]CCC(C(=O)O)N,,,,"['... Lambs were orally administered a single dose of selenium as either sodium selenite or selenomethionine and were monitored for 7 days, after which they were euthanized and necropsied. ... Analysis of liver, kidney cortex, heart, blood, and serum revealed linear, dose-dependent increases in selenium concentration. However, tissue selenium concentration in selenomethionine-treated lambs were significantly greater than that in lambs treated with equivalent doses of sodium selenite.', 'Se-Methylated selenoamino acids, Se-methylselenocysteine (MeSeCys) and selenomethionine (SeMet), are chemically inert storage forms of selenium in selenium-accumulators, and a nutritional and supplemental source. ... Male Wistar rats were depleted of endogenous natural abundance selenium with a single (80)Se-enriched isotope, and then (76)Se-MeSeCys, (77)Se-SeMet and (82)Se-selenite were orally administered simultaneously at 25 ug Se/kg body weight each. Organs and body fluids were obtained at 3, 6, 9 and 12 hr, and 1 and 2 days later, and subjected to speciation analysis. The main characteristics of the metabolism were as follows; MeSeCys was incorporated into selenoprotein P slightly more than or at a comparable level to that of SeMet but less than that of selenite. MeSeCys and SeMet but not selenite was taken up by organs in their intact forms. MeSeCys and SeMet were delivered specifically to the pancreas and present in a form bound to an identical or similar protein. Trimethylselenonium (TMSe) was only produced from MeSeCys, i.e., not from SeMet or selenite, in the kidneys. Both selenosugars A and B of MeSeCys, SeMet and selenite origin were detected in the liver but only selenosugar B in the kidneys...', '... Rats were depleted of endogenous natural abundance selenium by feeding a single selenium stable isotope ((82)Se-selenite) and then administered (76)Se-selenite and (77)Se-selenomethionine ((77)Se-SeMet)simultaneously. Biological samples were subjected to quantification and speciation analysis by HPLC-ICPMS. Metabolites of the labeled (76)Se and (77)Se and interaction with endogenous selenium were traced and examined without interference from the corresponding endogenous natural abundance isotopes. Differences in the distribution and metabolism among organs and between the two nutritional selenocompounds were compared under exactly identical biological and analytical conditions: (1) selenite was distributed more efficiently than SeMet in organs and body fluids except the pancreas. (2) SeMet was taken up by organs in its intact form. (3) Selenium of SeMet origin was distributed selectively in the pancreas and mostly bound to a protein together with intact SeMet. (4) Selenosugars A and B but not trimethylselenonium (TMSe) were detected in the liver. (5) Selenosugar B and TMSe were detected in the kidneys.', '... More than 80% of orally administered selenomethionine ... is absorbed by rats.', 'For more Absorption, Distribution and Excretion (Complete) data for SELENIUM METHIONINE (15 total), please visit the HSDB record page.']","['Most dietary selenium is in the form of selenomethionine ... or selenocysteine, both of which are well absorbed. Other forms of selenium include selenate and selenite, which are not major dietary constituents, but are commonly used in fortified foods and dietary supplements. Two pools of reserve selenium are present in the body. The first is as selenomethionine, which is not known to have a physiological function separate from that of methionine. The second reserve pool is the selenium found in liver glutathione peroxidase. Ingested selenite, selenate, and selenocysteine are all metabolized directly to selenide, the reduced form of selenium. Selenomethionine can also be metabolized to selenide.', 'To obtain quantitative information on human metabolism of selenium, ... selenium speciation analysis /was performed/ by HPLC/ICPMS on samples of human urine from one volunteer over a 48-hour period after ingestion of selenium (1.0 mg) as sodium selenite, L-selenomethionine, or DL-selenomethionine. The three separate experiments were performed in duplicate. Normal background urine from the volunteer contained total selenium concentrations of 8-30 ug Se/L (n=22) but ...  only about 30-70% could be quantified by HPLC/ICPMS. The major species in background urine were two selenosugars, namely methyl-2-acetamido-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 1) and its deacylated analog methyl-2-amino-2-deoxy-1-seleno-beta-D-galactopyranoside (selenosugar 3). Selenium was rapidly excreted after ingestion of the selenium compounds: the peak concentrations (approximately 250-400 ug Se/L, normalized concentrations) were recorded within 5-9 hours, and concentrations had returned to close to background levels within 48 hours, by which time 25-40% of the ingested selenium, depending on the species ingested, had been accounted for in the urine. In all experiments, the major metabolite was selenosugar 1, constituting either approximately 80% of the total selenium excreted over the first 24 hours after ingestion of selenite or L-selenomethionine or approximately 65% after ingestion of DL-selenomethionine. Selenite was not present at significant levels (<1 ug Se/L) in any of the samples; selenomethionine was present in only trace amounts (approximately 1 ug/L, equivalent to less than 0.5% of the total Se) following ingestion of L-selenomethionine, but it constituted about 20% of the excreted selenium (first 24 hours) after ingestion of DL-selenomethionine, presumably because the D form was not efficiently metabolized. Trimethylselenonium ion, a commonly reported urine metabolite, could not be detected (<1 ug/L) in the urine samples after ingestion of selenite or selenomethionine. Cytotoxicity studies on selenosugar 1 and its glucosamine isomer (selenosugar 2, methyl-2-acetamido-2-deoxy-1-seleno-beta-D-glucosopyranoside) were performed with HepG2 cells derived from human hepatocarcinoma, and these showed that both compounds had low toxicity (about 1000-fold less toxic than sodium selenite). The results support earlier studies showing that selenosugar 1 is the major urinary metabolite after increased selenium intake, and they suggest that previously accepted pathways for human metabolism of selenium involving trimethylselenonium ion as the excretionary end product may need to be re-evaluated.', 'When selenium is consumed as selenomethionine or other organic forms that occur naturally in foods, it is released as selenite by postabsorptive catabolism.', 'A major source of selenium in the diet is selenomethionine. Once ingested by an animal, it enters the methionine pool and is not distinguished from methionine. Thus, much of the selenium in animal tissues is selenomethionine that is non-specifically incorporated in proteins at methionine positions. When selenomethionine is catabolized, its selenium becomes available to the selenium metabolic.', 'For more Metabolism/Metabolites (Complete) data for SELENIUM METHIONINE (6 total), please visit the HSDB record page.']","['The long term fate of an oral dose of (75)Se selenomethionine has been studied in 4 women. Intestinal absorption amounted to 95-97% of the dose, the first 2-wk urinary excretion accounted for 6-9% & after 8 wk, the whole body retention of (75)Se decreased exponentially with a half life of 207-290 days. ... (75)Se selenomethionine was found to be more completely absorbed and had a greater body retention of (75)Se with smaller urinary and fecal losses than (75)Se from (75)Se selenite.', 'The half life of selenium methionine is 234 days.']"
5103,15104,Selenocystine,C(C(C(=O)O)N)[Se][Se]CC(C(=O)O)N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
5104,15105,2-(Vinyloxy)ethyl methacrylate,CC(=C)C(=O)OCCOC=C,,,,,,
5105,15106,N-(1-Naphthyl)ethylenediamine dihydrochloride,C1=CC=C2C(=C1)C=CC=C2NCCN.Cl.Cl,,,,,,
5106,15107,N-(1-Naphthyl)ethylenediamine,C1=CC=C2C(=C1)C=CC=C2NCCN,,,,,,
5107,15108,[2-[4-[Bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride,C1=CC(=CC=C1CC(C(=O)O)[NH3+])N(CCCl)CCCl.[Cl-],,,,,,
5108,15109,"2,6-Dimethoxybenzoic acid",COC1=C(C(=CC=C1)OC)C(=O)O,,,,,,
5109,15110,Acetylsalicylic anhydride,CC(=O)OC1=CC=CC=C1C(=O)OC(=O)C2=CC=CC=C2OC(=O)C,,,,,,
5110,15111,"6-Phenoxy-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)N)N,,,,,,
5111,15112,Dimethylcyanamide,CN(C)C#N,,,,['IT WAS READILY ABSORBED THROUGH GUINEA PIG SKIN ... .'],,
5112,15113,CID 15113,C12=NNNC1=NC(=O)NC2=O,,,,,,
5113,15114,4-Benzoylmorpholine,C1COCCN1C(=O)C2=CC=CC=C2,,,,,,
5114,15115,Dimexano,COC(=S)SSC(=S)OC,,,,,,
5115,15116,3-Acetylthiophene,CC(=O)C1=CSC=C1,,,,,,
5116,15117,Propylene sulfite,CC1COS(=O)O1,,,,,,
5117,15118,5-Indanol,C1CC2=C(C1)C=C(C=C2)O,,,,,,
5118,15119,"1-Propene, 3-propoxy-",CCCOCC=C,,,,,,
5119,15120,Dimethyl tridecanedioate,COC(=O)CCCCCCCCCCCC(=O)OC,,,,,,
5120,15121,"3-Methoxyestra-1(10),2,4-triene-16,17-diol",CC12CCC3C(C1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)OC,,,,,,
5121,15122,"1,4-Dichloro-2-butene",C(C=CCCl)Cl,,,,,"['AN OXIDATION OF THE DOUBLE BOND IN CERTAIN HALO-OLEFINS, WHICH IS DEPENDENT ON MICROSOMAL MONO-OXYGENASES PROBABLY IS A COMMON PATHWAY IN THE FORMATION OF BIOLOGICALLY REACTIVE INTERMEDIATES.']",
5122,15123,Allyl isocyanate,C=CCN=C=O,,,,,,
5123,15124,"Indol-6-OL, 3-(2-(dimethylamino)ethyl)-",CN(C)CCC1=CNC2=C1C=CC(=C2)O,,,,,,
5124,15125,CID 15125,CC1=C(C=CC2=C1OC(=C(C2=O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)[O-])OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O.[Na+],,,,,,
5125,15126,Magnesium ATP,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Mg+2],,,,,,
5126,15127,CID 15127,CCC1=C(C2=CC=CC=C2O1)C(=O)C3CCC(CC3)O,,,,,,
5127,15128,"N,N'-Bis(dichloroacetyl)-N,N'-diethyl-1,4-xylylenediamine",CCN(CC1=CC=C(C=C1)CN(CC)C(=O)C(Cl)Cl)C(=O)C(Cl)Cl,,,,,,
5128,15129,Noracymethadol,CCC(C(CC(C)NC)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,['NorLAAM is a known human metabolite of alphacetylmethadol.'],
5129,15130,Levomethadyl acetate,CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,['For the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.'],"['Levomethadyl acetate (also known as LAAM) is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, levomethadyl acetate is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. In this respect, the drug is similar to Methadone and also has structural similarities to it. The levomethadyl acetate abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.']","['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",['Levomethadyl acetate is rapidly absorbed from an oral solution.'],['Levomethadyl acetate is demethylated to nor-levomethadyl acetate which is again demethylated to dinor-levomethadyl acetate. This extensive first pass metabolism produces 2 metabolites that are more active than the parent drug.'],['2.6 days']
5130,15131,"[2,2-Dichloro-3-(4-chlorophenyl)-3-hydroxypropyl] carbamate",C1=CC(=CC=C1C(C(COC(=O)N)(Cl)Cl)O)Cl,,,,,,
5131,15132,2-Amino-4-methylbenzothiazole,CC1=C2C(=CC=C1)SC(=N2)N,,,,,,
5132,15133,m-Xylylenediamine,C1=CC(=CC(=C1)CN)CN,,,,,,
5133,15134,Fertilysin,C(CCCCNC(=O)C(Cl)Cl)CCCNC(=O)C(Cl)Cl,,,,,,
5134,15135,"(6aS)-6-prop-2-enyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-10,11-diol;chloride",C=CC[NH+]1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.[Cl-],,,,,,
5135,15136,Lopac-D-042,C=CCN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,,,,,,
5136,15137,ethyl N-[1-(4-fluorophenyl)ethylamino]carbamate,CCOC(=O)NNC(C)C1=CC=C(C=C1)F,,,,,,
5137,15138,"BENZOIC ACID, p-FLUORO-, 2-(2-(BENZYLCARBAMOYL)ETHYL)HYDRAZIDE",C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=C(C=C2)F,,,,,,
5138,15139,Fluanisone,COC1=CC=CC=C1N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
5139,15140,1-(4-Chlorophenyl)-3-cyanoguanidine,C1=CC(=CC=C1N=C(N)NC#N)Cl,,,,,,
5140,15141,"Benzene, 2,4-dimethyl-1-(1-methylpropyl)-",CCC(C)C1=C(C=C(C=C1)C)C,,,,,,
5141,15142,9-Methylcarbazole,CN1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
5142,15143,9-Vinylcarbazole,C=CN1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
5143,15144,2-Piperidineethanol,C1CCNC(C1)CCO,,,,,,
5144,15145,"2,3-Dihydro-5-methylfuran",CC1=CCCO1,,,,,,
5145,15146,Methyl 3-hydroxybutyrate,CC(CC(=O)OC)O,,,,,,
5146,15147,"1,2,3-Trifluorobenzene",C1=CC(=C(C(=C1)F)F)F,,,,,,
5147,15148,Naftalofos,CCOP(=O)(OCC)ON1C(=O)C2=CC=CC3=C2C(=CC=C3)C1=O,,,,,,
5148,15149,"[(9S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] adamantane-1-carboxylate",CC12CC[C@H]3C([C@@H]1CC[C@@H]2OC(=O)C45CC6CC(C4)CC(C6)C5)CCC7=CC(=O)CCC37,,,,,,
5149,15150,CID 15150,C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2],,,,,,
5150,15151,"BENZO(h)PHENALENO(1,9-bc)ACRIDINE, 7-METHYL-",CC1=C2C=CC3=CC=CC=C3C2=NC4=C1C=C5C=CC6=C7C5=C4C=CC7=CC=C6,,,,,,
5151,15152,"Acetanilide, 4'-(bis(2-chloroethyl)amino)-2-fluoro-",C1=CC(=CC=C1NC(=O)CF)N(CCCl)CCCl,,,,,,
5152,15153,Formyl fluoride,C(=O)F,,,,,,
5153,15154,"BENZOIC ACID, p-FLUORO-, 2-PHENYLHYDRAZIDE",C1=CC=C(C=C1)NNC(=O)C2=CC=C(C=C2)F,,,,,,
5154,15155,"6-Azaspiro[3.4]octane-5,7-dione",C1CC2(C1)CC(=O)NC2=O,,,,,,
5155,15156,"Phosphonochloridothioic acid, ethyl-, O-ethyl ester",CCOP(=S)(CC)Cl,,,,,,
5156,15157,Dichloroethylphosphine,CCP(Cl)Cl,,,,,,
5157,15158,Ethyl dichlorophosphate,CCOP(=O)(Cl)Cl,,,,,,
5158,15159,"9,10-Diphenylanthracene",C1=CC=C(C=C1)C2=C3C=CC=CC3=C(C4=CC=CC=C42)C5=CC=CC=C5,,,,,,
5159,15160,Hippurohydroxamic acid,C1=CC=C(C=C1)C(=O)NCC(=O)NO,,,,,,
5160,15161,CID 15161,C1=CN=C2C1=C(NC=N2)N,,,,,,
5161,15162,"Ketone, 4-ethyl-3,5-dimethylpyrrol-2-YL methyl",CCC1=C(NC(=C1C)C(=O)C)C,,,,,,
5162,15163,"3-Acetyl-2,4-dimethylpyrrole",CC1=CNC(=C1C(=O)C)C,,,,,,
5163,15164,"Cyclododecene, (E)-",C1CCCCCC=CCCCC1,,,,,,
5164,15165,Rimantadine hydrochloride,CC(C12CC3CC(C1)CC(C3)C2)N.Cl,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)']",,,
5165,15166,Cyclodecanol,C1CCCCC(CCCC1)O,,,,,,
5166,15167,Methylcyclooctane,CC1CCCCCCC1,,,,,,
5167,15168,"[(4aR,7S,12bS)-9-acetyloxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] acetate;chloride",CC(=O)O[C@H]1C=C[C@H]2C3CC4=C5[C@]2(C1OC5=C(C=C4)OC(=O)C)CC[NH+]3C.[Cl-],,,,,,
5168,15169,"[(4aR,7S,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate",CC(=O)O[C@H]1C=C[C@H]2C3CC4=C5[C@]2(C1OC5=C(C=C4)OC(=O)C)CCN3C,,,,,,
5169,15170,CID 15170,COC1=CC=C(C=C1)C(=CC2=CC=C(C=C2)Cl)C3=CC=CC=C3,,,,,,
5170,15171,N-(4-Chlorophenyl)-N-hydroxyacetamide,CC(=O)N(C1=CC=C(C=C1)Cl)O,,,,,,
5171,15172,"3-Buten-2-ol, 4-phenyl-",CC(C=CC1=CC=CC=C1)O,,,,,,
5172,15173,"2-Propenal, 3-(2-methoxyphenyl)-",COC1=CC=CC=C1C=CC=O,,,,,,
5173,15174,"Butyramide, 2-methyl-2-(1-naphthyl)-4-piperidino-",CC(CCN1CCCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)N,,,,,,
5174,15175,"Butyramide, 2-methyl-4-morpholino-2-(1-naphthyl)-",CC(CCN1CCOCC1)(C2=CC=CC3=CC=CC=C32)C(=O)N,,,,,,
5175,15176,Butidrine hydrochloride,CCC(C)[NH2+]CC(C1=CC2=C(CCCC2)C=C1)O.[Cl-],,,,,,
5176,15177,Butidrine,CCC(C)NCC(C1=CC2=C(CCCC2)C=C1)O,,,,,,
5177,15178,N-Methyl-N-2-propynyl-1-indanamine hydrochloride,CN(CC#C)C1CCC2=CC=CC=C12.Cl,,,,,,
5178,15179,N-methyl-N-2-propynyl-1-indanamine,CN(CC#C)C1CCC2=CC=CC=C12,,,,,,
5179,15180,"ACETIC ACID, THIO-, S-ESTER with 4-(BIS(2-CHLOROETHYL)AMINO)BENZENE THIOL",CC(=O)SC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
5180,15181,"Ethanol, 2-(2-(3-(m-methoxyphenyl)-3-propyl-1-pyrrolidinyl)ethoxy)-, hydrochloride",CCCC1(CC[NH+](C1)CCOCCO)C2=CC(=CC=C2)OC.[Cl-],,,,,,
5181,15182,2-(2-(3-(m-Methoxyphenyl)-3-propylpyrrolidinyl)ethoxy)ethanol,CCCC1(CCN(C1)CCOCCO)C2=CC(=CC=C2)OC,,,,,,
5182,15183,CID 15183,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=CC=C3)Br,,,,,,
5183,15184,NSC 72274; Podophyllic acid ethylhydrazide; Podophyllinic acid 2-ethylhydrazide,CCNNC(=O)C1C(C(C2=CC3=C(C=C2C1C4=CC(=C(C(=C4)OC)OC)OC)OCO3)O)CO,,,,,,
5184,15185,"1-(3,5-Dimethyl-2-oxocyclohexyl)-2-(2,6-dioxo-4-piperidinyl)ethyl acetate",CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)OC(=O)C)C,,,,,,
5185,15186,"COUMARIN, 7-HYDROXY-3-(p-METHOXYPHENYL)-4-PHENYL-, ACETATE (ester)",CC(=O)OC1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=C(C=C3)OC)C4=CC=CC=C4,,,,,,
5186,15187,"Acetic acid 3,4-diphenyl-2-oxo-2H-benzopyran-7-yl ester",CC(=O)OC1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5187,15188,CID 15188,COC1=CC=C(C=C1)C2=C(OC3=CC(=O)C=CC3=C2C4=CC=CC=C4)O,,,,,,
5188,15189,"COUMARIN, 4-(p-HYDROXYPHENYL)-3-(p-METHOXYPHENYL)-, ACETATE (ester)",CC(=O)OC1=CC=C(C=C1)C2=C(C(=O)OC3=CC=CC=C32)C4=CC=C(C=C4)OC,,,,,,
5189,15190,Phloraspidinol,CCCC(=O)C1=C(C(=C(C=C1O)OC)CC2=C(C(=C(C(=C2O)C(=O)CCC)O)C)OC)O,,,,,,
5190,15191,alpha-sec-Butyl-alpha-(2-(dimethylamino)ethyl)-1-naphthaleneacetonitrile,CCC(C)C(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5191,15192,1-Dodecanesulfonic acid,CCCCCCCCCCCCS(=O)(=O)O,,,,,,
5192,15193,4-Fluorofluoren-9-one,C1=CC=C2C(=C1)C3=C(C2=O)C=CC=C3F,,,,,,
5193,15194,Fluoroacetyl fluoride,C(C(=O)F)F,,,,,,
5194,15195,"1,3-Butadienyl acetate",CC(=O)OC=CC=C,,,,,,
5195,15196,CID 15196,CC=CC=CCOC(=O)C,,,,,,
5196,15197,"ANISOLE, p-NITROSO-",COC1=CC=C(C=C1)N=O,,,,,,
5197,15198,Allyltrimethylammonium chloride,C[N+](C)(C)CC=C.[Cl-],,,,,,
5198,15199,2-Methylcyclobutanone,CC1CCC1=O,,,,,,
5199,15200,Isosaccharinic acid,C(C(CO)O)C(CO)(C(=O)O)O,,,,,,
5200,15201,Diethylammonium diethyldithiocarbamate,CCNCC.CCN(CC)C(=S)S,,,,,,
5201,15202,4-Cyclopentylphenol,C1CCC(C1)C2=CC=C(C=C2)O,,,,,"['4-Cyclopentylphenol has known human metabolites that include (2S,3S,4S,5R)-6-(4-cyclopentylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
5202,15203,"1,3-Diphenylbutane",CC(CCC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5203,15204,"2,3-Dimethoxybenzoic acid",COC1=CC=CC(=C1OC)C(=O)O,,,,,,
5204,15205,4-(Diethylamino)-4-oxobutanoic acid,CCN(CC)C(=O)CCC(=O)O,,,,,,
5205,15206,"3-Bromo-2,2-bis(bromomethyl)propanol",C(C(CBr)(CBr)CBr)O,,,,,,
5206,15207,3-Nitrophenyl acetate,CC(=O)OC1=CC=CC(=C1)[N+](=O)[O-],,,,,,
5207,15208,"2,2,2-Trifluoroethyl allyl ether",C=CCOCC(F)(F)F,,,,,,
5208,15209,Flurandrenolide,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,"['For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions']","['Flurandrenolide is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids', 'Topical corticosteroids can be absorbed from normal intact skin. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.', 'Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. ... Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. /Topical corticosteroids/']","['Primarily hepatic', '/Topical corticosteroids/ are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. /Topical corticosteroids/']",
5209,15210,2-(Phenylthio)benzoic acid,C1=CC=C(C=C1)SC2=CC=CC=C2C(=O)O,,,,,,
5210,15211,2-[2-(Phenylthio)Phenyl]Acetic Acid,C1=CC=C(C=C1)SC2=CC=CC=C2CC(=O)O,,,,,,
5211,15212,"2-((10,11-Dihydrodibenzo(b,f)thiepin-10-yl)oxy)-N,N-dimethylethylamine",CN(C)CCOC1CC2=CC=CC=C2SC3=CC=CC=C13,,,,,,
5212,15213,Dibutyl(dimethyl)stannane,CCCC[Sn](C)(C)CCCC,,,,,,
5213,15214,Tributylmethylstannane,CCCC[Sn](C)(CCCC)CCCC,,,,,,
5214,15215,"Isophthalic acid, diisobutyl ester",CC(C)COC(=O)C1=CC(=CC=C1)C(=O)OCC(C)C,,,,,,
5215,15216,"4,4'-Dinitrobiphenyl",C1=CC(=CC=C1C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,"[""FOLLOWING THE ORAL OR IP ADMIN OF 4,4'-DINITROBIPHENYL TO GUINEA PIGS, 4,4'-DIACETYLBENZIDINE (4,4'-DIACETYLAMINOBIPHENYL) WAS EXCRETED IN THE URINE. THE METABOLISM OF 4,4'-DINITROBIPHENYL IN THE RAT WAS CONSIDERABLY SLOWER THAN IN THE GUINEA PIG. 3-CHLORO-4-AMINO-4'-NITROBIPHENYL & 3-CHLORO-4-ACETAMIDO-4'-NITROBIPHENYL WERE FOUND IN THE URINE OF RATS BUT NOT OF GUINEA PIGS. APPARENTLY, IN THE RAT HALOGENATION OCCURS IN A METABOLIC PATHWAY FOR THE METABOLITES OF 4,4'-DINITROBIPHENYL, 4-AMINO-4'-NITROBIPHENYL & 4-ACETAMIDO-4'-NITROBIPHENYL.""]",
5216,15217,N-P-Chlorophenylbenzohydroxamic acid,C1=CC=C(C=C1)C(=O)N(C2=CC=C(C=C2)Cl)O,,,,,,
5217,15218,Aluminum;icosane,CCCCCCCCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCCCCCCCC[CH2-].[Al+3],,,,,,
5218,15219,Aluminum;tetradecane,CCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCC[CH2-].[Al+3],,,,,,
5219,15220,Aluminum;dodecane,CCCCCCCCCCC[CH2-].CCCCCCCCCCC[CH2-].CCCCCCCCCCC[CH2-].[Al+3],,,,,,
5220,15221,"1,2,3,4-Tetrabromobutane",C(C(C(CBr)Br)Br)Br,,,,,,
5221,15222,4-Piperidinocyclohexyl butyrate,CCCC(=O)OC1CCC(CC1)N2CCCCC2,,,,,,
5222,15223,"Isobutyric acid, 4-piperidinocyclohexyl ester",CC(C)C(=O)OC1CCC(CC1)N2CCCCC2,,,,,,
5223,15224,"Isobutyric acid, 4-piperidinocyclohexyl ester, hydrochloride",CC(C)C(=O)OC1CCC(CC1)[NH+]2CCCCC2.[Cl-],,,,,,
5224,15225,"Isovaleric acid, 4-piperidinocyclohexyl ester",CC(C)CC(=O)OC1CCC(CC1)N2CCCCC2,,,,,,
5225,15226,"Isovaleric acid, 4-piperidinocyclohexyl ester, hydrochloride",CC(C)CC(=O)OC1CCC(CC1)[NH+]2CCCCC2.[Cl-],,,,,,
5226,15227,"Benzoic acid, 3,4,5-trimethoxy-, 4-piperidinocyclohexyl ester",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCC(CC2)N3CCCCC3,,,,,,
5227,15228,"3,4,5-Trimethoxybenzoic acid 4-piperidinocyclohexyl ester hydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OC2CCC(CC2)[NH+]3CCCCC3.[Cl-],,,,,,
5228,15229,3-Dodecanone,CCCCCCCCCC(=O)CC,,,,,,
5229,15230,"Isothiocyanic acid, 5-fluoropentyl ester",C(CCN=C=S)CCF,,,,,,
5230,15231,"Acetic acid, fluoro-, (2-chloroethyl) ester",C(CCl)OC(=O)CF,,,,,,
5231,15232,Benzathine benzylpenicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCCNCC2=CC=CC=C2,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
5232,15233,Butyl N-phenylcarbamate,CCCCOC(=O)NC1=CC=CC=C1,,,,,,
5233,15234,Trimethylacetic anhydride,CC(C)(C)C(=O)OC(=O)C(C)(C)C,,,,,,
5234,15235,"3-(1-Methylethyl)pentane-2,4-dione",CC(C)C(C(=O)C)C(=O)C,,,,,,
5235,15236,"6H-(1)BENZOTHIOPYRANO(4,3-b)QUINOLINE, 7-METHYL-",CC1=C2CSC3=CC=CC=C3C2=NC4=CC=CC=C14,,,,,,
5236,15237,Dodecylidene-bis(2-hydroxyethyl)azanium,CCCCCCCCCCCC=[N+](CCO)CCO,,,,,,
5237,15238,"N,N-Bis(2-chloroethyl)-m-fluorobenzylamine",C1=CC(=CC(=C1)F)CN(CCCl)CCCl,,,,,,
5238,15239,"N,N-Bis(2-chloroethyl)-o-fluorobenzylamine",C1=CC=C(C(=C1)CN(CCCl)CCCl)F,,,,,,
5239,15240,"N,N-Bis(2-chloroethyl)-p-fluorobenzylamine",C1=CC(=CC=C1CN(CCCl)CCCl)F,,,,,,
5240,15241,4-Fluorophenyl isothiocyanate,C1=CC(=CC=C1N=C=S)F,,,,,,
5241,15242,"(4R,8S,12R,19S)-12,19-difluoro-8-(2-fluoroacetyl)-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC1(O[C@@H]2CC3C4C[C@@H](C5=CC(=O)C=CC5([C@]4(C(CC3([C@@]2(O1)C(=O)CF)C)O)F)C)F)C,,,,,,
5242,15243,"2,2,3,3,4,4,5,5,6,6,7,7-Dodecafluoroheptanoic acid",C(C(C(C(C(C(C(=O)O)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
5243,15244,"4,4,4-Trifluoro-3-hydroxy-3-(trifluoromethyl)butanoic acid",C(C(=O)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
5244,15245,1-Chloro-6-fluorohexane,C(CCCCl)CCF,,,,,,
5245,15246,Isopropyl methyl sulfide,CC(C)SC,,,,,,
5246,15247,"2,5-Dimethyltetrahydrothiophene",CC1CCC(S1)C,,,,,,
5247,15248,"alpha-(((4-Methoxybutyl)amino)methyl)-1,4-benzodioxan-2-methanol",COCCCCNCC(C1COC2=CC=CC=C2O1)O,,,,,,
5248,15249,"Acetamide, N,N'-octamethylenebis(2-(1-aziridinyl)-",C1CN1CC(=O)NCCCCCCCCNC(=O)CN2CC2,,,,,,
5249,15250,Ibufenac,CC(C)CC1=CC=C(C=C1)CC(=O)O,,,,,,
5250,15251,"9-Octadecenoic acid (9Z)-, magnesium salt",CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].[Mg+2],,,,,,
5251,15252,"N-(3-Aminopropyl)-N-butyl-1,3-propanediamine",CCCCN(CCCN)CCCN,,,,,,
5252,15253,"Benzoic acid, 3-acetamido-5-acetamidomethyl-2,4,6-triiodo-, 2-hydroxyethyl ester",CC(=O)NCC1=C(C(=C(C(=C1I)NC(=O)C)I)C(=O)OCCO)I,,,,,,
5253,15254,CID 15254,CC[NH+](CC)CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O.[Cl-],,,,,,
5254,15255,CID 15255,CCN(CC)CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O,,,,,,
5255,15256,4-Methyl-9H-fluorene,CC1=C2C(=CC=C1)CC3=CC=CC=C32,,,,,,
5256,15257,"4,6-Dimethylpyrimidine",CC1=CC(=NC=N1)C,,,,,,
5257,15258,Trichloro(chloromethyl)silane,C([Si](Cl)(Cl)Cl)Cl,,,,,,
5258,15259,"5-Methyl-3-nonyne-1,5-diol",CCCCC(C)(C#CCCO)O,,,,,,
5259,15260,2-(2-Ethylhexyloxy)ethanol,CCCCC(CC)COCCO,,,,,,
5260,15261,"5-Methyl-3-octyne-1,5-diol",CCCC(C)(C#CCCO)O,,,,,,
5261,15262,"1-Methyl-1,2,3,4-tetrahydronaphthalene",CC1CCCC2=CC=CC=C12,,,,,,
5262,15263,m-Methylallylbenzene,CC=CCC1=CC=CC=C1,,,,,,
5263,15264,2-Methyloctadecane,CCCCCCCCCCCCCCCCC(C)C,,,,,,
5264,15265,2-Methylheptadecane,CCCCCCCCCCCCCCCC(C)C,,,,,,
5265,15266,2-Methylhexadecane,CCCCCCCCCCCCCCC(C)C,,,,,,
5266,15267,2-Methylpentadecane,CCCCCCCCCCCCCC(C)C,,,,,,
5267,15268,2-Methyltetradecane,CCCCCCCCCCCCC(C)C,,,,,,
5268,15269,2-Methyltridecane,CCCCCCCCCCCC(C)C,,,,,,
5269,15270,2-Methyldodecane,CCCCCCCCCCC(C)C,,,,,,
5270,15271,4-Methylhexanoic acid,CCC(C)CCC(=O)O,,,,,,
5271,15272,"3,3-Dichloroacrylic acid",C(=C(Cl)Cl)C(=O)O,,,,,,
5272,15273,"1,1,1,9-Tetrachlorononane",C(CCCCCl)CCCC(Cl)(Cl)Cl,,,,,,
5273,15274,2-Chlorocyclohexanol,C1CCC(C(C1)O)Cl,,,,,,
5274,15275,CID 15275,C(CS(=O)(=O)[O-])O.[Na+],,,,,,
5275,15276,"Benzoic acid, 4-(phenylazo)-",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
5276,15277,"4,4'-Azoxyanisole",COC1=CC=C(C=C1)N=[N+](C2=CC=C(C=C2)OC)[O-],,,,,,
5277,15278,"2,3-Dihydro-2,2-dimethyl-7-benzofuranol",CC1(CC2=C(O1)C(=CC=C2)O)C,,,,,"['ALFALFA CONTAINING CARBOFURAN RESIDUES WAS ADMIN TO A COW. THESE RESIDUES WERE METABOLIZED AND EXCRETED AS SULFATES OF 3-KETO-7-PHENOL (65%), THE 7-PHENOL (9.4%) AND THE 3,7-DIOL (6.4%).', '(14)C-CARBOFURAN WAS APPLIED TO SOLN IN WHICH THE ROOTS OF 3-4 YEAR OLD MUGHO PINE WERE IMMERSED. ... IN ADDN TO TWO UNIDENTIFIED COMPD, CARBOFURAN PHENOL AND LESSER AMOUNTS OF 3-HYDROXYFURAN AND 3-KETOCARBOFURAN PHENOL WERE PRESENT.', 'RATS WITH THEIR BILE DUCTS CANNULATED WERE GIVEN AN ORAL DOSE OF RING-LABELED CARBOFURAN; WITHIN 48 HR THEY HAD EXCRETED 28.5% OF THE DOSE IN THEIR BILE, 65.4% IN THEIR URINE, AND 0.4% IN THEIR FECES. ...THE RELEASED COMPD...INCLUDED...CARBOFURAN PHENOL...']",
5278,15279,Decarbofuran,CC1CC2=C(O1)C(=CC=C2)OC(=O)NC,,,,,,
5279,15280,N-Acetyl-N-propylacetamide,CCCN(C(=O)C)C(=O)C,,,,,,
5280,15281,CID 15281,CCCC[NH+](CCCC)CCCCNC(=O)C1=C(OC2=C(C=CC=C2C1=O)C)O.[Cl-],,,,,,
5281,15282,CID 15282,CCCCN(CCCC)CCCCNC(=O)C1=C(OC2=C(C=CC=C2C1=O)C)O,,,,,,
5282,15283,2-Phenylbutan-2-ol,CCC(C)(C1=CC=CC=C1)O,,,,,,
5283,15284,Silux,CC(=C)C(=O)OCC(COC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OCC(COC(=O)C(=C)C)O)O,,,,,,
5284,15285,4-Methoxy-2-nitrophenol,COC1=CC(=C(C=C1)O)[N+](=O)[O-],,,,,,
5285,15286,1-Propoxy-2-propanol,CCCOCC(C)O,,,,,,
5286,15287,1-Ethoxy-2-propanol,CCOCC(C)O,,,,,,
5287,15288,3-Methyl-5-hexen-3-ol,CCC(C)(CC=C)O,,,,,,
5288,15289,Pent-3-en-2-ol,CC=CC(C)O,,,,,,
5289,15290,Cyclohexanethiol,C1CCC(CC1)S,,,,,,
5290,15291,Ethyl isonicotinate,CCOC(=O)C1=CC=NC=C1,,,,,,
5291,15292,"2,4-Dichloro-6-methylphenol",CC1=CC(=CC(=C1O)Cl)Cl,,,,,,
5292,15293,"2-Cyclohexyl-1,3-propanediol",C1CCC(CC1)C(CO)CO,,,,,,
5293,15294,Methyl 4-formylbenzoate,COC(=O)C1=CC=C(C=C1)C=O,,,,,,
5294,15295,Phenylphosphonic acid,C1=CC=C(C=C1)P(=O)(O)O,,,,,,
5295,15296,9-Benzylfluorene,C1=CC=C(C=C1)CC2C3=CC=CC=C3C4=CC=CC=C24,,,,,,
5296,15297,"3,6-Dimethyl-3-heptanol",CCC(C)(CCC(C)C)O,,,,,,
5297,15298,"1,2,3,4-Tetrachlorobut-2-ene",C(C(=C(CCl)Cl)Cl)Cl,,,,,,
5298,15299,"1,2,2,3,3,4-Hexachlorobutane",C(C(C(CCl)(Cl)Cl)(Cl)Cl)Cl,,,,,,
5299,15300,"1,3-Butadiene, 1,2,3-trichloro-",C=C(C(=CCl)Cl)Cl,,,,,,
5300,15301,"Penta-1,3-diene",CC=CC=C,,,,,,
5301,15302,2-Oxobutyl acetate,CCC(=O)COC(=O)C,,,,,,
5302,15303,4-Methylbenzenesulfonohydrazide,CC1=CC=C(C=C1)S(=O)(=O)NN,,,,,,
5303,15304,"3,6-Dimethylphenanthrene",CC1=CC2=C(C=C1)C=CC3=C2C=C(C=C3)C,,,,,,
5304,15305,"2,7-Dimethylphenanthrene",CC1=CC2=C(C=C1)C3=C(C=C2)C=C(C=C3)C,,,,,,
5305,15306,Pent-2-en-1-ol,CCC=CCO,,,,,,
5306,15307,Oct-3-enoic acid,CCCCC=CCC(=O)O,,,,,,
5307,15308,5-Hexenoic acid,C=CCCCC(=O)O,,,,,,
5308,15309,"Furfurylamine, N-(3-triethylsilylpropyl)-",CC[Si](CC)(CC)CCCNCC1=CC=CO1,,,,,,
5309,15310,2-Fluoro-3-methylbutanoic acid,CC(C)C(C(=O)O)F,,,,,,
5310,15311,"N,N-diethyl-4-[(4-fluorophenyl)diazenyl]aniline",CCN(CC)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)F,,,,,,
5311,15312,4-Fluorophthalic acid,C1=CC(=C(C=C1F)C(=O)O)C(=O)O,,,,,,
5312,15313,1-Bromo-4-ethylbenzene,CCC1=CC=C(C=C1)Br,,,,,,
5313,15314,Benzenepentacarboxylic acid,C1=C(C(=C(C(=C1C(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
5314,15315,"10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-ylammonium chloride",C1C(C2=CC=CC=C2CC3=CC=CC=C31)[NH3+].[Cl-],,,,,,
5315,15316,"10,11-Dihydro-5H-dibenzo[a,d]cycloheptene-10-amine",C1C(C2=CC=CC=C2CC3=CC=CC=C31)N,,,,,,
5316,15317,1-Allyl-2-methylbenzene,CC1=CC=CC=C1CC=C,,,,,,
5317,15318,"Methane, dichlorodinitro-",C([N+](=O)[O-])([N+](=O)[O-])(Cl)Cl,,,,,,
5318,15319,1-Phenylcyclohexanol,C1CCC(CC1)(C2=CC=CC=C2)O,,,,,,
5319,15320,2-Cyclohexylidenehydrazinecarboxamide,C1CCC(=NNC(=O)N)CC1,,,,,,
5320,15321,"[1,1'-Biphenyl]-4,4'-dicarbonitrile",C1=CC(=CC=C1C#N)C2=CC=C(C=C2)C#N,,,,,,
5321,15322,4-Iodobiphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)I,,,,,,
5322,15323,4'-((p-(Dimethylamino)phenyl)azo)acetanilide,CC(=O)NC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
5323,15324,Calcium stearate,CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Ca+2],,,,,,
5324,15325,"2,4-Dinitrophenyl thiocyanate",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])SC#N,,,,,,
5325,15326,N-Hydroxyisonicotinimidamide,C1=CN=CC=C1C(=NO)N,,,,,,
5326,15327,"Benzene, 1-butyl-3-methyl-",CCCCC1=CC=CC(=C1)C,,,,,,
5327,15328,"Benzene, 1-butyl-4-methyl-",CCCCC1=CC=C(C=C1)C,,,,,,
5328,15329,Propoxyphene-d7 hydrochloride salt(mixture of diastereoisomers),CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C.Cl,,,,,,
5329,15330,l-Propoxyphene,CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C,,,,,,
5330,15331,Daminozide,CN(C)NC(=O)CCC(=O)O,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']","['Daminozide has been studied in minipigs chosen because of the similar stomach conditions to the human. They were given oral doses of radio-labelled test material at 5 mg/kg bw. It was found to be rapidly excreted with approximately 60% excreted by 48 hours. The metabolite (UDMH) was found in urine at up to 2.8 ppm; lesser amounts were found in the feces. Radio-labelled 1,1-dimethylnitrosamine at levels of 0.69 ppm... were also found in the urine of the test animals. A second study was performed with a dermal application of radio-labelled daminozide covering dermal surfaces with concentrations of 0.5, 0.05, or 0.005 mg/cu cm for periods up to 24 hours. As much as 1.8% of the dose was absorbed and excreted by the test animals in 24 hours.', 'Distribution and metabolic fate of (14)C daminozide in Silver maple and American sycamore seedlings were studied by auto radiography. Radioactivity was detected in all parts of plant. (14)C concentrated in meristematic regions of leaves.', 'Analysis of extracts from red oak (Quercus rubra) administered (14)C-labeled maleic hydrazide or daminozide indicated that both growth inhibitors were distributed acropetally as well as basipetally over a 22 day period.', ""When leaves of 3 yr old apple trees, CV Cox's orange pippin, were painted with (14)C-labeled daminozide, over half of radioactivity accumulated in fruits.""]","['Metabolites /in plants/ include 1,1-dimethylhydrazine.']",
5331,15332,CID 15332,C[C@@H]1CC2C3CCC4=CC(=O)C=CC4([C@]3([C@H](CC2(C1C(=O)COC(=O)C)C)O)F)C,,,,,,
5332,15333,"[2-[(6S,11S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=CC4(C3[C@H](CC2([C@]1(C(=O)COC(=O)C)O)C)O)C)F,,,,,,
5333,15334,"s-Triazine, 2,4-bis(diethylamino)-6-fluoro-",CCN(CC)C1=NC(=NC(=N1)F)N(CC)CC,,,,,,
5334,15335,"1,2,2-Trichloropentafluoropropane",C(C(F)(F)F)(C(F)(F)Cl)(Cl)Cl,,,,,,
5335,15336,"4-Methyl-2-pentyl-1,3-dioxolane",CCCCCC1OCC(O1)C,,,,,,
5336,15337,Mercury(II) acetate,CC(=O)[O-].CC(=O)[O-].[Hg+2],,,,,,
5337,15338,"1-Propene, 1,1,2,3,3-pentachloro-",C(C(=C(Cl)Cl)Cl)(Cl)Cl,,,,,,
5338,15339,Methyl 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC,,,,,,
5339,15340,"4,4'-Dichloroazobenzene",C1=CC(=CC=C1N=NC2=CC=C(C=C2)Cl)Cl,,,,,"[""THE MICROBIAL OXIDATION OF 4-CHLOROANILINE BY THE SOIL FUNGUS FUSARIUM OXYSPORUM WAS STUDIED...METABOLITES INCLUDED 4,4'-DICHLOROAZOXYBENZENE & 4,4'-DICHLOROAZOBENZENE."", ""Lignin peroxidase H2 (LP H2) from Phanerochaete chrysosporium oxidized 4 chloroaniline to form several oligomers. Included among the compounds identified were: 4,4' dichloroazobenzene, 2 (4 chloroanilino) 5 hydroxybenzoquinone di 4 chloroanil and 2 amino S (4 chloroanilino) benzoquinone di 4 chloroanil. In contrast to results by others, we showed that oligomers of 4 chloroaniline were also formed by the fungus in vivo. It was also demonstrated that, although these potentially toxic intermediates are made, they are also degraded."", ""4 chloroaniline was oxidized by soya cell wall peroxidases in the presence of hydrogen peroxide. The main product, an orange compound with a maximal absorbance at 455 nm, was probably 4,4' dichloroazobenzene. The optimum pH of the reaction was 4. Michaelis constants, determined as described by Dalziel, were 21 mM for 4 chloroaniline and 94 uM for hydrogen peroxide. Syringaldazine was an uncompetitive inhibitor of 4 chloroaniline peroxidation (Ki = 46 uM) and modified the progress of the reaction with the appearance of a lag period. By contrast, 4 chloroaniline was a non competitive inhibitor of syringaldazine peroxidation with a Ki value of 21 mmx at pH 7.5. Therefore, these two inhibiting effects were compatible with the presence of two binding sites for two different hydrogen donors. Both sites were linked by allosteric interactions. The inferences on chloroaniline binding are discussed.""]",
5340,15341,Hexadecylammonium chloride,CCCCCCCCCCCCCCCC[NH3+].[Cl-],,,,,,
5341,15342,"3-Methylhepta-1,4-diene",CCC=CC(C)C=C,,,,,,
5342,15343,"Acetanilide, 2-(bis(2-chloroethyl)amino)-N-methyl-, hydrochloride",CN(C1=CC=CC=C1)C(=O)C[NH+](CCCl)CCCl.[Cl-],,,,,,
5343,15344,2-[bis(2-chloroethyl)amino]-N-methyl-N-phenylacetamide,CN(C1=CC=CC=C1)C(=O)CN(CCCl)CCCl,,,,,,
5344,15345,N-Benzyl-N-(3-morpholinopropyl)benzamide hydrochloride,C1COCC[NH+]1CCCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
5345,15346,n-Benzyl-n-[3-(morpholin-4-yl)propyl]benzamide,C1COCCN1CCCN(CC2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
5346,15347,2-Amino-3-methylpyridine,CC1=C(N=CC=C1)N,,,,,,
5347,15348,2-Amino-5-methylpyridine,CC1=CN=C(C=C1)N,,,,,,
5348,15349,Ethyl benzoylformate,CCOC(=O)C(=O)C1=CC=CC=C1,,,,,,
5349,15350,Dimethyl methylsuccinate,CC(CC(=O)OC)C(=O)OC,,,,,,
5350,15351,"cis-2,3-Diphenylaziridine",C1=CC=C(C=C1)[C@H]2[C@H](N2)C3=CC=CC=C3,,,,,,
5351,15352,1-Aminopyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)N,,,,,['1-aminopyrene has known human metabolites that include N-hydroxy-1-aminopyrene.'],
5352,15353,Pentrinitrol,C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O,,,,,,
5353,15354,Bromotriphenylethylene,C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Br)C3=CC=CC=C3,,,,,,
5354,15355,Hexamethylphosphorous triamide,CN(C)P(N(C)C)N(C)C,,,,,,
5355,15356,N-Cyano-N'-methylguanidine,CN=C(N)NC#N,,,,,,
5356,15357,Ethyl 2-ethylperoxy-2-oxoacetate,CCOC(=O)C(=O)OOCC,,,,,,
5357,15358,1-(N-piperidin-4-ylanilino)propan-2-one,CC(=O)CN(C1CCNCC1)C2=CC=CC=C2,,,,,,
5358,15359,Atraton,CCNC1=NC(=NC(=N1)OC)NC(C)C,,,,,,
5359,15360,CID 15360,CCC=C(C)CO,,,,,,
5360,15361,"3,5-Dibromotoluene",CC1=CC(=CC(=C1)Br)Br,,,,,,
5361,15362,"2-Methyl-1,2,3,4-tetrahydroisoquinoline",CN1CCC2=CC=CC=C2C1,,,,,,
5362,15363,"5-Phenyl-1,3,4-oxadiazol-2-amine",C1=CC=C(C=C1)C2=NN=C(O2)N,,,,,,
5363,15364,Stearyldimethylammonium chloride,CCCCCCCCCCCCCCCCCC[NH+](C)C.[Cl-],,,,,,
5364,15365,Dymanthine,CCCCCCCCCCCCCCCCCCN(C)C,,,,,,
5365,15366,Quinoline 1-oxide,C1=CC=C2C(=C1)C=CC=[N+]2[O-],,,,,['Quinoline 1-oxide is a known human metabolite of quinoline.'],
5366,15367,Thiane,C1CCSCC1,,,,,,
5367,15368,CID 15368,C1=CC(=CC=C1C(=O)N=O)N(O)O,,,,,,
5368,15369,CID 15369,C1=CC(=CC=C1C2=CC=C(C=C2)N=C(N)S)N=C(N)S,,,,,,
5369,15370,"5H-DIBENZO(a,d)CYCLOHEPTENE-5-PROPYLAMINE, N,N-DIMETHYL-, HYDROCHLORIDE",C[NH+](C)CCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.[Cl-],,,,,,
5370,15371,"2-Propenoic acid, 3-(4-chlorophenyl)-",C1=CC(=CC=C1C=CC(=O)O)Cl,,,,,,
5371,15372,"1H,3H-2,1,3-Benzothiadiazole 2,2-dioxide",C1=CC=C2C(=C1)NS(=O)(=O)N2,,,,,,
5372,15373,1-Chloro-1-fluoroethane,CC(F)Cl,,,,,,
5373,15374,"1,2-Diethylhydrazine",CCNNCC,,,,"['Radioactivity was detected in the urine and bile of rats following sc injection of 21 mg/kg 1,2-di(3)H-ethylhydrazine. Peak concentrations occurred 6 hours postinjection, which was the maximum sampling time after administration.', ""To elucidate the role of p53 in colon tumorigenesis in mice, we examined allele loss and mutational alteration of the p53 gene in colon tumors induced by 1,2-dimethylhydrazine in Fl hybrid mice. Intragenic polymorphism of the p53 gene among parental strains enabled us to assess allele loss of the p53 gene and also to determine parental origin of mutated and/or lost alleles. Allele loss was detected in two of 163 tumors heterozygous for the p53 gene. Polymerase chain reaction-single-strand conformation polymorphism analysis of p53 exons 5-8 revealed 33 mutations in 20 of 182 colon tumors, the incidence being lower than that in human colon cancers. The majority of these mutations were of transition type: G:A transitions at nonCpG sites were most prevalent, while those at CpG sites were less common. Distribution of the mutations along p53 amino acid sequence revealed a difference in the location of 'hot spots' between mice and humans. Incidence of p53 alterations did not differ among alleles of different parental origins, suggesting that genetic changes in 1,2-dimethylhydrazine-induced mouse colon tumors had occurred independently of parental origin and 1,2-dimethylhydrazine susceptibility. Detailed analysis of p53 mutations on each allele revealed intratumoral heterogenelty in mouse colon tumors. The low incidence of p53 mutations and rare allele loss suggest that p53 alteration plays only a minor role in colon tumorigenesis in mice.""]",,
5374,15375,2-Methoxyethyl carbamate,COCCOC(=O)N,,,,,,
5375,15376,Vincamine,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']","['In a crossover study of six healthy volunteers the pharmacokinetics and the bioavailability of vincamine were studied after administration of two oral forms. All subjects received an oral dose of 60 mg vincamine. ...The drug generally follows a one-compartment kinetic model. The average value of Tmax is 1.4 +/- 0.5/hr with the tablets and 1 +/- 0.6/hr with the solution; the Cmax are, respectively, 155 +/- 82 micrograms . 1(-1) and 133 +/- 104 micrograms . 1(-1). The AUC are 443 +/- 156 micrograms . 1(-1) hr with the tablets and 315 +/- 178 micrograms . 1(-1) hr with the solution.', 'Vincamine HCl was biopharmaceutically and pharmacokinetically evaluated. For biopharmaceutical characterization of the drug the apparent lipoid/water partition coefficient (APC), pKa, extent of protein (bovine) binding and the erythrocyte (human) uptake were determined. Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6% bound to erythrocytes. Because the gerbil was used as model in pharmacodynamic studies, the pharmacokinetic drug disposition was determined in this species and compared to parameters reported in the literature for other species. The terminal half-life is about 1 hour, the apparent volume of distribution 2.9 L/kg, and the total clearance is about 33.3 mL/min/kg. The parameters are comparable to other species including man. The brain concentration is about 5-fold that in plasma. A therapeutic steady state concentration for effectiveness in gerbils has been estimated to be 0.02 ug/mL.', 'Pharmacokinetic parameters of vincamine in rats were measured after oral administration of 20 mg base/kg bw and intravenous injection of 10 mg vincamine hydrochloride/kg bw. After oral administration, a bioavailability of 58% was found and the concentration/time curve showed a two-compartment open model. The following parameters were observed: an elimination half-life of 1.71 hours, a t-max of 1.27 hours, a C-max of 0.87 ug/ml, a total clearance of 0.818 1/h (higher than the plasma perfusion volume, which indicates a very quick metabolism in other organs in addition to the liver), and a volume of distribution of 2.018 liters. The amount of unchanged vincamine excreted was very low with 3 to 11% in urine and 2 to 5% in bile. Vincamine is taken up in high concentrations into the different organs resulting in the following ratios: lung/plasma 21, brain/plasma 14.6, kidneys/plasma 14.3, liver/plasma 8.9, heart/plasma 7.6. However, elimination from these organs was significantly more rapid than from plasma. After intravenous injection the pharmacokinetic parameters observed were an elimination half-life of 1.68 hours, a C-max of 5.46 ug/ml, a total clearance of 0.866 1/hour, and a volume of distribution of 2.104 liters. The values for elimination half-life, volume of distribution and total clearance did not differ significantly between oral and intravenous administration.', 'Pharmacokinetics of vincamine in dogs also followed a two-compartment open model. Doses of 10, 20 and 40 mg intravenously showed dose-dependent half-life and clearance rate. After oral administration of 20 mg vincamine hydrochloride, bioavailability ranged between 23 and 58%. Vincamine could be detected in the urine at up to 9.5% depending on urinary pH.', 'For more Absorption, Distribution and Excretion (Complete) data for VINCAMINE (6 total), please visit the HSDB record page.']","['The metabolism of vincamine hydrochloride was studied in the rat after oral administration of the drug. Vincamine is almost completely metabolized, only a small fraction of the original compound being excreted in the urine. The metabolites detected in blood, urine and tissues were purified by preparative thin layer and column chromatography in several solvent systems, and analyzed by mass spectrometry. It was found that the main urinary metabolites were vincamine conjugates (sulphates and glucuronides). Two new metabolites were detected in all the biological fluids and specimens analyzed: these compounds are more polar than vincamine and their structure was characterized by mass spectrometry, I.R. and U.V. spectroscopy and confirmed by synthesis in our laboratory.[Vigano V et al; Farmaco', 'Vincamine is very extensively metabolised with only a small percentage of unchanged compound detectable in the urine. Radiolabel studies in rats after an oral dose of 10 mg/kg bw demonstrate the metabolic pathway of vincamine. On the one hand it is hydrolysed by the plasma esterases to the unstable vincaminic acid. The latter is quickly decarboxylised and oxidised to eburnamenine. On the other hand vincamine is hydroxylated to the major metabolite 6-beta-hydroxy-vincamine, which accounts for 40% of total urinary and biliary radioactivity, followed by 6-alpha-hydroxy-vtncamine (8%) and 6-keto-vincamine, the oxidized metabolite of both previous metabolites (about 10% of the administered dose). 6-Keto-vincamine is eliminated by conjugation. The same metabolites (hydroxy.-keto) could also be detected in the urine of rabbits, dogs and man. Within 72 hours 40% of the total radioactivity are excreted in twine and 23% in the feces.']","['After intravenous injection /of vincamine hydrochloride to rats/ the pharmacokinetic parameters observed were an elimination half-life of 1.68 hours /Vincamine hydrochloride/.', 'The following parameters were observed /after oral administration of 20 mg/kg vincamine (base) to rats/: an elimination half-life of 1.71 hours...', 'After oral administration of 4 mg vincamine hydrochloride/kg bw /in dogs/ an elimination half-life of 4.5 hours (longer than for rats) and a total clearance of 0.52 1/hour were observed. /vincamine hydrochloride/', 'Half-life of elimination for the solution was 0.57 to 1.07 hours/for 169 mg vincamine hydrochloride and 33.81 mg vincamine hydrochloride control-released tablets respectively/.', 'Vincamine HCl was biopharmaceutically and pharmacokinetically evaluated. ...The terminal half-life is about 1 hour... .']"
5376,15377,Ambenoxan hydrochloride,COCCOCC[NH2+]CC1COC2=CC=CC=C2O1.[Cl-],,,,,,
5377,15378,Ambenoxan,COCCOCCNCC1COC2=CC=CC=C2O1,,,,,,
5378,15379,"2,6-Dimethyldecalin",CC1CCC2CC(CCC2C1)C,,,,,,
5379,15380,Bis(methylthio)methane,CSCSC,,,,,,
5380,15381,3-Quinuclidinol,C1CN2CCC1C(C2)O,,,,,['3-Quinuclidinol (Q) and benzilic acid (BA) /are the 2 major metabolites of 3-quinuclidinyl benzilate/.'],
5381,15382,Diethyl dimethylmalonate,CCOC(=O)C(C)(C)C(=O)OCC,,,,,,
5382,15383,3-Hydroxyphenyltrimethylammonium bromide,C[N+](C)(C)C1=CC(=CC=C1)O.[Br-],,,,,,
5383,15384,3-Hydroxyphenyltrimethylammonium,C[N+](C)(C)C1=CC(=CC=C1)O,,,,,,
5384,15385,2-Chloroethanesulfonyl chloride,C(CCl)S(=O)(=O)Cl,,,,,,
5385,15386,Buronil,CC1CC[NH+](CC1)CCCC(=O)C2=CC=C(C=C2)F.[Cl-],,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
5386,15387,Melperone,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,"['For the treatment of schizophrenia, sleep, disorders, agitation and mentally confused states.']",['Melperone has been demonstrated to produce an antipsychotic effect at doses that cause minimal extrapyramidal symptoms frequently associated with more traditional antipsychotics.'],"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']","['Oral doses are rapidly absorbed (Tmax 1.53.0 hours post oral ingestion).', 'Excreted mainly in the urine, with small amounts of unchanged drug.']",['Mainly hepatic.'],"['Approximately 3-4 hours after oral administration. After intramuscular injection, the half-life has been found to be approximately 6 hours.']"
5387,15388,Heptafluoropropyl trifluorovinyl ether,C(=C(F)F)(OC(C(C(F)(F)F)(F)F)(F)F)F,,,,,,
5388,15389,Butyl dihydrogen phosphate,CCCCOP(=O)(O)O,,,,,,
5389,15390,Triallyl phosphate,C=CCOP(=O)(OCC=C)OCC=C,,,,,,
5390,15391,Isopropyl dihydrogen phosphate,CC(C)OP(=O)(O)O,,,,,,
5391,15392,3-Methyl-3-phenylazetidin-2-one,CC1(CNC1=O)C2=CC=CC=C2,,,,,,
5392,15393,"2-(p-N,N-dimethylaminostyryl)benzothiazole",CN(C)C1=CC=C(C=C1)C=CC2=NC3=CC=CC=C3S2,,,,,,
5393,15394,Ethyl vinyl ketone,CCC(=O)C=C,,,,,,
5394,15395,1-Hexen-3-one,CCCC(=O)C=C,,,,,,
5395,15396,"1,3-Benzenediamine, 2,4,6-trinitro-",C1=C(C(=C(C(=C1[N+](=O)[O-])N)[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
5396,15397,"1,3-Dimethyl-5-(4-nitrophenoxy)benzene",CC1=CC(=CC(=C1)OC2=CC=C(C=C2)[N+](=O)[O-])C,,,,,,
5397,15398,"N-(2-Hydroxyethyl)-N-propargyl-2,4-dichlorobenzylamine",C#CCN(CCO)CC1=C(C=C(C=C1)Cl)Cl,,,,,,
5398,15399,"1-(4-Methylphenyl)-1H-pyrrole-2,5-dione",CC1=CC=C(C=C1)N2C(=O)C=CC2=O,,,,,,
5399,15400,"1-(4-Chlorophenyl)-1H-pyrrole-2,5-dione",C1=CC(=CC=C1N2C(=O)C=CC2=O)Cl,,,,,,
5400,15401,"1,2-Dihtiolan-4-amine, N,N-dimethyl-, oxalate (1:1)",C[NH+](C)C1CSSC1.C(=O)(C(=O)[O-])O,,,,,,
5401,15402,Nereistoxin,CN(C)C1CSSC1,,,,,,
5402,15403,"1,3-Dithiolan-2-one, O-((methylamino)carbonyl)oxime",CNC(=O)ON=C1SCCS1,,,,,,
5403,15404,2-Ethyl-1-hexene,CCCCC(=C)CC,,,,,,
5404,15405,"1,2-Diazabicyclo[2.2.2]octan-3-one",C1CN2CCC1C(=O)N2,,,,,,
5405,15406,Fenchol,CC1(C2CCC(C2)(C1O)C)C,,,,,,
5406,15407,Strontium carbonate,C(=O)([O-])[O-].[Sr+2],,,,,,
5407,15408,2-Dimethylamino-2-phenylacetophenone hydrochloride hemihydrate,C[NH+](C)C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
5408,15409,"2-(Dimethylamino)-1,2-diphenylethanone",CN(C)C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
5409,15410,3-Chloropropanesulfonyl chloride,C(CS(=O)(=O)Cl)CCl,,,,,,
5410,15411,"1,4-Butane sultone",C1CCS(=O)(=O)OC1,,,,,,
5411,15412,Tetrabutylthiuram disulfide,CCCCN(CCCC)C(=S)SSC(=S)N(CCCC)CCCC,,,,,,
5412,15413,Methyl tert-butyl ether,CC(C)(C)OC,,,"['Any substance in the air which could, if present in high enough concentration, harm humans, animals, vegetation or materials. Substances include GASES; PARTICULATE MATTER; and volatile ORGANIC CHEMICALS. (See all compounds classified as Air Pollutants.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['... 10 healthy male volunteers /were exposed/ to methyl tert-butyl ether (MTBE) vapor at 5, 25 and 50 ppm for 2 hr during light physical exercise. Uptake and disposition were studied by measuring MTBE and tert-butyl alcohol (TBA) in inhaled and exhaled air, blood and urine. Low uptake, high post-exposure exhalation, and low blood clearance indicate slow metabolism of MTBE relative to many other solvents. A low recovery of TBA in urine (below 1% of uptake) indicates further metabolism of TBA. The concentration of MTBE and TBA in blood was proportional to exposure level suggesting linear kinetics up to 50 ppm. The half life of 7-10 hr in blood and urine indicates that TBA would be more suitable than the parent compound as a biomarker for MTBE exposure. Subjective ratings (discomfort, irritative symptoms, CNS effects) and eye (redness, tear film break-up time, conjunctival damage, blinking frequency) and nose (peak expiratory flow, acoustic rhinometry, inflammatory markers in nasal lavage) measurements indicated no or minimal effects of MTBE.', 'After inhalation exposure methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE) and tert-amyl methyl ether (TAME) are rapidly taken up by both rats and humans; after termination of exposure, clearance by exhalation and biotransformation to urinary metabolites is rapid in rats. In humans, clearance by exhalation is slower in comparison to rats. Biotransformation of MTBE and ETBE is both qualitatively and quantitatively similar in humans and rats after inhalation exposure under identical conditions. The extent of biotransformation of TAME is also quantitatively similar in rats and humans; the metabolic pathways, however, are different. ...', 'Groups of male and female rats /strain not specified/ received a single 6 hr exposure to methyl tert-butyl ether (MTBE) vapor in nose-only inhalation chambers at targeted MTBE concentrations of 400 and 8000 ppm and daily repeat 6 hr exposures for 15 days at a targeted MTBE concentration of 400 ppm. Four rats/sex/group were then euthanized and examined. Steady-state plasma concentrations were reached at approximately 4 to 6 hr for MTBE and roughly 6.5 hr for TBA /tert-butyl alcohol/, the principal metabolite of MTBE. MTBE-metabolizing enzymes were saturated during high-concentration exposure. The elimination half-life (t1/2) of MTBE was approximately the same after single low- and high-concentration exposures (0.52 and 0.63 hr, respectively). After the repeat exposures, the MTBE t1/2 was slightly shorter (0.48 and 0.51, respectively). The TBA t1/2 ranged from 2.8 to 3.4 hr after the low- and high-concentration single exposures. After the repeat exposure regimen, the TBA t1/2 was significantly lower (1.8 and 1.5 hr in the male and female rats, respectively). There was a slight, but statistically significant, sex difference in the pharmacokinetics of MTBE (e.g., plasma clearance was faster in females), but no sex differences in the elimination kinetics of TBA were observed.', 'In a group of 2 healthy men and 2 healthy women experimentally exposed to 1.7 ppm methyl tert-butyl ether (MTBE) for 1 hr, mean blood levels of MTBE rose steeply from a level of 0.83 ug/L preexposure to 17.14 ug/L at the end of the 1-hr exposure, followed by a decline to an average level of 9.74 ug/L at 40 minutes postexposure and 6.32 ug/L at 60 minutes postexposure.', 'For more Absorption, Distribution and Excretion (Complete) data for Methyl t-butyl ether (9 total), please visit the HSDB record page.']","['The biotransformation of methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE), and tert-amyl methyl ether (TAME) was studied in humans and in rats after inhalation of 4 and 40 ppm of MTBE, ETBE, and TAME, respectively, for 4 hours, and the biotransformation of MTBE and TAME was studied after ingestion exposure in humans to 5 and 15 mg in water. tert-Butyl alcohol (TBA), a TBA conjugate, 2-methyl-1,2-propanediol, and 2-hydroxyisobutyrate were found to be metabolites of MTBE and ETBE. tert-Amyl alcohol (TAA), free and glucuronidated 2-methyl-2,3-butanediol (a glucuronide of TAA), 2-hydroxy-2-methyl butyrate, and 3-hydroxy-3-methyl butyrate were found to be metabolites of TAME. After inhalation, MTBE, ETBE, and TAME were rapidly taken up by both rats and humans; after termination of exposure, clearance from blood of the ethers by exhalation and biotransformation to urinary metabolites occurred with half-times of less than 7 hours in rats and humans. Biotransformation of MTBE and ETBE was similar in humans and rats after inhalation exposure. 2-Hydroxyisobutyrate was recovered as a major product in urine. All metabolites of MTBE and ETBE excreted with urine were eliminated with half-times of less than 20 hours. Biotransformation of TAME was qualitatively similar in rats and humans, but the metabolic pathways were different. In humans, 2-methyl-2,3-butanediol, 2-hydroxy-2-methyl butyrate, and 3-hydroxy-3methyl butyrate were recovered as major urinary products. In rats, however, 2-methyl-2,3-butanediol and its glucuronide were major TAME metabolites recovered in urine. After ingestion of MTBE and TAME, both compounds were rapidly absorbed from the gastrointestinal tract. Hepatic first-pass metabolism of these ethers was not observed, and a significant part of the administered dose was transferred into blood and cleared by exhalation. Metabolic pathways for MTBE and TAME and kinetics of excretion were identical after ingestion and inhalation exposures. ...', 'Methyl tert-butyl ether (MTBE) is ... metabolized to tert-butanol in rats. The metabolism of (14)C-MTBE has been studied in Fischer 344 rats exposed by the inhalation, oral, dermal, and intravenous routes. Respiratory and urinary metabolites were generally similar following exposure of Fischer 344 rats by all routes, indicating pathways are not route-dependent. After exposure by all routes, most of the exhaled radioactivity was due to unchanged MTBE and tert-butanol, with MTBE predominating. Only a small amount of (14)C-carbon dioxide was detected. MTBE and tert-butanol were generally not found in the urine, but four urinary metabolites were isolated, with two identified as alpha-hydroxyisobutyric acid and 2-methyl-1,2-propanediol. The two other metabolites remained unidentified. After inhalation and oral exposure, there was a larger fraction of exhaled tert-butanol in low dose rats than in high dose rats. In inhalation experiments, rats were exposed to (14)C-MTBE at 400 or 8000 ppm for 6 hr or to 400 ppm unlabeled MTBE for 6 hr per day for 14 days, then to 400 ppm (14)C-MTBE on day 15. tert-Butanol accounted for 25 and 30% of the recovered radioactivity in expired air at 3 hr after the single and repeated low exposure concentration, respectively. Exposure to the higher concentration for 6 hr resulted in a lower fraction recovered (7-10%) as a result of to tert-butanol. At 3-6 hr after exposure, tert-butanol represented 72-80% of the radioactivity at the low dose in the single and repeated exposure experiments and 43-54% at the high dose.  Results of dosing Fischer 344 rats with (14)C-MTBE intravenously were similar to those obtained by the inhalation, oral and dermal routes. In Charles River CD (Sprague-Dawley) rats injected with a single intraperitoneal dose of 232 mg/kg (14)C-MTBE, blood, tissue, expired air, urine, and feces were sampled at various times up to 48 hr. At 6 hr about 92% of the radioactive dose was eliminated in expired air, 99.1% of which was unchanged MTBE. An average of 7.38% of the administered dose was expired as radiolabeled carbon dioxide. Analysis of the urine revealed that radiolabeled formic acid accounted for 96.6% of the urinary radioactivity. The remaining radioactivity in the urine was assumed to be radiolabeled methanol and formaldehyde. Methanol and formic acid were also detected in plasma, kidney, and liver. No tert-butanol was found in the urine. The metabolism of MTBE to formaldehyde was studied using liver microsomes from control and phenobarbital-pretreated rats (strain not specified). Phenobarbital pretreatment approximately doubled the formation of formaldehyde from MTBE. Further metabolism of formaldehyde yields methanol and/or formic acid; the probable enzymes and cofactors are alcohol dehydrogenase and NADH for the formation of methanol and aldehyde dehydrogenase and NAD for the formation of formic acid.', 'Exposure to methyl tertiary-butyl ether (MTBE) previously /has/ been shown to alter various muscle, kidney, and liver metabolic activities. In the present study, the metabolism of MTBE by liver microsomes from acetone- or phenobarbital-treated Sprague-Dawley rats was studied at concn of up to 5 mM MTBE. Equimolar amounts of tertiary- butanol, as measured by head-space gas chromatography, and formaldehyde were formed. The Vmax for the demethylation increased by 4 fold and 5.5 fold after acetone and phenobarbital treatments, respectively. The apparent Km value of 0.70 mM using control microsomes was decreased slightly after acetone treatment, but was increased by 2 fold after phenobarbital treatment. The metabolism of MTBE (1 mM) was inhibited by 35% by monoclonal antibodies against p450IIE1, the acetone/ethanol inducible form of cytochrome p450, suggesting a partial contribution by this isozyme. A single 18 hr pretreatment of rats with 1 or 5 mL/kg MTBE (ip) resulted in a 50 fold induction of liver microsomal pentoxyresorufin dealkylase activity but no change in N-nitrosodimethylamine demethylase activity. These trends in activity agreed with immunoblot analysis which showed an elevation in p450IIB1 but no change in p450IIE1 level.', '/The/ human liver is active in the oxidative metabolism of ETBE and TAME. A large interindividual variation in metabolizing these gasoline ethers was observed in 15 human liver microsomal samples. The microsomal activities in metabolizing methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE), and tert-amyl methyl ether (TAME) were highly correlated among each other (r, 0.91-0.96), suggesting that these ethers are metabolized by the same enzyme(s). Correlation analysis of the ether-metabolizing activities with individual CYP enzyme activities in the liver microsomes showed that the highest degree of correlation was with human CYP2A6 (r, 0.90-0.95) ... CYP2A6 displayed the highest turnover number in metabolizing gasoline ethers among a battery of human CYP enzymes expressed in human B-lymphoblastoid cells. Kinetic studies on MTBE metabolism with three human liver microsomes exhibited apparent Km values that ranged from 28 to 89 uM and the V(max) values from 215 to 783 pmol/min/mg, with similar catalytic efficiency values (7.7 to 8.8 uL/min/mg protein). Metabolism of MTBE, ETBE, and TAME by human liver microsomes was inhibited by coumarin, a known substrate of human CYP2A6, in a concentration-dependent manner. Monoclonal antibody against human CYP2A6 caused a significant inhibition (75% to 95%) of the metabolism of MTBE, ETBE, and TAME in human liver microsomes. ...', 'For more Metabolism/Metabolites (Complete) data for Methyl t-butyl ether (9 total), please visit the HSDB record page.', 'Tert-butyl methyl ether has known human metabolites that include tert-butanol.']","['MTBE is rapidly metabolized and excreted with a half-life of approximately 30 min /Rats/.', 'Groups of male and female rats /strain not specified/ received a single 6 hr exposure to methyl tert-butyl ether (MTBE) vapor in nose-only inhalation chambers at targeted MTBE concentrations of 400 and 8000 ppm and daily repeat 6 hr exposures for 15 days at a targeted MTBE concentration of 400 ppm ... The elimination half-life (t1/2) of MTBE was approximately the same after single low- and high-concentration exposures (0.52 and 0.63 hr, respectively). After the repeat exposures, the MTBE t1/2 was slightly shorter (0.48 and 0.51, respectively). The TBA /tert-butyl alcohol/ t1/2 ranged from 2.8 to 3.4 hr after the low- and high-concentration single exposures. After the repeat exposure regimen, the TBA t1/2 was significantly lower (1.8 and 1.5 hr in the male and female rats, respectively).', 'Healthy male volunteers were exposed via inhalation to gasoline oxygenates methyl tert-butyl ether (MTBE)...  The half-times for MTBE in blood were about 1.7 and 3.8 hr.  In urine, /MTBE/ showed half-times of about 4 hr ... .', 'MTBE was rapidly cleared from blood with a half-life of 2.6 +/- 0.9 hr in humans and 0.5 +/- 0.2 hr in rats.', 'The biotransformation of methyl tert-butyl ether (MTBE), ethyl tert-butyl ether (ETBE), and tert-amyl methyl ether (TAME) was studied in humans and in rats after inhalation of 4 and 40 ppm of MTBE, ETBE, and TAME, respectively, for 4 hours, and the biotransformation of MTBE and TAME was studied after ingestion exposure in humans to 5 and 15 mg in water. tert-Butyl alcohol (TBA), a TBA conjugate, 2-methyl-1,2-propanediol, and 2-hydroxyisobutyrate were found to be metabolites of MTBE and ETBE. ... After termination of exposure, clearance from blood of the ethers by exhalation and biotransformation to urinary metabolites occurred with half-times of less than 7 hours in rats and humans. ... All metabolites of MTBE and ETBE excreted with urine were eliminated with half-times of less than 20 hours. ...']"
5413,15414,1-Butylnaphthalene,CCCCC1=CC=CC2=CC=CC=C21,,,,,,
5414,15415,Malaoxon,CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Eight autopsy samples from an individual who had ingested a large amt of malathion were analyzed for 4 components: intact pesticide, malaoxon, malathion monocarboxylic acid (MCA), and malathion dicarboxylic acid (DCA). Malathion was present in all samples except liver. The highest concn were found in the gastric content (8621 ppm) and adipose tissue (76.4 ppm). Malaoxon was identified in some tissues at very low levels; a significant amt was found only in fat (8.2 ppm). The MCA and DCA were detected in all tissues. The former was found in greater abundance: 221 ppm in bile, 106 ppm in kidney, and 103 ppm in the gastric content.', 'The fate of malaoxon was studied in a susceptible and a resistant strain of housefly following topical application. Sublethal doses were used: 160 pmol for the S-strain (0.17 times LD50) and 1570 pmol for the R-strain (0.1 times LD50). The penetration rates are dose dependent and semilog plots of the external amt versus time show that these rates are not proportional to this external amt. Internal concn of malaoxon rapidly increase following administration, reach max values between 30 min and 2 hr (depending on dose), and then slowly decrease. The rate of metabolic degradation is highest in the early stage of the intoxication process. A 3 compartment pharmacokinetic model is postulated to explain the experimental data quantitatively. The 1st compartment represents external malaoxon, the other 2 represent internal parent cmpd. Statistical analysis shows that the penetration rate is better described with a sum of 2 exponentials rather than with a single exponential decay. In the model, degradation occurs in the 1st internal compartment and is assumed to be 1st order. Malaoxon is distributed between the 2 internal compartments slowly with 1st order kinetics. Parameter estimations with curve fitting procedures for the internal processes (degradation and exchange) shows that there is not one set of parameter values that can be used for both strains simultaneously. Interstrain differences in degradation capacity studies showed that in vitro the R-strain had a 4-fold higher oxidative breakdown rate. Taking this difference into account, it is possible to explain the 2 sets of data with one kinetic model, although other alternatives cannot be excluded.', '... 7% OF TOTAL METABOLITES IN FECES /FROM COW GIVEN MALATHION ORALLY/ WAS CHLOROFORM SOLUBLE, OF WHICH 855 WAS MALATHION & 12% MALAOXON. THE MILK CONTAINED A SMALL AMOUNT OF MALATHION METABOLITES (9.2% OF TOTAL DOSE AFTER 7 DAYS); OF THIS, ONLY 29% WAS EXTRACTABLE OUT OF MILK AND PARTITIONED IN FAVOR OF WATER OVER BENZENE, INDICATING THE ABSENCE OF EITHER MALATHION OR MALAOXON.', 'Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'For more Absorption, Distribution and Excretion (Complete) data for MALAOXON (10 total), please visit the HSDB record page.']","['ALTHOUGH NO METABOLITE FOR MALAOXON WITH HYDROLYZED CARBOETHOXY GROUP HAS BEEN IDENTIFIED, CARBOXYESTERASE HYDROLYSIS OF MALAOXON UNDOUBTEDLY MUST OCCUR IN VIEW OF GREAT DIFFICULTY ENCOUNTERED IN DETECTING MALAOXON IN ANIMAL TISSUE.', 'IN VITRO STUDIES WITH MOUSE LIVER INDICATED THAT ONLY ABOUT HALF OF TOTAL MALAOXON DETOXIFICATION WAS ACCOUNTED FOR BY CARBOXYESTERASE HYDROLYSIS.', 'WITH RESISTANT & NON-RESISTANT HOUSEFLY STRAINS, IN VITRO STUDIES SHOWED THAT RESISTANT STRAINS DEGRADED MALAOXON OXIDATIVELY @ RATE 10X HIGHER THAN THAT OF SUSCEPTIBLE STRAIN. THE OXIDATION PRODUCT WAS MALAOXON BETA-MONOCARBOXYLIC ACID WHEN A SUSCEPTIBLE STRAIN WAS USED. THE RESISTANT STRAIN PRODUCED SOME BETA MONOACID BUT THE MALAOXON ALPHA-MONOACID WAS PROBABLY THE MAIN METABOLITE.', 'A ""BINDING"" TYPE OF INACTIVATION BY LIVER & OTHER TISSUES HAS BEEN DEMONSTRATED FOR ... MALAOXON. THIS APPEARS TO REPRESENT A LOSS OF THE ACTIVE CHOLINESTERASE INHIBITORS TO NONCRITICAL TISSUE BINDING SITES, THEREBY SPARING CRITICAL ACETYLCHOLINESTERASE OF NERVE TISSUE FROM INHIBITION.', 'For more Metabolism/Metabolites (Complete) data for MALAOXON (12 total), please visit the HSDB record page.', 'Maloxon is a known human metabolite of Malathion.']",
5415,15416,"1-bromo-N-tert-butyl-N,3-dimethylbutan-2-amine",CC(C)C(CBr)N(C)C(C)(C)C,,,,,,
5416,15417,Bicyclopentyl,C1CCC(C1)C2CCCC2,,,,,,
5417,15418,"1,3-Butadiene, 1,2,3,4-tetrachloro-",C(=C(C(=CCl)Cl)Cl)Cl,,,,,,
5418,15419,2-methyl-4-(7H-purin-6-ylamino)but-2-en-1-ol,CC(=CCNC1=NC=NC2=C1NC=N2)CO,,,,,,
5419,15420,4-Butylphenol,CCCCC1=CC=C(C=C1)O,,,,,"['4-n-Butylphenol has known human metabolites that include (2S,3S,4S,5R)-6-(4-butylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
5420,15421,"1,1-Dimethylcyclopentane",CC1(CCCC1)C,,,,,,
5421,15422,1-Heptanethiol,CCCCCCCS,,,,,,
5422,15423,"6-(4-Methylphenoxy)-1,3,5-triazine-2,4-diamine",CC1=CC=C(C=C1)OC2=NC(=NC(=N2)N)N,,,,,,
5423,15424,Propoxyphene hydrochloride,CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
5424,15425,CID 15425,CCCCCCCCOC(=O)CC(C(=O)OCCCCCCCC)S(=O)(=O)[O-].[Na+],,,,,,
5425,15426,"Succinic acid, sulfo-, 1,4-dioctyl ester",CCCCCCCCOC(=O)CC(C(=O)OCCCCCCCC)S(=O)(=O)O,,,,"['... Docusate sodium is absorbed, appears in the bile in significant concn ... .']",,
5426,15427,"2,3,3-Trimethylindolenine",CC1=NC2=CC=CC=C2C1(C)C,,,,,,
5427,15428,CID 15428,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC(=CC(=C3)Cl)Cl,,,,,,
5428,15429,CID 15429,CCC(=O)N1C2CCC1C[NH+](C2)CC=CC3=CC=C(C=C3)Cl.[Cl-],,,,,,
5429,15430,"1-[3-[3-(4-Chlorophenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one",CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=C(C=C3)Cl,,,,,,
5430,15431,Ethylcyclopentane,CCC1CCCC1,,,,,,
5431,15432,Diethylcarbamazine citrate,CCN(CC)C(=O)N1CCN(CC1)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,"['Pharmacological agents destructive to nematodes in the superfamily Filarioidea. (See all compounds classified as Filaricides.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)']","['Diethylcarbamazine is readily absorbed from the gastrointestinal tract. After a single oral dose of 200 to 400 mg, the concentration in plasma peaks in 1 to 2 hours ... Excretion is nearly all urinary, & more than 70% of the drug appears as metabolites. The compound is distributed almost completely throughout all body compartments with the exception of fat. Little accumulation occurs when repeated doses are given. /Diethylcarbamazine/']","['Only 10-25% of the drug is excreted unchanged; the remainder is excreted as one of four known metabolites, all of which contain the intact piperazine ring.']",['... the plasma half-life /in man/ is about 8 hr after a 200 mg dose and 12 hr after an 800 mg dose.']
5432,15433,Lauramine oxide,CCCCCCCCCCCC[N+](C)(C)[O-],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)', 'Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']","['(1-Dodecyl-14C)lauramine oxide (10 mg with 100 uCi of 14C) was applied to the skin of two humans to study cutaneous absorption and metabolism of lauramine oxide. Ninety-two percent of the applied radioactivity was recovered from the skin of the test subjects 8 hr after dosing, and 0.1 and 0.23% of the radioactivity was recovered from the excretion products of the test subjects. The stratum corneum contained <0.2% of the applied dose.', 'Oral administration of a solution containing 50 mg (1-dodecyl-14C)lauramine oxide (100 uCi of 14C) to two humans resulted in excretion patterns of radioactivity similar to that of the other species studied. Fifty percent and 37% of the radioactivity was found in the urine within 24 hr of dosing, and expired 14C02 contained between 18 and 22% of the radioactivity administered.', 'Four Sprague-Dawley rats were given intraperitoneal injections of 22 mg (methyl-14C)lauramine oxide kg (specific activity 1.3 mCi/g). Sixty-seven percent of the total radioactivity was eliminated in the urine, 8% was expired as I4CO2, and 6% was eliminated in the feces within 24 hr. The distribution of radioactivity was essentially the same as that seen in rats given oral doses of lauramine oxide. The conclusion was that ""... microbial metabolism by gastrointestinal flora does not play a major role in the absorption and excretion of [lauramine oxide] in rats.""', 'Aqueous (methyl-14C)lauramine oxide (10 mg containing 1.3 mCi/g) was applied to the skin of four Sprague-Dawley rats to test metabolism and absorption of the compound. Over 72 hr, 14.2% of the total radioactivity was found in the urine, 2.5% in the CO2, and 1.8% in the feces. Radioactivity was detected in the liver, kidneys, testes, blood, and expired CO2.', 'For more Absorption, Distribution and Excretion (Complete) data for LAURAMINE OXIDE (7 total), please visit the HSDB record page.']","['Metabolic profiles for different species (rat, human, mouse, rabbit) did not have any significant differences in metabolites, but the degree of absorption, especially in cutaneous applications, varied from species to species.', 'Characterization of metabolites of lauramine oxide resulted in the positive identification of only one metabolite, N-dimethyl-4-aminobutyric acid N-oxide. Several pathways exist for metabolism of lauramine oxide: omega,beta-oxidation of alkyl chains (the most common pathway for surfactant metabolism), hydroxylation of alkyl chains, and reduction of the amine oxide group.', 'Urinary metabolites in rats, rabbits and humans suggested metabolism via omega, beta-oxidation of the aliphatic chain, amine oxide reduction and aliphatic, mid-chain hydroxylation. N,N-dimethyl-4-aminobutyric acid and its N-oxide accounted for 28, 28 and 23% in man, rats and rabbits, respectively.']",
5433,15434,p-Fluoro-di-(2-chloroethyl)-benzylamine hydrochloride,C1=CC(=CC=C1C[NH+](CCCl)CCCl)F.[Cl-],,,,,,
5434,15435,2-Acetylbenzofuran,CC(=O)C1=CC2=CC=CC=C2O1,,,,,,
5435,15436,Aldicarb oxime,CC(C)(C=NO)SC,,,,,"['ORAL ADMIN OF ALDICARB TO RATS RESULTED IN 80 % OF THE DOSE BEING ELIMINATED IN URINE WITHIN 24 HR. AN ADDITIONAL 4 % WAS DETECTED IN FECES. ONLY A TRACE AMOUNT OF ALDICARB ITSELF WAS FOUND IN THE EXCRETA, INDICATING A VERY RAPID DEGRADATION WITHIN THE ANIMALS. THE ALDICARB METABOLITES ISOLATED FROM THE URINE INCLUDED ALDICARB OXIME.']",
5436,15437,[(2-methyl-2-methylsulfinylpropylidene)amino] N-methylcarbamate,CC(C)(C=NOC(=O)NC)S(=O)C,,,,,,
5437,15438,[(2-methyl-2-methylsulfonylpropylidene)amino] N-methylcarbamate,CC(C)(C=NOC(=O)NC)S(=O)(=O)C,,,,,,
5438,15439,"1,9-Decadiene",C=CCCCCCCC=C,,,,,,
5439,15440,(2-Bromoethyl)cyclohexane,C1CCC(CC1)CCBr,,,,,,
5440,15441,CID 15441,C(CCCCC=CC(=O)O)CCCCF,,,,,,
5441,15442,"1,2-Dichloro-1,1-difluoroethane",C(C(F)(F)Cl)Cl,,,,"['... MAIN FACTOR AFFECTING FATE OF FLUOROCARBONS IS BODY FAT, WHERE THEY ARE CONCENTRATED & SLOWLY RELEASED INTO BLOOD @ CONCN THAT SHOULD NOT CAUSE ANY RISK OF CARDIAC SENSITIZATION. /FLUOROCARBONS/', 'THERE IS A SIGNIFICANT ACCUMULATION OF FLUOROCARBONS IN BRAIN, LIVER & LUNG COMPARED TO BLOOD LEVELS, SIGNIFYING A TISSUE DISTRIBUTION OF FLUOROCARBONS SIMILAR TO THAT OF CHLOROFORM. /FLUOROCARBONS/', 'Absorption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'Although fluorocarbons cause cardiac sensitization in certain animal species, rapid elimination prevents the development of cardiotoxic concentrations from aerosol bronchodilator use except at exceedingly high doses (12 to 24 doses in 2 minutes). /Fluorocarbons/', 'FLUOROCARBON COMPOUNDS ARE LIPID-SOLUBLE AND THUS ARE GENERALLY WELL ABSORBED THROUGH LUNG. ABSORPTION AFTER INGESTION IS 35 TO 48 TIMES LOWER THAN AFTER INHALATION. ... FLUOROCARBONS ARE ELIMINATED BY WAY OF LUNG. /FLUOROCARBON COMPOUNDS/']","['... It is expected that /HCFCs/ would be metabolized by a cytochrome P-450-dependent monooxygenase liver enzyme to give reactive metabolic products. /HCFCs/', 'In a metabolism study using intraperitoneal admin of HCFC 132b to rats, 2-chloro-2,2-difluoroethylglucuronide, chlorodifluoroacetaldehyde (hydrated & conjugated) & chlorodifluoroacetic acid were identified in the urine. Formation & excretion of chlorodifluoroacetic acid were incr after repeated injection of the animals with HCFC 132b. In vitro experiments using rat liver microsomes suggested the involvement of cytochrome P-450 IIEI in the initial hydroxylation step. No evidence for covalent binding of fluorinated metabolites to liver proteins has been observed.', 'The chlorofluorocarbon substitute 1,1,1,2-tetrafluoroethane (HFC-134a) is subject to metabolism by cytochrome p450 in hepatic microsomes from rat, rabbit, and human. In rat and rabbit, the p450 form 2E1 is a predominant low-KM, high-rate catalyst of HFC-134a biotranformation and is prominently involved in the metabolism of other tetrahaloalkanes of greater toxicity than HFC-134a (e.g. 1,2-dichloro-1,1-difluoroethane (HCFC-132b)). In this study, we determined that the human ortholog of p450 2E1 plays a role of similar importance in the metabolism of HFC-134a. In human hepatic microsomes from 12 individuals, preparations from subjects with relatively high p450 2E1 levels were shown to metabolize HFC-134a at rates 5- to 10-fold greater than microsomes of individuals with lower levels of this enzyme; the increased rate of metabolism of HFC-134a was specifically linked to increased expression of p450 2E1. The primary evidence for the conclusion is drawn from studies using mechanism-based inactivation of p450 2E1 by diethyldithiocarbamate, competitive inhibition of HFC-134a oxidation by p-nitrophenol (a high-affinity substrate for p450 2E1), strong positive correlations of rates of HFC-134a defluorination with p-nitrophenol hydroxylation in the study population, and correlation of p450 2E1 levels with rates of halocarbon oxidation. Thus, our findings support the conclusion that human metabolism of HFC-134a is qualitatively similar to that of the species (rat and rabbit) used for toxicological assessment of this halocarbon. Although hazard from HFC-134a exposure is not anticipated in most humans (based on toxicological evaluation in laboratory animals), our results suggest that HFC-134a exposure should be minimized for individuals with chemical exposure histories commensurate with elevation of p450 2E1 (i.e. frequent contact with agents such as ethanol, trichloroethylene, or pyridine). Furthermore, these findings suggest that toxicity assessment of certain other haloethanes currently under consideration as replacements for chlorofluorocarbons should be considered in animals with elevated p450 2E1.', '1-Fluoro-1,1,2-trichloroethane (HCFC-131a), 1,2-dichloro-1,1-difluoroethane (HCFC-132b), and 1,1,1-trifluoro-2-chloroethane (HCFC-133a) were chosen as models for comparative metabolism studies on 1,1,1,2-tetrahaloethanes, which are under consideration as replacements for ozone-depleting chlorofluorocarbons (CFCs). Male Fischer 344 rats were given 10 mmol/kg ip 1-fluoro-1,1,2-trichloroethane or 1,2-dichloro-1,1-difluoroethane or exposed by inhalation to 1% 1,1,1-trifluoro-2-chloroethane for 2 hr. Urine collected in the first 24 hr after exposure was analyzed by 19F NMR and GC/MS and with a fluoride-selective ion electrode for the formation of fluorine-containing metabolites. Metabolites of 1-fluoro-1,1,2-trichloroethane included 2,2-dichloro-2-fluoroethyl glucuronide, 2,2-dichloro-2-fluoroethyl sulfate, dichlorofluoroacetic acid, and inorganic fluoride. Metabolites of 1,2-dichloro-1,1-difluoroethane were characterized as 2-chloro-2,2-difluoroethyl glucuronide, 2-chloro-2,2-difluoroethyl sulfate, chlorodifluoroacetic acid, chlorodifluoroacetaldehyde hydrate, chlorodifluoroacetaldehyde-urea adduct, and inorganic fluoride. 1,1,1-Trifluoro-2-chloroethane was metabolized to 2,2,2-trifluoroethyl glucuronide, trifluoroacetic acid, trifluoroacetaldehyde hydrate, trifluoroacetaldehyde-urea adduct, inorganic fluoride, and a minor, unidentified metabolite. With 1-Fluoro-1,1,2-trichloroethane and 1,2-dichloro-1,1-difluoroethane, glucuronide conjugates of 2,2,2-trihaloethanols were the major urinary metabolites, whereas with 1,1,1-trifluoro-2-chloroethane, a trifluoroacetaldehyde-urea adduct was the major urinary metabolite. Analysis of metabolite distribution in vivo indicated that aldehydic metabolites increased as fluorine substitution increased in the order 1-Fluoro-1,1,2-trichloroethane < 1,2-dichloro-1,1-difluoroethane < 1,1,1-trifluoro-2-chloroethane. With NADPH-fortified rat liver microsomes, 1,1,1-trifluoro-2-chloroethane and 1,2-dichloro-1,1-difluoroethane were biotransformed to trifluoroacetaldehyde and chlorodifluoroacetaldehyde, respectively, whereas 1-Fluoro-1,1,2-trichloroethane was converted to dichlorofluoroacetic acid. No covalently bound metabolites of 1-Fluoro-1,1,2-trichloroethane and 1,1,1-trifluoro-2-chloroethane metabolites were detected by 19F NMR spectroscopy. The nature of the identified organic fluorine-containing metabolites indicates that cytochrome p450-dependent oxidation predominates in the metabolism of these 1,1,1,2-tetrahaloethanes. The generation of fluoride from the fluorodihalomethyl group (-CFX2) apparently arises from a separate dehalogenation pathway.', 'For more Metabolism/Metabolites (Complete) data for 1,2-DICHLORO-1,1-DIFLUOROETHANE (7 total), please visit the HSDB record page.']",
5442,15443,Azaperone,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=N3,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)', 'Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)']",,,
5443,15444,"(2R,5S,17S)-2-fluoro-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one",CC12CCC3C(C1CC[C@@H]2O)CC[C@@H]4C3(C[C@H](C(=O)C4)F)C,,,,,,
5444,15445,"6-Fluoro-N~2~,N~4~-diphenyl-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)F)NC3=CC=CC=C3,,,,,,
5445,15446,"4,6-Difluoro-1,3,5-triazin-2-amine",C1(=NC(=NC(=N1)F)F)N,,,,,,
5446,15447,"2,3-Dichloro-1,3-butadiene",C=C(C(=C)Cl)Cl,,,,,,
5447,15448,2-Undecanol,CCCCCCCCCC(C)O,,,,,,
5448,15449,2-Tridecanol,CCCCCCCCCCCC(C)O,,,,,,
5449,15450,6-Methyl-1-heptanol,CC(C)CCCCCO,,,,,,
5450,15451,"N,N-dimethyl-1-(7-nitro-1H-indol-3-yl)methanamine",CN(C)CC1=CNC2=C1C=CC=C2[N+](=O)[O-],,,,,,
5451,15452,Bis(2-cyanoethyl) ether,C(COCCC#N)C#N,,,,,,
5452,15453,CID 15453,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C4=CC=CC=C43)S(=O)(=O)[O-])O.[Na+],,,,,,
5453,15454,4-((2-Hydroxy-1-naphthyl)azo)naphthalenesulphonic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C4=CC=CC=C43)S(=O)(=O)O)O,,,,,,
5454,15455,Tetraethyl methylenediphosphonate,CCOP(=O)(CP(=O)(OCC)OCC)OCC,,,,,,
5455,15456,Meturedepa,CCOC(=O)NP(=O)(N1CC1(C)C)N2CC2(C)C,,,,,,
5456,15457,2-Methoxyethyl vinyl ether,COCCOC=C,,,,,,
5457,15458,tert-Butyl acrylate,CC(C)(C)OC(=O)C=C,,,,,,
5458,15459,Metaxalone,CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C,['For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.'],"['Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.']","['Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS. (See all compounds classified as Neuromuscular Agents.)']","['The absolute bioavailability of metaxalone from Skelaxin tablets is not known.', 'Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.', '800 L', '68 +/- 50 L/h [Subjects received 1400mg tablet under fasted conditions]', 'Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.', 'Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 + or -  4.8 hours. Doubling the dose of skelaxin from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known']","['Probably hepatic.', 'Biotransformations...studied in dogs and in man. 5-(3-methyl-5-carboxyphenoxymethyl)-2-oxazolidinone, major metabolite, is excreted in urine and feces; this also occurs in urine as ester glucuronide. Fission of ether linkage...affords...3,5-xylenol and 5-hydroxymethyloxazolidinone. Oxazolidinone ring is stable in mammals.', 'Yields 5-(5-carboxy-3-methylphenoxymethyl)-2-oxazolidone in man & in dogs, yields 3,5-dimethylphenol in man and in dogs.  /From table/', 'Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.']","['9.2 (+/- 4.8) hours', 'Terminal half-life /is/  9.0 + or -  4.8 hours']"
5459,15460,Diphenyl diselenide,C1=CC=C(C=C1)[Se][Se]C2=CC=CC=C2,,,,,,
5460,15461,"2',4',6'-Trimethylacetophenone",CC1=CC(=C(C(=C1)C)C(=O)C)C,,,,,,
5461,15462,2-Chloromesitylene,CC1=CC(=C(C(=C1)C)Cl)C,,,,,,
5462,15463,4-(Chloromethyl)biphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)CCl,,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
5463,15464,"Benzylamine, N-octyl-",CCCCCCCCNCC1=CC=CC=C1,,,,,,
5464,15465,CID 15465,C1=CC=C(C(=C1)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=CC=CC=C4[As](=O)(O)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O)[As](=O)(O)O,,,,,,
5465,15466,"2-Amino-4-methoxy-6-methyl-1,3,5-triazine",CC1=NC(=NC(=N1)OC)N,,,,,,
5466,15467,"10,11-Dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepine, 10-(2-(dimethylamino)ethyl)-8-methoxy-",CN(C)CCN1C2=C(C=CC(=C2)OC)NC3=CC=CC=C3C1=O,,,,,,
5467,15468,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-8-methyl-",CC1=CC2=C(C=C1)NC3=CC=CC=C3C(=O)N2CCN(C)C,,,,,,
5468,15469,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-3-chloro-10-(2-(dimethylamino)ethyl)-",CN(C)CCN1C2=CC=CC=C2NC3=C(C1=O)C=CC(=C3)Cl,,,,,,
5469,15470,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-7-chloro-10-(2-(dimethylamino)ethyl)-5-methyl-, hydrochloride",CN1C2=CC=CC=C2C(=O)N(C3=C1C=C(C=C3)Cl)CC[NH+](C)C.[Cl-],,,,,,
5470,15471,"2-Chloro-5-[2-(dimethylamino)ethyl]-11-methylbenzo[b][1,4]benzodiazepin-6-one",CN1C2=CC=CC=C2C(=O)N(C3=C1C=C(C=C3)Cl)CCN(C)C,,,,,,
5471,15472,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-2-methoxy-5-methyl-, hydrochloride",CN1C2=C(C=C(C=C2)OC)C(=O)N(C3=CC=CC=C31)CC[NH+](C)C.[Cl-],,,,,,
5472,15473,"5-[2-(Dimethylamino)ethyl]-8-methoxy-11-methylbenzo[b][1,4]benzodiazepin-6-one",CN1C2=C(C=C(C=C2)OC)C(=O)N(C3=CC=CC=C31)CCN(C)C,,,,,,
5473,15474,6'-Methoxycinchonan-9-ol--hydrogen chloride (1/1),COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3CC4CCN3C[C@@H]4C=C)O.Cl,,,,,,
5474,15475,Oct-3-en-2-one,CCCCC=CC(=O)C,,,,,,
5475,15476,N-(2-Chloroethyl)-N-methylaniline,CN(CCCl)C1=CC=CC=C1,,,,,,
5476,15477,1-Methyl-2-nitroimidazole,CN1C=CN=C1[N+](=O)[O-],,,,,,
5477,15478,Digoxigenin,C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O)O,,,,"['A method was developed for the specific determination of digoxin and digitoxin, as well as their semisynthetic derivatives and dependent cardioactive metabolites, in autopsy samples of heart and kidney. A collective of 6 patients on long-term treatment with therapeutic doses of beta-acetyldigoxin had a mean myocardial digoxin content of 46.1 +/- 25.0 ng/g (SD); kidney: 50.3 +/- 30.3 ng/g. Digoxigenin bisdigitoxoside represented the second most important metabolite in heart and kidney; digoxigenin monodigitoxoside and digoxigenin follow, respectively. In a collective of seven patients on maintenance treatment with digitoxin, the mean tissue levels were higher but the metabolic pattern was similar (myocardial digitoxin content: 78.9 +/- 38.4 ng/g, renal content: 104.1 +/- 44.1 ng/g). The amount of digoxin formed by hydroxylation under long-term treatment with digitoxin in heart and kidney were approx 10 ng/g. A case of digoxin intoxication differed both in the tissue content and in the metabolic distribution.']","['In vitro metabolism of digoxin and its cleavage-related compounds was investigated using hepatocytes in primary culture and microsomal fractions both isolated from human livers. On these models, digoxin (DG3) and digoxigenin bisdigitoxoside (DG2) were not shown to be significantly metabolized in vitro ... Therefore, it appeared that the stepwise cleavage of DG3 and DG2 sugars was not cytochrome P450 dependent. This enzymatic system probably plays a minor role in humans for this particular reaction. However, digoxigenin monodigitoxoside (DG1) and digoxigenin (DG0) which are known to be formed after intra-gastric hydrolysis of DG3, were extensively converted to polar compounds (mainly glucuronides). In addition, using human liver microsomes, a wide variability in UDP-glucuronyl transferase (UDPGT) activities responsible for DG1 glucuronidation was demonstrated. These results suggest that two main factors may contribute to the overall interindividual variability of digoxin biotransformation: 1), the individual intra-gastric pH which influences the sugar cleavage leading to DG1 and DG0; ii), a variability in the level of the hepatic UDPGT specific for digitalis compounds conjugation.', 'Digoxigenin (I) biotransformation was investigated in 2 healthy men following ingestion of labeled (7.5 ug) and unlabeled (3 mg) I. Of the radioactivity in serum at 30 min, <26% chromatographed with I; the rest chromatographed as metabolites, most of which were polar. The main polar metabolites identified were glucuronides of 3-epidigoxigenin. There was extensive cross reactivity between metabolites and antisera to digoxin.', 'The sequential metabolism of digoxin (Dg3) to digoxigenin bis-digitoxoside (Dg2), digoxigenin mono-digitoxoside (Dg1) and digoxigenin (Dg0) was investigated in rat liver microsomes. Kinetic studies produced results consistent with a single enzyme mechanism describing the successive oxidative cleavages. Formation of Dg2 was catalysed with mean (+/-SD) Km and Vmax of 125 +/- 22 uM and 362 +/- 37 pmol/min/mg protein, respectively. The corresponding values for the formation of Dg1 were 61 +/- 5 microM and 7 +/-1 pmol/min/mg protein. Dg0 formation was catalysed with the apparent values of 30 +/- 9 uM and 310 +/- 30 pmol/min/mg protein. Chemical inhibition of cytochrome P450 (CYP) 3A subfamily with ketoconazole and triacetyoleandomycin decreased the formation of Dg2 and Dg1 by up to 90%. Antibodies specific to rat CYP3A2 lowered the rate of oxidative cleavage of Dg3 and Dg2 by up to 85%. Inhibition of CYP2E1, CYP2C subfamily and CYP1A2 by chemical and immuno-inhibition did not affect initial rates of metabolism of Dg3 and Dg2. In contrast, Dg1 metab was not affected by triacetyloleandomycin as well as by antibodies to CYP3A2, CYP2C11, CYP2E1, CYP2B1/2B2 and CYP1A2. It was however inhibited by >80% by gestodene and 17alpha-ethynylestradiol (selective inhibitors of human CYP3A). Collectively, these data support the involvement of CYP3A in the cleavage of Dg3 and Dg2 in rat liver microsomes. The enzyme-metabolizing Dg1 remains to be identified.', 'Human liver alcohol dehydrogenase (alcohol: NAD"" oxidoreductase, EC 1.1.1.1) catalyzes the oxidation of the 3 beta-OH group of digitoxigenin, digoxigenin, and gitoxigenin to their 3-keto derivatives. Human liver alcohol dehydrogenase is the NAD(H)-dependent liver enzyme specific for the free hydroxyl group at C3 of the cardiac genins; this hydroxyl is the critical site of the genins\' enzymatic oxidation and concomitant pharmacological inactivation in humans. Several kinetic approaches have demonstrated that ethanol and the pharmacologically active components of the digitalis glycosides are oxidized with closely similar kcat/Km values at the same site on human liver alcohol dehydrogenase, for which they compete. Human liver alcohol dehydrogenase thereby becomes an important biochemical link in the metabolism, pharmacology, and toxicology of ethanol and these glycosides, structurally unrelated agents that are both used widely.']",
5478,15479,CID 15479,C1CC(OC1C=CC=NN2CC(=O)NC2=O)[N+](=O)[O-],,,,,,
5479,15480,"1,2-Dimethylcyclohexene",CC1=C(CCCC1)C,,,,,,
5480,15481,"1,2-Dichloropentane",CCCC(CCl)Cl,,,,,,
5481,15482,Methophenazine diethanesulfonate,CCS(=O)(=O)O.CCS(=O)(=O)O.COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl,,,,,,
5482,15483,CID 15483,CCCCCCCCCCCC[NH2+]C(=NC(=N)N)N.[N+](=O)([O-])[O-],,,,,,
5483,15484,Laurylbiguanid,CCCCCCCCCCCCN=C(N)N=C(N)N,,,,,,
5484,15485,(N'-carbamimidoylcarbamimidoyl)-methylazanium;chloride,C[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
5485,15486,1-Methylbiguanide,CN=C(N)N=C(N)N,,,,,,
5486,15487,Denatonium Chloride,CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C.[Cl-],,,"['Chemicals added to pharmacologic preparations, poisonous household goods, and other chemicals to discourage their abuse or consumption. (See all compounds classified as Aversive Agents.)']",,,
5487,15488,Denatonium,CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C,,,"['Chemicals added to pharmacologic preparations, poisonous household goods, and other chemicals to discourage their abuse or consumption. (See all compounds classified as Aversive Agents.)']",,,
5488,15489,"1-(2-(2,2,4-Trimethyl-1-pyrrolidinyl)ethyl)-1,3-dihydro-3,5,7-trimethyl-2H-azepin-2-one",CC1CC(N(C1)CCN2C(=CC(=CC(C2=O)C)C)C)(C)C,,,,,,
5489,15490,"2H-Azepin-2-one, 1,3-dihydro-1-(2-(1-pyrrolidinyl)ethyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CC[NH+]2CCCC2)C)C.[Cl-],,,,,,
5490,15491,"1,3-Dihydro-1-[2-(1-pyrrolidinyl)ethyl]-3,5,7-trimethyl-2H-azepin-2-one",CC1C=C(C=C(N(C1=O)CCN2CCCC2)C)C,,,,,,
5491,15492,"2H-Azepin-2-one, 1,3-dihydro-1-(3-dimethylaminopropyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CCC[NH+](C)C)C)C.[Cl-],,,,,,
5492,15493,"1,3-Dihydro-1-[3-(dimethylamino)propyl]-3,5,7-trimethyl-2H-azepin-2-one",CC1C=C(C=C(N(C1=O)CCCN(C)C)C)C,,,,,,
5493,15494,"2H-Azepin-2-one, 1,3-dihydro-1-(2-(hexahydro-1H-azepin-1-yl)ethyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CC[NH+]2CCCCCC2)C)C.[Cl-],,,,,,
5494,15495,"1,3-Dihydro-1-[2-[(hexahydro-1H-azepin)-1-yl]ethyl]-3,5,7-trimethyl-2H-azepin-2-one",CC1C=C(C=C(N(C1=O)CCN2CCCCCC2)C)C,,,,,,
5495,15496,"2H-Azepin-2-one, 1,3-dihydro-1-(3-piperidinopropyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CCC[NH+]2CCCCC2)C)C.[Cl-],,,,,,
5496,15497,"1,3-Dihydro-1-(3-piperidinopropyl)-3,5,7-trimethyl-2H-azepin-2-one",CC1C=C(C=C(N(C1=O)CCCN2CCCCC2)C)C,,,,,,
5497,15498,"2H-Azepin-2-one, 1,3-dihydro-1-(2-morpholinoethyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CCC2C[NH2+]CCO2)C)C.[Cl-],,,,,,
5498,15499,"3,5,7-trimethyl-1-(2-morpholin-2-ylethyl)-3H-azepin-2-one",CC1C=C(C=C(N(C1=O)CCC2CNCCO2)C)C,,,,,,
5499,15500,"3,3',4,4'-Bis(methylenedioxy)diphenethylamine hydrochloride",C1OC2=C(O1)C=C(C=C2)CC[NH2+]CCC3=CC4=C(C=C3)OCO4.[Cl-],,,,,,
5500,15501,"Bis[2-(1,3-benzodioxole-5-yl)ethyl]amine",C1OC2=C(O1)C=C(C=C2)CCNCCC3=CC4=C(C=C3)OCO4,,,,,,
5501,15502,CID 15502,CN1C2=CC=CC=C2C(=O)C=C1O,,,,,,
5502,15503,"2,4-dinitro-N-(1-phenylethylideneamino)aniline",CC(=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])C2=CC=CC=C2,,,,,,
5503,15504,Ethylcyclohexane,CCC1CCCCC1,,,,,,
5504,15505,Propylcyclohexane,CCCC1CCCCC1,,,,,,
5505,15506,Butylcyclohexane,CCCCC1CCCCC1,,,,,,
5506,15507,"1,2,3-Trimethylcyclohexane",CC1CCCC(C1C)C,,,,,,
5507,15508,Isobutylcyclohexane,CC(C)CC1CCCCC1,,,,,,
5508,15509,"2,9-Dimethylpicene",CC1=CC2=C(C=C1)C=CC3=C2C=CC4=C3C=CC5=C(C=CC=C54)C,,,,,,
5509,15510,Cyclopentanethiol,C1CCC(C1)S,,,,,,
5510,15511,2-Methyl-2-butanethiol,CCC(C)(C)S,,,,,,
5511,15512,3-Cyclohexene-1-methanol,C1CC(CC=C1)CO,,,,,,
5512,15513,4-(Methoxycarbonyl)benzoic acid,COC(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
5513,15514,"6-Methyl-1,2,3,4-tetrahydronaphthalene",CC1=CC2=C(CCCC2)C=C1,,,,,,
5514,15515,4-Acetyl-4-methylheptanedinitrile,CC(=O)C(C)(CCC#N)CCC#N,,,,,,
5515,15516,5-Fluorobenzo[d]oxazol-2-amine,C1=CC2=C(C=C1F)N=C(O2)N,,,,,,
5516,15517,CID 15517,C1CCC2=NC3=CC=CC=C3C(=C2C1)[NH3+].[Cl-],,,,,,
5517,15518,"4,6-Dimethylindan",CC1=CC(=C2CCCC2=C1)C,,,,,,
5518,15519,Xanthomegnin,CC1CC2=CC3=C(C(=C2C(=O)O1)O)C(=O)C(=C(C3=O)OC)C4=C(C(=O)C5=C(C4=O)C(=C6C(=C5)CC(OC6=O)C)O)OC,,,,,,
5519,15520,CID 15520,C[C@@]1(CCC2C(=CCC3[C@@]2(CCCC3(C)C)C)C1)C=C.COC=O,,,,,,
5520,15521,CID 15521,C[C@@]1(CCC2C(=CCC3[C@@]2(CCCC3(C)C)C)C1)C=C,,,,,,
5521,15522,"1,2-Cyclohexanedicarboxylic acid",C1CCC(C(C1)C(=O)O)C(=O)O,,,,,,
5522,15523,2-Ethyl-5-methylphenol,CCC1=C(C=C(C=C1)C)O,,,,,,
5523,15524,1-Camphorimidomethylpiperidine,CC1(C2CCC1(C(=O)N(C2=O)CN3CCCCC3)C)C,,,,,,
5524,15525,N-(Morpholinomethyl)camphorimide,CC1(C2CCC1(C(=O)N(C2=O)CN3CCOCC3)C)C,,,,,,
5525,15526,"3-(N,N-Dimethylalanyl)-1,8,8-trimethyl-3-azabicyclo(3.2.1)octane",CC(C(=O)N1CC2CCC(C1)(C2(C)C)C)N(C)C,,,,,,
5526,15527,"1-Butanone, 1-(4-aminophenyl)-",CCCC(=O)C1=CC=C(C=C1)N,,,,,,
5527,15528,2-tert-Butylthiophene,CC(C)(C)C1=CC=CS1,,,,,,
5528,15529,4-Hydroxyazobenzene,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)O,,,,"['DOSES OF 500 & 700 MG 4-HYDROXYAZOBENZENE, WHICH DID NOT PRODUCE TOXIC EFFECTS, WERE COMPLETELY ABSORBED FROM THE DIET OF RABBITS & WERE EXCRETED MAINLY IN THE URINE AS GLUCURONIDE.']","['THE URINE OF RABBITS GIVEN 4-HYDROXYAZOBENZENE CONTAINED 2-ACETAMIDOPHENOL, 4-ACETAMIDOPHENOL, CONJUGATED 4-AMINOPHENOL, CONJUGATED 2-AMINOPHENOL, & 4-HYDROXYAZOBENZENE GLUCURONIDE.', 'The azoreduction of phenylazo-2-naphthol (Sudan I), 5-(phenylazo)-6-hydroxynaphthalene-2-sulfonic acid (aniline subsidiary color of FD&C Yellow No. 6 (ANSC)), and phenylazophenol (Solvent Yellow 7 (SY7)) in skin during percutaneous absorption was measured and the contributions of cytosolic and microsomal reductions were characterized. By using a series of azo dyes with a common U-14C-labeled phenylazo moiety, percutaneous absorption and metabolism were measured in vitro in flow through diffusion cells with Sencar mouse, hairless guinea pig, and human skin. Azoreductase assays using subcellular fractions from skin of all species were used to examine intracellular rates and distribution for the series of dyes. The absorption of the lipophilic dyes Sudan I and SY7 from a finite surface dose of 5 ug/sq cm was extensive in all species. In mouse, 32.8 + or - 2.8% of the applied Sudan I Jose and 64.1 + or - 3.3% of the applied SY7 Jose were absorbed in 24 hr. In the hairless guinea pig, 57.6 + or - 5.9% of the applied Sudan I dose and 67.8 + or - 4.6% of the applied SY7 dose were absorbed in 24 hr. Human skin was least permeable, with 26.4 + or - 6.7% of the applied Sudan I Jose and 36.1 + or 4.5% of the applied SY7 dose absorbed in 24 hr. Sudan I and SY7 were extensively reduced in skin of all species during percutaneous absorption (29.5 and 26.5%, respectively, of the absorbed dose in human skin and greater than 50% of the applied Jose in other species). ANSC was the least absorbed, with 5% or less penetrating. SY7 was preferentially reduced in the skin cytosol of all species, whereas Sudan I was equally reduced in the skin cytosol and microsomal fractions. The site of azoreduction in the cell may affect the metabolic fate of the liberated arylamine. The extensive azoreduction observed during percutaneous absorption may modulate the toxicities of these compounds and must be considered when effective doses are determined for quantitative risk assessments from dermal exposures.', 'A study was made of the chemical structural requirements for binding to microsomal cytochrome p450 and enzymic reduction of the azo linkage in p-dimethylaminoazobenzene (DAB) and related azo dye carcinogens. Liver microsomes were prepared from male Wistar rats, some of which had been pretreated with microsomal enzyme inducers. Dimethylaminoazobenzene, its corresponding primary and secondary amines, and p-hydroxyazobenzene showed high substrate reactivity for reduction by microsomes. ... Active substrates showed type I (p-hydroxy derivative) or type 11 binding spectra, while inactive substrates showed only weak binding with microsomes. When two inactive compounds were incubated with microsomes under aerobic conditions, allowing preliminary hydroxylation to occur, there was marked facilitation of azoreduction. /It was/ concluded that p-substituted azobenzenes with electron donating groups facilitate azo dye reduction by rat liver microsomes, with good correlation between cytochrome p450 binding and substrate reactivity. Hydroxylation facilitates reduction of otherwise nonreactive compounds.', '4-Phenylazophenol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(4-phenyldiazenylphenoxy)oxane-2-carboxylic acid.']",
5529,15530,Ioxynil,C1=C(C=C(C(=C1I)O)I)C#N,,,,"['NO RESIDUES OF IOXYNIL WERE FOUND IN MILK OF DAIRY COW. NO IOXYNIL OR A POSSIBLE METABOLITE, 3,5-DIIODO-4-HYDROXYBENZOIC ACID, WERE FOUND IN THE MILK, URINE, OR FECES BY GAS CHROMATOGRAPHY ANALYSIS.', '...IOXYNIL.../IS/ ABSORBED BY FOLIAGE & TRANSLOCATED. ...PRIMARY ROUTE OF FOLIAR PENETRATION...APPEARS TO BE CUTICULAR RATHER THAN STOMATAL... TRANSLOCATION STUDIES WITH (14)C-BROMOXYNIL HAVE SHOWN THAT MOST OF THE (14)C REMAINS IN TREATED LEAVES OF BOTH RESISTANT & SUSCEPTIBLE SPECIES. ... SIMILAR OBSERVATIONS, WHICH SUGGEST LIMITED SYMPLASTIC TRANSLOCATION, HAVE ALSO BEEN REPORTED FOR IOXYNIL.', 'AUTORADIOGRAPHY OF [CYANO-(14)C]IOXYNIL-TREATED MUSTARD, COTTON...BEAN, BARLEY, & PEA PLANTS HAS SHOWN THAT MOST OF THE RADIOACTIVITY REMAINS AT OR CLOSE TO SITE OF FOLIAR APPLICATION. BASIPETAL MOVEMENT OF (14)C TO BASE OF PETIOLE WAS OBSERVED IN MOST OF TREATED LEAVES AFTER 5 HR. FURTHER MOVEMENT UP THE STEM TO YOUNGER LEAVES & THE SHOOT APEX...WITH BYPASSING OF MATURE LEAVES WAS...OBSERVED. OUTWARD MOVEMENT TO TIPS OF TREATED LEAVES WAS NOTED, BUT TRANSLOCATION OF (14)C FROM TREATED ROOTS WAS LIMITED. STEM TREATMENTS RESULTED IN CONSIDERABLE UPWARD (14)C MOVEMENT, PARTICULARLY WHEN THE HERBICIDE WAS PLACED OVER AN INCISION. CONCENTRATED AREAS OF (14)C WERE NOTED IN THE VEINS OF THE LEAVES AFTER STEM TREATMENT.', '... Binding /of ioxynil/ to human plasma proteins was compaired with that of T3, to gain insight into possible effects in humans. after incubating human serum with (125)I ioxynil, 2DIEP against anti-whole human serum and rocket immunoelectrophoresis against anti-TBPA, albumin or TBG were carried out. Ioxynil bound to TBPA but not to TBG nor albumin. The Ka calculated for the TBPA-ioxynil complex was 2.6x10(6) l mol/l. Ioxynil competed for the iodothymidine binding sites of TBPA.']","['FOUR DAYS AFTER FOLIAR TREATMENT WITH [CYANO-(14)C]IOXYNIL, UNCHANGED IOXYNIL, TRACE AMT OF BENZAMIDE & BENZOIC ACID DERIVATIVES, AND AT LEAST 2 OTHER UNKNOWN (14)C COMPOUNDS WERE TENTATIVELY IDENTIFIED IN RESISTANT BARLEY. ... THESE LIMITED DEGRADATION STUDIES /OF SUSCEPTIBLE COAST FIDDLENECK AND RESISTANT WINTER WHEAT/ SUGGEST THAT THE UNHINDERED NITRILE GROUPS OF ... IOXYNIL ARE SLOWLY HYDROLYZED IN THE PLANT TO THE CORRESPONDING BENZAMIDE AND BENZOIC ACID DERIVATIVES WITH POSSIBLE FURTHER DEGRADATION THROUGH DECARBOXYLATION, DEHALOGENATION, OR CONJUGATION OF THE BENZYL MOIETY OR THE AROMATIC RING. DECARBOXYLATION &...CONJUGATION REACTIONS MAY BE MUCH FASTER THAN HYDROLYSIS. THIS IS SUPPORTED BY THE DETECTION OF TRACE AMT OF THE HYDROLYSIS PRODUCTS & THE RAPID ACCUMULATION OF INSOLUBLE RESIDUES WITH (CYANO-14C)IOXYNIL...', 'BREAKDOWN OF IOXYNIL IN ROOT-TREATED BEAN PLANTS TO...BENZOIC ACID & IODIDE IONS HAS BEEN SUGGESTED & IODIDE HAS...BEEN SHOWN TO BE PRESENT IN BEAN PLANTS TREATED WITH IOXYNIL.']",
5530,15531,Bromoxynil,C1=C(C=C(C(=C1Br)O)Br)C#N,,,,"['The absorption, distribution, excretion and metabolism of bromoxynil octanoate were studied in male and female Sprague Dawley rats given single oral doses of (14)C-bromoxynil octanoate by gavage at dose levels of 2 or 20 mg/kg or at a dose level of 2 mg/kg following 14 days of unlabeled bromoxynil octanoate administered by oral gavage at a dose level of 2 mg/kg/day. Results were similar regardless of dosing regimen. The rate of absorption in both sexes was such that peak plasma concentrations of radioactivity were not reached until 7-10 hours after dosing. Radioactivity was distributed in most tissues; highest concentrations were observed in blood, plasma, liver, kidneys and thyroid (especially in females). Levels of radioactivity in tissues were generally higher in females than in males. Most radioactivity was excreted in the urine (about 84-89% in males and 76-80% in females at 7 days) and considerably lesser amounts in the feces (about 6-10% in both males and females at 7 days). Excretion was more rapid in males than in females. Retention of radioactivity in tissues after 7 days was about 2-3% in males and 7-9% in females. /Bromoxynil octanoate/', '/In rats/ bromoxynil heptanoate and octanoate are rapidly absorbed and widely distributed in most tissues. Most of the radioactivity was excreted in the urine, mostly in the form of bromoxynil phenol. There was no significant retention in tissues after 7 days. /Bromoxynil heptaonate and octanoate/', 'A study with the octanoate ester in rats showed that after an oral dose, uptake was moderate. Peak plasma levels were attained 7 to 10 hrs after dosing. Most of the dose was eliminated within 7 days, primarily in the urine.', 'Dermal uptake studies in rats show an absorption in 24 hours of 11 to 18% for the octanoate depending on concentration, and about 3% for the phenol.', 'For more Absorption, Distribution and Excretion (Complete) data for BROMOXYNIL (8 total), please visit the HSDB record page.']","['The available data show that once absorbed, bromoxynil octanoate is converted to bromoxynil phenol. Essentially all bromoxynil octanoate was rapidly and nearly completely converted to bromoxynil phenol via ester hydrolysis. In special distribution studies, the only chemical species identified in tissues was bromoxynil phenol per se; no bromoxynil octanoate was identified in tissues. In urine, the only major species was free and conjugated bromoxynil phenol with no bromoxynil octanoate being present. In feces, however, some bromoxynil octanoate was identified. /Bromoxynil octanoate/', 'Bromoxynil heptaonate and octanoate were metabolized to bromoxynil phenol via ester hydrolysis. /Bromoxynil heptaonate and octanoate/', 'The octanoate ester was rapidly and completely converted to the free phenol and excreted in the urine either as the phenol or its conjugates. The heptanoate is also converted to the phenol rapidly and completely in vivo.', 'Nine days after feeding bromoxynil /to cows/, less than 20% of herbicide was excreted in urine as parent compound. Acid hydrolysis of urine released additional 11% of herbicide as unknown conjugate. Bromoxynil was stable when incubated with rumen juice and beef liver.', 'For more Metabolism/Metabolites (Complete) data for BROMOXYNIL (6 total), please visit the HSDB record page.']",
5531,15532,Nitroxinil,C1=C(C=C(C(=C1[N+](=O)[O-])O)I)C#N,,,"['Agents used to treat cestode, trematode, or other flatworm infestations in man or animals. (See all compounds classified as Antiplatyhelmintic Agents.)']",,,
5532,15533,Bromoxynil octanoate,CCCCCCCC(=O)OC1=C(C=C(C=C1Br)C#N)Br,,,,"['The absorption, distribution, excretion and metabolism of bromoxynil octanoate were studied in male and female Sprague Dawley rats given single oral doses of 14C-bromoxynil octanoate by gavage at dose levels of 2 or 20 mg/kg or at a dose level of 2 mg/kg following 14 days of unlabeled bromoxynil octanoate administered by oral gavage at a dose level of 2 mg/kg/day. Results were similar regardless of the dosing regimen. The rate of absorption was moderate in both males and females. Peak plasma concentrations of radioactivity were not reached until 7-10 hours after dosing. Radioactivity was widely distributed in most tissues. The highest concentrations were observed in blood, plasma, liver, kidneys and thyroid (especially in females). Levels of radioactivity in tissues were generally higher in females than in males. Most radioactivity was excreted in the urine (about 84-89% in males and 76-80% in females at 7 days) and considerably lesser amounts in the feces (about 6-10% in both males and females at 7 days). Excretion was more rapid in males than in females. Retention of radioactivity in tissues after 7 days was about 2-3% in males and 7-9% in females.', '14C-Bromoxynil octanoate, incorporated into the end-use product Buctril, which contained 33.4% bromoxynil octanoate as the active ingredient, was topically applied to the skin of male Sprague Dawley rats at doses of 0.08, 0.4 or 3.4 mg/rat for durations of exposure of 0.5, 1, 2, 4, 10 or 24 hours (4 rats/dose/duration of exposure). The quantity of radioactivity absorbed increased with dose and duration of exposure. Percent dermal absorption at 10 hours was 10.32%, 7.07% and 4.51% for doses of 0.08, 0.4 and 3.4 mg/rat respectively. Following a soap and water wash (at 10 hours), 6.46%, 8.06% and 6.13% of the respective doses remained in/on the skin. Percent dermal absorption at 24 hours was 17.58%, 18.43% and 10.88% for doses of 0.08, 0.4 and 3.4 mg/rat respectively. Following a soap and water wash (at 24 hours), 7.91%, 9.50% and 4.97% of the respective doses remained in/on the skin.', 'A study with the octanoate ester in rats showed that after an oral dose, uptake was moderate. Peak plasma levels were attained 7 to 10 hours after dosing. Most of the dose was eliminated within 7 days, primarily in the urine.', 'Dermal uptake studies in rats show an absorption in 24 hr of 11 to 18 % for the octanoate ester depending on concentration...']","['The absorption, distribution, excretion and metabolism of bromoxynil octanoate were studied in male and female Sprague Dawley rats given single oral doses of 14C-bromoxynil octanoate by gavage at dose levels of 2 or 20 mg/kg or at a dose level of 2 mg/kg following 14 days of unlabeled bromoxynil octanoate administered by oral gavage at a dose level of 2 mg/kg/day. Results were similar regardless of the dosing regimen. ...Essentially all bromoxynil octanoate was rapidly and nearly completely converted to bromoxynil phenol via ester hydrolysis. In special studies, the only chemical species identified in tissues was bromoxynil phenol per se; no bromoxynil octanoate was identified in tissues. In urine, the only major species was free and conjugated bromoxynil phenol with no bromoxynil octanoate present. In feces, however, some bromoxynil octanoate was identified.', 'The octanoate ester was rapidly and completely converted to the phenol and excreted in the urine as either the phenol or it conjugates.']",
5533,15534,1-(2-Chlorophenyl)propyl carbamate,CCC(C1=CC=CC=C1Cl)OC(=O)N,,,,,,
5534,15535,Methyl 1-methylpiperidine-3-carboxylate,CN1CCCC(C1)C(=O)OC,,,,,,
5535,15536,CID 15536,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-].[Na+],,,,,,
5536,15537,"(1E,4E)-4-{[4-(Dimethylamino)phenyl](4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)methylidene}-N-ethyl-N-[(3-sulfophenyl)methyl]cyclohexa-2,5-dien-1-iminium",CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](C)C)C=C3)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)O,,,,,,
5537,15538,Tert-butyl acetoacetate,CC(=O)CC(=O)OC(C)(C)C,,,,,,
5538,15539,Desmethylmedazepam,C1CN=C(C2=C(N1)C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
5539,15540,2-Nitrobenzenesulfonyl chloride,C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)Cl,,,,,,
5540,15541,Spectinomycin,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,['For use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of <i>Neisseria gonorrhoeae</i>.'],['Spectinomycin is an aminocyclitol antibiotic produced by a species of soil microorganism designated as S<i>treptomyces spectabilis</i>. In vitro studies have shown spectinomycin to be active against most strains of <i>Neisseria gonorrhoeae</i> (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Rapidly and almost completely absorbed after intramuscular injection.'],,['1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance &lt; 20 mL per minute.']
5541,15542,"N,N-Diethylbenzamide",CCN(CC)C(=O)C1=CC=CC=C1,,,,,,
5542,15543,4-Acetylmorpholine,CC(=O)N1CCOCC1,,,,,,
5543,15544,"N,N'-Ethylenebis((bis(2-chloroethyl)amino)acetamide) dihydrochloride",C(CNC(=O)C[NH+](CCCl)CCCl)NC(=O)C[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
5544,15545,2-[bis(2-chloroethyl)amino]-N-[2-[[2-[bis(2-chloroethyl)amino]acetyl]amino]ethyl]acetamide,C(CNC(=O)CN(CCCl)CCCl)NC(=O)CN(CCCl)CCCl,,,,,,
5545,15546,Chloridazon,C1=CC=C(C=C1)N2C(=O)C(=C(C=N2)N)Cl,,,,"['The toxicokinetic data indicate that pyrazon is readily absorbed by the rat gastrointestinal tract. The major excretory route is via the urine with most being excreted in 24 hours for low doses and 48 hours for higher doses. Biliary excretion is significant but a minor route. Females may excrete Pyrazon at lower rates than males based on the 14 day repeat dose study. Tissue burden is low with up to only 3.28% remaining ... Parent compound was detected only in small amounts in the urine and feces. Minor quantitative differences related to gender were identified.', 'Approximately half amount of pyrazon /fed/ ... to rabbits was excreted in urine within 24 hr ... Urinary excretion products resulting from oral administration of technical pyrazon /to rabbits/ included...unchanged pyrazon and p-hydroxy metabolite ... also isopyrazon, present in technical formulation as impurity, and its p-hydroxy metabolites. Similar results were obtained with cats and dogs ...', 'Foliar absorption occurs but is not of major importance to herbicidal action. Translocation from treated leaves is limited. ... Root absorption is rapid and subsequent translocation to all plant parts suggests xylem transport.', 'In lambsquarters, (Chenopodium album L), pyrazon was accumulate in the leaves but metabolized by roots.', 'For more Absorption, Distribution and Excretion (Complete) data for PYRAZON (6 total), please visit the HSDB record page.']","['Approximately half amount of pyrazon /fed/ ... to rabbits was excreted ... /as/ unchanged chemical and ... 2-(p-hydroxyphenyl) analog. ... Similar results were obtained with cats and dogs although ... more p-hydroxy metabolite was excreted than unchanged pyrazon. Studies with pyrazon indicated that 5-amino-4-chloro-3-oxo-(2H)-pyridazine was formed after application to beets. A second metabolite was also detected ... but was not identified.', '/Pyrazon/ ... /In rats/ A total of 10 fractions (nine metabolites and one isomer) in the urine and 5 fractions in the feces were noted. The major urinary metabolites were sulfate and glucuronide conjugates and the major fecal metabolite was a p-hydroxy derivative of Pyrazon. The sulfate and glucuronide conjugates and p-hydroxy derivative of pyrazon were recognized as the biliary metabolites ...', 'A photochemically controlled process was involved in the degradation of pyrazon in the leaves of beets. No degradation occurs in the dark. In sugar beets and red beets, pyrazon formed N-glucosylpyrazone. In addition 5-amino-4-chloro-3(2H)-pyridazinone and a strongly hydrophilic compound were formed.']",
5546,15547,Proquinolate,CC(C)OC1=C(C=C2C(=C1)C(=O)C(=CN2)C(=O)OC)OC(C)C,,,,,,
5547,15548,Laudanosine,CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC,,,"['A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into &quot;specific&quot; agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and &quot;nonspecific&quot; agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p252) (See all compounds classified as Central Nervous System Agents.)']",,,
5548,15549,"2,4-Dichloro-6-phenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)Cl)Cl,,,,,,
5549,15550,"Cycloocta-1,3-diene",C1CCC=CC=CC1,,,,,,
5550,15551,4-Butyrylpyridine,CCCC(=O)C1=CC=NC=C1,,,,,,
5551,15552,"Butyric acid, 4-piperidinocyclohexyl ester, hydrochloride",CCCC(=O)OC1CCC(CC1)[NH+]2CCCCC2.[Cl-],,,,,,
5552,15553,Clopyralid,C1=CC(=NC(=C1Cl)C(=O)O)Cl,,,,"['The patterns of absorption and translocation of 14(C) clopyralid commercially formulated as the acid, monoethanolamine salt, potassium salt, 2-ethylhexyl ester and 1-decyl ester were compared in Cirsium arvense and Polygonum convolvulus grown under three environmental regimes. Plants were grown under a 35% or 65% RH regime in silica sand maintained at 33% w/w moisture or under a water stress regime at 65% RH. Approximately 26, 39, 86, 93 and 100% of the applied 14(C)-activity from the 2-ethylhexyl ester, acid, monoethanolamine salt, 1-decyl ester and potassium salt, respectively, were recovered 72 h after application to glass cover slips placed in the growth room. However, loss of applied 14(C)-activity after application of the five formulations to both plant species was significant only for the 2-ethylhexyl ester. Regardless of environmental regime, the acid was the most readily absorbed formulation. In contrast to the acid, the salts and esters were less readily absorbed. When the data were expressed as a percentage of absorbed radioactivity, there was no significant difference in translocation when the acid, monoethanolamine salt and potassium salt were compared. However, significantly smaller quantities of the absorbed 2-ethylhexyl and 1-decyl ester were exported from the treated leaf. These results indicate that once absorbed, the esters do not readily partition out of the cuticle, whereas the acid and two salts move into the symplast for subsequent translocation. When the results of the three environmental regimes were compared, the absorption of the monoethanolamine and potassium salts were greatly reduced under low humidity or water stress, whereas the acid and esters were not affected.', 'Groups of 5 Crl:CD (F-344) BR rats/sex were dosed with single iv treatments of (14)C-labeled clopyralid, either 5 mg/kg in saline, by single gavage doses of 5 or 150 mg/kg (14)C-clopyralid. An additional 5 rats/sex were dosed daily with 5 mg/kg/day unlabeled clopyralid for 14 days, followed by a single treatment with 5 mg/kg/day  of (14)C-clopyralid. No label was found in expired air. Tissue levels at 72 hour sacrifices were either very low (carcass or stomach) or non-detectable for the several treatment regiments. Generally, over 90% of label was found in urine collected within 24 hr, regardless of administration method. Small amounts of label (1-5%) were found in feces. An analysis of the only detectable urinary labeled fraction found this to be unaltered clopyralid.']","['Groups of 5 Crl:CD (F-344) BR rats/sex were dosed with single iv treatments of (14)C-labeled clopyralid, either 5 mg/kg in saline, by single gavage doses of 5 or 150 mg/kg (14)C-clopyralid. An additional 5 rats/sex were dosed daily with 5 mg/kg/day unlabeled clopyralid for 14 days, followed by a single treatment with 5 mg/kg/day  of (14)C-clopyralid. No label was found in expired air. Tissue levels at 72 hour sacrifices were either very low (carcass or stomach) or non-detectable for the several treatment regiments. Generally, over 90% of label was found in urine collected within 24 hr, regardless of administration method. Small amounts of label (1-5%) were found in feces. An analysis of the only detectable urinary labeled fraction found this to be unaltered clopyralid.']",
5553,15554,"1,2,5,6-Tetrahydro-1,3-dimethyl-4-(4-nitrobenzamido)pyridine",CC1=C(CCN(C1)C)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
5554,15555,"N-(4-Ethoxycarbonyloxy-3,5-dimethoxybenzoyl)morpholine",CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)N2CCOCC2)OC,,,,,,
5555,15556,"[2,6-Dimethoxy-4-(piperidine-1-carbonyl)phenyl] ethyl carbonate",CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)N2CCCCC2)OC,,,,,,
5556,15557,"Carbonic acid, ethyl ester, ester with 1-(4-hydroxy-3,5-dimethoxybenzoyl)pyrrolidine",CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)N2CCCC2)OC,,,,,,
5557,15558,"[2,6-Dimethoxy-4-(4-methylpiperazine-1-carbonyl)phenyl] ethyl carbonate",CCOC(=O)OC1=C(C=C(C=C1OC)C(=O)N2CCN(CC2)C)OC,,,,,,
5558,15559,"2,5-Heptanedione",CCC(=O)CCC(=O)C,,,,,,
5559,15560,"1,2,3,4-Butanetetracarboxylic acid",C(C(C(CC(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
5560,15561,CID 15561,C(C[Se]C(=N)[NH3+])[NH3+].[Br-].[Br-],,,,,,
5561,15562,4-Amino-2-selenabutanamidine,C(C[Se]C(=N)N)N,,,,,,
5562,15563,CID 15563,CC(=O)N=C1N=C(N=N1)C2=CC=C(O2)N(O)O,,,,,,
5563,15564,6-Methylchrysene,CC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C14,,,,,"['6-methylchrysene has known human metabolites that include 6-MeC-1,2-diol.']",
5564,15565,3-Methylfluoranthene,CC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43,,,,,,
5565,15566,"Phosphinic acid, diphenyl-, phenyl ester",C1=CC=C(C=C1)OP(=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5566,15567,Diphenylphosphinic acid,C1=CC=C(C=C1)P(=O)(C2=CC=CC=C2)O,,,,,,
5567,15568,Metazide,C1=CN=CC=C1C(=O)NNCNNC(=O)C2=CC=NC=C2,,,,,,
5568,15569,Bindone,C1C(=C2C(=O)C3=CC=CC=C3C2=O)C4=CC=CC=C4C1=O,,,,,,
5569,15570,"2,5-Dihydrofuran",C1C=CCO1,,,,,,
5570,15571,"2-Hexyl-1,3-dioxolane-4-methanol",CCCCCCC1OCC(O1)CO,,,,,,
5571,15572,"2-Phenyl-1,3-dioxolane-4-methanol",C1C(OC(O1)C2=CC=CC=C2)CO,,,,,,
5572,15573,"1,3-DIOXOLANE-4-METHANOL, 2-(alpha-FURYL)-",C1C(OC(O1)C2=CC=CO2)CO,,,,,,
5573,15574,Hex-3-enyl acetate,CCC=CCCOC(=O)C,,,,,,
5574,15575,Isopropyl nitrate,CC(C)O[N+](=O)[O-],,,,,,
5575,15576,"3-(Acetylamino)-5-amino-2,4,6-triiodobenzoic acid",CC(=O)NC1=C(C(=C(C(=C1I)N)I)C(=O)O)I,,,,,,
5576,15577,MCPA-isobutyl,CC1=C(C=CC(=C1)Cl)OCC(=O)OCC(C)C,,,,,,
5577,15578,MCPA-butyl,CCCCOC(=O)COC1=C(C=C(C=C1)Cl)C,,,,,,
5578,15579,Butyl 2-(4-chloro-2-methylphenoxy)propionate,CCCCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,,,,,,
5579,15580,"Isobutyl 2,4-dichlorophenoxyacetate",CC(C)COC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
5580,15581,"Benzophenone, 4,4'-bis(dimethylamino)-, oxime",CN(C)C1=CC=C(C=C1)C(=NO)C2=CC=C(C=C2)N(C)C,,,,,,
5581,15582,CID 15582,CC12CC(C3C(C1CCC2(C(=O)COC(=O)CCC(=O)[O-])O)CCC4=CC(=O)C=CC34C)O.[Na+],,,,,,
5582,15583,Bromociclen,C1C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)CBr,,,,,,
5583,15584,"p-CYMENE-2-CARBOXYLIC ACID, 3-METHOXY-, p-AMINOPHENYL ESTER",CC1=C(C(=C(C=C1)C(C)C)OC)C(=O)OC2=CC=C(C=C2)N,,,,,,
5584,15585,CID 15585,C1=CC=C(C=C1)CCCC(=O)[O-].[Na+],,,,,,
5585,15586,"1,1-Dichloro-1-fluoroethane",CC(F)(Cl)Cl,,,,"['... MAIN FACTOR AFFECTING FATE OF FLUOROCARBONS IS BODY FAT, WHERE THEY ARE CONCENTRATED & SLOWLY RELEASED INTO BLOOD @ CONCN THAT SHOULD NOT CAUSE ANY RISK OF CARDIAC SENSITIZATION. /FLUOROCARBONS/', 'THERE IS A SIGNIFICANT ACCUMULATION OF FLUOROCARBONS IN BRAIN, LIVER & LUNG COMPARED TO BLOOD LEVELS, SIGNIFYING A TISSUE DISTRIBUTION OF FLUOROCARBONS SIMILAR TO THAT OF CHLOROFORM. /FLUOROCARBONS/', 'Absorption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'Although fluorocarbons cause cardiac sensitization in certain animal species, rapid elimination prevents the development of cardiotoxic concentrations from aerosol bronchodilator use except at exceedingly high doses (12 to 24 doses in 2 minutes). /Fluorocarbons/', 'FLUOROCARBON COMPOUNDS ARE LIPID-SOLUBLE AND THUS ARE GENERALLY WELL ABSORBED THROUGH LUNG. ABSORPTION AFTER INGESTION IS 35 TO 48 TIMES LOWER THAN AFTER INHALATION. ... FLUOROCARBONS ARE ELIMINATED BY WAY OF LUNG. /FLUOROCARBON COMPOUNDS/']","['A single fluorinated urinary metabolite, identified as 2,2-dichloro-2-fluoro-ethyl glucuronide, was found in rats exposed to HCFC 141b (56 g/cu m) in air for 2 hr. The metabolism was reported to be similar to that of its chlorinated analogue 1,1,1-trichloroethane, which is metabolized to 2,2,2-trichloroethanol and excreted as it glucuronate conjugate and as trichloroacetic acid.', 'In a pilot study for absorption and metabolism of HCFC 141b, seven groups of five male rats were exposed to the vapor by inhalation in a closed loop exposure system (concentrations ranging from 0.4 to 12 g/cu m). No metabolism was detected but the sensitivity of the method is such that it will not detect metabolism below 0.15%.', ""Human subjects were exposed by inhalation to 250, 500, and 1000 ppm 1,1-dichloro-1-fluoroethane (HCFC-141b) for 4 hr, and urine samples were collected from 0-4, 4-12, and 12-24 hr for metabolite analysis. 'OF nuclear magnetic resonance spectroscopic analysis of urine samples from exposed subjects showed that 2,2-dichloro-2-fluoroethyl glucuronide and dichlorofluoroacetic acid were the major and minor metabolites, respectively, of 1,1-dichloro-1-fluoroethane. Urinary 2,2-dichloro-2-fluoroethyl glucuronide was hydrolyzed to 2,2-dichloro-2-fluoroethanol by incubation with beta-glucuronidase, and the released 2,2-dichloro-2-fluoroethanol was quantified by gas chromatography/mass spectrometry. Concentrations of 2,2-dichloro-2-fluoroethanol were highest in the urine samples collected 4-12 hr after exposure, but 2,2-dichloro-2-fluoroethanol was also detected in the samples collected 0-4 and 12-24 hr after exposure. Exposure concentration-dependent excretion of 2,2-dichloro-2-fluoroethanol, obtained by hydrolysis of 2,2-dichloro-2-fluoroethyl glucuronide, was observed in seven of the eight subjects studied. In conclusion, 1,1-dichloro-1-fluoroethane is metabolized in human subjects to 2,2-dichloro-2-fluoroethanol, which is conjugated with glucuronic acid and excreted as its glucuronide in urine in a time- and exposure concentration-dependent manner.""]",
5586,15587,Sodium 5-[(4-nitrophenyl)azo]salicylate,C1=CC(=CC=C1N=NC2=CC(=C(C=C2)[O-])C(=O)O)[N+](=O)[O-].[Na+],,,,,,
5587,15588,Alizarine Yellow R,C1=CC(=CC=C1N=NC2=CC(=C(C=C2)O)C(=O)O)[N+](=O)[O-],,,,,,
5588,15589,Dichlorodiethylsilane,CC[Si](CC)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
5589,15590,"Benzene, 1,1'-(1,3,5-hexatriene-1,6-diyl)bis-",C1=CC=C(C=C1)C=CC=CC=CC2=CC=CC=C2,,,,,,
5590,15591,"2,3-Dimethylquinoline",CC1=CC2=CC=CC=C2N=C1C,,,,,,
5591,15592,1-Methylisoquinoline,CC1=NC=CC2=CC=CC=C12,,,,,,
5592,15593,"2,4-Dimethyl-1,3,5-triazine",CC1=NC(=NC=N1)C,,,,,,
5593,15594,"2-Phenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC=NC=N2,,,,,,
5594,15595,Cyclododecanol,C1CCCCCC(CCCCC1)O,,,,,"['Microbiological oxygenation of the monocyclic alcohol, cyclododecanol, by Sporotrichum sulfurescens produced a mixture of cylcododecanol dioxygenated products.']",
5595,15596,Oxacyclotetradecan-2-one,C1CCCCCCOC(=O)CCCCC1,,,,,,
5596,15597,"(3E)-1,2,3,4,5,6-Hexachlorohex-3-ene",C(C(C(=C(C(CCl)Cl)Cl)Cl)Cl)Cl,,,,,,
5597,15598,Aluminum;hexadecane,CCCCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCCCC[CH2-].CCCCCCCCCCCCCCC[CH2-].[Al+3],,,,,,
5598,15599,Aluminum;decane,CCCCCCCCC[CH2-].CCCCCCCCC[CH2-].CCCCCCCCC[CH2-].[Al+3],,,,,,
5599,15600,Decane,CCCCCCCCCC,,,,"['Decane, a 10-carbon n-alkane and one of the highest vapor phase constituents of jet propellent-8 (JP-8), was selected to represent the semivolatile fraction for the initial development of a physiologically based pharmacokinetic (PBPK) model for JP-8. Rats were exposed to decane vapors at time-weighted average concentrations of 1200, 781, or 273 ppm in a 32-L Leach chamber for 4 hr. Time-course samples for 1200 ppm and end-of-exposure samples for 781 and 273 ppm decane exposures were collected from blood, brain, liver, fat, bone marrow, lung, skin, and spleen. The pharmacokinetics of decane could not be described by flow-limited assumptions and measured in vitro tissue/air partition coefficients. A refined PBPK model for decane was then developed using flow-limited (liver and lung) and diffusion-limited (brain, bone marrow, fat, skin, and spleen) equations to describe the uptake and clearance of decane in the blood and tissues. Partition coefficient values for blood/air and tissue/blood were estimated by fitting end-of-exposure pharmacokinetic data and assumed to reflect the available decane for rapid exchange with blood. A portion of decane is speculated to be sequestered in ""deep"" pools in the body, unavailable for rapid exchange with blood. PBPK model predictions were adequate in describing the tissues and blood kinetics. For model validation, the refined PBPK model for decane had mixed successes at predicting tissue and blood concentrations for lower concentrations of decane vapor, suggesting that further improvements in the model may be necessary to extrapolate to lower concentrations.', 'Rat tissue:air and blood:air partition coefficients (PCs) for octane, nonane, decane, undecane, and dodecane (n-C8 to n-C12 n-alkanes) were determined by vial equilibration. The blood:air PC values for n-C8 to n-C12 were 3.1, 5.8, 8.1, 20.4, and 24.6, respectively. The lipid solubility of n-alkanes increases with carbon length, suggesting that lipid solubility is an important determinant in describing n-alkane blood:air PC values. The muscle:blood, liver: blood, brain:blood, and fat:blood PC values were octane (1.0, 1.9, 1.4, and 247), nonane (0.8, 1.9, 3.8, and 274), decane (0.9, 2.0, 4.8, and 328), undecane (0.7, 1.5, 1.7, and 529), and dodecane (1.2, 1.9, 19.8, and 671), respectively. The tissue:blood PC values were greatest in fat and the least in muscle. The brain:air PC value for undecane was inconsistent with other n-alkane values. Using the measured partition coefficient values of these n-alkanes, linear regression was used to predict tissue (except brain) and blood:air partition coefficient values for larger n-alkanes, tridecane, tetradecane, pentadecane, hexadecane, and heptadecane (n-C13 to n-C17). Good agreement between measured and predicted tissue:air and blood:air partition coefficient values for n-C8 to n-Cl2 offer confidence in the partition coefficient predictions for longer chain n-alkanes.', 'Dermal absorption of alkanes with more than eight carbons (octane) occurs very slowly. The distribution of the C10-C12 aliphatics would likely follow the same pattern reported for n-octane. /Decane, undecane, and dodecane (C10-C12)/', 'Absorption of decane occurs mainly by inhalation.', 'For more Absorption, Distribution and Excretion (Complete) data for n-Decane (6 total), please visit the HSDB record page.']","['Alternative fuels are being considered for civilian and military uses. One of these is S-8, a replacement jet fuel synthesized using the Fischer-Tropsch process, which contains no aromatic compounds and is mainly composed of straight and branched alkanes. Metabolites of S-8 fuel in laboratory animals have not been identified. The goal of this study was to identify metabolic products from exposure to aerosolized S-8 and a designed straight-chain alkane/polyaromatic mixture (decane, undecane, dodecane, tridecane, tetradecane, pentadecane, naphthalene, and 2-methylnaphthalene) in male Fischer 344 rats. Collected blood and tissue samples were analyzed for 70 straight and branched alcohols and ketones ranging from 7 to 15 carbons. No fuel metabolites were observed in the blood, lungs, brain, and fat following S-8 exposure. Metabolites were detected in the liver, urine, and feces. Most of the metabolites were 2- and 3-position alcohols and ketones of prominent hydrocarbons with very few 1- or 4-position metabolites. Following exposure to the alkane mixture, metabolites were observed in the blood, liver, and lungs. Interestingly, heavy metabolites (3-tridecanone, 2-tridecanol, and 2-tetradecanol) were observed only in the lung tissues possibly indicating that metabolism occurred in the lungs. With the exception of these heavy metabolites, the metabolic profiles observed in this study are consistent with previous studies reporting on the metabolism of individual alkanes. Further work is needed to determine the potential metabolic interactions of parent, primary, and secondary metabolites and identify more polar metabolites. Some metabolites may have potential use as biomarkers of exposure to fuels.', 'Jet propellant 8 (JP-8) jet fuel is a complex mixture of aromatic and aliphatic hydrocarbons. The aim of this study was to determine in vitro metabolic rate constants for semivolatile n-alkanes, nonane (C9), decane (C10), and tetradecane (C14), by rat liver microsomal oxidation. The metabolism was assessed by measuring the disappearance of parent compound by gas chromatography. Various concentrations of n-alkanes were incubated with liver microsomes from adult male F-344 rats. Nonlinear kinetic constants for nonane and decane were V(max) (nmol/mg protein/min) = 7.26 +/- 0.20 and 2.80 +/- 0.35, respectively, and K(M) (micro M) = 294.83 +/- 68.67 and 398.70 +/- 42.70, respectively. Metabolic capacity as assessed by intrinsic clearance (V(max)/K(M)) was approximately four-fold higher for nonane (0.03 +/- 0.005) than for decane (0.007 +/- 0.001). There was no appreciable metabolism of tetradecane even with higher microsomal protein concentration and longer incubation time. These results show a negative correlation between metabolic clearance and chain length of n-alkanes. These metabolic rate constants will be used to update existing physiologically based pharmacokinetic (PBPK) models for nonane and decane as part of developing a PBPK model for JP-8.', 'Decane is metabolized in rats to hydroxy derivates before being converted to the respective keto form, using a cytochrome P450-microsomal oxidase mixed function. Decane hydroxylation has been observed in liver microsomal fractions obtained from mice, rats, rabbits, cows, pigeons, and chick embryos. In rats, hydroxylation takes place not only in liver, but in other organs and microsomes isolated from the kidney and lungs.', 'Decane was oxidized by microsomes from livers of mouse, rat, rabbit, beef, pigeon and chick embryo. The oxidation of decane by mouse liver microsomes required NADPH and oxygen. Decanol, decanoic acid and decamethylene glycol were major metabolites of decane oxidation, suggesting that decane oxidation is inititated by hydroxylation of decane to decanol.', 'For more Metabolism/Metabolites (Complete) data for n-Decane (8 total), please visit the HSDB record page.']",
5600,15601,"Carbamic acid, isopropyl-, 2-methyl-2-propyltrimethylene ester",CCCC(C)(COC(=O)NC(C)C)COC(=O)NC(C)C,,,,,,
5601,15602,"1,1,3,3-Tetramethylguanidine hydrochloride",CN(C)C(=[N+](C)C)N.[Cl-],,,,,,
5602,15603,"1,1,3,3-Tetramethylguanidinium",CN(C)C(=[N+](C)C)N,,,,,,
5603,15604,1-Methylfluorene,CC1=C2CC3=CC=CC=C3C2=CC=C1,,,,,,
5604,15605,Undecyl acetate,CCCCCCCCCCCOC(=O)C,,,,,,
5605,15606,Methyl nonanoate,CCCCCCCCC(=O)OC,,,,,,
5606,15607,Methyl undecanoate,CCCCCCCCCCC(=O)OC,,,,,,
5607,15608,Methyl tridecanoate,CCCCCCCCCCCCC(=O)OC,,,,,,
5608,15609,Methyl heptadecanoate,CCCCCCCCCCCCCCCCC(=O)OC,,,,,,
5609,15610,Methyl nonadecanoate,CCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
5610,15611,Dimethyl suberate,COC(=O)CCCCCCC(=O)OC,,,,,,
5611,15612,Dimethyl azelate,COC(=O)CCCCCCCC(=O)OC,,,,,,
5612,15613,Isopropyl 3-methyl-2-butenoate,CC(C)OC(=O)C=C(C)C,,,,,,
5613,15614,"2-Propenal, 3-(4-nitrophenyl)-",C1=CC(=CC=C1C=CC=O)[N+](=O)[O-],,,,,,
5614,15615,3-(Dimethylamino)propanenitrile,CN(C)CCC#N,,,,,,
5615,15616,Z-Gly-ONp,C1=CC=C(C=C1)COC(=O)NCC(=O)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
5616,15617,"1,2-Dimethylimidazole",CC1=NC=CN1C,,,,,,
5617,15618,"1,4a-Dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid",CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)C(=O)O)C,,,,,,
5618,15619,"1,1-Dimethoxy-2-methylpropane",CC(C)C(OC)OC,,,,,,
5619,15620,Amyl methyl sulfide,CCCCCSC,,,,,,
5620,15621,1-(4-Methoxyphenyl)propan-2-ylhydrazine,CC(CC1=CC=C(C=C1)OC)NN,,,,,,
5621,15622,(alpha-Methylphenethyl)hydrazine oxalate,CC(CNN)C1=CC=CC=C1.C(=O)(C(=O)O)O,,,,,,
5622,15623,"6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline",COC1=C(C=C2CNCCC2=C1)OC,,,,,,
5623,15624,2-Allylphenol,C=CCC1=CC=CC=C1O,,,,,,
5624,15625,"2,3,7,8-Tetrachlorodibenzo-P-dioxin",C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,,,"['An agent that causes the production of physical defects in the developing embryo. (See all compounds classified as Teratogens.)', 'Substances or energies, for example heat or light, which when introduced into the air, water, or land threaten life or health of individuals or ECOSYSTEMS. (See all compounds classified as Environmental Pollutants.)']","['Following single oral administration of 50 ug/kg bw (14)C-TCDD to rats, almost 30% was eliminated in feces during first 48 hr; excretion of (14)C activity via feces after this time was from 1-2%/day. After its absorption in the body, most of the activity derived from (14)C-TCDD is localized in liver and fat: the level in these tissues is 10 times that in other tissues. A total of 53.2% of the dose was eliminated via feces and 13.2% and 3.2% via urine and expired air respectively within 21 days.', 'In female guinea pigs administered a single oral dose of 2,3,7,8-TCDD only 1/2 of dose was absorbed. 22 days after dosing, fat, liver, adrenals and thymus contained 0.75, ...0.40, ...0.33, ...and 0.72% ...respectively.', '... Distribution of (14)C-TCDD in the young following a single oral dose to the mother at the rate of 0.005 mg/kg was consistent with enzyme induction following a single oral dose. TCDD was found in fetuses sampled on gestation days 14, 18, or 21 but at far lower concentrations than in young examined 3, 7, 10, or 14 days after birth. Cross fostering tests indicated that TCDD was excreted in milk, and this accounted for the greater transfer to the neonate.', 'The liver concentration of TCDD was measured as a means of following the uptake of this chemical by the intestinal and dermal routes. Accumulation of the (radiolabelled) compound in the liver was found to provide a good and reproducible method of comparing TCDD uptake from different formulations. After oral administration of 14.7 ng TCDD using 50% ethanol as vehicle, 36.7% of the total dose was found in the liver after 24 hr. When the cmpd was administered in a mixture with soil particles, adsorption occurred and only about half of this amount was found in the liver. The liver level also decreased with increasing duration of contact between the soil and the dioxin. Adsorption onto activated carbon almost completely prevented uptake of the cmpd. Similar effects were observed after dermal application of TCDD in the various formulations. The highest liver content, 14.8% of the dose, was found after contact of the pure cmpd with the skin surface. The inhibiting effects of soil and activated carbon were even more pronounced. After incorporation of the dioxin into vaseline (a lipophilic ointment), 1.4% of the dose was found in the liver, wheras, after incorporation into polyethylene glycol 1500 (a hydrophilic ointment) containing 15% water, 14.1% was found in the liver.', 'For more Absorption, Distribution and Excretion (Complete) data for 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (19 total), please visit the HSDB record page.']","['This study presents evidence for the in vivo biotransformation of TCDD in the rat. Three male rats were implanted with indwelling bile loop cannulas. They were then given oral doses of 15 ug (14)C-TCDD/kg. After 2, 4, or 6 doses, the bile loop of one rat was opened and bile was collected for 24 hr. Biliary (14)C was excreted at a rate similar to the excretion of (14)C in the feces of rats fed (14)C-TCDD in a previous study. Selective solvent extraction revealed that the biliary (14)C activity was due to compound more polar than TCDD itself. Incubation of bile with beta-glucuronidase resulted in the extraction of more (14)C activity, implying the presence of glucuronide conjugates of (14)C-TCDD metabolites. Liquid chromatography of bile has revealed the presence of at least 5 distinct radioactive peaks, none of which was due to (14)C-TCDD. The data did not indicate extensive enterohepatic circulation of radioactivity derived from (14)C-TCDD. These results, in conjunction with the results of previous studies, indicate that TCDD is slowly metabolized in the liver to a variety of polar metabolites, which are then excreted in the bile.', 'Thin layer and gas chromatographic examination of the bile of dogs which were given tritium labelled TCDD revealed the presence of several polar biotransformation products. The structure of 5 phenolic metabolites was elucidated by combined gas chromatography-mass spectrometry. A metabolic breakdown scheme for TCDD in the dog is proposed /which includes 1,3,7,8-tetrachloro-2-methoxydibenzo-p-dioxin, 2,7,8-trichloro-3-methoxydibenzo-p-dioxin, trichloro-dimethoxydibenzo-p-dioxins, tetrachloro-dimethoxy diphenylether, and 1,2-dichloro-4,5-dimethyoxybenzene/.', 'The in vitro metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin in isolated rat hepatocytes /was investigated/. ... The metabolites were ... identified as 1-hydroxy-2,3,7,8-TCDD and 8-hydroxy-2,3,7-trichlorodibenzo-p-dioxin.', 'The major metabolite /of 2,3,7,8-TCDD in dogs/ is 1,3,7,8-tetrachloro-2-hydroxydibenzo-p-dioxin.', 'For more Metabolism/Metabolites (Complete) data for 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (6 total), please visit the HSDB record page.']","['Whole body: 7.1 years (2.9 to 26.9 years); [TDR, p. 1111] Estimated at around 7 years; [Reference #2, p. 379]', '(14)C-labeled tetrachlorodibenzo-p-dioxin was administered by gavage to guinea pigs. Half-life for elimination was estimated to be between 22 and 43 days.', 'Rats were given a single oral dose of 1.0 ug of (14)C-2,3,7,8-tetrachlorodibenzo-p-dioxin (14)C-TCDD/kg/day, or repeated oral doses of 0.01, 0.1, or 1.0 ug of (14)C-TCDD/kg/day Monday through Friday for 7 weeks. Following a single oral dose of 1.0 ug of (14)C-TCDD/kg, (14)C activity could be detected only in feces, but not in urine. The half-life of (14)C activity in the body was 31 + or - 6 days ... .', 'Dioxins are present in milk of dairy cattle following feeding of technical grade pentachlorophenol. A dioxin concentration as high as 85 ug/kg is found in milk after feeding pentachlorophenol for 10 days at 20 mg/kg/day and then for an additional 60 days at 10 mg/kg/day. The elimination half-life of dioxin in milk is approximately 50 days.', 'After a single oral dose administration of (14C)-TCDD to rats, (14C) was detected in feces but not urine with a body t(1/2) = 31 +/- 6 days.', 'For more Biological Half-Life (Complete) data for 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (10 total), please visit the HSDB record page.']"
5625,15626,CID 15626,C=COP(=O)O,,,,,,
5626,15627,4-tert-Butylstyrene,CC(C)(C)C1=CC=C(C=C1)C=C,,,,,,
5627,15628,Isopropyl carbamate,CC(C)OC(=O)N,,,,,,
5628,15629,Monolinuron,CN(C(=O)NC1=CC=C(C=C1)Cl)OC,,,,"['WHEN (14)C-LABELED MONOLINURON WAS FED TO HENS AT 0.25 & 25 MG/KG, 85-87% OF RADIOACTIVITY WAS EXCRETED IN URINE & FECES WITHIN 96 HR; MOST WAS IN URINE. THE ORGANS, INCLUDING BLOOD & BILE, CONTAINED APPROX 1% OF DOSE, & MUSCLE WAS ALMOST RESIDUE-FREE. EGG WHITES CONTAINED 0.31 & 0.53% AFTER 0.25 & 25 MG/KG; EGG YOLKS CONTAINED 1.82 & 3.72%. NO UNCHANGED MONOLINURON WAS FOUND IN FECES & URINE.', 'Absorbed by leaves & roots.', 'PENETRATES INTO WEEDS MAINLY THROUGH ROOTS BEING TRANSLOCATED IN PLANTS PREDOMINANTLY ACROPETAL.']","[""WHEN...FED TO ALBINO RATS, THE FOLLOWING METABOLITES WERE FOUND...FREE & BOUND AS GLUCURONIDES OR SULFATES: N-(2-HYDROXY-4-CHLOROPHENYL)-N'-METHYLUREA; N-(3-HYDROXY-4-CHLOROPHENYL)-UREA; TRACES OF N-(4-CHLOROPHENYL)-N'-METHOXYUREA, 2-AMINO-5-CHLOROPHENOL, 2-ACETAMINO-5-CHLOROPHENOL, N,N'-BIS-(4-CHLOROPHENYL)UREA, 2-ACETAMINO-6-CHLOROPHENOL, & N-(2-HYDROXY-4-CHLOROPHENYL)-N'-METHYL-N'-METHOXYUREA. N-(4-CHLOROPHENYL)UREA & TRACE OF 4-CHLOROANILINE WERE FOUND FREE ONLY. N-(2-HYDROXY-4-CHLOROPHENYL)-N'-METHYLUREA WAS FOUND IN BOUND STATE ONLY."", 'WHEN (14)C-LABELED MONOLINURON WAS FED TO HENS AT 0.25 & 25 MG/KG, 26% OF EXCRETED RADIOACTIVITY WAS PRESENT AS METABOLITE 4-CHLOROPHENYLUREA. 1-(2-HYDROXY-4-CHLOROPHENYL)UREA AND 1-(3-HYDROXY-4-CHLOROPHENYL)UREA ACCOUNTED FOR 21% OF EXCRETED RADIOACTIVITY.', 'In...plants, cleavage of the methyl & methoxy groups on the terminal nitrogen atom, simultaneous ring hydroxylation & formation of 3-(2-hydroxy-4-chlorophenyl)urea & the corresponding 3-hydroxy compound. Further degradation is presumably by way of formation of the aniline derivative & ring splitting.', 'Six hours after administration of monolinuron to pigs, collected urine was analyzed. The biotransformation products found included 3-(4-chlorophenyl)-1-hydroxymethyl-1-methoxyurea, desmethyl monolinuron, 4-chlorophenylurea, (4-chloro-2-hydroxyphenyl)urea, (4-chloro-3-hydroxyphenyl)urea, and glucuronides and/or sulfates of the latter two hydroxy compounds.', 'For more Metabolism/Metabolites (Complete) data for MONOLINURON (8 total), please visit the HSDB record page.']",
5629,15630,2-Amino-6-methoxybenzothiazole,COC1=CC2=C(C=C1)N=C(S2)N,,,,,,
5630,15631,N-(2-fluorophenyl)benzamide,C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2F,,,,,,
5631,15632,"Ethyl 2-[3-[(5-nitrofuran-2-yl)methylideneamino]-2,5-dioxoimidazolidin-1-yl]acetate",CCOC(=O)CN1C(=O)CN(C1=O)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
5632,15633,"5H-Dibenzo(a,d)cycloheptene-5-propylamine, 10,11-dihydro-N-methyl-, hydrochloride",C[NH2+]CCCC1C2=CC=CC=C2CCC3=CC=CC=C13.[Cl-],,,,,,
5633,15634,"10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene",CNCCCC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
5634,15635,"Benzoxazole, 2-amino-5-chloro-6-hydroxy-",C1=C2C(=CC(=C1Cl)O)OC(=N2)N,,,,,,
5635,15636,5-Chloro-6-methoxy-2-benzoxazolinone,COC1=C(C=C2C(=C1)OC(=O)N2)Cl,,,,,,
5636,15637,"5-(2-Methylphenyl)-1,3,4-oxadiazol-2-amine",CC1=CC=CC=C1C2=NN=C(O2)N,,,,,,
5637,15638,"N-(3-(2-Methoxyethoxy)propyl)-1,4-benzodioxan-2-methylamine hydrochloride",COCCOCCC[NH2+]CC1COC2=CC=CC=C2O1.[Cl-],,,,,,
5638,15639,"N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-(2-methoxyethoxy)propan-1-amine",COCCOCCCNCC1COC2=CC=CC=C2O1,,,,,,
5639,15640,CID 15640,CC(=NN=C(N)S)C,,,,,,
5640,15641,Dioctyl phenylphosphonate,CCCCCCCCOP(=O)(C1=CC=CC=C1)OCCCCCCCC,,,,,,
5641,15642,Diethyl phenylphosphonate,CCOP(=O)(C1=CC=CC=C1)OCC,,,,,,
5642,15643,Diamidafos,CNP(=O)(NC)OC1=CC=CC=C1,,,,"['AFTER ADMIN OF (14)C-DIAMIDFOS TO RATS IN IV DOSES OF 1 AND 25 MG/KG, CLEARANCE OF (14)C ACTIVITY FROM PLASMA WAS BY AN APPARENT FIRST ORDER PROCESS WITH HALF-LIFE VALUES OF 2.94 AND 3.08 HR, RESPECTIVELY.', 'APPROX 84% OF ORAL OR IV DOSE OF DIAMIDAFOS IN SPRAGUE-DAWLEY RATS WAS EXCRETED IN URINE DURING FIRST 36 HR & APPROX 4% MORE OVER NEXT 36 HR.', '/Nellite/ ... is readily absorbed from the gut ... also ... through intact skin ...']","[""THE PHOSPHORODIAMIDATE, DIAMIDAFOS (PHENYL N,N'-DIMETHYLPHOSPHORODIAMIDATE), WAS RAPIDLY METABOLIZED BY THE RAT TO YIELD PRODUCTS OF OXIDATIVE ATTACK AT THE N-METHYL GROUP...& OF HYDROLYTIC ATTACK AT THE P-O BOND TO YIELD PHENOL (AS CONJUGATE). ANALYSIS OF MILK FOLLOWING DOSAGE...TO COW REVEALED...SAME METABOLITES."", 'When tobacco was treated with (14)C-diamidfos, in addition to unchanged diamidfos and unextractable material, phenyl beta-D-glucopyranoside and a glycoside of phenol were observed. In tobacco smoke, the major breakdown product was phenol.', 'URINE FROM SPRAGUE-DAWLEY RATS AFTER ORAL OR IV ADMIN OF DIAMIDAFOS CONTAINED PHENYL N-METHYL-PHOSPHORODIAMIDATE, PHENYL N-METHYL-N-FORMYL PHOSPHORODIAMIDATE, AND CONJUGATED PHENOL.']",
5643,15644,Carbestrol,CCC1=C(CCC(C1C)C(=O)O)C2=CC=C(C=C2)OC,,,,,,
5644,15645,CID 15645,CN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
5645,15646,"7-chloro-5-(2-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-3H-1,4-benzodiazepin-2-one",CN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F,,,,,,
5646,15647,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(o-fluorophenyl)-1-(2-(4-methyl-1-piperazinyl)ethyl)-, trihydrochloride",CN1CCN(CC1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F.Cl.Cl.Cl,,,,,,
5647,15648,"7-chloro-5-(2-fluorophenyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]-3H-1,4-benzodiazepin-2-one",CN1CCN(CC1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F,,,,,,
5648,15649,Akton,CCOP(=S)(OCC)OC(=CCl)C1=C(C=CC(=C1)Cl)Cl,,,,,,
5649,15650,3-Methylcyclopentanone,CC1CCC(=O)C1,,,,,,
5650,15651,2-Phenoxyethylamine,C1=CC=C(C=C1)OCCN,,,,,,
5651,15652,"1,2-Diaminoanthraquinone",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)N)N,,,,,,
5652,15653,2-Ethyl-p-xylene,CCC1=C(C=CC(=C1)C)C,,,,,,
5653,15654,4-Methyl-5-vinylthiazole,CC1=C(SC=N1)C=C,,,,,,
5654,15655,Cyclopropanecarboxylic acid,C1CC1C(=O)O,,,,,,
5655,15656,"trans-1,3-Dimethylcyclopentane",C[C@@H]1CC[C@H](C1)C,,,,,,
5656,15657,N-Cyclohexylbenzamide,C1CCC(CC1)NC(=O)C2=CC=CC=C2,,,,,,
5657,15658,4-Methylcyclopentene,CC1CC=CC1,,,,,,
5658,15659,N-[3-(Trimethoxysilyl)propyl]ethylenediamine,CO[Si](CCCNCCN)(OC)OC,,,,,,
5659,15660,"4,4'-Methylenedicyclohexanamine",C1CC(CCC1CC2CCC(CC2)N)N,,,,,,
5660,15661,Ethyltrimethyllead,CC[Pb](C)(C)C,,,,"['In contrast to relative insignificance of skin as route of inorg lead absorption, alkyl lead compounds are absorbed to such a degree that toxicity among handlers of these compounds in blending of leaded gasoline has been attributed to skin absorption. /Alkyl lead compounds/']","['The concentration of lead in blood varies, in general, it is slightly elevated but in some cases of poisoning it is nearly normal. In cases of repeated gasoline sniffing the content of lead in blood is high. No close correlation exists between blood lead levels and the severity of intoxication. The urinary excretion of lead is increased markedly ...']",
5661,15662,Diethyldimethyllead,CC[Pb](C)(C)CC,,,,,"['The concentration of lead in blood varies, in general, it is slightly elevated but in some cases of poisoning it is nearly normal. In cases of repeated gasoline sniffing the content of lead in blood is high. No close correlation exists between blood lead levels and the severity of intoxication. The urinary excretion of lead is increased markedly ...']",
5662,15663,Triethylmethyllead,CC[Pb](C)(CC)CC,,,,"['Seven autopsy cases due to accidental tetraalkyllead poisoning are described. The victims died 5-19 days after poisoning. The highest lead concn was detected in the liver, spleen & kidney. Gas chromatographic analysis of oil tank contents responsible for the poisonings showed presence of methyltriethyllead. .']","['The concentration of lead in blood varies, in general, it is slightly elevated but in some cases of poisoning it is nearly normal. In cases of repeated gasoline sniffing the content of lead in blood is high. No close correlation exists between blood lead levels and the severity of intoxication. The urinary excretion of lead is increased markedly ...']",
5663,15664,Abametapir,CC1=CN=C(C=C1)C2=NC=C(C=C2)C,"['Abametapir is indicated, in the context of an overall lice management program, for the topical treatment of head lice infestation in patients 6 months of age and older.']","['Abametavir has been shown to inhibit all stages of embryo development in both head and body lice by interfering with enzymes critical to this process. It is relatively unique amongst lice treatments in that it requires only a single application, whereas many current therapies require two applications, due to its exceptional potency and unique mechanism. Its predominant metabolite, abametapir carboxyl, has a prolonged residence time in the body, with an estimated half-life of 71  40 hours or longer in adults - as this metabolite has been shown to inhibit cytochrome P450 enzymes _in vitro_, the use of substrates of CYP3A4, CYP2B6, or CYP1A2 should be avoided for two weeks following the administration of abametapir.   Abametapir lotion is formulated with [benzyl alcohol], which has been associated with significant toxicity following unintentional systemic exposure, particularly in neonates and low birth weight infants. Benzyl alcohol-containing formulations should not be administered to patients <6 months of age, and should be administered to pediatric patients cautiously and under direct supervision of an adult to mitigate the risk of unintentional oral ingestion.']",,"['In a pharmacokinetic trial with both adult and pediatric patients, the C<sub>max</sub> and AUC<sub>0-8h</sub> in the adult group were 41 ng/mL and 121 ng.h/mL and the C<sub>max</sub> and AUC<sub>0-8h</sub> in the pediatric group were 73 ng/mL and 264 ng.h/mL. In general, systemic exposure to abametapir appears to decrease with increasing age. The median T<sub>max</sub> of abemetapir is 0.57 - 1.54 hours.  Following topical administration, benzyl alcohol was found in detectable quantities in the serum of 7 out of 39 pediatric patients. The C<sub>max</sub> of benzyl alcohol in these subjects ranged from 0.52 to 3.57 g/mL.  The predominant circulating metabolite of abemetapir (abemtapir carboxylate) is eliminated slowly from the circulation and is therefore found at higher serum concentrations than its parent drug - based on data collected for 72 hours post-administration, the ratios of serum C<sub>max</sub> and AUC<sub>0-72h</sub> between abametapir and abametapir carboxylate were approximately 30 and 250, respectively.', 'The clearance and excretion of abametapir has not been examined in patients.', 'Data regarding the volume of distribution of abametapir are not available.', 'The clearance and excretion of abametapir has not been examined in patients.']","['The biotransformation of abametapir is extensive and primarily mediated by CYP1A2. It is metabolized first to abametapir hydroxyl and then further to abametapir carboxyl - the latter is cleared slowly from the plasma, resulting in higher systemic concentrations than that of the parent drug. _In vitro_ studies suggest that abametapir carboxyl may act as an inhibitor of CYP3A4, CYP2B6, and CYP1A2, particularly at the relatively high and prolonged concentrations observed following topical administration of abametapir.']","['The elimination half-lives of abametapir and its metabolites have not been well-characterized, but the estimated half-life of abametapir carboxyl is 71  40 hours (or longer) in adults.']"
5664,15665,"Coumarin, 7-(2-(diethylamino)ethoxy)-3,4-diphenyl-",CCN(CC)CCOC1=CC2=C(C=C1)C(=C(C(=O)O2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5665,15666,Ammonium thiocyanate,C(#N)[S-].[NH4+],,,,"['The thiocyanate ion is slowly excreted in the urine; it is not decomposed to cyanide in appreciable quantities. /Thiocyanate salts/', 'The thiocyanate ion is slowly excreted in thr urine; it is not decomposed to cyanide in appreciable quantities. The thiocyanate ion readily diffuses into all tissues. It appears early in saliva and urine.', 'Can be absorbed through skin ... .', 'Therapeutic or normal level in human blood is 8.0-14.0 mg% or 80.0-140.0 ug/mL. /Thiocyanate/']",,
5666,15667,"S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] hexadecanethioate",CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O,,,,,,
5667,15668,Phloraspine,CCCC(=O)C1=C(C(=C(C=C1O)OC)CC2=C(C(=C(C(=C2O)C)O)C(=O)CCC)O)O,,,,,,
5668,15669,"4,4,4-Trifluoro-3-(trifluoromethyl)crotonic acid",C(=C(C(F)(F)F)C(F)(F)F)C(=O)O,,,,,,
5669,15670,"DIBENZ(a,h)ANTHRACENE, 6-FLUORO-",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C(=CC5=CC=CC=C54)F,,,,,,
5670,15671,Epitizide,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)CSCC(F)(F)F,,,,,,
5671,15672,Butyl cyanate,CCCCOC#N,,,,,,
5672,15673,Pentachloroacetone,C(C(=O)C(Cl)(Cl)Cl)(Cl)Cl,,,,,,
5673,15674,CID 15674,CC1=NC(=O)C2=CC=CC=C2N1,,,,,,
5674,15675,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-cyano-5-(3-dimethylaminopropyl)-, hydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)C#N.[Cl-],,,,,,
5675,15676,"2-[3-(Dimethylamino)propyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carbonitrile",CN(C)CCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)C#N,,,,,,
5676,15677,Methometon,COCCCNC1=NC(=NC(=N1)OC)NCCCOC,,,,,,
5677,15678,"1,3,6-Hexanetricarbonitrile",C(CC#N)CC(CCC#N)C#N,,,,,,
5678,15679,Carbasulam,COC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC(=O)OC,,,,,,
5679,15680,p-Tolyl sulfoxide,CC1=CC=C(C=C1)S(=O)C2=CC=C(C=C2)C,,,,,,
5680,15681,2-Amino-5-nitrobenzophenone,C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)[N+](=O)[O-])N,,,,,,
5681,15682,"3-(2,4-Dihydroxyphenyl)-1-phenyl-2-propen-1-one",C1=CC=C(C=C1)C(=O)C=CC2=C(C=C(C=C2)O)O,,,,,,
5682,15683,3-Methyl-4-pentenal,CC(CC=O)C=C,,,,,,
5683,15684,"2,4-Dichlorobenzyl alcohol",C1=CC(=C(C=C1Cl)Cl)CO,['Dichlorobenzyl alcohol in combination with [DB13908] is available in over-the-counter products used for symptomatic relief of acute sore throat and postoperative sore throat.'],"['In vitro studies with the combination of dichlorobenzyl alcohol and amylmetacresol have shown a virucidal against a number of viruses associated with the common cold which is observed by a reduction in the viral load. In clinical trials, administration of dichlorobenzyl alcohol lozenges has been shown to generate a reduced throat soreness and to provide pain relief and relief from difficulty in swallowing 5 minutes after administration. This effect can last for even 2 hours. The relief effect was shown to reach a steady-state after 45 minutes.']",,"['Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes. The concentration in saliva after 120 minutes represents about 50% of the administered dose.', 'In preclinical trials, dermal administration of dichlorobenzyl alcohol results in renal elimination of 90% of the administered dose. After metabolism, dichlorobenzyl alcohol is excreted in the urine.', 'This pharmacokinetic property has not been fully studied.', 'This pharmacokinetic property has not been fully studied.']",['Dichlorobenzyl alcohol is metabolized in the liver to form hippuric acid.'],['This pharmacokinetic property has not been fully studied.']
5684,15685,N-(4-Ethoxy-3-nitrophenyl)acetamide,CCOC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],,,,,,
5685,15686,20-Oxopregn-5-en-3-yl acetate,CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C)C)C,,,,,,
5686,15687,"1,3,6-Trioxocane",C1COCOCCO1,,,,,,
5687,15688,"Aluminum, chlorobis(2-methylpropyl)-",CC(C)C[Al](CC(C)C)Cl,,,,,,
5688,15689,2-Amino-2-thiazoline,C1CSC(=N1)N,,,,,,
5689,15690,"2,4,5,6-Tetrachloropyrimidine",C1(=C(N=C(N=C1Cl)Cl)Cl)Cl,,,,,,
5690,15691,"3,4,5,6-Tetrachlorocyclohexene",C1=CC(C(C(C1Cl)Cl)Cl)Cl,,,,,,
5691,15692,"N,N-Dimethyl-N'-phenylformamidine",CN(C)C=NC1=CC=CC=C1,,,,,,
5692,15693,3-(Methylthio)aniline,CSC1=CC=CC(=C1)N,,,,,,
5693,15694,"6,9,12-Eicosatriensaure",CCCCCCCC=CCC=CCC=CCCCCC(=O)O,,,,,,
5694,15695,"1,3,5-Triphenyl-1,3,5-triazinane-2,4,6-trione",C1=CC=C(C=C1)N2C(=O)N(C(=O)N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5695,15696,"N-(1,7-dichloro-9-oxofluoren-4-yl)acetamide",CC(=O)NC1=C2C3=C(C=C(C=C3)Cl)C(=O)C2=C(C=C1)Cl,,,,,,
5696,15697,"2,7-dibromo-9H-fluoren-4-amine",C1C2=C(C=CC(=C2)Br)C3=C1C=C(C=C3N)Br,,,,,,
5697,15698,"Fluoren-9-one, 4-acetamido-2,7-dibromo-",CC(=O)NC1=C2C3=C(C=C(C=C3)Br)C(=O)C2=C(C=C1)Br,,,,,,
5698,15699,"1,6-Pyrenedione",C1=CC2=C3C(=CC=C4C3=C1C=CC4=O)C=CC2=O,,,,,,
5699,15700,Dibenzosuberone oxime,C1CC2=CC=CC=C2C(=NO)C3=CC=CC=C31,,,,,,
5700,15701,CID 15701,C1=CC=C(C=C1)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
5701,15702,Cembrane,CC1CCCC(CCC(CCC(CCC1)C)C(C)C)C,,,,,,
5702,15703,"1,3-Dicarbamoyl-2,4,5,6-tetrachlorobenzene",C1(=C(C(=C(C(=C1Cl)Cl)Cl)C(=O)N)Cl)C(=O)N,,,,,,
5703,15704,CID 15704,C1=CC=C2C(=C1)C=CC(=NN=C3C4=C(C=C(C=C4)N(O)O)C(=CC3=O)S(=O)(=O)[O-])C2=O.[Na+],,,,,,
5704,15705,"N-[6-[2-(5-nitrofuran-2-yl)ethenyl]-1,2,4-triazin-3-yl]acetamide",CC(=O)NC1=NC=C(N=N1)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
5705,15706,Dichloro(ethyl)silane,CC[SiH](Cl)Cl,,,,,,
5706,15707,"1,2,4-Trichlorobutane",C(CCl)C(CCl)Cl,,,,,,
5707,15708,CID 15708,CN1C2=C(N=C1S)N(C(=O)N(C2=O)C)C,,,,,,
5708,15709,CID 15709,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=CC=C3Br,,,,,,
5709,15710,"Thiophene, 2,3,4-trimethyl-",CC1=CSC(=C1C)C,,,,,,
5710,15711,2-Methyltetrahydrothiophene,CC1CCCS1,,,,,,
5711,15712,Octylcyclohexane,CCCCCCCCC1CCCCC1,,,,,,
5712,15713,Decylcyclohexane,CCCCCCCCCCC1CCCCC1,,,,,,
5713,15714,Dodecylcyclohexane,CCCCCCCCCCCCC1CCCCC1,,,,,,
5714,15715,Tetradecylcyclohexane,CCCCCCCCCCCCCCC1CCCCC1,,,,,,
5715,15716,"Cyclohexene, 1,3,5-trimethyl-",CC1CC(C=C(C1)C)C,,,,,,
5716,15717,Allyl phenylacetate,C=CCOC(=O)CC1=CC=CC=C1,,,,,,
5717,15718,4-Tert-butylphenoxyacetic acid,CC(C)(C)C1=CC=C(C=C1)OCC(=O)O,,,,,,
5718,15719,3-Methoxyphenylacetic acid,COC1=CC=CC(=C1)CC(=O)O,,,,,,
5719,15720,(4-Nitrophenoxy)acetic acid,C1=CC(=CC=C1[N+](=O)[O-])OCC(=O)O,,,,,,
5720,15721,"3-Allyl-8-propionyl-3,8-diazabicyclo(3.2.1)octane",CCC(=O)N1C2CCC1CN(C2)CC=C,,,,,,
5721,15722,Azacyclonol hydrochloride,C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O.Cl,,,,,,
5722,15723,Azacyclonol,C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,['Azacyclonol is a known human metabolite of terfenadine.'],
5723,15724,"1-[8-(3-Phenylprop-2-enyl)-3,8-diazabicyclo[3.2.1]octan-3-yl]propan-1-one",CCC(=O)N1CC2CCC(C1)N2CC=CC3=CC=CC=C3,,,,,,
5724,15725,"5,6-Dimethyl-2-trifluoromethylbenzimidazole",CC1=CC2=C(C=C1C)N=C(N2)C(F)(F)F,,,,,,
5725,15726,"(6S,11S,14S,16R,17R)-17-acetyl-6-fluoro-11,17-dihydroxy-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one",C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=CC4(C3[C@H](CC2([C@]1(C(=O)C)O)C)O)C)F,,,,,,
5726,15727,"(2,2'-Biindan)-1,1',3,3'-tetrone, 2,2'-diphenyl-",C1=CC=C(C=C1)C2(C(=O)C3=CC=CC=C3C2=O)C4(C(=O)C5=CC=CC=C5C4=O)C6=CC=CC=C6,,,,,,
5727,15728,"3,4-Dichlorobenzyl alcohol",C1=CC(=C(C=C1CO)Cl)Cl,,,,,,
5728,15729,2-Fluoro-7-nitrofluorene,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)F,,,,,,
5729,15730,4-Octylphenol,CCCCCCCCC1=CC=C(C=C1)O,,,"['Non-steroidal compounds with estrogenic activity. (See all compounds classified as Estrogens, Non-Steroidal.)']",,,
5730,15731,"2,2'-Biphenol",C1=CC=C(C(=C1)C2=CC=CC=C2O)O,,,,,,
5731,15732,Popop,C1=CC=C(C=C1)C2=CN=C(O2)C3=CC=C(C=C3)C4=NC=C(O4)C5=CC=CC=C5,,,,,,
5732,15733,Trioctyl phosphate,CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCC,,,,,,
5733,15734,8-Methylcoumarin,CC1=C2C(=CC=C1)C=CC(=O)O2,,,,,,
5734,15735,"4,4'-Methylenebis(N-methylaniline)",CNC1=CC=C(C=C1)CC2=CC=C(C=C2)NC,,,,"[""Studies on the in vivo and in vitro disposition of 4,4'-[14C]-methylenebis(N,N-dimethyl)benzamine (reduced Michler's ketone, RMK) were performed. Osborne-Mendel rats retained, after 24 hr, 78% of a /oral/ dose of [14C]RMK. At 24 hr after an i.p. dose, fat, liver, and intestine represented major sites for deposition of radioactivity. ...""]","[""... The major urinary metabolite of 4,4'-[14C]-methylenebis(N,N-dimethyl)benzamine (RMK), representing 36% of the total radioactivity recovered in the urine /of rats/, was N,N'-diacetyl-4,4'-(hydroxymethylene)dianiline. In vitro microsomal metabolism of RMK involved demethylation. Products included N,N-dimethyl-4,4'-methylenedianiline, N,N'-dimethyl-4,4'-methylenedianiline, N-methyl-4,4'-methylenedianiline, and 4,4'-methylenedianiline, representing 44.7, 5.3, 11.8, and 6.9%, respectively, of the total radioactivity recovered from the reaction mixture. ...""]",
5735,15736,beta-(p-Bromobenzhydryloxy)ethyldimethylamine hydrochloride,C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br.[Cl-],,,,,,
5736,15737,"(5Z,8Z,11Z,14Z)-Ethyl icosa-5,8,11,14-tetraenoate",CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC,,,,,,
5737,15738,3-Bromopentane,CCC(CC)Br,,,,,,
5738,15739,Dibutyl hydrogen phosphite,CCCCOP(O)OCCCC,,,,,,
5739,15740,Dipropoxyphosphinylradical,CCCOP(=O)OCCC,,,,,,
5740,15741,CID 15741,C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)[NH3+].C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
5741,15742,1-Ethyl-2-phenylbenzene,CCC1=CC=CC=C1C2=CC=CC=C2,,,,,,
5742,15743,Dihexadecyl dimethyl ammonium chloride,CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC.[Cl-],,,,,,
5743,15744,Dimethyldipalmitylammonium,CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC,,,,,,
5744,15745,"2,2'-Difluorodiethylamine hydrobromide",C(CF)[NH2+]CCF.[Br-],,,,,,
5745,15746,Bis(2-fluoroethyl)amine,C(CF)NCCF,,,,,,
5746,15747,"1,1,1,2,2-Pentafluoropropane",CC(C(F)(F)F)(F)F,,,,,,
5747,15748,5-fluoro-3-(1-methylpyrrolidin-2-yl)-1H-indole,CN1CCCC1C2=CNC3=C2C=C(C=C3)F,,,,,,
5748,15749,1-Isopropyl-4-nitrobenzene,CC(C)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
5749,15750,"3-Methyl-2,4-dinitrophenol",CC1=C(C=CC(=C1[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
5750,15751,"4-Methyl-2,6-bis(1-phenylethyl)phenol",CC1=CC(=C(C(=C1)C(C)C2=CC=CC=C2)O)C(C)C3=CC=CC=C3,,,,,,
5751,15752,"2-Bromo-4,6-dinitroaniline",C1=C(C=C(C(=C1[N+](=O)[O-])N)Br)[N+](=O)[O-],,,,,,
5752,15753,Bis(4-nitrophenyl)methane,C1=CC(=CC=C1CC2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5753,15754,"1-Naphthol, 1,2,3,4-tetrahydro-1-(p-(2-(diethylamino)ethoxy)phenyl)-2-phenyl-, hydrochloride",CC[NH+](CC)CCOC1=CC=C(C=C1)C2(C(CCC3=CC=CC=C32)C4=CC=CC=C4)O.[Cl-],,,,,,
5754,15755,"1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenyl-3,4-dihydro-2H-naphthalen-1-ol",CCN(CC)CCOC1=CC=C(C=C1)C2(C(CCC3=CC=CC=C32)C4=CC=CC=C4)O,,,,,,
5755,15756,"3-(3-Cyclohexenyl)-2,4-dioxaspiro(5.5)undec-8-ene",C1CC=CC(C1)C2OCC3(CCC=CC3)CO2,,,,,,
5756,15757,"2,4,2',4'-Tetranitrobiphenyl",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5757,15758,5-Chlorouracil,C1=C(C(=O)NC(=O)N1)Cl,,,,,,
5758,15759,2-Propylaniline,CCCC1=CC=CC=C1N,,,,,,
5759,15760,5-Methyltryptamine,CC1=CC2=C(C=C1)NC=C2CCN,,,,,,
5760,15761,2-Phenylpropanenitrile,CC(C#N)C1=CC=CC=C1,,,,,,
5761,15762,"2-N-butan-2-yl-6-chloro-4-N-(3-methoxypropyl)-1,3,5-triazine-2,4-diamine",CCC(C)NC1=NC(=NC(=N1)NCCCOC)Cl,,,,,,
5762,15763,Ethiazide,CCC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,,,,,,
5763,15764,"7-Chloro-1,3,4,5-tetrahydro-5-phenyl-2H-1,4-benzodiazepin-2-one",C1C(=O)NC2=C(C=C(C=C2)Cl)C(N1)C3=CC=CC=C3,,,,,,
5764,15765,2-Amino-6-methylpyridine,CC1=NC(=CC=C1)N,,,,,,
5765,15766,Pentachlorothioanisole,CSC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,"['1-DAY-OLD WHITE LEGHORN CHICKS FED GRADED LEVELS (0-1000 PPM) OF PENTACHLORONITROBENZENE LESS THAN OR EQUAL TO 8 WK. BIOACCUMULATION OF PENTACHLORONITROBENZENE OR ITS METABOLITES, PENTACHLOROANILINE & PENTACHLOROPHENYL METHYL SULFIDE IN TISSUES OCCURRED IN TRACE OR LOW CONCN.', 'PENTACHLOROTHIOANISOLE WAS IDENTIFIED IN LIVER OF RATS AFTER ADMIN OF HEXACHLOROBENZENE. FOLLOWING ADMIN OF SULFOXIDE & SULFONE OF PENTACHLOROTHIOANISOLE, IT & ITS METABOLITES WERE DETECTED IN EXCRETA, NO EVIDENCE WAS OBTAINED THAT PENTACHLOROTHIOANISOLE WAS EXCRETED UNCHANGED.', 'TISSUE DISTRIBUTION OF METHYL PENTACHLOROPHENYL SULFIDE WAS STUDIED IN PREGNANT C57B1/6 MICE.', 'METHYL PENTACHLOROPHENYL SULFIDE, METABOLITE OF PENTACHLORONITROBENZENE, WAS FOUND IN TISSUE OF TREATED ANIMALS (RAT, DOG, COW), WHICH TOGETHER WITH ABSENCE OF PENTACHLORONITROBENZENE INDICATED RAPID METABOLISM OF LATTER.', 'For more Absorption, Distribution and Excretion (Complete) data for PENTACHLOROPHENYL METHYL SULFIDE (9 total), please visit the HSDB record page.']","['PENTACHLOROTHIOANISOLE IS A METABOLITE OF PESTICIDES PENTACHLORONITROBENZENE & HEXACHLOROBENZENE.', 'PURE PENTACHLORONITROBENZENE ADMIN TO RHESUS MONKEYS AS SINGLE ORAL DOSES OF 0.5, 2 OR 91 MG/KG & IN 70-DAY FEEDING STUDY @ 2 PPM IN DAILY DIET. PENTACHLOROTHIOANISOLE WAS A MAJOR METABOLITE.']",
5766,15767,Pentachloroanisole,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,"['RELATIVE TISSUE CONCN & TOTAL BIRD LEVELS OF CHLOROANISOLES IN COMMERCIAL BROILERS REARED ON LITTER REPORTED. ALTHOUGH HIGHEST CONCN OCCURRED IN BONE & ADIPOSE TISSUE, GREATEST CONTRIBUTION TO WHOLE BIRD LEVELS IN EDIBLE TISSUE WAS PREDOMINANTLY PENTACHLOROANISOLE.', 'PENTACHLOROANISOLE (PCA) TAKEN UP RAPIDLY BY RAINBOW TROUT @ 0.025 MG/L IN WATER. AFTER 24 HR, CONCN IN LIVER, BLOOD, FAT & MUSCLE WERE 16, 6.5, 80, & 1.0 UG/G, RESPECTIVELY; T/2 OF 6.9, 6.3, 23, & 6.3 DAYS, RESPECTIVELY.', 'Tissue distribution, excretion and metabolism studies of pentachloroanisole (PCA), an environmental metabolite of pentachlorophenol (PCP), were conducted in the beagle dog and miniature pig following single oral doses (25 mg/kg) of radiolabelled PCA. PCA was readily demethylated by both species, with a half-life of 5-8 min. The resultant PCP was the major metabolite in dogs and pigs. In the dog, an average of 21.9% of the administered radiolabel was excreted in the urine and 62.3% in the feces during a 7 day period. Of the tissues analyzed, an average of 3.2% of the radiolabel remained in the liver, and blood and muscle accounted for averages of 3.0 and 2.3%, respectively, of the dose. Free and conjugated PCP were found in the urine of dogs; no PCA or tetrachlorohydroquinone (TCH) were found. In dog feces, PCP and a trace of polar material were observed; no PCA was excreted in dog feces. In the miniature pig, an average of 25.8% of the administered radiolabel was excreted in the urine and 32.0% in the feces during a 2-wk period. An average of 4.4% of the radiolabel was found in the liver, 8.8% in the blood, 7.1% in the muscle and 6.4% in the fat. In pig urine, PCP and conjugated PCP were the only metabolites observed; no PCA or TCH was found. Pig feces contained a trace of unchanged PCA; PCP and polar metabolites were also found. Since pig tissues retained a sizeable residue 2 wk after a single dose of PCA, various agents were used in an attempt to decrease the tissue level of radiolabel in pigs; anion exchange resin was found to be the most effective.', 'Toxicokinetics of pentachloroanisole (PCA) were studied in F344 rat and B6C3F1 mouse of both sexes by gavage at doses of 10, 20 and 40 mg/kg and by iv at 10 mg/kg. PCA was rapidly demethylated to pentachlorophenol (PCP) in both rat and mouse and the resulting PCP plasma concentrations were much higher than that of parent PCA due to the much smaller apparent volume of distribution of PCP. Peak plasma concentrations of PCA and PCP increased with dose in both rat and mouse. Bioavailability of PCA was low in both rat and mouse and was sex independent. The high plasma concentrations and relatively long biological half-life of PCP in both species after both iv and oral dosing with PCA indicate possible bioaccumulation of PCP upon multiple oral administrations of PCA.', 'Male Sprague-Dawley rats and New Zealand White rabbits were admin (14)C-labelled pentachloroanisole (PCA) in corn oil by gavage as single doses of 25 mg/kg and were then placed in individual metabolism cages for as long as 4 days. Peak blood level of radioactivity occurred 6 hr after admin of the dose to rats and between 3 and 4 hr in rabbits; the blood elimination half-life ranged from 8 to 15 hr in rats and averaged 6 hr in rabbits. Rats excreted an average of 54.2% of the admin radiolabel in the urine and 32.4% in the feces during the 96 hr following the dose; rabbits excreted an average of 84.2 and 13.1% of the radiolabel in the urine and faces, respectively, during this time. Examination of the metabolites in the rat showed that 60% of the urinary radioactivity was attributable to tetrachlorohydroquinone (TCH), 3% to free pentachlorophenol (PCP) and 29% to conjugated PCP; fecal metabolites were PCP (85.7%), TCH (4.3%) and polar metabolites (10.0%). In the rabbit, 58% of the urinary radioactivity was attributable to TCH, 8% to free PCP and 34% to conjugated PCP. Fecal metabolites consisted of PCP and conjugated material']","['PENTACHLOROPHENOL WAS METHYLATED INTO PENTACHLOROANISOLE BY TRICHODERMA VIRGATUM IN LIQUID CULTURES.', 'DURING THE DECOMPOSITION OF SODIUM PENTACHLOROPHENOLATE BY ALCALIGENES EUTROPHUS, AEROMONAS HYDROPHILIA VARIETY HYDROPHILIA AND VARIETY ANAEROGENES, AZOTOBACTER CHROOCOCCUM, AZOTOBACTER VINELANDII, FLAVOBACTERIUM AQUATILE, PSEUDOMONAS FLUORESCENS, CYTOPHAGA JOHNSONAE, CORYNEBACTERIUM AQUATICUM, BREVIBACTERIUM TESTACEUUM, AND ARTHROBACTER GLOBIFORMIS THE FOLLOWING /METABOLITES WERE IDENTIFIED/: PENTACHLOROANISOLE, 2,3,4,5-TETRACHLOROANISOLE, 2,3,4,6-TETRACHLOROANISOLE, 2,3,5,6-TETRACHLOROANISOLE, 2,3,4,5-TETRACHLOROPHENOL, 2,3,5,6-TETRACHLOROPHENOL, TETRACHLORORESORCINOL, TETRACHLOROHYDROQUINONE, AND TETRACHLOROACETECHOL DIACETATE, THE PRINCIPAL METABOLITE BEING PENTACHLOROPHENOL ACETATE. UP TO 6.2% OF THE SODIUM PENTACHLOROPHENOLATE WAS RECOVERED AS PENTCHLOROPHENOL ACETATE, WHILE ALL OTHER METABOLITES WERE FOUND IN AMT LESS THAN 1% OF STARTING CMPD.', 'Spent sawdust cultures of the Shiitake mushroom (Lentinus edodes) metabolized pentachlorophenol in soil to a significant (p<0.05) extent with 60.5, 57.3 and 44.4 % disappearance recorded for strains LE2 866 and R26 respectively. Addition of H202 markedly enhanced pentachlorophenol metabolism. Analysis of metabolites by GC/MS showed that pentachloroanisole was a metabolic product. These results suggest that there is potential for commercial application ln bioremediation.']",
5767,15768,"1,5-Dichloronaphthalene",C1=CC2=C(C=CC=C2Cl)C(=C1)Cl,,,,,,
5768,15769,"1,4-Dichloronaphthalene",C1=CC=C2C(=C1)C(=CC=C2Cl)Cl,,,,,,
5769,15770,Ethoxydimethylphenylsilane,CCO[Si](C)(C)C1=CC=CC=C1,,,,,,
5770,15771,Methoxytrimethylsilane,CO[Si](C)(C)C,,,,,,
5771,15772,Ethoxytrimethylsilane,CCO[Si](C)(C)C,,,,,,
5772,15773,Fluorophenothiazine dihydrochloride,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCOCCO.Cl.Cl,,,,,,
5773,15774,2-[2-[4-[3-[2-(Trifluoromethyl)-10H-phenothiazine-10-yl]propyl]piperazino]ethoxy]ethanol,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCOCCO,,,,,,
5774,15775,Bis(4-fluorophenyl)iodonium chloride,C1=CC(=CC=C1F)[I+]C2=CC=C(C=C2)F.[Cl-],,,,,,
5775,15776,Bis(4-fluorophenyl)iodonium,C1=CC(=CC=C1F)[I+]C2=CC=C(C=C2)F,,,,,,
5776,15777,Phosphonic acid ethylmethyl ester,CCOP(=O)OC,,,,,,
5777,15778,Isopropyl methylphosphonate,CC(C)OP(=O)(C)O,,,,,,
5778,15779,Dioctyl methylphosphonate,CCCCCCCCOP(=O)(C)OCCCCCCCC,,,,,,
5779,15780,Benzylchlorodimethylsilane,C[Si](C)(CC1=CC=CC=C1)Cl,,,,,,
5780,15781,"1-(3,4-Dimethoxyphenyl)propan-1-one",CCC(=O)C1=CC(=C(C=C1)OC)OC,,,,,,
5781,15782,1-(4-Hydroxy-3-methoxyphenyl)propan-1-one,CCC(=O)C1=CC(=C(C=C1)O)OC,,,,,,
5782,15783,Tetrafluoroterephthalonitrile,C(#N)C1=C(C(=C(C(=C1F)F)C#N)F)F,,,,,,
5783,15784,CID 15784,C1=CC=C(C(=C1)C(=O)[O-])N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
5784,15785,"o-(2-Hydroxy-3,6-disulfo-1-naphthylazo)benzoic acid",C1=CC=C(C(=C1)C(=O)O)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
5785,15786,1-Chloro-4-(4-nitrophenoxy)benzene,C1=CC(=CC=C1[N+](=O)[O-])OC2=CC=C(C=C2)Cl,,,,,,
5786,15787,Nitrofen,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Chemicals used to destroy pests of any sort. The concept includes fungicides (FUNGICIDES, INDUSTRIAL); INSECTICIDES; RODENTICIDES; etc. (See all compounds classified as Pesticides.)']","['... NO RESIDUES OF NITROFEN & ITS METABOLITE ... WERE FOUND IN MILK, URINE, OR FECES OF A COW FED 5 PPM OF THE HERBICIDE.', '... STUDIED /NITROFEN/ ABSORPTION & TRANSLOCATION USING RAPE, REDROOT PIGWEED, & GREEN FOXTAIL. ... FOUND ONLY SLIGHT TRANSLOCATION OF FOLIARLY APPLIED (14)C-NITROFEN & DIFFERENT ANATOMICAL EFFECTS BETWEEN THE WEEDS & RAPE. ... NITROFEN HAD ALMOST NO EFFECT ON TOPS OF BARNYARD GRASS WHEN HERBICIDE WAS APPLIED TO SOIL ONLY UNDER WEED SEEDS. LOW TRANSLOCATION & LACK OF LIGHT UNDER SOIL MAY BE REASONS FOR THIS ... WEEDS ABSORB THE CHEM DURING THEIR GERMINATION & ELONGATION THROUGH TREATED SOILS, & AFTER EXPOSURE TO SUNLIGHT THEY DIE.', 'NOT READILY ABSORBED FROM SOIL INTO PLANTS. ... NOT SIGNIFICANTLY TRANSLOCATED IN CROPS OR WEEDS.', '(14)C Labelled nitrofen was administered orally to a sheep at a dose of 40 mg/kg body weight. After 99 hr, 76.2% of the applied dose was accounted for in the excreta. After 100 hr, radioactivity was highest in fat (23 mg/kg); the liver, thyroid, mammary gland, adrenal gland, kidney, lung, muscle, skin and spleen contained levels of 1-3 mg/kg.', 'Oral exposure of pregnant Long Evans rats on day 11 of gestation to nitrofen which was uniformly labeled with (14)C in the nitrophenyl ring, resulted in the accumulation of radioactivity in maternal fat with lesser amounts found in liver, kidney, other tissues, and in the embryonic compartment. The peak concn of radioactivity occurred 7-9 hr after dosing and the half-life of the label in maternal blood was approx 8 days. In the embryonic compartment, radioactivity was first detected at 2 hr after dosing, peaked at 4-6 hr, and declined to half of that initially seen by 24 hr.']","['THE FATE OF /LABELED/ NITROFEN IN ... PLANTS/ ... WAS STUDIED ... /BY INVESTIGATORS/, WHO REPORTED THAT RAPE ... REDROOT PIGWEED ... & GREEN FOXTAIL ... LEAVES TREATED WITH 2 DROPS OF (14)C-NITROFEN ... UNDER HIGH LIGHT CONDITIONS, PRODUCED SEVERAL LABELED CMPD OF DIFFERENT MOLECULAR SIZE & CHROMATOGRAPHIC PROPERTIES. THEY THEORIZED THAT AT LEAST 2 OF THESE CMPD WERE LIPID-NITROFEN CONJUGATES OR NITROFEN POLYMERS, WHILE THE OTHERS MIGHT BE FORMED BY CLEAVAGE OF NITROFEN AT THE ETHER LINKAGE. IDENTIFICATION OF THE DERIVATIVES WERE NOT POS ... . ALL RADIOACTIVITY RECOVERED FROM PLANTS GROWN UNDER CONDITIONS OF LOW LIGHT INTENSITY & HIGH TEMP WAS FOUND ONLY IN THE (14)C-NITROFEN PEAK. HOWEVER, 2 RADIOACTIVE CMPD, IN ADDITION TO (14)-C NITROFEN, WERE DETECTED IN PLANT EXTRACTS 2 DAYS AFTER TREATMENT UNDER HIGHER LIGHT INTENSITY & LOWER TEMP. ... /IT WAS/ ... PROPOSED THAT A LIGHT-CONTROLLED BIOCHEM PROCESS APPARENTLY CAUSES (14)-C-NITROFEN TO POLYMERIZE OR ENABLES IT TO COMBINE WITH UNIDENTIFIED CELL LIPIDS.', '... NITROFEN IN FRESH RUMEN FLUID IN VITRO /SHOWED/ ... A METABOLITE RAPIDLY PRODUCED WHICH WAS ... P-AMINOPHENYL 2,4-DICHLOROPHENYL ETHER, A REDUCED COMPD OF NITROFEN.', 'Rat liver homogenates incubated with amino derivatives of nitrofen, an NADPH-generating system and erythrocytes from rats or humans metabolized the amino derivatives to methemoglobin forming metabolites. ... (14)C Labelled nitrofen was administered orally to a sheep at a dose of 40 mg/kg body weight. ... The predominant metabolites were 2,4-dichlorophenyl 4-aminophenyl ether, 2,4-dichloro-5-hydroxyphenyl-4-nitrodiphenyl ether, 2,4-dichlorophenol, 2-chlorophenyl-4-nitrophenyl ether & conjugates.', ""Oral exposure of pregnant Long Evans rats on day 11 of gestation to nitrofen which was uniformly labeled with (14)C in the nitrophenyl ring, resulted in the accumulation of radioactivity in maternal fat with lesser amounts found in liver, kidney, other tissues, and in the embryonic compartment. High performance liquid chromatography of embryo placental extracts revealed 4 metabolites in addition to the parent cmpd: 4'-amino and 4'-acetylamino derivatives plus 2 hydroxylated derivatives. A similar metabolic profiles was observed in maternal blood and liver."", 'For more Metabolism/Metabolites (Complete) data for NITROFEN (6 total), please visit the HSDB record page.']",
5787,15788,Chlornitrofen,C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2Cl)Cl)Cl,,,,,,
5788,15789,Ethacridine lactate,CCOC1=CC2=C(C3=C(C=C(C=C3)N)N=C2C=C1)N.CC(C(=O)O)O,,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
5789,15790,Heptadecanamine hydrochloride,CCCCCCCCCCCCCCCCC[NH3+].[Cl-],,,,,,
5790,15791,Heptadecylamine,CCCCCCCCCCCCCCCCCN,,,,,,
5791,15792,"1-Octadecanamine, hydrochloride",CCCCCCCCCCCCCCCCCC[NH3+].[Cl-],,,,,,
5792,15793,Octadecylamine,CCCCCCCCCCCCCCCCCCN,,,,,,
5793,15794,N-(3-Hydroxy-2-fluorenyl)acetamide,CC(=O)NC1=C(C=C2C(=C1)CC3=CC=CC=C32)O,,,,,,
5794,15795,Agn-PC-0jkcic,CCOC(=O)C1(C=CCN(C=C1C)C)C2=CC=CC=C2,,,,,,
5795,15796,"Methane, fluorotrinitro-",C([N+](=O)[O-])([N+](=O)[O-])([N+](=O)[O-])F,,,,,,
5796,15797,Octabenzone,CCCCCCCCOC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,,,,['18 male albino rats (3 groups of six rats each) were fed with a control diet and one containing 12500 or 50000 ppm of unlabelled product for a period over 35 days. /Test chemical/ is weakly absorbed after oral administration. Up to 90% were recovered unchanged from the feces. 10% were excreted as a glucuronide conjugate in the urine. The total recovery of 100% of the test article indicates that the product is not accumulated in the body.'],['18 male albino rats (3 groups of six rats each) were fed with a control diet and one containing 12500 or 50000 ppm of unlabelled product for a period over 35 days. ... 10% were excreted as a glucuronide conjugate in the urine.'],
5797,15798,Tris(carbamoylmethyl) isocyanurate,C(C(=O)N)N1C(=O)N(C(=O)N(C1=O)CC(=O)N)CC(=O)N,,,,,,
5798,15799,3-Benzoylcoumarin,C1=CC=C(C=C1)C(=O)C2=CC3=CC=CC=C3OC2=O,,,,,,
5799,15800,Ethyl coumarin-3-carboxylate,CCOC(=O)C1=CC2=CC=CC=C2OC1=O,,,,,,
5800,15801,CID 15801,CCCCCCCCC=CCCCCCCCCOS(=O)(=O)[O-].[Na+],,,,,,
5801,15802,Octadec-9-en-1-yl hydrogen sulfate,CCCCCCCCC=CCCCCCCCCOS(=O)(=O)O,,,,,,
5802,15803,CID 15803,CCCCCCCCCCCCOC(=O)CS(=O)(=O)[O-].[Na+],,,,,,
5803,15804,"Acetic acid, sulfo-, 1-dodecyl ester",CCCCCCCCCCCCOC(=O)CS(=O)(=O)O,,,,,,
5804,15805,Nafoxidine hydrochloride,COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5.Cl,,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)']",,,
5805,15806,3-Hydroxy-3-phenylindolin-2-one,C1=CC=C(C=C1)C2(C3=CC=CC=C3NC2=O)O,,,,,,
5806,15807,2-Ethylbenzimidazole,CCC1=NC2=CC=CC=C2N1,,,,,,
5807,15808,"2,4-DI-Sec-butylphenol",CCC(C)C1=CC(=C(C=C1)O)C(C)CC,,,,,,
5808,15809,4-Nitrothiophenol,C1=CC(=CC=C1[N+](=O)[O-])S,,,,,,
5809,15810,Benzoyl sulfide,C1=CC=C(C=C1)C(=O)SC(=O)C2=CC=CC=C2,,,,,,
5810,15811,alpha-(1-(1-Methylhydrazino)ethyl)benzyl alcohol hydrochloride,CC(C(C1=CC=CC=C1)O)[NH+](C)N.[Cl-],,,,,,
5811,15812,2-[Amino(methyl)amino]-1-phenylpropan-1-ol,CC(C(C1=CC=CC=C1)O)N(C)N,,,,,,
5812,15813,"1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, N-oxide, (R-(R*,R*))-",C[N+]1(CCC2=CC3=C(C(=C2[C@@H]1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3)[O-],,,,,,
5813,15814,Bis(ethoxythiocarbonyl) tetrasulfide,CCOC(=S)SSSSC(=S)OCC,,,,,,
5814,15815,Bisethylxanthate trisulfide,CCOC(=S)SSSC(=S)OCC,,,,,,
5815,15816,Undecanedioic acid,C(CCCCC(=O)O)CCCCC(=O)O,,,,,,
5816,15817,N-(Butoxymethyl)acrylamide,CCCCOCNC(=O)C=C,,,,,,
5817,15818,"5alpha-Androstane-3alpha,17beta-diol",C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)O,,,,,,
5818,15819,"6-Benzyl-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)CC2=NC(=NC(=N2)N)N,,,,,,
5819,15820,"2-Amino-4,6-dimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)N)C,,,,,,
5820,15821,"2-Amino-4-methyl-6-phenyl-1,3,5-triazine",CC1=NC(=NC(=N1)N)C2=CC=CC=C2,,,,,,
5821,15822,"4-Phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC=N2)N,,,,,,
5822,15823,"4-(Chloromethyl)-6-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC(=N2)CCl)N,,,,,,
5823,15824,"4,5-Dihydroxy-1,3-bis(hydroxymethyl)imidazolidin-2-one",C(N1C(C(N(C1=O)CO)O)O)O,,,,,,
5824,15825,"1-Phenylpropane-1,2-diol",CC(C(C1=CC=CC=C1)O)O,,,,,,
5825,15826,"3-[2-[[3-(2-carboxyethyl)-5-[[(2S)-3-ethyl-4-methyl-5-oxo-1,2-dihydropyrrol-2-yl]methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[[(2S)-4-ethyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl]methyl]-4-methylpyrrol-3-yl]propanoic acid",CCC1=C(C(=O)N[C@H]1CC2=C(C(=C(N2)C=C3C(=C(C(=N3)C[C@H]4C(=C(C(=O)N4)CC)C)C)CCC(=O)O)CCC(=O)O)C)C,,,,,,
5826,15827,5-Methylhexanal,CC(C)CCCC=O,,,,,,
5827,15828,1-(Benzyloxy)-2-methoxy-4-(2-nitrovinyl)benzene,COC1=C(C=CC(=C1)C=C[N+](=O)[O-])OCC2=CC=CC=C2,,,,,,
5828,15829,Tritac,CC(COCC1=C(C=CC(=C1Cl)Cl)Cl)O,,,,,,
5829,15830,Ammonium Benzoate,C1=CC=C(C=C1)C(=O)[O-].[NH4+],,,,,,
5830,15831,"3-Buten-2-one, 4,4-diphenyl-1-piperidino-",C1CCN(CC1)CC(=O)C=C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5831,15832,CID 15832,C1CCN(CC1)CC(=O)C=C(C2=CC=CC=C2)C3=CC=CS3,,,,,,
5832,15833,Cinnamyl guanidine,C1=CC=C(C=C1)C=CCN=C(N)N,,,,,,
5833,15834,Prop-2-enyl 3-phenylprop-2-enoate,C=CCOC(=O)C=CC1=CC=CC=C1,,,,,,
5834,15835,"2-Propenoic acid, 3-(4-methylphenyl)-",CC1=CC=C(C=C1)C=CC(=O)O,,,,,,
5835,15836,CID 15836,CC1=NC(=C2C=CN=C2N1)NCC3=CC=CC=C3,,,,,,
5836,15837,"3-Buten-2-one, 1-(diethylamino)-4,4-diphenyl-",CCN(CC)CC(=O)C=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5837,15838,CID 15838,C1COCCN1CC(=O)C=C(C2=CC=CC=C2)C3=CC=CS3,,,,,,
5838,15839,Methylisopropoxyphosphorylthiocholine iodide,CC(C)OP(=O)(C)SCC[N+](C)(C)C.[I-],,,,,,
5839,15840,"Ethanaminium, N,N,N-trimethyl-2-((methyl(1-methylethoxy)phosphinyl)thio)-",CC(C)OP(=O)(C)SCC[N+](C)(C)C,,,,,,
5840,15841,[1-[4-(Dicyanomethyldiazenyl)phenyl]ethylideneamino]urea,CC(=NNC(=O)N)C1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
5841,15842,Benzylbromomalononitrile,C1=CC=C(C=C1)C(C(C#N)C#N)Br,,,,,,
5842,15843,Bromo(p-chlorobenzyl)malononitrile,C1=CC(=CC=C1C(C(C#N)C#N)Br)Cl,,,,,,
5843,15844,((p-Ethoxyphenyl)azo)methylmalononitrile,CCOC1=CC=C(C=C1)N=NCC(C#N)C#N,,,,,,
5844,15845,((p-Ethoxyphenyl)azo)ethylmalononitrile,CCOC1=CC=C(C=C1)N=NCCC(C#N)C#N,,,,,,
5845,15846,Benzylmalononitrile,C1=CC=C(C=C1)CC(C#N)C#N,,,,,,
5846,15847,4-Chlorobenzylidenemalononitrile,C1=CC(=CC=C1C=C(C#N)C#N)Cl,,,,,,
5847,15848,((p-Acetylphenyl)azo)malononitrile,CC(=O)C1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
5848,15849,CID 15849,CC(=NO)C1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
5849,15850,Clomethiazole edisilate,CC1=C(SC=N1)CCCl.C(CS(=O)(=O)O)S(=O)(=O)O,,,,,,
5850,15851,Ketamine hydrochloride,CNC1(CCCCC1=O)C2=CC=CC=C2Cl.Cl,,,"['Intravenous anesthetics that induce a state of sedation, immobility, amnesia, and marked analgesia. Subjects may experience a strong feeling of dissociation from the environment. The condition produced is similar to NEUROLEPTANALGESIA, but is brought about by the administration of a single drug. (From Gilman et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) (See all compounds classified as Anesthetics, Dissociative.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)']",,,
5851,15852,Dibutadiamin dihydrochloride,CC(C)(C)[NH2+]CCCC[NH3+].[Cl-].[Cl-],,,,,,
5852,15853,Dibutadiamine,CC(C)(C)NCCCCN,,,,,,
5853,15854,Margaspidin,CCCC(=O)C1=C(C(=C(C(=C1O)CC2=C(C(=C(C(=C2O)C(=O)CCC)O)C)OC)O)C)O,,,,,,
5854,15855,"(2-(alpha-(alpha,alpha,alpha-Trifluoro-m-tolyl)benzyloxy)ethyl)trimethylammonium iodide",C[N+](C)(C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)C(F)(F)F.[I-],,,,,,
5855,15856,Trimethyl[2-[[alpha-phenyl-3-(trifluoromethyl)benzyl]oxy]ethyl]aminium,C[N+](C)(C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)C(F)(F)F,,,,,,
5856,15857,"2,4-Dinitro-N-(3-(trifluoromethyl)phenyl)aniline",C1=CC(=CC(=C1)NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])C(F)(F)F,,,,,,
5857,15858,Cetamiphen,CCC(C1=CC=CC=C1)C(=O)O.C(CO)N,,,,,,
5858,15859,3-Chloro-2-chloromethyl-1-propene,C=C(CCl)CCl,,,,,,
5859,15860,CID 15860,CC1C2=CC(=C(C=C2CC[NH+]1CCC3=CC=C(C=C3)Cl)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
5860,15861,"2-[2-(4-Chlorophenyl)ethyl]-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline",CC1C2=CC(=C(C=C2CCN1CCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
5861,15862,"2-Propenoic acid, 3-(5-nitro-2-furanyl)-, ethyl ester",CCOC(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
5862,15863,3-(5-Nitrofuran-2-yl)prop-2-enal,C1=C(OC(=C1)[N+](=O)[O-])C=CC=O,,,,,,
5863,15864,Methyl 3-(5-nitrofuran-2-yl)prop-2-enoate,COC(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
5864,15865,Dimethylbenzylammonium chloride,C[NH+](C)CC1=CC=CC=C1.[Cl-],,,,,,
5865,15866,"Magnesium 9,10-epoxyoctadecanoate",CCCCCCCCCCC1C(O1)CCCCCC(=O)[O-].CCCCCCCCC1C(O1)CCCCCCCC(=O)[O-].[Mg+2],,,,,,
5866,15867,"trans-7,8-Epoxystearic acid",CCCCCCCCCCC1C(O1)CCCCCC(=O)O,,,,,,
5867,15868,"9,10-Epoxystearic acid",CCCCCCCCC1C(O1)CCCCCCCC(=O)O,,,,,,
5868,15869,"1,4-Bicyclo(2.2.2)octanebis(methylamine), N,N'-bis(2-chlorobenzyl)-, dihydrochloride",C1CC2(CCC1(CC2)C[NH2+]CC3=CC=CC=C3Cl)C[NH2+]CC4=CC=CC=C4Cl.[Cl-].[Cl-],,,,,,
5869,15870,1-(2-chlorophenyl)-N-[[4-[[(2-chlorophenyl)methylamino]methyl]-1-bicyclo[2.2.2]octanyl]methyl]methanamine,C1CC2(CCC1(CC2)CNCC3=CC=CC=C3Cl)CNCC4=CC=CC=C4Cl,,,,,,
5870,15871,"2-(Diethylamino)butyric acid 2,6-xylyl ester hydrochloride",CCC(C(=O)OC1=C(C=CC=C1C)C)[NH+](CC)CC.[Cl-],,,,,,
5871,15872,"(2,6-Dimethylphenyl) 2-(diethylamino)butanoate",CCC(C(=O)OC1=C(C=CC=C1C)C)N(CC)CC,,,,,,
5872,15873,"N,N-Diethylglycine 2,6-diisopropylphenyl ester hydrochloride",CC[NH+](CC)CC(=O)OC1=C(C=CC=C1C(C)C)C(C)C.[Cl-],,,,,,
5873,15874,"(Diethylamino)acetic acid 2,6-diisopropylphenyl ester",CCN(CC)CC(=O)OC1=C(C=CC=C1C(C)C)C(C)C,,,,,,
5874,15875,3-Cyanobenzoic acid,C1=CC(=CC(=C1)C(=O)O)C#N,,,,,,
5875,15876,3-Nitrophenylacetic acid,C1=CC(=CC(=C1)[N+](=O)[O-])CC(=O)O,,,,,,
5876,15877,2-Methyl-1-butanethiol,CCC(C)CS,,,,,,
5877,15878,(Indan-5-yloxy)-acetic acid,C1CC2=C(C1)C=C(C=C2)OCC(=O)O,,,,,,
5878,15879,3-Chlorophenylacetic acid,C1=CC(=CC(=C1)Cl)CC(=O)O,,,,,,
5879,15880,4-Chlorophenylacetic acid,C1=CC(=CC=C1CC(=O)O)Cl,,,,,,
5880,15881,4-Hydroxyphenoxyacetic acid,C1=CC(=CC=C1O)OCC(=O)O,,,,,,
5881,15882,(2-Methoxyphenoxy)acetic acid,COC1=CC=CC=C1OCC(=O)O,,,,,,
5882,15883,(2-Nitrophenoxy)acetic acid,C1=CC=C(C(=C1)[N+](=O)[O-])OCC(=O)O,,,,,,
5883,15884,"2-tert-Butyl-4,6-dimethylphenol",CC1=CC(=C(C(=C1)C(C)(C)C)O)C,,,,,,
5884,15885,1-Methoxy-4-(methylthio)benzene,COC1=CC=C(C=C1)SC,,,,,,
5885,15886,N-amino-4-[carboxy(methyl)amino]benzenesulfonimidic acid,CN(C1=CC=C(C=C1)S(=NN)(=O)O)C(=O)O,,,,,,
5886,15887,"Butyrophenone, 4'-fluoro-4-(4-morpholino-4-propionylpiperidino)-, dihydrochloride",CCC(=O)C1(CC[NH+](CC1)CCCC(=O)C2=CC=C(C=C2)F)[NH+]3CCOCC3.[Cl-].[Cl-],,,,,,
5887,15888,1-(4-Fluorophenyl)-4-(4-morpholino-4-propanoyl-1-piperidyl)butan-1-one,CCC(=O)C1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)N3CCOCC3,,,,,,
5888,15889,"(17S)-4-fluoro-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",CC12CCC3C(C1CC[C@@H]2O)CCC4=C3C=CC(=C4F)O,,,,,,
5889,15890,Phenyl(p-tolyl)acetic acid,CC1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)O,,,,,,
5890,15891,Phenyl chloroformate,C1=CC=C(C=C1)OC(=O)Cl,,,,,,
5891,15892,"3,4,5-Trimethoxybenzonitrile",COC1=CC(=CC(=C1OC)OC)C#N,,,,,,
5892,15893,CID 15893,C1=CC(=C(C(=C1)Cl)CON=C([NH3+])N)Cl.[Cl-],,,,,,
5893,15894,"2-[(2,6-Dichlorophenyl)methoxy]guanidine",C1=CC(=C(C(=C1)Cl)CON=C(N)N)Cl,,,,,,
5894,15895,CID 15895,C1CCC(CC1)NS(=O)(=O)[O-].C1=CC=C(C=C1)CCON=C([NH3+])N,,,,,,
5895,15896,N-(2-Phenylethoxy)guanidine,C1=CC=C(C=C1)CCON=C(N)N,,,,,,
5896,15897,Norfenfluramine,CC(CC1=CC(=CC=C1)C(F)(F)F)N,,,"['Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)', 'Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)']",,['Nordexfenfluramine is a known human metabolite of dexfenfluramine.'],
5897,15898,"2-Azetidinone, 3-ethyl-N-methyl-3-phenyl-",CCC1(CN(C1=O)C)C2=CC=CC=C2,,,,,,
5898,15899,tert-Butyl sulfone,CC(C)(C)S(=O)(=O)C(C)(C)C,,,,,,
5899,15900,Dodecyl benzenesulfonate,CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1,,,,,,
5900,15901,"2,5-Dimethyl-3-hexanone",CC(C)CC(=O)C(C)C,,,,,,
5901,15902,Hexachloropropene,C(=C(Cl)Cl)(C(Cl)(Cl)Cl)Cl,,,,,,
5902,15903,"1,5-Hexadiene diepoxide",C1C(O1)CCC2CO2,,,,,,
5903,15904,N-Acetylcaprolactam,CC(=O)N1CCCCCC1=O,,,,,,
5904,15905,2-Chloroethyl methacrylate,CC(=C)C(=O)OCCCl,,,,,,
5905,15906,2-Hydroxyethyl disulfide,C(CSSCCO)O,,,,,,
5906,15907,2-(4-Chlorophenoxy)ethanol,C1=CC(=CC=C1OCCO)Cl,,,,,,
5907,15908,1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide,CCN=C=NCCCN(C)C,,,,,,
5908,15909,4-Phenyl-3-buten-2-one,CC(=O)C=CC1=CC=CC=C1,,,,,,
5909,15910,Chlorothalonil,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)C#N)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)', 'Agents destructive to snails and other mollusks. (See all compounds classified as Molluscacides.)']","['Following administration of 1 mg/kg body weight (14)C chlorothalonil to male Sprague-Dawley rats by endotracheal instillation, gavage or dermal application, less than 6% of the administered dose was recovered in the blood or urine within 48 hr after dosing.', 'In rats, given a single, oral low dose (1.5mg/kg) of chlorothalonil, around 20-22% of the absorbed dose is excreted in bile and around 10% in urine. At higher dose (200 mg/kg) a considerably lower proportion (8%) of the absorbed dose is excreted in bile, indicating that this is a saturable process. These data indicate that overall absorption from the GI tract is in the order of 30-32% of the administered dose. The majority ... is excreted in feces with at least 80% of administered dose excreted by this route within 96 hr. Approximately 90% of the administered dose was excreted within 34-48 hr although excretion was less rapid at doses of 50 mg/kg and above. Highest tissue concentrations were observed in the kidney, approximately 0.1% of the dose. A similar metabolic profile was seen on repeated dosing and there was no evidence of bioaccumulation.', '... Data for the monkey show that, following a single oral dose of 50 mg/kg, 1.8-4.15% of the dose appeared in urine with very low levels of thiol-derived metabolites appearing in urine. Fecal excretion predominated with around 92% of the dose eliminated via this route over 96 hr. Absorption and excretion were rapid and there was no evidence of bioaccumulation.', 'Low levels of /orally administered chlorothalonil to mouse/ were found in the tissues and urinary excretion indicated that at least 10% of the dose was absorbed with the majority (70-80%) of the dose excreted in feces.', 'For more Absorption, Distribution and Excretion (Complete) data for CHLOROTHALONIL (12 total), please visit the HSDB record page.']","['When yeast cells were exposed to TCIN, derivatives formed resembled those formed by reaction of glutathione with TCIN in vitro. Coenzyme A and 2-mercaptoethanol also ... formed derivatives with TCIN in vitro. Infrared spectra and chromatography of the 4 derivatives ... indicated ... 1-4 halogens ... substituted by 2-mercaptoethanol. ... Daconil decomposed in fresh rumen contents with production of two unidentified metabolites.', 'In plants, 4-hydroxy-2,5,6-trichloroisophthalonitrile is found as a metabolite.', 'The metabolism of chlorothalonil was investigated in liver and gill cytosolic and microsomal fractions from channel catfish (Ictalurus punctatus) using HPLC. All fractions catalyzed the metabolism of chlorothalonil to polar metabolites. Chlorothalonil metabolism by cytosolic fractions was reduced markedly when glutathione was omitted from the reaction mixtures. The lack of microsomal metabolism in the presence of either NADPH or an NADPH-regenerating system indicated direct glutathione S-transferase catalyzed conjugation with glutathione without prior oxidation by cytochrome P450. Cytosolic and microsomal glutathione S-transferases from both tissues were also active toward 1-chloro-2,4-dinitrobenzene, a commonly employed reference substrate. In summary, channel catfish detoxified chlorothalonil in vitro by glutathione S-transferase-catalyzed glutathione conjugation in the liver and gill. The present report is the first to confirm microsomal glutathione S-transferase activity toward 1-chloro-2,4-dinitrobenzene in gill and toward chlorothalonil in liver, and also of gill cytosolic glutathione S-transferase activity towards chlorothalonil, in an aquatic species.', 'Male Sprague-Dawley rats were administered, via oral gavage, (14)C-chlorothalonil (purity 99.7%) at a dose level of 200 mg/kg in order to isolate and identify the urinary metabolites. Urine was collected 17, 24 and 48 hr after dosing. Urinary metabolites accounted for 2.4% of the administered dose and, except for 30% of the radiolabel which was non-extractable from the urine, were found to be trimethylthiomonochloro-isophthalonitrile and dimethylthiodichloro-isophthalonitrile. These thiols were excreted in urine both as free thiols and as their methylated derivatives. ...A metabolic pathway /was suggested/ such that hepatic metabolism proceeds through conjugation with GSH followed by enzymatic degradation. The smaller conjugates are then transported via the bloodstream to the kidney, where they are converted to thiol metabolites and excreted in the urine.', 'For more Metabolism/Metabolites (Complete) data for CHLOROTHALONIL (12 total), please visit the HSDB record page.']",
5910,15911,DPPH radical,C1=CC=C(C=C1)[N+](=NC2=C(C=C(C=C2[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])C3=CC=CC=C3,,,,,,
5911,15912,"2,4-Diphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC=N2)C3=CC=CC=C3,,,,,,
5912,15913,Phenyltrimethylammonium hydroxide,C[N+](C)(C)C1=CC=CC=C1.[OH-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
5913,15914,Phenyltrimethylammonium,C[N+](C)(C)C1=CC=CC=C1,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
5914,15915,"2H-Azepin-2-one, 1,3-dihydro-1-(2-diethylaminoethyl)-3,5,7-trimethyl-, hydrochloride",CC[NH+](CC)CCN1C(=CC(=CC(C1=O)C)C)C.[Cl-],,,,,,
5915,15916,"1-[2-(diethylamino)ethyl]-3,5,7-trimethyl-1,3-dihydro-2H-azepin-2-one",CCN(CC)CCN1C(=CC(=CC(C1=O)C)C)C,,,,,,
5916,15917,"Isoquinoline, 1,2,3,4-tetrahydro-2-(4-(p-chlorophenyl)butyl)-6,7-dimethoxy-1-methyl-, oxalate",CC1C2=CC(=C(C=C2CC[NH+]1CCCCC3=CC=C(C=C3)Cl)OC)OC.C(=O)(C(=O)[O-])O,,,,,,
5917,15918,"2-[4-(4-chlorophenyl)butyl]-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinoline",CC1C2=CC(=C(C=C2CCN1CCCCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
5918,15919,"2H-Azepin-2-one, 1,3-dihydro-1-((2-methyl-2-(1-pyrrolidinyl)ethyl)-3,5,7-trimethyl-, hydrochloride",CC1C=C(C=C(N(C1=O)CC(C)[NH+]2CCCC2)C)C.[Cl-],,,,,,
5919,15920,"3,5,7-Trimethyl-1-(2-(1-pyrrolidinyl)propyl)-1,3-dihydro-2H-azepin-2-one",CC1C=C(C=C(N(C1=O)CC(C)N2CCCC2)C)C,,,,,,
5920,15921,"[17-(5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)C)C)C)C(C)C,,,,,,
5921,15922,"N',N'-bis(2-chloroethyl)-3-(furan-2-yl)prop-2-enehydrazide",C1=COC(=C1)C=CC(=O)NN(CCCl)CCCl,,,,,,
5922,15923,"2-Furamide, N,N-bis(2-chloroethyl)-",C1=COC(=C1)C(=O)N(CCCl)CCCl,,,,,,
5923,15924,CID 15924,C1=COC(=C1)C=CC(=O)N(CCCl)CCCl,,,,,,
5924,15925,"2-Furamide, N,N-bis(2-chloroethyl)-5-nitro-",C1=C(OC(=C1)[N+](=O)[O-])C(=O)N(CCCl)CCCl,,,,,,
5925,15926,CID 15926,C1=CC=C(C=C1)C2=NN=C(O2)[NH3+].[Cl-],,,,,,
5926,15927,1-Ethylpyridinium bromide,CC[N+]1=CC=CC=C1.[Br-],,,,,,
5927,15928,1-Ethylpyridin-1-ium,CC[N+]1=CC=CC=C1,,,,,,
5928,15929,CID 15929,CC[SnH](CC)CC.CC(=O)O,,,,,,
5929,15930,"Barbituric acid, 1,3-bis(4-(diethylamino)-2-butynyl)-5-ethyl-5-phenyl-, dihydrochloride",CCC1(C(=O)N(C(=O)N(C1=O)CC#CCN(CC)CC)CC#CCN(CC)CC)C2=CC=CC=C2.Cl.Cl,,,,,,
5930,15931,"1,3-Bis[4-(diethylamino)but-2-ynyl]-5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)N(C(=O)N(C1=O)CC#CCN(CC)CC)CC#CCN(CC)CC)C2=CC=CC=C2,,,,,,
5931,15932,5-Ethyl-5-(4-diethylamino-2-butynyl)barbituric acid hydrochloride,CCC1(C(=O)NC(=O)NC1=O)CC#CC[NH+](CC)CC.[Cl-],,,,,,
5932,15933,"5-[4-(Diethylamino)but-2-ynyl]-5-ethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)NC(=O)NC1=O)CC#CCN(CC)CC,,,,,,
5933,15934,4'-((2-(Diethylamino)ethyl)sulfamoyl)acetanilide hydrochloride,CC[NH+](CC)CCNS(=O)(=O)C1=CC=C(C=C1)NC(=O)C.[Cl-],,,,,,
5934,15935,N-[4-[2-(diethylamino)ethylsulfamoyl]phenyl]acetamide,CCN(CC)CCNS(=O)(=O)C1=CC=C(C=C1)NC(=O)C,,,,,,
5935,15936,4'-((2-Morpholinoethyl)sulfamoyl)acetanilide hydrochloride,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NCCC2C[NH2+]CCO2.[Cl-],,,,,,
5936,15937,N-[4-(2-morpholin-2-ylethylsulfamoyl)phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NCCC2CNCCO2,,,,,,
5937,15938,Paraquat dichloride,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,,"['Animal studies: less than 6 hours; other animal studies have found measurable paraquat 26 days after ingestion;  [TDR, p. 991]']"
5938,15939,Paraquat,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In a fatal case of paraquat poisoning in a pregnant woman, who developed the typical symptoms and signs of paraquat poisoning and at postmortem had the typical lung pathology of paraquat poisoning, the fetal lungs were normal. ...However, ...the details /as reported/ of nine pregnant women who deliberately ingested paraquat, stated that paraquat in one case was concentrated 4-6 times in the fetus. In another of the cases, the amniotic fluid contained paraquat at twice the concentration of that in the maternal blood.', 'Paraquat was poorly absorbed after oral administration to rats, dogs and mice. Once absorbed, paraquat was rapidly distributed to most tissues but especially to lungs and kidneys. Tissues other than lungs did not retain paraquat.', 'In a dermal absorption study with healthy adult male volunteers, 0.3% of the applied (14)C-paraquat dichloride was absorbed through the intact skin (forearms, and back of the hands and lower legs) during the 24-hour exposure period. /Paraquat dichloride/', 'Absorbed paraquat is distributed via the bloodstream to practically all organs and tissues of the body, but no prolonged storage takes place in any tissue. The distribution of paraquat is best described by a three-compartment open model with input to and elimination from the central compartment ... The lung then selectively accumulates paraquat from the plasma, by an energy dependent process.', 'For more Absorption, Distribution and Excretion (Complete) data for Paraquat (28 total), please visit the HSDB record page.']","['Paraquat was not metabolized by rats. After oral administration (gastric intubation) of single doses of paraquat dichloride or dimethylsulfate to Wistar strain male and female rats, most of the administered radioactivity (69-96%) was excreted in feces as unchanged paraquat. After subcutaneous injection of these compounds, unchanged paraquat appeared mostly in urine (73-96% of the administered radioactivity). Paraquat used in this study (radiochemical purity: 99-100%) was labeled with (14)C in the methyl groups. The doses used for gastric intubation ranged from 0.5 to 50 mg/kg and for subcutaneous injection, from 12.5 to 24 mg/kg. Most of the radioactivity was detected in feces within 2-3 days after dosing and in urine, within 1 day after dosing. Following oral administration of paraquat, up to 30% of the dose appeared in feces in a degraded form. This was due to the microbial degradation of paraquat in the gut. That microbial degradation of paraquat occurred in feces was shown in an in vitro experiment in which fecal homogenates were incubated with added paraquat for 24 hours. In that experiment, 40-50% of paraquat was destroyed. However, a similar experiment with sterilized fecal homogenates produced only minor loss (trace amounts) of added paraquat. /Paraquat dichloride/', ""Three Warren hens were given gelatin capsules containing (14)C-ring-labelled paraquat (purity, 99.7%; specific activity, 1.216 x 105 dpm/mg) at a daily dose of 4.52 mg of paraquat ion (0.247 mCi) for 10 days. ...Residues in tissues were generally unchanged paraquat. A small amount of a metabolite, 1-methyl-(4'-pyridyl), was found in the livers and kidneys."", ""An English white nanny goat was dosed with (14)C-ring-labelled paraquat (purity, 99.7%; specific activity, 2.28 x 104 dpm/ug) in the diet at a dose equivalent to 100 ug of paraquat ion/g of diet ... for 7 days. ... Residues in tissues were generally unchanged paraquat. In the liver, small amounts of 4-(1,2-dihydro-1-methyl-2-oxo-4-pyridyl)-1-methyl pyridinium ion and 1-methyl-4-(4'-pyridyl) pyridinium ion were found. The latter compound was also found in peritoneal fat.""]","['Assessment of accumulation of paraquat in the lungs: 3 week inhalation study in rats (15 exposures). ...Lung concentrations in the high dose group peaked on about day 4 (4.71 mg paraquat/l), dropping to about half that concentration with continued dosing. Mean lung weights increased sharply after the fifth exposure in the high dose group to about 170% of controls. The elimination half-life was about 2 days.', '... The concentration-time curve in 15 adult patients (not hemodialyzed) was best described by a bi-exponential curve, with the elimination half-lives of the early and late phase being 5 and 84 hours, respectively.', 'A biexponential body burden curve was observed in hamsters following intratracheal instillation of (14)C paraquat. Elimination rate was slow, beta value of 0.014 hr which corresponds to a half-life of 50 hr.', 'Half-life for absorption of radioactivity from lung of hamster administered dichloride salt intratracheally was 21 hr.', 'For more Biological Half-Life (Complete) data for Paraquat (6 total), please visit the HSDB record page.']"
5939,15940,(2-(o-Aminobenzamido)ethyl)diethylmethylammonium bromide,CC[N+](C)(CC)CCNC(=O)C1=CC=CC=C1N.[Br-],,,,,,
5940,15941,2-[(2-Aminobenzoyl)amino]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCNC(=O)C1=CC=CC=C1N,,,,,,
5941,15942,"BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-o-NITRO-, HYDROCHLORIDE",CC[NH+](CC)CCNC(=O)C1=CC=CC=C1[N+](=O)[O-].[Cl-],,,,,,
5942,15943,n-[2-(Diethylamino)ethyl]-2-nitrobenzamide,CCN(CC)CCNC(=O)C1=CC=CC=C1[N+](=O)[O-],,,,,,
5943,15944,Isopropyl o-((2-(diethylamino)ethyl)carbamoyl)carbanilate hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC=CC=C1NC(=O)OC(C)C.[Cl-],,,,,,
5944,15945,propan-2-yl N-[2-[2-(diethylamino)ethylcarbamoyl]phenyl]carbamate,CCN(CC)CCNC(=O)C1=CC=CC=C1NC(=O)OC(C)C,,,,,,
5945,15946,CID 15946,CN1C2=CC=CC=C2C(=C1O)N=NC(=N)S,,,,,,
5946,15947,"5-Methyl-1,3,5-triazinan-2-one",CN1CNC(=O)NC1,,,,,,
5947,15948,"(16S,17R)-16,17-dihydroxy-13,16-dimethyl-1,2,6,7,8,9,10,11,12,14,15,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CC2C3CCC4=CC(=O)CCC4C3CCC2([C@H]1O)C)O,,,,,,
5948,15949,Methylbis(2-furyl)silane,C[SiH](C1=CC=CO1)C2=CC=CO2,,,,,,
5949,15950,Ipazine,CCN(CC)C1=NC(=NC(=N1)NC(C)C)Cl,,,,,,
5950,15951,Trietazine,CCNC1=NC(=NC(=N1)Cl)N(CC)CC,,,,,,
5951,15952,"Ethanesulfonic acid, methyl ester",CCS(=O)(=O)OC,,,,,,
5952,15953,Butyl methanesulfonate,CCCCOS(=O)(=O)C,,,,,,
5953,15954,Octadec-9-enoate;tin(2+),CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].[Sn+2],,,,,,
5954,15955,"Fluorene-2-carbamic acid, 1,3,4,7-tetrachloro-, ethyl ester",CCOC(=O)NC1=C(C2=C(C3=C(C2)C=C(C=C3)Cl)C(=C1Cl)Cl)Cl,,,,,,
5955,15956,"Methyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OC,,,,,,
5956,15957,"6-(2-phenylethenyl)-1H-1,3,5-triazine-2,4-dione",C1=CC=C(C=C1)C=CC2=NC(=O)NC(=O)N2,,,,,,
5957,15958,CID 15958,C1=CC=C(C=C1)C2=NC(=O)N=C(N2)C3=CC=C(C=C3)Cl,,,,,,
5958,15959,CID 15959,CCC1=NC(=O)N=C(N1)C2=CC=CC=C2,,,,,,
5959,15960,CID 15960,C1=CC=C(C=C1)C2=NC(=O)N=C(N2)C(Cl)(Cl)Cl,,,,,,
5960,15961,"4-Methylsulfanyl-6-phenyl-1,3,5-triazin-2-ol",CSC1=NC(=O)NC(=N1)C2=CC=CC=C2,,,,,,
5961,15962,CID 15962,C1=CC=C(C=C1)C2=NC(=O)N=C(N2)C3=CC=CC=C3,,,,,,
5962,15963,"2,4-D pentyl ester",CCCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
5963,15964,"Hexyl (3,5-dichlorophenoxy)acetate",CCCCCCOC(=O)COC1=CC(=CC(=C1)Cl)Cl,,,,,,
5964,15965,Picloram,C1(=C(C(=NC(=C1Cl)Cl)C(=O)O)Cl)N,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['Disposition studies in young cattle confirm that tissue retention is minimal with dietary intakes of 2.6-23 mg/kg per day. At the highest dietary intake level studied (1600 ppm [mg/kg]), tissue concentrations were recorded as (ppm (mg/kg)): kidney, 15-18; blood, 1.4-2; liver, 1.1-1.6; and muscle and fat, 0.3-0.5. Clearance was rapid after cessation of intake.', ""The fate of picloram (4-amino-3,5,6-trichloropicolinic acid), an active ingredient in TORDON brand herbicides, was defined in 6 healthy male volunteers following single /oral/ doses of 5.0 and 0.5 mg/kg, and a dermal dose of 2.0 mg/kg. Picloram was administered orally as the sodium salt in grape juice. The dermal dose was applied to the volunteers' backs as the free acid dissolved in ethanol. The data indicate picloram was rapidly absorbed from the gastrointestinal tract (t1/2 = 20 min) and rapidly excreted unchanged in the urine. Over 90% of the /oral/ dose was recovered as unchanged picloram in the urine excreted through 72 hr; most of the dose (>75%) was excreted within 6 hr and the remainder was excreted with an average half-life of 27 hr. By comparison picloram was slowly absorbed through the skin (t1/2 = 12 hr) and, based on the quantity of picloram excreted in the urine, only a small fraction (0.2%) of the picloram applied to the skin was absorbed. These data indicate that picloram because of its rapid excretion has a low potential to accumulate in man during repeated or prolonged exposure. In addition, picloram was poorly absorbed through human skin and it is unlikely that acutely toxic quatities will be absorbed by this route."", 'Picloram is rapidly absorbed from the GI tract & is excreted virtually unchanged in the urine & feces of male Fischer 344 rats within 48 hr. Following a 10 mg/kg (14)C-picloram intravenous dose, the isotope was cleared biphasically & excreted in the urine. ... Balance studies in rats indicated that 98.4% of the dose was recovered. Urinary excretion resulted in an 80% to 84% recovery, fecal excretion resulted in approx 15% recovery, less than 0.5% was recovered in the bile, and virtually no radioactivity was recovered as trapped (14)CO2 or as other volatile compounds.', 'Studies with (14)C-picloram showed that 90% of the compound fed in the diet to dogs was excreted within 48 hr in the urine, with small amounts appearing in the feces.', 'For more Absorption, Distribution and Excretion (Complete) data for PICLORAM (6 total), please visit the HSDB record page.']","['The major metabolite was 2-ethyl-1,6-hexanoic acid /after administration of 14C-picloram isooctyl ester/. This study supports the fact that picloram ethylhexyl ester is hydrolyzed rapidly to picloram (free acid) and 2-ethyl hexanol...', 'No measurable residues were found in milk samples from dairy cows fed 10-100 ppm picloram in the feed. Milk samples from cows fed 150-1,000 ppm picloram in the feed contained low levels (0.05-0.29 ppm) of residue which declined rapidly and were undetectable 58 hours after withdrawal from the feed.']","['Following a 10 mg/kg (14)C-picloram intravenous dose /to rats/, the isotope was cleared biphasically and excreted in the urine. The half-time for rapid and slow clearance from plasma was 6.3 and 128 min, respectively. Oral admin of the same dose resulted in comparable half-times of 29 min and 3.8 hr, respectively. At higher (1400 mg/kg) oral doses, the plasma levels remained constant for 3 hr, then slowly declined.']"
5965,15966,Dipropalin,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])C)[N+](=O)[O-],,,,,,
5966,15967,Terbucarb,CC1=CC(=C(C(=C1)C(C)(C)C)OC(=O)NC)C(C)(C)C,,,,,,
5967,15968,CID 15968,C1=CC(=C(C(=C1)Cl)C(=N)S)Cl,,,,,,
5968,15969,"Methyl N-(3,4-dichlorophenyl)carbamate",COC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,"['Mice were orally administered 420 mg of phenyl-(14)C-labeled carbanilate/kg to 5-week-old male STD-DDY mice. Feces & urine were collected daily for 5 days. Swep was swiftly distributed throughout the mouse body & was almost completely excreted within 48 hr in urine & feces, especially urine. In feces swep was excreted unchanged.', '... Swep was found ... resistant to hydrolysis by rice plants. ... There was not a large incorporation of 3,4-dichloroaniline moiety of Swep into the insoluble lignin complex. Instead, intact herbicide incorporated directly.', 'The metabolism of methyl 3,4-dichlorocarbanilate (Swep) in the mouse was studied by orally administering 420 mg of phenyl-14C-labeled carbanilate/kg to 5-week-old male STD-ddy mice. Following herbicide administration their urine and feces were collected daily for 5 days to determine the radioactivity, and the organs of untreated control mice mouse were analyzed as well as the whole-body autoradiographs. It was shown that the orally administered swep was swiftly distributed throughout the mouse body and was almost completely excreted within 48 hr in urine and feces, especially urine.']","['In studies on the mouse, it was determined that in mouse urine, Swep was metabolized into water-soluble substances conjugated with glucuronic acid and sulfuric acid.', ""In soil ... Swep was transformed to 3,4-dichloroaniline, 3,3',4,4'-tetrachloroazobenzene ... & other unidentified compd. ... The nature of microflora responsible for biodegradation ... was not known."", 'In greenhouse studies Swep was applied to rice, carrots, oats, wheat, corn, & barnyard grass. There were indications that trace amounts of Swep were hydrolyzed in soil to 3,4-dichloroaniline. However ... most of the herbicide was immobilized & bound as a lignin complex...', '... In feces swep was excreted virtually unchanged, however, in urine it was metabolized into water-soluble substances conjugated with glucuronic acid and sulfuric acid.']",
5969,15970,2-Thiopheneacetic acid,C1=CSC(=C1)CC(=O)O,,,,,,
5970,15971,"2,4,6-Tris(4-chlorophenoxy)-1,3,5-triazine",C1=CC(=CC=C1OC2=NC(=NC(=N2)OC3=CC=C(C=C3)Cl)OC4=CC=C(C=C4)Cl)Cl,,,,,,
5971,15972,"2,4,6-Tris(3-methylphenoxy)-1,3,5-triazine",CC1=CC(=CC=C1)OC2=NC(=NC(=N2)OC3=CC=CC(=C3)C)OC4=CC=CC(=C4)C,,,,,,
5972,15973,"2,4,6-Triphenoxy-1,3,5-triazine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)OC3=CC=CC=C3)OC4=CC=CC=C4,,,,,,
5973,15974,CID 15974,C1C(=NN=C(N)S)CSS1,,,,,,
5974,15975,5-Hydroxy-3-(2-pyrrolidinylethyl)indole,C1CC(NC1)CCC2=CNC3=C2C=C(C=C3)O,,,,,,
5975,15976,Dodecyldimethylammonium acetate,CCCCCCCCCCCC[NH+](C)C.CC(=O)[O-],,,,,,
5976,15977,Methacrolein dimer,CC1=COC(CC1)(C)C=O,,,,,,
5977,15978,"Plumbane, tetrabutyl-",CCCC[Pb](CCCC)(CCCC)CCCC,,,,,,
5978,15979,Pristane,CC(C)CCCC(C)CCCC(C)CCCC(C)C,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['Studies were conducted to assess the normal tissue-associated levels of pristane (2,6,10,14,-tetramethylpentadecane) in Copenhagen rats during ontogeny and adult life and to address whether or not dietary pristane can be adsorbed from the gut and disseminated throughout the body. During the course of this study the possible effects of dietary pristane on chromatin conformation of lymphoid cells were also examined by flow cytometry. The data indicated that 1) pristane crossed the placenta and accumulated in fetal tissues, 2) neonates were exposed to pristane via the colostrum, 3) there were significant increases in the amount of tissue-associated pristane in young adults and subsequent redistribution of the pristane to the muscle and adipose tissues in older rats and 4) after dietary exposure, significantly elevated levels of pristane were associated with the tissues and concomitant changes in chromatin conformation were observed. Collectively, these results suggest that pristane was adsorbed from dietary sources, disseminated to the tissues and exerted a transient, yet marked effect on chromatin of lymphoid cells in rats.', 'The fate of pristane (2,6,10,14-tetramethylpentadecane), a widespread isoprenoid hydrocarbon, has been studied in rats after a single /oral/ administration of 3H-labeled pristane. The balance study showed an extensive fecal excretion (66%) mainly as unchanged hydrocarbon, whereas about 14% of ingested pristane was excreted in urine as pristane metabolites and tritiated water. After one wk, 8.3% of the ingested 3H still was stored in the carcass, and radioactive distribution in tissues and organs showed a preferential incorporation into adipose tissue and liver. Over 75% of the radioactivity stored in the carcass was associated with pristane metabolites and tritiated water. Tissue metabolites were characterized by thin layer chromatography, gas chromatography and mass spectrometric analyses. Four metabolites were identified: pristan-1-ol, pristane-2-ol, pristanic acid and 4,8,12-trimethyltridecanoic acid. These demonstrate that this isoprenoid hydrocarbon undergoes subterminal hydroxylation or terminal oxidation followed by the classical beta-oxidation process. Incorporation of metabolites in phospholipids and more particularly in the phosphatidylserine fraction has been observed and is discussed.']",,
5979,15980,alpha-(2-(2-Pyridylamino)ethyl)benzyl alcohol hydrochloride,C1=CC=C(C=C1)C(CCNC2=CC=CC=[NH+]2)O.[Cl-],,,,,,
5980,15981,1-Phenyl-3-(pyridin-2-ylamino)propan-1-ol,C1=CC=C(C=C1)C(CCNC2=CC=CC=N2)O,,,,,,
5981,15982,CID 15982,CCCC[NH+](CCCC)CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O.[Cl-],,,,,,
5982,15983,CID 15983,CCCCN(CCCC)CCNC(=O)C1=C(OC2=CC=CC=C2C1=O)O,,,,,,
5983,15984,CID 15984,CCCC(=O)NC1=C(C=C(C(=C1I)C=C(CC)C(=O)[O-])I)I.[Na+],,,,,,
5984,15985,Bunamiodyl,CCCC(=O)NC1=C(C=C(C(=C1I)C=C(CC)C(=O)O)I)I,,,,,,
5985,15986,"CARBAMIC ACID, (2-PHENYL-m-DIOXAN-5-YLIDENE)DIMETHYLENE ESTER",C1C(COC(O1)C2=CC=CC=C2)(COC(=O)N)COC(=O)N,,,,,,
5986,15987,"3,5,12,14,19-Pentahydroxycard-20(22)-enolide",C[C@@]12[C@H](CC[C@@]1(C3CC[C@@]4(C[C@H](CC[C@@]4(C3C[C@H]2O)CO)O)O)O)C5=CC(=O)OC5,,,,,,
5987,15988,N-Methyl-norgranatanol-3-alpha-benzhydrylaether [German],CN1C2CCCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
5988,15989,9-(2-Hydroxyethyl)-9-azabicyclo(3.3.1)nonane p-methylbenzilate,CC1=CC=C(C=C1)C(C2=CC=CC=C2)(C(=O)OCCN3C4CCCC3CCC4)O,,,,,,
5989,15990,"(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl) 2-hydroxy-2,2-diphenylacetate",CN1C2CCCC1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
5990,15991,"(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl) 2-chloro-2,2-diphenylacetate",CN1C2CCCC1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)Cl,,,,,,
5991,15992,"(9-Benzyl-9-azabicyclo[3.3.1]nonan-3-yl) 2-hydroxy-2,2-diphenylacetate",C1CC2CC(CC(C1)N2CC3=CC=CC=C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,,,,,,
5992,15993,2'-Deoxyadenosine 5'-triphosphate,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,,,,,,
5993,15994,"1,5-Naphthalenedisulfonyl chloride",C1=CC2=C(C=CC=C2S(=O)(=O)Cl)C(=C1)S(=O)(=O)Cl,,,,,,
5994,15995,"Ethyl 2,4,5-trichlorophenoxyacetate",CCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
5995,15996,"Octyl (2,4-dichlorophenoxy)acetate",CCCCCCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
5996,15997,"Acetic acid, (2,4-dichlorophenoxy)-, 3-butoxypropyl ester",CCCCOCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,"['Leaves absorb nonpolar (ester) forms most readily. ... The esters of 2,4-D tend to resist washing from plants and are rapidly converted to the acid by the plants. ... Following foliar absorption, 2,4-D translocates within the phloem, probably moving with food material. Following root absorption, it may move upward in the transpiration stream. Translocation is influenced by the growth status of the plant. Accumulation of the herbicide occurs principally at the meristematic regions of shoots and roots. /2,4-D and its esters/']","['Plants hydrolyze 2,4-D esters to 2,4-D, which is the active herbicide. ... Further metabolism ... occurs through three mechanisms, namely, side chain degradation, hydroxylation of the aromatic ring, and conjugation with plant constituents.', 'HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID. /2,4-D ESTER/', '2,4-D ESTERS ARE HYDROLYZED IN ANIMALS. THE PHENOXY ACIDS ARE EXCRETED PREDOMINANTLY AS SUCH IN THE URINE OF RATS AFTER THEIR ORAL ADMIN, ALTHOUGH MINOR PORTION IS CONJUGATED WITH AMINO ACIDS GLYCINE & TAURINE & WITH GLUCURONIC ACID. /2,4-D AND ESTERS/', 'Chlorophenoxy acid derivatives are metabolized via participation of the hepatic microsomal mixed-function oxidase system. Thus, administration of 2,4-D amine salt and its butyl ester ... to rats induced the enzyme system (aminopyrine demethylase ... and aniline hydroxylase) ... although the degree of induction was substantially lower than that from phenobarbital. Prolonged administration of 2,4-D amine salt (0.1 LD50) showed cumulative effects reflected by both clinical and biochemical changes. Stimulation of mixed-function oxidase system may be one of the methods for reducing toxicological effects of this type of compounds.', 'For more Metabolism/Metabolites (Complete) data for 2,4-D, BUTOXYPROPYL ESTER (10 total), please visit the HSDB record page.']",['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/']
5997,15998,"2,4,5-T 2-Ethylhexyl ester",CCCCC(CC)COC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
5998,15999,"2,4,5-T-3-butoxypropyl",CCCCOCCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
5999,16000,"2,4,5-t Butoxyethoxypropanol ester",CCCCOCCOCCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
6000,16001,"Propyl 2,4-dichlorophenoxyacetate",CCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
6001,16002,"2-Butoxyethyl 2,4-dichlorophenoxyacetate",CCCCOCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,"['Leaves absorb nonpolar (ester) forms most readily. ... The esters of 2,4-D tend to resist washing from plants and are rapidly converted to the acid by the plants. ... Following foliar absorption, 2,4-D translocates within the phloem, probably moving with food material. Following root absorption, it may move upward in the transpiration stream. Translocation is influenced by the growth status of the plant. Accumulation of the herbicide occurs principally at the meristematic regions of shoots and roots. /2,4-D and its esters/']","['Plants hydrolyze 2,4-D esters to 2,4-D, which is the active herbicide. ... Further metabolism ... occurs through three mechanisms, namely, side chain degradation, hydroxylation of the aromatic ring, and conjugation with plant constituents. /2,4-D esters/', 'HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID. /2,4-D ESTER/', '2,4-D ESTERS ARE HYDROLYZED IN ANIMALS. THE PHENOXY ACIDS ARE EXCRETED PREDOMINANTLY AS SUCH IN THE URINE OF RATS AFTER THEIR ORAL ADMIN, ALTHOUGH MINOR PORTION IS CONJUGATED WITH AMINO ACIDS GLYCINE & TAURINE & WITH GLUCURONIC ACID. /2,4-D AND ESTERS/', 'Metabolites of 2,4-D other than conjugates have not been detected in human urine.']",['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/']
6002,16003,Vernolate,CCCN(CCC)C(=O)SCCC,,,,"['/After preemergence treatment and upward translocation of (14)C throughout the entire plant/ higher concentration of (14)C vernolate was found in root and stem than in foliage.', 'Both peanut (Arachis hyogaea L) and soybean (Glycine may (L) merr) readily absorbed vernolate.', '... /In soybean seedlings/ (14)C vernolate reached max in 48 hr. During this stage, no absorbed herbicide was degraded until seedlings were 6-7 days old.', 'No ... percutaneous absorption ... .', 'Absorbed by the roots, with translocation to the stems and leaves.']","['...No degradation of vernolate was observed in germinating soybean seedlings during the first 5 days.', 'Both peanut (Arachis hyogaea L) and soybean (Glycine max (L) merr) readily absorbed vernolate. Chemical was degraded to carbon dioxide. 2 major and 2 minor metabolites were indicated... .', 'Vernolate gives sulfoxide degradation product in living mice. /from table/', 'Thiocarbamates are detected in the liver of mice 20 min after ip treatment with EPTC, molinate, pebulate, and vernolate at 1 m mole/kg but not after administration of benthiocarb, butylate, or cycloate.', 'One of the two major metabolic pathways for thiocarbamates in mammals is sulfoxidation, followed by conjugation with glutathione (GSH) by GSH S -transferase. The GSH conjugate is then cleaved to the cysteine derivative, which is subsequently acetylated and excreted as S -carbamoyl-mercapturic acid. ...Sulfoxidation of thiocarbamates such as EPTC, molinate, pebulate, and vernolate undoubtedly represents a detoxification mechanism in mammals, the sulfoxides generally being less toxic than the parent compounds. The lower toxicity of the sulfoxides is probably attributable to the high rate of cleavage and elimination as glutathione conjugates']",
6003,16004,Nitrapyrin,C1=CC(=NC(=C1)Cl)C(Cl)(Cl)Cl,,,,,,
6004,16005,CID 16005,CC1=C(C=CC(=C1)Cl)OC(C)C(=O)[O-].[K+],,,,,,
6005,16006,Methyl 2-naphthyloxyacetate,COC(=O)COC1=CC=CC2=CC=CC=C21,,,,,,
6006,16007,Benzthiazuron,CNC(=O)NC1=NC2=CC=CC=C2S1,,,,,,
6007,16008,"4-Chloro-3,5-dinitrobenzonitrile",C1=C(C=C(C(=C1[N+](=O)[O-])Cl)[N+](=O)[O-])C#N,,,,,,
6008,16009,4-Tert-butylperoxy-4-oxobut-2-enoic acid,CC(C)(C)OOC(=O)C=CC(=O)O,,,,,,
6009,16010,"4'-(3,3-Dimethyl-1-triazeno)acetanilide",CC(=O)NC1=CC=C(C=C1)N=NN(C)C,,,,,,
6010,16011,CID 16011,C1=CC=C(C=C1)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+],,,,,,
6011,16012,C.I. Acid orange 12,C1=CC=C(C=C1)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O,,,,,,
6012,16013,"trisodium 5-oxo-1-(4-sulfonatophenyl)-4-[(E)-(4-sulfonatophenyl)diazenyl]-2,5-dihydro-1H-pyrazole-3-carboxylate",C1=CC(=CC=C1N=NC2=C(NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
6013,16014,FD&C Yellow No. 5 free acid,C1=CC(=CC=C1N=NC2=C(NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)O)C(=O)O)S(=O)(=O)O,,,,,,
6014,16015,Orange G,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,"['OF 500 MG/KG BODY WT ORANGE G FED TO RABBITS, 40% IS EXCRETED IN THE URINE AS PARA-AMINOPHENOL, 3% AS ORTHO-AMINOPHENOL AND 0.6% AS FREE ANILINE... IN THE URINE OF RATS GIVEN SINGLE ORAL DOSES OF 250 MG/KG BODY WT, 61% APPEARS AS PARA-AMINOPHENOL, AND ANILINE IS FOUND IN FECES. NO UNCHANGED DYE IS FOUND IN EITHER THE URINE OR THE FECES...', 'THE URINE OF HUMANS GIVEN 20 MG/KG BODY WEIGHT ORANGE G CONTAINED 95% AS PARA-AMINOPHENOL, 0.5% AS ANILINE AND 1.3% AS UNCHANGED COLOR...', 'THE AZO LINKAGE OF ORANGE G IS REDUCED BY BACTERIA PRESENT IN RAT FECES AND BY RAT-LIVER HOMOGENATES...']",
6015,16016,orange G free acid,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
6016,16017,CID 16017,C(=N[NH3+])(N)N.[Cl-],,,,,,
6017,16018,"Disodium;3-[[4-[4-[(2,4-diaminophenyl)diazenyl]phenyl]phenyl]hydrazinylidene]-4-imino-5-oxo-6-(phenylhydrazinylidene)naphthalene-2,7-disulfonate",C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
6018,16019,"3-[[4-[4-[(2,4-Diaminophenyl)diazenyl]phenyl]phenyl]hydrazinylidene]-4-imino-5-oxo-6-(phenylhydrazinylidene)naphthalene-2,7-disulfonic acid",C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
6019,16020,"2'-(2,3-Dihydroxypropoxy)acetophenone",CC(=O)C1=CC=CC=C1OCC(CO)O,,,,,,
6020,16021,1-Ethylcyclohexanol,CCC1(CCCCC1)O,,,,,,
6021,16022,"4-Bromo-2,5-dichlorophenol",C1=C(C(=CC(=C1Cl)Br)Cl)O,,,,,,
6022,16023,Tetrachlorophene,C1=C(C=C(C(=C1CC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,,,,,,
6023,16024,9-Bromofluorene,C1=CC=C2C(=C1)C(C3=CC=CC=C32)Br,,,,,,
6024,16025,"2-(Diethylamino)butyric acid 2,6-dimethoxyphenyl ester hydrochloride",CCC(C(=O)OC1=C(C=CC=C1OC)OC)[NH+](CC)CC.[Cl-],,,,,,
6025,16026,"(2,6-Dimethoxyphenyl) 2-(diethylamino)butanoate",CCC(C(=O)OC1=C(C=CC=C1OC)OC)N(CC)CC,,,,,,
6026,16027,Tetrabutylammonium nitrate,CCCC[N+](CCCC)(CCCC)CCCC.[N+](=O)([O-])[O-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
6027,16028,Tetrabutylammonium,CCCC[N+](CCCC)(CCCC)CCCC,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
6028,16029,4-Octyne,CCCC#CCCC,,,,,,
6029,16030,5-Decyne,CCCCC#CCCCC,,,,,,
6030,16031,2-Diethylaminoethanethiol hydrochloride,CCN(CC)CCS.Cl,,,,,,
6031,16032,2-(Diethylamino)ethanethiol,CCN(CC)CCS,,,,,,
6032,16033,2-(4-tert-Butylphenoxy)cyclohexan-1-ol,CC(C)(C)C1=CC=C(C=C1)OC2CCCCC2O,,,,,,
6033,16034,Phenyl methylcarbamate,CNC(=O)OC1=CC=CC=C1,,,,,"['PHENYL N-METHYLCARBAMATE IS METABOLIZED TO PHENYL N-HYDROXYMETHYLCARBAMATE IN MOUSE. HOOK, GER & JN SMITH, BIOCHEM J 102: 504 (1967). /FROM TABLE/']",
6034,16035,2-Chloroethyl isocyanate,C(CCl)N=C=O,,,,,,
6035,16036,3-Cyclohexylphenol,C1CCC(CC1)C2=CC(=CC=C2)O,,,,,,
6036,16037,5-(1-Hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)resorcinol hydrobromide,CC(CC1=CC=C(C=C1)O)[NH2+]CC(C2=CC(=CC(=C2)O)O)O.[Br-],,,,,,
6037,16038,"Aniline, p-(2-(3-(m-methoxyphenyl)-3-propyl-1-pyrrolidinyl)ethyl)-, dihydrochloride",CCCC1(CC[NH+](C1)CCC2=CC=C(C=C2)[NH3+])C3=CC(=CC=C3)OC.[Cl-].[Cl-],,,,,,
6038,16039,1-(p-Aminophenethyl)-3-(m-methoxyphenyl)-3-propylpyrrolidine,CCCC1(CCN(C1)CCC2=CC=C(C=C2)N)C3=CC(=CC=C3)OC,,,,,,
6039,16040,"8,13-Abietadien-18-oic acid",CC(C)C1=CC2=C(CC1)C3(CCCC(C3CC2)(C)C(=O)O)C,,,,,,
6040,16041,"2,3-Dibromo-1,4-butanediol",C(C(C(CO)Br)Br)O,,,,,,
6041,16042,Dibromo-meso-erythritol,C([C@H]([C@H](CBr)O)O)Br,,,,,,
6042,16043,tert-Butylhydroquinone,CC(C)(C)C1=C(C=CC(=C1)O)O,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,"['TBHQ is readily metabolized. In mouse studies, metabolism primarily involved oxidation at the tert-butyl group, followed by formation of the glucuronide conjugate and excretion in the urine, or by excretion of the free acid in feces. In rats, 80-90% of the (14)C-radiolabel was excreted in urine or feces within 96 hours, mostly as the free acid in feces with smaller amounts in urine, and less than 0.3% in expired air. More than 43 metabolites were present in the urine and feces of mice and rats. In several studies with rats and dogs, TBHQ by the oral route was shown to be well absorbed and rapidly excreted, mainly in the urine. Primary urinary metabolites in both species are the 4-O-sulfate conjugate and the 4-O-glucuronide. Excretion seems to be essentially complete after 4 days.', 'The dominant metabolic pathway of the presumably carcinogenic food antioxidant 2(3)-tert-butyl-4-hydroxyanisole includes O-demethylation to 2-tert-butyl(1,4)hydroquinone and subsequent peroxidation to 2-tert-butyl(1,4)paraquinone. ...', 'The tert-butylsemiquinone anion radical is formed from tert-butylhydroquinone and from tert-butylquinone in rat liver microsomes.', 'After ip administration of 3-tert-butyl-4-hydroxyanisole to rats two previously undocumented metabolites 2-tert-butyl-5-methylthiohydroquinone and 2-tert-butyl-6-methylthiohydroquinone were identified in the urine. In addition to these metabolites 3-tert-butyl-4,5-dihydroxyanisole was also detected in the urine hydrolyzed by beta-glucuronidase/sulfatase. Administration of tert-butylhydroquinone, an O-demethylated metabolite of 3-tert-butyl-4-hydroxyanisole, also resulted in the formation of the S-containing metabolites, 2-tert-butyl-5-methylthiohydroquinone and 2-tert-butyl-6-methylthiohydroquinone. After incubation of tert-butylhydroquinone with rat liver microsomes in the presence of glutathione, two metabolites were isolated and purified by HPLC. The metabolites were identified as 2-tert-butyl-5-(glutathione-S-yl)hydroquinone and 2-tert-butyl-6-(glutathione-S-yl)hydroquinone.The formation of tert-butyl hydroquinone-glutathione conjugates required NADPH molecular oxygen and glutathione. Cytochrome p450 inhibitors such as SKF 525-A and metyrapone markedly inhibited the formation of tert-butylhydroquinone-glutathione conjugates in vitro. tert-Butylhydroquinone is converted by cytochrome p450-mediated monooxygenases to a reactive metabolite 2-tert-butyl-p-benzoquinone which then conjugates with glutathione to form tert-butylhydroquinone-glutathione conjugates. Glutathione S-transferase activities do not seen to play a role in glutathione conjugation reaction of 2-tert-butyl-p-benzoquinone because cytosol fraction from rat liver homogenates did not enhance the microsome-mediated production of tert-butylhydroquinone-glutathione conjugates.']",
6043,16044,Oxolamine dihydrogen phosphate,CC[NH+](CC)CCC1=[NH+]C(=[NH+]O1)C2=CC=CC=C2.[O-]P(=O)([O-])[O-],,,,,,
6044,16045,Oxolamine dihydrogen citrate,CC[NH+](CC)CCC1=NC(=NO1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
6045,16046,2-Methyl-4-phenylbutanoic acid,CC(CCC1=CC=CC=C1)C(=O)O,,,,,,
6046,16047,CID 16047,CCSC(=NCC1=CC=CC=C1)S,,,,,,
6047,16048,3-Chlorobutyric acid,CC(CC(=O)O)Cl,,,,,,
6048,16049,CID 16049,CC(C)NC(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
6049,16050,Diphenylacetic acid 1-methyl-4-piperidyl ester hydrochloride,C[NH+]1CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
6050,16051,4-Diphenylacetoxy-n-methylpiperidine,CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6051,16052,3-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid,C1=CC(=CC=C1C(CC(=O)O)N)N(CCCl)CCCl,,,,,,
6052,16053,7-Amino-9H-fluoren-2-ol,C1C2=C(C=CC(=C2)N)C3=C1C=C(C=C3)O,,,,,,
6053,16054,5-Hydroxyindole,C1=CC2=C(C=CN2)C=C1O,,,,,,
6054,16055,"cis-1,4-Bis-(methylsulfonyloxy)-but-2-ene",CS(=O)(=O)OCC=CCOS(=O)(=O)C,,,,,,
6055,16056,CID 16056,C1=CC(=C(C(=C1)Cl)C(=NCO)S)Cl,,,,,,
6056,16057,Tetrachlorophthalonitrile,C(#N)C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C#N,,,,,,
6057,16058,Etoglucid,C1C(O1)COCCOCCOCCOCC2CO2,,,"['A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']",,,
6058,16059,Pivalolactone,CC1(COC1=O)C,,,,,,
6059,16060,Diethyl(2-{4-[1-(hydroxyimino)ethyl]phenoxy}ethyl)amine,CCN(CC)CCOC1=CC=C(C=C1)C(=NO)C,,,,,,
6060,16061,"ethanone, 1-(2-thienyl)-, oxime, (1Z)-",CC(=NO)C1=CC=CS1,,,,,,
6061,16062,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-(2-(dimethylamino)ethyl)-5-phenyl-7-(trifluoromethyl)-, dihydrochloride",C[NH+](C)CCN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)C(F)(F)F)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
6062,16063,"1-[2-(dimethylamino)ethyl]-5-phenyl-7-(trifluoromethyl)-3H-1,4-benzodiazepin-4-ium-2-one",CN(C)CCN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)C(F)(F)F)C3=CC=CC=C3,,,,,,
6063,16064,3-Hydroxytetradecanoic acid,CCCCCCCCCCCC(CC(=O)O)O,,,,,,
6064,16065,"(9S,14S,17R)-17-acetyl-6-chloro-17-hydroxy-10,13-dimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one",CC(=O)[C@]1(CC[C@@H]2C1(CC[C@H]3C2C=C(C4=CC(=O)CCC34C)Cl)C)O,,,,,,
6065,16066,Dibutyl terephthalate,CCCCOC(=O)C1=CC=C(C=C1)C(=O)OCCCC,,,,,,
6066,16067,17-Hydroxy-17-methylestran-3-one,C[C@@]1(CCC2C1(CCC3C2CCC4C3CCC(=O)C4)C)O,,,,,,
6067,16068,"1,8-Diacetoxyanthraquinone",CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=CC=C3OC(=O)C,,,,,,
6068,16069,"4,4'-Dihydroxydiphenyl ether",C1=CC(=CC=C1O)OC2=CC=C(C=C2)O,,,,,,
6069,16070,2-[Bis(2-aminoethyl)amino]ethanol,C(CN(CCN)CCO)N,,,,,,
6070,16071,Bicyclo[3.2.1]octan-2-ol,C1CC2CC1CCC2O,,,,,,
6071,16072,Dichlormate,CNC(=O)OCC1=CC(=C(C=C1)Cl)Cl,,,,,,
6072,16073,Chlorbufam,CC(C#C)OC(=O)NC1=CC(=CC=C1)Cl,,,,,"['Chlorpropham and propham (and presumably chlorbufam) are metabolized by para-ring hydroxylation, carbamate hydrolysis, and side-chain oxidation. /Chlorpropham/', 'The first step in the metabolism of carbamates is hydrolysis to carbamic acid, which decomposes to carbon dioxide (CO2) and the corresponding amine. The mechanism of hydrolysis is different for  N -methyl and  N -dimethyl derivatives.  The  N -methyl carbamates pass through an isocyanate intermediate, whereas in the hydrolysis of  N - dimethylcarbamates, an addition product with a hydroxyl ion is formed yielding the alcohol and  N -dimethyl substituted acid.  The rate of hydrolysis by esterases is faster in mammals than in plants and insects. Apart from hydrolysis, oxidation also takes place including: hydroxylation of the aromatic ring,  O -dealkylation,  N -methyl hydroxylation,  N -dealkylation, oxidation of aliphatic side chains, and sulfoxidation to the corresponding sulfone. Oxidation is associated with the mixed-function oxidase (MFO) enzymes. Conjugation leads to the formation of  O - and  N -glucuronides, sulfates, and mercapturic acid derivatives in mammals.  Glycosides and phosphates are conjugation products more common in plants. /Carbamate Pesticides/']",
6073,16074,N-(4-bromophenyl)urea,C1=CC(=CC=C1NC(=O)N)Br,,,,,,
6074,16075,3-Chlorophenylurea,C1=CC(=CC(=C1)Cl)NC(=O)N,,,,,,
6075,16076,Pyriclor,C1=C(C(=O)C(=C(N1)Cl)Cl)Cl,,,,,,
6076,16077,"1,8,8-Trimethyl-3-azabicyclo[3.2.1]octane-2,4-dione",CC1(C2CCC1(C(=O)NC2=O)C)C,,,,,,
6077,16078,Dronabinol,CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,"['For the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments']","['Marinol may has complex effects on the central nervous system (CNS), including cannabinoid receptors. Dronabinol may inhibit endorphins in the emetic center, suppress prostaglandin synthesis, and/or inhibit medullary activity through an unspecified cortical action.']","['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Agonists.)']","['Dronabinol capsules are almost completely absorbed (90 to 95%) after single oral doses. Due to the combined effects of first pass hepatic metabolism and high lipid solubility, only 10 to 20% of the administered dose reaches the systemic circulation. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Following BID dosing of 2.5mg of dronabinol, Cmax was found to be 1.32ng/mL with a median Tmax of 1.00 hr.', 'Dronabinol and its biotransformation products are excreted in both feces and urine. Because of its large volume of distribution, dronabinol and its metabolites may be excreted at low levels for prolonged periods of time. Following single dose administration, low levels of dronabinol metabolites have been detected for more than 5 weeks in the urine and feces.', 'Dronabinol has a large apparent volume of distribution, approximately 10 L/kg, because of its lipid solubility.', 'Values for clearance average about 0.2 L/kg-hr, but are highly variable due to the complexity of cannabinoid distribution.', 'To establish a fast sensitive, reproducible LC-MS/MS method to study pharmacokinetic properties of THC, and compare relative bioavailability of THC and its solid dispersion in mice. 200 mice were divided randomly into two groups, and administered orally with THC and THC-solid dispersion after fasting (calculate on THC:400 mg x kg(-1)), used HPLC-MS/MS method to determine the THC concentration of each period at the following times: baseline ( predose ), 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 24 hr after dosing. Calculating the pharmacokinetic parameters according to the C-t curv, and then use the Phoenix WinNonlin software for data analysis. The calibration curves were linear over the range 9.06-972 ug/L for THC (R2 = 0.999). The limit of detection (LOD) was 0.7 ug/L, respectively. The average extraction recoveries for THC was above 75%, The methodology recoveries were between 79% and 108%. The intra-day and inter-day RSD were less than 13%, the stability test showed that the plasma samples was stable under different conditions (RSD < 15%). The precision, accuracy, recovery and applicability were found to be adequate for pharmacokinetic studies. Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 00.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51226.00 and 68031.48 mg/L x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L/min x kg. Compared with THC, the MRT and t1/2 of the THC-solid dispersion were all slightly extended, the t(max) was significantly reduced, AUC(0-24 hr), AUC(0-infinity) and C(max) were all significantly higher, the relative bioavailability of THC-solid dispersion is 1.34 times of THC. The results of the experiment shows that the precision, accuracy, recovery and applicability were found to be adequate for the pharmacokinetic studies. After oral administration to mice, the relative bioavailability of THC-solid dispersion show significant improvement compared to THC.', '/MILK/ Marijuana has not been well studied, but tetrahydrocannabinol can reach rather high levels in /breast/ milk, particularly with heavy use. Although adverse effects in infants have not been reported, breast feeding should probably be avoided in heavy users and during therapeutic dronabinol use. Breast feeding should probably be withheld for several hr after occasional marijuana use. Caution should also be used to avoid exposing the infant to marijuana smoke.', 'There is a great concern about the safety of THC-based drugs in older people (=65 years), as most of THC-trials did not include such group. In this phase 1, randomized, double-blind, double-dummy, placebo-controlled, cross-over trial, we evaluated the safety and pharmacokinetics of three oral doses of Namisol(), a novel THC in tablet form, in older subjects. Twelve healthy older subjects (6 male; mean age 72+/-5 years) randomly received a single oral dose of 3 mg, 5 mg, or 6.5 mg of THC or matching placebo, in a crossover manner, on each intervention day. The data for 11 subjects were included in the analysis. The data of 1 subject were excluded due to non-compliance to study medication. THC was safe and well tolerated. The most frequently reported adverse events (AEs) were drowsiness (27%) and dry mouth (11%). Subjects reported more AEs with THC 6.5mg than with 3mg (p=0.048), 5mg (p=0.034) and placebo (p=0.013). There was a wide inter-individual variability in plasma concentrations of THC. Subjects for whom the Cmax fell within the sampling period (over 2hr), Cmax was 1.42-4.57 ng/mL and Tmax was 67-92 min. The AUC0-2 hr (n=11) was 1.67-3.51 ng/mL. Overall, the pharmacodynamic effects of THC were smaller than effects previously reported in young adults. In conclusion, THC appeared to be safe and well tolerated by healthy older individuals. Data on safety and effectiveness of THC in frail older persons are urgently required, as this population could benefit from the therapeutic applications of THC.', 'RATIONALE: Data on safety, pharmacodynamics, and pharmacokinetics of tetrahydrocannabinol (THC) are lacking in dementia patients. METHODS: In this randomized, double-blind, placebo-controlled, crossover trial, we evaluated the safety, pharmacodynamics, and pharmacokinetics of THC in ten patients with dementia (mean age 77.3 +/-5.6). For 12 weeks, participants randomly received oral THC (weeks 1-6, 0.75 mg; weeks 7-12, 1.5 mg) or placebo twice daily for 3 days, separated by a 4-day washout period. RESULTS: Only 6 of the 98 reported adverse events were related to THC. Visual analog scale (VAS) feeling high, VAS external perception, body sway-eyes-open, and diastolic blood pressure were not significantly different with THC. After the 0.75-mg dose, VAS internal perception (0.025 units; 95% CI 0.010-0.040) and heart rate (2 beats/min; 95% CI 0.4-3.8) increased significantly. Body sway-eyes-closed increased only after 1.5 mg (0.59 deg/s; 95% CI 0.13-1.06). Systolic blood pressure changed significantly after both doses of THC (0.75 mg, -7 mmHg, 95% CI -11.4, -3.0; 1.5 mg, 5 mmHg, 95% CI 1.0-9.2). The median T max was 1-2 hr, with THC pharmacokinetics increasing linearly with increasing dose, with wide interindividual variability (CV% up to 140%). The mean C max (ng/mL) after the first dose (0-6 hr) was 0.41 (0.18-0.90) for the 0.75-mg dose and 1.01 (0.53-1.92) for the 1.5-mg dose. After the second dose (6-24 hr), the C max was 0.50 (0.27-0.92) and 0.98 (0.46-2.06), respectively. CONCLUSIONS: THC was rapidly absorbed and had dose-linear pharmacokinetics with considerable interindividual variation. Pharmacodynamic effects, including adverse events, were minor. Further studies are warranted to evaluate the pharmacodynamics and efficacy of higher THC doses in older persons with dementia.', 'For more Absorption, Distribution and Excretion (Complete) data for delta 9-Tetrahydrocannabinol (32 total), please visit the HSDB record page.']","[""THC is primarily metabolized in the liver by microsomal hydroxylation and oxidation reactions catalyzed by Cytochrome P450 enzymes. 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) is the primary active metabolite, capable of producing psychological and behavioural effects, which is then metabolized into 11-nor-9-carboxy- 9-tetrahydrocannabinol (THC-COOH), THC's primary inactive metabolite. Dronabinol and its principal active metabolite, 11-OH-delta-9-THC, are present in approximately equal concentrations in plasma. Concentrations of both parent drug and metabolite peak at approximately 0.5 to 4 hours after oral dosing and decline over several days."", 'The analgesic activity of delta-8- and delta-9-THC is mainly due to the 11-hydroxy metabolite.', 'The metabolism of delta(9)-tetrahydrocannabinol (THC) is relatively complex, and over 80 metabolites have been identified. However, much less is known about the formation and fate of cannabinoid conjugates. Bile excretion is known to be an important route for the elimination of phase II metabolites. A liquid chromatography-tandem mass spectrometry LC-MS/MS procedure for measuring cannabinoids in oral fluid was adapted, validated and applied to 10 bile samples. THC, 11-hydroxy-delta(9)-tetrahydrocannabinol (11-OH-THC), 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol (THCCOOH), cannabinol (CBN), cannabidiol (CBD), delta(9)-tetrahydrocannabinolic acid A (THC-A), 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol glucuronide (THCCOOH-gluc) and delta(9)-tetrahydrocannabinol glucuronide (THC-gluc) were determined following solid-phase extraction and LC-MS/MS. High concentrations of THCCOOH-gluc were found in bile samples (range: 139-21,275 ng/mL). Relatively high levels of THCCOOH (7.7-1548 ng/mL) and THC-gluc (38-1366 ng/mL) were also measured. THC-A, the plant precursor of THC, was the only cannabinoid that was not detected. These results show that biliary excretion is an important route of elimination for cannabinoids conjugates and that their enterohepatic recirculation is a significant factor to consider when analyzing blood elimination profiles of cannabinoids. Furthermore, we suggest that the bile is the matrix of choice for the screening of phase II cannabinoid metabolites.', 'The presence of the metabolite 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (C-THC) in hair is generally accepted as the definitive proof of delta-9-tetrahydrocannabinol (THC) ingestion. During hair analysis, the removal of any potential C-THC external contamination that could result from marijuana smoke or close personal contact via a wash procedure is critical. Here, we performed a series of experiments to demonstrate that C-THC is the reliable indicator of marijuana ingestion when paired with the correct washing procedure to remove potential external contamination.', 'Dronabinol undergoes extensive first-pass hepatic metabolism, primarily by microsomal hydroxylation, yielding both active and inactive metabolites. Dronabinol and its principal active metabolite, 11-OH-delta-9-THC, are present in approximately equal concentrations in plasma.', 'For more Metabolism/Metabolites (Complete) data for delta 9-Tetrahydrocannabinol (15 total), please visit the HSDB record page.', 'Delta-9-Tetrahydrocannabinol has known human metabolites that include 11-hydroxy-delata-Tetrahydrocannabinol, 7-hydroxy-delta-9-Tetrahydrocannabinol, 7alpha-hydroxy-delta-9-Tetrahydrocannabinol, 8-hydroxy-delta-9-Tetrahydrocannabinol, and 8alpha-hydroxy-delta-9-Tetrahydrocannabinol.']","['The elimination phase of dronabinol can be described using a two compartment model with an initial (alpha) half-life of about 4 hours and a terminal (beta) half-life of 25 to 36 hours.', 'The elimination phase of dronabinol can be described using a two compartment model with an initial (alpha) half-life of about 4 hours and a terminal (beta) half-life of 25 to 36 hours.', 'After the pseudo-equilibrium is reached, THC is then slowly eliminated. This slow elimination is primarily due to the slow return of THC from sequestered tissues to blood. The terminal half-life of THC is approximately 1 day. /Several investigators have/ suggested terminal half-life /ranging between/ 19 to 36 hours. There are no significant differences in plasma profiles for chronic and infrequent users or in half-lives in moderate users before and after a 2-week exposure of THC.', 'The elimination half-life of dronabinol (delta-1-tetrahydrocannabinol) in 3 chronic marihuana users following smoking 4 cigarettes over a 2 day period is reported. The elimination half-life in blood plasma was calculated to be 4.1 days (range 2.9-5.0 days).', 'The terminal plasma half-life of metabolites from THC administration is approximately 50 hours, which is longer than that of THC. ... /Metabolites/']"
6078,16079,"2H-1,4-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-, dihydrochloride",CC[NH+](CC)CCN1C(=O)C[NH2+]C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.[Cl-].[Cl-],,,,,,
6079,16080,"7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-4,5-dihydro-3H-1,4-benzodiazepin-2-one",CCN(CC)CCN1C(=O)CNC(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
6080,16081,"N~2~,N~4~-Diethyl-6-phenyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)C2=CC=CC=C2)NCC,,,,,,
6081,16082,"4-chloro-N-methyl-6-phenyl-1,3,5-triazin-2-amine",CNC1=NC(=NC(=N1)C2=CC=CC=C2)Cl,,,,,,
6082,16083,"2,4-Dichloro-6-methyl-1,3,5-triazine",CC1=NC(=NC(=N1)Cl)Cl,,,,,,
6083,16084,"1,3,5-Triazine-2,4,6-triamine, N,N',N''-triphenyl-",C1=CC=C(C=C1)NC2=NC(=NC(=N2)NC3=CC=CC=C3)NC4=CC=CC=C4,,,,,,
6084,16085,"N~2~,N~4~,6-Trimethyl-1,3,5-triazine-2,4-diamine",CC1=NC(=NC(=N1)NC)NC,,,,,,
6085,16086,"s-Triazine, 2,4-bis(ethylamino)-6-methyl-",CCNC1=NC(=NC(=N1)C)NCC,,,,,,
6086,16087,"4,6-diphenoxy-N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)OC3=CC=CC=C3)OC4=CC=CC=C4,,,,,,
6087,16088,"1,3,5-Triazine-2,4-diamine, 6-chloro-N,N'-diphenyl-",C1=CC=C(C=C1)NC2=NC(=NC(=N2)Cl)NC3=CC=CC=C3,,,,,,
6088,16089,1-Bromo-2-ethylbenzene,CCC1=CC=CC=C1Br,,,,,,
6089,16090,2-Bromoheptane,CCCCCC(C)Br,,,,,,
6090,16091,3-Bromoheptane,CCCCC(CC)Br,,,,,,
6091,16092,2-((2-(Diethylamino)ethyl)thio)benzoxazole hydrochloride,CC[NH+](CC)CCSC1=NC2=CC=CC=C2O1.[Cl-],,,,,,
6092,16093,"2-(1,3-benzoxazol-2-ylsulfanyl)-N,N-diethylethanamine",CCN(CC)CCSC1=NC2=CC=CC=C2O1,,,,,,
6093,16094,"Guanidine, 1-benzyl-1-ethyl-, tartrate",CCN(CC1=CC=CC=C1)C(=N)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
6094,16095,N-benzyl-N-ethylguanidine,CCN(CC1=CC=CC=C1)C(=N)N,,,,,,
6095,16096,2-Methyl-3-nitrobenzoic acid,CC1=C(C=CC=C1[N+](=O)[O-])C(=O)O,,,,,,
6096,16097,2-Methyl-6-nitrobenzoic acid,CC1=C(C(=CC=C1)[N+](=O)[O-])C(=O)O,,,,,,
6097,16098,Aluminum nicotinate,C1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].[Al+3],,,,,,
6098,16099,CID 16099,CC=C(C)C(=O)O[C@H]1CC[NH+]2C1C(=CC2)COC(=O)C([C@H](C)OC)(C(C)(C)O)O.[Cl-],,,,,,
6099,16100,CID 16100,CC=C(C)C(=O)O[C@H]1CCN2C1C(=CC2)COC(=O)C([C@H](C)OC)(C(C)(C)O)O,,,,,,
6100,16101,"3-Buten-2-one, 4,4-diphenyl-1-(1-pyrrolidinyl)-",C1CCN(C1)CC(=O)C=C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6101,16102,CID 16102,CC(=NNC1=CC=CC=C1)C2=CC=C(C=C2)N=NC(C#N)C#N,,,,,,
6102,16103,"11-(4-Methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine",CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=CC=CC=C42,,,,,,
6103,16104,"2-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine",CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C=C4)Cl,,,,,,
6104,16105,"DIBENZO(b,f)(1,4)THIAZEPINE, 11-(4-METHYL-1-PIPERAZINYL)-",CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=CC=CC=C42,,,,,,
6105,16106,Perlapine,CN1CCN(CC1)C2=NC3=CC=CC=C3CC4=CC=CC=C42,,,,,,
6106,16107,"4-(2,4-Dihydroxy-3,3-dimethylbutyramido)-2-hydroxybutyric acid",CC(C)(CO)C(C(=O)NCCC(C(=O)O)O)O,,,,,,
6107,16108,"4-(2,4-Dihydroxy-3,3-dimethylbutyramido)-3-hydroxybutyric acid",CC(C)(CO)C(C(=O)NCC(CC(=O)O)O)O,,,,,,
6108,16109,Methyl fluorophosphoryl homocholine iodide,C[N+](C)(C)CCCOP(=O)(C)F.[I-],,,,,,
6109,16110,(3-Hydroxypropyl)trimethylammonium ester with methylphosphonofluoridate,C[N+](C)(C)CCCOP(=O)(C)F,,,,,,
6110,16111,Benzodepa,C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3,,,,,,
6111,16112,CID 16112,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=O)N(CCCl)CCCl,,,,,,
6112,16113,CID 16113,CC1=CC(=NC(=N1)[N-]S(=O)(=O)C2=CC=C(C=C2)N)C.[Na+],,,,,,
6113,16114,"Homochlorcyclizine, dihydrochloride",C[NH+]1CCC[NH+](CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
6114,16115,Chloroxuron,CN(C)C(=O)NC1=CC=C(C=C1)OC2=CC=C(C=C2)Cl,,,,"['IT IS ABSORBED BY ROOTS AND LEAVES.', 'PLANTS GROWN IN NUTRIENT SOLN ACCUMULATE MORE (14)C-LABELED CHLOROXURON IN THE ROOTS THAN IN THE STEMS OR LEAVES. THE MAIN SITE OF ENTRY OF CHLOROXURON IS THE APICAL HALF OF ROOTS.', 'Following foliar application, chloroxuron is not translocated appreciably by the assimilate stream. It is strongly absorbed by root tissues once it has been carried into the root zone by water movement.']","['Following oral admin, metabolism proceeds by oxidative demethylation & 90-95% elimination occurs within 24 hr.', ""ZEA MAYS, VICIA FABA, PHASEOLUS VULGARIS, GALINSOGA PARVIFLORA, POLYGONUM CONVOLVULUS WERE EXPOSED TO LABELED N'-(4-CHLOROPHENOXY)-PHENYL-N,N-DIMETHYLUREA. ... N'-(4-CHLOROPHENOXY)-PHENYL-N-METHYLUREA AND N'-(4-CHLOROPHENOXY)-PHENYLUREA WERE IDENTIFIED BY INFRA RED."", 'OXIDATIVE REACTION TAKING PLACE WITH HERBICIDES IN PLANTS ARE, FOR EXAMPLE, DEMETHYLATION REACTIONS THAT HAVE BEEN REPORTED FOR CHLOROXURON ... THESE ... REACTIONS PROCEED PROBABLY VIA CORRESPONDING METHYLOL COMPOUNDS WHICH ... WILL DECOMP WITH FORMATION OF A METHYLAMINE & FORMALDEHYDE.', 'CHLOROXURON IS ENZYMATICALLY DEGRADED BY PLANTS TO THE MONOMETHYLATED & DEMETHYLATED DERIVATIVES, FOLLOWED BY DECARBOXYLATION OF THE PHENOXYPHENYLUREA TO FORM (4-CHLOROPHENOXY)ANILINE. THE ANILINE DERIVATIVE MAY BE FORMED BY DIRECT HYDROLYSIS OF CHLOROXURON. THERE IS NO EVIDENCE THAT CONJUGATION OF CHLOROXURON DEGRADATION PRODUCTS OCCUR.']",
6115,16116,Siduron,CC1CCCCC1NC(=O)NC2=CC=CC=C2,,,,['Most readily absorbed through root system; less so through foliage and stems. ... Experimental evidence indicates that Siduron is translocated in the xylem.'],"['Urine from a dog receiving 2500 ppm siduron in the diet was collected and analyzed for the parent compound and metabolites using a colorimetric method, and mass, IR, and NMR spectrometry, and a metabolic pathway was proposed; none of the parent compound was found, but three glucuronide conjugates of hydroxysubstituted siduron were isolated and identified, one substituted on the phenyl ring, one substituted on the cyclohexyl ring, and another substituted in both locations; it appears that siduron is first hydroxylated at either location, then both of these mono-hydroxylated compounds are hydroxylated again to form 1-(4-hydroxy-2-methylcyclo-hexyl)-3-p-hydroxyphenylurea; comparison of urine from the dog with that from a rat on a similar 2500 ppm diet, showed that the rat formed slightly less of the cyclohexyl-substituted compound than the dog; 800-1000 ppm of total siduron metabolites was bound in the urine of these two animals.', 'In studies with (14)C-labeled siduron, no metabolites ... were detectable in barley plants after an 8 day absorption period.', '... Both phenyl and cyclohexyl rings are subjected to hydroxylation in the dog. ... The pathways proposed ... show that siduron is either hydroxylated at para position of phenyl nucleus or at 4 position of 2-methylcyclohexyl moiety. Both metabolites are further hydroxylated to form 1-(4-hydroxy-2-methylcyclohexyl)-3-(p-hydroxyphenyl)urea.', 'When urine samples of both dogs and rats were subjected to hydrolysis and analyzed for aminophenol /as well as/ aniline, it was observed that hydroxylation of the phenyl moiety was more prominent in the rat than in dog. Apparently rats exhibit particular efficiency in hydroxylating the aromatic nucleus of phenylureas. In another study in which (14)C- carbonyl-labeled compound was applied ... microbial degradation was major route of siduron disappearance in soil. Metabolites separated on thin-layer plates had same characteristics as those identified in urine, and /it was/ ... concluded that ring hydroxylation was also operative in soil environment.', 'For more Metabolism/Metabolites (Complete) data for SIDURON (6 total), please visit the HSDB record page.']",
6116,16117,"4,5,7-Trichloro-2,1,3-benzothiadiazole",C1=C(C2=NSN=C2C(=C1Cl)Cl)Cl,,,,,,
6117,16118,Methionine sulfoximine,CS(=N)(=O)CCC(C(=O)O)N,,,,,,
6118,16119,CID 16119,COC1=C(C=CC(=C1C(=O)[O-])Cl)Cl.[Na+],,,,,,
6119,16120,Tributyltin fluoride,CCCC[Sn](CCCC)(CCCC)F,,,,,,
6120,16121,Paraquat diiodide,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[I-].[I-],,,,,,
6121,16122,1-Isocyanonaphthalene,[C-]#[N+]C1=CC=CC2=CC=CC=C21,,,,,,
6122,16123,CID 16123,CCCCCCCC(=O)[O-].[Na+],,,,,,
6123,16124,Methylenediphosphonic acid,C(P(=O)(O)O)P(=O)(O)O,,,['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],,,
6124,16125,"2,5-Dichloroanisole",COC1=C(C=CC(=C1)Cl)Cl,,,,,,
6125,16126,"2,3-Dichloroanisole",COC1=C(C(=CC=C1)Cl)Cl,,,,,,
6126,16127,"2,6-Dichloroanisole",COC1=C(C=CC=C1Cl)Cl,,,,,,
6127,16128,Diphenylacetic acid 2-(bis(2-hydroxyethyl)amino)ethyl ester hydrochloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCC[NH+](CCO)CCO.[Cl-],,,,,,
6128,16129,"2-[Bis(2-hydroxyethyl)amino]ethyl 2,2-diphenylacetate",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCN(CCO)CCO,,,,,,
6129,16130,"Acetic acid, methoxydiphenyl-, 2-(diethylamino)ethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
6130,16131,"Acetic acid, 2,2-diphenyl-2-methoxy-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
6131,16132,Sulfasymazine,CCC1=NC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)CC,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
6132,16133,4-Bromophenyl isothiocyanate,C1=CC(=CC=C1N=C=S)Br,,,,,,
6133,16134,"2,4-Diamino-6-dimethylamino-1,3,5-triazine",CN(C)C1=NC(=NC(=N1)N)N,,,,,,
6134,16135,Neopentyl glycol dimethacrylate,CC(=C)C(=O)OCC(C)(C)COC(=O)C(=C)C,,,,,,
6135,16136,"(1,1-Dimethylbutyl)benzene",CCCC(C)(C)C1=CC=CC=C1,,,,,,
6136,16137,"1,1-Dimethyltetralin",CC1(CCCC2=CC=CC=C21)C,,,,,,
6137,16138,"bis[(3,4-Epoxy-6-methylcyclohexyl)methyl] adipate",CC1CC2C(O2)CC1COC(=O)CCCCC(=O)OCC3CC4C(O4)CC3C,,,,,,
6138,16139,4-Hydroxy-9-fluorenone,C1=CC=C2C(=C1)C3=C(C2=O)C=CC=C3O,,,,,,
6139,16140,"ESTRA-1,3,5(10)-TRIEN-17-beta-OL, 17-alpha-BUTADIYNYL-3-METHOXY-",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#CC#C)O)CCC4=C3C=CC(=C4)OC,,,,,,
6140,16141,Bolandiol dipropionate,CCC(=O)O[C@H]1CCC2C3CCC4([C@H](CCC4C3CCC2=C1)OC(=O)CC)C,,,,,,
6141,16142,Calotropin,C[C@@H]1C[C@@H]([C@]2([C@@H](O1)O[C@@H]3C[C@@H]4CC[C@@H]5[C@@H]([C@]4(C[C@H]3O2)C=O)CC[C@]6([C@@]5(CC[C@@H]6C7=CC(=O)OC7)O)C)O)O,,,,,"['EARLY STUDIES ON CARDENOLIDE SEQUESTRATION FROM MILKWEEDS WERE CARRIED OUT WITH THE GRASSHOPPER, POEKILOCERUS BUFONIUS. THIS APOSEMATIC NORTH AFRICAN SPECIES, WHICH PROBABLY FEEDS EXCLUSIVELY UPON MILKWEEDS IN NATURE, HAS A POISON GLAND FROM WHICH THE CONTENTS MAY BE EJECTED AS SPRAY DURING THE IMMATURE HOPPER STAGE, OR AS A FOAMY FROTH IN THE ADULT STAGE. THE SECRETION CONTAINS HISTAMINE AND ONE CAT-LETHAL DOSE OF CARDENOLIDE. WHEN REARED ON CALOTROPIS PROCERA OR ASCLEPIAS CURASSAVICA, THE GRASSHOPPERS SECRETION CONTAINED ONLY CALACTIN AND CALOTROPIN IN APPRECIABLE QUANTITIES OF THE SEVEN OR SO RELATED CARDENOLIDES PRESENT IN THE PLANT.', ""SELECTIVE STORAGE OF SOME CARDENOLIDES FROM AMONG SEVERAL IN THE FOOD PLANT WAS CONFIRMED /IN MONARCH LARVAE/... THAT METABOLIC CONVERSION MIGHT BE INVOLVED IN THIS SELECTIVITY WAS PROVEN BY SEPARATE ADMIN OF GRADED DOSES OF INDIVIDUAL CARDENOLIDES TO MONARCH LARVAE, WITH SUBSEQUENT ANALYSIS OF THE CARDENOLIDE CONTENT OF THE LARVAE & ADULTS. CALACTIN & CALOTROPIN WERE STORED INTACT, BUT USCHARIDIN WAS METABOLIZED TO A MIXTURE OF CALACTIN & CALOTROPIN, WHICH WERE THE CARDENOLIDES STORED. THIS CONVERSION, A REDUCTION, OCCURRED VERY RAPIDLY DURING FEEDING, APPARENTLY IN THE GUT. REASONS OFFERED FOR THE STOREABILITY OF CALACTIN & CALOTROPIN, BUT NOT USCHARIDIN, INCL CHEMICAL INSTABILITY OF THE LATTER IN THE GUT MILIEU, POLARITY (CALACTIN & CALOTROPIN ARE MORE POLAR THAN USCHARIDIN), & THE POSSIBILITY THAT THE C-3'OH IN THE CALACTIN & CALOTROPIN WAS NEEDED FOR BINDING TO A CARRIER AND/OR TISSUE STORAGE SITE.""]",
6142,16143,4-Heptylphenol,CCCCCCCC1=CC=C(C=C1)O,,,,,,
6143,16144,"Butyric acid, 4-(2,4-dihydroxy-3,3-dimethylbutyramido)-, calcium salt (2:1)",CC(C)(CO)C(C(=O)NCCCC(=O)[O-])O.CC(C)(CO)C(C(=O)NCCCC(=O)[O-])O.[Ca+2],,,,,,
6144,16145,3-(2-Chloroethyl)-3-azoniabicyclo(3.2.2)nonane chloride,C1CC2CCC1C[NH+](C2)CCCl.[Cl-],,,,,,
6145,16146,3-(2-Chloroethyl)-3-azabicyclo[3.2.2]nonane,C1CC2CCC1CN(C2)CCCl,,,,,,
6146,16147,Triamcinolone acetonide sodium phosphate,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COP(=O)([O-])[O-])CCC5=CC(=O)C=C[C@@]53C)F)O.[Na+].[Na+],,,,,,
6147,16148,CID 16148,C[C@]12C[C@@H]([C@]3([C@H](C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COP(=O)(O)O)CCC5=CC(=O)C=C[C@@]53C)F)O,,,,,,
6148,16149,"2-Naphthol, 6-hexyl-",CCCCCCC1=CC2=C(C=C1)C=C(C=C2)O,,,,,,
6149,16150,"2,2,2-Trichloro-1-phenylethanol",C1=CC=C(C=C1)C(C(Cl)(Cl)Cl)O,,,,,,
6150,16151,Octyl o-((2-(diethylamino)ethyl)carbamoyl)carbanilate hydrochloride,CCCCCCCCOC(=O)NC1=CC=CC=C1C(=O)NCC[NH+](CC)CC.[Cl-],,,,,,
6151,16152,octyl N-[2-[2-(diethylamino)ethylcarbamoyl]phenyl]carbamate,CCCCCCCCOC(=O)NC1=CC=CC=C1C(=O)NCCN(CC)CC,,,,,,
6152,16153,N-Ethyl-2-pyrrolidylmethyl phenylcyclopentylglycolate hydrochloride,CCN1CCCC1COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.Cl,,,,,,
6153,16154,N-Ethyl-2-pyrrolidylmethyl phenylcyclopentylglycolate,CCN1CCCC1COC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
6154,16155,CID 16155,C1=CN=C(N=C1S)S,,,,,,
6155,16156,Edetate dipotassium,C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[K+].[K+],,,"['Substances that bind to and sequester CALCIUM ions. (See all compounds classified as Calcium Chelating Agents.)', 'Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)']",,,
6156,16157,1-Phenylguanidine,C1=CC=C(C=C1)N=C(N)N,,,,,,
6157,16158,"[2-[(6S,9R,11S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate",C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=CC4([C@]3([C@H](CC2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F,,,,,,
6158,16159,"9-Azabicyclo(3.3.1)nonane, 9-(2-hydroxyethyl)-, benzilate",C1CC2CCCC(C1)N2CCOC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
6159,16160,"9-Azabicyclo(3.3.1)nonane, 9-(3-hydroxypropyl)-, benzilate",C1CC2CCCC(C1)N2CCCOC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
6160,16161,CID 16161,C1=NC2=C(N1)C(=NC(=O)N2)S,,,,,,
6161,16162,CID 16162,C12=C(NC(=O)N1)NC(=O)N=C2S,,,,,,
6162,16163,"Diethylamine, 2-bromo-2'-chloro-, hydrobromide",C(CCl)[NH2+]CCBr.[Br-],,,,,,
6163,16164,N-(2-bromoethyl)-2-chloroethanamine,C(CCl)NCCBr,,,,,,
6164,16165,2-Bromo-2'-chloro-N-methyldiethylamine hydrobromide,C[NH+](CCCl)CCBr.[Br-],,,,,,
6165,16166,N-(2-bromoethyl)-2-chloro-N-methylethanamine,CN(CCCl)CCBr,,,,,,
6166,16167,CID 16167,CC[NH+]1CCN(C1=O)C2=CC=CC=C2.[Cl-],,,,,,
6167,16168,1-Ethyl-3-phenyl-2-imidazolidinone,CCN1CCN(C1=O)C2=CC=CC=C2,,,,,,
6168,16169,CID 16169,CC1C2=CC(=C(C=C2CC[NH+]1CC3=CC=C(C=C3)Cl)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
6169,16170,"2-[(4-chlorophenyl)methyl]-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinoline",CC1C2=CC(=C(C=C2CCN1CC3=CC=C(C=C3)Cl)OC)OC,,,,,,
6170,16171,CID 16171,CC1C2=CC(=C(C=C2CC[NH+]1CCCC3=CC=C(C=C3)Cl)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
6171,16172,"2-[3-(4-chlorophenyl)propyl]-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinoline",CC1C2=CC(=C(C=C2CCN1CCCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
6172,16173,"6H-Dibenzo[b,d]pyran-6-one",C1=CC=C2C(=C1)C3=CC=CC=C3OC2=O,,,,,,
6173,16174,Cytomycin,CN1CCC(N=C1N)CC(=O)NC2C=CC(OC2C(=O)O)N3C=CC(=NC3=O)N,,,,,,
6174,16175,Methyl 2-(2-methyl-4-oxoquinazolin-3-yl)benzoate,CC1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3C(=O)OC,,,,,,
6175,16176,"Disodium 4-amino-3-hydroxy-2,7-naphthalenedisulfonate",C1=CC2=C(C(=C(C=C2C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])O)N.[Na+].[Na+],,,,,,
6176,16177,"4-Amino-3-hydroxy-2,7-naphthalenedisulfonic acid",C1=CC2=C(C(=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)O)N,,,,,,
6177,16178,CID 16178,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=O)NN(CCCl)CCCl,,,,,,
6178,16179,2-Benzylbenzoxazole,C1=CC=C(C=C1)CC2=NC3=CC=CC=C3O2,,,,,,
6179,16180,"2,4-D dimethylamine salt",CNC.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,,,,"['The dimethylamine salt of (14)C-ring-labeled 2,4-D was administered to Fisher 344 rats orally (1 and 0.4 mg/kg body weight) and dermally (10 mg/kg body weight). Absorption, distribution, and elimination were determined from (14)C-labeled 2,4-D in blood, tissues, and excreta. Most of the orally administered dose (94-96%) became systemically available within 6 hr. Following dermal administration 10% of the dose became systemically available over 72 hr. However, peak concentrations in blood and kidney were achieved within 30 min of dosing by either route. By 1.5 hr after dosing, 2,4-D concentrations in blood, muscle, liver, and kidneys had decreased in both the orally dosed and dermally dosed animals. Between 2 and 8 hr, the blood, muscle, liver, and kidney concentrations in dermally dosed animals maintained a plateau while urinary excretion increased, presumably due to continued absorption 2,4-D from the skin. The concentrations in orally dosed animals continued to decrease. Following 7 hr of dermal exposure, skin cleansing removed about 63% of the applied dose; about 17% of the applied dose remained at the site of dermal dosing. At 8 hr, 2,4-D concentrations in blood, muscle, liver, and kidneys of dermally dosed animals began to decrease, most likely a result of the removal of the reservoir on the skin. However, 2,4-D continued to be absorbed from skin site, resulting in a slower decline of the 2,4-D concentrations in these tissues over remainder of the 72 hr study period. In animals that had been orally dosed, the absorbed dose was almost completely excreted within 24 hr.', 'Plant roots absorb polar (salt) forms /of 2,4-D/ most readily. ... Following root absorption, it may move upward in the transpiration stream. Translocation is influenced by the growth status of the plant. Accumulation of the herbicide occurs principally at the meristematic regions of shoots and roots. /2,4-D salt/']","['HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID.', 'Chlorophenoxy acid derivatives are metabolized via participation of the hepatic microsomal mixed-function oxidase system. Thus, administration of 2,4-D amine salt and its butyl ester ... to rats induced the enzyme system (aminopyrine demethylase ... and aniline hydroxylase) ... although the degree of induction was substantially lower than that from phenobarbital. Prolonged administration of 2,4-D amine salt (0.1 LD50) showed cumulative effects reflected by both clinical and biochemical changes. Stimulation of mixed-function oxidase system may be one of the methods for reducing toxicological effects of this type of compounds.']","['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/', 'Average, approximated half-lives for excretion were 39.5 + or - 8.1 hr for the acid application and 58.5 + or - 13.2 hr for the DMA application.']"
6180,16181,Butylate,CCSC(=O)N(CC(C)C)CC(C)C,,,,"['Absorbed by the roots and coleoptiles, with translocation acropetally.', 'The metabolism of the thiocarbamate herbicide SUTAN (butylate) was studied after administration of single oral doses of [isobutyl-1-(14)C]SUTAN to male and female rats. The radiolabelled dose was rapidly absorbed and excreted, with 79% of the dose excreted in the urine in 72 hr. The small percentages of radioactivity excreted in the feces and as (14)CO2 were significantly higher (P less than or equal to 0.05) in males than in females. SUTAN was extensively metabolized, and no unmetabolized SUTAN was found in the urine. A total of 18 of the 29 urinary metabolites were identified, and identified metabolites represented 83-88% of the urinary radioactivity. Diisobutylamine was the major urinary metabolite in both males and females, averaging 51% of the urinary radioactivity. Other significant urinary metabolites included primary hydroxylated and tertiary hydroxylated diisobutylamines and a series of mercapturic acid pathway metabolites, including an S-glucuronide and several hydroxylated and unhydroxylated mercapturates. Oxidations at the three alkyl groups produced a variety of minor urinary metabolites, and hydroxylation of the primary or tertiary carbon on the isobutyl groups, followed by an intramolecular reaction, generated a series of minor cyclized metabolites.']","['Metabolic pathway of butylate in rats proceeds as follows: thiocarbamate, thiocarbamate sulfoxide, S-(N,N-dialkylcarbamoyl)glutathione, D-(N,N-dialkylcarbamoyl)cysteine, S-(N,N-dialkylcarbamoyl)mercapturic acid, S-(N,N-dialkylcarbamoyl)mercaptoacetic acid, and N-(S-(N,N-dialkylcarbamoyl)mercaptoacetyl)glycine. S-(N-isobutylcarbamoyl)mercapturic acid is also formed. About 40% of the (14)CO-butylate administered is metabolized by ester cleavage and (14)CO2 liberation without going through the thiocarbamate sulfoxide as an intermediate.', 'When administered to rats, butylate yielded a glycine conjugate of the mercaptoacetic acid product that was not detected with EPTC; but the cysteine conjugate was not detected with butylate. An N-de-isobutylmercapturic acid was formed from butylate but the corresponding EPTC product was not seen.', 'In mammals, following oral administration, the major metabolite is the N,N-dialkylcarbamoyl conjugate.', 'The metabolism of the thiocarbamate herbicide SUTAN (butylate) was studied after administration of single oral doses of [isobutyl-1-(14)C]SUTAN to male and female rats. The radiolabelled dose was rapidly absorbed and excreted, with 79% of the dose excreted in the urine in 72 hr. The small percentages of radioactivity excreted in the feces and as (14)CO2 were significantly higher (P less than or equal to 0.05) in males than in females. SUTAN was extensively metabolized, and no unmetabolized SUTAN was found in the urine. A total of 18 of the 29 urinary metabolites were identified, and identified metabolites represented 83-88% of the urinary radioactivity. Diisobutylamine was the major urinary metabolite in both males and females, averaging 51% of the urinary radioactivity. Other significant urinary metabolites included primary hydroxylated and tertiary hydroxylated diisobutylamines and a series of mercapturic acid pathway metabolites, including an S-glucuronide and several hydroxylated and unhydroxylated mercapturates. Oxidations at the three alkyl groups produced a variety of minor urinary metabolites, and hydroxylation of the primary or tertiary carbon on the isobutyl groups, followed by an intramolecular reaction, generated a series of minor cyclized metabolites.']",
6181,16182,"2,4,5-T-triethylammonium",CCN(CC)CC.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)O,,,,,,
6182,16183,"2,6-Dichlorobenzamide",C1=CC(=C(C(=C1)Cl)C(=O)N)Cl,,,,"['/In foliar and roots/ ... 2,6-dichlorobenzamide is readily absorbed and translocated in xylem with the transpiration stream /and/ ... accumulates ... in foliar tissues. Autoradiograms of apple leaves from seedlings and young trees show that translocated [(14)C]2,6-dichlorobenzamide is distributed throughout the leaf and tends to accumulate at the leaf margins after prolonged periods of root uptake.']","['... Both free and conjugated 3-hydroxy-2,6-dichlorobenzamide were ... isolated as metabolites from apple ... leaves treated directly with 2,6-dichlorobenzamide. Free and conjugated 3-hydroxy-2,6-dichlorobenzamide have been detected chromatographically in wheat seedlings and kale (Brassica oleracea) plants after short-term (1-5 days) root and soil uptake studies with [(14)C]2,6-dichlorobenzamide.', 'Long-term soil uptake studies (14 weeks) with [(14)C]2,6-dichlorobenzamide showed that the major metabolites in leaves of young apple trees were 3- and 4-hydroxy-2,6-dichlorobenzamide in a ratio of 6:1. Approx 85% of the hydroxylated metabolites were conjugated as glycosides. ... It appears that plants are able to hydroxylate and conjugate ... 2,6-dichlorobenzamide and that hydroxylation at the 3 position ... is favored. A comparison of dichlobenil and 2,6-dichlorobenzamide metabolism after 5 days in root treated bean seedlings showed that 2,6-dichlorobenzamide was hydroxylated and conjugated much slower than dichlobenil.', '2,6-Dichlorobenzamide is metabolized to 2,6-dichlorobenzoic acid probably in phaseolus. /From table/']",
6183,16184,5-Methoxy-N-methyltryptamine,CNCCC1=CNC2=C1C=C(C=C2)OC,,,,,,
6184,16185,CID 16185,C1C(=O)N(C(=N1)S)C2=CC=CC=C2,,,,,,
6185,16186,CID 16186,C=CCN1C(=O)CN=C1S,,,,,,
6186,16187,"ANDROST-5-ENE-3-beta,17-beta-DIOL, 17-alpha-BUTADIYNYL-",C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#CC#C)O)C)O,,,,,,
6187,16188,"(17S)-17-buta-1,3-diynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC12CCC3C(C1CC[C@]2(C#CC#C)O)CCC4=CC(=O)CCC34,,,,,,
6188,16189,"(17S)-17-buta-1,3-diynyl-17-hydroxy-13-methyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC12CCC3C(C1CC[C@]2(C#CC#C)O)CCC4=C3CCC(=O)C4,,,,,,
6189,16190,"17-alpha-Butadiynylestra-1,3,5(10)-triene-3,17-beta-diol",CC12CCC3C(C1CC[C@]2(C#CC#C)O)CCC4=C3C=CC(=C4)O,,,,,,
6190,16191,"(15-Ethylidene-17-methyl-3-aza-17-azoniapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraen-13-yl)methanol;chloride",CC=C1C[N+]2(C3CC1C(C2CC4=C3NC5=CC=CC=C45)CO)C.[Cl-],,,,,,
6191,16192,Macusine B,CC=C1C[N+]2(C3CC1C(C2CC4=C3NC5=CC=CC=C45)CO)C,,,,,,
6192,16193,4-Methoxybenzylhydrazine hydrochloride,COC1=CC=C(C=C1)CN[NH3+].[Cl-],,,,,,
6193,16194,(4-Methoxybenzyl)hydrazine,COC1=CC=C(C=C1)CNN,,,,,,
6194,16195,"Acetic acid, (3-hydroxy-2,4,6-triiodophenoxy)-",C1=C(C(=C(C(=C1I)OCC(=O)O)I)O)I,,,,,,
6195,16196,"2,4,6-Triiodobenzoic acid",C1=C(C=C(C(=C1I)C(=O)O)I)I,,,,,,
6196,16197,2-(4-Chlorophenyl)-3-methylbutanoic acid,CC(C)C(C1=CC=C(C=C1)Cl)C(=O)O,,,,,,
6197,16198,CID 16198,CCC(=O)C(=O)[O-].[Na+],,,,,,
6198,16199,CID 16199,CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O)O)Cl)O,,,,,,
6199,16200,"N,N-Diethylglycine 2,6-xylyl ester hydrochloride",CC[NH+](CC)CC(=O)OC1=C(C=CC=C1C)C.[Cl-],,,,,,
6200,16201,"(2,6-Dimethylphenyl) 2-(diethylamino)acetate",CCN(CC)CC(=O)OC1=C(C=CC=C1C)C,,,,,,
6201,16202,"N,N-Dipropylglycine 2,6-xylyl ester hydrochloride",CCC[NH+](CCC)CC(=O)OC1=C(C=CC=C1C)C.[Cl-],,,,,,
6202,16203,"(2,6-Dimethylphenyl) 2-(dipropylamino)acetate",CCCN(CCC)CC(=O)OC1=C(C=CC=C1C)C,,,,,,
6203,16204,"N,N-Dibutylglycine 2,6-xylyl ester hydrochloride",CCCC[NH+](CCCC)CC(=O)OC1=C(C=CC=C1C)C.[Cl-],,,,,,
6204,16205,"(2,6-Dimethylphenyl) 2-(dibutylamino)acetate",CCCCN(CCCC)CC(=O)OC1=C(C=CC=C1C)C,,,,,,
6205,16206,"L-N,N-Diethylalanine 2,6-xylyl ester hydrochloride",CC[NH+](CC)C(C)C(=O)OC1=C(C=CC=C1C)C.[Cl-],,,,,,
6206,16207,"(2,6-Dimethylphenyl) 2-(diethylamino)propanoate",CCN(CC)C(C)C(=O)OC1=C(C=CC=C1C)C,,,,,,
6207,16208,"L-N,N-Diethylalanine 6-chloro-o-tolyl ester hydrochloride",CC[NH+](CC)C(C)C(=O)OC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
6208,16209,(2-Chloro-6-methylphenyl) 2-(diethylamino)propanoate,CCN(CC)C(C)C(=O)OC1=C(C=CC=C1Cl)C,,,,,,
6209,16210,"N,N-Diethylglycine mesityl ester hydrochloride",CC[NH+](CC)CC(=O)OC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
6210,16211,"(2,4,6-Trimethylphenyl) 2-(diethylamino)acetate",CCN(CC)CC(=O)OC1=C(C=C(C=C1C)C)C,,,,,,
6211,16212,3-Hydroxy-N-(beta-hydroxyphenethyl)-p-cymene-2-carboxamide,CC1=C(C(=C(C=C1)C(C)C)O)C(=O)NCC(C2=CC=CC=C2)O,,,,,,
6212,16213,CID 16213,C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
6213,16214,Nonylammonium chloride,CCCCCCCCC[NH3+].[Cl-],,,,,,
6214,16215,Nonylamine,CCCCCCCCCN,,,,,,
6215,16216,Octanamine acetate,CCCCCCCC[NH3+].CC(=O)[O-],,,,,,
6216,16217,Tetradecylamine,CCCCCCCCCCCCCCN,,,,,,
6217,16218,"N,N-Dimethyl-1-heptadecylamine hydrochloride",CCCCCCCCCCCCCCCCC[NH+](C)C.[Cl-],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
6218,16219,"1-Heptadecanamine, N,N-dimethyl-",CCCCCCCCCCCCCCCCCN(C)C,,,,,,
6219,16220,Hexadecyldimethylammonium chloride,CCCCCCCCCCCCCCCC[NH+](C)C.[Cl-],,,,,,
6220,16221,Hexadecyldimethylamine,CCCCCCCCCCCCCCCCN(C)C,,,,,,
6221,16222,Dodecyldimethylammonium chloride,CCCCCCCCCCCCN(C)C.Cl,,,,,,
6222,16223,"N,N-Dimethyl-1-octylamine hydrochloride",CCCCCCCC[NH+](C)C.[Cl-],,,,,,
6223,16224,"N,N-Dimethyloctylamine",CCCCCCCCN(C)C,,,,,,
6224,16225,"N,N-Dimethyl-1-heptylamine hydrochloride",CCCCCCC[NH+](C)C.[Cl-],,,,,,
6225,16226,"N,N-Dimethylheptylamine",CCCCCCCN(C)C,,,,,,
6226,16227,Hexadecylammonium acetate,CCCCCCCCCCCCCCCC[NH3+].CC(=O)[O-],,,,,,
6227,16228,Dodecylammonium acetate,CCCCCCCCCCCC[NH3+].CC(=O)[O-],,,,,,
6228,16229,Bamifylline,CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
6229,16230,Amiloride hydrochloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.Cl,,,"['A subclass of sodium channel blockers that are specific for EPITHELIAL SODIUM CHANNELS. (See all compounds classified as Epithelial Sodium Channel Blockers.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'A subclass of sodium channel blockers that are specific for ACID-SENSING SODIUM CHANNELS. (See all compounds classified as Acid Sensing Ion Channel Blockers.)']",,,
6230,16231,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,['For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.'],"['Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements.']","['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'A subclass of sodium channel blockers that are specific for EPITHELIAL SODIUM CHANNELS. (See all compounds classified as Epithelial Sodium Channel Blockers.)', 'A subclass of sodium channel blockers that are specific for ACID-SENSING SODIUM CHANNELS. (See all compounds classified as Acid Sensing Ion Channel Blockers.)']","['Readily absorbed following oral administration.', 'Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys.  About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours.']",['Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.'],['Plasma half-life varies from 6 to 9 hours.']
6231,16232,2-(N4-Acetylsulfanilamido)ethyl iodoacetate,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NCCOC(=O)CI,,,,,,
6232,16233,Dibutylcarbamic acid 2-(diethylamino)ethyl ester hydrochloride,CCCCN(CCCC)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
6233,16234,"2-(diethylamino)ethyl N,N-dibutylcarbamate",CCCCN(CCCC)C(=O)OCCN(CC)CC,,,,,,
6234,16235,Atrolactamide,CC(C1=CC=CC=C1)(C(=O)N)O,,,,,,
6235,16236,"N-Propyl-4-cyclohexene-1,2-dicarboximide",CCCN1C(=O)C2CC=CCC2C1=O,,,,,,
6236,16237,Ethyl 3-phenylpropionate,CCOC(=O)CCC1=CC=CC=C1,,,,,,
6237,16238,2-Isopropylnaphthalene,CC(C)C1=CC2=CC=CC=C2C=C1,,,,"['Pulmonary toxicity of 2-isopropylnaphthalene (2-IPN) and its photoproducts was studied in mice. Twenty-four hours after the intraperitoneal injection of 2-IPN or its photoproducts, 2-isopropenylnaphthalene (2-IPeN) (1000 mg/kg), 2-acetonaphthone (2-AN) (700 mg/kg), beta-naphthol (BN) (50 mg/kg), phthalide (PH) (500 mg/kg) and phthalic acid (PA) (100 mg/kg) produced pulmonary damage, but 2-IPN (3000 mg/kg) and 2-(2-naphthyl)-2-propanol (2-NP) (100 mg/kg) did not produce pulmonary damage. The maximum levels of 2-IPN in the lung, liver and kidney were observed 6 h after the administration, and then the levels decreased with time. The concentrations of 2-IPeN, 2-NP, 2-AN, BN, PH and PA in the tissues, reached the maximum levels within 1 or 2 hr, and then rapidly decreased with time. The binding of both 2-AN and BN to lung slices was greater than that of other compounds. The injections of 2-IPN, 2-IPeN, BN and PH caused considerable depletion of pulmonary GSH  (reduced glutathione).', 'Over 95% of orally admin 2-isopropylnaphthalene was absorbed within 24 hr from the GI tract in rats. Peak levels in the blood, liver, kidneys, brain, heart, spleen, and muscle were observed at 2 hr, whereas peak levels in the adipose tissue and skin were observed at 4-6 hr. Amount of unchanged 2-isopropylnaphthalene in urine was small. In rats fed the experimental diet containing 0.1% for 14 or 28 days, 2-isopropylnaphthalene in the adipose tissue decreased to 1/3 within 24 hr after halting continuous ingestion.']","['Metabolism of 2-isopropylnaphthalene in rats proceeded through oxidation of isopropyl chain of the molecule. Four unconjugated metabolites were isolated from urine and identified: 2-(2-naphthyl)propionic acid, 2-(2-naphthyl)-2-propanol, 2-(2-naphthyl)-1,2-propanediol and 2-(2-naphthyl)-2-hydroxypropionic acid, together with a small amount of unchanged compound.']",
6238,16239,3-Butyn-2-ol,CC(C#C)O,,,,,,
6239,16240,Octyl carbamate,CCCCCCCCOC(=O)N,,,,,,
6240,16241,Triethoxymethylsilane,CCO[Si](C)(OCC)OCC,,,,,,
6241,16242,CID 16242,C1=CC=C(C=C1)C2(C(=NC(=N2)S)S)C3=CC=CC=C3,,,,,,
6242,16243,"N,N'-bis-(4-Chlorophenyl)formamidine",C1=CC(=CC=C1NC=NC2=CC=C(C=C2)Cl)Cl,,,,,,
6243,16244,"Morpholine, 4-(thiobenzoyl)-",C1COCCN1C(=S)C2=CC=CC=C2,,,,,,
6244,16245,N-Morpholinylthiosalicylamide,C1COCCN1C(=S)C2=CC=CC=C2O,,,,,,
6245,16246,N-Piperidinylthiosalicylamide,C1CCN(CC1)C(=S)C2=CC=CC=C2O,,,,,,
6246,16247,Aminocarb,CC1=C(C=CC(=C1)OC(=O)NC)N(C)C,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['THESE CMPD ARE RAPIDLY METABOLIZED & EXCRETED IN URINE. /CARBAMATES/', 'Readily absorbed through intact skin ... .', 'Uptake and clearance of aminocarb by Caecidolea racovitzai racovitzai were shown to be proportional to exposure temp, indicating that they may be active processes. Control of clearance may be a function of the rate of metab of aminocarb in vivo. Both uptake and clearance were shown to occur in two compartments.', 'Penetration of the blood-brain barrier by the carbamates is insignificant; for this reason, fewer CNS symptoms occur. /Carbamate pesticides/', 'For more Absorption, Distribution and Excretion (Complete) data for AMINOCARB (6 total), please visit the HSDB record page.']","['YIELDS 4-DIMETHYLAMINO-3-METHYLPHENYL N-HYDROXYMETHYLCARBAMATE & 3-METHYL-4-METHYLAMINOPHENYL N-METHYLCARBAMATE IN MAN & IN RAT.', 'AFTER TREATMENT OF GROWING BEAN LEAVES WITH LABELED MATACIL, @ LEAST 8 COMPOUNDSWERE DETECTED. OF THESE, 4 ... IDENTIFIED AS 4-FORMAMIDO-, 4-METHYLFORMAMIDO-, 4-AMINO, & 4-METHYLAMINO-3-CRESYLMETHYLCARBAMATES.', 'AFTER EXPOSURE OF FLIES TO LABELED MATACIL, (14)CO2 AROSE THROUGH N-DEALKYLATION& HYDROLYSIS TO RESPECTIVE PHENOL & METHYLCARBAMIC ACID. LATTER DECOMP TO CO2 VIA FORMATE ... INCUBATION ... WITH FLY HOMOGENATES & NADPH2 GAVE RISE TO 4-FORMAMIDO-, 4-METHYLFORMAMIDO-, 4-AMINO-, & 4-METHYLAMINO-3-CRESYL METHYLCARBAMATES.', 'WHEN LABELED MATACIL WAS ADMIN TO RATS, (14)CO2 WAS OBSERVED. AFTER INCUBATION WITH RAT LIVER MICROSOME-NADPH SYSTEM, MATACIL WAS DEGRADED TO N-HYDROXYMETHYL MATACIL, 4-AMINO-3-CRESYL N-METHYLCARBAMATE, 4-METHYLAMINO-3-CRESYL N-METHYLCARBAMATE.', 'For more Metabolism/Metabolites (Complete) data for AMINOCARB (6 total), please visit the HSDB record page.']",
6247,16248,Methiocarb,CC1=CC(=CC(=C1SC)C)OC(=O)NC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Agents destructive to snails and other mollusks. (See all compounds classified as Molluscacides.)']","['In dermal toxicity studies, methiocarb was not readily absorbed via the skin, even in solvents expected to enhance dermal absorption. In a cow given 5 daily doses of ring-labeled methiocarb, radioactivity in the milk (due to methiocarb sulfoxide) peaked at 0.062 ppm after the third dose. Tissue residues were highest in the kidney (0.108 ppm) & liver (0.073 ppm); levels in other tissues did not exceed 0.02 ppm. Following subchronic dietary exposure of beef & dairy cattle to methiocarb, residues exceeded 0.005 ppm only in the liver (at dosages of 30 ppm or higher) & the kidney (at a dosage of 100 ppm); residues were not detected in the brain, heart, muscle, or fat. Milk collected on exposure days 28 & 29 contained methiocarb residues ranging from 0.005 ppm (at a dosage of 10 ppm) to 0.033 ppm (at a dosage of 100 ppm).', 'Of a single dose of carbonyl-labeled methiocarb to rats, more than 60% was eliminated as expired 14 CO2. In another study, about 66% was eliminated as 14 CO2, about 22% in the urine, & 2.5% in the feces; elimination was about 91% complete. Ring-labeled methiocarb was excreted almost entirely in the urine within 48 hr. Of a ring-labeled dose of methiocarb to a dairy cow, 96% appeared in the urine, 1% in the feces, and 1% in the milk within 144 hr.', 'In dogs & mice, following oral admin, methiocarb is rapidly absorbed & excreted, principally in the urine, with only a small proportion in the feces.']","['WHEN RAT & HUMAN LIVER WAS INCUBATED WITH MESUROL, ABOUT A DOZEN METABOLITES WERE OBSERVED ... MAJOR METABOLITE WAS MESUROL SULFOXIDE. SEVERAL METABOLIC PRODUCTS ... FROM HUMAN LIVER STUDIES, WERE NOT OBSERVED IN RAT STUDIES. HYDROLYSIS YIELDED THE PHENOLIC MOIETY OF MESUROL.', 'Methiocarb, an aromatic alkyl sulfide insecticide was enzymatically oxidized into sulfoxide by  microsomes from soybean cotyledons. No further oxidation into sulfone was detected.  Distribution of the sulfoxidase activity was studied in soybean seedlings & was maximal in  cotyledons. Subcellular fractionation of cotyledon homogenates indicated that the activity was  almost entirely associated with the microsomal fraction. Methiocarb did not require cofactors  such as NAD(P)H. Nevertheless, the sulfoxidase did not act as a peroxidase.', 'The oxidation of sulfide-containing organophosphate & carbamate pesticides by the flavin-containing monooxygenase was measured in mammalian microsomes made devoid of cytochrome p450 dependent activity, primarily through the use of inhibitory antibodies against reduced nicotinamide adenine dinucleotide phosphate cytochrome p450 reductase. Rates of metab were determined for mouse, rabbit & rat liver, lung & kidney microsomes, & for pig liver microsomes. Substrate specificity of the enzyme in different species & tissues is similar. Lung & kidney microsomes have high flavin-containing monooxygenase levels, & this enzyme is important relative to cytochrome p450 in these tissues. Thioether-containing organophosphates are effective substrates for the flavin-containing monooxygenase in mouse liver microsomes, with Km values between 3.5 & 36 muM. Thioether-containing carbamates are less effective substrates having Km values near 280 muM. ... /Thioether-containing organophosphate & carbamate pesticides/', 'The ability of purified microsomal FAD-containing monooxygenase from mouse & pig liver to oxidize pesticides was investigated. The kinetic constants were determined for a number of pesticide substrates including thioether-containing organophosphorus cmpds, carbamates /thiofanox, methiocarb, aldicarb/ & (di)alkyldithiocarbamates. The thioether-containing organophosphorus cmpds were the best substances for both enzymes followed by the thioether-containing carbamates. The (di)alkyldithiocarbamates were relatively poor substrates for both pig & mouse liver microsomal FAD-containing monooxygenases.', 'For more Metabolism/Metabolites (Complete) data for METHIOCARB (8 total), please visit the HSDB record page.']",
6248,16249,"2,2-Dimethyl-1,3-dioxane-4,6-dione",CC1(OC(=O)CC(=O)O1)C,,,,,,
6249,16250,1-Iodo-2-naphthol,C1=CC=C2C(=C1)C=CC(=C2I)O,,,,,,
6250,16251,"3,4-Dimethoxyphenol",COC1=C(C=C(C=C1)O)OC,,,,,,
6251,16252,Centalun,CC(C#C)(C(C1=CC=CC=C1)O)O,,,,,,
6252,16253,"2,4,5-Tribromoimidazole",C1(=C(N=C(N1)Br)Br)Br,,,,,,
6253,16254,CID 16254,COC1=CC2=CC(=C(OC2=CC1=O)O)OC3=CC4=C(C=C3)C=CC(=O)O4,,,,,,
6254,16255,3-Methylbutyl octanoate,CCCCCCCC(=O)OCCC(C)C,,,,,,
6255,16256,"Acetic acid, N,N-diethylaminomethyl ester",CCN(CC)COC(=O)C,,,,,,
6256,16257,3-Chlorothiophenol,C1=CC(=CC(=C1)Cl)S,,,,,,
6257,16258,Carsalam,C1=CC=C2C(=C1)C(=O)NC(=O)O2,,,,,,
6258,16259,3-Phenylpropylamine,C1=CC=C(C=C1)CCCN,,,,,,
6259,16260,"3,5-Diphenyl-4H-1,2,4-triazole",C1=CC=C(C=C1)C2=NC(=NN2)C3=CC=CC=C3,,,,,,
6260,16261,"N,N'-Diphenyl-6-methyl-1,3,5-triazine-2,4-diamine",CC1=NC(=NC(=N1)NC2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
6261,16262,"2-(Methylamino)-4,6-diphenyl-1,3,5-triazine",CNC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
6262,16263,4-Bromostyrene,C=CC1=CC=C(C=C1)Br,,,,,,
6263,16264,2-Bromostyrene,C=CC1=CC=CC=C1Br,,,,,,
6264,16265,"2,5-Dimethylstyrene",CC1=CC(=C(C=C1)C)C=C,,,,,,
6265,16266,"2,6-Dimethylstyrene",CC1=C(C(=CC=C1)C)C=C,,,,,,
6266,16267,"1-(2,6-Dimethoxyphenyl)ethanone",CC(=O)C1=C(C=CC=C1OC)OC,,,,,,
6267,16268,2-Bromo-6-chlorophenol,C1=CC(=C(C(=C1)Br)O)Cl,,,,,,
6268,16269,Butylcyclopentane,CCCCC1CCCC1,,,,,,
6269,16270,Propylcyclopentane,CCCC1CCCC1,,,,,,
6270,16271,4-Methyl-3-nitrophenol,CC1=C(C=C(C=C1)O)[N+](=O)[O-],,,,,,
6271,16272,2-Bromobenzonitrile,C1=CC=C(C(=C1)C#N)Br,,,,,,
6272,16273,"3,12-Dihydroxy-14,15-epoxybufa-20,22-dienolide",C[C@]12CC[C@@H](C[C@H]1CCC3C2C[C@H]([C@]4([C@]35[C@H](O5)C[C@@H]4C6=COC(=O)C=C6)C)O)O,,,,,,
6273,16274,Buthiazide,CC(C)CC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,,,"['Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
6274,16275,Cyclohexanecarboxaldehyde,C1CCC(CC1)C=O,,,,,,
6275,16276,"Tetrahydro-2,5-furandicarboxylic acid (trans)",C1CC(O[C@@H]1C(=O)O)C(=O)O,,,,,,
6276,16277,N-Methyl-2-pyridinethione,CN1C=CC=CC1=S,,,,,,
6277,16278,"N,N-Dimethylacetoacetamide",CC(=O)CC(=O)N(C)C,,,,,,
6278,16279,"Acetanilide, 4'-bis(2-iodoethyl)amino-",CC(=O)NC1=CC=C(C=C1)N(CCI)CCI,,,,,,
6279,16280,"BENZOIC ACID, p-(BIS(2-IODOETHYL)AMINO)-",C1=CC(=CC=C1C(=O)O)N(CCI)CCI,,,,,,
6280,16281,"ACETIC ACID, THIO-, S-ESTER with 4-(BIS(2-BROMOETHYL)AMINO)BENZENE THIOL",CC(=O)SC1=CC=C(C=C1)N(CCBr)CCBr,,,,,,
6281,16282,"Acetanilide, 4'-(bis(2-bromoethyl)amino)-",CC(=O)NC1=CC=C(C=C1)N(CCBr)CCBr,,,,,,
6282,16283,"BENZOIC ACID, p-(BIS(2-BROMOETHYL)AMINO)-",C1=CC(=CC=C1C(=O)O)N(CCBr)CCBr,,,,,,
6283,16284,"N,N-Bis(2-bromoethyl)aniline",C1=CC=C(C=C1)N(CCBr)CCBr,,,,,,
6284,16285,"BENZOIC ACID, p-(N-(2-CHLOROETHYL)-N-ETHYLAMINO)-",CCN(CCCl)C1=CC=C(C=C1)C(=O)O,,,,,,
6285,16286,"BENZOIC ACID, p-(2-CHLOROETHYL)AMINO-",C1=CC(=CC=C1C(=O)O)NCCCl,,,,,,
6286,16287,"CARBANILIC ACID, p-(BIS(2-CHLOROETHYL)AMINO)-, ISOPROPYL ESTER",CC(C)OC(=O)NC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
6287,16288,"Ethylenediamine, N-benzyl-N',N'-dimethyl-N-phenyl-, hydrochloride",C[NH+](C)CCN(CC1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
6288,16289,CID 16289,C[NH+](C)CCC=C1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
6289,16290,"3-(5-chloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,,,,,,
6290,16291,1-Amino-4-phenylisonipecotic acid ethyl ester hydrochloride,CCOC(=O)C1(CCN(CC1)[NH3+])C2=CC=CC=C2.[Cl-],,,,,,
6291,16292,Ethyl 1-amino-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)N)C2=CC=CC=C2,,,,,,
6292,16293,Diethyl 2-ethyl-2-methylmalonate,CCC(C)(C(=O)OCC)C(=O)OCC,,,,,,
6293,16294,Isopentylbenzene,CC(C)CCC1=CC=CC=C1,,,,,,
6294,16295,tert-Amylbenzene,CCC(C)(C)C1=CC=CC=C1,,,,,,
6295,16296,Pentyl benzoate,CCCCCOC(=O)C1=CC=CC=C1,,,,,,
6296,16297,"2,2-Dimethylpropyl butanoate",CCCC(=O)OCC(C)(C)C,,,,,,
6297,16298,Pentyl phenyl ether,CCCCCOC1=CC=CC=C1,,,,,,
6298,16299,Amyl salicylate,CCCCCOC(=O)C1=CC=CC=C1O,,,,,,
6299,16300,Diethyl pimelate,CCOC(=O)CCCCCC(=O)OCC,,,,,,
6300,16301,Diethyl suberate,CCOC(=O)CCCCCCC(=O)OCC,,,,,,
6301,16302,"3,5-Diethyltoluene",CCC1=CC(=CC(=C1)C)CC,,,,,,
6302,16303,"N-(2,4-Dimethylphenyl)acetamide",CC1=CC(=C(C=C1)NC(=O)C)C,,,,,"['N-(2,4-Dimethylphenyl)acetamide is a known human metabolite of 2,4-dimethylaniline.']",
6303,16304,"N-(2,5-Dimethylphenyl)acetamide",CC1=CC(=C(C=C1)C)NC(=O)C,,,,,"['N-(2,5-Dimethylphenyl)acetamide is a known human metabolite of 2,5-dimethylaniline.']",
6304,16305,Bis(4-bromophenyl) ether,C1=CC(=CC=C1OC2=CC=C(C=C2)Br)Br,,,,,,
6305,16306,Dibutyl oxalate,CCCCOC(=O)C(=O)OCCCC,,,,,,
6306,16307,"3,3'-Dichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=CC(=CC=C2)Cl,,,,,,
6307,16308,"4,4'-Dichlorobiphenyl",C1=CC(=CC=C1C2=CC=C(C=C2)Cl)Cl,,,,,"[""4,4'-Dichlorobiphenyl has known human metabolites that include 4,4--Dichloro-3-biphenylol.""]",
6308,16309,"1,2-Dichloronaphthalene",C1=CC=C2C(=C1)C=CC(=C2Cl)Cl,,,,,,
6309,16310,"1,7-Dichloronaphthalene",C1=CC2=C(C=C(C=C2)Cl)C(=C1)Cl,,,,,,
6310,16311,"1,8-Dichloronaphthalene",C1=CC2=C(C(=C1)Cl)C(=CC=C2)Cl,,,,,,
6311,16312,"2,3-Dichloronaphthalene",C1=CC=C2C=C(C(=CC2=C1)Cl)Cl,,,,,,
6312,16313,"2,4-Dichloro-1-naphthol",C1=CC=C2C(=C1)C(=CC(=C2O)Cl)Cl,,,,,,
6313,16314,1-Iododecane,CCCCCCCCCCI,,,,,,
6314,16315,Diallyl trisulfide,C=CCSSSCC=C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (See all compounds classified as Spermatocidal Agents.)']",,,
6315,16316,Dipentylamine,CCCCCNCCCCC,,,,,,
6316,16317,"5,6-Chrysenedione",C1=CC=C2C(=C1)C=CC3=C2C(=O)C(=O)C4=CC=CC=C34,,,,,,
6317,16318,Decachlorobiphenyl,C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
6318,16319,"2,6-Dimethyloctane",CCC(C)CCCC(C)C,,,,,,
6319,16320,4-Decanol,CCCCCCC(CCC)O,,,,,,
6320,16321,6-Chlorocoumarin,C1=CC2=C(C=CC(=O)O2)C=C1Cl,,,,,,
6321,16322,3-Chlorobiphenyl,C1=CC=C(C=C1)C2=CC(=CC=C2)Cl,,,,['Aroclors 1221 and 1254 were found to cross the placenta of rabbits when administered orally to does during gestation.'],,
6322,16323,4-Chlorobiphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)Cl,,,,,,
6323,16324,Allyl butyrate,CCCC(=O)OCC=C,,,,,,
6324,16325,Sudan Orange G,C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)O)O,,,,,,
6325,16326,"[1,1'-Biphenyl]-3-sulfonic acid, 4,4'-diamino-",C1=CC(=CC=C1C2=CC(=C(C=C2)N)S(=O)(=O)O)N,,,,,,
6326,16327,Dichlorodiphenylmethane,C1=CC=C(C=C1)C(C2=CC=CC=C2)(Cl)Cl,,,,,,
6327,16328,"4-Bromo-N,N-diethylaniline",CCN(CC)C1=CC=C(C=C1)Br,,,,,,
6328,16329,2-Bromobiphenyl,C1=CC=C(C=C1)C2=CC=CC=C2Br,,,,,,
6329,16330,Butyl salicylate,CCCCOC(=O)C1=CC=CC=C1O,,,,,,
6330,16331,Butyl levulinate,CCCCOC(=O)CCC(=O)C,,,,,,
6331,16332,CID 16332,C1=CC2=C(C=CC(=C2O)N=NC3=C(C=CC(=C3)S(=O)(=O)[O-])O)C(=C1)O.[Na+],,,,,,
6332,16333,"3-((1,5-Dihydroxy-2-naphthyl)azo)-4-hydroxybenzenesulphonic acid",C1=CC2=C(C=CC(=C2O)N=NC3=C(C=CC(=C3)S(=O)(=O)O)O)C(=C1)O,,,,,,
6333,16334,1-(2-Diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole hydrochloride,CC[NH+](CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OCC.[Cl-],,,,,,
6334,16335,alpha-(1-(Cyclohexylamino)ethyl)benzenemethanol,CC(C(C1=CC=CC=C1)O)NC2CCCCC2,,,,,,
6335,16336,CID 16336,C1CNC(=NC1)S,,,,,,
6336,16337,"N,N'-Bis(o-chlorobenzyl)ethylenediamine dihydrochloride",C1=CC=C(C(=C1)C[NH2+]CC[NH2+]CC2=CC=CC=C2Cl)Cl.[Cl-].[Cl-],,,,,,
6337,16338,"n,n'-Bis(2-chlorobenzyl)ethane-1,2-diamine",C1=CC=C(C(=C1)CNCCNCC2=CC=CC=C2Cl)Cl,,,,,,
6338,16339,"N,N'-Hexamethylenebis(2-chlorobenzylamine) dihydrochloride",C1=CC=C(C(=C1)C[NH2+]CCCCCC[NH2+]CC2=CC=CC=C2Cl)Cl.[Cl-].[Cl-],,,,,,
6339,16340,"N,N'-Bis(o-chlorobenzyl)-1,6-hexanediamine",C1=CC=C(C(=C1)CNCCCCCCNCC2=CC=CC=C2Cl)Cl,,,,,,
6340,16341,"1,7-Heptanediamine, N,N'-bis(o-chlorobenzyl)-, dihydrochloride",C1=CC=C(C(=C1)C[NH2+]CCCCCCC[NH2+]CC2=CC=CC=C2Cl)Cl.[Cl-].[Cl-],,,,,,
6341,16342,"N,N'-Bis(o-chlorobenzyl)-1,7-heptanediamine",C1=CC=C(C(=C1)CNCCCCCCCNCC2=CC=CC=C2Cl)Cl,,,,,,
6342,16343,"NONAMETHYLENEDIAMINE, N,N'-BIS(o-CHLOROBENZYL)-, DIHYDROCHLORIDE",C1=CC=C(C(=C1)C[NH2+]CCCCCCCCC[NH2+]CC2=CC=CC=C2Cl)Cl.[Na+].[Na+],,,,,,
6343,16344,"N,N'-bis[(2-chlorophenyl)methyl]nonane-1,9-diamine",C1=CC=C(C(=C1)CNCCCCCCCCCNCC2=CC=CC=C2Cl)Cl,,,,,,
6344,16345,"1,10-Decanediamine, N,N'-bis(o-chlorobenzyl)-, dihydrochloride",CCCCCCCCC=C([NH2+]CC1=CC=CC=C1Cl)[NH2+]CC2=CC=CC=C2Cl.[Cl-].[Cl-],,,,,,
6345,16346,"1-N,1-N'-bis[(2-chlorophenyl)methyl]dec-1-ene-1,1-diamine",CCCCCCCCC=C(NCC1=CC=CC=C1Cl)NCC2=CC=CC=C2Cl,,,,,,
6346,16347,Cintazone,CCCCCC1C(=O)N2C=C(C3=CC=CC=C3N2C1=O)C4=CC=CC=C4,,,,,,
6347,16348,CID 16348,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=N)C(=CC3=[N+](O)[O-])C(=O)O,,,,,,
6348,16349,CID 16349,C[C@@]1(C2C(C3C(C(=O)C(=C(N)O)C(=O)C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)[NH+](C)C)O)O.[Cl-],,,,,,
6349,16350,CID 16350,C[C@@]1(C2C(C3C(C(=O)C(=C(N)O)C(=O)C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O)O,,,,,,
6350,16351,Clothiapine,CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
6351,16352,"DIBENZ(b,f)(1,4)OXAZEPINE, 11-(4-METHYL-1-PIPERAZINYL)-",CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=CC=CC=C42,,,,,,
6352,16353,3'-Methyl-4-methylaminoazobenzene,CC1=CC(=CC=C1)N=NC2=CC=C(C=C2)NC,,,,,,
6353,16354,4-Ethylmethylaminoazobenzene,CCN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
6354,16355,N-Ethyl-4-aminoazobenzene,CCNC1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
6355,16356,CID 16356,CNC1=C2C=CC=CC2=NC1=O,,,,,,
6356,16357,"5-Bromo-1-methylindoline-2,3-dione",CN1C2=C(C=C(C=C2)Br)C(=O)C1=O,,,,,,
6357,16358,N-Methylisatin,CN1C2=CC=CC=C2C(=O)C1=O,,,,,,
6358,16359,"17-(3,3,3-Trifluoro-1-propynyl)estra-1,3,5(10)-trien-3,17-beta-diol",CC12CCC3C(C1CC[C@]2(C#CC(F)(F)F)O)CCC4=C3C=CC(=C4)O,,,,,,
6359,16360,CID 16360,CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C24C=CC5(C3(CC[C@@H](C5)O)C)OO4)C,,,,,,
6360,16361,"Butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)-, hydrochloride",C1C[NH+](CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F.[Cl-],,,,,,
6361,16362,Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,"[""Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.""]","[""Pimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).""]","['Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias. (See all compounds classified as Anti-Dyskinesia Agents.)']",['Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.'],"['Notable first-pass metabolism in the liver, primarily by N-dealkylation via the cytochrome P450 isoenzymes CYP3A and CYP1A2 (and possibly CYP2D6). The activity of the two major metabolites has not been determined.', 'Pimozide has known human metabolites that include 1,3- dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI).']",['29 &plusmn; 10 hours (single-dose study of healthy volunteers).']
6362,16363,Benperidol,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
6363,16364,"5-(2-Aminoethyl)-5H-dibenzo(B,F)azepine",C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2CCN,,,,,,
6364,16365,Methyl phenoxyacetate,COC(=O)COC1=CC=CC=C1,,,,,,
6365,16366,"2,6-Dichloronaphthalene",C1=CC2=C(C=CC(=C2)Cl)C=C1Cl,,,,,,
6366,16367,Pasiniazid,C1=CC(=C(C=C1N)O)C(=O)O.C1=CN=CC=C1C(=O)NN,,,,,,
6367,16368,5-Bromovaleric acid,C(CCBr)CC(=O)O,,,,,,
6368,16369,CID 16369,CC(CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)CCO,,,,,,
6369,16370,CID 16370,CCC1=CCN2CCC34C2C1C(C(C3N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)OC)C=O)(C(=O)OC)O)OC(=O)C.OS(=O)(=O)O,,,,,,
6370,16371,"Methyl 11-acetyloxy-13-ethyl-4-(17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl)-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate",CCC1=CCN2CCC34C2C1C(C(C3N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)OC)C=O)(C(=O)OC)O)OC(=O)C,,,,,,
6371,16372,(2S)-2-amino-4-oxo-4-(sulfanylamino)butanoic acid,C([C@@H](C(=O)O)N)C(=O)NS,,,,,,
6372,16373,Diethylaminoethyl diphenyl-alpha-ethyloxyacetate hydrochloride,CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
6373,16374,"2-(Diethylamino)ethyl 2-ethoxy-2,2-diphenylacetate",CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
6374,16375,4-Bromo-1H-pyrazole,C1=C(C=NN1)Br,,,,,,
6375,16376,4-Nitro-1H-pyrazole,C1=C(C=NN1)[N+](=O)[O-],,,,,,
6376,16377,o-Chlorocumene,CC(C)C1=CC=CC=C1Cl,,,,,,
6377,16378,"2,3,6-Trichlorotoluene",CC1=C(C=CC(=C1Cl)Cl)Cl,,,,,,
6378,16379,"Benzenamine, 2,6-dinitro-N-propyl-4-(trifluoromethyl)-",CCCNC1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],,,,,,
6379,16380,Blastizidin [German],CN(CC[C@@H](CC(=O)N[C@@H]1C=C[C@H](O[C@H]1C(=O)O)N2C=CC(=NC2=O)N)N)C(=N)N,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']","['Upon oral application to the mouse, blasticidin-S and metabolites were excreted in the urine and feces within 24 hr.']","['In rice plants, cytomycin and deaminohydroxy blasticidin-S were identified as the main metabolites.']",
6380,16381,CID 16381,CC(=O)C1=CC=C(C=C1)CCCN2CCCCC2,,,,,,
6381,16382,"(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate;trimethyl-[3-methyl-6-(trimethylazaniumyl)hexyl]azanium",CC(CCC[N+](C)(C)C)CC[N+](C)(C)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,,,,,,
6382,16383,Trimethyl-[3-methyl-6-(trimethylazaniumyl)hexyl]azanium,CC(CCC[N+](C)(C)C)CC[N+](C)(C)C,,,,,,
6383,16384,3-Ethyl-hexadiene,CCC=C(CC)C=C,,,,,,
6384,16385,"Cycloheptanol, 1-phenyl-",C1CCCC(CC1)(C2=CC=CC=C2)O,,,,,,
6385,16386,"Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate",CCCCCCCCCCCCCCCCCCOC(=O)CCC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,,,,,,
6386,16387,"1,4-Butanediol dimethacrylate",CC(=C)C(=O)OCCCCOC(=O)C(=C)C,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME A DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
6387,16388,Decyltrimethylammonium bromide,CCCCCCCCCC[N+](C)(C)C.[Br-],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
6388,16389,Decyltrimethylammonium,CCCCCCCCCC[N+](C)(C)C,,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
6389,16390,tert-Butyl-tert-pentylamine hydrochloride,CCC(C)(C)[NH2+]C(C)(C)C.[Cl-],,,,,,
6390,16391,tert-Amyl-tert-butylamine,CCC(C)(C)NC(C)(C)C,,,,,,
6391,16392,"N,N-Diethyl-2-phenyl-glycine 2,6-xylyl ester hydrochloride",CC[NH+](CC)C(C1=CC=CC=C1)C(=O)OC2=C(C=CC=C2C)C.[Cl-],,,,,,
6392,16393,"(2,6-Dimethylphenyl) 2-(diethylamino)-2-phenylacetate",CCN(CC)C(C1=CC=CC=C1)C(=O)OC2=C(C=CC=C2C)C,,,,,,
6393,16394,"N,N-Diethylglycine 2,6-diethylphenyl ester hydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)C[NH+](CC)CC.[Cl-],,,,,,
6394,16395,"(2,6-Diethylphenyl) 2-(diethylamino)acetate",CCC1=C(C(=CC=C1)CC)OC(=O)CN(CC)CC,,,,,,
6395,16396,"N,N-Diethylglycine 2,6-dimethoxyphenyl ester hydrochloride",CC[NH+](CC)CC(=O)OC1=C(C=CC=C1OC)OC.[Cl-],,,,,,
6396,16397,"(2,6-Dimethoxyphenyl) 2-(diethylamino)acetate",CCN(CC)CC(=O)OC1=C(C=CC=C1OC)OC,,,,,,
6397,16398,2-Methyl-2-phenyloxirane,CC1(CO1)C2=CC=CC=C2,,,,,,
6398,16399,2-Methyl-1-penten-3-OL,CCC(C(=C)C)O,,,,,,
6399,16400,Methylacetophos,CCOC(=O)CSP(=O)(OC)OC,,,,,,
6400,16401,6-Aminohexylazanium;chloride,C(CCCN)CC[NH3+].[Cl-],,,,,,
6401,16402,"1,6-Hexanediamine",C(CCCN)CCN,,,,"['.../HEXAMETHYLENE IS/ ABSORBED THROUGH THE SKIN.', 'Following oral administration of (14)C-labeled 1,6-diaminohexane to male rats, approx 20% of the administered dose was recovered as (14)CO2 after 72 hr. Urinary and fecal excretion accounted for 47 and 27% of the administered radioactivity, respectively. Of several tissues examined, the highest concn of residual radioactivity were found in the prostate at 24 and 72 hr post-administration.', 'An isocyanate generation apparatus was developed and stable isocyanate atmospheres were obtained. At a concn of 5 ug 1,6-hexamethylene diisocyanate (HD) per cu m the precision was found to be 7% (n = 5). Three volunteers were each exposed to the different concn of HI (11.9, 20.5, and 22.1 micrograms/ cu m) and three concns of isophorone diisocyanate (IPDI) (12.1, 17.7, and 50.7 micrograms/cu m), in an exposure chamber. The duration of the exposure was 2 hr. Urine and blood samples were collected, and hydrolyzed under alkaline conditions to the HI and IPDI corresponding amines, 1,6-hexamethylene diamine (HDA) and isophorone diamine (IPDA), determined as their pentafluoropropionic anhydride amides (HDA-PFPA and IPDA-PFPA). The HDA- and IPDA-PFPA derivatives were analyzed using liquid chromatography mass spectrometry with thermospray monitoring negative ions. When working up samples from the exposed persons without hydrolysis, no HDA or IPDA was seen. The average urinary excretion of the corresponding amine was 39% for HI and 27% for IPDI . An association between the estimated inhaled dose and the total excreted amount was seen. The average urinary elimination half-time for HDA was 2.5 hr and for IPDA, 2.8 hr. The hydrolysis condition giving the highest yield of HDA and IPDA in urine was found to be hydrolysis wi the 3 M sodium hydroxide during 4 hr. No HDA or IPDA could be found in hydrolyzed plasma (< ca 0.1 micrograms/l) .']",,
6402,16403,"Acetophenone, 2'-(2-(dimethylamino)ethoxy)-",CC(=O)C1=CC=CC=C1OCCN(C)C,,,,,,
6403,16404,"Heptane, 1,1-dicyclohexyl-",CCCCCCC(C1CCCCC1)C2CCCCC2,,,,,,
6404,16405,Promethazine hydroxyethyl chloride,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)[N+](C)(C)CCO.[Cl-],,,,,,
6405,16406,Promethazine hydroxyethyl,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)[N+](C)(C)CCO,,,,,,
6406,16407,"1,3,2-Dithiaphospholane, 2-(bis(2-chloroethyl)amino)-, 2-oxide",C1CSP(=O)(S1)N(CCCl)CCCl,,,,,,
6407,16408,1-Chloro-2-(4-nitrophenoxy)benzene,C1=CC=C(C(=C1)OC2=CC=C(C=C2)[N+](=O)[O-])Cl,,,,,,
6408,16409,CID 16409,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=CC(=C3)S(=O)(=O)[O-])O)O.[Na+],,,,,,
6409,16410,"Benzenesulfonic acid, 4-hydroxy-3-[(2-hydroxy-1-naphthalenyl)azo]-",C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=CC(=C3)S(=O)(=O)O)O)O,,,,,,
6410,16411,N-propan-2-ylidene-3-prop-1-en-2-ylbenzamide,CC(=NC(=O)C1=CC=CC(=C1)C(=C)C)C,,,,,,
6411,16412,Diglycidylaniline,C1C(O1)CN(CC2CO2)C3=CC=CC=C3,,,,,,
6412,16413,CID 16413,CCC(C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
6413,16414,7-Hydroxychlorpromazine,CN(C)CCCN1C2=C(C=C(C=C2)O)SC3=C1C=C(C=C3)Cl,,,,,['7-Hydroxychlorpromazine is a known human metabolite of chlorpromazine.'],
6414,16415,Methyl 2-chloro-3-dimethoxyphosphoryl-3-hydroxybutanoate,CC(C(C(=O)OC)Cl)(O)P(=O)(OC)OC,,,,,,
6415,16416,Phenylsilatrane,C1CO[Si]2(OCCN1CCO2)C3=CC=CC=C3,,,,,,
6416,16417,Ciproterone,CC(=O)[C@]1(CCC2C1(CCC3C2C=C(C4=CC(=O)[C@@H]5C[C@@H]5C34C)Cl)C)O,,,,,,
6417,16418,4-Pentenal,C=CCCC=O,,,,,,
6418,16419,"FORMAMIDINE, N'-(p-CHLOROPHENYL)-N,N-DIMETHYL-",CN(C)C=NC1=CC=C(C=C1)Cl,,,,,,
6419,16420,"4-(4-Nitrophenyl)-1,3-thiazol-2-amine",C1=CC(=CC=C1C2=CSC(=N2)N)[N+](=O)[O-],,,,,,
6420,16421,O-Ethyl O-(4-nitrophenyl) phenylphosphonothioate,CCOP(=S)(C1=CC=CC=C1)OC2=CC=C(C=C2)[N+](=O)[O-],,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['EPN is readily absorbed following either oral or dermal exposure. In rats, following a single oral dose of 1.5 mg/kg EPN, about 61-68% of the dose was excreted in urine and 7-21% of the dose was excreted in the feces. Metabolism was essentially complete because urinary excretion of metabolites totaled 60-68% of the total dose, the corresponding fecal values were 6.7-17.2%. ...In rats given 0.72 or 0.072 mg/kg EPN three times at 24 hr intervals, 14 and 26% of the dose was excreted as p-nitrophenol in urine. EPN was not detectable in blood at any time after the final dose but was detectable in adipose tissue (0.06 ppm) only on day 3.', 'Radioactivity of single dermal dose, 20.0 mg/kg of (14)C-EPN admin to adult male cats disappeared exponentially at rate constant of 0.46/day, corresponding to half-life of 1.5 days. Most of radioactivity was excreted in urine (29.9%); only 3.2% in feces. None was detected in expired CO2. Only traces of EPN were detected in urine and feces. EPN was major substance identified 0.5 day after admin in brain, spinal cord, sciatic nerve, adipose tissue, plasma, muscle, liver and kidney. Most radioactivity in liver and kidney after 4 days was identified as metabolites. Half-life of EPN elimination from plasma was 9.1 days. Relative residence of EPN relative to plasma was longest in sciatic nerve and shortest in kidney.', 'When a rat was preconditioned for 21 days on a diet that contained 450 ppm EPN, only traces of  the dose remained in body tissues after 72 hr. Thus, EPN was practically completely  metabolized and eliminated in rats. Two EPN conditioned hens that received 2.5 mg/kg EPN for 21  days and two unconditioned hens excreted 94-100% of a single oral, nonneurotoxic 4 mg/kg dose  with in 72 hr of admin. No significant difference was apparent in the dose excreted from  conditioned or unconditioned chickens. Small amounts of EPN remained in body tissues; only trace amounts were found in the brain and spinal cord. By contrast, a single oral neurotoxic  dose of 50 mg/kg EPN was slowly metabolized and excreted by chickens. Only 65% of the dose was  eliminated during the 72 hr test. Excreta extract contained the same five metabolites found in  the rat. Thus, the 50 mg/kg dose may have exceeded the metabolic capacity of the liver to detoxify EPN.', 'In cats, EPN was readily absorbed when a single dose of 20 mg/kg was dermally applied as reflected by disappearance of EPN from the application site. Most of the absorbed dose was excreted in urine (29.9%); 3.2% was recovered in the feces. In cats given daily dermal doses of 0.5 mg/kg EPN for 10 days, 62% fo the total dose was given daily dermal doses of 0.5 mg/kg EPN for 10 days, 62% of the total dose was eliminated in the urine. Thus, the metabolism and toxicokinetics of EPN in the cat are intermediate between those in the rat and in the chicken. Similarly to the rat, EPN is excreted as polar metabolite, mostly in the urine. As int he chicken, however, EPN is persistent in cat tissues, especially in nervous tissues. The finding that the cat is ten times less sensitive than the chicken to subchronic dermal exposure to EPN may be explained by the relatively rapid metabolism and elimination of EPN in the cat.', '...Elimination of the phosphorus-containing residue may be via the urine or feces. Some bound residues remain in exposed animals. Binding seems to be to proteins, principally, and the turnover appears to be related to the half-life of these proteins. There are limited data showing that incorporation of residues into DNA occurs only in trace amounts and not by direct alkylation, such as might be believed to be associated with genetic damage. /Organophosphorus Pesticides/']","['Yields p-aminophenyl ethyl benzenethiophosphonate in rat, guinea pig, mouse, sparrow, chicken, sucker, bass, alewife, flounder, sunfish, bullhead, sculpin and bluegill. /from table/', 'Rabbit sera brought about removal of sulfur and hydrolysis to p-nitrophenol. ...After incubation of EPN with nadph2, oxygen and microsomes of rat, housefly, or rabbit liver, corresponding phenol was found in each case. Oxon analog was also produced. Some conversion of oxon to corresponding phenol was also observed.', '.../Para-nitrophenol/ is formed either by way of esteratic cleavage of the /EPN/ oxon or directly from .../EPN/ by mono-oxygenase-catalyzed dearylation prompted by initial oxidative attack at p=s.', 'Metabolism of single 1 mg (2.7 uci/kg) oral dose of (14)C EPN in 1 wk old chicks produced o-ethyl phenylphosphonic acid, phenylphosphonic acid, and o-ethyl phenylphosphonothioic acid.', 'For more Metabolism/Metabolites (Complete) data for EPN (7 total), please visit the HSDB record page.']","['Single 1 mg (2.7 muci/kg) oral dose of (14)C EPN admin to 1 wk old chicks had half-life of 16 hr.', 'Radioactivity of single dermal dose, 20.0 mg/kg of (14)C EPN admin to adult male cats disappeared exponentially at rate constant of 0.46/day, corresponding to half-life of 1.5 days. Half-life of EPN elimination from plasma was 9.1 days', 'In rats, following a single oral dose of 1.5 mg/kg EPN, ...the plasma half-life was approximately 33.6 hr in males and 38.6 hr in females.']"
6421,16422,Bromofos,COP(=S)(OC)OC1=CC(=C(C=C1Cl)Br)Cl,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for BROMOPHOS (12 total), please visit the HSDB record page.']","['Plasma & tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase. The enzymes are found in plasma and in the hepatic endoplasmic reticulum & can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond. /Anticholinesterase agents/', 'These chemicals are detoxified by cytochrome p450 mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd. ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/', 'The detoxification of bromophos takes place at both the methyl and the phenyl phosphate bonds. Following dermal application to cows, bromophos could be detected in the blood at a concentration of about 0.01 ppm, but bromoxon was not detectable. The main metabolite in this species was desmethylbromophos, which was detected in concentrations of 0.4 to 0.7 ppm in both milk and blood. Following ingestion, guinea pigs excrete a substantial proportion of insecticidal material in their feces, either as the parent compound or as some unidentified, insecticidal metabolite.', 'For more Metabolism/Metabolites (Complete) data for BROMOPHOS (9 total), please visit the HSDB record page.']",
6422,16423,CID 16423,CC1=C2C(=CC(=O)C=C2OC(=C1)O)O,,,,,,
6423,16424,CID 16424,CC1=C2C=CC(=O)C(=C2OC(=C1)O)O,,,,,,
6424,16425,"1,1-Dichlorocyclohexane",C1CCC(CC1)(Cl)Cl,,,,,,
6425,16426,Butacetin,CC(=O)NC1=CC=C(C=C1)OC(C)(C)C,,,,,,
6426,16427,Diethyl(4-hydroxy-4-phenyl-4-(2-pyridyl)-2-butynyl)methylammonium bromide,CC[N+](C)(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CC=N2)O.[Br-],,,,,,
6427,16428,Diethyl-(4-hydroxy-4-phenyl-4-pyridin-2-ylbut-2-ynyl)-methylazanium,CC[N+](C)(CC)CC#CC(C1=CC=CC=C1)(C2=CC=CC=N2)O,,,,,,
6428,16429,(4-Hydroxy-4-phenyl-4-(2-pyridyl)-2-butynyl)trimethylammonium bromide,C[N+](C)(C)CC#CC(C1=CC=CC=C1)(C2=CC=CC=N2)O.[Br-],,,,,,
6429,16430,(4-Hydroxy-4-phenyl-4-pyridin-2-ylbut-2-ynyl)-trimethylazanium,C[N+](C)(C)CC#CC(C1=CC=CC=C1)(C2=CC=CC=N2)O,,,,,,
6430,16431,9-(3-Piperidino-1-propynyl)fluoren-9-ol hydrochloride,C1CC[NH+](CC1)CC#CC2(C3=CC=CC=C3C4=CC=CC=C42)O.[Cl-],,,,,,
6431,16432,9-(3-Piperidin-1-ylprop-1-ynyl)fluoren-9-ol,C1CCN(CC1)CC#CC2(C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
6432,16433,9-(3-(1-Pyrrolidinyl)-1-propynyl)fluoren-9-ol hydrochloride,C1CC[NH+](C1)CC#CC2(C3=CC=CC=C3C4=CC=CC=C42)O.[Cl-],,,,,,
6433,16434,9-[3-(Pyrrolidin-1-yl)prop-1-yn-1-yl]-9h-fluoren-9-ol,C1CCN(C1)CC#CC2(C3=CC=CC=C3C4=CC=CC=C42)O,,,,,,
6434,16435,9-(3-(Diethylamino)-1-propynyl)fluoren-9-ol hydrochloride,CC[NH+](CC)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O.[Cl-],,,,,,
6435,16436,9-[3-(Diethylamino)prop-1-ynyl]fluoren-9-ol,CCN(CC)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
6436,16437,(3-(9-Hydroxyfluoren-9-yl)-2-propynyl)trimethylammonium bromide,C[N+](C)(C)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O.[Br-],,,,,,
6437,16438,3-(9-Hydroxyfluoren-9-yl)prop-2-ynyl-trimethylazanium,C[N+](C)(C)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
6438,16439,(4-Cyclohexyl-4-hydroxy-4-phenyl-2-butynyl)diethylmethylammonium bromide,CC[N+](C)(CC)CC#CC(C1CCCCC1)(C2=CC=CC=C2)O.[Br-],,,,,,
6439,16440,(4-Cyclohexyl-4-hydroxy-4-phenylbut-2-ynyl)-diethyl-methylazanium,CC[N+](C)(CC)CC#CC(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
6440,16441,Perillaldehyde,CC(=C)C1CCC(=CC1)C=O,,,,,,
6441,16442,"2,4-Dichloro-6-(trichloromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)Cl)C(Cl)(Cl)Cl,,,,,,
6442,16443,"6-Methyl-1,3,5-triazine-2,4(1H,3H)-dione",CC1=NC(=O)NC(=O)N1,,,,,,
6443,16444,CID 16444,C1=CC(=CC(=C1)Cl)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
6444,16445,(N'-carbamimidoylcarbamimidoyl)-ethylazanium;chloride,CC[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
6445,16446,Ethylbiguanide,CCN=C(N)N=C(N)N,,,,,,
6446,16447,2-Acetamidobiphenyl,CC(=O)NC1=CC=CC=C1C2=CC=CC=C2,,,,,,
6447,16448,3-Acetamidobiphenyl,CC(=O)NC1=CC=CC(=C1)C2=CC=CC=C2,,,,,,
6448,16449,3-Bromobiphenyl,C1=CC=C(C=C1)C2=CC(=CC=C2)Br,,,,,,
6449,16450,3-Nitrobiphenyl,C1=CC=C(C=C1)C2=CC(=CC=C2)[N+](=O)[O-],,,,,,
6450,16451,p-Aminobiphenyl hydrochloride,C1=CC=C(C=C1)C2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
6451,16452,2-Bromopropiophenone,CC(C(=O)C1=CC=CC=C1)Br,,,,,,
6452,16453,CID 16453,C(=NC(=N)S)(N)N,,,,,,
6453,16454,Allyl carbamate,C=CCOC(=O)N,,,,,,
6454,16455,Methallyl carbamate,CC(=C)COC(=O)N,,,,,,
6455,16456,2-Chloroethyl carbamate,C(CCl)OC(=O)N,,,,,,
6456,16457,2-Acetoxy-1-phenylpropane,CC(CC1=CC=CC=C1)OC(=O)C,,,,,,
6457,16458,4-Benzylpyridine,C1=CC=C(C=C1)CC2=CC=NC=C2,,,,,,
6458,16459,CID 16459,C1CNCN=C1S,,,,,,
6459,16460,"4-Amino-3,5-diiodobenzoic acid",C1=C(C=C(C(=C1I)N)I)C(=O)O,,,,,,
6460,16461,4-Amino-3-iodobenzoic acid,C1=CC(=C(C=C1C(=O)O)I)N,,,,,,
6461,16462,"2-(2,4,5-Trichlorophenoxy)ethanol",C1=C(C(=CC(=C1Cl)Cl)Cl)OCCO,,,,,,
6462,16463,"5-(5-Nitro-2-furyl)-1,3,4-oxadiazole-2-ol",C1=C(OC(=C1)[N+](=O)[O-])C2=NNC(=O)O2,,,,,,
6463,16464,CID 16464,CN(C1=CC=CC=C1)C(=N)N=C([NH3+])N.[Cl-],,,,,,
6464,16465,1-Methyl-1-phenylbiguanide,CN(C1=CC=CC=C1)C(=N)N=C(N)N,,,,,,
6465,16466,CID 16466,CN(CC1=CC=CC=C1)C(=N)N=C([NH3+])N.[Cl-],,,,,,
6466,16467,1-Benzyl-3-(diaminomethylidene)-1-methylguanidine,CN(CC1=CC=CC=C1)C(=N)N=C(N)N,,,,,,
6467,16468,"2,4-Dichlorostyrene",C=CC1=C(C=C(C=C1)Cl)Cl,,,,,,
6468,16469,"2,3-Dichlorostyrene",C=CC1=C(C(=CC=C1)Cl)Cl,,,,,,
6469,16470,Phenpropyl-trimethylammonium iodide,C[N+](C)(C)CCCC1=CC=CC=C1.[I-],,,,,,
6470,16471,3-Phenylpropyltrimethylammonium,C[N+](C)(C)CCCC1=CC=CC=C1,,,,,,
6471,16472,Mebanazine oxalate,CC(C1=CC=CC=C1)NN.C(=O)(C(=O)O)O,,,,,,
6472,16473,Clorexolone,C1CCC(CC1)N2CC3=CC(=C(C=C3C2=O)S(=O)(=O)N)Cl,,,,,,
6473,16474,"2,2'-Dithiobis(5-nitropyridine)",C1=CC(=NC=C1[N+](=O)[O-])SSC2=NC=C(C=C2)[N+](=O)[O-],,,,,,
6474,16475,"Benzidine-3,3'-dicarboxylic acid",C1=CC(=C(C=C1C2=CC(=C(C=C2)N)C(=O)O)C(=O)O)N,,,,,,
6475,16476,Pentadecylbenzene,CCCCCCCCCCCCCCCC1=CC=CC=C1,,,,,,
6476,16477,"1,3,7-Trimethylnaphthalene",CC1=CC2=C(C=C(C=C2C=C1)C)C,,,,,,
6477,16478,"1,4,5-Trimethylnaphthalene",CC1=C2C(=CC=C(C2=CC=C1)C)C,,,,,,
6478,16479,"1,4,6-Trimethylnaphthalene",CC1=CC2=C(C=CC(=C2C=C1)C)C,,,,,,
6479,16480,4-Chlorophenyl isothiocyanate,C1=CC(=CC=C1N=C=S)Cl,,,,,,
6480,16481,3-Bromophenyl isothiocyanate,C1=CC(=CC(=C1)Br)N=C=S,,,,,,
6481,16482,"2,4-Bis(3,3-ethyleneureido)toluene",CC1=C(C=C(C=C1)NC(=O)N2CC2)NC(=O)N3CC3,,,,,,
6482,16483,"[6-[2-acetyloxy-1-[[(2S)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] acetate",CCCC1C[C@H](N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)OC(=O)C)O)O)C(C)OC(=O)C,,,,,,
6483,16484,"4,4'-Dimethoxy-1,1'-biphenyl",COC1=CC=C(C=C1)C2=CC=C(C=C2)OC,,,,,,
6484,16485,3-Methyl-3-phenylhexane,CCCC(C)(CC)C1=CC=CC=C1,,,,,,
6485,16486,(S)-Azetidine-2-carboxylic acid,C1CN[C@@H]1C(=O)O,,,,,,
6486,16487,"5,5'-Dehydrodivanillate",COC1=CC(=CC(=C1O)C2=C(C(=CC(=C2)C(=O)O)OC)O)C(=O)O,,,,,,
6487,16488,5-Carboxyvanillic acid,COC1=CC(=CC(=C1O)C(=O)O)C(=O)O,,,,,,
6488,16489,"(2S,4R,8S,11S,12R)-8-acetyl-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC(=O)[C@@]12[C@@H](C[C@@H]3C1(C[C@@H]([C@]4(C3CCC5=CC(=O)C=CC54C)F)O)C)OC(O2)(C)C,,,,,,
6489,16490,Flumethasone,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F,"['For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions']","['Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",['Minimal if applied topically'],['Primarily hepatic'],
6490,16491,2-(Tetradecyloxy)ethanol,CCCCCCCCCCCCCCOCCO,,,,,,
6491,16492,Ethylene glycol monohexadecyl ether,CCCCCCCCCCCCCCCCOCCO,,,,,,
6492,16493,Chlorthal,C1(=C(C(=C(C(=C1Cl)Cl)C(=O)O)Cl)Cl)C(=O)O,,,,,,
6493,16494,1-Chloro-2-(trichloromethyl)benzene,C1=CC=C(C(=C1)C(Cl)(Cl)Cl)Cl,,,,,,
6494,16495,"2,2',3,3',5,5',6,6'-Octachlorobiphenyl",C1=C(C(=C(C(=C1Cl)Cl)C2=C(C(=CC(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
6495,16496,4-Chlorocatechol,C1=CC(=C(C=C1Cl)O)O,,,,,,
6496,16497,4-Isopropylcatechol,CC(C)C1=CC(=C(C=C1)O)O,,,,,,
6497,16498,3-Isopropylcatechol,CC(C)C1=C(C(=CC=C1)O)O,,,,,,
6498,16499,"Benzoxazole, 2-amino-5-chloro-6-methoxy-",COC1=C(C=C2C(=C1)OC(=N2)N)Cl,,,,,,
6499,16500,ADP-glucose,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)N,,,,,,
6500,16501,3-Ethoxypropionitrile,CCOCCC#N,,,,,,
6501,16502,3'-Bromoacetophenone,CC(=O)C1=CC(=CC=C1)Br,,,,,,
6502,16503,2'-Ethylacetophenone,CCC1=CC=CC=C1C(=O)C,,,,,,
6503,16504,2-Isopropylacetophenone,CC(C)C1=CC=CC=C1C(=O)C,,,,,,
6504,16505,"1-(2,3-Dimethylphenyl)ethanone",CC1=C(C(=CC=C1)C(=O)C)C,,,,,,
6505,16506,"1-(2,6-Dimethylphenyl)ethanone",CC1=C(C(=CC=C1)C)C(=O)C,,,,,,
6506,16507,"2-Hydroxy-4,8-dimethylnona-3,7-dienal",CC(=CCCC(=CC(C=O)O)C)C,,,,,,
6507,16508,"cis-2,5-Dimethyltetrahydrofuran",C[C@@H]1CC[C@@H](O1)C,,,,,,
6508,16509,Paramethasone disodium phosphate,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)C)F.[Na+].[Na+],,,,,,
6509,16510,CID 16510,C[C@@H]1CC2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)C)F,,,,,,
6510,16511,3-(2-Pyridyl)-5-(2-piperidinoethyl)-isoxazole hydrochloride,C1CC[NH+](CC1)CCC2=CC(=NO2)C3=CC=CC=N3.[Cl-],,,,,,
6511,16512,"5-(2-Piperidin-1-ylethyl)-3-pyridin-2-yl-1,2-oxazole",C1CCN(CC1)CCC2=CC(=NO2)C3=CC=CC=N3,,,,,,
6512,16513,3-(p-Methoxyphenyl)-5-(2-piperidinoethyl)isoxazole hydrochloride,COC1=CC=C(C=C1)C2=NOC(=C2)CC[NH+]3CCCCC3.[Cl-],,,,,,
6513,16514,"3-(4-Methoxyphenyl)-5-(2-piperidin-1-ylethyl)-1,2-oxazole",COC1=CC=C(C=C1)C2=NOC(=C2)CCN3CCCCC3,,,,,,
6514,16515,3-(p-Methoxyphenyl)-5-(2-(diethylamino)ethyl)isoxazole hydrochloride,CC[NH+](CC)CCC1=CC(=NO1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
6515,16516,"N,N-diethyl-2-[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]ethanamine",CCN(CC)CCC1=CC(=NO1)C2=CC=C(C=C2)OC,,,,,,
6516,16517,3-(p-Methoxyphenyl)-5-(2-(dimethylamino)ethyl)-isoxazole hydrochloride,C[NH+](C)CCC1=CC(=NO1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
6517,16518,"2-[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]-N,N-dimethylethanamine",CN(C)CCC1=CC(=NO1)C2=CC=C(C=C2)OC,,,,,,
6518,16519,"propan-2-yl N-(2,4-dichlorophenyl)carbamate",CC(C)OC(=O)NC1=C(C=C(C=C1)Cl)Cl,,,,,,
6519,16520,"Isopropyl N-(3,4-dichlorophenyl)carbamate",CC(C)OC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
6520,16521,1-chloropropan-2-yl N-(3-chlorophenyl)carbamate,CC(CCl)OC(=O)NC1=CC(=CC=C1)Cl,,,,,,
6521,16522,"Methyl 3,4-dimethoxybenzoate",COC1=C(C=C(C=C1)C(=O)OC)OC,,,,,,
6522,16523,"Methyl 2,4-dihydroxybenzoate",COC(=O)C1=C(C=C(C=C1)O)O,,,,,,
6523,16524,Pyronine B,CCN(CC)C1=CC2=C(C=C1)C=C3C=CC(=[N+](CC)CC)C=C3O2.[Cl-],,,,,,
6524,16525,"Ethanaminium, N-[6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethyl-, chloride",CCN(CC)C1=CC2=C(C=C1)C=C3C=CC(=[N+](CC)CC)C=C3O2,,,,,,
6525,16526,2-Amino-2-thiazoline-4-carboxylic acid,C1C(N=C(S1)N)C(=O)O,,,,,,
6526,16527,CID 16527,C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3O)S(=O)(=O)[O-])N)O.[Na+],,,,,,
6527,16528,Alizarine Saphirol SE,C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3O)S(=O)(=O)O)N)O,,,,,,
6528,16529,Methyl N-(3-chlorophenyl)carbamate,COC(=O)NC1=CC(=CC=C1)Cl,,,,,,
6529,16530,"N-(3,4-Dichlorophenyl)acetamide",CC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
6530,16531,"N,N-Dimethyl-N'-phenylformamidine and methyl iodide",C[N+](C)(C)C=NC1=CC=CC=C1.[I-],,,,,,
6531,16532,Trimethyl(phenyliminomethyl)azanium,C[N+](C)(C)C=NC1=CC=CC=C1,,,,,,
6532,16533,Betamethasone valerate,CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
6533,16534,Spirit blue,C1=CC=C(C=C1)NC2=CC=C(C=C2)C(=C3C=CC(=NC4=CC=CC=C4)C=C3)C5=CC=C(C=C5)NC6=CC=CC=C6.Cl,,,,,,
6534,16535,Spirit blue base,C1=CC=C(C=C1)NC2=CC=C(C=C2)C(=C3C=CC(=NC4=CC=CC=C4)C=C3)C5=CC=C(C=C5)NC6=CC=CC=C6,,,,,,
6535,16536,2-chloro-N-(4-ethoxyphenyl)acetamide,CCOC1=CC=C(C=C1)NC(=O)CCl,,,,,,
6536,16537,Terpinyl formate,CC1=CCC(CC1)C(C)(C)OC=O,,,,,,
6537,16538,Metofoline,CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC,,,,,,
6538,16539,CID 16539,C(C(=O)[O-])(Cl)Cl.[Na+],,,,,,
6539,16540,N-Chloropiperidine,C1CCN(CC1)Cl,,,,,,
6540,16541,Decyl acrylate,CCCCCCCCCCOC(=O)C=C,,,,,,
6541,16542,Octyl methacrylate,CCCCCCCCOC(=O)C(=C)C,,,,,,
6542,16543,9-Fluorenone oxime,C1=CC=C2C(=C1)C3=CC=CC=C3C2=NO,,,,,,
6543,16544,"3-Cyclohexene-1,1-dimethanol",C1CC(CC=C1)(CO)CO,,,,,,
6544,16545,"Cycloheptimidazole, 2-(dimethylamino)-",CN(C)C1=NC2=CC=CC=CC2=N1,,,,,,
6545,16546,2-Methoxytropone,COC1=CC=CC=CC1=O,,,,,,
6546,16547,"2,4-Diacetylphloroglucinol",CC(=O)C1=C(C(=C(C=C1O)O)C(=O)C)O,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
6547,16548,5-Amino-2-benzoylbenzoic acid,C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)N)C(=O)O,,,,,,
6548,16549,"Carbodiimide, bis(2,6-diethylphenyl)-",CCC1=C(C(=CC=C1)CC)N(C#N)C2=C(C=CC=C2CC)CC,,,,,,
6549,16550,"1,2-Dichlorohexane",CCCCC(CCl)Cl,,,,,,
6550,16551,"1,6-Dichlorohexane",C(CCCCl)CCCl,,,,,,
6551,16552,Diethyl propylmalonate,CCCC(C(=O)OCC)C(=O)OCC,,,,,,
6552,16553,CID 16553,CCNC1=NC(=O)N=C(N1)NC(C)C,,,,,,
6553,16554,Cycluron,CN(C)C(=O)NC1CCCCCCC1,,,,['Herbicidal ureas are mainly absorbed via the plant roots and are translocated with the transpiration current to their site of action in the green plant parts. /Ureas/'],"['In ... plants, and warm-blooded animals, demethylation of the nitrogen atom, hydrolytic cleavage, and liberation of carbon dioxide and ammonia /occurs/.']",
6554,16555,3-Amino-4-hydroxyphenylarsonic acid,C1=CC(=C(C=C1[As](=O)(O)O)N)O,,,,,,
6555,16556,Noruron,CN(C)C(=O)NC1CC2CC1C3C2CCC3,,,,,,
6556,16557,CID 16557,C[As](=O)(O)[O-].[Na+],,,,,,
6557,16558,2-Bromo-6'-(t-butyl)-N-(methoxymethyl)-O-acetamide,CC1=C(C(=CC=C1)C(C)(C)C)N(COC)C(=O)CBr,,,,,,
6558,16559,Lenacil,C1CCC(CC1)N2C(=O)C3=C(CCC3)NC2=O,,,,,,
6559,16560,Chloranocryl,CC(=C)C(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
6560,16561,sec-Butyl N-(3-chlorophenyl)carbamate,CCC(C)OC(=O)NC1=CC(=CC=C1)Cl,,,,,,
6561,16562,Fluometuron,CN(C)C(=O)NC1=CC=CC(=C1)C(F)(F)F,,,,"['... UPTAKE BY ROOTS & TRANSLOCATION TO AERIAL PARTS OF (14)C-LABELED ... FLUOMETURON IN FRENCH DWARF BEAN SEEDLINGS, CULTURED IN NUTRIENT SOLN SUPPLIED WITH 2.5 PPM (AND EQUAL CONCN OF RADIOACTIVITY) OF ... HERBICIDE /WAS STUDIED/. ... FLUOMETURON ... /WAS/ RAPIDLY TRANSLOCATED INTO LEAVES. IN CONTRAST /TO BEING/ ... CONFINED TO TRACHEAL VEINS, FLUOMETURON HAD ALMOST COMPLETELY MOVED OUT INTO THE MESOPHYLL TISSUES.', 'FLUOMETURON IS MORE READILY ABSORBED BY ROOTS FROM SOIL APPLICATION THAN FROM FOLIAR APPLICATION. FOLIAR ABSORPTION IS AIDED BY ADDING SURFACTANT OR NONPHYTOTOXIC OIL TO SPRAY SOLN. ... TRANSLOCATION OF ROOT ABSORBED. ... IS VIA APOPLAST TO UPPER PLANT PARTS. FOLIAR APPLICATIONS ARE ALSO TRANSLOCATED IN APOPLAST ... .']","['... FLUOMETURON WAS METABOLIZED IN VIVO, PRIMARILY BY LIVER, TO N-DESMETHYL & N-DEMETHYLATED ANALOGS ... A SMALL AMT WAS EXCRETED AS ANILINE ANALOG. NO LABELED CO2 WAS DETECTED DURING FIRST 48 HR. AFTER TREATMENT OF CUCUMBERS & COTTON WITH FLUOMETURON, (14)C-METABOLITES WERE DETERMINED BY AUTORADIOGRAPHY. MONOMETHYLATED, DEMETHYLATED, & ANILINE DERIVATIVES WERE IDENTIFIED FROM COTTON. ONLY MONO- & DE-METHYLATED DERIVATIVES WERE IDENTIFIED FROM CUCUMBER.', 'FLUOMETURON HAS BEEN SHOWN TO UNDERGO A 3 STEP DEGRADATION PROCESS IN PLANTS. THE FIRST TWO STEPS ARE DEMETHYLATION TO A MONOMETHYL THEN TO A DEMETHYLATED INTERMEDIATE. THE THIRD STEP IS DEAMINATION-DECARBOXYLATION STEP THAT PRODUCES AN ANILINE MOLECULE.', 'Ring hydroxylation of phenylureas in animal tissues ... has been observed with fluometuron.', 'Cmpd that are rapidly translocated to aerial parts, such as ... fluometuron ... would be expected to be metabolized in the leaves.', 'For more Metabolism/Metabolites (Complete) data for FLUOMETURON (9 total), please visit the HSDB record page.']",
6562,16563,"6,7-Dichloro-1,4-benzodioxan-2-methanol",C1C(OC2=CC(=C(C=C2O1)Cl)Cl)CO,,,,,,
6563,16564,Guanoxan,C1C(OC2=CC=CC=C2O1)CN=C(N)N,,,,,,
6564,16565,2-Methyloxetane,CC1CCO1,,,,['Apparently butylene oxide is not absorbed through skin in amounts sufficient to cause systemic effects.'],,
6565,16566,"2-(Bis(2-chloroethyl)amino)-1,3,2-oxathiaphospholane 2-oxide",C1CSP(=O)(O1)N(CCCl)CCCl,,,,,,
6566,16567,Ethyl diatrizoate,CCOC(=O)C1=C(C(=C(C(=C1I)NC(=O)C)I)NC(=O)C)I,,,,,,
6567,16568,Dibutyl sulphoxide,CCCCS(=O)CCCC,,,,,,
6568,16569,"1,4-Bicyclo(2.2.2)octanebis(methylamine), N,N'-bis(cyclohexylmethyl)-, dihydrochloride",C1CCC(CC1)C[NH2+]CC2CC3CCC2CC3C[NH2+]CC4CCCCC4.[Cl-].[Cl-],,,,,,
6569,16570,1-cyclohexyl-N-[[5-[(cyclohexylmethylamino)methyl]-2-bicyclo[2.2.2]octanyl]methyl]methanamine,C1CCC(CC1)CNCC2CC3CCC2CC3CNCC4CCCCC4,,,,,,
6570,16571,N-(2-(Diethylamino)ethyl)-p-nitrobenzamide hydrochloride,CC[NH+](CC)CCNC(=O)C1=CC=C(C=C1)[N+](=O)[O-].[Cl-],,,,,,
6571,16572,N-[2-(diethylamino)ethyl]-4-nitrobenzamide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
6572,16573,N-Methyllaurotetanine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)OC,,,,,,
6573,16574,Azaribine,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,,,['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)'],,,
6574,16575,Brontisol,CN1C2CCC1CC(C2)OC3C4=CC=CC=C4CCC5=CC=CC=C35.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
6575,16576,Deptropine,CN1C2CCC1CC(C2)OC3C4=CC=CC=C4CCC5=CC=CC=C35,,,,,,
6576,16577,Veratraldehyde oxime,COC1=C(C=C(C=C1)C=NO)OC,,,,,,
6577,16578,"1,2,4,6,7,9-Hexabromo-3,8-dichlorodibenzo-P-dioxin",C12=C(C(=C(C(=C1Br)Cl)Br)Br)OC3=C(O2)C(=C(C(=C3Br)Cl)Br)Br,,,,,,
6578,16579,Octabromodibenzo-P-dioxin,C12=C(C(=C(C(=C1Br)Br)Br)Br)OC3=C(O2)C(=C(C(=C3Br)Br)Br)Br,,,,,,
6579,16580,"L-N,N-Diethylalanine mesityl ester hydrochloride",CC[NH+](CC)C(C)C(=O)OC1=C(C=C(C=C1C)C)C.[Cl-],,,,,,
6580,16581,"(2,4,6-Trimethylphenyl) 2-(diethylamino)propanoate",CCN(CC)C(C)C(=O)OC1=C(C=C(C=C1C)C)C,,,,,,
6581,16582,2-Isobutoxynaphthalene,CC(C)COC1=CC2=CC=CC=C2C=C1,,,,,,
6582,16583,"Acetophenone, 2'-(2-(diethylamino)ethoxy)-",CCN(CC)CCOC1=CC=CC=C1C(=O)C,,,,,,
6583,16584,Pentachloropyridine,C1(=C(C(=NC(=C1Cl)Cl)Cl)Cl)Cl,,,,"['PYRIDINE & ITS ALKYL DERIVATIVES ARE ABSORBED FROM GI TRACT, INTRAPERITONEAL CAVITY & LUNGS. PERITONEAL ABSORPTION IS APPARENTLY ONLY SLIGHTLY MORE RAPID & COMPLETE THAN GI ABSORPTION... IN GENERAL THE BASES ARE RAPIDLY ABSORBED THROUGH INTACT SKIN. /ALKYL DERIVATIVES OF PYRIDINE/']",,
6584,16585,Tetrapropylstannane,CCC[Sn](CCC)(CCC)CCC,,,,,,
6585,16586,3-(Chloromethyl)-3-ethyloxetane,CCC1(COC1)CCl,,,,,,
6586,16587,2-Methyl-1H-indene,CC1=CC2=CC=CC=C2C1,,,,,,
6587,16588,Methyl 7-methyloctanoate,CC(C)CCCCCC(=O)OC,,,,,,
6588,16589,Methiocarb sulfone,CC1=CC(=CC(=C1S(=O)(=O)C)C)OC(=O)NC,,,,,,
6589,16590,Diallyl disulfide,C=CCSSCC=C,,,"['Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)', 'Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (See all compounds classified as Spermatocidal Agents.)']",,['Diallyl disulfide has known human metabolites that include (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-[(E)-3-(prop-2-enyldisulfanyl)prop-1-enyl]sulfanylpropan-2-yl]amino]-5-oxopentanoic acid and DADSO.'],
6590,16591,Allyl propyl disulfide,CCCSSCC=C,,,,['The substance can be absorbed into the body by inhalation and by ingestion.'],,
6591,16592,Methyl propyl disulfide,CCCSSC,,,,,,
6592,16593,Hexyl sulfoxide,CCCCCCS(=O)CCCCCC,,,,,,
6593,16594,"potassium;(9S,14S)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthrene-17-carboxylic acid",CC12CCC(=O)C=C1C=CC3[C@@H]2CCC4([C@H]3CCC4(C(=O)O)O)C.[K+],,,,,,
6594,16595,"(9S,14S)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthrene-17-carboxylic acid",CC12CCC(=O)C=C1C=CC3[C@@H]2CCC4([C@H]3CCC4(C(=O)O)O)C,,,,,,
6595,16596,"methyl (1R,9R,10S,11R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5,13-tetraene-10-carboxylate",CCC12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=C4C=CC(=C5)OC)C,,,,,,
6596,16597,CID 16597,CCOC(=O)C(C1=COC2=CC=CC=C2C1=O)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
6597,16598,"2-(1-Methylpropyl)-4,6-dinitrophenyl 2-chlorobutanoate",CCC(C)C(CC)(C(=O)OC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
6598,16599,Victoria Blue R,CC[NH+]=C1C=CC(=C(C2=CC=C(C=C2)N(C)C)C3=CC=C(C=C3)N(C)C)C4=CC=CC=C14.[Cl-],,,,,,
6599,16600,"4-[[4-(dimethylamino)phenyl]-(4-ethyliminonaphthalen-1-ylidene)methyl]-N,N-dimethylaniline",CCN=C1C=CC(=C(C2=CC=C(C=C2)N(C)C)C3=CC=C(C=C3)N(C)C)C4=CC=CC=C14,,,,,,
6600,16601,"2-Biphenylamine, hydrochloride",C1=CC=C(C=C1)C2=CC=CC=C2[NH3+].[Cl-],,,,,,
6601,16602,p-Bis(2-chloroethyl)aminomethyl-phenylalanine dihydrochloride,C1=CC(=CC=C1CC(C(=O)O)[NH3+])C[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
6602,16603,2-Amino-3-[4-[bis(2-chloroethyl)aminomethyl]phenyl]propanoic acid,C1=CC(=CC=C1CC(C(=O)O)N)CN(CCCl)CCCl,,,,,,
6603,16604,3-(o-((Bis(2-chloroethyl)amino)methyl)phenyl)alanine dihydrochloride,C1=CC=C(C(=C1)CC(C(=O)O)[NH3+])C[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
6604,16605,2-Amino-3-[2-[bis(2-chloroethyl)aminomethyl]phenyl]propanoic acid,C1=CC=C(C(=C1)CC(C(=O)O)N)CN(CCCl)CCCl,,,,,,
6605,16606,Cresyl glycidyl ether,CC1=CC=C(C=C1)OCC2CO2,,,,"['In vitro skin penetration studies with dermatomized human and rat skin and whole mouse skin indicated that o-cresyl glycidyl ether has a potential to penetrate the skin. Permeability was in the order: mouse>rat>human. o-Cresyl glycidyl ether is rapidly hydrolyzed after penetration into the skin; however, a minimum of 10% of the applied dose may be present as unchanged material after absorption through the skin. /o-Cresyl glycidyl ether/', ""Glycidyl ethers (GE), an important class of industrial chemicals, are considered to be potentially mutagenic in vivo because some GE have been shown to be direct mutagens in short-term in vitro tests. The percutaneous penetration and metabolism of representatives of different classes of GE was studied in the fresh, full-thickness C3H mouse, and dermatomed human and Fisher 344 rat skin to determine the apparent permeability constants, lag times and metabolic profiles. Five different GE, the diglycidyl ethers of bisphenol A (BADGE), 4,4'-dihydroxy-3,3',5,5'-tetramethylbiphenyl (Epikote YX4000) and 1,6-hexanediol (HDDGE) and the GE of 1-dodecanol (C12GE) and o-cresol (o-CGE), were synthesized by reaction of their alcohols with epichlorohydrin. Their radiolabelled analogues were synthesized with a 14C-label using [U-14C]-epichlorohydrin. There was a large variation (four orders of magnitude) in percutaneous penetration between the five GE. In general, penetration through full-thickness mouse skin was higher than through dermatomed rat skin, whereas dermatomed human skin was the least permeable. The permeability increased in the order YX4000 < BADGE < C12GE < o-CGE < HDDGE. The relative skin permeability of the five GE could be explained for a significant part by the lipophilicity, expressed as log P(o/w), in combination with the molecular weight of the compounds.""]","['o-Cresyl glycidyl ether was converted rapidly to the corresponding diol compounds when incubated with guinea pig liver homogenate in vitro. /o-Cresyl glycidyl ether/', 'Studies in preparations of microsomal and cytosolic fractions of liver and lung derived from human, rat, and mouse showed that o-cresyl glycidyl ether is a good substrate for glutathione tranferase, with mice being the most efficient in enzymatic glutathione conjugation. Overall, enzymatic hydrolysis of the epoxide group is the most important route of in vitro biotransformation of o-cresyl glycidyl ether, with the highest activity located in the microsomes. Human samples generally had a higher efficiency for hydrolysis than mice or rats. /o-Cresyl glycidyl ether/', 'The urinary metabolite profile of o-cresyl glycidyl ether in rats, following ip administration of single doses up to 164 mg/kg, indicated that glutathione (GSH) conjugation and epoxide hydrolysis were key biotransformation pathways of o-cresyl glycidyl ether. At low dose levels GSH conjugation and epoxide hydrolysis accounted each for about 25% of urinary metabolites; however at higher doses epoxide hydrolysis became the most prominent route of detoxification (40%). /o-Cresyl glycidyl ether/', 'The urinary metabolite profiles of phenyl-glycidyl-ether (PGE) and its structural analogue ortho-cresyl-glycidyl-ether (oCGE) were determined in male Wistar-rats. Quantitative analytical methods were used to investigate the metabolites of PGE and oCGE, their dose excretion relationships and urinary excretion kinetics. Rats were dosed intraperitoneally with PGE or oCGE in doses ranging from 0.033 to 1.0 mmol/kg. ...Rats treated with oCGE excreted oCGEMA, COLA, and NAPS, showing that the metabolite profiles of PGE and oCGE were comparable. The quantitative methods developed to determine the urinary mercapturic-acid metabolites of PGE and oCGE offered enough selectivity and sensitivity for their determination as low as 0.033mmol/kg. The authors conclude the method can be used for humans with low potential exposures. Human excretion of lactic-acid and the novel serine metabolites of these glycidyl ethers should be further investigated, as possible inactivation of these epoxides may be by epoxide hydrolysis mediated routes.', '... During skin penetration, all GE were extensively metabolized to their corresponding (bis-)diols. Virtually no YX4000, and only very small amounts of C12GE and BADGE, penetrated the skin unchanged, but significant amounts of HDDGE and o-CGE penetrated the skin unchanged. For o-CGE, but none of the other GE, the percentage of the applied dose that penetrated the skin unchanged increased over time. The large variation in response observed with the five selected GE indicates that GE should not be considered as a single class of compounds but rather on the basis of their individual properties.']",
6606,16607,Octylbenzene,CCCCCCCCC1=CC=CC=C1,,,,,,
6607,16608,Octadecylammonium acetate,CCCCCCCCCCCCCCCCCC[NH3+].CC(=O)[O-],,,,,,
6608,16609,5-((Benzylthio)methyl)-5-phenylhydantoin,C1=CC=C(C=C1)CSCC2(C(=O)NC(=O)N2)C3=CC=CC=C3,,,,,,
6609,16610,Calcium octanoate,CCCCCCCC(=O)[O-].CCCCCCCC(=O)[O-].[Ca+2],,,,,,
6610,16611,1-(4-Fluorophenacyl)-4-piperonylpiperazine,C1CN(CCN1CC2OC3=CC=CC=C3O2)CC(=O)C4=CC=C(C=C4)F,,,,,,
6611,16612,CID 16612,C1=CN=CC=C1C(=N)S,,,,,,
6612,16613,CID 16613,C1=CC(=CC=C1C2=CC(=C3C=CC(=O)C=C3O2)O)O,,,,,,
6613,16614,"Octadeca-8,11-dienoic acid",CCCCCCC=CCC=CCCCCCCC(=O)O,,,,,,
6614,16615,"2,3-Dimethyl-1,4-naphthoquinone",CC1=C(C(=O)C2=CC=CC=C2C1=O)C,,,,,,
6615,16616,"N-(2,6-Dimethylphenyl)acetamide",CC1=C(C(=CC=C1)C)NC(=O)C,,,,,,
6616,16617,3-Methylbutyl hexanoate,CCCCCC(=O)OCCC(C)C,,,,,,
6617,16618,"1,3-Dichloronaphthalene",C1=CC=C2C(=C1)C=C(C=C2Cl)Cl,,,,,,
6618,16619,"2,7-Dichloronaphthalene",C1=CC(=CC2=C1C=CC(=C2)Cl)Cl,,,,,,
6619,16620,"1H-Pyrrole, 2,3,5-trimethyl-",CC1=CC(=C(N1)C)C,,,,,,
6620,16621,CID 16621,CC1=C(ON=C1C)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Na+],,,,,,
6621,16622,Eticyclidine,CCNC1(CCCCC1)C2=CC=CC=C2,,,,"['The uptake kinetics of [3H]-labelled phencyclidine (PCP) and N-ethyl-l-phenycyclohexylamine (PCE) in rats, measured in terms of decreases in the blood concentrations of the drugs after i.v. administration of a single 1.09 umol dose, were not significantly different. Within a week of administration, the rats excreted about 93% of the [3H]-PCP and about 65% of [3H]-PCE via their urine and feces; their urine contained nor [3H], mainly as metabolites of [3H]-PCP and of [3H]-PCE, than their feces. Similarly, more [3H] remained in the tissues of rats treated with [3H]-PCE than in the tissues of [3H4-PCP-treated rats. The fact that PCE is metabolized and excreted more slowly than PCP may account for the higher psychotropic effects of PCE.']","['The pharmacokinetics of three phencyclidine analogs--phenylcyclohexyldiethylamine (PCDE), phenylcyclohexylethylamine (PCE), and phenylcyclohexylamine (PCA)-were determined in rats after intravenous administration of each drug. Because PCE and PCA are major metabolites of PCDE, their plasma levels were also measured after administration of PCDE. Similarly, PCA concentrations was determined after administration of PCE. The data were combined and analyzed by nonlinear regression procedures using compartmental and noncompartmental models to determine the kinetic parameters of PCDE metabolism. The object was to estimate the kinetic constants for the metabolic sequence, PCDE to PCE to PCA. A 6-compartment model (two pools for each analyte) that included saturable components for the conversion of PCDE to PCE and PCE to PCA gave the best fit to the combined data. Despite large uncertainties for some microparameters, useful estimates were obtained for clearances, distribution volumes, and fraction of PCDE or PCE converted to PCE and PCA in vivo under nonsaturating conditions. The estimated fraction of PCDE converted to PCA and the apparent Km value for the conversion of PCDE to PCE were comparable to values obtained in vitro with microsomal preparations, suggesting that metabolic studies in vitro provide reasonable predictors of the biotransformation process in vivo for this class of compounds.', 'The isolated perfused lung (IPL) of rats were used to examine the pulmonary disposition and metabolism of radiolabeled phencyclidine (PCP) and N-ethyl-1-phenylcyclohexylamine (PCE). The IPL removed PCP and PCE from the perfusate and converted them to free and conjugated metabolites. At the conclusion of a 1-hr perfusion, the lung accumulated at least 20% of the administered radioactivity and metabolized more than 30% of the added drug. ...']",
6622,16623,Hydrocortisone hemisuccinate,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O,,,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
6623,16624,"5H-DIBENZO(b,e)(1,4)DIAZEPINE, 10,11-DIHYDRO-5-(3-(DIMETHYLAMINO)PROPYL)-",CN(C)CCCN1C2=CC=CC=C2CNC3=CC=CC=C31,,,,,,
6624,16625,1-(2-Chloroethyl)azepane,C1CCCN(CC1)CCCl,,,,,,
6625,16626,Tiomesterone,CC(=O)S[C@@H]1CC2=CC(=O)C[C@@H]([C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O)C)SC(=O)C,,,,,,
6626,16627,2-Chloroethyl acrylate,C=CC(=O)OCCCl,,,,,,
6627,16628,"cis-1,2-Dimethylcyclohexane",C[C@@H]1CCCC[C@@H]1C,,,,,,
6628,16629,"trans-1,3-Dimethylcyclohexane",C[C@@H]1CCC[C@H](C1)C,,,,,,
6629,16630,Aminorex,C1C(OC(=N1)N)C2=CC=CC=C2,,,,,,
6630,16631,4-[2-(Cyclohexylamino)-1-hydroxypropyl]phenol,CC(C(C1=CC=C(C=C1)O)O)NC2CCCCC2,,,,,,
6631,16632,Benzoylcholine,C[N+](C)(C)CCOC(=O)C1=CC=CC=C1,,,,,,
6632,16633,"Butyrimidic acid, ethyl ester, hydrochloride",CCCC(=[NH2+])OCC.[Cl-],,,,,,
6633,16634,Ethyl butyrimidate,CCCC(=N)OCC,,,,,,
6634,16635,"[2-(4-Chlorophenyl)-2-ethyl-1,3-dioxolan-4-yl]methanol",CCC1(OCC(O1)CO)C2=CC=C(C=C2)Cl,,,,,,
6635,16636,"[2-Methyl-2-(4-methylphenyl)-1,3-dioxolan-4-yl]methanol",CC1=CC=C(C=C1)C2(OCC(O2)CO)C,,,,,,
6636,16637,N-Isopropylacrylamide,CC(C)NC(=O)C=C,,,,['Not readily absorbed through skin.'],"['The in vitro biotransformations of acrylamide and ten related compounds in the hepatic enzyme system of the mouse were studied in order to learn more about their toxic actions in vivo. ...  The metabolite of N-isopropylacrylamide was identified as acrylamide by gas chromatography-mass spectrometry. ... Phenobarbital pretreatment of mice enhanced the metabolic reactions of the seven compounds, but did not elevate those of acrylamide and crotonamide. The Km value of N-isopropylacrylamide was 0.35 mM, which was the smallest of all the test analogues. All of the eleven analogues studied were found to be metabolized by hepatic glutathione S-transferases as well. This reaction was also elevated by the phenobarbital treatment of mice. ...']",
6637,16638,N-Propyl methacrylate,CCCOC(=O)C(=C)C,,,,,"['Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity.', 'Methyl methacrylate and other short chain alkyl-methacrylate esters are initially hydrolyzed by non-specific carboxylesterases to methacrylic acid and the structurally corresponding alcohol in several tissues. Methacrylic acid and the corresponding alcohol are subsequently cleared predominantly via the liver (valine pathway and the TCA (tricarboxylic acid) cycle, respectively). The carboxylesterases are a group of non-specific enzymes that are widely distributed throughout the body and are known to show high activity within many tissues and organs, including the liver, blood, GI tract, nasal epithelium and skin ... Those organs and tissues that play an important role and/or contribute substantially to the primary metabolism of the short-chain, volatile, alkyl-methacrylate esters are the tissues at the primary point of exposure, namely the nasal epithelia and the skin, and systemically, the liver and blood. /Short chain alkyl-methacrylate esters/', 'Recent studies have confirmed that alkyl-methacrylate esters are rapidly hydrolyzed by ubiquitous carboxylesterases ... First pass (local) hydrolysis of the parent ester has been shown to be significant for all routes of exposure. For example, no parent ester can be measured systemically following skin exposure to EMA and larger esters, as the lower rate of absorption for these esters is within the metabolic capacity of the skin ... Parent ester will also be effectively hydrolyzed within the G.I. tract and within the tissues of the upper respiratory tract (particularly the olfactory tissue). Systemically absorbed parent ester will be effectively removed during the first pass through the liver ... resulting in their relatively rapid elimination from the body ... /Short chain alkyl-methacrylate esters/', 'Methacrylate esters can conjugate with glutathione (GSH) in vitro, although they show a low reactivity, since the addition of a nucleophile at the double bond is hindered by the alpha-methyl side-group ... Hence, ester hydrolysis is considered to be the major metabolic pathway for alkyl-methacrylate esters, with GSH conjugation only playing a minor role in their metabolism, and then possibly only when very high tissue concentrations are achieved. /Short chain alkyl-methacrylate esters/', 'For more Metabolism/Metabolites (Complete) data for n-Propyl methacrylate (6 total), please visit the HSDB record page.']",
6638,16639,Mofebutazone,CCCCC1C(=O)NN(C1=O)C2=CC=CC=C2,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
6639,16640,O-Cresyl glycidyl ether,CC1=CC=CC=C1OCC2CO2,,,,,,
6640,16641,"1-Imidazolidineaceto-2',6'-xylidide, 3-methyl-2,4,5-trioxo-",CC1=C(C(=CC=C1)C)NC(=O)CN2C(=O)C(=O)N(C2=O)C,,,,,,
6641,16642,1-Methyl-3-(1-(o-tolylcarbamoyl)ethyl)imidazolidinetrione,CC1=CC=CC=C1NC(=O)C(C)N2C(=O)C(=O)N(C2=O)C,,,,,,
6642,16643,"1-Imidazolidineacetanilide, 3-methyl-2,4,5-trioxo-",CN1C(=O)C(=O)N(C1=O)CC(=O)NC2=CC=CC=C2,,,,,,
6643,16644,1-Benzylguanidine,C1=CC=C(C=C1)CN=C(N)N,,,,,,
6644,16645,Diisopropyl sulfoxide,CC(C)S(=O)C(C)C,,,,,,
6645,16646,2-[(4-Methoxyphenoxy)methyl]oxirane,COC1=CC=C(C=C1)OCC2CO2,,,,,,
6646,16647,CID 16647,CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
6647,16648,CID 16648,CCCCCCCCCCC(C)C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
6648,16649,"Benzenesulfonic acid, 4-(1-methylundecyl)-",CCCCCCCCCCC(C)C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
6649,16650,Chloromethylmethyldiethoxysilane,CCO[Si](C)(CCl)OCC,,,,,,
6650,16651,CID 16651,CCCCCCC(CCCCC)C1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
6651,16652,4-dodecan-6-ylbenzenesulfonic Acid,CCCCCCC(CCCCC)C1=CC=C(C=C1)S(=O)(=O)O,,,,,,
6652,16653,Molinate,CCSC(=O)N1CCCCCC1,,,"['Agents, either mechanical or chemical, which destroy spermatozoa in the male genitalia and block spermatogenesis. (See all compounds classified as Antispermatogenic Agents.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['IT IS RAPIDLY METABOLIZED BY RATS, ABOUT 50% TO CARBON DIOXIDE, 25% EXCRETED IN THE URINE AND 7 TO 20% IN THE FECES IN 3 DAYS.', 'MOLINATE IS RAPIDLY TAKEN UP BY ROOTS & TRANSLOCATED UPWARD TO LEAVES OF PLANTS.', '... Not absorbed percutaneously.', 'Excretion of ring labeled (14)C molinate by rats is 95-96% complete in 48 hr. Approximately 88% was in the urine ... and 11% in the feces. Less than 1% of the dose was found in the expired air. ... Tissue levels were approximately 13.8% of the administered dose after 1 day and 3.7% after 7 days,']","['... RICE SHOOTS HARVESTED 3 DAYS AFTER TREATMENT WITH CHAIN-LABELED MOLINATE SHOWED ... 16 RADIOACTIVE METABOLITES. 7 OF THESE RADIOACTIVE SPOTS COINCIDED WITH AMINO ACIDS ... 5 METABOLITES WERE ORG ACIDS, 2 OF WHICH WERE ... LACTIC & GLYCOLIC ACID.', 'IN JAPANESE CARP, MAJOR MOLINATE METABOLITES DETECTED WERE MOLINATE SULFOXIDE, 3-HYDROXYMOLINATE, 4-HYDROXYMOLINATE, 4-KETOMOLINATE, & ALPHA KETO HEXAMETHYLENEAMINE.', 'MOLINATE METABOLITE MOLINATE SULFOXIDE WAS CLEAVED IN VITRO BY JAPANESE CARP LIVER CYTOSOL FRACTION. MOLINATE MERCAPTURATE WAS RECOVERED FROM BILE OF MOLINATE TREATED CARP.', '(14)C Molinate ... was metabolized by rats, primarily to the sulfoxide, and thence to the mercapturic acid deriv. Ring hydroxylation, mainly at the 3- and 4- positions, followed by glucuronidation and cleavage of the C--N bond to yieldthe imide, were also observed.', 'For more Metabolism/Metabolites (Complete) data for MOLINATE (9 total), please visit the HSDB record page.']",
6653,16654,"1,3-Bis(tert-butylperoxyisopropyl)benzene",CC(C)(C)OOC(C)(C)C1=CC(=CC=C1)C(C)(C)OOC(C)(C)C,,,,,,
6654,16655,Methyl marasmate,CC1(C[C@H]2C=C([C@@]3(CC3([C@H]2C1)C(=O)OC)C=O)C=O)C,,,,,,
6655,16656,"2,4-Dimethylheptane",CCCC(C)CC(C)C,,,,,,
6656,16657,"2,4-Dimethyl-1-pentene",CC(C)CC(=C)C,,,,,,
6657,16658,1-Aminopiperidine,C1CCN(CC1)N,,,,,,
6658,16659,"2,3-Dichloroquinoxaline",C1=CC=C2C(=C1)N=C(C(=N2)Cl)Cl,,,,,,
6659,16660,Bis(diphenylarsinyl) oxide,C1=CC=C(C=C1)[As](C2=CC=CC=C2)O[As](C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
6660,16661,1-Nitro-2-phenoxybenzene,C1=CC=C(C=C1)OC2=CC=CC=C2[N+](=O)[O-],,,,,,
6661,16662,"2,5-Dimethylheptane",CCC(C)CCC(C)C,,,,,,
6662,16663,4-Ethylheptane,CCCC(CC)CCC,,,,,,
6663,16664,3-Methyloctane,CCCCCC(C)CC,,,,,,
6664,16665,4-Methyloctane,CCCCC(C)CCC,,,,,,
6665,16666,l-Menthol,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,"['Used to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.']","['Menthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol induces a cooling sensation on the skin upon inhalation, oral ingestion, or topical application by stimulating the cold-sensitive receptors expressed on the skin, without actually causing a drop in the skin temperature.']",,"['...THE PERCENTAGE OF A DOSE OF L-MENTHOL THAT IS EXCRETED COMBINED WITH GLUCURONIC ACID IN THE RABBIT DEPENDS ON THE MAGNITUDE OF THE DOSE; THE LARGER THE DOSE, THE LESS IS THE CONJUGATION.']","['L-MENTHOL CONJUGATES READILY IN RABBIT FORMING L-MENTHYL-BETA-D-GLUCURONIDE. ABOUT HALF OF THE L-MENTHOL FED TO RABBITS IS EXCRETED COMBINED WITH GLUCURONIC ACID; THE FATE OF OTHER HALF IS NOT KNOWN, BUT IT IS POSSIBLE THAT RING FISSION OCCURS WITH CONSIDERABLE DEGRADATION OF THE MENTHOL MOLECULE.', 'IN DOGS, MUCH OXIDATION OF MENTHOL TAKES PLACE AND ONLY ABOUT 5% OF THE DOSE CAN BE RECOVERED IN URINE AS THE GLUCURONIDE. /MENTHOL/', 'L-MENTHOL WAS RAPIDLY BUT INCOMPLETELY GLUCURONIDATED. THE OUTPUT OF L-MENTHOL GLUCURONIDE WAS INCR IN ALL BUT 1 SUBJECT PRETREATED WITH CIMETIDINE (1 G/DAY FOR 1 WK), AN INHIBITOR OF OXIDATIVE DRUG METABOLISM, & IN ALL SUBJECTS PRETREATED WITH A DRUG-METABOLIZING ENZYME INDUCER, PHENOBARBITONE (60 MG NIGHTLY FOR 10 DAYS).', 'Corynebacterium sp. strain RWM1 grew with (-)-menthol, (-)-menthone and other acyclic monoterpenes as sole carbon sources. Growth on menthol was very slow, with a doubling time of more than 24 h, and was not rapid with (-)-menthone (doubling time 12 h). Concentrations of either carbon source greater than 0.025% inhibited growth. (-)-Menthone-grown cultures transiently accumulated 3,7-dimethyl-6-hydroxyoctanoate during growth, and (-)-menthol-grown cells oxidized (-)-menthol, (-)-menthone, 3,7-dimethyl-6-octanolide and 3,7-dimethyl-6-hydroxyoctanoate. Although neither a menthol oxidase nor a menthol dehydrogenase could be detected in extracts of (-)-menthol- or (-)-menthone-grown cells, an induced NADPH-linked monooxygenase with activity towards (-)-menthone was readily detected. With crude cell extracts, only 3,7-dimethyl-6-hydroxyoctanoate was detected as the reaction product. When the (-)-menthone monooxygenase was separated from an induced 3,7-dimethyl-6-octanolide hydrolase by chromatography on hydroxyapatite, the lactone 3,7-dimethyl-6-octanolide was shown to be the product of oxygenation.', '(-)-Menthol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyoxane-2-carboxylic acid and p-Menthane-3,-8-diol.']",
6666,16667,N-methylnaphthalen-1-amine,CNC1=CC=CC2=CC=CC=C21,,,,,,
6667,16668,1-Methoxynaphthalene,COC1=CC=CC2=CC=CC=C21,,,,,,
6668,16669,Dibuprol,CCCCOCC(COCCCC)O,,,,,,
6669,16670,Heptyl propionate,CCCCCCCOC(=O)CC,,,,,,
6670,16671,"5,6,7,8-Tetrahydro-1-naphthylamine",C1CCC2=C(C1)C=CC=C2N,,,,,,
6671,16672,CID 16672,C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
6672,16673,"[1,1'-Biphenyl]-4-sulfonic acid",C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)O,,,,,,
6673,16674,"Ethyl N,N-dibutylcarbamate",CCCCN(CCCC)C(=O)OCC,,,,,,
6674,16675,CID 16675,C(C(=O)[O-])(F)F.[Na+],,,,,,
6675,16676,Cloral betaine,C[N+](C)(C)CC(=O)[O-].C(C(Cl)(Cl)Cl)(O)O,,,,,,
6676,16677,(3-Amino-3-carboxypropoxy)-(diaminomethylidene)azanium;hydrogen sulfate,C(CO[NH+]=C(N)N)C(C(=O)O)N.OS(=O)(=O)[O-],,,,,,
6677,16678,2-tert-Butyl-6-methylphenol,CC1=C(C(=CC=C1)C(C)(C)C)O,,,,,,
6678,16679,"5H-Dibenzo[a,d]cyclohepten-5-one",C1=CC=C2C(=C1)C=CC3=CC=CC=C3C2=O,,,,,,
6679,16680,Neopentyl glycol diacrylate,CC(C)(COC(=O)C=C)COC(=O)C=C,,,,,,
6680,16681,Cadmium stearate,CCCCCCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)[O-].[Cd+2],,,,"['THE PERCUTANEOUS ABSORPTION OF CADMIUM STEARATE WAS INVESTIGATED IN MICE, RATS, GUINEA PIGS, AND RABBITS. IT PENETRATES THE INTACT SKIN EASILY AND IS RETAINED IN THE LIVER AND KIDNEYS FOR A LONG PERIOD BEFORE IT IS SLOWLY EXCRETED.', 'Gastrointestinal absorption is less than respiratory absorption and is about 5 to 8 percent. It is enhanced by dietary deficiencies of calcium and iron, and diets low in protein. Low dietary calcium stimulates synthesis of calcium binding protein which enhances cadmium absorption. Women with low serum ferritin levels have been shown to have twice the normal absorption of cadmium. Zinc decreases cadmium absorption probably by stimulating production of metallothionein. /Cadmium/', 'Excretion by feces of normal humans is ca 30-50 ug/day ... retention of ingested cadmium varied between 4.7-7% in 5 adult men ... only very small proportions of daily absorbed dose will be excreted ... normal urinary excretion in humans amount to CA 1-2 ug/day ... on occupational exposure, this level is not raised significantly ... . /Cadmium/', 'EXCRETION BY FECES OF NORMAL HUMANS IS ABOUT 30-50 UG/DAY ... RETENTION OF INGESTED CADMIUM VARIED BETWEEN 4.7-7% IN 5 ADULT MEN ... ONLY VERY SMALL PROP OF DAILY ABSORBED DOSE WILL BE EXCRETED ... NORMAL URINARY EXCRETION IN HUMANS AMT TO ABOUT 1-2 UG/DAY ... ON OCCUPATIONAL EXPOSURE, THIS LEVEL IS NOT RAISED SIGNIFICANTLY ... /CADMIUM/', 'About half of total body burden is found in liver & kidneys. Cadmium in these organs is mainly bound to /a/ low molecular weight protein, in form of metallothionein ... . /Cadmium/']",,"['SLOW EXCRETION RESULTS IN VERY LONG BIOLOGICAL HALF LIFE FOR ABSORBED CADMIUM, WHICH HAS BEEN EST TO BE 16-33 YR ... . /CADMIUM/']"
6681,16682,Asparagusic acid,C1C(CSS1)C(=O)O,,,,,,
6682,16683,Ethylene glycol diglycidyl ether,C1C(O1)COCCOCC2CO2,,,,,,
6683,16684,"1H-2,1,3-Benzothiadiazin-4(3H)-one, 3-methyl-, 2,2-dioxide",CN1C(=O)C2=CC=CC=C2NS1(=O)=O,,,,,,
6684,16685,Tetrasul,C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
6685,16686,Dienochlor,C1(=C(C(C(=C1Cl)Cl)(C2(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,"['In varying degrees, organochlorines are absorbed from the gut and also by the lung and across the skin. /Soild Organochlorines/', 'Within four days of receiving a single oral dose (1 mg/kg) of U-ring-(14)C dienochlor [bis(pentachloro-2,4-cyclopentadien-1-yl)] female rats excreted 2 and 88% of the applied (14)C in urine and feces, respectively. Metabolites could not be identified and the preponderance of the fecal radioactivity consisted of unextractable (14)C labeled residues. Within 1 day virtually all of the dienochlor had been degraded by rats, with only traces of parent dienochlor in excreta and tissues. After four days only 2% of the applied dose remained in tissues (mainly kidney, liver, and gastrointestinal tract). Pharmacokinetic studies with blood plasma and bile showed dienochlor (and/or its metabolites) to be poorly absorbed. Rats were exposed dermally for 24 hr to (14)C dienochlor formulated as Pentac WP miticide both as an aqueous suspension and as an undiluted wettable powder. Half of the dose adhered to the skin and the other half was found in gauze patches used to protect the treated skin. After a 24 hr exposure over 60% of the radiolabel that adhered to skin was removed by washing with an aqueous soap solution and 86% of this rinsing solution was unmetabolized dienochlor. The dienochlor and its metabolites were transported inefficiently from the application site; only 1% of the applied dose was detected in urine plus feces and less than or equal to 0.2% in tissues. With application rates that simulate field exposure by humans, the actual residue of dienochlor and metabolites in skin (eg, not removable by washing) is about thirteen times higher following exposure to dienochlor as undiluted wettable powder than as an aqueous suspension.']",,
6686,16687,CID 16687,C1=CC=C(C=C1)C(=N)S,,,,,,
6687,16688,4-tert-Butylcyclohexene,CC(C)(C)C1CCC=CC1,,,,,,
6688,16689,CID 16689,C(=NN)(NN)S,,,,,,
6689,16690,"1-Propene, 3,3,3-trichloro-",C=CC(Cl)(Cl)Cl,,,,,,
6690,16691,"2,3,4-Trimethylpyridine",CC1=C(C(=NC=C1)C)C,,,,,,
6691,16692,Octachloronaphthalene,C12=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C(=C(C(=C2Cl)Cl)Cl)Cl,,,,"['One day after a single intraperitoneal injection in mice of 1 mg per animal the highest concentration of octachloronaphthalene was found in the adipose tissue: 2.1% of the dose. Lower concentrations were found in the liver (1.9%), spleen (0.80%), and kidneys (0.32%). The concentration in adipose tissue increased gradually up to day 7.', 'Tissue distribution and biological half lives of 1,8-dichloronaphthalene), 2,7-dichloronaphthalene, and octachloronaphthalene were investigated in mice. Pathogen free male JCL/ICR mice were given a single ip dose of 1 mg of 5 mg/ml 1,8-dichloronaphthalene, 2,7-dichloronaphthalene, or octachloronaphthalene dissolved in olive oil. Controls were injected with vehicle only. Animals were killed by cervical dislocation 3 and 6 hr and 1, 3, 7, 14, and 28 days after injection. The brain, heart, lungs, liver, kidneys, testes, spleen, and adipose tissues were removed and the chloronaphthalenes were estimated by gas chromatography of tissue extracts. Biological half lives were calculated from elimination data. The highest percentage of each chloronaphthalene was found in the adipose tissue, attributable to lipophilic properties of chloronaphthalenes, and the lowest percentage was found in heart and brain tissues. The concentration of chloronaphthalenes in other tissues showed no fixed relationship. Octachloronaphthalene was present mostly in the adipose tissue, where little 1,8-dichloronaphthalene was present. The concentration of the three chloronaphthalenes, except for octachloronaphthalene in adipose tissues, increased to a maximum within 3 hr after dosing and decreased exponentially thereafter. The concentration of octachloronaphthalene increased gradually in adipose tissue up to day 7. The biological half life of 2,7-dichloronaphthalene was longer than that of 1,8-dichloronaphthalene in most of the tissues. It was concluded that the biological half life may be affected by the substituted position of chlorine in the chloronaphthalenes and that higher chlorinated naphthalenes are metabolized more slowly than lower chlorinated naphthalenes.', 'The uptake and elimination of three superlipophilic compounds (hexabromobenzene, PCB153, and octachloronaphthalene) after dietary uptake was studied in earthworms (Eisenia andrei). All three compounds were taken up from the food, although they did not significantly accumulate despite their hydrophobicity. Both uptake efficiencies (E) and biomagnification factors (BMF) were low. E varied between 0.70 and 7.5%, while BMF values were all below 0.17. The elimination of the compounds was slow, with elimination rate constants k2 varying between 0.04 and 0.09/day.']",,"['... /A/ study comparing di- and octachloronaphthalenes found higher half-lives for octachloronaphthalene (3.72 days) than for 1,8-dichloronaphthalene (0.27 days) or 2,7- dichloronaphthalene (0.80 days) in adipose tissue of mice, if calculated from tissue levels at various time points up to 28 days. Nevertheless, the half-life observed for octachloronaphthalene is unexpectedly short for such a highly chlorinated, lipophilic compound.', 'Several biological half-life times /in mice/ were calculated during the exponential elimination phase/after single ip injection/: 3.72 days for the adipose tissue, 3.39 days for the testes, 2.25 days for the spleen, 2.20 for the kidneys and as the fastest: 1.51 days for the lungs. The investigators did not recover 100% of the amount injected, probably a part remained at the site of injection.']"
6692,16693,"2',4'-Dichloroacetophenone",CC(=O)C1=C(C=C(C=C1)Cl)Cl,,,,,,
6693,16694,"2,4-Dimethylstyrene",CC1=CC(=C(C=C1)C=C)C,,,,,,
6694,16695,"Hexa-1,3,5-triene",C=CC=CC=C,,,,,,
6695,16696,Ethylmercury phosphate,CC[Hg+].OP(=O)(O)[O-],,,,,,
6696,16697,[Nitrilotris(methylene)]tris-phosphonic acid pentasodium salt,C(N(CP(=O)([O-])[O-])CP(=O)([O-])[O-])P(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
6697,16698,(Nitrilotris(methylene))triphosphonic acid,C(N(CP(=O)(O)O)CP(=O)(O)O)P(=O)(O)O,,,,,,
6698,16699,"N,N-Diethylacetoacetamide",CCN(CC)C(=O)CC(=O)C,,,,,,
6699,16700,Ammonium dodecyl sulfate,CCCCCCCCCCCCOS(=O)(=O)[O-].[NH4+],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
6700,16701,5-Phenylpentan-2-one,CC(=O)CCCC1=CC=CC=C1,,,,,,
6701,16702,3-Aminobenzonitrile,C1=CC(=CC(=C1)N)C#N,,,,,,
6702,16703,"2,4,6(1H,3H,5H)-Pyrimidinetrione,5-(1-buten-1-YL)-5-ethyl-",CCC=CC1(C(=O)NC(=O)NC1=O)CC,,,,,,
6703,16704,Diglycidyl ether,C1C(O1)COCC2CO2,,,,,,
6704,16705,CID 16705,CC=CC(CC[N+](C)(C)C)(C1=CC=CS1)O.[I-],,,,,,
6705,16706,CID 16706,CC=CC(CC[N+](C)(C)C)(C1=CC=CS1)O,,,,,,
6706,16707,(3-(p-Chlorophenyl)-3-hydroxy-5-hexenyl)trimethylammonium iodide,C[N+](C)(C)CCC(CC=C)(C1=CC=C(C=C1)Cl)O.[I-],,,,,,
6707,16708,[3-(4-Chlorophenyl)-3-hydroxyhex-5-enyl]-trimethylazanium,C[N+](C)(C)CCC(CC=C)(C1=CC=C(C=C1)Cl)O,,,,,,
6708,16709,"Benzyl alcohol, alpha-(2-(dimethylamino)ethyl)-p-methoxy-alpha-(2-methylallyl)-, hydrochloride",CC(=C)CC(CC[NH+](C)C)(C1=CC=C(C=C1)OC)O.[Cl-],,,,,,
6709,16710,1-(Dimethylamino)-3-(4-methoxyphenyl)-5-methylhex-5-en-3-ol,CC(=C)CC(CCN(C)C)(C1=CC=C(C=C1)OC)O,,,,,,
6710,16711,"(2R,3R,4S,5R,6R)-2-(2-amino-3-hydroxyoctadec-4-enoxy)-6-(hydroxymethyl)oxane-3,4,5-triol",CCCCCCCCCCCCCC=CC(C(CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)N)O,,,,,,
6711,16712,Isopropyl N-4-chlorophenylcarbamate,CC(C)OC(=O)NC1=CC=C(C=C1)Cl,,,,,,
6712,16713,CID 16713,C1CN(C(=N1)S)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
6713,16714,"(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amine",CNCC1COC2=CC=CC=C2O1,,,,,,
6714,16715,Nonanenitrile,CCCCCCCCC#N,,,,,,
6715,16716,2-Acetylphenyl acetate,CC(=O)C1=CC=CC=C1OC(=O)C,,,,,,
6716,16717,3-Aminobiphenyl,C1=CC=C(C=C1)C2=CC(=CC=C2)N,,,,,,
6717,16718,2-Naphthyl isocyanate,C1=CC=C2C=C(C=CC2=C1)N=C=O,,,,,,
6718,16719,"1,4-Naphthalenediamine",C1=CC=C2C(=C1)C(=CC=C2N)N,,,,,,
6719,16720,"1,5-Naphthalenediamine",C1=CC2=C(C=CC=C2N)C(=C1)N,,,,,,
6720,16721,"Naphthalene, 1,3,5-trinitro-",C1=CC2=C(C=C(C=C2[N+](=O)[O-])[N+](=O)[O-])C(=C1)[N+](=O)[O-],,,,,,
6721,16722,Undecanenitrile,CCCCCCCCCCC#N,,,,,,
6722,16723,"2,4,5,6(1H,3H)-Pyrimidinetetrone, monohydrate",C1(=O)C(=O)NC(=O)NC1=O.O,,,,,,
6723,16724,d-Carvone,CC1=CC[C@@H](CC1=O)C(=C)C,,,,,,
6724,16725,CID 16725,C1(=NC(=O)N(C(=O)N1Cl)Cl)[O-].[K+],,,,,,
6725,16726,Dichloroisocyanuric acid,C1(=O)NC(=O)N(C(=O)N1Cl)Cl,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)']","['Metabolism studies in both the rat and dog, following administration of (14)C-sodium isocyanurate by the oral and iv routes, demonstrated rapid absorption, distribution, and excretion of unmetabolized isocyanurate. ... At the 5 mg/kg dose, excretion was largely via the urine with about 5% in the feces. At the 500 mg/kg oral dose, 55-70% (rats) or 27-86% (dogs) was excreted in the feces and the remainder in the urine. /Sodium isocyanurate/']","['Both s-triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-trichloro- and s-triazine-2,4,6(1H,3H,5H)-trione, 1,3-dichloro-, sodium salt are unstable in the body (particularly the stomach) because the available chlorine is rapidly reduced. Cyanuric acid (or its monosodium salt) is the degradation product from both products.', 'Both s-triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-trichloro- and s-triazine-2,4,6(1H,3H,5H)-trione, 1,3-dichloro-, sodium salt are unstable in the body (particularly the stomach) because the available chlorine is rapidly reduced. Cyanuric acid (or its monosodium salt) is the degradation product from both products.']","['Administration of (14C)sodium isocyanurate by the oral and iv routes demonstrated rapid absorption, distribution, and excretion of unmetabolized isocyanurate. The elimination half-life in rats was 32-43 min following 5 mg/kg iv or oral administration. The half-life was 122-148 min after oral dosing at 500 mg/kg.']"
6726,16727,CID 16727,CN1C2=CC=CC=C2CN(C3=CC=CC=C31)CC[NH+](C)C.C(=CC(=O)[O-])C(=O)O,,,,,,
6727,16728,"N,N-dimethyl-2-(11-methyl-6H-benzo[b][1,4]benzodiazepin-5-yl)ethanamine",CN1C2=CC=CC=C2CN(C3=CC=CC=C31)CCN(C)C,,,,,,
6728,16729,CID 16729,C[NH+](C)CCN1CC2=CC=CC=C2NC3=CC=CC=C31.C(=CC(=O)[O-])C(=O)O,,,,,,
6729,16730,"2-(6,11-dihydrobenzo[b][1,4]benzodiazepin-5-yl)-N,N-dimethylethanamine",CN(C)CCN1CC2=CC=CC=C2NC3=CC=CC=C31,,,,,,
6730,16731,"5H-Dibenzo(b,e)(1,4)diazepine, 10,11-dihydro-7-chloro-10-(2-(dimethylamino)ethyl)-",CN(C)CCN1CC2=CC=CC=C2NC3=C1C=CC(=C3)Cl,,,,,,
6731,16732,"1,6,7-Trimethylnaphthalene",CC1=C2C=C(C(=CC2=CC=C1)C)C,,,,,,
6732,16733,1-Amino-2-methylnaphthalene,CC1=C(C2=CC=CC=C2C=C1)N,,,,,,
6733,16734,(p-Fluorophenoxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)COC1=CC=C(C=C1)F.[Cl-],,,,,,
6734,16735,2-(Dimethylamino)ethyl (4-fluorophenoxy)acetate,CN(C)CCOC(=O)COC1=CC=C(C=C1)F,,,,,,
6735,16736,5-(Trifluoromethyl)-1H-indazol-3-amine,C1=CC2=C(C=C1C(F)(F)F)C(=NN2)N,,,,,,
6736,16737,Dipropyl dithiophosphate,CCCOP(=S)(OCCC)S,,,,,,
6737,16738,Fenitrooxone,CC1=C(C=CC(=C1)OP(=O)(OC)OC)[N+](=O)[O-],,,,,,
6738,16739,"Butyrophenone, 4-(4-(m-chlorophenyl)-4-(1-pyrrolidinylcarbonyl)piperidino)-4-fluoro-, oxalate",C1CC[NH+](C1)C(=O)C2(CC[NH+](CC2)C(CCC(=O)C3=CC=CC=C3)F)C4=CC(=CC=C4)Cl.C(=O)(C(=O)[O-])[O-],,,,,,
6739,16740,4-[4-(3-Chlorophenyl)-4-(pyrrolidine-1-carbonyl)piperidin-1-yl]-4-fluoro-1-phenylbutan-1-one,C1CCN(C1)C(=O)C2(CCN(CC2)C(CCC(=O)C3=CC=CC=C3)F)C4=CC(=CC=C4)Cl,,,,,,
6740,16741,Phenethyl isothiocyanate,C1=CC=C(C=C1)CCN=C=S,,,"['Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,['Phenethyl isothiocyanate has known human metabolites that include (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-(2-phenylethylcarbamothioylsulfanyl)propan-2-yl]amino]-5-oxopentanoic acid.'],
6741,16742,"2,3,3-Trichloroacrylic acid",C(=C(Cl)Cl)(C(=O)O)Cl,,,,,,
6742,16743,"AMMONIUM, (OXALYLBIS(IMINOETHYLENE))BIS((o-BROMOBENZYL)DIETHYL-, DIBROMIDE",CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Br)CC2=CC=CC=C2Br.[Br-].[Br-],,,,,,
6743,16744,(2-Bromophenyl)methyl-[2-[[2-[2-[(2-bromophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Br)CC2=CC=CC=C2Br,,,,,,
6744,16745,"3-[[4-[3-[Diethyl(methyl)azaniumyl]propylamino]-3,6-dioxocyclohexa-1,4-dien-1-yl]amino]propyl-diethyl-methylazanium dibromide",CC[N+](C)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](C)(CC)CC.[Br-].[Br-],,,,,,
6745,16746,"3,3'-[(p-Benzoquinone-2,5-diyl)bis(imino)]bis(N,N-diethyl-N-methyl-1-propanaminium)",CC[N+](C)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](C)(CC)CC,,,,,,
6746,16747,(+)-trans-Chrysanthemic acid,CC(=C[C@@H]1[C@H](C1(C)C)C(=O)O)C,,,,,,
6747,16748,Acetiromate,CC(=O)OC1=C(C=C(C=C1)OC2=C(C=C(C=C2I)C(=O)O)I)I,,,,,,
6748,16749,4-Phenyl-1-(3-(tetrahydro-2-furyl)propyl)isonipecotic acid ethyl ester,CCOC(=O)C1(CCN(CC1)CCCC2CCCO2)C3=CC=CC=C3,,,,,,
6749,16750,4-Phenyl-1-(4-(tetrahydro-2-furyl)butyl)isonipecotic acid ethyl ester,CCOC(=O)C1(CCN(CC1)CCCCC2CCCO2)C3=CC=CC=C3,,,,,,
6750,16751,Flucarbril,CN1C2=C(C=CC1=O)C=C(C=C2)C(F)(F)F,,,,,,
6751,16752,Dexamethasone isonicotinate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C5=CC=NC=C5)O)C)O)F)C,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']",,,
6752,16753,Glaucine hydrochloride,C[NH+]1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC.[Cl-],,,,,,
6753,16754,Glaucine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
6754,16755,Diethyl(3-(9-hydroxyfluoren-9-yl)-2-propynyl)methylammonium bromide,CC[N+](C)(CC)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O.[Br-],,,,,,
6755,16756,Diethyl-[3-(9-hydroxyfluoren-9-yl)prop-2-ynyl]-methylazanium,CC[N+](C)(CC)CC#CC1(C2=CC=CC=C2C3=CC=CC=C31)O,,,,,,
6756,16757,5-Phenylvaleric acid,C1=CC=C(C=C1)CCCCC(=O)O,,,,,,
6757,16758,"1-Aziridinecarboxamide, N,N'-1,6-hexanediylbis-",C1CN1C(=O)NCCCCCCNC(=O)N2CC2,,,,,,
6758,16759,Ethanolamine oleate;Phlebocid;Thanomin,CCCCCCCCC=CCCCCCCCC(=O)O.C(CO)N,,,,,,
6759,16760,"1,3,5-Triazin-2-amine, 4,6-dichloro-N-(2-methylphenyl)-",CC1=CC=CC=C1NC2=NC(=NC(=N2)Cl)Cl,,,,,,
6760,16761,"2,4-Dichloro-6-(p-toluidino)-1,3,5-triazine",CC1=CC=C(C=C1)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
6761,16762,"N,N',N''-Tri(2-chlorophenyl)-1,3,5-triazine-2,4,6-triamine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)NC3=CC=CC=C3Cl)NC4=CC=CC=C4Cl)Cl,,,,,,
6762,16763,"4,6-dichloro-N-(4-chlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
6763,16764,"4,6-dichloro-N-(2,5-dichlorophenyl)-1,3,5-triazin-2-amine",C1=CC(=C(C=C1Cl)NC2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
6764,16765,"4,6-dichloro-N-(2,4,5-trichlorophenyl)-1,3,5-triazin-2-amine",C1=C(C(=CC(=C1Cl)Cl)Cl)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
6765,16766,"4,6-dichloro-N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
6766,16767,"Stannane, butylhydroxyoxo-",CCCC[Sn](=O)O,,,,,,
6767,16768,Diethylacetylurea,CCC(CC)C(=O)NC(=O)N,,,,,,
6768,16769,Rangado; Shell SD 8280,COP(=O)(OC)OC(=CCl)C1=C(C=C(C=C1)Cl)Cl,,,,,,
6769,16770,Chlorfensulphide,C1=CC(=CC=C1SN=NC2=CC(=C(C=C2Cl)Cl)Cl)Cl,,,,,,
6770,16771,"Glycine, N-dodecyl-",CCCCCCCCCCCCNCC(=O)O,,,,,,
6771,16772,6-Chloro-3-(hydroxymethyl)benzoxazol-2(3H)-one,C1=CC2=C(C=C1Cl)OC(=O)N2CO,,,,,,
6772,16773,Phenkapton,CCOP(=S)(OCC)SCSC1=C(C=CC(=C1)Cl)Cl,,,,,,
6773,16774,Prothoate,CCOP(=S)(OCC)SCC(=O)NC(C)C,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'Toxicants can be absorbed by inhalation, ingestion, and skin penetration. ... All undergo hydrolytic degradation in liver and other tissues, usually within hr of absorption. Degradation products are of low toxicity, and are excreted in urine and feces. /Organophosphate cholinesterase-inhibiting pesticides/', 'For more Absorption, Distribution and Excretion (Complete) data for TRIMETHOATE (6 total), please visit the HSDB record page.']","['Plasma and tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric and phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paraoxonases. These enzymes are found in the plasma and liver and hydrolyze a large number of organophosphorus compounds ... by cleaving the phosphoester, anhydride, P-F, or P-CN bonds. /Anticholinesterase agents/']",
6774,16775,3-(2-dimethoxyphosphorylsulfanylethylsulfanyl)-N-methylpropanamide,CNC(=O)CCSCCSP(=O)(OC)OC,,,,,,
6775,16776,CID 16776,CCOC(=NP(=O)(N1CC1)N2CC2)C,,,,,,
6776,16777,"4-Nonenal, (4E)-",CCCCC=CCCC=O,,,,,,
6777,16778,Non-6-enal,CCC=CCCCCC=O,,,,,,
6778,16779,Oxyclozanide,C1=C(C=C(C(=C1NC(=O)C2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl)Cl,,,"['Agents used to treat cestode, trematode, or other flatworm infestations in man or animals. (See all compounds classified as Antiplatyhelmintic Agents.)']",,,
6779,16780,"N,N'-Bis(2-chlorobenzyl)-1,4-bicyclo(2.2.2)octanediamine dihydrochloride",C1CC2(CCC1(CC2)[NH2+]CC3=CC=CC=C3Cl)[NH2+]CC4=CC=CC=C4Cl.[Cl-].[Cl-],,,,,,
6780,16781,"1-N,4-N-bis[(2-chlorophenyl)methyl]bicyclo[2.2.2]octane-1,4-diamine",C1CC2(CCC1(CC2)NCC3=CC=CC=C3Cl)NCC4=CC=CC=C4Cl,,,,,,
6781,16782,Peroxyacetyl nitrate,CC(=O)OO[N+](=O)[O-],,,,,,
6782,16783,Phenylmercuriurea,C1=CC=C(C=C1)[Hg]NC(=O)N,,,,,,
6783,16784,Tripropyltin chloride,CCC[Sn](CCC)(CCC)Cl,,,,,,
6784,16785,"4,6-Diamino-3-[(3-amino-3-deoxyhexopyranosyl)oxy]-2-hydroxycyclohexyl 2-amino-2-deoxyhexopyranoside",C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CO)O)O)N)N,,,,,,
6785,16786,"Benzamide, 3-amino-2,5-dichloro-",C1=C(C=C(C(=C1C(=O)N)Cl)N)Cl,,,,,,
6786,16787,M-(1-Methylbutyl)phenyl methylcarbamate,CCCC(C)C1=CC(=CC=C1)OC(=O)NC,,,,,,
6787,16788,"L-N,N-Diethylalanine 2,6-diethylphenyl ester hydrochloride",CCC1=C(C(=CC=C1)CC)OC(=O)C(C)[NH+](CC)CC.[Cl-],,,,,,
6788,16789,"(2,6-Diethylphenyl) 2-(diethylamino)propanoate",CCC1=C(C(=CC=C1)CC)OC(=O)C(C)N(CC)CC,,,,,,
6789,16790,2-Hydroxy-1-naphthoic acid,C1=CC=C2C(=C1)C=CC(=C2C(=O)O)O,,,,,,
6790,16791,"N,N-Diethylglycine 6-chloro-o-tolyl ester hydrochloride",CC[NH+](CC)CC(=O)OC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
6791,16792,(2-Chloro-6-methylphenyl) 2-(diethylamino)acetate,CCN(CC)CC(=O)OC1=C(C=CC=C1Cl)C,,,,,,
6792,16793,"[(17R)-3,17-diacetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl] acetate",CC(=O)O[C@H]1C(CC2C1(CCC3C2CCC4=C3C=CC(=C4)OC(=O)C)C)OC(=O)C,,,,,,
6793,16794,2-(Trifluoromethyl)phenyl isocyanate,C1=CC=C(C(=C1)C(F)(F)F)N=C=O,,,,,,
6794,16795,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-7-(trifluoromethyl)-",C1C(=O)NC2=C(C=C(C=C2)C(F)(F)F)C(=N1)C3=CC=CC=C3,,,,,,
6795,16796,"2-Propenoic acid, 3-(1,3-benzodioxol-5-yl)-2-cyano-, ethyl ester",CCOC(=O)C(=CC1=CC2=C(C=C1)OCO2)C#N,,,,,,
6796,16797,Methylsilatrane,C[Si]12OCCN(CCO1)CCO2,,,,,,
6797,16798,N-Methyl-norgranatan-3-ol beta-diphenylacetyl ester [German],CN1C2CCCC1CC(C2)OC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
6798,16799,CID 16799,COC1=CC=C(C=C1)N=C(N)S,,,,,,
6799,16800,2-Pentylpyridine,CCCCCC1=CC=CC=N1,,,,,,
6800,16801,9-Ethyl-9H-fluorene,CCC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
6801,16802,CID 16802,C1CC(=NC1)S,,,,,,
6802,16803,"Benzoxazole, 2-(3-pyridyl)-",C1=CC=C2C(=C1)N=C(O2)C3=CN=CC=C3,,,,,,
6803,16804,"Benzoxazole, 2-(4-pyridyl)-",C1=CC=C2C(=C1)N=C(O2)C3=CC=NC=C3,,,,,,
6804,16805,Androstenediol dipropionate,CCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4OC(=O)CC)C)C,,,"['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",,,
6805,16806,"(4,5-Dioxocyclohepta-2,6-dien-1-ylidene)amino acetate",CC(=O)ON=C1C=CC(=O)C(=O)C=C1,,,,,,
6806,16807,5-Nitrosotropolone,C1=CC(=O)C(=CC=C1N=O)O,,,,,,
6807,16808,"Benzenamine, 2-methyl-4-[(2-methylphenyl)azo]-, monohydrochloride",CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N)C.Cl,,,,,,
6808,16809,Diphenylcarbamic acid 2-(dimethylamino)ethyl ester hydrochloride,C[NH+](C)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
6809,16810,"N,N-Diphenylcarbamic acid 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
6810,16811,Dicamba-dimethylammonium,CNC.COC1=C(C=CC(=C1C(=O)O)Cl)Cl,,,,"['Dicamba is readily absorbed following ingestion, but only minimal absorption occurs after dermal exposure. Following ingestion, dicamba appears to be rapidly and nonselectively distributed to most organ systems. Most animal studies indicate greater than 90 % of the original dose ultimately undergoes urinary excretion. Small amounts of dicamba are excreted in the feces and have been shown to represent true elimination (indicated after sc administration ) and excretion of unabsorbed herbicide (following oral exposure). ... Elimination occurs rapidly, and there is no evidence of bioaccumulation in mammalian systems. /Dicamba/']","['Dicamba is excreted mostly in unmetabolized form but may also be conjugated with glucoronic acid or glycine. /Dicamba/', 'Holstein dairy cow was fed by catheter 5 ppm of Banvel-D (2-methoxy-3,6-dichlorobenzoic acid) for 4 days based on 22.7 kg daily feed ration. ...No residues were detected in either the milk or the feces; during the first 4 days of the feeding trial, only traces (not quantitatively measurable) were found of Banvel-D in the feces. The urine accounted for 73% of the excretion of the intact herbicide. From day 2 through day 7, the urinary concentrations were 3.4, 4.6, 4.3, 4.2, 4.1 and 0.1 ppm, respectively.']",
6811,16812,CID 16812,CC(=NN=C(N)S)C1=CC=CC=C1,,,,,,
6812,16813,Acid Red 13,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C=CC4=C3C=CC(=C4)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
6813,16814,Acid Red 13 free acid,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C=CC4=C3C=CC(=C4)S(=O)(=O)O)O,,,,,,
6814,16815,m-Chlorophenyl p-nitrophenyl ether,C1=CC(=CC(=C1)Cl)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
6815,16816,1-Methyl-3-(4-nitrophenoxy)benzene,CC1=CC(=CC=C1)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
6816,16817,Muscarine chloride,C[C@H]1[C@@H](C[C@H](O1)C[N+](C)(C)C)O.[Cl-],,,,['...VERY POORLY ABSORBED FROM GI TRACT... /MUSCARINE/'],,
6817,16818,"2,17beta-Dihydroxy-17-methylandrosta-1,4-dien-3-one",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC(=O)C(=C[C@]34C)O,,,,,,
6818,16819,"Chrysene-1,2-quinone",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C=CC(=O)C4=O,,,,,,
6819,16820,"1,8-Pyrenedione",C1=CC2=C3C(=CC=C4C3=C1C=CC4=O)C(=O)C=C2,,,,,,
6820,16821,gamma-Dodecalactone,CCCCCCCCC1CCC(=O)O1,,,,,,
6821,16822,Dihydroconiferyl alcohol,COC1=C(C=CC(=C1)CCCO)O,,,,,,
6822,16823,"Cyclohex-4-ene-1,2-dicarboxylic acid",C1C=CCC(C1C(=O)O)C(=O)O,,,,,,
6823,16824,Tricamba,COC1=C(C(=C(C=C1Cl)Cl)Cl)C(=O)O,,,,,,
6824,16825,"2,4-Dichlorophenoxyacetic acid diethanolamine salt",C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C(CO)NCCO,,,,,,
6825,16826,Pentanochlor,CCCC(C)C(=O)NC1=CC(=C(C=C1)C)Cl,,,,,,
6826,16827,"1,4-Benzodioxan-2-methylamine, N-(3-methoxypropyl)-, hydrochloride",COCCC[NH2+]CC1COC2=CC=CC=C2O1.[Cl-],,,,,,
6827,16828,Quiloflex,COCCCNCC1COC2=CC=CC=C2O1,,,,,,
6828,16829,"2,5-Piperazinedione, 3,6-bis(phenylmethyl)-",C1=CC=C(C=C1)CC2C(=O)NC(C(=O)N2)CC3=CC=CC=C3,,,,,,
6829,16830,Methyl 4-hydroxy-3-methoxy-cinnamate,COC1=C(C=CC(=C1)C=CC(=O)OC)O,,,,,,
6830,16831,Epipachysamine A,CC(C1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C(=O)C,,,,,,
6831,16832,Isopropyl hexanoate,CCCCCC(=O)OC(C)C,,,,,,
6832,16833,Isopropyl decanoate,CCCCCCCCCC(=O)OC(C)C,,,,,,
6833,16834,N-Benzyl-9-(tetrahydro-2H-pyran-2-YL)adenine,C1CCOC(C1)N2C=NC3=C(N=CN=C32)NCC4=CC=CC=C4,,,,,,
6834,16835,3-Methyl-2-hexanol,CCCC(C)C(C)O,,,,,,
6835,16836,Ethoxazene hydrochloride,CCOC1=CC=C(C=C1)N=NC2=C(C=C(C=C2)N)N.Cl,,,,,,
6836,16837,Ethoxazene,CCOC1=CC=C(C=C1)N=NC2=C(C=C(C=C2)N)N,,,,,,
6837,16838,Butylcaptax,CCCCSC1=NC2=CC=CC=C2S1,,,,,,
6838,16839,"3,5-Dichloro-4-hydroxybenzaldehyde",C1=C(C=C(C(=C1Cl)O)Cl)C=O,,,,,,
6839,16840,Dimethyl trithiocarbonate,CSC(=S)SC,,,,,,
6840,16841,Diethyl trithiocarbonate,CCSC(=S)SCC,,,,,,
6841,16842,N-Ethylsuccinimide,CCN1C(=O)CCC1=O,,,,,,
6842,16843,Trifluoroiodomethane,C(F)(F)(F)I,,,,,,
6843,16844,"2-Chloro-N,N-diethylacetamide",CCN(CC)C(=O)CCl,,,,,,
6844,16845,"29-[4-(6-Methylheptyl)phenoxy]-3,6,9,12,15,18,21,24,27-nonaoxanonacosan-1-ol",CC(C)CCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,,,,
6845,16846,Propyl benzoate,CCCOC(=O)C1=CC=CC=C1,,,,,,
6846,16847,beta-Conidendrol,C1C2C(COC2=O)C(C3=CC(=C(C=C31)O)O)C4=CC(=C(C=C4)O)O,,,,,,
6847,16848,"2-Propenoic acid, 3-(3,4-dimethoxyphenyl)-",COC1=C(C=C(C=C1)C=CC(=O)O)OC,,,,,,
6848,16849,CID 16849,CC=C1C[C@H]([C@@](C(=O)OCC2=CCN(CCC(C2=O)OC1=O)C)(C)O)C,,,,,,
6849,16850,Fluorescein,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,['For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.'],,"['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)', 'Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']","['Rapidly distributed', 'Fluorescein and its metabolites are mainly eliminated via renal excretion.', '0.5 L/kg', 'renal cl=1.75 mL/min/kg [After IV administration]', 'Fluorescence of skin persists for several hr, and dye appears in urine for as long as 30 hr.', 'Within 7 to 14 seconds after IV administration into antecubital vein, fluorescein usually appears in the central artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade after 6 to 12 hours of dosing. Various estimates of volume of distribution indicate that fluorescein distributes well into interstitial space (0.5 L/ kg).', 'Fluorescein and its metabolites are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.', 'Fluorescein sodium has been demonstrated to be excreted in human milk.', 'The permeability of the blood-retinal and blood-aqueous barriers to fluorescein and the rate of aqueous flow can be estimated by measurements of fluorescein in the vitreous, aqueous, and plasma after systemic administration. Fluorescein is commonly measured by fluorescence, but fluorescein glucuronide, a metabolite of fluorescein, also fluoresces. To assess the influence of fluorescein glucuronide on the quantitation of fluorescein by fluorescence, we studied the pharmacokinetics of fluorescein and fluorescein glucuronide for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. The plasma and the plasma ultrafiltrate were measured by fluorescence and by high performance liquid chromatography. In our fluorophotometer, fluorescein glucuronide was 0.124 times as fluorescent as fluorescein. Fluorescein was rapidly converted to fluorescein glucuronide, and within 10 min the concentration of unbound fluorescein glucuronide exceeded that of unbound fluorescein. The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, so that fluorescein glucuronide contributed almost all of the plasma fluorescence after 4-5 hr. Because fluorescein glucuronide was less bound in the plasma than fluorescein, the ratio of the fluorescence of the plasma ultrafiltrate to that of the plasma increased with time. The greatest proportion of the total fluorescein available to penetrate into the ocular compartments occurred shortly after injection. ...']","['The permeability of the blood-retinal and blood-aqueous barriers to fluorescein and the rate of aqueous flow can be estimated by measurements of fluorescein in the vitreous, aqueous, and plasma after systemic administration. Fluorescein is commonly measured by fluorescence, but fluorescein glucuronide, a metabolite of fluorescein, also fluoresces. To assess the influence of fluorescein glucuronide on the quantitation of fluorescein by fluorescence, we studied the pharmacokinetics of fluorescein and fluorescein glucuronide for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. The plasma and the plasma ultrafiltrate were measured by fluorescence and by high performance liquid chromatography. In our fluorophotometer, fluorescein glucuronide was 0.124 times as fluorescent as fluorescein. Fluorescein was rapidly converted to fluorescein glucuronide, and within 10 min the concentration of unbound fluorescein glucuronide exceeded that of unbound fluorescein. The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, so that fluorescein glucuronide contributed almost all of the plasma fluorescence after 4-5 hr. Because fluorescein glucuronide was less bound in the plasma than fluorescein, the ratio of the fluorescence of the plasma ultrafiltrate to that of the plasma increased with time. The greatest proportion of the total fluorescein available to penetrate into the ocular compartments occurred shortly after injection. ...', 'Fluorescein undergoes rapid metabolism to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose, indicating relatively rapid conjugation.', 'Fluorescein is a known human metabolite of zinc15020070.']","['... The pharmacokinetics of fluorescein and fluorescein glucuronide /were studied/ for 38 hr in the plasma of five normal subjects given 14 mg/kg of sodium fluorescein intravenously. ... The terminal half-lives of fluorescein and fluorescein glucuronide in the plasma ultrafiltrate were 23.5 and 264 min, respectively, ... .']"
6850,16851,Monoammonium methanearsonate,C[As](=O)(O)[O-].[NH4+],,,,,,
6851,16852,2-Iminocyclopentanecarbonitrile,C1CC(C(=N)C1)C#N,,,,,,
6852,16853,Profadol hydrochloride,CCCC1(CCN(C1)C)C2=CC(=CC=C2)O.Cl,,,,,,
6853,16854,"1-(3,4-Dichlorophenyl)urea",C1=CC(=C(C=C1NC(=O)N)Cl)Cl,,,,,,
6854,16855,Heliamine hydrochloride,COC1=C(C=C2C[NH2+]CCC2=C1)OC.[Cl-],,,,,,
6855,16856,2-(4-Butoxy-m-tolyl)acetohydroxamic acid,CCCCOC1=C(C=C(C=C1)CC(=O)NO)C,,,,,,
6856,16857,"3,4,5-Triiodobenzoic acid",C1=C(C=C(C(=C1I)I)I)C(=O)O,,,,,,
6857,16858,"Benzimidazole, 5,6-dinitro-2-(trifluoromethyl)-",C1=C2C(=CC(=C1[N+](=O)[O-])[N+](=O)[O-])N=C(N2)C(F)(F)F,,,,,,
6858,16859,"1H-Benzimidazole, 5,6-dichloro-2-(trifluoromethyl)-",C1=C2C(=CC(=C1Cl)Cl)N=C(N2)C(F)(F)F,,,,,,
6859,16860,"Benzimidazole, 4-chloro-2-(trifluoromethyl)-",C1=CC2=C(C(=C1)Cl)N=C(N2)C(F)(F)F,,,,,,
6860,16861,5-Fluorocytidine,C1=C(C(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)F,,,,,,
6861,16862,Faniline,C1=CC=C(C=C1)NNC(=O)CF,,,,,,
6862,16863,"2,4-Difluoro-6-(4-nitrophenoxy)-1,3,5-triazine",C1=CC(=CC=C1[N+](=O)[O-])OC2=NC(=NC(=N2)F)F,,,,,,
6863,16864,"Propanoic acid, 2-methyl-, (2E)-3,7-dimethyl-2,6-octadienyl ester",CC(C)C(=O)OCC=C(C)CCC=C(C)C,,,,,,
6864,16865,4-Acetoxybenzoic acid,CC(=O)OC1=CC=C(C=C1)C(=O)O,,,,,,
6865,16866,(2E)-3-Chloro-2-propenoic acid,C(=CCl)C(=O)O,,,,,,
6866,16867,2-Methyl-2-thiazoline,CC1=NCCS1,,,,,,
6867,16868,Food orange 2,C1=CC(=CC(=C1)S(=O)(=O)[O-])N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
6868,16869,"6-Oxo-5-[2-(3-sulfophenyl)hydrazinylidene]-5,6-dihydronaphthalene-2-sulfonic acid",C1=CC(=CC(=C1)S(=O)(=O)O)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O,,,,,,
6869,16870,"2-Dimethylamino-1,4-naphthoquinone",CN(C)C1=CC(=O)C2=CC=CC=C2C1=O,,,,,,
6870,16871,"2-Methoxy-1,4-naphthoquinone",COC1=CC(=O)C2=CC=CC=C2C1=O,,,,,,
6871,16872,Hexyl isobutyrate,CCCCCCOC(=O)C(C)C,,,,,,
6872,16873,CID 16873,C1(=NN=C(S1)S)N,,,,,,
6873,16874,"2,6-Bis(2-methylbutan-2-yl)benzene-1,4-diol",CCC(C)(C)C1=CC(=CC(=C1O)C(C)(C)CC)O,,,,,,
6874,16875,2-Chlorododecane,CCCCCCCCCCC(C)Cl,,,,,,
6875,16876,1-Chloro-5-methylheptane,CCC(C)CCCCCl,,,,,,
6876,16877,"Benzoic acid, p-methoxy-, 2-diethylaminoethyl ester, hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)OC.[Cl-],,,,,,
6877,16878,Anisic acid diethylaminoethyl ester,CCN(CC)CCOC(=O)C1=CC=C(C=C1)OC,,,,,,
6878,16879,p-Propoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)C(=O)OCC[NH+](CC)CC.[Cl-],,,,,,
6879,16880,"Benzoic acid, 4-propoxy-, 2-(diethylamino)ethyl ester",CCCOC1=CC=C(C=C1)C(=O)OCCN(CC)CC,,,,,,
6880,16881,Butoxycaine hydrochloride,CCCCOC1=CC=C(C=C1)C(=O)OCCN(CC)CC.Cl,,,,,,
6881,16882,Butoxycaine,CCCCOC1=CC=C(C=C1)C(=O)OCCN(CC)CC,,,,,,
6882,16883,4-Vinylbiphenyl,C=CC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
6883,16884,"4,6-Dichloro-N-(4-nitrophenyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)Cl)Cl)[N+](=O)[O-],,,,,,
6884,16885,"2-Chloro-4,6-bis(4-nitroanilino)-1,3,5-triazine",C1=CC(=CC=C1NC2=NC(=NC(=N2)Cl)NC3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6885,16886,"1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-",C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
6886,16887,Fast Green FCF,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)[O-].[Na+].[Na+],,,,"['Following i.v. injection in rats, over 90% of the /Fast Green FCF/ was excreted in the bile within 4 hours.', 'Dogs were given orally 200 mg of the /Fast Green FCF/... a bile fistula was made for bile analysis. ... The amount of /Fast Green FCF found in the bile/ never exceeded 5% of the given dose. ...', 'Rats ... were given orally 200 mg of the /Fast Green FCF/... the urine and feces were collected for 36 hours. ... Almost all the administered /Fast Green FCF/ was excreted unchanged in the feces of rats. No /Fast Green FCF/ was found in the urine. ...']",,
6887,16888,"N-ethyl-4-[(4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)(4-hydroxy-2-sulfophenyl)methylidene]-N-[(3-sulfophenyl)methyl]cyclohexa-2,5-dien-1-iminium",CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=C(C=C(C=C5)O)S(=O)(=O)O,,,,,,
6888,16889,Butropipazone,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=C3,,,,,,
6889,16890,"(2S,4R,8S,11S,12R)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-16-one",CC1(O[C@@H]2C[C@H]3C4CCC5CC(=O)CCC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)CO)C)O)F)C)C,,,,,,
6890,16891,Diethylene glycol dimethacrylate,CC(=C)C(=O)OCCOCCOC(=O)C(=C)C,,,,,,
6891,16892,"N,N-Bis(2-chloroethyl)-o-bromobenzylamine",C1=CC=C(C(=C1)CN(CCCl)CCCl)Br,,,,,,
6892,16893,"N,N-Bis(2-chloroethyl)-m-bromobenzylamine",C1=CC(=CC(=C1)Br)CN(CCCl)CCCl,,,,,,
6893,16894,o-Chloro-bis(2-chloroethyl)benzylamine,C1=CC=C(C(=C1)CN(CCCl)CCCl)Cl,,,,,,
6894,16895,"N,N-Bis(2-chloroethyl)-m-chlorobenzylamine",C1=CC(=CC(=C1)Cl)CN(CCCl)CCCl,,,,,,
6895,16896,4-Bromo-2-methylphenol,CC1=C(C=CC(=C1)Br)O,,,,,,
6896,16897,2-(Phenylazo)phenol,C1=CC=C(C=C1)N=NC2=CC=CC=C2O,,,,,,
6897,16898,Heneicosanoic acid,CCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
6898,16899,"Deca-2,4-dienal",CCCCCC=CC=CC=O,,,,,,
6899,16900,Oct-2-enal,CCCCCC=CC=O,,,,,,
6900,16901,"1,1'-Biphenyl, 3,3',4,4'-tetranitro-",C1=CC(=C(C=C1C2=CC(=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
6901,16902,(+)-Palmitoylcarnitine,CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(=O)[O-])C[N+](C)(C)C,,,,,,
6902,16903,[(S)-3-Carboxylato-2-(palmitoyloxy)propyl]trimethylaminium,CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(=O)O)C[N+](C)(C)C,,,,,,
6903,16904,"Isonicotinic acid, 2-ethylhydrazide",CCNNC(=O)C1=CC=NC=C1,,,,,,
6904,16905,CID 16905,C1=CC=C2C(=C1)C=CN=C2C=NN=C(N)S,,,,,,
6905,16906,Isatin 3-hydrazone,C1=CC=C2C(=C1)C(=C(N2)O)N=N,,,,,,
6906,16907,Methyl thioglycolate,COC(=O)CS,,,,,,
6907,16908,1-Fluorobutane,CCCCF,,,,,,
6908,16909,Methyl 4-fluorobut-2-enoate,COC(=O)C=CCF,,,,,,
6909,16910,"1,2,3,5-Tetrafluorobenzene",C1=C(C=C(C(=C1F)F)F)F,,,,,,
6910,16911,"2,2-Dimethylpentan-1-ol",CCCC(C)(C)CO,,,,,,
6911,16912,"2,2-Dimethyl-1-hexanol",CCCCC(C)(C)CO,,,,,,
6912,16913,2-Methylisoborneol,CC1(C2CCC1(C(C2)(C)O)C)C,,,,,,
6913,16914,CID 16914,CCCC[O-].[Na+],,,,,,
6914,16915,"Isonipecotic acid, 1-allyl-4-phenyl-, ethyl ester",CCOC(=O)C1(CCN(CC1)CC=C)C2=CC=CC=C2,,,,,,
6915,16916,Chloromethyl methyl sulfide,CSCCl,,,,,,
6916,16917,"2-Propenoic acid, 3-(1,3-benzodioxol-5-yl)-",C1OC2=C(O1)C=C(C=C2)C=CC(=O)O,,,,,,
6917,16918,"3,3'-Dihydroxybenzidine",C1=CC(=C(C=C1C2=CC(=C(C=C2)N)O)O)N,,,,"['The average environmental exposure levels of four of the workers /in a dye manufacturing facility/ were 4.3, 5.2, 11.7, and 17.4 mg total particulate/cu m. The corresponding urinary concentrations of benzidine average 52, 11, 10, and 112 ppb, respectively /SRP: from the precursor during manufacturing/. /Benzidine-based dyes/']","['Various bacteria and yeast normally found in the small and large intestine can reduce the azo bond in /some/ benzidine-based dyes and release benzidine. /Benzidine-based dyes/', 'Humans as well as other mammals can change (metabolize) /some/ benzidine-based dyes back to benzidine. The major organ in which /some/ benzidine-based dyes are metabolized to benzidine is the liver, but other organs also can do this to a greater or lesser degree. /Benzidine-based dyes/']",
6918,16919,"4-Bromo-2,6-dimethylphenol",CC1=CC(=CC(=C1O)C)Br,,,,,,
6919,16920,"1,5-Dimesyloxypentane",CS(=O)(=O)OCCCCCOS(=O)(=O)C,,,,,,
6920,16921,"Benzoic acid, 2-chloro-6-sulfamoyl-, isopropyl ester",CC(C)OC(=O)C1=C(C=CC=C1Cl)S(=O)(=O)N,,,,,,
6921,16922,CID 16922,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[Na+],,,,,,
6922,16923,Methylprednisolone hemisuccinate,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O,,"['Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.']","['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
6923,16924,Perfluoro-tert-butanol,C(C(F)(F)F)(C(F)(F)F)(C(F)(F)F)O,,,,,,
6924,16925,"2,3-Dimethylquinoxaline",CC1=NC2=CC=CC=C2N=C1C,,,,,,
6925,16926,6-Chloro-2-(6-chloro-4-methyl-3-oxo-benzothiophen-2-ylidene)-4-methyl-benzothiophen-3-one,CC1=CC(=CC2=C1C(=O)C(=C3C(=O)C4=C(S3)C=C(C=C4C)Cl)S2)Cl,,,,,,
6926,16927,"9,10-Anthracenedione, 1-amino-4-hydroxy-2-methoxy-",COC1=C(C2=C(C(=C1)O)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
6927,16928,Homovanillyl alcohol,COC1=C(C=CC(=C1)CCO)O,,,,,,
6928,16929,10-Methylbenz[a]anthracene,CC1=CC2=CC3=C(C=CC4=CC=CC=C43)C=C2C=C1,,,,,,
6929,16930,9-Methylbenz[a]anthracene,CC1=CC2=C(C=C1)C=C3C(=C2)C=CC4=CC=CC=C43,,,,,,
6930,16931,3-Methylbenzo[c]phenanthrene,CC1=CC2=C(C=C1)C3=C(C=CC4=CC=CC=C43)C=C2,,,,,,
6931,16932,1-Methylpyrene,CC1=C2C=CC3=CC=CC4=C3C2=C(C=C1)C=C4,,,,,"['Alkyl-substituted polycyclic aromatic hydrocarbons may be metabolized to highly reactive benzylic sulfuric acid esters via benzylic hydroxylation and subsequent sulfonation. We have studied the benzylic hydroxylation of 1-methylpyrene (MP), a hepatocarcinogen in rodents, and 1-ethylpyrene (EP), whose benzylic hydroxylation would produce a secondary alcohol (alpha-HEP), in contrast to the primary alcohol (alpha-HMP) formed from MP. The hydrocarbons were incubated with hepatic microsomal preparations from humans and rats, as well as with V79-derived cell lines engineered for the expression of individual cytochrome P450 (CYP) forms from human (1A1, 1A2, 1B1, 2A6, 2E1, 3A4) and rat (1A1, 1A2, 2B1). All microsomal systems and CYP-expressing cell lines used, but not CYP-deficient V79 cells, showed biotransformation of both hydrocarbons. Formation of the benzylic alcohol was detected in each case. alpha-HMP and its oxidation product, 1-pyrenylcarboxylic acid (COOH-P), accounted for a major part of the total amount of the metabolites formed from MP in the presence of human liver microsomes (38-64%) and cells expressing human 3A4, 2E1 or 1B1 (80-85%). Likewise, cells expressing human 1A1 showed a higher contribution of alpha-HMP and COOH-P to the total metabolites (45%) than cells expressing the orthologous enzyme of the rat (3%). EP was metabolized at a higher rate and with modified regioselectivity compared with MP, although omega-hydroxylation of the side chain was not detected with the cell lines and only accounted for a small percent of the biotransformation by the microsomal preparations. The highest contributions of alpha-HEP to the total metabolites from EP were detected with the cells expressing human 1A1, 1B1 and 3A4 (38-51%). alpha-HEP accounted for 16% of the metabolites formed in the presence of human hepatic microsomes. Thus, benzylic hydroxylation is a major initial step in the metabolism of MP and EP. This pathway appears to be even more important in humans than in rats. Previously, we had shown that the second step of the activation, the sulfonation of alpha-HMP and alpha-HEP, is also efficiently catalysed by various forms of human sulfotransferases.', '1-Methylpyrene, an alkylated polycyclic aromatic hydrocarbon and environmental carcinogen, is activated by side-chain hydroxylation to 1-hydroxymethylpyrene (1-HMP) and subsequent sulfo conjugation to the DNA-reactive 1-sulfooxymethylpyrene. In addition to the bioactivation, processes of metabolic detoxification and transport greatly influence the genotoxicity of 1-methylpyrene. For a better understanding of 1-HMP detoxification in vivo we studied urinary and fecal metabolites in rats following intraperitoneal doses of 19.3 mg 1-HMP/kg body weight (5 rats) or the same dose containing 200?Ci [(14)C]1-HMP/kg body weight (2 rats). After 48h, 48.0% (rat 1) and 29.1% (rat 2) of the radioactivity was recovered as 1-HMP in the feces. Six major metabolites were observed by UV and on-line radioactivity detection in urine samples and feces after HPLC separation. The compounds were characterized by mass spectrometry, (1)H NMR and (1)H-(1)H COSY NMR spectroscopy, which allowed assigning tentative molecular structures. Two prominent metabolites, 1-pyrene carboxylic acid (M-6) and the acyl glucuronide of 1-pyrene carboxylic acid (M-5) accounted for 17.7% (rat 1) and 25.2% (rat 2) of the overall radioactive dose. Further, we detected the acyl glucuronide of 6-hydroxy-1-pyrene carboxylic acid (M-1) and 8-sulfooxy-1-pyrene carboxylic acid (M-3) together with two regioisomers of M-3 (M-2 and M-4) differing in position of the sulfate group at the pyrene ring. In urine samples, the radioactivity of 1-pyrene carboxylic acid and its five derivatives amounted to 32.4% (rat 1) or 45.5% (rat 2) of the total [(14)C]1-HMP dose.', 'Transformation of nonsubstituted and alkyl-substituted polycyclic aromatic hydrocarbons (PAHs) by the benthic invertebrate Nereis diversicolor was compared in this study. Pyrene and 1-methylpyrene were used as model compounds for nonsubstituted and alkyl-substituted PAHs, respectively. Qualitative and quantitative analyses of metabolites and parent compounds in worm tissue, water, and sediment were performed. Transformation of 1-methylpyrene generated the benzylic hydroxylated phase I product, 1-pyrenecarboxylic acid that comprised 90% of the total metabolites of 1-methylpyrene, and was mainly found in water extracts. We tentatively identified 1-methylpyrene glucuronides and 1-carbonylpyrene glycine as phase II metabolites not previously reported in literature. Pyrene was biotransformed to 1-hydroxypyrene, pyrene-1-sulfate, pyrene-1-glucuronide, and pyrene glucoside sulfate, with pyrene-1-glucuronide as the most prominent metabolite. Transformation of 1-methylpyrene (21% transformed) was more than 3 times as efficient as pyrene transformation (5.6% transformed). Because crude oils contain larger amounts of C?-C?-substituted PAHs than nonsubstituted PAHs, the rapid and efficient transformation of sediment-associated 1-methylpyrene may result in a high exposure of water-living organisms to metabolites of alkyl-substituted PAHs, whose toxicities are unknown. ...', ""The common polycyclic aromatic hydrocarbon 1-methylpyrene is hepatocarcinogenic in the newborn mouse assay. In vitro studies showed that it is metabolically activated via benzylic hydroxylation and sulphation to a reactive ester, which forms benzylic DNA adducts, N(2)-(1-methylpyrenyl)-2'-deoxyguanosine (MPdG) and N(6)-(1-methylpyrenyl)-2'-deoxyadenosine (MPdA). Formation of these adducts was also observed in animals treated with the metabolites, 1-hydroxymethylpyrene and 1-sulphooxymethylpyrene (1-SMP), whereas corresponding data are missing for 1-methylpyrene. In the present study, we treated mice with 1-methylpyrene and subsequently analyzed blood serum for the presence of the reactive metabolite 1-SMP and tissue DNA for the presence of MPdG and MPdA adducts. We used wild-type mice and a mouse line transgenic for human sulphotransferases (SULT) 1A1 and 1A2, males and females. All analyses were conducted using ultra-performance liquid chromatography coupled with tandem mass spectrometry, for the adducts with isotope-labelled internal standards. 1-SMP was detected in all treated animals. Its serum level was higher in transgenic mice than in the wild-type (p < 0.001). Likewise, both adducts were detected in liver, kidney and lung DNA of all exposed animals. The transgene significantly enhanced the level of each adduct in each tissue of both sexes (p < 0.01-0.001). Adduct levels were highest in the liver, the target tissue of carcinogenesis, in each animal model used. MPdG and MPdA adducts were also observed in rats treated with 1-methylpyrene. Our findings corroborate the hypothesis that 1-SMP is indeed the ultimate carcinogen of 1-methylpyrene and that human SULT are able to mediate the terminal activation in vivo."", 'For more Metabolism/Metabolites (Complete) data for 1-Methylpyrene (6 total), please visit the HSDB record page.']",
6932,16933,8-Methylbenz[a]anthracene,CC1=C2C=C3C=CC4=CC=CC=C4C3=CC2=CC=C1,,,,,"['8-Methylbenz[a]anthracene (8-MeBaA) transdihydrodiol metabolites were isolated by reversed-phase and normal-phase HPLCs from incubations of 8-MeBaA with liver microsomes or a reconstituted system containing purified cytochrome P-448 and epoxide hydrolase. Regardless of the enzyme source, the metabolically formed 8-MeBaA trans-3,4- and -5,6-dihydrodiols were found to be enriched in one enantiomeric isomer and differed only in the degree of optical purity. The 8-MeBaA trans-8,9-dihydrodiol formed by liver microsomes from either untreated or phenobarbital-treated rats was enriched with the (+)-enantiomer. In contrast, the 8-MeBaA trans-8,9-dihydrodiol formed either by liver microsomes from 3-methylcholanthrene-treated rats or by the reconstituted rat liver enzyme system containing cytochrome P-448 and epoxide hydrolase was enriched with the (-)enantiomer. These results indicate that, in catalyzing the formation of 3,4- and 5,6-epoxide intermediates, the interaction with the unsubstituted 3,4- and 5,6-double bonds of 8-MeBaA by the different forms of cytochrome P-450 occur preferentially on the same face of the aromatic plane and they differ only in the degree of stereoselectivity. However, different forms of cytochrome P-450 may interact with different faces of the aromatic plane at the methyl-substituted 8,9-double bond of 8-MeBaA, resulting in the formation of trans-8,9-dihydrodiols enriched in different enantiomeric forms. This demonstrates that different forms of cytochrome P-450 may catalyze the epoxidation reaction preferentially at different sides of the methyl-substituted double bond of a planar polycyclic hydrocarbon molecule. These properties may be used to further classify and to understand the enzyme-substrate interactions of the different forms of cytochrome P-450 in the drug-metabolizing enzyme systems.', 'Metabolism of the carcinogen 8-hydroxymethylbenz[a]anthracene (8-HOCH2-BA) with liver microsomes from 3-methylcholanthrene-treated rats resulted in 12 identifiable metabolites. Trans-1,2-, 3,4-5,6-, 8,9-, and 10,11-dihydrodiols are among the identified metabolites. The major enantiomers of the trans-dihydrodiols have 1R,2R, 3R,4R, 5R,6R, 8S,9S, and 10R,11R absolute configurations, respectively. Metabolites formed by liver microsomes from untreated as well as 3-methylcholanthrene-, phenobarbital-, and polychlorinated biphenyl-treated immature male Sprague-Dawley rats were quantified by using specifically tritium-labeled [3H-CH2]8-HOCH2-BA as the substrate. The identification of an 8,9-dihydrodiol as a metabolite of 8-HOCH2-BA indicates that a hydroxymethyl substituent does not prevent the enzymatic oxidation at the hydroxymethyl-substituted 8,9-double bond of 8-HOCH2-BA. ...']",
6933,16934,6-Methylbenzo[c]phenanthrene,CC1=CC2=CC=CC=C2C3=C1C=CC4=CC=CC=C43,,,,,,
6934,16935,6-Methylbenzo[a]pyrene,CC1=C2C=CC3=C4C2=C(C=CC4=CC=C3)C5=CC=CC=C15,,,,,,
6935,16936,"7,10-Dimethylbenz[c]acridine",CC1=CC2=NC3=C(C=CC4=CC=CC=C43)C(=C2C=C1)C,,,,,,
6936,16937,"[(10S,13S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate",C[C@]12CCC3C(C1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5[C@@]3(CCC(=O)C5)C,,,,,,
6937,16938,Nile Blue chloride,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=C1)CC.[Cl-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
6938,16939,Nile blue,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=C1)CC,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
6939,16940,CID 16940,CCC=CCCCCCCCC(=O)O,,,,,,
6940,16941,"1-Propanaminium, 2-hydroxy-N,N,N-trimethyl-, chloride",CC(C[N+](C)(C)C)O.[Cl-],,,,,,
6941,16942,2-Methylcholine,CC(C[N+](C)(C)C)O,,,,,,
6942,16943,CID 16943,C1=CC=C2C(=C1)N=C(O2)S,,,,,,
6943,16944,4-Decyne,CCCCCC#CCCC,,,,,,
6944,16945,Mirex,C12(C3(C4(C5(C3(C(C1(C5(C2(C4(Cl)Cl)Cl)Cl)Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl,,,,"['Mirex is transferred across the placenta to the fetus and is excreted with the milk.', 'Mirex is a lipophilic compound and as such is stored in the adipose tissue to a much greater extent than in any other tissue. For rats /that/ were dosed with a single oral dose of mirex at 6 mg/kg body weight, the tissues and organs retained about 34% of the total dose, of which 28% was found in fat, 3.2% in muscle, 0.09% in the kidneys, and 1.8% in the liver.', 'Following oral ingestion, mirex is only partly absorbed into the body and the remainder, depending on the dose administered, is eliminated unchanged in the faeces.  Mirex can also be absorbed following inhalation and via the skin.', 'Approximately 55% of a single oral dose of 6 mg (14)C-mirex/kg body weight, administered to rats, was excreted unchanged in the feces within 48 hr.  When a lower concentration of mirex was administered (0.2 mg/kg body weight), only 15% of the administered mirex was excreted in 48 hr.', 'For more Absorption, Distribution and Excretion (Complete) data for MIREX (17 total), please visit the HSDB record page.']","['Preliminary disclosure that mirex yields no mammalian metabolites has ... been confirmed by a full report of long-term feeding trials in rat. In fat of female rats, concentrations of mirex had declined by only 40% some 10 mo after cessation of daily dosing. This ranks this polychlorinated  cmpd ... as one of most persistent xenobiotics yet encountered.', 'Mirex is not metabolized by humans or animals ... .', 'Mirex ... is the fully chlorinated cage molecule ... that might be expected to be rather resistant to enzymatic attack ... One chlorine atom is reductively replaced in the environment to give photomirex (8-monohydro-mirex), which appears to behave like mirex in the rat. Reductive dechlorination can occur in vivo; 2,8-dihydromirex and 5,10-dihydromirex have been identified as rat metabolites. Whereas 2,8-dihydromirex does no appear to be further metabolized, 5,10-dihydromirex appears to be converted into more polar metabolites, which appear in rat urine.', 'Mirex is probably oxidized to chlordecone. The main metabolite of chlordecone is chlordecone alcohol, which appears in human bile as glucuronic acid conjugates.']","['... IN RATS ... HALF LIVES FOR BIPHASIC EXCRETION OF MIREX WERE 38 HR & 100 DAYS, RESPECTIVELY.', 'In female goats, mirex levels decrease to one half their original concentration 34-52 wk after discontinuance of exposure. ...', 'Its elimination from the body is slow and, depending on the species, it has a half-life in the body of several months.']"
6945,16946,"ACETOHYDROXAMIC ACID, 2-(p-BUTYLTHIO)PHENYL-",CCCCSC1=CC=C(C=C1)CC(=O)NO,,,,,,
6946,16947,"ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate",CCOC(=O)C1=C(C(=C(N1)C)C(=O)C)C,,,,,,
6947,16948,CID 16948,CCCCCCCCCCCCS(=O)(=O)[O-].[Na+],,,,,,
6948,16949,"3,4-Epoxycyclohexylmethyl 3,4-epoxycyclohexanecarboxylate",C1CC2C(O2)CC1COC(=O)C3CCC4C(C3)O4,,,,,,
6949,16950,L-Argininosuccinic acid,C(C[C@@H](C(=O)O)N)CN=C(N)N[C@@H](CC(=O)O)C(=O)O,,,,,,
6950,16951,Undecyl hydrogen carbonate,CCCCCCCCCCCOC(=O)O,,,,,,
6951,16952,p-Isopropyl-alpha-methylstyrene,CC(C)C1=CC=C(C=C1)C(=C)C,,,,,,
6952,16953,Thioflavin T,CC1=CC2=C(C=C1)[N+](=C(S2)C3=CC=C(C=C3)N(C)C)C.[Cl-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
6953,16954,"2-[4-(Dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium",CC1=CC2=C(C=C1)[N+](=C(S2)C3=CC=C(C=C3)N(C)C)C,,,,,,
6954,16955,Ethyl violet,CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=CC=C(C=C3)N(CC)CC.[Cl-],,,,,,
6955,16956,"Ethanaminium, N-[4-[bis[4-(diethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-ethyl-",CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=[N+](CC)CC)C=C2)C3=CC=C(C=C3)N(CC)CC,,,,,,
6956,16957,Didecyldimethylammonium bromide,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],,,,,,
6957,16958,Didecyldimethylammonium,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC,,,,,,
6958,16959,CID 16959,CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O,,,,,,
6959,16960,Dexbrompheniramine,CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2,"['For treatment and relief of symptoms of allergies, hay fever, and colds']","['In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.']","['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",['Antihistamines are well absorbed from the gastrointestinal tract after oral administration.'],"['Hepatic (cytochrome P-450 system), some renal.']",['25 hours']
6960,16961,Dexamethasone sodium phosphate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+],,,"['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
6961,16962,"[2-[(8S,9R,10S,11S,13S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate",C[C@@H]1CC2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,,,,,,
6962,16963,Estrone benzoate,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,,,,,,
6963,16964,"[2-[(4R,8S,12R,19S)-19-chloro-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-8-yl]-2-oxoethyl] acetate",CC(=O)OCC(=O)[C@@]12[C@@H](CC3C1(CC([C@]4(C3C[C@@H](C5=CC(=O)CCC54C)Cl)F)O)C)OC(O2)(C)C,,,,,,
6964,16965,9-Methoxyanthracene,COC1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
6965,16966,4-Methoxyazobenzene,COC1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
6966,16967,4-(3-Methylbutoxy)butan-2-ol,CC(C)CCOCCC(C)O,,,,,,
6967,16968,"1,6-Heptadiene",C=CCCCC=C,,,,,,
6968,16969,"1,8-Nonadiyne",C#CCCCCCC#C,,,,,,
6969,16970,Ethyl hexadienoate,CCOC(=O)C=CC=CC,,,,,,
6970,16971,3-Bromoanisole,COC1=CC(=CC=C1)Br,,,,,,
6971,16972,7-Phenyleicosane,CCCCCCCCCCCCCC(CCCCCC)C1=CC=CC=C1,,,,,,
6972,16973,9-Phenyleicosane,CCCCCCCCCCCC(CCCCCCCC)C1=CC=CC=C1,,,,,,
6973,16974,2-Phenyleicosane,CCCCCCCCCCCCCCCCCCC(C)C1=CC=CC=C1,,,,,,
6974,16975,1-Phenyleicosane,CCCCCCCCCCCCCCCCCCCCC1=CC=CC=C1,,,,,,
6975,16976,Nicotinic acid N-oxide,C1=CC(=C[N+](=C1)[O-])C(=O)O,,,,,,
6976,16977,Tripotassium nitrilotriacetate,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[K+].[K+].[K+],,,,,,
6977,16978,"Glycine, N,N-bis(carboxymethyl)-, calcium salt (1:1)",C(C(=O)O)N(CC(=O)[O-])CC(=O)[O-].[Ca+2],,,,,,
6978,16979,"Benzene, (1-ethyldecyl)-",CCCCCCCCCC(CC)C1=CC=CC=C1,,,,,,
6979,16980,7-Phenyltridecane,CCCCCCC(CCCCCC)C1=CC=CC=C1,,,,,,
6980,16981,3-Phenyleicosane,CCCCCCCCCCCCCCCCCC(CC)C1=CC=CC=C1,,,,,,
6981,16982,4-Phenyleicosane,CCCCCCCCCCCCCCCCC(CCC)C1=CC=CC=C1,,,,,,
6982,16983,5-Phenyleicosane,CCCCCCCCCCCCCCCC(CCCC)C1=CC=CC=C1,,,,,,
6983,16984,"3-(Methylamino)-2,1-benzisothiazole",CNC1=C2C=CC=CC2=NS1,,,,,,
6984,16985,"4,6-dichloro-N,N-dimethyl-1,3,5-triazin-2-amine",CN(C)C1=NC(=NC(=N1)Cl)Cl,,,,,,
6985,16986,8-(Dimethylamino)methyleneamino-6-methoxyquinoline,CN(C)C=NC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
6986,16987,"1-Chloro-2,4-dinitronaphthalene",C1=CC=C2C(=C1)C(=CC(=C2Cl)[N+](=O)[O-])[N+](=O)[O-],,,,,,
6987,16988,"2,3-Dichloropyridine",C1=CC(=C(N=C1)Cl)Cl,,,,,,
6988,16989,"2,6-Dichloropyridine",C1=CC(=NC(=C1)Cl)Cl,,,,,,
6989,16990,"2,3,5,6-Tetrachloropyridine",C1=C(C(=NC(=C1Cl)Cl)Cl)Cl,,,,,,
6990,16991,"O,O-Diethyl S-methyl phosphorothioate",CCOP(=O)(OCC)SC,,,,,,
6991,16992,Bromocycloheptane,C1CCCC(CC1)Br,,,,,,
6992,16993,"1,2-Epoxydecane",CCCCCCCCC1CO1,,,,,,
6993,16994,Dibutyl methylphosphonate,CCCCOP(=O)(C)OCCCC,,,,,,
6994,16995,"Hydroxylamine, N,N-di-tert-butyl-",CC(C)(C)N(C(C)(C)C)O,,,,,,
6995,16996,Butylstannane,CCCC[SnH3],,,,,,
6996,16997,5-Ethyl-2(5H)-furanone,CCC1C=CC(=O)O1,,,,,,
6997,16998,CID 16998,CCCC(=O)OC(C)C(=NN=C(N)S)C=NN=C(N)S,,,,,,
6998,16999,Methyl 3-(aziridin-1-yl)prop-2-enoate,COC(=O)C=CN1CC1,,,,,,
6999,17000,"2,2,6-Trimethylcyclohexanone",CC1CCCC(C1=O)(C)C,,,,,,
7000,17001,"Fluorene-9,9-(bis)propylamine",C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCN)CCCN,,,,,,
7001,17002,"L-N,N-Diethylalanine 2,6-dimethoxyphenyl ester hydrochloride",CC[NH+](CC)C(C)C(=O)OC1=C(C=CC=C1OC)OC.[Cl-],,,,,,
7002,17003,"(2,6-Dimethoxyphenyl) 2-(diethylamino)propanoate",CCN(CC)C(C)C(=O)OC1=C(C=CC=C1OC)OC,,,,,,
7003,17004,2-tert-Butyl-4-methylphenol,CC1=CC(=C(C=C1)O)C(C)(C)C,,,,,,
7004,17005,alpha-Methyldopamine,CC(CC1=CC(=C(C=C1)O)O)N,,,,,"['Alpha-methyldopamine is a known human metabolite of 3,4-Methylenedioxymethamphetamine.']",
7005,17006,"Butyric acid, 2-chloro-, 2-(1-methylheptyl)-4,6-dinitrophenyl ester",CCCCCCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)C(CC)Cl,,,,,,
7006,17007,"2-Furaldehyde,semicarbazone",C1=COC(=C1)C=NNC(=O)N,,,,,,
7007,17008,Methyl 4-methylvalerate,CC(C)CCC(=O)OC,,,,,,
7008,17009,CID 17009,CCC(=O)N1C2CCC1C[NH+](C2)CC=CC3=CC=CC=C3Cl.[Cl-],,,,,,
7009,17010,CID 17010,CCC(=O)N1C2CCC1CN(C2)CC=CC3=CC=CC=C3Cl,,,,,,
7010,17011,Fupentixol dihydrochloride,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO.Cl.Cl,,,,,,
7011,17012,Flupenthixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
7012,17013,"(17R)-17-(2-chloroethynyl)-13-ethyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CCC12CCC3C(C1CC[C@@]2(C#CCl)O)CCC4=CC(=O)CCC34,,,,,,
7013,17014,Propylcyclopropane,CCCC1CC1,,,,,,
7014,17015,"Butanamide, N-(4-methylphenyl)-3-oxo-",CC1=CC=C(C=C1)NC(=O)CC(=O)C,,,,,,
7015,17016,"2,3,6-Trimethylphenol",CC1=C(C(=C(C=C1)C)O)C,,,,,,
7016,17017,"N-(p-Acetamidophenyl)-N',N'-dimethylformamidine hydrochloride",CC(=O)NC1=CC=C(C=C1)NC=[N+](C)C.[Cl-],,,,,,
7017,17018,(4-Acetamidoanilino)methylidene-dimethylazanium,CC(=O)NC1=CC=C(C=C1)NC=[N+](C)C,,,,,,
7018,17019,9-(Bromomethyl)anthracene,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2CBr,,,,,,
7019,17020,3-Bromopropionitrile,C(CBr)C#N,,,,,,
7020,17021,"1,4-Dichloro-2-butanol",C(CCl)C(CCl)O,,,,,,
7021,17022,3-Chloro-4-hydroxybenzaldehyde,C1=CC(=C(C=C1C=O)Cl)O,,,,,,
7022,17023,Cadmium 2-ethylhexanoate,CCCCC(CC)C(=O)[O-].CCCCC(CC)C(=O)[O-].[Cd+2],,,,,,
7023,17024,1-[Bis(2-hydroxybutyl)amino]butan-2-ol,CCC(CN(CC(CC)O)CC(CC)O)O,,,,,,
7024,17025,"4-Methyl-2-vinyl-1,3-dioxolane",CC1COC(O1)C=C,,,,,,
7025,17026,12-Methylbenz(a)anthracene,CC1=C2C(=CC3=CC=CC=C13)C=CC4=CC=CC=C42,,,,,"['Earlier studies ... demonstrated that benz[a]anthracene (BA), 7-methylbenz[a]anthracene (7-MBA) and 12-methylbenz[a]anthracene (12-MBA) undergo a bio-alkylation substitution reaction in the meso-anthracenic position(s) or L-region leading to the biosynthesis of the potent carcinogen 7,12-dimethylbenz[a]anthracene (7,12-DMBA). These results support the hypothesis that for most, if not all, unsubstituted polycyclic aromatic hydrocarbon carcinogens, the chemical or biochemical introduction of an alkyl group in the meso-anthracenic position(s) or L-region is a structural requirement for strong carcinogenic activity. Here we report that the L-region methyl derivatives 7-MBA, 12-MBA and 7,12-DMBA are oxidized to hydroxymethyl derivatives by a rat liver cytosol preparation without any apparent oxidation of the ring positions.', 'The homogeneous 3 alpha-hydroxysteroid-dihydrodiol dehydrogenase of rat liver cytosol catalyzes the NADP-dependent oxidation of a wide variety of polycyclic aromatic trans-dihydrodiols and has been implicated in their detoxification. This study examined the influence of methyl groups on the velocity and stereochemical course of enzymatic benz(a)anthracene (BA) trans-dihydrodiol oxidation. The racemic trans-3,4-dihydrodiols of BA and 7-methylbenz(a)anthracene (7-MBA) were completely consumed by the purified dehydrogenase, indicating that both stereoisomers are substrates. However, 50% of the ( +/- )-trans-3,4-dihydrodiols of 12-methylbenz(a)anthracene (12-MBA) and 7,12-dimethylbenz(a)-anthracene (DMBA) were oxidized, suggesting that only one stereoisomer is utilized in each case. At low substrate concentrations, enzymatic oxidation of the trans-3,4-dihydrodiols of BA, 12-MBA, and DMBA followed simple first-order kinetics. By contrast, oxidation of the 3,4-dihydrodiol of 7-MBA was of higher order, due to differences in the rate of oxidation of each stereoisomer. Rate constants estimated for each reaction indicate that the non-bay-region methyl group at position 7 has a greater enhancing effect on the rate of oxidation than the bay-region methyl group at position 12 (10- versus 4-fold, respectively). The 3,4-dihydrodiol of DMBA, which possesses both non-bay- and bay-region methyl groups, is oxidized more than 30 times faster than the unmethylated parent hydrocarbon. The absolute stereochemistry of the preferentially oxidized dihydrodiols was assigned by circular dichroism spectrometry. For the 3,4-dihydrodiols of DMBA and 12-MBA, the stereoisomer oxidized has the 3S,4S configuration. A large negative Cotton effect was observed in the circular dichroism spectrum of the 7-MBA 3,4-dihydrodiol which remained at the end of the rapid phase of oxidation of this racemic substrate, indicating that the dehydrogenase displays partial stereochemical preference for the 3S,4S enantiomer. These results suggest that methylation of BA at C-7 greatly enhances the oxidation of the 3S,4S-dihydrodiol, while the presence of a bay-region methyl group at C-12 completely blocks the oxidation of the 3R,4R-stereoisomer. Rapid, stereoselective oxidation of methylated polycyclic aromatic trans-dihydrodiols by this route in vivo may significantly influence their carcinogenicity.', 'Yields 4-hydroxy-12-methylbenzanthracene, 7-hydroxy-12-methylbenzanthracene, and 12-hydroxymethylbenzanthracene probably in rat. /From table/', 'Yields trans-5,6-dihydro-5,6-dihydroxy-12-methylbenzanthracene in rat; yields trans-8,9-dihydro-8,9-dihydroxy-12-methylbenzanthracene, S-(5,6-dihydro-6-hydroxy-12-methylbenzanthr-5-yl)glutathione, and 3-hydroxy-12-methylbenzanthracene probably in rat. /From table/', 'For more Metabolism/Metabolites (Complete) data for 12-Methylbenz(a)anthracene (6 total), please visit the HSDB record page.']",
7026,17027,"1,2-Divinylcyclobutane",C=CC1CCC1C=C,,,,,,
7027,17028,CID 17028,CCCCN=C(N(CCCC)CCCC)S,,,,,,
7028,17029,9-Octadecen-1-al,CCCCCCCCC=CCCCCCCCC=O,,,,,,
7029,17030,"2,6-Dimethyl-4-nitrophenol",CC1=CC(=CC(=C1O)C)[N+](=O)[O-],,,,,,
7030,17031,Diphenylthioacetic acid S-2-(dipropylamino)ethyl ester hydrochloride,CCC[NH+](CCC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
7031,17032,Diprofene,CCCN(CCC)CCSC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7032,17033,"Diethyl(2-hydroxyethyl)methylammonium iodide 2,2-diphenylpropionate",CC[N+](C)(CC)CCOC(=O)C(C)(C1=CC=CC=C1)C2=CC=CC=C2.[I-],,,,,,
7033,17034,"2-(2,2-Diphenylpropanoyloxy)ethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOC(=O)C(C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7034,17035,Estocin,CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
7035,17036,Dimenoxadol,CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
7036,17037,"5-Chloro-4-phenyl-3H-1,2-dithiol-3-one",C1=CC=C(C=C1)C2=C(SSC2=O)Cl,,,,,,
7037,17038,Captafol,C1C=CCC2C1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['When rats, dogs, & monkeys were fed (14)C captafol, almost 80% was excreted within 36 hr, mainly in the urine and none /as/ expired carbon dioxide. ... No unchanged captafol was detected in the blood, tissues, or urine.', 'Absorbed by skin.']","['No unchanged captafol was detected in the blood, tissues, or urine /in rats, dogs, & monkeys/. The major single metabolite, tetrahydrophthalimide, was detected in blood, feces, & urine, but most of the activity in the blood and urine was in the form of more soluble metabolites. No captafol epoxide was detected ... .', 'In mammals, following oral administration, /and in plants/ captafol is hydrolyzed to tetrahydrophthalimide and dichloroacetic acid. Tetrahydrophthalimide is degraded to tetrahydrophthalimidic acid and further to phthalic acid and ammonia.']",
7038,17039,"Carbamic acid, methyl-, 2-chloro-3,5-xylyl ester",CC1=CC(=C(C(=C1)OC(=O)NC)Cl)C,,,,,,
7039,17040,Xylylcarb,CC1=C(C=C(C=C1)OC(=O)NC)C,,,,,,
7040,17041,Acetoxon,CCOC(=O)CSP(=O)(OCC)OCC,,,,,,
7041,17042,"5,5-Bis(hydroxymethyl)-2-phenyl-1,3-dioxane",C1C(COC(O1)C2=CC=CC=C2)(CO)CO,,,,,,
7042,17043,1-Chlorotetradecane,CCCCCCCCCCCCCCCl,,,,,,
7043,17044,1-Chloro-2-nitropropane,CC(CCl)[N+](=O)[O-],,,,,,
7044,17045,N-tert-Butylformamide,CC(C)(C)NC=O,,,,,,
7045,17046,"1,4-Butanediol diglycidyl ether",C1C(O1)COCCCCOCC2CO2,,,,,,
7046,17047,Pigment red 3,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)[N+](=O)[O-],,,,,,
7047,17048,"1,2,7,8-Diepoxyoctane",C1C(O1)CCCCC2CO2,,,,,,
7048,17049,Butyl glycidyl ether,CCCCOCC1CO1,,,,"['When 14C-BGE was administered orally to male rats and rabbits (20 mg/kg), it was rapidly absorbed and metabolized. Most of the compound, 87% in the rat and 78% in the rabbit, was eliminated in the 0- to 24-hr urine.']","['BGE is rapidly absorbed and metabolized in both rats and rabbits. The major metabolite in urine was butoxyacetic acid; 23% of an oral (20 mg/kg) dose appeared in rat urine as 3-butoxy-2-acetylaminoproprionic acid. The latter metabolite was not detected in the rabbit.', 'The metabolism and urinary elimination of n-butyl-glycidyl-ether (2426086) were studied in male Wistar-rats and male New-Zealand-white-rabbits. Each of five rats received a single oral dose of corn-oil containing 20 milligrams per kilogram radiolabeled n-butyl-glycidyl-ether. Two rabbits received the equivalent dose in a gelatin capsule. Excretion was followed by scintillation counting over a period of 96 hours. Analytical methods applied to determine n-butyl-glycidyl-ether and metabolites in urine included thin layer chromatography, autoradiography, nuclear magnetic resonance spectroscopy, and mass spectrometry. Within 24 hours of administration, rats and rabbits excreted 87 percent and 78 percent of the n-butyl-glycidyl-ether dose, respectively. Further elimination was minimal. After 96 hours, total excretion was 92 percent for rats and 80 percent for rabbits. Major urinary metabolites in the rat were 3-butoxy-2-hydroxypropionic-acid, representing 9 percent of total metabolites, 3-butoxy-2-acetylaminopropionic-acid, representing 23 percent of total metabolites, and butoxyacetic-acid (2516930), representing 10 percent of total metabolites measured. In rabbits, the major metabolites included 3-butoxy-2-hydroxypropionic-acid, representing 35 percent of total metabolites, and butoxyacetic-acid, representing 5 percent of the metabolites measured. In both species, a major route of biotransformation was via the hydrolytic opening of the epoxide ring followed by oxidation of the resulting diol to 3-butoxy-2-hydroxypropionic-acid and subsequent oxidative decarboxylation to yield butoxyacetic-acid. The metabolite 3-butoxy-2-acetylaminopropionic-acid may have involved cleavage of the epoxide ring by ammonia (7664417) or an amine or may have occurred by animation of a keto acid. The authors note that these reactions represent efficient detoxication of n-butyl-glycidyl-ether.']",
7049,17050,2-(Diethylamino)ethyl acrylate,CCN(CC)CCOC(=O)C=C,,,,,,
7050,17051,6-Benzyloxy-5-methoxyindole,COC1=C(C=C2C(=C1)C=CN2)OCC3=CC=CC=C3,,,,,,
7051,17052,"Indole, 5-methoxy-3-(2-pyrrolidinylethyl)-, hydrochloride",COC1=CC2=C(C=C1)NC=C2CC[NH+]3CCCC3.[Cl-],,,,,,
7052,17053,"Indole, 5-methoxy-3-(2-(1-pyrrolidinyl)ethyl)-",COC1=CC2=C(C=C1)NC=C2CCN3CCCC3,,,,,,
7053,17054,Hexachloromelamine,C1(=NC(=NC(=N1)N(Cl)Cl)N(Cl)Cl)N(Cl)Cl,,,,,,
7054,17055,C.I. Direct blue 8,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
7055,17056,Benzoazurin,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)O)O)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)O,,,,,,
7056,17057,C.I. Direct Blue 2,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)[O-])N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+],,,,,,
7057,17058,Melantherine BH,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)O)S(=O)(=O)O)N)O,,,,,,
7058,17059,Direct blue 15,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)OC)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+],,,,"['The metabolism and distribution of Direct Red 2 (DR) and Direct Blue 15 (DB) were studied in rats. Male Fischer 344 rats were administered 12 mg/kg (14)C libeled DR or DB or molar equivalent doses of the corresponding amines, dimethylbenzidine or dimethoxybenzidine, respectively. Urine and feces samples were collected for up to 192 hours after dosing and assayed for (14)C activity and metabolites. Selected animals were killed 2 to 72 hours after administration and the tissue distribution of (14)C activity was determined. Most of the (14)C activity was excreted in the feces, 52.05 to 74.40% of the dose being eliminated. Urinary excretion amounted to 18.79 to 39.66% of the dose. ... The largest amounts of (14)C activity derived from both dyes were accumulated and retained in the liver, kidney, and lung. Similar distribution patterns were seen with the free amines. Both dyes accumulate in the liver, a known target organ for rats dosed with benzidine and the site of tumors in rats dosed with benzidine based azo dyes.', ""Environmental dyes and their derivatives, some of which are genotoxic, must be transported within the body to the tissues which they affect. One mechanism for this can be observed directly by crossed immunoelectrophoresis (X-IEP). Binding of these chemicals to certain serum proteins changes electrophoretic and immunoprecipitation morphology in X-IEP patterns. This is demonstrated here for four azo dyes derived from benzidine, 3,3'-dimethylbenzidine, and 3,3'-dimethoxybenzidine, and their parent aromatic amines. Direct Red 2 (a 3,3'-dimethylbenzidine-based dye), Direct Blue 15 (a 3,3'-dimethoxybenzidine-based dye), Direct Black 38 (a benzidine-based dye), and Evans Blue (a 3,3'-dimethylbenzidine-based dye) all bound to albumin, alpha 1-lipoprotein, beta-lipoprotein, and hemopexin. Direct Red 2 only slightly affected the mobilities of these proteins. Direct Blue 15 bound also to prealbumin and alpha 1-antichymotrypsin, and degraded C3 globulin. ..."", ""CI Direct Blue 15 (100 mg/kg) containing 46 ppm (mg/kg) 3,3'-dimethoxybenzidine as an impurity was administered once in the diet to two female mongrel dogs weighing 15 kg, and 48-hr urine was analysed for 3,3'-dimethoxybenzidine, the potential metabolic product (Lynn et al., 1980). Excretion was found to be 0.03% of the dose of dye administered, which cannot be attributed to the level of impurity. The same dose was also administered once to four male Sprague-Dawley rats by intragastric intubation; after 72 hr, 0.17 +/- 0.18% of the theoretical maximum was excreted as 3,3'-dimethoxybenzidine and the monoacetyl derivative, the latter constituting a substantial fraction."", 'Absorption, metabolism and tissue distribution studies were conducted in the rat with (14)C-labeled dyes (12 mg/kg, 62 uCi/kg) and molar equivalent doses of the respective amines were administered. ... A comparison of the metabolism of Direct Blue 15 with its base DiMxBzd, indicated that the base was more extensively metabolized and that most of the (14)C in various extracts was identified in known metabolites. ... Distribution studies conducted with both dyes showed that liver, kidney, and lung accumulated and retained higher levels of (14)C than other tissues (at 72 hours). Peak levels of (14)C, which occurred 8-12 hours after dosing, were significantly higher with Direct Red 2 than Direct Blue 15. Tissue distribution data (72 hour) for rats dosed with the free amines compared with the dyes showed a generally lower but similar distribution pattern.']","['C.I. Direct Blue 15, a dye that is metabolized to DMOB, yields DMOB upon metabolic reduction of the azo bonds ...', 'The metabolism and distribution of Direct Red 2 (DR) and Direct Blue 15 (DB) were studied in rats. Male Fischer 344 rats were administered 12 mg/kg (14)C libeled DR or DB or molar equivalent doses of the corresponding amines, dimethylbenzidine or dimethoxybenzidine, respectively. ...Dimethylbenzidine and dimethoxybenzidine were more extensively metabolized than the corresponding dyes, DR and DB. Urinary metabolites produced by DB included alkaline hydrolyzable conjugates, diacetyldimethoxybenzidine, monoacetyldimethoxybenzidine, and free dimethoxybenzidine. Ninety six percent of the (14)C activity, however, was non identifiable water soluble metabolites. ...', 'The purified azoreductase and nitroreductase of Clostridium perfringens, which have similar electrophoretic properties, both reacted in a Western blot (immunoblot) with a polyclonal antibody raised against the azoreductase. The activity of both enzymes was enhanced by flavin adenine dinucleotide and was inhibited by menadione, o-iodosobenzoic acid, and the antibody against azoreductase. Reduction of the azo dye Direct Blue 15 by the azoreductase was inhibited by nitroaromatic compounds. The apparent Km of the enzyme for reduction of Direct Blue 15 in the presence of 1-nitropyrene was higher than the Km with the azo dye alone, demonstrating competitive inhibition. The data show that the same protein in involved in the reduction of both azo dyes and nitroaromatic compounds.', ""The metabolism of a benzidine-based dye, Direct Black 38, a 3,3'-dimethylbenzidine-based dye, Direct Red 2 and a 3,3'-dimethoxybenzidine-based dye, Direct Blue 15 has been studied both in pure cultures of anaerobic bacteria and in bacterial suspensions derived from the intestinal contents of the rat. All of the pure cultures and the rat intestinal bacteria were able to reduce the azo linkages of Direct Black 38, Direct Red 2 and Direct Blue 15 with the subsequent formation of benzidine, 3,3'-dimethylbenzidine and 3,3'-dimethoxybenzidine, respectively. ... Results from this study indicate that in vitro anaerobic incubations of rat intestinal microorganisms were able to reduce and cleave the azo bonds of dyes derived from benzidine, 3,3'-dimethylbenzidine and 3,3'-dimethoxybenzidine.""]",
7059,17060,Pontamine sky blue 5B (acid form),COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)OC)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)O)S(=O)(=O)O)N)O,,,,,,
7060,17061,"C.I. Direct Orange 8, disodium salt",C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=CC(=C(C=C5)O)C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7061,17062,"5-({4'-[(1-Amino-4-sulfonaphthalen-2-yl)diazenyl][1,1'-biphenyl]-4-yl}diazenyl)-2-hydroxybenzoic acid",C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=CC(=C(C=C5)O)C(=O)O)S(=O)(=O)O,,,,,,
7062,17063,Acid Orange 45,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C6C=CC(=CC6=CC(=C5N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7063,17064,"3-Amino-4-{[4'-({4-[(4-methylbenzene-1-sulfonyl)oxy]phenyl}diazenyl)[1,1'-biphenyl]-4-yl]diazenyl}naphthalene-2,7-disulfonic acid",CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C6C=CC(=CC6=CC(=C5N)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7064,17065,Direct Brown 31,CC1=CC(=C(C(=C1N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)[O-])N)N=NC5=C(C=C6C=C(C(=C(C6=C5)O)N=NC7=CC=C(C8=CC=CC=C87)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
7065,17066,C.I. Direct Brown 31,CC1=CC(=C(C(=C1N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)O)N)N=NC5=C(C=C6C=C(C(=C(C6=C5)O)N=NC7=CC=C(C8=CC=CC=C87)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7066,17067,Direct Fast Brown M,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)[O-])N=NC5=CC(=C(C=C5)O)C(=O)[O-].[Na+].[Na+],,,,,,
7067,17068,"5-({4'-[(7-Amino-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl][1,1'-biphenyl]-4-yl}diazenyl)-2-hydroxybenzoic acid",C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O)N=NC5=CC(=C(C=C5)O)C(=O)O,,,,,,
7068,17069,CID 17069,CC1=CC(=C(C=C1N)N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)NN=C4C(=CC5=C(C4=N)C(=O)C(=NNC6=CC=CC=C6)C(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7069,17070,CID 17070,CC1=CC(=C(C=C1N)N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)NN=C4C(=CC5=C(C4=N)C(=O)C(=NNC6=CC=CC=C6)C(=C5)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7070,17071,"2,2,2-trichloro-N,N-diethylacetamide",CCN(CC)C(=O)C(Cl)(Cl)Cl,,,,,,
7071,17072,Isononyl alcohol,CC(C)CCCCCCO,,,,,,
7072,17073,"2,3,4-Trichloro-1-butene",C=C(C(CCl)Cl)Cl,,,,,,
7073,17074,"1,2,4-Trichloro-but-2-ene",C(C=C(CCl)Cl)Cl,,,,,,
7074,17075,"1,1,2,2,3,4-Hexachlorobutane",C(C(C(C(Cl)Cl)(Cl)Cl)Cl)Cl,,,,,,
7075,17076,"N,N-Diethyl-2-phenylacetamide",CCN(CC)C(=O)CC1=CC=CC=C1,,,['Substances causing insects to turn away from them or reject them as food. (See all compounds classified as Insect Repellents.)'],,,
7076,17077,"2,6-Dichloro-4-methylphenol",CC1=CC(=C(C(=C1)Cl)O)Cl,,,,,,
7077,17078,"2,6-Dibromo-4-methylphenol",CC1=CC(=C(C(=C1)Br)O)Br,,,,,,
7078,17079,6-Aminohexanenitrile,C(CCC#N)CCN,,,,,,
7079,17080,Sec-butyl thiohexanoate,CCCCCC(=O)SC(C)CC,,,,,,
7080,17081,Didecyl sebacate,CCCCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCCCC,,,,,,
7081,17082,Didodecyl phthalate,CCCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCCCC,,,,,,
7082,17083,11-Aminoundecanoic acid,C(CCCCCN)CCCCC(=O)O,,,,,,
7083,17084,Cycliton,CCN(CC)C(=O)C1=C(ON=C1C)C,,,,,,
7084,17085,Tricosanoic acid,CCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
7085,17086,3-(2-Aminoethyl)-7-methoxyindole,COC1=CC=CC2=C1NC=C2CC[NH3+].[Cl-],,,,,,
7086,17087,7-Methoxytryptamine,COC1=CC=CC2=C1NC=C2CCN,,,,,,
7087,17088,"4(3H)-Quinazolinone, 3-methyl-",CN1C=NC2=CC=CC=C2C1=O,,,,,,
7088,17089,Methyl 4-chloro-2-methylphenoxyacetate,CC1=C(C=CC(=C1)Cl)OCC(=O)OC,,,,,,
7089,17090,"3,7-Dimethylocta-1,6-diene",CC(CCC=C(C)C)C=C,,,,,,
7090,17091,"3,4-Dimethylquinoline",CC1=C(C2=CC=CC=C2N=C1)C,,,,,,
7091,17092,Dodecanenitrile,CCCCCCCCCCCC#N,,,,,,
7092,17093,Basic Green 4,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=CC=C3.C(=O)(C(=O)O)O.C(=O)(C(=O)[O-])O,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)', 'Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,,
7093,17094,"2,4,6-Tribromoresorcinol",C1=C(C(=C(C(=C1Br)O)Br)O)Br,,,,,,
7094,17095,1-Tridecene,CCCCCCCCCCCC=C,,,,,,
7095,17096,"2,3,4-Trimethylquinoline",CC1=C(C2=CC=CC=C2N=C1C)C,,,,,,
7096,17097,"2,2',4,4'-Tetrachlorobiphenyl",C1=CC(=C(C=C1Cl)Cl)C2=C(C=C(C=C2)Cl)Cl,,,,"['Experimental data on the percutaneous absorption of PCBs in humans is limited to in vitro studies that used human cadaver skin. These studies utilized (14)C-labeled Aroclor 1242 and 1254 (mixtures containing 42 or 54% chlorine by mass) in soil, mineral oil, and water. Over a 24-hour period, 2.6, 10, and 43% of the dose was retained in human skin when the Aroclor 1242 was formulated in soil, mineral oil, or water, respectively. Similar results were observed with Aroclor 1254, with 1.6, 6.4, and 44.3% of the dose retained in human skin, following PCB exposure in a soil, mineral oil, or water vehicle, respectively. The in vitro data indicate that PCBs readily enter human skin and are available for systemic absorption, and that the dosing vehicle has a major role in regulating the relative retention of PCBs in human skin.', '... The in vivo percutaneous absorption of PCBs /was assessed/ in adult female Rhesus monkeys. (14)C-Labeled Aroclor 1242 and 1254 were separately administered iv and topically to Rhesus monkeys and urinary and fecal excretion of radioactivity was measured for the next 30 days. Following iv administration, the 30-day cumulative excretion was 55% of the administered dose (39% urine, 16% feces) for Aroclor 1242 and 27% (7% urine, 20% feces) for Aroclor 1254. The percentage of the dose absorbed following topical administration to abdominal skin (after light clipping of hair) was estimated from the ratio of the total urinary and fecal excretion following topical and iv administration. Topical administration of Aroclor 1242 in soil, mineral oil, trichlorobenzene, or acetone resulted in 14, 20, 18, and 21% absorption of the administered dose, respectively.', 'The urinary excretion half-life of an undefined PCB containing 42% chlorine applied to the abdominal skin was 6.9 days in monkeys. In guinea pigs in which the same mixture was applied to the back of the ear, a 2-phase urinary excretion process was observed. The first phase was rapid, with an elimination half-life of 1.9 days, and was followed by a slower phase, with an elimination half-life of 12.6 days. However, the elimination half-life of a PCB containing 54% chlorine was 2.9 days and was linear for the duration (16 days) of the urine collection. /It was/ reported that following percutaneous application of 4 ug (14)C-labeled Aroclor 1242/sq cm to the abdominal skin of monkeys (four per group), a maximum of 11% of the dose (as (14)C-derived radioactivity) was excreted over a 30-day period when the solvent was mineral oil, while 10% was excreted when the solvent was trichlorobenzene (unspecified isomer). Excretion was virtually complete after the first 10 days. Urinary excretion of (14)C-derived radioactivity was approximately 2 times fecal excretion. Following application of 4.8 ug (14)C-labeled Aroclor 1254/sq cm in mineral oil or trichlorobenzene, 5.5 and 3.9% of the dose, respectively, was excreted over a 30 day period. The probability that ... only excretion for the most readily metabolized components /was measured/ is increased because in the most recent study, which specified Aroclor mixtures, urinary excretion was 2 times fecal excretion and urinary excretion was virtually complete after 10 days.', 'Following intravenous injection of 32.7 ug Aroclor 1242 to Rhesus monkeys, 39.4% of the administered dose was excreted in the urine, and 16.1% was excreted in the feces over a 34 day period; the bulk of the dose (> 90%) was excreted within the first 10 days. For Aroclor 1254, 7% of the administered dose (47.4 ug) was excreted in the urine and 19.7% in the feces over a 30-day period. The duration of the study probably accounted for only the most rapidly metabolized components of the mixtures.', 'For more Absorption, Distribution and Excretion (Complete) data for Aroclor 1242 (8 total), please visit the HSDB record page.']","['The metabolism of (14)C-labeled PCBs (polychlorinated biphenyls), which comprised the Aroclor 1242 mixture, was greatly enhanced by the addition of biphenyl (BP) to soil. After 49 days, only 25 to 35% of the original PCBs remained in the soil, and 48 to 49% was converted to (14)CO2 (including soil carbonates) in treatments enriched with biphenyl by contrast, 92% of the PCBs remained and less than 2% was converted to (14)CO2 in the unenriched control. Although the mineralization of PCBs in soils inoculated with Acinetobacter strain P6 was not greater than that in uninoculated biphenyl-enriched soils, the initial and maximum mineralization rates and the disappearance of more highly chlorinated PCBs were greater with Acinetobacter strain P6.']","['Serum: 1-3 years; [TDR, p. 1035]', 'In 1977 and 1985, serum polychlorinated biphenyl (PCB) concentrations were determined for 58 workers in a Bloomington, Indiana, factory that used polychlorinated biphenyls (PCBs) in capacitor manufacture until 1977. Less chlorinated PCBs were quantitated as Aroclor 1242, and more highly chlorinated PCBs were quantitated as Aroclor 1254. The median half-life was 2.6 yr for Aroclor 1242 and 4.8 y for Aroclor 1254. However, the half-life varied inversely with the initial serum concentration ...', 'Based on human blood serum levels of PCBs in 1977 and in 1984 with occupationally exposed humans and human controls the half-life of less chlorinated congeners (Aroclor 1242 exposed) in human blood serum was 6-7 months. ...', ""Twelve serum analytes (triglycerides, cholesterol, total and conjugated bilirubin, high-density-lipoprotein cholesterol (HDL-C), alcohol phosphatase (AP), gammaglutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), beta-glucuronidase (beta-glu), alanine aminopeptidase (AAP), and 5'-nucleotidase (5'nuc)) were measured to investigate their correlation with exposure to polychlorinated biphenyls (PCBs) and 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT). The relationship between serum lipids, lipohilic toxicants, and the analytes was also evaluated. The beta-glu, 5 nuc, triglycerides, cholesterol, and total bilirubin correlated positively and significantly with log concentrations of serum total PCBs and 1,1-dichloro-2,2-bis(p-chlorphenyl)ethylene (DDE), a metabolite of DDT. The more highly chlorinated PCBs (Aroclor 1260) had significant, positive correlations with several serum analytes, but the less chlorinated PCBs (Aroclor 1242) correlated significantly and negatively only with HDL-cholesterol. Triglyceride- and cholesterol-rich lipoproteins were added to serum to determine the effects of these assays. Several were spuriously elevated. AP and beta-gluc were not affected by lipoprotein addition with the methods used in this study. Alanine aminotransferase was increased significantly only at triglyceride concentrations exceeding 400 mg/dl.""]"
7097,17098,N-Propylacetanilide,CCCN(C1=CC=CC=C1)C(=O)C,,,,,,
7098,17099,2-Isopropylbenzoic acid,CC(C)C1=CC=CC=C1C(=O)O,,,,,,
7099,17100,alpha-TERPINEOL,CC1=CCC(CC1)C(C)(C)O,,,,"['... After iv injection of 0.1 mL/kg, death due to massive pulmonary edema occurred within minutes. In this animal blood and tissue levels of alpha-terpineol of between 150 and 300 ppm were observed. After smaller doses of pine oil (0.033 mL/kg), horses survived until euthanized up to 48 hr later. Blood levels of alpha-terpineol became undetectable in one of these animals after 2 hr, and no tissue levels were detected at postmortem....']","['The metabolic fate of alpha-terpineol administered orally to male albino-rats was investigated, and its effects on the liver microsomal cytochrome-P-450 system were studied. For metabolic studies, alpha-terpineol was given once daily for 20 days at a dose of 600mg/kg bw; cytochrome-P-450 studies involved dosing for up to 9 days. ...The neutral fraction isolated showed the presence of one major (alpha-terpineol) and two minor compounds. One of the minor compounds was identified as p-menthane-1,2,8-triol. Further study revealed the presence of the methyl esters of oleuropeic-acid and dihydrooleuropeic-acid. Allylic oxidation of C-1 methyl esters appeared to be the major metabolic pathway. It was considered likely that the allylic methyl group at C-7 was oxidized prior to the reduction of the 1,2-double bond. Administration of alpha-terpineol increased the levels of liver microsomal cytochrome-P-450 by 72, 104, 90, 54, and 52% after 1, 2, 3, 6, and 9 days of dosing, respectively. A moderate incr was noted in the levels of liver microsomal NADPH-cytochrome-c-reductase during the first 3 days of repeated dosing. No significant effect was noted on cytochrome-b5 and NADH-cytochrome-c-reductase. The authors conclude that the allylic methyl oxidation of alpha-terpineol is the major route for its metabolic transformation in the rat. The reduction of the endocyclic double bond was specifically noted in the formation of dihydrooleuropeic-acid from oleuropeic-acid.', 'Biotransformation of alpha-terpineol by the common cutworm (Spodoptera litura) larvae was investigated. alpha-Terpineol was mixed in an artificial diet, and the diet was fed to the larvae (fourth-fifth instar) of S. litura. Metabolites were isolated from the frass and analyzed spectroscopically. Main metabolites were 7-hydroxy-alpha-terpineol (p-menth-1-ene-7,8-diol) and oleuropeic acid (8-hydroxy-p-menth-1-en-7-oic acid). Intestinal bacteria from the frass of larvae did not participate in the metabolism of alpha-terpineol. alpha-Terpineol was preferentially oxidized at the C-7 position (allylic methyl group) by S. litura larvae.', 'Details of the metabolism of alpha-terpineol by Pseudomonas incognita are presented. Degradation of alpha-terpineol by this organism resulted in the formation of a number of acidic and neutral metabolites. Among the acidic metabolites, beta-isopropyl pimelic acid, 1-hydroxy-4-isopropenyl-cyclohexane-1-carboxylic acid, 8-hydroxycumic acid, oleuropeic acid, cumic acid, and p-isopropenyl benzoic acid have been identified. Neutral metabolites identified were limonene, p-cymene-8-ol, 2-hydroxycineole, and uroterpenol. ... /I/t appears that P. incognita degrades alpha-terpineol by at least three different routes. While one of the pathways seems to operate via oleuropeic acid, a second may be initiated through the aromatization of alpha-terpineol. The third pathway may involve the formation of limonene from alpha-terpineol and its further metabolism.', 'In a minor pathway, the endocyclic alkene of alpha-terpineol is epoxidized and then hydrolysed to yield a triol metabolite 1,2,8-trihydroxy- para-menthane, which was also reported in humans after inadvertent oral ingestion of a pine-oil disinfectant containing alpha-terpineol.', 'Metabolized primarily by conjugation with glucuronic acid and excreted in urine. Oxidation of the allylic methyl group followed by hydrogenation to yield the corresponding saturated acid may occur.']",
7100,17101,"N,N-Dimethyl-4-phenylazo-o-anisidine",CN(C)C1=C(C=C(C=C1)N=NC2=CC=CC=C2)OC,,,,,,
7101,17102,N-Hydroxy-2-acetylaminophenanthrene,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C=C2)O,,,,,,
7102,17103,"N,N,N,2-Tetramethyl-5-(1-methylethyl)-4-((1-piperidinylcarbonyl)oxy)benzenaminium chloride",CC1=CC(=C(C=C1[N+](C)(C)C)C(C)C)OC(=O)N2CCCCC2.[Cl-],,,,,,
7103,17104,Trimethyl-[2-methyl-4-[oxo(1-piperidinyl)methoxy]-5-propan-2-ylphenyl]ammonium,CC1=CC(=C(C=C1[N+](C)(C)C)C(C)C)OC(=O)N2CCCCC2,,,,,,
7104,17105,"5-Bromoindole-2,3-dione 3-hydrazone",C1=CC2=C(C=C1Br)C(=C(N2)O)N=N,,,,,,
7105,17106,L-Fucose,C[C@H]1[C@H]([C@H]([C@@H](C(O1)O)O)O)O,,,,,,
7106,17107,"2,3,5,6-Tetrachloro-4-nitroanisole",COC1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)Cl,,,,,,
7107,17108,CID 17108,C1=CC(=C(C(=C1Cl)CC(=O)[O-])Cl)Cl.[Na+],,,,,,
7108,17109,Chinomethionat,CC1=CC2=C(C=C1)N=C3C(=N2)SC(=O)S3,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['After intragastric administration of (35)S-labeled oxythioquinox, it forms a complex with plasma protein, particularly albumins, in vivo and in vitro. Elimination was slow after iv administration. Morestan concentration in plasma and peripheral compartment was in equilibrium.', 'Oxythioquinox was shown to be irreversibly bound to bovine serum albumin and to proteins in spider mite homogenate and in rat brain, liver and blood. The binding to proteins probably involved a mechanism by which SH-group of proteins initially attacks CO-group of oxythioquinox.', 'Both Morestan and 6-methyl-2,3-quinoxalinedithiol (a possible metabolite) were poorly absorbed from the gastrointestinal tracts of rats and mice.', 'When rats were fed carbonyl-14C-labelled oxythioquinox. It was found that most of the radioactivity was exhaled as 14CO2. After 2,3-14C- and 35S-labelled active ingredient was fed to rats, no 14CO2 was found in the air expired. In this particular case, most of the activity was present in the urine and in the feces. A small proportion of the activity was found in the blood plasma in protein-bound form. The activity is not present as oxythioquinox itself, but partially as 2,3-dithiol-6-methyl quinoxaline, in traces as the corresponding dihydroxy compound, and as other still unidentified metabolites. The quinoxaline ring is apparently not metabolized in the animal body.', 'The absorption and distribution of Morestan 35S in the organism of the rat were studied after administration by stomach tube. It was shown that Morestan, in vivo and in vitro, forms a complex with plasma proteins and particularly with albumins. Most of the plasma Morestan is distributed like this. After intravenous admininstration, the constant of elimination, K13, and the biological half-life determination show that plasma Morestan 35S is eliminated very slowly. The K12 and K21 constants indicate that there is an equilibrium between the plasma compartment and a peripheral compartment. After intragastric administration, the increase of radioactivity in epididymal adipose tissue, indicate that the peripheral compartment should include the adipose tissue.']","['The degradation of quinomethionate (q), used as a fungicide on cucumbers, by geen algae, ankistrodesmus falcatus isolated from seeds of a cucumber culture, was studied. The algae actively decomposed q to CO2. One of two intermediary metabolites of q resulting from biohalogenation was 6-meta-2-amino-3-chloroquinoxaline, which is highly toxic to plants.', 'In rats, following oral administration, chinomethionat is rapidly metabolised, and about 90% is eliminated within 3 days in the feces and urine. The main metabolite is chinomethionat acid (dimethylmercaptoquinoxaline-6-carboxylic acid), which also occurs in the conjugated form.', 'When rats were fed carbonyl-14C-labelled oxythioquinox. It was found that most of the radioactivity was exhaled as 14CO2. After 2,3-14C- and 35S-labelled active ingredient was fed to rats, no 14CO2 was found in the air expired. In this particular case, most of the activity was present in the urine and in the feces. A small proportion of the activity was found in the blood plasma in protein-bound form. The activity is not present as oxythioquinox itself, but partially as 2,3-dithiol-6-methyl quinoxaline, in traces as the corresponding dihydroxy compound, and as other still unidentified metabolites. The quinoxaline ring is apparently not metabolized in the animal body.', '... The biological half-life determination show that plasma Morestan 35S is eliminated very slowly.']",
7109,17110,Dodine,CCCCCCCCCCCCN=C(N)N.CC(=O)O,,,,"['NO TRANSLOCATION FROM FOLIAGE TO FRUIT & DEGRADATION PRODUCTS TRANSLOCATED ONLY VERY SLIGHTLY.', 'TRACES OF RADIOTAGGED CARBON APPEARED IN FRUIT. ... MOST OF RADIOACTIVITY SETTLED IN PROTEIN OR PEPTIDE PORTION OF FRUIT /AFTER APPLICATION TO APPLE TREES/.', 'It is absorbed across the skin ... .']","['... DEGRADATION OF (14)C DODINE OCCURRED AFTER APPLICATION TO APPLE TREES. ... ONE OF 4 CMPD DETECTED APPEARED TO BE GUANIDINE OR GUANIDINE MONOSUBSTITUTED WITH SMALL GROUP. NO METABOLITES HAVE BEEN DEMONSTRATED /IN FUNGI/.', 'IN PLANTS, DODINE IS CONVERTED TO CREATINE VIA THE ACTION OF A METHYLTRANSFERASEAND SIMULTANEOUS OXIDATIVE CLEAVAGE OF THE DODECYL MOIETY.']",
7110,17111,2-(Dimethylamino)ethyl acrylate,CN(C)CCOC(=O)C=C,,,,,,
7111,17112,Glyphosine,C(C(=O)O)N(CP(=O)(O)O)CP(=O)(O)O,,,,,,
7112,17113,Drometrizole,CC1=CC(=C(C=C1)O)N2N=C3C=CC=CC3=N2,,,,,,
7113,17114,Butanoic acid;phenylmercury,CCCC(=O)O.C1=CC=C(C=C1)[Hg],,,,,,
7114,17115,Chloropropylmercury,CCC[Hg]Cl,,,,,,
7115,17116,Ethylmercury;phosphoric acid,CC[Hg].CC[Hg].OP(=O)(O)O,,,,,,
7116,17117,Ethyl mercury,CC[Hg],,,,,,
7117,17118,Fenyripol hydrochloride,C1=CC=C(C=C1)C(CNC2=NC=CC=N2)O.Cl,,,,,,
7118,17119,Fenyripol,C1=CC=C(C=C1)C(CNC2=NC=CC=N2)O,,,,,,
7119,17120,3-Chlorocyclohexene,C1CC=CC(C1)Cl,,,,,,
7120,17121,1-Octen-3-yl acetate,CCCCCC(C=C)OC(=O)C,,,,,,
7121,17122,"2-[2-(1,3-Benzoxazol-2-yl)phenyl]-1,3-benzoxazole",C1=CC=C(C(=C1)C2=NC3=CC=CC=C3O2)C4=NC5=CC=CC=C5O4,,,,,,
7122,17123,P-Nitrophenyl O-tolyl ether,CC1=CC=CC=C1OC2=CC=C(C=C2)[N+](=O)[O-],,,,,['...DIPHENYL ETHER IS RELATIVELY STABLE IN BIOLOGICAL SYSTEMS. ... REDUCTION OF A NITRO GROUP TO AN AMINO GROUP IS ASSUMED. /DIPHENYL ETHERS/'],
7123,17124,2-Chlorophenylacetic acid,C1=CC=C(C(=C1)CC(=O)O)Cl,,,,,,
7124,17125,9-Vinylanthracene,C=CC1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
7125,17126,"4,4'-Dichlorodiphenyl ether",C1=CC(=CC=C1OC2=CC=C(C=C2)Cl)Cl,,,,,,
7126,17127,"Phenol, 4,4'-(1-methylethylidene)bis-, disodium salt",CC(C)(C1=CC=C(C=C1)[O-])C2=CC=C(C=C2)[O-].[Na+].[Na+],,,,,,
7127,17128,Urbacide,CN(C)C(=S)S[As](C)SC(=S)N(C)C,,,,,,
7128,17129,2-Methylbutyl 2-methylbutyrate,CCC(C)COC(=O)C(C)CC,,,,,,
7129,17130,3-Methylcoumarin,CC1=CC2=CC=CC=C2OC1=O,,,,,,
7130,17131,7-Methylcoumarin,CC1=CC2=C(C=C1)C=CC(=O)O2,,,,,,
7131,17132,4-Hexylphenol,CCCCCCC1=CC=C(C=C1)O,,,,,,
7132,17133,"24-Methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),3,8,11,13,15,17(21),22-octaene",C[N+]1=C2C3C=C4C(=CC3C=CC2=C5C=CC6=C(C5=C1)OCO6)OCO4,,,,,,
7133,17134,Sulfadoxine,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,['Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well. Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected.'],"['Sulfadoxine helps inhibit the enzyme dihydropteroate synthetase which is an enzyme necessary in the conversion of PABA to folic acid. As folic acid is vital to the synthesis, repair, and methylation of DNA which is vital to cell growth in Plasmodium falciparum. With this vital nutrient lacking, the parasite has difficulty in reproducing.']","['Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
7134,17135,"9-Azabicyclo(3.3.1)nonan-3-alpha-ol, 9-methyl-7-beta-phenyl-, acetate (ester), hydrochloride",CC(=O)OC1CC2CC(CC(C1)[NH+]2C)C3=CC=CC=C3.[Cl-],,,,,,
7135,17136,(9-Methyl-7-phenyl-9-azabicyclo[3.3.1]nonan-3-yl) acetate,CC(=O)OC1CC2CC(CC(C1)N2C)C3=CC=CC=C3,,,,,,
7136,17137,3-beta-Phenyl-9-benzyl-9-azabicyclo(3.3.1)nonane hydrochloride,C1CC2CC(CC(C1)[NH+]2CC3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
7137,17138,9-Benzyl-3-phenyl-9-azabicyclo[3.3.1]nonane,C1CC2CC(CC(C1)N2CC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
7138,17139,Propitan,C1CC[NH+](CC1)C2(CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N.[Cl-].[Cl-],,,,,,
7139,17140,Propynylamine,CC#CN,,,,,,
7140,17141,Terpin hydrate,CC1(CCC(CC1)C(C)(C)O)O.O,"['Terpin hydrate is used in the treatment of acute and chronic bronchitis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease, infectious and inflammatory diseases of the upper respiratory tract.']","['It acts to facilitate the removal of mucus from the respiratory tract. It prevents the exacerbation of excessive mucus production and secretion due to airway bacterial or viral infections, asthma or chronic bronchitis. Expectorants like terpin hydrate change mucus consistency and make coughing more productive.']","['Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",,,
7141,17142,Triglycidyl isocyanurate,C1C(O1)CN2C(=O)N(C(=O)N(C2=O)CC3CO3)CC4CO4,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],"['In an oral (gavage) study in mice, at least 17% of the administered dose was absorbed within 24 hr, with blood analysis indicating that the absorption of triglycidyl isocyanurate administered in aqueous solution was twice that of triglycidyl isocyanurate in sesame oil. Triglycidyl isocyanurate was distributed to the liver, stomach, and testes (the only tissues studied).', 'The only available human data are from clinical trials with alpha-triglycidyl isocyanurate (intravenous administration), which indicate that alpha-triglycidyl isocyanurate has ... total body clearance of 5.7 L/min. Less than 1% of the administered dose was recovered unchanged in urine within 24 hr.', 'In oral (gavage) and intravenous studies with [14C]alpha-triglycidyl isocyanurate in rabbits, the radioactivity recovered in urine within 24 hr was approximately 30% and 60-70%, respectively.']","['In an oral (gavage) study in mice, ... blood plasma analysis indicated that triglycidyl isocyanurate was metabolized by hydrolysis to the diol diepoxide, the bis-diol epoxide, and the fully hydrolysed tris-diol, with no free triglycidyl isocyanurate detected 8 hr after treatment.', 'In in vitro studies, rapid hydrolysis of triglycidyl isocyanurate involving the enzyme epoxide hydrolase was observed in mouse liver preparations. Hydrolysis was also observed in rat liver preparations but not in rat lung preparations. Microsomal epoxide hydrolase activity with triglycidyl isocyanurate as substrate measured in two human livers obtained from kidney donors was found to be greater than the activity in rat liver.', '... Metabolism of TGIC involves hydrolysis of the epoxy functions, leading to the formation of the trisdiol derivative, and is promoted by hepatic but not pulmonary epoxide hydrolase. Non-enzymatic hydrolysis of the epoxy functions occurs under conditions of low pH. Further mechanisms for the metabolism of TGIC have not been investigated. Excretion of TGIC and/or its metabolites is largely via the urine. Urinary metabolites of TGIC have not been identified.']","['In ... intravenous studies with [(14)C]alpha-triglycidyl isocyanurate in rabbits, ... the half-life of triglycidyl isocyanurate in the blood was <5 min.', 'The only available human data are from clinical trials with alpha-triglycidyl isocyanurate (intravenous administration), which indicate that alpha-triglycidyl isocyanurate has a mean half-life in the blood of approximately 1 min ... .']"
7142,17143,"Trimethyleneglycol, dibenzoate",C1=CC=C(C=C1)C(=O)OCCCOC(=O)C2=CC=CC=C2,,,,,,
7143,17144,ZINC laurate,CCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCC(=O)[O-].[Zn+2],,,,,,
7144,17145,beta-Diethylaminoethyl p-(dimethylaminomethyleneamino)benzoate dihydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)N=C[NH+](C)C.[Cl-].[Cl-],,,,,,
7145,17146,2-(Diethylamino)ethyl 4-(dimethylaminomethylideneamino)benzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N=CN(C)C,,,,,,
7146,17147,4-(Bis(2-hydroxyethyl)amino)azobenzene,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(CCO)CCO,,,,,,
7147,17148,"1,2-Dimethylcyclopentane",CC1CCCC1C,,,,,,
7148,17149,"1,3-Dimethylcyclopentane",CC1CCC(C1)C,,,,,,
7149,17150,Formebolone,C[C@@]1(CC[C@@H]2[C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)C(=C[C@]34C)C=O)O)C)O,['No approved indications. Studied experimentally as a treatment for non-pituitary growth retardation.'],,,,,
7150,17151,Tetrahydrofurfuryl methacrylate,CC(=C)C(=O)OCC1CCCO1,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME A DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
7151,17152,Decyl ether,CCCCCCCCCCOCCCCCCCCCC,,,,,,
7152,17153,"3,5-Dichloropyridine",C1=C(C=NC=C1Cl)Cl,,,,,,
7153,17154,4-Amino-2-chlorobenzoic acid,C1=CC(=C(C=C1N)Cl)C(=O)O,,,,,,
7154,17155,3-Phenyl-1H-pyrazole,C1=CC=C(C=C1)C2=CC=NN2,,,,,,
7155,17156,Dimethylethylenediamine tetra-acetic acid,CC(C(C)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
7156,17157,Isotrigonelline,C[N+]1=CC=C(C=C1)C(=O)[O-],,,,,,
7157,17158,1-Methyl-4-carboxypyridinium,C[N+]1=CC=C(C=C1)C(=O)O,,,,,,
7158,17159,Trimethyl trimellitate,COC(=O)C1=CC(=C(C=C1)C(=O)OC)C(=O)OC,,,,,,
7159,17160,"4,5-Dichloroguaiacol",COC1=CC(=C(C=C1O)Cl)Cl,,,,,,
7160,17161,"2,5-Di-tert-butyl-1,4-benzoquinone",CC(C)(C)C1=CC(=O)C(=CC1=O)C(C)(C)C,,,,,"['Quinones (ie, 6,12-dione) have been shown to undergo oxidation-reduction cycles involving quinone, hydroquinone, and molecular oxygen, resulting in the formation of oxygen radicals and semiquinone radicals. /Quinones/']",
7161,17162,2-Ethylhexyl glycidyl ether,CCCCC(CC)COCC1CO1,,,,,,
7162,17163,Lauryl glycidyl ether,CCCCCCCCCCCCOCC1CO1,,,,,,
7163,17164,"Methyl icosa-11,14-dienoate",CCCCCC=CCC=CCCCCCCCCCC(=O)OC,,,,,,
7164,17165,Epichlorohydrin carbonate,C1COC(=O)OC1Cl,,,,,,
7165,17166,Non-2-enal,CCCCCCC=CC=O,,,,,,
7166,17167,2-Hepten-1-al,CCCCC=CC=O,,,,,,
7167,17168,Dicapthon,COP(=S)(OC)OC1=C(C=C(C=C1)[N+](=O)[O-])Cl,,,,"['/ORGANOPHOSPHORUS INSECTICIDES/ ... ARE ABSORBED INTO BODY BY RESPIRATORY, GASTROINTESTINAL, & CUTANEOUS PATHWAYS. /ORGANOPHOSPHORUS INSECTICIDES/', 'IN GENERAL, BECAUSE OF RAPID HYDROLYSIS & EXCRETION IN URINE, ORGANOPHOSPHORUS COMPD ARE NOT ACCUMULATED & STORED IN ANIMAL BODY. /ORGANOPHOSPHORUS COMPD/']","['RABBIT & RAT LIVER MICROSOMES & HOUSEFLY MICROSOMES PLUS NADPH2 & O2 WERE INCUBATED WITH DICAPTHON. IN EACH CASE, CORRESPONDING PHENOL WAS FOUND. ACTIVATION OF DICAPTHON TO CORRESPONDING OXON ANALOG WAS OBSERVED. SOME CONVERSION OF OXON ANALOG TO CORRESPONDING PHENOL WAS ALSO OBSERVED ... .', 'YIELDS 2-CHLORO-4-NITROPHENOL IN RAT, IN RABBIT, IN FLY. YIELDS 2-CHLORO-4-NITROPHENYL DIMETHYL PHOSPHATE IN RAT, IN RABBIT, IN FLY. /FROM TABLE/', 'A relatively high proportion of the total metabolism in the rat involves alkyl phosphate hydrolysis, as is true of other dialkyl compounds, in contrast to diethyl compounds.']",
7168,17169,Chlorflurecol,C1=CC=C2C(=C1)C3=C(C2(C(=O)O)O)C=C(C=C3)Cl,,,,,,
7169,17170,Auramine O,CN(C)C1=CC=C(C=C1)C(=N)C2=CC=C(C=C2)N(C)C.Cl,,,"['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)', 'Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
7170,17171,Acridine red,CNC1=CC2=C(C=C1)C=C3C=CC(=[NH+]C)C=C3O2.[Cl-],,,,"['OF THE 20 DYES TESTED, ALL PREVIOUSLY CLAIMED TO BE ELIMINATED THROUGH THE PANCREAS, ONLY 6 APPEARED IN THE PANCREATIC JUICE OF DOGS. THE INTENSITY OF DYE COLOR IN PANCREATIC JUICE DECREASED IN THE ORDER: BASIC FUCHSINE, ACRIDINE RED, NEW FUCHSINE, RHODAMINE B, PHENOL RED, & RHODAMINE 6G. THE CHLORINE CONTENT WAS RELATED TO AMYLASE OR DYE CONTENT, BUT WAS INVERSELY RELATED TO SECRETED VOLUME.']",,
7171,17172,N-methyl-6-methyliminoxanthen-3-amine,CNC1=CC2=C(C=C1)C=C3C=CC(=NC)C=C3O2,,,,,,
7172,17173,CID 17173,CCOP(=O)(OCC)S,,,,,,
7173,17174,N-Acetylimidazole,CC(=O)N1C=CN=C1,,,,,,
7174,17175,"1,1,1,5-Tetrachloropentane",C(CCCl)CC(Cl)(Cl)Cl,,,,,,
7175,17176,Trioctyl borate,B(OCCCCCCCC)(OCCCCCCCC)OCCCCCCCC,,,,,,
7176,17177,Tris(2-ethylhexyl) borate,B(OCC(CC)CCCC)(OCC(CC)CCCC)OCC(CC)CCCC,,,,,,
7177,17178,"Boric acid, tridodecyl ester",B(OCCCCCCCCCCCC)(OCCCCCCCCCCCC)OCCCCCCCCCCCC,,,,,,
7178,17179,Tribenzyl borate,B(OCC1=CC=CC=C1)(OCC2=CC=CC=C2)OCC3=CC=CC=C3,,,,,,
7179,17180,"2-(1-Aminoethyl)-1,4-benzodioxane",CC(C1COC2=CC=CC=C2O1)N,,,,,,
7180,17181,"1,3-Bis(3-aminopropyl)tetramethyldisiloxane",C[Si](C)(CCCN)O[Si](C)(C)CCCN,,,,,,
7181,17182,Dixyrazine,CC(CN1CCN(CC1)CCOCCO)CN2C3=CC=CC=C3SC4=CC=CC=C42,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)']",,,
7182,17183,"1H-Indene, 1-ethenyl-",C=CC1C=CC2=CC=CC=C12,,,,,,
7183,17184,"Atropine, sulfate (2:1)",CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.OS(=O)(=O)O,,,,,,
7184,17185,1-Chlorononane,CCCCCCCCCCl,,,,,,
7185,17186,1-Chloroundecane,CCCCCCCCCCCCl,,,,,,
7186,17187,"Arsine, bis(dodecylthio)methyl-",CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC,,,,,,
7187,17188,Vat Blue 4B,C1=C(C=C(C2=C1C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4Br)Br)O)Br)Br,,,,,,
7188,17189,"1,4-Bis(methylamino)anthraquinone",CNC1=C2C(=C(C=C1)NC)C(=O)C3=CC=CC=C3C2=O,,,,,,
7189,17190,Disperse blue 1,C1=CC(=C2C(=C1N)C(=O)C3=C(C=CC(=C3C2=O)N)N)N,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7190,17191,Disperse blue 3,CNC1=C2C(=C(C=C1)NCCO)C(=O)C3=CC=CC=C3C2=O,,,,,,
7191,17192,Methyl-di-(beta-chloroethyl)ammonium picrate,C[NH+](CCCl)CCCl.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
7192,17193,"1,4-Bicyclo(2.2.2)octanebis(methylamine), N,N'-bis(2-trifluoromethylbenzyl)-, dihydrochloride",C1CC2(CCC1(CC2)C[NH2+]CC3=CC=CC=C3C(F)(F)F)C[NH2+]CC4=CC=CC=C4C(F)(F)F.[Cl-].[Cl-],,,,,,
7193,17194,1-[2-(trifluoromethyl)phenyl]-N-[[4-[[[2-(trifluoromethyl)phenyl]methylamino]methyl]-1-bicyclo[2.2.2]octanyl]methyl]methanamine,C1CC2(CCC1(CC2)CNCC3=CC=CC=C3C(F)(F)F)CNCC4=CC=CC=C4C(F)(F)F,,,,,,
7194,17195,"N,N'-Dicyclohexyl-1,4-bicyclo(2.2.2)octanebis(methylamine) dihydrochloride",C1CCC(CC1)[NH2+]CC23CCC(CC2)(CC3)C[NH2+]C4CCCCC4.[Cl-].[Cl-],,,,,,
7195,17196,N-[[4-[(cyclohexylamino)methyl]-1-bicyclo[2.2.2]octanyl]methyl]cyclohexanamine,C1CCC(CC1)NCC23CCC(CC2)(CC3)CNC4CCCCC4,,,,,,
7196,17197,Lauryl isoquinolinium saccharinate,CCCCCCCCCCCC[N+]1=CC2=CC=CC=C2C=C1.C1=CC=C2C(=C1)C(=NS2(=O)=O)[O-],,,,,,
7197,17198,Acetosyringone,CC(=O)C1=CC(=C(C(=C1)OC)O)OC,,,"['Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
7198,17199,Methylethoxyphosphorylthiocholine iodide,CCOP(=O)(C)SCC[N+](C)(C)C.[I-],,,,,,
7199,17200,(2-Mercaptoethyl)trimethylammonium S-ester with O-ethylmethylphosphonothioate,CCOP(=O)(C)SCC[N+](C)(C)C,,,,,,
7200,17201,"1,3-Bis(4-aminophenoxy)benzene",C1=CC(=CC(=C1)OC2=CC=C(C=C2)N)OC3=CC=C(C=C3)N,,,,,,
7201,17202,1-Phenyl-2-piperidin-1-ylethanol,C1CCN(CC1)CC(C2=CC=CC=C2)O,,,,,,
7202,17203,4-(1-Hydroxyethyl)-2-methoxyphenol,CC(C1=CC(=C(C=C1)O)OC)O,,,,,,
7203,17204,4-(Diethylamino)azobenzene,CCN(CC)C1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
7204,17205,"1,1,1,2,3,4,4,4-Octachloro-2-butene",C(=C(C(Cl)(Cl)Cl)Cl)(C(Cl)(Cl)Cl)Cl,,,,,,
7205,17206,Methyl nitroacetate,COC(=O)C[N+](=O)[O-],,,,,,
7206,17207,"Ammonium, benzyltriethyl-, nitrate",CC[N+](CC)(CC)CC1=CC=CC=C1.[N+](=O)([O-])[O-],,,,,,
7207,17208,Benzyltriethylammonium,CC[N+](CC)(CC)CC1=CC=CC=C1,,,,,,
7208,17209,6-Dehydrotestosterone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)C=CC4=CC(=O)CC[C@]34C,,,,,,
7209,17210,Azobenzene-4-sulfonic acid,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
7210,17211,4-Amino-3-chlorobenzoic acid,C1=CC(=C(C=C1C(=O)O)Cl)N,,,,,,
7211,17212,"(2-Tert-butyl-3-methyl-4,6-dinitrophenyl) acetate",CC1=C(C(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])OC(=O)C)C(C)(C)C,,,,,,
7212,17213,CID 17213,C1=NC2=C(N1)C(=O)N=C(N2)S,,,,,,
7213,17214,"17-[(Cyclopent-1-en-1-yl)oxy]androsta-1,4-dien-3-one",CC12CCC3C(C1CCC2OC4=CCCC4)CCC5=CC(=O)C=CC35C,,,,,,
7214,17215,Trimethoxy-silane,CO[SiH](OC)OC,,,,,,
7215,17216,CID 17216,CN=C(N(C)C)S,,,,,,
7216,17217,1-Allylnaphthalene,C=CCC1=CC=CC2=CC=CC=C21,,,,,,
7217,17218,2-Methyl-1-hexadecanol,CCCCCCCCCCCCCCC(C)CO,,,,,,
7218,17219,Methyl 14-methylheptadecanoate,CCCC(C)CCCCCCCCCCCCC(=O)OC,,,,,,
7219,17220,Cme-carbodiimide,CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+]1(CCOCC1)CCN=C=NC2CCCCC2,,,,,,
7220,17221,"Morpholinium, 4-(2-((cyclohexylcarbonimidoyl)amino)ethyl)-4-methyl-",C[N+]1(CCOCC1)CCN=C=NC2CCCCC2,,,,,,
7221,17222,4-Nitroazobenzene,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
7222,17223,CID 17223,C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)S(=O)(=O)[O-].[Na+],,,,,,
7223,17224,4-((4-Aminophenyl)diazenyl)benzenesulfonic acid,C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)S(=O)(=O)O,,,,,,
7224,17225,4'-Nitro-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
7225,17226,4'-Chloro-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)Cl,,,,,,
7226,17227,"2,5-Bis(4-methylphenyl)-1,3,4-oxadiazole",CC1=CC=C(C=C1)C2=NN=C(O2)C3=CC=C(C=C3)C,,,,,,
7227,17228,CID 17228,C1=CC=C2C(=C1)N=C(S2)[S-].[Na+],,,,,,
7228,17229,2-(1-Phenylethylidene)-1-hydrazine carboxamide,CC(=NNC(=O)N)C1=CC=CC=C1,,,,,,
7229,17230,5-Nitrofurfuryl alcohol,C1=C(OC(=C1)[N+](=O)[O-])CO,,,,,,
7230,17231,4-Octyloxybenzoic acid,CCCCCCCCOC1=CC=C(C=C1)C(=O)O,,,,,,
7231,17232,Butyrylcholine iodide,CCCC(=O)OCC[N+](C)(C)C.[I-],,,,,,
7232,17233,Butyrylcholine,CCCC(=O)OCC[N+](C)(C)C,,,,,,
7233,17234,Tridecyl methacrylate,CCCCCCCCCCCCCOC(=O)C(=C)C,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME A DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
7234,17235,Hexadecyl methacrylate,CCCCCCCCCCCCCCCCOC(=O)C(=C)C,,,,,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme A derivative, which then enters the normal lipid metabolism. /Methacrylates/', 'Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Methacrylates/']",
7235,17236,Benzyl methacrylate,CC(=C)C(=O)OCC1=CC=CC=C1,,,,,,
7236,17237,CID 17237,C=CCS(=O)(=O)[O-].[Na+],,,,,,
7237,17238,2-Propene-1-sulfonic acid,C=CCS(=O)(=O)O,,,,,,
7238,17239,Demeton-S Sulfone,CCOP(=O)(OCC)SCCS(=O)(=O)CC,,,,,,
7239,17240,PO systox sulfoxide,CCOP(=O)(OCC)SCCS(=O)CC,,,,,,
7240,17241,Disulfoton sulfone,CCOP(=S)(OCC)SCCS(=O)(=O)CC,,,,,,
7241,17242,Oxydisulfoton,CCOP(=S)(OCC)SCCS(=O)CC,,,,,['Disulfoton sulfoxide is a known human metabolite of Disulfoton.'],
7242,17243,Hex-2-enyl acetate,CCCC=CCOC(=O)C,,,,,,
7243,17244,2-Hexen4-one,CCC(=O)C=CC,,,,,,
7244,17245,"3,6,9,12,15-Pentaoxaheptadecan-1-ol, 17-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-",CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCO,,,,,,
7245,17246,CID 17246,CCC(CC1=C(C(=C(C=C1I)I)N)I)C(=O)[O-].[Na+],,,,,,
7246,17247,"2-Chloro-3,5-dinitrobenzoic acid",C1=C(C=C(C(=C1C(=O)O)Cl)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7247,17248,Tetrapentylammonium iodide,CCCCC[N+](CCCCC)(CCCCC)CCCCC.[I-],,,,,,
7248,17249,Tetrapentylammonium,CCCCC[N+](CCCCC)(CCCCC)CCCCC,,,,,,
7249,17250,"3-Hydroxy-N,N,N-trimethylbenzenaminium iodide",C[N+](C)(C)C1=CC(=CC=C1)O.[I-],,,,,,
7250,17251,[5-(4-Amino-5-iodo-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate,C1C(C(OC1N2C=C(C(=NC2=O)N)I)COP(=O)(O)O)O,,,,,,
7251,17252,"Benz[a]anthracene, 5-fluoro-7-methyl-",CC1=C2C=C(C3=CC=CC=C3C2=CC4=CC=CC=C14)F,,,,,,
7252,17253,"1,2-Benzanthraquinone",C1=CC=C2C(=C1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
7253,17254,3-Methylbenz[a]anthracene,CC1=CC2=C(C=C1)C3=CC4=CC=CC=C4C=C3C=C2,,,,,,
7254,17255,2-Methylbenz[a]anthracene,CC1=CC2=C(C=C1)C=CC3=CC4=CC=CC=C4C=C32,,,,,,
7255,17256,1-Methylbenz(A)anthracene,CC1=C2C(=CC=C1)C=CC3=CC4=CC=CC=C4C=C32,,,,,,
7256,17257,Heptyl acrylate,CCCCCCCOC(=O)C=C,,,,,,
7257,17258,Octyl acrylate,CCCCCCCCOC(=O)C=C,,,,,,
7258,17259,Hexyl acrylate,CCCCCCOC(=O)C=C,,,,,,
7259,17260,"Benzimidazole, 5,6-dichloro-1-(2-dimethylaminoethyl)-2-(p-ethoxybenzyl)-, hydrochloride",CCOC1=CC=C(C=C1)CC2=NC3=CC(=C(C=C3N2CC[NH+](C)C)Cl)Cl.[Cl-],,,,,,
7260,17261,"2-[5,6-dichloro-2-[(4-ethoxyphenyl)methyl]benzimidazol-1-yl]-N,N-dimethylethanamine",CCOC1=CC=C(C=C1)CC2=NC3=CC(=C(C=C3N2CCN(C)C)Cl)Cl,,,,,,
7261,17262,"2-Propanone, 1-(4-hydroxy-3-methoxyphenyl)-",CC(=O)CC1=CC(=C(C=C1)O)OC,,,,,,
7262,17263,"Tetrasodium;2-[[4-[[4-[(6-anilino-2-hydroxy-3-sulfonatonaphthalen-1-yl)diazenyl]naphthalen-1-yl]diazenyl]-6-sulfonatonaphthalen-1-yl]diazenyl]benzene-1,4-disulfonate",C1=CC=C(C=C1)NC2=CC3=CC(=C(C(=C3C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=C7C=C(C=CC7=C(C=C6)N=NC8=C(C=CC(=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
7263,17264,"2-[[4-[[4-[(6-Anilino-2-hydroxy-3-sulfonaphthalen-1-yl)diazenyl]naphthalen-1-yl]diazenyl]-6-sulfonaphthalen-1-yl]diazenyl]benzene-1,4-disulfonic acid",C1=CC=C(C=C1)NC2=CC3=CC(=C(C(=C3C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=C7C=C(C=CC7=C(C=C6)N=NC8=C(C=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)O)S(=O)(=O)O,,,,,,
7264,17265,"Berbine, 2,3,9,10-tetramethoxy-, hydrochloride",COC1=C(C2=C(CC3C4=CC(=C(C=C4CC[NH+]3C2)OC)OC)C=C1)OC.[Cl-],,,,,,
7265,17266,"(5-Dimethylamino-2,4-pentadi-enylidene)dimethylammonium perchlorate",CN(C)C=CC=CC=[N+](C)C.[O-]Cl(=O)(=O)=O,,,,,,
7266,17267,"Methanaminium, N-[5-(dimethylamino)-2,4-pentadienylidene]-N-methyl-",CN(C)C=CC=CC=[N+](C)C,,,,,,
7267,17268,Physalaemin,CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C4CCC(=O)N4,,,"['Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Neurotransmitter Agents.)']",,,
7268,17269,CID 17269,CCOC(C)C(=NN=C(N)S)C=NN=C(N)S,,,,,,
7269,17270,7-Fluoro-n-hydroxy-n-2-acetylaminofluorene,CC(=O)N(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)F)O,,,,,,
7270,17271,2-Nitrosofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['N-HYDROXY DERIVATIVES /OF AROMATIC AMINES/ CAN BE FORMED BY REDUCTION. WITHIN TISSUES ... ARE ... REDUCTASES ... WHICH REDUCE ... NITROSO ... GROUPS TO N-HYDROXY DERIVATIVES. ... 2-NITROSOFLUORENE, AN OXIDN PRODUCT OF N-HYDROXY-2-FLUORENAMINE, CAN BE CONVERTED BACK TO PARENT CMPD ENZYMATICALLY. HAMSTER & RABBIT LIVER SOL ENZYMES HAD CONSIDERABLY MORE ACTIVITY IN CARRYING OUT THIS REDUCTION THAN THOSE FROM THE RAT.', 'STUDIES OF NONENZYMIC REACTIONS OF TRANS-4-NITROSOSTILBENE, 4-NITROSOBIBENZYL, 2-NITROSOFLUORENE & P-NITROSOTOLUENE WITH GLUTATHIONE REVEALED THE CORRESPONDING HYDROXYLAMINE, AMINE & WATER-SOL ADDUCT, WHICH HYDROLYZED UNDER ACIDIC OR ALKALINE CONDITIONS TO AMINE & GLUTATHIONE SULFINIC ACID. REDUCTION TO THE AMINE IS EXPLAINED BY FORMATION OF ADDUCTS WHICH ARE REDUCED BY GLUTATHIONE WITH THE PRODUCTION OF OXIDIZED GLUTATHIONE.', 'THE CARCINOGEN 2-NITROSOFLUORENE REACTED WITH LIPID MOLECULES CONTAINING CARBON-CARBON DOUBLE BONDS TO YIELD FREE RADICALS (NITROXYL FREE RADICAL OF 2-NITROSOFLUORENE COVALENTLY BOUND TO THE LIPID).']",
7271,17272,N-Hydroxy-N-2-naphthalenylacetamide,CC(=O)N(C1=CC2=CC=CC=C2C=C1)O,,,,,,
7272,17273,"[(16R,17R)-16,17-diacetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate",CC(=O)O[C@@H]1CC2C3CCC4=C(C3CCC2([C@H]1OC(=O)C)C)C=CC(=C4)OC(=O)C5=CC=CC=C5,,,,,,
7273,17274,CID 17274,C(=CNC(=CN=O)O)C(=O)N,,,,,,
7274,17275,Antazoline hydrochloride,C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3.Cl,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)']",,,
7275,17276,Methyldopate hydrochloride,CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N.Cl,,,,,,
7276,17277,Methyldopate,CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N,,,"['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
7277,17278,"Malononitrile, (2-indanylidene)-",C1C(=C(C#N)C#N)CC2=CC=CC=C21,,,,,,
7278,17279,9-Cyanophenanthrene,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)C#N,,,,,,
7279,17280,Diethyl phenyl phosphate,CCOP(=O)(OCC)OC1=CC=CC=C1,,,,,,
7280,17281,CID 17281,CCOP(=O)(C)CSCC,,,,,,
7281,17282,Ethylphosphonothioic acid O-ethyl S-methyl ester,CCOP(=O)(CC)SC,,,,,,
7282,17283,CID 17283,CC1=CC(=C(C=C1)NN=C(C(=O)C)C(=O)NC2=CC=CC=C2)[N+](=O)[O-],,,,,,
7283,17284,Ethylene glycol bis(trichloroacetate),C(COC(=O)C(Cl)(Cl)Cl)OC(=O)C(Cl)(Cl)Cl,,,,,,
7284,17285,"N-(2,4-dibromophenyl)benzenecarbohydrazonoyl bromide",C1=CC=C(C=C1)C(=NNC2=C(C=C(C=C2)Br)Br)Br,,,,,,
7285,17286,5-Chloro-2-nitrobenzoic acid,C1=CC(=C(C=C1Cl)C(=O)O)[N+](=O)[O-],,,,,,
7286,17287,2-Chloro-5-nitrobenzoic acid,C1=CC(=C(C=C1[N+](=O)[O-])C(=O)O)Cl,,,,,,
7287,17288,Azetidine-2-carboxylic acid,C1CNC1C(=O)O,,,,,,
7288,17289,CID 17289,CCC(C(=O)[O-])(Cl)Cl.[Na+],,,,,,
7289,17290,"2,2-Dichlorobutanoic acid",CCC(C(=O)O)(Cl)Cl,,,,,,
7290,17291,3-Methoxy-1-butanol,CC(CCO)OC,,,,,,
7291,17292,5-Ethylbarbituric acid,CCC1C(=O)NC(=O)NC1=O,,,,,,
7292,17293,Black PN,CC(=O)NC1=C2C(=C(C=C1)S(=O)(=O)[O-])C=C(C(=C2O)N=NC3=C4C=C(C=CC4=C(C=C3)N=NC5=CC=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
7293,17294,Brilliant Black BN,CC(=O)NC1=C2C(=C(C=C1)S(=O)(=O)O)C=C(C(=C2O)N=NC3=C4C=C(C=CC4=C(C=C3)N=NC5=CC=C(C=C5)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7294,17295,CID 17295,CC1=NC(=O)N=C(N1)C2=CC=CC=C2,,,,,,
7295,17296,Ethyl o-(2-methyl-3-(4(3H)-quinazolinonyl))carbanilate hydrochloride,CCOC(=O)NC1=CC=CC=C1[NH+]2C(=NC3=CC=CC=C3C2=O)C.[Cl-],,,,,,
7296,17297,ethyl N-[2-(2-methyl-4-oxoquinazolin-3-yl)phenyl]carbamate,CCOC(=O)NC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C,,,,,,
7297,17298,Encyprate,CCOC(=O)N(CC1=CC=CC=C1)C2CC2,,,,,,
7298,17299,9-Methylfluorene,CC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
7299,17300,2-Chlorofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)Cl,,,,,,
7300,17301,2-Methoxy-9H-fluorene,COC1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
7301,17302,9H-Fluorene-2-carbonitrile,C1C2=CC=CC=C2C3=C1C=C(C=C3)C#N,,,,,,
7302,17303,O-Methyl dichlorothiophosphate,COP(=S)(Cl)Cl,,,,,,
7303,17304,Dimethyl chlorothiophosphate,COP(=S)(OC)Cl,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/']",,
7304,17305,"O,O-Diethyl chlorothiophosphate",CCOP(=S)(OCC)Cl,,,,,,
7305,17306,"O,O,S-Triethyl dithiophosphate",CCOP(=S)(OCC)SCC,,,,,,
7306,17307,Ethyl picolinate,CCOC(=O)C1=CC=CC=N1,,,,,,
7307,17308,"Aniline, N-acetyl-3-methylthio-",CC(=O)NC1=CC=CC(=C1)CS,,,,,,
7308,17309,"1,2,6-Trimethylpyridinium iodide",CC1=[N+](C(=CC=C1)C)C.[I-],,,,,,
7309,17310,"1,2,6-Trimethylpyridinium",CC1=[N+](C(=CC=C1)C)C,,,,,,
7310,17311,"2,17-alpha-Dimethyl-5-alpha-androst-2-en-17-beta-ol",CC1=CC[C@@H]2CC[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@]2(C1)C)C)(C)O,,,,,,
7311,17312,Dibutyl phenyl phosphate,CCCCOP(=O)(OCCCC)OC1=CC=CC=C1,,,,,,
7312,17313,Heptanoyl chloride,CCCCCCC(=O)Cl,,,,,,
7313,17314,"2,3,6-Trimethylbenzoic acid",CC1=C(C(=C(C=C1)C)C(=O)O)C,,,,,,
7314,17315,"[(9R,17R)-17-acetyl-9-fluoro-11-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate",CC(=O)[C@]1(CCC2C1(CC([C@]3(C2CCC4=CC(=O)CCC43C)F)O)C)OC(=O)C,,,,,,
7315,17316,"17-Hydroxy-13-methyl-17-(2-methylprop-2-enyl)-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC(=C)CC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O,,,,,,
7316,17317,(3-Glycidoxypropyl)trimethoxysilane,CO[Si](CCCOCC1CO1)(OC)OC,,,,,,
7317,17318,3-(Trimethoxysilyl)propyl methacrylate,CC(=C)C(=O)OCCC[Si](OC)(OC)OC,,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme derivative, which then enters the normal lipid metabolism. /Methacrylates/']",
7318,17319,Piperylone,CCC1=C(NN(C1=O)C2CCN(CC2)C)C3=CC=CC=C3,,,,,,
7319,17320,Calcium DTPA,C(CN(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-].[Ca+2],,,,,,
7320,17321,2-Methylphenanthrene,CC1=CC2=C(C=C1)C3=CC=CC=C3C=C2,,,,,,
7321,17322,CID 17322,C1=CC(=CC=C1C(=O)[O-])Br.[Na+],,,,,,
7322,17323,CID 17323,C1=CC=C(C(=C1)C(=O)[O-])I.[Na+],,,,,,
7323,17324,CID 17324,C1=CC(=CC(=C1)I)C(=O)[O-].[Na+],,,,,,
7324,17325,Pyramat,CCCC1=NC(=CC(=N1)OC(=O)N(C)C)C,,,,,,
7325,17326,"cis-1,3-Dimethylcyclopentane",C[C@@H]1CC[C@@H](C1)C,,,,,,
7326,17327,CID 17327,CC1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3C(=O)[O-].[Na+],,,,,,
7327,17328,2-(2-Methyl-4-oxoquinazolin-3(4h)-yl)benzoic acid,CC1=NC2=CC=CC=C2C(=O)N1C3=CC=CC=C3C(=O)O,,,,,,
7328,17329,"6-Heptadecyl-1,3,5-triazine-2,4-diamine",CCCCCCCCCCCCCCCCCC1=NC(=NC(=N1)N)N,,,,,,
7329,17330,"Arsine, methylthioxo-",C[As]=S,,,,,,
7330,17331,"N-(3,4-dichlorophenyl)hexanamide",CCCCCC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,,
7331,17332,"1,6-Hexanediamine, N,N'-dinitro-",C(CCCN[N+](=O)[O-])CCN[N+](=O)[O-],,,,,,
7332,17333,"1,3-Dinitro-2-imidazolidinone",C1CN(C(=O)N1[N+](=O)[O-])[N+](=O)[O-],,,,,,
7333,17334,Chlorflurenol-methyl,COC(=O)C1(C2=CC=CC=C2C3=C1C=C(C=C3)Cl)O,,,,,,
7334,17335,2-Amino-6-methylbenzothiazole,CC1=CC2=C(C=C1)N=C(S2)N,,,,,,
7335,17336,Proxibarbal,CC(CC1(C(=O)NC(=O)NC1=O)CC=C)O,,,['Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)'],,,
7336,17337,Tetramethylammonium perchlorate,C[N+](C)(C)C.[O-]Cl(=O)(=O)=O,,,['Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non-nicotinic effects on postganglionic neurons are not included here nor are the nonspecific cholinergic agonists. (See all compounds classified as Ganglionic Stimulants.)'],,,
7337,17338,CID 17338,CC[GeH](CC)CC.CC[GeH](CC)CC.O,,,,,,
7338,17339,"Germane, triethyl-",CC[GeH](CC)CC,,,,,,
7339,17340,CID 17340,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])O)O.[Na+],,,,,,
7340,17341,3-Hydroxy-4-((2-hydroxynaphthyl)azo)naphthalene-1-sulphonic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)O)O)O,,,,,,
7341,17342,"1,2,3-Trichloro-4,5,6-trimethoxybenzene",COC1=C(C(=C(C(=C1OC)Cl)Cl)Cl)OC,,,,,,
7342,17343,Tetrachloroguaiacol,COC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)O,,,,,,
7343,17344,"3,4,5-Trichloro-2,6-dimethoxyphenol",COC1=C(C(=C(C(=C1Cl)Cl)Cl)OC)O,,,,,,
7344,17345,Formothion,CN(C=O)C(=O)CSP(=S)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Single oral doses of 10 mg/kg body-weight of formothion, labelled with carbon-14 in the carbamoyl group, were administered by stomach tube to male rats. Autoradiographs indicated that the compound was readily absorbed from the stomach. Within 30 minutes after giving the dose, a high level of radioactivity was found in the liver and kidney, although the major activity was still in the stomach. Six hours after administration the activity in the stomach area was low; the main activity then being in the kidneys, with less activity in the liver, intestines, pancreas and thymus. After 24 hours from the time of administration of the dose, distinct radioactivity was found only in the thymus. The urine was the major source of excretion; it contained 98-99% of the radioactivity compared to the feces which had only 1-2%. A total of 51% of the administered  radioactivity had been excreted in the urine after 4 hr and 96% after 24 hr. The presence of considerable radioactivity in the bile indicated that there was also excretion of the compound and its metabolites in the bile. However, because so little radioactivity was encountered in the feces nearly all of these compounds must be re-absorbed in the intestine.', 'Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for FORMOTHION (10 total), please visit the HSDB record page.']","['Metabolites include dimethoate, bis(dimethylthiophosphoryl)disulfide and dimethyldithiophosphorylacetic acid...', 'Hydrolytic attack causes rapid degradation of formothion on bean plants to dimethoate and o,o-dimethyl dithiophosphorylacetic acid. Further breakdown products are methoxon, o,o-dimethyldithiophosphoric acid, and bis(o,o-dimethylthiophosphoryl) disulfide.', ""Incubation of (14)C-labeled formothion with three subcellular rat liver fractions at 37 C and pH 7.4 resulted in alteration of all of the formothion within 30 min. The denatured non-enzymatic control gave identical results, indicating that the mechanism for the formation of dimethoate and dimethoate monoacid was not dependent on enzymatic oxidation or reduction reactions. The only metabolites identified were dimethoate and dimethoate monoacid. No dimethoxon was found. Incubation of (14)C-formothion at various pH's at 37 C resulted in formation of dimethoate and dimethoate monoacid. At an acid pH the rate of formation was much slower than at an alkali pH."", 'Formothion metabolism in plants has been shown to result in formation of dimethoate and formothion acid (o,o-dimethyl phosphoryl acetic acid). The same transformation of formothion to dimethoate has been observed in animals.', 'For more Metabolism/Metabolites (Complete) data for FORMOTHION (8 total), please visit the HSDB record page.']","['Following oral administration of (14)C-labelled formothion to rats within 24 hr 97% of radioactivity is excreted in urine. With half life of 4 hr it is rapidly broken down, and excreted in form of nontoxic metabolic products.']"
7345,17346,"Benz(a)anthracene, 6-fluoro-7-methyl-",CC1=C2C(=CC3=CC=CC=C13)C4=CC=CC=C4C=C2F,,,,,,
7346,17347,7-Methylbenz[a]anthracene,CC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C14,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['The fungal metabolism of 7-methylbenz[a]anthracene (7-MBA) and 7-hydroxymethylbenz[a]anthracene (7-OHMBA) was studied. 7-MBA was metabolized by Cunninghamella elegans to form 7-OHMBA-trans-8,9-dihydrodiol and 7-OHMBA-trans-3,4-dihydrodiol as the predominant metabolites. Other metabolites were identified as 7-OHMBA, 7-MBA-trans-8,9-dihydrodiol and 7-MBA-trans-3,4-dihydrodiol, and 7-MBA-8,9,10,11-tetraol. Incubation of 7-OHMBA with C. elegans cells indicated that 7-OHMBA-trans-8,9-dihydrodiol and 7-OHMBA-trans-3,4-dihydrodiol were major metabolites. The metabolism of 7-MBA by rat liver microsomes from 3-methylcholanthrene-treated rats showed that the metabolites were qualitatively similar to those formed by C. elegans, except additional dihydrodiol metabolites were formed at the 5,6 and 10,11 positions. The metabolites formed were isolated by high-performance liquid chromatography and identified by comparing their chromatographic, UV-visible absorption and mass spectral properties with those of reference compounds.', '7-Methylbenz[a]anthracene (7-MBA) was metabolized stereoselectively by rat liver microsomes to form five optically active dihydrodiols as the predominant metabolites. The dihydrodiols were purified by a combination of reversed-phase and normal-phase high performance liquid chromatography (HPLC). By comparison of their circular dichroism (CD) spectra with the corresponding benz[a]anthracene (BA) dihydrodiols of known absolute stereochemistry, the major dihydrodiol enantiomers of 7-MBA have been determined to have 1R,2R-, 3R,4R- and 10R , 11R - absolute configurations, respectively. Due to their quasi- diaxial conformations, the absolute configuration of trans-5,6- and trans-8,9-dihydrodiols, the two most abundant metabolites of 7-MBA, could not be determined by simple comparisons of their circular dichroism spectra with those of the quasidi -equatorial BA 5R, 6R - and 8R , 9R -dihydrodiols. The major enantiomers of the quasi- diaxial trans-5,6- and trans-8,9-dihydrodiol metabolites of 7-MBA were determined by comparison to the CD spectrum of 7-bromo-BA 5R, 6R -dihydrodiol and by the exciton chirality method to have R,R absolute stereochemistry. This study also revealed that the circular dichroism Cotton effects of an enantiomeric dihydrodiol of polycyclic aromatic hydrocarbons can be drastically altered if the conformation (quasi- diaxial vs. quasi di-equatorial ) of the dihydrodiol is changed.', 'The metabolism of 7-ethyl (7-EBA) and 7-methylbenz[a]anthracene (7-MBA) to dihydrodiols has been compared in incubations with hepatic microsomal fractions prepared from untreated rats. Although both hydrocarbons were found to be metabolized to similar extents, the relative proportions of their diols that were detected differed. For 7-MBA, the principal diols identified were the 8,9- and 5,6-derivatives, whereas for 7-EBA the 8,9- and 1,2-diols predominated; the 5,6-diol was only present as a minor product. These results imply that the presence of the sterically bulky ethyl group at position seven in the benz[a]anthracene ring system may, when compared to the analogous methyl derivative, enhance diol formation on the angular 1,2,3,4 benzo-ring, at the expense of metabolism at the K-region.', 'The carcinogen 7-methylbenz[a]anthracene (7-MBA) is considered to be metabolically activated via its bay-region dihydrodiol-epoxide, trans-3,4-dihydro-3,4-dihydroxy-7-methyl-benz[a]anthracene 1,2-oxide (7-MBA-3,4-diol 1,2-oxide). When tested on mouse skin, a target tissue for polycylic aromatic hydrocarbon carcinogenesis, 7-ethylbenz[a]anthracene (7-EBA) was much less active than 7-MBA, and this difference may be due to differences in the pathways by which the two compounds are metabolized and activated. In the present work, the metabolism by mouse-skin microsomes of both hydrocarbons to dihydrodiols has been examined. Both were metabolized to a similar extent with the 8,9-dihydrodiols being detected as the predominant metabolites. The 3,4-, 5,6-and 10,11-dihydrodiols of 7-MBA and the 3,4- and 10, 11-dihydrodiols of 7-EBA, were also detected. 7-MBA was found to bind covalently to microsomal protein at 10 times the level of 7-EBA. The covalent binding of benz[a]anthracene (BA), 7-EBA and 7-MBA to DNA in mouse skin following topical application was determined using the 32P-postlabelling assay. The results correlated with the relative carcinogenic activities of the compounds with 7-MBA binding at five and nine times the level of 7-EBA and BA respectively. For all three hydrocarbons, the major hydrocarbon: 32P-labelled nucleoside bisphosphate, eluted in the same area of the TLC maps, suggesting the involvement of a common type of bay-region dihydrodiol-epoxide intermediate.', 'For more Metabolism/Metabolites (Complete) data for 7-Methylbenz(a)anthracene (13 total), please visit the HSDB record page.']",
7347,17348,"2,3,4,5,6-Pentachlorobiphenyl",C1=CC=C(C=C1)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
7348,17349,"2,4,5-T butoxyethyl ester",CCCCOCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,"['IN SHEEP GIVEN ORAL DOSE OF 25 MG/KG OF 2,4,5-T ESTER PEAK PLASMA CONCN OF 10 PPM ... FOUND 3-4 HR LATER; 86% OF ADMIN DOSE WAS RECOVERED FROM URINE IN UNALTERED FORM, & 1.4% AS FREE ACID, WITHIN 72 HR. THERE WAS LESS THAN 0.1 PPM OF 2,4,5-T IN TISSUES, BUT IN SHEEP POISONED BY REPEATED DOSES OF 2,4,5-T TISSUE LEVELS WERE 368 PPM. /2,4,5-T ESTERS/', 'The chlorophenoxy compounds are absorbed across the gut wall, lung, and skin. They are not significantly fat storable. Excretion occurs almost entirely by way of the urine. /Chlorophenoxy herbicides/']",['CHLOROPHENOXY CMPD ... ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED ... . /CHLOROPHENOXY HERBICIDES/'],['THESE HERBICIDES /CHLOROPHENOXY CMPD/ DO NOT ACCUM IN ANIMALS. ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY HERBICIDES/']
7349,17350,CID 17350,C1(=C(C(=NC(=C1Cl)Cl)C(=O)[O-])Cl)N.[K+],,,,,,
7350,17351,Tetradecyl methacrylate,CCCCCCCCCCCCCCOC(=O)C(=C)C,,,,,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme A derivative, which then enters the normal lipid metabolism. /Methacrylates/', 'Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Acrylates and Methacrylates/']",
7351,17352,2-Ethylaziridine,CCC1CN1,,,,,,
7352,17353,4-(2-Ethylhexyloxy)-2-hydroxybenzophenone,CCCCC(CC)COC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,,,,,,
7353,17354,"cis-1,4-Bis(aminomethyl)cyclohexane",C1CC(CCC1CN)CN,,,,,,
7354,17355,Benzylacetone,CC(=O)CCC1=CC=CC=C1,,,,,,
7355,17356,Dicyclohexyl disulfide,C1CCC(CC1)SSC2CCCCC2,,,,,,
7356,17357,Chlorbicyclen,C(C1C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)CCl)Cl,,,,,,
7357,17358,Sulfur hexafluoride,FS(F)(F)(F)(F)F,['Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border.  Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.'],"['Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended).  For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.']",,"['The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women).  After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.', 'The SF6 component of Lumason is eliminated via the lungs.', 'In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively.  Preferential distribution to the lung is likely responsible for these values.', 'SonoVue, is a new echo contrast agent based on stabilized sulfur hexafluoride (SF6) microbubbles ... The blood kinetics and pulmonary elimination of SF6 after intravenous bolus injection of two dosage levels (0.03 and 0.3 mL/kg) of SonoVue were evaluated in 12 healthy subjects (7 men, 5 women). In addition, safety and tolerability were evaluated by monitoring vital signs, adverse effects, discomfort, and physical examination and laboratory parameters associated with the SonoVue injection. The blood kinetics of SF6 was not dose dependent. SF6 was rapidly removed from the blood by the pulmonary route, with 40% to 50% of the injected dose eliminated within the first minute after administration and 80% to 90% eliminated by 11 minutes after administration; the elimination was similar in men and women and independent of dose. Both dosages were well tolerated. No adverse effects were observed immediately or during the 24-hour follow-up period. ... The route of SF6 elimination was by means of the lungs in the expired air. ...', 'Sonovue (trade mark) is a new echo contrast agent made of microbubbles stabilized by phospholipids and containing sulphur hexafluoride (SF6), an innocuous gas. ... With regard to the gas contained in the bubbles, its pharmacokinetics have been assessed during a study in human volunteers. Following intravenous administration of 0.3 mL/kg of SonoVue (trade mark) (i.e., approximately ten times the imaging dose), the blood level curve showed a distribution half-life of about 1 minute and an elimination half-life of about 6 minutes. More than 80% of the administered gas is exhaled via the lungs after 11 minutes. ...', 'The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses. The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.) The area-under-the-curve of SF6 was dose-proportional over the dose range studied.', 'In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.', 'For more Absorption, Distribution and Excretion (Complete) data for SULFUR HEXAFLUORIDE (6 total), please visit the HSDB record page.']","['SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.', 'SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.', 'Under brief and prolonged exposures, sulfur hexafluoride was biologically inert and did not metabolize.']","['The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)', 'The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason... The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.) The area-under-the-curve of SF6 was dose-proportional over the dose range studied.', '... Following intravenous administration of 0.3 mL/kg of SonoVue (trade mark) (i.e., approximately ten times the imaging dose), the blood level curve showed a distribution half-life of about 1 minute and an elimination half-life of about 6 minutes. ...', 'In a study of patients with pulmonary impairment, blood concentrations of SF6 peaked at 1 to 4 minutes following Lumason administration. The cumulative recovery of SF6 in expired air was 102 +/- 18% (mean +/- standard deviation), and the terminal half-life of SF6 in blood was similar to that measured in healthy subjects.']"
7358,17359,CID 17359,C1=CC=C(C=C1)CN=C([NH3+])N.OS(=O)(=O)[O-],,,,,,
7359,17360,"N,N,N-Triethyl-2-[4-(2-phenylethenyl)phenoxy]ethanaminium iodide",CC[N+](CC)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2.[I-],,,,,,
7360,17361,"N,N,N-Triethyl-2-[4-(2-phenylethenyl)phenoxy]ethan-1-aminium",CC[N+](CC)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2,,,,,,
7361,17362,"6,8-Dioxa-2-thiaspiro(3.5)nonane, 7-phenyl-",C1C2(COC(O1)C3=CC=CC=C3)CSC2,,,,,,
7362,17363,"4,6-Dimethyloctanoic acid",CCC(C)CC(C)CCC(=O)O,,,,,,
7363,17364,CID 17364,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C(=O)C,,,,,,
7364,17365,Ethyl phenoxyacetate,CCOC(=O)COC1=CC=CC=C1,,,,,,
7365,17366,"Vanillic acid, 5-(4-carboxy-2-methoxyphenoxy)-",COC1=C(C=CC(=C1)C(=O)O)OC2=CC(=CC(=C2O)OC)C(=O)O,,,,,,
7366,17367,"1,4-Diisocyanatocyclohexane",C1CC(CCC1N=C=O)N=C=O,,,,,,
7367,17368,"Disulfide, bis(dipropylthiocarbamoyl)",CCCN(CCC)C(=S)SSC(=S)N(CCC)CCC,,,,,,
7368,17369,N-Methylcaprolactam,CN1CCCCCC1=O,,,,,,
7369,17370,"1H-Indole-3-ethanamine, N,N-diethyl-6-fluoro-, monohydrochloride",CCN(CC)CCC1=CNC2=C1C=CC(=C2)F.Cl,,,,,,
7370,17371,"6-Fluoro-N,N-diethyltryptamine",CCN(CC)CCC1=CNC2=C1C=CC(=C2)F,,,,,,
7371,17372,CID 17372,C12=C(NC(=NC1=NC(=N2)Cl)Cl)Cl,,,,,,
7372,17373,Trichloroacetanilide,C1=CC=C(C=C1)NC(=O)C(Cl)(Cl)Cl,,,,,,
7373,17374,N-(4-Bromophenyl)-2-chloroacetamide,C1=CC(=CC=C1NC(=O)CCl)Br,,,,,,
7374,17375,"7,12-Dihydroxymethylbenz(a)anthracene",C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C(=C32)CO)CO,,,,,,
7375,17376,"Barbituric acid, 5-allyl-",C=CCC1C(=O)NC(=O)NC1=O,,,,,,
7376,17377,3-Hydroxy-2-methylpropanenitrile,CC(CO)C#N,,,,,,
7377,17378,"1,1,3-Trichloropropene",C(C=C(Cl)Cl)Cl,,,,,,
7378,17379,Dibutoxymethane,CCCCOCOCCCC,,,,,,
7379,17380,"Methane, di-sec-butoxy-",CCC(C)OCOC(C)CC,,,,,,
7380,17381,"2-Ethyl-1,3-dioxolane",CCC1OCCO1,,,,,,
7381,17382,"2-(2,4-Dichlorophenoxy)-2-oxoethanolate;tris(1-hydroxyethyl)azanium",CC([NH+](C(C)O)C(C)O)O.C1=CC(=C(C=C1Cl)Cl)OC(=O)C[O-],,,,,,
7382,17383,Nitrilotri-2-ethanol,CC(N(C(C)O)C(C)O)O,,,,,,
7383,17384,"(2,4-Dichlorophenyl) 2-hydroxyacetate",C1=CC(=C(C=C1Cl)Cl)OC(=O)CO,,,,,,
7384,17385,"Pyridine, 4-(phenylazo)-",C1=CC=C(C=C1)N=NC2=CC=NC=C2,,,,,,
7385,17386,Pentadecylamine,CCCCCCCCCCCCCCCN,,,,,,
7386,17387,Coronopolin,C[C@H]1CC[C@@H]2[C@H]([C@]3([C@@]1(CCC3=O)O)C)OC(=O)C2=C,,,,,,
7387,17388,"1-Octadecanamine, N,N-dimethyl-, N-oxide",CCCCCCCCCCCCCCCCCC[N+](C)(C)[O-],,,,,,
7388,17389,Phenylacetic acid 2-(diethylamino)ethyl ester,CCN(CC)CCOC(=O)CC1=CC=CC=C1,,,,,,
7389,17390,"Benzoic acid, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C1=CC=CC=C1,,,,,,
7390,17391,"6-chloro-N,N'-bis(4-chlorophenyl)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)Cl)NC3=CC=C(C=C3)Cl)Cl,,,,,,
7391,17392,alpha-(2-(N-Benzyl-N-methylamino)ethyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CC(C)C(CCN(C)CC1=CC=CC=C1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
7392,17393,alpha-(2-(N-Ethyl-N-methylamino)ethyl)-1-naphthaleneacetonitrile,CCN(C)CCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
7393,17394,alpha-(2-(Diethylamino)ethyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CCN(CC)CCC(C#N)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
7394,17395,alpha-(2-(Diethylamino)ethyl)-1-naphthaleneacetonitrile,CCN(CC)CCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
7395,17396,alpha-(2-Morpholinoethyl)-1-naphthaleneacetonitrile,C1COCCN1CCC(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
7396,17397,"1-NAPHTHALENEACETONITRILE, alpha-ISOPROPYL-alpha-(2-PIPERIDINOETHYL)-",CC(C)C(CCN1CCCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
7397,17398,alpha-(2-(Dimethylamino)ethyl)-alpha-methyl-1-naphthaleneacetonitrile,CC(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
7398,17399,Methyl 9-oxodecanoate,CC(=O)CCCCCCCC(=O)OC,,,,,,
7399,17400,"Ammonium, oxydiethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCOCC[N+](C)(C)C.[I-].[I-],,,,,,
7400,17401,"N,N,N-trimethyl-2-[2-(trimethylammonio)ethoxy]-1-ethanaminium",C[N+](C)(C)CCOCC[N+](C)(C)C,,,,,,
7401,17402,2-Bromoethylammonium bromide,C(CBr)[NH3+].[Br-],,,,,,
7402,17403,"5-Amino-2-(1,3,4-oxadiazol-2-yl)phenol",C1=CC(=C(C=C1N)O)C2=NN=CO2,,,,,,
7403,17404,Metabromsalan,C1=CC=C(C=C1)NC(=O)C2=C(C(=CC(=C2)Br)Br)O,,,,,,
7404,17405,"N-(5-(5-Nitro-2-furanyl)-1,3,4-thiadiazol-2-yl)acetamide",CC(=O)NC1=NN=C(S1)C2=CC=C(O2)[N+](=O)[O-],,,,,,
7405,17406,"1,3-Cyclohexanedimethanamine",C1CC(CC(C1)CN)CN,,,,,,
7406,17407,Basic blue 26,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[NH+]C3=CC=CC=C3)C4=CC=CC=C24)C5=CC=C(C=C5)N(C)C.[Cl-],,,,,,
7407,17408,"4-[[4-(dimethylamino)phenyl]-(4-phenyliminonaphthalen-1-ylidene)methyl]-N,N-dimethylaniline",CN(C)C1=CC=C(C=C1)C(=C2C=CC(=NC3=CC=CC=C3)C4=CC=CC=C24)C5=CC=C(C=C5)N(C)C,,,,,,
7408,17409,Reactive Blue 19,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=CC=C4)S(=O)(=O)CCOS(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7409,17410,"2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-((3-((2-(sulfooxy)ethyl)sulfonyl)phenyl)amino)-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=CC=C4)S(=O)(=O)CCOS(=O)(=O)O)S(=O)(=O)O)N,,,,,,
7410,17411,ISOAPO-beta-ERYTHROIDINE,C1CN2CCC3=C2C(=CC=C3)C4=CC(=O)OCC41,,,,,,
7411,17412,3-Methyl-4-nitrophenol,CC1=C(C=CC(=C1)O)[N+](=O)[O-],,,,,,
7412,17413,"5,5'-Methylenedi-2,3-cresotic acid",CC1=CC(=CC(=C1O)C(=O)O)CC2=CC(=C(C(=C2)C)O)C(=O)O,,,,,,
7413,17414,Disperse Orange 1,C1=CC=C(C=C1)NC2=CC=C(C=C2)N=NC3=CC=C(C=C3)[N+](=O)[O-],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7414,17415,(2-Benzothiazolyl)-guanidine,C1=CC=C2C(=C1)N=C(S2)N=C(N)N,,,,,,
7415,17416,CID 17416,CC1(C(=NC(N1)(C)C)S)C,,,,,,
7416,17417,"Disodium 5-((4'-((2,6-diamino-3-methyl-5-((4-sulphonatophenyl)azo)phenyl)azo)(1,1'-biphenyl)-4-yl)azo)salicylate",CC1=CC(=C(C(=C1N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)[O-])N)N=NC5=CC=C(C=C5)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7417,17418,C.I. Direct Brown 1A,CC1=CC(=C(C(=C1N)N=NC2=CC=C(C=C2)C3=CC=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)O)N)N=NC5=CC=C(C=C5)S(=O)(=O)O,,,,,,
7418,17419,Direct Violet R,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=CC4=C(C=CC(=C43)O)S(=O)(=O)[O-])N)N=NC5=C(C=CC6=C(C=CC(=C65)O)S(=O)(=O)[O-])N.[Na+].[Na+],,,,,,
7419,17420,6-Amino-5-[[4-[4-[(2-amino-8-hydroxy-5-sulfonaphthalen-1-yl)diazenyl]phenyl]phenyl]diazenyl]-4-hydroxynaphthalene-1-sulfonic acid,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C=CC4=C(C=CC(=C43)O)S(=O)(=O)O)N)N=NC5=C(C=CC6=C(C=CC(=C65)O)S(=O)(=O)O)N,,,,,,
7420,17421,CID 17421,CCCC[GeH](CCCC)CCCC.CCCC[GeH](CCCC)CCCC.O,,,,,,
7421,17422,Tributylgermane,CCCC[GeH](CCCC)CCCC,,,,,,
7422,17423,Demephion-S,COP(=O)(OC)SCCSC,,,,,,
7423,17424,Phorate sulfoxide,CCOP(=S)(OCC)SCS(=O)CC,,,,,['Phorate sulfoxide is a known human metabolite of Phorate.'],
7424,17425,Phorate sulfone,CCOP(=S)(OCC)SCS(=O)(=O)CC,,,,,,
7425,17426,Phoratoxon sulfoxide,CCOP(=O)(OCC)SCS(=O)CC,,,,,,
7426,17427,Phoratoxon sulfone,CCOP(=O)(OCC)SCS(=O)(=O)CC,,,,,,
7427,17428,"Benzothiazole, ethylsulfonyl-",CCS(=O)(=O)C1=NC2=CC=CC=C2S1,,,,,,
7428,17429,N-Formylpiperidine,C1CCN(CC1)C=O,,,,,,
7429,17430,p-((p-Methoxyphenyl)azo)aniline,COC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,,,,,,
7430,17431,CID 17431,C1=CC=C(C(=C1)C(=O)N)[O-].[Na+],,,,,,
7431,17432,Etridiazole,CCOC1=NC(=NS1)C(Cl)(Cl)Cl,,,,,"['Etridiazole, 5-ethoxy-3-trichloromethyl-1,2,4-thiadiazole, was orally administered to rats and human volunteers. Two metabolites of etridiazole were synthesized: 5-ethoxy-1,2,4-thiadiazole-3-carboxylic acid (ET-CA) and N-acetyl-S-(5-ethoxy-1,2,4-thiadiazol-3-yl-methyl)-L-cysteine (ET-MA). Selective and sensitive analytical procedures to determine etridiazole, the carboxylic acid ET-CA and the mercapturic acid ET-MA in urine were developed. The detection limit of etridiazole, applying GC with nitrogen selective detection (GC-NPD), was 36 micrograms/l urine (CV = 15.4%, n = 3). The detection limit of ET-CA, applying GC with sulphur selective detection (GC-FPD), was 100 micrograms/l urine (CV = 9.8%, n = 3). In urine of rats orally treated with etridiazole, ET-CA and ET-MA were identified as metabolites of etridiazole, whereas in urine of humans given oral etridiazole, only ET-CA was identified. Unmetabolized etridiazole was excreted for less than 0.1% of the administered dose in rats. ET-CA, however, accounted for 22 +/- 9% of the administered dose of etridiazole in rats and for 13 +/- 6% in humans. ET-MA appeared to be a minor urinary metabolite of etridiazole. ET-CA is proposed as a possible biomarker for the biological monitoring of etridiazole.']",
7432,17433,Ethyl isopropylcarbamate,CCOC(=O)NC(C)C,,,,,,
7433,17434,Mecarbam,CCOC(=O)N(C)C(=O)CSP(=S)(OCC)OCC,,,,"['Following single oral doses of (14)C mecarbam to rats, tissue levels were highest in the liver and kidneys; some label was still found in the stomach up to 48 hr after administration. In rats given radiolabeled mecarbam iv, residues declined most rapidly during the first 40 min after administration; removal from the blood was nearly complete in 6 hr. Rats given single oral doses of radiolabeled mecarbam eliminated about 80-92% of the dose in the urine, 2-3% in the feces, and 0.2-5% as exhaled (14)CO2 within 48 hr. Urinary radioactivity was associated mainly with seven major polar metabolites; little or no unchanged mecarbam was found in the urine. Mecarbam in the diet of cows for days at 10 ppm was excreted in the milk at levels not exceeding 10 ppm.', ""- A suicidal poisoning committed by a 19-year-old pregnant woman, who ingested an unknown quantity of an aqueous solution mecarbam (trade name includes Murfotox) containing 68 g/l of S-(N-ethoxycarbonyl-N-methylcarbamoyl methyl) O,O-diethyl phosphorodithioate (CR Worthing (Ed), The Pesticide Manual, 6th end, BCPC, 1980) is described. The pesticide crossed the placental Barrier and caused the death of the fetus. Toxicologic analysis of mecarbam in several tissues and fluids of mother-fetus revealed its distribution. The analysis was performed by thin-layer chromatography and gas-1iquid chromatography. The case described serves to point out the ease with which mecarbam crossed the placental barrier, its high concentration in the lungs and the considerably higher concentrations in fetal than in mother's tissues.""]","['Rats metabolized mecarbam primarily by hydrolysis, oxidative desulfuration and degradation of the carbamoyl moiety; O-deethylation was a minor pathway. At least 10 nonconjugated metabolites and 1 conjugate were found in the urine, but little or no unchanged mecarbam. Mecarbam orally administered to a lactating goat was metabolized mainly at the carbamoyl moiety, with minor O-deethylation; at least 6 nonconjugated metabolites appeared in the urine.']",
7434,17435,Phenthoate,CCOC(=O)C(C1=CC=CC=C1)SP(=S)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'Following their absorption, most organophosphorus cmpd are excreted almost entirely as hydrolysis products in the urine. /Anticholinesterase agents/', 'For more Absorption, Distribution and Excretion (Complete) data for PHENTHOATE (6 total), please visit the HSDB record page.']","['ELSAN DEGRADED RAPIDLY IN /CABBAGE SEEDLING, STRAWBERRY & APPLE FRUIT/ ... & WAS HYDROLYZED TO NON-TOXIC DERIVATIVES. MAIN METABOLITES ... WERE ELSAN CARBOXY DERIVATIVES, MANDELIC ACID & BIS(CARBETHOXYBENZYL)DISULFIDE.', 'MAJOR URINARY METABOLITES /OF PHENTHOATE IN MICE/ @ DOSAGE OF 30 MG/KG WERE THE O-DEMETHYLATED ACID (25.8%), THE O-DEMETHYLATED OXON ACID (18.4%) & DIMETHYL PHOSPHORODITHIONATE (16.9%). INITIAL PRODUCT OF P-S CLEAVAGE ... WAS FURTHER METABOLIZED INTO CORRESPONDING SULFIDE, MANDELIC ACID, & S-METHYLATED DERIV.', 'In plants, there is oxidation to the thiophosphate, followed by hydrolysis. Identified metabolites are phosphoric acid, dimethyl and monomethyl phosphate.', 'Five metabolites were detected in the plasma and urine of a patient following ingestion of the organophosphate insecticide, phenthoate. Intact phenthoate was detected only in gastric lavage fluid. After methylation of acidic extracts of plasma and urine, phenthoate acid, demethyl phenthoate, demethyl phenthoate oxon acid, demethyl phenthoate S-isomer, and demethyl phenthoate acid S-isomer were identified with synthesized phenthoate analogues by gas chromatography and gas chromatograph-mass spectrometry. The main metabolites were phenthoate acid and demethyl phenthoate oxon acid. Although demethyl phenthoate oxon acid was a significant metabolite, no phenthoate oxon, phenthoate oxon acid or demethyl phenthoate oxon were detected. If the oxon was formed in the patient, it may have been rapidly degraded by carboxylesterase or glutathione transferase to demethyl phenthoate oxon acid.', 'For more Metabolism/Metabolites (Complete) data for PHENTHOATE (7 total), please visit the HSDB record page.']",
7435,17436,Acetylurethane,CCOC(=O)NC(=O)C,,,,,,
7436,17437,Ethylmercurichlorendimide,CC[Hg]N1C(=O)C2C(C1=O)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7437,17438,Chlorendic imide,C12C(C(=O)NC1=O)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
7438,17439,"(2,3-Dihydroxypropylthio)methylmercury",C[Hg]SCC(CO)O,,,,,,
7439,17440,Methylmercury cyanide,C[Hg]C#N,,,,,,
7440,17441,"HYDRAZINE, 1-(o-METHYLPHENETHYL)-, SULFATE (1:1)",CC1=CC=CC=C1CCN[NH3+].OS(=O)(=O)[O-],,,,,,
7441,17442,"HYDRAZINE, (o-METHYLPHENETHYL)-",CC1=CC=CC=C1CCNN,,,,,,
7442,17443,"HYDRAZINE, 1-(o-METHOXYPHENETHYL)-, SULFATE (1:1)",COC1=CC=CC=C1CCN[NH3+].OS(=O)(=O)[O-],,,,,,
7443,17444,o-Methoxyphenelzine,COC1=CC=CC=C1CCNN,,,,,,
7444,17445,1-(2-(o-Methylphenoxy)ethyl)hydrazine hydrogen sulfate,CC1=CC=CC=C1OCCN[NH3+].OS(=O)(=O)[O-],,,,,,
7445,17446,(2-(o-Tolyloxy)ethyl)hydrazine,CC1=CC=CC=C1OCCNN,,,,,,
7446,17447,1-(alpha-Methylphenethyl)-2-phenethylhydrazine,CC(CC1=CC=CC=C1)NNCCC2=CC=CC=C2,,,,,,
7447,17448,CID 17448,CCNC1=NC(=O)N=C(N1)NCC,,,,,,
7448,17449,C.I. Direct Blue 6,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+],,,,"['Rhesus monkeys excreted an average of 1.25% benzidine plus monoacetylbenzidine of the benzidine moiety in Direct Blue 6 in the urine after receiving two different doses by gavage, whereas gavage with pure benzidine yielded 1.45%.']","['Benzidine derived azo dyes may be degraded metabolically in the gut or liver in man to free benzidine or monoacetylbenzidine. /Benzidine derived azo dyes/', 'Environmental and urine samples were collected at six factories where workers were potentially exposed to benzidine based dyes (two benzidine based dye manufacturers, two textile dyeing plants, a leather dyeing plant and a mill where paper was dyed). Monoacetylbenzidine was detected in the urine of 2/8 workers at one of the dye manufacturing plants at levels of 3 and 7 ppb. At the second factory, 4 workers exposed to average levels of 7.9, 5.2, 11.7 and 17.4 mg total particulate/cu m had corresponding urinary concentrations of 52, 11, 10 and 112 ppb benzidine; 590, 248 and 22 ppb monoacetylbenzidine were detected in urine samples containing 112, 52 and 11 ppb benzidine. Traces of diacetylbenzidine, ortho-tolidine and ortho-dianisidine were also detected. Benzidine (0-39 ppb) and/or monoacetylbenzidine was detected in the urine of workers in one textile dyeing factory where Direct Black 38 and Direct Blue 2 were being used. The total level of airborne particulates (measured gravimetrically) was 1-4 mg/cu m. Benzidine was not detected in the urine of workers from the other facilities. Minute levels of impurities in the dyestuffs could not account for the quantity of benzidine and its derivatives that were found in the urine samples.', ""Six azodyes derived from benzidine, o-tolidine or o-dianisidine were separately administered orally by gavage to rats. Urine was collected over a 24 hr period. All six dyes, direct black 38, direct brown 95, direct blue 6, Congo red, trypan blue and Chicago sky blue were found to be reduced, N-acetylated and N-conjugated. However, no N,N'-diacetylated metabolites were detected. After administration of the same dyes via injection into the hepatic portal vein, bile was collected over a 3 hr period by cannulation of the bile duct. Urine was withdrawn from the bladder by syringe at the end of the three hours. Both body fluids were analyzed for reduction products which were found only in the case of direct black 38, direct brown 95 and direct blue 6. Of the six dyes examined only the three direct dyes were mutagenic to S. typhimurium strains TA98 and TA1538 in the absence of flavin mononucleotide. The same three dyes were also substrates for rat liver microsomal azoreductase enzymes whereas Congo red, trypan blue and Chicago sky blue were shown to be inactive."", 'The azo reduction and acetylation in vitro and the mutagenic activation in vivo of three azo dyes were studied. In the presence of rat-liver 9000 g supernatant benzidine was released from direct black 38 and direct brown 95, whereas hardly any benzidine was produced during incubation of direct blue 6. Incubation of benzidine with isolated rat hepatocytes resulted in the appearance of diacetylbenzidine. No diacetylbenzidine was formed during incubation of benzidine with rat-liver 9000 g supernatant, unless the cofactor for the acetylation reaction, acetyl coenzyme A, was added to the incubation medium. Isolated rat hepatocytes were capable to produce diacetylbenzidine from direct black 38, direct blue 6 or direct brown 95 without supplementation with acetyl coenzyme A. Rat liver has a considerable capacity to reduce azo compounds.']",
7449,17450,"3,3'-[[1,1'-Biphenyl]-4,4'-diylbis(diazene-2,1-diyl)]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid)",C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)N)O)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)O)S(=O)(=O)O)N)O,,,,,,
7450,17451,Methyl phenylcarbamate,COC(=O)NC1=CC=CC=C1,,,,,,
7451,17452,"2,3,5,6-Tetramethylbenzoic acid",CC1=CC(=C(C(=C1C)C(=O)O)C)C,,,,,,
7452,17453,Methyl (triphenylphosphoranylidene)acetate,COC(=O)C=P(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7453,17454,2-Methylbenzo(c)phenanthrene,CC1=CC2=C(C=C1)C=CC3=C2C4=CC=CC=C4C=C3,,,,,,
7454,17455,"(6S,9R,16R)-6,9-difluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one",C[C@@H]1CC2C3C[C@@H](C4=CC(=O)C=CC4([C@]3(C(CC2(C1C(=O)CO)C)O)F)C)F,,,,,,
7455,17456,"BENZOTHIAZOLE, 5-CHLORO-2-(p-(2-(DIETHYLAMINO)ETHOXY)PHENYL)-, HYDROCHLORIDE",CC[NH+](CC)CCOC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl.[Cl-],,,,,,
7456,17457,Haletazole,CCN(CC)CCOC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl,,,,,,
7457,17458,Piposulfan,CS(=O)(=O)OCCC(=O)N1CCN(CC1)C(=O)CCOS(=O)(=O)C,,,,,,
7458,17459,"2,4-Pentadienal, 5-(4-nitrophenyl)-",C1=CC(=CC=C1C=CC=CC=O)[N+](=O)[O-],,,,,,
7459,17460,Chicago Sky Blue 6B,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])O)OC)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7460,17461,Direct Blue 1,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)OC)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7461,17462,Direct red 81,C1=CC=C(C=C1)C(=O)NC2=CC3=CC(=C(C(=C3C=C2)O)N=NC4=CC=C(C=C4)N=NC5=CC=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7462,17463,7-(Benzoylamino)-4-hydroxy-3-((4-((4-sulfophenyl)azo)phenyl)azo)-2-naphthalenesulfonic acid,C1=CC=C(C=C1)C(=O)NC2=CC3=CC(=C(C(=C3C=C2)O)N=NC4=CC=C(C=C4)N=NC5=CC=C(C=C5)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7463,17464,CID 17464,CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)[O-].[K+],,,,,,
7464,17465,"3-Cyclohexene-1-carboxylic acid, 3-cyclohexen-1-ylmethyl ester",C1CC(CC=C1)COC(=O)C2CCC=CC2,,,,,,
7465,17466,Ponceau 4R,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['THE BILIARY EXCRETION RATES OF NEW COCCINE 50-100 UMOLE ADMINISTERED IV TO RATS WITH LIGATED RENAL PEDICLES, REACHED APPARENT MAXIMA WHICH WERE DEPRESSED BY PHENOLPHTHALEIN GLUCURONIDE OR PROBENECID (BOTH 50 UMOLE). BILIARY EXCRETION MAY INVOLVE AN ACTIVE TRANSPORT PROCESS.']",,
7466,17467,"7-Hydroxy-8-[(4-sulphonaphthyl)azo]naphthalene-1,3-disulphonic acid",C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)O)S(=O)(=O)O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7467,17468,Clonitrate,C(C(CCl)O[N+](=O)[O-])O[N+](=O)[O-],,,,,,
7468,17469,"2-(Dichloromethyl)-1,3-dioxolane",C1COC(O1)C(Cl)Cl,,,,,,
7469,17470,"2,3-Dihydro-1,1,3-trimethyl-1H-indene",CC1CC(C2=CC=CC=C12)(C)C,,,,,,
7470,17471,4-Acetylphenyl ether,CC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C,,,,,,
7471,17472,Hexaethylene glycol,C(COCCOCCOCCOCCOCCO)O,"['Indicated as a lubricant in over-the-counter ophthalmic solutions to temporarily relieve redness, burning and irritation of the eyes.']","['PEGs act as nonionic surfactant to decrease surface tension and condition the stratum corneum, thus enhance the diffusion of other molecules or drugs through the skin.']",,"['PEGs can be absorbed by the gastrointestinal tract following oral administration with the fraction absorbed being dependent on the molecular weight of the compound. It is likely to display minimal absorption through the intact skin, but may penetrate through injured skin with compromised barrier function.', 'After oral and intravenous exposure, PEGs are excreted mainly unchanged in the urine and faeces.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.']","['Proportion of absorbed PEGs may be metabolized to lower oligomers, glycolic acid, hydroxyglycolic acids and the diglycolic acids homologs, carbon dioxide that is exhaled, and to a minor extent, oxalic acid.']",['No pharmacokinetic data available.']
7472,17473,Uridine diphosphate glucuronic acid,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)O)O,,,,,,
7473,17474,N-(4-Bromophenyl)formamide,C1=CC(=CC=C1NC=O)Br,,,,,,
7474,17475,N-(4-Chlorophenyl)formamide,C1=CC(=CC=C1NC=O)Cl,,,,,,
7475,17476,CID 17476,C(C(=O)[O-])N(C=O)O.[Na+],,,,,,
7476,17477,Ioglycamic Acid,C1=C(C(=C(C(=C1I)NC(=O)COCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
7477,17478,Iodipamide sodium,C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)[O-])I)I)I)C(=O)[O-])I.[Na+].[Na+],,,,,,
7478,17479,"Acetic acid, diphenyl-, 2-(dimethylamino)ethyl ester",CN(C)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7479,17480,"Acetamide, N-(2-(diethylamino)ethyl)-2,2-diphenyl-",CCN(CC)CCNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7480,17481,1-Naphthyl dimethylcarbamate,CN(C)C(=O)OC1=CC=CC2=CC=CC=C21,,,,,,
7481,17482,"Benzoic acid, 2-(2-methyl-4-oxo-3(4H)-quinazolinyl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C.[Cl-],,,,,,
7482,17483,2-(Diethylamino)ethyl 2-(2-methyl-4-oxoquinazolin-3-yl)benzoate,CCN(CC)CCOC(=O)C1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C,,,,,,
7483,17484,"Benzoic acid, 3-methyl-2-(2-methyl-4-oxo-3(4H)-quinazolinyl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC=CC(=C1N2C(=NC3=CC=CC=C3C2=O)C)C.[Cl-],,,,,,
7484,17485,2-(Diethylamino)ethyl 3-methyl-2-(2-methyl-4-oxoquinazolin-3-yl)benzoate,CCN(CC)CCOC(=O)C1=CC=CC(=C1N2C(=NC3=CC=CC=C3C2=O)C)C,,,,,,
7485,17486,"Benzoic acid, 4-methyl-3-(2-methyl-4-oxo-3(4H)-quinazolinyl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)C)N2C(=NC3=CC=CC=C3C2=O)C.[Cl-],,,,,,
7486,17487,2-(Diethylamino)ethyl 4-methyl-2-(2-methyl-4-oxoquinazolin-3-yl)benzoate,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)C)N2C(=NC3=CC=CC=C3C2=O)C,,,,,,
7487,17488,"N,N-Bis(2-chloroethyl)glycine hydrochloride",C(CCl)[NH+](CCCl)CC(=O)O.[Cl-],,,,,,
7488,17489,"Glycine, N,N-bis(2-chloroethyl)-",C(CCl)N(CCCl)CC(=O)O,,,,,,
7489,17490,"Acetamide, N,N'-ethylenebis(chloro-",C(CNC(=O)CCl)NC(=O)CCl,,,,,,
7490,17491,4-Chlorophenyl methylcarbamate,CNC(=O)OC1=CC=C(C=C1)Cl,,,,,,
7491,17492,"2,2'-Dithiobis(N-butylbenzamide)",CCCCNC(=O)C1=CC=CC=C1SSC2=CC=CC=C2C(=O)NCCCC,,,,,,
7492,17493,"Benzene, 1-chloro-4-(1-methylethyl)-",CC(C)C1=CC=C(C=C1)Cl,,,,,,
7493,17494,"2',5'-Dichloroacetanilide",CC(=O)NC1=C(C=CC(=C1)Cl)Cl,,,,,,
7494,17495,"2,5-Dichlorocarbanilic acid ethyl ester",CCOC(=O)NC1=C(C=CC(=C1)Cl)Cl,,,,,,
7495,17496,Ethyl N-(4-chlorophenyl)carbamate,CCOC(=O)NC1=CC=C(C=C1)Cl,,,,,,
7496,17497,Vinylcyclohexene,C=CC1=CCCCC1,,,,,,
7497,17498,Diphenylborinic acid,B(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
7498,17499,Diacetamate,CC(=O)NC1=CC=C(C=C1)OC(=O)C,,,,,,
7499,17500,CID 17500,C1=CC(=CC=C1N=NC2=CC=C(C=C2)S(=O)(=O)[O-])O.[Na+],,,,,,
7500,17501,4-[(4-Hydroxyphenyl)diazenyl]benzenesulfonic acid,C1=CC(=CC=C1N=NC2=CC=C(C=C2)S(=O)(=O)O)O,,,,,,
7501,17502,"5,8-Dimethylquinoline",CC1=C2C=CC=NC2=C(C=C1)C,,,,,,
7502,17503,2-Bromoheptanoic acid,CCCCCC(C(=O)O)Br,,,,,,
7503,17504,CID 17504,C1(=O)NC(=NC(=O)N1)[O-].[Na+],,,,,,
7504,17505,CID 17505,CCCCCCCCCCCCCCCC(=O)[O-].[K+],,,,,,
7505,17506,Etamsylate,CCNCC.C1=CC(=C(C=C1O)S(=O)(=O)O)O,,,['Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)'],,,
7506,17507,"2,5-Dihydroxybenzenesulfonic Acid",C1=CC(=C(C=C1O)S(=O)(=O)O)O,,,['Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)'],,,
7507,17508,CID 17508,CCN(CCOS(=O)(=O)[O-])S(=O)(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F.[Na+],,,,,,
7508,17509,Mono(N-ethyl-2-perfluorooctylsulfonaminoethyl)hydrogen sulfate,CCN(CCOS(=O)(=O)O)S(=O)(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
7509,17510,"5H-DIBENZO(a,d)CYCLOHEPTEN-5-OL, 10,11-DIHYDRO-5-(3-MORPHOLINOPROPYL)-",C1CC2=CC=CC=C2C(C3=CC=CC=C31)(CCCN4CCOCC4)O,,,,,,
7510,17511,"10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenzo(a,d)cyclohepten-5-ol",CC(CC1(C2=CC=CC=C2CCC3=CC=CC=C31)O)CN(C)C,,,,,,
7511,17512,CID 17512,CCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
7512,17513,Acadesine,C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N,"['Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.']","['Acadesine has been shown to induce cell death apoptosis selectively in B-cells taken from healthy subjects and patients with B-CLL, with little effect on T-cells. As T-cells have an important role in fighting infection, it is anticipated that patients treated with acadesine will have a reduced risk of serious infections compared to those on current chemotherapies.']",,,,['1 week']
7513,17514,N-Ethylammelide,CCNC1=NC(=O)NC(=O)N1,,,,,,
7514,17515,"Carbamic acid, N-methyl-, 3-diethylaminophenyl ester",CCN(CC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
7515,17516,Promecarb,CC1=CC(=CC(=C1)OC(=O)NC)C(C)C,,,,"['... /CARBAMATE INSECTICIDES/ ARE RAPIDLY METABOLIZED, 80% OF DOSE BEING ELIMINATED IN URINE, MAINLY AS SULFATE OR GLUCURONIDE CONJUGATE, WITHIN 24 HR; 0.5 TO 1.5% IS FOUND IN FECES, 0.1 TO 1.0% IN THE MILK. /CARBAMATES/', 'In order to learn why cholinesterase remains inhibited longer in workers exposedto promecarb than in those exposed to propoxur, dogs were injected im or iv with approximately equitoxic doses of the compounds. It required 3 full days for cholinesterase activity to return to normal in a dog that received promecarb intramuscularly at a rate of 60 mg/kg, but recovery of cholinesterase activity was rapid after doses of propoxur sufficient to cause convulsions and marked ataxia. However, inhibition of cholinesterase activity was transient following intravenous administration of promecarb. It was concluded that prolonged inhibition of cholinesterase activity in days following im injection was the result of slow, continuing absorption and that, by extension, prolonged inhibition in workers has the same cause.', 'Penetration of the blood-brain barrier by the carbamates is insignificant; for this reason, fewer CNS symptoms occur. /Carbamate pesticides/']","['Promecarb was rapidly metabolized and eliminated when administered orally to rats. By 96 hours after administration, over 90% had been recovered from the urine and feces, mainly the former. Promecarb equivalent radioactivity in the tissues did not exceed 0.02 ppm.', '(5-(14)C)Promecarb was administered orally to male Sprague Dawley rats. Within 4 days, about 88% of the dose was eliminated in the urine. In addition to isothymol, there were unidentified metabolites. Hydrolysis with glucuronidase indicated the conjugation of isothymol with glucuronic acid. Other conjugates present were not identified.', 'Promecarb was applied to soil and then corn seedlings were planted. Analyses of stem and leaves of the plants indicated the presence of isothymol and four unidentified metabolites as early as 15 days after application.', 'Spontaneous hydrolysis of the carbamate-cholinesterase complex occurs in vivo, leading to the disappearance of clinical effects within 24 hr. /Carbamate pesticides/']",
7516,17517,Isoprocarb,CC(C)C1=CC=CC=C1OC(=O)NC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
7517,17518,"1,3,5-Trichloro-2,4,6-trinitrobenzene",C1(=C(C(=C(C(=C1Cl)[N+](=O)[O-])Cl)[N+](=O)[O-])Cl)[N+](=O)[O-],,,,,,
7518,17519,"O,O-Dimethyl 2-ethylmercaptoethyl thiophosphate",CCOP(=S)(OC)OC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
7519,17520,"1,2-Benzisothiazol-3(2H)-one",C1=CC=C2C(=C1)C(=O)NS2,,,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']","['A dermal penetration study was conducted in rats in which a 10mg/kg dermal dose of 1,2-benzisothiazolin-3-one was applied to the skin for durations of 4, 8, 24, 48 or 72 hours. At 72 hours a maximum dermal penetration of 40.6% was achieved.']",,
7520,17521,Methiocarb sulfoxide,CC1=CC(=CC(=C1S(=O)C)C)OC(=O)NC,,,,,,
7521,17522,Cyanophos,COP(=S)(OC)OC1=CC=C(C=C1)C#N,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'Following their absorption, most organophosphorus cmpd are excreted almost entirely as hydrolysis products in the urine. /Anticholinesterase agents/', 'For more Absorption, Distribution and Excretion (Complete) data for CYANOPHOS (7 total), please visit the HSDB record page.']","['Plasma and tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric and phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paraoxonases. These enzymes are found in the plasma and liver and hydrolyze a large number of organophosphorus compounds ... by cleaving the phosphoester, anhydride, P-F, or P-CN bonds. /Anticholinesterase agents/']",
7522,17523,CID 17523,C1=CC=NC(=C1)S,,,,,,
7523,17524,CID 17524,C1=CC=C2C(=C1)C=CC(=N2)S,,,,,,
7524,17525,Hexyl butyrate,CCCCCCOC(=O)CCC,,,,,,
7525,17526,Diisopropylphosphorylthiocholine iodide,CC(C)OP(=O)(OC(C)C)SCC[N+](C)(C)C.[I-],,,,,,
7526,17527,2-Di(propan-2-yloxy)phosphorylsulfanylethyl-trimethylazanium,CC(C)OP(=O)(OC(C)C)SCC[N+](C)(C)C,,,,,,
7527,17528,Diisopropoxyphosphorylcholine iodide,CC(C)OP(=O)(OCC[N+](C)(C)C)OC(C)C.[I-],,,,,,
7528,17529,2-Di(propan-2-yloxy)phosphoryloxyethyl-trimethylazanium,CC(C)OP(=O)(OCC[N+](C)(C)C)OC(C)C,,,,,,
7529,17530,CID 17530,C1=CC=C2C(=C1)C(=CN2)OS(=O)(=O)[O-].[K+],,,,,,
7530,17531,Azinphos-ethyl,CCOP(=S)(OCC)SCN1C(=O)C2=CC=CC=C2N=N1,,,,"['In mammals, following oral administration, >90% is eliminated in the urine and feces within 2 days.', '...Absorption of azinphos ethyl is possible through intact skin, from the GI tract, and by mist and dust inhalation.', 'Following oral and IV administration of 14C-labelled azinphos-ethyl to male rats in doses of 0.1 or 2 mg/kg bw, about 60% of the activity was excreted in urine and 30% in feces in 48 hours. Approximately 30% of a 2 mg/kg dose was eliminated in bile within 24 hours; <0.1% was eliminated in expired air, indicating that the benzotriazine ring does not undergo extensive degradation. Approximately 6% of activity was present in the body 48 hours after administration, the mean concentration in tissues being equivalent to 0.1 ppm. The highest equivalent concentration (0.2-0.3 ppm (0.00002%-0.00003%)) was found in blood and 0.15-0.2 ppm (0.000015%-0.00002%) was found in lungs, liver and kidneys.', 'Many of /the organophosphorus insecticides/ are excreted in the milk ... /Organophosphorus insecticides/']","['In plants, metabolites identified include azinphos-ethyl-oxon, benzazimide, dimethylbenzazimide sulfide and dimethylbenzazimide disulfide.', 'In mammals, following oral administration, ...the major metabolites are the monodesethyl compound and benzazimide.', 'Plasma and tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric and phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paraoxonases. These enzymes are found in the plasma and liver and hydrolyze a large number of organophosphorus compounds ... by cleaving the phosphoester, anhydride, P-F, or P-CN bonds. /Anticholinesterase agents/']",
7531,17532,"1,1-Bis(p-chlorophenyl)-2-chloroethane",C1=CC(=CC=C1C(CCl)C2=CC=C(C=C2)Cl)Cl,,,,"['In varying degrees, organochlorines are absorbed from the gut and also by the lung and across the skin. /Soild Organochlorines/']","['At 24 hr after injection into rainbow trout (Salmo gairdnerii) 2,2-bis(p-chlorophenyl)-1-chloroethane was metabolized at level of 0.5% to 1,1-bis(p-chlorophenyl)ethylene; the latter was not metabolized further.', ""Groups of 5 or 10 rainbow trout fry weighing approx 1 g were injected im with P,P'-DDMS, P,P'-DDNU, P,P'-DDMU. P,P'(14)C-DDMS was dehydrochlorinated to p,p'-DDMU. Second exposure did not confirm. P,P'-DDMU appears to be one of end products of DDT metabolism by trout."", 'In rats, DDD is rapidly detoxified by way of DDMU to 1-chloro-2,2-bis(p-chlorophenyl) ethane (DDMS) and then to DDNU. Metabolism of DDMS to DDNU occurs in both the liver and kidney, but the kidney is the primary site.', ""... Perfusion of isolated rat liver with p,p'-isomer of carbon labeled DDT, DDE, DDD, DDMU(1-chloro-bis(p- chlorophenyl)ethylene), or DDMS(1-chloro-2,2-bis(p- chlorophenyl)ethane), indicates that DDT is converted only as far as p, p'-DDNU(unsym-bis(p-chlorophenyl)ethylene) in this organ."", 'Principal products formed when DDT was incubated anaerobically with resting cell suspensions or cell-free preparations of Hydrogenomonas sp. included TDE, DDE, DBP (dichlorobenzophenone), and 1-chloro-2,2-bis(p-chlorophenyl)ethane. Addition of both fresh resting cells and oxygen to the reaction mixture resulted in the synthesis of p-chlorophenylacetic acid, demonstrating cleavage of a DDT ring by a single organism.']",
7532,17533,"2,2-Bis(4-chlorophenyl)ethanol",C1=CC(=CC=C1C(CO)C2=CC=C(C=C2)Cl)Cl,,,,,,
7533,17534,6-Chrysenamine,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)N,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,"['6-chrysenamine has known human metabolites that include 6-MeC-1,2-diol and N-Hydroxychrysene.']",
7534,17535,"3,4-Dichloroamphetamine",CC(CC1=CC(=C(C=C1)Cl)Cl)N,,,,,,
7535,17536,Oxypeucedanin hydrate,CC(C)([C@@H](COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O)O,,,,,,
7536,17537,"Glycine, N,N-dibutyl-, ethyl ester",CCCCN(CCCC)CC(=O)OCC,,,,,,
7537,17538,"Glycine, N,N-diisobutyl-, ethyl ester",CCOC(=O)CN(CC(C)C)CC(C)C,,,,,,
7538,17539,"Glycine, N,N-dihexyl-, ethyl ester",CCCCCCN(CCCCCC)CC(=O)OCC,,,,,,
7539,17540,"Glycine, N,N-dicyclohexyl-, ethyl ester",CCOC(=O)CN(C1CCCCC1)C2CCCCC2,,,,,,
7540,17541,"Glycine, N,N-diallyl-, ethyl ester",CCOC(=O)CN(CC=C)CC=C,,,,,,
7541,17542,2-(Dipropylamino)acetohydrazide,CCCN(CCC)CC(=O)NN,,,,,,
7542,17543,"Glycine, N,N-diisopropyl-, hydrazide",CC(C)N(CC(=O)NN)C(C)C,,,,,,
7543,17544,"Glycine, N,N-dibutyl-, hydrazide",CCCCN(CCCC)CC(=O)NN,,,,,,
7544,17545,"Glycine, N,N-diisobutyl-, hydrazide",CC(C)CN(CC(C)C)CC(=O)NN,,,,,,
7545,17546,"Glycine, N,N-dipentyl-, hydrazide",CCCCCN(CCCCC)CC(=O)NN,,,,,,
7546,17547,"Glycine, N,N-diisopentyl-, hydrazide",CC(C)CCN(CCC(C)C)CC(=O)NN,,,,,,
7547,17548,Hydrazine dihydrochloride,NN.Cl.Cl,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
7548,17549,4-Nitrohippuric acid,C1=CC(=CC=C1C(=O)NCC(=O)O)[N+](=O)[O-],,,,,,
7549,17550,Oil Orange ss,CC1=CC=CC=C1N=NC2=C(C=CC3=CC=CC=C32)O,,,,,"['The structure activity relationship of 40 azo compounds in their ability to induce cytochrome P448 and associated monooxygenase activities, and UDP-glucuronyltransferase activity was investigated. Only those lipophilic azo dyes with 1-azo-2-naphthol or 1-azo-2-naphthylamine moieties were able to induce cytochrome P448 and related monooxygenase activities and UDP-glucuronyltransferase activity.']",
7550,17551,CID 17551,C[C@@H](CCC(=O)[O-])[C@@H]1CC[C@H]2C1(CC[C@@H]3C2[C@H](CC4C3(CC[C@@H](C4)O)C)O)C.[Na+],,,,,,
7551,17552,CID 17552,C[C@@H](CCC(=O)O)C1CC[C@H]2C1(CC[C@@H]3C2[C@H](CC4C3(CC[C@@H](C4)O)C)O)C,,,,,,
7552,17553,(4-Hydroxy-3-iodo-5-nitrophenyl)acetic acid,C1=C(C=C(C(=C1[N+](=O)[O-])O)I)CC(=O)O,,,,,,
7553,17554,"3,3-Dichloroacrolein",C(=C(Cl)Cl)C=O,,,,,,
7554,17555,"1,1-Dichloro-2-hexanone",CCCCC(=O)C(Cl)Cl,,,,,,
7555,17556,"4,4-Dichloro-3-hexanone",CCC(=O)C(CC)(Cl)Cl,,,,,,
7556,17557,"2-[(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-1-yl)methyl]-3-ethyl-9,10-dimethoxy-1,4,5,6,7,11b-hexahydrobenzo[a]quinolizin-5-ium;dibromide",CCC1=C(CC2C3=CC(=C(C=C3CC[NH+]2C1)OC)OC)CC4C5=CC(=C(C=C5CC[NH2+]4)OC)OC.[Br-].[Br-],,,,,,
7557,17558,"Emetine, dehydro-",CCC1=C(CC2C3=CC(=C(C=C3CCN2C1)OC)OC)CC4C5=CC(=C(C=C5CCN4)OC)OC,,,,,,
7558,17559,C.I. Acid Blue 9,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[NH4+].[NH4+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['FOLLOWING ADMIN OF A SINGLE ORAL DOSE OF BRILLIANT BLUE FCF AT EITHER 30 MUG/KG OR 3 MG/KG TO MALE OR FEMALE RATS, SUBSTANTIALLY ALL OF THE DOSE WAS EXCRETED UNCHANGED IN FECES WITHIN 72 HR. PRETREATING MALE RATS WITH UNLABELED BRILLIANT BLUE FCF IN THE DIET (30 MG/KG/DAY) FOR 21 DAYS PRIOR TO DOSING WITH (14)C-LABELED COLORING HAD NO EFFECT ON ROUTE OF EXCRETION OR THE TIME TAKEN TO ELIMINATE ALL OF THE LABEL. SIMILARLY, MALE MICE & GUINEA PIGS EXCRETED IN THE FECES ALL OF A SINGLE ORAL DOSE OF BRILLIANT FCF. THE LACK OF ABSORPTION & METABOLISM OF THE LABELED DYE IN GI TRACT OF ALL 3 SPECIES INVESTIGATED WAS CONFIRMED BY STUDIES USING ISOLATED LOOPS OF SMALL INTESTINE. NO RADIOACTIVITY WAS TAKEN UP BY THE FETUSES OF PREGNANT RATS GIVEN (14)C-LABELED BRILLIANT BLUE FCF.']",,
7559,17560,Food Blue 1,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=CC=CC=C5S(=O)(=O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7560,17561,"1,2-Diphenylpyrazolidine-3,5-dione",C1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7561,17562,"N,N'-Bis(chloroacetyl)-p-phenylenediamine",C1=CC(=CC=C1NC(=O)CCl)NC(=O)CCl,,,,,,
7562,17563,"3,5-Xylyl methylcarbamate",CC1=CC(=CC(=C1)OC(=O)NC)C,,,,"['These compounds are rapidly metabolized, 80% of the dose being eliminated in the urine within 24 hours, 0.5-15% in the feces and 0.1-1.0% in the milk. /Carbamate insecticides/', 'Carbamate pesticides are absorbed from the skin, lungs, and GI tract and distributed throughout the body. They do not accumulate in any particular tissue. ... /Carbamate pesticides/']","['XMC was applied to the green rice leafhopper (Nephotettix cincticeps Uhler) and the smaller brown planthopper (Laodelphax striatellus Fallen). Penetration into the insect was rapid and about 10-12 metabolites were formed. Only the N-hydroxymethyl metabolite was identified.', 'In insects, metabolism mainly involves hydroxylation of the benzene ring and the ring methyl substituents.', '... Blood esterases would tend to inactivate a portion of the circulating carbamates. Liver microsomal enzymes break down the compounds within hours of exposure. Carbamates do not require activation by liver enzymes and therefore may be more hazardous for very young animals, in which hepatic degradative enzymes are deficient. Carbamates cross the rat placenta, depress fetal acetylcholinesterase, and are not readily metabolized in the fetus. ... /Carbamate pesticides/']",
7563,17564,Butacarb,CC(C)(C)C1=CC(=CC(=C1)OC(=O)NC)C(C)(C)C,,,,"['In vivo studies have shown that carbamates are almost completely absorbed during normal transit through the gastrointestinal tract. ...In mice, all carbamates were rapidly distributed to the tissues and organs. The half-life values of penetration ranged from 8-17 min for carbamates. ...In animals, oxidation of carbamates often, but not always, results in detoxification. Oxidative metabolism generally leads to products of greater polarity and water solubility, and these can be more readily eliminated through the urine and feces than the parent compound. /Carbamate pesticides/', 'Little information is available on the distribution of carbamates in the various organs and tissues in mammals following exposure by inhalation or the oral route. The organs in which residues have been reported are the liver, kidneys, brain, fat, and muscle. The half-life in the rat is of the order of 3-8 hr. It seems that the excretion of carbamates via urine is also rapid in man, and that the metabolic pathways in man are the same as those in the rat. /Carbamate pesticides/']","['When butacarb was incubated with mouse liver 10,000xg supernatant, eleven metabolites were detected. Hydrolysis produced only 6 phenols. One of these, the major metabolite, was identified as 3,5-di-tert-butylphenol. Other metabolites were characterized but not all were completely identified: two acid metabolites containing a carboxyl & carbamoyl group; two containing a carbamoyl & two hydroxy groups (but not dihydroxybenzenoid); a hydroxybutylphenol; one containing a carbamoyl & hydroxy group; two dihydroxybutylphenols; n-hydroxymethyl butacarb; & n-hydroxymethyl hydroxybutyl analog. Studies with housefly (musca domestica), blowfly (lucilia sericata) & grass grubs (costelytra zealandica) gave results quant similar to those with mouse liver enzymes.', ""...Butacarb.../is/ cleaved to phenolic products by enzyme system in liver microsomes, which requires nadph & is inhibited by carbon monoxide...it is likely that this...microsomal mono-oxygenation is very important in 'hydrolysis' of carbamates."", 'The principal route of metabolism of insecticidal carbamate esters is oxidative and is generally associated with the mixed-function oxidase (MFO) enzymes, which are present in several tissues. /Carbamate pesticides/', 'The metabolism of 3,5-di-tert-butylphenyl-N-methylcarbamate (butacarb) was studied in insects and mouse liver enzymes. Tritium (H-3) labeled butacarb was incubated with 10,000 times the force of gravity supernatants from mouse liver or housefly and blowfly enzyme preparations, obtained from their abdomens. The reaction mixtures were analyzed for metabolites. Eleven oxidation products were detected in each species. In-vivo, adult houseflies and blowflies were dosed topically with H-3 labeled butacarb. The insects were then extracted by grinding them with sand and ether. Ether extracts were examined for metabolites. The water soluble fraction was also examined. Both fractions consisted of complex mixtures. The ether fraction was hydrolyzed with sodium-hydroxide, and the water soluble portion was analyzed. Six phenolic metabolites were detected. The major phenolic product was 3,5-di-tert-butylphenol, which accounted for more than half of the dose.']",
7564,17565,Heptylhydrazine,CCCCCCCNN,,,,,,
7565,17566,"7-Oxo-8-[2-(4-sulfophenyl)hydrazinylidene]-7,8-dihydronaphthalene-1,3-disulfonic acid",C1=CC(=CC=C1N=NC2=C(C=CC3=CC(=CC(=C32)S(=O)(=O)O)S(=O)(=O)O)O)S(=O)(=O)O,,,,,,
7566,17567,2-Methyl-1-propanimine,CC(C)C=N,,,,,,
7567,17568,"9-Octadecenamide, N,N-dimethyl-",CCCCCCCCC=CCCCCCCCC(=O)N(C)C,,,,,,
7568,17569,Dodecyl 4-hydroxybenzoate,CCCCCCCCCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
7569,17570,"4,4'-Thiodiphenol",C1=CC(=CC=C1O)SC2=CC=C(C=C2)O,,,,,,
7570,17571,Colep,CP(=S)(OC1=CC=CC=C1)OC2=CC=C(C=C2)[N+](=O)[O-],,,,"['Phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. The transport of phosphate from the lumen of the gut is an active, energy-dependent process, and there are factors that appear to modify the degree of its intestinal absorption. ... Vitamin D stimulates phosphate absorption, and this effect has been reported to precede the action of the vitamin on transport of calcium ion. In general, in adults, about two thirds of the ingested phosphate is absorbed from the bowel, and that which is absorbed from the gut is almost entirely excreted into the urine. In growing children, there is a positive balance of phosphate. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/', 'Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for PHOSPHONOTHIOIC ACID, METHYL-, O-(4-NITROPHENYL) O-PHENYL ESTER (8 total), please visit the HSDB record page.']","['The biotransformation of COLEP is compatible with an analogous mechanism in plants, but the data for rats do not appear to be so firmly established. The phenolic metabolites, which occurred as glucosides in plants, were probably present as sulfates in the rats ... .', '... COLEP is metabolized in apple and in cotton plants to O-phenyl methylphosphonic acid, the oxygen analog O-phenyl O-(p-nitrophenyl) methyl-phosphonate, and various conjugates of phenol. Analysis of urine from orally treated rats showed only the presence of phenol conjugates.', 'Plasma & tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds.', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase. The enzymes are found in plasma and in the hepatic endoplasmic reticulum & can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond.', 'These chemicals are detoxified by cytochrome p450-mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/']",
7571,17572,"Phosphonic acid, (1-hydroxyethylidene)bis-, trisodium salt",CC(O)(P(=O)(O)[O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+],,,,,,
7572,17573,CID 17573,CC(=O)N(C)C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+],,,,,,
7573,17574,"4-[[4-(Acetylmethylamino)phenyl]amino]-1-amino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid",CC(=O)N(C)C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O,,,,,,
7574,17575,CID 17575,COC(=S)[S-].[K+],,,,,,
7575,17576,"Carbonodithioic acid, O-methyl ester",COC(=S)S,,,,,,
7576,17577,"4,5,6-Trichloroguaiacol",COC1=CC(=C(C(=C1O)Cl)Cl)Cl,,,,,,
7577,17578,"[1,1'-Biphenyl]-4-ol, 3,5-bis(1,1-dimethylethyl)-",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CC=CC=C2,,,,,,
7578,17579,"O,O-Diethyl O-naphthaloximide phosphorothioate",CCOP(=S)(OCC)ON1C(=O)C2=CC=CC3=C2C(=CC=C3)C1=O,,,,,,
7579,17580,Lythidathion,CCOC1=NN(C(=O)S1)CSP(=S)(OC)OC,,,,,,
7580,17581,Chloroneb,COC1=CC(=C(C=C1Cl)OC)Cl,,,,"['In varying degrees, organochlorines are absorbed from the gut and also by the lung and across the skin. /Solid Organochlorines/', 'Chloroneb was fed to rats, cows and dogs. In urine, metabolite found was 2,5-dichloro-4-methoxyphenol in free and conjugated form probably as glucuronides and sulfates. This was not detected in hydrolyzed feces. No metabolites were found in milk.', 'It is a systemic fungicide which is taken up by roots, concentrated in the roots and in lower stem portions, rendering them fungistatic.']","['Chloroneb was fed to rats, cows and dogs. In urine, metabolite found was 2,5-dichloro-4-methoxyphenol in free and conjugated form probably as glucuronides and sulfates. This was not detected in hydrolyzed feces. No metabolites were found in milk. After incubation of chloroneb with 10,000g supernate fraction of beef liver, the same metabolite was observed. Snapbeans, grown in a greenhouse, were treated with (14)C-ring-labeled chloroneb. Analysis of plant tissues showed presence of 2,5-dichloro-4-methoxyphenol, 2,5-dichlorohydroquinone and 2,5-dichloroquinone.', '2,5-Dichloro-4-methoxyphenol was isolated as the only metabolite of chloroneb in urine of dogs, rats, and cows maintained on chloroneb-containing diets. 2,5-Dichloro-4-methoxyphenol was found in both free form and as conjugates, presumably glucuronides and sulfonates.', 'Chloroneb ... is metabolized to its corresponding p-quinone in plants.', '/Young bean plants metabolized chloroneb/ ...to 2,5-dichloro-4-methoxyphenol (DCMP) and then converted to the beta-d-glucoside. ...Eight organisms demethylated chloroneb and methylated 2,5-dichloro-4-methoxyphenol (DCMP) /during incubation/: Fusarium solani (F pisi), Fusarium solani (F phaseoli), Mucor ramannianus, Cephalosporium gramineum, Aspergillus fumigatus, Verticillium albo-otrum, Cephalosporium gregatum, and Chaetomium globosum. Six organisms were capable only of demethylating chloroneb: Sclerotinia sclerotiorum, Helminthosporium victoriae, Corynebacterium fascians, Stemphyllium sarcinaeforme, Cladosporium cucumerinum, and Helminthosporium sativum. Three organisms were capable of methylating 2,5-dichloro-4-methoxyphenol (DCMP) but did not degrade chloroneb to decomposition: Trichoderma viride, Penicillium frequentans, and Rhizoctonia solani. In other studies, mycelium of Rhizooctonia solani degraded chloroneb to 2,5-dichloro-4-methoxyphenol (DCMP) ...Neurospora crassa metabolized chloroneb slowly to a compound thought to be an aglycoside.', '... Chloroneb was stable when incubated with rumen fluid up to 6 hr. A metabolite was produced with the fungicide was incubated with the 10,000-G superntant beef liver fraction. Its gas chromatographic retention time was identical to that of the 2,5- dichloro-4-methoxyphenol metabolite mentioned above. In hydrolyzed urine, a peak having the identical retention time of this phenol metabolite was also observed.']",
7581,17582,"1-Chloro-2,3,4-trimethoxybenzene",COC1=C(C(=C(C=C1)Cl)OC)OC,,,,,,
7582,17583,"N,N-Diethylacrylamide",CCN(CC)C(=O)C=C,,,,,,
7583,17584,"1,2,4-Trichloro-3,5-dinitrobenzene",C1=C(C(=C(C(=C1Cl)Cl)[N+](=O)[O-])Cl)[N+](=O)[O-],,,,,,
7584,17585,"1,6-Hexanedithiol diacetate",CC(=O)SCCCCCCSC(=O)C,,,,,,
7585,17586,2-Ethoxybutane,CCC(C)OCC,,,,,,
7586,17587,"N,N-Dimethylacrylamide",CN(C)C(=O)C=C,,,,,,
7587,17588,CID 17588,CC12CC(C3C(C1CCC2(C(=O)COP(=O)(O)[O-])O)CCC4=CC(=O)C=CC34C)O.[Na+],,,,,,
7588,17589,Acetyldiazomethane,CC(=O)C=[N+]=[N-],,,,,,
7589,17590,CID 17590,CC(=C[N+]#N)O,,,,,,
7590,17591,Amphenone B,CC(=O)C(C)(C1=CC=C(C=C1)N)C2=CC=C(C=C2)N,,,,,,
7591,17592,"3,4,5-Trimethylphenyl methylcarbamate",CC1=CC(=CC(=C1C)C)OC(=O)NC,,,,,,
7592,17593,"2,3-Diaminotoluene",CC1=C(C(=CC=C1)N)N,,,,,"['The acetylation of amino groups, oxidation of methyl groups, and ring hydroxylation appear to be the major metabolic steps. Phenolic metabolites and trace amounts of unchanged diaminotoluenes are excreted in the urine of experimental animals.']",
7593,17594,N-[4-(4-aminophenoxy)phenyl]acetamide,CC(=O)NC1=CC=C(C=C1)OC2=CC=C(C=C2)N,,,,,,
7594,17595,1-Ethyl-2-pyrrolidinone,CCN1CCCC1=O,,,,,,
7595,17596,Octogen,C1N(CN(CN(CN1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,"['Substances that are energetically unstable and can produce a sudden expansion of the material, called an explosion, which is accompanied by heat, pressure and noise. Other things which have been described as explosive that are not included here are explosive action of laser heating, human performance, sudden epidemiological outbreaks, or fast cell growth. (See all compounds classified as Explosive Agents.)']","['Studies in animals exposed to HMX by the oral and parenteral route suggest that HMX is poorly absorbed from the gastrointestinal tract, and may preferentially distribute to the lungs, liver, heart, and kidney, and that most of an absorbed dose of HMX is excreted in the urine.']",,
7596,17597,"AMMONIUM, (OXALYLBIS(IMINOETHYLENE))BIS(DIETHYL(o-FLUOROBENZYL)-, DIIODIDE",CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1F)CC2=CC=CC=C2F.[I-].[I-],,,,,,
7597,17598,2-[[2-[2-[Diethyl-[(2-fluorophenyl)methyl]azaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl-diethyl-[(2-fluorophenyl)methyl]azanium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1F)CC2=CC=CC=C2F,,,,,,
7598,17599,3-Aminofluoranthene,C1=CC=C2C(=C1)C3=C4C2=CC=CC4=C(C=C3)N,,,,,,
7599,17600,"17-Methylandrosta-1,5-diene-3,17-diol",C[C@@]1(CCC2C1(CCC3C2CC=C4C3(C=CC(C4)O)C)C)O,,,,,,
7600,17601,Nitrosyl chloride,N(=O)Cl,,,,,,
7601,17602,"1-Propanesulfonic acid, methyl ester",CCCS(=O)(=O)OC,,,,,,
7602,17603,MCPA-ethyl,CCOC(=O)COC1=C(C=C(C=C1)Cl)C,,,,,,
7603,17604,2-Chlorobenzylidenemalononitrile,C1=CC=C(C(=C1)C=C(C#N)C#N)Cl,,,"['Chemical substances which are employed during a riot in order to control or disperse the rioting parties. (See all compounds classified as Riot Control Agents, Chemical.)']","['... Rats exposed to CS aerosols at concn of 14-245 mg/cu m for 5 min absorbed measurable quantities of the compound. Both CS and a reduction product, 2-chlorobenzyl malononitrile, were detected in the blood.']","['... METABOLITE IN BLOOD OF CATS & RATS, TO WHICH CS, O-CHLOROBENZYLIDENE MALONONITRILE, HAD BEEN ADMINISTERED, HAS ... BEEN /IDENTIFIED/ ... AS O-CHLOROBENZYLMALONONITRILE. REDUCTION OF THE BENZYLIDENE DOUBLE BOND, WHICH OCCURS IN THE ERYTHROCYTE CYTOPLASM, IS ASSOCIATED WITH THE DETOXIFICATION OF CS.', 'IN RABBITS ADMINISTERED IV DOSES 2 REACTIONS TAKE PLACE HYDROLYSIS & REDUCTION. O-CHLOROBENZALDEHYDE & MALONONITRILE ARE PRODUCTS OF HYDROLYSIS & O-CHLOROBENZYL MALONONITRILE IS PRODUCT OF REDUCTION. BIOTRANSFORMATION TAKES PLACE MAINLY IN THE BLOOD, BUT LIVER, IN CONTRAST TO KIDNEYS, IS ALSO IMPORTANT IN THE TRANSFORMATION. O-CHLOROBENZYLIDENE MALONONITRILE & ITS BASIC METABOLITES, O-CHLOROBENZALDEHYDE & O-CHLOROBENZYL MALONONITRILE HAVE SHORT HALF-LIVES IN THE BLOOD.', 'MICE RECEIVED O-CHLOROBENZYLIDENE MALONONITRILE BY IP INJECTION (0.5 LD50) OR BY AEROSOL EXPOSURE (20000 MG/MIN/CU M). INCREASED EXCRETION OF THIOCYANATE IN THE URINE WAS OBSERVED, INDICATING A TRANSFORMATION OF CS TO CYANIDE IN VIVO.', 'The fate of (3)H-ring labeled, (14(C-cyanide labeled, and (14C=C) side chain-labeled CS was studied in Porton rats given intraperitoneal or gavage doses ranging from 0.08 to 159 umol/kg. In most cases, the largest proportion (44%-100%) of the dose was eliminated in the urine. The major urinary metabolites identified were 2-chlorohippuric acid, 1-O-(2-chlorobenzyl)glucuronic acid, 2-chlorobenzyl cysteine, and 2-chlorobenzoic acid. Minor metabolites identified included 2-chlorobenzyl alcohol and 2-chlorophenyl-2-cyanopropionate.', '... Six male volunteers /were exposed/ to CS at concn of 0.5-1.5 mg/cu m for 90 min. Neither CS nor 2-chlorobenzaldehyde was detected in the blood of those persons, and only in one was a trace of 2-chlorobenzyl malononitrile detected.']",
7604,17605,"MALONONITRILE, o-BROMOBENZYLIDENE-",C1=CC=C(C(=C1)C=C(C#N)C#N)Br,,,,,,
7605,17606,"MALONONITRILE, (o-FLUOROBENZYLIDENE)-",C1=CC=C(C(=C1)C=C(C#N)C#N)F,,,,,,
7606,17607,Sulfuryl fluoride,O=S(=O)(F)F,,,,"['Solutions of fluoride salts are rapidly and almost completely absorbed from the gastrointestinal tract, probably by simple diffusion ... Less than 10% of the ingested fluoride is excreted in the feces, but the proportion varies with circumstances ... The simultaneous presence of strongly fluoride-binding ions, especially calcium ions, will reduce the absorption of fluoride ... In patients ingesting aluminum-containing antacids, fluoride absorption decr to about 40%, and the retention decr to nil. /Fluorides/', 'In the industrial environment, the respiratory tract is the major route of absorption of both gaseous and particulate fluoride. Hydrogen fluoride being highly soluble in water is rapidly taken up in the upper respiratory tract ... Depending on their aerodynamic characteristics, fluoride-containing particles will be deposited in the nasopharynx, the tracheo-bronchial tree and the alveoli ... Dermal absorption of fluoride has only been reported in the case of burns resulting from exposure to hydrofluoric acid ... . /Fluorides/', 'About 75% of the blood fluoride is present in the plasma; the rest is mainly in or on the red blood cells ... Fluoride in human serum exists in both ionic and nonionic forms. ... For the general population under steady-state conditions of exposure, the concn of fluoride ions in plasma is directly related to the fluoride content of the drinking water. /Fluorides/', 'Fluoride ions are taken up rapidly by bone by replacing hydroxyl ions in bone apatite. /Fluorides/', 'For more Absorption, Distribution and Excretion (Complete) data for SULFURYL FLUORIDE (9 total), please visit the HSDB record page.']","['Identification of fluorosulfate and sulfate in blood and urine suggests that SO(2)F(2) is hydrolyzed to fluorosulfate, with release of fluoride, followed by further hydrolysis to sulfate and release of the remaining fluoride.', '4 jugular vein cannulated Fischer 344 male rats and 4 non-cannulated males per group received nose-only inhalation exposure (4 hours) to 35S-Sulfuryl Fluoride at 30 and 300 ppm. Additionally, 18 non-cannulated males per group were exposed (4 hours, nose-only inhalation) to non-radiolabelled sulfuryl fluoride at 30 and 300 ppm and 8 non-cannulated males served as a vehicle control (dry, compressed air) group. Time-weighted actual exposure concentrations over the 4-hour treatment period with 35S-sulfuryl fluoride were 28.4 ppm (0.26 uCi/L of atmosphere) and 274 ppm (2.8 uCi/L of atmosphere) at the 30 ppm and 300 ppm nominal levels respectively. Values were 31.2 ppm and 312 ppm at 30 ppm and 300 ppm respectively for non-radiolabelled sulfuryl fluoride exposures. Venous blood samples (0.15 mL) were collected from cannulated rats at 0.25, 0.5, 1, 2, 3, and 4 hours during inhalation exposure and 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-exposure. 3 animals per group exposed to non-radiolabelled sulfuryl fluoride were sacrificed after 2 and 4 hours of exposure and 2, 4, 8, and 20 hours post exposure to measure fluoride ion content in plasma, brain, and kidney. Additionally, fluoride ion content was determined in plasma, brain, and kidney of 2 control rats per group at the beginning and end of exposure and 4 and 8 hours post-exposure. No radioactivity was detected in expired air of the 300 ppm group animals at 24 hours post exposure, therefore, collection of expired air was not continued for the remaining sampling intervals of the group and not performed at all for 30 ppm animals. ... Metabolites Identified Following 35S-Sulfuryl Fluoride Exposure. Two radiolabeled metabolites, sulfate and fluorosulfate, both hydrolysis products of sulfuryl fluoride, were identified in whole blood and urine. ... Metabolic release of fluoride ions was proposed as the cause of toxicity in sulfuryl fluoride exposure ... therefore, quantification was performed. Elevated levels of fluoride ion were detected in urine, plasma, kidney, and brain during and after exposure to non-radiolabelled sulfuryl fluoride. Most returned to background levels at varying times post-exposure.', '... It was shown that termites fumigated with a nonlethal concentration of (35)S-sulfuryl fluoride excreted inorganic sulfate, indicating that fluoride had been released. Then, using the labeled metabolic pool technique, separate studies of termites prefed sodium (14)C-acetate or on (32)P-phosphate showed that fumigated termites exhibited a spectrum of metabolic changes characteristic of fluoride toxicity.']","['... Bone retains about 60% of iv-injected fluoride and that the half-time for this uptake is only about 13 min; both blood and extracellular fluid levels therefore decr rapidly. After ingestion of sodium fluoride, plasma fluoride levels show a much slower change with a half-life of about 3 hr ... /Fluorides/']"
7607,17608,Benzylidenemalononitrile,C1=CC=C(C=C1)C=C(C#N)C#N,,,,,,
7608,17609,"1,2-Dichloro-1-(methylsulfonyl)ethene",CS(=O)(=O)C(=CCl)Cl,,,,,,
7609,17610,"(2R)-17-acetyl-2,10,13-trimethyl-2,6,7,8,9,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-dione",C[C@@H]1CC2(C3C(CCC2=CC1=O)C4CCC(C4(CC3=O)C)C(=O)C)C,,,,,,
7610,17611,CID 17611,C1=CC(=C(C=C1Cl)Cl)OC(=O)C[O-].[Na+],,,,,,
7611,17612,"Phosphonothioic acid, methyl-, O-ethyl O-(4-(methylthio)phenyl) ester",CCOP(=S)(C)OC1=CC=C(C=C1)SC,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/']",,
7612,17613,3-Chlorobutyl isopropyl ether,CC(C)OCCC(C)Cl,,,,,,
7613,17614,Benzyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OCC1=CC=CC=C1)OP(=O)(OC)OC,,,,,,
7614,17615,CID 17615,CC(C)OP(=O)(OCC(C)Cl)OC(=CC(=O)OC)C,,,,,,
7615,17616,"2-(3-Acetyl-2,2-dimethylcyclobutyl)acetaldehyde",CC(=O)C1CC(C1(C)C)CC=O,,,,,,
7616,17617,Allyl cyclohexanepropionate,C=CCOC(=O)CCC1CCCCC1,,,,,,
7617,17618,CID 17618,C(=O)C(=O)[O-].[Na+],,,,,,
7618,17619,2-[Bis(2-hydroxyethyl)amino]ethanol;octadec-9-enoic acid,CCCCCCCCC=CCCCCCCCC(=O)O.C(CO)N(CCO)CCO,,,,,,
7619,17620,"Hydantoin, 3-(4-(diethylamino)-2-butynyl)-5,5-diphenyl-, hydrochloride",CC[NH+](CC)CC#CCN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3.[Cl-],,,,,,
7620,17621,"3-(4-Diethylamino-but-2-ynyl)-5,5-diphenyl-imidazolidine-2,4-dione",CCN(CC)CC#CCN1C(=O)C(NC1=O)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
7621,17622,CID 17622,CC(=O)N=NC1=C(C=C(C=C1)N(O)O)[N+](=O)[O-],,,,,,
7622,17623,Methyl N-acetylanthranilate,CC(=O)NC1=CC=CC=C1C(=O)OC,,,,,,
7623,17624,CID 17624,CC(=O)N=NC1=CC=C(C=C1)N(O)O,,,,,,
7624,17625,2-Acetamidothiazole,CC(=O)NC1=NC=CS1,,,,,,
7625,17626,4-Cyanophenyl isothiocyanate,C1=CC(=CC=C1C#N)N=C=S,,,,,,
7626,17627,2-Phenylpentane,CCCC(C)C1=CC=CC=C1,,,,,,
7627,17628,2-Phenyldodecane,CCCCCCCCCCC(C)C1=CC=CC=C1,,,,,,
7628,17629,6-Phenyldodecane,CCCCCCC(CCCCC)C1=CC=CC=C1,,,,,,
7629,17630,5-Phenyldodecane,CCCCCCCC(CCCC)C1=CC=CC=C1,,,,,,
7630,17631,4-Phenyldodecane,CCCCCCCCC(CCC)C1=CC=CC=C1,,,,,,
7631,17632,CID 17632,CCCOC(=S)[S-].[K+],,,,,,
7632,17633,Propylxanthogenate,CCCOC(=S)S,,,,,,
7633,17634,CID 17634,CCCCCOC(=S)[S-].[K+],,,,,,
7634,17635,Pentoxymethanedithioic acid,CCCCCOC(=S)S,,,,,,
7635,17636,CID 17636,CCCCCCOC(=S)[S-].[K+],,,,,,
7636,17637,o-Hexyl hydrogen carbonodithioate,CCCCCCOC(=S)S,,,,,,
7637,17638,CID 17638,C1CCC(CC1)OC(=S)[S-].[K+],,,,,,
7638,17639,Cyclohexoxymethanedithioic acid,C1CCC(CC1)OC(=S)S,,,,,,
7639,17640,CID 17640,C1=CC=C(C=C1)COC(=S)[S-].[K+],,,,,,
7640,17641,Benzyloxymethanedithioic acid,C1=CC=C(C=C1)COC(=S)S,,,,,,
7641,17642,CID 17642,CCCCCCCCOC(=S)[S-].[K+],,,,,,
7642,17643,O-Octyl hydrogen dithiocarbonate,CCCCCCCCOC(=S)S,,,,,,
7643,17644,2-(Dimethylamino)ethyl diphenylacetate hydrochloride,C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
7644,17645,CID 17645,CN=C(NC1=CC=CC=C1)S,,,,,,
7645,17646,"5,10-Dihydro-7-chloro-10-(2-(dimethylamino)ethyl)-11H-dibenzo(b,e)(1,4)diazepin-11-one HCl",C[NH+](C)CCN1C2=C(C=C(C=C2)Cl)NC3=CC=CC=C3C1=O.[Cl-],,,,,,
7646,17647,CID 17647,CCC(C1=CC=C(C=C1)Cl)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
7647,17648,Thiocolchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC,,,,,,
7648,17649,N-Deacetylthiocolchicine,COC1=C(C(=C2C(=C1)CC[C@@H](C3=CC(=O)C(=CC=C32)SC)N)OC)OC,,,,,,
7649,17650,N-(Formyldeacetyl)thiocolchicine,COC1=C(C(=C2C(=C1)CC[C@@H](C3=CC(=O)C(=CC=C32)SC)NC=O)OC)OC,,,,,,
7650,17651,C.I. Disperse Red 19,C1=CC(=CC=C1N=NC2=CC=C(C=C2)[N+](=O)[O-])N(CCO)CCO,,,,,,
7651,17652,"2,4-Dimethoxyaniline",COC1=CC(=C(C=C1)N)OC,,,,,,
7652,17653,6-Methoxytryptamine hydrochloride,COC1=CC2=C(C=C1)C(=CN2)CC[NH3+].[Cl-],,,,,,
7653,17654,6-Methoxytryptamine,COC1=CC2=C(C=C1)C(=CN2)CCN,,,,,,
7654,17655,"2,4-Dichloro-5-sulfamoylbenzoic acid",C1=C(C(=CC(=C1S(=O)(=O)N)Cl)Cl)C(=O)O,,,,,,
7655,17656,2-Methyl-2-hexene,CCCC=C(C)C,,,,,,
7656,17657,Remeflin,CC1=C(OC2=C(C1=O)C=CC(=C2C[NH+](C)C)OC)C3=CC=CC=C3.[Cl-],,,,,,
7657,17658,"Acetic acid, 2,2-diphenyl-2-methoxy-, (3-(diethylamino)propyl) ester, hydrochloride",CC[NH+](CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
7658,17659,"3-(Diethylamino)propyl 2-methoxy-2,2-diphenylacetate",CCN(CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
7659,17660,"2,2-Diphenyl-2-ethoxyacetic acid (3-(diethylamino)propyl) ester hydrochloride",CC[NH+](CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
7660,17661,Ethpenal,CCN(CC)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
7661,17662,"(17S)-17-hydroxy-13,17-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CCC2C1(CCC3C2CCC4=C3CCC(=O)C4)C)O,,,,,,
7662,17663,"N,N-Bis(2-chloroethyl)-p-bromobenzylamine",C1=CC(=CC=C1CN(CCCl)CCCl)Br,,,,,,
7663,17664,p-Bromo-di-(2-chloroethyl)-benzylamine hydrochloride,C1=CC(=CC=C1C[NH+](CCCl)CCCl)Br.[Cl-],,,,,,
7664,17665,"2,4,6-Cycloheptatrien-1-one, 2-((2-(dimethylamino)ethyl)amino)-",CN(C)CCNC1=CC=CC=CC1=O,,,,,,
7665,17666,alpha-Ethyl-alpha-(2-morpholinoethyl)-1-naphthaleneacetonitrile,CCC(CCN1CCOCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
7666,17667,4-Dimethylaminoazobenzene amine N-oxide,C[N+](C)(C1=CC=C(C=C1)N=NC2=CC=CC=C2)[O-],,,,,,
7667,17668,"2-N,4-N,6-N-tris(4-chlorophenyl)-1,3,5-triazine-2,4,6-triamine",C1=CC(=CC=C1NC2=NC(=NC(=N2)NC3=CC=C(C=C3)Cl)NC4=CC=C(C=C4)Cl)Cl,,,,,,
7668,17669,"1-Propanaminium, 3,3'-((3,6-dioxo-1,4-cyclohexadiene-1,4-diyl)diimino)bis(N,N,N-triethyl-, dibromide",CC[N+](CC)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
7669,17670,"3-[[3,6-Dioxo-4-[3-(triethylazaniumyl)propylamino]cyclohexa-1,4-dien-1-yl]amino]propyl-triethylazanium",CC[N+](CC)(CC)CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CC,,,,,,
7670,17671,Miripirium chloride,CCCCCCCCCCCCCC[N+]1=CC=C(C=C1)C.[Cl-],,,,,,
7671,17672,Miripirium,CCCCCCCCCCCCCC[N+]1=CC=C(C=C1)C,,,,,,
7672,17673,"1,3-Dimethyl-5-pyrazolone",CC1=NN(C(=O)C1)C,,,,,,
7673,17674,CID 17674,CCN(CC)C(=O)COC1=C2C3=C(C(=C1)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](C=CO[C@@]4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O,,,,,,
7674,17675,Oleandocetin,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
7675,17676,Acetophenazine,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO,['For the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)'],['Acetophenzine is a phenothiazine antipsychotic intended for the management of schizophrenia and other psychotic disorders.'],,,,
7676,17677,"Alanine, N,N-bis(2-chloroethyl)-, hydrochloride, DL-",CC(C(=O)O)[NH+](CCCl)CCCl.[Cl-],,,,,,
7677,17678,"N,N-Bis(2-chloroethyl)alanine",CC(C(=O)O)N(CCCl)CCCl,,,,,,
7678,17679,"[(2R,3R,5R,6S,8R,10R,17S)-8-acetyloxy-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@](C3OC(=O)C4=CC=CC=C4)([C@H](C1O)OC)O)C56[C@@H]7C(C2[C@H]5N(CC7(C(CC6OC)O)COC)C)OC,,,,,,
7679,17680,"Carbamic acid, methyl-, carvacryl ester",CC1=C(C=C(C=C1)C(C)C)OC(=O)NC,,,,,,
7680,17681,2-Chloro-5-(1-methylethyl)phenol methylcarbamate,CC(C)C1=CC(=C(C=C1)Cl)OC(=O)NC,,,,,,
7681,17682,Butyl diphenyl phosphate,CCCCOP(=O)(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
7682,17683,Mebeverine hydrochloride,CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC.Cl,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)']",,,
7683,17684,"5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ol hydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2CCC3=CC=CC=C31)O.[Cl-],,,,,,
7684,17685,"(4,7,7-Trimethyl-2-bicyclo[2.2.1]heptanyl) propanoate",CCC(=O)OC1CC2(CCC1C2(C)C)C,,,,,,
7685,17686,"2-Isoindolineacetic acid, 1,3-dioxo-, vinyl ester",C=COC(=O)CN1C(=O)C2=CC=CC=C2C1=O,,,,,,
7686,17687,Dithallium malonate,C(C(=O)[O-])C(=O)[O-].[Tl+].[Tl+],,,,"['The distribution and elimination patterns of thallous malonate were studied and compared to those of thallous sulfate. Male Syrian golden hamsters were divided into 3 groups. The first group (control) received distilled water. Animals in group 2 received either a single oral dose or an ip dose of 12.5 mg/kg of thallous malonate. The third group of animals received either a single oral dose or an ip dose of 12.35 mg/kg of thallous sulfate. By 1 hour after thallous malonate adminstration, thallium was detected in all organs. Thallium was detected only in the heart, liver and kidney in the group given thallous sulfate. By 12 hours the maximum values, except for muscle and testes, were observed in both treated groups, and the distribution patterns were similar. At this time, although the thallium concentration in the brain was less than in the other organs, thallium was rapidly deposited in the brain in both treated groups. The liver, heart, kidney and whole blood had short half-lives in the alpha phase. The beta phase in these tissues and in the brain, muscle and testes had long half lives, indicating that thallium disappeared slowly from organs. In the group receiving oral thallous malonate the urinary elmination rate constant was 0.175/day, and the fecal rate was 0.500. In the group receiving thallous malonate ip the urinary elimination rate constant was 0.086, and the fecal rate was 0.081. The urinary elimination rate constant in animals treated orally with thallous sulfate was 0.073 and the fecal rate was 0.054. Ip treatment with thallous sulfate resulted in a urinary elimination rate of 0.063 and fecal rate of 0.084. It was concluded that thallous malonate, an organic thallium compound, showed slightly higher elimination rate constants but similar toxicity and distribution patterns to thallous sulfate, an inorganic thallium compound.', 'In acute thallium poisoning, human brain areas densely populated with neurons were found to accumulate thallium more than other areas, and the gray matter contained higher thallium levels than nonneural tissues. /Soluble thallium cmpd/']",,['BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']
7687,17688,L-Agaritine,C1=CC(=CC=C1CO)NNC(=O)CCC(C(=O)O)N,,,,,,
7688,17689,(2-Bromoethyl)trimethylammonium bromide,C[N+](C)(C)CCBr.[Br-],,,,,,
7689,17690,2-Bromoethyl(trimethyl)azanium,C[N+](C)(C)CCBr,,,,,,
7690,17691,3-Methyl-2-cyclopenten-1-one,CC1=CC(=O)CC1,,,,,,
7691,17692,N-(4-Chlorophenyl)propanamide,CCC(=O)NC1=CC=C(C=C1)Cl,,,,,,
7692,17693,Cypromid,C1CC1C(=O)NC2=CC(=C(C=C2)Cl)Cl,,,,,,
7693,17694,3-Hydroxypropyl methacrylate,CC(=C)C(=O)OCCCO,,,,,,
7694,17695,Pentyltriethoxysilane,CCCCC[Si](OCC)(OCC)OCC,,,,,,
7695,17696,"2,4,6-Trimethyl-1,3,5-trithiane",CC1SC(SC(S1)C)C,,,,,,
7696,17697,Pentadecanal,CCCCCCCCCCCCCCC=O,,,,,,
7697,17698,"Glycine, N,N-diisopentyl-, ethyl ester",CCOC(=O)CN(CCC(C)C)CCC(C)C,,,,,,
7698,17699,2-(Dimethylamino)ethyl diphenyl(prop-2-ynyloxy)acetate hydrochloride,C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC#C.[Cl-],,,,,,
7699,17700,Pargeverine,CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC#C,,,,,,
7700,17701,Triethyltin bromide,CC[Sn](CC)(CC)Br,,,,,,
7701,17702,"Stannane, bromotripropyl-",CCC[Sn](CCC)(CCC)Br,,,,,,
7702,17703,5-Methyl-1-nonanol,CCCCC(C)CCCCO,,,,,,
7703,17704,Quinaldine blue,CCN1C(=CC=CC2=[N+](C3=CC=CC=C3C=C2)CC)C=CC4=CC=CC=C41.[Cl-],,,,,,
7704,17705,Pinacyanol cation,CCN1C(=CC=CC2=[N+](C3=CC=CC=C3C=C2)CC)C=CC4=CC=CC=C41,,,,,,
7705,17706,Direct Red 17,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=C5C(=CC=C6)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7706,17707,C.I. Direct Red 17,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=C5C(=CC=C6)S(=O)(=O)O)O)S(=O)(=O)O,,,,,,
7707,17708,4'-Hydroxy-2-phenylbutyranilide,CCC(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)O,,,,,,
7708,17709,"Formanilide, 2-phenoxy-",C1=CC=C(C=C1)OC2=CC=CC=C2NC=O,,,,,,
7709,17710,CID 17710,C1(=NC(=NC(=N1)S)S)N,,,,,,
7710,17711,1-(p-Methoxyphenethyl)hydrazine hydrogen sulfate,COC1=CC=C(C=C1)CCN[NH3+].OS(=O)(=O)[O-],,,,,,
7711,17712,"HYDRAZINE, (p-METHOXYPHENETHYL)-",COC1=CC=C(C=C1)CCNN,,,,,,
7712,17713,"4,5-Dichloroveratrole",COC1=CC(=C(C=C1OC)Cl)Cl,,,,,,
7713,17714,Quotane,CCCCC1=CC2=CC=CC=C2C(=N1)OCC[NH+](C)C.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
7714,17715,CID 17715,C1=CC(=CC=C1N=NC2=CC=C(C=C2)Cl)S(=O)[O-].[Na+],,,,,,
7715,17716,4-[(4-Chlorophenyl)diazenyl]benzenesulfinic acid,C1=CC(=CC=C1N=NC2=CC=C(C=C2)Cl)S(=O)O,,,,,,
7716,17717,Endothion,COC1=COC(=CC1=O)CSP(=O)(OC)OC,,,,,"['Endothion was applied to several species of insects and the degree of penetration and metabolism was studied. Three metabolites were isolated but the quantities were insufficient to permit rigorous identification. After treatment of plants with (35)S-endothion, the monomethyl derivative was detected.']",
7717,17718,"1,4-Bis(1-isocyanato-1-methylethyl)benzene",CC(C)(C1=CC=C(C=C1)C(C)(C)N=C=O)N=C=O,,,,,,
7718,17719,"1,3-Bis(1-isocyanato-1-methylethyl)benzene",CC(C)(C1=CC(=CC=C1)C(C)(C)N=C=O)N=C=O,,,,,,
7719,17720,Stearyl stearate,CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC,,,,,,
7720,17721,"Peroxide, [1,4-phenylenebis(1-methylethylidene)]bis[(1,1-dimethylethyl)",CC(C)(C)OOC(C)(C)C1=CC=C(C=C1)C(C)(C)OOC(C)(C)C,,,,,,
7721,17722,Diethyl bis(2-hydroxyethyl)aminomethylphosphonate,CCOP(=O)(CN(CCO)CCO)OCC,,,,,,
7722,17723,"D-Arabinono-1,4-lactone",C([C@@H]1[C@H]([C@@H](C(=O)O1)O)O)O,,,,,,
7723,17724,CID 17724,C1(=NC(=O)N=C(N1)Cl)Cl,,,,,,
7724,17725,Tetramethylthiourea,CN(C)C(=S)N(C)C,,,,,,
7725,17726,"1-Butene, 2-nitro-",CCC(=C)[N+](=O)[O-],,,,,,
7726,17727,"1,12-Dodecanediamine",C(CCCCCCN)CCCCCN,,,,,,
7727,17728,"3-Methyl-2-[(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1,3-benzothiazol-3-ium iodide",CN1C2=CC=CC=C2SC1=CC3=[N+](C4=CC=CC=C4S3)C.[I-],,,,,,
7728,17729,2-[3-Methylbenzothiazol-2(3H)-ylidenemethyl]-3-methylbenzothiazol-3-ium,CN1C2=CC=CC=C2SC1=CC3=[N+](C4=CC=CC=C4S3)C,,,,,,
7729,17730,Sunset Yellow FCF,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],,,['Natural or synthetic dyes used as coloring agents in processed foods. (See all compounds classified as Food Coloring Agents.)'],"['When color is given orally to rats, 3% is absorbed and excreted unchanged in urine and in bile: thus little is reduced in liver. ...After its iv injection in rats, 20-30% was excreted in bile.', '... A trace to 1.5 percent of unchanged monomeric dyes was excreted in urine and bile during the first 24 hr after dosing. No unchanged dye was absorbed after administration of the polymeric derivatives. In animals dosed with sunset yellow and its polymer derivative, absorption of the azo-bound cleavage product 1-amino-2-naphthol-6-sulphonic acid was 8.5 and 6.9 percent, respectively, while absorption of the cleavage product sulphanilic acid was 37.4 and 0 percent, respectively. ...', 'In 5 animals dosed with 14C-sunset yellow (2.7 mg, 4.62 uCi) after 96 hours urinary excretion of radioactivity was 8.5 +/- 3.4% of the dose. The 24 hours urine collection from the sunset yellow rats contained 40% of the molar equivalents of sulfanilic acid. Intact dye in the 24 hours urine represented 1-2% of the dose. Peak fecal excretion occurred during the first 24 hours. The recovery of radioactivity was 94.5 +/- 5.7%. Total recovery of radioactivity was 103 +/- 3.3%.', 'Fourteen rats were dosed with sunset yellow within the range of 2-25 mg and within 72 hours excreted 0.3 and 1.5% of the administered dye in urine and bile respectively and 37% of the sulfanilic acid equivalents in the urine.']","['When color is given orally to rats... unabsorbed was mainly reduced by intestinal bacteria and excreted as sulfanilic acid and 1-amino-2-hydroxy-6-naphthalenesulfonic acid in urine. ...n-Acetylsulfanilic acid as metabolite in rabbits after oral administration...', 'Sunset yellow FCF is easily reduced in vitro by bacteria present in intestine and cecum of rats. It binds with serum proteins.', 'The anaerobic reduction of 4... sulfonated azo dyes, amaranth, sunset yellow, new coccine and tartrazine, has been studied by incubating bacterial suspensions isolated from human feces and from the intestinal contents of rats with 50 um concentrations of the dyes in phosphate buffer pH 4 /with/ nitrogen as the gaseous phase. Human fecal flora from 5 male volunteers reduced the 4 dyes at mean rates of 38.4, 25.1, 18.2 and 6.5 nmol/mg/protein/hr, respectively. For each dye, there was little difference in the reduction rates effected by the bacterial suspensions from the different individuals in spite of considerable divergence in age, daily diets and living circumstances. ...The rates of amaranth and sunset yellow reduction by rat gut flora were 4-5 times higher than those by human fecal flora, but there was no significant difference between the two types of bacterial suspension in the reduction rates for new coccine and tartrazine. ...', 'When rabbits were fed 0.5 g/kg bw of the color, the following metabolites could be identified in 48 hours urine: sunset yellow (2%), sulfanilic acid (54%), p-acetamido benzene-sulfonic acid (23%), 1-amino-2-naphthol-6-sulfonic acid (55% in 24 hours). ... The metabolites in the urine were predominantly products resulting from the reductive fission of the azolinkage. The liver enzyme that reduces azolinkages plays little part in metabolism. Reduction of the color by the intestinal bacteria is therefore the most probable way to aromatic amines and aminosulfonic acids; these are then partly absorbed by the intestinal tract.', 'The sodium salt of 6-hydroxy-5-(phenylazo)-2-naphthalenesulfonic acid (SS-AN), which is a subsidiary color present in Food Yellow No. 5 [Sunset Yellow FCF, disodium salt of 6-hydroxy-5-(4-sulfophenylazo)-2-naphthalenesulfonic acid], was orally administered to Sprague-Dawley rats. Metabolite A, metabolite B, and unaltered SS-AN were detected as colored metabolites in the rat urine. Analysis of the chemical structures showed that metabolite A (major peak) was 6-hydroxy-5-(4-sulfooxyphenylazo)-2-naphthalenesulfonic acid, the sulfuric acid conjugate of SS-AN, and metabolite B (minor peak) was 6-hydroxy-5-(4-hydroxyphenylazo)-2-naphthalenesulfonic acid (SS-PAP), which is a derivative of metabolite A without the sulfuric acid. ...The orally administered SS-AN had been metabolized to the colorless metabolites (p-aminophenol 45.3%, o-aminophenol 9.4%, aniline 0.4%) in the 24-hr urine samples. Analysis of the colored metabolites... indicated the presence of metabolite A (0.29%), SS-PAP (0.01%), and SS-AN (0.02%) were detected in the 24-hr urine samples. Approximately 56% of SS-AN was excreted into the urine and the rest is probably excreted into feces.']",
7730,17731,6-Hydroxy-5-((4-sulphophenyl)azo)naphthalene-2-sulphonic acid,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O)S(=O)(=O)O,,,['Natural or synthetic dyes used as coloring agents in processed foods. (See all compounds classified as Food Coloring Agents.)'],,,
7731,17732,"5-(4-Hydroxyphenyl)-5-phenylimidazolidine-2,4-dione",C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=C(C=C3)O,,,,,"['4-Hydroxyphenytoin has known human metabolites that include 4-Hydroxyphenytoin glucuronide and 5-(3,4-Dihydroxyphenyl)-5-phenylhydantoin.']",
7732,17733,1-Hydroxy-2-acetamidofluorene,CC(=O)NC1=C(C2=C(C=C1)C3=CC=CC=C3C2)O,,,,,,
7733,17734,HC Blue 1,CNC1=C(C=C(C=C1)N(CCO)CCO)[N+](=O)[O-],,,,"['About 85 g of a commercial semi-permanent hair dye formulation containing 1.48% HC Blue No. 1 enriched with 113.6 uCi/mg (ring (14)C labelled HC Blue No. 1 was applied on two occasions to the hair of human volunteers, worked in gently for 5-8 minutes and allowed to remain in contact with the hair and scalp for an additional 30 minutes. On the first occasion, the hair was shaven, and radiolabel accounting for 0.09-0.15% of that applied was detected in the urine over a seven day period; half was excreted in the urine after 18 hours. On the second occasion, the hair was shaven only after 30 days: cumulative absorption was 0.15% on the first day and 0.5% on the 30th day; half of the radiolabel was excreted after 138 hours.', '/About 85 g of a commercial semi-permanent hair dye formulation containing 1.48% HC Blue No. 1 enriched with 113.6 uCi/mg (ring (14 C)) labelled HC Blue No. 1/ was applied to the scalp hair of rhesus monkeys and allowed to remain in contact for 30 minutes. Radiolabel accounting for 0.12-0.13% of that applied was detected in urine over a seven day period; half was excreted in the urine after 40 hours.', 'Following intraperitoneal or subcutaneous injection of 2.5, 3.5, 4.0, 5.0, or 100 mg/kg body weight HC Blue No. 1 (98% pure, containing four minor components) to adult Fischer rats or rabbits, over 90% was recovered in bile or urine within 6 hours of administration. Following application of about 1 mg/cm sq (250 ug/ml in saline) HC Blue No. 1 to the skin, about 1% of the dose was recovered in the bile and slightly more in the urine of rats and an average of 4.5% of the dose in the rune of rabbits after 48 hours.']","['Up to 40% of radiolabel was recovered in the urine of B6C3F1 mice and Fischer 344/N rats after oral administration by gavage of 100 mg/kg body weight (ring-(14)C) Blue No. 1 (29 mCi/mmol (113.6 uCi/mg); 97% pure). HC Blue No.1 administered orally to B6C3F1 mice yielded three metabolites in equal proportions, which were more water soluble than the parent compound; one was a glucuronide of the parent compound. Metabolism of (ring-(14)C) HC Blue No. 1 (200 uM (51 mg)) by hepatocytes isolated from mice and rats yielded profiles similar to those seen in vivo. High-performance liquid chromatography separation showed that HC Blue No.1 is metabolized extensively in mice to five major metabolites. Thermospray liquid chromatography mass spectrometry of these metabolites provided tentative evidence for nitroreduction, N-demethylation and conjugation (glucuronidation of a demethylated product and acetylation). In rats, HC Blue No. 1 produced three metabolites similar to those fund in mice.', 'HC BLUE NUMBER 1, A COMPONENT OF HAIR DYE, WAS ABSORBED PERCUTANEOUSLY BY RATS & RABBITS AFTER APPLICATION OF 250 MUG/ML SOLN. IT WAS ALSO INJECTED IP & SC. DYE WAS EXCRETED IN URINE & BILE BUT NO METABOLIC ALTERATION OCCURRED DURING THE IN VIVO TRANSIT.']",
7734,17735,Myristylpyridinium chloride,CCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Cl-],,,,,,
7735,17736,Myristylpyridinium,CCCCCCCCCCCCCC[N+]1=CC=CC=C1,,,,,,
7736,17737,"3,5-Dimethylcatechol",CC1=CC(=C(C(=C1)O)O)C,,,,,,
7737,17738,"3,4-Dimethylbenzene-1,2-diol",CC1=C(C(=C(C=C1)O)O)C,,,,,,
7738,17739,2-Methoxy-4-propylphenol,CCCC1=CC(=C(C=C1)O)OC,,,,,,
7739,17740,C.I. Pigment Red 170,CCOC1=CC=CC=C1NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=CC=C(C=C4)C(=O)N,,,,,,
7740,17741,CID 17741,CCCCCCCC[SnH](CCCCCCCC)CCCCCCCC.CCCCCCCC[SnH](CCCCCCCC)CCCCCCCC.O,,,,,,
7741,17742,Trioctylstannane,CCCCCCCC[SnH](CCCCCCCC)CCCCCCCC,,,,,,
7742,17743,9-Nitrosocarbazole,C1=CC=C2C(=C1)C3=CC=CC=C3N2N=O,,,,,,
7743,17744,3-Fluoro-alpha-(methylaminomethyl)benzyl alcohol hydrobromide,C[NH2+]CC(C1=CC(=CC=C1)F)O.[Br-],,,,,,
7744,17745,1-(3-Fluorophenyl)-2-(methylamino)ethanol,CNCC(C1=CC(=CC=C1)F)O,,,,,,
7745,17746,2-Fluoroethyl glycine hydrochloride,C(CF)OC(=O)C[NH3+].[Cl-],,,,,,
7746,17747,2-Fluoroethyl 2-aminoacetate,C(CF)OC(=O)CN,,,,,,
7747,17748,"2-Amino-3-chloro-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)N,,,,,,
7748,17749,"1,1'-((6-Amino-1,3,5-triazine-2,4-diyl)bis(azanediyl))bis(2,2,2-trichloroethanol)",C1(=NC(=NC(=N1)NC(C(Cl)(Cl)Cl)O)NC(C(Cl)(Cl)Cl)O)N,,,,,,
7749,17750,"1,1'-Sebacoylbisaziridine",C1CN1C(=O)CCCCCCCCC(=O)N2CC2,,,,,,
7750,17751,4-Methylpentadecane,CCCCCCCCCCCC(C)CCC,,,,,,
7751,17752,"Isoquinoline, 1,2,3,4-tetrahydro-1-(2-amino-4-fluorobenzyl)-2-methyl-, dihydrochloride",C[NH+]1CCC2=CC=CC=C2C1CC3=C(C=C(C=C3)F)[NH3+].[Cl-].[Cl-],,,,,,
7752,17753,"5-fluoro-2-[(2-methyl-3,4-dihydro-1H-isoquinolin-1-yl)methyl]aniline",CN1CCC2=CC=CC=C2C1CC3=C(C=C(C=C3)F)N,,,,,,
7753,17754,"Cyclohexane, 2-propynylidene-",C#CC=C1CCCCC1,,,,,,
7754,17755,3-Ethoxypropionaldehyde,CCOCCC=O,,,,,,
7755,17756,2-Propoxyethanol,CCCOCCO,,,,['... The material may be absorbed through the skin in lethal amounts.'],,
7756,17757,"5,8-Dihydroxy-2,7-dimethoxy-1,4-naphthoquinone",COC1=CC(=O)C2=C(C1=O)C(=C(C=C2O)OC)O,,,,,,
7757,17758,4-(Dimethylamino)-2-methyl-2-phenylbutyronitrile,CC(CCN(C)C)(C#N)C1=CC=CC=C1,,,,,,
7758,17759,4-(Dimethylamino)-2-ethyl-2-phenylbutyronitrile,CCC(CCN(C)C)(C#N)C1=CC=CC=C1,,,,,,
7759,17760,4-(Dimethylamino)-2-isopropyl-2-phenylbutyronitrile,CC(C)C(CCN(C)C)(C#N)C1=CC=CC=C1,,,,,,
7760,17761,"Butyronitrile, 4-(dimethylamino)-2-(2-(dimethylamino)ethyl)-2-phenyl-",CN(C)CCC(CCN(C)C)(C#N)C1=CC=CC=C1,,,,,,
7761,17762,2-Methyl-2-phenyl-4-piperidinobutyronitrile,CC(CCN1CCCCC1)(C#N)C2=CC=CC=C2,,,,,,
7762,17763,2-Phenyl-2-(2-piperidinoethyl)butyronitrile,CCC(CCN1CCCCC1)(C#N)C2=CC=CC=C2,,,,,,
7763,17764,2-Phenyl-2-(2-piperidinoethyl)-3-methylbutyronitrile,CC(C)C(CCN1CCCCC1)(C#N)C2=CC=CC=C2,,,,,,
7764,17765,2-(2-Morpholinoethyl)-2-phenylbutyronitrile,CCC(CCN1CCOCC1)(C#N)C2=CC=CC=C2,,,,,,
7765,17766,alpha-(2-(Dimethylamino)ethyl)-1-naphthaleneacetonitrile,CN(C)CCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
7766,17767,alpha-(2-(N-Ethyl-N-methylamino)ethyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CCN(C)CCC(C#N)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
7767,17768,"Naphthalene, 1,2,3,4-tetrahydro-5-methyl-",CC1=C2CCCCC2=CC=C1,,,,,,
7768,17769,2-Octyne,CCCCCC#CC,,,,,,
7769,17770,"1-NAPHTHALENEACETONITRILE, alpha,alpha-BIS(2-(DIMETHYLAMINO)ETHYL)-",CN(C)CCC(CCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
7770,17771,"3,4,5,6-Tetrabromo-O-xylene",CC1=C(C(=C(C(=C1Br)Br)Br)Br)C,,,,,,
7771,17772,S-Methyl chlorothioformate,CSC(=O)Cl,,,,,,
7772,17773,chloromethanethioic S-acid;S-(chloromethyl) ethanethioate,CC(=O)SCCl.C(=O)(S)Cl,,,,,,
7773,17774,S-(chloromethyl) ethanethioate,CC(=O)SCCl,,,,,,
7774,17775,Chlorothioformic acid,C(=O)(S)Cl,,,,,,
7775,17776,Dinoseb acetate,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)C,,,,,,
7776,17777,CID 17777,CC1=CC(=O)N=C(N1)C(C)C,,,,,,
7777,17778,C.I. Pigment Red 4,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])Cl)O,,,,,,
7778,17779,"1,2,4-Trimethylcyclopentane",CC1CC(C(C1)C)C,,,,,,
7779,17780,"2,6-Dimethylcyclohexanone",CC1CCCC(C1=O)C,,,,,,
7780,17781,CID 17781,CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl.[K+],,,,,,
7781,17782,2-Methylbenzoselenazole,CC1=NC2=CC=CC=C2[Se]1,,,,,,
7782,17783,Pentamethylphenol,CC1=C(C(=C(C(=C1C)C)O)C)C,,,,,,
7783,17784,Nicotinhydrochlorid,CN1CCCC1C2=CN=CC=C2.Cl,,,,,,
7784,17785,3-(1-Methylpyrrolidin-2-yl)-1-oxidopyridin-1-ium,CN1CCCC1C2=C[N+](=CC=C2)[O-],,,,,,
7785,17786,"[(6S,9R,11S,14S,16R,17R)-6,9-difluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate",C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=CC4([C@]3([C@H](CC2([C@]1(C(=O)CO)OC(=O)C)C)O)F)C)F,,,,,,
7786,17787,"Acetamide, N-(5-fluorofluoren-2-YL)-",CC(=O)NC1=CC2=C(C=C1)C3=C(C2)C=CC=C3F,,,,,,
7787,17788,"Acetamide, N-(4-fluorofluoren-2-YL)-",CC(=O)NC1=CC2=C(C3=CC=CC=C3C2)C(=C1)F,,,,,,
7788,17789,"Acetamide, N-(3-fluorofluoren-2-YL)-",CC(=O)NC1=C(C=C2C(=C1)CC3=CC=CC=C32)F,,,,,,
7789,17790,"Acetamide, N-(6-fluorofluoren-2-YL)-",CC(=O)NC1=CC2=C(C=C1)C3=C(C2)C=CC(=C3)F,,,,,,
7790,17791,"Acetamide, N-(8-fluorofluoren-2-YL)-",CC(=O)NC1=CC2=C(C=C1)C3=C(C2)C(=CC=C3)F,,,,,,
7791,17792,"Acetamide, N-(1-fluorofluoren-2-YL)-",CC(=O)NC1=C(C2=C(C=C1)C3=CC=CC=C3C2)F,,,,,,
7792,17793,"(8R,9R,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-17-(2-methylprop-2-enyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CC(=C)C[C@@]1(CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2CCC4=CC(=O)CC[C@@]34C)C)O,,,,,,
7793,17794,Formocortalum,CC(=O)OCC(=O)[C@@]12[C@@H](CC3C1(CC([C@]4(C3CC(=C5C4(CCC(=C5)OCCCl)C)C=O)F)O)C)OC(O2)(C)C,,,,,,
7794,17795,Tetrahydrodicyclopentadiene,C1CC2C3CCC(C3)C2C1,,,,,,
7795,17796,(2-Nitrobenzylidene)malononitrile,C1=CC=C(C(=C1)C=C(C#N)C#N)[N+](=O)[O-],,,,,,
7796,17797,(3-Nitrobenzylidene)malononitrile,C1=CC(=CC(=C1)[N+](=O)[O-])C=C(C#N)C#N,,,,,,
7797,17798,"Colchicoinamide, N-Methyl-",CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)NC)OC)OC)OC,,,,,,
7798,17799,"2-(2-(Bis(2,6-dimethylphenyl)methoxy)ethoxy)-N,N-dimethylethanamine hydrochloride",CC1=C(C(=CC=C1)C)C(C2=C(C=CC=C2C)C)OCCOCC[NH+](C)C.[Cl-],,,,,,
7799,17800,Xyloxemine,CC1=C(C(=CC=C1)C)C(C2=C(C=CC=C2C)C)OCCOCCN(C)C,,,,,,
7800,17801,"BENZO(c)PHENANTHRIDIN-7(8H)-ONE, 9,10-DIHYDRO-",C1CC2=C3C=CC4=CC=CC=C4C3=NC=C2C(=O)C1,,,,,,
7801,17802,"s-Triazine, 4,6-diamino-2-ethoxy-",CCOC1=NC(=NC(=N1)N)N,,,,,,
7802,17803,"6-Methoxy-1,3,5-triazine-2,4-diamine",COC1=NC(=NC(=N1)N)N,,,,,,
7803,17804,TriMM,CNC1=NC(=NC(=N1)NC)NC,,,,,,
7804,17805,"MELAMINE, N(sup 2),N(sup 2),N(sup 4),N(sup 4)-TETRAMETHYL-",CN(C)C1=NC(=NC(=N1)N)N(C)C,,,,,,
7805,17806,"2,4,6-Tris(diethylamino)-1,3,5-triazine",CCN(CC)C1=NC(=NC(=N1)N(CC)CC)N(CC)CC,,,,,,
7806,17807,alpha-Ethyl-alpha-(2-piperidinoethyl)-1-naphthaleneacetonitrile,CCC(CCN1CCCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
7807,17808,Acetone O-carbaniloyloxime,CC(=NOC(=O)NC1=CC=CC=C1)C,,,,,,
7808,17809,1-(4-Chlorophenyl)-2-[(4-methoxyphenyl)methylidene]hydrazine,COC1=CC=C(C=C1)C=NNC2=CC=C(C=C2)Cl,,,,,,
7809,17810,"2,4-Dichloro-1,3,5-triazine",C1=NC(=NC(=N1)Cl)Cl,,,,,,
7810,17811,Disperse yellow 3,CC1=CC(=C(C=C1)O)N=NC2=CC=C(C=C2)NC(=O)C,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
7811,17812,11-Bromoundecanoic acid,C(CCCCCBr)CCCCC(=O)O,,,,,,
7812,17813,2-[(2-Methoxyphenyl)methylidene]propanedinitrile,COC1=CC=CC=C1C=C(C#N)C#N,,,,,,
7813,17814,CID 17814,C(=N[NH3+])(N)N.OS(=O)(=O)[O-],,,,,,
7814,17815,4-Amino-1-naphthol,C1=CC=C2C(=C1)C(=CC=C2O)N,,,,,,
7815,17816,Allyl isovalerate,CC(C)CC(=O)OCC=C,,,,,,
7816,17817,3-Aminobenzophenone,C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)N,,,,,,
7817,17818,5-Amino-2-methylphenol,CC1=C(C=C(C=C1)N)O,,,,"['/Percutaneous absorption of 5-amino-o-cresol in a hair dye was studied under the conditions of usage. Radiolabeled 5-amino-o-cresol was added to a commercial dye containing 0.69% non-radioactive 5-amino-o-cresol; the mixture was applied to dry hair of three volunteers, worked in to the hair mass for 5-8 min, and rinsed off after an additional 20 min; the urine samples were collected for as long as radioactivity was detected, approximately 144 hr. The total urinary excretion of radioactivity was 0.2% with 50% of the radioactivity excreted in 24 hr./', '/A/ ...series of experiments /compared/ the skin permeability of a number of hair dyes obtained in two different laboratories. /Both pig skin (in vitro) and rat skin (in vivo) are permeable to 5-amino-o-cresol, the latter being more permeable.', 'A 94% recovery of radioactivity (corrected for incomplete excretion from internal application) in human urine after oral administration of radioactive 4-amino-2-hydroxytoluene /was reported/.']",,['/The total urinary excretion of radioactivity was 0.2% with 50% of the radioactivity excreted in 24 hr./']
7818,17819,4-Amino-3-methylphenol,CC1=C(C=CC(=C1)O)N,,,,,,
7819,17820,3-Amino-4-methylphenol,CC1=C(C=C(C=C1)O)N,,,,,,
7820,17821,CID 17821,C(C(=O)[O-])O.[Na+],,,,,,
7821,17822,"2-Chloro-1,1,1,2-tetrafluoroethane",C(C(F)(F)F)(F)Cl,,,,"['Fischer rats, 200g, were individually exposed to 1% (10,000 ppm) HCFC-124 in a small exposure chamber, which was periodically ""topped up"" with oxygen. Following the end of exposure, animals were immediately transferred into a metabolism cage, 20 hour urine collected and stored frozen until analysis by (19)F-NMR. During the exposure, chamber concentrations of HCFC-124 decreased with time, with similar rates of decrease between 30-90 minutes of the 2 hour exposure. The reduction demonstrates uptake by the rat. The (19)F-NMR analysis showed the urine sample contained trifluoroacetic acid (TFA, 156 umol) and fluoride (not quantified). No other metabolites were detected. Average excretion rate of 1.3 umol of TFA/24 hours was estimated.', '... Main factor affecting fate of fluorocarbons is body fat, where they are concentrated & slowly released into blood at concentrations that should not cause any risk of cardiac sensitization. Fluorocarbons/', 'There is a significant accumulation of fluorocarbons in brain, liver & lung compared to blood levels, signifying a tissue distribution of fluorocarbons similar to that of chloroform. /Fluorocarbons/', 'Abosrption of fluorocarbons is much lower after oral ingestion (35-48 times) than after inhalation. ... The lung generally has the highest fluorocarbon concentrations on autopsy. /Fluorocarbons/', 'For more Absorption, Distribution and Excretion (Complete) data for 2-CHLORO-1,1,1,2-TETRAFLUOROETHANE (7 total), please visit the HSDB record page.']","[""HCFC-124 has been studied with the other halocarbons due to structural similarities (all contain a geminal dihalomethyl group [-CHX2]) with halothane, a known hepatotoxin. Only the results for HCFC-124 and it's comparison to the other compounds is discussed here. Trifluoroacetic acid (TFA) was excreted in urine following 6 hour exposure to 1% HCFC-124 - 15.6 umol/12hour/kg. TFA excretion rank order HCFC-123=halothane>HCFC-124>HCFC-125. HCFC-124 showed a pattern of TFA-proteins (microsomal and cytosolic) similar to that seen following halothane exposure, although the immunoreactivity of individual bands was lower. TFA-protein formation rank order halothane=HCFC-123>>HCFC-124>HCFC-125. ... The proposed bioactivation scheme for halothane and HCFC-124 is: cytochrome P-450 catalyzed hydrogen abstraction to yield the intermediate 1,1-dihalo-2,2,2,-trifluoroethyl radical: oxygen rebound would give the geminal halohydrin: loss of HX would give trifluoroacetylchloride or fluoride which may undergo oxidation to give TFA or may react with nucleophilic sites in proteins to give TFA-protein. The data support the theory that cytochrome P-450-catalyzed formation of halohydrins is the rate-limiting step in the production of TFA and TFA-protein adducts. The data demonstrates increasing fluorination on the dihalomethyl group (CHX2) decreases in vivo metabolism."", 'Metabolism studies were conducted using Fischer 344 and Sprague-Dawley rats following inhalation exposure to 1.0% (v/v) air atmospheres of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123), 2-chloro-1,1,1,2-tetrafluoroethane (HCFC-124), 1-chloro-1,1-difluoroethane (HCFC-142b), bromochlorodifluoromethane (Halon 1211), and perfluorohexane (PFH) for 2 hr. There were no remarkable differences in results between the two strains of rats. Animals exposed to HCFC-123 or HCFC-124 excreted trifluoroacetic acid in their urine. Urinary fluoride concentrations were increased in rats exposed to HCFC-124, and urinary bromide levels were increased in rats exposed to Halon 1211. ...', 'Gas-uptake pharmacokinetics & metab of the chlorofluorocarbon replacement 2-chloro-1,1,1,2-tetrafluoroethane (HCFC-124) were investigated in rats, mice, & hamsters. Species differences in the rate of uptake of HCFC-124 and urinary excretion of trifluoroacetic acid were observed. In rats & mice, the uptake of HCFC-124 was described by both saturable & first-order components, whereas in the hamster only first-order uptake was observed. The in vivo metabolic rate constants obtained from computer simulation of the gas-uptake data were: for rats-KM= 1.2 mg liter-1 (8.79 mmol liter-1, Vmaxc= 0.35 : 0.01 mg kg-1 hr-1 (2.56 : 0.01 mmol kg-1 hr-1), & kfc= 1.25 : 0.01 hr-1 kg231; for mice-KM= 1.2 mg liter-1 (8.79 mmol liter-1), Vmaxc= 1.78 : 0.01 mg kg-1 hr-1 (13.0 : 0.007 mmol kg-1 hr-1), & kfc= 4.08 : 0.01 hr-1 kg-1; & for hamsters-kfc= 1.47 : 0.02 hr-1 kg-1. The production & excretion of trifluoroacetic acid, the major urinary metabolite of HCFC-124, were also simulated in rats & mice, but not in hamsters, by the physiologically based pharmacokinetic model when the in vivo metabolic rate constants obtained in the gas-uptake simulation studies were used. The blood:air partition coefficient of HCFC-124 in the hamster was lower than in the rat or mouse. A low blood:air partition coefficient may limit the pulmonary uptake of volatile chemicals.']",
7822,17823,3-Amino-4-methoxybenzoic acid,COC1=C(C=C(C=C1)C(=O)O)N,,,,,,
7823,17824,2-methyl-9H-fluoren-9-one,CC1=CC2=C(C=C1)C3=CC=CC=C3C2=O,,,,,,
7824,17825,"p-ACETOTOLUIDIDE, 2,2-DICHLORO-",CC1=CC=C(C=C1)NC(=O)C(Cl)Cl,,,,,,
7825,17826,"Ethanol, 2-(phenethylamino)-",C1=CC=C(C=C1)CCNCCO,,,,,,
7826,17827,N-Cyclohexylethanolamine,C1CCC(CC1)NCCO,,,,,,
7827,17828,"3,14-Dihydroxy-12-oxocard-20(22)-enolide",C[C@]12CC[C@@H](C[C@H]1CCC3C2CC(=O)[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O,,,,,,
7828,17829,3-Acetyl-12-dehydrodigoxigenin,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC(=O)[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)C,,,,,,
7829,17830,alpha-(Aminomethyl)-alpha-ethylbenzyl alcohol hydrochloride,CCC(C[NH3+])(C1=CC=CC=C1)O.[Cl-],,,,,,
7830,17831,1-Amino-2-phenylbutan-2-ol,CCC(CN)(C1=CC=CC=C1)O,,,,,,
7831,17832,CID 17832,C1C(=NNC(=O)O1)C2=CC=NC=C2,,,,,,
7832,17833,3-Chloroanisole,COC1=CC(=CC=C1)Cl,,,,,,
7833,17834,Zinc malate,C(C(C(=O)[O-])O)C(=O)[O-].[Zn+2],,,,,,
7834,17835,4-Methyldecane,CCCCCCC(C)CCC,,,,,,
7835,17836,Lorazepam acetate,CC(=O)OC1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3Cl,,,,,,
7836,17837,"5H-DIBENZO(d,f)(1,3)DIAZEPINE, 6-PIPERIDINO-",C1CCN(CC1)C2=NC3=CC=CC=C3C4=CC=CC=C4N2,,,,,,
7837,17838,"6-(Dimethylamino)-5H-dibenzo(d,f)(1,3)diazepine hydrochloride",C[NH+](C)C1=NC2=CC=CC=C2C3=CC=CC=C3N1.[Cl-],,,,,,
7838,17839,"N,N-dimethyl-7H-benzo[d][1,3]benzodiazepin-6-amine",CN(C)C1=NC2=CC=CC=C2C3=CC=CC=C3N1,,,,,,
7839,17840,"6-Morpholino-5H-dibenzo(d,f)(1,3)diazepine hydrochloride",C1COCC[NH+]1C2=NC3=CC=CC=C3C4=CC=CC=C4N2.[Cl-],,,,,,
7840,17841,"4-(7H-benzo[d][1,3]benzodiazepin-6-yl)morpholine",C1COCCN1C2=NC3=CC=CC=C3C4=CC=CC=C4N2,,,,,,
7841,17842,"6-(1-Pyrrolidinyl)-5H-dibenzo(d,f)(1,3)diazepine hydrochloride",C1CC[NH+](C1)C2=NC3=CC=CC=C3C4=CC=CC=C4N2.[Cl-],,,,,,
7842,17843,"6-pyrrolidin-1-yl-7H-benzo[d][1,3]benzodiazepine",C1CCN(C1)C2=NC3=CC=CC=C3C4=CC=CC=C4N2,,,,,,
7843,17844,"p-TOLUENESULFONAMIDE, N-(tert-BUTYL)-",CC1=CC=C(C=C1)S(=NC(C)(C)C)(=O)O,,,,,,
7844,17845,Dibutylarsinic acid,CCCC[As](=O)(CCCC)O,,,,,,
7845,17846,"N,N-dimethyl-1H-benzo[d]imidazol-2-amine",CN(C)C1=NC2=CC=CC=C2N1,,,,,,
7846,17847,"1,3-Butadiene, 1,1,2-trichloro-",C=CC(=C(Cl)Cl)Cl,,,,,,
7847,17848,Bis(3-methylphenyl)methanone,CC1=CC(=CC=C1)C(=O)C2=CC=CC(=C2)C,,,,,,
7848,17849,CID 17849,CC[N-]C1=NC(=NC(=N1)N[N+]#N)NC(C)(C)C,,,,,,
7849,17850,CID 17850,CCNC1=NC(=NC(=N1)N[N+]#N)NC(C)(C)C,,,,,,
7850,17851,CID 17851,CC[N-]C1=NC(=NC(=N1)N[N+]#N)NC(C)C,,,,,,
7851,17852,CID 17852,CCNC1=NC(=NC(=N1)N[N+]#N)NC(C)C,,,,,,
7852,17853,CID 17853,CCNC1=NC(=NC(=N1)[N-]CC)N[N+]#N,,,,,,
7853,17854,CID 17854,CCNC1=NC(=NC(=N1)N[N+]#N)NCC,,,,,,
7854,17855,CID 17855,CC[N-]C1=NC(=NC(=N1)N[N+]#N)N(CC)CC,,,,,,
7855,17856,CID 17856,CCNC1=NC(=NC(=N1)N(CC)CC)N[N+]#N,,,,,,
7856,17857,Isophorone diamine,CC1(CC(CC(C1)(C)CN)N)C,,,,,,
7857,17858,"1,2-Epoxydodecane",CCCCCCCCCCC1CO1,,,,,,
7858,17859,Modaline sulfate,CC1=NC=CN=C1N2CCCCC2.OS(=O)(=O)O,,,,,,
7859,17860,Modaline,CC1=NC=CN=C1N2CCCCC2,,,,,,
7860,17861,3-Pyridinepropanol,C1=CC(=CN=C1)CCCO,,,,,,
7861,17862,"1-(3,4-Dichlorophenyl)-3-methylpyrrolidin-2-one",CC1CCN(C1=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
7862,17863,2-Bromoethyldimethylammonium bromide,C[NH+](C)CCBr.[Br-],,,,,,
7863,17864,2-Bromoethyldimethylamine,CN(C)CCBr,,,,,,
7864,17865,10-Chlorophenoxarsine,C1=CC=C2C(=C1)OC3=CC=CC=C3[As]2Cl,,,,,,
7865,17866,"Glycine, N,N-dihexyl-, hydrazide",CCCCCCN(CCCCCC)CC(=O)NN,,,,,,
7866,17867,"2,2'-Thiophene-2,5-diylbis(benzoxazole)",C1=CC=C2C(=C1)N=C(O2)C3=CC=C(S3)C4=NC5=CC=CC=C5O4,,,,,,
7867,17868,alpha-Thujene,CC1=CCC2(C1C2)C(C)C,,,,,,
7868,17869,2-(Dimethylamino)ethyl methacrylate,CC(=C)C(=O)OCCN(C)C,,,"['Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) (See all compounds classified as Reducing Agents.)']",,"['2-(Dimethylamino)ethyl methacrylate was rapidly hydrolyzed to methacrylic acid (CAS 79-41-4) and N,N,-dimethylaminoethanol (CAS 108-01-0) when incubated with simulated saliva or simulated intestinal fluid in vitro, but not with simulated gastric fluid.. 90% degradation was observed in simulated saliva after 4 hours at 37 C, 86% degradation after incubation with simulated intestinal fluid for 4 hours at 37 C. Degradation was below 8% after incubation with simulated gastric fluid for 4 hours at 37 C.']",
7869,17870,"DIBENZ(b,f)(1,4)OXAZEPINE, 11-METHYL-",CC1=NC2=CC=CC=C2OC3=CC=CC=C13,,,,,,
7870,17871,"1-Naphthalenesulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-amino-, disodium salt",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])N)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N.[Na+].[Na+],,,,,,
7871,17872,4-amino-3-[(E)-[4-[4-[(E)-(1-amino-4-sulfo-2-naphthyl)azo]-3-methoxy-phenyl]-2-methoxy-phenyl]azo]naphthalene-1-sulfonic acid,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)O)N)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)N,,,,,,
7872,17873,"NAPHTHO(1,2,3,4-def)CHRYSENE, 5-METHYL-",CC1=CC2=C(C=C1)C3=CC4=CC=CC=C4C5=C3C6=C(C=CC=C26)C=C5,,,,,,
7873,17874,"NAPHTHO(1,2,3,4-def)CHRYSENE, 6-METHYL-",CC1=CC2=C(C=C1)C3=CC=CC4=C3C5=C(C=C4)C6=CC=CC=C6C=C25,,,,,,
7874,17875,"DIBENZO(def,p)CHRYSENE-10-CARBOXALDEHYDE",C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=C4)C=C6C=CC=C(C6=C25)C=O,,,,,,
7875,17876,"DIBENZO(def,p)CHRYSENE, 10-METHYL-",CC1=C2C(=CC=C1)C=C3C=CC4=C5C3=C2C6=CC=CC=C6C5=CC=C4,,,,,,
7876,17877,2-Ethyl-m-xylene,CCC1=C(C=CC=C1C)C,,,,,,
7877,17878,"5H-Dibenzo(d,f)(1,3)diazepine, 6-(hexahydro-1H-azepin-1-yl)-, compd. with ethanol",CCO.C1CCC=[N+](CC1)C2=NC3=CC=CC=C3C4=CC=CC=C4N2,,,,,,
7878,17879,"6-(3,4,5,6-tetrahydro-2H-azepin-1-ium-1-yl)-7H-benzo[d][1,3]benzodiazepine",C1CCC=[N+](CC1)C2=NC3=CC=CC=C3C4=CC=CC=C4N2,,,,,,
7879,17880,"Sodium 6,6'-(ethene-1,2-diyl)bis(3-((4-ethoxyphenyl)diazenyl)benzenesulfonate)",CCOC1=CC=C(C=C1)N=NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)OCC)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
7880,17881,5-[(4-Ethoxyphenyl)diazenyl]-2-[2-[4-[(4-ethoxyphenyl)diazenyl]-2-sulfophenyl]ethenyl]benzenesulfonic acid,CCOC1=CC=C(C=C1)N=NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)OCC)S(=O)(=O)O)S(=O)(=O)O,,,,,,
7881,17882,Atropine methylbromide,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-],,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
7882,17883,CID 17883,C1=CC(=NCCO)C(=CC1=N)N(O)O,,,,,,
7883,17884,1-Amino-4-chloroanthraquinone,C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)Cl)N,,,,,,
7884,17885,Disperse red 11,COC1=C(C2=C(C(=C1)N)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
7885,17886,Disperse red 1,CCN(CCO)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
7886,17887,Pentanedioyl dichloride,C(CC(=O)Cl)CC(=O)Cl,,,,,,
7887,17888,Diacetone acrylamide,CC(=O)CC(C)(C)NC(=O)C=C,,,,,,
7888,17889,2-tert-Butylnaphthalene,CC(C)(C)C1=CC2=CC=CC=C2C=C1,,,,,,
7889,17890,1'-Butyronaphthone,CCCC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
7890,17891,Methyl 1-naphthaleneacetate,COC(=O)CC1=CC=CC2=CC=CC=C21,,,,,,
7891,17892,Pentachlorophenoxyacetic acid,C(C(=O)O)OC1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
7892,17893,"p-((2,4,6-Triamino-5-pyrimidinyl)azo)benzoic acid",C1=CC(=CC=C1C(=O)O)N=NC2=C(N=C(N=C2N)N)N,,,,,,
7893,17894,CID 17894,CC(C)NC1=NC2=CC=CC=C2C3=CC=CC=C3N1,,,,,,
7894,17895,"6-Diethylamino-5H-dibenzo(d,f)(1,3)diazepine hydrochloride",CC[NH+](CC)C1=NC2=CC=CC=C2C3=CC=CC=C3N1.[Cl-],,,,,,
7895,17896,"N,N-diethyl-7H-benzo[d][1,3]benzodiazepin-6-amine",CCN(CC)C1=NC2=CC=CC=C2C3=CC=CC=C3N1,,,,,,
7896,17897,"9-[[(2S)-3,3-dimethyloxiran-2-yl]methoxy]furo[3,2-g]chromen-7-one",CC1([C@@H](O1)COC2=C3C(=CC4=C2OC=C4)C=CC(=O)O3)C,,,,,,
7897,17898,2-Methoxy-3-methylpyrazine,CC1=NC=CN=C1OC,,,,,,
7898,17899,3-Methylpentadecane,CCCCCCCCCCCCC(C)CC,,,,,,
7899,17900,Nonylcyclohexane,CCCCCCCCCC1CCCCC1,,,,,,
7900,17901,2-Cyclohexyloctane,CCCCCCC(C)C1CCCCC1,,,,,,
7901,17902,"1,6-Heptadien-4-OL",C=CCC(CC=C)O,,,,,,
7902,17903,Azaron,CC=CC1=CC(=C(C=C1OC)OC)OC,,,"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
7903,17904,1-(3-Chloro-4-methylphenyl)-3-methylpyrrolidin-2-one,CC1CCN(C1=O)C2=CC(=C(C=C2)C)Cl,,,,,,
7904,17905,1-Octadecanethiol,CCCCCCCCCCCCCCCCCCS,,,,,,
7905,17906,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-4-piperidyl)methyl ester, hydrochloride",C[NH+]1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7906,17907,"(1-Methylpiperidin-4-yl)methyl 2-methoxy-2,2-diphenylacetate",CN1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7907,17908,Desmethyldoxepine (hydrochloride),CNCCC=C1C2=CC=CC=C2COC3=CC=CC=C31.Cl,,,,,,
7908,17909,3-Chlorobenzenesulfonyl chloride,C1=CC(=CC(=C1)Cl)S(=O)(=O)Cl,,,,,,
7909,17910,3-Chloro-3-(4-nitrophenyl)-2-propenal,C1=CC(=CC=C1C(=CC=O)Cl)[N+](=O)[O-],,,,,,
7910,17911,"Benzene, 1-(1-isocyanato-1-methylethyl)-4-(1-methylethenyl)-",CC(=C)C1=CC=C(C=C1)C(C)(C)N=C=O,,,,,,
7911,17912,"2,3-Dihydro-5-phenyl-7-(trifluoromethyl)-1H-1,4-benzodiazepine",C1CN=C(C2=C(N1)C=CC(=C2)C(F)(F)F)C3=CC=CC=C3,,,,,,
7912,17913,"3,4-Dihydroxy-3-cyclobutene-1,2-dione",C1(=C(C(=O)C1=O)O)O,,,,,,
7913,17914,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-ethyl-4-piperidyl)methyl ester, hydrochloride",CC[NH+]1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
7914,17915,"(1-Ethylpiperidin-4-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCN1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
7915,17916,"Ethanol, 2-(ethylmethylamino)-",CCN(C)CCO,,,,,,
7916,17917,"Acetic acid, 2,2-diphenyl-2-methoxy-, 3-(dimethylamino)butyl ester, hydrochloride",CC(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)[NH+](C)C.[Cl-],,,,,,
7917,17918,"3-(Dimethylamino)butyl 2-methoxy-2,2-diphenylacetate",CC(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)N(C)C,,,,,,
7918,17919,"2,2-Diphenyl-2-ethoxyacetic acid 3-(dimethylamino)butyl ester hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCC(C)[NH+](C)C.[Cl-],,,,,,
7919,17920,"3-(Dimethylamino)butyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCC(C)N(C)C,,,,,,
7920,17921,"1-Chloro-4,6-dioxo-1,3,5-triazin-2-olate;chloride",C1(=O)NC(=O)N(C(=N1)[O-])Cl.[Cl-],,,,,,
7921,17922,Chloroisocyanuric acid,C1(=O)NC(=O)N(C(=O)N1)Cl,,,,,,
7922,17923,CID 17923,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)[O-])NN=C4C=CC(=O)C(=NNC5=CC=C(C=C5)S(=O)(=O)[O-])C4=O.[Na+].[Na+],,,,,,
7923,17924,CID 17924,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O)NN=C4C=CC(=O)C(=NNC5=CC=C(C=C5)S(=O)(=O)O)C4=O,,,,,,
7924,17925,Delorazepam,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3Cl,"['Mainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. Anti-anxiety effects also appear to be weaker in elderly patients.   Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal.']",,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],"['77-87% oral bioavailability, with a relatively slow absorption rate. Reaches peak plasma levels within 1-2 hours of administration. Food may slow absorption, however other pharmacokinetic variables remain unchanged. After multiple doses delorazepam accumulates, although accumulation is slower in younger patients.', 'Renally eliminated.', '140 L/kg apparent volume of distribution in 11 patients with normal renal function; 47 L/kg in 11 patients with renal failure and on regular hemodialysis.  In another study, apparent volume of distribution was 65 L/kg in 8 patients with liver disease and 118.4 L/kg in 12 healthy controls.', 'Still detectable 72 hours after dosing in healthy patients. Patients with liver disease experienced a reduction in clearance from 0.13 to 0.25 ng/mLh.']",['Delorazepam is metabolized at a relatively slow pace by the liver. The major metabolite (15-34% of the parent drug) is lorazepam. Older patients metabolize delorazepam slower than younger patients.'],"['Very long elimination half life of 80-115 hours, varying with age. Elimination is slower as age increases. [1] Liver disease also impacts elimination half life, with impairment resulting in half lives up to 395 hours.']"
7925,17926,"Butyrophenone, 4'-chloro-4-(pyrrolidinyl)-",C1CCN(C1)CCCC(=O)C2=CC=C(C=C2)Cl,,,,,,
7926,17927,4-Ethylresorcinol,CCC1=C(C=C(C=C1)O)O,,,,,,
7927,17928,Alonimid,C1CC2(CCC(=O)NC2=O)C3=CC=CC=C3C1=O,,,,,,
7928,17929,"1H-1,4-Benzodiazepine, 2,3-dihydro-7-amino-1-methyl-5-phenyl-",CN1CCN=C(C2=C1C=CC(=C2)N)C3=CC=CC=C3,,,,,,
7929,17930,"7-chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-ium;chloride",C[NH+]1CCN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.[Cl-],,,,,,
7930,17931,Sulazepam,CN1C(=S)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
7931,17932,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-ethyl-4-piperidyl)methyl ester, hydrochloride",CC[NH+]1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7932,17933,"(1-Ethylpiperidin-4-yl)methyl 2-methoxy-2,2-diphenylacetate",CCN1CCC(CC1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7933,17934,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-methyl-4-piperidyl)methyl ester, hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CC[NH+](CC3)C.[Cl-],,,,,,
7934,17935,"(1-Methylpiperidin-4-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCN(CC3)C,,,,,,
7935,17936,N-Carbobenzoxyglycine cyanomethyl ester,C1=CC=C(C=C1)COC(=O)NCC(=O)OCC#N,,,,,,
7936,17937,3-(4-Chlorophenyl)-2-(4-nitrophenyl)prop-2-enenitrile,C1=CC(=CC=C1C=C(C#N)C2=CC=C(C=C2)[N+](=O)[O-])Cl,,,,,,
7937,17938,2-Benzyl-2-(p-chlorophenyl)hexanoic acid ethyl ester,CCCCC(CC1=CC=CC=C1)(C2=CC=C(C=C2)Cl)C(=O)OCC,,,,,,
7938,17939,Diphenylacetic acid 2-(diethylamino)propyl ester hydrochloride,CC[NH+](CC)C(C)COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
7939,17940,"2-(Diethylamino)propyl 2,2-diphenylacetate",CCN(CC)C(C)COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
7940,17941,"2-Chloro-2,2-diphenylacetyl chloride",C1=CC=C(C=C1)C(C2=CC=CC=C2)(C(=O)Cl)Cl,,,,,,
7941,17942,2-Methylnon-2-en-4-one,CCCCCC(=O)C=C(C)C,,,,,,
7942,17943,3-Bromobenzenesulfonyl chloride,C1=CC(=CC(=C1)Br)S(=O)(=O)Cl,,,,,,
7943,17944,"2,3-Dichlorobenzoyl chloride",C1=CC(=C(C(=C1)Cl)Cl)C(=O)Cl,,,,,,
7944,17945,"2,5-Dichlorobenzoyl chloride",C1=CC(=C(C=C1Cl)C(=O)Cl)Cl,,,,,,
7945,17946,Methyl 3-chlorobenzoate,COC(=O)C1=CC(=CC=C1)Cl,,,,,,
7946,17947,"Methyl 2,5-dichlorobenzoate",COC(=O)C1=C(C=CC(=C1)Cl)Cl,,,,,,
7947,17948,Serotonin sulfate,C1=CC2=C(C=C1O)C(=CN2)CC[NH3+].OS(=O)(=O)[O-],,,,,,
7948,17949,"Ethylamine, 2-(1,4-benzodioxan-5-yloxy)-N-methyl-, hydrochloride",C[NH2+]CCOC1=CC=CC2=C1OCCO2.[Cl-],,,,,,
7949,17950,"2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N-methylethanamine",CNCCOC1=CC=CC2=C1OCCO2,,,,,,
7950,17951,"2-(1,4-Benzodioxan-5-yloxy)diethylamine hydrochloride",CC[NH2+]CCOC1=CC=CC2=C1OCCO2.[Cl-],,,,,,
7951,17952,"2-[(2,3-Dihydro-1,4-benzodioxin-5-yl)oxy]-N-ethylethanamine",CCNCCOC1=CC=CC2=C1OCCO2,,,,,,
7952,17953,"Benzylamine, N-(2-(1,4-benzodioxan-5-yloxy)ethyl)-, hydrochloride",C1COC2=C(O1)C=CC=C2OCC[NH2+]CC3=CC=CC=C3.[Cl-],,,,,,
7953,17954,"N-benzyl-2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)ethanamine",C1COC2=C(O1)C=CC=C2OCCNCC3=CC=CC=C3,,,,,,
7954,17955,"Ethylamine, 2-(1,4-benzodioxan-5-yloxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCOC1=CC=CC2=C1OCCO2.[Cl-],,,,,,
7955,17956,"2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N,N-dimethylethanamine",CN(C)CCOC1=CC=CC2=C1OCCO2,,,,,,
7956,17957,"1-(2-(1,4-Benzodioxan-5-yloxy)ethyl)hexahydro-1H-azepine hydrochloride",C1CCC[NH+](CC1)CCOC2=CC=CC3=C2OCCO3.[Cl-],,,,,,
7957,17958,"1-[2-(2,3-Dihydro-1,4-benzodioxin-5-yloxy)ethyl]azepane",C1CCCN(CC1)CCOC2=CC=CC3=C2OCCO3,,,,,,
7958,17959,"Ethylamine, 2-(1,4-benzodioxan-6-yloxy)-N-methyl-, hydrochloride",C[NH2+]CCOC1=CC2=C(C=C1)OCCO2.[Cl-],,,,,,
7959,17960,"2-(2,3-dihydro-1,4-benzodioxin-6-yloxy)-N-methylethanamine",CNCCOC1=CC2=C(C=C1)OCCO2,,,,,,
7960,17961,"(2-(1,4-Benzodioxan-5-yloxy)ethyl)trimethylammonium iodide",C[N+](C)(C)CCOC1=CC=CC2=C1OCCO2.[I-],,,,,,
7961,17962,"2-(2,3-Dihydro-1,4-benzodioxin-5-yloxy)ethyl-trimethylazanium",C[N+](C)(C)CCOC1=CC=CC2=C1OCCO2,,,,,,
7962,17963,"1-(2-(1,4-Benzodioxan-5-yloxy)ethyl)-1-methylhexahydro-1H-azepinium iodide",C[N+]1(CCCCCC1)CCOC2=CC=CC3=C2OCCO3.[I-],,,,,,
7963,17964,"1-[2-(2,3-Dihydro-1,4-benzodioxin-5-yloxy)ethyl]-1-methylazepan-1-ium",C[N+]1(CCCCCC1)CCOC2=CC=CC3=C2OCCO3,,,,,,
7964,17965,4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazinethyl acetate dihydrochloride,CC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,,,,,,
7965,17966,"1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-, acetate",CC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,,,,,,
7966,17967,"N-(2,4-Dinitrophenyl)-2,4-dinitroaniline",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
7967,17968,3-Chlorophenyl isocyanate,C1=CC(=CC(=C1)Cl)N=C=O,,,,,,
7968,17969,"2-Butoxy-2,2-diphenylacetic acid (1-methyl-3-piperidyl) ester hydrochloride",CCCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCC[NH+](C3)C.[Cl-],,,,,,
7969,17970,"(1-Methylpiperidin-3-yl) 2-butoxy-2,2-diphenylacetate",CCCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCCN(C3)C,,,,,,
7970,17971,"2,2-Diphenyl-2-methoxyacetic acid (1-ethyl-3-piperidyl) ester hydrochloride",CC[NH+]1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7971,17972,"(1-Ethylpiperidin-3-yl) 2-methoxy-2,2-diphenylacetate",CCN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7972,17973,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-4-piperidyl) ester, hydrochloride",C[NH+]1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7973,17974,1-Methyl-4-piperidinyl alpha-methoxy-alpha-phenylbenzeneacetate,CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7974,17975,"2,2-Diphenyl-2-ethoxyacetic acid (1-ethyl-4-piperidyl) ester hydrochloride",CC[NH+]1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
7975,17976,"(1-Ethylpiperidin-4-yl) 2-ethoxy-2,2-diphenylacetate",CCN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
7976,17977,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-2-piperidyl)methyl ester, hydrochloride",C[NH+]1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7977,17978,"(1-Methylpiperidin-2-yl)methyl 2-methoxy-2,2-diphenylacetate",CN1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7978,17979,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-ethyl-2-piperidyl)methyl ester, hydrochloride",CC[NH+]1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
7979,17980,"(1-Ethylpiperidin-2-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCN1CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
7980,17981,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-3-piperidyl)methyl ester, hydrochloride",C[NH+]1CCCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
7981,17982,"(1-Methylpiperidin-3-yl)methyl 2-methoxy-2,2-diphenylacetate",CN1CCCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
7982,17983,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(dibutylamino)ethyl) ester, hydrochloride",CCCC[NH+](CCCC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
7983,17984,"2-(Dibutylamino)ethyl 2-methoxy-2,2-diphenylacetate",CCCCN(CCCC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
7984,17985,"Acetic acid, 2,2-diphenyl-2-methoxy-, (3-(N-ethyl-N-methylamino)propyl) ester, hydrochloride",CC[NH+](C)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
7985,17986,"3-[Ethyl(methyl)amino]propyl 2-methoxy-2,2-diphenylacetate",CCN(C)CCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
7986,17987,"s-Triazine, 4,6-bis(methylamino)-2-chloro-",CNC1=NC(=NC(=N1)Cl)NC,,,,,,
7987,17988,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-butyl-N-methylamino)ethyl) ester, hydrochloride",CCCC[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
7988,17989,"2-[Butyl(methyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCCCN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
7989,17990,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-ethyl-N-propylamino)ethyl) ester, hydrochloride",CCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
7990,17991,"2-[Ethyl(propyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
7991,17992,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-ethyl-N-isopropylamino)ethyl) ester, hydrochloride",CC[NH+](CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)C(C)C.[Cl-],,,,,,
7992,17993,"2-[Ethyl(propan-2-yl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCN(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)C(C)C,,,,,,
7993,17994,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-ethyl-N-isopropylamino)ethyl) ester, hydrochloride",CC[NH+](CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC)C(C)C.[Cl-],,,,,,
7994,17995,"2-[Ethyl(propan-2-yl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCN(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC)C(C)C,,,,,,
7995,17996,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-butyl-N-ethylamino)ethyl) ester, hydrochloride",CCCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
7996,17997,"2-[Butyl(ethyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
7997,17998,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-ethyl-N-isobutylamino)ethyl) ester, hydrochloride",CC[NH+](CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)CC(C)C.[Cl-],,,,,,
7998,17999,"2-[Ethyl(2-methylpropyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCN(CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC)CC(C)C,,,,,,
7999,18000,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-sec-butyl-N-ethylamino)ethyl) ester, hydrochloride",CCC(C)[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8000,18001,"2-[Butan-2-yl(ethyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCC(C)N(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8001,18002,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-sec-butyl-N-ethylamino)ethyl) ester, hydrochloride",CCC(C)[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
8002,18003,"2-[Butan-2-yl(ethyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCC(C)N(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
8003,18004,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-ethyl-N-pentylamino)ethyl) ester, hydrochloride",CCCCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8004,18005,"2-[Ethyl(pentyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCCCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8005,18006,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-ethyl-N-pentylamino)ethyl) ester, hydrochloride",CCCCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
8006,18007,"2-[Ethyl(pentyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCCCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
8007,18008,(2-(Diphenylamino)ethyl)trimethylammonium bromide,C[N+](C)(C)CCN(C1=CC=CC=C1)C2=CC=CC=C2.[Br-],,,,,,
8008,18009,"Ethanaminium, 2-(diphenylamino)-N,N,N-trimethyl-",C[N+](C)(C)CCN(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8009,18010,2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cycloheptanol,CN(C)CC1CCCCCC1(C2=CC(=CC=C2)OC)O,,,,,,
8010,18011,Dioctyl but-2-enedioate,CCCCCCCCOC(=O)C=CC(=O)OCCCCCCCC,,,,,,
8011,18012,"Ethanol, 2-(triethylsilyl)-",CC[Si](CC)(CC)CCO,,,,,,
8012,18013,2-(Trimethylsilyl)ethanol,C[Si](C)(C)CCO,,,,,,
8013,18014,2-Chloro-5-(1-methylpropyl)phenol methylcarbamate,CCC(C)C1=CC(=C(C=C1)Cl)OC(=O)NC,,,,,,
8014,18015,1-Hexadecanethiol,CCCCCCCCCCCCCCCCS,,,,,,
8015,18016,Dibutyl azelate,CCCCOC(=O)CCCCCCCC(=O)OCCCC,,,,,,
8016,18017,CID 18017,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCCOCCS(=O)(=O)[O-].[Na+],,,,,,
8017,18018,Entsufon,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCCOCCS(=O)(=O)O,,,,,,
8018,18019,"1,4-Dimethanesulfonoxy-2-butyne",CS(=O)(=O)OCC#CCOS(=O)(=O)C,,,,,,
8019,18020,"Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-16-methylene-, acetate",CC1=CC2C(CCC3(C2CC(=C)C3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,,,,,,
8020,18021,4-Cyanobiphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)C#N,,,,,,
8021,18022,2-Aminooxyacetic acid;carboxymethoxyazanium;chloride,C(C(=O)O)O[NH3+].C(C(=O)O)ON.[Cl-],,,,,,
8022,18023,"2-Chlorohexahydro-4-methyl 4H-1,3,2-benzodioxaphosphorin 2-sulfide",CC1C2CCCCC2OP(=S)(O1)Cl,,,,,,
8023,18024,n-Heptanoylcholine iodide,CCCCCCC(=O)OCC[N+](C)(C)C.[I-],,,,,,
8024,18025,Heptanoylcholine,CCCCCCC(=O)OCC[N+](C)(C)C,,,,,,
8025,18026,Butaxamine,CC(C(C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C,,,"['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs that bind to and block the activation of ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Antagonists.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)']",,,
8026,18027,2-Heptadecanone,CCCCCCCCCCCCCCCC(=O)C,,,,,,
8027,18028,Clamoxyquin pamoate,CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)Cl.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
8028,18029,Clamoxyquine,CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)Cl,,,,,,
8029,18030,"BENZOIC ACID, p-FLUORO-, 2-ISOPROPYLHYDRAZIDE",CC(C)NNC(=O)C1=CC=C(C=C1)F,,,,,,
8030,18031,"N-(2-chlorophenyl)-4,6-difluoro-1,3,5-triazin-2-amine",C1=CC=C(C(=C1)NC2=NC(=NC(=N2)F)F)Cl,,,,,,
8031,18032,"Acetamide, N-(7-nitrofluoren-2-YL)-2,2,2-trifluoro-",C1C2=C(C=CC(=C2)NC(=O)C(F)(F)F)C3=C1C=C(C=C3)[N+](=O)[O-],,,,,,
8032,18033,"BORIC ACID, (2,6-DI-tert-BUTYL-p-TOLYL) DIISOPROPYL ESTER",B(OC1=C(C=C(C=C1C(C)(C)C)C)C(C)(C)C)(OC(C)C)OC(C)C,,,,,,
8033,18034,"Isophthalaldehyde, 5-ethoxy-4-hydroxy-",CCOC1=CC(=CC(=C1O)C=O)C=O,,,,,,
8034,18035,4-Hydroxy-5-methoxyisophthalaldehyde,COC1=CC(=CC(=C1O)C=O)C=O,,,,,,
8035,18036,(2-(N-Cyclohexylanilino)ethyl)triethylammonium bromide,CC[N+](CC)(CC)CCN(C1CCCCC1)C2=CC=CC=C2.[Br-],,,,,,
8036,18037,2-(N-cyclohexylanilino)ethyl-triethylazanium,CC[N+](CC)(CC)CCN(C1CCCCC1)C2=CC=CC=C2,,,,,,
8037,18038,(2-(N-Cyclohexylanilino)ethyl)trimethylammonium bromide,C[N+](C)(C)CCN(C1CCCCC1)C2=CC=CC=C2.[Br-],,,,,,
8038,18039,2-(N-cyclohexylanilino)ethyl-trimethylazanium,C[N+](C)(C)CCN(C1CCCCC1)C2=CC=CC=C2,,,,,,
8039,18040,(2-(Diphenylamino)ethyl)diisopropylmethylammonium bromide,CC(C)[N+](C)(CCN(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C.[Br-],,,,,,
8040,18041,methyl-[2-(N-phenylanilino)ethyl]-di(propan-2-yl)azanium,CC(C)[N+](C)(CCN(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
8041,18042,(2-(Diphenylamino)ethyl)triethylammonium bromide,CC[N+](CC)(CC)CCN(C1=CC=CC=C1)C2=CC=CC=C2.[Br-],,,,,,
8042,18043,triethyl-[2-(N-phenylanilino)ethyl]azanium,CC[N+](CC)(CC)CCN(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8043,18044,CID 18044,CCC1(C(=O)NC(=NC1=O)[O-])CC=CC.[Na+],,,,,,
8044,18045,5-Athyl-5-crotylbarbitursaure,CCC1(C(=O)NC(=O)NC1=O)CC=CC,,,,,,
8045,18046,"2-Amino-4,5,6,7-tetrahydrobenzothiazole",C1CCC2=C(C1)N=C(S2)N,,,,,,
8046,18047,Toliprolol,CC1=CC(=CC=C1)OCC(CNC(C)C)O,,,,,,
8047,18048,"2,4-Diisopropylphenol",CC(C)C1=CC(=C(C=C1)O)C(C)C,,,,,,
8048,18049,"2,5-Hexanediol",CC(CCC(C)O)O,,,,,,
8049,18050,Methyl 3-mercaptopropionate,COC(=O)CCS,,,,,,
8050,18051,3-(2-Aminoethyl)indole acetate,CC(=O)[O-].C1=CC=C2C(=C1)C(=CN2)CC[NH3+],,,,,,
8051,18052,Allyl chloroformate,C=CCOC(=O)Cl,,,,,,
8052,18053,"2-Methyl-1,4-butanediol",CC(CCO)CO,,,,,,
8053,18054,1-Phenylpropan-1-amine,CCC(C1=CC=CC=C1)N,,,,,,
8054,18055,Ethiolate,CCN(CC)C(=O)SCC,,,,,,
8055,18056,"Carbonochloridothioic acid, S-ethyl ester",CCSC(=O)Cl,,,,,,
8056,18057,4-Nitro-1H-indazole,C1=CC2=C(C=NN2)C(=C1)[N+](=O)[O-],,,,,,
8057,18058,Thymine glycol,CC1(C(NC(=O)NC1=O)O)O,,,,,,
8058,18059,CID 18059,CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)N)OC)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)[O-].[Na+],,,,,,
8059,18060,6-Amino-3-((4-((4-aminophenyl)azo)-6-methoxy-m-tolyl)azo)-4-hydroxynaphthalene-2-sulphonic acid,CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)N)OC)N=NC3=C(C=C4C=CC(=CC4=C3O)N)S(=O)(=O)O,,,,,,
8060,18061,Ethyladrenaline,CCNCC(C1=CC(=C(C=C1)O)O)O,,,,,,
8061,18062,"1,4-Bis(2-hydroxy-2-propyl)benzene",CC(C)(C1=CC=C(C=C1)C(C)(C)O)O,,,,,,
8062,18063,Tetraisopropyltin,CC(C)[Sn](C(C)C)(C(C)C)C(C)C,,,,,,
8063,18064,S-Methyl methanethiosulfonate,CSS(=O)(=O)C,,,,,,
8064,18065,"O,O,S-Trimethyl dithiophosphate",COP(=S)(OC)SC,,,,,,
8065,18066,"1,2,3,4-Tetrahydro-1-naphthylamine",C1CC(C2=CC=CC=C2C1)N,,,,,,
8066,18067,3-Eicosanone,CCCCCCCCCCCCCCCCCC(=O)CC,,,,,,
8067,18068,Galactose-uridine-5'-diphosphate,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
8068,18069,"2-Amino-2',5-dichlorobenzophenone",C1=CC=C(C(=C1)C(=O)C2=C(C=CC(=C2)Cl)N)Cl,,,,,,
8069,18070,"2,3,6-Trichloroquinoxaline",C1=CC2=C(C=C1Cl)N=C(C(=N2)Cl)Cl,,,,,,
8070,18071,CID 18071,[Li+].C1=C(C=C(C(=C1I)[O-])I)C#N,,,,,,
8071,18072,CID 18072,C1=C(C=C(C(=C1I)[O-])I)C#N.[Na+],,,,,,
8072,18073,CID 18073,C1=C(C=C(C(=C1Br)[O-])Br)C#N.[K+],,,,,,
8073,18074,"2,4,6-CYCLOHEPTATRIEN-1-ONE, 2-HYDROXY-3-IODO-, p-NITROBENZOATE",C1=CC(=C(C(=O)C=C1)OC(=O)C2=CC=C(C=C2)[N+](=O)[O-])I,,,,,,
8074,18075,"Phenol, 2-(1H-benzimidazol-2-yl)-",C1=CC=C(C(=C1)C2=NC3=CC=CC=C3N2)O,,,,,,
8075,18076,Valerylcholine iodide,CCCCC(=O)OCC[N+](C)(C)C.[I-],,,,,,
8076,18077,Pentanoylcholine,CCCCC(=O)OCC[N+](C)(C)C,,,,,,
8077,18078,"Indol-5-OL, 3-(2-(dimethylamino)ethyl)-, oxalate",C[NH+](C)CCC1=C[NH2+]C2=C1C=C(C=C2)O.C(=O)(C(=O)[O-])[O-],,,,,,
8078,18079,Diberal,CCC1(C(=O)NC(=O)NC1=O)C(C)CC(C)C,,,,,,
8079,18080,CID 18080,CC(=NN=C([NH3+])N)C1=CC=C(C=C1)N=C(N)N=C([NH3+])N.[Cl-].[Cl-],,,,,,
8080,18081,CID 18081,CC(=NN=C(N)N)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
8081,18082,"MALONONITRILE, (p-CHLOROBENZYL)-",C1=CC(=CC=C1CC(C#N)C#N)Cl,,,,,,
8082,18083,"Butyramide, 4-morpholino-2-(2-morpholinoethyl)-2-phenyl-",C1COCCN1CCC(CCN2CCOCC2)(C3=CC=CC=C3)C(=O)N,,,,,,
8083,18084,"Adipic acid, methyl vinyl ester",COC(=O)CCCCC(=O)OC=C,,,,,,
8084,18085,Diphenyltrichloroethane,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(Cl)(Cl)Cl,,,,,,
8085,18086,"2,4-D chlorocrotyl ester",C1=CC(=C(C=C1Cl)Cl)OCC(=O)OCC=CCCl,,,,,"['Plants hydrolyze 2,4-D esters to 2,4-D, which is the active herbicide. ... Further metabolism ... occurs through three mechanisms, namely, side chain degradation, hydroxylation of the aromatic ring, and conjugation with plant constituents. /2,4-D esters/', 'HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID. /2,4-D ESTERS/', '2,4-D ESTERS ARE HYDROLYZED IN ANIMALS. THE PHENOXY ACIDS ARE EXCRETED PREDOMINANTLY AS SUCH IN THE URINE OF RATS AFTER THEIR ORAL ADMIN, ALTHOUGH MINOR PORTION IS CONJUGATED WITH AMINO ACIDS GLYCINE & TAURINE & WITH GLUCURONIC ACID. /2,4-D AND ESTERS/', 'Metabolites of 2,4-D other than conjugates have not been detected in human urine.']",['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/']
8086,18087,Clopidol,CC1=C(C(=O)C(=C(N1)C)Cl)Cl,,,['Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)'],,,
8087,18088,"2-Chloro-4,6-diphenoxy-1,3,5-triazine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)Cl)OC3=CC=CC=C3,,,,,,
8088,18089,"2,4-Dichlorobenzylidenemalononitrile",C1=CC(=C(C=C1Cl)Cl)C=C(C#N)C#N,,,,,,
8089,18090,"Malononitrile, (2,4-dimethoxybenzylidene)-",COC1=CC(=C(C=C1)C=C(C#N)C#N)OC,,,,,,
8090,18091,Piperonylidenemalononitrile,C1OC2=C(O1)C=C(C=C2)C=C(C#N)C#N,,,,,,
8091,18092,(1-Naphthylmethylene)malononitrile,C1=CC=C2C(=C1)C=CC=C2C=C(C#N)C#N,,,,,,
8092,18093,"Malononitrile, (2-naphthylmethylene)-",C1=CC=C2C=C(C=CC2=C1)C=C(C#N)C#N,,,,,,
8093,18094,"1-Chloro-1,1-dinitroethane",CC([N+](=O)[O-])([N+](=O)[O-])Cl,,,,,,
8094,18095,"Methane, dibromodinitro-",C([N+](=O)[O-])([N+](=O)[O-])(Br)Br,,,,,,
8095,18096,Diisopropyl sulfate,CC(C)OS(=O)(=O)OC(C)C,,,,,,
8096,18097,"MALEIMIDE, N-(o-NITROPHENYL)-",C1=CC=C(C(=C1)N2C(=O)C=CC2=O)[N+](=O)[O-],,,,,,
8097,18098,N-Allylmaleimide,C=CCN1C(=O)C=CC1=O,,,,,,
8098,18099,5-Bromovanillin,COC1=C(C(=CC(=C1)C=O)Br)O,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)']",,,
8099,18100,"3,5-Dibromo-4-hydroxybenzaldehyde",C1=C(C=C(C(=C1Br)O)Br)C=O,,,,,,
8100,18101,"3,4'-Dichlorobiphenyl",C1=CC(=CC(=C1)Cl)C2=CC=C(C=C2)Cl,,,,,,
8101,18102,"3,4-Dichlorobiphenyl",C1=CC=C(C=C1)C2=CC(=C(C=C2)Cl)Cl,,,,,,
8102,18103,CID 18103,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
8103,18104,Carfenazine,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO,['Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.'],['Carphenazine is a phenothiazine antipsychotic agent with a piperazine side-chain.'],,,,
8104,18105,"2,3-Dichlorophenoxyacetic acid",C1=CC(=C(C(=C1)Cl)Cl)OCC(=O)O,,,,,,
8105,18106,"Butyramide, 4-(dimethylamino)-2-methyl-2-phenyl-",CC(CCN(C)C)(C1=CC=CC=C1)C(=O)N,,,,,,
8106,18107,"Butyramide, 4-(dimethylamino)-2-ethyl-2-phenyl-",CCC(CCN(C)C)(C1=CC=CC=C1)C(=O)N,,,,,,
8107,18108,"Butyramide, 4-(dimethylamino)-2-isopropyl-2-phenyl-",CC(C)C(CCN(C)C)(C1=CC=CC=C1)C(=O)N,,,,,,
8108,18109,"Butyramide, 2-methyl-2-phenyl-4-piperidino-",CC(CCN1CCCCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
8109,18110,"Butyramide, 2-ethyl-2-phenyl-4-piperidino-",CCC(CCN1CCCCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
8110,18111,"Butyramide, 2-isopropyl-2-phenyl-4-piperidino-",CC(C)C(CCN1CCCCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
8111,18112,"Butyramide, 2-phenyl-4-piperidino-2-(2-piperidinoethyl)-",C1CCN(CC1)CCC(CCN2CCCCC2)(C3=CC=CC=C3)C(=O)N,,,,,,
8112,18113,"Butyramide, 2-methyl-4-morpholino-2-phenyl-",CC(CCN1CCOCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
8113,18114,"Butyramide, 2-ethyl-4-morpholino-2-phenyl-",CCC(CCN1CCOCC1)(C2=CC=CC=C2)C(=O)N,,,,,,
8114,18115,N-(alpha-Methylphenethyl)furfurylamine acetate,CC(CC1=CC=CC=C1)[NH2+]CC2=CC=CO2.CC(=O)[O-],,,,,,
8115,18116,Furfurylamphetamine,CC(CC1=CC=CC=C1)NCC2=CC=CO2,,,,,,
8116,18117,"Ammonium 4,6-dinitro-o-tolyl oxide",CC1=CC(=CC(=C1[O-])[N+](=O)[O-])[N+](=O)[O-].[NH4+],,,,,,
8117,18118,1-(Cyclohex-1-en-1-yl)piperidine,C1CCN(CC1)C2=CCCCC2,,,,,,
8118,18119,"1-NAPHTHALENEACETONITRILE, alpha,alpha-BIS(2-PIPERIDINOETHYL)-",C1CCN(CC1)CCC(CCN2CCCCC2)(C#N)C3=CC=CC4=CC=CC=C43,,,,,,
8119,18120,alpha-Methyl-alpha-(2-morpholinoethyl)-1-naphthaleneacetonitrile,CC(CCN1CCOCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
8120,18121,CID 18121,C1=CC=C(C=C1)CC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)[O-].[Na+],,,,,,
8121,18122,"(4-Benzyl-phenyl)-oxo-acetaldehyde, bisulfite",C1=CC=C(C=C1)CC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)O,,,,,,
8122,18123,CID 18123,C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)[O-].[Na+],,,,,,
8123,18124,1-Hydroxy-2-oxo-2-(4-phenethylphenyl)ethanesulfonic acid,C1=CC=C(C=C1)CCC2=CC=C(C=C2)C(=O)C(O)S(=O)(=O)O,,,,,,
8124,18125,"1,3-Butadiene, 1,4-dichloro-, (E,E)-",C(=CCl)C=CCl,,,,,,
8125,18126,"1,2-Epoxyoctane",CCCCCCC1CO1,,,,,,
8126,18127,S-(4-Chlorophenyl) O-ethyl ethylphosphonodithioate,CCOP(=S)(CC)SC1=CC=C(C=C1)Cl,,,,,,
8127,18128,CID 18128,CC(C)NC(=NC(C)C)S,,,,,,
8128,18129,3-Bromophenylurea,C1=CC(=CC(=C1)Br)NC(=O)N,,,,,,
8129,18130,"p,p'-Dibromodiphenyl trichloroethane",C1=CC(=CC=C1C(C2=CC=C(C=C2)Br)C(Cl)(Cl)Cl)Br,,,,,,
8130,18131,"(2-(1,4-Benzodioxan-5-yloxy)ethyl)diethylmethylammonium iodide",CC[N+](C)(CC)CCOC1=CC=CC2=C1OCCO2.[I-],,,,,,
8131,18132,"2-(2,3-Dihydro-1,4-benzodioxin-5-yloxy)ethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOC1=CC=CC2=C1OCCO2,,,,,,
8132,18133,CID 18133,CCN(CC(=O)[O-])S(=O)(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F.[K+],,,,,,
8133,18134,N-Ethyl-N-[(heptadecafluorooctyl)sulphonyl]glycine,CCN(CC(=O)O)S(=O)(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
8134,18135,"[2-[(6S,17S)-16-acetyloxy-6-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate",CC(=O)OCC(=O)[C@]1(C(CC2C1(CC(C3C2C[C@@H](C4C3(CCC(=O)C4)C)F)O)C)OC(=O)C)O,,,,,,
8135,18136,"[2-(19-Fluoro-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-8-yl)-2-oxoethyl] acetate",CC(=O)OCC(=O)C12C(CC3C1(CCC4C3CC(C5=CC(=O)CCC45C)F)C)OC(O2)(C)C,,,,,,
8136,18137,Phenyltrimethoxysilane,CO[Si](C1=CC=CC=C1)(OC)OC,,,,,,
8137,18138,"Dibenzo[b,e]fluoranthene",C1=CC=C2C(=C1)C=C3C4=CC=CC=C4C5=CC6=CC=CC=C6C2=C35,,,,,,
8138,18139,Diallyl adipate,C=CCOC(=O)CCCCC(=O)OCC=C,,,,,,
8139,18140,"(17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl) N,N-bis(2-chloroethyl)carbamate",CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)']",,,
8140,18141,"Magnesium, dimethyl-",[CH3-].[CH3-].[Mg+2],,,,,,
8141,18142,Quingestanol acetate,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CCC(=C4)OC5CCCC5)C)C#C,,,,,,
8142,18143,"3,4-Dichlorosulfolane",C1C(C(CS1(=O)=O)Cl)Cl,,,,,,
8143,18144,"4,5-Dihydroxy-1,3-bis(methoxymethyl)imidazolidin-2-one",COCN1C(C(N(C1=O)COC)O)O,,,,,,
8144,18145,2-Octanethiol,CCCCCCC(C)S,,,,,,
8145,18146,Triethanolamine tristearate,CCCCCCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCCCCCC)CCOC(=O)CCCCCCCCCCCCCCCCC,,,,,,
8146,18147,m-Hydroxyephedrine,CC(C(C1=CC(=CC=C1)O)O)NC,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
8147,18148,Tetrabutylammonium p-Nitrophenoxide,CCCC[N+](CCCC)(CCCC)CCCC.C1=CC(=CC=C1[N+](=O)[O-])[O-],,,,,,
8148,18149,Lanthanum citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[La+3],,,,,,
8149,18150,Tetrahydrofurfuryl chloride,C1CC(OC1)CCl,,,,,,
8150,18151,CID 18151,C1=CC=C(C=C1)C2=NN=C(O2)S,,,,,,
8151,18152,2-Methoxy-4-isopropylamino-6-diethylamino-s-triazine,CCN(CC)C1=NC(=NC(=N1)NC(C)C)OC,,,,,,
8152,18153,Norazine,CC(C)NC1=NC(=NC(=N1)NC)Cl,,,,,,
8153,18154,"Benzeneacetic acid, 3,6-dichloro-2-methoxy-",COC1=C(C=CC(=C1CC(=O)O)Cl)Cl,,,,,,
8154,18155,"2,3-Dibromo-N-methylmaleimide",CN1C(=O)C(=C(C1=O)Br)Br,,,,,,
8155,18156,"N,N'-1,3-Phenylenedimaleimide",C1=CC(=CC(=C1)N2C(=O)C=CC2=O)N3C(=O)C=CC3=O,,,,,,
8156,18157,Didodecylamine,CCCCCCCCCCCCNCCCCCCCCCCCC,,,,,,
8157,18158,4-Methylquinolinium chloride,CC1=CC=[NH+]C2=CC=CC=C12.[Cl-],,,,,,
8158,18159,"N,N-Dimethyldodecanamide",CCCCCCCCCCCC(=O)N(C)C,,,,,,
8159,18160,4'-Methoxy-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)OC,,,,,,
8160,18161,2'-Methoxy-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2OC,,,,,,
8161,18162,(Cyanomethyl)diethylmethylammonium iodide,CC[N+](C)(CC)CC#N.[I-],,,,,,
8162,18163,Cyanomethyl-diethyl-methylazanium,CC[N+](C)(CC)CC#N,,,,,,
8163,18164,Piperidinoacetonitrile,C1CCN(CC1)CC#N,,,,,,
8164,18165,"p-PHENYLENEDIAMINE, N,N'-DIETHYL-",CCNC1=CC=C(C=C1)NCC,,,,,,
8165,18166,"N,N-Dimethyl-p-((o-nitrophenyl)azo)aniline",CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2[N+](=O)[O-],,,,,,
8166,18167,2'-Chloro-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC=C2Cl,,,,,,
8167,18168,4'-Methyl-p-dimethylaminoazobenzene,CC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
8168,18169,4-Hydroxy-3-nitrobenzaldehyde,C1=CC(=C(C=C1C=O)[N+](=O)[O-])O,,,,,,
8169,18170,Benzyl thiocyanate,C1=CC=C(C=C1)CSC#N,,,,,,
8170,18171,Diammonium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)O)O.[NH4+].[NH4+],,,,"['...The distribution of (15)N from ammonium citrate, administered by different routes, into the proteins of various tissues of hypophysectomized rats /was examined/. The liver, kidney, and spleen contained greater concentrations of (15)N incorporated into proteins than heart or muscle fractions during 72 hr following intragastric, intraperitoneal, and subcutaneous administration of 15N-ammonium citrate. After the first 6 hr, during which the intragastric route gave higher values, the quantity of (15)N incorporated into liver-protein was not substantially affected by the route of administration. In most of the other tissues studied, however, (15)N incorporation tended to be least by the intragastric route, followed, in increasing order, by the intraperitoneal and subcutaneous routes. By the last route, more labelled ammonia was apparently made available to the widely distributed glutamine-synthetase (EC 6.3.1.2) system. /Ammonium citrate/']","['Results of studies on the metabolic fate of dietary ammonium citrate and intravenously-administered ammonium lactate in rats showed that urea synthesis represented a nearly constant fraction of the administered ammonia over a large concentration range. Besides glutamine and urea, labelled nitrogen also appeared in creatine, glycine, alanine, proline, histidine, arginine, glutamic acid, and aspartic acid. ...The incorporation of (15)N from ammonium citrate into proteins of liver, heart, kidney, spleen, and muscle fractions of untreated and growth hormone-treated, hypophysectomized rats /was examined/, and found differences in the metabolic fate, depending on the route of administration. Subcutaneous injection facilitated the labelling of amide nitrogen, indicating extensive disposition via glutamine synthesis. In contrast, intragastric or intraperitoneal administration resulted in the labelling of arginine, glutamic acid, and other alpha-amino acids of the liver. Amide-nitrogen was labelled to a much lesser extent than by the subcutaneous route. The tissue distribution of the label also differed according to the route of entry. /Ammonium citrate/']",
8171,18172,"9,10-12,13-Diepoxyoctadecanoate",CCCCCC1C(O1)CC2C(O2)CCCCCCCC(=O)O,,,,,,
8172,18173,1-Methyl-1H-benzoimidazole-2-carbaldehyde oxime,CN1C2=CC=CC=C2N=C1C=NO,,,,,,
8173,18174,Cobalt(II) thiocyanate,C(#N)[S-].C(#N)[S-].[Co+2],,,,,,
8174,18175,2-Bromo-1-chloropropane,CC(CCl)Br,,,,,,
8175,18176,1-Bromo-2-chloropropane,CC(CBr)Cl,,,,,,
8176,18177,Dichloroacetonitrile,C(#N)C(Cl)Cl,,,,"['The excretion and tissue distribution of (1-14C)dichloroacetonitrile and (2-14C)dichloroacetonitrile were studied in male Fischer 344 rats and male B6C3F1 mice. Three dose levels of dichloroacetonitrile (DCAN) (0.2, 2, or 15 mg/kg) were administered to rats and two dose levels of DCAN (2 or 15 mg/kg) to mice. Daily excreta including exhaled volatiles and radiolabeled carbon dioxide (14CO2) were analyzed for radiolabeled carbon (14C) until greater than 70% of the radioactivity was excreted. At that time the animals were sacrificed and tissues were collected. Tissues and excreta were analyzed for 14C by combustion and liquid scintillation counting. Rats administered (1-14C)DCAN excreted 62 to 73% of the 14C in 6 days, with 42 to 45% in urine, 14 to 20% in feces, and 3 to 8% as CO2. Rats administered (2-14C)DCAN excreted 82 to 86% of the 14C in 48 hr, with 35 to 40% in urine, 33 to 34% as CO2, and 10 to 13% in feces. Mice administered (1-14C)DCAN excreted 83 to 85% of the 14C in 24 hr, with 64 to 70% in urine, 9 to 13% in feces, and 5 to 6% as CO2. Mice administered (2-14C)DCAN excreted 84 to 88% of the 14C in 24 hr with 42 to 43% in urine, 8 to 11% in feces, and 31 to 37% as CO2. Liver tissues retained the most 14C in all studies except the study of (1-14C)DCAN in rats, where blood contained the most 14C. These results indicate that DCAN was absorbed rapidly after oral administration in water. The differences in the route of excretion of (1-14C)DCAN compared to (2-14C)DCAN indicated that the molecule was being cleaved in the body and metabolized by different mechanisms.', 'After oral administration of 0.02 mmol/kg body weight (2.0 mg/kg body weight) or 0.14 mmol/kg body weight (15 mg/kg body weight) (14)C-dichloroacetonitrile to mice by gavage in water, 85 and 83%, respectively, of the dose was eliminated in the urine, feces and expired air (as (14)C-carbon dioxide) by 24 hours. The urine contained 64-70% of the dose, the feces contained 9-13% and about 5% was eliminated as carbon dioxide; 11-12% was retained in the tissues. The largest amount of radiolabel was found in the liver about 4% of dose, muscle and skin (about 2%) and blood and fat (about 1%). When mice were given 0.02 mmol/kg body weight (2.0 mg/kg) or 0.14 mmol/kg body weight (15 mg/kg) 2-(14)C-dichloroacetonitrile by gavage in water, 84-88% of the dose was eliminated in the urine, feces and expired air (as (14)C-carbon dioxide) within 24 hours; the urine (42-43% of dose) and expired air 31-37%) contained the most radiolabel. Nine percent of the administered radiolabel was retained in the tissues after 24 hours; most was found in the liver (about 5% of dose), and 0.5-1% of the dose was present in muscle, kidney and skin.', 'Studies with [1-14C]dichloroacetonitrile in rats and mice and [2-14C]dichloroacetonitrile in rats indicated that the substance is rapidly absorbed after oral administration in water. Excretion of radioactivity following dosing with [1-14C]dichloroacetonitrile is more rapid in mice than in rats. In mice, approximately 84% of the dose was excreted in 24 hr (67% in urine, 11% in feces, 5% as CO2), compared with 67% in rats in six days (44% in urine, 17% in feces, 6% as CO2). Excretion of [2-14C]dichloroacetonitrile radioactivity in rats accounted for about 84% of the dose within 48 hr (38% in urine, 12% in feces, 34% as CO2). The quantitative differences in the route of excretion of the two labels in rats indicate that dichloroacetonitrile is being cleaved in vivo. The 1-14Clabelled compound behaved like cyanide']","['When administered orally to rats, the haloacetonitriles (HAN) were metabolized to cyanide and excreted in the urine as thiocyanate. The extent of thiocyanate excretion was chloroacetonitrile (CAN) greater than bromochloroacetonitrile (BCAN) greater than dichloroacetonitrile (DCAN)  greater than dibromoacetonitrile (DBAN)  much greater than trichloroacetonitrile (TCAN).', 'The excretion and tissue distribution of (1-14C)dichloroacetonitrile and (2-14C)dichloroacetonitrile were studied in male Fischer 344 rats and male B6C3F1 mice. ...The differences in the route of excretion of (1-14C)DCAN compared to (2-14C)DCAN indicated that the molecule was being cleaved in the body and metabolized by different mechanisms.']",
8177,18178,"1-Phenyl-1,2,3,4-tetrahydronaphthalene",C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,,,,,,
8178,18179,"2,4-Dichloro-6-phenylsulfanyl-1,3,5-triazine",C1=CC=C(C=C1)SC2=NC(=NC(=N2)Cl)Cl,,,,,,
8179,18180,CID 18180,CC1=CC(=CC=C1)[O-].[Na+],,,,,,
8180,18181,"Butyramidine, hydrochloride",CCCC(=[NH2+])N.[Cl-],,,,,,
8181,18182,Butanimidamide,CCCC(=N)N,,,,,,
8182,18183,"Chlorosulfurous acid, 2-[4-(1,1-dimethylethyl)phenoxy]cyclohexyl ester",CC(C)(C)C1=CC=C(C=C1)OC2CCCCC2OS(=O)Cl,,,,,,
8183,18184,"Perfluoro-2,7-dimethyloctane",C(C(C(C(C(C(C(F)(F)F)(C(F)(F)F)F)(F)F)(F)F)(F)F)(F)F)(C(F)(F)F)(C(F)(F)F)F,,,,,,
8184,18185,"4a(2H)-Naphthalenecarboxylic acid, octahydro-, trans-",C1CCC2(CCCCC2C1)C(=O)O,,,,,,
8185,18186,4-Diethylamino-4'-nitroazobenzene,CCN(CC)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
8186,18187,"N,N-Dimethyl-p-(3,4-xylylazo)aniline",CC1=C(C=C(C=C1)N=NC2=CC=C(C=C2)N(C)C)C,,,,,,
8187,18188,CID 18188,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)N(O)O)N,,,,,,
8188,18189,4-Acetamidobutyric acid,CC(=O)NCCCC(=O)O,,,,,,
8189,18190,CID 18190,CCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+],,,,,,
8190,18191,Mono-C10-16-alkyl sulfates,CCCCCCCCCCCCCOS(=O)(=O)O,,,,,,
8191,18192,Dodecylpyridinium iodide,CCCCCCCCCCCC[N+]1=CC=CC=C1.[I-],,,,,,
8192,18193,Dimethoxymethylphenylsilane,CO[Si](C)(C1=CC=CC=C1)OC,,,,,,
8193,18194,"3-Nitro-1,8-naphthalic anhydride",C1=CC2=CC(=CC3=C2C(=C1)C(=O)OC3=O)[N+](=O)[O-],,,,,,
8194,18195,"6-chloro-4-N-ethyl-2-N-[2-(trichloromethylsulfanyl)ethyl]-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)Cl)NCCSC(Cl)(Cl)Cl,,,,,,
8195,18196,"1,1,4,7,7-Pentamethyldiethylenetriamine",CN(C)CCN(C)CCN(C)C,,,,,,
8196,18197,"1,3,6-Trimethylnaphthalene",CC1=CC2=CC(=CC(=C2C=C1)C)C,,,,,,
8197,18198,"3-Hexyne-2,5-diol",CC(C#CC(C)O)O,,,,,,
8198,18199,Methyl hydroperoxide,COO,,,,,,
8199,18200,"Hydroperoxide, 1-methylethyl",CC(C)OO,,,,,,
8200,18201,Methylmercury;methylmercury(1+);sulfanide,C[Hg].C[Hg+].[SH-],,,,,,
8201,18202,CID 18202,CCCCCCCC[SnH+]CCCCCCCC.C(C[S-])C(=O)O,,,,,,
8202,18203,"Stannane, dioctyl pound>>Dioctyltin",CCCCCCCC[SnH2]CCCCCCCC,,,,,,
8203,18204,Bis(2-dimethylaminoethyl) ether,CN(C)CCOCCN(C)C,,,,"['DMAEE vapor was readily absorbed at a constant rate, slowly eliminated mainly by urinary excretion, and without preferential specific organ/tissue accumulation.']",,
8204,18205,"2,3-Epoxypropyltrimethylammonium chloride",C[N+](C)(C)CC1CO1.[Cl-],,,,,,
8205,18206,"N,N,N-trimethyl(oxiran-2-yl)methanaminium",C[N+](C)(C)CC1CO1,,,,,,
8206,18207,CID 18207,C1=CC=C(C(=C1)N=N)N(O)O,,,,,,
8207,18208,4-Nitroimidazole,C1=C(NC=N1)[N+](=O)[O-],,,,,,
8208,18209,1-Methyl-4-nitroimidazole,CN1C=C(N=C1)[N+](=O)[O-],,,,,,
8209,18210,1-Methyl-5-nitroimidazole,CN1C=NC=C1[N+](=O)[O-],,,,,,
8210,18211,2-Bromo-5-nitrothiazole,C1=C(SC(=N1)Br)[N+](=O)[O-],,,,,,
8211,18212,"s-Triazine, 2-isopropylamino-4-methoxy-6-methylamino-",CC(C)NC1=NC(=NC(=N1)NC)OC,,,,,,
8212,18213,"1,3-Butadienyl methyl ether",COC=CC=C,,,,,,
8213,18214,4-(Diethoxymethylsilyl)butylamine,CCO[Si](C)(CCCCN)OCC,,,,,,
8214,18215,"2-IMIDAZOLINE, 2-(o-TRIFLUOROMETHYLBENZYL)-",C1CN=C(N1)CC2=CC=CC=C2C(F)(F)F,,,,,,
8215,18216,"2-IMIDAZOLINE, 2-(o-METHYLBENZYL)-",CC1=CC=CC=C1CC2=NCCN2,,,,,,
8216,18217,"2-IMIDAZOLINE, 2-(m-TRIFLUOROMETHYLBENZYL)-",C1CN=C(N1)CC2=CC(=CC=C2)C(F)(F)F,,,,,,
8217,18218,"2-IMIDAZOLINE, 2-(p-TRIFLUOROMETHYLBENZYL)-",C1CN=C(N1)CC2=CC=C(C=C2)C(F)(F)F,,,,,,
8218,18219,"2-IMIDAZOLINE, 2-(p-METHYLBENZYL)-",CC1=CC=C(C=C1)CC2=NCCN2,,,,,,
8219,18220,"Hydrazine, 2-isopropyl-1-nicotinoyl-",CC(C)NNC(=O)C1=CN=CC=C1,,,,,,
8220,18221,"Dimethylphenethyl((2,6-xylylcarbamoyl)methyl)ammonium bromide",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CCC2=CC=CC=C2.[Br-],,,,,,
8221,18222,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-dimethyl-(2-phenylethyl)azanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CCC2=CC=CC=C2,,,,,,
8222,18223,Dibromoacetaldehyde,C(=O)C(Br)Br,,,,,,
8223,18224,"2-[2-(Diethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one;hydrochloride",CCN(CC)CCOC1CCC2=CCC3C4CCC(=O)C4(CCC3C2(C1)C)C.Cl,,,,,,
8224,18225,"2-[2-(Diethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one",CCN(CC)CCOC1CCC2=CCC3C4CCC(=O)C4(CCC3C2(C1)C)C,,,,,,
8225,18226,"Carbostyril, 3,4-dihydro-1-(2-morpholinoethyl)-, picrate",C1CC(=O)N(C2=CC=CC=C21)CC[NH+]3CCOCC3.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
8226,18227,"1-(2-Morpholin-4-ylethyl)-3,4-dihydroquinolin-2-one",C1CC(=O)N(C2=CC=CC=C21)CCN3CCOCC3,,,,,,
8227,18228,"3,4-Dihydro-1-(2-(dimethylamino)ethyl)carbostyril hydrochloride",C[NH+](C)CCN1C(=O)CCC2=CC=CC=C21.[Cl-],,,,,,
8228,18229,"1-(2-(Dimethylamino)ethyl)-3,4-dihydroquinolin-2(1H)-one",CN(C)CCN1C(=O)CCC2=CC=CC=C21,,,,,,
8229,18230,Acetyl-d-carnitine,CC(=O)O[C@@H](CC(=O)[O-])C[N+](C)(C)C,,,,,,
8230,18231,"(S)-2-(Acetyloxy)-3-carboxy-N,N,N-trimethyl-1-propanaminium",CC(=O)O[C@@H](CC(=O)O)C[N+](C)(C)C,,,,,,
8231,18232,2-Piperidinoethanol,C1CCN(CC1)CCO,,,,,,
8232,18233,"1,4-Dioxan-2-one",C1COC(=O)CO1,,,,,,
8233,18234,2-Phenylmalononitrile,C1=CC=C(C=C1)C(C#N)C#N,,,,,,
8234,18235,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-3-pyrrolidinyl) ester, hydrochloride",C[NH+]1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8235,18236,"(1-Methylpyrrolidin-3-yl) 2-methoxy-2,2-diphenylacetate",CN1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8236,18237,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-ethyl-3-pyrrolidinyl) ester, hydrochloride",CC[NH+]1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8237,18238,"(1-Ethylpyrrolidin-3-yl) 2-methoxy-2,2-diphenylacetate",CCN1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8238,18239,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-ethyl-3-pyrrolidinyl) ester, hydrochloride",CC[NH+]1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
8239,18240,"(1-Ethylpyrrolidin-3-yl) 2-ethoxy-2,2-diphenylacetate",CCN1CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
8240,18241,"Acetic acid, 2,2-diphenyl-2-propoxy-, (1-methyl-2-pyrrolidinyl)methyl ester, hydrochloride",CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCC[NH+]3C.[Cl-],,,,,,
8241,18242,"(1-Methylpyrrolidin-2-yl)methyl 2,2-diphenyl-2-propoxyacetate",CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCCN3C,,,,,,
8242,18243,"Acetic acid, 2-butoxy-2,2-diphenyl-, (1-methyl-2-pyrrolidinyl)methyl ester, hydrochloride",CCCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCC[NH+]3C.[Cl-],,,,,,
8243,18244,"(1-Methylpyrrolidin-2-yl)methyl 2-butoxy-2,2-diphenylacetate",CCCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCCN3C,,,,,,
8244,18245,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-ethyl-2-pyrrolidinyl)methyl ester, hydrochloride",CC[NH+]1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8245,18246,"(1-Ethylpyrrolidin-2-yl)methyl 2-methoxy-2,2-diphenylacetate",CCN1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8246,18247,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-propyl-2-pyrrolidinyl)methyl ester, hydrochloride",CCC[NH+]1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8247,18248,"(1-Propylpyrrolidin-2-yl)methyl 2-methoxy-2,2-diphenylacetate",CCCN1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8248,18249,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-isopropyl-2-pyrrolidinyl)methyl ester, hydrochloride",CC(C)[NH+]1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8249,18250,"(1-Propan-2-ylpyrrolidin-2-yl)methyl 2-methoxy-2,2-diphenylacetate",CC(C)N1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8250,18251,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-isopropyl-2-pyrrolidinyl)methyl ester, hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCC[NH+]3C(C)C.[Cl-],,,,,,
8251,18252,"(1-Propan-2-ylpyrrolidin-2-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCCN3C(C)C,,,,,,
8252,18253,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-3-pyrrolidinyl)methyl ester, hydrochloride",C[NH+]1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8253,18254,"(1-Methylpyrrolidin-3-yl)methyl 2-methoxy-2,2-diphenylacetate",CN1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8254,18255,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-ethyl-3-pyrrolidinyl)methyl ester, hydrochloride",CC[NH+]1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8255,18256,"(1-Ethylpyrrolidin-3-yl)methyl 2-methoxy-2,2-diphenylacetate",CCN1CCC(C1)COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8256,18257,"Acetic acid, 2,2-diphenyl-2-methoxy-, 2-(1-methyl-2-pyrrolidinyl)ethyl ester, hydrochloride",C[NH+]1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8257,18258,"2-(1-Methylpyrrolidin-2-yl)ethyl 2-methoxy-2,2-diphenylacetate",CN1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8258,18259,"2,2-Diphenyl-2-ethoxyacetic acid (2-(methylamino)ethyl) ester hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH2+]C.[Cl-],,,,,,
8259,18260,"2-(Methylamino)ethyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCNC,,,,,,
8260,18261,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-ethyl-N-methylamino)ethyl) ester, hydrochloride",CC[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8261,18262,"2-[Ethyl(methyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8262,18263,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-ethyl-N-methylamino)ethyl) ester, hydrochloride",CC[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
8263,18264,"2-[Ethyl(methyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
8264,18265,"2,2-Diphenyl-2-methoxyacetic acid, (2-(N-isopropyl-N-methylamino)ethyl) ester hydrochloride",CC(C)[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8265,18266,"2-[Methyl(propan-2-yl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CC(C)N(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8266,18267,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-isopropyl-N-methylamino)ethyl) ester, hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+](C)C(C)C.[Cl-],,,,,,
8267,18268,"2-[Methyl(propan-2-yl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C(C)C,,,,,,
8268,18269,"[(4R,8S,19S)-8-acetyl-19-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-yl] acetate",CC(=O)[C@@]12[C@@H](CC3C1(CC(C4C3C[C@@H](C5=CC(CCC45C)OC(=O)C)F)O)C)OC(O2)(C)C,,,,,,
8269,18270,"[(3S,9S,14S,17R)-17-acetyl-17-acetyloxy-6-chloro-10,13-dimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate",CC(=O)[C@]1(CC[C@@H]2C1(CC[C@H]3C2C=C(C4=C[C@H](CCC34C)OC(=O)C)Cl)C)OC(=O)C,,,,,,
8270,18271,"Ethanol, 2-(butylphenylamino)-",CCCCN(CCO)C1=CC=CC=C1,,,,,,
8271,18272,4-Methylbenzothiazole,CC1=C2C(=CC=C1)SC=N2,,,,,,
8272,18273,5-Vinyl-2-norbornene,C=CC1CC2CC1C=C2,,,,,,
8273,18274,"3,8-Dimethyl-2,7-dioxaspiro[4.4]nonane-1,6-dione",CC1CC2(CC(OC2=O)C)C(=O)O1,,,,,,
8274,18275,Murexide,C1(=C(NC(=O)NC1=O)[O-])N=C2C(=O)NC(=O)NC2=O.[NH4+],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
8275,18276,Purpursaure,C1(=C(NC(=O)NC1=O)O)N=C2C(=O)NC(=O)NC2=O,,,,,,
8276,18277,"Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[2-(4-hydroxyphenyl)diazenyl]-, sodium salt (1:2)",C1=CC(=CC=C1N=NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
8277,18278,CID 18278,C1=CC(=CC=C1N=NC2=CC(=C(C=C2)C=CC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)O)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
8278,18279,2-Sulfododecanoic acid,CCCCCCCCCCC(C(=O)O)S(=O)(=O)O,,,,,,
8279,18280,"2,3,4-Trimethylpentan-2-ol",CC(C)C(C)C(C)(C)O,,,,,,
8280,18281,Pentaethylene glycol monododecyl ether,CCCCCCCCCCCCOCCOCCOCCOCCOCCO,,,,,,
8281,18282,Hexaethylene glycol monododecyl ether,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO,,,,,,
8282,18283,Stavudine,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,['For the treatment of human immunovirus (HIV) infections.'],"[""Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.""]","['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']","['Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).', '46  21 L', 'Renal cl=272 mL/min [Healthy subjects receiving 80 mg PO]', 'Stavudine is rapidly absorbed following oral administration, and peak plasma concentrations of the drug are attained within 1 hour after the dose. Oral bioavailability of stavudine is reported to be about 86% in adults and 77% in pediatric patients 5 weeks to 15 years of age.', 'Data from single- and multiple-dose studies indicate that peak plasma concentrations and AUC of stavudine increase in proportion to dose over the dosage range 0.03 -4 mg/kg; there is no evidence that accumulation occurs following multiple doses.', 'Binding of stavudine to serum proteins is negligible over the concentration range of 0.01-11.4 ug/mL.', 'Distribution of stavudine into body tissues and fluids has not been fully characterized. The apparent volume of distribution of stavudine following a single oral dose averages 66 L in HIV-infected adults. Following a single IV dose in HIV-infected individuals, the volume of distribution is 58 L in adults and 0.73 L/kg in pediatric patients 5 weeks to 15 years of age.', 'For more Absorption, Distribution and Excretion (Complete) data for STAVUDINE (12 total), please visit the HSDB record page.']","['Phosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase.', 'The metabolic fate of stavudine has not been elucidated in humans. Intracellularly, in both virus-infected and uninfected cells, stavudine is converted to stavudine monophosphate by cellular thymidine kinase. The monophosphate is subsequently converted to stavudine diphosphate and then to stavudine triphosphate, presumably by the same cellular kinases involved in the metabolism of zidovudine. Intracellular (host cell) conversion of stavudine to the triphosphate derivative is necessary for the antiviral activity of the drug.']","['0.8-1.5 hours (in adults)', 'Intracellular half life of stavudine triphosphate: Approximately 3.5 hours. /Stavudine triphosphate/', 'Normal renal function: Adults: 0.8 to 1.5 hours (intravenous); 1.14 to 1.74 hours (oral). Children (5 weeks to 15 years): 0.83 to 1/39 hours (intravenous); 0.7 to 1.22 hours (oral). Neonates (14 to 28 days) 1.3 to 1.88 (oral). Neonates (day of birth): 3.26 to 7.28 (oral). Renal function impairment (creatinine clearance 26 to 50 mL/min): Approximately 1 to 6 hours. Renal function impairment (creatinine clearance 9 to 25 mL/min): Approximately 3.7 to 5.5 hours. Renal function impairment (creatinine clearance > 50 mL/min): Approximately 1.3 to 2.1 hours. Renal function impairment (hemodialysis patients): Approximately 4.0 to 6.8 hours.', 'Twenty-two patients were studied after the first oral dose of 0.67, 1.33, 2.67, or 4 mg/kg of body weight; 17 of them underwent an additional steady-state pharmacokinetic evaluation after thrice-daily dosing of the above doses. ...  The mean values for plasma elimination half-life ranged from 1 to 1.6 hr.']"
8283,18284,"1,3,3-trimethyl-2-[2-(2-methyl-1H-indol-3-yl)ethenyl]indol-1-ium;chloride",CC1=C(C2=CC=CC=C2N1)C=CC3=[N+](C4=CC=CC=C4C3(C)C)C.[Cl-],,,,,,
8284,18285,"1,3,3-Trimethyl-2-[2-(2-methyl-1H-indol-3-yl)vinyl]-3H-indolium",CC1=C(C2=CC=CC=C2N1)C=CC3=[N+](C4=CC=CC=C4C3(C)C)C,,,,,,
8285,18286,s-Triaminotrinitrobenzene,C1(=C(C(=C(C(=C1[N+](=O)[O-])N)[N+](=O)[O-])N)[N+](=O)[O-])N,,,,,,
8286,18287,CID 18287,CCC(CC)(C1=CC=CC2=CC=CC=C21)C(=O)[O-].[Na+],,,,,,
8287,18288,gamma-Amino-beta-phenylbutyric acid hydrochloride,C1=CC=C(C=C1)C(CC(=O)O)C[NH3+].[Cl-],,,,,,
8288,18289,"2,2-Diphenylglycine",C1=CC=C(C=C1)C(C2=CC=CC=C2)(C(=O)O)N,,,,,,
8289,18290,Metobromuron,CN(C(=O)NC1=CC=C(C=C1)Br)OC,,,,"['METOBROMURON IS ABSORBED BY ROOTS AND LEAVES ...', '... Different urea herbicides exhibit different mobilities in plant systems. ... Uptake and translocation of chloroxuron, fluometuron, and metobromuron by bean plants when supplied to nutrient cultures in equal concn (essentially equimolar) and specific radioactivities were studied. Whereas the movement of chloroxuron to aerial parts was found to be restricted under the short-term conditions applied, both fluometuron and metobromuron were rapidly translocated into leaves. However, the two latter cmpd differed strikingly with regard to their distribution pattern within the leaves. In contrast to metobromuron, which was mainly confined to tracheal veins, fluometuron had almost completely moved out into the mesophyll tissues. Although no extensive comparisons of the movement of different urea structures are available at this time, it would appear that their apoplastic distribution in plants is regulated in part by the same physical-chemical phenomena which control the mobility and availability of the cmpd in soil.']","['METOBROMURON IS METABOLIZED IN PLANTS & ANIMALS BY N-DEMETHYLATION & N-DEMETHOXYLATION, RESPECTIVELY.', '... RING-LABELED (14)C-METOBROMURON WAS SUPPLIED TO POTATOES AND CORN SEEDLINGS. ... FOLLOWING METABOLITES ... /WERE IDENTIFIED/: 3-(4-BROMOPHENYL)-1-METHOXYUREA, 3-(4-BROMOPHENYL)-1-METHYLUREA, AND 4-BROMOPHENYLUREA.', 'METOBROMURON YIELDS 3-(P-BROMOPHENYL)-1-METHYLUREA AND 3-(P-BROMOPHENYL)-1-METHOXYUREA IN TALAROMYCES. /FROM TABLE/', '(14)C-Metobromuron was incubated with human embryonic lung (HEL) cells. More than 95% of the label was recovered as unchanged metobromuron. Of four metabolites, three were identified: 3-(4-bromophenyl)-1-methylurea; 4-bromophenylurea; and 3-(4-bromophenyl)-1-methylurea.']",
8290,18291,1-Cyanovinyl acetate,CC(=O)OC(=C)C#N,,,,,,
8291,18292,Cmp-nana,CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1C(C(CO)O)O)(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O,,,,,,
8292,18293,Sodium stibocaptate,C1(C(S[Sb](S1)SC(C(C(=O)[O-])S[Sb]2SC(C(S2)C(=O)[O-])C(=O)[O-])C(=O)[O-])C(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
8293,18294,"Ethanamine, 2,2'-(1,2-ethanediylbis(oxy))bis(N,N-dimethyl-",CN(C)CCOCCOCCN(C)C,,,,,,
8294,18295,"Benzothiazolium, 3-ethyl-2-[3-(3-ethyl-2(3H)-benzothiazolylidene)-2-methyl-1-propenyl]-, iodide",CCN1C2=CC=CC=C2SC1=CC(=CC3=[N+](C4=CC=CC=C4S3)CC)C.[I-],,,,,,
8295,18296,"2-[(1E,3Z)-2-Methyl-3-(2,3-dihydro-3-ethylbenzothiazole-2-ylidene)-1-propenyl]-3-ethylbenzothiazole-3-ium",CCN1C2=CC=CC=C2SC1=CC(=CC3=[N+](C4=CC=CC=C4S3)CC)C,,,,,,
8296,18297,"2,3-Dibromopropyl methacrylate",CC(=C)C(=O)OCC(CBr)Br,,,,,,
8297,18298,Cyclohexyl acrylate,C=CC(=O)OC1CCCCC1,,,,,,
8298,18299,"Benzo(A)pyrene-6,12-dione",C1=CC=C2C(=C1)C3=CC(=O)C4=CC=CC5=C4C3=C(C2=O)C=C5,,,,,,
8299,18300,"Benzo[a]pyrene-1,6-dione",C1=CC=C2C(=C1)C3=CC=C4C(=O)C=CC5=C4C3=C(C2=O)C=C5,,,,,,
8300,18301,"Benzo(a)pyrene-3,6-quinone",C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C=CC5=O)C2=O,,,,,,
8301,18302,"1,2,4-Butanetriol",C(CO)C(CO)O,,,,,,
8302,18303,beta-Butyrolactone,CC1CC(=O)O1,,,,,,
8303,18304,"6-chloro-2-N,4-N-dipropyl-1,3,5-triazine-2,4-diamine",CCCNC1=NC(=NC(=N1)Cl)NCCC,,,,,,
8304,18305,"3,3'-Diethylthiatricarbocyanine iodide",CCN1C2=CC=CC=C2SC1=CC=CC=CC=CC3=[N+](C4=CC=CC=C4S3)CC.[I-],,,,,,
8305,18306,CID 18306,CCN1C2=CC=CC=C2SC1=CC=C/C=C/C=CC3=[N+](C4=CC=CC=C4S3)CC,,,,,,
8306,18307,Acid Black 24,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC=CC7=C6C=CC=C7S(=O)(=O)[O-])C=CC=C3S(=O)(=O)[O-].[Na+].[Na+],,,,,,
8307,18308,8-(Phenylamino)-5-[[4-[(5-sulpho-1-naphthyl)azo]-1-naphthyl]azo]naphthalene-1-sulphonic acid,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC=CC7=C6C=CC=C7S(=O)(=O)O)C=CC=C3S(=O)(=O)O,,,,,,
8308,18309,"1,1,3-Trimethylcyclohexane",CC1CCCC(C1)(C)C,,,,,,
8309,18310,6H-benzo[cd]pyren-6-one,C1=CC2=C3C(=C1)C(=O)C4=CC=CC5=C4C3=C(C=C2)C=C5,,,,,,
8310,18311,11H-benzo[b]fluoren-11-one,C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC=C4C3=O,,,,,,
8311,18312,4-Ethyl-2-methylhexane,CCC(CC)CC(C)C,,,,,,
8312,18313,3-Ethyl-3-methylhexane,CCCC(C)(CC)CC,,,,,,
8313,18314,3-Ethyl-4-methylhexane,CCC(C)C(CC)CC,,,,,,
8314,18315,Ethylene bis(butylxanthate),CCCCOC(=S)SCCSC(=S)OCCCC,,,,,,
8315,18316,Tridecyl acrylate,CCCCCCCCCCCCCOC(=O)C=C,,,,,,
8316,18317,"Octadecanoic acid, 2-sulfo-, 1-methyl ester",CCCCCCCCCCCCCCCCC(C(=O)OC)S(=O)(=O)O,,,,,,
8317,18318,Chloro[p-[(2-hydroxy-1-naphthyl)azo]phenyl]mercury,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)[Hg]Cl)O,,,,,,
8318,18319,Dodecyl methyl sulfoxide,CCCCCCCCCCCCS(=O)C,,,,,,
8319,18320,"N,N'-Bis(1,4-dimethylpentyl)-P-phenylenediamine",CC(C)CCC(C)NC1=CC=C(C=C1)NC(C)CCC(C)C,,,,,,
8320,18321,"1,2-Epoxy-3,3,3-trichloropropane",C1C(O1)C(Cl)(Cl)Cl,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
8321,18322,"1,2-Epoxy-4,4,4-trichlorobutane",C1C(O1)CC(Cl)(Cl)Cl,,,,,,
8322,18323,Spongouridine,C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
8323,18324,"3,4-Dihydro-9-chloro-6-methyl-1H-azepino(5,4,3-cd)indole",CC1=NCCC2=CNC3=C(C=CC1=C23)Cl,,,,,,
8324,18325,"2,4,5-T propylene glycol butyl ether ester",CCCCOC(C)COC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
8325,18326,2-Chloro-4-methylamino-6-ethylamino-S-triazine,CCNC1=NC(=NC(=N1)NC)Cl,,,,,,
8326,18327,"2-Bromo-4,6-bis(ethylamino)-S-triazine",CCNC1=NC(=NC(=N1)Br)NCC,,,,,,
8327,18328,Diisobutyl sulfoxide,CC(C)CS(=O)CC(C)C,,,,,,
8328,18329,4-Chlorophenyl sulfoxide,C1=CC(=CC=C1S(=O)C2=CC=C(C=C2)Cl)Cl,,,,,,
8329,18330,"2,2'-Sulfinyldiethanol",C(CS(=O)CCO)O,,,,,,
8330,18331,"1,4-Benzenediamine, N-(1-methylethyl)-N-phenyl-",CC(C)N(C1=CC=CC=C1)C2=CC=C(C=C2)N,,,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
8331,18332,"BENZOIC ACID, m-(BIS(2-CHLOROETHYL)AMINO)-",C1=CC(=CC(=C1)N(CCCl)CCCl)C(=O)O,,,,,,
8332,18333,"Anthranilic acid, N,N-bis(2-chloroethyl)-",C1=CC=C(C(=C1)C(=O)O)N(CCCl)CCCl,,,,,,
8333,18334,"3,4,5-Trimethoxybenzamide",COC1=CC(=CC(=C1OC)OC)C(=O)N,,,,,,
8334,18335,CID 18335,CCCCCCCCCCCCOCCOCCOS(=O)(=O)[O-].[Na+],,,,,,
8335,18336,Laureth-2 sulfate,CCCCCCCCCCCCOCCOCCOS(=O)(=O)O,,,,,,
8336,18337,(2-Chloroethenyl)arsanone,C(=C[As]=O)Cl,,,,,,
8337,18338,1-Piperidinepropanenitrile,C1CCN(CC1)CCC#N,,,,,,
8338,18339,Nonylboronic acid,B(CCCCCCCCC)(O)O,,,,,,
8339,18340,Midodrine hydrochloride,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O.Cl,,,"['Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
8340,18341,CID 18341,CC1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)C=CC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)COC(=O)C(C(C(=O)O)O)O)C)O)F)C)C,,,,,,
8341,18342,"(2S,4R,8S,12R)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one",CC1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)CCC5([C@]4(C(CC3([C@@]2(O1)C(=O)CCl)C)O)F)C)C,,,,,,
8342,18343,Doxifluridine,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS. (See all compounds classified as Appetite Stimulants.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']",,,
8343,18344,Iron(II) acetate,CC(=O)[O-].CC(=O)[O-].[Fe+2],,,,,,
8344,18345,"Benzoic acid, 3,5-dimethyl-4-(2-piperidinopropionamido)-, propyl ester, perchlorate",CCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)C(C)[NH+]2CCCCC2)C.[O-]Cl(=O)(=O)=O,,,,,,
8345,18346,"Propyl 3,5-dimethyl-4-(2-piperidin-1-ylpropanoylamino)benzoate",CCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)C(C)N2CCCCC2)C,,,,,,
8346,18347,"Benzoic acid, 4-(2-(cyclohexylamino)acetamido)-3,5-dimethyl-, propyl ester",CCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)CNC2CCCCC2)C,,,,,,
8347,18348,"Benzoic acid, 4-(2-(diethylamino)acetamido)-3,5-dimethyl-, propyl ester",CCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)CN(CC)CC)C,,,,,,
8348,18349,"Benzoic acid, 4-(2-(diethylamino)acetamido)-3,5-dimethyl-, ethyl ester",CCN(CC)CC(=O)NC1=C(C=C(C=C1C)C(=O)OCC)C,,,,,,
8349,18350,"Benzoic acid, 4-(2-(diethylamino)acetamido)-3,5-dimethyl-, butyl ester, hydrochloride",CCCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)C[NH+](CC)CC)C.[Cl-],,,,,,
8350,18351,"Butyl 4-[[2-(diethylamino)acetyl]amino]-3,5-dimethylbenzoate",CCCCOC(=O)C1=CC(=C(C(=C1)C)NC(=O)CN(CC)CC)C,,,,,,
8351,18352,Ammonium bitartrate,[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.N,,,,,,
8352,18353,Methyl (diethoxyphosphinyl)acetate,CCOP(=O)(OCC)OC(=O)C,,,,,,
8353,18354,"9H-Fluoren-9-one, 2-chloro-",C1=CC=C2C(=C1)C3=C(C2=O)C=C(C=C3)Cl,,,,,,
8354,18355,N-(9-Oxo-2-fluorenyl)acetamide,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2=O,,,,,,
8355,18356,2-Nitro-9-fluorenone,C1=CC=C2C(=C1)C3=C(C2=O)C=C(C=C3)[N+](=O)[O-],,,,,,
8356,18357,2-Amino-9-fluorenone,C1=CC=C2C(=C1)C3=C(C2=O)C=C(C=C3)N,,,,,,
8357,18358,3-(Chloromethyl)pyridine,C1=CC(=CN=C1)CCl,,,,,,
8358,18359,"Butyranilide, 2'-chloro-4-(diethylamino)-5'-ethyl-",CCC1=CC(=C(C=C1)Cl)NC(=O)CCCN(CC)CC,,,,,,
8359,18360,p-tert-Butylphenyl glycidyl ether,CC(C)(C)C1=CC=C(C=C1)OCC2CO2,,,,,,
8360,18361,(2-(N-Cyclohexylanilino)ethyl)diisopropylmethylammonium iodide,CC(C)[N+](C)(CCN(C1CCCCC1)C2=CC=CC=C2)C(C)C.[I-],,,,,,
8361,18362,2-(N-cyclohexylanilino)ethyl-methyl-di(propan-2-yl)azanium,CC(C)[N+](C)(CCN(C1CCCCC1)C2=CC=CC=C2)C(C)C,,,,,,
8362,18363,"6,7-trans-Dihydroxydihydroaldrin",C1C2C3C(C1C(C2O)O)C4(C(=C(C3(C4(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8363,18364,CID 18364,C(C(=O)O)(C(=O)[O-])F.[K+],,,,,,
8364,18365,2-fluoropropanedioic Acid,C(C(=O)O)(C(=O)O)F,,,,,,
8365,18366,"1-Hexanol, 4,4,5,5,6,6,6-heptafluoro-2-iodo-, acetate",CC(=O)OCC(CC(C(C(F)(F)F)(F)F)(F)F)I,,,,,,
8366,18367,Dechlorohaloperidol,C1CN(CCC1(C2=CC=CC=C2)O)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
8367,18368,CID 18368,CCOC(=NC1=CC=CC=C1)S,,,,,,
8368,18369,Methyl phenyl sulfone,CS(=O)(=O)C1=CC=CC=C1,,,,,,
8369,18370,3-Methyl-4-nitrobenzoic acid,CC1=C(C=CC(=C1)C(=O)O)[N+](=O)[O-],,,,,,
8370,18371,5-Methyl-2-nitrobenzoic acid,CC1=CC(=C(C=C1)[N+](=O)[O-])C(=O)O,,,,,,
8371,18372,"2-(4-Chlorophenyl)-4,6-diphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4,,,,,,
8372,18373,"2,4,6-Tris(4-chlorophenyl)-1,3,5-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)Cl,,,,,,
8373,18374,"Cyclohexane-1,4-diamine",C1CC(CCC1N)N,,,,,,
8374,18375,"Acetic acid, 2,2-diphenyl-2-ethoxy-, 2-(1-ethyl-2-pyrrolidinyl)ethyl ester, hydrochloride",CC[NH+]1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
8375,18376,"2-(1-Ethylpyrrolidin-2-yl)ethyl 2-ethoxy-2,2-diphenylacetate",CCN1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
8376,18377,Iobenzamic acid,C1=CC=C(C=C1)N(CCC(=O)O)C(=O)C2=C(C(=C(C=C2I)I)N)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
8377,18378,CID 18378,CC(=NN=C(N)S)C1=CC=NC=C1,,,,,,
8378,18379,2-Butylhexanoic acid,CCCCC(CCCC)C(=O)O,,,,,,
8379,18380,2-(4-Nonylphenoxy)acetic acid,CCCCCCCCCC1=CC=C(C=C1)OCC(=O)O,,,,,,
8380,18381,Dicloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,['Used to treat infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.'],"['Dicloxacillin is a beta-lactamase resistant penicillin similar to oxacillin. Dicloxacillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of dicloxacillin results from the inhibition of cell wall synthesis and is mediated through dicloxacillin binding to penicillin binding proteins (PBPs). Dicloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Absorption of the isoxazolyl penicillins after oral administration is rapid but incomplete: peak blood levels are achieved in 1-1.5 hours. Oral absorption of cloxacillin, dicloxacillin, oxacillin and nafcillin is delayed when the drugs are administered after meals.', 'Dicloxacillin sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.', 'Differences in the elimination, distribution, and absorption of dicloxacillin and cloxacillin were studied in a group of healthy individuals with the use of a 2-compartment model. In patients on chronic intermittent hemodialysis, only dicloxacillin was investigated and the results were compared with data obtained in earlier studies on cloxacillin and flucloxacillin. In healthy volunteers the bioavailability after oral administration of 2 g dicloxacillin or 2 g cloxacillin amounted to 48.8% and 36.9% of the dose, respectively, when calculated from the area under the serum concentration-time curve, and to 74.1% and 48.5%, respectively, when calculated from the urinary excretion. Individual variation in bioavailability after oral administration was slightly lower for docloxacillin than for cloxacillin. The higher serum concentrations of dicloxacillin, as compared with cloxacillin, are also attributable to slower (renal) elimination (T 1/2: 42 and 33 min, respectively). Analysis of serum concentrations after intravenous administration of 1 and 2 g dicloxacillin to healthy subjects revealed concentration-dependent kinetics with respect ot renal elimination. In hemodialysis patients the elimination rate of dicloxacillin (T 1/2: 129 min) corresponds with the extrarenal elimination rate in healthy subjects. The bioavailability after oral administration of 1 g in patients is good (75.9% of the dose).', 'Dicloxacillin, a semisynthetic isoxazolyl penicillin antibiotic, has antimicrobial activity against a wide variety of gram-positive bacteria including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus epidermidis, Streptococcus viridans, Streptococcus agalactiae, and Neisseria meningitidis. The objective of this study was to evaluate the safety and pharmacokinetic profile of dicloxacillin after single and multiple oral dose in healthy Chinese volunteers. A single-center, open-label, randomized, two-phase study was conducted in 16 subjects. In the single-dose phase, subjects were randomly assigned to receive single doses of 0.25, 0.5, 1.0, and 2.0 g of dicloxacillin sodium capsule in a 4-way crossover design with a 5-day washout period between administrations. In the multiple-dose phase, subjects were assigned to receive 0.25 or 0.5 g every 6 hours for 3 days in a 2-way crossover design. Plasma and urine pharmacokinetic samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated and analyzed statistically. Safety assessments were conducted throughout the study. Following a single oral dose of 0.25-2.0 g dicloxacillin sodium, the maximum plasma drug concentration (Cmax) and the corresponding values for the area under the concentration- time curve from 0 to 10 hours (AUC0-10 hr) increased in a dose-proportional manner. The mean elimination half-life (t1/2) was in the range of 1.38-1.71 hours. Dicloxacillin was excreted in its unchanged form via the kidney, with no tendency of accumulation, and varied from 38.65% to 50.10%. No appreciable accumulation of drug occurred with multiple oral doses of dicloxacillin. No serious adverse events were reported. Adverse events were generally mild. Dicloxacillin was safe and well tolerated in the volunteers and displayed linear increases in the Cmax and AUC0-10 hr values.', 'The purpose of antibiotic treatment in pregnant women is to treat the mother and/or the fetus since it is known that antibiotics administered to the mother cross the placenta and reach the fetus. A comparison of the drug concentration in maternal and fetal plasma gives an indication of the exposure of the fetus to the maternally administered antibiotics. The aim of this study was to review the literature pertaining to the placental transfer of antibiotics in man and to classify the antibiotics according to the type of transfer involved ... 3 types of placental transfers were identified. A few antibiotics cross the placenta rapidly and equilibrate in the maternal and cord plasma; this type of transfer is termed ""complete"" and include the antibiotics ampicillin, methicillin, cefmenoxime and cefotiam. Antibiotics which show incomplete transfer to the placenta where concentrations are lower in the cord than maternal plasma are said to have ""incomplete"" transfer and these include azlocillin, dicloxacillin, piperacillin, sulbenicillin, cefoxitin, amikacin, gentamicin, kanamycin, streptomycin, fosfomycin, thiamphenicol, griseofulvin, vancomycin and colistimethate. ... All examined antibiotics cross the human placenta including those with a molecular weight greater than 1000 kDa such as vancomycin and colistimethate but there are 3 distinct types of placental transfer: complete, incomplete and exceeding and most antibiotics exhibit incomplete transfer.', '/The objective of the study was/ to determine whether upregulation of P-glycoprotein is responsible for the enhanced renal clearance of dicloxacillin in patients with cystic fibrosis ... Eleven patients with cystic fibrosis and 11 age-matched healthy volunteers /were used/. All subjects received a single oral dose of dicloxacillin 500 mg alone, dicloxacillin 500 mg plus probenecid (an organic anion transport inhibitor) 1 g, and dicloxacillin 500 mg plus cyclosporine (a P-glycoprotein inhibitor) 5 mg/kg; each treatment was separated by a washout period of 48 hours. A bolus dose of iothalamate meglumine 456 mg was administered on each study day as a marker of glomerular filtration. Blood and urine samples were taken serially up to 6 hours after each dose. Pharmacokinetics of dicloxacillin and iothalamate were determined by using compartmental and noncompartmental methods. Quantitative polymerase chain reaction was performed on peripheral blood mononuclear cells to measure expression of multidrug resistance 1 (MDR1) messenger RNA (mRNA). Genotyping for ABCB1 was performed to determine the presence of single nucleotide polymorphisms (exons 21 and 26). In both healthy subjects and patients with cystic fibrosis, compared with dicloxacillin alone, coadministration with probenecid produced a significantly lower renal clearance of dicloxacillin, whereas coadministration with cyclosporine resulted in no significant change; renal clearance was not significantly different between the two study groups. No correlation was found between MDR1 mRNA expression and renal clearance of dicloxacillin. The renal excretion of dicloxacillin was significantly greater in subjects with the ABCB1 exon 26 TT polymorphism when compared with subjects with the CT genotype. We found no significant difference in the pharmacokinetics of dicloxacillin between patients with cystic fibrosis and healthy volunteers. Renal clearance of dicloxacillin was significantly reduced in the presence of probenecid but not with cyclosporine, suggesting that the rate-limiting step in tubular secretion of dicloxacillin is uptake mediated by the organic anion transporter, and not P-glycoprotein inhibition.', 'For more Absorption, Distribution and Excretion (Complete) data for Dicloxacillin (22 total), please visit the HSDB record page.']","['Dicloxacillin is partially metabolized to active and inactive metabolites. In one study following administration of a single 500-mg oral dose of dicloxacillin, 10% of the absorbed drug was hydrolyzed to penicilloic acids which are microbiologically inactive. Dicloxacillin is also hydroxylated to a small extent to a microbiologically active metabolite which appears to be slightly less active than dicloxacillin.']","['The elimination half-life for dicloxacillin is about 0.7 hour.', '... In hemodialysis patients the elimination rate of dicloxacillin (T 1/2: 129 min) corresponds with the extrarenal elimination rate in healthy subjects ...', '... Following a single oral dose of 0.25-2.0 g dicloxacillin sodium, the maximum plasma drug concentration (Cmax) and the corresponding values for the area under the concentration- time curve from 0 to 10 hours (AUC0-10 hr) increased in a dose-proportional manner. The mean elimination half-life (t1/2) was in the range of 1.38-1.71 hours ...', 'The serum half-life of dicloxacillin in adults with normal renal function is 0.6-0.8 hours. In one study in children 2-16 years of age, the serum half-life of the drug averaged 1.9 hours.', 'The serum half-life of dicloxacillin is slightly prolonged in patients with impaired renal function and has been reported to range from 1-2.2 hours in patients with severe renal impairment.']"
8381,18382,"Acetanilide, 2'-chloro-2-(diethylamino)-5'-ethyl-",CCC1=CC(=C(C=C1)Cl)NC(=O)CN(CC)CC,,,,,,
8382,18383,"o-ACETANISIDIDE, 2-(DIETHYLAMINO)-5'-ETHYL-",CCC1=CC(=C(C=C1)OC)NC(=O)CN(CC)CC,,,,,,
8383,18384,2-Phenoxy-2-phenylacetic acid,C1=CC=C(C=C1)C(C(=O)O)OC2=CC=CC=C2,,,,,,
8384,18385,N-(3-(Cyclohexylamino)propyl)mandelamide,C1CCC(CC1)NCCCNC(=O)C(C2=CC=CC=C2)O,,,,,,
8385,18386,Sudan II,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)C,,,,,,
8386,18387,"3-Amino-2,4,6-triiodobenzoic acid",C1=C(C(=C(C(=C1I)N)I)C(=O)O)I,,,,,,
8387,18388,"Acetic acid, (3-acetamido-2,4,6-triiodophenyl)-",CC(=O)NC1=C(C=C(C(=C1I)CC(=O)O)I)I,,,,,,
8388,18389,"Acetic acid, (3-amino-2,4,6-triiodophenyl)-",C1=C(C(=C(C(=C1I)N)I)CC(=O)O)I,,,,,,
8389,18390,"Butyramide, 4-(dimethylamino)-2-(2-(dimethylamino)ethyl)-2-phenyl-",CN(C)CCC(CCN(C)C)(C1=CC=CC=C1)C(=O)N,,,,,,
8390,18391,3-Methyl-4-(methylthio)phenol,CC1=C(C=CC(=C1)O)SC,,,,,,
8391,18392,2-Methoxyethyl acrylate,COCCOC(=O)C=C,,,,,,
8392,18393,"4,4-Dimethyl-1-pentanol",CC(C)(C)CCCO,,,,,,
8393,18394,"Butanol, 4-(trimethylsilyl)-, carbamate",C[Si](C)(C)CCCCOC(=O)N,,,,,,
8394,18395,"1-Hexanol, 5,5-dimethyl-, carbamate",CC(C)(C)CCCCOC(=O)N,,,,,,
8395,18396,CID 18396,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)NC(=NC2=O)N,,,,,,
8396,18397,Colchiceinamid,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)N)OC)OC)OC,,,,,,
8397,18398,"5,5-Dimethyldihydrofuran-2(3h)-one",CC1(CCC(=O)O1)C,,,,,,
8398,18399,"Ethanol, 2-(trimethylsilyl)-, carbamate",C[Si](C)(C)CCOC(=O)N,,,,,,
8399,18400,"1-Butanol, 3,3-dimethyl-, carbamate",CC(C)(C)CCOC(=O)N,,,,,,
8400,18401,"1-Hexanol, 2,2-dimethyl-, carbamate",CCCCC(C)(C)COC(=O)N,,,,,,
8401,18402,"1-Butanol, 2,2-dimethyl-, carbamate",CCC(C)(C)COC(=O)N,,,,,,
8402,18403,"(17S)-17-(2-chloroethynyl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",CC12CCC3=C4CCC(=O)C=C4CCC3C1CC[C@]2(C#CCl)O,,,,,,
8403,18404,"ISOTHIOCYANIC ACID, m-PHENYLENE ESTER",C1=CC(=CC(=C1)N=C=S)N=C=S,,,,,,
8404,18405,Dibutyl isophthalate,CCCCOC(=O)C1=CC(=CC=C1)C(=O)OCCCC,,,,,,
8405,18406,Propyl glycidyl ether,CCCOCC1CO1,,,,,,
8406,18407,4-Acetylbutyric acid,CC(=O)CCCC(=O)O,,,,,,
8407,18408,S-Phenyl p-nitrothiobenzoate,C1=CC=C(C=C1)SC(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
8408,18409,Diana,C1CCC(CC1)[NH2+]C2CCCCC2.N(=O)[O-],,,,,,
8409,18410,"Bis(3,4-epoxycyclohexylmethyl) adipate",C1CC2C(O2)CC1COC(=O)CCCCC(=O)OCC3CCC4C(C3)O4,,,,,,
8410,18411,4-Phthalimidobutyric acid,C1=CC=C2C(=C1)C(=O)N(C2=O)CCCC(=O)O,,,,,,
8411,18412,Phenacridane chloride,CCCCCCOC1=CC=C(C=C1)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C.[Cl-],,,,,,
8412,18413,Phenacridane,CCCCCCOC1=CC=C(C=C1)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C,,,,,,
8413,18414,"Carbamic acid, (((p-(bis(2-chloroethyl)amino)phenyl)carbamoyl)methyl)-, methyl ester",COC(=O)NCC(=O)NC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
8414,18415,"Acetanilide, 2-acetamido-4'-(bis(2-chloroethyl)amino)-",CC(=O)NCC(=O)NC1=CC=C(C=C1)N(CCCl)CCCl,,,,,,
8415,18416,2-Amino-4'-(bis(2-chloroethyl)amino)acetanilide hydrochloride,C1=CC(=CC=C1NC(=O)CN)[NH+](CCCl)CCCl.[Cl-],,,,,,
8416,18417,2-amino-N-[4-[bis(2-chloroethyl)amino]phenyl]acetamide,C1=CC(=CC=C1NC(=O)CN)N(CCCl)CCCl,,,,,,
8417,18418,"(9S,14S)-3,4-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one",CC12CC[C@H]3C([C@@H]1CCC2=O)CCC4=C3C=CC(=C4O)O,,,,,,
8418,18419,"N-benzyl-N-(4,5-dihydro-1H-imidazol-1-ium-2-ylmethyl)aniline;methanesulfonate",CS(=O)(=O)[O-].C1CN=C([NH2+]1)CN(CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8419,18420,Dimethylphenethyl((phenylcarbamoyl)methyl)ammonium bromide,C[N+](C)(CCC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Br-],,,,,,
8420,18421,(2-Anilino-2-oxoethyl)-dimethyl-(2-phenylethyl)azanium,C[N+](C)(CCC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2,,,,,,
8421,18422,Dimethyl((phenylcarbamoyl)methyl)(3-phenylpropyl)ammonium bromide,C[N+](C)(CCCC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Br-],,,,,,
8422,18423,(2-Anilino-2-oxoethyl)-dimethyl-(3-phenylpropyl)azanium,C[N+](C)(CCCC1=CC=CC=C1)CC(=O)NC2=CC=CC=C2,,,,,,
8423,18424,"Benzenepropanaminium, N-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-N,N-dimethyl-, bromide",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CCCC2=CC=CC=C2.[Br-],,,,,,
8424,18425,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-dimethyl-(3-phenylpropyl)azanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CCCC2=CC=CC=C2,,,,,,
8425,18426,Dimethylphenacyl((phenylcarbamoyl)methyl)ammonium bromide,C[N+](C)(CC(=O)C1=CC=CC=C1)CC(=O)NC2=CC=CC=C2.[Br-],,,,,,
8426,18427,(2-Anilino-2-oxoethyl)-dimethyl-phenacylazanium,C[N+](C)(CC(=O)C1=CC=CC=C1)CC(=O)NC2=CC=CC=C2,,,,,,
8427,18428,"Dimethylphenacyl((2,6-xylylcarbamoyl)methyl)ammonium bromide",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)C2=CC=CC=C2.[Br-],,,,,,
8428,18429,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-dimethyl-phenacylazanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)C2=CC=CC=C2,,,,,,
8429,18430,Epibromohydrin,C1C(O1)CBr,,,,,,
8430,18431,1-Tricosanol,CCCCCCCCCCCCCCCCCCCCCCCO,,,,,,
8431,18432,Phenobenzuron,CN(C)C(=O)N(C1=CC(=C(C=C1)Cl)Cl)C(=O)C2=CC=CC=C2,,,,,,
8432,18433,3-(Dimethylamino)-3-azaspiro(5.5)undecane hydrochloride,C[NH+](C)N1CCC2(CCCCC2)CC1.[Cl-],,,,,,
8433,18434,"N,N-dimethyl-3-azaspiro[5.5]undecan-3-amine",CN(C)N1CCC2(CCCCC2)CC1,,,,,,
8434,18435,"ARSINE, (p-NITROPHENYL)OXO-",C1=CC(=CC=C1[N+](=O)[O-])[As]=O,,,,,,
8435,18436,"ARSINE, (p-CHLOROPHENYL)OXO-",C1=CC(=CC=C1Cl)[As]=O,,,,,,
8436,18437,"ARSINE, (o-CHLOROPHENYL)OXO-",C1=CC=C(C(=C1)Cl)[As]=O,,,,,,
8437,18438,"(16R)-17-acetyl-10,13-dimethyl-16-methylsulfanyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",CC(=O)C1[C@@H](CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)SC,,,,,,
8438,18439,"Acetic acid, 2,2-diphenyl-2-methoxy-, 2-(1-ethyl-2-pyrrolidinyl)ethyl ester, hydrochloride",CC[NH+]1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8439,18440,"2-(1-Ethylpyrrolidin-2-yl)ethyl 2-methoxy-2,2-diphenylacetate",CCN1CCCC1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8440,18441,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(methylamino)ethyl) ester, hydrochloride",C[NH2+]CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8441,18442,"2-(Methylamino)ethyl 2-methoxy-2,2-diphenylacetate",CNCCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8442,18443,"Pregn-4-en-20-one, 17-hydroxy-6alpha-methyl-, acetate",CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CCCC4)C,,,,,,
8443,18444,N-(3-Isothiocyanatophenyl)acetamide,CC(=O)NC1=CC(=CC=C1)N=C=S,,,,,,
8444,18445,"Acetic acid, 2,2-diphenyl-2-methoxy-, (1-methyl-3-piperidyl) ester, hydrochloride",C[NH+]1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC.[Cl-],,,,,,
8445,18446,"(1-Methylpiperidin-3-yl) 2-methoxy-2,2-diphenylacetate",CN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC,,,,,,
8446,18447,"2,2-Diphenyl-2-ethoxyacetic acid (1-methyl-3-piperidyl) ester hydrochloride",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCC[NH+](C3)C.[Cl-],,,,,,
8447,18448,"(1-Methylpiperidin-3-yl) 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCCN(C3)C,,,,,,
8448,18449,"2,3-Bis(bromomethyl)quinoxaline",C1=CC=C2C(=C1)N=C(C(=N2)CBr)CBr,,,,,,
8449,18450,"2-Chloro-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)Cl)OC,,,,,,
8450,18451,Diethoxyphenylarsine,CCO[As](C1=CC=CC=C1)OCC,,,,,,
8451,18452,"3,4-Dibromothiophene",C1=C(C(=CS1)Br)Br,,,,,,
8452,18453,"2,5-Dibromothiophene",C1=C(SC(=C1)Br)Br,,,,,,
8453,18454,"Acetic acid, 2,2-diphenyl-2-(2-methylbutoxy)-, 2-(dimethylamino)ethyl ester, hydrochloride",CCC(C)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
8454,18455,"2-(Dimethylamino)ethyl 2-(2-methylbutoxy)-2,2-diphenylacetate",CCC(C)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
8455,18456,"2,2-Diphenyl-2-((2-methylpentyl)oxy)acetic acid 2-(dimethylamino)ethyl ester hydrochloride",CCCC(C)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
8456,18457,"2-(Dimethylamino)ethyl 2-(2-methylpentoxy)-2,2-diphenylacetate",CCCC(C)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
8457,18458,"2-Pentenoic acid, 2-methyl-",CCC=C(C)C(=O)O,,,,,,
8458,18459,"Isophthalic acid, dipropyl ester",CCCOC(=O)C1=CC(=CC=C1)C(=O)OCCC,,,,,,
8459,18460,1-Butanesulfonamide,CCCCS(=O)(=O)N,,,,,,
8460,18461,"1-Butanesulfonamide, 4-chloro-",C(CCCl)CS(=O)(=O)N,,,,,,
8461,18462,Camphorsulfonic acid,CC1(C2CCC1(C(=O)C2)CS(=O)(=O)O)C,,,,,,
8462,18463,"3-Oxatricyclo[3.2.1.02,4]octane",C1CC2CC1C3C2O3,,,,,,
8463,18464,"3,5-Dibromosalicylic acid",C1=C(C=C(C(=C1C(=O)O)O)Br)Br,,,,,,
8464,18465,Dhpta,C(C(CN(CC(=O)O)CC(=O)O)O)N(CC(=O)O)CC(=O)O,,,,,,
8465,18466,Phenbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1,,,,,,
8466,18467,2-Methoxypyrazine,COC1=NC=CN=C1,,,,,,
8467,18468,"Methyl 2,3,4,6-tetra-O-methyl-beta-D-glucopyranoside",COCC1[C@H](C(C([C@@H](O1)OC)OC)OC)OC,,,,,,
8468,18469,"1H-Pyrrole-2-propanoic acid, 1-(2-methoxyphenyl)-5-(4-methoxyphenyl)-",COC1=CC=C(C=C1)C2=CC=C(N2C3=CC=CC=C3OC)CCC(=O)O,,,,,,
8469,18470,Tribenzyltin chloride,C1=CC=C(C=C1)C[Sn](CC2=CC=CC=C2)(CC3=CC=CC=C3)Cl,,,,,,
8470,18471,Hetaflur,CCCCCCCCCCCCCCCCN.F,,,,,,
8471,18472,CID 18472,C1=CC(=CC=C1CSC(=NC2=CC=C(C=C2)Br)S)Cl,,,,,,
8472,18473,CID 18473,C1=CC(=CC=C1CSC(=NC2=CC=C(C=C2)I)S)Cl,,,,,,
8473,18474,Ethyl 4-chlorobutyrate,CCOC(=O)CCCCl,,,,,,
8474,18475,Diphenyl oxalate,C1=CC=C(C=C1)OC(=O)C(=O)OC2=CC=CC=C2,,,,,,
8475,18476,"2-[(2,4-dichlorophenoxy)methyl]-1H-benzimidazole",C1=CC=C2C(=C1)NC(=N2)COC3=C(C=C(C=C3)Cl)Cl,,,,,,
8476,18477,1-Nitro-1-propene,CC=C[N+](=O)[O-],,,,,,
8477,18478,Bis(1-naphthyl)carbonate,C1=CC=C2C(=C1)C=CC=C2OC(=O)OC3=CC=CC4=CC=CC=C43,,,,,,
8478,18479,CID 18479,CC(C)C(=O)C=CC1=CC=CC=C1,,,,,,
8479,18480,Piperonal acetone,CC(=O)C=CC1=CC2=C(C=C1)OCO2,,,,,,
8480,18481,N-(3-Chloropropyl)dibenzylamine hydrochloride,C1=CC=C(C=C1)C[NH+](CCCCl)CC2=CC=CC=C2.[Cl-],,,,,,
8481,18482,"N,N-dibenzyl-3-chloropropan-1-amine",C1=CC=C(C=C1)CN(CCCCl)CC2=CC=CC=C2,,,,,,
8482,18483,Azabutyrone,C1CC2CN(CCN2C1)CCCC(=O)C3=CC=C(C=C3)F.Cl.Cl,,,,,,
8483,18484,Azabuperone,C1CC2CN(CCN2C1)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
8484,18485,"2-(3,4-Dichlorophenyl)benzoxazole",C1=CC=C2C(=C1)N=C(O2)C3=CC(=C(C=C3)Cl)Cl,,,,,,
8485,18486,"Ammonium [R-(R*,R*)]-tartrate",[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.N.N,,,,,,
8486,18487,4-Chloro-2-methylaniline hydrochloride,CC1=C(C=CC(=C1)Cl)N.Cl,,,"['Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens). (See all compounds classified as Chromogenic Compounds.)']",,,
8487,18488,Toluzide,CCC(CC)(C(=O)NNC1=CC=CC=C1C)O,,,,,,
8488,18489,"BUTYRIC ACID, 2-ETHYL-2-HYDROXY-, 2-(p-BROMOPHENYL)HYDRAZIDE",CCC(CC)(C(=O)NNC1=CC=C(C=C1)Br)O,,,,,,
8489,18490,"Glycolic acid, diethyl-, phenylhydrazide",CCC(CC)(C(=O)NNC1=CC=CC=C1)O,,,,,,
8490,18491,Diethylglycolic acid m-tolylhydrazide,CCC(CC)(C(=O)NNC1=CC=CC(=C1)C)O,,,,,,
8491,18492,Diethylglycolic acid p-tolylhydrazide,CCC(CC)(C(=O)NNC1=CC=C(C=C1)C)O,,,,,,
8492,18493,Methylbenactyzium bromide,CC[N+](C)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
8493,18494,"Ammonium, thiodiethylenebis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCSCC[N+](C)(CC)CC.[I-].[I-],,,,,,
8494,18495,2-[2-[Diethyl(methyl)azaniumyl]ethylsulfanyl]ethyl-diethyl-methylazanium,CC[N+](C)(CC)CCSCC[N+](C)(CC)CC,,,,,,
8495,18496,6-Aminonicotinic acid,C1=CC(=NC=C1C(=O)O)N,,,,,,
8496,18497,Hydroxyhexamide,CC(C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2)O,,,,,,
8497,18498,1-(p-Acetylphenylsulfonyl)-3-(hexahydro-1H-azepin-1-yl)urea,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,,,,,,
8498,18499,"AMMONIUM, (o-BROMOBENZYL)ETHYLDIMETHYL-, BROMIDE",CC[N+](C)(C)CC1=CC=CC=C1Br.[Br-],,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
8499,18500,Hydrogenperoxide(1-),O[O-],,,,,,
8500,18501,"2,5-Dichlorothiophene",C1=C(SC(=C1)Cl)Cl,,,,,,
8501,18502,Cyclohexyl isocyanate,C1CCC(CC1)N=C=O,,,,,,
8502,18503,"1,5-Diisocyanatonaphthalene",C1=CC2=C(C=CC=C2N=C=O)C(=C1)N=C=O,,,,,,
8503,18504,5-(4-Methylbenzylidene)-3-methylhydantoin,CC1=CC=C(C=C1)C=C2C(=O)N(C(=O)N2)C,,,,,,
8504,18505,"1,2,2-Trichloropropane",CC(CCl)(Cl)Cl,,,,,,
8505,18506,"4,11-Diamino-2-butyl-1H-naphth(2,3-f)isoindole-1,3,5,10(2H)-tetrone",CCCCN1C(=O)C2=C(C3=C(C(=C2C1=O)N)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
8506,18507,1-Methoxy-2-naphthylamine,COC1=C(C=CC2=CC=CC=C21)N,,,,,,
8507,18508,Tert-butylcyclohexane,CC(C)(C)C1CCCCC1,,,,,,
8508,18509,CID 18509,C1=NNC(=N1)S,,,,,,
8509,18510,Decyl methacrylate,CCCCCCCCCCOC(=O)C(=C)C,,,,,,
8510,18511,3-(Diethoxymethylsilyl)propylamine,CCO[Si](C)(CCCN)OCC,,,,,,
8511,18512,Diethylaminoethyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCCN(CC)CC,,,,,,
8512,18513,2-[N-(2-hydroxyethyl)-4-methyl-3-[(4-nitrophenyl)diazenyl]anilino]ethanol,CC1=C(C=C(C=C1)N(CCO)CCO)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
8513,18514,Disperse blue 7,C1=CC(=C2C(=C1NCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCO,,,,,,
8514,18515,2-Butylphenol,CCCCC1=CC=CC=C1O,,,,,,
8515,18516,Disperse Red 13,CCN(CCO)C1=CC=C(C=C1)N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl,,,,,,
8516,18517,"1-(3,5'-Dichlorophenyl)-2,2-dimethyl-4,6-diamino-1,2-dihydro-S-triazine",CC1(N=C(N=C(N1C2=CC(=CC(=C2)Cl)Cl)N)N)C,,,,,,
8517,18518,"1-((3,4-Dihydroxyphenyl)methyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrochloride",C1C[NH2+]C(C2=CC(=C(C=C21)O)O)CC3=CC(=C(C=C3)O)O.[Cl-],,,,,,
8518,18519,Tetrahydropapaveroline,C1CNC(C2=CC(=C(C=C21)O)O)CC3=CC(=C(C=C3)O)O,,,,,,
8519,18520,Alipamide,CN(C)NC(=O)C1=CC(=C(C=C1)Cl)S(=O)(=O)N,,,,,,
8520,18521,Methyl p-tolyl sulfone,CC1=CC=C(C=C1)S(=O)(=O)C,,,,,,
8521,18522,2-Methyltetrahydrofuran-3-one,CC1C(=O)CCO1,,,,,,
8522,18523,Chloromethyl ethyl ether,CCOCCl,,,,,,
8523,18524,"Isoindoline, 2-(3-morpholinopropyl)-",C1COCCN1CCCN2CC3=CC=CC=C3C2,,,,,,
8524,18525,"Isoindolium, 2-methyl-2-(3-(4-methyl-4-morpholinio)propyl)-, diiodide",C[N+]1(CCOCC1)CCC[N+]2(CC3=CC=CC=C3C2)C.[I-].[I-],,,,,,
8525,18526,"4-Methyl-4-[3-(2-methyl-1,3-dihydroisoindol-2-ium-2-yl)propyl]morpholin-4-ium",C[N+]1(CCOCC1)CCC[N+]2(CC3=CC=CC=C3C2)C,,,,,,
8526,18527,CID 18527,C1CCC[NH+](CC1)CCC(=NO)[NH3+].[Cl-].[Cl-],,,,,,
8527,18528,3-(azepan-1-yl)-N'-hydroxypropanimidamide,C1CCCN(CC1)CCC(=NO)N,,,,,,
8528,18529,"1,2,5,6,9,10-Hexabromocyclododecane",C1CC(C(CCC(C(CCC(C1Br)Br)Br)Br)Br)Br,,,,"['1,2,5,6,9,10-Hexabromocyclododecane (HBCD) is a high production volume cycloaliphatic used as an additive flame retardant primarily in polystyrene foam building materials. HBCD mixtures contain three major stereoisomers, alpha (a), beta (b), and gamma (g), at a typical ratio of 1.2:0.6:8.2. The toxicokinetic properties of the a and g isomers differ. For instance, a-HBCD has greater bioavailability and potential for accumulation in mice than g-HBCD. The present study reports comparative kinetics data for b-HBCD needed to support toxicological evaluations of HBCD mixtures. Results indicated that a single oral dose of 3mg/kg of [(14)C]-labeled b-HBCD was absorbed rapidly (> or = 85% total dose) in the female C57BL/6 mouse. The C max for b-HBCD-derived radioactivity in tissues, except adipose, was observed 3hr following gavage. Approximately 90% of the administered dose was excreted in urine and feces within 24hr, primarily as b-HBCD-derived metabolites. A portion of the dose (circa 9%) was excreted in feces as g-HBCD. Oral administration of 30 or 100mg/kg of b-HBCD resulted initially in slower rates of [(14)C] elimination; however, cumulative excretion data were similar across the dosing range 4 days postdosing. Residual concentrations of [(14)C] in tissues were highest in adipose and liver. b-HBCD-derived radioactivity accumulated in most tissues following four consecutive daily oral doses of 3mg/kg. The extent of metabolism and excretion of b-HBCD in female C57BL/6 mice was similar to that for g-HBCD. The potential for accumulation of b-HBCD-derived material in most tissues appeared to be less than for a-HBCD.']","['1,2,5,6,9,10-hexabromocyclododecane (HBCD) is a brominated flame retardant consisting of a mixture of diastereomeric pairs of enantiomers that is a known omnipresent, environmental contaminant. The present study investigated the possibility of bioisomerization of HBCD stereoisomers. Therefore, mirror carps (Cyprinus carpio morpha noblis) were exposed to pure (+)- and (-)-gamma-HBCD, randomly sampled biweekly over a period of three and a half months and the fillets were subjected to enantiomer-specific determination of HBCD. Considering the background contamination of the fish at the beginning of the feeding period, significant enrichment of the respectively fed gamma-enantiomer was already detectable after two weeks of exposure. However, no significant enrichment of the respectively expected alpha-enantiomer was observed within this period. Thus, no evidence for the isomerization of HBCD stereoisomers was found in mirror carp under the applied conditions.']",
8529,18530,N-Methyl-N-vinylacetamide,CC(=O)N(C)C=C,,,,,,
8530,18531,"Acetamide, N-ethyl-N-vinyl-",CCN(C=C)C(=O)C,,,,,,
8531,18532,"1,4-Dihydro-2,3-dimethyl-4-phenyl-1,4-ethanoisoquinolinium chloride",CC1=[N+](C2CCC1(C3=CC=CC=C23)C4=CC=CC=C4)C.[Cl-],,,,,,
8532,18533,"1,4-Dihydro-2,3-dimethyl-4-phenyl-1,4-ethanoisoquinolin-2-ium",CC1=[N+](C2CCC1(C3=CC=CC=C23)C4=CC=CC=C4)C,,,,,,
8533,18534,"4-Methyl-2,6,7-trioxa-1-phosphabicyclo(2.2.2)octane-1-sulfide",CC12COP(=S)(OC1)OC2,,,,,,
8534,18535,"Benzyl alcohol, alpha-cyclopentyl-alpha-(3-(diethylamino)-1-propynyl)-, hydrochloride",CC[NH+](CC)CC#CC(C1CCCC1)(C2=CC=CC=C2)O.[Cl-],,,,,,
8535,18536,1-Cyclopentyl-4-(diethylamino)-1-phenyl-2-butyn-1-ol,CCN(CC)CC#CC(C1CCCC1)(C2=CC=CC=C2)O,,,,,,
8536,18537,"alpha-(1-Aminopropyl)-3,4-dihydroxybenzyl alcohol hydrochloride",CCC(C(C1=CC(=C(C=C1)O)O)O)[NH3+].[Cl-],,,,,,
8537,18538,Ethylnorepinephrine,CCC(C(C1=CC(=C(C=C1)O)O)O)N,,,,,,
8538,18539,"1,2,3,4-Tetrahydro-5-aminoacridine",C1CCC2=C(C1)C=C3C=CC=C(C3=N2)N,,,,,,
8539,18540,"Ammonium, (2-(2-(1-naphthylmethyl)-3-(tetrahydro-2-furyl)propoxy)ethyl)trimethyl-, iodide",C[N+](C)(C)CCOCC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.[I-],,,,,,
8540,18541,Trimethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propoxy]ethyl]azanium,C[N+](C)(C)CCOCC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32,,,,,,
8541,18542,Praxilene,CC[NH+](CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
8542,18543,Diethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoyl]oxyethyl]azanium;4-hydroxy-4-oxobut-2-enoate,CC[NH+](CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.C(=CC(=O)[O-])C(=O)O,,,,,,
8543,18544,"Formamidine, N,N'-bis(3-methoxyphenyl)-",COC1=CC=CC(=C1)NC=NC2=CC(=CC=C2)OC,,,,,,
8544,18545,Perchlorocyclobutenone,C1(=C(C(C1=O)(Cl)Cl)Cl)Cl,,,,,,
8545,18546,"ethyl N-(4-methyl-1,3-oxazol-5-yl)-N-propylcarbamate",CCCN(C1=C(N=CO1)C)C(=O)OCC,,,,,,
8546,18547,"Alanine, N-piperonyl-",CC(C(=O)O)NCC1=CC2=C(C=C1)OCO2,,,,,,
8547,18548,"FURFURYLAMINE, alpha-BENZYL-N-METHYL-",CNC(CC1=CC=CC=C1)C2=CC=CO2,,,,,,
8548,18549,alpha-Benzyl-N-propylfurfurylamine,CCCNC(CC1=CC=CC=C1)C2=CC=CO2,,,,,,
8549,18550,Benapryzine hydrochloride,CCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.Cl,,,,,,
8550,18551,Benapryzine,CCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O,,,,,,
8551,18552,"2-(4,6-Diphenyl-1,3,5-triazin-2-yl)phenol",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=CC=C3O)C4=CC=CC=C4,,,,,,
8552,18553,"Cyclobutanecarboxylic acid, 3-cyclohexyl-",C1CCC(CC1)C2CC(C2)C(=O)O,,,,,,
8553,18554,2-Ethylfuran,CCC1=CC=CO1,,,,,,
8554,18555,"2,3-Dichloronitrobenzene",C1=CC(=C(C(=C1)Cl)Cl)[N+](=O)[O-],,,,"['/Rabbits/ were dosed orally with 2,3-dichloronitrobenzene (0.1 g/kg) and their urine and feces were collected for 72 hr. About 5% of the dose was recovered in feces /and/ ... about 84% of the dose was recovered in urine ... .']","['2,3-Dichloronitrobenzene undergoes extensive biotransformation in the rabbit. The animals were dosed orally with 2,3-dichloronitrobenzene (0.1 g/kg) and their urine and feces were collected for 72 hr. About 5% of the dose was recovered in feces as 2,3-dichloronitrobenzene and dichloroaniline. About 84% of the dose was recovered in urine, in the form of amino and nitrodichlorophenols: mercapturic acid (0% of dose), glucuronides (47%), sulfates (17%), dichloroaniline-free (15%), dichloroaniline-conjugated (5%), and chlorazoxybenzene (0%).']",
8555,18556,alpha-(1-Naphthylmethyl)tetrahydro-2-furanpropionic acid 2-(1-pyrrolidinyl)ethyl ester oxalate,C1CC[NH+](C1)CCOC(=O)C(CC2CCCO2)CC3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O,,,,,,
8556,18557,2-Pyrrolidin-1-ylethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate,C1CCN(C1)CCOC(=O)C(CC2CCCO2)CC3=CC=CC4=CC=CC=C43,,,,,,
8557,18558,alpha-(1-Naphthylmethyl)tetrahydro-2-furanpropionic acid 2-morpholinoethyl ester oxalate,C1CC(OC1)CC(CC2=CC=CC3=CC=CC=C32)C(=O)OCC[NH+]4CCOCC4.C(=O)(C(=O)[O-])O,,,,,,
8558,18559,2-Morpholin-4-ylethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate,C1CC(OC1)CC(CC2=CC=CC3=CC=CC=C32)C(=O)OCCN4CCOCC4,,,,,,
8559,18560,alpha-(1-Naphthylmethyl)tetrahydro-2-furanpropionic acid 2-(dimethylamino)ethyl ester oxalate,C[NH+](C)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O,,,,,,
8560,18561,2-(Dimethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate,CN(C)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32,,,,,,
8561,18562,alpha-(1-Naphthylmethyl)tetrahydro-2-furanpropionic acid 2-piperidinoethyl ester oxalate,C1CC[NH+](CC1)CCOC(=O)C(CC2CCCO2)CC3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O,,,,,,
8562,18563,2-Piperidin-1-ylethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate,C1CCN(CC1)CCOC(=O)C(CC2CCCO2)CC3=CC=CC4=CC=CC=C43,,,,,,
8563,18564,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (2-(N-butyl-N-ethylamino)ethyl) ester, hydrochloride",CCCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC.[Cl-],,,,,,
8564,18565,"2-[Butyl(ethyl)amino]ethyl 2-ethoxy-2,2-diphenylacetate",CCCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC,,,,,,
8565,18566,"Cyclobutane-1,2-dicarbonitrile",C1CC(C1C#N)C#N,,,,,,
8566,18567,"Acetic acid, 2-benzyloxy-2,2-diphenyl-, (1-methyl-2-pyrrolidinyl)methyl ester, hydrochloride",C[NH+]1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC4=CC=CC=C4.[Cl-],,,,,,
8567,18568,"(1-Methylpyrrolidin-2-yl)methyl 2,2-diphenyl-2-phenylmethoxyacetate",CN1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC4=CC=CC=C4,,,,,,
8568,18569,Cyclopentenol,C1CC=C(C1)O,,,,,,
8569,18570,"o-ACETOTOLUIDIDE, 2-DIETHYLAMINO-",CCN(CC)CC(=O)NC1=CC=CC=C1C,,,,,,
8570,18571,2-(Diethylamino)acetanilide hydrochloride,CC[NH+](CC)CC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
8571,18572,2-(diethylamino)-N-phenylacetamide,CCN(CC)CC(=O)NC1=CC=CC=C1,,,,,,
8572,18573,Diphenylacetic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CC[NH+](CC)CC(C)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
8573,18574,1-(Diethylamino)propan-2-yl diphenylacetate,CCN(CC)CC(C)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
8574,18575,Direct Yellow 50,CC1=C(C=CC(=C1)NC(=O)NC2=CC(=C(C=C2)N=NC3=CC4=C(C=CC=C4S(=O)(=O)[O-])C(=C3)S(=O)(=O)[O-])C)N=NC5=CC6=C(C=CC=C6S(=O)(=O)[O-])C(=C5)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
8575,18576,"1,5-Naphthalenedisulfonic acid, 3,3'-[carbonylbis[imino(2-methyl-4,1-phenylene)azo]]bis-",CC1=C(C=CC(=C1)NC(=O)NC2=CC(=C(C=C2)N=NC3=CC4=C(C=CC=C4S(=O)(=O)O)C(=C3)S(=O)(=O)O)C)N=NC5=CC6=C(C=CC=C6S(=O)(=O)O)C(=C5)S(=O)(=O)O,,,,,,
8576,18577,"3,3-Dimethyl-4-(dimethylamino)-4-(p-methoxyphenyl)butyl p-methoxyphenyl ketone",CC(C)(CCC(=O)C1=CC=C(C=C1)OC)C(C2=CC=C(C=C2)OC)N(C)C,,,,,,
8577,18578,"3,3-Dimethyl-4-(dimethylamino)-4-(o-methoxyphenyl)butyl o-methoxyphenyl ketone",CC(C)(CCC(=O)C1=CC=CC=C1OC)C(C2=CC=CC=C2OC)N(C)C,,,,,,
8578,18579,"5,5-Dimethyl-6-(dimethylamino)-2-heptanone",CC(C(C)(C)CCC(=O)C)N(C)C,,,,,,
8579,18580,"3,3-Dimethyl-4-(dimethylamino)-4-(p-tolyl)butyl p-tolyl ketone",CC1=CC=C(C=C1)C(C(C)(C)CCC(=O)C2=CC=C(C=C2)C)N(C)C,,,,,,
8580,18581,"3,3-Dimethyl-4-(dimethylamino)-4-(m-tolyl)butyl m-tolyl ketone",CC1=CC(=CC=C1)C(C(C)(C)CCC(=O)C2=CC=CC(=C2)C)N(C)C,,,,,,
8581,18582,"3,3-Dimethyl-4-(dimethylamino)-4-(o-tolyl)butyl o-tolyl ketone",CC1=CC=CC=C1C(C(C)(C)CCC(=O)C2=CC=CC=C2C)N(C)C,,,,,,
8582,18583,CID 18583,C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)C(F)(F)F.C(=CC(=O)[O-])C(=O)O,,,,,,
8583,18584,"N,N-Dimethyl-2-[phenyl[3-(trifluoromethyl)phenyl]methoxy]ethanamine",CN(C)CCOC(C1=CC=CC=C1)C2=CC(=CC=C2)C(F)(F)F,,,,,,
8584,18585,2-(Diethylamino)ethyl alpha-allyl-1-naphthaleneacetate,CCN(CC)CCOC(=O)C(CC=C)C1=CC=CC2=CC=CC=C21,,,,,,
8585,18586,2-(Diethylamino)ethyl alpha-(2-furylmethyl)-1-naphthaleneacetate,CCN(CC)CCOC(=O)C(CC1=CC=CO1)C2=CC=CC3=CC=CC=C32,,,,,,
8586,18587,"4-Bromo-2,6-dichlorophenol",C1=C(C=C(C(=C1Cl)O)Cl)Br,,,,,,
8587,18588,2-(Chloromethyl)thiirane,C1C(S1)CCl,,,,,,
8588,18589,"N-Benzyl-N',N'-bis(2-chloroethyl)-N-methylethylenediamine dihydrochloride",C[NH+](CC[NH+](CCCl)CCCl)CC1=CC=CC=C1.[Cl-].[Cl-],,,,,,
8589,18590,"N-benzyl-N',N'-bis(2-chloroethyl)-N-methylethane-1,2-diamine",CN(CCN(CCCl)CCCl)CC1=CC=CC=C1,,,,,,
8590,18591,2-Methyloctane,CCCCCCC(C)C,,,,,,
8591,18592,Chloroallene,C=C=CCl,,,,,,
8592,18593,1-Amino-4-chloro-2-methylanthraquinone,CC1=CC(=C2C(=C1N)C(=O)C3=CC=CC=C3C2=O)Cl,,,,,,
8593,18594,2-Hexylphenol,CCCCCCC1=CC=CC=C1O,,,,,,
8594,18595,Ammonium dimethyldithiocarbamate,CN(C)C(=S)[S-].[NH4+],,,,,,
8595,18596,Zirconium(2+) acetate,CC(=O)[O-].[Zr],,,,,,
8596,18597,4-Isopropyl-3-methylphenol,CC1=C(C=CC(=C1)O)C(C)C,,,,,,
8597,18598,2-Isopropyl-6-methylphenol,CC1=C(C(=CC=C1)C(C)C)O,,,,,,
8598,18599,Ornithylaspartate,C(C[C@@H](C(=O)O)N)C[NH3+].C([C@@H](C(=O)[O-])N)C(=O)O,,,,,,
8599,18600,3-(2-Carboxyethylsulfanylmethylsulfanyl)propanoic acid;dibutyltin,CCCC[Sn]CCCC.C(CSCSCCC(=O)O)C(=O)O,,,,,,
8600,18601,"3,3'-(Methylenebis(thio))bispropionic acid",C(CSCSCCC(=O)O)C(=O)O,,,,,,
8601,18602,"1,3,5-Triazine-2,4-diamine, 6-butyl-",CCCCC1=NC(=NC(=N1)N)N,,,,,,
8602,18603,"2,3-Dibromobut-2-ene-1,4-diol",C(C(=C(CO)Br)Br)O,,,,,,
8603,18604,"1,2-Epoxytetradecane",CCCCCCCCCCCCC1CO1,,,,,,
8604,18605,Myristyl myristate,CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC,,,,,,
8605,18606,Furfurylidenemalononitrile,C1=COC(=C1)C=C(C#N)C#N,,,,,,
8606,18607,3-(4-Chlorophenyl)propiolic acid,C1=CC(=CC=C1C#CC(=O)O)Cl,,,,,,
8607,18608,Carbenzide,CCOC(=O)NNC(C)C1=CC=CC=C1,,,,,,
8608,18609,Aspon,CCCOP(=S)(OCCC)OP(=S)(OCCC)OCCC,,,,,,
8609,18610,Dipropionyl peroxide,CCC(=O)OOC(=O)CC,,,,,,
8610,18611,"Benzenamine, 4-((4-amino-3-methylphenyl)(4-imino-3-methyl-2,5-cyclohexadien-1-ylidene)methyl)-2-methyl-, monohydrochloride",CC1=CC(=C(C2=CC(=C(C=C2)N)C)C3=CC(=C(C=C3)N)C)C=CC1=[NH2+].[Cl-],,,,,,
8611,18612,New fuchsin free base,CC1=CC(=C(C2=CC(=C(C=C2)N)C)C3=CC(=C(C=C3)N)C)C=CC1=N,,,,,,
8612,18613,"E,Z-2,4-Hexadienedial",C(=CC=O)C=CC=O,,,,,,
8613,18614,Methyl 4-aminobutanoate,COC(=O)CCCN,,,,,,
8614,18615,4-Aminobutanamide,C(CC(=O)N)CN,,,,,,
8615,18616,Cupric nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Cu+2],,,,,,
8616,18617,Dibromoacetonitrile,C(#N)C(Br)Br,,,,"['Approximately 8% of a single oral dose of 149 mg/kg bw of dibromoacetonitrile to rats was excreted in urine within 24 hr as thiocyanate, the product of released cyanide metabolized by rhodanese.']","['When administered orally to rats, the haloacetonitriles (HAN) were metabolized to cyanide and excreted in the urine as thiocyanate. The extent of thiocyanate excretion was chloroacetonitrile (CAN) greater than bromochloroacetonitrile (BCAN) greater than dichloroacetonitrile (DCAN)  greater than dibromoacetonitrile (DBAN)  much greater than trichloroacetonitrile (TCAN).', 'Approximately 8% of a single oral dose of 149 mg/kg bw of dibromoacetonitrile to rats was excreted in urine within 24 hr as thiocyanate, the product of released cyanide metabolized by rhodanese.']",
8617,18618,Laudexium metilsulfate,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCCCCCCCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.COS(=O)(=O)[O-].COS(=O)(=O)[O-],,,,,,
8618,18619,Laudexium,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCCCCCCCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,,,,,,
8619,18620,Convallatoxol,CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)CO)O)O)O,,,,,,
8620,18621,Dimethyl P-(methylthio)phenyl phosphate,COP(=O)(OC)OC1=CC=C(C=C1)SC,,,,"['AFTER IP INJECTION OF (32)C-LABELED GC-6506 INTO FEMALE WHITE SPRAGUE-DAWLEY RATS, OVER 90% OF THE DOSE WAS EXCRETED IN THE URINE. ... WHEN RATS WERE TREATED WITH (14)C-LABELED GC-6506, ABOUT 80% OF DOSE WAS EXCRETED IN URINE WITHIN 16 HR.', 'Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/', 'The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'For more Absorption, Distribution and Excretion (Complete) data for DIMETHYL P-(METHYLTHIO)PHENYL PHOSPHATE (8 total), please visit the HSDB record page.']","['BIOLOGICAL HALF-LIVES OF GC-6506 & ITS OXIDATIVE DERIVATIVES INSIDE COTTON PLANT DID NOT EXCEED TWO DAYS. SMALL CONCN OF O-DEMETHYL GC-6506-SO & -SO2 WERE PRESENT AS WELL AS O-DEMETHYL GC-6506. AFTER IP INJECTION OF (32)P-LABELED GC-6506 INTO FEMALE WHITE SPRAGUE-DAWLEY RATS, OVER 90% OF THE DOSE WAS EXCRETED IN THE URINE. DIMETHYL PHOSPHATE WAS THE PREDOMINANT PRODUCT. ... /IN INSTAR BUDWORMS/. INITIALLY APPROX EQUIV CLEAVAGE OF O-METHYL & P-O-PHENYL LINKAGES OCCURRED. O-DEMETHYLATION WAS GLUTATHIONE DEPENDENT; P-O PHENYL CLEAVAGE ... ASSOC WITH 2 ENZYMES. STUDIES WITH PHENOL -SO2 INDICATED ... MATERIAL WAS CONVERTED INTO UNIDENTIFIED CONJUGATES.', 'Plasma & tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds.', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase. The enzymes are found in plasma and in the hepatic endoplasmic reticulum & can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond.', 'These chemicals are detoxified by cytochrome p450-mediated monooxygenases in the liver, but some metabolites are more toxic than parent cmpd ... Metabolites usually are detected from 12 to 48 hr postexposure. /Organophosphate cmpd/']",['BIOLOGICAL HALF-LIVES OF GC-6506 & ITS OXIDATIVE DERIVATIVES INSIDE COTTON PLANT DID NOT EXCEED TWO DAYS.']
8621,18622,Doxenitoin,C1NC(=O)C(N1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8622,18623,CID 18623,C1C(N(C(=O)N=C1NO)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)NO,,,,,,
8623,18624,5-Allyl-5-(2-hydroxy-3-iodopropyl)barbituric acid,C=CCC1(C(=O)NC(=O)NC1=O)CC(CI)O,,,,,,
8624,18625,A'-Neo-30-norgammacerane,CCC1CCC2(C1CCC3(C2CCC4C3(CCC5C4(CCCC5(C)C)C)C)C)C,,,,,,
8625,18626,6-Ethoxy-2-(6-ethoxy-3-oxo-1-benzothiophen-2-ylidene)-1-benzothiophen-3-one,CCOC1=CC2=C(C=C1)C(=O)C(=C3C(=O)C4=C(S3)C=C(C=C4)OCC)S2,,,,,,
8626,18627,2-Amino-2-phenylacetamide hydrobromide,C1=CC=C(C=C1)C(C(=O)N)[NH3+].[Br-],,,,,,
8627,18628,"N-[1-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)ethylidene]hydroxylamine",CC(=NO)C1CC2=CC=CC=C12,,,,,,
8628,18629,CID 18629,CC(=CC(=O)C)O.CC(=CC(=O)C)O.[Ni],,,,,,
8629,18630,"3-penten-2-one, 4-hydroxy-, (3Z)-",CC(=CC(=O)C)O,,,,,,
8630,18631,(Z)-3-(Hydroxyimino)-1-methylindolin-2-one,CN1C2=CC=CC=C2C(=C1O)N=O,,,,,,
8631,18632,"2,3-Epoxybutane",CC1C(O1)C,,,,,,
8632,18633,Cobalt succinate,C(CC(=O)[O-])C(=O)[O-].[Co+2],,,,,,
8633,18634,CID 18634,CCC[SnH](CCC)CCC.CC(=O)O,,,,,,
8634,18635,3-(Methylthio)propionaldehyde,CSCCC=O,,,['Compounds that inhibit the action of prostaglandins. (See all compounds classified as Prostaglandin Antagonists.)'],,"['Four commonly used food antioxidants, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate and octyl gallate, were tested for their ability to inhibit the formation of ethylene from methional in NADPH-oxidizing rat liver microsomes. It is assumed that the action of the antioxidants on ethylene formation reflects their free radical scavenging activity. Only propyl gallate and octyl gallate are efficient inhibitors of ethylene formation. BHT is inhibitory only at very high concentrations, and BHA tends to increase ethylene formation. It is concluded that gallic acid ester antioxidants may possess a protective potential during chemical-induced microsomal oxidations.']",
8635,18636,OCTACHLORODIBENZO-p-DIOXIN,C12=C(C(=C(C(=C1Cl)Cl)Cl)Cl)OC3=C(O2)C(=C(C(=C3Cl)Cl)Cl)Cl,,,,"['Male Wistar rats fed 22.7 (+ or -) ug or 120.7 (+ or - 2.9) ug octachlorodibenzo-p-dioxin over a 2 wk period were found to retain about 1-2% of the given dose in the liver. The heart, kidneys, spleen, lung, skeletal muscle, testes, and urine contained no detectable levels of octachlorodibenzo-p-dioxin, but minor amounts were found in the adipose tissue of the high dose group. Feces contained 61% and 37%, respectively, of the low and high doses given. The presence of a large quantity of octachlorodibenzo-p- dioxin in the feces compared to that in the bile 24-72 hr after a single oral dose of 58 ug octachlorodibenzo-p-dioxin to bile-cannulated male Wistar rats (400 g) indicated that the dioxin present in the feces was mainly unabsorbed octachlorodibenzo-p-dioxin.', 'After 21 daily doses of 100 ug octachlorodibenzo-p-dioxin containing 12.6 picograms (35)S-thio-heptachlorodibenzo-p-dioxin to male Sprague Dawley rats, the radioactivity was mainly recovered in the feces and urine, the percentages of the ingested radioactive dose being 93 (+ or - 6) and 5.2 (+ or - 0.8)% respectively. The high fecal excretion suggests poor absorption. Of the radioactive body burden, 50% was contained in the liver. The microsomal fraction contained 96.3 (+ or - 8.2)% of the hepatic radioactivity.', '...The disposition of (14)C-octachlorodibenzo-p-dioxin was studied in male Fischer 344 rats in order to better assess the significance of chronic environmental exposure to octachlorodibenzo-p-dioxin. Rats were treated with 50 ug octachlorodibenzo-p-dioxin/kg iv, and 50, 500, or 5,000 ug/kg orally and held in individual metabolism cages for 3 days. Additional rats treated iv were held up to 56 days to follow elimination of octachlorodibenzo-p-dioxin derived radioactivity and to determine terminal tissue distribution. Feces was the major route of elimination after both routes of exposure with little radioactivity ever appearing in the urine. GI absorption was nonlinear between 500 and 5,000 ug/kg, never exceeding 10% of the administered dose. Liver was the major depot, followed by adipose tissue and skin. No metabolites of octachlorodibenzo-p-dioxin were detected in tissues, bile, or excreta. The whole body half-life for the elimination of octachlorodibenzo-p-dioxin was between 3 and 5 months. Repeated oral exposure resulted in linear accumulation of octachlorodibenzop-dioxin in the tissues. Thus, octachlorodibenzo-p-dioxin while poorly absorbed, can accumulate upon low-dose, repeated exposure and concentrate in the liver and adipose tissue.', 'A study of dibenzo-p-dioxins concn in human milk was conducted. A total of 168 milk samples were obtained from mothers who breast fed their children. Seventy nine samples were obtained from mothers nursing their first child, 74 from mothers nursing their second child, and 15 samples were collected from mothers nursing their third or fourth child. Milk samples were obtained from a single mother 1, 5, 10 to 13, and 52 to 60 wk after delivery and analyzed for dibenzo-p-dioxins. Dibenzo-p-dioxins with 2,3,7,8-chlorine substitution were found in all samples. The mean concn of dibenzo-p-dioxins was 195 parts per trillion for octachlorodibenzo-p-dioxin. The dibenzo-p-dioxin concn in the samples decreased with increasing number of children who were breast fed. The concn of dibenzo-p-dioxins in the breast milk from the single mother decreased to about 30 to 40% of their initial value 52 wk after delivery. The largest decreases generally occurred 1 to 5 wk after delivery. It was concluded that dibenzo-p-dioxins residues in human milk from mothers who nurse their infants decrease from the first to the second child and with time after delivery. Lactation can be regarded as an excretory process for the mother.', 'For more Absorption, Distribution and Excretion (Complete) data for OCTACHLORODIBENZO-P-DIOXIN (12 total), please visit the HSDB record page.']",,"['/In a/... study of 48 workers at a German pesticide facility, elimination half times were estimated for several CDD congeners. The estimated half-/life was/... 6.7 years for /octachlorodibenzo-p-dioxin/... .', 'Elimination half life estimate for OCDD from 1 individual exposed to technical pentachlorophenol in the wood of his/her home was 5.7 yr, based on 2 adipose tissue samples taken over a 28 month period. /from table/', '...The disposition of (14)C-octachlorodibenzo-p-dioxin was studied in male Fischer 344 rats ...treated with 50 ug octachlorodibenzo-p-dioxin/kg iv, and 50, 500, or 5,000 ug/kg orally and held in individual metabolism cages for 3 days. Additional rats treated iv were held up to 56 days... . The whole body half-life for the elimination of octachlorodibenzo-p-dioxin was between 3 and 5 months. ...']"
8636,18637,Nifuraldezone,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)C(=O)N,,,,,,
8637,18638,CID 18638,CCOP(=S)(OCC)OC1=CC(=C(C=C1)[N+](=O)[O-])C2=CC=CC=C2,,,,,,
8638,18639,"(2Z,4E)-2-hydroxy-6-oxohexa-2,4-dienoic acid",C(=CC(=O)C(=O)O)C=CO,,,,,,
8639,18640,"6-Methoxy-2-methyl-1H-benzo[de]isoquinoline-1,3(2H)-dione",CN1C(=O)C2=C3C(=C(C=C2)OC)C=CC=C3C1=O,,,,,,
8640,18641,"Anthra[2,1,9-mna]naphth[2,3-h]acridine-5,10,15(16H)-trione",C1=CC=C2C(=C1)C3=C4C(=C2O)C=CC5=C6C=CC7=C(C6=NC(=C54)C=C3)C(=O)C8=CC=CC=C8C7=O,,,,,,
8641,18642,CID 18642,CCC[NH+](CCC)CCN=C([NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
8642,18643,2-[2-(Dipropylamino)ethyl]guanidine,CCCN(CCC)CCN=C(N)N,,,,,,
8643,18644,CID 18644,CCN(CC)CC[NH2+]C(=N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
8644,18645,N-(2-Diethylamino-ethyl)-guanidine,CCN(CC)CCN=C(N)N,,,,,,
8645,18646,2-Methoxyanthraquinone,COC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
8646,18647,2-Propylhexanoic acid,CCCCC(CCC)C(=O)O,,,,,,
8647,18648,2-Ethylheptanoic acid,CCCCCC(CC)C(=O)O,,,,,,
8648,18649,"Piperidine, N-(ethoxymethyl)-",CCOCN1CCCCC1,,,,,,
8649,18650,"5B-Androstan-3-on-17B-ol, 17A-methyl",C[C@@]1(CCC2C1(CCC3C2CC[C@H]4C3(CCC(=O)C4)C)C)O,,,,,,
8650,18651,Desoxymethyltestosterone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC=CC4)C,,,,,,
8651,18652,"2,5-Dimethoxybenzylamine",COC1=CC(=C(C=C1)OC)CN,,,,,,
8652,18653,beta-p-N-Di(beta-chloroethyl)aminophenylbutyric acid hydrochloride,CC(CC1=CC=C(C=C1)N(CCCl)CCCl)C(=O)O.Cl,,,,,,
8653,18654,3-[4-[Bis(2-chloroethyl)amino]phenyl]-2-methylpropanoic acid,CC(CC1=CC=C(C=C1)N(CCCl)CCCl)C(=O)O,,,,,,
8654,18655,"BENZIMIDAZOLE, 1-(2-(DIETHYLAMINO)ETHYL)-2-((p-PROPOXYPHENYL)THIO)-",CCCOC1=CC=C(C=C1)SC2=NC3=CC=CC=C3N2CCN(CC)CC,,,,,,
8655,18656,"BENZIMIDAZOLE, 1-(2-(DIETHYLAMINO)ETHYL)-2-((p-(PROPYLAMINO)PHENYL)THIO)-",CCCNC1=CC=C(C=C1)SC2=NC3=CC=CC=C3N2CCN(CC)CC,,,,,,
8656,18657,"Benzoic acid, 3,5-dimethyl-4-(2-(propylamino)propionamido)-, propyl ester, perchlorate",CCC[NH2+]C(C)C(=O)NC1=C(C=C(C=C1C)C(=O)OCCC)C.[O-]Cl(=O)(=O)=O,,,,,,
8657,18658,"Propyl 3,5-dimethyl-4-[2-(propylamino)propanoylamino]benzoate",CCCNC(C)C(=O)NC1=C(C=C(C=C1C)C(=O)OCCC)C,,,,,,
8658,18659,"1,1,3,3-Tetramethyl-disiloxane",C[SiH](C)O[SiH](C)C,,,,,,
8659,18660,Chloropon,C(C(C(=O)O)(Cl)Cl)Cl,,,,,,
8660,18661,4-tert-Butyl-2-nitrophenol,CC(C)(C)C1=CC(=C(C=C1)O)[N+](=O)[O-],,,,,,
8661,18662,o-(2-Propynyloxy)phenyl methylcarbamate,CNC(=O)OC1=CC=CC=C1OCC#C,,,,,,
8662,18663,2-Methyl-3-phenylbutan-2-ol,CC(C1=CC=CC=C1)C(C)(C)O,,,,,,
8663,18664,"Benzoic acid, 3-methyl-4-(2-methyl-4-oxo-3(4H)-quinazolinyl)-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)N2C(=NC3=CC=CC=C3C2=O)C)C.[Cl-],,,,,,
8664,18665,2-(Diethylamino)ethyl 3-methyl-4-(2-methyl-4-oxoquinazolin-3-yl)benzoate,CCN(CC)CCOC(=O)C1=CC(=C(C=C1)N2C(=NC3=CC=CC=C3C2=O)C)C,,,,,,
8665,18666,o-Cyclopentylphenyl methylcarbamate,CNC(=O)OC1=CC=CC=C1C2CCCC2,,,,,,
8666,18667,Diazoacetophenone,C1=CC=C(C=C1)C(=O)C=[N+]=[N-],,,,,,
8667,18668,2-Hydroxy-2-phenylethenediazonium,C1=CC=C(C=C1)C(=C[N+]#N)O,,,,,,
8668,18669,Didodecyldimethylammonium bromide,CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC.[Br-],,,,,,
8669,18670,Didodecyldimethylammonium,CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC,,,,,,
8670,18671,CID 18671,CCCCC(CC)CCC(CCC(CC)CC)S(=O)(=O)[O-].[Na+],,,,,,
8671,18672,"3,9-Diethyltridecane-6-sulfonic acid",CCCCC(CC)CCC(CCC(CC)CC)S(=O)(=O)O,,,,,,
8672,18673,"6-Pentyl-1,3,5-triazine-2,4-diamine",CCCCCC1=NC(=NC(=N1)N)N,,,,,,
8673,18674,Usaf LA-19,C[NH+](CCN[NH3+])CC1=CC(=CC=C1)OC.[Cl-].[Cl-],,,,,,
8674,18675,1-[2-[(m-Methoxybenzyl)methylamino]ethyl]hydrazine,CN(CCNN)CC1=CC(=CC=C1)OC,,,,,,
8675,18676,Ethyl 5-acetyl-3-((dimethylamino)methyl)-2-indolecarboxylate hydrochloride,CCOC(=O)C1=C(C2=C(N1)C=CC(=C2)C(=O)C)C[NH+](C)C.[Cl-],,,,,,
8676,18677,ethyl 5-acetyl-3-[(dimethylamino)methyl]-1H-indole-2-carboxylate,CCOC(=O)C1=C(C2=C(N1)C=CC(=C2)C(=O)C)CN(C)C,,,,,,
8677,18678,"Phenol, 2,4-bis(1,1-dimethylethyl)-6-(phenylmethyl)-",CC(C)(C)C1=CC(=C(C(=C1)C(C)(C)C)O)CC2=CC=CC=C2,,,,,,
8678,18679,"Dithiophosphoric acid O,O-dihexyl S-potassium salt",CCCCCCOP(=S)(OCCCCCC)[S-].[K+],,,,,,
8679,18680,"O,O-Dihexyl hydrogen dithiophosphate",CCCCCCOP(=S)(OCCCCCC)S,,,,,,
8680,18681,CID 18681,C1=CC=C(C=C1)C[NH3+].[Cl-],,,,,,
8681,18682,"O,O-Diethyl S-methyl dithiophosphate",CCOP(=S)(OCC)SC,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/']",,
8682,18683,"1,1,1-Trimethylhydrazinium iodide",C[N+](C)(C)N.[I-],,,,,,
8683,18684,"1,1,1-Trimethylhydrazinium",C[N+](C)(C)N,,,,,,
8684,18685,"ACETOHYDROXAMIC ACID, 2-(p-tert-BUTYLPHENYL)-",CC(C)(C)C1=CC=C(C=C1)CC(=O)NO,,,,,,
8685,18686,Ethyl cyclohexanecarboxylate,CCOC(=O)C1CCCCC1,,,,,,
8686,18687,2-Methyl-3-phenyl-1-propene,CC(=C)CC1=CC=CC=C1,,,,,,
8687,18688,"2,4,4,4-Tetrachlorobutan-1-ol",C(C(CO)Cl)C(Cl)(Cl)Cl,,,,,,
8688,18689,Trimethylolpropane trimethacrylate,CCC(COC(=O)C(=C)C)(COC(=O)C(=C)C)COC(=O)C(=C)C,,,,,,
8689,18690,"Acridine, 2-methoxy-",COC1=CC2=CC3=CC=CC=C3N=C2C=C1,,,,,,
8690,18691,"Carbanilic acid, N-methyl-, isopropyl ester",CC(C)OC(=O)N(C)C1=CC=CC=C1,,,,,,
8691,18692,"2,2-Bis(bromomethyl)-1,3-propanediol",C(C(CO)(CBr)CBr)O,,,,"['... Studies were performed to characterize the dispositional and metabolic fate of 2,2-bis(bromomethyl)-1,3-propanediol (BMP)  after oral or intravenous administration to male Fischer-344 rats. After a single oral administration of (14)C-BMP (10 or 100 mg/kg) >80% of the low dose and 48% of the high dose were excreted by 12 hr in the urine predominantly as a glucuronide metabolite. After repeated daily oral doses for 5 or 10 days, route and rate of elimination were similar to those obtained after single administrations of BMP. In all studies, the radioactivity recovered in feces was low (<15%). The total amount of radioactivity remaining in tissues at 72 hr after a single oral administration of BMP (100 mg/kg) was less than 1% of the dose, and repeated daily dosing did not lead to retention in tissues. After intravenous administration, the radiolabel found in blood decreased rapidly. Excretion profiles were similar to those after oral administration. Parent BMP and BMP glucuronide were present in blood plasma after oral or intravenous dosing. After an intravenous dose of BMP (15 mg/kg) the hepatic BMP glucuronide was primarily exported into the bile (>50% within 6 hr), but it underwent enterohepatic recycling with subsequent elimination in the urine. These data indicate that the extensive extraction and rapid glucuronidation by the liver limits exposure of internal tissues to BMP by greatly reducing its systemic bioavailability after oral exposure.', 'Analysis of selected tissues indicated an increase in bromide content in tissues of rats ingesting 100 mg FR 1138/kg/day. At 5 mg FR 1138/kg/day, there was only a marginal increase in bromide content of some tissues, with most values in same range as controls.']","['In a 2-year bioassay 2,2-bis(bromomethyl)-1,3-propanediol (BMP)  was shown to be a multisite carcinogen in rats and mice. Because glucuronidation is the key metabolic transformation of BMP by rats, in this study the in vitro hepatic glucuronidation of BMP was compared across several species. In addition, the glucuronidation activities of human intestinal microsomes and specific human hepatic UDP-glucuronosyltransferase (UGT) enzymes for BMP were determined. To explore other possible routes of metabolism for BMP, studies were conducted with rat and human hepatocytes. Incubation of hepatic microsomes with BMP in the presence of UDP-glucuronic acid resulted in the formation of a BMP monoglucuronide. The order of hepatic microsomal glucuronidation activity of BMP was rats, mice >> hamsters > monkeys >>> humans. The rate of glucuronidation by rat hepatic microsomes was 90-fold greater than that of human hepatic microsomes. Human intestinal microsomes converted BMP to BMP glucuronide at a rate even lower than that of human hepatic microsomes. Among the human UGT enzymes tested, only UGT2B7 had detectable glucuronidation activity for BMP. BMP monoglucuronide was the only metabolite formed when BMP was incubated with suspensions of freshly isolated hepatocytes from male F-344 rats or with cryopreserved human hepatocytes. Glucuronidation of BMP in human hepatocytes was extremely low. Overall, the results support in vivo studies in rats in which BMP glucuronide was the only metabolite found. The poor glucuronidation capacity of humans for BMP suggests that the pharmacokinetic profile of BMP in humans will be dramatically different from that of rodents.', 'Pentaerythritol Dibromide has known human metabolites that include (2R,3R,4R,5S,6S)-6-[2,2-Bis(bromomethyl)-3-hydroxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid.']",
8692,18693,(1-Ethoxyethyl)benzene,CCOC(C)C1=CC=CC=C1,,,,,,
8693,18694,4-(Diethylamino)butan-2-one,CCN(CC)CCC(=O)C,,,,,,
8694,18695,p-Oxalotoluidide,CC1=CC=C(C=C1)NC(=O)C(=O)NC2=CC=C(C=C2)C,,,,,,
8695,18696,"9H-Fluorene, 9-(1-methylethyl)-",CC(C)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
8696,18697,"3-(4-chlorophenyl)-1-(1H-imidazol-2-ylmethyl)-2,3,4,5-tetrahydro-1-benzazepine",C1CC2=CC=CC=C2N(CC1C3=CC=C(C=C3)Cl)CC4=NC=CN4,,,,,,
8697,18698,delta-Nonalactone,CCCCC1CCCC(=O)O1,,,,,,
8698,18699,"2,2,4,4-Tetramethylpentanoic acid",CC(C)(C)CC(C)(C)C(=O)O,,,,,,
8699,18700,"3,4-Dihydro-1-(2-piperidinopropyl)carbostyril",CC(CN1C(=O)CCC2=CC=CC=C21)N3CCCCC3,,,,,,
8700,18701,CID 18701,CC(=O)[NH2+][C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)O)OC)OC.CC(=O)[O-],,,,,,
8701,18702,1-Demethylcolchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)O)OC)OC,,,,,,
8702,18703,2-(4-Chlorophenoxy)propionic acid,CC(C(=O)O)OC1=CC=C(C=C1)Cl,,,,,,
8703,18704,"2-(3,4-Dichlorophenoxy)propanoic acid",CC(C(=O)O)OC1=CC(=C(C=C1)Cl)Cl,,,,,,
8704,18705,2-Phenylpyridin-3-ol,C1=CC=C(C=C1)C2=C(C=CC=N2)O,,,,,,
8705,18706,[4-(3-Carboxypropyl)phenyl]-bis(2-chloroethyl)azanium;chloride,C1=CC(=CC=C1CCCC(=O)O)[NH+](CCCl)CCCl.[Cl-],,,,,,
8706,18707,"BENZIMIDAZOLE, 1-(2-(DIETHYLAMINO)ETHYL)-2-(p-ETHOXYPHENOXY)-",CCN(CC)CCN1C2=CC=CC=C2N=C1OC3=CC=C(C=C3)OCC,,,,,,
8707,18708,"Ethylamine, 2-(1,4-benzodioxan-6-yloxy)-N,N-dimethyl-, hydrochloride",C[NH+](C)CCOC1=CC2=C(C=C1)OCCO2.[Cl-],,,,,,
8708,18709,"2-(2,3-dihydro-1,4-benzodioxin-6-yloxy)-N,N-dimethylethanamine",CN(C)CCOC1=CC2=C(C=C1)OCCO2,,,,,,
8709,18710,2-Hydroxy-3-methylcholanthrene,CC1=C2C(CC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)O,,,,,,
8710,18711,(4-Chlorophenyl)methyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OCC1=CC=C(C=C1)Cl)OP(=O)(OC)OC,,,,,,
8711,18712,"Podocarp-8(14)-en-15-oic acid, 13-isopropylidene-, methyl ester",CC(=C1CCC2C(=C1)CCC3C2(CCCC3(C)C(=O)OC)C)C,,,,,,
8712,18713,2-Amino-4-methoxybutyric acid,COCCC(C(=O)O)N,,,,,,
8713,18714,CID 18714,CN1CC2=CC=CC=C2C(C3=CC=CC=C31)CCCN4CCCCC4.C(=CC(=O)O)C(=O)O,,,,,,
8714,18715,"5-Methyl-11-(3-piperidin-1-ylpropyl)-6,11-dihydrobenzo[c][1]benzazepine",CN1CC2=CC=CC=C2C(C3=CC=CC=C31)CCCN4CCCCC4,,,,,,
8715,18716,CID 18716,CNCCCC1C2=CC=CC=C2CN(C3=CC=CC=C13)C.C(=CC(=O)O)C(=O)O,,,,,,
8716,18717,"N-methyl-3-(5-methyl-6,11-dihydrobenzo[c][1]benzazepin-11-yl)propan-1-amine",CNCCCC1C2=CC=CC=C2CN(C3=CC=CC=C13)C,,,,,,
8717,18718,N-(3-Aminopropyl)cyclohexylamine,C1CCC(CC1)NCCCN,,,,,,
8718,18719,N-Acetylglycine 2-(alpha-methylphenethyl)hydrazide,CC(CC1=CC=CC=C1)C(C(=O)NN)NC(=O)C,,,,,,
8719,18720,"Benzoxazole, 2-(3,4-methylenedioxyphenyl)-",C1OC2=C(O1)C=C(C=C2)C3=NC4=CC=CC=C4O3,,,,,,
8720,18721,Apigenin triacetate,CC(=O)OC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3OC(=O)C)OC(=O)C,,,,,,
8721,18722,"2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-1-yl)methyl]-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine;chloride",CCC1=C(CC2C3=CC(=C(C=C3CCN2C1)OC)OC)CC4C5=CC(=C(C=C5CC[NH2+]4)OC)OC.[Cl-],,,,,,
8722,18723,"1-Phenylpentane-2,4-dione",CC(=O)CC(=O)CC1=CC=CC=C1,,,,,,
8723,18724,1-Cyclohexylpiperidine,C1CCC(CC1)N2CCCCC2,,,,,,
8724,18725,Tris(2-ethylhexyl) trimellitate,CCCCC(CC)COC(=O)C1=CC(=C(C=C1)C(=O)OCC(CC)CCCC)C(=O)OCC(CC)CCCC,,,,"['The absorption and metabolism of TOTM have been studied in male rats treated by oral intubation with 100mg/kg in corn oil. Based on excretion of 75% of the dose in feces, 85% of which was unchanged, little TOTM is absorbed. Urinary excretion accounted for 16% of the dose with 1.9% exhaled as CO(2). The ester is hydrolyzed to 2-ethylhexonal (2EH) and mono-(2-ethylhexyl)trimellitate (MEHT). The 2EH is further metabolized, and those metabolites are excreted along with MEHT in the urine. Less than 1.0% of the dose was retained in the animal after 144 hr.']","['The absorption and metabolism of TOTM have been studied in male rats treated by oral intubation with 100mg/kg in corn oil. ... The ester is hydrolyzed to 2-ethylhexonal and mono-(2-ethylhexyl)trimellitate (MEHT). The 2EH is further metabolized, and those metabolites are excreted along with MEHT in the urine. Less than 1.0% of the dose was retained in the animal after 144 hr.']",
8725,18726,"2-(2-Hexan-3-yloxy-2,2-diphenylacetyl)oxyethyl-dimethylazanium;chloride",CCCC(CC)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC[NH+](C)C.[Cl-],,,,,,
8726,18727,Diphenyl(1-ethylbutoxy)acetic acid 2-(dimethylamino)ethyl ester,CCCC(CC)OC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
8727,18728,"1,2-Dibromo-4-(1,2-dibromoethyl)cyclohexane",C1CC(C(CC1C(CBr)Br)Br)Br,,,,"['Stereoisomeric compositions of 1,2,5,6,9,10-hexabromocyclododecane (HBCD) and 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) were investigated in the blubber of two species of marine mammals, finless porpoises (Neophocaena phocaenoides) and Indo-Pacific humpback dolphins (Sousa chinensis), from the South China Sea between 2005 and 2015. The concentrations of sigma-HBCD in samples of porpoise (n = 59) and dolphin (n = 32) ranged from 97.2 to 6,260 ng/g lipid weight (lw) and from 447 to 45,800 ng/g lw, respectively, while those of sigma-TBECH were both roughly 2 orders of magnitude lower. A significant increasing trend of SHBCD was found in dolphin blubber over the past decade. The diastereomeric profiles exhibited an absolute predominance of alpha-HBCD (mostly >90%), while the proportions of four TBECH diastereomers in the samples appeared similar. A preferential enrichment of the (-)-enantiomers of alpha-, beta-, and gamma-HBCD was found in most blubber samples. Interestingly, the body lengths of porpoises showed a significant negative correlation with the enantiomer fractions of alpha-HBCD. Significant racemic deviations were also observed for alpha-, gamma-, and sigma-TBECH enantiomeric pairs. This is the first report of the presence of TBECH enantiomers in the environment. The estimated hazard quotient indicates that there is a potential risk to dolphins due to HBCD exposure.', ""Technical 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane or tetrabromoethylcyclohexane (TBECH) used primarily as an additive flame retardant in polystyrene foams, contains two diastereoisomers, alpha- and beta- present in equimolar amounts. At temperatures in excess of 125 C, isomerization to two other isoforms, sigma- and gamma- is possible. The recent detection of TBECH in the environment and studies suggesting that isomers are androgenic prompted us to examine the toxicokinetics and biochemical effects of one of the isomers, beta-, in a controlled laboratory environment. Juvenile brown trout (Salmo trutta) were exposed to three different amounts of the beta-isomer (low, medium and high) via the food followed by a period in which they were exposed to unfortified food. A fourth group of fish was exposed to unfortified food for the duration of the experiment. On days 0, 7, 14, 21, 35, 49, 56, 63, 77, 91, 105, and 133, eight fish from each treatment group were euthanized and liver, plasma, lower jaw (i.e., thyroid tissue) and gonad were collected and the remaining tissue ('whole-fish') was retained. beta-Isomer content was measured in whole-fish and in liver while estradiol (E2), 11-ketotestosterone (11-KT) and testosterone (T) were measured in plasma. Based on liver and gonad somatic indices, no apparent effects on liver or gonad development in fish from any of the treatment groups were observed. The bioaccumulation of beta-isomer was similar in fish from all treatment groups with steady-state occurring before the end of the uptake phase. Depuration of the beta-isomer from fish obeyed first order kinetics and there were no statistically significant differences in the depuration half life (t(1/2)) among the treatment groups: 22.5 +/- 10.4 (low), 13.5 +/- 5.9 (med) and 13.8 +/- 2.2 (high) days. Steady-state biomagnification factors were much smaller than 1 for fish in all treatment groups. Debrominated metabolites were not detected in composite liver or whole-fish extracts and there was no evidence of isomerization of the beta-isomer to other isoforms in vivo. While there were occasional differences among treatment groups in circulating plasma E2, T and 11-KT levels there was no clear, temporal trend or dose-response."", ""Zebrafish (Danio rerio) were fed a diet containing a mixture of 11 structurally diverse brominated flame retardants (BFRs) at nominal concentrations of either 1 or 100 nmol/g for up to 42 days, followed by an elimination period of 14 days. Uptake rates and elimination constants for five of the BFRs were calculated from measurements of their concentrations in the male fish during the exposure and elimination phases. Observed uptake efficiencies were highest for 2,4,4'-tribromodiphenyl ether (BDE 28) and 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH) and were lowest for decabromodiphenyl ether (BDE 209). Estimated half-lives for TBECH and 2,4,6-tribromophenol were short (<2 days). Four BFR metabolites were identified in the fish: 2,2',3,4',5',6-Hexabromodiphenyl ether (BDE 149), 2,2',4,4',5,6'-hexabromodiphenyl ether (BDE 154), 2,4,6-tribromoanisole, and 1,2,4,5-hexabromobenzene. These metabolites were still present in the zebrafish after the 14-d elimination period. No relationship between the BFR concentrations in the zebrafish and their log octanol-water partition coefficient (KOW) values was found. Generally, low tendencies to bioaccumulate were observed for perbrominated and hydroxylated compounds. The observed accumulation of BFR metabolites in fish, however, shows that low concentration of a BFR does not provide, in isolation, a sound indication that the BFR poses low risks.""]","['The brominated flame retardant TBECH is used as an additive to delay ignition and inhibit fires in construction materials and consumer goods. Trends in human exposure are not clear, although humans may be exposed to TBECH via indoor dust and air. In birds and fish there is some evidence of disruption in endocrine and reproductive parameters due to TBECH. In vitro studies indicate that TBECH is an androgen receptor agonist. In this study rats were exposed to 0, 10, 50, 250, 1250 or 5000 mg/kg technical TBECH for 28 days in diet, corresponding to 0, 0.9, 4.2, 21.3, 98.0 or 328.9 mg TBECH/kg bw/d in males and 0, 0.8, 3.9, 19.4, 91.7 or 321.4 mg TBECH/kg bw/d in females. Dose-dependent increases in alpha- and beta- TBECH were detected in serum, liver and adipose. ...', ""Zebrafish (Danio rerio) were fed a diet containing a mixture of 11 structurally diverse brominated flame retardants (BFRs) at nominal concentrations of either 1 or 100 nmol/g for up to 42 days, followed by an elimination period of 14 days. ... Four BFR metabolites were identified in the fish: 2,2',3,4',5',6-Hexabromodiphenyl ether (BDE 149), 2,2',4,4',5,6'-hexabromodiphenyl ether (BDE 154), 2,4,6-tribromoanisole, and 1,2,4,5-hexabromobenzene. These metabolites were still present in the zebrafish after the 14-d elimination period. No relationship between the BFR concentrations in the zebrafish and their log octanol-water partition coefficient (KOW) values was found. Generally, low tendencies to bioaccumulate were observed for perbrominated and hydroxylated compounds. The observed accumulation of BFR metabolites in fish, however, shows that low concentration of a BFR does not provide, in isolation, a sound indication that the BFR poses low risks."", 'The technical mixture of 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (TBECH or DBE-DBCH) and the pure beta-TBECH isomer were subjected to in vitro biotransformation by human liver microsomes (HLM). After 60 min of incubation, 5 potential metabolites of TBECH were identified in microsomal assays of both the TBECH mixture and beta-TBECH using ultraperformance liquid chromatography-Q-Exactive Orbitrap mass spectrometry. These include mono- and dihydroxylated TBECH and mono- and dihydroxylated TriBECH as well as an alpha-oxidation metabolite bromo-(1,2-dibromocyclohexyl)-acetic acid. Our results indicate potential hepatic biotransformation of TBECH via cyctochrome P450-catalyzed hydroxylation, debromination, and alpha-oxidation. Kinetic studies revealed that the formation of monohydroxy-TBECH, dihydroxy-TBECH, and monohydroxy-TriBECH were best fitted to a Michaelis-Menten enzyme kinetic model. Respective estimated Vmax values (maximum metabolic rate) for these metabolites were 11.8 +/- 4, 0.6 +/- 0.1, and 10.1 +/- 0.8 pmol/min/mg protein in TBECH mixture and 4992 +/- 1340, 14.1 +/- 4.9, and 66.1 +/- 7.3 pmol/min/mg protein in beta-TBECH. This indicates monohydroxy-TBECH as the major metabolite of TBECH by in vitro HLM-based assay. The estimated in vitro intrinsic clearance (Clint) of TBECH mixture was slower (P < 0.05) than that of pure beta-TBECH. While the formation of monohydroxy-TBECH may reduce the bioaccumulation potential and provide a useful biomarker for monitoring TBECH exposure, further studies are required to fully understand the levels and toxicological implications of the identified metabolites.']","[""... Juvenile brown trout (Salmo trutta) were exposed to three different amounts of the beta-isomer (low, medium and high) via the food followed by a period in which they were exposed to unfortified food. A fourth group of fish was exposed to unfortified food for the duration of the experiment. On days 0, 7, 14, 21, 35, 49, 56, 63, 77, 91, 105, and 133, eight fish from each treatment group were euthanized and liver, plasma, lower jaw (i.e., thyroid tissue) and gonad were collected and the remaining tissue ('whole-fish') was retained. beta-Isomer content was measured in whole-fish and in liver while estradiol (E2), 11-ketotestosterone (11-KT) and testosterone (T) were measured in plasma ... Depuration of the beta-isomer from fish obeyed first order kinetics and there were no statistically significant differences in the depuration half life (t(1/2)) among the treatment groups: 22.5 +/- 10.4 (low), 13.5 +/- 5.9 (med) and 13.8 +/- 2.2 (high) days ..."", 'Zebrafish (Danio rerio) were fed a diet containing a mixture of 11 structurally diverse brominated flame retardants (BFRs) at nominal concentrations of either 1 or 100 nmol/g for up to 42 days, followed by an elimination period of 14 days. ... Estimated half-lives for TBECH and 2,4,6-tribromophenol were short (<2 days).']"
8728,18729,CID 18729,CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)O.CN(C)CCO,,,,,,
8729,18730,Fluorescein-5-isothiocyanate,C1=CC2=C(C=C1N=C=S)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
8730,18731,Furan-2-carbohydrazide,C1=COC(=C1)C(=O)NN,,,,,,
8731,18732,(3-Chloro-2-hydroxypropyl)trimethylammonium chloride,C[N+](C)(C)CC(CCl)O.[Cl-],,,,,,
8732,18733,"3-chloro-2-hydroxy-N,N,N-trimethylpropan-1-aminium",C[N+](C)(C)CC(CCl)O,,,,,,
8733,18734,CID 18734,CC(C)C1(C(=O)N=C(N(C1=O)C)[O-])CC(=C)Br.[Na+],,,,,,
8734,18735,Narcobarbital,CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC(=C)Br,,,,,,
8735,18736,"(5R)-2,4'-dimethylspiro[2-azabicyclo[2.2.2]octane-5,2'-3H-pyran]-6'-one",CC1=CC(=O)O[C@]2(C1)CC3CCC2CN3C,,,,,,
8736,18737,CID 18737,CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC(=C)Br.[Na+],,,,,,
8737,18738,CID 18738,CCCC(C)C1(C(=O)NC(=O)N=C1[O-])CC.[Ca+2],,,,,,
8738,18739,"1-Tetradecanamine, N,N-dimethyl-, N-oxide",CCCCCCCCCCCCCC[N+](C)(C)[O-],,,,,,
8739,18740,CID 18740,CN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
8740,18741,"7-Chloro-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]-5-phenyl-2H-1,4-benzodiazepin-2-one",CN1CCN(CC1)CCCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4,,,,,,
8741,18742,"1,1-Dimethylpiperidinium iodide",C[N+]1(CCCCC1)C.[I-],,,,,,
8742,18743,Mepiquat,C[N+]1(CCCCC1)C,,,,,,
8743,18744,"2,3-Diphenylpropionic acid",C1=CC=C(C=C1)CC(C2=CC=CC=C2)C(=O)O,,,,,,
8744,18745,Tetramethylsuccinonitrile,CC(C)(C#N)C(C)(C)C#N,,,,"['/It was/... reported that uptake occurs after inhalation and through the skin, but no quantitative data are available.', 'The substance can be absorbed into the body by inhalation of its aerosol, through the skin and by ingestion.']",,
8745,18746,Nickel carbonate,C(=O)([O-])[O-].[Ni+2],,,,['NICKEL CARBONATE WAS GIVEN INTRATRACHEALLY TO MICE (0.05 MG) & URINARY EXCRETION & LUNG CLEARANCE OF NICKEL DETERMINED 1-6 DAYS FOLLOWING ADMIN. MORE NICKEL EXCRETED IN URINE DURING 1ST DAY THAN REMAINDER OF WK. CLEARANCE OF NICKEL CARBONATE FROM LUNG WAS MODERATE.'],,
8746,18747,"2,6-Dichloro-4-hydroxybenzonitrile",C1=C(C=C(C(=C1Cl)C#N)Cl)O,,,,,,
8747,18748,"2,6-Dichloro-3-hydroxybenzonitrile",C1=CC(=C(C(=C1O)Cl)C#N)Cl,,,,,,
8748,18749,"3,5-Dichloro-4-hydroxybenzoic acid",C1=C(C=C(C(=C1Cl)O)Cl)C(=O)O,,,,,,
8749,18750,4-Hydroxyisoquinoline,C1=CC=C2C(=C1)C=NC=C2O,,,,,,
8750,18751,"Carbamic acid, ((p-nitrophenyl)sulfonyl)-, methyl ester",COC(=O)NS(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
8751,18752,Asulam,COC(=O)NS(=O)(=O)C1=CC=C(C=C1)N,,,,"['... Two goats were dosed with ring-labeled (14)C-asulam at 20 ppm in the diet for 7 consecutive days. The total radioactive residues were nondetectable (<0.005 ppm) in fat and muscle, 0.162 ppm in kidneys, 0.090 ppm in liver, and up to 0.021 ppm in milk. The parent compound, asulam, constituted the majority of the residues in milk (81% of total reactive reside (TRR)) and kidneys (100% of TRR) and its metabolite N4-acetylsulfanilamide constitutes the majority of residues in liver (58% of TRR). The parent was not identified in liver samples. In a previous study, sulfanilamide was found in ruminant liver and muscle, and N4-acetylasulam was found in liver, kidney, milk, muscle, and fat.', '... Laying hens were dosed with ring-labeled (14)C-asulam at 22.5 ppm in the diet for 7 consecutive days. The maximum total radioactive residues were 0.027 ppm in egg yolks, 0.062 ppm in egg whites, 0.011 ppm in fat, 0.074 ppm in muscle, 0.444 ppm in kidneys, and 0.086 ppm in liver. The parent compound asulam, and its metabolite N4-acetylsulfanilamide constituted the majority of the residues in poultry, comprising 63 and 44% of the total reactive reside (TRR), respectively, in egg yolks, 21 and 52% of the TRR, respectively, in egg whites, 35 and 51% of the TRR, respectively, in muscle, and 83 and 14% of the TRR, respectively, in kidney. The parent was not identified in liver samples; N4-acetyl sulfanilamide represented 81% of the TRR in liver samples.', 'Metabolism studies were conducted in male and female Sprague- Dawley rats. The tests used a single oral or iv dose, or repeated i.v. doses for 14 days. The pharmacokinetics of asulam were similar after all dose regimens in both sexes. Peak blood levels were attained at 0.5 hours. No unusual localization of asulam occurred in tissues and all tissue levels were low at 72 hours. Asulam was rapidly eliminated, mostly within 24 hours. 76.5% to 101.5% of the administered dose was eliminated in the urine, and 1.4% to 25.3% of the dose in feces. The major excretory product was unchanged parent compound (70% to 80%), with acetylasulam (3% to 8%) and acetylsulphanilamide (<3%) being the two major metabolites.', 'The metabolism of [ring-(14)C]asulam, a systemic herbicide highly effective against bracken, has been studied in rats. Most of the radioactivity (76-100% dose) administered orally or intravenously is excreted in the urine in 24 hr as unchanged asulam (61-74% dose), N4-acetylasulam (8-14%) and N4-acetylsulphanilamide (0.1-2.6%). Small amounts of radioactivity (0.3-7.4% dose) were present in the feces, only traces (0.2-0.3%) were excreted in the bile, and no significant (14)CO2 was detected. Perfusion of rat liver with (14)C-asulam resulted in more extensive metabolism. Total amounts present in perfusate (81% total), bile (1%) plus liver (14%) were 23.1% for unchanged asulam, 25.7% for acetylasulam, less than 1% for acetylsulphanilamide, and 4.5% as conjugates of asulam and acetylasulam, together with several other unidentified metabolites. Asulam is acetylated more readily than sulphanilamide, by rat-liver homogenate, and the highest enzyme activity was associated with the mitochondrial fraction (2.4 pmol/mg protein per min). Although not hydroxylated by rats in vivo, evidence was obtained for the hydroxylation of asulam by rat-liver microsomal preparations in vitro.']","['... Two goats were dosed with ring-labeled (14)C-asulam at 20 ppm in the diet for 7 consecutive days. The total radioactive residues were nondetectable (<0.005 ppm) in fat and muscle, 0.162 ppm in kidneys, 0.090 ppm in liver, and up to 0.021 ppm in milk. The parent compound, asulam, constituted the majority of the residues in milk (81% of total reactive reside (TRR)) and kidneys (100% of TRR) and its metabolite N4-acetylsulfanilamide constitutes the majority of residues in liver (58% of TRR). The parent was not identified in liver samples. In a previous study, sulfanilamide was found in ruminant liver and muscle, and N4-acetylasulam was found in liver, kidney, milk, muscle, and fat.', '... Laying hens were dosed with ring-labeled (14)C-asulam at 22.5 ppm in the diet for 7 consecutive days. The maximum total radioactive residues were 0.027 ppm in egg yolks, 0.062 ppm in egg whites, 0.011 ppm in fat, 0.074 ppm in muscle, 0.444 ppm in kidneys, and 0.086 ppm in liver. The parent compound asulam, and its metabolite N4-acetylsulfanilamide constituted the majority of the residues in poultry, comprising 63 and 44% of the total reactive reside (TRR), respectively, in egg yolks, 21 and 52% of the TRR, respectively, in egg whites, 35 and 51% of the TRR, respectively, in muscle, and 83 and 14% of the TRR, respectively, in kidney. The parent was not identified in liver samples; N4-acetyl sulfanilamide represented 81% of the TRR in liver samples.', 'Metabolism studies were conducted in male and female Sprague- Dawley rats. The tests used a single oral or iv dose, or repeated i.v. doses for 14 days. The pharmacokinetics of asulam were similar after all dose regimens in both sexes. Peak blood levels were attained at 0.5 hours. No unusual localization of asulam occurred in tissues and all tissue levels were low at 72 hours. Asulam was rapidly eliminated, mostly within 24 hours. 76.5% to 101.5% of the administered dose was eliminated in the urine, and 1.4% to 25.3% of the dose in feces. The major excretory product was unchanged parent compound (70% to 80%), with acetylasulam (3% to 8%) and acetylsulphanilamide (<3%) being the two major metabolites.', 'The metabolism of [ring-(14)C]asulam, a systemic herbicide highly effective against bracken, has been studied in rats. Most of the radioactivity (76-100% dose) administered orally or intravenously is excreted in the urine in 24 hr as unchanged asulam (61-74% dose), N4-acetylasulam (8-14%) and N4-acetylsulphanilamide (0.1-2.6%). Small amounts of radioactivity (0.3-7.4% dose) were present in the feces, only traces (0.2-0.3%) were excreted in the bile, and no significant (14)CO2 was detected. Perfusion of rat liver with (14)C-asulam resulted in more extensive metabolism. Total amounts present in perfusate (81% total), bile (1%) plus liver (14%) were 23.1% for unchanged asulam, 25.7% for acetylasulam, less than 1% for acetylsulphanilamide, and 4.5% as conjugates of asulam and acetylasulam, together with several other unidentified metabolites. Asulam is acetylated more readily than sulphanilamide, by rat-liver homogenate, and the highest enzyme activity was associated with the mitochondrial fraction (2.4 pmol/mg protein per min). Although not hydroxylated by rats in vivo, evidence was obtained for the hydroxylation of asulam by rat-liver microsomal preparations in vitro.']",
8752,18753,"Quinazoline, 4-((2-(dimethylamino)ethyl)amino)-",CN(C)CCNC1=NC=NC2=CC=CC=C21,,,,,,
8753,18754,Sodium;diethoxy-sulfanylidene-sulfido-lambda5-phosphane,CCOP(=S)(OCC)[S-].[Na+],,,,,,
8754,18755,DL-N-Benzyloxycarbonyl-3-phenylalanine cyanomethyl ester,C1=CC=C(C=C1)CC(C(=O)OCC#N)NC(=O)OCC2=CC=CC=C2,,,,,,
8755,18756,Ocimene,CC(=CCC=C(C)C=C)C,,,,,,
8756,18757,9-Anilinoacridine,C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
8757,18758,"17-methoxyimino-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-ol",CC12CCC3C(C1CCC2=NOC)CCC4=C3C=CC(=C4)O,,,,,,
8758,18759,1-Hydroxy-3-methylcholanthrene,CC1=C2CC(C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1)O,,,,,,
8759,18760,3-Methylcholanthrene-1-one,CC1=C2CC(=O)C3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,,,,,,
8760,18761,3-Methylcholanthrylene,CC1=C2C=CC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,,,,,,
8761,18762,11-Hydroxy-3-methylcholanthrene,CC1=C2CCC3=C2C(=CC4=C3C=C(C5=CC=CC=C54)O)C=C1,,,,,,
8762,18763,4-[Methoxy(methylsulfanyl)phosphoryl]oxy-2-methyl-1-nitrobenzene,CC1=C(C=CC(=C1)OP(=O)(OC)SC)[N+](=O)[O-],,,,,,
8763,18764,"N,N'-bis[[(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methyl]ethane-1,2-diamine;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@](C3CC2)(C)CNCCNC[C@@]4(CCC[C@]5(C4CCC6=C5C=CC(=C6)C(C)C)C)C)C.CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,,,,,,
8764,18765,"N,N'-bis[[(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methyl]ethane-1,2-diamine",CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@](C3CC2)(C)CNCCNC[C@@]4(CCC[C@]5(C4CCC6=C5C=CC(=C6)C(C)C)C)C)C,,,,,,
8765,18766,"1,12-Dibromododecane",C(CCCCCCBr)CCCCCBr,,,,,,
8766,18767,"Ammonium, diethylmethyl(2-(3-(1-naphthyl)-2-(tetrahydrofurfuryl)propoxy)ethyl)-, iodide",CC[N+](C)(CC)CCOCC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.[I-],,,,,,
8767,18768,Diethyl-methyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propoxy]ethyl]azanium,CC[N+](C)(CC)CCOCC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32,,,,,,
8768,18769,Chlorhydrate de diamino-3-alpha 17-beta androstene-5 [French],C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2[NH3+])CC=C4[C@@]3(CC[C@H](C4)[NH3+])C.[Cl-].[Cl-],,,,,,
8769,18770,CID 18770,C[C@]12CCC3[C@H]([C@@H]1CC[C@@H]2N)CC=C4[C@@]3(CC[C@H](C4)N)C,,,,,,
8770,18771,Dithianon,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)SC(=C(S3)C#N)C#N,,,,"['Groups of 5 laying hens were given capsules containing 0, 0.36 or 3.6 mg 14C-dithianon/day (purity 99.3%), orally for 5 consecutive days. These doses were equivalent to 3 or 30 ppm in the feed, respectively. Excreta and eggs were collected twice daily. Radioactivity was excreted very rapidly and at a constant rate. Irrespective of the dose, 4 days after the last administration, total recovery of 14C was about 94% of the dose with about 90% recovered in the excreta and 3-5% in the GIT contents. Detectable tissue residues were found in kidney and liver (0.03% and 0.02%, respectively). The 14C recovered in eggs comprised less than 0.01% of the total radioactive dose. The radioactivity in egg yolk was higher than in egg white and was maximal at sacrifice (0.005 mg/kg and 0.075 mg/kg at the low- and the high-dose, respectively)']",,
8771,18772,"ACETOHYDROXAMIC ACID, 2-(p-ISOBUTYLPHENYL)-",CC(C)CC1=CC=C(C=C1)CC(=O)NO,,,,,,
8772,18773,"(3S)-10,13-dimethyl-17-(6-methylheptan-2-yl)-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5-diol",CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4(C3(CC[C@@H](C4)O)C)O)C,,,,,,
8773,18774,3-Methyl-5-phenyl-1H-pyrazole,CC1=CC(=NN1)C2=CC=CC=C2,,,,,,
8774,18775,"ACETIC ACID, ANHYDRIDE with O,O-DIMETHYL PHOSPHOROTHIOATE",CC(=O)OP(=S)(OC)OC,,,,,,
8775,18776,Acid blue 113,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC(=CC=C6)S(=O)(=O)[O-])C=CC=C3S(=O)(=O)[O-].[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
8776,18777,Acid Fast Blue 5R,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC(=CC=C6)S(=O)(=O)O)C=CC=C3S(=O)(=O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
8777,18778,"5-bromo-1-[(2R,4S,5R)-5-ethyl-4-hydroxyoxolan-2-yl]-5-fluoro-6-methoxy-1,3-diazinane-2,4-dione",CC[C@@H]1[C@H](C[C@@H](O1)N2C(C(C(=O)NC2=O)(F)Br)OC)O,,,,,,
8778,18779,1-Methylchrysene,CC1=C2C=CC3=C(C2=CC=C1)C=CC4=CC=CC=C43,,,,,,
8779,18780,4-Methylchrysene,CC1=C2C(=CC=C1)C=CC3=C2C=CC4=CC=CC=C43,,,,,,
8780,18781,3-Methylchrysene,CC1=CC2=C(C=C1)C=CC3=C2C=CC4=CC=CC=C43,,,,,,
8781,18782,2-Methylchrysene,CC1=CC2=C(C=C1)C3=C(C=C2)C4=CC=CC=C4C=C3,,,,,,
8782,18783,"N,N-Diethyldodecanamide",CCCCCCCCCCCC(=O)N(CC)CC,,,,,,
8783,18784,4-Methylpyrene,CC1=CC2=CC=CC3=C2C4=C(C=CC=C14)C=C3,,,,,,
8784,18785,"N,N-Diethyl-1-methylnipecotamide",CCN(CC)C(=O)C1CCCN(C1)C,,,,,,
8785,18786,"3-Phenyl-1H-1,2,4-triazole",C1=CC=C(C=C1)C2=NC=NN2,,,,,,
8786,18787,N-Acetylbenzidine,CC(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)N,,,,,"['N-Acetylbenzidine has known human metabolites that include N-Acetylbenzidine, N-glucuronide.']",
8787,18788,"Hydantoin, 3-(3-(chloromercuri)-2-methoxypropyl)-1-methyl-",CN1CC(=O)N(C1=O)CC(C[Hg]Cl)OC,,,,,,
8788,18789,3-(3-Chloromercuri-2-methoxy-1-propyl)hydantoin,COC(CN1C(=O)CNC1=O)C[Hg]Cl,,,,,,
8789,18790,5-(3-Chloromercuri-2-methoxy-1-propyl)-3-methylhydantoin,CN1C(=O)C(NC1=O)CC(C[Hg]Cl)OC,,,,,,
8790,18791,"Chloro((3-(2,4-dioxo-5-imidazolidinyl)-2-methoxy)propyl)mercury",COC(CC1C(=O)NC(=O)N1)C[Hg]Cl,,,,,,
8791,18792,"Mercury, chloro(3-(2,4-dioxo-1-imidazolidinyl)-2-methoxypropyl)-",COC(CN1CC(=O)NC1=O)C[Hg]Cl,,,,,,
8792,18793,"N,N-Diethylpiperidine-3-carboxamide",CCN(CC)C(=O)C1CCCNC1,,,,,,
8793,18794,Benzolamide,C1=CC=C(C=C1)S(=O)(=O)NC2=NN=C(S2)S(=O)(=O)N,,,['A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)'],,,
8794,18795,N-(4-Methyl-2-pyridyl)mandelamide hydrochloride,CC1=CC(=[NH+]C=C1)NC(=O)C(C2=CC=CC=C2)O.[Cl-],,,,,,
8795,18796,2-hydroxy-N-(4-methylpyridin-2-yl)-2-phenylacetamide,CC1=CC(=NC=C1)NC(=O)C(C2=CC=CC=C2)O,,,,,,
8796,18797,alpha-((4-Methyl-2-pyridylamino)methyl)benzyl alcohol hydrochloride,CC1=CC(=[NH+]C=C1)NCC(C2=CC=CC=C2)O.[Cl-],,,,,,
8797,18798,2-[(4-Methylpyridin-2-yl)amino]-1-phenylethanol,CC1=CC(=NC=C1)NCC(C2=CC=CC=C2)O,,,,,,
8798,18799,5-Benzylthiotryptamine hydrochloride,C1=CC=C(C=C1)CSC2=CC3=C(C=C2)NC=C3CC[NH3+].[Cl-],,,,,,
8799,18800,2-(5-benzylsulfanyl-1H-indol-3-yl)ethanamine,C1=CC=C(C=C1)CSC2=CC3=C(C=C2)NC=C3CCN,,,,,,
8800,18801,"1,3-Dichloro-2-methylpropene",CC(=CCl)CCl,,,,,,
8801,18802,3-(2-Hydroxypropyl)-5-methyl-2-oxazolidinone,CC1CN(C(=O)O1)CC(C)O,,,,,,
8802,18803,"2-Propanone, O-(phenylmethyl)oxime",CC(=NOCC1=CC=CC=C1)C,,,,,,
8803,18804,Norpropoxyphene,CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CNC,,,,,['Nordextropropoxyphene is a known human metabolite of dextropropoxyphene.'],
8804,18805,2-Bromohexane,CCCCC(C)Br,,,,,,
8805,18806,3-Bromohexane,CCCC(CC)Br,,,,,,
8806,18807,5-Chloro-2-(4-chlorophenoxy)phenol,C1=CC(=CC=C1OC2=C(C=C(C=C2)Cl)O)Cl,,,,,,
8807,18808,(3-Phenylpropyl)hydrazine oxalate,C1=CC=C(C=C1)CCCN[NH3+].C(=O)(C(=O)[O-])O,,,,,,
8808,18809,3-Phenylpropylhydrazine,C1=CC=C(C=C1)CCCNN,,,,,,
8809,18810,"(10,13-dimethyl-17-octan-2-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl) 4-methylbenzenesulfonate",CCCCCCC(C)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)OS(=O)(=O)C5=CC=C(C=C5)C)C)C,,,,,,
8810,18811,2-Benzyloxybenzyl alcohol,C1=CC=C(C=C1)COC2=CC=CC=C2CO,,,,,,
8811,18812,9(R)-Hydroxyoctadecanoic acid,CCCCCCCCC[C@H](CCCCCCCC(=O)O)O,,,,,,
8812,18813,"7-(1,3-Benzodioxol-5-yl)-3-methoxyhepta-2,4-dienoic acid",COC(=CC(=O)O)C=CCCC1=CC2=C(C=C1)OCO2,,,,,,
8813,18814,"1,3-Cyclohexanediamine",C1CC(CC(C1)N)N,,,,,,
8814,18815,1-Chlorooctadecane,CCCCCCCCCCCCCCCCCCCl,,,,,,
8815,18816,"disodium;[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate",C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)([O-])[O-])O)O.[Na+].[Na+],,,,,,
8816,18817,Uracil arabinose-5'-phosphate,C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
8817,18818,Sabinene,CC(C)C12CCC(=C)C1C2,,,,,,
8818,18819,"2-(3,4-Epoxycyclohexyl)ethyltrimethoxysilane",CO[Si](CCC1CCC2C(C1)O2)(OC)OC,,,,,,
8819,18820,"1,2,3,4,7,7-Hexachlorobicyclo[2.2.1]hepta-2,5-diene",C1=CC2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
8820,18821,"5,5-Diethyl-1,3-dioxane",CCC1(COCOC1)CC,,,,,,
8821,18822,"Coumarin, 6-nitro-3-(4-pyridyl)-",C1=CC2=C(C=C1[N+](=O)[O-])C=C(C(=O)O2)C3=CC=NC=C3,,,,,,
8822,18823,6-Amino-3-(4-pyridyl)coumarin,C1=CC2=C(C=C1N)C=C(C(=O)O2)C3=CC=NC=C3,,,,,,
8823,18824,"Coumarin, 6-nitro-3-(2-pyridyl)-",C1=CC=NC(=C1)C2=CC3=C(C=CC(=C3)[N+](=O)[O-])OC2=O,,,,,,
8824,18825,1-(4-Chlorophenyl)ethanol,CC(C1=CC=C(C=C1)Cl)O,,,,,,
8825,18826,"1,7-Dioxacycloheptadecan-8-one",C1CCCCC(=O)OCCCCCOCCCC1,,,,,,
8826,18827,1-Octen-3-OL,CCCCCC(C=C)O,,,,,,
8827,18828,5-Ethylideneoxolan-2-one,CC=C1CCC(=O)O1,,,,,,
8828,18829,4-Hydroxy-3-methyl-2-butanone,CC(CO)C(=O)C,,,,,,
8829,18830,Ornipressin acetate,C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN)C(=O)NCC(=O)N,,,,,,
8830,18831,"6-Chloro-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)Cl)N)N,,,,,,
8831,18832,1-Phenethyl-4-phenyl-4-propionyloxyazacycloheptane,CCC(=O)OC1(CCCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
8832,18833,CID 18833,C=CCCCCCCCCC(=O)[O-].[Na+],,,,,,
8833,18834,Methyl streptonigrin,CC1=C(C(=C(N=C1C(=O)OC)C2=NC3=C(C=C2)C(=O)C(=C(C3=O)N)OC)N)C4=C(C(=C(C=C4)OC)OC)O,,,,,,
8834,18835,"tert-Butylamine, N-ethyl-N-nitroso-",CCN(C(C)(C)C)N=O,,,,,,
8835,18836,alpha-(3-(Dimethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CC(C)C(CCCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
8836,18837,"1-NAPHTHALENEACETONITRILE, alpha-(3-(DIMETHYLAMINO)PROPYL)-",CN(C)CCCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
8837,18838,"Heptanamide, N-methyl-",CCCCCCC(=O)NC,,,,,,
8838,18839,N-Methyl-1-naphthalenecarboxamide,CNC(=O)C1=CC=CC2=CC=CC=C21,,,,,,
8839,18840,Cyclopentanecarboxylic acid,C1CCC(C1)C(=O)O,,,,,,
8840,18841,Tetrasodium dicarboxyethyl stearyl sulfosuccinamate,CCCCCCCCCCCCCCCCCCN(C(CC(=O)[O-])C(=O)[O-])C(=O)C(CC(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
8841,18842,n-(3-Carboxy-2-sulfopropanoyl)-n-octadecylaspartic acid,CCCCCCCCCCCCCCCCCCN(C(CC(=O)O)C(=O)O)C(=O)C(CC(=O)O)S(=O)(=O)O,,,,,,
8842,18843,Didodecyldimethylammonium chloride,CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC.[Cl-],,,,,,
8843,18844,"3,6-Dichloro-2-hydroxybenzoic acid",C1=CC(=C(C(=C1Cl)C(=O)O)O)Cl,,,,,,
8844,18845,"(2S,3R,4R,5S)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid",C(=O)[C@H]([C@@H]([C@H]([C@@H](C(=O)O)O)O)O)O,,,,,,
8845,18846,"but-2-enedioic acid;3-(2-methoxyphenothiazin-10-yl)-N,N-dimethylpropan-1-amine",CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC.C(=CC(=O)O)C(=O)O,,,,,,
8846,18847,Methopromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC,,,,,,
8847,18848,3-Methyl-1-hexene,CCCC(C)C=C,,,,,,
8848,18849,5-Methylhex-2-ene,CC=CCC(C)C,,,,,,
8849,18850,"2-Ethyl-1,3-butadiene",CCC(=C)C=C,,,,,,
8850,18851,"2,3-Dimethyl-1-pentene",CCC(C)C(=C)C,,,,,,
8851,18852,"3,3-Dimethyl-1-pentene",CCC(C)(C)C=C,,,,,,
8852,18853,"2,5-Dimethyl-2-hexene",CC(C)CC=C(C)C,,,,,,
8853,18854,"1,2,3,4-Tetrachlorobutane",C(C(C(CCl)Cl)Cl)Cl,,,,,,
8854,18855,N-Methyldibutylamine,CCCCN(C)CCCC,,,,,,
8855,18856,N-(1-Adamantyl)formamide,C1C2CC3CC1CC(C2)(C3)NC=O,,,,,,
8856,18857,Nobutan,C[N+]1(C2CCCC1CN(C2)CCCCN3CC4CCCC(C3)[N+]4(C)C)C.[I-].[I-],,,,,,
8857,18858,"3-[4-(9,9-Dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonan-3-yl)butyl]-9,9-dimethyl-3-aza-9-azoniabicyclo[3.3.1]nonane",C[N+]1(C2CCCC1CN(C2)CCCCN3CC4CCCC(C3)[N+]4(C)C)C,,,,,,
8858,18859,"2-Furanpropionic acid, alpha-(1-naphthylmethyl)-, 3-(diethylamino)propyl ester, oxalate (1:1)",CC[NH+](CC)CCCOC(=O)C(CC1=CC=CC2=CC=CC=C21)CC3=CC=CO3.C(=O)(C(=O)[O-])O,,,,,,
8859,18860,3-(Diethylamino)propyl 2-(furan-2-ylmethyl)-3-naphthalen-1-ylpropanoate,CCN(CC)CCCOC(=O)C(CC1=CC=CC2=CC=CC=C21)CC3=CC=CO3,,,,,,
8860,18861,"2-Furanpropionic acid, alpha-(1-naphthylmethyl)-, 4-(diethylamino)butyl ester, oxalate (1:1)",CC[NH+](CC)CCCCOC(=O)C(CC1=CC=CC2=CC=CC=C21)CC3=CC=CO3.C(=O)(C(=O)[O-])O,,,,,,
8861,18862,4-(Diethylamino)butyl 2-(furan-2-ylmethyl)-3-naphthalen-1-ylpropanoate,CCN(CC)CCCCOC(=O)C(CC1=CC=CC2=CC=CC=C21)CC3=CC=CO3,,,,,,
8862,18863,"ARSINE, (o-NITROPHENYL)OXO-",C1=CC=C(C(=C1)[N+](=O)[O-])[As]=O,,,,,,
8863,18864,9-Hydrazinoacridine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NN,,,,,,
8864,18865,"Acridine-2,6-diamine",C1=CC(=CC2=NC3=C(C=C21)C=C(C=C3)N)N,,,,,,
8865,18866,"Acridine, 9-amino-3-chloro-",C1=CC=C2C(=C1)C(=C3C=CC(=CC3=N2)Cl)N,,,,,,
8866,18867,"Acridine, 9-amino-2-methoxy-",COC1=CC2=C(C3=CC=CC=C3N=C2C=C1)N,,,,,,
8867,18868,"Benzoic acid, isopropylidenehydrazide",CC(=NNC(=O)C1=CC=CC=C1)C,,,,,,
8868,18869,"Benzoic acid, 2-isopropylhydrazide",CC(C)NNC(=O)C1=CC=CC=C1,,,,,,
8869,18870,"3-(4-Bromophenyl)-1,1-dimethylurea",CN(C)C(=O)NC1=CC=C(C=C1)Br,,,,,,
8870,18871,"threo-2,3-Hexodiulosonic acid",C([C@H]([C@@H](C(=O)C(=O)C(=O)O)O)O)O,,,,,,
8871,18872,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-ethyl-2-pyrrolidinyl)methyl ester, hydrochloride",CC[NH+]1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC.[Cl-],,,,,,
8872,18873,"(1-Ethylpyrrolidin-2-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCN1CCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCC,,,,,,
8873,18874,2-(2-Hydroxyphenyl)benzothiazole,C1=CC=C(C(=C1)C2=NC3=CC=CC=C3S2)O,,,,,,
8874,18875,"Acetic acid, 2,2-diphenyl-2-methoxy-, (2-(N-ethyl-N-propylamino)ethyl) ester, hydrochloride",CCC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC.[Cl-],,,,,,
8875,18876,"2-[Ethyl(propyl)amino]ethyl 2-methoxy-2,2-diphenylacetate",CCCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OC,,,,,,
8876,18877,DBED dihydrochloride,C1=CC=C(C=C1)C[NH2+]CC[NH2+]CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
8877,18878,4-Phenoxypiperidine,C1CNCCC1OC2=CC=CC=C2,,,,,,
8878,18879,"(R)-(6-ethoxyquinolin-4-yl)-[(2S,5R)-5-ethyl-2,5-dimethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride",CC[C@]1(CN2CCC1C[C@@]2(C)[C@@H](C3=C4C=C(C=CC4=NC=C3)OCC)O)C.Cl,,,,,,
8879,18880,"(R)-(6-ethoxyquinolin-4-yl)-[(2S,5R)-5-ethyl-2,5-dimethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol",CC[C@]1(CN2CCC1C[C@@]2(C)[C@@H](C3=C4C=C(C=CC4=NC=C3)OCC)O)C,,,,,,
8880,18881,6-N-Hydroxyadenosine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NO,,,,,,
8881,18882,"Indole, 3-((dimethylamino)methyl)-5-nitro-",CN(C)CC1=CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
8882,18883,"Indole, 3-((dipropylamino)methyl)-5-nitro-",CCCN(CCC)CC1=CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
8883,18884,"Indole, 3-((dibutylamino)methyl)-5-nitro-",CCCCN(CCCC)CC1=CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
8884,18885,"Indole, 5-nitro-3-(piperidinomethyl)-",C1CCN(CC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8885,18886,4-((5-Nitro-1H-indol-3-yl)methyl)morpholine,C1COCCN1CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8886,18887,3-((4-Methylpiperazin-1-YL)methyl)-5-nitro-1H-indole,CN1CCN(CC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-],,,,,,
8887,18888,"Indole, 3-((4-benzylpiperazinyl)methyl)-5-nitro-",C1CN(CCN1CC2=CC=CC=C2)CC3=CNC4=C3C=C(C=C4)[N+](=O)[O-],,,,,,
8888,18889,"Isonipecotic acid, 1-(5-nitro-3-indolylmethyl)-4-phenyl-, ethyl ester, hydrochloride",CCOC(=O)C1(CC[NH+](CC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4.[Cl-],,,,,,
8889,18890,ethyl 1-[(5-nitro-1H-indol-3-yl)methyl]-4-phenylpiperidine-4-carboxylate,CCOC(=O)C1(CCN(CC1)CC2=CNC3=C2C=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4,,,,,,
8890,18891,"Indole, 5-amino-3-((dimethylamino)methyl)-",CN(C)CC1=CNC2=C1C=C(C=C2)N,,,,,,
8891,18892,"Indole, 5-amino-3-(1-pyrrolidinylmethyl)-",C1CCN(C1)CC2=CNC3=C2C=C(C=C3)N,,,,,,
8892,18893,"Indole, 5-amino-3-(piperidinomethyl)-",C1CCN(CC1)CC2=CNC3=C2C=C(C=C3)N,,,,,,
8893,18894,"Indole, 5-amino-3-((4-benzylpiperazinyl)methyl)-",C1CN(CCN1CC2=CC=CC=C2)CC3=CNC4=C3C=C(C=C4)N,,,,,,
8894,18895,CID 18895,C1=CC=C(C=C1)C2=NC(=NN2)S,,,,,,
8895,18896,"(17S)-4-chloro-17-hydroxy-13,17-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CCC2C1(CCC3C2CCC4=C(C(=O)CCC34)Cl)C)O,,,,,,
8896,18897,Glucosamine,C(C1[C@@H](C(C([C@H](O1)O)N)O)O)O,,,,,,
8897,18898,Isomaltol,CC(=O)C1=C(C=CO1)O,,,,,,
8898,18899,Cyclopentyl N-phenylcarbamate,C1CCC(C1)OC(=O)NC2=CC=CC=C2,,,,,,
8899,18900,Ethylnorepinephrine hydrochloride,CCC(C(C1=CC(=C(C=C1)O)O)O)N.Cl,,,,,,
8900,18901,"Cyclotrisiloxane, 2,4,6-trimethyl-2,4,6-triphenyl-",C[Si]1(O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
8901,18902,CID 18902,CC(=C(Cl)Cl)C(C1=CC=C(C=C1)Cl)C2=CC=CC=C2Cl,,,,,,
8902,18903,Trimethyl-[3-[4-[2-(1-methylindol-3-yl)ethyl]pyridin-1-ium-1-yl]propyl]azanium;dihydroxide,CN1C=C(C2=CC=CC=C21)CCC3=CC=[N+](C=C3)CCC[N+](C)(C)C.[OH-].[OH-],,,,,,
8903,18904,Methindethyrium ion,CN1C=C(C2=CC=CC=C21)CCC3=CC=[N+](C=C3)CCC[N+](C)(C)C,,,,,,
8904,18905,"2,3,6-Trichlorobenzoic acid dimethylamine salt",C[NH2+]C.C1=CC(=C(C(=C1Cl)C(=O)[O-])Cl)Cl,,,,,,
8905,18906,"6-chloro-2-N,4-N-bis(3-methoxypropyl)-1,3,5-triazine-2,4-diamine",COCCCNC1=NC(=NC(=N1)Cl)NCCCOC,,,,,,
8906,18907,Benzyl hydroxycarbamate,C1=CC=C(C=C1)COC(=O)NO,,,,,,
8907,18908,"Phosphorodichloridous acid, phenyl ester",C1=CC=C(C=C1)OP(Cl)Cl,,,,,,
8908,18909,"4,5-Dichlorocatechol",C1=C(C(=CC(=C1Cl)Cl)O)O,,,,,,
8909,18910,"9-Methyl-3,9-diazabicyclo(3.3.1)nonane dihydrochloride",CN1C2CCCC1CNC2.Cl.Cl,,,,,,
8910,18911,"9-Methyl-3,9-diazabicyclo[3.3.1]nonane",CN1C2CCCC1CNC2,,,,,,
8911,18912,"3,9-Dimethyl-3,9-diazabicyclo(3.3.1)nonane dihydrochloride",CC1CC2CN(CC(C1)N2)C.Cl.Cl,,,,,,
8912,18913,"3,7-Dimethyl-3,9-diazabicyclo[3.3.1]nonane",CC1CC2CN(CC(C1)N2)C,,,,,,
8913,18914,"Carbamic acid, dimethyldithio-, 2-benzothiazolyl ester",CN(C)C(=S)SC1=NC2=CC=CC=C2S1,,,,,,
8914,18915,Ethyl 9-oxononanoate,CCOC(=O)CCCCCCCC=O,,,,,,
8915,18916,"Acetanilide, 2',5'-dichloro-2-fluoro-",C1=CC(=C(C=C1Cl)NC(=O)CF)Cl,,,,,,
8916,18917,2-Fluoro-2'-nitroacetanilide,C1=CC=C(C(=C1)NC(=O)CF)[N+](=O)[O-],,,,,,
8917,18918,"Acetanilide, 2-fluoro-3'-nitro-",C1=CC(=CC(=C1)[N+](=O)[O-])NC(=O)CF,,,,,,
8918,18919,2-hydroxyethyl N-[(5-nitrofuran-2-yl)methylideneamino]carbamate,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)OCCO,,,,,,
8919,18920,N-propylazepan-1-amine,CCCNN1CCCCCC1,,,,,,
8920,18921,2-Iodothiophene,C1=CSC(=C1)I,,,,,,
8921,18922,4-Methylpyrimidine,CC1=NC=NC=C1,,,,,,
8922,18923,4-Phenylpyrimidine,C1=CC=C(C=C1)C2=NC=NC=C2,,,,,,
8923,18924,"Acetophenone, 3'-methoxy-4'-(4-(4-phenyl-1-piperazinyl)butoxy)-, monohydrochloride",CC(=O)C1=CC(=C(C=C1)OCCCCN2CCN(CC2)C3=CC=CC=C3)OC.Cl,,,,,,
8924,18925,1-[3-Methoxy-4-[4-(4-phenylpiperazin-1-yl)butoxy]phenyl]ethanone,CC(=O)C1=CC(=C(C=C1)OCCCCN2CCN(CC2)C3=CC=CC=C3)OC,,,,,,
8925,18926,"1,3,5-Triazin-2-amine, 4,6-dichloro-N-ethyl-",CCNC1=NC(=NC(=N1)Cl)Cl,,,,,,
8926,18927,"Plumbane, tetrapropyl-",CCC[Pb](CCC)(CCC)CCC,,,,,,
8927,18928,Disodium;4-hydroxy-6-[(5-hydroxy-6-phenyldiazenyl-7-sulfonatonaphthalen-2-yl)carbamoylamino]-3-[[4-(2-oxoethylamino)phenyl]diazenyl]naphthalene-2-sulfonate,C1=CC=C(C=C1)N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=C(C(=C(C=C5C=C4)S(=O)(=O)[O-])N=NC6=CC=C(C=C6)NCC=O)O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
8928,18929,4-Hydroxy-6-[(5-hydroxy-6-phenyldiazenyl-7-sulfonaphthalen-2-yl)carbamoylamino]-3-[[4-(2-oxoethylamino)phenyl]diazenyl]naphthalene-2-sulfonic acid,C1=CC=C(C=C1)N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=C(C(=C(C=C5C=C4)S(=O)(=O)O)N=NC6=CC=C(C=C6)NCC=O)O)S(=O)(=O)O,,,,,,
8929,18930,(2-(o-Methoxyphenoxy)ethyl)hydrazine hydrochloride,COC1=CC=CC=C1OCCN[NH3+].[Cl-],,,,,,
8930,18931,2-(2-Methoxyphenoxy)ethylhydrazine,COC1=CC=CC=C1OCCNN,,,,,,
8931,18932,2-Methylpyrene,CC1=CC2=C3C(=C1)C=CC4=CC=CC(=C43)C=C2,,,,,,
8932,18933,Aminochlorthenoxazin hydrochloride,C1=CC2=C(C=C1[NH3+])C(=O)NC(O2)CCCl.[Cl-],,,,,,
8933,18934,Aminochlorthenoxazin,C1=CC2=C(C=C1N)C(=O)NC(O2)CCCl,,,,,,
8934,18935,p-Hydroxydiisopropylbenzene,CC(C)C1=CC=C(C=C1)C(C)(C)O,,,,,,
8935,18936,1-Eicosene,CCCCCCCCCCCCCCCCCCC=C,,,,,,
8936,18937,1-Nonyne,CCCCCCCC#C,,,,,,
8937,18938,"3,5,5-Trimethyl-1-hexanol",CC(CCO)CC(C)(C)C,,,,,,
8938,18939,3-Methyl-1(3H)-isobenzofuranone,CC1C2=CC=CC=C2C(=O)O1,,,,,,
8939,18940,4-Ethylstyrene,CCC1=CC=C(C=C1)C=C,,,,,,
8940,18941,"Dithiophosphoric acid O,O-diethyl S-potassium salt",CCOP(=S)(OCC)[S-].[K+],,,,,,
8941,18942,"7-Chloro-1-methyl-4,1-benzoxazepine-2,5-dione",CN1C(=O)COC(=O)C2=C1C=CC(=C2)Cl,,,,,,
8942,18943,4-(5-Nitrofuran-2-yl)but-3-en-2-one,CC(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
8943,18944,[4-(5-Nitrofuran-2-yl)but-3-en-2-ylideneamino]urea,CC(=NNC(=O)N)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
8944,18945,5-Fluoro-2-nitrophenylacetonitrile,C1=CC(=C(C=C1F)CC#N)[N+](=O)[O-],,,,,,
8945,18946,"4,4'-Dichlorobenzil",C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)Cl)Cl,,,,,,
8946,18947,CID 18947,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)[NH3+].[Cl-],,,,,,
8947,18948,Bis(3-mesyloxypropyl)amine hydrochloride,CS(=O)(=O)OCCC[NH2+]CCCOS(=O)(=O)C.[Cl-],,,,,,
8948,18949,Improsulfan,CS(=O)(=O)OCCCNCCCOS(=O)(=O)C,,,,,,
8949,18950,D-Mannose,C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)O)O)O)O,,,,,,
8950,18951,CID 18951,C1=CC=C(C=C1)CN=C(N)N[NH3+].[I-],,,,,,
8951,18952,N-amino-N'-benzylguanidine,C1=CC=C(C=C1)CN=C(N)NN,,,,,,
8952,18953,2-Benzyl-1-(benzylideneamino)guanidine,C1=CC=C(C=C1)CN=C(N)NN=CC2=CC=CC=C2,,,,,,
8953,18954,Triammonium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[NH4+].[NH4+].[NH4+],,,,"['...The distribution of (15)N from ammonium citrate, administered by different routes, into the proteins of various tissues of hypophysectomized rats /was examined/. The liver, kidney, and spleen contained greater concentrations of (15)N incorporated into proteins than heart or muscle fractions during 72 hr following intragastric, intraperitoneal, and subcutaneous administration of 15N-ammonium citrate. After the first 6 hr, during which the intragastric route gave higher values, the quantity of (15)N incorporated into liver-protein was not substantially affected by the route of administration. In most of the other tissues studied, however, (15)N incorporation tended to be least by the intragastric route, followed, in increasing order, by the intraperitoneal and subcutaneous routes. By the last route, more labelled ammonia was apparently made available to the widely distributed glutamine-synthetase (EC 6.3.1.2) system. /Ammonium citrate/']","['Results of studies on the metabolic fate of dietary ammonium citrate and intravenously-administered ammonium lactate in rats showed that urea synthesis represented a nearly constant fraction of the administered ammonia over a large concentration range. Besides glutamine and urea, labelled nitrogen also appeared in creatine, glycine, alanine, proline, histidine, arginine, glutamic acid, and aspartic acid. ...The incorporation of (15)N from ammonium citrate into proteins of liver, heart, kidney, spleen, and muscle fractions of untreated and growth hormone-treated, hypophysectomized rats /was examined/, and found differences in the metabolic fate, depending on the route of administration. Subcutaneous injection facilitated the labelling of amide nitrogen, indicating extensive disposition via glutamine synthesis. In contrast, intragastric or intraperitoneal administration resulted in the labelling of arginine, glutamic acid, and other alpha-amino acids of the liver. Amide-nitrogen was labelled to a much lesser extent than by the subcutaneous route. The tissue distribution of the label also differed according to the route of entry. /Ammonium citrate/']",
8954,18955,"1-Naphthylamine, 1,2,3,4-tetrahydro-, hydrochloride",C1CC(C2=CC=CC=C2C1)[NH3+].[Cl-],,,,,,
8955,18956,CID 18956,COCCOC1=CC(=CC=C1)S(=O)(=O)[N-]C2=NC=CC=N2.[Na+],,,,,,
8956,18957,3-(2-Methoxyethoxy)-N-(pyrimidin-2-yl)benzene-1-sulfonamide,COCCOC1=CC(=CC=C1)S(=O)(=O)NC2=NC=CC=N2,,,,,,
8957,18958,"2-Isoindolinebutyramide, 1,3-dioxo-",C1=CC=C2C(=C1)C(=O)N(C2=O)CCCC(=O)N,,,,,,
8958,18959,CID 18959,CC=CCC(C1=CC=CC2=CC=CC=C21)C(=O)[O-].[Na+],,,,,,
8959,18960,(E)-2-naphthalen-1-ylhex-4-enoic acid,C/C=C/CC(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
8960,18961,"Acetic acid, 2-(2-furylmethyl)-2-(2-methyl-1-naphthyl)-",CC1=C(C2=CC=CC=C2C=C1)C(CC3=CC=CO3)C(=O)O,,,,,,
8961,18962,"N,N-Dimethyl-N'-(2,3-dimethylphenyl)formamidine",CC1=C(C(=CC=C1)N=CN(C)C)C,,,,,,
8962,18963,"2,5-Dimethyl-4-nitroaniline",CC1=CC(=C(C=C1[N+](=O)[O-])C)N,,,,,,
8963,18964,CID 18964,CC(=O)C1CCCO1.C1=CN=CC=C1C(=O)NN,,,,,,
8964,18965,1-(Oxolan-2-yl)ethan-1-one,CC(=O)C1CCCO1,,,,,,
8965,18966,Morpholinoethyl 3-methylflavone-8-carboxylate hydrochloride,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCC[NH+]3CCOCC3)C4=CC=CC=C4.[Cl-],,,,,,
8966,18967,2-Morpholin-4-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCOCC3)C4=CC=CC=C4,,,,,,
8967,18968,Dimethylaminoethyl 3-methylflavone-8-carboxylate hydrochloride,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
8968,18969,2-(Dimethylamino)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN(C)C)C3=CC=CC=C3,,,,,,
8969,18970,Diethylaminoethyl 3-methylflavone-8-carboxylate hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3.[Cl-],,,,,,
8970,18971,2-(Diethylamino)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CCN(CC)CCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3,,,,,,
8971,18972,Dipropylaminoethyl 3-methylflavone-8-carboxylate hydrochloride,CCC[NH+](CCC)CCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3.[Cl-],,,,,,
8972,18973,2-(Dipropylamino)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CCCN(CCC)CCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3,,,,,,
8973,18974,Diisopropylamino 3-methylflavone-8-carboxylate hydrochloride,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCC[NH+](C(C)C)C(C)C)C3=CC=CC=C3.[Cl-],,,,,,
8974,18975,2-[Di(propan-2-yl)amino]ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN(C(C)C)C(C)C)C3=CC=CC=C3,,,,,,
8975,18976,"4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 3-(dimethylamino)propyl ester, hydrochloride",CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
8976,18977,3-(Dimethylamino)propyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCCN(C)C)C3=CC=CC=C3,,,,,,
8977,18978,"4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 3-(diethylamino)propyl ester, hydrochloride",CC[NH+](CC)CCCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3.[Cl-],,,,,,
8978,18979,3-(Diethylamino)propyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CCN(CC)CCCOC(=O)C1=CC=CC2=C1OC(=C(C2=O)C)C3=CC=CC=C3,,,,,,
8979,18980,"1,3-Diiminoisoindoline",C1=CC=C2C(=C1)C(=NC2=N)N,,,,,,
8980,18981,Pigment orange 5,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
8981,18982,Benzotrifuroxan,C12=NO[N+](=C1C3=NO[N+](=C3C4=NO[N+](=C24)[O-])[O-])[O-],,,,,,
8982,18983,N-Propylsuccinamide,CCCN1C(=O)CCC1=O,,,,,,
8983,18984,1-Butylpyrrolidin-2-one,CCCCN1CCCC1=O,,,,,,
8984,18985,Anabaseine,C1CCN=C(C1)C2=CN=CC=C2,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
8985,18986,5-Methoxyindole-3-acetic acid,COC1=CC2=C(C=C1)NC=C2CC(=O)O,,,,,,
8986,18987,Dipyraphene,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)C4C(=O)N(N(C4=O)C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
8987,18988,Trimethylnitrosourea,CN(C)C(=O)N(C)N=O,,,,,,
8988,18989,Thiamine triphosphorate,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)OP(=O)(O)[O-],,,"['A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
8989,18990,"N-(4-Dimethylamino-3,5-dinitrophenyl)maleimide",CN(C)C1=C(C=C(C=C1[N+](=O)[O-])N2C(=O)C=CC2=O)[N+](=O)[O-],,,,,,
8990,18991,N-Deacetylcolchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)N,,,,,,
8991,18992,"4(1H)-Quinazolinone, 1-methyl-",CN1C=NC(=O)C2=CC=CC=C21,,,,,,
8992,18993,"3-(3-Chloromercuri-2-methoxy-1-propyl)-5,5-dimethylhydantoin",CC1(C(=O)N(C(=O)N1)CC(C[Hg]Cl)OC)C,,,,,,
8993,18994,CID 18994,CCCCCCOCC(COC1=CC=CC=C1C(=O)[O-])O.[Na+],,,,,,
8994,18995,Exiproben,CCCCCCOCC(COC1=CC=CC=C1C(=O)O)O,,,,,,
8995,18996,Piperalin,CC1CCCCN1CCCOC(=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
8996,18997,N-Chlorophthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)Cl,,,,,,
8997,18998,"2,3,5,6-Tetrachloroaniline",C1=C(C(=C(C(=C1Cl)Cl)N)Cl)Cl,,,,,,
8998,18999,Deacetylcolchiceine,COC1=C(C(=C2C(=C1)CCC(C3=CC(=O)C(=CC=C32)O)N)OC)OC,,,,,,
8999,19000,"(3R,5S,17S)-3-methoxy-10,13,17-trimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-ol",C[C@@]1(CCC2C1(CCC3C2CC[C@@H]4C3(CC[C@H](C4)OC)C)C)O,,,,,,
9000,19001,Dithiothreitol,C(C(C(CS)O)O)S,,,,"['Two male patients with late stage (uremic) infantile nephropathic cystinosis (INC) were treated by mouth with the reducing agent dithiothreitol (DTT), at doses not exceeding 25 mg/kg body weight three times per day. Three sequential periods of observation were obtained in both patients: on thiol (8.5 months); off thiol (8-9 months); on thiol again (7 months or longer)... Whereas chemical methods are not reliable for detecting and measuring DTT in biologic fluids, preliminary evidence indicates that a silylated derivative of oxidized DTT can be detected in the urine of patients receiving DTT by mouth. This finding suggests that the thiol is absorbed and excreted.']","['Two male patients with late stage (uremic) infantile nephropathic cystinosis (INC) were treated by mouth with the reducing agent dithiothreitol (DTT), at doses not exceeding 25 mg/kg body weight three times per day. Three sequential periods of observation were obtained in both patients: on thiol (8.5 months); off thiol (8-9 months); on thiol again (7 months or longer)... Whereas chemical methods are not reliable for detecting and measuring DTT in biologic fluids, preliminary evidence indicates that a silylated derivative of oxidized DTT can be detected in the urine of patients receiving DTT by mouth. This finding suggests that the thiol is absorbed and excreted.']",
9001,19002,"BENZOIC ACID, p-(2-(DIETHYLAMINO)ETHOXY)-, METHYL ESTER",CCN(CC)CCOC1=CC=C(C=C1)C(=O)OC,,,,,,
9002,19003,Cyclacillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C,['For the treatment of bacterial infections caused by susceptible organisms.'],"['Cyclacillin, a penicillin, is a cyclohexylamido analog of penicillanic acid. Cyclacillin is more resistant to beta-lactamase hydrolysis than ampicillin, is much better absorbed when given by mouth and, as a result, the levels reached in the blood and in the urine are considerably higher than those obtained with the same dose of ampicillin. Cyclacillin has been replaced by newer penicillin treatments.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Moderately absorbed.'],,
9003,19004,Clidinium bromide,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Br-],,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
9004,19005,ZINC carbonate,C(=O)([O-])[O-].[Zn+2],,,,"['The effects of different amounts of dietary zinc on the zinc absorption rate and on zinc, calcium and magnesium concn in tissues of MOPC104E tumor bearing Balb/c female mice were determined. Three groups of 7 mice each (each mouse inoculated with approx 1.25 million MOPC104E cells) were given one of three experimental diets containing adequate amounts of zinc (40 ug zinc/g), a zinc deficient diet (1.0 ug zinc/g), or a zinc excess diet (1 mg zinc/g). A group of 7 nontumor bearing mice was fed laboratory mice chow as a control. The zinc deficient diet contained 37.5 ug zinc/g. For the zinc adequate diet, 71.0 mg zinc carbonate/kg diet was added to the zinc deficient diet. For the zinc excess diet 1917.9 mg zinc carbonate/kg diet was added. After 14 days on the special diets, mice were given an intragastric dose of a 200 ul solution containing 0.37 MBq (65)zinc (specific activity: 37 MBq/mg). (65)Zn was determined in various organs by gamma counting. Another set of 28 mice were placed in the same experimental conditions as described above. After anesthesia with nembutal injection, each organ was analyzed for concn of zinc, calcium, and magnesium by atomic absorption spectrophotometry. The zinc absorption rate was inversely related to the amounts of zinc in the diet and was lower than that of nontumor bearing control mice fed a laboratory mice chow. Zinc concn of tumor bearing mice were also low compared with control mice but tumor zinc concn, regardless of the concn of zinc in the diets, were higher than those of normal tissues of the host other than the pancreas.']",,
9005,19006,(+)-Diethyl(2-hydroxyethyl)methylammonium iodide alpha-phenylcyclohexaneglycolate,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2.[I-],,,,,,
9006,19007,"2-[[(Cyclohexyl)phenylacetyl]oxy]-N,N-diethyl-N-methylethanaminium",CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2,,,,,,
9007,19008,(-)-Diethyl(2-hydroxyethyl)methylammonium iodide alpha-phenylcyclohexaneglycolate,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.[I-],,,,,,
9008,19009,Palmatine,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC,,,,,,
9009,19010,CID 19010,CCC(C)C1(C(=O)NC(=NC1=O)[O-])CC(=C)Br.[Na+],,,,,,
9010,19011,"1H-1,4-Benzodiazepine-7-carbonitrile, 2,3-dihydro-1-methyl-2-oxo-5-phenyl-",CN1C(=O)CN=C(C2=C1C=CC(=C2)C#N)C3=CC=CC=C3,,,,,,
9011,19012,"1,4-Bis(4-aminophenoxy)benzene",C1=CC(=CC=C1N)OC2=CC=C(C=C2)OC3=CC=C(C=C3)N,,,,,,
9012,19013,"1-Acetoxyocta-2,7-diene",CC(=O)OCC=CCCCC=C,,,,,,
9013,19014,Chlorquinox,C1=CN=C2C(=C(C(=C(C2=N1)Cl)Cl)Cl)Cl,,,,,,
9014,19015,"1,2-Dichlorocyclobutane-1,2-dicarbonitrile",C1CC(C1(C#N)Cl)(C#N)Cl,,,,,,
9015,19016,Phenylphosphonothioic dichloride,C1=CC=C(C=C1)P(=S)(Cl)Cl,,,,"['Most organophosphate compounds are ... absorbed from skin, conjunctiva, gastrointestinal tract, & lung. /Organophosphate compounds/']",,
9016,19017,"2-((4-chlorophenyl)(pyridin-2-yl)methoxy)-N,N-dimethylethanamine maleate",CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O,,,,,,
9017,19018,"Ammonium, bis(3-hydroxypropyl)dimethyl-, 2,4,6-trinitrobenzenesulfonate, dimethanesulfonate, (ester)",C[N+](C)(CCCOS(=O)(=O)C)CCCOS(=O)(=O)C.C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
9018,19019,Dimethyl-bis(3-methylsulfonyloxypropyl)azanium,C[N+](C)(CCCOS(=O)(=O)C)CCCOS(=O)(=O)C,,,,,,
9019,19020,2-amino-N-[5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide;hydrochloride,CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl,,,,,,
9020,19021,[4-(4-Nitrophenyl)butan-2-ylideneamino]urea,CC(=NNC(=O)N)CCC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
9021,19022,1-Bromoheptadecane,CCCCCCCCCCCCCCCCCBr,,,,,,
9022,19023,"2,4-Pentanedione, 3-(2-propenyl)-",CC(=O)C(CC=C)C(=O)C,,,,,,
9023,19024,2-Isopropyl-2-phenylacetic acid,CC(C)C(C1=CC=CC=C1)C(=O)O,,,,,,
9024,19025,"2,3-Dichlorotetrahydrofuran",C1COC(C1Cl)Cl,,,,,,
9025,19026,3-(piperidin-4-ylmethyl)-1H-indole,C1CNCCC1CC2=CNC3=CC=CC=C32,,,,,,
9026,19027,"Indole, 5-methoxy-3-(4-piperidylmethyl)-",COC1=CC2=C(C=C1)NC=C2CC3CCNCC3,,,,,,
9027,19028,"Indole, 3-(1-phenethyl-4-piperidylmethyl)-",C1CN(CCC1CC2=CNC3=CC=CC=C32)CCC4=CC=CC=C4,,,,,,
9028,19029,"Indole, 5-methoxy-3-(1-phenethyl-4-piperidyl)methyl-",COC1=CC2=C(C=C1)NC=C2CC3CCN(CC3)CCC4=CC=CC=C4,,,,,,
9029,19030,"Indole, 3-(1-benzyl-4-piperidylmethyl)-5-methoxy-, hydrochloride",COC1=CC2=C(C=C1)NC=C2CC3CC[NH+](CC3)CC4=CC=CC=C4.[Cl-],,,,,,
9030,19031,3-[(1-benzylpiperidin-4-yl)methyl]-5-methoxy-1H-indole,COC1=CC2=C(C=C1)NC=C2CC3CCN(CC3)CC4=CC=CC=C4,,,,,,
9031,19032,"Indole, 1-methyl-3-(1-phenethyl-4-piperidylmethyl)-",CN1C=C(C2=CC=CC=C21)CC3CCN(CC3)CCC4=CC=CC=C4,,,,,,
9032,19033,"2(1H)-ISOQUINOLINEPROPANOL, 3,4-DIHYDRO-alpha,alpha-DIPHENYL-",C1CN(CC2=CC=CC=C21)CCC(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
9033,19034,"3,4-Dihydro-alpha,alpha-diphenyl-beta-methyl-2(1H)-isoquinolinepropanol",CC(CN1CCC2=CC=CC=C2C1)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
9034,19035,"Benz(c)acridine, 5-methyl-",CC1=CC2=C(C=C1)C=CC3=CC4=CC=CC=C4N=C32,,,,,,
9035,19036,4-[[2-Chloro-4-[3-chloro-4-[(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)diazenyl]phenyl]phenyl]diazenyl]-5-methyl-2-phenyl-1H-pyrazol-3-one,CC1=C(C(=O)N(N1)C2=CC=CC=C2)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(NN(C5=O)C6=CC=CC=C6)C)Cl)Cl,,,,,,
9036,19037,Eromycin,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']",,,
9037,19038,"[4-(dimethylamino)-2-[[(3R,4S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] propanoate",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,,,,,,
9038,19039,Endocistobil;Endografin,CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
9039,19040,1-Hepten-4-OL,CCCC(CC=C)O,,,,,,
9040,19041,"2,2,5-Trimethylhexane",CC(C)CCC(C)(C)C,,,,,,
9041,19042,Pentaerythritol triacrylate,C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C,,,,,,
9042,19043,CID 19043,CC1=CC(=O)N=CN1,,,,,,
9043,19044,N-(7-Methylcoumaran-3-yl)guanidine nitrate,CC1=C2C(=CC=C1)C(CO2)[NH2+]C(=N)N.[N+](=O)([O-])[O-],,,,,,
9044,19045,"2-(7-Methyl-2,3-dihydro-1-benzofuran-3-yl)guanidine",CC1=C2C(=CC=C1)C(CO2)N=C(N)N,,,,,,
9045,19046,"3,9-Diazabicyclo(3.3.1)nonane, 3-(3-(dimethylamino)propyl)-9-methyl-, trihydrochloride",CN1C2CCCC1CN(C2)CCCN(C)C.Cl.Cl.Cl,,,,,,
9046,19047,"N,N-dimethyl-3-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)propan-1-amine",CN1C2CCCC1CN(C2)CCCN(C)C,,,,,,
9047,19048,Thiochroman-4-one,C1CSC2=CC=CC=C2C1=O,,,,,,
9048,19049,3-(Piperidin-1-yl)propan-1-amine,C1CCN(CC1)CCCN,,,,,,
9049,19050,3-Nitrophenyl isothiocyanate,C1=CC(=CC(=C1)[N+](=O)[O-])N=C=S,,,,,,
9050,19051,"Acetic acid, 1-methylhydrazide",CC(=O)N(C)N,,,,,,
9051,19052,"2-Chloro-4,6-dinitroaniline",C1=C(C=C(C(=C1[N+](=O)[O-])N)Cl)[N+](=O)[O-],,,,,,
9052,19053,Tetraisobutyltin,CC(C)C[Sn](CC(C)C)(CC(C)C)CC(C)C,,,,,,
9053,19054,"2H-1,3-Benzoxazine, 3,4-dihydro-3,8-dimethyl-",CC1=C2C(=CC=C1)CN(CO2)C,,,,,,
9054,19055,4-Aminopyridine 1-oxide,C1=CN(C=CC1=N)O,,,,,,
9055,19056,"(6S,17R)-17-acetyl-17-bromo-6-fluoro-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CC(=O)[C@]1(CCC2C1(CCC3C2C[C@@H](C4=CC(=O)CCC34C)F)C)Br,,,,,,
9056,19057,3-Phenyl-2-propenoic acid hydrazide,C1=CC=C(C=C1)C=CC(=O)NN,,,,,,
9057,19058,Maleohydrazide,C(=CC(=O)NN)C(=O)NN,,,,,,
9058,19059,Hexadecyl dihydrogen phosphate,CCCCCCCCCCCCCCCCOP(=O)(O)O,,,,,,
9059,19060,4-Phenyl-1-(2-(tetrahydro-2-furyl)ethyl)isonipecotic acid ethyl ester,CCOC(=O)C1(CCN(CC1)CCC2CCCO2)C3=CC=CC=C3,,,,,,
9060,19061,4-Phenyl-1-(5-(tetrahydro-2-furyl)pentyl)isonipecotic acid ethyl ester,CCOC(=O)C1(CCN(CC1)CCCCCC2CCCO2)C3=CC=CC=C3,,,,,,
9061,19062,3-Methoxy-4-aminoazobenzene,COC1=C(C=CC(=C1)N=NC2=CC=CC=C2)N,,,,,,
9062,19063,Iproclozide,CC(C)NNC(=O)COC1=CC=C(C=C1)Cl,['For the treatment of depression.'],,,,,
9063,19064,Propylbutamide,CCCN(C(CC)C(=O)N(C)C)C(=O)C=CC,,,,,,
9064,19065,CID 19065,C1=CC=C(C=C1)OCC[NH2+]C(=N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
9065,19066,"Guanidine, (2-phenoxyethyl)-",C1=CC=C(C=C1)OCCN=C(N)N,,,,,,
9066,19067,CID 19067,CC1=CC=C(C=C1)CN=C(N)N[NH3+].[N+](=O)([O-])[O-],,,,,,
9067,19068,1-(4-Methylbenzyl)-2-aminoguanidine,CC1=CC=C(C=C1)CN=C(N)NN,,,,,,
9068,19069,CID 19069,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC=NC4=O)O)OP(=O)(O1)O,,,,,,
9069,19070,N-Hydroxyglycine,C(C(=O)O)NO,,,,,,
9070,19071,"3,6-Naphthalenedisulfonic acid, 1,7-diamino-8-hydroxy-",C1=C2C=C(C(=C(C2=C(C=C1S(=O)(=O)O)N)O)N)S(=O)(=O)O,,,,,,
9071,19072,Cholest-5-en-3-yl {4-[bis(2-chloroethyl)amino]phenyl}acetate,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)C)C,,,,,,
9072,19073,"3,3'-Dimethyl-N,N'-diacetylbenzidine",CC1=C(C=CC(=C1)NC(=O)C)C2=C(C=C(C=C2)NC(=O)C)C,,,,,,
9073,19074,"3,3'-Dimethyl-N-acetylbenzidine",CC1=C(C=CC(=C1)C2=CC(=C(C=C2)NC(=O)C)C)N,,,,,,
9074,19075,CID 19075,C=CCC1(C(=NC(=NC1=O)S)[O-])C2CCCC=C2.[Na+],,,,,,
9075,19076,"Benzene, 1,1'-ethylidenebis(4-chloro-",CC(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)Cl,,,,,,
9076,19077,4-(4-Chlorophenoxy)butanoic acid,C1=CC(=CC=C1OCCCC(=O)O)Cl,,,,,,
9077,19078,"3,4-Dihydro-6-methyl-1H-azepino(5,4,3-cd)indole",CC1=NCCC2=CNC3=CC=CC1=C23,,,,,,
9078,19079,2-(Octylthio)ethanol,CCCCCCCCSCCO,,,,,,
9079,19080,9-Amino-6-chloro-2-methoxyacridine,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)N,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)']",,['9-Amino-6-chloro-2-methoxyacridine is a known human metabolite of qun.'],
9080,19081,4-Methyl-9-acridinamine,CC1=CC=CC2=C(C3=CC=CC=C3N=C12)N,,,,,,
9081,19082,Ethyl 11-cyclopent-2-enylundecanoate,CCOC(=O)CCCCCCCCCCC1CCC=C1,,,,,,
9082,19083,Ethyl diethylcarbamate,CCN(CC)C(=O)OCC,,,,,,
9083,19084,Allyl pentabromophenyl ether,C=CCOC1=C(C(=C(C(=C1Br)Br)Br)Br)Br,,,,,,
9084,19085,4-(1-Methylpropyl)-2-nitrophenol,CCC(C)C1=CC(=C(C=C1)O)[N+](=O)[O-],,,,,,
9085,19086,Tetrakis(trimethylsiloxy)silane,C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C,,,,,,
9086,19087,"Indole, 1-methyl-3-(4-piperidylmethyl)-, hydrochloride",CN1C=C(C2=CC=CC=C21)CC3CC[NH2+]CC3.[Cl-],,,,,,
9087,19088,1-Methyl-3-(piperidin-4-ylmethyl)-1h-indole,CN1C=C(C2=CC=CC=C21)CC3CCNCC3,,,,,,
9088,19089,(2-Methoxyethyl)benzene,COCCC1=CC=CC=C1,,,,,,
9089,19090,Megestrol,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C,,,"['Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)', 'Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)', 'Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)']","['Megestrol acetate appears to be well absorbed from the GI tract. The relative oral bioavailability of megestrol acetate suspensions and tablets has not been evaluated.', 'Plasma megestrol acetate concentrations achieved with a 625-mg dose of the more concentrated oral suspension (Megace ES 625 mg/5 mL) are equivalent to those achieved with an 800-mg dose of the original formulation (200 mg/5 mL) under fed conditions.', 'The effect of food on the bioavailability of Megestrol Acetate Oral Suspension has not been evaluated.', 'Peak concentrations and AUC were 54.8 and 43.3% higher, respectively, under fed conditions compared with fasting for the concentrated suspension and were 12.9 and 24.4% higher, respectively, under fed conditions compared with fasting for the original formulation.', 'For more Absorption, Distribution and Excretion (Complete) data for MEGESTROL (13 total), please visit the HSDB record page.']","['Megestrol acetate appears to be completely metabolized in the liver to free steroids and glucuronide conjugates of 17alpha-acetoxy-2alpha-hydroxy-6-methylpregna-4,6-diene-3,20-dione, 17alpha-acetoxy-6-hydroxymethylpregna-4,6-diene-3,20-dione, and 17alpha-acetoxy-2alpha-hydroxy-6-hydroxymethylpregna-4,6-diene-3,20-dione.', 'Completely metabolized in liver to free steroids and glucuronide conjugates of 17alpha-acetoxy-2alpha-hydroxy-6-methylpregna-4,6-diene-3,20-dione, 17alpha-acetoxy-6-hydroxymethylpregna-4,6-diene-3,20-dione, & 17alpha-acetoxy-2alpha-hydroxy-6-hydroxymethylpregna-4,6-diene-3,20-dione /Human, oral/']",['Plasma elimination half-life ranged from 13 to 104.9 hours (mean 34.2 hours).']
9090,19091,"1,1'-(1,2-Ethanediylbis(sulfonyl))bispropane",CCCS(=O)(=O)CCS(=O)(=O)CCC,,,,,,
9091,19092,Sesquimustard,C(CSCCCl)SCCCl,,,,,"['Sesqui- and oxy-mustards pose a significant threat to military forces and civilians because they are potent vesicants. We have developed an isotope-dilution high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method utilizing negative ion multiple reaction monitoring for the analysis of sesqui-mustard metabolites bis(2-hydroxyethylthio)alkanes (n = 1-5) and oxy-mustard metabolite bis(2-hydroxyethylthioethyl)ether in human urine. Relative standard deviations were < 10% and the reportable limits of detection were 1 ng/mL in 0.5 mL of urine. We applied this method to 100 samples collected from individuals with no known exposure to sesqui- or oxy-mustards, and no urines showed detectable levels of any of the analytes, suggesting that these metabolites may be used for monitoring exposure to sesqui- and oxy-mustards.']",
9092,19093,Tetrachloro DDT,C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(C(Cl)(Cl)Cl)Cl)Cl,,,,,,
9093,19094,Chloralodol,CC(CC(C)(C)O)OC(C(Cl)(Cl)Cl)O,,['Chloral hydrate has sedative/hypnotic activity which has been shown to extend the sleep of normal made adults via a dose-response relationship. [1]'],,,,
9094,19095,Ponceau 3R,CC1=CC(=C(C=C1C)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],,,,,"['FOLLOWING ITS ORAL ADMINISTRATION TO RABBITS, 0.4% UNCHANGED DYE & 44% 2,4,5-TRIMETHYLANILINE WERE EXCRETED IN URINE...', '...METABOLIZED BY REDUCTION OF AZO LINKAGE TO YIELD 1-A MINO-2-NAPHTHOL-3,6-DISULFONIC ACID, TOGETHER WITH VARIETY OF ANILINE DERIVATIVES INCLUDING 2,4,5- & 2,4,6-TRIMETHYLANILINE, & 2,4-, 2,5- & 2,6-XYLIDINES.', 'AMINONAPHTHOL-DISULFONIC ACID /METABOLITE/ IS EXCRETED UNCHANGED, BUT ANILINE DERIVATIVES /METABOLITES/ ARE FURTHER METABOLIZED BY OXIDATION OF ONE OF SUBSTITUENT METHYL GROUPS, & IN CASE OF 2,5- & 2,6-XYLIDINE ONLY, BY HYDROXYLATION OF AROMATIC RING.']",
9095,19096,Ponceau 3R free acid,CC1=CC(=C(C=C1C)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)O)S(=O)(=O)O)C,,,,,,
9096,19097,CID 19097,C1=CC=C2C(=C1)C=CC(=C2O)N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])O.[Na+],,,,,,
9097,19098,"1-Naphthalenesulfonic acid, 3-hydroxy-4-[(1-hydroxy-2-naphthalenyl)azo]-",C1=CC=C2C(=C1)C=CC(=C2O)N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)O)O,,,,,,
9098,19099,"10,11-Dihydrocarbamazepine",C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,,,,,,
9099,19100,Menthoglycol,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)(C)O,,,,,"['P-Menthane-3,-8-diol is a known human metabolite of (-)-Menthol.']",
9100,19101,CID 19101,C1=C(C(=NC(=N1)S)[O-])I.[Na+],,,,,,
9101,19102,CID 19102,C1=C(C(=O)NC(=N1)S)I,,,,,,
9102,19103,5-Nitroso-8-hydroxyquinoline,C1=CC2=C(C=CC(=C2N=C1)O)N=O,,,['Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. (See all compounds classified as Histone Deacetylase Inhibitors.)'],,,
9103,19104,Anisoperidone,COC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)C3=CC=CC=C3,,,,,,
9104,19105,Embramine,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Br)OCCN(C)C,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
9105,19106,3-Methyl-4-(methylthio)phenyl methylcarbamate,CC1=C(C=CC(=C1)OC(=O)NC)SC,,,,,,
9106,19107,Methylcarbamic acid 2-chloro-m-cumenyl ester,CC(C)C1=C(C(=CC=C1)OC(=O)NC)Cl,,,,,,
9107,19108,"4-methoxy-N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]benzenesulfonimidic acid",CC(C)CC1=NN=C(S1)N=S(=O)(C2=CC=C(C=C2)OC)O,,,,,,
9108,19109,"CARBAMIC ACID, 3-(o-CHLOROPHENYL)-2,2-DICHLORO-3-HYDROXYPROPYL ESTER",C1=CC=C(C(=C1)C(C(COC(=O)N)(Cl)Cl)O)Cl,,,,,,
9109,19110,"CARBAMIC ACID, 3-(m-CHLOROPHENYL)-2,2-DICHLORO-3-HYDROXYPROPYL ESTER",C1=CC(=CC(=C1)Cl)C(C(COC(=O)N)(Cl)Cl)O,,,,,,
9110,19111,Carfimate,C#CC(C1=CC=CC=C1)OC(=O)N,,,,,,
9111,19112,"Carbamic acid, dimethyl-, 2,6-dimethyl-4-pyridinyl ester",CC1=CC(=CC(=N1)C)OC(=O)N(C)C,,,,,,
9112,19113,"1-(3,4-Dichlorophenyl)-3-methylurea",CNC(=O)NC1=CC(=C(C=C1)Cl)Cl,,,,,['N-demethyldiuron is a known human metabolite of Diuron.'],
9113,19114,"C.I. Acid Red 88, disodium salt",CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
9114,19115,"7-Hydroxy-8-{[4'-({4-[(4-methylbenzene-1-sulfonyl)oxy]phenyl}diazenyl)[1,1'-biphenyl]-4-yl]diazenyl}naphthalene-1,3-disulfonic acid",CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC=C(C=C3)C4=CC=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
9115,19116,Azo fuchsine,C1=CC=C(C=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+],,,,,,
9116,19117,"2,7-Naphthalenedisulfonic acid, 5-amino-4-hydroxy-3-(phenylazo)-",C1=CC=C(C=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)N)O,,,,,,
9117,19118,Carmoisine,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O.[Na+].[Na+],,,,"['FOLLOWING IV ADMIN OF 1 MG...TO RATS, 30-40% OF COLOR WAS EXCRETED UNCHANGED IN BILE. IT IS REDUCED BY LACTIC ACID BACTERIA.', 'BILIARY EXCRETION RATE OF AZO RUBINE S ADMIN IV TO RATS WITH LIGATED RENAL PEDICLES, REACHED APPARENT MAX WHICH WAS DEPRESSED BY PHENOLPHTHALEIN GLUCURONIDE OR PROBENECID. BILIARY EXCRETION OF THE DYE MAY INVOLVE AN ACTIVE TRANSPORT PROCESS.']",,
9118,19119,Azo rubin S,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)O)O,,,,,,
9119,19120,3-Trichloromethylthiobenzoxazolone,C1=CC=C2C(=C1)N(C(=O)O2)SC(Cl)(Cl)Cl,,,,,,
9120,19121,N-Trichloromethylthiobenzothiazolone,C1=CC=C2C(=C1)N(C(=O)S2)SC(Cl)(Cl)Cl,,,,,,
9121,19122,Sulfamethoxypyridazine acetyl,CC(=O)N(C1=NN=C(C=C1)OC)S(=O)(=O)C2=CC=C(C=C2)N,,,,,,
9122,19123,"2-Hydroxy-3-(2-methyloctyl)-1,4-naphthoquinone",CCCCCCC(C)CC1=C(C2=CC=CC=C2C(=O)C1=O)O,,,,,,
9123,19124,3-Chloropropyl octyl sulfoxide,CCCCCCCCS(=O)CCCCl,,,,,,
9124,19125,"2-Norbornanecarboxylic acid, 1-phenyl-, 2-(1-pyrrolidinyl)ethyl ester",C1CCN(C1)CCOC(=O)C2(CC3CCC2C3)C4=CC=CC=C4,,,,,,
9125,19126,"(3S,5aS,10bS)-3-hydroxy-3,3a,5b-trimethyl-1,2,4,5,5a,6,7,10,10a,10b-decahydrocyclopenta[a]fluoren-8-one",C[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CC4=CC(=O)CCC34C)C)O,,,,,,
9126,19127,Ethomoxane,CCCCNCC1COC2=C(O1)C(=CC=C2)OCC,,,,,,
9127,19128,2-Chloroethyl methanesulfonate,CS(=O)(=O)OCCCl,,,,,,
9128,19129,CID 19129,C1=C(C(=CC(=C1Cl)Cl)Cl)OCCOS(=O)(=O)[O-].[Na+],,,,,,
9129,19130,"2-(2,4,5-Trichlorophenoxy)ethyl hydrogen sulfate",C1=C(C(=CC(=C1Cl)Cl)Cl)OCCOS(=O)(=O)O,,,,,,
9130,19131,CID 19131,C1=C(OC(=C1)N(O)O)C2=CSC(=N2)N=NC=O,,,,,,
9131,19132,"Anthrone, 1,8-dihydroxy-3-methoxy-6-methyl-",CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2)C=C(C=C3O)OC,,,,,,
9132,19133,Anethocurarium diiodide,CC(C)C(CC1=CC=C(C=C1)OCC[N+](C)(C)C)C2=CC=C(C=C2)OCC[N+](C)(C)C.[I-].[I-],,,,,,
9133,19134,"2,2'-(1-Isopropyl-1,2-ethanediyl)bis(4,1-phenyleneoxy)bis(N,N,N-trimethylethanaminium)",CC(C)C(CC1=CC=C(C=C1)OCC[N+](C)(C)C)C2=CC=C(C=C2)OCC[N+](C)(C)C,,,,,,
9134,19135,Estradiol undecylate,CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,,,,,,
9135,19136,Metaterol,CC(C)NCC(C1=CC(=CC=C1)O)O,,,,,,
9136,19137,4-(3-Oxobutyl)phenyl acetate,CC(=O)CCC1=CC=C(C=C1)OC(=O)C,,,,,,
9137,19138,Phenocarb,CCC(CC)(C(=O)NC1=CC=C(C=C1)OCC)Br,,,,,,
9138,19139,"Ammonium, (3,6-pyridazinediylbis(oxytrimethylene))bis(diethylmethyl-, diiodide",CC[N+](C)(CC)CCCOC1=NN=C(C=C1)OCCC[N+](C)(CC)CC.[I-].[I-],,,,,,
9139,19140,3-[6-[3-[Diethyl(methyl)azaniumyl]propoxy]pyridazin-3-yl]oxypropyl-diethyl-methylazanium,CC[N+](C)(CC)CCCOC1=NN=C(C=C1)OCCC[N+](C)(CC)CC,,,,,,
9140,19141,3-Amino-2-methyl-5-nitrobenzamide,CC1=C(C=C(C=C1N)[N+](=O)[O-])C(=O)N,,,,,,
9141,19142,Moxastine,CC(C1=CC=CC=C1)(C2=CC=CC=C2)OCCN(C)C,,,,,,
9142,19143,Cyclazocine,CC1C2CC3=C(C1(CCN2CC4CC4)C)C=C(C=C3)O,,,"['A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)']",,,
9143,19144,CID 19144,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NCS(=O)(=O)[O-].[Na+],,,,,,
9144,19145,Sulfamidopyrine,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NCS(=O)(=O)O,,,,,,
9145,19146,"1,1,2,4-Tetrachlorobut-2-ene",C(C=C(C(Cl)Cl)Cl)Cl,,,,,,
9146,19147,4-Octylbenzoic acid,CCCCCCCCC1=CC=C(C=C1)C(=O)O,,,,,,
9147,19148,CID 19148,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CO3)C(=O)[O-].[Na+],,,,,,
9148,19149,3-(Furan-2-yl)-2-naphthalen-1-ylpropanoic acid,C1=CC=C2C(=C1)C=CC=C2C(CC3=CC=CO3)C(=O)O,,,,,,
9149,19150,Cephaloglycin,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,['For treatment of severe infections caused by susceptible bacteria.'],['Cephaloglycin is an antibiotic related to cephalosporin but no longer in common use. It is an orally absorbed derivative of cephalosporin C.'],['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Well absorbed following oral administration.', 'MOST OF CEPHALOGLYCIN THAT IS ABSORBED IS EXCRETED IN URINE AS DEACETYLCEPHALOGLYCIN, AN ANTIMICROBIALLY ACTIVE METABOLITE. URINARY CONCN OF METABOLITE AVG 350 UG/ML OVER 8-HR PERIOD FOLLOWING ADMIN OF 500 MG OF CEPHALOGLYCIN...', 'CEPHALOGLYCIN IS NOT DESTROYED IN GASTRIC ACID, BUT IT GRADUALLY DECOMP IN NEUTRAL & ALKALINE SECRETIONS OF INTESTINES. ONLY 1/4 TO 1/3 IS ABSORBED. /DIHYDRATE/', '...CEPHALOSPORINS ARE UNPREDICTABLE IN MANNER IN WHICH THEY CROSS BLOOD-BRAIN BARRIER & THEY PENETRATE POORLY INTO CEREBROSPINAL FLUID... /CEPHALOSPORINS/']","['MOST OF CEPHALOGLYCIN THAT IS ABSORBED IS EXCRETED...AS DEACETYLCEPHALOGLYCIN, AN ANTIMICROBIALLY ACTIVE METABOLITE.']","['THIS ANTIBIOTIC IS PARTIALLY ABSORBED FROM GI TRACT... PLASMA CONCN REACH PEAK OF ONLY 2-6 UG/ML @ ABOUT 2 HR FOLLOWING SINGLE DOSE OF 0.5 G; DRUG IS NO LONGER DETECTABLE IN PLASMA 8 HR AFTER THIS DOSE. HALF-LIFE...IS ABOUT 4 HR.', 'PLASMA LEVELS AFTER ORAL ADMIN VARY WIDELY AMONG PT. PEAK LEVEL OF AT LEAST 0.6 UG/ML IS USUALLY ACHIEVED WITH ORAL DOSE OF 500 MG, & IT MAY REACH 6 UG/ML IN FAIR PROP OF CASES. FOOD IN STOMACH INTERFERES WITH ABSORPTION. HALF-LIFE IN PLASMA...ABOUT 3-5 HR, BUT WHEN...SEVERE RENAL IMPAIRMENT...MAY BE 9-20 HR. /DIHYDRATE/']"
9150,19151,2-Amino-5-sulfobenzoic acid,C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)N,,,,,,
9151,19152,"Acetic acid, 2,2-diphenyl-, 3-(diethylamino)propyl ester",CCN(CC)CCCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
9152,19153,"Acetamide, N-(2-(dimethylamino)ethyl)-2,2-diphenyl-2-(2-ethylbutoxy)-N-methyl-, hydrochloride",CCC(CC)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CC[NH+](C)C.[Cl-],,,,,,
9153,19154,"N-[2-(dimethylamino)ethyl]-2-(2-ethylbutoxy)-N-methyl-2,2-diphenylacetamide",CCC(CC)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(C)CCN(C)C,,,,,,
9154,19155,"Acetic acide, magnesium salt, octahydrate",CC(=O)[O-].[Mg+2],,,,,,
9155,19156,"Butyronitrile, 2-(2-dimethylaminoethyl)-2-isopropyl-3-methyl-",CC(C)C(CCN(C)C)(C#N)C(C)C,,,,,,
9156,19157,"Butyramide, 2-(2-dimethylaminoethyl)-2-isopropyl-3-methyl-",CC(C)C(CCN(C)C)(C(C)C)C(=O)N,,,,,,
9157,19158,alpha-(2-Dimethylaminoethyl)-2-naphthylacetonitrile,CN(C)CCC(C#N)C1=CC2=CC=CC=C2C=C1,,,,,,
9158,19159,alpha-Isopropyl-alpha-(2-dimethylaminoethyl)-2-naphthylacetonitrile,CC(C)C(CCN(C)C)(C#N)C1=CC2=CC=CC=C2C=C1,,,,,,
9159,19160,"1,4-Dichloro-2,3-epoxybutane",C(C1C(O1)CCl)Cl,,,,,,
9160,19161,Bumadizone,CCCCC(C(=O)N(C1=CC=CC=C1)NC2=CC=CC=C2)C(=O)O,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
9161,19162,"2,4-Bis(trichloromethyl)-6-(p-tolyl)-1,3,5-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9162,19163,"2-(4-Methoxyphenyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",COC1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9163,19164,"2-Benzyl-4,6-bis(trichloromethyl)-1,3,5-triazine",C1=CC=C(C=C1)CC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9164,19165,3-Phenoxytoluene,CC1=CC(=CC=C1)OC2=CC=CC=C2,,,,,,
9165,19166,2-Ethylacrylic acid,CCC(=C)C(=O)O,,,,,,
9166,19167,Asomate,CN(C)C(=S)S[As](SC(=S)N(C)C)SC(=S)N(C)C,,,,,,
9167,19168,2-Nitroanthracene,C1=CC=C2C=C3C=C(C=CC3=CC2=C1)[N+](=O)[O-],,,,,,
9168,19169,"2,3-Dimethoxy-1,3-butadiene",COC(=C)C(=C)OC,,,,,,
9169,19170,"3-Chloro-N,N-dimethyl-10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-propylamine hydrochloride",C[NH+](C)CCCC1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
9170,19171,"3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-5-propylamine",CN(C)CCCC1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,,,,,,
9171,19172,"GLYCINE, N-(m-NITROPHENYL)-, ETHYL ESTER",CCOC(=O)CNC1=CC(=CC=C1)[N+](=O)[O-],,,,,,
9172,19173,"GLYCINE, N-(p-NITROPHENYL)-, ETHYL ESTER",CCOC(=O)CNC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
9173,19174,"13-Methyl-17-(oxan-2-yloxy)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol",CC12CCC3C(C1CCC2OC4CCCCO4)CCC5=C3C=CC(=C5)O,,,,,,
9174,19175,Acetyl sulfamethoxypyrazine,CC(=O)N(C1=NC=CN=C1OC)S(=O)(=O)C2=CC=C(C=C2)N,,,,,,
9175,19176,"N,N-Bis(2-chloropropyl)amine hydrochloride",CC(C[NH2+]CC(C)Cl)Cl.[Cl-],,,,,,
9176,19177,"N,N-bis(2-chloro-n-propyl)amine",CC(CNCC(C)Cl)Cl,,,,,,
9177,19178,N-Propylcyclohexanamine,CCCNC1CCCCC1,,,,,,
9178,19179,Butyltripropylammonium iodide,CCCC[N+](CCC)(CCC)CCC.[I-],,,,,,
9179,19180,Butyltripropylaminium,CCCC[N+](CCC)(CCC)CCC,,,,,,
9180,19181,"(+-)-3,4-Dihydroxy-alpha-((ethylamino)methyl)benzyl alcohol hydrochloride",CC[NH2+]CC(C1=CC(=C(C=C1)O)O)O.[Cl-],,,,,,
9181,19182,"Benzylamine, p-chloro-N,N-bis(2-chloroethyl)-, hydrochloride",C1=CC(=CC=C1C[NH+](CCCl)CCCl)Cl.[Cl-],,,,,,
9182,19183,"BENZYLAMINE, N,N-BIS(2-CHLOROETHYL)-p-CHLORO-",C1=CC(=CC=C1CN(CCCl)CCCl)Cl,,,,,,
9183,19184,p-Methyl-di-(2-chloroethyl)-benzylamine hydrochloride,CC1=CC=C(C=C1)C[NH+](CCCl)CCCl.[Cl-],,,,,,
9184,19185,"BENZYLAMINE, N,N-BIS(2-CHLOROETHYL)-p-METHYL-",CC1=CC=C(C=C1)CN(CCCl)CCCl,,,,,,
9185,19186,4-Biphenylmethanol,C1=CC=C(C=C1)C2=CC=C(C=C2)CO,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
9186,19187,CID 19187,C1=CC=C(C=C1)OCC(=O)[O-].[Na+],,,,,,
9187,19188,Phenoxyacetic acid,C1=CC=C(C=C1)OCC(=O)O,,,,,,
9188,19189,1-(10-(3-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone maleate;1-(10-(3-(dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone maleate,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C.C(=CC(=O)O)C(=O)O,,,,,,
9189,19190,Cardio-Green,CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])C=CC=CC=CC=C4C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['FOLLOWING IV INJECTION, INDOCYANINE GREEN IS RAPIDLY BOUND TO PLASMA PROTEIN, QUICKLY REMOVED FROM CIRCULATION BY LIVER, & EXCRETED IN BILE IN UNCONJUGATED FORM.', 'WITH INDOCYANINE GREEN, IT HAS BEEN SHOWN THAT RAT HAS HIGHER MAX BILIARY EXCRETION RATE (0.065 MG/KG/MIN) THAN DOES RABBIT (0.05 MG/KG/MIN) OR DOG (0.027 MG/KG/MIN).', 'T/2 INCR WITH INCR DOSAGE. ... CONSIDERABLE DIFFERENCE HAS BEEN NOTED BETWEEN NORMAL MONGRELS & PUREBRED BEAGLES IN CLEARANCE TIMES.', 'APPARENT HEPATIC EXTRACTION OF INDOCYANINE GREEN IN RATS WAS SURPRISINGLY LOW @ DOSES ABOVE 1 MG/KG. CHANGES IN HEPATIC BLOOD FLOW WOULD NOT ALTER CLEARANCE.', 'For more Absorption, Distribution and Excretion (Complete) data for INDOCYANINE GREEN (10 total), please visit the HSDB record page.']",['...INDOCYANINE GREEN...APPEARS IN BILE UNCHANGED'],
9190,19191,"2-[7-[1,1-Dimethyl-3-(4-sulfobutyl)-1H-benzo[e]indole-2(3H)-ylidene]-1,3,5-heptatrienyl]-3-(4-sulfonatobutyl)-1,1-dimethyl-1H-benzo[e]indole-3-ium",CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)O)C=CC=CC=CC=C4C(C5=C(N4CCCCS(=O)(=O)O)C=CC6=CC=CC=C65)(C)C)C,,,,,,
9191,19192,"2,4-Dichlorophenoxyacetic acid ethanolamine salt",C1=CC(=C(C=C1Cl)Cl)OCC(=O)[O-].C(CO)[NH3+],,,,,,
9192,19193,"2-Ethyl-1,3,5-triazine",CCC1=NC=NC=N1,,,,,,
9193,19194,"2,4-Diethyl-1,3,5-triazine",CCC1=NC(=NC=N1)CC,,,,,,
9194,19195,"2,4-Dimethyl-6-phenyl-1,3,5-triazine",CC1=NC(=NC(=N1)C2=CC=CC=C2)C,,,,,,
9195,19196,"2-Methyl-4,6-diphenyl-1,3,5-triazine",CC1=NC(=NC(=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9196,19197,"2-Methoxy-4,6-dimethyl-1,3,5-triazine",CC1=NC(=NC(=N1)OC)C,,,,,,
9197,19198,"2-Ethyl-4,6-bis(trichloromethyl)-1,3,5-triazine",CCC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9198,19199,"2-(3-Nitrophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C1=CC(=CC(=C1)[N+](=O)[O-])C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9199,19200,"2-Pyridin-4-yl-4,6-bis(trichloromethyl)-1,3,5-triazine",C1=CN=CC=C1C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9200,19201,"2,4-Bis(trichloromethyl)-1,3,5-triazine",C1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9201,19202,"N-(4-Chlorophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazin-2-amine",C1=CC(=CC=C1NC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
9202,19203,"2-Methylthio-4,6-bis(trichloromethyl)-s-triazine",CSC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9203,19204,"2-Phenyl-4-(p-tolyl)-6-trichloromethyl-1,3,5-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=CC=C3)C(Cl)(Cl)Cl,,,,,,
9204,19205,"2-(4-Chlorophenyl)-4-phenyl-6-trichloromethyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C3=CC=C(C=C3)Cl,,,,,,
9205,19206,"2-(3-Nitrophenyl)-4-phenyl-6-(trichloromethyl)-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C3=CC(=CC=C3)[N+](=O)[O-],,,,,,
9206,19207,"2-(4-Methoxyphenyl)-4-phenyl-6-(trichloromethyl)-1,3,5-triazine",COC1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=CC=C3)C(Cl)(Cl)Cl,,,,,,
9207,19208,"2-Methyl-1,3,5-triazine",CC1=NC=NC=N1,,,,,,
9208,19209,"p-Cresol, 2-methoxy-alpha-(4-(2-pyrimidinyl)-1-piperazinyl)-, hydrochloride, hydrate (2:4:1)",COC1=C(C=CC(=C1)CN2CCN(CC2)C3=NC=CC=N3)O.Cl.Cl,,,,,,
9209,19210,2-Methoxy-4-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenol,COC1=C(C=CC(=C1)CN2CCN(CC2)C3=NC=CC=N3)O,,,,,,
9210,19211,"2-tert-Butyl-1,4-benzoquinone",CC(C)(C)C1=CC(=O)C=CC1=O,,,,,,
9211,19212,Ecdysone,C[C@@H]([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)[C@@H](CCC(C)(C)O)O,,,,,,
9212,19213,"5,8-Dichloronaphthalen-1-amine",C1=CC2=C(C=CC(=C2C(=C1)N)Cl)Cl,,,,,,
9213,19214,1-(3-Chloro-4-methylphenyl)-4-[2-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethylsulfonyl]ethyl]piperazine,CC1=C(C=C(C=C1)N2CCN(CC2)CCS(=O)(=O)CCN3CCN(CC3)C4=CC(=C(C=C4)C)Cl)Cl,,,,,,
9214,19215,"1,1,1,3,3,3-Hexachloropropane",C(C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
9215,19216,CID 19216,CCCCCCC(=NN=C(N)S)C1=CC=NC=C1,,,,,,
9216,19217,Benzo[b]thiophene-4-ol,C1=CC(=C2C=CSC2=C1)O,,,,,,
9217,19218,Triethylene glycol monomethyl ether acetate,CC(=O)OCCOCCOCCOC,,,,,,
9218,19219,"1H-Indole-3-ethanamine, 4-methoxy-",COC1=CC=CC2=C1C(=CN2)CCN,,,,,,
9219,19220,1-Benzyl-4-piperidone,C1CN(CCC1=O)CC2=CC=CC=C2,,,,,,
9220,19221,"Nicotinic acid, ethylene ester",C1=CC(=CN=C1)C(=O)OCCOC(=O)C2=CN=CC=C2,,,,,,
9221,19222,Etofibrate 2-hydroxymethylnicotinate,C1=CC(=CN=C1)C(=O)OCCO,,,,,,
9222,19223,"7-Methoxy-3,7-dimethyloctanal",CC(CCCC(C)(C)OC)CC=O,,,,,,
9223,19224,"Acetanilide, 2,2-dichloro-4'-hydroxy-N-(2-hydroxyethyl)-",C1=CC(=CC=C1N(CCO)C(=O)C(Cl)Cl)O,,,,,,
9224,19225,"Acetanilide, 2,2-dichloro-2'-hydroxy-N-(2-hydroxyethyl)-",C1=CC=C(C(=C1)N(CCO)C(=O)C(Cl)Cl)O,,,,,,
9225,19226,"ACETAMIDE, N-ISOPROPYL-N-(p-(METHYLSULFONYL)BENZYL)-",CC(C)N(CC1=CC=C(C=C1)S(=O)(=O)C)C(=O)C,,,,,,
9226,19227,"N,N'-Bis(dichloroacetyl)-N,N'-diethyl-1,6-hexanediamine",CCN(CCCCCCN(CC)C(=O)C(Cl)Cl)C(=O)C(Cl)Cl,,,,,,
9227,19228,"N,N-Diethyl-2-phenoxyacetamide",CCN(CC)C(=O)COC1=CC=CC=C1,,,,,,
9228,19229,"Acetanilide, 2-(diethylamino)-4'-hydroxy-N-methyl-",CCN(CC)CC(=O)N(C)C1=CC=C(C=C1)O,,,,,,
9229,19230,"Ammonium, hexamethylenebis(dimethylethyl-, dibromide",CC[N+](C)(C)CCCCCC[N+](C)(C)CC.[Br-].[Br-],,,,,,
9230,19231,Hexamethylenebis(dimethylethylaminium),CC[N+](C)(C)CCCCCC[N+](C)(C)CC,,,,,,
9231,19232,Chlorflurazole,C1=CC(=C(C2=C1NC(=N2)C(F)(F)F)Cl)Cl,,,,"['FOLLOWING ORAL ADMIN TO RATS & RABBITS OF (14)C-LABELED 4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE, (14)C WAS EXCRETED IN THE URINE IN 3 DAYS.']","['YIELDS 4,5-DICHLORO-6-HYDROXY-2-TRIFLUOROMETHYLBENZIMIDAZOLE & 4,5-DICHLORO-7-HYDROXY-2-TRIFLUOROMETHYLBENZIMIDAZOLE IN RABBIT & RAT. /FROM TABLE/', 'MICROSOMAL MIXED FUNCTION OXIDASES OF MOUSE LIVER HYDROXYLATED THE BENZENE MOIETY OF CHLOROFLUORAZOLE. URINE OF RATS ADMIN 1.5 MG ORALLY CONTAINED 6-HYDROXY-4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE CONJUGATES MAJOR, 7-HYDROXY-4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE CONJUGATES MINOR, & 5-HYDROXY-4,6-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE CONJUGATES MINOR.', '1ST 24-HR URINARY METAB AFTER ORAL ADMIN TO RABBITS & RATS CONTAINED AFTER ACID HYDROLYSIS 7-HYDROXY-4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE, 6-HYDROXY-4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE, & 6,7-DIOXO-4,5-DICHLORO-2-TRIFLUOROMETHYLBENZIMIDAZOLE GLUCURONIDES & SULFATES']",
9232,19233,"(2R,3R,4S,5S)-2,3,4,5-tetrahydroxyhexanal",C[C@@H]([C@@H]([C@H]([C@H](C=O)O)O)O)O,,,,,,
9233,19234,Phytin,C1(C(C(C(C(C1OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Mg+2].[Ca+2],,,,,,
9234,19235,UDP-xylose,C1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O)O)O,,,,,,
9235,19236,Cyclic cmp,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)OP(=O)(O1)O,,,,,,
9236,19237,Sodium 3-hydroxy-4-((2-hydroxynaphthyl)azo)-7-nitronaphthalene-1-sulphonate,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C4C=CC(=CC4=C(C=C3)S(=O)(=O)[O-])[N+](=O)[O-])O.[Na+],,,,,,
9237,19238,4-[(2-Hydroxynaphthalen-1-yl)diazenyl]-7-nitronaphthalene-1-sulfonic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C4C=CC(=CC4=C(C=C3)S(=O)(=O)O)[N+](=O)[O-])O,,,,,,
9238,19239,Isobutyric acid hydrazide,CC(C)C(=O)NN,,,,,,
9239,19240,Dimethylaminoethyl vinyl ether,CN(C)CCOC=C,,,,,,
9240,19241,N-Butylbenzenesulfonamide,CCCCNS(=O)(=O)C1=CC=CC=C1,,,"['Materials incorporated mechanically in plastics (usually PVC) to increase flexibility, workability or distensibility; due to the non-chemical inclusion, plasticizers leach out from the plastic and are found in body fluids and the general environment. (See all compounds classified as Plasticizers.)', 'Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
9241,19242,4-Methylcaprolactam,CC1CCCNC(=O)C1,,,,,,
9242,19243,Neomenthol,C[C@@H]1CC[C@@H](C(C1)O)C(C)C,,,,,,
9243,19244,Neoisomenthol,C[C@@H]1CC[C@@H]([C@@H](C1)O)C(C)C,,,,,,
9244,19245,"C.I. Mordant blue 9, disodium salt",C1=CC2=C(C=CC(=C2O)N=NC3=C(C(=CC(=C3)Cl)S(=O)(=O)[O-])O)C(=C1)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
9245,19246,6-[(5-Chloro-2-hydroxy-3-sulfophenyl)diazenyl]-5-hydroxynaphthalene-1-sulfonic acid,C1=CC2=C(C=CC(=C2O)N=NC3=C(C(=CC(=C3)Cl)S(=O)(=O)O)O)C(=C1)S(=O)(=O)O,,,,,,
9246,19247,Metabutoxycaine,CCCCOC1=C(C=CC=C1N)C(=O)OCCN(CC)CC,,,,,,
9247,19248,CID 19248,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCSC3=CC=CC=C3C(=O)[O-].[Na+],,,,,,
9248,19249,"2-[2-(1,3-Dimethyl-2,6-dioxopurin-7-yl)ethylsulfanyl]benzoic acid",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCSC3=CC=CC=C3C(=O)O,,,,,,
9249,19250,Biallylamicol hydrochloride,CC[NH+](CC)CC1=CC(=CC(=C1O)CC=C)C2=CC(=C(C(=C2)C[NH+](CC)CC)O)CC=C.[Cl-].[Cl-],,,,,,
9250,19251,"5-(1,3-Dimethyl-2-butenyl)-5-ethylbarbituric acid",CCC1(C(=O)NC(=O)NC1=O)C(C)C=C(C)C,,,,,,
9251,19252,"Barbituric acid, 5,5-diallyl-1-benzyl-3-(2-(diethylamino)ethyl)-, hydrochloride",CC[NH+](CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)CC=C.[Cl-],,,,,,
9252,19253,"5,5-Diallyl-1-benzyl-3-[2-(diethylamino)ethyl]barbituric acid",CCN(CC)CCN1C(=O)C(C(=O)N(C1=O)CC2=CC=CC=C2)(CC=C)CC=C,,,,,,
9253,19254,Reposal,CCC1(C(=O)NC(=O)NC1=O)C2=CC3CCC(C3)C2,,,,,,
9254,19255,Dotriacontanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
9255,19256,Nile Blue A,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=C1)CC.CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)N)OC2=C1)CC.[O-]S(=O)(=O)[O-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
9256,19257,CID 19257,C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=CC=C(C=C6)O)C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
9257,19258,CID 19258,C1=CC=C(C=C1)NN=C2C(=CC3=C(C2=O)C(=N)C(=NNC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=CC=C(C=C6)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
9258,19259,4-Phenylpiperidine-4-carboxylic acid,C1CNCCC1(C2=CC=CC=C2)C(=O)O,,,,,,
9259,19260,Phenoperidine hydrochloride,CCOC(=O)C1(CCN(CC1)CCC(C2=CC=CC=C2)O)C3=CC=CC=C3.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)']",,,
9260,19261,"Magnesium;2,3,4,5,6-pentahydroxyhexanoate",C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Mg+2],,,,,,
9261,19262,"1,3-Bis(isocyanatomethyl)benzene",C1=CC(=CC(=C1)CN=C=O)CN=C=O,,,,,,
9262,19263,((3-((o-Chlorophenoxy)methyl)-3-oxetanyl)methyl)diethylmethylammonium bromide,CC[N+](C)(CC)CC1(COC1)COC2=CC=CC=C2Cl.[Br-],,,,,,
9263,19264,[3-[(2-Chlorophenoxy)methyl]oxetan-3-yl]methyl-diethyl-methylazanium,CC[N+](C)(CC)CC1(COC1)COC2=CC=CC=C2Cl,,,,,,
9264,19265,Deanol acetamidobenzoate,CC(=O)NC1=CC=C(C=C1)C(=O)O.CN(C)CCO,,,,,,
9265,19266,4-Acetamidobenzoic acid,CC(=O)NC1=CC=C(C=C1)C(=O)O,,,,,,
9266,19267,"2,4-Dichloro-6-methoxy-1,3,5-triazine",COC1=NC(=NC(=N1)Cl)Cl,,,,,,
9267,19268,"[(17S)-17-ethyl-17-hydroxy-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] propanoate",CCC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CC[C@]4(CC)O)C,,,,,,
9268,19269,"3,4-Dihydro-1-isoquinolineacetamide",C1CN=C(C2=CC=CC=C21)CC(=O)N,,,,,,
9269,19270,"10-(Cyclobutylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol",CC1C2CC3=C(C1(CCN2CC4CCC4)C)C=C(C=C3)O,,,,,,
9270,19271,DL-alpha-Amino-3-carboxy-4-methoxy-hydrocinnamic acid hydrochloride,COC1=C(C=C(C=C1)CC(C(=O)O)N)C(=O)O.Cl,,,,,,
9271,19272,"Alanine, 3-carboxy-4-methoxyphenyl-, DL-",COC1=C(C=C(C=C1)CC(C(=O)O)N)C(=O)O,,,,,,
9272,19273,"6-Methylpregn-4-ene-3,11,20-trione",CC1CC2C3CCC(C3(CC(=O)C2C4(C1=CC(=O)CC4)C)C)C(=O)C,,,,,,
9273,19274,Cetadiol,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H](C2)O)CC=C4[C@@]3(CC[C@@H](C4)O)C,,,,,,
9274,19275,Oxogestone,C[C@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)O,,,,,,
9275,19276,"2,8-Dichloro-6,12-diphenyldibenzo[b,f][1,5]diazocine",C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)C(=NC4=C2C=C(C=C4)Cl)C5=CC=CC=C5,,,,,,
9276,19277,"1-AZIRIDINECARBOXAMIDE, N-(o-METHOXYPHENYL)-",COC1=CC=CC=C1NC(=O)N2CC2,,,,,,
9277,19278,"1-AZIRIDINECARBOXAMIDE, N-(p-METHOXYPHENYL)-",COC1=CC=C(C=C1)NC(=O)N2CC2,,,,,,
9278,19279,"1-Aziridinecarboxamide, N-(3-chlorophenyl)-",C1CN1C(=O)NC2=CC(=CC=C2)Cl,,,,,,
9279,19280,"1-Aziridinecarboxamide, N-(4-chlorophenyl)-",C1CN1C(=O)NC2=CC=C(C=C2)Cl,,,,,,
9280,19281,"1-AZIRIDINECARBOXAMIDE, N-(p-NITROPHENYL)-",C1CN1C(=O)NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
9281,19282,N-naphthalen-1-ylazirine-1-carboxamide,C1=CC=C2C(=C1)C=CC=C2NC(=O)N3C=C3,,,,,,
9282,19283,Diundecyl phthalate,CCCCCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCCCCC,,,,,,
9283,19284,Diheptyl phthalate,CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC,,,,,,
9284,19285,"3H-Indolium, 2-[2-[4-[(2-chloroethyl)methylamino]phenyl]ethenyl]-1,3,3-trimethyl-, chloride (1:1)",CC1(C2=CC=CC=C2[N+](=C1C=CC3=CC=C(C=C3)N(C)CCCl)C)C.[Cl-],,,,,,
9285,19286,"N-(2-chloroethyl)-N-methyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]aniline",CC1(C2=CC=CC=C2[N+](=C1C=CC3=CC=C(C=C3)N(C)CCCl)C)C,,,,,,
9286,19287,"Methyl podocarpa-8,11,13-triem-15-oate",C[C@]12CCC[C@](C1CCC3=CC=CC=C23)(C)C(=O)OC,,,,,,
9287,19288,Diallyldichlorosilane,C=CC[Si](CC=C)(Cl)Cl,,,,,,
9288,19289,"Acetamide, N-(5-(4-pyridyl)-1,3,4-thiadiazol-2-YL)-",CC(=O)NC1=NN=C(S1)C2=CC=NC=C2,,,,,,
9289,19290,2-Methyl-9H-carbazole,CC1=CC2=C(C=C1)C3=CC=CC=C3N2,,,,,,
9290,19291,"2-(1,4-Benzodioxan-2-ylmethyl)hexahydro-1H-azepine",C1CCCN(CC1)CC2COC3=CC=CC=C3O2,,,,,,
9291,19292,CID 19292,CC1=C(C=CC(=C1)Cl)OCC(=O)[O-].[Na+],,,,,,
9292,19293,"[2-[Acetyl-[(4-methylsulfonylphenyl)methyl]amino]-2,2-dichloroethyl] 2,2-dichloroacetate",CC(=O)N(CC1=CC=C(C=C1)S(=O)(=O)C)C(COC(=O)C(Cl)Cl)(Cl)Cl,,,,,,
9293,19294,Disodium lauriminodipropionate,CCCCCCCCCCCCN(CCC(=O)[O-])CCC(=O)[O-].[Na+].[Na+],,,,,,
9294,19295,N-(2-Carboxyethyl)-N-dodecyl-beta-alanine,CCCCCCCCCCCCN(CCC(=O)O)CCC(=O)O,,,,,,
9295,19296,"5-Carboxymethyl-3-methyl-2H-1,3,5-thiadiazine-2-thione",CN1CN(CSC1=S)CC(=O)O,,,,,,
9296,19297,Methyl(phenylazo)malononitrile,C1=CC=C(C=C1)N=NCC(C#N)C#N,,,,,,
9297,19298,Methyl(m-tolylazo)malononitrile,CC1=CC(=CC=C1)N=NCC(C#N)C#N,,,,,,
9298,19299,Methyl(p-tolylazo)malononitrile,CC1=CC=C(C=C1)N=NCC(C#N)C#N,,,,,,
9299,19300,((o-Chlorophenyl)azo)methylmalononitrile,C1=CC=C(C(=C1)N=NCC(C#N)C#N)Cl,,,,,,
9300,19301,((m-Chlorophenyl)azo)methylmalononitrile,C1=CC(=CC(=C1)Cl)N=NCC(C#N)C#N,,,,,,
9301,19302,((p-Chlorophenyl)azo)methylmalononitrile,C1=CC(=CC=C1N=NCC(C#N)C#N)Cl,,,,,,
9302,19303,Ethyl(phenylazo)malononitrile,C1=CC=C(C=C1)N=NCCC(C#N)C#N,,,,,,
9303,19304,Ethyl(o-tolylazo)malononitrile,CC1=CC=CC=C1N=NCCC(C#N)C#N,,,,,,
9304,19305,Ethyl(m-tolylazo)malononitrile,CC1=CC(=CC=C1)N=NCCC(C#N)C#N,,,,,,
9305,19306,Ethyl(p-tolylazo)malononitrile,CC1=CC=C(C=C1)N=NCCC(C#N)C#N,,,,,,
9306,19307,"Bicarbamimide, N-cyclohexyl-2-phenyl-",C1CCC(CC1)N2C(=O)NC(=O)N2C3=CC=CC=C3,,,,,,
9307,19308,Phosphorous acid bis(2-ethylhexyl) ester,CCCCC(CC)COP(O)OCC(CC)CCCC,,,,,,
9308,19309,Furaneol,CC1C(=O)C(=C(O1)C)O,,,,"[""2,5-Dimethyl-4-hydroxy-3[2H]furanone (Furaneol, DMHF) [3658-77-3], an important flavor constituent of strawberry fruit, was administered to four male and two female volunteers using fresh strawberries as a natural DMHF source. The amount excreted was determined by measuring urinary levels of DMHF and DMHF glucuronide. DMHF glucuronide was synthesized and the structure elucidated by mens of (1)H, (13)C and two dimensional nuclear magnetic resonance, as well as mass spectral data. Identification and quantification of DMHF glucuronide in human urine were achieved after solid phase extraction on XAD-2 using reverse-phase reverse-phase HPLC with either on-line UV/VIS or electrospray tandem mass spectrometry detection. Male and female volunteers excreted 59-69% and 81-94%, respectively, of the DMHF dose (total of free and glycosidically bound DMHF in strawberries) as DMHF glucuronide in urine within 24 hr. The amount of DMHF excretion was independent of the dose size and the ratio of free to glycosidically bound forms of DMHF in strawberry fruit. DMHF, DMHF glucoside and its 6'-O-malonyl derivative, naturally occurring in strawberries, were not detected in human urine."", 'Fragrant hydroxyfuranone and dihydroxypyranone derivatives generated in the Maillard reaction of sugars and amino acids are detected in various processed foods and have been shown active to break DNA single-strand in the in vitro studies. In the present study, absorption of 2,5-dimethyl-4-hydroxy-3(2 H)-furanone (DMHF) and 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2 H)-furanone (HEMF), both found in soy sauce, into plasma after a single intraperitoneal or oral administration at doses of 0.5-1.0 g/kg to mice was examined. Both compounds appeared in plasma 15 min after intraperitoneal administration and disappeared 2 hr after the administration. They appeared in plasma 5 min after oral administration, reached maximum after 15-45 min, and gradually disappeared after 2 h, indicating that they are absorbed by the digestive tract. Both DMHF and HEMF induced micronucleated reticulocytes (MNRETs) in mouse peripheral blood in a dose-dependent manner after oral administration. The results indicate that DMHF and HEMF can cause genetic damage after oral administration.', '4-Hydroxy-2,5-dimethyl-3(2H)-furanone is expected to share the same metabolic fate as the primary material, i.e. conjugation with glucuronic acid and excretion in the urine.']","['4-Hydroxy-2,5-dimethyl-3(2H)-furanone is expected to share the same metabolic fate as the primary material, i.e. conjugation with glucuronic acid and excretion in the urine.']",
9309,19310,Dimethyl trisulfide,CSSSC,,,,,,
9310,19311,"Carbamic acid, dimethyldithio-, acetamidomethyl ester",CC(=O)NCSC(=S)N(C)C,,,,,,
9311,19312,"N-(1,2,2,2-Tetrachloroethyl)formamide",C(=O)NC(C(Cl)(Cl)Cl)Cl,,,,,,
9312,19313,"4-Butylbenzene-1,2-diamine",CCCCC1=CC(=C(C=C1)N)N,,,,,,
9313,19314,"2-Hydroxymethyl-1,4-benzodioxane",C1C(OC2=CC=CC=C2O1)CO,,,,,,
9314,19315,7-Octen-2-one,CC(=O)CCCCC=C,,,,,,
9315,19316,"4,8-Dimethyl-7-nonen-2-one",CC(CCC=C(C)C)CC(=O)C,,,,,,
9316,19317,3-Hydroxy-2-naphthamide,C1=CC=C2C=C(C(=CC2=C1)C(=O)N)O,,,,,,
9317,19318,N-Ethyl-4-nitroaniline,CCNC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
9318,19319,"beta-8-Methyl-8-phenyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC1(CCC2(CC1)OCC(O2)C3CCCC[NH2+]3)C4=CC=CC=C4.[Cl-],,,,,,
9319,19320,"2-(8-Methyl-8-phenyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC1(CCC2(CC1)OCC(O2)C3CCCCN3)C4=CC=CC=C4,,,,,,
9320,19321,"2,2-Dibenzyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)(CC3=CC=CC=C3)CC4=CC=CC=C4.[Cl-],,,,,,
9321,19322,"2-(2,2-Dibenzyl-1,3-dioxolan-4-yl)piperidine",C1CCNC(C1)C2COC(O2)(CC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
9322,19323,"2-(2-Ethyl-2-phenyl-1,3-dioxolan-4-yl)piperidin-1-ium;chloride",CCC1(OCC(O1)C2CCCC[NH2+]2)C3=CC=CC=C3.[Cl-],,,,,,
9323,19324,"2-(2-Ethyl-2-phenyl-1,3-dioxolan-4-yl)piperidine",CCC1(OCC(O1)C2CCCCN2)C3=CC=CC=C3,,,,,,
9324,19325,"1,3-DIOXOLANE, 2-DIPHENYLMETHYL-2-METHYL-4-(2-PIPERIDYL)-, HYDROCHLORIDE, beta-",CC1(OCC(O1)C2CCCC[NH2+]2)C(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9325,19326,"2-(2-Benzhydryl-2-methyl-1,3-dioxolan-4-yl)piperidine",CC1(OCC(O1)C2CCCCN2)C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9326,19327,"alpha-2-Benzyl-2-phenyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)(CC3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9327,19328,"2-(2-Benzyl-2-phenyl-1,3-dioxolan-4-yl)piperidine",C1CCNC(C1)C2COC(O2)(CC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9328,19329,"beta-4-(1-(2-Diethylaminoethyl)-2-piperidyl)-2,2-diphenyl-1,3-dioxolane dihydrochloride",CCN(CC)CCC1CC[NH2+]C(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9329,19330,"2-[2-(2,2-diphenyl-1,3-dioxolan-4-yl)piperidin-4-yl]-N,N-diethylethanamine",CCN(CC)CCC1CCNC(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9330,19331,"1-Adamantanamine, N-isopropyl-, hydrochloride",CC(C)NC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
9331,19332,"Tricyclo(3.3.1.1(3,7))decan-1-amine, N-(1-methylethyl)-",CC(C)NC12CC3CC(C1)CC(C3)C2,,,,,,
9332,19333,(p-Methoxyphenyl)phenylacetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
9333,19334,2-(Diethylamino)ethyl 2-(4-methoxyphenyl)-2-phenylacetate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=C(C=C2)OC,,,,,,
9334,19335,N-Hydroxy-3-phenyl-2-propenamide,C1=CC=C(C=C1)C=CC(=O)NO,,,,,,
9335,19336,CID 19336,C1=CC=C(C=C1)CC(=NN=C(N)S)C2=CC=NC=C2,,,,,,
9336,19337,"Indole, 3-(1-methyl-3-pyrrolidinyl)-",CN1CCC(C1)C2=CNC3=CC=CC=C32,,,,,,
9337,19338,3-(1-ethylpyrrolidin-3-yl)-1H-indole,CCN1CCC(C1)C2=CNC3=CC=CC=C32,,,,,,
9338,19339,"Indole, 3-(1-(2-morpholinoethyl)-3-pyrrolidinyl)-, dihydrochloride",C1C[NH+](CC1C2=CNC3=CC=CC=C32)CC[NH+]4CCOCC4.[Cl-].[Cl-],,,,,,
9339,19340,3-(1-(2-(4-morpholinyl)ethyl)-3-pyrrolidinyl)-1H-indole,C1CN(CC1C2=CNC3=CC=CC=C32)CCN4CCOCC4,,,,,,
9340,19341,"Benzimidazole, 6-chloro-4-nitro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)[N+](=O)[O-])Cl,,,,,,
9341,19342,"Benzimidazole, 5-fluoro-2-(trifluoromethyl)-",C1=CC2=C(C=C1F)NC(=N2)C(F)(F)F,,,,,,
9342,19343,5-Bromo-2-(trifluoromethyl)-1H-benzimidazole,C1=CC2=C(C=C1Br)NC(=N2)C(F)(F)F,,,,,,
9343,19344,"Benzimidazole-5-carbonitrile, 2-(trifluoromethyl)-",C1=CC2=C(C=C1C#N)NC(=N2)C(F)(F)F,,,,,,
9344,19345,5-Amino-2-(trifluoromethyl)benzimidazole,C1=CC2=C(C=C1N)NC(=N2)C(F)(F)F,,,,,,
9345,19346,"BENZIMIDAZOLE, 5-tert-BUTYL-2-(TRIFLUOROMETHYL)-",CC(C)(C)C1=CC2=C(C=C1)N=C(N2)C(F)(F)F,,,,,,
9346,19347,N-Hydroxy-N-(2-fluorenyl)benzamide,C1C2=CC=CC=C2C3=C1C=C(C=C3)N(C(=O)C4=CC=CC=C4)O,,,,,,
9347,19348,"alpha-(Aminomethyl)-3,4-dichlorobenzyl alcohol hydrochloride",C1=CC(=C(C=C1C(C[NH3+])O)Cl)Cl.[Cl-],,,,,,
9348,19349,"alpha-(Aminomethyl)-3,4-dichlorobenzyl alcohol",C1=CC(=C(C=C1C(CN)O)Cl)Cl,,,,,,
9349,19350,"2,3,5-Trimethylphenanthrene",CC1=C2C(=CC=C1)C=CC3=C2C=C(C(=C3)C)C,,,,,,
9350,19351,2-Ethylphenanthrene,CCC1=CC2=C(C=C1)C3=CC=CC=C3C=C2,,,,,,
9351,19352,9-Ethylphenanthrene,CCC1=CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
9352,19353,CID 19353,CC(=NNC(=O)C1=CC=NC=C1)C(=O)[O-].[Na+],,,,,,
9353,19354,Methyl vinyl sulfone,CS(=O)(=O)C=C,,,,,,
9354,19355,CID 19355,C1=CC2=C(C=C1N(O)O)C(=O)N=NC2=O,,,,,,
9355,19356,2-(Phenylazo)benzoic acid,C1=CC=C(C=C1)N=NC2=CC=CC=C2C(=O)O,,,,,,
9356,19357,CID 19357,C1=CSN=C1C=NN=C(N)S,,,,,,
9357,19358,CID 19358,CC1=NSC(=C1Br)C(=NN=C(N)S)C,,,,,,
9358,19359,CID 19359,CC1=NSC(=C1)C=NNC(=NCCCOC)S,,,,,,
9359,19360,CID 19360,CC1=NSC(=C1)C=NN=C(N(C)C)S,,,,,,
9360,19361,CID 19361,CC1=NSC(=C1Br)C=NN=C(N)SC.[I-],,,,,,
9361,19362,CID 19362,CC1=NSC(=C1Br)C=NN=C(N)SC,,,,,,
9362,19363,CID 19363,C1=C(SN=C1)C=NN=C(N)S,,,,,,
9363,19364,CID 19364,CC1=NSC=C1C=NN=C(N)S,,,,,,
9364,19365,CID 19365,CC1=NSC(=C1)C=NN=C(N)S,,,,,,
9365,19366,CID 19366,CC1=C(SN=C1)C=NN=C(N)S,,,,,,
9366,19367,CID 19367,CC(=NN=C(N)S)C1=CC=NS1,,,,,,
9367,19368,CID 19368,CC(=NN=C(N)S)C1=NSC=C1,,,,,,
9368,19369,CID 19369,CC1=NSC=C1C(=NN=C(N)S)C,,,,,,
9369,19370,CID 19370,CC1=NSC(=C1)C(=NN=C(N)S)C,,,,,,
9370,19371,CID 19371,C1=NSC(=C1Cl)C=NN=C(N)S,,,,,,
9371,19372,CID 19372,C1=NSC(=C1I)C=NN=C(N)S,,,,,,
9372,19373,CID 19373,CC(=NN=C(N)S)C1=NSC=C1Br,,,,,,
9373,19374,CID 19374,CC1=NSC(=C1Br)C(=NN=C(N2CCOCC2)S)C,,,,,,
9374,19375,2-Anilino-2-phenylacetic acid,C1=CC=C(C=C1)C(C(=O)O)NC2=CC=CC=C2,,,,,,
9375,19376,N-Nitrosomethylaminoacetonitrile,CN(CC#N)N=O,,,,,,
9376,19377,Diphenylacetic acid N-phenethyl-4-piperidyl ester hydrochloride,C1C[NH+](CCC1OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)CCC4=CC=CC=C4.[Cl-],,,,,,
9377,19378,"[1-(2-Phenylethyl)piperidin-4-yl] 2,2-diphenylacetate",C1CN(CCC1OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)CCC4=CC=CC=C4,,,,,,
9378,19379,Meclofenoxate hydrochloride,CN(C)CCOC(=O)COC1=CC=C(C=C1)Cl.Cl,,,"['Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
9379,19380,CID 19380,C1=CC(=CC=C1C(=O)[O-])Cl.[Na+],,,,,,
9380,19381,p-Propoxybenzoic acid 2-(1-pyrrolidinyl)ethyl ester hydrochloride,CCCOC1=CC=C(C=C1)C(=O)OCC[NH+]2CCCC2.[Cl-],,,,,,
9381,19382,2-Pyrrolidin-1-ylethyl 4-propoxybenzoate,CCCOC1=CC=C(C=C1)C(=O)OCCN2CCCC2,,,,,,
9382,19383,p-(p-Phenylphenacylideneamino)benzoic acid,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C=NC3=CC=C(C=C3)C(=O)O,,,,,,
9383,19384,"Benzoic acid, p-(methylsulfonyl)-, ester with 2,2-dichloro-4'-hydroxy-N-methylacetanilide",CN(C1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)S(=O)(=O)C)C(=O)C(Cl)Cl,,,,,,
9384,19385,"1,3,4-Oxadiazole-2(3H)-thione, 5-(4-amino-2-hydroxyphenyl)-",C1=CC(=C(C=C1N)O)C2N=NC(=S)O2,,,,,,
9385,19386,CID 19386,CCCCCCC(C)C1=CC(=C(C(=C1O)[N+](=O)[O-])C)[N+](=O)[O-],,,,,,
9386,19387,"3H-Indol-3-one, 5-bromo-2-(9-chloro-3-oxonaphtho[1,2-b]thien-2(3H)-ylidene)-1,2-dihydro-",C1=CC2=C(C(=C1)Cl)C3=C(C=C2)C(=C(S3)C4=NC5=C(C4=O)C=C(C=C5)Br)O,,,,,,
9387,19388,"1,2-Diisothiocyanatoethane",C(CN=C=S)N=C=S,,,,,,
9388,19389,Aminochlorambucil,C1=CC(=CC=C1CCC(C(=O)O)N)N(CCCl)CCCl,,,,,,
9389,19390,"2-Furanacetamide, alpha-[(5-nitro-2-furanyl)methylene]-",C1=COC(=C1)C(=CC2=CC=C(O2)[N+](=O)[O-])C(=O)N,,,,"['Following an oral dose of 1.3 mg/kg bw (14)C-AF-2 to rats, 83% of the radioactivity was excreted in the feces and 21% in the urine within 48 hr ... .']","['AF 2 WAS REDUCED TO THE CORRESPONDING RADICAL ANION BY XANTHINE OXIDASE, LIPOYL DEHYDROGENASE, DT-DIAPHORASE, OR LIVER MICROSOMES IN THE PRESENCE OF AN ELECTRON DONOR.', 'AFTER ORAL ADMIN OF 3 MG/KG DOSES OF 2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE IN RATS IT WAS MAINLY METABOLIZED IN SMALL INTESTINE. PERMEABILITY OF SMALL INTESTINE TO METABOLITES WAS LESS THAN THAT OF PARENT COMPD. XANTHINE OXIDASE WAS INVOLVED IN METAB.', 'AFTER ORAL ADMIN OF AF-2 TO RABBITS A METABOLITE WAS IDENTIFIED AS 2-(BETA-CARBOXYPROPIONYL)-3-(5-METHYLTHIO-2-FURYL)ACRYLAMIDE BY ITS MASS, IR & NMR SPECTRUM DATA. A SECOND METABOLITE THOUGHT TO BE CIS-TRANS ISOMER OF THE ABOVE WAS IDENTIFIED CONSIDERING ITS UV & MASS SPECTRAL DATA & BEHAVIOR ON TLC.', 'GENETIC ACTIVITY OF AF-2 IN BACTERIA & YEAST RAPIDLY DISAPPEARED IN PRESENCE OF RAT LIVER MICROSOMAL FRACTION (S9 MIX). INCUBATION WITH S9 MIX EVEN FOR 10 MINUTES AT 37 C WAS SUFFICIENT FOR COMPLETE INACTIVATION. ACTIVATION IS APPARENTLY NECESSARY FOR GENOTOXIC EFFECT. ACTIVATION STEP MAY INVOLVE REDUCTION OF NITROFURAN TO AN AMINO GROUP. MOST CULTURED CELL SYSTEMS, SUCH AS BACTERIA, YEAST, NEUROSPORA, MAMMALIAN CELLS & HUMAN LYMPHOCYTES, CAN PROBABLY BRING ABOUT THIS REDUCTION. RAPID DISAPPEARANCE OF GENETIC ACTIVITY OF AF-2 IN PRESENCE OF RAT LIVER HOMOGENATE SUGGESTS THAT RAT LIVER MICROSOMES MAY FURTHER METABOLIZE THE REDUCTION PRODUCTS TO INACTIVE FORMS.', 'For more Metabolism/Metabolites (Complete) data for FURYLFURAMIDE (7 total), please visit the HSDB record page.']",
9390,19391,"but-2-enedioic acid;1-N,1-N,2-N,2-N-tetramethyl-3-phenothiazin-10-ylpropane-1,2-diamine",CN(C)CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.C(=CC(=O)O)C(=O)O,,,,,,
9391,19392,Aminopromazine,CN(C)CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,,,,,,
9392,19393,CID 19393,C[N@@+]1(CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O)[O-],,,,,,
9393,19394,Diapamide,CNC(=O)C1=CC(=C(C=C1)Cl)S(=O)(=O)NC,,,,,,
9394,19395,Sulfotep,CCOP(=S)(OCC)OP(=S)(OCC)OCC,,,,"['Orally admin sulfotep was absorbed relatively quickly by rats. Elimination took place quickly via the kidney. The main elimination product is the diethylthiophosphate.', '... Based on what is known about other organophosphates, it is likely to be  well absorbed via all routes of exposures, rapidly oxidatively desulfurated to oxon  derivatives, and/or hydrolyzed to dimethyl thiophosphoric acid or diethyl phosphoric acids.']","['In plants: Major metabolites are monothiotep, tetraethylpyrophosphate, diethylthiophosphonic acid, & diethylphosphonic acid.']",
9395,19396,Oxomemazine,CC(CN1C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C31)CN(C)C,,,,,,
9396,19397,2-(Bis(beta-chloroethyl)aminomethyl)benzimidazole,C1=CC=C2C(=C1)NC(=N2)CN(CCCl)CCCl,,,,,,
9397,19398,Phenthoate oxon,CCOC(=O)C(C1=CC=CC=C1)SP(=O)(OC)OC,,,,,,
9398,19399,5-ethylidene-2(5H)-Furanone,CC=C1C=CC(=O)O1,,,,,,
9399,19400,N-(2-(Diethylamino)ethyl)benzamide,CCN(CC)CCNC(=O)C1=CC=CC=C1,,,,,,
9400,19401,Aethoxen,C=CC(CN1CC1)O,,,,,,
9401,19402,Chlorophacinone,C1=CC=C(C=C1)C(C2=CC=C(C=C2)Cl)C(=O)C3C(=O)C4=CC=CC=C4C3=O,,,"['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Substances used to destroy or inhibit the action of rats, mice, or other rodents. (See all compounds classified as Rodenticides.)']","['In mammals, following oral administration, 90% is eliminated in the feces within 48 hr in the form of metabolites.', 'Can be absorbed through skin.', 'In .../a/ blood kinetics assay, 4 rats each received orally 1 mg of (14)C-labeled chlorophacinone. The following mean blood concns were measured...: Mean Blood Concn (in ug equivalents): 1.4 (30 min), 2.4 (1 hr), 4.1 (2 hr), 6.4 (4 hr), 6.4 (6 hr), 5.9 (8 hr), 1.8 (24 hr), 0.3 (48 hr) /from table/. Chromatography and autoradiography demonstrated that the chlorophacinone remained unchanged in plasma, with a blood half-life of about 10 hours. Organs of the rats used in the ...blood kinetics study were assayed for radioactivity. The following results were obtained...: Mean concn of chlorophacinone (ug/g of organ): Liver 31.1 (4 hr), 2.9 (48 hr); Kidney 6.6 (4 hr), 1.2 (48 hr); Lung 4.5 (4 hr), 0.4 (48 hr); Heart 3.1 (4 hr), 0.2 (48 hr); Muscle (thigh) 2.0 (4 hr), 0.1 (48 hr; Fat 1.2 (4 hr), 0.7 (48 hr); Carcass 5.2 (4 hr), 0.3 (48 hr). /from table/', 'In a biliary excretion assay, two rats were used. Each received 1.4 mg of chlorophacinone intraduodenally. Bile was collected for 8 hours and total radioactivity was measured. TLC and autoradiography were performed on the bile directly before and after hydrolysis with glucuronidase. Two hours after administration of chlorophacinone in the duodenum, biliary elimination was constant. At the end of 8 hours, an average of 26% of the administered radioactivity was eliminated in the bile.']","['Warfarin is a widely used anticoagulant in the treatment and prevention of thrombosis, in the treatment for chronic atrial fibrillation, mechanical valves, pulmonary embolism, and dilated cardiomyopathy. It is tasteless and colorless, was used as a poison, and is still marketed as a pesticide against rats and mice. Several long-acting warfarin derivatives-superwarfarin anticoagulants-such as brodifacoum, diphenadione, chlorophacinone, bromadiolone, are used as pesticides and can produce profound and prolonged anticoagulation. Several factors increase the risk of warfarin toxicity. However, polymorphisms in cytochrome P450 genes and drug interactions account for most of the risk for toxicity complications. Each person is unique in their degree of susceptibility to toxic agents. The toxicity interpretation and the health risk of most toxic substances are a subject of uncertainty. Genetically determined low metabolic capacity in an individual can dramatically alter the toxin and metabolite levels from those normally expected, which is crucial for drugs with a narrow therapeutic index, like warfarin. Personalized approaches in interpretation have the potential to remove some of the scientific uncertainties in toxicity cases.', '/The objective was/ to assess the rate and extent of ruminal degradation of warfarin, chlorophacinone, and bromadiolone in vitro and determine the oral availability and clinical and hemostatic effects of each anticoagulant rodenticide in adult sheep... Samples of ruminal fluid were incubated with each of the anticoagulants to assess the kinetics of ruminal degradation over 24 hours. To determine the plasma kinetics of the anticoagulants, each /of 3/ sheep received each of the anticoagulants IV or via a rumenimplanted cannula at 2-month intervals (3 rodenticide exposures/sheep). At intervals during a 240- to 360- hour period after treatment, prothrombin time (PT) was measured, plasma anticoagulant concentration was assessed, and clinical signs of rodenticide poisoning were monitored. In plasma and rumen extracts, anticoagulant concentrations were determined via high-performance liquid chromatography... In the rumen extracts, anticoagulants were slightly degraded (< 15%) over 24 hours. In vivo, oral availability of warfarin, chlorophacinone, and bromadiolone was estimated at 79%, 92%, and 88%, respectively. Although maximum PT was 80 seconds after chlorophacinone and bromadiolone treatments, no clinical signs of toxicosis were detected; PT returned to baseline values within 2 weeks...  In sheep, warfarin, chlorophacinone, and bromadiolone were not degraded in the rumen but their bioavailabilities were high after oral administration; the kinetics of these compounds in sheep and other mammals are quite similar. These data suggest that the lack of susceptibility of ruminants to these anticoagulant rodenticides cannot be explained by either ruminal degradation or the specific toxicokinetics of these anticoagulants.', 'Long-acting compounds are metabolized by hepatic cytochrome P-450 isozymes (e.g., CYP3A4). /Long-Acting Rodenticides/']","['After intentional chlorophacinone ingestion, the plasma half-life was 6. to 22.8 days.', 'In .../a/ blood kinetics assay, 4 rats each received orally 1 mg of (14)C-labeled chlorophacinone. ...Chromatography and autoradiography demonstrated that the chlorophacinone remained unchanged in plasma, with a blood half-life of about 10 hours.', 'Half-life in blood /of rats/  0.4 days...Half-life in liver /of rats/ less than 2 days. /From table/']"
9402,19403,3-Propargyloxyphenyl-N-methyl-carbamate,CNC(=O)OC1=CC=CC(=C1)OCC#C,,,,,,
9403,19404,"3H-1,4-Benzodiazepine, 7-chloro-2-dimethylamino-5-phenyl-, 4-oxide",CN(C)C1=NC2=C(C=C(C=C2)Cl)C(=[N+](C1)[O-])C3=CC=CC=C3,,,,,,
9404,19405,2-Dibenzofuranamine,C1=CC=C2C(=C1)C3=C(O2)C=CC(=C3)N,,,,,,
9405,19406,"(4R,8S,12R,19S)-11,12-dichloro-19-fluoro-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC1(O[C@@H]2CC3C4C[C@@H](C5=CC(=O)C=CC5([C@]4(C(CC3([C@@]2(O1)C(=O)CO)C)Cl)Cl)C)F)C,,,,,,
9406,19407,Diethyl methylenedicarbamate,CCOC(=O)NCNC(=O)OCC,,,,,,
9407,19408,4-Chlorobenzyl isothiocyanate,C1=CC(=CC=C1CN=C=S)Cl,,,,,,
9408,19409,4-Methylbenzyl isothiocyanate,CC1=CC=C(C=C1)CN=C=S,,,,,,
9409,19410,4-Iodobenzyl isothiocyanate,C1=CC(=CC=C1CN=C=S)I,,,,,,
9410,19411,CID 19411,C1=CC(=N)C(=N)C(=C1)N(O)O,,,,,,
9411,19412,3-Chlorobenzyl isothiocyanate,C1=CC(=CC(=C1)Cl)CN=C=S,,,,,,
9412,19413,"Malononitrile, phenethylidene-",C1=CC=C(C=C1)CC=C(C#N)C#N,,,,,,
9413,19414,Methyl benzylidenecyanoacetate,COC(=O)C(=CC1=CC=CC=C1)C#N,,,,,,
9414,19415,Methyl 2-cyano-3-furan-2-ylacrylate,COC(=O)C(=CC1=CC=CO1)C#N,,,,,,
9415,19416,2-Cyano-3-(furan-2-yl)prop-2-enamide,C1=COC(=C1)C=C(C#N)C(=O)N,,,,,,
9416,19417,3-(4-Chlorophenyl)-2-phenylprop-2-enenitrile,C1=CC=C(C=C1)C(=CC2=CC=C(C=C2)Cl)C#N,,,,,,
9417,19418,4-Chloro-alpha-(phenylmethylene)benzeneacetonitrile,C1=CC=C(C=C1)C=C(C#N)C2=CC=C(C=C2)Cl,,,,,,
9418,19419,"2,3-Bis(4-chlorophenyl)prop-2-enenitrile",C1=CC(=CC=C1C=C(C#N)C2=CC=C(C=C2)Cl)Cl,,,,,,
9419,19420,2-(4-Nitrophenyl)-3-phenylprop-2-enenitrile,C1=CC=C(C=C1)C=C(C#N)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
9420,19421,"Malononitrile, (1-methyl-3-oxobutylidene)-",CC(=C(C#N)C#N)CC(=O)C,,,,,,
9421,19422,"1,5-Hexadiene-1,1,6,6-tetracarbonitrile, 2,5-dimethyl-",CC(=C(C#N)C#N)CCC(=C(C#N)C#N)C,,,,,,
9422,19423,CID 19423,CC1=CC=C(C=C1)NN=NC(=NC#N)N,,,,,,
9423,19424,2-[(4-Hydroxy-3-methoxyphenyl)methylidene]propanedinitrile,COC1=C(C=CC(=C1)C=C(C#N)C#N)O,,,,,,
9424,19425,2-Methylmalononitrile,CC(C#N)C#N,,,,,,
9425,19426,Ethylmalononitrile,CCC(C#N)C#N,,,,,,
9426,19427,5-Methylchrysene,CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4C=C3,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['The metabolic activation of the environmental carcinogen 5-methylchrysene was studied by combining high-pressure liquid chromatographic analysis of metabolites formed in vitro with assays of these metabolites for mutagenic activity toward Salmonella typhimurium. Metabolites were formed by incubation of 5-methylchrysene with the 9000 from Aroclor-treated rat livers. With the use of reverse-phase columns, the metabolites were resolved into 9 peaks, A to I. Each peak was collected and tested for mutagenicity with activation. Significant mutagenic activity was observed primarily in peak E and to a lesser extent in peak D. None of the other metabolites showed significant mutagenic activity. The major mutagenic metabolite (peak E) was identified as 1,2-dihydro-1,2-dihydroxy-5-methylchrysene (7.0% from 5-methylchrysene); peak D was 7,8-dihydro-7,8-dihydroxy-5-methylchrysene (2.6% from 5-methylchrysene). Other metabolites included 9,10-dihydro-9,10-dihydroxy-5-methylchrysene, 9-hydroxy-5-methylchrysene, 7-hydroxy-5-methylchrysene, 1-hydroxy-5-methylchrysene and 5-hydroxymethylchrysene. These results indicate that 1,2-dihydro-1,2-dihydroxy-5-methylchrysene is a major proximate mutagen of 5-methylchrysene.', '1,2- & 7,8-Dihydrodiols were the major metabolites of 5-methylchrysene, 7 small amounts of the 9,10-dihydrodiol were also formed following incubation of the compound with rat-liver preparations. Other metabolites detected include 1-, 7- & 9-hydroxy-5-methylchrysene & 5-hydroxymethylchrysene.', 'The metabolic activation in mouse skin of the strong carcinogen, 5-methylchrysene (5-MeC) was compared to that of the inactive compound, 6-nitro-5-methylchrysene (6-NO2-5-MeC). Metabolites of 6-NO2-5-MeC, formed using rat liver homogenates, were identified based on their spectral properties and were used as markers for studies performed in vivo. In mouse epidermis in vivo, the identified metabolites of 6-NO2-5-MeC were trans-1,2-dihydro-1,2-dihydroxy-6-nitro-5-methylchrysene (6-NO2-5-MeC-1,2-diol), the precursor to a bay region dihydrodiol epoxide, trans-9,10-dihydro-9,10-dihydroxy-6-nitro-5-methylchrysene, and 6-nitro-5-hydroxymethylchrysene. The levels of 6-NO2-5-MeC-1,2-diol formed in mouse epidermis from 6-NO2-5-MeC were greater than those of the proximate carcinogen trans-1,2-dihydro-1,2-dihydroxy-5-methylchrysene (5-MeC-1,2-diol) formed from 5-MeC. The further metabolism of 6-NO2-5-MeC-1,2-diol was examined in mouse epidermis under conditions similar to those described previously for 5-MeC-1,2-diol. The extents of formation of 1,2,3,4-tetraols from both dihydrodiols were similar. The chromatographic patterns of DNA adducts formed in mouse epidermis from 6-NO2-5-MeC and 5-MeC were qualitatively similar; however, the extent of formation of DNA adducts from 5-MeC was 15-fold greater than from 6-NO2-5-MeC. The reactions between calf thymus DNA and the bay region 1,2-diol-3,4-epoxides of 5-MeC and 6-NO2-5-MeC were compared; the levels of adducts formed from the bay region diol epoxide of 5-MeC were about four times greater than those formed from the bay region diol epoxide of 6-NO2-5-MeC. The results indicate that the relatively low DNA binding in vivo of 6-NO2-5-MeC may be responsible for its apparent lack of tumorigenicity compared to 5-MeC. It is likely that nitro substitution at the 6-position of 5-MeC interferes with the structural requirements of the 1,2-diol-3,4-epoxide which are necessary for specific DNA interactions.', 'We have investigated the metabolism of chrysene (CHR) and 5-methychyrsene (5-MeCHR) by Shasta rainbow trout (Oncorhyncus mykiss) and Long Evans rat liver microsomes to assess the effect of a non-benzo ring methyl substituent on the reactions involved in the metabolism of polycyclic aromatic hydrocarbons (PAHs). Trout as well as rat liver microsomes metabolized both CHR and 5-MeCHR at essentially similar rates, indicating that the methyl substituent does not alter the substrate specificity of the cytochrome P450(s) involved in the metabolism of the two PAHs. Dihydrodiols were the major CHR metabolites formed by both trout and rat liver microsomes, whereas the trout liver microsomes formed a considerably higher proportion of 5-MeCHR phenols compared to diols, indicating that 5-methyl substitution alters the substrate specificity of trout microsomal epoxide hydrolase for 5-MeCHR epoxides. Unlike trout liver microsomes, rat liver microsomes formed a much greater proportion of 5-MeCHR diols compared to 5-MeCHR phenols, suggesting that 5-MeCHR epoxides are better substrates for the microsomal epoxide hydrolase present in rat liver than for the enzyme in trout liver. Both trout and rat liver microsomes are more efficient at attacking the bay-region bond versus the non-bay-region double bond in chrysene. In contrast the reverse is true in the case of 5-MeCHR, indicating that a non-benzo ring methyl substituent alters the regioselectivity of the enzymes involved in the oxidative metabolism of PAHs.', 'For more Metabolism/Metabolites (Complete) data for 5-Methylchrysene (10 total), please visit the HSDB record page.', '5-methylchrysene has known human metabolites that include 5-Methyl-1,2-dihydrochrysene-1,2-diol.']",
9427,19428,"1,2-Dihydrobenz(e)aceanthrylene",C1CC=C2C(=C1)C=C3C=CC4=C3C2=CC5=CC=CC=C45,,,,,,
9428,19429,"5,6-Dimethylchrysene",CC1=C(C2=C(C=CC3=CC=CC=C32)C4=CC=CC=C14)C,,,,,,
9429,19430,7-Ethylbenz(A)anthracene,CCC1=C2C=CC3=CC=CC=C3C2=CC4=CC=CC=C41,,,,,,
9430,19431,"2,3,4,6-Tetranitroaniline",C1=C(C(=C(C(=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
9431,19432,((o-Chlorophenyl)azo)ethylmalononitrile,C1=CC=C(C(=C1)N=NCCC(C#N)C#N)Cl,,,,,,
9432,19433,((m-Chlorophenyl)azo)ethylmalononitrile,C1=CC(=CC(=C1)Cl)N=NCCC(C#N)C#N,,,,,,
9433,19434,((p-Chlorophenyl)azo)ethylmalononitrile,C1=CC(=CC=C1N=NCCC(C#N)C#N)Cl,,,,,,
9434,19435,Benzyl(phenylazo)malononitrile,C1=CC=C(C=C1)C(C(C#N)C#N)N=NC2=CC=CC=C2,,,,,,
9435,19436,Benzyl(o-tolylazo)malononitrile,CC1=CC=CC=C1N=NC(C2=CC=CC=C2)C(C#N)C#N,,,,,,
9436,19437,Benzyl(m-tolylazo)malononitrile,CC1=CC(=CC=C1)N=NC(C2=CC=CC=C2)C(C#N)C#N,,,,,,
9437,19438,Benzyl(p-tolylazo)malononitrile,CC1=CC=C(C=C1)N=NC(C2=CC=CC=C2)C(C#N)C#N,,,,,,
9438,19439,Benzyl((o-chlorophenyl)azo)malononitrile,C1=CC=C(C=C1)C(C(C#N)C#N)N=NC2=CC=CC=C2Cl,,,,,,
9439,19440,Benzyl((m-chlorophenyl)azo)malononitrile,C1=CC=C(C=C1)C(C(C#N)C#N)N=NC2=CC(=CC=C2)Cl,,,,,,
9440,19441,Benzyl((p-chlorophenyl)azo)malononitrile,C1=CC=C(C=C1)C(C(C#N)C#N)N=NC2=CC=C(C=C2)Cl,,,,,,
9441,19442,(p-Chlorobenzyl)(m-tolylazo)malononitrile,CC1=CC(=CC=C1)N=NC(C2=CC=C(C=C2)Cl)C(C#N)C#N,,,,,,
9442,19443,(p-Chlorobenzyl)(p-tolylazo)malononitrile,CC1=CC=C(C=C1)N=NC(C2=CC=C(C=C2)Cl)C(C#N)C#N,,,,,,
9443,19444,(p-Chlorobenzyl)((m-chlorophenyl)azo)malononitrile,C1=CC(=CC(=C1)Cl)N=NC(C2=CC=C(C=C2)Cl)C(C#N)C#N,,,,,,
9444,19445,(p-Chlorobenzyl)((p-chlorophenyl)azo)malononitrile,C1=CC(=CC=C1C(C(C#N)C#N)N=NC2=CC=C(C=C2)Cl)Cl,,,,,,
9445,19446,"1-Phenyl-2-(m-tolylazo)-1,3-butanedione",CC1=CC(=CC=C1)N=NC(C(=O)C)C(=O)C2=CC=CC=C2,,,,,,
9446,19447,"2-((m-Chlorophenyl)azo)-1-phenyl-1,3-butanedione",CC(=O)C(C(=O)C1=CC=CC=C1)N=NC2=CC(=CC=C2)Cl,,,,,,
9447,19448,"2-((p-Chlorophenyl)azo)-1-phenyl-1,3-butanedione",CC(=O)C(C(=O)C1=CC=CC=C1)N=NC2=CC=C(C=C2)Cl,,,,,,
9448,19449,2-((p-Acetylphenyl)azo)acetoacetic acid ethyl ester,CCOC(=O)C(C(=O)C)N=NC1=CC=C(C=C1)C(=O)C,,,,,,
9449,19450,CID 19450,CC(=NN=C(C)C1=CC=C(C=C1)N=NC(C#N)C#N)C2=CC=C(C=C2)N=NC(C#N)C#N,,,,,,
9450,19451,"Disodium 4-hydroxy-3-((4'-((2-hydroxynaphthyl)azo)-2,2'-dimethyl(1,1'-biphenyl)-4-yl)azo)naphthalene-2,7-disulphonate",CC1=C(C=CC(=C1)N=NC2=C(C=CC3=CC=CC=C32)O)C4=C(C=C(C=C4)N=NC5=C(C=C6C=C(C=CC6=C5O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],,,,,,
9451,19452,"4-Hydroxy-3-({4'-[(2-hydroxynaphthalen-1-yl)diazenyl]-2,2'-dimethyl[1,1'-biphenyl]-4-yl}diazenyl)naphthalene-2,7-disulfonic acid",CC1=C(C=CC(=C1)N=NC2=C(C=CC3=CC=CC=C32)O)C4=C(C=C(C=C4)N=NC5=C(C=C6C=C(C=CC6=C5O)S(=O)(=O)O)S(=O)(=O)O)C,,,,,,
9452,19453,"2,4-Dichloro-6-isopropylamino-1,3,5-triazine",CC(C)NC1=NC(=NC(=N1)Cl)Cl,,,,,,
9453,19454,"(9S,17S)-17-hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC1CC2=CC(=O)CCC2[C@@H]3C1C4CC[C@](C4(CC3)C)(C)O,,,,,,
9454,19455,N-Ethyl-N-methylguanidine tartrate,CCN(C)C(=N)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
9455,19456,N-Ethyl-N-methylguanidine,CCN(C)C(=N)N,,,,,,
9456,19457,2-(Methylsulfonyl)-1-phenylethanone,CS(=O)(=O)CC(=O)C1=CC=CC=C1,,,,,,
9457,19458,"Disodium 4,4'-dinitro-2,2'-stilbenedisulfonic acid",C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)[O-])C=CC2=C(C=C(C=C2)[N+](=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
9458,19459,"4,4'-Dinitro-2,2'-stilbenesulfonic acid",C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)O)C=CC2=C(C=C(C=C2)[N+](=O)[O-])S(=O)(=O)O,,,,,,
9459,19460,"1,7-Octadiene",C=CCCCCC=C,,,,,,
9460,19461,"Octa-1,6-diene",CC=CCCCC=C,,,,,,
9461,19462,"2,4-Dimethylfuran",CC1=CC(=CO1)C,,,,,,
9462,19463,"N,N-Diethylhydroxylamine",CCN(CC)O,,,,,,
9463,19464,"2-(4-Chlorophenyl)-4,6-bis(trichloromethyl)-1,3,5-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)Cl,,,,,,
9464,19465,"Malononitrile, (2-(2-naphthyl)ethylidene)-",C1=CC=C2C=C(C=CC2=C1)CC=C(C#N)C#N,,,,,,
9465,19466,D-fucopyranose,C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)O)O)O)O,,,,,,
9466,19467,12-beta-Hydroxybufalin [German],C[C@]12CC[C@@H](C[C@H]1CCC3C2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O)O,,,,,,
9467,19468,"1,2,3,5-Tetrachloro-4-nitrobenzene",C1=C(C(=C(C(=C1Cl)Cl)Cl)[N+](=O)[O-])Cl,,,,,,
9468,19469,1-Aziridinecarboxamide,C1CN1C(=O)N,,,,,,
9469,19470,"1-Aziridinecarboxamide, N,N-dimethyl-",CN(C)C(=O)N1CC1,,,,,,
9470,19471,"1-Aziridinecarboxamide, N-isopropyl-",CC(C)NC(=O)N1CC1,,,,,,
9471,19472,"4,5-dihydro-1H-imidazol-2-yl(5,6,7,8-tetrahydronaphthalen-1-yl)azanium;chloride",C1CCC2=C(C1)C=CC=C2[NH2+]C3=NCCN3.[Cl-],,,,,,
9472,19473,CID 19473,C1CN(C(=N1)S)N=O,,,,,,
9473,19474,"1-Cyclobutene-1,2-dicarbonitrile",C1CC(=C1C#N)C#N,,,,,,
9474,19475,p-Tolualdoxime,CC1=CC=C(C=C1)C=NO,,,,,,
9475,19476,N-methyladamantan-1-amine,CNC12CC3CC(C1)CC(C3)C2,,,,,,
9476,19477,N-methyladamantan-1-amine hydrochloride,CNC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
9477,19478,"N,N-Dimethyl-1-adamantanamine",CN(C)C12CC3CC(C1)CC(C3)C2,,,,,,
9478,19479,N-ethyladamantan-1-amine hydrochloride,CCNC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
9479,19480,N-Ethyl-1-adamantanamine,CCNC12CC3CC(C1)CC(C3)C2,,,,,,
9480,19481,"1-Adamantanamine, N-propyl-, hydrochloride",CCCNC12CC3CC(C1)CC(C3)C2.Cl,,,,,,
9481,19482,N-propyladamantan-1-amine,CCCNC12CC3CC(C1)CC(C3)C2,,,,,,
9482,19483,2-Piperidin-1-ium-4-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate;chloride,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCC3CC[NH2+]CC3)C4=CC=CC=C4.[Cl-],,,,,,
9483,19484,2-Piperidin-4-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCC3CCNCC3)C4=CC=CC=C4,,,,,,
9484,19485,"3,5-Dimethylpyridine-N-oxide",CC1=CC(=C[N+](=C1)[O-])C,,,,,,
9485,19486,"DIBENZ(a,h)ANTHRACENE-5,6-DIOL, 5,6-DIHYDRO-, (Z)-",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@@H]([C@@H](C5=CC=CC=C54)O)O,,,,,,
9486,19487,"Dibenz(a,h)anthracene-5,6-diol",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)[C@H]([C@@H](C5=CC=CC=C54)O)O,,,,,,
9487,19488,CID 19488,C1C[C@H](CC=C1)C(=O)C(=O)[O-].[K+],,,,,,
9488,19489,(R)-alpha-Oxo-3-cyclohexene-1-acetic acid,C1C[C@H](CC=C1)C(=O)C(=O)O,,,,,,
9489,19490,"Tetrahydro-3,6-dimethyl-2H-pyran-2-one",CC1CCC(OC1=O)C,,,,,,
9490,19491,p-((Dicyanomethyl)azo)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
9491,19492,((m-Chlorophenyl)azo)malononitrile,C1=CC(=CC(=C1)Cl)N=NC(C#N)C#N,,,,,,
9492,19493,Parnate,C1[C@H]([C@@H]1N)C2=CC=CC=C2,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']","['THE MAO INHIBITORS ARE ABSORBED READILY WHEN GIVEN BY MOUTH. THESE DRUGS PRODUCE MAXIMAL INHIBITION OF MAO WITHIN 5-10 DAYS. ... ALTHOUGH THEIR BIOLOGICAL ACTIVITY IS PROLONGED BECAUSE OF THE CHARACTERISTICS OF THEIR INTERACTION WITH THE ENZYME, THEIR CLINICAL EFFICACY APPEARS TO BE REDUCED WHEN THE DRUG IS GIVEN LESS FREQUENTLY THAN ONCE DAILY. /MAO INHIBITORS/']",,
9493,19494,Cyclobutanecarboxylic acid,C1CC(C1)C(=O)O,,,,,,
9494,19495,2-[(4-Nitrophenyl)hydrazinylidene]propanedinitrile,C1=CC(=CC=C1NN=C(C#N)C#N)[N+](=O)[O-],,,,,,
9495,19496,((p-Nitrophenyl)azo)malononitrile,C1=CC(=CC=C1N=NC(C#N)C#N)[N+](=O)[O-],,,,,,
9496,19497,(m-Tolylazo)malononitrile,CC1=CC(=CC=C1)N=NC(C#N)C#N,,,,,,
9497,19498,2-(Methylthio)benzoic acid,CSC1=CC=CC=C1C(=O)O,,,,,,
9498,19499,2-Butenoic acid,CC=CC(=O)O,,,,,,
9499,19500,CID 19500,C(CSP(=O)(O)[O-])N.[Na+],,,,,,
9500,19501,CID 19501,C(CS[P+](O)(O)O)N,,,,,,
9501,19502,"Cyclopentane, 1-ethyl-3-methyl-",CCC1CCC(C1)C,,,,,,
9502,19503,1-Ethyl-4-methylcyclohexane,CCC1CCC(CC1)C,,,,,,
9503,19504,Ethyl 2-diethoxyphosphoryloxy-3-oxobutanoate,CCOC(=O)C(C(=O)C)OP(=O)(OCC)OCC,,,,,,
9504,19505,"Methyl pimara-8(14),15-dien-18-oate",C[C@]12CCC[C@@](C1CCC3=CC(CCC23)(C)C=C)(C)C(=O)OC,,,,,,
9505,19506,"2,5-Dimethyl-2-hexanol",CC(C)CCC(C)(C)O,,,,,,
9506,19507,Quinuclidin-3-one,C1CN2CCC1C(=O)C2,,,,,,
9507,19508,2'-Methyl-4-dimethylaminoazobenzene,CC1=CC=CC=C1N=NC2=CC=C(C=C2)N(C)C,,,,"[""THE LEVEL OF BINDING OF TRITIATED PARA-DIMETHYLAMINOAZOBENZENE & THE NON- CARCINOGENIC 2-METHYL-4-DIMETHYLAMINOAZOBENZENE TO DIFFERENT CELL FRACTIONS OF RAT LIVER & SPLEEN FOLLOWING SINGLE ORAL ADMIN WERE SIMILAR, EXCEPT THAT MORE DNA WAS BOUND TO THE CARCINOGEN BETWEEN 4 & 8 HR AFTER ADMIN. ...BINDING OF CARCINOGENIC 3'-METHYL-4-DIMETHYLAMINOAZOBENZENE TO DNA WAS 6 TIMES GREATER THAN THAT OF 2-METHYL-4-DIMETHYLAMINOAZOBENZENE. WHEN (14)C-LABELED PARA-DIMETHYLAMINOAZOBENZENE OR 2-METHYL-4-DIMETHYLAMINOAZOBENZENE WERE GIVEN CONTINUOUSLY TO RATS IN DIET, BINDING OF 2-METHYL-4-DIMETHYLAMINOAZOBENZENE TO LIVER PROTEIN WAS SLIGHTLY HIGHER THAN THAT OF CARCINOGENIC COMPD. PARA-DIMETHYLAMINOAZOBENZENE, WAS HOWEVER, BOUND MUCH MORE TO DNA OF LIVER THAN WAS NON-CARCINOGENIC ANALOGUE.""]",,
9508,19509,2-Pyridinemethanamine,C1=CC=NC(=C1)CN,,,,,,
9509,19510,Thiohempa,CN(C)P(=S)(N(C)C)N(C)C,,,,,,
9510,19511,"DIBENZ(a,h)ANTHRACENE-5,6-DIONE",C1=CC=C2C(=C1)C=CC3=CC4=C(C=C32)C(=O)C(=O)C5=CC=CC=C54,,,,,,
9511,19512,Hexopyrronium bromide,C[N+]1(CCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O)C.[Br-],,,,,,
9512,19513,Hexopyrronium,C[N+]1(CCC(C1)OC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O)C,,,,,,
9513,19514,Prodilidine,CCC(=O)OC1(CCN(C1C)C)C2=CC=CC=C2,,,,,,
9514,19515,CID 19515,C1C(=O)C(=C(O1)O)CC2=CC=CC=C2,,,,,,
9515,19516,Metfendrazine,CC(CC1=CC=CC=C1)N(C)N,,,,,,
9516,19517,1-Isopropyl-2-(alpha-methyl)phenethylhydrazine,CC(C)NNC(C)CC1=CC=CC=C1,,,,,,
9517,19518,Denatonium benzoate,CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C.C1=CC=C(C=C1)C(=O)[O-],,,"['Chemicals added to pharmacologic preparations, poisonous household goods, and other chemicals to discourage their abuse or consumption. (See all compounds classified as Aversive Agents.)']",,,
9518,19519,Chlordene,C1C=CC2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,"['...Chlorinated cyclodienes... are efficiently absorbed through the skin. /Chlorinated Cyclodiene insecticides/', 'Organochlorines are well absorbed from the lung, gastrointestinal tract, and skin. /Organochlorines/', 'The chief route of excretion is biliary, although nearly all organochlorines yield measurable urinary metabolites. ... Many of the unmetabolized pesticides are efficiently reabsorbed by the intestine (enterohepatic circulation) substantially retarding fecal excretion. /Solid organochlorine insecticides/']","['Hepatic mixed function oxidase ... was investigated. When chlordene was used as substrate, hydroxylation preceded epoxidation. With preparations from the kissing gourami (helostoma sp) and pigeon, 1-hydroxy-2,3-epoxychlordene formed after the epoxide.', 'A 3-day aquatic system was used to evaluate uptake and biotransformation of chlordene ... chlordene epoxide, 1-hydroxychlordene, 1-hydroxychlordene epoxide and a polar metabolite /were formed in/ oedogonium, physa, culex and gambusia. Two unknowns /were formed in/ physa and gambusia.', 'Chlorodene metabolism ... studies with salt marsh caterpillar, estigmane acrea, and sheep liver microsomes ... /yielded/ chlordene epoxide, 1-hydroxychlordene, 1-hydroxychlordene epoxide, 2 unknowns and 1 polar metabolite. Sheep liver microsomes /yielded/ 1 unknown not found in salt marsh caterpillar.', 'Houseflies converted chlordene into an epoxide and two compounds identified as 1-hydroxychlordene and the 1-hydroxy epoxide. ... When incubated with pig liver microsomes, chlordene epoxide was converted into a diol.', 'For more Metabolism/Metabolites (Complete) data for CHLORDENE (8 total), please visit the HSDB record page.']",
9519,19520,Nonachlor,C12C(C(C(C1Cl)Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Trans-nonachlor, one of the major constituents of technical chlordane, is an important compound, since it is known to accumulate in humans ... . /trans- Nonachlor/', 'Organochlorines are well absorbed from the lung, gastrointestinal tract, and skin. /Organochlorines/', 'The chief route of excretion is biliary, although nearly all organochlorines yield measurable urinary metabolites. ... Many of the unmetabolized pesticides are efficiently reabsorbed by the intestine (enterohepatic circulation) substantially retarding fecal excretion. /Solid organochlorine insecticides/', 'Organochlorine insecticides ... do appear in breast milk. /Organochlorines/', 'For more Absorption, Distribution and Excretion (Complete) data for NONACHLOR (6 total), please visit the HSDB record page.']","['(14)C-trans-nonachlor, which comprises about 7% of technical chlordane, was administered to rats in corn oil as a single dose. Feces and urine were collected. The bulk of the radioactivity appeared in the feces and was identified as: 1,2-dihydroxydihydrochlordene (17.9%), 1-hydroxy-2-chlordene (15.4%), chlordene chlorohydrin (13.5%), oxychlordane (4.1%), trans-chlordane (0.8%), and 1-hydroxy-2-chloro-2,3-epoxychlordene. There were two unidentified compounds and unchanged nonachlor ... .', 'In vitro studies with human and rat liver microsomal preparations showed the presence of trans-chlordane, oxychlordane, chlordene chlorohydrin, and 1,2-dihydroxydihydrochlordene. With human liver preparations, the level of metabolites was very low. This correlates with the finding of trans-nonachlor as the major chlordane residue found in human tissues ... .', 'The estuarine fish, spot (Leiostomus xanthurus), was exposed to technical heptachlor for 24 days. Heptachlor, t-chlordane, cis-chlordane, and nonachlor, which were present in the technical grade heptachlor, accumulated in edible fish tissue. Heptachlor epoxide formed and was also accumulated ... .', 'Rats were fed a diet containing 10 ppm of technical chlordane for 28 days. The depuration of the various chlordane compounds was then followed for 32 days. The concn of 14 components or metabolites of technical chlordane were measured in the adipose tissues of 21 rats, using electron capture, negative ionization mass spectrometry, coupled with capillary gas chromatography. The half-lives of the two major octachloro isomers, gamma- and alpha-chlordane, were determined to be 7.1 and 5.9 d respectively. The half-lives of the nonachlors were 9.7 (cis-nonachlor), 14.3 (trans-nonachlor), and 54.1 days (nonachlor III). The depuration rates seem to be controlled by three structural features of the molecules; the total number and configuration of the chlorines on ring 1 and the number of chlorines on carbon 2.', 'The toxic effects of the organochlorine insecticide chlordane were compared in man... . Analysis of blood for chlordane metabolites showed their presence in the descending order of trans-nonachlor, oxychlordane, hepatachlorepoxide and cis-nonachlor. The total range of chlordane and its metabolites in the sera of workers was 9.84 : 4.47 ng/g. Serum levels of triglycerides, creatine phosphokinase and lactate dehydrogenase activities were also found to be higher in pest control operators ...']",
9520,19521,(3-Nitrophenyl)methyl 3-dimethoxyphosphoryloxybut-2-enoate,CC(=CC(=O)OCC1=CC(=CC=C1)[N+](=O)[O-])OP(=O)(OC)OC,,,,,,
9521,19522,Acid red 1,CC(=O)NC1=C2C(=CC(=C1)S(=O)(=O)[O-])C=C(C(=C2O)N=NC3=CC=CC=C3)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
9522,19523,"5-Acetamido-4-hydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid",CC(=O)NC1=C2C(=CC(=C1)S(=O)(=O)O)C=C(C(=C2O)N=NC3=CC=CC=C3)S(=O)(=O)O,,,,,,
9523,19524,Azoaldrin,C1C2C3C(C1N=N2)C4(C(=C(C3(C4(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
9524,19525,Amiton oxalate,CCN(CC)CCSP(=O)(OCC)OCC.C(=O)(C(=O)O)O,,,,,,
9525,19526,Methyl dimethyldithiocarbamate,CN(C)C(=S)SC,,,,,,
9526,19527,Fenethylline,CC(CC1=CC=CC=C1)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']","['The limit for detecting fenethylline and its metabolite amphetamine in GLC with N-FID is in the range of nanograms. The elimination of these substances in urine was measured after giving different quantities of Captagon to six volunteers. The concentrations of fenethylline and amphetamine in urine allow to estimate with some limitations time and amount of consuming Captagon for forensic purposes', 'The incorporation tendency of fenethylline (FNT) and its metabolite into rat hair and the discrimination between FNT use and amphetamine (AP) use by hair analysis using gas chromatography-mass spectrometry with selected ion monitoring are described. After the intraperitoneal administrations of FNT to pigmented hairy rats (5 mg/kg/day, 10 days, n = 3), concentrations of FNT and its metabolite, AP, in the rat hair newly grown over 4 weeks were compared with area under the concentration versus time curves (AUCs) of the drugs in the rat plasma. The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively. The ratios of the hair concentrations to the AUCs of FNT and AP were 0.93 and 0.22, respectively. This suggests that FNT tends to be highly incorporated into hair from blood. The analytical method was applied to the determination of the metabolites in scalp hair of humans who were given FNT orally in multiple doses (50 mg/day, 3 days, n = 5) or in a single dose (50 mg/day, 1 day, n = 1). FNT and AP were detected at 0.51 +/- 0.23 and 0.35 +/- 0.12 ng/mg, respectively, in the proximal 1-cm hair segments from subjects given FNT orally for 3 days and 0.25 and 0.11 ng/mg, respectively, in the single-dose sample. In addition, it was found that the concentrations of FNT were 1.2 to 2.7 times greater than those of AP in the human hair samples, except for one sample, although FNT rapidly disappeared from the urine compared with AP. It was concluded that hair would be a good specimen for disclosure of drug history of FNT and for discrimination between FNT use and AP abuse.']","['Metabolic fate of 7-[2-(alpha-methylphenylethylamino)ethyl]theophylline hydrochloride (fenetylline) was investigated in male Sprague-Dawley rats and three male volunteers. Six metabolites were identified in the rat urine as amphetamine (AP), p-hydroxy-AP, acetylaminoethyl-theophylline(TP), aminoethyl-TP, hydroxyethyl-TP and carboxymethyl-TP by comparison of their spectral properties and H.P.L.C. and G.L.C. characteristics with those of authentic samples. All these metabolites was also detected in the urine of humans receiving fenetylline. Quantification of these metabolites using H.P.L.C. and G.L.C. showed that carboxymethyl-TP, p-hydroxy-AP and acetylaminoethyl-TP were the major metabolites in 0-24 hr rat urine at 13.7%, 11.2% and 9.3% of dose, respectively. In men, carboxymethyl-TP(39-43% dose) and AP(23-33% dose) were the major metabolites in 0-48 hr urine. These results suggest that fenetylline metabolism proceeds via oxidative cleavage at two different sites to produce aminoethyl-TP and AP, respectively. The pathway producing AP predominates, in both man and rat, but is more predominant in the former.', 'Fenetylline is metabolized in humans on two pathways. In addition to previously described degradation to amphetamine and 7-oxyethyltheophylline fenetylline undergoes moreover oxydative N-dealkylation to yield 7-aminoethyltheophylline and phenylacetone.', 'In the fenetylline molecule, theophylline is covalently linked with amphetamine via an alkyl chain. The inclusion of amphetamine and results from early metabolic studies have led to speculation that fenetylline may be merely a prodrug for amphetamine and/or theophylline. Although previous studies are not consistent with this hypothesis, additional studies were conducted to comparatively evaluate the profiles of activity exhibited by fenetylline and its two postulated primary metabolites, (+/-)-amphetamine and theophylline. Investigations were also initiated using newly developed high pressure liquid chromatography (HPLC) techniques to further characterize the metabolic pattern that fenetylline undergoes and to examine the relationship between plasma pharmacokinetics and the pharmacodynamic actions of the drug. Fenetylline inhibits activity associated with amphetamine in certain test systems, an effect similar to that previously observed with fenfluramine. Only small amounts of the amphetamine theoretically available in the fenetylline molecule are released. Pharmacodynamic activity associated with fenetylline administration is more closely tied to plasma levels of the parent compound than to any (+/-)-amphetamine produced.', 'The interpretation of methamphetamine and amphetamine positive test results in biological samples is a challenge to clinical and forensic toxicology for several reasons. The effects of pH and dilution of urine samples and the knowledge about legitimate and illicit sources have to be taken into account. Besides a potentially legal prescription of amphetamines, many substances metabolize to methamphetamine or amphetamine in the body: amphetaminil, benzphetamine, clobenzorex, deprenyl, dimethylamphetamine, ethylamphetamine, famprofazone, fencamine, fenethylline, fenproporex, furfenorex, mefenorex, mesocarb, and prenylamine. Especially the knowledge of potential origins of methamphetamine and amphetamine turns out to be very important to prevent a misinterpretation of the surrounding circumstances and to prove illegal drug abuse. In this review, potential precursor compounds are described, including their medical use and major clinical effects and their metabolic profiles, as well as some clues which help to identify the sources.', 'For more Metabolism/Metabolites (Complete) data for Fenetylline (6 total), please visit the HSDB record page.']",
9527,19528,"Acetamide, 2-(acetyl-(4-ethoxyphenyl)amino)-N,N-dimethyl-",CCOC1=CC=C(C=C1)N(CC(=O)N(C)C)C(=O)C,,,,,,
9528,19529,Diloxanide furoate,CN(C1=CC=C(C=C1)OC(=O)C2=CC=CO2)C(=O)C(Cl)Cl,"['Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis.']","['Diloxanide is a luminal amebicide, however the mechanism of action of diloxanide is unknown. Diloxanide destroys the trophozoites of E. histolytica that eventually form into cysts. The cysts are then excreted by persons infected with asymptomatic amebiasis. Diloxanide furoate is a prodrug, and is hydrolyzed in the gastrointestinal tract to produce diloxanide, the active ingredient.']","['Agents which are destructive to amebae, especially the parasitic species causing AMEBIASIS in man and animal. (See all compounds classified as Amebicides.)']","['Bioavailability is 90% (in diloxanide parental form), however diloxanide furoate is slowly absorbed from the gastrointestinal tract.', 'Renal (90%, rapidly excreted as glucuronide metabolite). 10% is excreted in the feces as diloxanide.']","['Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation (99% of diloxanide occurs as glucuronide and 1% as free diloxanide in the systemic circulation).']",['3 hours']
9529,19530,3-Bromo-1-chloroprop-1-ene,C(C=CCl)Br,,,,,,
9530,19531,"2,6-Dimethyl-4-propoxy-benzoic acid 2-(1-pyrrolidinyl)propyl ester hydrochloride",CCCOC1=CC(=C(C(=C1)C)C(=O)OCC(C)[NH+]2CCCC2)C.[Cl-],,,,,,
9531,19532,"2-Pyrrolidin-1-ylpropyl 2,6-dimethyl-4-propoxybenzoate",CCCOC1=CC(=C(C(=C1)C)C(=O)OCC(C)N2CCCC2)C,,,,,,
9532,19533,Ioglycamide disodium,C1=C(C(=C(C(=C1I)NC(=O)COCC(=O)NC2=C(C=C(C(=C2I)C(=O)[O-])I)I)I)C(=O)[O-])I.[Na+].[Na+],,,,,,
9533,19534,p-(2-((Diethylamino)methyl)butoxy)benzoic acid p-methoxyphenyl ester hydrochloride,CCCC(C[NH+](CC)CC)OC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)OC.[Cl-],,,,,,
9534,19535,(4-Methoxyphenyl) 4-[1-(diethylamino)pentan-2-yloxy]benzoate,CCCC(CN(CC)CC)OC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)OC,,,,,,
9535,19536,Phenylacetylglycine dimethylamide,CC(=O)N(CC(=O)N(C)C)C1=CC=CC=C1,,,,,,
9536,19537,"Carbamic acid, phenyl-, 2-(diethylamino)ethyl ester, monohydrochloride",CC[NH+](CC)CCOC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
9537,19538,"Ethanol, 2-diethylamino-, carbanilate",CCN(CC)CCOC(=O)NC1=CC=CC=C1,,,,,,
9538,19539,3-Phenoxybenzoic acid,C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)O,,,['Specific effects of drugs and substances on metabolic pathways such as those occurring through the CYTOCHROME P-450 ENZYME SYSTEM. These include effects that often result in DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; and HERB-DRUG INTERACTIONS. (See all compounds classified as Metabolic Side Effects of Drugs and Substances.)'],,['3-Phenoxybenozoic acid has known human metabolites that include 3-Phenoxybenzoic acid glucuronide and 3-Phenoxybenzoylglycine.'],
9539,19540,Pentylcyclopentane,CCCCCC1CCCC1,,,,,,
9540,19541,"1,3,2-Dithiarsolane, 2-chloro-",C1CS[As](S1)Cl,,,,,,
9541,19542,"2-Methoxy-1,3,2-dioxaphospholane",COP1OCCO1,,,,,,
9542,19543,"4-Penten-2-one, 4-methyl-",CC(=C)CC(=O)C,,,,,,
9543,19544,"(4R,8S,12R)-11,12-dichloro-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC1(O[C@@H]2CC3C4CCC5=CC(=O)C=CC5([C@]4(C(CC3([C@@]2(O1)C(=O)CO)C)Cl)Cl)C)C,,,,,,
9544,19545,"2,4-Dimethyl-6-(methylthio)-1,3,5-triazine",CC1=NC(=NC(=N1)SC)C,,,,,,
9545,19546,"Acetic acid, mercapto-, dodecyl ester",CCCCCCCCCCCCOC(=O)CS,,,,,,
9546,19547,"N,N-Diheptyl-4-methoxy-1-naphthamidine hydrochloride",CCCCCCC[NH+](CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
9547,19548,Wln: L66J byum&N7&7 EO1 &GH,CCCCCCCN(CCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
9548,19549,2-Chloroethyl N-phenylcarbamate,C1=CC=C(C=C1)NC(=O)OCCCl,,,,,,
9549,19550,"N,N-Dibutyl-4-pentyloxy-1-naphthamidine hydrochloride",CCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCC)CCCC.[Cl-],,,,,,
9550,19551,"N,N-dibutyl-4-pentoxynaphthalene-1-carboximidamide",CCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCC)CCCC,,,,,,
9551,19552,"4-Butoxy-N,N-dipentyl-1-naphthamidine hydrochloride",CCCCC[NH+](CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC.[Cl-],,,,,,
9552,19553,"4-butoxy-N,N-dipentylnaphthalene-1-carboximidamide",CCCCCN(CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC,,,,,,
9553,19554,"N,N-Dipentyl-4-hexyloxy-1-naphthamidine hydrochloride",CCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCCC)CCCCC.[Cl-],,,,,,
9554,19555,"4-hexoxy-N,N-dipentylnaphthalene-1-carboximidamide",CCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCCC)CCCCC,,,,,,
9555,19556,"4-Butoxy-N,N-dihexyl-1-naphthamidine hydrochloride",CCCCCC[NH+](CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC.[Cl-],,,,,,
9556,19557,"4-butoxy-N,N-dihexylnaphthalene-1-carboximidamide",CCCCCCN(CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC,,,,,,
9557,19558,"N,N-Dioctyl-4-methoxy-1-naphthamidine hydrochloride",CCCCCCCC[NH+](CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC.[Cl-],,,,,,
9558,19559,"4-methoxy-N,N-dioctylnaphthalene-1-carboximidamide",CCCCCCCCN(CCCCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OC,,,,,,
9559,19560,"N,N-Dihexyl-4-heptyloxy-1-naphthamidine hydrochloride",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)[NH+](CCCCCC)CCCCCC.[Cl-],,,,,,
9560,19561,"4-heptoxy-N,N-dihexylnaphthalene-1-carboximidamide",CCCCCCCOC1=CC=C(C2=CC=CC=C21)C(=N)N(CCCCCC)CCCCCC,,,,,,
9561,19562,"2,3,5,6-Tetramethylpyridine",CC1=CC(=C(N=C1C)C)C,,,,,,
9562,19563,CID 19563,CC(C)[SnH](C(C)C)C(C)C.CC(C)[SnH](C(C)C)C(C)C,,,,,,
9563,19564,Unii-T2hkh2CC8B,CC(C)[SnH](C(C)C)C(C)C,,,,,,
9564,19565,Primocarcin,CC(=O)NC(=C)C(=O)CCC(=O)N,,,,,,
9565,19566,Apocannoside,CC1[C@H](C(C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C=O)OC)O,,,,,,
9566,19567,3-(2-Chlorophenyl)acrylic acid,C1=CC=C(C(=C1)C=CC(=O)O)Cl,,,,,,
9567,19568,Ambusida,CC(=O)C=CNC1=CC(=C(C=C1S(=O)(=O)NCC=C)S(=O)(=O)N)Cl,,,,,,
9568,19569,"2-(1-Ethylaminoethyl)-1,4-benzodioxane",CCNC(C)C1COC2=CC=CC=C2O1,,,,,,
9569,19570,p-CYMENE-2-CARBOXYLIC ACID,CC1=C(C=C(C=C1)C(C)C)C(=O)O,,,,,,
9570,19571,Estradiol propionate,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,,,,,,
9571,19572,2-(Diethylamino)ethyl 3-amino-4-butoxybenzoate,CCCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,,,,,,
9572,19573,2-Hydroxyethyldimethyl-3-stearamidopropylammonium phosphate,CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CCO.OP(=O)(O)[O-],,,,,,
9573,19574,2-Hydroxyethyl-dimethyl-[3-(octadecanoylamino)propyl]azanium,CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CCO,,,,,,
9574,19575,1-Naphthyl chloroformate,C1=CC=C2C(=C1)C=CC=C2OC(=O)Cl,,,,,,
9575,19576,2-Ethylcyclohexanol,CCC1CCCCC1O,,,,,,
9576,19577,Mesulfenfos,CC1=C(C=CC(=C1)OP(=S)(OC)OC)S(=O)C,,,,,,
9577,19578,Fenthion sulfone,CC1=C(C=CC(=C1)OP(=S)(OC)OC)S(=O)(=O)C,,,,,,
9578,19579,"Disodium;4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,6-disulfonate",CC1=CC(=C(C=C1)N=NC2=C3C=C(C=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+],,,,,,
9579,19580,"4-[(2,4-Dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,6-disulfonic acid",CC1=CC(=C(C=C1)N=NC2=C3C=C(C=CC3=CC(=C2O)S(=O)(=O)O)S(=O)(=O)O)C,,,,,,
9580,19581,"2-Chloroethyl 2-(2-(4-(1,1-dimethylethyl)phenoxy)-1-methylethoxy)-1-methylethyl sulfuroate",CC(COC1=CC=C(C=C1)C(C)(C)C)OCC(C)OS(=O)OCCCl,,,,,,
9581,19582,CID 19582,C[C@@H]1CC2=CC(=O)CCC2C3C1C4CCC(C4(CC3)C)O,,,"['Postcoital contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Postcoital, Hormonal.)']",,,
9582,19583,Glenbar,COC(=O)C1=C(C(=C(C(=C1Cl)Cl)C(=O)SC)Cl)Cl,,,,,,
9583,19584,"Benzimidazole, 5-iodo-2-(trifluoromethyl)-",C1=CC2=C(C=C1I)NC(=N2)C(F)(F)F,,,,,,
9584,19585,3-(pyrrolidin-2-yl)-1H-indole,C1CC(NC1)C2=CNC3=CC=CC=C32,,,,,,
9585,19586,CID 19586,C=CCN=C(NN)S,,,,,,
9586,19587,Buturon,CC(C#C)N(C)C(=O)NC1=CC=C(C=C1)Cl,,,,,,
9587,19588,Fenobucarb,CCC(C)C1=CC=CC=C1OC(=O)NC,,,,,,
9588,19589,4-Methyl-1-hexene,CCC(C)CC=C,,,,,,
9589,19590,"Ethanol, 2,2'-[[4-[(2-chloro-4-nitrophenyl)azo]-3-methylphenyl]imino]bis-",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl,,,,,,
9590,19591,4-Methyl-9H-carbazole,CC1=C2C3=CC=CC=C3NC2=CC=C1,,,,,,
9591,19592,Nafenopin,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,,,"['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration. (See all compounds classified as Peroxisome Proliferators.)']",,,
9592,19593,"2,2'-((3-Methyl-4-(phenylazo)phenyl)imino)bisethanol",CC1=C(C=CC(=C1)N(CCO)CCO)N=NC2=CC=CC=C2,,,,,,
9593,19594,"Benzoic acid, p-(butylamino)-, 2-(methylmethylthioethylamino)ethyl ester, hydrobromide",CCCCNC1=CC=C(C=C1)C(=O)OCC[NH+](C)CCSC.[Br-],,,,,,
9594,19595,2-[Methyl(2-methylsulfanylethyl)amino]ethyl 4-(butylamino)benzoate,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)CCSC,,,,,,
9595,19596,Sulfametomidine,CC1=NC(=CC(=N1)OC)NS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
9596,19597,"2,4,5-Trichlorothiophenol",C1=C(C(=CC(=C1Cl)Cl)Cl)S,,,,,,
9597,19598,CID 19598,CC1=C(OC2=C(N1)C=CC(=O)C2=O)O,,,,,,
9598,19599,CID 19599,CC1=C(OC2=CC=CC(=O)C2=N1)O,,,,,,
9599,19600,4-hydroxy-N-sulfidobenzonitrilium,C1=CC(=CC=C1C#[N+][S-])O,,,,,,
9600,19601,2-(Tert-butylamino)ethyl methacrylate,CC(=C)C(=O)OCCNC(C)(C)C,,,,,"['SMALL QUANTITIES OF METHACRYLATES MAY READILY BE METABOLIZED BY SAPONIFICATION INTO THE ALCOHOL AND METHACRYLIC ACID. THE LATTER MAY FORM AN ACETYL-COENZYME DERIVATIVE, WHICH THEN ENTERS THE NORMAL LIPID METABOLISM. /METHACRYLATES/']",
9601,19602,2-Pentylfuran,CCCCCC1=CC=CO1,,,,,,
9602,19603,2-Heptylfuran,CCCCCCCC1=CC=CO1,,,,,,
9603,19604,Todralazine hydrochloride,CCOC(=O)NNC1=NN=CC2=CC=CC=C21.Cl,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
9604,19605,"Ethanol, 2-(phenethylthio)-",C1=CC=C(C=C1)CCSCCO,,,,,,
9605,19606,((2-Chloro-4-nitrophenyl)azo)malononitrile,C1=CC(=C(C=C1[N+](=O)[O-])Cl)N=NC(C#N)C#N,,,,,,
9606,19607,Propyperone,CCC(=O)C1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)N3CCCCC3,,,,,,
9607,19608,Ethyl p-((p-phenylbenzylidene)amino)benzoate,CCOC(=O)C1=CC=C(C=C1)N=CC2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
9608,19609,3-{[Hydroxy(phenyl)acetyl]oxy}-8-methyl-8-(2-oxo-2-phenylethyl)-8-azabicyclo[3.2.1]octan-8-ium chloride,C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)CC(=O)C4=CC=CC=C4.[Cl-],,,,,,
9609,19610,3-{[Hydroxy(phenyl)acetyl]oxy}-8-methyl-8-(2-oxo-2-phenylethyl)-8-azabicyclo[3.2.1]octan-8-ium,C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)CC(=O)C4=CC=CC=C4,,,,,,
9610,19611,"1-Ethyl-2,6-bis[2-(4-pyrrolidin-1-ylphenyl)ethenyl]pyridin-1-ium;iodide",CC[N+]1=C(C=CC=C1C=CC2=CC=C(C=C2)N3CCCC3)C=CC4=CC=C(C=C4)N5CCCC5.[I-],,,,,,
9611,19612,"1-Ethyl-2,6-bis[2-[4-(1-pyrrolidinyl)phenyl]ethenyl]pyridinium",CC[N+]1=C(C=CC=C1C=CC2=CC=C(C=C2)N3CCCC3)C=CC4=CC=C(C=C4)N5CCCC5,,,,,,
9612,19613,4-Methylbenzenesulfonate;1-methyl-4-[10-(1-methylpyridin-1-ium-4-yl)sulfanyldecylsulfanyl]pyridin-1-ium,CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+]1=CC=C(C=C1)SCCCCCCCCCCSC2=CC=[N+](C=C2)C,,,,,,
9613,19614,UTH-31 cation,C[N+]1=CC=C(C=C1)SCCCCCCCCCCSC2=CC=[N+](C=C2)C,,,,,,
9614,19615,"8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",CN1CCC2=C(C1)C3=C(N2)C=CC(=C3)Cl,,,,,,
9615,19616,2-Chloro-N-(2-methyl-6-tert-butylphenyl)acetamide,CC(=O)NC1=C(C=CC=C1C(C)(C)C)CCl,,,,,,
9616,19617,"Acetic acid, bromo-, 2-((dichloroacetyl)((4-(methylsulfonyl)phenyl)methyl)amino)ethyl ester",CS(=O)(=O)C1=CC=C(C=C1)CN(CCOC(=O)CBr)C(=O)C(Cl)Cl,,,,,,
9617,19618,Ethylene bromoacetate,C(COC(=O)CBr)OC(=O)CBr,,,,,,
9618,19619,alpha-Cyano-4-(dimethylamino)-cinnamamide,CN(C)C1=CC=C(C=C1)C=C(C#N)C(=O)N,,,,,,
9619,19620,Wln: T6N CN enj BN2CN&2CN DR& FN2CN&2CN,C1=CC=C(C=C1)C2=NC(=NC(=N2)N(CCC#N)CCC#N)N(CCC#N)CCC#N,,,,,,
9620,19621,Dihydrodigitoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@H]7C8CC(=O)OC8)O)C)C)C)C)O)O,,,,,,
9621,19622,"Cyclopentane-1,2,3,4-tetracarboxylic acid",C1C(C(C(C1C(=O)O)C(=O)O)C(=O)O)C(=O)O,,,,,,
9622,19623,"2,3,3-Trichloropropenal",C(=O)C(=C(Cl)Cl)Cl,,,,,,
9623,19624,CID 19624,CC1=NSC(=C1Br)C(=NNC(=NCCCOC)S)C,,,,,,
9624,19625,3'-Chloro-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC(=CC=C2)Cl,,,,,,
9625,19626,1-(3-((4-(Dimethylamino)phenyl)azo)phenyl)ethanone,CC(=O)C1=CC(=CC=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
9626,19627,"BARBITURIC ACID, 5-ALLYL-5-(p-FLUOROPHENYL)-",C=CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)F,,,,,,
9627,19628,Silver heptafluorobutyrate,C(=O)(C(C(C(F)(F)F)(F)F)(F)F)[O-].[Ag+],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
9628,19629,"Phosphonic acid, (1-hydroxyethylidene)bis-, tetrasodium salt",CC(O)(P(=O)([O-])[O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
9629,19630,"Oxamide, N,N'-bis(2-(1-aziridinyl)ethyl)-",C1CN1CCNC(=O)C(=O)NCCN2CC2,,,,,,
9630,19631,"N-[3-[2-(diethylamino)ethylamino]-3-oxo-1-(3,4,5-trimethoxyphenyl)prop-1-en-2-yl]benzamide",CCN(CC)CCNC(=O)C(=CC1=CC(=C(C(=C1)OC)OC)OC)NC(=O)C2=CC=CC=C2,,,,,,
9631,19632,N-[3-[2-(diethylamino)ethylamino]-1-(4-methoxyphenyl)-3-oxoprop-1-en-2-yl]benzamide,CCN(CC)CCNC(=O)C(=CC1=CC=C(C=C1)OC)NC(=O)C2=CC=CC=C2,,,,,,
9632,19633,"6,10-Dimethylundeca-5,9-dien-2-one",CC(=CCCC(=CCCC(=O)C)C)C,,,,,,
9633,19634,"2-Diethylamino-4-ethylamino-6-fluoro-1,3,5-triazine",CCNC1=NC(=NC(=N1)F)N(CC)CC,,,,,,
9634,19635,1-(o-Fluoro-alpha-methylphenethyl)hydrazine hydrochloride,CC(CC1=CC=CC=C1F)N[NH3+].[Cl-],,,,,,
9635,19636,1-(1-(2-Fluorophenyl)propan-2-YL)hydrazine,CC(CC1=CC=CC=C1F)NN,,,,,,
9636,19637,4'-Fluoro-4-(morpholino)butyrophenone,C1COCCN1CCCC(=O)C2=CC=C(C=C2)F,,,,,,
9637,19638,"[(6S,9R,17R)-17-acetyl-9-fluoro-11-hydroxy-6,10,13-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate",C[C@H]1CC2C3CC[C@@](C3(CC([C@@]2(C4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)OC(=O)C,,,,,,
9638,19639,((3-((o-Chlorophenoxy)methyl)-3-oxetanyl)methyl)trimethylammonium bromide,C[N+](C)(C)CC1(COC1)COC2=CC=CC=C2Cl.[Br-],,,,,,
9639,19640,[3-[(2-Chlorophenoxy)methyl]oxetan-3-yl]methyl-trimethylazanium,C[N+](C)(C)CC1(COC1)COC2=CC=CC=C2Cl,,,,,,
9640,19641,((3-((p-Chlorophenoxy)methyl)-3-oxetanyl)methyl)diethylmethylammonium bromide,CC[N+](C)(CC)CC1(COC1)COC2=CC=C(C=C2)Cl.[Br-],,,,,,
9641,19642,[3-[(4-Chlorophenoxy)methyl]oxetan-3-yl]methyl-diethyl-methylazanium,CC[N+](C)(CC)CC1(COC1)COC2=CC=C(C=C2)Cl,,,,,,
9642,19643,CID 19643,C1=CN=CC=C1C(=O)NNCS(=O)(=O)[O-].[Na+],,,,,,
9643,19644,4'-Bromo-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)Br,,,,,,
9644,19645,"3,9-Bis(octadecyloxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane",CCCCCCCCCCCCCCCCCCOP1OCC2(CO1)COP(OC2)OCCCCCCCCCCCCCCCCCC,,,,,,
9645,19646,Tenonitrozole,C1=CSC(=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-],,,,,,
9646,19647,"1-(1,4-Benzodioxan-2-ylmethyl)octahydroazocine",C1CCCN(CCC1)CC2COC3=CC=CC=C3O2,,,,,,
9647,19648,Streptomycin sulfate,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O.C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
9648,19649,Streptomycin,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,"['Although streptomycin was the first antibiotic available for the treatment of mycobacterium tuberculosis, it is now largely a second line option due to resistance and toxicity. Streptomycin may also be used to treat a variety of other infections caused by susceptible strains of aerobic bacteria where other less toxic agents are ineffective. Examples include: _Yersinia pestis_, _Francisella tularensis_, _Brucella_, _Calymmatobacterium granulomatis_ (donovanosis, granuloma inguinale), _H. ducreyi_ (chancroid), _H. influenzae_ (in respiratory, endocardial, and meningeal infections - concomitantly with another antibacterial agents). _K. pneumoniae_ pneumonia (concomitantly with another antibacterial agent), _E.coli_, _Proteus_, _A.aerogenes_, _K. pneumoniae_, and  _Enterococcus faecalis_ in urinary tract infections, _Streptococcus viridans_, _Enterococcus faecalis_ (in endocardial infections - concomitantly with penicillin), and Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent).']","['Although streptomycin originally had broad gram-negative and gram-positive coverage, its spectrum of activity has been significantly narrowed due to antibiotic resistance. Streptomycins current spectrum of activity includes susceptible strains of Yersinia pestis, Francisella tularensis, Brucella, Calymmatobacterium granulomatis, H. ducreyi, H. influenza, K. pneumoniae pneumonia, E.coli, Proteus, A. aerogenes, K. pneumoniae, Enterococcus faecalis, Streptococcus viridans, Enterococcus faecalis, and Gram-negative bacillary bacteremia. Streptomycin is not reliably active against pseudomonas aeruginosa.   Similar to other aminoglycosides, streptomycin is considered to have a narrow therapeutic index. Characteristic toxicities of streptomycin include nephrotoxicity and ototoxicity. Patients should be carefully monitored for early signs of hearing loss and vestibular dysfunction in order to prevent permanent damage to sensorineural cells. Neuromuscular blockade has also been rarely reported.']","['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']","['Due to poor oral absorption, aminoglycosides including streptomycin are administered parenterally. Streptomycin is available as an intramuscular injection, and in some cases may be administered intravenously. A peak serum concentration of 25-50 mcg/mL is achieved within 1 hour after intramuscular administration of 1 gram of streptomycin.', 'Approximately 50% of streptomycin is eliminated in the urine within 24 hours after intravenous or intramuscular administration.', 'Following intramuscular injection of 1 g of streptomycin as the sulfate, a peak serum level of 25 to 50 ug/mL is reached within 1 hour, diminishing slowly to about 50 percent after 5 to 6 hours.  Appreciable concentrations are found in all organ tissues except the brain. Significant amounts have been found in pleural fluid and tuberculous cavities. Streptomycin passes through the placenta with serum levels in the cord blood similar to maternal levels. Small amounts are excreted in milk, saliva, and sweat.', 'Streptomycin is not absorbed from the GI tract.', 'Streptomycin is rapidly absorbed after IM injection. Following IM administration of a single 1-g dose of streptomycin in adults with normal renal function, peak serum streptomycin concentrations are attained within 1 hour and range from 25-50 ug/mL; serum concentrations decrease 50% by 5-6 hours after the dose.', 'In one study in premature infants, mean peak serum concentrations of about 29 ug/mL were attained within 2 hours following IM administration of streptomycin 10-11 mg/kg; serum concentrations averaged 11 ug/mL at 12 hours.', 'For more Absorption, Distribution and Excretion (Complete) data for Streptomycin (16 total), please visit the HSDB record page.']",['Aminoglycosides are not metabolized and are excreted unchanged in the urine primarily by glomerular filtration. /Aminoglycosides/'],"['Streptomycins serum half-life is estimated to be 2.5 hours.', 'The plasma elimination half-life of streptomycin is usually 2-3 hours in adults with normal renal function and has been reported to range up to 110 hours in adults with severe renal impairment. The plasma elimination half-life of streptomycin has been reported to range from 4-10 hours in premature and newborn infants. In patients with impaired hepatic and renal function, the plasma elimination half-life has been reported to be more prolonged than in patients with renal impairment alone.']"
9649,19650,"Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride",CCOC(=O)C1(CC[NH+](CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9650,19651,Methylmercury;sulfuric acid,C[Hg].C[Hg].OS(=O)(=O)O,,,,,,
9651,19652,Digoxigenone,C[C@]12CCC(=O)C[C@H]1CCC3C2CC(=O)[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C,,,,,,
9652,19653,CID 19653,[O-]Cl(=O)=O.[K+],,,,,,
9653,19654,Chloric acid,OCl(=O)=O,,,,,,
9654,19655,Diethylmethyl(2-(N-methylbenzilamido)ethyl)ammonium bromide,CC[N+](C)(CC)CCN(C)C(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[Br-],,,,,,
9655,19656,4'-(Acetylsulfamoyl)succinanilic acid,CC(=O)NS(=O)(=O)C1=CC=C(C=C1)NC(=O)CCC(=O)O,,,,,,
9656,19657,Dioxabenzofos,COP1(=S)OCC2=CC=CC=C2O1,,,,,,
9657,19658,Sodium Omadine,C1=CC(=S)N(C=C1)[O-].[Na+],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
9658,19659,1-Oxidopyridine-2-thione,C1=CC(=S)N(C=C1)[O-],,,,,,
9659,19660,Carbonate Ion,C(=O)([O-])[O-],,,,,,
9660,19661,N-ethyl-2-(2-methoxyphenyl)-N-(2-morpholin-4-ylethyl)ethanamine,CCN(CCC1=CC=CC=C1OC)CCN2CCOCC2,,,,,,
9661,19662,Benazolin,C1=CC2=C(C(=C1)Cl)N(C(=O)S2)CC(=O)O,,,,,,
9662,19663,"2,4,5-T-trolamine",C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)O.C(CO)N(CCO)CCO,,,,,,
9663,19664,CID 19664,CC(CN=C(C(=NCC(C)O)S)S)O,,,,,,
9664,19665,N-Butyl-N-(4-hydroxybutyl)nitrosamine,CCCCN(CCCCO)N=O,,,,,,
9665,19666,CID 19666,C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CC=C2.C1=CC=C2C=C(C(=CC2=C1)C(=O)[O-])O,,,,,,
9666,19667,Bephenium,C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CC=C2,,,,"['AFTER ORAL ADMIN OF THERAPEUTIC DOSE OF BEPHENIUM HYDROXYNAPHTHOATE NOT MORE THAN 0.5% IS EXCRETED IN URINE WITHIN 24 HR. /HYDROXYNAPHTHOATE/', 'NOT ORDINARILY ABSORBED FROM GI TRACT, BUT IF INTESTINES ARE INFLAMED, SOME DRUG MAY BE ABSORBED...EXCRETED IN URINE. /HUMAN, ORAL/']",,
9667,19668,Betoxycaine,CCCCOC1=C(C=C(C=C1)C(=O)OCCOCCN(CC)CC)N,,,,,,
9668,19669,"2,3-Dimethyl-7-methoxy-8-(morpholinomethyl)chromone",CC1=C(OC2=C(C1=O)C=CC(=C2CN3CCOCC3)OC)C,,,,,,
9669,19670,Dodeconium,CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC.[Cl-].[Cl-],,,,,,
9670,19671,"N,N'-Bis[2-(dodecyloxy)-2-oxoethyl]-N,N,N',N'-tetramethyl-1,6-hexanediaminium",CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC,,,,,,
9671,19672,"Acetamide, N,N-diethyl-2-(2-methoxy-4-propylphenoxy)-",CCCC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OC,,,,,,
9672,19673,"Phenyl 3-(piperidinomethyl)-1,4-benzodioxan-6-yl ketone hydrochloride",C1CC[NH+](CC1)CC2COC3=C(O2)C=C(C=C3)C(=O)C4=CC=CC=C4.[Cl-],,,,,,
9673,19674,"Phenyl-[3-(piperidin-1-ylmethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]methanone",C1CCN(CC1)CC2COC3=C(O2)C=C(C=C3)C(=O)C4=CC=CC=C4,,,,,,
9674,19675,Piperacetazine,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO,,,,,,
9675,19676,"5-Isoindolinesulfonamide, 2-(2-bromoethyl)-6-chloro-1,3-dioxo-",C1=C2C(=CC(=C1S(=O)(=O)N)Cl)C(=O)N(C2=O)CCBr,,,,,,
9676,19677,2-Ethoxy-5-fluorobenzoic acid 3-(dibutylamino)propyl ester hydrochloride,CCCC[NH+](CCCC)CCCOC(=O)C1=C(C=CC(=C1)F)OCC.[Cl-],,,,,,
9677,19678,3-(Dibutylamino)propyl 2-ethoxy-5-fluorobenzoate,CCCCN(CCCC)CCCOC(=O)C1=C(C=CC(=C1)F)OCC,,,,,,
9678,19679,4-Ethoxy-3-fluorobenzoic acid 3-(dibutylamino)propyl ester hydrochloride,CCCC[NH+](CCCC)CCCOC(=O)C1=CC(=C(C=C1)OCC)F.[Cl-],,,,,,
9679,19680,3-(Dibutylamino)propyl 4-ethoxy-3-fluorobenzoate,CCCCN(CCCC)CCCOC(=O)C1=CC(=C(C=C1)OCC)F,,,,,,
9680,19681,2-Ethoxy-5-fluorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=C(C=CC(=C1)F)OCC.[Cl-],,,,,,
9681,19682,2-(Diethylamino)ethyl 2-ethoxy-5-fluorobenzoate,CCN(CC)CCOC(=O)C1=C(C=CC(=C1)F)OCC,,,,,,
9682,19683,"(6S,9R,11S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",C[C@@H]1CC2C3C[C@@H](C4=CC(=O)CCC4([C@]3([C@H](CC2([C@]1(C(=O)CO)O)C)O)F)C)F,,,,,,
9683,19684,"6-Dodecanone, 12-fluoro-",CCCCCC(=O)CCCCCCF,,,,,,
9684,19685,10-Fluoroaporphine hydrochloride,C[NH+]1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)F.[Cl-],,,,,,
9685,19686,"(6aS)-10-fluoro-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline",CN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C=C(C=C4)F,,,,,,
9686,19687,Homofenazine,C1CN(CCN(C1)CCO)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,,,,,,
9687,19688,"[(9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate",CCCCCCC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3C2CCC4=CC(=O)CC[C@H]34)C)C#C,,,,,,
9688,19689,3'-Ethoxy-4-dimethylaminoazobenzene,CCOC1=CC=CC(=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
9689,19690,3'-Nitro-4-dimethylaminoazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
9690,19691,2-Chlorotropone,C1=CC=C(C(=O)C=C1)Cl,,,,,,
9691,19692,2-(2-Methylphenoxy)aniline,CC1=CC=CC=C1OC2=CC=CC=C2N,,,,,,
9692,19693,Trisodium 5-((4-((4-((6-amino-1-hydroxy-3-sulphonato-2-naphthyl)azo)-1-naphthyl)azo)-6-sulphonato-1-naphthyl)azo)salicylate,C1=CC=C2C(=C1)C(=CC=C2N=NC3=C(C=C4C=C(C=CC4=C3O)N)S(=O)(=O)[O-])N=NC5=C6C=C(C=CC6=C(C=C5)N=NC7=CC(=C(C=C7)O)C(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
9693,19694,5-[2-[4-[2-[4-[2-(6-Amino-1-hydroxy-3-sulfo-2-naphthalenyl)diazenyl]-1-naphthalenyl]diazenyl]-6-sulfo-1-naphthalenyl]diazenyl]-2-hydroxybenzoic acid,C1=CC=C2C(=C1)C(=CC=C2N=NC3=C(C=C4C=C(C=CC4=C3O)N)S(=O)(=O)O)N=NC5=C6C=C(C=CC6=C(C=C5)N=NC7=CC(=C(C=C7)O)C(=O)O)S(=O)(=O)O,,,,,,
9694,19695,"1,1-Diethoxy-3-methylbutane",CCOC(CC(C)C)OCC,,,,,,
9695,19696,"4-chloro-N,6-diphenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC(=N2)Cl)NC3=CC=CC=C3,,,,,,
9696,19697,"4-Chloro-6-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC(=N2)Cl)N,,,,,,
9697,19698,"2-Chloro-4,6-diphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)Cl)C3=CC=CC=C3,,,,,,
9698,19699,Methyl(o-tolylazo)malononitrile,CC1=CC=CC=C1N=NCC(C#N)C#N,,,,,,
9699,19700,Brilliant Blue FCF,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5S(=O)(=O)[O-].[Na+].[Na+],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['The absorption, metabolism and excretion of (14)C-labelled Green S and Brilliant Blue FCF have been studied in the rat, mouse and guinea-pig. Following administration of a single oral dose of Green S at either 100 ug/kg or 10 mg/kg of Brilliant Blue FCF at either 30 ug/kg or 3 mg/kg to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hr. Pretreating male rats with unlabelled Green S or Brilliant Blue FCF in the diet (100 or 30 mg/kg day, respectively) for 21 days prior to dosing with (14)C-labelled coloring had no effect on the route of excretion or the time taken to eliminate all of the label. Similarly male mice and guinea-pigs excreted in the feces all of a single oral dose of Green S or Brilliant Blue FCF. The lack of absorption and metabolism of the labelled dye in the gastro-intestinal tract of all three species investigated was confirmed by studies using isolated loops of small intestine. It was shown that no radioactivity was taken up by the fetuses of pregnant rats given (14)C-labelled Green S or Brilliant Blue FCF.', 'Female Sprague-Dawley rats were given a single dose (0.27 mg; 1.74 uCi) of the (14)C-labelled coloring by gavage. In bile-duct ligated rats, intestinal absorption of FD & C Blue No.1 (estimated from urinary (14)C excretion, expired (14)CO2 and residual radioactivity in internal organs and tissues 96 hr after oral administration) averaged 2.05% of the dose.  Mean fecal excretion was 97.28% and the total recovery of administered radioactivity was 99.38%. Intestinal absorption (14)C-FD & C Blue No. 1 in intact rats averaged only 0.27% (91% recovery), while biliary excretion in bile-duct cannulated animals averaged 1.32% of the dose. Thin-layer chromatography of urine and bile samples revealed that about 95% of excreted radioactivity was unaltered FD & C Blue No. 1 and that about 5% was an unidentified metabolite or degradation product of FD & C Blue No. 1. The results show that FD & C Blue No.1 is poorly absorbed from the gastro-intestinal tract, and undergoes subsequent rapid and complete biliary excretion /of the absorbed compound/.', '... Less than 0.05% of a labeled dose of 3 mg/kg bw was excreted in the bile of rats over a 5-hour period. Very little radioactivity (0.004 - 0.006% of dose) was detected on day 11 in the fetuses of pregnant rats given (14)C-labelled Brilliant Blue FCF orally on day 8 of gestation. ... Brilliant Blue FCF was labeled with (14)C in the central methane ring and had a radioactive purity of greater than 95%. ...', 'Following administration of either 30 ug/kg bw or 3 mg/kg bw of (14)C-Brilliant Blue FCF by gavage to male or female rats, substantially all of the dose was excreted unchanged in the feces within 72 hours (99.9% at low dose, 95.4% at high dose). No radioactivity was detected in the expired air and less than 0.5% was detected in the urine. ...', 'For more Absorption, Distribution and Excretion (Complete) data for Brilliant Blue (6 total), please visit the HSDB record page.']",,
9700,19701,"Biurea, 1,6-dimethyl-1,6-dinitroso-",CN(C(=O)NNC(=O)N(C)N=O)N=O,,,,,,
9701,19702,1-Nitroso-2-imidazolidinone,C1CN(C(=O)N1)N=O,,,,,,
9702,19703,"4H-1-Benzopyran-2-carboxanilide, 4-oxo-4'-sulfamoyl-",C1=CC=C2C(=C1)C(=O)C=C(O2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N,,,,,,
9703,19704,Teroxalene hydrochloride,CCC(C)(C)C1=CC=C(C=C1)OCCCCCCN2CCN(CC2)C3=CC(=C(C=C3)C)Cl.Cl,,,,,,
9704,19705,Teroxalene,CCC(C)(C)C1=CC=C(C=C1)OCCCCCCN2CCN(CC2)C3=CC(=C(C=C3)C)Cl,,,,,,
9705,19706,"2,4-Diethyl-6-(methylsulfanyl)-1,3,5-triazine",CCC1=NC(=NC(=N1)SC)CC,,,,,,
9706,19707,"2,3-Hexanedione",CCCC(=O)C(=O)C,,,,,,
9707,19708,Diphenyl phenylphosphoramidate,C1=CC=C(C=C1)NP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
9708,19709,"3,3-Dimethylbutylamine",CC(C)(C)CCN,,,,,,
9709,19710,Methyl 3-methoxypropionate,COCCC(=O)OC,,,,,,
9710,19711,"6,6-Dimethyl-7-(dimethylamino)-3-nonanone",CCC(C(C)(C)CCC(=O)CC)N(C)C,,,,,,
9711,19712,2-(Dimethoxyphosphinothioylsulfanylmethylsulfanyl)ethyl carbamate,COP(=S)(OC)SCSCCOC(=O)N,,,,,,
9712,19713,2-((((Methoxy(1-methylethoxy)phosphinothioyl)thio)methyl)thio)ethyl ethylcarbamate,CCNC(=O)OCCSCSP(=S)(OC)OC(C)C,,,,,,
9713,19714,(4-(2-Oxo-1-pyrrolidinyl)-2-butynyl)trimethylammonium iodide,C[N+](C)(C)CCC#CN1CCCC1=O.[I-],,,,,,
9714,19715,Trimethyl-[4-(2-oxopyrrolidin-1-yl)but-3-ynyl]azanium,C[N+](C)(C)CCC#CN1CCCC1=O,,,,,,
9715,19716,"Acetamide, N-methyl-N-(4-(1-pyrrolidinyl)-2-butynyl)-",CC(=O)N(C)CC#CCN1CCCC1,,,,,,
9716,19717,"Acetamide, N-(4-(dimethylamino)-2-butynyl)-N-methyl-, oxalate (1:1)",CC(=O)N(C)CC#CCN(C)C.C(=O)(C(=O)O)O,,,,,,
9717,19718,N-[4-(dimethylamino)but-2-ynyl]-N-methylacetamide,CC(=O)N(C)CC#CCN(C)C,,,,,,
9718,19719,Trimethyl(4-(N-methyl-acetamido)but-2-ynyl)ammonium iodide,CC(=O)N(C)CC#CC[N+](C)(C)C.[I-],,,,,,
9719,19720,4-[Acetyl(methyl)amino]but-2-ynyl-trimethylazanium,CC(=O)N(C)CC#CC[N+](C)(C)C,,,,,,
9720,19721,"Ammonium, trimethyl(4-(trimethylureido)-2-butynyl)-, iodide",CN(C)C(=O)N(C)CC#CC[N+](C)(C)C.[I-],,,,,,
9721,19722,4-[Dimethylcarbamoyl(methyl)amino]but-2-ynyl-trimethylazanium,CN(C)C(=O)N(C)CC#CC[N+](C)(C)C,,,,,,
9722,19723,4-Dimethylaminobut-2-ynyl dimethylcarbamate hydrochloride,C[NH+](C)CC#CCOC(=O)N(C)C.[Cl-],,,,,,
9723,19724,Dimethylcarbamic acid 4-(dimethylamino)-2-butynyl ester,CN(C)CC#CCOC(=O)N(C)C,,,,,,
9724,19725,Copaene,CC1=CCC2C3C1C2(CCC3C(C)C)C,,,,,,
9725,19726,Butylammonium chloride,CCCC[NH3+].[Cl-],,,,,,
9726,19727,Nesacaine,CC[NH+](CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
9727,19728,"6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one",CN1CCC2=CC3=C(C(=C2[C@@H]1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,,,,,,
9728,19729,C.I. Disperse blue 26,CNC1=C2C(=C(C=C1)O)C(=O)C3=C(C=CC(=C3C2=O)O)NC,,,,,,
9729,19730,Ioxynil octanoate,CCCCCCCC(=O)OC1=C(C=C(C=C1I)C#N)I,,,,,,
9730,19731,Anazolene sodium,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=C5C(=CC(=C4)S(=O)(=O)[O-])C=C(C=C5O)S(=O)(=O)[O-])C=CC=C3S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
9731,19732,Anazolene,C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=C5C(=CC(=C4)S(=O)(=O)O)C=C(C=C5O)S(=O)(=O)O)C=CC=C3S(=O)(=O)O,,,,,,
9732,19733,4-(Aminosulfonyl)-5-chlorophthalimide,C1=C2C(=CC(=C1S(=O)(=O)N)Cl)C(=O)NC2=O,,,,,,
9733,19734,"5-Isoindolinesulfonamide, 2-allyl-6-chloro-1,3-dioxo-",C=CCN1C(=O)C2=CC(=C(C=C2C1=O)Cl)S(=O)(=O)N,,,,,,
9734,19735,"4-Bis(3,4-dimethylphenyl)phosphoryl-1,2-dimethylbenzene",CC1=C(C=C(C=C1)P(=O)(C2=CC(=C(C=C2)C)C)C3=CC(=C(C=C3)C)C)C,,,,,,
9735,19736,Trixylenyl phosphate,CC1=CC(=C(C=C1)OP(=O)(OC2=C(C=C(C=C2)C)C)OC3=C(C=C(C=C3)C)C)C,,,,,,
9736,19737,"N-[3-[2-(diethylamino)ethylamino]-1-(2,4-dimethoxyphenyl)-3-oxoprop-1-en-2-yl]-3,5-dimethoxybenzamide",CCN(CC)CCNC(=O)C(=CC1=C(C=C(C=C1)OC)OC)NC(=O)C2=CC(=CC(=C2)OC)OC,,,,,,
9737,19738,"[2-[(17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate",CC12CCC(=O)C=C1CCC3C2C(CC4(C3CC[C@@]4(C(=O)COP(=O)(O)O)O)C)O,,,,,,
9738,19739,"p-CYMENE-2-CARBOXAMIDE, 3-HYDROXY-N-(2-HYDROXYETHYL)-",CC1=C(C(=C(C=C1)C(C)C)O)C(=O)NCCO,,,,,,
9739,19740,CID 19740,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CN=CC=C3)C(=O)[O-])C.[K+],,,,,,
9740,19741,"3,3-Dimethyl-7-oxo-6-[(2-pyridin-3-ylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CN=CC=C3)C(=O)O)C,,,,,,
9741,19742,"3H-1,4-Benzodiazepine, 7-chloro-2-(cyclopropylamino)-5-phenyl-, 4-oxide",C1CC1N=C2CN(C(=C3C=C(C=CC3=N2)Cl)C4=CC=CC=C4)O,,,,,,
9742,19743,"Ammonium, octamethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCCCCCCC[N+](C)(C)C.[I-].[I-],,,,,,
9743,19744,Octamethonium,C[N+](C)(C)CCCCCCCC[N+](C)(C)C,,,,,,
9744,19745,"N-[3-[2-(diethylamino)ethylamino]-1-(2,4-dimethoxyphenyl)-3-oxoprop-1-en-2-yl]benzamide",CCN(CC)CCNC(=O)C(=CC1=C(C=C(C=C1)OC)OC)NC(=O)C2=CC=CC=C2,,,,,,
9745,19746,Triamcinolone acetonide acetate,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3C1(C[C@@H]([C@]4(C3CCC5=CC(=O)C=CC54C)F)O)C)OC(O2)(C)C,,,,,,
9746,19747,Moperone hydrochloride,CC1=CC=C(C=C1)C2(CC[NH+](CC2)CCCC(=O)C3=CC=C(C=C3)F)O.[Cl-],,,,,,
9747,19748,Methyl fluorophosphoryl beta-methylcholine iodide,CC(C[N+](C)(C)C)OP(=O)(C)F.[I-],,,,,,
9748,19749,(2-Hydroxypropyl)trimethylammonium ester with methylphosphonofluoridate,CC(C[N+](C)(C)C)OP(=O)(C)F,,,,,,
9749,19750,4-Chloro-4'-fluorobutyrophenone,C1=CC(=CC=C1C(=O)CCCCl)F,,,,,,
9750,19751,Isopropylcyclopentane,CC(C)C1CCCC1,,,,,,
9751,19752,Clominorex,C1C(OC(=N1)N)C2=CC=C(C=C2)Cl,,,,,,
9752,19753,"1,2,8-Trimethylnaphthalene",CC1=C2C(=C(C=CC2=CC=C1)C)C,,,,,,
9753,19754,Methyl propyl sulfide,CCCSC,,,,,,
9754,19755,2-Methyltetralin,CC1CCC2=CC=CC=C2C1,,,,,,
9755,19756,Fuberidazole,C1=CC=C2C(=C1)NC(=N2)C3=CC=CO3,,,,,,
9756,19757,"3-Acetyl-5-[2-(5-nitrofuran-2-yl)ethenyl]-1,3,4-oxadiazol-2-one",CC(=O)N1C(=O)OC(=N1)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
9757,19758,Triphenylphosphine sulfide,C1=CC=C(C=C1)P(=S)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
9758,19759,Benzoic acid-alpha-13C,C1=CC=C(C=C1)[13C](=O)O,,,,,,
9759,19760,Dicyclohexylamine nitrate,C1CCC(CC1)[NH2+]C2CCCCC2.[N+](=O)([O-])[O-],,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
9760,19761,CID 19761,C1CSC(=N1)[NH3+].[Cl-],,,,,,
9761,19762,"(3S)-2,3-dichloro-1,4-dioxane",C1COC([C@@H](O1)Cl)Cl,,,,,,
9762,19763,"2,2-Dimethyl-1,3-cyclopentanedione",CC1(C(=O)CCC1=O)C,,,,,,
9763,19764,"Acetamide, N-dodecyl-",CCCCCCCCCCCCNC(=O)C,,,,,,
9764,19765,"N,N-Dimethylstearamide",CCCCCCCCCCCCCCCCCC(=O)N(C)C,,,,,,
9765,19766,"N,N-Dimethylhexadecanamide",CCCCCCCCCCCCCCCC(=O)N(C)C,,,,,,
9766,19767,"6-Methyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indole-2-carboxylic acid ethyl ester",CCOC(=O)C1=C2CCNC(C3=C2C(=CC=C3)N1)C,,,,,,
9767,19768,"6-Methyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indolyl piperidino ketone",CC1C2=C3C(=C(NC3=CC=C2)C(=O)N4CCCCC4)CCN1,,,,,,
9768,19769,"9-Chloro-6-methyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indole",CC1C2=C3C(=CNC3=C(C=C2)Cl)CCN1,,,,,,
9769,19770,"1H-AZEPINO(5,4,3-cd)INDOLE-2-METHANOL, 3,4,5,6-TETRAHYDRO-9-CHLORO-6-METHYL-",CC1C2=C3C(=C(NC3=C(C=C2)Cl)CO)CCN1,,,,,,
9770,19771,"9-Chloro-5,6-dimethyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indole",CC1C2=C3C(=CNC3=C(C=C2)Cl)CCN1C,,,,,,
9771,19772,"Aziridine, 1-stearoyl-",CCCCCCCCCCCCCCCCCC(=O)N1CC1,,,,,,
9772,19773,"2,6,10-Trimethyldodecane",CCC(C)CCCC(C)CCCC(C)C,,,,,,
9773,19774,"2,6,10-Trimethyltridecane",CCCC(C)CCCC(C)CCCC(C)C,,,,,,
9774,19775,"2,6,10-Trimethylpentadecane",CCCCCC(C)CCCC(C)CCCC(C)C,,,,,,
9775,19776,N-Ethyl-3-isopropyl-6-methylsalicylamide,CCNC(=O)C1=C(C=CC(=C1O)C(C)C)C,,,,,,
9776,19777,"p-CYMENE-2-CARBOXAMIDE, N-BENZYL-3-HYDROXY-",CC1=C(C(=C(C=C1)C(C)C)O)C(=O)NCC2=CC=CC=C2,,,,,,
9777,19778,"p-CYMENE-2-CARBOXANILIDE, 4'-HYDROXY-3-METHOXY-",CC1=C(C(=C(C=C1)C(C)C)OC)C(=O)NC2=CC=C(C=C2)O,,,,,,
9778,19779,3-Hydroxy-N-(beta-hydroxyphenethyl)-p-cymene-2-carboxamide diacetate,CC1=C(C(=C(C=C1)C(C)C)OC(=O)C)C(=O)NCC(C2=CC=CC=C2)OC(=O)C,,,,,,
9779,19780,"p-CYMENE-2-CARBOXAMIDE, 3-HYDROXY-N-(2-HYDROXYETHYL)-, DIACETATE",CC1=C(C(=C(C=C1)C(C)C)OC(=O)C)C(=O)NCCOC(=O)C,,,,,,
9780,19781,"p-CYMENE-2-CARBOXAMIDE, 3-HYDROXY-N-PHENETHYL-, ACETATE",CC1=C(C(=C(C=C1)C(C)C)OC(=O)C)C(=O)NCCC2=CC=CC=C2,,,,,,
9781,19782,1-(2-(2-Ethoxyethoxy)ethoxy)butane,CCCCOCCOCCOCC,,,,,,
9782,19783,"8-(4-(4-Fluorophenyl)-4-oxobutyl)-2,4-dimethyl-2,8-diazaspiro(4.5)decane-1,3-dione",CC1C(=O)N(C(=O)C12CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C,,,,,,
9783,19784,"N,N-Bis(2-chloroethyl)-N',N'-diethyl-1,4-butanediamine dihydrochloride",CC[NH+](CC)CCCC[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
9784,19785,"N,N-Bis(2-chloroethyl)-N',N'-diethyl-1,4-butanediamine",CCN(CC)CCCCN(CCCl)CCCl,,,,,,
9785,19786,CID 19786,C=CCC1(C(=O)NC(=NC1=O)S)C2=CCCCC2,,,,,,
9786,19787,Hexyl dihydrogen phosphate,CCCCCCOP(=O)(O)O,,,,,,
9787,19788,N-Diethylaminoethylbenzoxazolone hydrochloride,CC[NH+](CC)CCN1C2=CC=CC=C2OC1=O.[Cl-],,,,,,
9788,19789,"3-[2-(diethylamino)ethyl]-1,3-benzoxazol-2(3H)-one",CCN(CC)CCN1C2=CC=CC=C2OC1=O,,,,,,
9789,19790,"Disulfide, bis(2-amino-4-sulfamoylphenyl)",C1=CC(=C(C=C1S(=O)(=O)N)N)SSC2=C(C=C(C=C2)S(=O)(=O)N)N,,,,,,
9790,19791,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-7-chloro-10-(2-(piperidino)ethyl)-",C1CCN(CC1)CCN2C3=C(C=C(C=C3)Cl)NC4=CC=CC=C4C2=O,,,,,,
9791,19792,"5H-Dibenzo(b,e)(1,4)diazepin-11-one, 10,11-dihydro-10-(2-(dimethylamino)ethyl)-3-methoxy-",CN(C)CCN1C2=CC=CC=C2NC3=C(C1=O)C=CC(=C3)OC,,,,,,
9792,19793,"1-Phenyl-1,3,3-trimethylindan",CC1(CC(C2=CC=CC=C21)(C)C3=CC=CC=C3)C,,,,,,
9793,19794,2-Nonynamide,CCCCCCC#CC(=O)N,,,,,,
9794,19795,2-(Phenyldithio)ethylamine hydrochloride,C1=CC=C(C=C1)SSCC[NH3+].[Cl-],,,,,,
9795,19796,2-(Phenyldisulfanyl)ethanamine,C1=CC=C(C=C1)SSCCN,,,,,,
9796,19797,"GUANIDINE, 2-(o-CHLOROBENZYL)-1-METHYL-",CN=C(N)NCC1=CC=CC=C1Cl,,,,,,
9797,19798,"GUANIDINE, (o-BROMOBENZYL)-",C1=CC=C(C(=C1)CN=C(N)N)Br,,,,,,
9798,19799,"Guanidine, (2,4-dichlorobenzyl)-",C1=CC(=C(C=C1Cl)Cl)CN=C(N)N,,,,,,
9799,19800,2-Butyl-1-octanol,CCCCCCC(CCCC)CO,,,,,,
9800,19801,Dec-2-enal,CCCCCCCC=CC=O,,,,,,
9801,19802,"Butanoic acid, 3-methyl-, (2E)-3,7-dimethyl-2,6-octadienyl ester",CC(C)CC(=O)OCC=C(C)CCC=C(C)C,,,,,,
9802,19803,"Hepta-3,5-dien-2-one",CC=CC=CC(=O)C,,,,,,
9803,19804,"1-Naphthaleneacetamide, 5,6,7,8-tetrahydro-N,N-dimethyl-",CN(C)C(=O)CC1=CC=CC2=C1CCCC2,,,,,,
9804,19805,"Barbituric acid, 1,3-bis(4-(diethylamino)-2-butynyl)-5,5-diethyl-, dihydrochloride",CCC1(C(=O)N(C(=O)N(C1=O)CC#CCN(CC)CC)CC#CCN(CC)CC)CC.Cl.Cl,,,,,,
9805,19806,"1,3-Bis[4-(diethylamino)but-2-ynyl]-5,5-diethyl-1,3-diazinane-2,4,6-trione",CCC1(C(=O)N(C(=O)N(C1=O)CC#CCN(CC)CC)CC#CCN(CC)CC)CC,,,,,,
9806,19807,Ethyl aminooxyacetate hydrochloride,CCOC(=O)CO[NH3+].[Cl-],,,,,,
9807,19808,Ethyl (aminooxy)acetate,CCOC(=O)CON,,,,,,
9808,19809,2-((2-Piperidinoethyl)thio)benzoxazole hydrochloride,C1CC[NH+](CC1)CCSC2=NC3=CC=CC=C3O2.[Cl-],,,,,,
9809,19810,"2-{[2-(Piperidin-1-yl)ethyl]sulfanyl}-1,3-benzoxazole",C1CCN(CC1)CCSC2=NC3=CC=CC=C3O2,,,,,,
9810,19811,Trimethyl(4-(2-oxocyclopentyl)but-2-ynyl)ammonium iodide,C[N+](C)(C)CC#CCC1CCCC1=O.[I-],,,,,,
9811,19812,Trimethyl-[4-(2-oxocyclopentyl)but-2-ynyl]azanium,C[N+](C)(C)CC#CCC1CCCC1=O,,,,,,
9812,19813,"5-Heptyn-2-one, 7-(1-pyrrolidinyl)-, oxalate (1:1)",CC(=O)CCC#CC[NH+]1CCCC1.C(=O)(C(=O)[O-])O,,,,,,
9813,19814,7-Pyrrolidin-1-ylhept-5-yn-2-one,CC(=O)CCC#CCN1CCCC1,,,,,,
9814,19815,"5-Heptyn-2-one, 7-(dimethylamino)-, oxalate (1:1)",CC(=O)CCC#CC[NH+](C)C.C(=O)(C(=O)[O-])O,,,,,,
9815,19816,7-Dimethylamino-hept-5-yn-2-one,CC(=O)CCC#CCN(C)C,,,,,,
9816,19817,Trimethyl(6-oxohept-2-ynyl)ammonium iodide,CC(=O)CCC#CC[N+](C)(C)C.[I-],,,,,,
9817,19818,Trimethyl(6-oxohept-2-ynyl)azanium,CC(=O)CCC#CC[N+](C)(C)C,,,,,,
9818,19819,(4-Acetoxybut-2-ynyl)trimethylammonium iodide,CC(=O)OCC#CC[N+](C)(C)C.[I-],,,,,,
9819,19820,4-Acetoxy-2-butynyltrimethylaminium,CC(=O)OCC#CC[N+](C)(C)C,,,,,,
9820,19821,"1,1,1,7-Tetrachloroheptane",C(CCCCl)CCC(Cl)(Cl)Cl,,,,,,
9821,19822,"(3S,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione",C[C@H]1C[C@]2(CO2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1OC3C(C(CC(O3)C)N(C)C)O)C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Macrolides become widely distributed in tissues, and concentrations are about the same as in plasma, or even higher in some instances. They actually accumulate within many cells, including macrophages, in which they may be > or = 20 times the plasma concentration. This accumulation accounts in part for the long dosing interval that characterizes some macrolides (eg, tilmicosin). ... Macrolides tend to concentrate in the spleen, liver, kidneys, and particularly the lungs. They enter pleural and ascitic fluids but not the CSF (only 2-13% of plasma concentration unless the meninges are inflamed). They concentrate in the bile and milk. Up to 75% of the dose is bound to plasma proteins, and they bind to alpha1-acid glycoproteins rather than to albumin. /Macrolides/', 'Macrolides are readily absorbed from the GI tract if not inactivated by gastric acid. ... Plasma levels peak within 1-2 hours in most cases, although absorption patterns may be erratic due to the presence of food and may depend on the salt or ester used. Absorption from the ruminoreticulum is usualy delayed and is unreliable. /Macrolides/', 'Macrolide antibiotics and their metabolites are excreted mainly in the bile (> 60%) and often undergo enterohepatic cycling. Urinary clearance may be slow and variable (often <10%) but my represent a more significant route of elimination after parenteral administration. The concentration of macrolides in milk often is several times greater than in plasma, especially in mastitis. /Macrolide/', 'The pharmacokinetics of oleandomycin (OLD) after intravenous and oral administration, both alone and after intramuscular pretreatment with metamizole or dexamethasone, were studied in healthy dogs. After intravenous injection of oleandomycin alone (10 mg/kg as bolus), the elimination half-life (t 1/2 beta, volume of distribution (Vd, area), body clearance (ClB) and area under the concentration time curve (AUC) were 1.60 hr, 1.11 L/kg. 7.36 (ml/kg)/min and 21.66 ug hr/ml, respectively. There were no statistically significant differences following pretreatment with metamizole or dexamethasone. After oral administration of oleandomycin alone, the t 1/2 beta, maximum plasma concentrations (Cmax), time of Cmax (tmax), mean absorption time and absolute bioavailability (Fabs) were 1.6 hr, 5.34 ug/ml, 1.5 hr, 1.34 hr and 84.29%, respectively. Pretreatment with metamizole caused a significantly decreased value for Cmax (2.93 ug/ml) but the mean absorption time value (2.23 hr) was significantly increased. Statistically significant changes in the pharmacokinetic parameters of oleandomycin following oral administration were also observed as a result of pretreatment with dexamethasone. The Cmax was increased (8.24 ug/ml) and the tmax (0.5 hr) and mean absorption time (0.45 hr) were lower.', 'Knowledge of the disposition of macrolides in a single animal species has been insufficient for the prediction of the pharmacokinetics of macrolides in humans. To better understand the species differences in the pharmacokinetics of macrolide antibiotics, the disposition of erythromycin, oleandomycin, and tylosin in several mammalian species was examined. Generally, the serum concentration versus time profiles of these drugs after intravenous administration were described by two-compartment kinetic models and were similar within each species. These drugs were rapidly cleared, resulting in terminal half-lives of less than 2 h. Comparison of their pharmacokinetics showed greater variation in antibiotic disposition among animal species than noted for the differences within a species. When the pharmacokinetic data was fitted to an allometric model, the logarithms of volume of distribution, clearance, and half-life were linearly related to the logarithms of body weight. From these relationships, the human pharmacokinetics of erythromycin and oleandomycin were extrapolated and found to approximate observed human pharmacokinetics.']","['Metabolic inactivation of the macrolides is usually extensive, but the relative proportion depends on the route of administration and th particular antibiotic. ... /Macrolides/']","['The plasma half-lives of macrolides usually are 1-3 hr, ... /Macrolides/']"
9822,19823,CID 19823,CCC1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)C=CC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)CO)C)O)F)C)CC,,,,,,
9823,19824,"Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-6-hydroxy-",CN(C)CCCN1C2=C(C(=CC=C2)O)SC3=C1C=C(C=C3)Cl,,,,,,
9824,19825,8-Hydroxychlorpromazine,CN(C)CCCN1C2=C(C=CC(=C2)O)SC3=C1C=C(C=C3)Cl,,,,,,
9825,19826,"2(3H)-Furanone, 3-allyldihydro-5-methyl-",CC1CC(C(=O)O1)CC=C,,,,,,
9826,19827,"2,3-Dihydroxy-4-methylbenzoic acid",CC1=C(C(=C(C=C1)C(=O)O)O)O,,,,,,
9827,19828,"Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-3-hydroxy-",CN(C)CCCN1C2=CC=CC=C2SC3=CC(=C(C=C31)Cl)O,,,,,,
9828,19829,"3,4-Dihydroxy-5-methoxybenzoic acid",COC1=CC(=CC(=C1O)O)C(=O)O,,,,,,
9829,19830,"Acetophenone, 3,4-dihydroxy-5-methoxy-",CC(=O)C1=CC(=C(C(=C1)OC)O)O,,,,,,
9830,19831,gamma-Morpholino-butyrophenone,C1COCCN1CCCC(=O)C2=CC=CC=C2,,,,,,
9831,19832,4-(4-Oxo-4-phenylbutyl)morpholin-4-ium chloride,C1COCC[NH+]1CCCC(=O)C2=CC=CC=C2.[Cl-],,,,,,
9832,19833,"4-Butoxy-N,N-dibutyl-1-naphthamidine hydrochloride",CCCC[NH+](CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC.[Cl-],,,,,,
9833,19834,"4-butoxy-N,N-dibutylnaphthalene-1-carboximidamide",CCCCN(CCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCC,,,,,,
9834,19835,"1,9-Nonanediol",C(CCCCO)CCCCO,,,,,,
9835,19836,"(4R,8S,10R)-8-acetyl-10-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one",CC(=O)[C@@]12[C@@H](CC3C1([C@H](C(C4C3CCC5=CC(=O)CCC45C)O)F)C)OC(O2)(C)C,,,,,,
9836,19837,"3-Isopropylphenyl N,N-dimethylcarbamate",CC(C)C1=CC(=CC=C1)OC(=O)N(C)C,,,,,,
9837,19838,Ethyl pivalate,CCOC(=O)C(C)(C)C,,,,,,
9838,19839,CID 19839,C[NH2+]NCCOC1=CC=CC=C1.C(=CC(=O)[O-])C(=O)O,,,,,,
9839,19840,1-Methyl-2-(2-phenoxyethyl)hydrazine,CNNCCOC1=CC=CC=C1,,,,,,
9840,19841,2-Chlorophenyl methylcarbamate,CNC(=O)OC1=CC=CC=C1Cl,,,,,,
9841,19842,"Carbamic acid, methyl-, thymyl ester",CC1=CC(=C(C=C1)C(C)C)OC(=O)NC,,,,,,
9842,19843,"Carbamic acid, dimethyl-, 4-(1-pyrrolidinyl)-2-butynyl ester",CN(C)C(=O)OCC#CCN1CCCC1,,,,,,
9843,19844,Methyl vanillate,COC1=C(C=CC(=C1)C(=O)OC)O,,,,,,
9844,19845,"Ethyl 4-hydroxy-3,5-dimethoxybenzoate",CCOC(=O)C1=CC(=C(C(=C1)OC)O)OC,,,,,,
9845,19846,1-Isopropoxy-2-propanol,CC(C)OCC(C)O,,,,,,
9846,19847,"1,2-Bis(2-chloroethylsulfonyl)ethane",C(CS(=O)(=O)CCCl)S(=O)(=O)CCCl,,,,,,
9847,19848,1-Methylquinolinium iodide,C[N+]1=CC=CC2=CC=CC=C21.[I-],,,,,,
9848,19849,1-Methylquinolinium,C[N+]1=CC=CC2=CC=CC=C21,,,,,,
9849,19850,2-Methylisoquinolinium iodide,C[N+]1=CC2=CC=CC=C2C=C1.[I-],,,,,,
9850,19851,N-Methylisoquinolinium,C[N+]1=CC2=CC=CC=C2C=C1,,,,,,
9851,19852,"3,4-Dihydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium iodide",C[N+]1=C(C2=CC(=C(C=C2CC1)OC)OC)CC3=CC(=C(C=C3)OC)OC.[I-],,,,,,
9852,19853,"2-Methyl-3,4-dihydropapaverinium",C[N+]1=C(C2=CC(=C(C=C2CC1)OC)OC)CC3=CC(=C(C=C3)OC)OC,,,,,,
9853,19854,"2,4,6-Tris(1-naphthyloxy)-1,3,5-triazine",C1=CC=C2C(=C1)C=CC=C2OC3=NC(=NC(=N3)OC4=CC=CC5=CC=CC=C54)OC6=CC=CC7=CC=CC=C76,,,,,,
9854,19855,2-Ethylbutyl acrylate,CCC(CC)COC(=O)C=C,,,,,,
9855,19856,CID 19856,CCOC1=CC=CC=C1NN=NC(=NC#N)N,,,,,,
9856,19857,N-Acetylglycine 2-(1-methyl-3-phenylpropyl)hydrazide,CC(CCC1=CC=CC=C1)C(C(=O)NN)NC(=O)C,,,,,,
9857,19858,"2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-, disodium salt",C1=C2C=C(C=C(C2=C(C=C1S(=O)(=O)[O-])N)O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
9858,19859,4-Bromo-2-chlorophenol,C1=CC(=C(C=C1Br)Cl)O,,,,,,
9859,19860,3-Chloro-4-hydroxybenzoic acid,C1=CC(=C(C=C1C(=O)O)Cl)O,,,,,,
9860,19861,Azatadine,CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1,"['For the relief of the symptoms of upper respiratory mucosal congestion in perennial and allergic rhinitis, and for the relief of nasal congestion and eustachian t.b. congestion.']","['Azatadine is an antihistamine, related to cyproheptadine, with anti-serotonin, anticholinergic (drying), and sedative effects. Azatadine is in the same class of drugs as chlorpromazine (Thorazine) and trifluoperazine (Stelazine); however, unlike the other drugs in this class, azatadine is not used clinically as an anti-psychotic. Antihistamines antagonize the vasodilator effect of endogenously released histamine, especially in small vessels, and mitigate the effect of histamine which results in increased capillary permeability and edema formation. As consequences of these actions, antihistamines antagonize the physiological manifestations of histamine release in the nose following antigen-antibody interaction, such as congestion related to vascular engorgement, mucosal edema, and profuse, watery secretion, and irritation and sneezing resulting from histamine action on afferent nerve terminals.']","['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)']",['Well absorbed after oral administration.'],['Hepatic.'],
9861,19862,"2,4-D 2-butoxyisopropyl ester",CCCCOCC(C)OC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
9862,19863,"3-[(8R,9S,13S,14S,17S)-17-hydroxy-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]prop-2-ynyl 3-phenylpropanoate",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#CCOC(=O)CCC4=CC=CC=C4)O)CCC5=C3C=CC(=C5)OC,,,,,,
9863,19864,CID 19864,C1=CC=C(C=C1)C=CC(=O)N[O-].[Na+],,,,,,
9864,19865,N-oxido-3-phenylprop-2-enamide,C1=CC=C(C=C1)C=CC(=O)N[O-],,,,,,
9865,19866,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-bromo-1-(2-diethylamino)ethyl-5-(2-pyridyl)-, hydrochloride",CC[NH+](CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Br)C3=CC=CC=N3.[Cl-],,,,,,
9866,19867,"7-bromo-1-[2-(diethylamino)ethyl]-5-pyridin-2-yl-3H-1,4-benzodiazepin-2-one",CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Br)C3=CC=CC=N3,,,,,,
9867,19868,"4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one",CC1CC(=O)NC2=CC=CC=C2N1,,,,,,
9868,19869,"4,5-Dichloro-1,3-dioxolan-2-one",C1(C(OC(=O)O1)Cl)Cl,,,,,,
9869,19870,2-Chloro-3-nitrobenzoic acid,C1=CC(=C(C(=C1)[N+](=O)[O-])Cl)C(=O)O,,,,,,
9870,19871,"2,2-Dimethyl-3-pentanol",CCC(C(C)(C)C)O,,,,,,
9871,19872,2-Ethyloctanedioic acid,CCC(CCCCCC(=O)O)C(=O)O,,,,,,
9872,19873,"Carbamic acid, methyl-, 2,3,4-trimethylphenyl ester",CC1=C(C(=C(C=C1)OC(=O)NC)C)C,,,,,,
9873,19874,"Ethane, 2,2-bis(4-iodophenyl)-1,1,1-trichloro-",C1=CC(=CC=C1C(C2=CC=C(C=C2)I)C(Cl)(Cl)Cl)I,,,,,,
9874,19875,"ACETIC ACID, 2-(alpha-METHYLBENZYL)HYDRAZIDE",CC(C1=CC=CC=C1)NNC(=O)C,,,,,,
9875,19876,"2,4,6-Trimethylbiphenyl",CC1=CC(=C(C(=C1)C)C2=CC=CC=C2)C,,,,,,
9876,19877,"3,4-Dichlorocatechol",C1=CC(=C(C(=C1O)O)Cl)Cl,,,,,,
9877,19878,4-tert-Butylpyridine,CC(C)(C)C1=CC=NC=C1,,,,,,
9878,19879,(alpha-Methylbenzyl)hydrazine sulfate,CC(C1=CC=CC=C1)N[NH3+].OS(=O)(=O)[O-],,,,,,
9879,19880,Peripalloside,CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C)O)O)O,,,,,,
9880,19881,"3-[(3S,5S,8R,10R,12R,13S,14S,17R)-5,12,14-trihydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1C(C(C(C(O1)O[C@H]2CC[C@@]3(C4C[C@H]([C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O,,,,,,
9881,19882,"1,3,3,5-Tetramethyl-1,1,5,5-tetraphenyltrisiloxane",C[Si](C)(O[Si](C)(C1=CC=CC=C1)C2=CC=CC=C2)O[Si](C)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9882,19883,Thiophosphoryl chloride,P(=S)(Cl)(Cl)Cl,,,,,,
9883,19884,"AMMONIUM, (o-HYDROXYPHENYL)TRIMETHYL-, IODIDE, METHYLCARBAMATE",CNC(=O)OC1=CC=CC=C1[N+](C)(C)C.[I-],,,,,,
9884,19885,"n,n,n-Trimethyl-2-[(methylcarbamoyl)oxy]anilinium",CNC(=O)OC1=CC=CC=C1[N+](C)(C)C,,,,,,
9885,19886,"Ammonium, (3-(methylcarbamoyloxy)phenyl)trimethyl-, iodide",CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[I-],,,,,,
9886,19887,"Benzenaminium, N,N,N-trimethyl-3-(((methylamino)carbonyl)oxy)-",CNC(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
9887,19888,"AMMONIUM, (p-HYDROXYPHENYL)TRIMETHYL-, IODIDE, METHYLCARBAMATE",CNC(=O)OC1=CC=C(C=C1)[N+](C)(C)C.[I-],,,,,,
9888,19889,"4-[[(Methylamino)carbonyl]oxy]-N,N,N-trimethylbenzenaminium",CNC(=O)OC1=CC=C(C=C1)[N+](C)(C)C,,,,,,
9889,19890,2H-1-Benzopyran-2-thione,C1=CC=C2C(=C1)C=CC(=S)O2,,,,,,
9890,19891,3-Phenyl-1-(thiophen-2-yl)prop-2-en-1-one,C1=CC=C(C=C1)C=CC(=O)C2=CC=CS2,,,,,,
9891,19892,Octyl dihydrogen phosphate,CCCCCCCCOP(=O)(O)O,,,,,,
9892,19893,Ethyl 2-cyano-2-[(3-methylphenyl)hydrazinylidene]acetate,CCOC(=O)C(=NNC1=CC=CC(=C1)C)C#N,,,,,,
9893,19894,Ethyl 2-[2-(4-chlorophenyl)hydrazono]-2-cyanoacetate,CCOC(=O)C(=NNC1=CC=C(C=C1)Cl)C#N,,,,,,
9894,19895,1-Methyl-4-nitro-1H-pyrazole,CN1C=C(C=N1)[N+](=O)[O-],,,,,,
9895,19896,"4,6-dichloro-N-methyl-N-phenyl-1,3,5-triazin-2-amine",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)Cl)Cl,,,,,,
9896,19897,"6-Chloro-N~2~,N~4~-dimethyl-N~2~,N~4~-diphenyl-1,3,5-triazine-2,4-diamine",CN(C1=CC=CC=C1)C2=NC(=NC(=N2)Cl)N(C)C3=CC=CC=C3,,,,,,
9897,19898,Medinoterb,CC1=C(C=C(C(=C1[N+](=O)[O-])O)C(C)(C)C)[N+](=O)[O-],,,,,,
9898,19899,"3-(3,3-Diphenylpropyl)-3-azabicyclo(3.2.2)nonane hydrochloride",C1CC2CCC1C[NH+](C2)CCC(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
9899,19900,"3-(3,3-Diphenylpropyl)-3-azabicyclo[3.2.2]nonane",C1CC2CCC1CN(C2)CCC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
9900,19901,3-Ethyl-5-methylpyridine,CCC1=CN=CC(=C1)C,,,,,,
9901,19902,"1,2,3-Triaminoguanidine;nitrate",C(=NN)(NN)NN.[N+](=O)([O-])[O-],,,,,,
9902,19903,"1,2,3-Triaminoguanidine",C(=NN)(NN)NN,,,,,,
9903,19904,"2,4-Dimethoxy-6-methyl-1,3,5-triazine",CC1=NC(=NC(=N1)OC)OC,,,,,,
9904,19905,"((2,5-Dichlorophenyl)azo)malononitrile",C1=CC(=C(C=C1Cl)N=NC(C#N)C#N)Cl,,,,,,
9905,19906,"6-Methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride",COC1=CC2=C(CC(CC2)[NH3+])C=C1.[Cl-],,,,,,
9906,19907,"6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine",COC1=CC2=C(CC(CC2)N)C=C1,,,,,,
9907,19908,1-Nitro-2-(2-phenylethenyl)benzene,C1=CC=C(C=C1)C=CC2=CC=CC=C2[N+](=O)[O-],,,,,,
9908,19909,"2-Amino-1,3,4-thiadiazole",C1=NN=C(S1)N,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
9909,19910,Nitroxoline,C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-],['Nitroxoline is an antibiotic agent.'],,"['Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
9910,19911,"[Amino-[(3,6-dihydroxy-1-methylindol-5-yl)diazenyl]methylidene]azanium;methanesulfonate",CN1C=C(C2=CC(=C(C=C21)O)N=NC(=[NH2+])N)O.CS(=O)(=O)[O-],,,,,,
9911,19912,"1-(3,6-Dihydroxy-1-methylindol-5-yl)iminoguanidine",CN1C=C(C2=CC(=C(C=C21)O)N=NC(=N)N)O,,,,,,
9912,19913,(1-Methoxyethyl)benzene,CC(C1=CC=CC=C1)OC,,,,,,
9913,19914,Nicotinoyl azide,C1=CC(=CN=C1)C(=O)N=[N+]=[N-],,,,,,
9914,19915,CID 19915,C1=CC(=CN=C1)C(=O)N[N+]#N,,,,,,
9915,19916,N-Isopropyl-6-methyl-2-heptylamine hydrochloride,CC(C)CCCC(C)[NH2+]C(C)C.[Cl-],,,,,,
9916,19917,Iproheptine,CC(C)CCCC(C)NC(C)C,,,,,,
9917,19918,Quazodine,CCC1=NC=NC2=CC(=C(C=C21)OC)OC,,,,,,
9918,19919,Ethyl glycidyl ether,CCOCC1CO1,,,,,,
9919,19920,Isopropyl glycidyl ether,CC(C)OCC1CO1,,,,,,
9920,19921,CID 19921,CCCCCCCCCCC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
9921,19922,"Dodecanoic acid, 2-sulfo-, 1-methyl ester",CCCCCCCCCCC(C(=O)OC)S(=O)(=O)O,,,,,,
9922,19923,CID 19923,CCCCCCCCCCCCC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
9923,19924,"Tetradecanoic acid, 2-sulfo-, 1-methyl ester",CCCCCCCCCCCCC(C(=O)OC)S(=O)(=O)O,,,,,,
9924,19925,CID 19925,CCCCCCCCCCCCCCC(C(=O)OCC)S(=O)(=O)[O-].[Na+],,,,,,
9925,19926,2-Sulfohexadecanoic acid 1-ethyl ester,CCCCCCCCCCCCCCC(C(=O)OCC)S(=O)(=O)O,,,,,,
9926,19927,"AZIRIDINE, 1-tert-BUTYL-",CC(C)(C)N1CC1,,,,,,
9927,19928,3-Chlorocatechol,C1=CC(=C(C(=C1)Cl)O)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
9928,19929,5-Chloro-3-(4-chlorophenyl)-4'-chlorosalicylanilide,C1=CC(=CC=C1C2=C(C(=CC(=C2)Cl)C(=O)NC3=CC=C(C=C3)Cl)O)Cl,,,,,,
9929,19930,CID 19930,CCN(CC)C1=NC(=NC(=N1)S)N(CC)CC,,,,,,
9930,19931,"1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-phenyl-",CC1(N=C(N=C(N1C2=CC=CC=C2)N)N)C,,,,,,
9931,19932,CID 19932,C1=CC(=CC=C1N=C(N)N=C([NH3+])N)Cl.[Cl-],,,,,,
9932,19933,4-Chlorophenylbiguanide,C1=CC(=CC=C1N=C(N)N=C(N)N)Cl,,,,,['4-Chlorophenylbiguanide is a known human metabolite of Proguanil.'],
9933,19934,"N,N-Dimethyl-2-(alpha-(p-tolyl)benzyloxy)ethylamine hydrochloride",CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[NH+](C)C.[Cl-],,,,,,
9934,19935,Toladryl,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCCN(C)C,,,,,,
9935,19936,Perchlorocyclohex-2-en-1-one,C1(=C(C(C(C(C1=O)(Cl)Cl)(Cl)Cl)(Cl)Cl)Cl)Cl,,,,,,
9936,19937,Deacetylcinobufagin,C[C@]12CC[C@@H](C[C@H]1CCC3C2CC[C@]4([C@]35[C@H](O5)[C@@H]([C@@H]4C6=COC(=O)C=C6)O)C)O,,,,,,
9937,19938,Acetylcinobufagin,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@]35[C@H](O5)[C@@H]([C@@H]4C6=COC(=O)C=C6)OC(=O)C)C)C,,,,,,
9938,19939,Dequalinium acetate,CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.CC(=O)[O-].CC(=O)[O-],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
9939,19940,Acetylresibufogenin,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@]35[C@H](O5)C[C@@H]4C6=COC(=O)C=C6)C)C,,,,,,
9940,19941,Acetylmarinobufogenin,CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](C[C@@H]5[C@@]4(C3CC[C@@]2(C1)O)O5)C6=COC(=O)C=C6)C)C,,,,,,
9941,19942,"1-Hydroxy-6-imino-4-methyl-1,3,5-triazin-2-amine",CC1=NC(=N)N(C(=N1)N)O,,,,,,
9942,19943,Diquat dichloride,C1C[N+]2=CC=CC=C2C3=CC=CC=[N+]31.[Cl-].[Cl-],,,,,,
9943,19944,"2,3,6-Trimethylheptane",CC(C)CCC(C)C(C)C,,,,,,
9944,19945,2-Amino-3-(2-carboxyethylsulfanyl)propanoic acid,C(CSCC(C(=O)O)N)C(=O)O,,,,,,
9945,19946,((3-((p-Chlorophenoxy)methyl)-3-oxetanyl)methyl)trimethylammonium bromide,C[N+](C)(C)CC1(COC1)COC2=CC=C(C=C2)Cl.[Br-],,,,,,
9946,19947,[3-[(4-Chlorophenoxy)methyl]oxetan-3-yl]methyl-trimethylazanium,C[N+](C)(C)CC1(COC1)COC2=CC=C(C=C2)Cl,,,,,,
9947,19948,"((3-((2,4-Dichlorophenoxy)methyl)-3-oxetanyl)methyl)trimethylammonium bromide",C[N+](C)(C)CC1(COC1)COC2=C(C=C(C=C2)Cl)Cl.[Br-],,,,,,
9948,19949,"[3-[(2,4-Dichlorophenoxy)methyl]oxetan-3-yl]methyl-trimethylazanium",C[N+](C)(C)CC1(COC1)COC2=C(C=C(C=C2)Cl)Cl,,,,,,
9949,19950,"1,3,5-Tris(6-isocyanatohexyl)biuret",C(CCCN=C=O)CCNC(=O)N(CCCCCCN=C=O)C(=O)NCCCCCCN=C=O,,,,,,
9950,19951,3-Ethyl-1-pentene,CCC(CC)C=C,,,,,,
9951,19952,"N-methyl-1,3,5-triazin-2-amine",CNC1=NC=NC=N1,,,,,,
9952,19953,"N,N-dimethyl-1,3,5-triazin-2-amine",CN(C)C1=NC=NC=N1,,,,,,
9953,19954,2-Benzylamino-S-triazine,C1=CC=C(C=C1)CNC2=NC=NC=N2,,,,,,
9954,19955,"N-phenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)NC2=NC=NC=N2,,,,,,
9955,19956,5-Azacytosine,C1=NC(=O)NC(=N1)N,,,,,,
9956,19957,"2,5-Dimethylcyclopent-2-en-1-one",CC1CC=C(C1=O)C,,,,,,
9957,19958,Bitoscanate,C1=CC(=CC=C1N=C=S)N=C=S,,,,"['After oral administration of the anthelmintic, (14)C-bitoscanate to dogs, renal elimination ... and fall-off of blood concentrations ... of (14)C- were biphasic. Similar results were obtained in man except that urinary excretion was more delayed, and more (14)C- was excreted renally. Much of the (14)C- had been excreted within 5 days from both species, but excretion of the remainder was protracted. Thus after 3 weeks, the dog had excreted 80% in the feces, and 12% in the urine, and after 5 weeks, man had excreted respectively 55 and 28% by these routes; 3% still circulated in the blood. Fetuses contained 3% of the dose, 16 hr after admin of (14)C-bitoscanate to a pregnant dog. The data indicated that part of the (14)C binding to the tissues was only slowly excreted, possibly because (14)C-bitoscanate was irreversibly bound to biological macromolecules through its isothiocyanate groups. ... final rates of excretion of (14)C reflected rates of metabolism and excretion of the endogenous macromolecules to which bitoscanate was bound.', 'Bitoscanate is partly absorbed from the gastro-intestinal tract and slowly excreted ...']",,"['Half-life of 0.5 and 8 days in renal elimination and fall-off of blood concentrations of half-life of 0.8 and 12 days /occurred after oral admin of bitoscanate to dogs/. /Similar results were obtained in man except that urinary excretion was more delayed, and more (14)C-bitoscanate was excreted renally/.', '... a half-life of 26 days has been reported /in humans/.']"
9958,19959,"3-((5-Methyl-5H-as-triazino(5,6-b)indol-3-yl)amino)-1-propanol",CN1C2=CC=CC=C2C3=C1N=C(N=N3)NCCCO,,,,,,
9959,19960,6-Amino-1-hexanol,C(CCCO)CCN,,,,,,
9960,19961,"[(7R,8S)-11-amino-5-heptanoyl-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCCCCCC(=O)N1C2C1[C@@]3([C@@H](C4=C(N3C2)C(=O)C(=C(C4=O)N)C)COC(=O)N)OC,,,,,,
9961,19962,"[(7R,8S)-11-(cyclohexylamino)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)NC5CCCCC5,,,,,,
9962,19963,"[(7R,8S)-11-(dimethylamino)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)N(C)C,,,,,,
9963,19964,"ethyl (7R,8S)-11-amino-8-(carbamoyloxymethyl)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-diene-5-carboxylate",CCOC(=O)N1C2C1[C@@]3([C@@H](C4=C(N3C2)C(=O)C(=C(C4=O)N)C)COC(=O)N)OC,,,,,,
9964,19965,"2-Methyl-1,5-hexadiene",CC(=C)CCC=C,,,,,,
9965,19966,2-Hexene,CCCC=CC,,,,,,
9966,19967,CID 19967,CC1(C(N2C(S1)C(C2=O)N3C(=O)C(NC3(C)C)C4=CC=CC=C4)C(=O)[O-])C.[K+],,,,,,
9967,19968,4-Methylquinoline 1-oxide,CC1=CC=[N+](C2=CC=CC=C12)[O-],,,,,,
9968,19969,"1,3-Cycloheptadiene",C1CC=CC=CC1,,,,,,
9969,19970,"(6-Amino-1-butanoyl-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CCCC(=O)N1C2C1C3([C@@H](C4=C(N3C2)C(=O)C(=C(C4=O)N)C)COC(=O)N)OC,,,,,,
9970,19971,"[(8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-5-propanoyl-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCC(=O)N1C2C1C3([C@@H](C4=C(N3C2)C(=O)C(=C(C4=O)N)C)COC(=O)N)OC,,,,,,
9971,19972,Mitomycin A,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC,,,,,,
9972,19973,Mitomycin B,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@H]2COC(=O)N)O)N4C)OC,,,,,,
9973,19974,"2,6-Dimethyl-2-octene",CCC(C)CCC=C(C)C,,,,,,
9974,19975,"Dimethyl((phenylcarbamoyl)methyl)((2,6-xylylcarbamoyl)methyl)ammonium chloride",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
9975,19976,"(2-Anilino-2-oxoethyl)-[2-(2,6-dimethylanilino)-2-oxoethyl]-dimethylazanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2,,,,,,
9976,19977,"Dimethyl((phenylcarbamoyl)methyl)(3-(2,6-xylylcarbamoyl)propyl)ammonium chloride",CC1=C(C(=CC=C1)C)NC(=O)CCC[N+](C)(C)CC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
9977,19978,"(2-Anilino-2-oxoethyl)-[4-(2,6-dimethylanilino)-4-oxobutyl]-dimethylazanium",CC1=C(C(=CC=C1)C)NC(=O)CCC[N+](C)(C)CC(=O)NC2=CC=CC=C2,,,,,,
9978,19979,"Ammonium, (((6-chloro-o-tolyl)carbamoyl)methyl)dimethyl((phenylcarbamoyl)methyl)-, chloride",CC1=C(C(=CC=C1)Cl)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2.[Cl-],,,,,,
9979,19980,(2-Anilino-2-oxoethyl)-[2-(2-chloro-6-methylanilino)-2-oxoethyl]-dimethylazanium,CC1=C(C(=CC=C1)Cl)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2,,,,,,
9980,19981,(p-Chlorobenzyl)(phenylazo)malononitrile,C1=CC=C(C=C1)N=NC(C2=CC=C(C=C2)Cl)C(C#N)C#N,,,,,,
9981,19982,CID 19982,CCCCCCCCCCCCCCCCC(C(=O)OC)S(=O)(=O)[O-].[Na+],,,,,,
9982,19983,"CARBAMIC ACID, N-METHYL-, o-(ALLYLOXY)PHENYL ESTER",CNC(=O)OC1=CC=CC=C1OCC=C,,,,,,
9983,19984,"1,2:3,4-Di-O-isopropylidene-D-galactopyranose",CC1(OC2C(OC3C(C2O1)OC(O3)(C)C)CO)C,,,,,,
9984,19985,Hellebrigenin-3-acetate,CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H](CC[C@@]4(C3CC[C@@]2(C1)O)O)C5=COC(=O)C=C5)C)C=O,,,,,,
9985,19986,alpha-Ethyl-alpha-phenyl-gamma-butyrolactone,CCC1(CCOC1=O)C2=CC=CC=C2,,,,,,
9986,19987,"N-[4-[acetyl(ethyl)amino]-6-chloro-1,3,5-triazin-2-yl]-N-ethylacetamide",CCN(C1=NC(=NC(=N1)Cl)N(CC)C(=O)C)C(=O)C,,,,,,
9987,19988,Sulisobenzone,COC1=C(C=C(C(=C1)O)C(=O)C2=CC=CC=C2)S(=O)(=O)O,"['Sunscreening agents are used to prevent sunburn, actinic keratosis, and premature skin aging and to reduce the incidence of skin cancer.']","['Benzophenone sunscreens, applied topically, protect the skin from these harmful effects of ultraviolet light by chemically absorbing light energy (photons). Correct use of sunscreens serves to reduce the risk of sunburn. Sunscreen agents prevent the occurrence of squamous-cell carcinoma of the skin when used mainly during unintentional sun exposure. No conclusion can be drawn about the cancer-preventive activity of topical use of sunscreens against both basal-cell carcinoma and cutaneous melanoma. Use of sunscreens can extend the duration of intentional sun exposure, such as bathing in the sun.']",,"['Does not penetrate the skin to a large degree, but enhances the ability of other chemicals to penetrate.', ""This drug's main metabolite is excreted in urine conjugated with glucuronic acid.  No p-hydroxybenzohydrol was detected in urine or feces, in a study of pharmacokinetics in rats."", 'Solvents used in sunscreen products affect the stability and binding of the drug to the skin; in general, alcoholic solvents allow for the most rapid and deepest epidermal penetration of sunscreens. It appears that sunscreen agents are absorbed by the intact epidermis to varying degrees. /Sunscreens/']","[""Benzophenone's main metabolic pathway in the rabbit is by reduction to benzhydrol. A small amount (1%) is converted to p-hydroxybenzophenone following oral administration to rats.""]",
9988,19989,"MALEIMIDE, N-o-TOLYL-",CC1=CC=CC=C1N2C(=O)C=CC2=O,,,,,,
9989,19990,Pentaethylenehexamine,C(CNCCNCCNCCNCCN)N,,,,,,
9990,19991,"1,4-Diphenylbut-2-ene-1,4-dione",C1=CC=C(C=C1)C(=O)C=CC(=O)C2=CC=CC=C2,,,,,,
9991,19992,(p-Nitrophenyl)phenyliodonium bromide,C1=CC=C(C=C1)[I+]C2=CC=C(C=C2)[N+](=O)[O-].[Br-],,,,,,
9992,19993,"IODONIUM, (p-NITROPHENYL)PHENYL-, BROMIDE",C1=CC=C(C=C1)[I+]C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
9993,19994,3-Butylphenol,CCCCC1=CC(=CC=C1)O,,,,,,
9994,19995,"Benzothiazole, 2-dimethylamino-",CN(C)C1=NC2=CC=CC=C2S1,,,,,,
9995,19996,Diethylene glycol diacrylate,C=CC(=O)OCCOCCOC(=O)C=C,,,,,,
9996,19997,Divinyl adipate,C=COC(=O)CCCCC(=O)OC=C,,,,,,
9997,19998,4-Acetylaminobiphenyl,CC(=O)NC1=CC=C(C=C1)C2=CC=CC=C2,,,,['THE BINDING TO LIVER RNA & DNA WAS STUDIED 24 HR AFTER SINGLE IP INJECTION OF (3)H-LABELED COMPD.'],"['REDUCTION OF N-HYDROXY-4-ACETYLAMINOBIPHENYL BY INTESTINAL MICROFLORA OF THE RAT TO 4-ACETYLAMINOBIPHENYL WAS EXAMINED.', '...NONBASIC NITROGEN-CONTAINING COMPD...4-ACETYLAMINOBIPHENYL UTILIZE A CYTOCHROME P-450-DEPENDENT SYSTEM.', 'ABILITY OF ARYLACETAMINE DEACETYLASE ENZYME SYSTEMS OF DOG LIVER TO DEACETYLATE 4-ACETYLAMINOBIPHENYL WAS EXAMINED. ENZYME ACTIVITY WAS GREATEST IN LIVER TISSUE, WAS LOCALIZED IN MICROSOMAL SUBCELLULAR FRACTION & REQUIRED NO COFACTORS.']",
9998,19999,Calcium propionate,CCC(=O)[O-].CCC(=O)[O-].[Ca+2],,,,,['PROPIONATE IS METABOLIZED LIKE OTHER FATTY ACIDS IN THE MAMMALIAN BODY ... /PROPIONATE/'],
9999,20000,(2-(2-(2-Oxo-1-pyrrolidinyl)ethoxy)ethyl)trimethylammonium iodide,C[N+](C)(C)CCOCCN1CCCC1=O.[I-],,,,,,
